cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
KIRP	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-25.14	8.46e-72	9.91e-66	-1.17	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-24.83	8.7e-71	9.48e-65	-1.15	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-24.81	1.03e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-24.77	1.35e-70	9.48e-65	-1.12	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-24.76	1.41e-70	9.48e-65	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-24.76	1.41e-70	9.48e-65	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-24.76	1.41e-70	9.48e-65	-1.14	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-24.76	1.44e-70	9.48e-65	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-24.65	3.29e-70	1.96e-64	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-24.65	3.29e-70	1.96e-64	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-24.65	3.29e-70	1.96e-64	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-24.65	3.29e-70	1.96e-64	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-24.65	3.29e-70	1.96e-64	-1.13	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-24.54	7.17e-70	4.14e-64	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-24.48	1.19e-69	6.66e-64	-1.14	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-24.45	1.49e-69	7.24e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	24.43	1.71e-69	8.03e-64	1.15	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-24.41	1.95e-69	9.03e-64	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-24.41	2e-69	9.05e-64	-1.12	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-24.23	7.55e-69	3.14e-63	-1.14	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	24.23	7.71e-69	3.14e-63	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	24.23	7.71e-69	3.14e-63	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	24.23	7.71e-69	3.14e-63	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	24.23	7.71e-69	3.14e-63	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-24.23	7.71e-69	3.14e-63	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-24.23	7.71e-69	3.14e-63	-1.13	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	24.12	1.77e-68	6.77e-63	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	24.03	3.39e-68	1.28e-62	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	23.98	4.84e-68	1.8e-62	1.13	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-23.92	7.92e-68	2.91e-62	-1.14	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	23.77	2.38e-67	8.67e-62	1.15	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	23.74	3.1e-67	1.12e-61	1.14	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-23.59	9.29e-67	3.32e-61	-1.13	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	23.53	1.5e-66	5.3e-61	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-23.51	1.69e-66	5.93e-61	-1.07	-0.82	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	23.45	2.72e-66	9.45e-61	1.14	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	23.42	3.46e-66	1.14e-60	0.99	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
KIRP	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-23.41	3.6e-66	1.14e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-23.4	3.9e-66	1.23e-60	-1.14	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-23.32	7.29e-66	2.21e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-23.32	7.29e-66	2.21e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	23.23	1.39e-65	4.16e-60	1.06	0.82	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
KIRP	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-23.21	1.63e-65	4.81e-60	-1.06	-0.82	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
KIRP	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-23.21	1.63e-65	4.81e-60	-1.06	-0.82	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	23.2	1.77e-65	5.19e-60	1.12	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
KIRP	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	23.2	1.84e-65	5.36e-60	1.06	0.82	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	23.17	2.31e-65	6.66e-60	1.06	0.82	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	23.16	2.36e-65	6.76e-60	0.85	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
KIRP	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	23.15	2.61e-65	7.1e-60	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-23.15	2.61e-65	7.1e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-23.15	2.61e-65	7.1e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-23.15	2.61e-65	7.1e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-23.15	2.61e-65	7.1e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-23.15	2.61e-65	7.1e-60	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	23.11	3.47e-65	9.36e-60	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	23.1	3.74e-65	1e-59	1.1	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
KIRP	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-23.08	4.42e-65	1.18e-59	-1.07	-0.82	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-23.08	4.45e-65	1.18e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	23.08	4.53e-65	1.19e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	22.91	1.64e-64	3.83e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-22.91	1.64e-64	3.83e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-22.91	1.64e-64	3.83e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-22.91	1.64e-64	3.83e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-22.91	1.64e-64	3.83e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-22.91	1.64e-64	3.83e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	22.91	1.66e-64	3.85e-59	1.11	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	22.91	1.7e-64	3.9e-59	1.05	0.82	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
KIRP	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-22.9	1.78e-64	4.07e-59	-1.06	-0.82	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-22.89	1.86e-64	4.24e-59	-1.08	-0.82	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-22.89	1.94e-64	4.38e-59	-1.13	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	22.88	2.01e-64	4.5e-59	0.91	0.82	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-22.88	2.11e-64	4.69e-59	-1.08	-0.82	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-22.84	2.82e-64	6.23e-59	-1.11	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	22.74	5.79e-64	1.26e-58	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	22.66	1.07e-63	2.3e-58	1.11	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	22.61	1.66e-63	3.5e-58	1.15	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-22.49	4.2e-63	8.61e-58	-1.09	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
KIRP	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-22.48	4.49e-63	9.11e-58	-1.07	-0.81	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	22.46	5.34e-63	1.07e-57	1.16	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-22.45	5.61e-63	1.12e-57	-1.09	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	22.35	1.22e-62	2.38e-57	1.09	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	22.35	1.22e-62	2.38e-57	1.09	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	22.35	1.22e-62	2.38e-57	1.09	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	22.34	1.34e-62	2.58e-57	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	22.33	1.41e-62	2.71e-57	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	22.31	1.59e-62	3.03e-57	0.97	0.81	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	22.3	1.83e-62	3.46e-57	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	22.29	1.89e-62	3.57e-57	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	22.23	3.1e-62	5.79e-57	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	22.21	3.51e-62	6.49e-57	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	22.21	3.51e-62	6.49e-57	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
KIRP	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-22.21	3.59e-62	6.6e-57	-1.08	-0.81	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	22.2	3.77e-62	6.89e-57	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	22.19	4.01e-62	7.27e-57	1.09	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	22.19	4.28e-62	7.72e-57	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
KIRP	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	22.15	5.71e-62	1.03e-56	1.11	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	22.11	7.57e-62	1.35e-56	1.04	0.81	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	22.06	1.14e-61	1.95e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	22.05	1.19e-61	2.02e-56	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	22.02	1.5e-61	2.53e-56	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	22	1.74e-61	2.91e-56	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	21.97	2.24e-61	3.74e-56	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	21.89	4.16e-61	6.9e-56	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-21.87	4.83e-61	7.92e-56	-1.09	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-21.86	5.4e-61	8.77e-56	-1.06	-0.8	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	21.82	7.06e-61	1.14e-55	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	21.82	7.06e-61	1.14e-55	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	21.81	7.95e-61	1.27e-55	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	21.81	7.95e-61	1.27e-55	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	21.79	8.81e-61	1.4e-55	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
KIRP	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	21.76	1.13e-60	1.78e-55	0.87	0.8	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
KIRP	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	21.75	1.27e-60	2e-55	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	21.63	3.1e-60	4.72e-55	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	21.63	3.18e-60	4.83e-55	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	21.63	3.27e-60	4.95e-55	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
KIRP	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-21.57	4.95e-60	7.46e-55	-1.04	-0.8	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	21.43	1.49e-59	2.19e-54	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	21.32	3.48e-59	4.57e-54	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	21.3	4.25e-59	5.55e-54	1.08	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	21.3	4.26e-59	5.55e-54	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	21.28	4.7e-59	6.11e-54	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	21.28	4.72e-59	6.11e-54	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	21.26	5.51e-59	7.11e-54	0.81	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
KIRP	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-21.21	8.47e-59	1.08e-53	-0.88	-0.79	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
KIRP	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-21.21	8.47e-59	1.08e-53	-0.88	-0.79	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
KIRP	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-21.21	8.47e-59	1.08e-53	-0.88	-0.79	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
KIRP	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	21.21	8.63e-59	1.1e-53	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	21.2	8.84e-59	1.11e-53	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	21.2	8.84e-59	1.11e-53	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	21.2	8.84e-59	1.11e-53	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-21.2	9.09e-59	1.11e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-21.2	9.09e-59	1.11e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-21.2	9.09e-59	1.11e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
KIRP	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-21.2	9.25e-59	1.12e-53	-0.88	-0.79	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
KIRP	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-21.16	1.23e-58	1.48e-53	-1.03	-0.79	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	21.13	1.63e-58	1.95e-53	0.88	0.79	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-21.12	1.68e-58	1.98e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-21.1	1.95e-58	2.29e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	21.09	2.2e-58	2.56e-53	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	21.09	2.2e-58	2.56e-53	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	21.06	2.74e-58	3.16e-53	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-21	4.34e-58	4.86e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-21	4.34e-58	4.86e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-21	4.34e-58	4.86e-53	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	20.99	4.82e-58	5.38e-53	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	20.96	6.11e-58	6.81e-53	0.96	0.79	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	20.92	7.97e-58	8.84e-53	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	20.92	7.99e-58	8.84e-53	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
KIRP	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-20.91	9.13e-58	1e-52	-1.02	-0.79	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	20.88	1.16e-57	1.19e-52	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-20.85	1.44e-57	1.46e-52	-1.1	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	20.84	1.5e-57	1.52e-52	0.87	0.79	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	20.84	1.59e-57	1.6e-52	0.87	0.79	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	20.84	1.59e-57	1.6e-52	0.87	0.79	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-20.83	1.69e-57	1.67e-52	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	20.83	1.69e-57	1.67e-52	0.87	0.79	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	20.83	1.69e-57	1.67e-52	0.87	0.79	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	20.82	1.72e-57	1.69e-52	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	20.82	1.72e-57	1.69e-52	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-20.81	1.97e-57	1.91e-52	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	20.81	1.97e-57	1.91e-52	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	20.81	1.97e-57	1.91e-52	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-20.76	2.76e-57	2.65e-52	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-20.75	3.04e-57	2.91e-52	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	20.72	4.01e-57	3.81e-52	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	20.71	4.18e-57	3.96e-52	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	20.7	4.53e-57	4.27e-52	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	20.7	4.53e-57	4.27e-52	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	20.66	6.43e-57	6.01e-52	0.88	0.79	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	20.64	7.17e-57	6.67e-52	0.88	0.79	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	20.6	1.01e-56	9.39e-52	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	20.6	1.02e-56	9.41e-52	1.3	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	20.6	1.02e-56	9.41e-52	1.3	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	20.6	1.02e-56	9.41e-52	1.3	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
KIRP	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	20.59	1.11e-56	1.02e-51	0.87	0.79	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	20.58	1.2e-56	1.1e-51	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	20.57	1.3e-56	1.19e-51	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	20.56	1.44e-56	1.31e-51	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	20.54	1.57e-56	1.42e-51	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	20.54	1.57e-56	1.42e-51	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-20.48	2.65e-56	2.38e-51	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-20.47	2.79e-56	2.51e-51	-1.07	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-20.39	5.4e-56	4.81e-51	-1.07	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	20.37	6.15e-56	5.45e-51	0.88	0.78	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	20.37	6.39e-56	5.64e-51	1.05	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	20.35	7.3e-56	6.43e-51	0.88	0.78	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	20.3	1.04e-55	9.07e-51	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	20.3	1.04e-55	9.07e-51	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	20.3	1.05e-55	9.13e-51	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
KIRP	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	20.28	1.25e-55	1.08e-50	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	20.27	1.36e-55	1.17e-50	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	20.27	1.36e-55	1.17e-50	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	20.27	1.36e-55	1.17e-50	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	20.27	1.37e-55	1.17e-50	1.09	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	20.27	1.37e-55	1.17e-50	1.09	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	20.2	2.33e-55	1.98e-50	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	20.2	2.43e-55	2.06e-50	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	20.17	2.95e-55	2.49e-50	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	20.16	3.22e-55	2.71e-50	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	20.12	4.4e-55	3.69e-50	0.88	0.78	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-20.12	4.48e-55	3.75e-50	-1.07	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
KIRP	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	20.11	4.9e-55	4.1e-50	1.01	0.78	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	20.1	5.12e-55	4.26e-50	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	20.1	5.2e-55	4.3e-50	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
KIRP	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	20.08	6.38e-55	5.27e-50	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	20.01	1.08e-54	8.86e-50	1.08	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	20	1.17e-54	9.57e-50	1.08	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	19.98	1.37e-54	1.12e-49	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-19.98	1.37e-54	1.12e-49	-0.88	-0.78	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-19.98	1.41e-54	1.15e-49	-1.07	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	19.96	1.59e-54	1.29e-49	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	19.85	3.81e-54	3.01e-49	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	19.83	4.54e-54	3.58e-49	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-19.82	4.73e-54	3.72e-49	-0.88	-0.77	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-19.82	4.73e-54	3.72e-49	-0.88	-0.77	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	19.81	5.25e-54	4.12e-49	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-19.74	9.45e-54	7.37e-49	-0.88	-0.77	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	19.73	9.84e-54	7.66e-49	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	19.73	1.02e-53	7.93e-49	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	19.69	1.35e-53	1.04e-48	1.28	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
KIRP	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	19.69	1.39e-53	1.07e-48	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-19.66	1.7e-53	1.31e-48	-1.12	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	19.65	1.84e-53	1.41e-48	1.07	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-19.64	2.11e-53	1.62e-48	-0.95	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	19.59	3e-53	2.29e-48	1.07	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	19.56	3.71e-53	2.82e-48	1.12	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-19.56	4e-53	3.03e-48	-1.12	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-19.53	4.9e-53	3.69e-48	-1.02	-0.77	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-19.52	5.3e-53	3.99e-48	-0.87	-0.77	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	19.51	5.62e-53	4.16e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-19.47	7.73e-53	5.64e-48	-0.89	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	19.47	7.85e-53	5.71e-48	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-19.47	8.08e-53	5.72e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-19.41	1.3e-52	9.05e-48	-1.11	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	19.4	1.35e-52	9.33e-48	1.13	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	19.37	1.75e-52	1.21e-47	1.28	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	19.37	1.75e-52	1.21e-47	1.28	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
KIRP	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-19.37	1.78e-52	1.22e-47	-0.94	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	19.36	1.84e-52	1.26e-47	1.06	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-19.33	2.45e-52	1.66e-47	-0.85	-0.77	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-19.33	2.45e-52	1.66e-47	-0.85	-0.77	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	19.33	2.45e-52	1.66e-47	0.85	0.77	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	19.32	2.61e-52	1.77e-47	0.88	0.77	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	19.3	3.01e-52	2.03e-47	0.94	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	19.3	3.01e-52	2.03e-47	0.94	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	19.24	5.01e-52	3.36e-47	1.1	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
KIRP	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	19.22	5.97e-52	3.98e-47	1.06	0.76	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
KIRP	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	19.21	6.19e-52	4.12e-47	1.06	0.76	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
KIRP	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	19.21	6.28e-52	4.18e-47	1.28	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
KIRP	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	19.2	6.94e-52	4.49e-47	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-19.2	6.94e-52	4.49e-47	-1.12	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-19.2	6.94e-52	4.49e-47	-1.12	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-19.18	7.83e-52	5.06e-47	-1.1	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
KIRP	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-19.14	1.06e-51	6.85e-47	-0.85	-0.76	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
KIRP	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	19.04	2.37e-51	1.5e-46	1.06	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	19.03	2.7e-51	1.71e-46	1.3	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
KIRP	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-19.02	2.79e-51	1.73e-46	-1.11	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-19.02	2.79e-51	1.73e-46	-1.11	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-19.02	2.79e-51	1.73e-46	-1.11	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-19.02	2.79e-51	1.73e-46	-1.11	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-19.02	2.79e-51	1.73e-46	-1.11	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	19.02	2.79e-51	1.73e-46	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	19.02	2.79e-51	1.73e-46	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	19.02	2.79e-51	1.73e-46	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	19.02	2.79e-51	1.73e-46	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	19.02	2.79e-51	1.73e-46	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	19	3.29e-51	2.03e-46	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	19	3.5e-51	2.16e-46	1.12	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
KIRP	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	18.94	5.56e-51	3.39e-46	0.94	0.76	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
KIRP	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	18.92	6.46e-51	3.91e-46	1.04	0.76	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
KIRP	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	18.91	7.06e-51	4.26e-46	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	18.85	1.11e-50	6.67e-46	1.28	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
KIRP	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	18.84	1.17e-50	7.03e-46	1.05	0.76	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
KIRP	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	18.84	1.17e-50	7.03e-46	1.05	0.76	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
KIRP	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	18.83	1.35e-50	8.06e-46	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-18.74	2.64e-50	1.56e-45	-1.1	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
KIRP	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	18.74	2.66e-50	1.57e-45	1.06	0.76	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
KIRP	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	18.74	2.66e-50	1.57e-45	1.06	0.76	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
KIRP	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	18.71	3.49e-50	2.05e-45	1.11	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	18.63	6.85e-50	3.96e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	18.62	7.42e-50	4.25e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
KIRP	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	18.59	8.97e-50	5.11e-45	1.04	0.75	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
KIRP	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	18.57	1.03e-49	5.86e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	18.55	1.23e-49	6.93e-45	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	18.53	1.43e-49	8.08e-45	0.85	0.75	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	18.49	2.02e-49	1.14e-44	0.84	0.75	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
KIRP	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	18.39	4.51e-49	2.49e-44	1.23	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
KIRP	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	18.39	4.56e-49	2.52e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	18.39	4.59e-49	2.53e-44	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
KIRP	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-18.39	4.69e-49	2.59e-44	-0.88	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	18.38	5.11e-49	2.81e-44	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	18.37	5.2e-49	2.85e-44	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
KIRP	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	18.35	6.3e-49	3.46e-44	1.07	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	18.33	7.39e-49	4.01e-44	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	18.33	7.46e-49	4.04e-44	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	18.3	9.19e-49	4.96e-44	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
KIRP	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	18.23	1.6e-48	8.53e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	18.23	1.6e-48	8.53e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	18.23	1.6e-48	8.53e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	18.23	1.6e-48	8.53e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	18.23	1.6e-48	8.53e-44	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	18.23	1.67e-48	8.89e-44	1.04	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	18.23	1.71e-48	9.04e-44	1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	18.23	1.71e-48	9.04e-44	1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	18.23	1.71e-48	9.04e-44	1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
KIRP	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	18.22	1.82e-48	9.58e-44	1.07	0.75	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
KIRP	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	18.14	3.43e-48	1.76e-43	1.2	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	18.14	3.43e-48	1.76e-43	1.2	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
KIRP	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	18.1	4.52e-48	2.3e-43	1.01	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	18.07	6.08e-48	3.07e-43	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
KIRP	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	18.07	6.21e-48	3.14e-43	1.03	0.74	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
KIRP	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	18.05	7.02e-48	3.54e-43	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-18.05	7.12e-48	3.57e-43	-1.07	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-18.04	7.61e-48	3.8e-43	-0.8	-0.74	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
KIRP	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-17.98	1.25e-47	6.16e-43	-0.85	-0.74	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
KIRP	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-17.95	1.59e-47	7.67e-43	-0.82	-0.74	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	17.95	1.63e-47	7.84e-43	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	17.95	1.63e-47	7.84e-43	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-17.92	2.01e-47	9.64e-43	-0.8	-0.74	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	17.88	2.69e-47	1.29e-42	1.18	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
KIRP	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	17.88	2.75e-47	1.31e-42	0.98	0.74	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
KIRP	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-17.87	2.96e-47	1.41e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	17.87	2.97e-47	1.41e-42	0.97	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
KIRP	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-17.87	3e-47	1.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-17.85	3.46e-47	1.62e-42	-0.82	-0.74	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	17.85	3.59e-47	1.68e-42	0.99	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
KIRP	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-17.85	3.66e-47	1.71e-42	-1.07	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	17.82	4.59e-47	2.13e-42	1.04	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
KIRP	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-17.8	5.29e-47	2.41e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-17.79	5.75e-47	2.61e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-17.79	5.75e-47	2.61e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
KIRP	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	17.78	6.07e-47	2.74e-42	0.97	0.74	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
KIRP	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-17.77	6.63e-47	2.95e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	17.77	6.82e-47	3.03e-42	1.08	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	17.77	6.82e-47	3.03e-42	1.08	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
KIRP	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-17.77	7.01e-47	3.1e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-17.76	7.15e-47	3.16e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-17.76	7.15e-47	3.16e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	17.74	8.39e-47	3.69e-42	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
KIRP	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-17.74	8.57e-47	3.76e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-17.71	1.08e-46	4.72e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-17.7	1.17e-46	5.05e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	17.69	1.24e-46	5.39e-42	1.03	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-17.67	1.5e-46	6.4e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-17.67	1.5e-46	6.4e-42	-0.81	-0.74	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-17.66	1.69e-46	7.17e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-17.65	1.84e-46	7.68e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	17.63	2.05e-46	8.46e-42	0.99	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
KIRP	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-17.62	2.34e-46	9.58e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-17.62	2.34e-46	9.58e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-17.62	2.36e-46	9.67e-42	-0.8	-0.74	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	17.61	2.52e-46	1.03e-41	1.01	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
KIRP	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-17.6	2.72e-46	1.11e-41	-0.82	-0.74	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-17.6	2.76e-46	1.12e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-17.6	2.76e-46	1.12e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-17.6	2.76e-46	1.12e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-17.59	2.85e-46	1.15e-41	-0.79	-0.74	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	17.59	2.89e-46	1.16e-41	1.08	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-17.59	2.92e-46	1.17e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-17.59	2.92e-46	1.17e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
KIRP	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	17.59	2.94e-46	1.18e-41	0.82	0.74	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
KIRP	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-17.59	2.95e-46	1.18e-41	-0.8	-0.74	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-17.54	4.18e-46	1.66e-41	-0.88	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
KIRP	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	17.54	4.36e-46	1.73e-41	0.99	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
KIRP	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-17.54	4.45e-46	1.76e-41	-0.89	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
KIRP	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-17.54	4.49e-46	1.77e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-17.54	4.49e-46	1.77e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-17.53	4.52e-46	1.78e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-17.53	4.52e-46	1.78e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-17.53	4.69e-46	1.84e-41	-0.78	-0.73	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-17.53	4.72e-46	1.84e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-17.53	4.72e-46	1.84e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-17.52	5.04e-46	1.96e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	17.52	5.14e-46	1.99e-41	1.18	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
KIRP	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-17.52	5.16e-46	2e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-17.52	5.16e-46	2e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-17.52	5.31e-46	2.05e-41	-0.82	-0.73	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	17.5	5.78e-46	2.21e-41	1.08	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
KIRP	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-17.49	6.39e-46	2.42e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-17.49	6.51e-46	2.44e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-17.47	7.57e-46	2.8e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	17.47	7.92e-46	2.91e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-17.46	7.98e-46	2.92e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-17.46	8.54e-46	3.09e-41	-0.81	-0.73	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-17.46	8.54e-46	3.09e-41	-0.81	-0.73	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-17.46	8.54e-46	3.09e-41	-0.81	-0.73	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-17.46	8.54e-46	3.09e-41	-0.81	-0.73	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-17.45	9.25e-46	3.34e-41	-0.82	-0.73	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-17.43	1.08e-45	3.89e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-17.43	1.08e-45	3.89e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-17.43	1.08e-45	3.89e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-17.43	1.08e-45	3.89e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-17.43	1.1e-45	3.93e-41	-0.82	-0.73	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	17.42	1.16e-45	4.14e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	17.42	1.16e-45	4.14e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	17.42	1.16e-45	4.14e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	17.42	1.16e-45	4.14e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-17.42	1.17e-45	4.18e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-17.41	1.21e-45	4.31e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-17.4	1.32e-45	4.68e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-17.4	1.32e-45	4.68e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-17.4	1.32e-45	4.68e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-17.39	1.47e-45	5.17e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-17.37	1.66e-45	5.84e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-17.37	1.66e-45	5.84e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-17.37	1.66e-45	5.84e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	17.37	1.67e-45	5.84e-41	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-17.37	1.69e-45	5.91e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-17.36	1.88e-45	6.56e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	17.34	2.14e-45	7.42e-41	1.11	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-17.33	2.35e-45	8.1e-41	-0.79	-0.73	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	17.33	2.44e-45	8.42e-41	1.08	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
KIRP	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-17.32	2.53e-45	8.71e-41	-0.8	-0.73	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	17.32	2.58e-45	8.88e-41	0.76	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
KIRP	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-17.29	3.27e-45	1.11e-40	-0.89	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
KIRP	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-17.29	3.4e-45	1.15e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	17.29	3.4e-45	1.15e-40	0.8	0.73	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-17.28	3.53e-45	1.2e-40	-1.09	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	17.27	3.93e-45	1.32e-40	0.79	0.73	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-17.26	4.25e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-17.26	4.25e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-17.26	4.25e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-17.26	4.25e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-17.26	4.25e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-17.26	4.27e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-17.26	4.27e-45	1.42e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-17.25	4.39e-45	1.46e-40	-0.89	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	17.25	4.45e-45	1.48e-40	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
KIRP	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	17.25	4.67e-45	1.55e-40	1.04	0.73	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
KIRP	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	17.24	4.76e-45	1.57e-40	0.98	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	17.24	4.76e-45	1.57e-40	0.98	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
KIRP	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	17.23	5.35e-45	1.76e-40	0.92	0.73	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
KIRP	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-17.22	5.74e-45	1.88e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-17.22	5.74e-45	1.88e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-17.22	5.99e-45	1.96e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	17.15	1.02e-44	3.19e-40	0.87	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	17.15	1.02e-44	3.19e-40	0.87	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
KIRP	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-17.15	1.04e-44	3.23e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-17.15	1.04e-44	3.23e-40	-0.8	-0.73	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	17.15	1.06e-44	3.3e-40	0.99	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	17.14	1.09e-44	3.37e-40	0.76	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
KIRP	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-17.14	1.09e-44	3.37e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	17.12	1.3e-44	3.9e-40	1.18	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
KIRP	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	17.11	1.4e-44	4.15e-40	0.96	0.73	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
KIRP	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	17.11	1.45e-44	4.3e-40	1.08	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-17.1	1.55e-44	4.59e-40	-0.81	-0.73	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	17.1	1.55e-44	4.59e-40	0.76	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	17.1	1.57e-44	4.63e-40	0.87	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
KIRP	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-17.08	1.79e-44	5.26e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-17.08	1.79e-44	5.26e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-17.07	1.98e-44	5.77e-40	-0.79	-0.73	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-17.04	2.56e-44	7.42e-40	-0.78	-0.72	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-17.04	2.56e-44	7.42e-40	-0.78	-0.72	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-17.03	2.68e-44	7.69e-40	-0.79	-0.72	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-17.03	2.68e-44	7.69e-40	-0.79	-0.72	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-17.03	2.68e-44	7.69e-40	-0.79	-0.72	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-17.03	2.68e-44	7.69e-40	-0.79	-0.72	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.652	rs874115	ENSG00000253404.1	AC034243.1	17.03	2.75e-44	7.88e-40	1.01	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944367	chr5:138744434~138753309:-
KIRP	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-17.02	2.92e-44	8.35e-40	-0.78	-0.72	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-17.02	3e-44	8.58e-40	-0.76	-0.72	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	17	3.41e-44	9.72e-40	0.75	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
KIRP	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-16.99	3.6e-44	1.03e-39	-0.98	-0.72	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
KIRP	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-16.98	4.19e-44	1.18e-39	-0.78	-0.72	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	16.95	5.16e-44	1.45e-39	0.75	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	16.95	5.2e-44	1.46e-39	0.87	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
KIRP	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	16.94	5.78e-44	1.62e-39	0.96	0.72	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
KIRP	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-16.93	6.03e-44	1.67e-39	-0.76	-0.72	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
KIRP	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	16.91	7.02e-44	1.92e-39	0.96	0.72	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	16.91	7.02e-44	1.92e-39	0.96	0.72	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	16.88	8.93e-44	2.43e-39	0.95	0.72	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	16.87	9.8e-44	2.65e-39	0.95	0.72	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
KIRP	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-16.85	1.16e-43	3.12e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-16.85	1.16e-43	3.12e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	16.82	1.49e-43	3.99e-39	1.08	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	16.82	1.52e-43	4.07e-39	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	16.79	1.9e-43	5.05e-39	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
KIRP	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	16.78	2.1e-43	5.57e-39	1.12	0.72	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
KIRP	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-16.75	2.65e-43	6.97e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-16.71	3.53e-43	9.2e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-16.71	3.53e-43	9.2e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
KIRP	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-16.71	3.53e-43	9.2e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-16.71	3.53e-43	9.2e-39	-0.75	-0.72	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
KIRP	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	16.71	3.64e-43	9.38e-39	0.95	0.72	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	16.7	3.91e-43	1.01e-38	0.95	0.72	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
KIRP	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	16.69	4.24e-43	1.09e-38	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
KIRP	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-16.68	4.55e-43	1.16e-38	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
KIRP	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	16.68	4.64e-43	1.19e-38	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	16.68	4.64e-43	1.19e-38	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	16.68	4.75e-43	1.21e-38	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
KIRP	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-16.66	5.28e-43	1.34e-38	-0.76	-0.72	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	16.65	6e-43	1.51e-38	0.93	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
KIRP	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	16.64	6.2e-43	1.56e-38	1.04	0.72	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
KIRP	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	16.64	6.2e-43	1.56e-38	1.04	0.72	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
KIRP	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	16.63	6.85e-43	1.72e-38	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	16.62	7.31e-43	1.83e-38	0.93	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	16.62	7.31e-43	1.83e-38	0.93	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
KIRP	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	16.62	7.62e-43	1.91e-38	0.94	0.72	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
KIRP	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	16.61	8.14e-43	2.04e-38	0.74	0.72	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	16.6	8.55e-43	2.13e-38	0.94	0.72	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
KIRP	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	16.6	8.72e-43	2.17e-38	1.01	0.72	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
KIRP	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	16.59	9.29e-43	2.31e-38	0.94	0.72	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
KIRP	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-16.58	1.06e-42	2.63e-38	-0.97	-0.72	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
KIRP	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	16.54	1.39e-42	3.44e-38	0.96	0.71	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
KIRP	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	16.53	1.56e-42	3.85e-38	0.94	0.71	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
KIRP	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-16.51	1.84e-42	4.49e-38	-0.8	-0.71	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
KIRP	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	16.51	1.85e-42	4.5e-38	0.94	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
KIRP	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	16.5	1.94e-42	4.72e-38	0.94	0.71	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
KIRP	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	16.43	3.45e-42	8.34e-38	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	16.43	3.45e-42	8.34e-38	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	16.43	3.48e-42	8.41e-38	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
KIRP	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	16.42	3.67e-42	8.8e-38	0.96	0.71	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-16.41	4.22e-42	1e-37	-0.89	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
KIRP	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	16.4	4.43e-42	1.05e-37	0.93	0.71	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	16.4	4.67e-42	1.11e-37	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
KIRP	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	16.38	5.35e-42	1.26e-37	0.94	0.71	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
KIRP	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	16.38	5.45e-42	1.29e-37	1.01	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	16.37	5.63e-42	1.33e-37	0.92	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
KIRP	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	16.34	7.39e-42	1.69e-37	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	16.34	7.39e-42	1.69e-37	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	16.34	7.39e-42	1.69e-37	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
KIRP	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	16.26	1.35e-41	3.06e-37	0.92	0.71	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
KIRP	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	16.25	1.5e-41	3.4e-37	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-16.24	1.64e-41	3.71e-37	-0.86	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
KIRP	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	16.23	1.74e-41	3.92e-37	0.93	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
KIRP	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	16.22	1.91e-41	4.3e-37	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
KIRP	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	16.18	2.66e-41	5.79e-37	0.74	0.71	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	16.18	2.66e-41	5.79e-37	0.74	0.71	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	16.18	2.66e-41	5.79e-37	0.74	0.71	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	16.18	2.66e-41	5.79e-37	0.74	0.71	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
KIRP	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	16.18	2.68e-41	5.84e-37	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-16.13	3.89e-41	8.42e-37	-0.73	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	16.13	3.91e-41	8.45e-37	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
KIRP	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	16.13	3.95e-41	8.53e-37	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-16.12	4.22e-41	9.07e-37	-0.96	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
KIRP	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-16.12	4.26e-41	9.15e-37	-1.09	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	16.1	5e-41	1.07e-36	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
KIRP	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	16.09	5.7e-41	1.22e-36	0.92	0.7	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
KIRP	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-16.04	8.4e-41	1.79e-36	-1.04	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
KIRP	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	16.03	8.8e-41	1.88e-36	0.94	0.7	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	16.03	8.91e-41	1.9e-36	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
KIRP	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	16.03	9.08e-41	1.93e-36	0.92	0.7	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	16.03	9.3e-41	1.98e-36	0.74	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
KIRP	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	16.02	9.85e-41	2.1e-36	0.89	0.7	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
KIRP	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-16.02	1.02e-40	2.17e-36	-0.78	-0.7	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-15.99	1.3e-40	2.66e-36	-0.79	-0.7	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	15.98	1.34e-40	2.74e-36	0.72	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	15.96	1.54e-40	3.14e-36	0.72	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	15.96	1.54e-40	3.14e-36	0.72	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
KIRP	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	15.94	1.82e-40	3.7e-36	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
KIRP	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	15.92	2.2e-40	4.45e-36	0.73	0.7	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
KIRP	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	15.91	2.4e-40	4.84e-36	0.74	0.7	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
KIRP	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	15.9	2.61e-40	5.24e-36	0.89	0.7	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	15.9	2.61e-40	5.24e-36	0.89	0.7	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	15.9	2.61e-40	5.24e-36	0.89	0.7	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
KIRP	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	15.9	2.68e-40	5.39e-36	0.79	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
KIRP	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-15.88	3.07e-40	6.15e-36	-1.09	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-15.88	3.07e-40	6.15e-36	-1.09	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-15.88	3.07e-40	6.15e-36	-1.09	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-15.88	3.07e-40	6.15e-36	-1.09	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-15.88	3.07e-40	6.15e-36	-1.09	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
KIRP	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-15.87	3.44e-40	6.89e-36	-0.7	-0.7	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
KIRP	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	15.85	3.98e-40	7.94e-36	0.74	0.7	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
KIRP	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-15.85	4.05e-40	8.08e-36	-1.05	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	15.84	4.08e-40	8.15e-36	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
KIRP	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-15.83	4.73e-40	9.41e-36	-0.77	-0.7	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
KIRP	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-15.83	4.73e-40	9.41e-36	-0.77	-0.7	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-15.83	4.73e-40	9.41e-36	-0.77	-0.7	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-15.83	4.73e-40	9.41e-36	-0.77	-0.7	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	15.8	5.89e-40	1.16e-35	0.89	0.7	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	15.8	5.89e-40	1.16e-35	0.89	0.7	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
KIRP	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	15.8	5.98e-40	1.18e-35	0.71	0.7	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-15.79	6.5e-40	1.28e-35	-0.77	-0.7	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-15.79	6.54e-40	1.29e-35	-0.78	-0.7	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-15.79	6.54e-40	1.29e-35	-0.78	-0.7	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-15.79	6.54e-40	1.29e-35	-0.78	-0.7	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-15.79	6.54e-40	1.29e-35	-0.78	-0.7	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-15.79	6.54e-40	1.29e-35	-0.78	-0.7	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
KIRP	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	15.79	6.55e-40	1.29e-35	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
KIRP	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-15.77	7.56e-40	1.49e-35	-1.03	-0.7	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
KIRP	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	15.76	7.89e-40	1.52e-35	0.73	0.7	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	15.73	1.04e-39	1.99e-35	0.72	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
KIRP	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-15.72	1.1e-39	2.11e-35	-0.78	-0.7	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-15.72	1.1e-39	2.11e-35	-0.78	-0.7	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-15.72	1.1e-39	2.11e-35	-0.78	-0.7	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-15.72	1.1e-39	2.11e-35	-0.78	-0.7	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	15.71	1.25e-39	2.38e-35	0.73	0.7	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-15.71	1.25e-39	2.38e-35	-0.73	-0.7	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	15.7	1.34e-39	2.53e-35	0.74	0.7	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	15.7	1.34e-39	2.53e-35	0.74	0.7	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	15.7	1.34e-39	2.53e-35	0.74	0.7	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	15.69	1.4e-39	2.65e-35	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	15.69	1.44e-39	2.73e-35	0.75	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
KIRP	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	15.68	1.52e-39	2.87e-35	1.08	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-15.68	1.62e-39	3.05e-35	-1.04	-0.7	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-15.68	1.62e-39	3.05e-35	-1.04	-0.7	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-15.68	1.62e-39	3.05e-35	-1.04	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
KIRP	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-15.67	1.74e-39	3.26e-35	-0.77	-0.7	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-15.67	1.74e-39	3.26e-35	-0.77	-0.7	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-15.67	1.74e-39	3.26e-35	-0.77	-0.7	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-15.67	1.74e-39	3.26e-35	-0.77	-0.7	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	15.66	1.8e-39	3.38e-35	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
KIRP	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	15.64	2.07e-39	3.88e-35	1.08	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
KIRP	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	15.62	2.5e-39	4.67e-35	0.73	0.69	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	15.62	2.52e-39	4.71e-35	0.73	0.69	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	15.62	2.58e-39	4.81e-35	0.93	0.69	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
KIRP	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	15.61	2.73e-39	5.09e-35	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
KIRP	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-15.61	2.86e-39	5.32e-35	-0.78	-0.69	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-15.61	2.86e-39	5.32e-35	-0.78	-0.69	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-15.61	2.86e-39	5.32e-35	-0.78	-0.69	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	15.6	2.88e-39	5.34e-35	0.93	0.69	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	15.6	2.91e-39	5.4e-35	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
KIRP	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-15.6	2.95e-39	5.48e-35	-0.78	-0.69	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-15.6	2.95e-39	5.48e-35	-0.78	-0.69	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-15.59	3.26e-39	6.03e-35	-0.76	-0.69	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-15.58	3.52e-39	6.5e-35	-0.78	-0.69	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
KIRP	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-15.58	3.61e-39	6.67e-35	-0.77	-0.69	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
KIRP	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-15.57	3.77e-39	6.94e-35	-1.06	-0.69	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
KIRP	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-15.57	3.91e-39	7.19e-35	-0.78	-0.69	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-15.57	3.91e-39	7.19e-35	-0.78	-0.69	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-15.56	4.17e-39	7.67e-35	-0.78	-0.69	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-15.55	4.5e-39	8.26e-35	-0.77	-0.69	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
KIRP	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-15.54	4.74e-39	8.7e-35	-1.03	-0.69	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
KIRP	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-15.54	4.78e-39	8.76e-35	-0.77	-0.69	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-15.54	4.78e-39	8.76e-35	-0.77	-0.69	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-15.54	4.78e-39	8.76e-35	-0.77	-0.69	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-15.54	4.78e-39	8.76e-35	-0.77	-0.69	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
KIRP	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	15.54	4.91e-39	8.98e-35	0.79	0.69	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
KIRP	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-15.53	5.06e-39	9.23e-35	-0.78	-0.69	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-15.53	5.06e-39	9.23e-35	-0.78	-0.69	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-15.53	5.06e-39	9.23e-35	-0.78	-0.69	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-15.53	5.06e-39	9.23e-35	-0.78	-0.69	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-15.53	5.06e-39	9.23e-35	-0.78	-0.69	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
KIRP	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	15.53	5.13e-39	9.35e-35	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
KIRP	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	15.52	5.71e-39	1.04e-34	0.73	0.69	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	15.52	5.71e-39	1.04e-34	0.73	0.69	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
KIRP	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	15.51	6.19e-39	1.12e-34	1.1	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	15.51	6.19e-39	1.12e-34	1.1	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
KIRP	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	15.51	6.4e-39	1.16e-34	0.92	0.69	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	15.51	6.4e-39	1.16e-34	0.92	0.69	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-15.5	6.52e-39	1.18e-34	-0.77	-0.69	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-15.5	6.52e-39	1.18e-34	-0.77	-0.69	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
KIRP	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-15.5	6.72e-39	1.21e-34	-0.78	-0.69	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
KIRP	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-15.5	6.92e-39	1.24e-34	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
KIRP	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-15.49	7.17e-39	1.29e-34	-0.77	-0.69	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
KIRP	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	15.49	7.31e-39	1.31e-34	0.75	0.69	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
KIRP	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-15.48	7.64e-39	1.37e-34	-0.77	-0.69	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-15.48	7.68e-39	1.38e-34	-0.73	-0.69	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
KIRP	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-15.47	8.71e-39	1.56e-34	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
KIRP	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-15.46	9.46e-39	1.69e-34	-0.78	-0.69	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-15.46	9.46e-39	1.69e-34	-0.78	-0.69	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-15.44	1.08e-38	1.92e-34	-0.77	-0.69	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	15.44	1.08e-38	1.93e-34	0.72	0.69	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	15.44	1.13e-38	2e-34	0.93	0.69	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
KIRP	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	15.44	1.13e-38	2.01e-34	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
KIRP	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	15.43	1.17e-38	2.07e-34	0.89	0.69	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	15.43	1.18e-38	2.1e-34	0.77	0.69	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
KIRP	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-15.38	1.76e-38	3.09e-34	-1.01	-0.69	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	15.38	1.77e-38	3.1e-34	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	15.38	1.77e-38	3.1e-34	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	15.38	1.77e-38	3.1e-34	0.84	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
KIRP	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	15.36	2.05e-38	3.58e-34	0.72	0.69	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
KIRP	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-15.36	2.1e-38	3.67e-34	-1.01	-0.69	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
KIRP	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	15.35	2.2e-38	3.83e-34	0.82	0.69	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
KIRP	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	15.35	2.29e-38	3.98e-34	0.77	0.69	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	15.35	2.3e-38	4e-34	0.94	0.69	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	15.35	2.3e-38	4e-34	0.94	0.69	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	15.35	2.3e-38	4e-34	0.94	0.69	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	15.34	2.37e-38	4.11e-34	0.89	0.69	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	15.34	2.37e-38	4.11e-34	0.89	0.69	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-15.33	2.75e-38	4.56e-34	-0.77	-0.69	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
KIRP	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-15.33	2.77e-38	4.59e-34	-1.01	-0.69	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
KIRP	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-15.33	2.77e-38	4.59e-34	-1.07	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
KIRP	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	15.32	2.8e-38	4.63e-34	0.73	0.69	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-15.31	3.11e-38	5.14e-34	-0.76	-0.69	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	15.31	3.18e-38	5.25e-34	0.93	0.69	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	15.3	3.4e-38	5.56e-34	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
KIRP	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-15.3	3.44e-38	5.62e-34	-0.81	-0.69	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
KIRP	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	15.29	3.71e-38	6.05e-34	0.9	0.69	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-15.29	3.8e-38	6.2e-34	-0.76	-0.69	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	15.28	3.93e-38	6.4e-34	0.88	0.69	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-15.28	4.12e-38	6.7e-34	-0.77	-0.69	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-15.27	4.21e-38	6.84e-34	-0.76	-0.69	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	15.27	4.3e-38	6.99e-34	0.72	0.69	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	15.27	4.46e-38	7.25e-34	0.89	0.69	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	15.26	4.9e-38	7.96e-34	0.92	0.69	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-15.25	5.04e-38	8.17e-34	-0.76	-0.69	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-15.25	5.16e-38	8.38e-34	-0.76	-0.69	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	15.23	6.21e-38	1e-33	0.73	0.69	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-15.22	6.36e-38	1.02e-33	-0.76	-0.69	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
KIRP	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-15.22	6.68e-38	1.07e-33	-1	-0.68	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
KIRP	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-15.21	6.84e-38	1.1e-33	-0.77	-0.68	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	15.21	7.06e-38	1.13e-33	0.72	0.68	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
KIRP	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	15.21	7.27e-38	1.16e-33	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
KIRP	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-15.19	8.12e-38	1.3e-33	-0.76	-0.68	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	15.17	9.5e-38	1.51e-33	0.77	0.68	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-15.16	1.03e-37	1.64e-33	-0.76	-0.68	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-15.16	1.07e-37	1.7e-33	-0.77	-0.68	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-15.15	1.12e-37	1.77e-33	-0.74	-0.68	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-15.15	1.13e-37	1.79e-33	-0.77	-0.68	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-15.15	1.19e-37	1.89e-33	-0.77	-0.68	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	15.14	1.28e-37	2.02e-33	0.77	0.68	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-15.13	1.33e-37	2.09e-33	-0.76	-0.68	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-15.12	1.44e-37	2.26e-33	-0.77	-0.68	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-15.12	1.44e-37	2.26e-33	-0.77	-0.68	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	15.12	1.52e-37	2.38e-33	0.87	0.68	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	15.12	1.52e-37	2.38e-33	0.87	0.68	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	15.12	1.52e-37	2.38e-33	0.87	0.68	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
KIRP	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	15.12	1.52e-37	2.38e-33	0.87	0.68	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
KIRP	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-15.11	1.58e-37	2.47e-33	-1.01	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
KIRP	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-15.1	1.8e-37	2.8e-33	-0.76	-0.68	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-15.1	1.8e-37	2.8e-33	-0.76	-0.68	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-15.1	1.8e-37	2.8e-33	-0.76	-0.68	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
KIRP	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	15.09	1.83e-37	2.86e-33	0.88	0.68	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	15.09	1.83e-37	2.86e-33	0.88	0.68	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
KIRP	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-15.09	1.85e-37	2.88e-33	-0.76	-0.68	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
KIRP	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-15.08	2.08e-37	3.22e-33	-1.08	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-15.08	2.08e-37	3.22e-33	-1.08	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
KIRP	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	15.04	2.78e-37	4.29e-33	0.88	0.68	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	15.04	2.78e-37	4.29e-33	0.88	0.68	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	15.04	2.78e-37	4.29e-33	0.88	0.68	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	15.04	2.78e-37	4.29e-33	0.88	0.68	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	15.01	3.62e-37	5.55e-33	0.73	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
KIRP	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-15	3.92e-37	5.99e-33	-0.76	-0.68	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
KIRP	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-15	3.94e-37	6.03e-33	-1.02	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	14.99	4.32e-37	6.59e-33	0.87	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-14.98	4.43e-37	6.74e-33	-0.82	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	14.98	4.74e-37	7.19e-33	0.71	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	14.98	4.74e-37	7.19e-33	0.71	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	14.98	4.74e-37	7.19e-33	0.71	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
KIRP	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-14.96	5.3e-37	8.04e-33	-0.75	-0.68	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-14.96	5.49e-37	8.31e-33	-0.75	-0.68	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
KIRP	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	14.95	5.75e-37	8.7e-33	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	14.94	6.18e-37	9.33e-33	0.7	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
KIRP	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	14.93	7e-37	1.06e-32	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
KIRP	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-14.92	7.65e-37	1.15e-32	-0.86	-0.68	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
KIRP	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-14.92	7.65e-37	1.15e-32	-0.98	-0.68	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	14.91	8.26e-37	1.24e-32	0.85	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
KIRP	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	14.9	8.72e-37	1.31e-32	0.8	0.68	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	14.9	8.72e-37	1.31e-32	0.8	0.68	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	14.9	8.72e-37	1.31e-32	0.8	0.68	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	14.89	9.43e-37	1.42e-32	0.8	0.68	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-14.89	9.59e-37	1.44e-32	-0.7	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
KIRP	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-14.89	9.84e-37	1.47e-32	-0.79	-0.68	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-14.88	1.05e-36	1.56e-32	-1.01	-0.68	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	14.87	1.11e-36	1.65e-32	0.84	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-14.87	1.11e-36	1.65e-32	-0.72	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
KIRP	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	14.86	1.17e-36	1.75e-32	0.79	0.68	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
KIRP	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.86	1.22e-36	1.82e-32	0.79	0.68	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
KIRP	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-14.85	1.26e-36	1.87e-32	-1	-0.68	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
KIRP	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	14.79	2.17e-36	3.2e-32	0.7	0.67	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	14.78	2.4e-36	3.49e-32	0.79	0.67	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
KIRP	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-14.77	2.44e-36	3.55e-32	-0.77	-0.67	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
KIRP	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-14.74	3.14e-36	4.55e-32	-0.93	-0.67	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-14.72	3.71e-36	5.37e-32	-0.88	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
KIRP	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	14.68	5.37e-36	7.71e-32	0.76	0.67	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
KIRP	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	14.67	5.67e-36	8.13e-32	0.9	0.67	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	14.66	5.88e-36	8.44e-32	0.91	0.67	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
KIRP	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-14.64	6.97e-36	9.98e-32	-0.99	-0.67	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
KIRP	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	14.64	7.21e-36	1.03e-31	0.89	0.67	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
KIRP	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-14.64	7.45e-36	1.07e-31	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	14.63	8.06e-36	1.15e-31	0.91	0.67	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
KIRP	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	14.62	8.34e-36	1.19e-31	0.79	0.67	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	14.62	8.34e-36	1.19e-31	0.79	0.67	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	14.61	9.16e-36	1.3e-31	0.8	0.67	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-14.61	9.21e-36	1.31e-31	-0.78	-0.67	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-14.6	9.89e-36	1.4e-31	-0.79	-0.67	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
KIRP	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-14.59	1.06e-35	1.5e-31	-0.85	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
KIRP	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	14.59	1.07e-35	1.51e-31	0.79	0.67	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	14.59	1.07e-35	1.51e-31	0.71	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
KIRP	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	14.59	1.09e-35	1.54e-31	0.79	0.67	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
KIRP	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	14.56	1.35e-35	1.9e-31	0.89	0.67	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
KIRP	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	14.56	1.35e-35	1.9e-31	0.89	0.67	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	14.52	1.96e-35	2.73e-31	0.78	0.67	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	14.52	1.96e-35	2.73e-31	0.78	0.67	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	14.5	2.21e-35	3.08e-31	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	14.49	2.39e-35	3.32e-31	0.78	0.67	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	14.49	2.51e-35	3.49e-31	0.78	0.67	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	14.48	2.56e-35	3.57e-31	0.78	0.67	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
KIRP	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	14.47	2.94e-35	4.07e-31	0.78	0.67	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	14.47	2.95e-35	4.07e-31	0.79	0.67	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	14.46	2.98e-35	4.11e-31	0.78	0.67	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	14.44	3.53e-35	4.87e-31	0.79	0.67	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	14.43	3.93e-35	5.42e-31	0.69	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
KIRP	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	14.42	4.36e-35	5.99e-31	0.79	0.67	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	14.42	4.36e-35	5.99e-31	0.79	0.67	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
KIRP	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	14.41	4.67e-35	6.41e-31	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
KIRP	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-14.4	4.91e-35	6.75e-31	-0.8	-0.66	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-14.38	5.89e-35	8.08e-31	-0.81	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
KIRP	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	14.37	6.17e-35	8.45e-31	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
KIRP	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-14.37	6.28e-35	8.58e-31	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-14.37	6.28e-35	8.58e-31	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-14.37	6.28e-35	8.58e-31	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-14.37	6.28e-35	8.58e-31	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-14.37	6.28e-35	8.58e-31	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
KIRP	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	14.34	7.82e-35	1.07e-30	0.76	0.66	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	14.32	9.15e-35	1.24e-30	0.78	0.66	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	14.32	9.15e-35	1.24e-30	0.78	0.66	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
KIRP	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-14.3	1.08e-34	1.46e-30	-0.75	-0.66	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
KIRP	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	14.3	1.12e-34	1.51e-30	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	14.29	1.2e-34	1.61e-30	0.78	0.66	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	14.29	1.2e-34	1.61e-30	0.78	0.66	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
KIRP	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	14.27	1.37e-34	1.83e-30	0.67	0.66	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
KIRP	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-14.26	1.56e-34	2.04e-30	-0.74	-0.66	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	14.24	1.77e-34	2.27e-30	0.7	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
KIRP	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	14.24	1.79e-34	2.3e-30	0.75	0.66	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
KIRP	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	14.24	1.86e-34	2.39e-30	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
KIRP	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-14.24	1.89e-34	2.41e-30	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-14.23	1.9e-34	2.43e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
KIRP	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-14.23	1.94e-34	2.49e-30	-0.77	-0.66	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	14.23	1.98e-34	2.53e-30	0.77	0.66	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	14.23	2.02e-34	2.58e-30	0.77	0.66	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-14.22	2.2e-34	2.8e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-14.22	2.2e-34	2.8e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-14.22	2.2e-34	2.8e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	14.21	2.26e-34	2.87e-30	0.78	0.66	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
KIRP	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	14.21	2.35e-34	2.98e-30	0.79	0.66	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	14.19	2.62e-34	3.32e-30	0.69	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-14.19	2.68e-34	3.4e-30	-0.86	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-14.17	3.12e-34	3.95e-30	-0.69	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
KIRP	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-14.17	3.29e-34	4.16e-30	-0.78	-0.66	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
KIRP	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	14.15	3.77e-34	4.76e-30	0.75	0.66	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	14.15	3.77e-34	4.76e-30	0.75	0.66	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-14.14	3.95e-34	4.96e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	14.14	3.96e-34	4.97e-30	0.78	0.66	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
KIRP	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-14.14	4.02e-34	5.05e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
KIRP	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	14.13	4.29e-34	5.37e-30	0.78	0.66	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	14.13	4.29e-34	5.37e-30	0.78	0.66	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	14.13	4.29e-34	5.37e-30	0.78	0.66	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	14.13	4.29e-34	5.37e-30	0.78	0.66	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	14.13	4.29e-34	5.37e-30	0.78	0.66	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	14.11	5.35e-34	6.66e-30	0.78	0.66	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
KIRP	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-14.11	5.35e-34	6.66e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-14.11	5.35e-34	6.66e-30	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
KIRP	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-14.1	5.8e-34	7.19e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-14.1	5.8e-34	7.19e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-14.1	5.8e-34	7.19e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-14.1	5.8e-34	7.19e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-14.1	5.8e-34	7.19e-30	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
KIRP	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	14.09	6.14e-34	7.6e-30	0.79	0.66	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
KIRP	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	14.07	7.17e-34	8.83e-30	0.79	0.66	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	14.07	7.17e-34	8.83e-30	0.79	0.66	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	14.07	7.17e-34	8.83e-30	0.79	0.66	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	14.07	7.17e-34	8.83e-30	0.79	0.66	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	14.07	7.17e-34	8.83e-30	0.79	0.66	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
KIRP	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	14.06	7.84e-34	9.64e-30	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
KIRP	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	14.04	8.82e-34	1.08e-29	0.95	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	14.03	9.88e-34	1.21e-29	0.7	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	14	1.27e-33	1.55e-29	0.69	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	14	1.27e-33	1.55e-29	0.86	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
KIRP	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	14	1.3e-33	1.59e-29	0.74	0.65	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
KIRP	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	13.99	1.31e-33	1.6e-29	0.67	0.65	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-13.98	1.48e-33	1.8e-29	-0.74	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	13.97	1.54e-33	1.87e-29	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	13.97	1.56e-33	1.9e-29	0.69	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
KIRP	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	13.97	1.65e-33	2.01e-29	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-13.96	1.75e-33	2.13e-29	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	13.94	2.04e-33	2.47e-29	0.78	0.65	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-13.93	2.15e-33	2.59e-29	-0.74	-0.65	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
KIRP	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	13.93	2.16e-33	2.6e-29	0.69	0.65	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
KIRP	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	13.93	2.23e-33	2.69e-29	0.68	0.65	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
KIRP	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	13.92	2.32e-33	2.78e-29	0.75	0.65	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-13.89	3e-33	3.58e-29	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	13.87	3.64e-33	4.33e-29	0.84	0.65	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-13.86	3.97e-33	4.64e-29	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-13.86	3.97e-33	4.64e-29	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
KIRP	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	13.84	4.6e-33	5.37e-29	0.87	0.65	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	13.83	4.9e-33	5.7e-29	0.77	0.65	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	13.83	4.9e-33	5.7e-29	0.77	0.65	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
KIRP	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-13.83	5.1e-33	5.94e-29	-0.87	-0.65	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
KIRP	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-13.82	5.13e-33	5.96e-29	-1.05	-0.65	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
KIRP	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	13.82	5.34e-33	6.2e-29	0.76	0.65	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	13.82	5.43e-33	6.31e-29	0.78	0.65	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	13.8	6.36e-33	7.34e-29	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
KIRP	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	13.77	7.9e-33	9.08e-29	0.74	0.65	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
KIRP	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	13.76	8.39e-33	9.61e-29	0.9	0.65	Shingles;	chr7:38346957	chr7:38343894~38350022:-
KIRP	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	13.76	8.5e-33	9.74e-29	0.77	0.65	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
KIRP	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-13.76	8.51e-33	9.75e-29	-0.74	-0.65	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
KIRP	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-13.76	8.82e-33	1.01e-28	-0.81	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
KIRP	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	13.74	9.99e-33	1.14e-28	0.8	0.65	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
KIRP	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-13.74	1.01e-32	1.16e-28	-0.74	-0.65	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
KIRP	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	13.73	1.12e-32	1.28e-28	0.77	0.65	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	13.73	1.12e-32	1.28e-28	0.77	0.65	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
KIRP	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	13.72	1.15e-32	1.31e-28	0.75	0.65	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	13.72	1.15e-32	1.31e-28	0.85	0.65	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
KIRP	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	13.72	1.16e-32	1.31e-28	0.74	0.65	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	13.72	1.16e-32	1.31e-28	0.74	0.65	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	13.72	1.19e-32	1.35e-28	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
KIRP	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-13.71	1.34e-32	1.52e-28	-0.72	-0.65	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
KIRP	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	13.7	1.39e-32	1.58e-28	0.77	0.65	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
KIRP	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	13.7	1.41e-32	1.59e-28	0.76	0.65	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
KIRP	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	13.69	1.48e-32	1.67e-28	0.77	0.65	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
KIRP	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-13.69	1.5e-32	1.7e-28	-0.74	-0.65	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-13.69	1.5e-32	1.7e-28	-0.74	-0.65	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
KIRP	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-13.69	1.53e-32	1.73e-28	-0.63	-0.65	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-13.69	1.53e-32	1.73e-28	-0.63	-0.65	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-13.69	1.53e-32	1.73e-28	-0.63	-0.65	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-13.69	1.53e-32	1.73e-28	-0.63	-0.65	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
KIRP	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-13.68	1.58e-32	1.78e-28	-0.78	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
KIRP	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	13.67	1.73e-32	1.94e-28	0.87	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
KIRP	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	13.66	2e-32	2.23e-28	0.76	0.64	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
KIRP	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	13.65	2.02e-32	2.25e-28	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
KIRP	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	13.65	2.13e-32	2.38e-28	0.78	0.64	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	13.65	2.13e-32	2.38e-28	0.78	0.64	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
KIRP	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	13.63	2.4e-32	2.67e-28	0.74	0.64	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	13.62	2.63e-32	2.92e-28	0.77	0.64	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	13.61	2.82e-32	3.13e-28	0.76	0.64	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	13.61	2.82e-32	3.13e-28	0.76	0.64	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	13.61	2.82e-32	3.13e-28	0.76	0.64	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
KIRP	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-13.61	2.89e-32	3.21e-28	-0.73	-0.64	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
KIRP	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-13.61	2.89e-32	3.21e-28	-0.73	-0.64	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
KIRP	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	13.61	2.98e-32	3.31e-28	0.86	0.64	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
KIRP	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	13.61	2.98e-32	3.31e-28	0.86	0.64	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	13.6	3.04e-32	3.37e-28	0.76	0.64	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	13.6	3.17e-32	3.51e-28	0.76	0.64	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
KIRP	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	13.59	3.37e-32	3.72e-28	0.87	0.64	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
KIRP	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	13.57	3.99e-32	4.39e-28	0.85	0.64	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
KIRP	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-13.57	4.01e-32	4.41e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
KIRP	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	13.56	4.13e-32	4.54e-28	0.85	0.64	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	13.56	4.13e-32	4.54e-28	0.85	0.64	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
KIRP	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	13.56	4.28e-32	4.7e-28	0.75	0.64	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
KIRP	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-13.56	4.32e-32	4.73e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
KIRP	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	13.55	4.7e-32	5.14e-28	0.73	0.64	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-13.54	4.93e-32	5.39e-28	-0.77	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
KIRP	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	13.54	5.06e-32	5.53e-28	0.76	0.64	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	13.54	5.07e-32	5.53e-28	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
KIRP	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-13.54	5.09e-32	5.54e-28	-0.62	-0.64	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	13.54	5.1e-32	5.54e-28	0.63	0.64	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-13.54	5.1e-32	5.54e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	13.54	5.2e-32	5.65e-28	0.76	0.64	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	13.53	5.32e-32	5.77e-28	0.67	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
KIRP	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	13.53	5.56e-32	6.02e-28	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
KIRP	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-13.53	5.56e-32	6.02e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-13.53	5.56e-32	6.02e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-13.53	5.56e-32	6.02e-28	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	13.52	5.82e-32	6.29e-28	0.75	0.64	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-13.52	5.91e-32	6.39e-28	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	13.51	6.59e-32	7.12e-28	0.76	0.64	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
KIRP	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	13.48	8.24e-32	8.83e-28	0.84	0.64	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
KIRP	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	13.47	8.53e-32	9.13e-28	0.76	0.64	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	13.47	8.7e-32	9.29e-28	0.74	0.64	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	13.47	8.7e-32	9.29e-28	0.74	0.64	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	13.47	8.7e-32	9.29e-28	0.74	0.64	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	13.47	8.7e-32	9.29e-28	0.74	0.64	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
KIRP	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-13.47	8.72e-32	9.31e-28	-0.71	-0.64	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
KIRP	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	13.47	9.19e-32	9.78e-28	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
KIRP	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	13.46	9.51e-32	1.01e-27	0.84	0.64	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	13.46	9.51e-32	1.01e-27	0.84	0.64	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	13.46	9.55e-32	1.01e-27	0.84	0.64	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	13.46	9.81e-32	1.04e-27	0.84	0.64	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	13.45	1e-31	1.06e-27	0.85	0.64	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
KIRP	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-13.45	1.05e-31	1.1e-27	-0.62	-0.64	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	13.44	1.08e-31	1.14e-27	0.74	0.64	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
KIRP	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-13.44	1.09e-31	1.15e-27	-0.72	-0.64	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-13.43	1.18e-31	1.24e-27	-0.72	-0.64	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
KIRP	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	13.43	1.2e-31	1.27e-27	0.76	0.64	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	13.43	1.2e-31	1.27e-27	0.76	0.64	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
KIRP	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-13.43	1.24e-31	1.31e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-13.43	1.24e-31	1.31e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
KIRP	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-13.42	1.27e-31	1.34e-27	-0.87	-0.64	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
KIRP	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-13.42	1.32e-31	1.39e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
KIRP	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	13.42	1.34e-31	1.4e-27	0.85	0.64	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	13.41	1.4e-31	1.46e-27	0.76	0.64	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	13.41	1.43e-31	1.49e-27	0.66	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
KIRP	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-13.41	1.43e-31	1.5e-27	-0.62	-0.64	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
KIRP	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-13.41	1.47e-31	1.53e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-13.41	1.47e-31	1.53e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-13.41	1.47e-31	1.53e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-13.4	1.49e-31	1.55e-27	-0.62	-0.64	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-13.4	1.49e-31	1.55e-27	-0.62	-0.64	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
KIRP	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-13.4	1.52e-31	1.58e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-13.4	1.52e-31	1.58e-27	-0.75	-0.64	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-13.4	1.56e-31	1.63e-27	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-13.4	1.56e-31	1.63e-27	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-13.39	1.62e-31	1.68e-27	-0.63	-0.64	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
KIRP	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	13.39	1.65e-31	1.71e-27	0.72	0.64	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	13.39	1.7e-31	1.77e-27	0.76	0.64	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	13.39	1.7e-31	1.77e-27	0.76	0.64	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
KIRP	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	13.38	1.75e-31	1.81e-27	0.84	0.64	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	13.38	1.79e-31	1.85e-27	0.84	0.64	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
KIRP	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-13.38	1.81e-31	1.87e-27	-0.82	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-13.38	1.81e-31	1.87e-27	-0.82	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
KIRP	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-13.37	1.91e-31	1.97e-27	-0.74	-0.64	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
KIRP	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	13.37	2e-31	2.06e-27	0.72	0.64	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	13.36	2.05e-31	2.11e-27	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
KIRP	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	13.35	2.31e-31	2.37e-27	0.85	0.64	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	13.34	2.47e-31	2.54e-27	0.7	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
KIRP	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	13.34	2.54e-31	2.61e-27	0.83	0.64	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	13.34	2.54e-31	2.61e-27	0.83	0.64	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	13.31	3.15e-31	3.22e-27	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
KIRP	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	13.31	3.18e-31	3.26e-27	0.83	0.64	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
KIRP	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	13.3	3.55e-31	3.61e-27	0.74	0.63	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-13.27	4.28e-31	4.33e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-13.27	4.28e-31	4.33e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-13.27	4.28e-31	4.33e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-13.27	4.28e-31	4.33e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-13.27	4.28e-31	4.33e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-13.27	4.31e-31	4.36e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	13.26	4.83e-31	4.85e-27	0.72	0.63	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
KIRP	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-13.25	4.95e-31	4.97e-27	-0.76	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
KIRP	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	13.24	5.38e-31	5.38e-27	0.83	0.63	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
KIRP	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-13.24	5.74e-31	5.73e-27	-0.64	-0.63	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
KIRP	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-13.23	5.79e-31	5.78e-27	-0.72	-0.63	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
KIRP	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-13.22	6.6e-31	6.53e-27	-0.62	-0.63	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-13.22	6.6e-31	6.53e-27	-0.62	-0.63	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	13.2	7.67e-31	7.53e-27	0.76	0.63	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
KIRP	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	13.19	8.14e-31	7.98e-27	0.85	0.63	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
KIRP	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	13.19	8.14e-31	7.98e-27	0.85	0.63	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
KIRP	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	13.19	8.4e-31	8.22e-27	0.72	0.63	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	13.19	8.4e-31	8.22e-27	0.72	0.63	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
KIRP	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	13.17	9.67e-31	9.43e-27	0.85	0.63	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
KIRP	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-13.17	9.78e-31	9.54e-27	-0.74	-0.63	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
KIRP	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	13.17	9.84e-31	9.59e-27	0.79	0.63	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
KIRP	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-13.17	9.94e-31	9.69e-27	-0.72	-0.63	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
KIRP	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-13.15	1.14e-30	1.11e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-13.15	1.14e-30	1.11e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-13.15	1.14e-30	1.11e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-13.14	1.19e-30	1.15e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-13.14	1.19e-30	1.15e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-13.14	1.19e-30	1.15e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-13.14	1.19e-30	1.15e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
KIRP	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	13.14	1.21e-30	1.17e-26	0.83	0.63	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
KIRP	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-13.14	1.27e-30	1.22e-26	-0.69	-0.63	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
KIRP	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-13.12	1.39e-30	1.34e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-13.12	1.39e-30	1.34e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-13.12	1.41e-30	1.36e-26	-0.77	-0.63	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-13.12	1.43e-30	1.38e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-13.12	1.43e-30	1.38e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
KIRP	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	13.11	1.53e-30	1.47e-26	0.77	0.63	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
KIRP	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-13.11	1.57e-30	1.5e-26	-0.65	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	13.1	1.74e-30	1.66e-26	0.82	0.63	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	13.09	1.79e-30	1.7e-26	0.67	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
KIRP	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-13.09	1.89e-30	1.79e-26	-0.81	-0.63	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
KIRP	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	13.08	1.99e-30	1.89e-26	0.75	0.63	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
KIRP	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-13.08	2.01e-30	1.9e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
KIRP	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	13.08	2.03e-30	1.92e-26	0.66	0.63	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
KIRP	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-13.07	2.22e-30	2.1e-26	-0.98	-0.63	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
KIRP	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	13.05	2.48e-30	2.33e-26	0.8	0.63	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
KIRP	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-13.05	2.49e-30	2.35e-26	-0.86	-0.63	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	13.05	2.53e-30	2.38e-26	0.81	0.63	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-13.05	2.54e-30	2.39e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-13.05	2.54e-30	2.39e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-13.05	2.54e-30	2.39e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	13.04	2.63e-30	2.46e-26	0.74	0.63	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
KIRP	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	13.04	2.78e-30	2.6e-26	0.73	0.63	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
KIRP	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-13.04	2.79e-30	2.62e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-13.03	2.94e-30	2.75e-26	-0.65	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
KIRP	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-13.03	2.98e-30	2.79e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
KIRP	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	13.03	3.01e-30	2.81e-26	0.66	0.63	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
KIRP	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	13.03	3.01e-30	2.81e-26	0.66	0.63	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
KIRP	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-13.02	3.15e-30	2.94e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-13.02	3.21e-30	2.99e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-13.02	3.33e-30	3.1e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-13.01	3.37e-30	3.14e-26	-0.61	-0.63	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-13.01	3.37e-30	3.14e-26	-0.61	-0.63	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
KIRP	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-13.01	3.53e-30	3.27e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-13.01	3.53e-30	3.27e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-13.01	3.53e-30	3.27e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-13.01	3.53e-30	3.27e-26	-0.73	-0.63	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
KIRP	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	13.01	3.53e-30	3.27e-26	0.82	0.63	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	13.01	3.53e-30	3.27e-26	0.82	0.63	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	13.01	3.53e-30	3.27e-26	0.82	0.63	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
KIRP	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	13.01	3.57e-30	3.31e-26	0.85	0.63	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
KIRP	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-13	3.73e-30	3.45e-26	-0.78	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	13	3.77e-30	3.49e-26	0.73	0.63	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
KIRP	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	12.97	4.58e-30	4.22e-26	0.72	0.63	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-12.97	4.94e-30	4.54e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-12.97	4.94e-30	4.54e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-12.97	4.94e-30	4.54e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-12.97	4.94e-30	4.54e-26	-0.72	-0.63	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
KIRP	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-12.97	4.94e-30	4.54e-26	-0.72	-0.63	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	12.96	5.18e-30	4.74e-26	0.72	0.62	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	12.95	5.39e-30	4.94e-26	0.72	0.62	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
KIRP	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	12.95	5.44e-30	4.98e-26	0.65	0.62	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	12.95	5.5e-30	5.03e-26	0.73	0.62	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
KIRP	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	12.95	5.67e-30	5.18e-26	0.92	0.62	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
KIRP	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	12.95	5.73e-30	5.23e-26	0.74	0.62	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-12.94	5.84e-30	5.33e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
KIRP	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	12.93	6.6e-30	5.97e-26	0.82	0.62	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
KIRP	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	12.91	7.54e-30	6.79e-26	0.6	0.62	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
KIRP	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-12.91	7.56e-30	6.81e-26	-0.73	-0.62	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
KIRP	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	12.91	7.61e-30	6.85e-26	0.8	0.62	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
KIRP	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-12.9	8.21e-30	7.36e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
KIRP	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-12.9	8.32e-30	7.46e-26	-0.75	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-12.9	8.61e-30	7.71e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-12.9	8.61e-30	7.71e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-12.9	8.61e-30	7.71e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-12.89	8.83e-30	7.9e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-12.89	8.83e-30	7.9e-26	-0.72	-0.62	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	12.89	8.83e-30	7.9e-26	0.72	0.62	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
KIRP	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	12.88	9.78e-30	8.7e-26	0.8	0.62	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
KIRP	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	12.87	1.05e-29	9.32e-26	0.71	0.62	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
KIRP	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-12.86	1.14e-29	1.01e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-12.86	1.16e-29	1.03e-25	-0.54	-0.62	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
KIRP	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	12.86	1.17e-29	1.04e-25	0.73	0.62	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-12.85	1.27e-29	1.12e-25	-0.72	-0.62	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
KIRP	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-12.84	1.3e-29	1.14e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	12.84	1.37e-29	1.21e-25	0.67	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
KIRP	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-12.84	1.39e-29	1.22e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-12.84	1.39e-29	1.22e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
KIRP	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-12.83	1.42e-29	1.25e-25	-0.71	-0.62	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-12.83	1.43e-29	1.26e-25	-0.73	-0.62	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-12.83	1.43e-29	1.26e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-12.83	1.43e-29	1.26e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-12.83	1.43e-29	1.26e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-12.83	1.43e-29	1.26e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-12.83	1.43e-29	1.26e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
KIRP	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	12.83	1.45e-29	1.27e-25	0.91	0.62	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
KIRP	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	12.82	1.53e-29	1.34e-25	0.7	0.62	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
KIRP	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	12.82	1.58e-29	1.38e-25	0.9	0.62	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
KIRP	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-12.81	1.68e-29	1.47e-25	-0.72	-0.62	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
KIRP	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	12.81	1.71e-29	1.5e-25	0.68	0.62	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
KIRP	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	12.8	1.84e-29	1.61e-25	0.72	0.62	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	12.8	1.84e-29	1.61e-25	0.72	0.62	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
KIRP	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	12.79	1.94e-29	1.69e-25	0.92	0.62	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-12.79	2.03e-29	1.77e-25	-0.75	-0.62	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-12.79	2.03e-29	1.77e-25	-0.75	-0.62	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-12.78	2.09e-29	1.81e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-12.78	2.17e-29	1.88e-25	-0.73	-0.62	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-12.78	2.19e-29	1.89e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-12.78	2.19e-29	1.89e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-12.78	2.19e-29	1.89e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-12.78	2.23e-29	1.93e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-12.77	2.25e-29	1.94e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-12.76	2.45e-29	2.11e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-12.76	2.45e-29	2.11e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-12.76	2.45e-29	2.11e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-12.76	2.53e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-12.76	2.54e-29	2.17e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-12.75	2.65e-29	2.27e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-12.75	2.69e-29	2.3e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-12.75	2.69e-29	2.3e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-12.75	2.69e-29	2.3e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-12.75	2.69e-29	2.3e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-12.75	2.69e-29	2.3e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-12.75	2.71e-29	2.31e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
KIRP	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-12.74	2.94e-29	2.5e-25	-0.53	-0.62	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
KIRP	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	12.74	3e-29	2.55e-25	0.78	0.62	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-12.74	3.06e-29	2.6e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
KIRP	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	12.73	3.1e-29	2.63e-25	0.84	0.62	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
KIRP	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-12.73	3.14e-29	2.66e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
KIRP	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
KIRP	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-12.73	3.23e-29	2.73e-25	-0.53	-0.62	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
KIRP	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	12.73	3.27e-29	2.76e-25	0.98	0.62	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-12.72	3.42e-29	2.89e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-12.72	3.46e-29	2.91e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	12.72	3.59e-29	3.02e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
KIRP	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	12.71	3.62e-29	3.04e-25	0.73	0.62	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	12.71	3.62e-29	3.04e-25	0.74	0.62	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	12.71	3.69e-29	3.09e-25	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
KIRP	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	12.7	4.01e-29	3.36e-25	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	12.7	4.17e-29	3.49e-25	0.78	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
KIRP	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-12.69	4.28e-29	3.58e-25	-0.71	-0.62	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	12.68	4.89e-29	4.07e-25	0.67	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
KIRP	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	12.68	4.92e-29	4.09e-25	0.72	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	12.68	4.93e-29	4.1e-25	0.67	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
KIRP	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	12.67	5.12e-29	4.26e-25	0.74	0.62	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-12.67	5.32e-29	4.42e-25	-0.76	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-12.66	5.54e-29	4.6e-25	-0.76	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-12.66	5.6e-29	4.65e-25	-0.71	-0.62	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-12.66	5.6e-29	4.65e-25	-0.71	-0.62	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-12.65	5.85e-29	4.86e-25	-0.7	-0.62	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	12.64	6.46e-29	5.36e-25	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	12.64	6.46e-29	5.36e-25	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-12.64	6.5e-29	5.38e-25	-0.71	-0.62	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	12.64	6.53e-29	5.41e-25	0.89	0.62	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-12.64	6.58e-29	5.44e-25	-0.72	-0.62	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
KIRP	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	12.63	7.09e-29	5.85e-25	0.72	0.62	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
KIRP	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	12.62	7.59e-29	6.25e-25	0.53	0.61	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
KIRP	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	12.62	7.88e-29	6.46e-25	0.71	0.61	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	12.61	8.31e-29	6.81e-25	0.87	0.61	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-12.61	8.39e-29	6.87e-25	-0.72	-0.61	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
KIRP	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-12.6	8.79e-29	7.19e-25	-0.71	-0.61	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
KIRP	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-12.6	8.79e-29	7.19e-25	-0.71	-0.61	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-12.6	8.79e-29	7.19e-25	-0.71	-0.61	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
KIRP	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	12.6	9.1e-29	7.44e-25	0.64	0.61	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
KIRP	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	12.6	9.12e-29	7.45e-25	0.71	0.61	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
KIRP	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	12.59	9.52e-29	7.76e-25	0.64	0.61	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	12.59	9.52e-29	7.76e-25	0.64	0.61	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	12.59	9.52e-29	7.76e-25	0.64	0.61	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	12.58	1.04e-28	8.42e-25	0.64	0.61	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-12.58	1.07e-28	8.69e-25	-0.72	-0.61	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-12.58	1.08e-28	8.74e-25	-0.71	-0.61	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-12.57	1.09e-28	8.87e-25	-0.74	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	12.57	1.17e-28	9.49e-25	0.7	0.61	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-12.56	1.22e-28	9.93e-25	-0.53	-0.61	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-12.56	1.22e-28	9.93e-25	-0.53	-0.61	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
KIRP	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-12.56	1.22e-28	9.93e-25	-0.53	-0.61	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
KIRP	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-12.55	1.29e-28	1.04e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-12.55	1.32e-28	1.07e-24	-0.53	-0.61	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-12.55	1.35e-28	1.09e-24	-0.53	-0.61	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
KIRP	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-12.55	1.36e-28	1.09e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
KIRP	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	12.54	1.42e-28	1.14e-24	0.64	0.61	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	12.53	1.54e-28	1.24e-24	0.71	0.61	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
KIRP	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-12.53	1.57e-28	1.26e-24	-0.53	-0.61	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-12.53	1.57e-28	1.26e-24	-0.53	-0.61	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
KIRP	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	12.52	1.62e-28	1.31e-24	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-12.52	1.63e-28	1.31e-24	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	12.52	1.69e-28	1.36e-24	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	12.52	1.7e-28	1.37e-24	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-12.52	1.74e-28	1.4e-24	-0.63	-0.61	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
KIRP	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	12.51	1.79e-28	1.44e-24	0.69	0.61	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
KIRP	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-12.51	1.87e-28	1.5e-24	-0.58	-0.61	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
KIRP	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	12.5	1.89e-28	1.52e-24	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
KIRP	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-12.5	1.99e-28	1.6e-24	-0.63	-0.61	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
KIRP	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	12.49	2.05e-28	1.64e-24	0.98	0.61	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
KIRP	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	12.48	2.3e-28	1.83e-24	0.7	0.61	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-12.47	2.41e-28	1.92e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-12.47	2.41e-28	1.92e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	12.47	2.46e-28	1.96e-24	0.7	0.61	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
KIRP	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	12.47	2.57e-28	2.04e-24	0.91	0.61	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
KIRP	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-12.46	2.71e-28	2.15e-24	-0.85	-0.61	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
KIRP	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-12.45	2.88e-28	2.28e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
KIRP	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	12.44	3.03e-28	2.4e-24	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	12.44	3.12e-28	2.47e-24	0.84	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
KIRP	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	12.44	3.15e-28	2.49e-24	0.87	0.61	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	12.44	3.15e-28	2.49e-24	0.87	0.61	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	12.44	3.15e-28	2.49e-24	0.87	0.61	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-12.44	3.27e-28	2.59e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	12.43	3.3e-28	2.61e-24	0.86	0.61	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
KIRP	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-12.43	3.42e-28	2.7e-24	-0.71	-0.61	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
KIRP	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-12.41	3.84e-28	3.02e-24	-0.49	-0.61	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
KIRP	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	12.41	4.01e-28	3.14e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	12.41	4.01e-28	3.14e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	12.41	4.01e-28	3.14e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	12.41	4.01e-28	3.14e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	12.41	4.01e-28	3.14e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
KIRP	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	12.41	4.11e-28	3.22e-24	0.77	0.61	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
KIRP	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	12.4	4.23e-28	3.3e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
KIRP	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	12.4	4.32e-28	3.38e-24	0.54	0.61	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
KIRP	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-12.4	4.34e-28	3.39e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
KIRP	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	12.39	4.52e-28	3.53e-24	1.01	0.61	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
KIRP	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-12.39	4.68e-28	3.64e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-12.39	4.81e-28	3.74e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
KIRP	cis	rs2698530	0.634	rs2555438	ENSG00000225889.6	AC074289.1	-12.38	4.97e-28	3.87e-24	-0.56	-0.61	Iron status biomarkers;	chr2:64248986	chr2:64143239~64252859:+
KIRP	cis	rs2698530	0.624	rs2247947	ENSG00000225889.6	AC074289.1	-12.38	4.97e-28	3.87e-24	-0.56	-0.61	Iron status biomarkers;	chr2:64249344	chr2:64143239~64252859:+
KIRP	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	12.38	5.21e-28	4.05e-24	0.95	0.61	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	12.38	5.21e-28	4.05e-24	0.95	0.61	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	12.38	5.21e-28	4.05e-24	0.95	0.61	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	12.38	5.21e-28	4.05e-24	0.95	0.61	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
KIRP	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-12.37	5.42e-28	4.21e-24	-0.69	-0.61	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
KIRP	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	12.37	5.48e-28	4.26e-24	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
KIRP	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
KIRP	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
KIRP	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
KIRP	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
KIRP	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-12.36	6.03e-28	4.66e-24	-0.52	-0.61	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
KIRP	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-12.36	6.09e-28	4.71e-24	-0.63	-0.61	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
KIRP	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	12.36	6.12e-28	4.74e-24	0.89	0.61	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
KIRP	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-12.35	6.35e-28	4.9e-24	-0.7	-0.61	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-12.35	6.35e-28	4.9e-24	-0.7	-0.61	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-12.35	6.35e-28	4.9e-24	-0.7	-0.61	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-12.35	6.45e-28	4.98e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
KIRP	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	12.35	6.63e-28	5.11e-24	0.77	0.61	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	12.34	6.68e-28	5.15e-24	0.65	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
KIRP	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	12.33	7.27e-28	5.6e-24	0.7	0.61	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	12.33	7.27e-28	5.6e-24	0.67	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
KIRP	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-12.33	7.42e-28	5.71e-24	-0.71	-0.61	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
KIRP	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-12.33	7.61e-28	5.86e-24	-0.71	-0.61	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
KIRP	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	12.32	7.84e-28	6.03e-24	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-12.32	7.87e-28	6.05e-24	-0.71	-0.61	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	12.32	7.95e-28	6.11e-24	0.53	0.61	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
KIRP	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	12.31	8.63e-28	6.63e-24	0.64	0.61	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
KIRP	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	12.31	8.76e-28	6.73e-24	0.78	0.61	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
KIRP	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	12.31	8.86e-28	6.8e-24	0.78	0.61	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
KIRP	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-12.3	9.13e-28	7.01e-24	-0.5	-0.61	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
KIRP	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	12.3	9.22e-28	7.08e-24	0.81	0.61	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	12.3	9.32e-28	7.15e-24	0.81	0.61	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-12.3	9.34e-28	7.16e-24	-0.74	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	12.3	9.37e-28	7.18e-24	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
KIRP	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-12.3	9.43e-28	7.23e-24	-0.68	-0.61	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
KIRP	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	12.3	9.48e-28	7.27e-24	0.76	0.61	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
KIRP	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	12.29	9.87e-28	7.55e-24	0.79	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
KIRP	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-12.29	1.01e-27	7.73e-24	-0.52	-0.6	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-12.29	1.01e-27	7.73e-24	-0.52	-0.6	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
KIRP	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	12.29	1.04e-27	7.94e-24	0.83	0.6	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
KIRP	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-12.28	1.13e-27	8.6e-24	-0.52	-0.6	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
KIRP	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	12.27	1.21e-27	9.18e-24	0.68	0.6	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
KIRP	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	12.26	1.28e-27	9.74e-24	0.76	0.6	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	12.26	1.29e-27	9.83e-24	0.7	0.6	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	12.26	1.29e-27	9.83e-24	0.7	0.6	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	12.26	1.29e-27	9.83e-24	0.7	0.6	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	12.26	1.3e-27	9.86e-24	0.69	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
KIRP	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	12.26	1.3e-27	9.88e-24	0.88	0.6	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
KIRP	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	12.26	1.31e-27	9.94e-24	0.53	0.6	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
KIRP	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	12.26	1.31e-27	9.94e-24	0.53	0.6	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
KIRP	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-12.25	1.37e-27	1.04e-23	-0.5	-0.6	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
KIRP	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-12.25	1.39e-27	1.06e-23	-0.7	-0.6	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	12.25	1.4e-27	1.06e-23	0.66	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
KIRP	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-12.25	1.41e-27	1.06e-23	-0.53	-0.6	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
KIRP	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-12.25	1.43e-27	1.08e-23	-0.79	-0.6	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
KIRP	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	12.25	1.45e-27	1.1e-23	0.88	0.6	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	12.24	1.49e-27	1.13e-23	0.88	0.6	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
KIRP	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	12.24	1.49e-27	1.13e-23	0.53	0.6	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
KIRP	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	12.23	1.64e-27	1.24e-23	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
KIRP	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	12.23	1.65e-27	1.24e-23	0.71	0.6	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	12.23	1.65e-27	1.24e-23	0.71	0.6	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	12.23	1.65e-27	1.24e-23	0.71	0.6	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	12.23	1.67e-27	1.26e-23	0.69	0.6	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	12.23	1.67e-27	1.26e-23	0.69	0.6	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	12.23	1.67e-27	1.26e-23	0.69	0.6	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-12.23	1.67e-27	1.26e-23	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-12.23	1.67e-27	1.26e-23	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
KIRP	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	12.23	1.68e-27	1.26e-23	0.76	0.6	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
KIRP	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-12.23	1.69e-27	1.27e-23	-0.67	-0.6	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-12.22	1.73e-27	1.3e-23	-0.8	-0.6	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
KIRP	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	12.22	1.74e-27	1.31e-23	0.71	0.6	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	12.22	1.84e-27	1.38e-23	0.7	0.6	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
KIRP	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	12.21	1.87e-27	1.4e-23	0.53	0.6	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
KIRP	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	12.21	1.88e-27	1.41e-23	0.71	0.6	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
KIRP	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-12.2	2e-27	1.49e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-12.2	2.04e-27	1.53e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-12.2	2.04e-27	1.53e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
KIRP	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	12.18	2.4e-27	1.79e-23	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
KIRP	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	12.18	2.4e-27	1.79e-23	0.7	0.6	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-12.18	2.45e-27	1.82e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
KIRP	cis	rs2698530	0.634	rs6750096	ENSG00000225889.6	AC074289.1	-12.18	2.45e-27	1.83e-23	-0.57	-0.6	Iron status biomarkers;	chr2:64246935	chr2:64143239~64252859:+
KIRP	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-12.18	2.46e-27	1.83e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-12.18	2.46e-27	1.83e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-12.18	2.46e-27	1.83e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
KIRP	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-12.18	2.48e-27	1.85e-23	-0.7	-0.6	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-12.18	2.48e-27	1.85e-23	-0.7	-0.6	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
KIRP	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-12.17	2.52e-27	1.87e-23	-0.6	-0.6	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
KIRP	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-12.17	2.53e-27	1.88e-23	-0.69	-0.6	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
KIRP	cis	rs2698530	0.634	rs1365482	ENSG00000225889.6	AC074289.1	12.17	2.55e-27	1.89e-23	0.55	0.6	Iron status biomarkers;	chr2:64248838	chr2:64143239~64252859:+
KIRP	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-12.17	2.56e-27	1.9e-23	-0.7	-0.6	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-12.16	2.83e-27	2.1e-23	-0.71	-0.6	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
KIRP	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-12.16	2.91e-27	2.15e-23	-0.7	-0.6	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-12.15	2.97e-27	2.19e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-12.15	2.97e-27	2.19e-23	-0.71	-0.6	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
KIRP	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	12.15	3.06e-27	2.26e-23	0.95	0.6	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
KIRP	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-12.15	3.16e-27	2.33e-23	-0.71	-0.6	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
KIRP	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-12.15	3.17e-27	2.34e-23	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
KIRP	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-12.14	3.22e-27	2.37e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
KIRP	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-12.14	3.23e-27	2.38e-23	-0.7	-0.6	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-12.14	3.23e-27	2.38e-23	-0.7	-0.6	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-12.14	3.23e-27	2.38e-23	-0.7	-0.6	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-12.14	3.23e-27	2.38e-23	-0.7	-0.6	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-12.14	3.23e-27	2.38e-23	-0.7	-0.6	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
KIRP	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-12.14	3.38e-27	2.49e-23	-0.59	-0.6	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
KIRP	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-12.13	3.45e-27	2.54e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-12.13	3.45e-27	2.54e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-12.13	3.45e-27	2.54e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
KIRP	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-12.13	3.47e-27	2.55e-23	-0.7	-0.6	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
KIRP	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	12.13	3.49e-27	2.57e-23	0.8	0.6	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
KIRP	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-12.13	3.52e-27	2.59e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-12.13	3.58e-27	2.63e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
KIRP	cis	rs2698530	0.634	rs1019685	ENSG00000225889.6	AC074289.1	-12.13	3.66e-27	2.68e-23	-0.57	-0.6	Iron status biomarkers;	chr2:64233984	chr2:64143239~64252859:+
KIRP	cis	rs2698530	0.634	rs2059634	ENSG00000225889.6	AC074289.1	-12.13	3.66e-27	2.68e-23	-0.57	-0.6	Iron status biomarkers;	chr2:64234480	chr2:64143239~64252859:+
KIRP	cis	rs2698530	0.634	rs2555425	ENSG00000225889.6	AC074289.1	-12.13	3.66e-27	2.68e-23	-0.57	-0.6	Iron status biomarkers;	chr2:64239648	chr2:64143239~64252859:+
KIRP	cis	rs2698530	0.634	rs2555426	ENSG00000225889.6	AC074289.1	-12.13	3.66e-27	2.68e-23	-0.57	-0.6	Iron status biomarkers;	chr2:64243051	chr2:64143239~64252859:+
KIRP	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	12.13	3.69e-27	2.71e-23	0.67	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
KIRP	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-12.12	3.79e-27	2.78e-23	-0.69	-0.6	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	12.12	3.82e-27	2.79e-23	0.66	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
KIRP	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	12.12	3.87e-27	2.83e-23	0.62	0.6	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
KIRP	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	12.12	3.96e-27	2.88e-23	0.95	0.6	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
KIRP	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	12.12	4.01e-27	2.92e-23	0.78	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
KIRP	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-12.12	4.02e-27	2.93e-23	-0.58	-0.6	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
KIRP	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	12.11	4.12e-27	3e-23	0.79	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
KIRP	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	12.11	4.25e-27	3.09e-23	0.58	0.6	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
KIRP	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-12.11	4.3e-27	3.13e-23	-0.7	-0.6	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-12.11	4.34e-27	3.15e-23	-0.7	-0.6	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
KIRP	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	12.1	4.41e-27	3.21e-23	0.67	0.6	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
KIRP	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-12.1	4.43e-27	3.21e-23	-0.7	-0.6	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	12.09	4.95e-27	3.58e-23	0.69	0.6	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	12.09	4.95e-27	3.58e-23	0.69	0.6	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	12.09	4.95e-27	3.58e-23	0.69	0.6	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
KIRP	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	12.09	4.99e-27	3.61e-23	0.87	0.6	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
KIRP	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-12.08	5.13e-27	3.71e-23	-0.69	-0.6	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
KIRP	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	12.08	5.17e-27	3.74e-23	0.63	0.6	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-12.07	5.54e-27	4e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
KIRP	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-12.07	5.72e-27	4.13e-23	-0.8	-0.6	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
KIRP	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-12.07	5.87e-27	4.24e-23	-0.52	-0.6	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
KIRP	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-12.06	5.98e-27	4.31e-23	-0.7	-0.6	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	12.06	6.01e-27	4.33e-23	0.7	0.6	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
KIRP	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	12.06	6.01e-27	4.33e-23	0.85	0.6	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	12.06	6.01e-27	4.33e-23	0.85	0.6	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	12.06	6.01e-27	4.33e-23	0.85	0.6	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	12.06	6.01e-27	4.33e-23	0.85	0.6	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
KIRP	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-12.05	6.65e-27	4.78e-23	-0.71	-0.6	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-12.05	6.65e-27	4.78e-23	-0.71	-0.6	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	12.05	6.68e-27	4.8e-23	0.84	0.6	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
KIRP	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-12.05	6.81e-27	4.89e-23	-0.7	-0.6	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	12.05	6.85e-27	4.91e-23	0.62	0.6	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
KIRP	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-12.05	6.94e-27	4.97e-23	-0.7	-0.6	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-12.05	6.94e-27	4.97e-23	-0.7	-0.6	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
KIRP	cis	rs2698530	0.634	rs1582792	ENSG00000225889.6	AC074289.1	-12.04	7.08e-27	5.08e-23	-0.56	-0.6	Iron status biomarkers;	chr2:64250409	chr2:64143239~64252859:+
KIRP	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	12.04	7.09e-27	5.09e-23	0.83	0.6	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
KIRP	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-12.04	7.21e-27	5.16e-23	-0.7	-0.6	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-12.04	7.21e-27	5.16e-23	-0.7	-0.6	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-12.04	7.21e-27	5.16e-23	-0.7	-0.6	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-12.04	7.21e-27	5.16e-23	-0.7	-0.6	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-12.04	7.25e-27	5.19e-23	-0.7	-0.6	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-12.04	7.25e-27	5.19e-23	-0.7	-0.6	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-12.04	7.34e-27	5.25e-23	-0.7	-0.6	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	12.04	7.42e-27	5.3e-23	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
KIRP	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-12.03	7.58e-27	5.41e-23	-0.66	-0.6	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
KIRP	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-12.03	7.65e-27	5.46e-23	-0.52	-0.6	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
KIRP	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-12.03	7.65e-27	5.46e-23	-0.52	-0.6	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
KIRP	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-12.03	7.65e-27	5.46e-23	-0.52	-0.6	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
KIRP	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-12.02	8.19e-27	5.83e-23	-0.77	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
KIRP	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-12.02	8.39e-27	5.97e-23	-0.7	-0.6	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	12.02	8.47e-27	6.02e-23	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
KIRP	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	12.02	8.49e-27	6.04e-23	0.71	0.6	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
KIRP	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	12.02	8.53e-27	6.06e-23	0.81	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
KIRP	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-12.02	8.67e-27	6.16e-23	-0.7	-0.6	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-12.01	8.88e-27	6.3e-23	-0.7	-0.6	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-12.01	8.88e-27	6.3e-23	-0.7	-0.6	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
KIRP	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	12.01	8.98e-27	6.38e-23	0.76	0.6	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-12.01	9.02e-27	6.4e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-12.01	9.16e-27	6.5e-23	-0.7	-0.6	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
KIRP	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-12	9.67e-27	6.85e-23	-0.49	-0.6	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
KIRP	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-12	9.67e-27	6.85e-23	-0.49	-0.6	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
KIRP	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-12	9.95e-27	7.05e-23	-0.69	-0.6	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
KIRP	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	12	1e-26	7.11e-23	0.62	0.6	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
KIRP	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-11.99	1.06e-26	7.48e-23	-0.61	-0.6	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	11.99	1.1e-26	7.78e-23	0.75	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
KIRP	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	11.98	1.13e-26	8e-23	0.62	0.59	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	11.98	1.13e-26	8e-23	0.62	0.59	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	11.98	1.13e-26	8e-23	0.62	0.59	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	11.98	1.13e-26	8e-23	0.62	0.59	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	11.98	1.13e-26	8e-23	0.62	0.59	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
KIRP	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	11.98	1.15e-26	8.13e-23	0.69	0.59	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	11.98	1.15e-26	8.13e-23	0.69	0.59	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
KIRP	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	11.98	1.16e-26	8.15e-23	0.83	0.59	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
KIRP	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-11.98	1.2e-26	8.41e-23	-0.69	-0.59	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-11.98	1.2e-26	8.41e-23	-0.69	-0.59	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-11.98	1.2e-26	8.42e-23	-0.69	-0.59	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
KIRP	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	11.97	1.27e-26	8.93e-23	0.69	0.59	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	11.97	1.29e-26	9.08e-23	0.81	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
KIRP	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	11.96	1.31e-26	9.22e-23	0.65	0.59	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
KIRP	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	11.96	1.32e-26	9.23e-23	0.68	0.59	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	11.96	1.34e-26	9.37e-23	0.68	0.59	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	11.96	1.36e-26	9.54e-23	0.69	0.59	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
KIRP	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-11.96	1.36e-26	9.55e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-11.96	1.36e-26	9.55e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-11.96	1.36e-26	9.55e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-11.95	1.41e-26	9.86e-23	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	11.95	1.41e-26	9.86e-23	0.57	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
KIRP	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-11.95	1.43e-26	9.97e-23	-0.69	-0.59	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-11.95	1.45e-26	1.01e-22	-0.68	-0.59	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-11.95	1.45e-26	1.01e-22	-0.68	-0.59	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
KIRP	cis	rs2698530	0.634	rs2698523	ENSG00000225889.6	AC074289.1	-11.95	1.46e-26	1.02e-22	-0.55	-0.59	Iron status biomarkers;	chr2:64249202	chr2:64143239~64252859:+
KIRP	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-11.95	1.47e-26	1.03e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-11.95	1.47e-26	1.03e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-11.95	1.47e-26	1.03e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-11.95	1.47e-26	1.03e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
KIRP	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	11.95	1.48e-26	1.03e-22	0.63	0.59	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
KIRP	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	11.95	1.5e-26	1.04e-22	0.69	0.59	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
KIRP	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-11.94	1.52e-26	1.06e-22	-0.68	-0.59	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	11.94	1.53e-26	1.06e-22	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	11.94	1.59e-26	1.1e-22	0.65	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	11.94	1.61e-26	1.12e-22	0.65	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
KIRP	cis	rs858239	0.931	rs9690941	ENSG00000230658.1	KLHL7-AS1	11.93	1.65e-26	1.14e-22	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23242134	chr7:23101228~23105703:-
KIRP	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	11.93	1.74e-26	1.2e-22	0.66	0.59	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
KIRP	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	11.92	1.84e-26	1.27e-22	0.69	0.59	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	11.92	1.84e-26	1.27e-22	0.69	0.59	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	11.92	1.84e-26	1.27e-22	0.69	0.59	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	11.92	1.84e-26	1.27e-22	0.69	0.59	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-11.92	1.91e-26	1.32e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	11.91	1.96e-26	1.35e-22	0.67	0.59	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
KIRP	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	11.91	2e-26	1.38e-22	0.69	0.59	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-11.91	2.01e-26	1.39e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-11.9	2.11e-26	1.45e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-11.9	2.11e-26	1.45e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-11.9	2.11e-26	1.45e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-11.9	2.14e-26	1.47e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-11.89	2.27e-26	1.56e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
KIRP	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	11.89	2.28e-26	1.57e-22	0.67	0.59	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
KIRP	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	11.89	2.29e-26	1.57e-22	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
KIRP	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-11.89	2.31e-26	1.58e-22	-0.7	-0.59	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
KIRP	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	11.89	2.41e-26	1.65e-22	0.69	0.59	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
KIRP	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	11.89	2.41e-26	1.65e-22	0.81	0.59	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
KIRP	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-11.88	2.45e-26	1.68e-22	-0.66	-0.59	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
KIRP	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	11.87	2.66e-26	1.81e-22	0.68	0.59	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
KIRP	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	11.87	2.7e-26	1.84e-22	0.66	0.59	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	11.87	2.7e-26	1.84e-22	0.66	0.59	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	11.87	2.7e-26	1.84e-22	0.66	0.59	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	11.87	2.7e-26	1.84e-22	0.66	0.59	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
KIRP	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-11.87	2.73e-26	1.86e-22	-0.74	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
KIRP	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	11.87	2.77e-26	1.88e-22	0.68	0.59	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
KIRP	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	11.87	2.8e-26	1.9e-22	0.67	0.59	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
KIRP	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	11.86	2.85e-26	1.93e-22	0.8	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-11.86	2.86e-26	1.94e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
KIRP	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	11.86	2.93e-26	1.99e-22	0.7	0.59	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
KIRP	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-11.86	2.94e-26	1.99e-22	-0.7	-0.59	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-11.86	2.97e-26	2.01e-22	-0.58	-0.59	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-11.86	3.04e-26	2.06e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-11.86	3.04e-26	2.06e-22	-0.57	-0.59	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
KIRP	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-11.85	3.14e-26	2.12e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-11.85	3.16e-26	2.14e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-11.84	3.31e-26	2.23e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
KIRP	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-11.84	3.31e-26	2.23e-22	-0.69	-0.59	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
KIRP	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-11.84	3.37e-26	2.27e-22	-0.52	-0.59	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
KIRP	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-11.84	3.44e-26	2.31e-22	-0.67	-0.59	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
KIRP	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	11.84	3.47e-26	2.33e-22	0.62	0.59	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
KIRP	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	11.84	3.52e-26	2.36e-22	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
KIRP	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-11.83	3.58e-26	2.4e-22	-0.67	-0.59	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
KIRP	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	11.83	3.62e-26	2.42e-22	0.52	0.59	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
KIRP	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-11.83	3.62e-26	2.43e-22	-0.67	-0.59	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
KIRP	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-11.83	3.66e-26	2.45e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
KIRP	cis	rs2698530	0.634	rs1025210	ENSG00000225889.6	AC074289.1	-11.82	3.92e-26	2.61e-22	-0.55	-0.59	Iron status biomarkers;	chr2:64251945	chr2:64143239~64252859:+
KIRP	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	11.82	3.96e-26	2.63e-22	0.68	0.59	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
KIRP	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	11.82	3.98e-26	2.65e-22	0.66	0.59	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
KIRP	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	11.82	4.02e-26	2.68e-22	0.68	0.59	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
KIRP	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	11.81	4.28e-26	2.84e-22	0.66	0.59	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
KIRP	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-11.81	4.28e-26	2.85e-22	-0.66	-0.59	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
KIRP	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-11.81	4.34e-26	2.88e-22	-0.7	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	11.8	4.52e-26	3e-22	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
KIRP	cis	rs2698530	0.607	rs1019686	ENSG00000225889.6	AC074289.1	-11.8	4.63e-26	3.07e-22	-0.56	-0.59	Iron status biomarkers;	chr2:64234988	chr2:64143239~64252859:+
KIRP	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	11.8	4.82e-26	3.19e-22	0.67	0.59	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	11.8	4.84e-26	3.2e-22	0.81	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
KIRP	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-11.79	5e-26	3.31e-22	-0.66	-0.59	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
KIRP	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-11.78	5.29e-26	3.49e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-11.78	5.29e-26	3.49e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
KIRP	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	11.78	5.59e-26	3.68e-22	0.49	0.59	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
KIRP	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	11.77	5.77e-26	3.8e-22	0.69	0.59	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	11.77	5.88e-26	3.87e-22	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
KIRP	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-11.77	5.88e-26	3.87e-22	-0.66	-0.59	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
KIRP	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-11.77	5.9e-26	3.88e-22	-0.67	-0.59	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
KIRP	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	11.77	5.94e-26	3.91e-22	0.82	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
KIRP	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	11.77	5.98e-26	3.93e-22	0.65	0.59	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
KIRP	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	11.77	6.02e-26	3.96e-22	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
KIRP	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	11.77	6.04e-26	3.96e-22	0.68	0.59	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	11.77	6.04e-26	3.96e-22	0.68	0.59	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	11.77	6.04e-26	3.96e-22	0.68	0.59	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-11.76	6.24e-26	4.09e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-11.76	6.26e-26	4.1e-22	-0.67	-0.59	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
KIRP	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-11.76	6.34e-26	4.15e-22	-1.02	-0.59	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
KIRP	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	11.76	6.36e-26	4.16e-22	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-11.75	6.88e-26	4.49e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	11.75	7.01e-26	4.58e-22	0.81	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
KIRP	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	11.75	7.11e-26	4.64e-22	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
KIRP	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	11.74	7.67e-26	4.99e-22	0.66	0.59	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	11.74	7.67e-26	4.99e-22	0.66	0.59	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
KIRP	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-11.74	7.71e-26	5.02e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
KIRP	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-11.73	7.97e-26	5.18e-22	-0.69	-0.59	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
KIRP	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	11.73	8.12e-26	5.26e-22	0.68	0.59	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	11.73	8.15e-26	5.28e-22	0.75	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
KIRP	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-11.72	8.7e-26	5.63e-22	-0.68	-0.59	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
KIRP	cis	rs2698530	0.634	rs871776	ENSG00000225889.6	AC074289.1	-11.72	8.94e-26	5.78e-22	-0.57	-0.59	Iron status biomarkers;	chr2:64228540	chr2:64143239~64252859:+
KIRP	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-11.72	9.03e-26	5.83e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
KIRP	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-11.71	9.06e-26	5.85e-22	-0.66	-0.59	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
KIRP	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	11.71	9.06e-26	5.85e-22	0.64	0.59	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
KIRP	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-11.71	9.1e-26	5.88e-22	-0.67	-0.59	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
KIRP	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-11.71	9.23e-26	5.94e-22	-0.67	-0.59	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
KIRP	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	11.71	9.5e-26	6.1e-22	0.87	0.59	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
KIRP	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	11.71	9.62e-26	6.17e-22	0.62	0.59	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
KIRP	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-11.71	9.62e-26	6.17e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-11.71	9.67e-26	6.2e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-11.71	9.67e-26	6.2e-22	-0.7	-0.59	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
KIRP	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	11.7	9.83e-26	6.3e-22	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
KIRP	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-11.7	9.87e-26	6.32e-22	-0.53	-0.59	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
KIRP	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-11.7	9.91e-26	6.34e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
KIRP	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	11.7	9.98e-26	6.39e-22	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-11.7	9.99e-26	6.39e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-11.7	9.99e-26	6.39e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-11.7	9.99e-26	6.39e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-11.7	9.99e-26	6.39e-22	-0.69	-0.59	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
KIRP	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-11.7	1e-25	6.4e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	11.7	1.01e-25	6.47e-22	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-11.69	1.06e-25	6.78e-22	-0.71	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
KIRP	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	11.69	1.09e-25	6.95e-22	0.66	0.59	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	11.69	1.09e-25	6.95e-22	0.66	0.59	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
KIRP	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-11.69	1.09e-25	6.97e-22	-0.65	-0.59	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
KIRP	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-11.69	1.11e-25	7.09e-22	-0.68	-0.59	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	11.69	1.11e-25	7.09e-22	0.75	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-11.68	1.17e-25	7.44e-22	-0.68	-0.59	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
KIRP	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-11.68	1.19e-25	7.58e-22	-0.69	-0.59	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	11.67	1.33e-25	8.45e-22	0.68	0.58	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	11.66	1.35e-25	8.55e-22	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
KIRP	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-11.66	1.37e-25	8.65e-22	-0.57	-0.58	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
KIRP	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	11.66	1.42e-25	8.99e-22	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-11.65	1.44e-25	9.13e-22	-0.69	-0.58	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
KIRP	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	11.65	1.46e-25	9.23e-22	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
KIRP	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-11.65	1.49e-25	9.4e-22	-0.56	-0.58	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-11.65	1.49e-25	9.4e-22	-0.56	-0.58	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
KIRP	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-11.65	1.49e-25	9.45e-22	-0.67	-0.58	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-11.65	1.51e-25	9.55e-22	-0.57	-0.58	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
KIRP	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	11.65	1.51e-25	9.56e-22	0.66	0.58	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
KIRP	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	11.65	1.51e-25	9.56e-22	0.48	0.58	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	11.65	1.55e-25	9.77e-22	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
KIRP	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	11.64	1.57e-25	9.91e-22	0.68	0.58	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
KIRP	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	11.64	1.57e-25	9.93e-22	0.65	0.58	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
KIRP	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	11.64	1.58e-25	9.98e-22	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-11.64	1.58e-25	9.99e-22	-0.67	-0.58	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
KIRP	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	11.64	1.67e-25	1.05e-21	0.68	0.58	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-11.63	1.76e-25	1.11e-21	-0.67	-0.58	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
KIRP	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	11.62	1.86e-25	1.17e-21	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
KIRP	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	11.62	1.86e-25	1.17e-21	0.69	0.58	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	11.62	1.91e-25	1.2e-21	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
KIRP	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	11.62	1.92e-25	1.21e-21	0.65	0.58	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
KIRP	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-11.61	1.96e-25	1.23e-21	-0.6	-0.58	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
KIRP	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	11.61	2.07e-25	1.3e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
KIRP	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	11.6	2.16e-25	1.36e-21	0.79	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	11.6	2.27e-25	1.42e-21	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
KIRP	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	11.6	2.29e-25	1.43e-21	0.73	0.58	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	11.59	2.43e-25	1.52e-21	0.65	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
KIRP	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-11.59	2.46e-25	1.53e-21	-0.7	-0.58	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-11.58	2.49e-25	1.55e-21	-0.69	-0.58	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	11.58	2.49e-25	1.55e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-11.58	2.5e-25	1.56e-21	-0.68	-0.58	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
KIRP	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-11.58	2.58e-25	1.6e-21	-0.67	-0.58	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
KIRP	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-11.58	2.61e-25	1.62e-21	-0.68	-0.58	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
KIRP	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	11.58	2.66e-25	1.65e-21	0.47	0.58	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
KIRP	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	11.57	2.81e-25	1.74e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	11.57	2.81e-25	1.74e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	11.57	2.83e-25	1.76e-21	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
KIRP	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	11.57	2.87e-25	1.78e-21	0.7	0.58	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
KIRP	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	11.57	2.88e-25	1.78e-21	0.74	0.58	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
KIRP	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-11.56	2.91e-25	1.8e-21	-0.67	-0.58	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
KIRP	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	11.56	2.96e-25	1.83e-21	0.68	0.58	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
KIRP	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-11.56	2.97e-25	1.84e-21	-0.65	-0.58	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
KIRP	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	11.56	3e-25	1.86e-21	0.67	0.58	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	11.56	3.03e-25	1.87e-21	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
KIRP	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
KIRP	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	11.56	3.07e-25	1.9e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
KIRP	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	11.56	3.1e-25	1.92e-21	0.69	0.58	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	11.55	3.19e-25	1.97e-21	0.66	0.58	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	11.55	3.19e-25	1.97e-21	0.77	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
KIRP	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-11.55	3.33e-25	2.05e-21	-0.69	-0.58	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	11.54	3.37e-25	2.08e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
KIRP	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	11.54	3.42e-25	2.11e-21	0.49	0.58	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
KIRP	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-11.54	3.46e-25	2.13e-21	-0.67	-0.58	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	11.53	3.67e-25	2.26e-21	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	11.53	3.67e-25	2.26e-21	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	11.53	3.67e-25	2.26e-21	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
KIRP	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-11.53	3.71e-25	2.28e-21	-0.65	-0.58	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
KIRP	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	11.53	3.81e-25	2.34e-21	0.65	0.58	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
KIRP	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	11.53	3.9e-25	2.4e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
KIRP	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	11.52	4.05e-25	2.49e-21	0.48	0.58	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
KIRP	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	11.52	4.08e-25	2.5e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	11.52	4.08e-25	2.5e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	11.52	4.08e-25	2.5e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-11.52	4.15e-25	2.54e-21	-0.69	-0.58	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
KIRP	cis	rs9660180	0.967	rs66701417	ENSG00000231050.1	RP1-140A9.1	11.52	4.16e-25	2.55e-21	0.66	0.58	Body mass index;	chr1:1766653	chr1:1891471~1892658:+
KIRP	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	11.52	4.21e-25	2.58e-21	0.55	0.58	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
KIRP	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	11.51	4.28e-25	2.62e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
KIRP	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-11.51	4.36e-25	2.67e-21	-0.68	-0.58	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-11.51	4.36e-25	2.67e-21	-0.67	-0.58	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	11.51	4.39e-25	2.68e-21	0.67	0.58	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	11.51	4.39e-25	2.69e-21	0.67	0.58	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	11.51	4.39e-25	2.69e-21	0.67	0.58	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	11.51	4.39e-25	2.69e-21	0.67	0.58	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	11.51	4.4e-25	2.69e-21	0.67	0.58	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
KIRP	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-11.51	4.48e-25	2.74e-21	-0.6	-0.58	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
KIRP	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-11.5	4.63e-25	2.83e-21	-0.66	-0.58	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
KIRP	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-11.5	4.87e-25	2.97e-21	-0.67	-0.58	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
KIRP	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	11.49	5.06e-25	3.09e-21	0.67	0.58	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
KIRP	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	11.49	5.22e-25	3.17e-21	0.66	0.58	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
KIRP	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	11.49	5.25e-25	3.19e-21	0.59	0.58	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
KIRP	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-11.49	5.28e-25	3.21e-21	-0.69	-0.58	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
KIRP	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	11.49	5.34e-25	3.24e-21	0.79	0.58	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
KIRP	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	11.48	5.36e-25	3.26e-21	0.67	0.58	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
KIRP	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	11.48	5.39e-25	3.27e-21	0.8	0.58	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
KIRP	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	11.48	5.41e-25	3.28e-21	0.72	0.58	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
KIRP	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	11.48	5.49e-25	3.33e-21	0.61	0.58	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
KIRP	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	11.48	5.49e-25	3.33e-21	0.61	0.58	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
KIRP	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-11.47	5.99e-25	3.63e-21	-0.67	-0.58	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
KIRP	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	11.47	6.2e-25	3.75e-21	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-11.46	6.26e-25	3.79e-21	-0.67	-0.58	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
KIRP	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-11.46	6.28e-25	3.8e-21	-0.67	-0.58	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	11.46	6.63e-25	4.01e-21	0.66	0.58	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	11.45	6.83e-25	4.13e-21	0.66	0.58	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
KIRP	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-11.45	6.89e-25	4.16e-21	-0.67	-0.58	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
KIRP	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	11.45	6.92e-25	4.18e-21	0.69	0.58	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
KIRP	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-11.45	7.11e-25	4.29e-21	-0.69	-0.58	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
KIRP	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-11.45	7.12e-25	4.3e-21	-0.52	-0.58	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
KIRP	cis	rs2698530	0.634	rs1025209	ENSG00000225889.6	AC074289.1	-11.45	7.15e-25	4.32e-21	-0.54	-0.58	Iron status biomarkers;	chr2:64251926	chr2:64143239~64252859:+
KIRP	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	11.45	7.21e-25	4.35e-21	0.69	0.58	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	11.44	7.42e-25	4.47e-21	0.67	0.58	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
KIRP	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	11.44	7.48e-25	4.51e-21	0.73	0.58	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-11.43	7.91e-25	4.76e-21	-0.58	-0.58	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-11.43	7.98e-25	4.8e-21	-0.75	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
KIRP	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	11.43	8.1e-25	4.87e-21	0.71	0.58	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-11.43	8.19e-25	4.93e-21	-0.67	-0.58	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-11.43	8.19e-25	4.93e-21	-0.67	-0.58	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	11.43	8.27e-25	4.97e-21	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	11.43	8.41e-25	5.06e-21	0.67	0.58	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
KIRP	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	11.43	8.45e-25	5.07e-21	0.66	0.58	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	11.42	8.65e-25	5.2e-21	0.67	0.58	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
KIRP	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	11.42	9.09e-25	5.46e-21	0.79	0.58	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	11.42	9.14e-25	5.48e-21	0.79	0.58	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
KIRP	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	11.41	9.17e-25	5.5e-21	0.81	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	11.41	9.17e-25	5.5e-21	0.81	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
KIRP	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-11.41	9.38e-25	5.63e-21	-0.66	-0.58	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
KIRP	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	11.41	9.48e-25	5.68e-21	0.67	0.58	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	11.41	9.7e-25	5.81e-21	0.67	0.58	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
KIRP	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-11.4	9.99e-25	5.98e-21	-0.57	-0.58	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
KIRP	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	11.4	1.03e-24	6.13e-21	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	11.4	1.06e-24	6.35e-21	0.67	0.58	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	11.4	1.06e-24	6.35e-21	0.67	0.58	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	11.39	1.12e-24	6.7e-21	0.66	0.58	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
KIRP	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-11.39	1.14e-24	6.8e-21	-0.66	-0.58	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
KIRP	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	11.38	1.16e-24	6.92e-21	0.73	0.58	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
KIRP	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-11.38	1.17e-24	6.97e-21	-0.66	-0.58	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
KIRP	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	11.38	1.18e-24	7.02e-21	0.49	0.58	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
KIRP	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-11.38	1.18e-24	7.03e-21	-0.68	-0.58	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
KIRP	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	11.38	1.21e-24	7.2e-21	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-11.38	1.22e-24	7.26e-21	-0.66	-0.58	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-11.38	1.22e-24	7.26e-21	-0.66	-0.58	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
KIRP	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	11.38	1.22e-24	7.29e-21	0.68	0.58	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	11.37	1.27e-24	7.53e-21	0.65	0.57	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	11.37	1.27e-24	7.53e-21	0.65	0.57	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	11.37	1.27e-24	7.53e-21	0.65	0.57	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	11.37	1.29e-24	7.67e-21	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	11.37	1.31e-24	7.8e-21	0.68	0.57	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-11.37	1.31e-24	7.82e-21	-0.66	-0.57	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-11.37	1.33e-24	7.93e-21	-0.68	-0.57	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-11.37	1.33e-24	7.93e-21	-0.68	-0.57	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
KIRP	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-11.36	1.35e-24	8.02e-21	-0.67	-0.57	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-11.36	1.36e-24	8.07e-21	-0.68	-0.57	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	11.36	1.37e-24	8.16e-21	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
KIRP	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	11.36	1.38e-24	8.21e-21	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	11.36	1.4e-24	8.28e-21	0.66	0.57	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
KIRP	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	11.36	1.4e-24	8.32e-21	0.61	0.57	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	11.35	1.45e-24	8.59e-21	0.65	0.57	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	11.35	1.48e-24	8.73e-21	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	11.35	1.49e-24	8.79e-21	0.67	0.57	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
KIRP	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-11.35	1.49e-24	8.81e-21	-0.57	-0.57	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	11.35	1.49e-24	8.82e-21	0.75	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
KIRP	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-11.35	1.5e-24	8.88e-21	-0.68	-0.57	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	11.35	1.51e-24	8.93e-21	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	11.35	1.54e-24	9.11e-21	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-11.34	1.65e-24	9.73e-21	-0.7	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-11.34	1.65e-24	9.74e-21	-0.67	-0.57	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-11.34	1.65e-24	9.74e-21	-0.67	-0.57	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-11.34	1.65e-24	9.74e-21	-0.67	-0.57	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	11.34	1.65e-24	9.74e-21	0.7	0.57	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
KIRP	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	11.34	1.66e-24	9.79e-21	0.69	0.57	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
KIRP	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	11.33	1.71e-24	1e-20	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
KIRP	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-11.33	1.73e-24	1.01e-20	-0.67	-0.57	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	11.33	1.73e-24	1.02e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	11.33	1.73e-24	1.02e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	11.33	1.73e-24	1.02e-20	0.84	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
KIRP	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	11.33	1.77e-24	1.04e-20	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	11.33	1.8e-24	1.06e-20	0.85	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-11.32	1.83e-24	1.07e-20	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	11.32	1.83e-24	1.07e-20	0.76	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	11.32	1.88e-24	1.1e-20	0.69	0.57	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
KIRP	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-11.32	1.9e-24	1.11e-20	-0.49	-0.57	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
KIRP	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-11.32	1.96e-24	1.14e-20	-0.66	-0.57	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
KIRP	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-11.32	1.96e-24	1.14e-20	-0.66	-0.57	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-11.32	1.96e-24	1.14e-20	-0.66	-0.57	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-11.31	2.02e-24	1.18e-20	-0.61	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
KIRP	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	11.31	2.07e-24	1.21e-20	0.7	0.57	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	11.31	2.08e-24	1.21e-20	0.67	0.57	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	11.31	2.09e-24	1.22e-20	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
KIRP	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-11.29	2.31e-24	1.35e-20	-0.66	-0.57	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
KIRP	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-11.29	2.32e-24	1.35e-20	-0.49	-0.57	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
KIRP	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	11.29	2.39e-24	1.39e-20	0.68	0.57	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	11.29	2.43e-24	1.41e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	11.29	2.43e-24	1.41e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-11.29	2.45e-24	1.42e-20	-0.66	-0.57	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-11.29	2.46e-24	1.43e-20	-0.77	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	11.28	2.51e-24	1.46e-20	0.67	0.57	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
KIRP	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-11.28	2.51e-24	1.46e-20	-0.72	-0.57	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
KIRP	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	11.28	2.55e-24	1.47e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
KIRP	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-11.28	2.66e-24	1.54e-20	-0.85	-0.57	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	11.28	2.66e-24	1.54e-20	0.81	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	11.27	2.73e-24	1.58e-20	0.69	0.57	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	11.27	2.74e-24	1.58e-20	0.48	0.57	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
KIRP	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	11.27	2.76e-24	1.59e-20	0.67	0.57	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	11.27	2.83e-24	1.64e-20	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	11.27	2.84e-24	1.64e-20	0.67	0.57	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	11.27	2.84e-24	1.64e-20	0.67	0.57	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	11.27	2.88e-24	1.66e-20	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
KIRP	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-11.26	2.9e-24	1.67e-20	-0.68	-0.57	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
KIRP	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	11.26	2.94e-24	1.7e-20	0.68	0.57	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
KIRP	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-11.26	2.97e-24	1.71e-20	-0.68	-0.57	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	11.26	3.03e-24	1.75e-20	0.83	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	11.26	3.06e-24	1.76e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
KIRP	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	11.26	3.07e-24	1.77e-20	0.49	0.57	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
KIRP	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	11.25	3.16e-24	1.82e-20	0.67	0.57	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
KIRP	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	11.25	3.28e-24	1.89e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	11.25	3.28e-24	1.89e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
KIRP	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	11.25	3.28e-24	1.89e-20	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	11.25	3.36e-24	1.93e-20	0.65	0.57	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
KIRP	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-11.24	3.39e-24	1.95e-20	-0.5	-0.57	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
KIRP	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	11.24	3.42e-24	1.96e-20	0.81	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	11.24	3.46e-24	1.99e-20	0.66	0.57	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	11.24	3.49e-24	2e-20	0.81	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	11.23	3.79e-24	2.17e-20	0.67	0.57	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	11.23	3.9e-24	2.24e-20	0.66	0.57	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	11.22	3.94e-24	2.26e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	11.22	4.01e-24	2.29e-20	0.67	0.57	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	11.22	4.05e-24	2.32e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	11.22	4.05e-24	2.32e-20	0.82	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	11.22	4.05e-24	2.32e-20	0.66	0.57	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
KIRP	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	11.22	4.16e-24	2.38e-20	0.66	0.57	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	11.22	4.18e-24	2.39e-20	0.66	0.57	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
KIRP	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	11.22	4.2e-24	2.4e-20	0.85	0.57	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
KIRP	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-11.22	4.21e-24	2.4e-20	-0.7	-0.57	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
KIRP	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-11.21	4.36e-24	2.49e-20	-0.52	-0.57	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
KIRP	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	11.21	4.51e-24	2.58e-20	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
KIRP	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	11.21	4.52e-24	2.58e-20	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	11.21	4.57e-24	2.6e-20	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	11.21	4.57e-24	2.6e-20	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	11.21	4.57e-24	2.6e-20	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	11.21	4.57e-24	2.6e-20	0.66	0.57	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	11.2	4.75e-24	2.7e-20	0.67	0.57	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
KIRP	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-11.2	4.75e-24	2.7e-20	-0.64	-0.57	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
KIRP	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	11.2	4.79e-24	2.72e-20	0.81	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	11.2	4.89e-24	2.77e-20	0.65	0.57	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	11.2	4.89e-24	2.77e-20	0.65	0.57	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	11.2	4.9e-24	2.78e-20	0.65	0.57	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	11.19	4.95e-24	2.81e-20	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	11.19	4.95e-24	2.81e-20	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	11.19	4.96e-24	2.81e-20	0.74	0.57	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
KIRP	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-11.19	5.17e-24	2.93e-20	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
KIRP	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	11.18	5.36e-24	3.03e-20	0.66	0.57	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-11.18	5.37e-24	3.04e-20	-0.67	-0.57	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
KIRP	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	11.18	5.41e-24	3.06e-20	0.65	0.57	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
KIRP	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	11.18	5.46e-24	3.09e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
KIRP	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-11.18	5.67e-24	3.21e-20	-0.69	-0.57	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	11.17	5.88e-24	3.32e-20	0.67	0.57	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	11.16	6.22e-24	3.51e-20	0.66	0.57	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	11.16	6.29e-24	3.55e-20	0.65	0.57	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	11.16	6.29e-24	3.55e-20	0.65	0.57	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
KIRP	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	11.16	6.31e-24	3.56e-20	0.64	0.57	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
KIRP	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	11.16	6.37e-24	3.59e-20	0.66	0.57	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	11.16	6.46e-24	3.64e-20	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
KIRP	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	11.16	6.61e-24	3.72e-20	0.72	0.57	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	11.16	6.68e-24	3.76e-20	0.83	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	11.16	6.68e-24	3.76e-20	0.83	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
KIRP	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	11.15	6.83e-24	3.84e-20	0.7	0.57	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-11.15	6.83e-24	3.84e-20	-0.7	-0.57	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
KIRP	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	11.15	6.84e-24	3.85e-20	0.49	0.57	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
KIRP	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	11.15	6.84e-24	3.85e-20	0.49	0.57	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
KIRP	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	11.15	6.95e-24	3.91e-20	0.64	0.57	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	11.15	7.01e-24	3.94e-20	0.65	0.57	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	11.15	7.01e-24	3.94e-20	0.65	0.57	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	11.15	7.08e-24	3.98e-20	0.61	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
KIRP	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-11.15	7.14e-24	4.01e-20	-0.58	-0.57	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
KIRP	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	11.14	7.26e-24	4.08e-20	0.65	0.57	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
KIRP	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	11.14	7.28e-24	4.09e-20	0.59	0.57	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
KIRP	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	11.14	7.3e-24	4.1e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-11.14	7.31e-24	4.1e-20	-0.66	-0.57	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	11.14	7.38e-24	4.14e-20	0.65	0.57	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	11.14	7.39e-24	4.14e-20	0.6	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
KIRP	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	11.14	7.51e-24	4.21e-20	0.76	0.57	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
KIRP	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	11.14	7.51e-24	4.21e-20	0.66	0.57	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
KIRP	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	11.14	7.61e-24	4.26e-20	0.66	0.57	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	11.13	7.82e-24	4.37e-20	0.65	0.57	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	11.13	7.82e-24	4.37e-20	0.65	0.57	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	11.13	7.91e-24	4.41e-20	0.67	0.57	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
KIRP	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	11.13	8.07e-24	4.5e-20	0.6	0.57	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
KIRP	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	11.13	8.07e-24	4.5e-20	0.74	0.57	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
KIRP	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	11.13	8.23e-24	4.59e-20	0.68	0.57	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
KIRP	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	11.13	8.26e-24	4.6e-20	0.66	0.57	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	11.13	8.26e-24	4.6e-20	0.66	0.57	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
KIRP	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	11.13	8.3e-24	4.62e-20	0.65	0.57	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	11.13	8.37e-24	4.66e-20	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
KIRP	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-11.12	8.48e-24	4.72e-20	-0.65	-0.57	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	11.12	8.5e-24	4.72e-20	0.56	0.57	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	11.12	8.59e-24	4.78e-20	0.57	0.57	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	11.12	8.75e-24	4.86e-20	0.65	0.57	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	11.12	8.75e-24	4.86e-20	0.65	0.57	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
KIRP	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-11.12	8.82e-24	4.9e-20	-0.62	-0.57	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
KIRP	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	11.12	9.01e-24	5e-20	0.66	0.57	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	11.12	9.01e-24	5e-20	0.66	0.57	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
KIRP	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-11.12	9.07e-24	5.03e-20	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-11.11	9.09e-24	5.05e-20	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	11.11	9.11e-24	5.06e-20	0.61	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
KIRP	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	11.11	9.11e-24	5.06e-20	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	11.11	9.23e-24	5.12e-20	0.65	0.57	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	11.11	9.27e-24	5.14e-20	0.68	0.57	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
KIRP	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-11.11	9.44e-24	5.23e-20	-0.67	-0.57	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
KIRP	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-11.11	9.44e-24	5.23e-20	-0.67	-0.57	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	11.11	9.48e-24	5.26e-20	0.66	0.57	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	11.11	9.48e-24	5.26e-20	0.66	0.57	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	11.11	9.5e-24	5.27e-20	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-11.11	9.57e-24	5.3e-20	-0.66	-0.57	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	11.11	9.6e-24	5.32e-20	0.65	0.57	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	11.11	9.6e-24	5.32e-20	0.65	0.57	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	11.11	9.65e-24	5.35e-20	0.66	0.57	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-11.11	9.77e-24	5.41e-20	-0.67	-0.57	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	11.1	9.94e-24	5.5e-20	0.66	0.57	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	11.1	9.94e-24	5.5e-20	0.66	0.57	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	11.1	9.94e-24	5.5e-20	0.66	0.57	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-11.1	1.02e-23	5.63e-20	-0.67	-0.57	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	11.1	1.03e-23	5.68e-20	0.65	0.57	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
KIRP	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-11.09	1.06e-23	5.87e-20	-0.64	-0.57	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
KIRP	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	11.09	1.07e-23	5.92e-20	0.67	0.57	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
KIRP	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	11.09	1.12e-23	6.17e-20	0.6	0.57	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
KIRP	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-11.09	1.12e-23	6.17e-20	-0.59	-0.57	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
KIRP	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	11.09	1.12e-23	6.18e-20	0.7	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
KIRP	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-11.09	1.13e-23	6.21e-20	-0.68	-0.57	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
KIRP	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	11.08	1.15e-23	6.32e-20	0.8	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
KIRP	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	11.08	1.16e-23	6.37e-20	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
KIRP	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	11.08	1.16e-23	6.37e-20	0.66	0.56	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	11.08	1.16e-23	6.37e-20	0.66	0.56	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	11.08	1.17e-23	6.44e-20	0.65	0.56	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-11.08	1.17e-23	6.45e-20	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	11.08	1.18e-23	6.47e-20	0.64	0.56	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	11.08	1.19e-23	6.53e-20	0.68	0.56	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	11.08	1.22e-23	6.71e-20	0.67	0.56	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	11.08	1.22e-23	6.71e-20	0.67	0.56	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	11.07	1.23e-23	6.76e-20	0.67	0.56	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
KIRP	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	11.07	1.23e-23	6.76e-20	0.67	0.56	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	11.07	1.24e-23	6.79e-20	0.65	0.56	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	11.07	1.25e-23	6.86e-20	0.65	0.56	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	11.07	1.26e-23	6.9e-20	0.65	0.56	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	11.07	1.26e-23	6.9e-20	0.65	0.56	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	11.07	1.26e-23	6.9e-20	0.65	0.56	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
KIRP	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	11.07	1.27e-23	6.98e-20	0.48	0.56	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
KIRP	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	11.07	1.29e-23	7.07e-20	0.64	0.56	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	11.07	1.31e-23	7.17e-20	0.65	0.56	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	11.07	1.31e-23	7.17e-20	0.65	0.56	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	11.06	1.35e-23	7.37e-20	0.62	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
KIRP	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-11.06	1.42e-23	7.75e-20	-0.59	-0.56	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	11.06	1.42e-23	7.77e-20	0.56	0.56	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	11.06	1.43e-23	7.8e-20	0.6	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	11.06	1.43e-23	7.8e-20	0.6	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
KIRP	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	11.05	1.44e-23	7.88e-20	0.66	0.56	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-11.05	1.47e-23	8.05e-20	-0.67	-0.56	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
KIRP	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	11.05	1.48e-23	8.09e-20	0.66	0.56	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	11.05	1.48e-23	8.09e-20	0.66	0.56	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	11.05	1.48e-23	8.1e-20	0.65	0.56	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	11.05	1.55e-23	8.4e-20	0.65	0.56	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	11.04	1.55e-23	8.41e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	11.04	1.55e-23	8.41e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	11.04	1.59e-23	8.62e-20	0.65	0.56	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	11.04	1.61e-23	8.71e-20	0.61	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
KIRP	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	11.04	1.63e-23	8.83e-20	0.66	0.56	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
KIRP	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	11.04	1.63e-23	8.86e-20	0.49	0.56	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	11.03	1.68e-23	9.09e-20	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
KIRP	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	11.03	1.68e-23	9.09e-20	0.66	0.56	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
KIRP	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	11.03	1.69e-23	9.16e-20	0.6	0.56	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
KIRP	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	11.03	1.7e-23	9.17e-20	0.48	0.56	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
KIRP	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	11.03	1.74e-23	9.41e-20	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	11.03	1.76e-23	9.5e-20	0.65	0.56	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	11.03	1.76e-23	9.5e-20	0.65	0.56	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-11.02	1.82e-23	9.82e-20	-0.59	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
KIRP	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	11.02	1.85e-23	1e-19	0.68	0.56	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	11.02	1.85e-23	1e-19	0.68	0.56	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	11.02	1.85e-23	1e-19	0.68	0.56	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
KIRP	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-11.02	1.91e-23	1.03e-19	-0.44	-0.56	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
KIRP	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-11.02	1.91e-23	1.03e-19	-0.44	-0.56	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
KIRP	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	11.02	1.94e-23	1.04e-19	0.65	0.56	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	11.01	1.94e-23	1.05e-19	0.65	0.56	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
KIRP	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	11.01	1.97e-23	1.06e-19	0.58	0.56	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
KIRP	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-11.01	1.98e-23	1.07e-19	-0.67	-0.56	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
KIRP	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-11.01	2e-23	1.08e-19	-0.64	-0.56	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	11.01	2.07e-23	1.11e-19	0.66	0.56	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	11.01	2.07e-23	1.11e-19	0.66	0.56	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	11.01	2.07e-23	1.11e-19	0.66	0.56	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	11.01	2.07e-23	1.11e-19	0.66	0.56	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	11.01	2.07e-23	1.11e-19	0.66	0.56	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
KIRP	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-11	2.12e-23	1.14e-19	-0.63	-0.56	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
KIRP	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-11	2.12e-23	1.14e-19	-0.63	-0.56	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
KIRP	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-11	2.12e-23	1.14e-19	-0.63	-0.56	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
KIRP	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	11	2.16e-23	1.16e-19	0.8	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
KIRP	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	11	2.24e-23	1.2e-19	0.57	0.56	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	10.99	2.32e-23	1.25e-19	0.65	0.56	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	10.99	2.35e-23	1.26e-19	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
KIRP	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	10.99	2.41e-23	1.29e-19	0.67	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	10.99	2.43e-23	1.31e-19	0.65	0.56	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
KIRP	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-10.98	2.5e-23	1.34e-19	-0.72	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
KIRP	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-10.98	2.58e-23	1.38e-19	-0.64	-0.56	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-10.98	2.58e-23	1.38e-19	-0.64	-0.56	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-10.98	2.58e-23	1.38e-19	-0.64	-0.56	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
KIRP	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-10.97	2.7e-23	1.44e-19	-0.53	-0.56	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
KIRP	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	10.96	2.86e-23	1.52e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	10.96	2.86e-23	1.52e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	10.96	2.86e-23	1.52e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	10.96	2.86e-23	1.52e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	10.96	2.86e-23	1.52e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
KIRP	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	10.96	2.94e-23	1.56e-19	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	10.96	3.01e-23	1.6e-19	0.66	0.56	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
KIRP	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	10.96	3.01e-23	1.6e-19	0.65	0.56	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
KIRP	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-10.96	3.02e-23	1.6e-19	-0.72	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
KIRP	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	10.96	3.02e-23	1.6e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	10.96	3.02e-23	1.6e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	10.96	3.02e-23	1.6e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	10.96	3.02e-23	1.6e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	10.96	3.02e-23	1.6e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	10.96	3.06e-23	1.62e-19	0.65	0.56	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	10.96	3.06e-23	1.62e-19	0.65	0.56	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
KIRP	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-10.95	3.11e-23	1.65e-19	-0.74	-0.56	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
KIRP	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	10.95	3.12e-23	1.65e-19	0.7	0.56	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
KIRP	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	10.95	3.12e-23	1.66e-19	0.65	0.56	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	10.95	3.12e-23	1.66e-19	0.65	0.56	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	10.95	3.12e-23	1.66e-19	0.65	0.56	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
KIRP	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-10.95	3.17e-23	1.68e-19	-0.93	-0.56	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
KIRP	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	10.95	3.24e-23	1.72e-19	0.66	0.56	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	10.95	3.28e-23	1.74e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	10.95	3.28e-23	1.74e-19	0.75	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
KIRP	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	10.95	3.28e-23	1.74e-19	0.67	0.56	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	10.95	3.28e-23	1.74e-19	0.67	0.56	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-10.94	3.36e-23	1.78e-19	-0.64	-0.56	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
KIRP	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	10.94	3.37e-23	1.78e-19	0.68	0.56	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
KIRP	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-10.94	3.42e-23	1.81e-19	-0.54	-0.56	Breast cancer;	chr11:743813	chr11:779617~780755:+
KIRP	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	10.94	3.44e-23	1.82e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
KIRP	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-10.94	3.51e-23	1.85e-19	-1.02	-0.56	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-10.93	3.63e-23	1.92e-19	-0.67	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
KIRP	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	10.93	3.68e-23	1.94e-19	0.91	0.56	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
KIRP	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	10.93	3.68e-23	1.94e-19	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	10.93	3.76e-23	1.98e-19	0.65	0.56	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
KIRP	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	10.92	3.9e-23	2.05e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
KIRP	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-10.92	3.98e-23	2.09e-19	-0.77	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	10.92	3.99e-23	2.1e-19	0.68	0.56	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	10.91	4.22e-23	2.21e-19	0.64	0.56	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	10.91	4.39e-23	2.3e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	10.91	4.39e-23	2.3e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	10.91	4.39e-23	2.3e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	10.9	4.52e-23	2.36e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	10.9	4.52e-23	2.36e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	10.9	4.52e-23	2.36e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	10.9	4.52e-23	2.36e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	10.9	4.52e-23	2.36e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	10.9	4.66e-23	2.43e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	10.9	4.67e-23	2.44e-19	0.55	0.56	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	10.9	4.67e-23	2.44e-19	0.55	0.56	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
KIRP	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	10.9	4.72e-23	2.46e-19	0.59	0.56	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	10.9	4.76e-23	2.48e-19	0.67	0.56	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	10.89	4.83e-23	2.52e-19	0.64	0.56	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
KIRP	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	10.89	4.83e-23	2.52e-19	0.52	0.56	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
KIRP	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	10.89	4.86e-23	2.53e-19	0.69	0.56	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
KIRP	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	10.89	4.9e-23	2.55e-19	0.72	0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
KIRP	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	10.89	4.91e-23	2.56e-19	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	10.89	4.97e-23	2.59e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	10.89	4.97e-23	2.59e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	10.89	5e-23	2.6e-19	0.65	0.56	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	10.89	5.05e-23	2.63e-19	0.65	0.56	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
KIRP	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	10.89	5.15e-23	2.68e-19	0.48	0.56	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
KIRP	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	10.89	5.15e-23	2.68e-19	0.48	0.56	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
KIRP	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	10.88	5.25e-23	2.73e-19	0.59	0.56	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	10.88	5.29e-23	2.75e-19	0.65	0.56	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
KIRP	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-10.88	5.45e-23	2.83e-19	-0.64	-0.56	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
KIRP	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	10.87	5.61e-23	2.91e-19	0.55	0.56	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	10.87	5.69e-23	2.95e-19	0.67	0.56	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	10.87	5.73e-23	2.97e-19	0.65	0.56	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
KIRP	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-10.87	5.79e-23	3e-19	-0.67	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
KIRP	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-10.86	6.13e-23	3.17e-19	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
KIRP	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	10.85	6.68e-23	3.45e-19	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	10.85	6.7e-23	3.46e-19	0.66	0.56	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	10.85	6.74e-23	3.48e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	10.85	6.74e-23	3.48e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	10.85	6.74e-23	3.48e-19	0.67	0.56	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
KIRP	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	10.85	6.81e-23	3.51e-19	0.52	0.56	Breast cancer;	chr11:750849	chr11:779617~780755:+
KIRP	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	10.84	7.05e-23	3.63e-19	0.64	0.56	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	10.84	7.06e-23	3.64e-19	0.65	0.56	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
KIRP	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-10.84	7.44e-23	3.83e-19	-0.98	-0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
KIRP	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	10.83	7.75e-23	3.99e-19	0.65	0.56	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	10.83	7.9e-23	4.06e-19	0.66	0.56	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
KIRP	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-10.83	8.05e-23	4.14e-19	-0.62	-0.56	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-10.83	8.05e-23	4.14e-19	-0.62	-0.56	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
KIRP	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	10.83	8.08e-23	4.15e-19	0.66	0.56	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
KIRP	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-10.83	8.16e-23	4.2e-19	-0.65	-0.56	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
KIRP	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-10.82	8.31e-23	4.27e-19	-0.66	-0.56	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
KIRP	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-10.82	8.31e-23	4.27e-19	-0.64	-0.56	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
KIRP	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	10.82	8.39e-23	4.31e-19	0.64	0.56	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	10.82	8.39e-23	4.31e-19	0.64	0.56	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
KIRP	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-10.82	8.48e-23	4.35e-19	-0.63	-0.56	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
KIRP	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	10.82	8.62e-23	4.42e-19	0.48	0.56	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
KIRP	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-10.82	8.63e-23	4.43e-19	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
KIRP	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-10.81	8.9e-23	4.56e-19	-0.46	-0.56	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
KIRP	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	10.81	9.07e-23	4.64e-19	1	0.56	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
KIRP	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	10.81	9.17e-23	4.7e-19	0.57	0.56	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
KIRP	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-10.81	9.42e-23	4.82e-19	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
KIRP	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	10.8	9.57e-23	4.89e-19	0.73	0.56	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
KIRP	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	10.8	9.6e-23	4.9e-19	0.71	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
KIRP	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-10.8	9.97e-23	5.08e-19	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
KIRP	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	10.8	1.01e-22	5.13e-19	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
KIRP	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-10.79	1.02e-22	5.22e-19	-0.72	-0.55	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
KIRP	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	10.79	1.05e-22	5.33e-19	0.67	0.55	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
KIRP	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	10.79	1.05e-22	5.34e-19	0.67	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
KIRP	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-10.79	1.08e-22	5.51e-19	-0.55	-0.55	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
KIRP	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-10.79	1.09e-22	5.53e-19	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-10.79	1.09e-22	5.53e-19	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
KIRP	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	10.78	1.11e-22	5.63e-19	0.64	0.55	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	10.78	1.15e-22	5.85e-19	0.67	0.55	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
KIRP	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	10.78	1.16e-22	5.87e-19	0.77	0.55	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
KIRP	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-10.78	1.16e-22	5.9e-19	-0.63	-0.55	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
KIRP	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	10.78	1.16e-22	5.91e-19	0.81	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
KIRP	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.67	0.55	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	10.78	1.18e-22	5.99e-19	0.64	0.55	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
KIRP	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-10.78	1.19e-22	6.01e-19	-0.64	-0.55	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
KIRP	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-10.78	1.19e-22	6.01e-19	-0.64	-0.55	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
KIRP	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	10.77	1.22e-22	6.17e-19	0.75	0.55	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
KIRP	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	10.77	1.23e-22	6.24e-19	0.77	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	10.77	1.24e-22	6.29e-19	0.64	0.55	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	10.77	1.25e-22	6.3e-19	0.77	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
KIRP	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-10.77	1.28e-22	6.49e-19	-0.64	-0.55	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
KIRP	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	10.76	1.3e-22	6.57e-19	0.66	0.55	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
KIRP	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-10.76	1.3e-22	6.59e-19	-0.6	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	10.76	1.31e-22	6.64e-19	0.63	0.55	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	10.76	1.33e-22	6.71e-19	0.66	0.55	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	10.76	1.34e-22	6.77e-19	0.65	0.55	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
KIRP	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	10.76	1.37e-22	6.89e-19	1.01	0.55	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
KIRP	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	10.76	1.37e-22	6.92e-19	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
KIRP	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-10.75	1.43e-22	7.2e-19	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-10.75	1.43e-22	7.2e-19	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-10.75	1.43e-22	7.2e-19	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
KIRP	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-10.75	1.45e-22	7.29e-19	-0.53	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
KIRP	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	10.75	1.46e-22	7.34e-19	0.65	0.55	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	10.75	1.46e-22	7.34e-19	0.65	0.55	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
KIRP	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-10.75	1.47e-22	7.37e-19	-0.7	-0.55	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-10.74	1.5e-22	7.52e-19	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-10.74	1.5e-22	7.52e-19	-0.7	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
KIRP	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	10.74	1.54e-22	7.71e-19	0.65	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	10.74	1.54e-22	7.71e-19	0.65	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
KIRP	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	10.74	1.56e-22	7.84e-19	0.67	0.55	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	10.74	1.56e-22	7.84e-19	0.67	0.55	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	10.74	1.57e-22	7.86e-19	0.65	0.55	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
KIRP	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	10.74	1.57e-22	7.86e-19	0.65	0.55	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	10.74	1.6e-22	8.04e-19	0.66	0.55	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	10.73	1.65e-22	8.25e-19	0.64	0.55	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
KIRP	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-10.73	1.69e-22	8.44e-19	-0.56	-0.55	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
KIRP	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	10.72	1.75e-22	8.75e-19	0.46	0.55	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	10.72	1.75e-22	8.75e-19	0.46	0.55	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	10.72	1.75e-22	8.75e-19	0.46	0.55	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
KIRP	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	10.72	1.85e-22	9.23e-19	0.64	0.55	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
KIRP	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-10.72	1.85e-22	9.23e-19	-0.68	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
KIRP	cis	rs2698530	0.791	rs890481	ENSG00000225889.6	AC074289.1	-10.72	1.85e-22	9.23e-19	-0.52	-0.55	Iron status biomarkers;	chr2:64265382	chr2:64143239~64252859:+
KIRP	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-10.71	1.88e-22	9.4e-19	-0.61	-0.55	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
KIRP	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	10.71	1.91e-22	9.54e-19	0.67	0.55	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
KIRP	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	10.71	1.93e-22	9.66e-19	0.64	0.55	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	10.71	1.96e-22	9.79e-19	0.64	0.55	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
KIRP	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	10.71	1.98e-22	9.85e-19	0.65	0.55	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	10.71	1.98e-22	9.85e-19	0.65	0.55	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	10.71	1.98e-22	9.85e-19	0.65	0.55	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	10.71	1.98e-22	9.85e-19	0.65	0.55	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-10.71	2.01e-22	1e-18	-0.59	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
KIRP	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	10.7	2.1e-22	1.05e-18	0.55	0.55	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
KIRP	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	10.7	2.11e-22	1.05e-18	0.81	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	10.7	2.11e-22	1.05e-18	0.81	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
KIRP	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	10.7	2.16e-22	1.07e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
KIRP	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-10.7	2.16e-22	1.07e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
KIRP	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	10.69	2.17e-22	1.08e-18	1.1	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
KIRP	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	10.69	2.22e-22	1.1e-18	0.53	0.55	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
KIRP	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	10.69	2.28e-22	1.13e-18	0.65	0.55	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	10.69	2.32e-22	1.15e-18	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
KIRP	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-10.69	2.32e-22	1.15e-18	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
KIRP	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	10.68	2.38e-22	1.17e-18	0.64	0.55	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	10.68	2.39e-22	1.18e-18	0.65	0.55	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
KIRP	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	10.68	2.39e-22	1.18e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	10.68	2.39e-22	1.18e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	10.68	2.39e-22	1.18e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	10.68	2.39e-22	1.18e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
KIRP	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	10.68	2.4e-22	1.18e-18	0.64	0.55	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	10.68	2.41e-22	1.19e-18	0.66	0.55	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
KIRP	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	10.68	2.42e-22	1.19e-18	0.54	0.55	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
KIRP	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	10.68	2.44e-22	1.2e-18	0.65	0.55	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-10.68	2.44e-22	1.2e-18	-0.59	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
KIRP	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	10.68	2.45e-22	1.2e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	10.68	2.46e-22	1.21e-18	0.65	0.55	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	10.68	2.51e-22	1.23e-18	0.58	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-10.68	2.52e-22	1.24e-18	-0.64	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
KIRP	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	10.67	2.56e-22	1.26e-18	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	10.67	2.58e-22	1.27e-18	1.04	0.55	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	10.67	2.58e-22	1.27e-18	1.04	0.55	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
KIRP	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	10.67	2.65e-22	1.3e-18	0.8	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
KIRP	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-10.67	2.69e-22	1.32e-18	-0.62	-0.55	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	10.67	2.69e-22	1.32e-18	0.66	0.55	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
KIRP	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	10.66	2.73e-22	1.33e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
KIRP	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	10.66	2.74e-22	1.34e-18	0.79	0.55	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
KIRP	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	10.66	2.76e-22	1.35e-18	0.54	0.55	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
KIRP	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	10.66	2.88e-22	1.4e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
KIRP	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-10.65	2.97e-22	1.45e-18	-0.61	-0.55	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
KIRP	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	10.65	2.98e-22	1.45e-18	0.65	0.55	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
KIRP	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	10.65	3.1e-22	1.51e-18	1.04	0.55	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	10.65	3.1e-22	1.51e-18	1.04	0.55	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	10.65	3.11e-22	1.51e-18	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
KIRP	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	10.65	3.12e-22	1.52e-18	0.7	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
KIRP	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-10.65	3.13e-22	1.52e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-10.65	3.13e-22	1.52e-18	-0.7	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
KIRP	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-10.65	3.14e-22	1.52e-18	-0.56	-0.55	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
KIRP	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-10.65	3.14e-22	1.52e-18	-0.56	-0.55	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	10.64	3.19e-22	1.55e-18	0.53	0.55	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
KIRP	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	10.64	3.24e-22	1.57e-18	0.68	0.55	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
KIRP	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	10.64	3.26e-22	1.58e-18	0.64	0.55	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
KIRP	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-10.64	3.28e-22	1.59e-18	-0.6	-0.55	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	10.64	3.33e-22	1.61e-18	0.63	0.55	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
KIRP	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	10.64	3.4e-22	1.64e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	10.64	3.4e-22	1.64e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
KIRP	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-10.63	3.47e-22	1.67e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-10.63	3.47e-22	1.67e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-10.63	3.47e-22	1.67e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-10.63	3.47e-22	1.67e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-10.63	3.47e-22	1.67e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
KIRP	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	10.63	3.48e-22	1.68e-18	0.99	0.55	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
KIRP	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	10.63	3.59e-22	1.73e-18	0.45	0.55	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
KIRP	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	10.63	3.59e-22	1.73e-18	0.56	0.55	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	10.63	3.6e-22	1.73e-18	0.54	0.55	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
KIRP	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	10.63	3.63e-22	1.75e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
KIRP	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-10.63	3.65e-22	1.76e-18	-0.43	-0.55	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	10.62	3.69e-22	1.77e-18	0.59	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
KIRP	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	10.61	4.01e-22	1.93e-18	0.64	0.55	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	10.61	4.01e-22	1.93e-18	0.64	0.55	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
KIRP	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-10.61	4.07e-22	1.95e-18	-0.73	-0.55	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
KIRP	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-10.61	4.16e-22	1.99e-18	-0.63	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
KIRP	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-10.6	4.28e-22	2.05e-18	-0.56	-0.55	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	10.6	4.31e-22	2.06e-18	0.72	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
KIRP	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-10.6	4.37e-22	2.09e-18	-0.55	-0.55	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
KIRP	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	10.6	4.4e-22	2.1e-18	0.64	0.55	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
KIRP	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	10.6	4.41e-22	2.11e-18	0.7	0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
KIRP	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-10.6	4.42e-22	2.11e-18	-0.69	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
KIRP	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	10.6	4.58e-22	2.19e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	10.6	4.58e-22	2.19e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	10.6	4.58e-22	2.19e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	10.6	4.58e-22	2.19e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	10.59	4.7e-22	2.24e-18	0.64	0.55	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	10.59	4.7e-22	2.24e-18	0.64	0.55	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
KIRP	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-10.59	4.77e-22	2.27e-18	-0.61	-0.55	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
KIRP	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-10.59	4.83e-22	2.3e-18	-0.61	-0.55	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
KIRP	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-10.58	5.27e-22	2.5e-18	-0.55	-0.55	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	10.58	5.28e-22	2.51e-18	0.54	0.55	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
KIRP	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	10.57	5.34e-22	2.54e-18	0.78	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
KIRP	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	10.57	5.34e-22	2.54e-18	0.78	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
KIRP	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-10.57	5.39e-22	2.56e-18	-0.78	-0.55	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-10.57	5.45e-22	2.58e-18	-0.65	-0.55	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	10.57	5.49e-22	2.6e-18	0.79	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
KIRP	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-10.57	5.59e-22	2.65e-18	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
KIRP	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-10.57	5.64e-22	2.67e-18	-0.63	-0.55	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
KIRP	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	10.56	5.79e-22	2.73e-18	0.64	0.55	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
KIRP	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-10.56	5.79e-22	2.73e-18	-0.44	-0.55	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
KIRP	cis	rs977987	0.806	rs11643209	ENSG00000261783.1	RP11-252K23.2	-10.56	5.89e-22	2.78e-18	-0.66	-0.55	Dupuytren's disease;	chr16:75297146	chr16:75379818~75381260:-
KIRP	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	10.56	5.9e-22	2.78e-18	0.62	0.55	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	10.55	6.24e-22	2.94e-18	0.62	0.55	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	10.55	6.24e-22	2.94e-18	0.62	0.55	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	10.55	6.24e-22	2.94e-18	0.62	0.55	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	10.55	6.24e-22	2.94e-18	0.62	0.55	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
KIRP	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	10.55	6.42e-22	3.02e-18	0.66	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
KIRP	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-10.54	6.73e-22	3.16e-18	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-10.54	6.73e-22	3.16e-18	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-10.54	6.73e-22	3.16e-18	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
KIRP	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-10.54	6.76e-22	3.17e-18	-0.71	-0.55	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
KIRP	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	10.54	6.84e-22	3.21e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	10.54	6.84e-22	3.21e-18	0.9	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
KIRP	cis	rs2698530	0.791	rs890482	ENSG00000225889.6	AC074289.1	10.54	6.84e-22	3.21e-18	0.52	0.55	Iron status biomarkers;	chr2:64265801	chr2:64143239~64252859:+
KIRP	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-10.54	6.87e-22	3.22e-18	-0.63	-0.55	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
KIRP	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	10.54	6.87e-22	3.22e-18	0.67	0.55	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	10.54	6.94e-22	3.25e-18	0.63	0.55	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
KIRP	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-10.54	7.01e-22	3.29e-18	-0.43	-0.55	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
KIRP	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-10.53	7.71e-22	3.6e-18	-0.43	-0.55	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
KIRP	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-10.52	7.82e-22	3.65e-18	-0.44	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
KIRP	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	10.52	7.86e-22	3.67e-18	0.64	0.55	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	10.52	7.86e-22	3.67e-18	0.64	0.55	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	10.52	7.86e-22	3.67e-18	0.64	0.55	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-10.52	8.15e-22	3.8e-18	-0.53	-0.54	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
KIRP	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-10.52	8.28e-22	3.86e-18	-0.45	-0.54	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
KIRP	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	10.52	8.33e-22	3.88e-18	0.68	0.54	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
KIRP	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-10.51	8.37e-22	3.9e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
KIRP	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	10.5	9.15e-22	4.25e-18	1	0.54	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
KIRP	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-10.5	9.18e-22	4.27e-18	-0.59	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
KIRP	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-10.5	9.3e-22	4.32e-18	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-10.5	9.3e-22	4.32e-18	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
KIRP	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	10.49	9.91e-22	4.59e-18	0.65	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	10.49	9.91e-22	4.59e-18	0.65	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
KIRP	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	10.49	1e-21	4.63e-18	0.64	0.54	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
KIRP	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-10.49	1.01e-21	4.66e-18	-0.62	-0.54	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-10.49	1.01e-21	4.66e-18	-0.62	-0.54	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
KIRP	cis	rs2698530	0.791	rs869739	ENSG00000225889.6	AC074289.1	-10.49	1.03e-21	4.75e-18	-0.51	-0.54	Iron status biomarkers;	chr2:64266012	chr2:64143239~64252859:+
KIRP	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-10.48	1.09e-21	5.03e-18	-0.68	-0.54	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
KIRP	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-10.48	1.09e-21	5.05e-18	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
KIRP	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	10.48	1.11e-21	5.14e-18	0.55	0.54	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
KIRP	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	10.47	1.16e-21	5.31e-18	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-10.47	1.16e-21	5.31e-18	-0.89	-0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
KIRP	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	10.47	1.17e-21	5.37e-18	0.55	0.54	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
KIRP	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	10.47	1.18e-21	5.4e-18	0.65	0.54	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	10.47	1.18e-21	5.4e-18	0.65	0.54	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
KIRP	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-10.47	1.2e-21	5.51e-18	-0.55	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-10.46	1.22e-21	5.62e-18	-0.6	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
KIRP	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	10.46	1.23e-21	5.62e-18	0.74	0.54	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
KIRP	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-10.46	1.24e-21	5.67e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-10.46	1.24e-21	5.7e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-10.46	1.25e-21	5.73e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
KIRP	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-10.46	1.27e-21	5.82e-18	-0.7	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
KIRP	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	10.45	1.32e-21	6.04e-18	0.64	0.54	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
KIRP	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	10.45	1.36e-21	6.22e-18	0.55	0.54	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
KIRP	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	10.45	1.38e-21	6.33e-18	0.67	0.54	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	10.45	1.4e-21	6.37e-18	0.61	0.54	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-10.44	1.44e-21	6.56e-18	-0.63	-0.54	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-10.44	1.49e-21	6.79e-18	-0.53	-0.54	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
KIRP	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-10.44	1.5e-21	6.84e-18	-0.62	-0.54	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
KIRP	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	10.44	1.51e-21	6.87e-18	0.55	0.54	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
KIRP	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-10.44	1.51e-21	6.87e-18	-0.64	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
KIRP	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	10.43	1.55e-21	7.05e-18	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
KIRP	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-10.43	1.56e-21	7.11e-18	-0.6	-0.54	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
KIRP	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-10.43	1.57e-21	7.16e-18	-0.62	-0.54	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
KIRP	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-10.43	1.59e-21	7.24e-18	-0.61	-0.54	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
KIRP	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	10.43	1.59e-21	7.24e-18	0.63	0.54	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
KIRP	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	10.43	1.62e-21	7.38e-18	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	10.42	1.64e-21	7.44e-18	0.57	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
KIRP	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	10.42	1.65e-21	7.5e-18	0.64	0.54	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
KIRP	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-10.42	1.68e-21	7.64e-18	-1.06	-0.54	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
KIRP	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-10.42	1.7e-21	7.74e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	10.42	1.73e-21	7.85e-18	0.62	0.54	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
KIRP	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-10.42	1.75e-21	7.94e-18	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
KIRP	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-10.41	1.76e-21	8e-18	-0.6	-0.54	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
KIRP	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	10.41	1.78e-21	8.09e-18	0.65	0.54	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
KIRP	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	10.41	1.82e-21	8.24e-18	0.66	0.54	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	10.41	1.86e-21	8.41e-18	0.63	0.54	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
KIRP	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	10.41	1.86e-21	8.42e-18	0.77	0.54	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-10.41	1.88e-21	8.53e-18	-0.63	-0.54	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
KIRP	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-10.41	1.89e-21	8.57e-18	-0.67	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
KIRP	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	10.4	1.91e-21	8.62e-18	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
KIRP	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-10.4	1.92e-21	8.7e-18	-1.01	-0.54	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
KIRP	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	10.4	1.93e-21	8.72e-18	0.6	0.54	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
KIRP	cis	rs2698530	0.791	rs2555442	ENSG00000225889.6	AC074289.1	-10.4	1.95e-21	8.8e-18	-0.52	-0.54	Iron status biomarkers;	chr2:64262157	chr2:64143239~64252859:+
KIRP	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	10.4	1.95e-21	8.8e-18	0.62	0.54	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
KIRP	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-10.4	1.99e-21	9e-18	-0.53	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	10.39	2.08e-21	9.38e-18	0.62	0.54	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
KIRP	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	10.39	2.13e-21	9.61e-18	0.68	0.54	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
KIRP	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-10.39	2.18e-21	9.83e-18	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
KIRP	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	10.39	2.19e-21	9.87e-18	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
KIRP	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-10.38	2.21e-21	9.93e-18	-0.56	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	10.38	2.22e-21	9.97e-18	0.63	0.54	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
KIRP	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-10.38	2.24e-21	1.01e-17	-0.46	-0.54	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
KIRP	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-10.38	2.27e-21	1.02e-17	-0.43	-0.54	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
KIRP	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	10.38	2.28e-21	1.03e-17	0.61	0.54	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
KIRP	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	10.38	2.35e-21	1.06e-17	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
KIRP	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	10.37	2.41e-21	1.08e-17	0.61	0.54	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
KIRP	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	10.37	2.44e-21	1.1e-17	0.61	0.54	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
KIRP	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-10.37	2.46e-21	1.1e-17	-0.7	-0.54	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-10.37	2.46e-21	1.1e-17	-0.7	-0.54	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-10.37	2.46e-21	1.1e-17	-0.7	-0.54	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
KIRP	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	10.37	2.5e-21	1.12e-17	0.63	0.54	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
KIRP	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-10.37	2.51e-21	1.13e-17	-0.71	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-10.37	2.51e-21	1.13e-17	-0.71	-0.54	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
KIRP	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	10.37	2.54e-21	1.14e-17	0.55	0.54	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
KIRP	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-10.36	2.62e-21	1.17e-17	-0.54	-0.54	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
KIRP	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	10.36	2.68e-21	1.2e-17	0.45	0.54	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
KIRP	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-10.36	2.69e-21	1.21e-17	-0.54	-0.54	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
KIRP	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-10.35	2.87e-21	1.28e-17	-1.01	-0.54	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
KIRP	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-10.35	2.89e-21	1.29e-17	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
KIRP	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-10.35	2.9e-21	1.29e-17	-0.65	-0.54	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	10.35	2.92e-21	1.3e-17	0.46	0.54	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
KIRP	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	10.35	2.95e-21	1.31e-17	0.88	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	10.35	2.95e-21	1.31e-17	0.88	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
KIRP	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	10.34	3.09e-21	1.37e-17	0.81	0.54	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
KIRP	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-10.34	3.1e-21	1.38e-17	-0.69	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
KIRP	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-10.34	3.16e-21	1.4e-17	-0.55	-0.54	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
KIRP	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-10.33	3.22e-21	1.43e-17	-0.6	-0.54	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
KIRP	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-10.33	3.26e-21	1.45e-17	-0.44	-0.54	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
KIRP	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	10.33	3.32e-21	1.47e-17	0.46	0.54	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
KIRP	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	10.33	3.32e-21	1.47e-17	0.65	0.54	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
KIRP	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	10.33	3.33e-21	1.48e-17	0.55	0.54	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
KIRP	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	10.33	3.34e-21	1.48e-17	0.64	0.54	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
KIRP	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	10.33	3.37e-21	1.49e-17	0.77	0.54	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
KIRP	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	10.33	3.39e-21	1.5e-17	0.67	0.54	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	10.32	3.46e-21	1.53e-17	0.62	0.54	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
KIRP	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	10.32	3.54e-21	1.55e-17	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
KIRP	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	10.32	3.69e-21	1.62e-17	1.03	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
KIRP	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	10.31	3.76e-21	1.65e-17	0.46	0.54	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
KIRP	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-10.31	3.79e-21	1.66e-17	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
KIRP	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-10.31	3.88e-21	1.7e-17	-1.03	-0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
KIRP	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-10.31	3.91e-21	1.71e-17	-0.6	-0.54	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
KIRP	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	10.3	4.09e-21	1.79e-17	0.46	0.54	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-10.3	4.25e-21	1.86e-17	-0.46	-0.54	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
KIRP	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	10.29	4.29e-21	1.87e-17	0.61	0.54	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	10.29	4.35e-21	1.9e-17	0.6	0.54	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
KIRP	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	10.29	4.55e-21	1.99e-17	0.76	0.54	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
KIRP	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-10.29	4.56e-21	1.99e-17	-0.43	-0.54	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
KIRP	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-10.29	4.56e-21	1.99e-17	-0.43	-0.54	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
KIRP	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-10.29	4.56e-21	1.99e-17	-0.43	-0.54	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
KIRP	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-10.28	4.63e-21	2.02e-17	-0.54	-0.54	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
KIRP	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-10.28	4.72e-21	2.06e-17	-0.44	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
KIRP	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	10.28	4.73e-21	2.06e-17	0.99	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
KIRP	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	10.28	4.79e-21	2.09e-17	0.65	0.54	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	10.28	4.79e-21	2.09e-17	0.65	0.54	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	10.28	4.79e-21	2.09e-17	0.65	0.54	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
KIRP	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	10.28	4.85e-21	2.11e-17	1.04	0.54	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
KIRP	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-10.27	5.23e-21	2.27e-17	-0.43	-0.54	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
KIRP	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-10.27	5.26e-21	2.28e-17	-0.47	-0.54	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
KIRP	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-10.27	5.32e-21	2.31e-17	-0.46	-0.54	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
KIRP	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-10.26	5.46e-21	2.37e-17	-0.42	-0.54	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	10.26	5.56e-21	2.41e-17	0.58	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
KIRP	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	10.26	5.64e-21	2.44e-17	1.03	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
KIRP	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-10.26	5.65e-21	2.45e-17	-0.44	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
KIRP	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-10.26	5.67e-21	2.45e-17	-0.52	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-10.26	5.67e-21	2.45e-17	-0.52	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
KIRP	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-10.26	5.75e-21	2.49e-17	-0.53	-0.54	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
KIRP	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	10.26	5.76e-21	2.49e-17	0.99	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
KIRP	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	10.25	5.84e-21	2.52e-17	0.7	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
KIRP	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	10.25	5.84e-21	2.52e-17	0.59	0.54	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
KIRP	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	10.25	5.91e-21	2.56e-17	1	0.54	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
KIRP	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	10.25	6.04e-21	2.6e-17	0.54	0.53	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
KIRP	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	10.25	6.1e-21	2.63e-17	1.02	0.53	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
KIRP	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-10.25	6.16e-21	2.65e-17	-0.52	-0.53	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
KIRP	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-10.24	6.26e-21	2.69e-17	-0.61	-0.53	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
KIRP	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-10.24	6.29e-21	2.71e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
KIRP	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	10.24	6.56e-21	2.82e-17	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	10.24	6.56e-21	2.82e-17	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	10.23	6.69e-21	2.87e-17	0.66	0.53	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
KIRP	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-10.23	7.08e-21	3.03e-17	-0.59	-0.53	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
KIRP	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	10.23	7.11e-21	3.04e-17	0.51	0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
KIRP	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-10.22	7.24e-21	3.09e-17	-0.6	-0.53	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
KIRP	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-10.22	7.41e-21	3.17e-17	-0.68	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
KIRP	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-10.22	7.51e-21	3.21e-17	-0.61	-0.53	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
KIRP	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	10.22	7.52e-21	3.21e-17	0.45	0.53	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	10.22	7.52e-21	3.21e-17	0.45	0.53	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
KIRP	cis	rs2698530	0.791	rs2698526	ENSG00000225889.6	AC074289.1	10.22	7.68e-21	3.28e-17	0.49	0.53	Iron status biomarkers;	chr2:64272389	chr2:64143239~64252859:+
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-10.22	7.73e-21	3.29e-17	-0.69	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
KIRP	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-10.21	7.85e-21	3.35e-17	-0.64	-0.53	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
KIRP	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-10.21	7.93e-21	3.38e-17	-0.52	-0.53	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
KIRP	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-10.21	8.14e-21	3.46e-17	-0.67	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
KIRP	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-10.21	8.2e-21	3.49e-17	-0.59	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
KIRP	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-10.21	8.29e-21	3.53e-17	-0.43	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
KIRP	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-10.2	8.44e-21	3.59e-17	-0.61	-0.53	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
KIRP	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-10.2	8.46e-21	3.6e-17	-0.52	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-10.2	8.46e-21	3.6e-17	-0.52	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-10.2	8.46e-21	3.6e-17	-0.52	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-10.2	8.46e-21	3.6e-17	-0.52	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-10.2	8.46e-21	3.6e-17	-0.52	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
KIRP	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-10.2	8.47e-21	3.6e-17	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	10.2	8.55e-21	3.63e-17	0.59	0.53	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
KIRP	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-10.2	8.59e-21	3.65e-17	-0.76	-0.53	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
KIRP	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	10.2	8.61e-21	3.66e-17	0.95	0.53	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
KIRP	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	10.2	8.63e-21	3.66e-17	0.43	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
KIRP	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	10.2	8.76e-21	3.72e-17	0.62	0.53	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
KIRP	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-10.2	8.79e-21	3.73e-17	-0.69	-0.53	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-10.2	8.79e-21	3.73e-17	-0.69	-0.53	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
KIRP	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	10.2	8.81e-21	3.73e-17	0.66	0.53	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
KIRP	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	10.2	8.86e-21	3.75e-17	0.54	0.53	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
KIRP	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	10.19	9.02e-21	3.82e-17	0.75	0.53	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
KIRP	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-10.19	9.27e-21	3.92e-17	-0.42	-0.53	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-10.19	9.32e-21	3.95e-17	-0.59	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
KIRP	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-10.19	9.35e-21	3.96e-17	-0.43	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
KIRP	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	10.19	9.65e-21	4.08e-17	0.6	0.53	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	10.18	1.01e-20	4.25e-17	0.46	0.53	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
KIRP	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-10.18	1.02e-20	4.29e-17	-0.69	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
KIRP	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	10.17	1.06e-20	4.47e-17	0.45	0.53	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
KIRP	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	10.17	1.09e-20	4.6e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
KIRP	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	10.16	1.13e-20	4.77e-17	0.7	0.53	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
KIRP	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	10.16	1.14e-20	4.79e-17	0.64	0.53	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
KIRP	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	10.16	1.16e-20	4.86e-17	1.04	0.53	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
KIRP	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-10.16	1.18e-20	4.95e-17	-1.03	-0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
KIRP	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-10.16	1.2e-20	5.02e-17	-0.63	-0.53	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
KIRP	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-10.16	1.2e-20	5.03e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	10.15	1.26e-20	5.28e-17	0.58	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
KIRP	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-10.15	1.3e-20	5.41e-17	-0.41	-0.53	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
KIRP	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-10.14	1.31e-20	5.45e-17	-0.55	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	10.14	1.31e-20	5.47e-17	0.62	0.53	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
KIRP	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-10.14	1.33e-20	5.57e-17	-0.42	-0.53	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
KIRP	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-10.14	1.33e-20	5.57e-17	-0.42	-0.53	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
KIRP	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-10.14	1.34e-20	5.61e-17	-0.71	-0.53	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
KIRP	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-10.14	1.38e-20	5.75e-17	-0.55	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
KIRP	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-10.14	1.38e-20	5.75e-17	-0.6	-0.53	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
KIRP	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	10.13	1.42e-20	5.91e-17	0.96	0.53	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
KIRP	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-10.13	1.43e-20	5.93e-17	-0.51	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
KIRP	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	10.13	1.49e-20	6.17e-17	0.41	0.53	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
KIRP	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-10.13	1.5e-20	6.22e-17	-0.54	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-10.13	1.5e-20	6.22e-17	-0.54	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
KIRP	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	10.12	1.53e-20	6.35e-17	0.53	0.53	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
KIRP	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-10.12	1.6e-20	6.6e-17	-0.44	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
KIRP	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	10.12	1.6e-20	6.61e-17	0.97	0.53	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
KIRP	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	10.11	1.62e-20	6.68e-17	0.65	0.53	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
KIRP	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-10.11	1.62e-20	6.69e-17	-0.54	-0.53	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
KIRP	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	10.11	1.62e-20	6.69e-17	0.59	0.53	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
KIRP	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-10.11	1.66e-20	6.86e-17	-0.59	-0.53	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-10.11	1.66e-20	6.86e-17	-0.59	-0.53	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	10.11	1.69e-20	6.99e-17	0.59	0.53	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	10.11	1.69e-20	6.99e-17	0.59	0.53	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
KIRP	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-10.11	1.72e-20	7.08e-17	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-10.11	1.72e-20	7.08e-17	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-10.11	1.72e-20	7.08e-17	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
KIRP	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	10.1	1.76e-20	7.26e-17	0.61	0.53	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
KIRP	cis	rs2698530	0.634	rs1816618	ENSG00000225889.6	AC074289.1	-10.1	1.81e-20	7.45e-17	-0.49	-0.53	Iron status biomarkers;	chr2:64220750	chr2:64143239~64252859:+
KIRP	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-10.1	1.82e-20	7.48e-17	-0.69	-0.53	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
KIRP	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-10.1	1.84e-20	7.57e-17	-0.55	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
KIRP	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	10.1	1.84e-20	7.58e-17	0.53	0.53	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
KIRP	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-10.1	1.84e-20	7.58e-17	-0.69	-0.53	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
KIRP	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-10.09	1.89e-20	7.76e-17	-0.42	-0.53	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
KIRP	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	10.09	1.94e-20	7.95e-17	0.63	0.53	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
KIRP	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-10.08	2.04e-20	8.37e-17	-0.54	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
KIRP	cis	rs2698530	0.583	rs2698527	ENSG00000225889.6	AC074289.1	-10.08	2.06e-20	8.45e-17	-0.49	-0.53	Iron status biomarkers;	chr2:64272495	chr2:64143239~64252859:+
KIRP	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-10.08	2.1e-20	8.58e-17	-0.66	-0.53	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
KIRP	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	10.08	2.11e-20	8.62e-17	0.64	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	10.08	2.11e-20	8.62e-17	0.64	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
KIRP	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-10.08	2.12e-20	8.65e-17	-0.6	-0.53	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
KIRP	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	10.08	2.12e-20	8.67e-17	0.98	0.53	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
KIRP	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	10.08	2.13e-20	8.69e-17	1.03	0.53	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
KIRP	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	10.07	2.18e-20	8.9e-17	0.6	0.53	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
KIRP	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	10.07	2.18e-20	8.91e-17	0.61	0.53	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
KIRP	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	10.07	2.21e-20	9.03e-17	1.04	0.53	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
KIRP	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-10.07	2.23e-20	9.09e-17	-0.54	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
KIRP	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-10.07	2.27e-20	9.24e-17	-0.66	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
KIRP	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	10.06	2.43e-20	9.86e-17	0.7	0.53	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
KIRP	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	10.06	2.48e-20	1.01e-16	0.6	0.53	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
KIRP	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-10.06	2.5e-20	1.01e-16	-0.6	-0.53	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
KIRP	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	10.05	2.53e-20	1.03e-16	0.45	0.53	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
KIRP	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-10.05	2.55e-20	1.04e-16	-0.97	-0.53	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-10.05	2.57e-20	1.04e-16	-0.67	-0.53	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
KIRP	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-10.05	2.57e-20	1.04e-16	-0.61	-0.53	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	10.05	2.62e-20	1.06e-16	0.57	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
KIRP	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-10.05	2.7e-20	1.09e-16	-0.55	-0.53	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
KIRP	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	10.04	2.72e-20	1.1e-16	0.63	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
KIRP	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	10.04	2.75e-20	1.11e-16	0.95	0.53	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
KIRP	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	10.04	2.79e-20	1.13e-16	0.69	0.53	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-10.04	2.85e-20	1.15e-16	-0.68	-0.53	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
KIRP	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-10.04	2.86e-20	1.15e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
KIRP	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	10.04	2.89e-20	1.17e-16	0.63	0.53	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
KIRP	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	10.03	2.93e-20	1.18e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
KIRP	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	10.03	2.94e-20	1.19e-16	1	0.53	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
KIRP	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	10.03	2.94e-20	1.19e-16	0.54	0.53	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
KIRP	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	10.03	2.95e-20	1.19e-16	0.61	0.53	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
KIRP	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-10.03	2.97e-20	1.2e-16	-0.59	-0.53	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
KIRP	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-10.03	3.07e-20	1.24e-16	-0.68	-0.53	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
KIRP	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-10.03	3.07e-20	1.24e-16	-0.68	-0.53	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-10.03	3.08e-20	1.24e-16	-0.68	-0.53	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
KIRP	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	10.03	3.1e-20	1.25e-16	0.82	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
KIRP	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-10.03	3.11e-20	1.25e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
KIRP	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	10.03	3.12e-20	1.25e-16	0.44	0.53	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
KIRP	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-10.02	3.15e-20	1.26e-16	-0.67	-0.53	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
KIRP	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-10.02	3.16e-20	1.27e-16	-0.48	-0.53	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
KIRP	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	10.02	3.18e-20	1.28e-16	0.45	0.53	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
KIRP	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	10.02	3.19e-20	1.28e-16	0.46	0.53	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
KIRP	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-10.02	3.25e-20	1.3e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-10.02	3.25e-20	1.3e-16	-0.57	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
KIRP	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	10.02	3.3e-20	1.32e-16	0.59	0.53	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	10.02	3.31e-20	1.33e-16	0.65	0.53	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
KIRP	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	10.02	3.34e-20	1.34e-16	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
KIRP	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	10.01	3.41e-20	1.37e-16	0.85	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
KIRP	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	10.01	3.43e-20	1.37e-16	0.6	0.53	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-10.01	3.47e-20	1.39e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-10.01	3.47e-20	1.39e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
KIRP	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	10.01	3.57e-20	1.43e-16	0.6	0.53	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-10.01	3.57e-20	1.43e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-10.01	3.57e-20	1.43e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-10.01	3.57e-20	1.43e-16	-0.59	-0.53	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-10.01	3.61e-20	1.44e-16	-0.61	-0.53	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-10.01	3.61e-20	1.44e-16	-0.6	-0.53	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-10.01	3.61e-20	1.44e-16	-0.6	-0.53	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
KIRP	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	10	3.64e-20	1.45e-16	0.6	0.53	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
KIRP	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	10	3.65e-20	1.45e-16	0.45	0.53	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
KIRP	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	10	3.65e-20	1.45e-16	0.59	0.53	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
KIRP	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	10	3.71e-20	1.48e-16	0.6	0.53	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
KIRP	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-10	3.71e-20	1.48e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-10	3.71e-20	1.48e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-10	3.71e-20	1.48e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-10	3.75e-20	1.49e-16	-0.59	-0.53	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
KIRP	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	10	3.82e-20	1.52e-16	0.76	0.53	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
KIRP	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-10	3.88e-20	1.54e-16	-0.57	-0.53	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-9.99	3.97e-20	1.58e-16	-0.58	-0.53	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
KIRP	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	9.98	4.22e-20	1.68e-16	0.59	0.52	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	9.98	4.22e-20	1.68e-16	0.59	0.52	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	9.98	4.31e-20	1.71e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
KIRP	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-9.98	4.34e-20	1.72e-16	-0.59	-0.52	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
KIRP	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	9.98	4.35e-20	1.72e-16	0.54	0.52	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
KIRP	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	9.98	4.48e-20	1.77e-16	0.68	0.52	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
KIRP	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-9.97	4.53e-20	1.79e-16	-0.43	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-9.97	4.53e-20	1.79e-16	-0.43	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
KIRP	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-9.97	4.56e-20	1.8e-16	-0.69	-0.52	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-9.97	4.56e-20	1.8e-16	-0.69	-0.52	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
KIRP	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	9.97	4.62e-20	1.82e-16	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	9.97	4.66e-20	1.84e-16	0.63	0.52	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
KIRP	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-9.97	4.71e-20	1.86e-16	-0.59	-0.52	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
KIRP	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-9.97	4.72e-20	1.86e-16	-0.51	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-9.97	4.73e-20	1.86e-16	-0.51	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-9.97	4.74e-20	1.86e-16	-0.51	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
KIRP	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-9.96	5.06e-20	1.99e-16	-0.41	-0.52	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
KIRP	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	9.96	5.19e-20	2.04e-16	0.52	0.52	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
KIRP	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	9.95	5.22e-20	2.05e-16	0.63	0.52	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
KIRP	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	9.95	5.29e-20	2.08e-16	0.6	0.52	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	9.95	5.29e-20	2.08e-16	0.6	0.52	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
KIRP	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	9.95	5.44e-20	2.13e-16	0.45	0.52	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
KIRP	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-9.95	5.46e-20	2.14e-16	-0.59	-0.52	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
KIRP	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-9.94	5.64e-20	2.21e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-9.94	5.64e-20	2.21e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	9.94	5.71e-20	2.24e-16	0.62	0.52	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
KIRP	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-9.94	5.76e-20	2.26e-16	-0.48	-0.52	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
KIRP	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-9.94	5.78e-20	2.26e-16	-0.65	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-9.94	5.79e-20	2.27e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
KIRP	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-9.94	5.8e-20	2.27e-16	-0.53	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
KIRP	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-9.94	5.85e-20	2.29e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
KIRP	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-9.93	6.06e-20	2.37e-16	-0.63	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
KIRP	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-9.93	6.1e-20	2.38e-16	-0.68	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-9.93	6.1e-20	2.38e-16	-0.68	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
KIRP	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	9.93	6.13e-20	2.39e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	9.93	6.14e-20	2.4e-16	0.64	0.52	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
KIRP	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-9.93	6.34e-20	2.47e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
KIRP	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-9.93	6.35e-20	2.48e-16	-0.4	-0.52	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
KIRP	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-9.93	6.41e-20	2.5e-16	-0.45	-0.52	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
KIRP	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	9.92	6.49e-20	2.53e-16	0.64	0.52	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
KIRP	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	9.92	6.49e-20	2.53e-16	0.41	0.52	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
KIRP	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-9.92	6.62e-20	2.57e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
KIRP	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-9.92	6.63e-20	2.58e-16	-0.83	-0.52	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
KIRP	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	9.92	6.65e-20	2.59e-16	0.61	0.52	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
KIRP	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	9.92	6.68e-20	2.59e-16	1	0.52	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
KIRP	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	9.92	6.7e-20	2.6e-16	0.58	0.52	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
KIRP	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-9.92	6.72e-20	2.61e-16	-0.58	-0.52	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-9.92	6.72e-20	2.61e-16	-0.58	-0.52	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-9.92	6.72e-20	2.61e-16	-0.58	-0.52	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
KIRP	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	9.92	6.82e-20	2.65e-16	0.62	0.52	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	9.92	6.82e-20	2.65e-16	0.62	0.52	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
KIRP	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-9.92	6.94e-20	2.69e-16	-0.68	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
KIRP	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	9.91	7.08e-20	2.74e-16	0.6	0.52	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
KIRP	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	9.91	7.18e-20	2.78e-16	0.58	0.52	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
KIRP	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	9.91	7.43e-20	2.88e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
KIRP	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
KIRP	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-9.91	7.49e-20	2.89e-16	-0.58	-0.52	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	9.9	7.75e-20	2.99e-16	0.61	0.52	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-9.9	7.82e-20	3.02e-16	-0.62	-0.52	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
KIRP	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-9.9	7.94e-20	3.06e-16	-0.51	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
KIRP	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	9.9	8.03e-20	3.1e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-9.9	8.04e-20	3.1e-16	-0.6	-0.52	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-9.89	8.13e-20	3.13e-16	-0.6	-0.52	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
KIRP	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-9.89	8.19e-20	3.15e-16	-0.69	-0.52	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
KIRP	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-9.89	8.33e-20	3.2e-16	-0.89	-0.52	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
KIRP	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-9.89	8.42e-20	3.24e-16	-0.53	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
KIRP	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-9.89	8.46e-20	3.25e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
KIRP	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	9.89	8.65e-20	3.32e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
KIRP	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	9.89	8.67e-20	3.33e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	9.89	8.67e-20	3.33e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	9.88	8.78e-20	3.37e-16	0.62	0.52	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
KIRP	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	9.88	8.89e-20	3.41e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	9.88	8.89e-20	3.41e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	9.88	8.89e-20	3.41e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
KIRP	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-9.88	9.18e-20	3.52e-16	-0.53	-0.52	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
KIRP	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	9.88	9.22e-20	3.53e-16	0.62	0.52	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	9.88	9.26e-20	3.55e-16	0.59	0.52	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
KIRP	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	9.87	9.35e-20	3.58e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	9.87	9.35e-20	3.58e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	9.87	9.35e-20	3.58e-16	0.62	0.52	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
KIRP	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	9.87	9.41e-20	3.6e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	9.87	9.41e-20	3.6e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	9.87	9.42e-20	3.6e-16	0.61	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-9.87	9.46e-20	3.62e-16	-0.6	-0.52	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
KIRP	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	9.87	9.46e-20	3.62e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	9.87	9.46e-20	3.62e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
KIRP	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	9.87	9.6e-20	3.67e-16	0.57	0.52	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
KIRP	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	9.87	9.63e-20	3.68e-16	0.58	0.52	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	9.87	9.63e-20	3.68e-16	0.58	0.52	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
KIRP	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	9.87	9.65e-20	3.69e-16	0.57	0.52	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
KIRP	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-9.87	9.7e-20	3.7e-16	-1.02	-0.52	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
KIRP	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-9.87	9.7e-20	3.7e-16	-1.02	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-9.87	9.7e-20	3.7e-16	-1.02	-0.52	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
KIRP	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	9.87	9.74e-20	3.72e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-9.87	9.79e-20	3.74e-16	-0.6	-0.52	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	9.87	9.8e-20	3.74e-16	0.64	0.52	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	9.87	9.83e-20	3.75e-16	0.57	0.52	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
KIRP	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	9.87	9.96e-20	3.8e-16	0.72	0.52	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
KIRP	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-9.86	1e-19	3.83e-16	-0.42	-0.52	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
KIRP	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	9.86	1.01e-19	3.83e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
KIRP	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-9.86	1.01e-19	3.84e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
KIRP	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-9.86	1.03e-19	3.94e-16	-0.53	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-9.86	1.03e-19	3.94e-16	-0.53	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
KIRP	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	9.86	1.04e-19	3.98e-16	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	9.86	1.05e-19	4e-16	0.57	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
KIRP	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	9.86	1.05e-19	4.01e-16	1	0.52	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
KIRP	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-9.85	1.08e-19	4.12e-16	-0.67	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
KIRP	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-9.85	1.09e-19	4.13e-16	-0.56	-0.52	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
KIRP	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	9.85	1.13e-19	4.28e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
KIRP	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	9.85	1.13e-19	4.28e-16	0.44	0.52	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
KIRP	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	9.85	1.13e-19	4.3e-16	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	9.85	1.13e-19	4.3e-16	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	9.85	1.13e-19	4.3e-16	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
KIRP	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	9.85	1.15e-19	4.37e-16	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	9.85	1.15e-19	4.37e-16	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
KIRP	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	9.85	1.16e-19	4.39e-16	0.95	0.52	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
KIRP	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	9.84	1.16e-19	4.4e-16	0.73	0.52	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
KIRP	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	9.84	1.16e-19	4.4e-16	0.73	0.52	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
KIRP	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	9.84	1.16e-19	4.4e-16	0.73	0.52	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
KIRP	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-9.84	1.16e-19	4.41e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.84	1.18e-19	4.45e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
KIRP	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-9.84	1.19e-19	4.52e-16	-0.51	-0.52	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
KIRP	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	9.84	1.2e-19	4.53e-16	0.58	0.52	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
KIRP	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	9.84	1.21e-19	4.57e-16	0.59	0.52	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
KIRP	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	9.84	1.23e-19	4.65e-16	0.62	0.52	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
KIRP	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	9.83	1.26e-19	4.76e-16	0.57	0.52	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
KIRP	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-9.83	1.27e-19	4.79e-16	-0.67	-0.52	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
KIRP	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-9.83	1.27e-19	4.81e-16	-0.51	-0.52	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-9.83	1.27e-19	4.81e-16	-0.51	-0.52	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.9e-16	-0.51	-0.52	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.92e-16	-0.51	-0.52	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.92e-16	-0.51	-0.52	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.92e-16	-0.51	-0.52	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-9.83	1.3e-19	4.92e-16	-0.51	-0.52	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
KIRP	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	9.83	1.31e-19	4.96e-16	0.73	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
KIRP	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-9.83	1.32e-19	4.98e-16	-1.02	-0.52	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
KIRP	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-9.83	1.33e-19	5.03e-16	-0.71	-0.52	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
KIRP	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	9.83	1.34e-19	5.05e-16	0.62	0.52	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
KIRP	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-9.82	1.34e-19	5.07e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-9.82	1.34e-19	5.07e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
KIRP	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	9.82	1.36e-19	5.11e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
KIRP	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-9.82	1.37e-19	5.17e-16	-0.4	-0.52	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
KIRP	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	9.82	1.37e-19	5.17e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
KIRP	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-9.82	1.39e-19	5.24e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
KIRP	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	9.82	1.39e-19	5.24e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	9.82	1.39e-19	5.24e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	9.82	1.39e-19	5.24e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	9.82	1.39e-19	5.24e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	9.82	1.4e-19	5.26e-16	0.58	0.52	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-9.82	1.41e-19	5.32e-16	-0.61	-0.52	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
KIRP	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-9.81	1.47e-19	5.54e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
KIRP	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	9.81	1.47e-19	5.54e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	9.81	1.47e-19	5.54e-16	0.51	0.52	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
KIRP	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-9.81	1.49e-19	5.6e-16	-0.68	-0.52	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-9.81	1.49e-19	5.6e-16	-0.67	-0.52	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
KIRP	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	9.81	1.53e-19	5.73e-16	0.58	0.52	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	9.81	1.55e-19	5.8e-16	0.59	0.52	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	9.81	1.55e-19	5.8e-16	0.59	0.52	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
KIRP	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	9.8	1.57e-19	5.87e-16	1.02	0.52	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	9.8	1.57e-19	5.87e-16	1.02	0.52	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
KIRP	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	9.8	1.6e-19	5.99e-16	0.63	0.52	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
KIRP	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	9.8	1.63e-19	6.1e-16	0.96	0.52	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
KIRP	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-9.8	1.64e-19	6.14e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
KIRP	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	9.8	1.64e-19	6.15e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	9.8	1.64e-19	6.15e-16	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
KIRP	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-9.8	1.67e-19	6.23e-16	-0.58	-0.52	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
KIRP	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	9.79	1.67e-19	6.24e-16	0.65	0.52	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
KIRP	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-9.79	1.68e-19	6.26e-16	-0.52	-0.52	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
KIRP	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	9.79	1.69e-19	6.3e-16	0.66	0.52	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
KIRP	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	9.79	1.69e-19	6.32e-16	0.58	0.52	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	9.79	1.69e-19	6.32e-16	0.58	0.52	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
KIRP	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-9.79	1.71e-19	6.37e-16	-0.6	-0.52	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	9.79	1.72e-19	6.42e-16	0.6	0.52	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	9.79	1.72e-19	6.42e-16	0.6	0.52	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
KIRP	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	9.79	1.73e-19	6.45e-16	0.64	0.52	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
KIRP	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	9.79	1.73e-19	6.45e-16	0.6	0.52	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
KIRP	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	9.79	1.73e-19	6.46e-16	0.63	0.52	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
KIRP	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	9.79	1.74e-19	6.5e-16	0.58	0.52	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	9.79	1.76e-19	6.57e-16	0.6	0.52	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	9.79	1.76e-19	6.57e-16	0.6	0.52	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
KIRP	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.79	1.78e-19	6.61e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
KIRP	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-9.79	1.78e-19	6.61e-16	-0.51	-0.52	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-9.79	1.78e-19	6.61e-16	-0.51	-0.52	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-9.79	1.78e-19	6.62e-16	-0.59	-0.52	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
KIRP	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	9.79	1.78e-19	6.63e-16	0.73	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	9.79	1.78e-19	6.63e-16	0.73	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
KIRP	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-9.78	1.85e-19	6.89e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
KIRP	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	9.78	1.87e-19	6.94e-16	0.58	0.52	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
KIRP	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	9.78	1.9e-19	7.05e-16	0.6	0.52	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	9.78	1.9e-19	7.05e-16	0.6	0.52	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
KIRP	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	9.78	1.9e-19	7.05e-16	0.58	0.52	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
KIRP	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-9.78	1.9e-19	7.06e-16	-0.51	-0.52	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-9.78	1.91e-19	7.09e-16	-0.51	-0.52	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-9.78	1.91e-19	7.09e-16	-0.51	-0.52	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-9.78	1.91e-19	7.09e-16	-0.51	-0.52	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-9.78	1.91e-19	7.09e-16	-0.51	-0.52	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
KIRP	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	9.77	1.98e-19	7.34e-16	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
KIRP	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-9.77	2.01e-19	7.45e-16	-0.41	-0.52	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
KIRP	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	9.77	2.03e-19	7.5e-16	0.5	0.52	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	9.76	2.08e-19	7.68e-16	0.6	0.52	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
KIRP	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	9.76	2.09e-19	7.73e-16	0.5	0.52	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
KIRP	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-9.76	2.12e-19	7.82e-16	-0.57	-0.52	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
KIRP	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	9.76	2.16e-19	7.96e-16	0.58	0.52	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	9.76	2.16e-19	7.96e-16	0.58	0.52	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-9.76	2.18e-19	8.03e-16	-0.58	-0.52	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
KIRP	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-9.76	2.2e-19	8.11e-16	-0.51	-0.52	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
KIRP	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-9.76	2.22e-19	8.18e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-9.76	2.22e-19	8.18e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-9.76	2.22e-19	8.18e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
KIRP	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-9.75	2.25e-19	8.27e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	9.75	2.28e-19	8.39e-16	0.61	0.52	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
KIRP	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-9.75	2.29e-19	8.41e-16	-0.43	-0.52	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
KIRP	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	9.75	2.34e-19	8.58e-16	0.57	0.52	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
KIRP	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-9.75	2.37e-19	8.69e-16	-0.61	-0.52	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
KIRP	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-9.75	2.38e-19	8.74e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-9.75	2.38e-19	8.74e-16	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
KIRP	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.74	2.43e-19	8.89e-16	-0.59	-0.52	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
KIRP	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	9.74	2.45e-19	8.97e-16	0.63	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
KIRP	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	9.74	2.45e-19	8.97e-16	0.5	0.52	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
KIRP	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-9.74	2.49e-19	9.1e-16	-0.58	-0.52	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
KIRP	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-9.74	2.5e-19	9.13e-16	-0.51	-0.52	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
KIRP	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	9.74	2.5e-19	9.13e-16	0.59	0.52	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	9.74	2.51e-19	9.18e-16	0.5	0.52	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
KIRP	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-9.74	2.52e-19	9.2e-16	-0.39	-0.52	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-9.74	2.52e-19	9.2e-16	-0.39	-0.52	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
KIRP	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	9.74	2.52e-19	9.23e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	9.74	2.52e-19	9.23e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	9.74	2.52e-19	9.23e-16	0.61	0.52	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
KIRP	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-9.74	2.56e-19	9.35e-16	-0.43	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
KIRP	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	9.73	2.58e-19	9.43e-16	0.57	0.52	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	9.73	2.58e-19	9.43e-16	0.57	0.52	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	9.73	2.61e-19	9.52e-16	0.58	0.52	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	9.73	2.61e-19	9.52e-16	0.58	0.52	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
KIRP	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-9.73	2.68e-19	9.79e-16	-0.5	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
KIRP	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-9.73	2.69e-19	9.8e-16	-0.41	-0.52	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
KIRP	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-9.73	2.71e-19	9.89e-16	-0.58	-0.52	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
KIRP	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-9.72	2.77e-19	1.01e-15	-0.67	-0.51	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
KIRP	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	9.72	2.8e-19	1.02e-15	0.57	0.51	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	9.72	2.82e-19	1.03e-15	0.62	0.51	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
KIRP	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.72	2.84e-19	1.03e-15	0.51	0.51	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.72	2.84e-19	1.03e-15	-0.51	-0.51	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
KIRP	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-9.72	2.85e-19	1.04e-15	-0.58	-0.51	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-9.72	2.85e-19	1.04e-15	-0.58	-0.51	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
KIRP	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	9.72	2.87e-19	1.04e-15	0.73	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
KIRP	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	9.72	2.87e-19	1.04e-15	0.73	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
KIRP	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-9.72	2.88e-19	1.04e-15	-0.57	-0.51	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-9.72	2.88e-19	1.04e-15	-0.57	-0.51	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-9.72	2.88e-19	1.04e-15	-0.57	-0.51	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
KIRP	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	9.72	2.9e-19	1.05e-15	0.59	0.51	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
KIRP	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-9.72	2.91e-19	1.05e-15	-0.58	-0.51	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
KIRP	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-9.72	2.94e-19	1.06e-15	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
KIRP	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	9.71	2.97e-19	1.07e-15	0.43	0.51	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-9.71	3e-19	1.08e-15	-0.59	-0.51	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
KIRP	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-9.71	3.08e-19	1.11e-15	-0.58	-0.51	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-9.71	3.13e-19	1.13e-15	-0.59	-0.51	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-9.71	3.13e-19	1.13e-15	-0.59	-0.51	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
KIRP	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-9.71	3.14e-19	1.13e-15	-0.47	-0.51	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-9.71	3.14e-19	1.13e-15	-0.47	-0.51	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-9.71	3.14e-19	1.13e-15	-0.47	-0.51	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-9.71	3.14e-19	1.13e-15	-0.47	-0.51	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
KIRP	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-9.71	3.16e-19	1.13e-15	-0.58	-0.51	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-9.71	3.16e-19	1.14e-15	-0.59	-0.51	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
KIRP	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	9.71	3.17e-19	1.14e-15	0.5	0.51	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-9.71	3.18e-19	1.14e-15	-0.51	-0.51	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
KIRP	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-9.71	3.18e-19	1.14e-15	-0.51	-0.51	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
KIRP	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	9.71	3.19e-19	1.14e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	9.71	3.19e-19	1.14e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-9.7	3.24e-19	1.16e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-9.7	3.24e-19	1.16e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	9.7	3.24e-19	1.16e-15	0.62	0.51	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
KIRP	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	9.7	3.34e-19	1.2e-15	0.94	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
KIRP	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	9.7	3.34e-19	1.2e-15	0.45	0.51	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
KIRP	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	9.7	3.42e-19	1.22e-15	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
KIRP	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	9.69	3.45e-19	1.24e-15	0.57	0.51	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	9.69	3.46e-19	1.24e-15	0.57	0.51	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
KIRP	cis	rs2698530	0.762	rs2698541	ENSG00000225889.6	AC074289.1	-9.69	3.47e-19	1.24e-15	-0.48	-0.51	Iron status biomarkers;	chr2:64261545	chr2:64143239~64252859:+
KIRP	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	9.69	3.48e-19	1.24e-15	0.64	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
KIRP	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-9.69	3.53e-19	1.26e-15	-0.53	-0.51	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
KIRP	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-9.69	3.6e-19	1.29e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
KIRP	cis	rs7115242	0.66	rs236911	ENSG00000254851.1	RP11-109L13.1	9.69	3.66e-19	1.31e-15	0.99	0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117214554	chr11:117135528~117138582:+
KIRP	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	9.68	3.7e-19	1.32e-15	0.59	0.51	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
KIRP	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-9.68	3.7e-19	1.32e-15	-0.58	-0.51	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
KIRP	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-9.68	3.7e-19	1.32e-15	-0.58	-0.51	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
KIRP	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-9.68	3.7e-19	1.32e-15	-0.58	-0.51	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-9.68	3.72e-19	1.33e-15	-0.57	-0.51	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-9.68	3.72e-19	1.33e-15	-0.57	-0.51	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-9.68	3.72e-19	1.33e-15	-0.57	-0.51	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-9.68	3.78e-19	1.35e-15	-0.62	-0.51	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
KIRP	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	9.68	3.78e-19	1.35e-15	0.99	0.51	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
KIRP	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-9.68	3.82e-19	1.36e-15	-0.82	-0.51	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
KIRP	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	9.68	3.83e-19	1.37e-15	0.57	0.51	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
KIRP	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-9.68	3.86e-19	1.37e-15	-0.57	-0.51	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
KIRP	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	9.68	3.87e-19	1.38e-15	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	9.68	3.87e-19	1.38e-15	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
KIRP	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-9.68	3.93e-19	1.4e-15	-1	-0.51	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
KIRP	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-9.67	3.98e-19	1.41e-15	-0.52	-0.51	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
KIRP	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	9.67	4e-19	1.42e-15	0.57	0.51	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
KIRP	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-9.67	4e-19	1.42e-15	-0.57	-0.51	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
KIRP	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-9.67	4e-19	1.42e-15	-0.46	-0.51	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
KIRP	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	9.67	4.03e-19	1.43e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
KIRP	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	9.67	4.06e-19	1.44e-15	0.57	0.51	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-9.67	4.07e-19	1.44e-15	-0.59	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	9.67	4.13e-19	1.46e-15	0.59	0.51	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
KIRP	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-9.67	4.16e-19	1.47e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	9.67	4.22e-19	1.49e-15	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
KIRP	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	9.66	4.32e-19	1.53e-15	0.64	0.51	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.887	rs4870139	ENSG00000231760.4	RP11-350J20.5	9.66	4.4e-19	1.55e-15	0.61	0.51	Lung cancer;	chr6:149575182	chr6:149796151~149826294:-
KIRP	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	9.66	4.41e-19	1.56e-15	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
KIRP	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-9.66	4.46e-19	1.58e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
KIRP	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-9.66	4.49e-19	1.58e-15	-0.51	-0.51	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
KIRP	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	9.66	4.51e-19	1.59e-15	0.57	0.51	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
KIRP	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	9.66	4.56e-19	1.61e-15	0.72	0.51	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
KIRP	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	9.66	4.56e-19	1.61e-15	0.72	0.51	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
KIRP	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-9.65	4.61e-19	1.62e-15	-0.59	-0.51	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
KIRP	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-9.65	4.68e-19	1.65e-15	-0.57	-0.51	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-9.65	4.71e-19	1.66e-15	-0.59	-0.51	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-9.65	4.71e-19	1.66e-15	-0.59	-0.51	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
KIRP	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	9.65	4.77e-19	1.68e-15	0.63	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-9.65	4.89e-19	1.72e-15	-0.59	-0.51	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
KIRP	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	9.64	4.95e-19	1.74e-15	0.94	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-9.64	4.96e-19	1.74e-15	-0.59	-0.51	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-9.64	4.96e-19	1.74e-15	-0.59	-0.51	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-9.64	4.96e-19	1.74e-15	-0.59	-0.51	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
KIRP	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-9.64	4.99e-19	1.75e-15	-0.41	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
KIRP	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	9.64	5.15e-19	1.8e-15	0.59	0.51	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-9.64	5.18e-19	1.81e-15	-0.59	-0.51	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-9.64	5.18e-19	1.81e-15	-0.59	-0.51	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	9.64	5.18e-19	1.81e-15	0.57	0.51	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	9.64	5.18e-19	1.81e-15	0.57	0.51	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
KIRP	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-9.64	5.21e-19	1.82e-15	-0.49	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
KIRP	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	9.64	5.26e-19	1.84e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
KIRP	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-9.63	5.33e-19	1.86e-15	-0.62	-0.51	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
KIRP	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-9.63	5.37e-19	1.87e-15	-0.67	-0.51	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
KIRP	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	9.63	5.39e-19	1.88e-15	0.5	0.51	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
KIRP	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-9.63	5.4e-19	1.88e-15	-0.51	-0.51	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
KIRP	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	9.63	5.41e-19	1.89e-15	0.62	0.51	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
KIRP	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-9.63	5.42e-19	1.89e-15	-0.51	-0.51	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
KIRP	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-9.63	5.43e-19	1.89e-15	-0.41	-0.51	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
KIRP	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	9.63	5.44e-19	1.89e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	9.63	5.44e-19	1.89e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
KIRP	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	9.63	5.45e-19	1.9e-15	0.63	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
KIRP	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-9.63	5.5e-19	1.91e-15	-0.63	-0.51	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
KIRP	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-9.63	5.5e-19	1.92e-15	-0.7	-0.51	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
KIRP	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	9.63	5.51e-19	1.92e-15	0.62	0.51	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
KIRP	cis	rs5760092	0.842	rs5760103	ENSG00000218537.1	MIF-AS1	9.63	5.58e-19	1.94e-15	0.77	0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23894426~23898930:-
KIRP	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-9.63	5.62e-19	1.95e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	9.63	5.62e-19	1.96e-15	0.57	0.51	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-9.63	5.63e-19	1.96e-15	-0.59	-0.51	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
KIRP	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-9.62	5.82e-19	2.02e-15	-0.44	-0.51	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
KIRP	cis	rs5760092	0.842	rs5751763	ENSG00000218537.1	MIF-AS1	9.62	5.82e-19	2.02e-15	0.73	0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23894426~23898930:-
KIRP	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-9.62	5.84e-19	2.03e-15	-0.51	-0.51	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-9.62	5.91e-19	2.05e-15	-0.62	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
KIRP	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	9.62	5.93e-19	2.06e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
KIRP	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	9.62	5.93e-19	2.06e-15	0.63	0.51	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
KIRP	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	9.62	5.96e-19	2.07e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	9.62	6.02e-19	2.09e-15	0.64	0.51	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-9.62	6.03e-19	2.09e-15	-0.59	-0.51	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
KIRP	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-9.62	6.04e-19	2.09e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
KIRP	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-9.62	6.1e-19	2.11e-15	-0.41	-0.51	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
KIRP	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	9.61	6.13e-19	2.12e-15	0.68	0.51	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
KIRP	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-9.61	6.16e-19	2.13e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
KIRP	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-9.61	6.2e-19	2.15e-15	-0.44	-0.51	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
KIRP	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-9.61	6.24e-19	2.16e-15	-0.63	-0.51	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
KIRP	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-9.61	6.27e-19	2.17e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	9.61	6.27e-19	2.17e-15	0.57	0.51	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
KIRP	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-9.61	6.31e-19	2.18e-15	-0.57	-0.51	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
KIRP	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-9.61	6.41e-19	2.21e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
KIRP	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	9.61	6.41e-19	2.21e-15	0.62	0.51	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	9.61	6.42e-19	2.22e-15	0.57	0.51	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
KIRP	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-9.61	6.47e-19	2.23e-15	-0.41	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
KIRP	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-9.6	6.71e-19	2.31e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-9.6	6.71e-19	2.31e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
KIRP	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-9.6	6.75e-19	2.32e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
KIRP	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-9.6	6.84e-19	2.35e-15	-0.5	-0.51	Breast cancer;	chr11:825777	chr11:779617~780755:+
KIRP	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	9.6	6.84e-19	2.35e-15	0.61	0.51	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	9.6	6.86e-19	2.36e-15	0.57	0.51	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
KIRP	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-9.6	6.89e-19	2.37e-15	-0.81	-0.51	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
KIRP	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-9.6	6.93e-19	2.38e-15	-0.56	-0.51	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
KIRP	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-9.6	7.01e-19	2.41e-15	-0.46	-0.51	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
KIRP	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	9.6	7.02e-19	2.41e-15	0.59	0.51	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
KIRP	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-9.59	7.12e-19	2.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-9.59	7.12e-19	2.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-9.59	7.12e-19	2.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-9.59	7.12e-19	2.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-9.59	7.12e-19	2.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-9.59	7.15e-19	2.45e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	9.59	7.17e-19	2.46e-15	0.64	0.51	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
KIRP	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	9.59	7.18e-19	2.46e-15	0.63	0.51	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	9.59	7.24e-19	2.48e-15	0.44	0.51	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
KIRP	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-9.59	7.28e-19	2.49e-15	-0.68	-0.51	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
KIRP	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-9.59	7.3e-19	2.5e-15	-0.6	-0.51	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
KIRP	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	9.59	7.36e-19	2.52e-15	0.57	0.51	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
KIRP	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	9.59	7.41e-19	2.54e-15	0.57	0.51	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
KIRP	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-9.59	7.5e-19	2.56e-15	-0.58	-0.51	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
KIRP	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-9.59	7.53e-19	2.57e-15	-0.51	-0.51	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
KIRP	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-9.58	7.65e-19	2.61e-15	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-9.58	7.65e-19	2.61e-15	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	9.58	7.72e-19	2.64e-15	0.58	0.51	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
KIRP	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	9.58	7.76e-19	2.65e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	9.58	7.91e-19	2.7e-15	0.57	0.51	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
KIRP	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	9.58	7.94e-19	2.71e-15	0.7	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
KIRP	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	9.58	7.95e-19	2.71e-15	0.57	0.51	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	9.58	7.95e-19	2.71e-15	0.57	0.51	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	9.58	7.95e-19	2.71e-15	0.57	0.51	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
KIRP	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-9.58	8.13e-19	2.77e-15	-0.65	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
KIRP	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	9.57	8.24e-19	2.81e-15	0.76	0.51	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
KIRP	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-9.57	8.55e-19	2.91e-15	-0.52	-0.51	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
KIRP	cis	rs2698530	0.762	rs2555441	ENSG00000225889.6	AC074289.1	-9.57	8.64e-19	2.94e-15	-0.49	-0.51	Iron status biomarkers;	chr2:64261741	chr2:64143239~64252859:+
KIRP	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	9.57	8.66e-19	2.95e-15	0.57	0.51	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
KIRP	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-9.57	8.68e-19	2.95e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
KIRP	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-9.57	8.7e-19	2.96e-15	-0.83	-0.51	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
KIRP	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	9.57	8.72e-19	2.96e-15	0.59	0.51	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	9.56	8.83e-19	3e-15	0.58	0.51	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
KIRP	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	9.56	8.88e-19	3.01e-15	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
KIRP	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	9.56	8.9e-19	3.02e-15	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
KIRP	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-9.56	8.92e-19	3.03e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
KIRP	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	9.56	8.93e-19	3.03e-15	0.64	0.51	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	9.56	8.94e-19	3.03e-15	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
KIRP	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-9.56	9.04e-19	3.06e-15	-0.78	-0.51	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
KIRP	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-9.56	9.07e-19	3.07e-15	-0.58	-0.51	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
KIRP	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	9.56	9.11e-19	3.09e-15	0.94	0.51	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
KIRP	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	9.56	9.11e-19	3.09e-15	0.66	0.51	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
KIRP	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-9.56	9.12e-19	3.09e-15	-0.52	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	9.56	9.21e-19	3.11e-15	0.56	0.51	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
KIRP	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	9.56	9.27e-19	3.13e-15	0.49	0.51	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
KIRP	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-9.55	9.47e-19	3.2e-15	-0.58	-0.51	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
KIRP	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-9.55	9.48e-19	3.2e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-9.55	9.54e-19	3.22e-15	-0.58	-0.51	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
KIRP	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-9.55	9.54e-19	3.22e-15	-0.58	-0.51	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
KIRP	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-9.55	9.6e-19	3.24e-15	-0.72	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
KIRP	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-9.55	9.81e-19	3.3e-15	-0.59	-0.51	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
KIRP	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-9.55	9.89e-19	3.33e-15	-0.79	-0.51	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
KIRP	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-9.55	9.99e-19	3.36e-15	-0.61	-0.51	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
KIRP	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	9.55	1e-18	3.37e-15	0.56	0.51	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
KIRP	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	9.55	1e-18	3.37e-15	0.58	0.51	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
KIRP	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-9.54	1.01e-18	3.39e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-9.54	1.01e-18	3.39e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-9.54	1.01e-18	3.39e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-9.54	1.01e-18	3.39e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
KIRP	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	9.54	1.01e-18	3.39e-15	0.55	0.51	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
KIRP	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-9.54	1.02e-18	3.44e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
KIRP	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	9.54	1.02e-18	3.44e-15	0.57	0.51	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
KIRP	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	9.54	1.02e-18	3.44e-15	0.57	0.51	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
KIRP	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-9.54	1.03e-18	3.45e-15	-0.52	-0.51	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
KIRP	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	9.54	1.03e-18	3.47e-15	0.66	0.51	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
KIRP	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	9.54	1.04e-18	3.48e-15	0.58	0.51	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
KIRP	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.54	1.05e-18	3.51e-15	0.63	0.51	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
KIRP	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-9.54	1.05e-18	3.52e-15	-0.52	-0.51	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
KIRP	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-9.54	1.06e-18	3.53e-15	-0.65	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
KIRP	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-9.54	1.06e-18	3.56e-15	-0.41	-0.51	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
KIRP	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	9.54	1.07e-18	3.59e-15	0.62	0.51	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-9.54	1.07e-18	3.59e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
KIRP	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-9.54	1.08e-18	3.6e-15	-0.58	-0.51	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
KIRP	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	9.53	1.08e-18	3.62e-15	0.66	0.51	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
KIRP	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	9.53	1.1e-18	3.66e-15	0.65	0.51	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
KIRP	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-9.53	1.1e-18	3.69e-15	-0.51	-0.51	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
KIRP	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-9.53	1.1e-18	3.69e-15	-0.51	-0.51	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
KIRP	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-9.53	1.13e-18	3.76e-15	-0.66	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
KIRP	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9.53	1.13e-18	3.77e-15	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
KIRP	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-9.53	1.16e-18	3.86e-15	-0.56	-0.51	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-9.53	1.16e-18	3.86e-15	-0.56	-0.51	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
KIRP	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	9.52	1.17e-18	3.88e-15	0.58	0.51	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
KIRP	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-9.52	1.19e-18	3.95e-15	-0.74	-0.51	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
KIRP	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-9.52	1.19e-18	3.96e-15	-0.45	-0.51	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
KIRP	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-9.52	1.19e-18	3.96e-15	-0.42	-0.51	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
KIRP	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	9.52	1.2e-18	3.99e-15	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-9.52	1.22e-18	4.05e-15	-0.57	-0.51	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
KIRP	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	9.52	1.23e-18	4.08e-15	0.7	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
KIRP	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-9.52	1.24e-18	4.11e-15	-0.44	-0.51	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
KIRP	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-9.52	1.25e-18	4.14e-15	-0.52	-0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
KIRP	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-9.51	1.25e-18	4.16e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
KIRP	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	9.51	1.26e-18	4.17e-15	0.62	0.51	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
KIRP	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	9.51	1.31e-18	4.34e-15	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	9.51	1.31e-18	4.34e-15	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
KIRP	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	9.51	1.32e-18	4.38e-15	0.56	0.51	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	9.51	1.32e-18	4.38e-15	0.56	0.51	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
KIRP	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	9.51	1.33e-18	4.4e-15	0.43	0.51	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	9.51	1.33e-18	4.4e-15	0.43	0.51	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	9.51	1.33e-18	4.4e-15	0.43	0.51	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
KIRP	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	9.51	1.33e-18	4.41e-15	0.57	0.51	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	9.51	1.33e-18	4.42e-15	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
KIRP	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-9.51	1.34e-18	4.43e-15	-0.44	-0.51	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
KIRP	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-9.51	1.34e-18	4.44e-15	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
KIRP	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-9.5	1.35e-18	4.45e-15	-0.5	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
KIRP	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	9.5	1.37e-18	4.51e-15	0.49	0.51	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
KIRP	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-9.5	1.37e-18	4.52e-15	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	9.5	1.41e-18	4.67e-15	0.67	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
KIRP	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	9.5	1.42e-18	4.69e-15	0.59	0.51	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	9.5	1.42e-18	4.69e-15	0.59	0.51	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	9.5	1.42e-18	4.69e-15	0.59	0.51	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	9.5	1.42e-18	4.69e-15	0.59	0.51	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
KIRP	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	9.49	1.48e-18	4.88e-15	0.62	0.51	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
KIRP	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-9.49	1.5e-18	4.92e-15	-0.42	-0.51	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
KIRP	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-9.48	1.55e-18	5.1e-15	-0.45	-0.51	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
KIRP	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-9.48	1.56e-18	5.11e-15	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
KIRP	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-9.48	1.56e-18	5.12e-15	-0.51	-0.51	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
KIRP	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-9.48	1.57e-18	5.16e-15	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
KIRP	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-9.48	1.59e-18	5.2e-15	-0.67	-0.51	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
KIRP	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-9.48	1.59e-18	5.22e-15	-0.56	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
KIRP	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-9.48	1.6e-18	5.24e-15	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-9.48	1.62e-18	5.29e-15	-0.58	-0.51	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
KIRP	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-9.48	1.64e-18	5.37e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
KIRP	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-9.48	1.66e-18	5.42e-15	-0.62	-0.51	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-9.47	1.67e-18	5.45e-15	-0.74	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
KIRP	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-9.47	1.68e-18	5.48e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-9.47	1.68e-18	5.48e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-9.47	1.68e-18	5.48e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
KIRP	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-9.47	1.68e-18	5.48e-15	-0.49	-0.51	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-9.47	1.69e-18	5.51e-15	-0.55	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
KIRP	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	9.47	1.69e-18	5.53e-15	0.57	0.51	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
KIRP	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	9.47	1.7e-18	5.55e-15	0.58	0.51	Height;	chr11:118703185	chr11:118688039~118690600:-
KIRP	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	9.47	1.7e-18	5.55e-15	0.58	0.51	Height;	chr11:118703207	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	9.47	1.7e-18	5.55e-15	0.58	0.51	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
KIRP	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	9.47	1.7e-18	5.55e-15	0.58	0.51	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
KIRP	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	9.47	1.71e-18	5.57e-15	0.58	0.51	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
KIRP	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-9.47	1.71e-18	5.58e-15	-0.57	-0.51	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	9.46	1.79e-18	5.83e-15	0.56	0.5	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	9.46	1.79e-18	5.83e-15	0.56	0.5	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	9.46	1.79e-18	5.83e-15	0.56	0.5	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	9.46	1.79e-18	5.83e-15	0.56	0.5	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	9.46	1.79e-18	5.83e-15	0.56	0.5	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
KIRP	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	9.46	1.8e-18	5.86e-15	0.61	0.5	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
KIRP	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-9.46	1.83e-18	5.95e-15	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	9.46	1.86e-18	6.04e-15	0.56	0.5	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	9.46	1.86e-18	6.04e-15	0.56	0.5	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	9.46	1.88e-18	6.09e-15	0.43	0.5	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
KIRP	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	9.46	1.88e-18	6.09e-15	0.46	0.5	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
KIRP	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	9.46	1.9e-18	6.18e-15	0.61	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
KIRP	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	9.46	1.9e-18	6.18e-15	0.56	0.5	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-9.45	1.93e-18	6.25e-15	-0.58	-0.5	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
KIRP	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-9.45	1.98e-18	6.43e-15	-0.57	-0.5	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
KIRP	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	9.45	1.99e-18	6.45e-15	0.43	0.5	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
KIRP	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-9.45	1.99e-18	6.47e-15	-0.66	-0.5	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
KIRP	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	9.45	2.01e-18	6.52e-15	0.58	0.5	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
KIRP	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	9.45	2.02e-18	6.55e-15	0.56	0.5	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
KIRP	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-9.45	2.03e-18	6.59e-15	-0.38	-0.5	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
KIRP	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	9.44	2.1e-18	6.78e-15	0.55	0.5	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
KIRP	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-9.44	2.14e-18	6.92e-15	-0.5	-0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
KIRP	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	9.44	2.16e-18	6.97e-15	0.62	0.5	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
KIRP	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	9.44	2.17e-18	7.02e-15	0.56	0.5	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
KIRP	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	9.44	2.17e-18	7.02e-15	0.56	0.5	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
KIRP	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-9.44	2.18e-18	7.04e-15	-0.61	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
KIRP	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	9.44	2.2e-18	7.1e-15	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	9.44	2.2e-18	7.1e-15	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	9.43	2.23e-18	7.2e-15	0.59	0.5	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
KIRP	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-9.43	2.24e-18	7.21e-15	-0.45	-0.5	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
KIRP	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-9.43	2.24e-18	7.23e-15	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
KIRP	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-9.43	2.24e-18	7.23e-15	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	9.43	2.25e-18	7.25e-15	0.6	0.5	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
KIRP	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	9.43	2.26e-18	7.27e-15	0.45	0.5	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
KIRP	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-9.43	2.26e-18	7.27e-15	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-9.43	2.26e-18	7.3e-15	-0.58	-0.5	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
KIRP	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-9.43	2.27e-18	7.3e-15	-0.58	-0.5	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
KIRP	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	9.43	2.32e-18	7.47e-15	0.72	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
KIRP	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-9.43	2.33e-18	7.5e-15	-0.6	-0.5	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
KIRP	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	9.43	2.37e-18	7.61e-15	0.72	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
KIRP	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-9.43	2.37e-18	7.62e-15	-0.67	-0.5	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
KIRP	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.42	2.42e-18	7.76e-15	-0.5	-0.5	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
KIRP	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	9.42	2.43e-18	7.8e-15	0.56	0.5	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-9.42	2.46e-18	7.87e-15	-0.43	-0.5	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	9.42	2.48e-18	7.93e-15	0.43	0.5	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
KIRP	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	9.42	2.49e-18	7.96e-15	0.94	0.5	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
KIRP	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-9.42	2.52e-18	8.06e-15	-0.43	-0.5	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
KIRP	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-9.42	2.52e-18	8.06e-15	-0.44	-0.5	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
KIRP	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	9.42	2.54e-18	8.13e-15	0.56	0.5	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	9.42	2.54e-18	8.13e-15	0.56	0.5	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	9.42	2.54e-18	8.13e-15	0.56	0.5	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
KIRP	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-9.41	2.55e-18	8.16e-15	-0.38	-0.5	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
KIRP	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	9.41	2.61e-18	8.33e-15	0.64	0.5	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
KIRP	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	9.41	2.7e-18	8.62e-15	0.89	0.5	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	9.41	2.7e-18	8.62e-15	0.89	0.5	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
KIRP	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	9.4	2.77e-18	8.83e-15	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
KIRP	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-9.4	2.79e-18	8.87e-15	-0.57	-0.5	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-9.4	2.79e-18	8.87e-15	-0.57	-0.5	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
KIRP	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	9.4	2.82e-18	8.99e-15	0.6	0.5	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	9.4	2.83e-18	9.02e-15	0.66	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
KIRP	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.4	2.86e-18	9.11e-15	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.4	2.86e-18	9.11e-15	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	9.4	2.87e-18	9.14e-15	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
KIRP	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	9.4	2.88e-18	9.16e-15	0.56	0.5	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
KIRP	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-9.4	2.91e-18	9.23e-15	-0.55	-0.5	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
KIRP	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-9.39	2.95e-18	9.38e-15	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
KIRP	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-9.39	2.95e-18	9.38e-15	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
KIRP	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-9.39	2.96e-18	9.39e-15	-0.57	-0.5	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-9.39	2.96e-18	9.39e-15	-0.57	-0.5	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
KIRP	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-9.39	2.98e-18	9.46e-15	-0.55	-0.5	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-9.39	2.98e-18	9.46e-15	-0.55	-0.5	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	9.39	2.99e-18	9.49e-15	0.57	0.5	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
KIRP	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-9.39	3.07e-18	9.71e-15	-0.71	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
KIRP	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	9.39	3.09e-18	9.78e-15	0.57	0.5	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	9.39	3.09e-18	9.78e-15	0.57	0.5	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
KIRP	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-9.39	3.11e-18	9.83e-15	-0.57	-0.5	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-9.39	3.11e-18	9.83e-15	-0.57	-0.5	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
KIRP	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	9.39	3.13e-18	9.88e-15	0.56	0.5	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	9.39	3.13e-18	9.88e-15	0.56	0.5	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
KIRP	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-9.38	3.17e-18	1e-14	-0.42	-0.5	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
KIRP	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	9.38	3.18e-18	1e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
KIRP	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	9.38	3.25e-18	1.02e-14	0.56	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
KIRP	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-9.38	3.27e-18	1.03e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
KIRP	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-9.38	3.33e-18	1.05e-14	-0.52	-0.5	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
KIRP	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-9.38	3.33e-18	1.05e-14	-0.43	-0.5	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-9.38	3.33e-18	1.05e-14	-0.43	-0.5	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
KIRP	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	9.38	3.38e-18	1.06e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
KIRP	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-9.37	3.41e-18	1.07e-14	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
KIRP	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	9.37	3.42e-18	1.08e-14	0.55	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
KIRP	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-9.37	3.43e-18	1.08e-14	-0.48	-0.5	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
KIRP	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-9.37	3.44e-18	1.08e-14	-0.43	-0.5	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-9.37	3.44e-18	1.08e-14	-0.44	-0.5	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
KIRP	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-9.37	3.49e-18	1.1e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
KIRP	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-9.37	3.54e-18	1.11e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
KIRP	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-9.37	3.54e-18	1.11e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-9.37	3.55e-18	1.11e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	9.37	3.58e-18	1.12e-14	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
KIRP	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-9.37	3.6e-18	1.12e-14	-0.43	-0.5	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
KIRP	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	9.37	3.61e-18	1.13e-14	0.58	0.5	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	9.37	3.61e-18	1.13e-14	0.58	0.5	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	9.36	3.64e-18	1.14e-14	0.56	0.5	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	9.36	3.64e-18	1.14e-14	0.56	0.5	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	9.36	3.64e-18	1.14e-14	0.56	0.5	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	9.36	3.64e-18	1.14e-14	0.56	0.5	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	9.36	3.64e-18	1.14e-14	0.56	0.5	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
KIRP	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-9.36	3.65e-18	1.14e-14	-0.5	-0.5	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
KIRP	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-9.36	3.66e-18	1.14e-14	-0.38	-0.5	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
KIRP	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-9.36	3.7e-18	1.16e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
KIRP	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-9.36	3.7e-18	1.16e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
KIRP	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	9.36	3.73e-18	1.17e-14	0.61	0.5	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
KIRP	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-9.36	3.75e-18	1.17e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
KIRP	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-9.36	3.76e-18	1.17e-14	-0.51	-0.5	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
KIRP	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-9.36	3.78e-18	1.18e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
KIRP	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-9.36	3.79e-18	1.18e-14	-0.96	-0.5	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
KIRP	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-9.36	3.81e-18	1.19e-14	-0.66	-0.5	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
KIRP	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-9.36	3.9e-18	1.22e-14	-0.61	-0.5	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
KIRP	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-9.35	3.97e-18	1.23e-14	-0.58	-0.5	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	9.35	4.02e-18	1.25e-14	0.56	0.5	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
KIRP	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	9.35	4.07e-18	1.26e-14	0.59	0.5	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	9.35	4.07e-18	1.26e-14	0.59	0.5	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	9.34	4.22e-18	1.31e-14	0.55	0.5	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
KIRP	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-9.34	4.28e-18	1.32e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
KIRP	cis	rs9399135	0.682	rs9402684	ENSG00000232876.1	CTA-212D2.2	-9.34	4.28e-18	1.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135098167	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.715	rs7743042	ENSG00000232876.1	CTA-212D2.2	-9.34	4.28e-18	1.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135098696	chr6:135055033~135060550:+
KIRP	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	9.34	4.32e-18	1.33e-14	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	9.34	4.32e-18	1.33e-14	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
KIRP	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	9.34	4.35e-18	1.34e-14	0.51	0.5	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
KIRP	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-9.34	4.35e-18	1.34e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-9.34	4.35e-18	1.34e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
KIRP	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-9.34	4.41e-18	1.36e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-9.34	4.41e-18	1.36e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-9.34	4.41e-18	1.36e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-9.34	4.41e-18	1.36e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-9.34	4.46e-18	1.38e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-9.34	4.46e-18	1.38e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-9.34	4.46e-18	1.38e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-9.34	4.46e-18	1.38e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
KIRP	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	9.34	4.48e-18	1.38e-14	0.96	0.5	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
KIRP	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-9.33	4.51e-18	1.39e-14	-0.44	-0.5	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-9.33	4.57e-18	1.4e-14	-0.43	-0.5	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
KIRP	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	9.33	4.58e-18	1.41e-14	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	9.33	4.58e-18	1.41e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	9.33	4.58e-18	1.41e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
KIRP	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	9.33	4.63e-18	1.42e-14	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	9.33	4.65e-18	1.43e-14	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	9.33	4.65e-18	1.43e-14	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	9.33	4.65e-18	1.43e-14	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	9.33	4.65e-18	1.43e-14	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
KIRP	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	9.33	4.73e-18	1.45e-14	0.56	0.5	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
KIRP	cis	rs1799949	0.757	rs9915489	ENSG00000198496.9	NBR2	-9.33	4.8e-18	1.47e-14	-0.5	-0.5	Menopause (age at onset);	chr17:43021209	chr17:43125610~43153671:+
KIRP	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-9.33	4.82e-18	1.48e-14	-0.4	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
KIRP	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-9.32	4.87e-18	1.49e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-9.32	4.87e-18	1.49e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-9.32	4.87e-18	1.49e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
KIRP	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-9.32	4.96e-18	1.52e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
KIRP	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	9.32	4.99e-18	1.53e-14	0.57	0.5	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
KIRP	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-9.32	5e-18	1.53e-14	-0.54	-0.5	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
KIRP	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	9.32	5.01e-18	1.53e-14	0.64	0.5	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
KIRP	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.32	5.12e-18	1.57e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
KIRP	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	9.32	5.16e-18	1.58e-14	0.58	0.5	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
KIRP	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-9.32	5.17e-18	1.58e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-9.32	5.17e-18	1.58e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-9.31	5.21e-18	1.59e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
KIRP	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	9.31	5.22e-18	1.6e-14	0.64	0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
KIRP	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-9.31	5.32e-18	1.63e-14	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
KIRP	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	9.31	5.43e-18	1.66e-14	0.57	0.5	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	9.31	5.43e-18	1.66e-14	0.57	0.5	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	9.31	5.43e-18	1.66e-14	0.57	0.5	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	9.31	5.43e-18	1.66e-14	0.57	0.5	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
KIRP	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-9.31	5.49e-18	1.67e-14	-0.57	-0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
KIRP	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-9.31	5.56e-18	1.7e-14	-0.55	-0.5	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-9.3	5.64e-18	1.72e-14	-0.56	-0.5	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
KIRP	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	9.3	5.65e-18	1.72e-14	0.56	0.5	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
KIRP	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-9.3	5.66e-18	1.72e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
KIRP	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-9.3	5.66e-18	1.72e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
KIRP	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	9.3	5.8e-18	1.76e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
KIRP	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-9.3	5.81e-18	1.77e-14	-0.49	-0.5	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
KIRP	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-9.3	5.82e-18	1.77e-14	-0.71	-0.5	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
KIRP	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-9.3	5.86e-18	1.78e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-9.3	5.86e-18	1.78e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-9.3	5.86e-18	1.78e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
KIRP	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-9.3	5.9e-18	1.79e-14	-0.57	-0.5	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
KIRP	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	9.29	6.01e-18	1.83e-14	0.74	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	9.29	6.05e-18	1.84e-14	0.59	0.5	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
KIRP	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.29	6.1e-18	1.85e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.29	6.1e-18	1.85e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
KIRP	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-9.29	6.11e-18	1.86e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
KIRP	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-9.29	6.13e-18	1.86e-14	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
KIRP	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-9.29	6.16e-18	1.87e-14	-0.48	-0.5	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
KIRP	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.29	6.17e-18	1.87e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.29	6.17e-18	1.87e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.29	6.17e-18	1.87e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
KIRP	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-9.29	6.26e-18	1.9e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
KIRP	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	9.29	6.29e-18	1.91e-14	0.57	0.5	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	9.29	6.3e-18	1.91e-14	0.55	0.5	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-9.29	6.31e-18	1.91e-14	-0.43	-0.5	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-9.29	6.31e-18	1.91e-14	-0.43	-0.5	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-9.29	6.31e-18	1.91e-14	-0.43	-0.5	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-9.29	6.31e-18	1.91e-14	-0.43	-0.5	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
KIRP	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-9.29	6.31e-18	1.91e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-9.29	6.31e-18	1.91e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-9.29	6.31e-18	1.91e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-9.29	6.31e-18	1.91e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
KIRP	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-9.29	6.33e-18	1.91e-14	-0.51	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-9.29	6.38e-18	1.93e-14	-0.56	-0.5	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
KIRP	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.29	6.39e-18	1.93e-14	-0.57	-0.5	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
KIRP	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.29	6.39e-18	1.93e-14	-0.57	-0.5	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
KIRP	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	9.28	6.45e-18	1.95e-14	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	9.28	6.45e-18	1.95e-14	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	9.28	6.46e-18	1.95e-14	0.59	0.5	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	9.28	6.46e-18	1.95e-14	0.59	0.5	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.28	6.46e-18	1.95e-14	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
KIRP	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	9.28	6.52e-18	1.97e-14	0.55	0.5	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	9.28	6.52e-18	1.97e-14	0.55	0.5	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
KIRP	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-9.28	6.52e-18	1.97e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-9.28	6.52e-18	1.97e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	9.28	6.53e-18	1.97e-14	0.56	0.5	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
KIRP	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-9.28	6.74e-18	2.03e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-9.28	6.74e-18	2.03e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-9.28	6.74e-18	2.03e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-9.28	6.74e-18	2.03e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
KIRP	cis	rs67311347	1	rs11707673	ENSG00000230274.1	PGAM1P3	9.28	6.86e-18	2.07e-14	0.51	0.5	Renal cell carcinoma;	chr3:40409113	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs4973993	ENSG00000230274.1	PGAM1P3	9.28	6.86e-18	2.07e-14	0.51	0.5	Renal cell carcinoma;	chr3:40411469	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs4973994	ENSG00000230274.1	PGAM1P3	9.28	6.86e-18	2.07e-14	0.51	0.5	Renal cell carcinoma;	chr3:40411533	chr3:40322715~40323279:-
KIRP	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-9.27	6.94e-18	2.09e-14	-0.37	-0.5	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
KIRP	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	9.27	7.14e-18	2.15e-14	0.69	0.5	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
KIRP	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	9.27	7.15e-18	2.15e-14	0.56	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
KIRP	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	9.27	7.24e-18	2.18e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
KIRP	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	9.27	7.27e-18	2.19e-14	0.55	0.5	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
KIRP	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	9.27	7.28e-18	2.19e-14	0.65	0.5	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
KIRP	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	9.27	7.37e-18	2.22e-14	0.57	0.5	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
KIRP	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-9.26	7.47e-18	2.25e-14	-0.5	-0.5	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
KIRP	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-9.26	7.53e-18	2.26e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-9.26	7.53e-18	2.26e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-9.26	7.53e-18	2.26e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-9.26	7.53e-18	2.26e-14	-0.46	-0.5	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
KIRP	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	9.26	7.54e-18	2.27e-14	0.61	0.5	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
KIRP	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-9.26	7.61e-18	2.29e-14	-0.54	-0.5	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
KIRP	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-9.26	7.62e-18	2.29e-14	-0.45	-0.5	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
KIRP	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	9.26	7.67e-18	2.31e-14	0.73	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	9.26	7.67e-18	2.31e-14	0.73	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
KIRP	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-9.26	7.82e-18	2.35e-14	-0.58	-0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
KIRP	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-9.26	7.88e-18	2.36e-14	-0.56	-0.5	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
KIRP	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	9.26	7.88e-18	2.36e-14	0.89	0.5	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
KIRP	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	9.25	8.12e-18	2.43e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
KIRP	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	9.25	8.14e-18	2.43e-14	0.55	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
KIRP	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	9.25	8.15e-18	2.44e-14	0.38	0.5	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
KIRP	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	9.25	8.22e-18	2.46e-14	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
KIRP	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	9.25	8.29e-18	2.48e-14	0.97	0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
KIRP	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	9.25	8.36e-18	2.49e-14	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
KIRP	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	9.25	8.45e-18	2.52e-14	0.51	0.5	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
KIRP	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	9.24	8.51e-18	2.53e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	9.24	8.51e-18	2.53e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
KIRP	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	9.24	8.82e-18	2.62e-14	0.61	0.5	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
KIRP	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-9.24	8.98e-18	2.67e-14	-0.75	-0.5	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
KIRP	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	9.23	9.23e-18	2.74e-14	0.56	0.5	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
KIRP	cis	rs67311347	1	rs11707278	ENSG00000230274.1	PGAM1P3	9.23	9.35e-18	2.77e-14	0.5	0.5	Renal cell carcinoma;	chr3:40445584	chr3:40322715~40323279:-
KIRP	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	9.23	9.45e-18	2.8e-14	0.61	0.5	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-9.23	9.58e-18	2.84e-14	-0.55	-0.5	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
KIRP	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.23	9.61e-18	2.85e-14	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
KIRP	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-9.22	9.92e-18	2.94e-14	-0.43	-0.5	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-9.22	9.92e-18	2.94e-14	-0.43	-0.5	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
KIRP	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	9.22	1e-17	2.96e-14	0.72	0.5	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
KIRP	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	9.22	1.02e-17	3e-14	0.61	0.49	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
KIRP	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	9.22	1.02e-17	3.01e-14	0.77	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	9.22	1.02e-17	3.01e-14	0.77	0.49	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	9.22	1.02e-17	3.01e-14	0.77	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	9.22	1.02e-17	3.01e-14	0.77	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
KIRP	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	9.22	1.03e-17	3.05e-14	0.56	0.49	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
KIRP	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	9.22	1.04e-17	3.06e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
KIRP	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	9.22	1.04e-17	3.06e-14	0.55	0.49	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-9.22	1.04e-17	3.07e-14	-0.43	-0.49	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-9.21	1.06e-17	3.13e-14	-0.43	-0.49	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
KIRP	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	9.21	1.06e-17	3.14e-14	0.54	0.49	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
KIRP	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	9.21	1.07e-17	3.14e-14	0.72	0.49	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
KIRP	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	9.21	1.07e-17	3.14e-14	0.72	0.49	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
KIRP	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	9.21	1.07e-17	3.17e-14	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.21	1.08e-17	3.19e-14	0.6	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
KIRP	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	9.21	1.11e-17	3.26e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
KIRP	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-9.21	1.11e-17	3.27e-14	-0.56	-0.49	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-9.21	1.11e-17	3.27e-14	-0.56	-0.49	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-9.21	1.11e-17	3.27e-14	-0.56	-0.49	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	9.21	1.12e-17	3.31e-14	0.56	0.49	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
KIRP	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-9.21	1.12e-17	3.31e-14	-0.49	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
KIRP	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.13e-17	3.33e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
KIRP	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	9.2	1.15e-17	3.38e-14	0.62	0.49	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	9.2	1.16e-17	3.4e-14	0.57	0.49	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-9.2	1.16e-17	3.41e-14	-0.63	-0.49	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	9.2	1.16e-17	3.41e-14	0.84	0.49	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-9.2	1.16e-17	3.41e-14	-0.64	-0.49	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
KIRP	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-9.2	1.17e-17	3.43e-14	-0.46	-0.49	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
KIRP	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	9.2	1.18e-17	3.48e-14	0.6	0.49	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
KIRP	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	9.2	1.18e-17	3.48e-14	0.39	0.49	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
KIRP	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	9.19	1.25e-17	3.66e-14	0.55	0.49	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
KIRP	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-9.18	1.3e-17	3.82e-14	-0.43	-0.49	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
KIRP	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	9.18	1.32e-17	3.87e-14	0.74	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
KIRP	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	9.18	1.32e-17	3.87e-14	0.71	0.49	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
KIRP	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-9.18	1.32e-17	3.87e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-9.18	1.34e-17	3.9e-14	-0.54	-0.49	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
KIRP	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-9.18	1.34e-17	3.91e-14	-0.38	-0.49	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
KIRP	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-9.18	1.34e-17	3.92e-14	-0.48	-0.49	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
KIRP	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	9.18	1.35e-17	3.95e-14	0.64	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
KIRP	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-9.18	1.36e-17	3.96e-14	-0.58	-0.49	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	9.18	1.37e-17	3.99e-14	0.56	0.49	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
KIRP	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	9.18	1.38e-17	4.02e-14	0.54	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
KIRP	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-9.17	1.39e-17	4.06e-14	-0.5	-0.49	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
KIRP	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	9.17	1.42e-17	4.13e-14	0.69	0.49	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
KIRP	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	9.17	1.42e-17	4.13e-14	0.69	0.49	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
KIRP	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	9.17	1.42e-17	4.13e-14	0.69	0.49	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
KIRP	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-9.17	1.44e-17	4.18e-14	-0.63	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
KIRP	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	9.17	1.44e-17	4.19e-14	0.72	0.49	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
KIRP	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-9.17	1.45e-17	4.23e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-9.17	1.45e-17	4.23e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-9.17	1.45e-17	4.23e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
KIRP	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	9.17	1.46e-17	4.25e-14	0.4	0.49	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
KIRP	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-9.17	1.46e-17	4.25e-14	-0.54	-0.49	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-9.17	1.46e-17	4.25e-14	-0.54	-0.49	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-9.17	1.46e-17	4.25e-14	-0.54	-0.49	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
KIRP	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-9.17	1.46e-17	4.25e-14	-0.54	-0.49	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
KIRP	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	9.17	1.48e-17	4.32e-14	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
KIRP	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
KIRP	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.51e-17	4.39e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
KIRP	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	9.16	1.54e-17	4.47e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
KIRP	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-9.16	1.58e-17	4.59e-14	-0.56	-0.49	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	9.16	1.59e-17	4.59e-14	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
KIRP	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	9.15	1.64e-17	4.73e-14	0.8	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
KIRP	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-9.15	1.67e-17	4.82e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-9.15	1.67e-17	4.82e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-9.15	1.67e-17	4.82e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-9.15	1.67e-17	4.82e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-9.15	1.67e-17	4.82e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-9.15	1.68e-17	4.85e-14	-0.63	-0.49	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-9.15	1.68e-17	4.85e-14	-0.63	-0.49	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
KIRP	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	9.15	1.69e-17	4.86e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
KIRP	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-9.15	1.69e-17	4.88e-14	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
KIRP	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	9.15	1.69e-17	4.88e-14	0.67	0.49	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
KIRP	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	9.15	1.71e-17	4.92e-14	0.56	0.49	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	9.15	1.71e-17	4.94e-14	0.65	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
KIRP	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-9.14	1.72e-17	4.95e-14	-0.82	-0.49	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
KIRP	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	9.14	1.75e-17	5.03e-14	0.55	0.49	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
KIRP	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-9.14	1.76e-17	5.07e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
KIRP	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-9.14	1.77e-17	5.08e-14	-0.63	-0.49	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	9.14	1.77e-17	5.09e-14	0.58	0.49	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
KIRP	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.14	1.78e-17	5.1e-14	0.61	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	9.14	1.78e-17	5.1e-14	0.61	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	9.14	1.78e-17	5.1e-14	0.61	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
KIRP	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-9.14	1.8e-17	5.16e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
KIRP	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	9.14	1.81e-17	5.18e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
KIRP	cis	rs67311347	1	rs73078169	ENSG00000230274.1	PGAM1P3	9.14	1.83e-17	5.25e-14	0.5	0.49	Renal cell carcinoma;	chr3:40442307	chr3:40322715~40323279:-
KIRP	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	9.14	1.83e-17	5.25e-14	0.77	0.49	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	9.13	1.87e-17	5.34e-14	0.77	0.49	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-9.13	1.89e-17	5.39e-14	-0.56	-0.49	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-9.13	1.89e-17	5.39e-14	-0.56	-0.49	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	9.13	1.89e-17	5.4e-14	0.55	0.49	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
KIRP	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	9.13	1.89e-17	5.41e-14	0.77	0.49	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
KIRP	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	9.13	1.9e-17	5.42e-14	0.59	0.49	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
KIRP	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	9.13	1.9e-17	5.44e-14	0.55	0.49	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
KIRP	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	9.13	1.9e-17	5.44e-14	0.55	0.49	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
KIRP	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-9.13	1.91e-17	5.46e-14	-0.58	-0.49	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	9.13	1.91e-17	5.46e-14	0.64	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
KIRP	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-9.12	1.98e-17	5.65e-14	-0.45	-0.49	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
KIRP	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-9.12	2e-17	5.7e-14	-0.55	-0.49	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
KIRP	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-9.12	2.02e-17	5.75e-14	-0.63	-0.49	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
KIRP	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	9.12	2.03e-17	5.77e-14	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	9.12	2.03e-17	5.77e-14	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
KIRP	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-9.12	2.03e-17	5.78e-14	-0.59	-0.49	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
KIRP	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-9.12	2.04e-17	5.8e-14	-0.39	-0.49	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
KIRP	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-9.12	2.07e-17	5.89e-14	-0.63	-0.49	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-9.12	2.07e-17	5.89e-14	-0.63	-0.49	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-9.12	2.07e-17	5.89e-14	-0.63	-0.49	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
KIRP	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	9.12	2.08e-17	5.92e-14	0.41	0.49	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
KIRP	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-9.12	2.1e-17	5.98e-14	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
KIRP	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	9.12	2.11e-17	6.01e-14	0.56	0.49	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
KIRP	cis	rs67311347	1	rs73078164	ENSG00000230274.1	PGAM1P3	9.11	2.16e-17	6.14e-14	0.5	0.49	Renal cell carcinoma;	chr3:40438798	chr3:40322715~40323279:-
KIRP	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	9.11	2.16e-17	6.14e-14	0.58	0.49	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
KIRP	cis	rs67311347	1	rs9833430	ENSG00000230274.1	PGAM1P3	9.11	2.17e-17	6.16e-14	0.5	0.49	Renal cell carcinoma;	chr3:40417552	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9857824	ENSG00000230274.1	PGAM1P3	9.11	2.17e-17	6.16e-14	0.5	0.49	Renal cell carcinoma;	chr3:40417921	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.784	rs13326389	ENSG00000230274.1	PGAM1P3	9.11	2.17e-17	6.16e-14	0.5	0.49	Renal cell carcinoma;	chr3:40418233	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs12492035	ENSG00000230274.1	PGAM1P3	9.11	2.17e-17	6.16e-14	0.5	0.49	Renal cell carcinoma;	chr3:40425619	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs73078158	ENSG00000230274.1	PGAM1P3	9.11	2.17e-17	6.16e-14	0.5	0.49	Renal cell carcinoma;	chr3:40431076	chr3:40322715~40323279:-
KIRP	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-9.11	2.18e-17	6.18e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-9.11	2.18e-17	6.18e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
KIRP	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	9.11	2.21e-17	6.28e-14	0.54	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
KIRP	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	9.11	2.22e-17	6.29e-14	0.53	0.49	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
KIRP	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	9.1	2.28e-17	6.45e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
KIRP	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	9.1	2.29e-17	6.49e-14	0.62	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
KIRP	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	9.1	2.29e-17	6.49e-14	0.62	0.49	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	9.1	2.29e-17	6.49e-14	0.62	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
KIRP	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	9.1	2.31e-17	6.53e-14	0.6	0.49	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
KIRP	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-9.1	2.37e-17	6.7e-14	-0.55	-0.49	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
KIRP	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	9.1	2.37e-17	6.7e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
KIRP	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	9.1	2.4e-17	6.78e-14	0.62	0.49	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
KIRP	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-9.09	2.45e-17	6.91e-14	-0.68	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
KIRP	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	9.09	2.45e-17	6.92e-14	0.57	0.49	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
KIRP	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	9.09	2.45e-17	6.92e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	9.09	2.45e-17	6.92e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
KIRP	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-9.09	2.47e-17	6.95e-14	-0.61	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
KIRP	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	9.09	2.48e-17	6.98e-14	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
KIRP	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	9.09	2.53e-17	7.13e-14	0.69	0.49	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
KIRP	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-9.09	2.54e-17	7.14e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-9.09	2.54e-17	7.14e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-9.09	2.54e-17	7.14e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-9.09	2.54e-17	7.14e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
KIRP	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-9.09	2.54e-17	7.14e-14	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
KIRP	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	9.09	2.6e-17	7.3e-14	0.6	0.49	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
KIRP	cis	rs5760092	0.842	rs5751763	ENSG00000273295.1	AP000350.5	9.09	2.6e-17	7.31e-14	0.6	0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23901432~23907068:-
KIRP	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	9.08	2.62e-17	7.36e-14	0.55	0.49	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
KIRP	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-9.08	2.67e-17	7.48e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-9.08	2.67e-17	7.48e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-9.08	2.67e-17	7.48e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
KIRP	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	9.08	2.69e-17	7.53e-14	0.54	0.49	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
KIRP	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-9.08	2.74e-17	7.67e-14	-0.87	-0.49	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
KIRP	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-9.08	2.74e-17	7.69e-14	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
KIRP	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-9.08	2.75e-17	7.69e-14	-0.63	-0.49	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
KIRP	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	9.08	2.75e-17	7.7e-14	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-9.08	2.75e-17	7.71e-14	-0.56	-0.49	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
KIRP	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-9.08	2.77e-17	7.76e-14	-0.55	-0.49	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
KIRP	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-9.08	2.8e-17	7.83e-14	-0.65	-0.49	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
KIRP	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	9.07	2.8e-17	7.84e-14	0.5	0.49	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
KIRP	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-9.07	2.81e-17	7.85e-14	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-9.07	2.81e-17	7.85e-14	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
KIRP	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	9.07	2.84e-17	7.95e-14	0.75	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
KIRP	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-9.07	2.87e-17	8.03e-14	-0.36	-0.49	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-9.07	2.87e-17	8.03e-14	-0.36	-0.49	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
KIRP	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-9.07	2.92e-17	8.16e-14	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
KIRP	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-9.07	2.92e-17	8.16e-14	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
KIRP	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	9.07	2.93e-17	8.18e-14	0.53	0.49	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
KIRP	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	9.07	2.94e-17	8.2e-14	0.54	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
KIRP	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	9.07	2.94e-17	8.2e-14	0.54	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
KIRP	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-9.07	2.98e-17	8.3e-14	-0.5	-0.49	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
KIRP	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-9.07	3e-17	8.37e-14	-0.42	-0.49	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
KIRP	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	9.06	3.03e-17	8.45e-14	0.56	0.49	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
KIRP	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-9.06	3.04e-17	8.48e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-9.06	3.04e-17	8.48e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
KIRP	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	9.06	3.06e-17	8.53e-14	0.61	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
KIRP	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	9.06	3.06e-17	8.53e-14	0.73	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
KIRP	cis	rs67311347	1	rs1123019	ENSG00000230274.1	PGAM1P3	9.06	3.07e-17	8.54e-14	0.5	0.49	Renal cell carcinoma;	chr3:40446789	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs2371186	ENSG00000230274.1	PGAM1P3	9.06	3.07e-17	8.54e-14	0.5	0.49	Renal cell carcinoma;	chr3:40447222	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9827461	ENSG00000230274.1	PGAM1P3	9.06	3.07e-17	8.54e-14	0.5	0.49	Renal cell carcinoma;	chr3:40447860	chr3:40322715~40323279:-
KIRP	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-9.06	3.08e-17	8.57e-14	-0.6	-0.49	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
KIRP	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	9.06	3.08e-17	8.58e-14	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
KIRP	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	9.06	3.09e-17	8.6e-14	0.55	0.49	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
KIRP	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-9.06	3.13e-17	8.7e-14	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
KIRP	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-9.06	3.13e-17	8.71e-14	-0.62	-0.49	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
KIRP	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	9.06	3.16e-17	8.77e-14	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
KIRP	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-9.06	3.2e-17	8.88e-14	-0.56	-0.49	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
KIRP	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	9.06	3.22e-17	8.93e-14	0.76	0.49	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
KIRP	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-9.05	3.24e-17	8.99e-14	-0.63	-0.49	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-9.05	3.28e-17	9.09e-14	-0.63	-0.49	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
KIRP	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	9.05	3.28e-17	9.1e-14	0.77	0.49	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	9.05	3.28e-17	9.1e-14	0.77	0.49	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	9.05	3.28e-17	9.1e-14	0.77	0.49	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
KIRP	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	9.05	3.29e-17	9.11e-14	0.55	0.49	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	9.05	3.29e-17	9.11e-14	0.55	0.49	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	9.05	3.29e-17	9.11e-14	0.55	0.49	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	9.05	3.29e-17	9.11e-14	0.55	0.49	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-9.05	3.3e-17	9.12e-14	-0.55	-0.49	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-9.05	3.31e-17	9.15e-14	-0.55	-0.49	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
KIRP	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	9.05	3.31e-17	9.15e-14	0.56	0.49	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
KIRP	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-9.05	3.35e-17	9.27e-14	-0.57	-0.49	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
KIRP	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.05	3.39e-17	9.37e-14	-0.48	-0.49	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
KIRP	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	9.05	3.42e-17	9.44e-14	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
KIRP	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-9.05	3.44e-17	9.48e-14	-0.55	-0.49	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
KIRP	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-9.05	3.44e-17	9.49e-14	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
KIRP	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	9.04	3.5e-17	9.64e-14	0.56	0.49	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
KIRP	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	9.04	3.52e-17	9.71e-14	0.56	0.49	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	9.04	3.52e-17	9.71e-14	0.56	0.49	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	9.04	3.52e-17	9.71e-14	0.56	0.49	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-9.04	3.54e-17	9.75e-14	-0.55	-0.49	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
KIRP	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	9.04	3.59e-17	9.88e-14	0.55	0.49	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
KIRP	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	9.04	3.63e-17	9.99e-14	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	9.04	3.63e-17	9.99e-14	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
KIRP	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-9.04	3.64e-17	1e-13	-0.56	-0.49	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-9.04	3.66e-17	1.01e-13	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
KIRP	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-9.03	3.71e-17	1.02e-13	-0.54	-0.49	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
KIRP	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-9.03	3.78e-17	1.04e-13	-0.59	-0.49	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
KIRP	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-9.03	3.8e-17	1.04e-13	-0.5	-0.49	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
KIRP	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-9.03	3.82e-17	1.05e-13	-0.47	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
KIRP	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	9.03	3.86e-17	1.06e-13	0.61	0.49	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	9.03	3.86e-17	1.06e-13	0.61	0.49	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	9.03	3.86e-17	1.06e-13	0.61	0.49	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
KIRP	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	9.03	3.86e-17	1.06e-13	0.61	0.49	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
KIRP	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-9.03	3.86e-17	1.06e-13	-0.55	-0.49	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-9.03	3.86e-17	1.06e-13	-0.55	-0.49	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
KIRP	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-9.03	3.94e-17	1.08e-13	-0.4	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
KIRP	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-9.02	4e-17	1.1e-13	-0.54	-0.49	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-9.02	4e-17	1.1e-13	-0.54	-0.49	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-9.02	4e-17	1.1e-13	-0.54	-0.49	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-9.02	4e-17	1.1e-13	-0.54	-0.49	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
KIRP	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-9.02	4.01e-17	1.1e-13	-0.48	-0.49	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
KIRP	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	9.02	4.03e-17	1.1e-13	0.55	0.49	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
KIRP	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	9.02	4.09e-17	1.12e-13	0.61	0.49	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
KIRP	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	9.02	4.11e-17	1.12e-13	0.71	0.49	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
KIRP	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	9.02	4.15e-17	1.13e-13	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	9.02	4.15e-17	1.13e-13	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-9.02	4.15e-17	1.13e-13	-0.62	-0.49	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
KIRP	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-9.02	4.17e-17	1.14e-13	-0.55	-0.49	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
KIRP	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	9.02	4.17e-17	1.14e-13	0.56	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
KIRP	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-9.02	4.22e-17	1.15e-13	-0.36	-0.49	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
KIRP	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.01	4.28e-17	1.17e-13	0.6	0.49	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
KIRP	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	9.01	4.28e-17	1.17e-13	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
KIRP	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-9.01	4.28e-17	1.17e-13	-0.54	-0.49	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-9.01	4.28e-17	1.17e-13	-0.54	-0.49	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
KIRP	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-9.01	4.3e-17	1.17e-13	-0.62	-0.49	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-9.01	4.3e-17	1.17e-13	-0.62	-0.49	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
KIRP	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	9.01	4.35e-17	1.19e-13	0.54	0.49	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
KIRP	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	9.01	4.35e-17	1.19e-13	0.63	0.49	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
KIRP	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-9.01	4.36e-17	1.19e-13	-0.54	-0.49	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-9.01	4.36e-17	1.19e-13	-0.54	-0.49	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
KIRP	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-9.01	4.36e-17	1.19e-13	-0.55	-0.49	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
KIRP	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	9.01	4.37e-17	1.19e-13	0.54	0.49	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
KIRP	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	9.01	4.42e-17	1.2e-13	0.57	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
KIRP	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	9.01	4.43e-17	1.2e-13	0.72	0.49	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
KIRP	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-9.01	4.46e-17	1.21e-13	-0.47	-0.49	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
KIRP	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-9.01	4.47e-17	1.21e-13	-0.6	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
KIRP	cis	rs10262624	0.967	rs7804966	ENSG00000234286.1	AC006026.13	-9	4.61e-17	1.25e-13	-0.49	-0.49	Schizophrenia;	chr7:23865141	chr7:23680195~23680786:-
KIRP	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-9	4.67e-17	1.27e-13	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
KIRP	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-9	4.69e-17	1.27e-13	-0.55	-0.49	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
KIRP	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-9	4.71e-17	1.28e-13	-0.57	-0.49	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
KIRP	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	9	4.72e-17	1.28e-13	0.56	0.49	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	9	4.72e-17	1.28e-13	0.56	0.49	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	9	4.72e-17	1.28e-13	0.56	0.49	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	9	4.72e-17	1.28e-13	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	9	4.72e-17	1.28e-13	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	9	4.75e-17	1.28e-13	0.56	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
KIRP	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	9	4.76e-17	1.29e-13	0.41	0.49	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
KIRP	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-9	4.78e-17	1.29e-13	-0.57	-0.49	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
KIRP	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-9	4.82e-17	1.3e-13	-0.6	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
KIRP	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	9	4.89e-17	1.32e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
KIRP	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-8.99	4.94e-17	1.33e-13	-0.53	-0.49	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
KIRP	cis	rs67311347	1	rs6793596	ENSG00000230274.1	PGAM1P3	8.99	4.99e-17	1.35e-13	0.5	0.49	Renal cell carcinoma;	chr3:40416304	chr3:40322715~40323279:-
KIRP	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	8.99	5.01e-17	1.35e-13	0.56	0.49	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
KIRP	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-8.99	5.01e-17	1.35e-13	-0.41	-0.49	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
KIRP	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-8.99	5.03e-17	1.36e-13	-0.53	-0.49	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-8.99	5.04e-17	1.36e-13	-0.53	-0.49	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-8.99	5.04e-17	1.36e-13	-0.53	-0.49	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-8.99	5.04e-17	1.36e-13	-0.53	-0.49	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
KIRP	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-8.99	5.09e-17	1.37e-13	-0.58	-0.49	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
KIRP	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	8.99	5.12e-17	1.38e-13	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	8.99	5.12e-17	1.38e-13	0.58	0.49	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
KIRP	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-8.99	5.14e-17	1.38e-13	-0.43	-0.49	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
KIRP	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	8.99	5.19e-17	1.4e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	8.99	5.19e-17	1.4e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	8.99	5.19e-17	1.4e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	8.99	5.19e-17	1.4e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	8.99	5.19e-17	1.4e-13	0.57	0.49	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs9371504	ENSG00000216906.2	RP11-350J20.9	8.99	5.2e-17	1.4e-13	0.59	0.49	Testicular germ cell tumor;	chr6:149862944	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs9371505	ENSG00000216906.2	RP11-350J20.9	8.99	5.2e-17	1.4e-13	0.59	0.49	Testicular germ cell tumor;	chr6:149863012	chr6:149904243~149906418:+
KIRP	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-8.99	5.22e-17	1.4e-13	-0.56	-0.49	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
KIRP	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	8.99	5.24e-17	1.41e-13	0.52	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
KIRP	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-8.98	5.29e-17	1.42e-13	-0.56	-0.49	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
KIRP	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	8.98	5.3e-17	1.42e-13	0.56	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
KIRP	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-8.98	5.35e-17	1.44e-13	-0.62	-0.49	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	8.98	5.46e-17	1.46e-13	0.81	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
KIRP	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-8.98	5.54e-17	1.48e-13	-0.57	-0.49	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
KIRP	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-8.98	5.6e-17	1.5e-13	-0.57	-0.48	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-8.98	5.6e-17	1.5e-13	-0.57	-0.48	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-8.98	5.6e-17	1.5e-13	-0.57	-0.48	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
KIRP	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.97	5.63e-17	1.51e-13	-0.54	-0.48	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000218537.1	MIF-AS1	8.97	5.64e-17	1.51e-13	0.71	0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23894426~23898930:-
KIRP	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-8.97	5.69e-17	1.52e-13	-0.55	-0.48	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
KIRP	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	8.97	5.69e-17	1.52e-13	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-8.97	5.73e-17	1.53e-13	-0.61	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
KIRP	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-8.97	5.78e-17	1.55e-13	-0.55	-0.48	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	8.97	5.79e-17	1.55e-13	0.63	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
KIRP	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	8.97	5.82e-17	1.56e-13	0.55	0.48	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
KIRP	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	8.97	5.85e-17	1.56e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-8.97	5.95e-17	1.59e-13	-0.63	-0.48	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
KIRP	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-8.97	5.97e-17	1.59e-13	-0.39	-0.48	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
KIRP	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-8.97	5.97e-17	1.59e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
KIRP	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	8.97	5.99e-17	1.6e-13	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	8.97	5.99e-17	1.6e-13	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	8.97	5.99e-17	1.6e-13	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
KIRP	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-8.96	6.1e-17	1.62e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
KIRP	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-8.96	6.1e-17	1.62e-13	-0.39	-0.48	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
KIRP	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-8.96	6.1e-17	1.62e-13	-0.39	-0.48	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
KIRP	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	8.96	6.13e-17	1.63e-13	0.68	0.48	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
KIRP	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-8.96	6.14e-17	1.64e-13	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-8.96	6.14e-17	1.64e-13	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
KIRP	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.96	6.16e-17	1.64e-13	0.53	0.48	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
KIRP	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	8.96	6.18e-17	1.65e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
KIRP	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	8.96	6.2e-17	1.65e-13	0.54	0.48	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
KIRP	cis	rs67311347	1	rs28491638	ENSG00000230274.1	PGAM1P3	8.96	6.25e-17	1.66e-13	0.5	0.48	Renal cell carcinoma;	chr3:40454772	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs28536038	ENSG00000230274.1	PGAM1P3	8.96	6.25e-17	1.66e-13	0.5	0.48	Renal cell carcinoma;	chr3:40454891	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.955	rs2085114	ENSG00000230274.1	PGAM1P3	8.96	6.25e-17	1.66e-13	0.5	0.48	Renal cell carcinoma;	chr3:40455946	chr3:40322715~40323279:-
KIRP	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-8.96	6.38e-17	1.7e-13	-0.63	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
KIRP	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-8.96	6.43e-17	1.71e-13	-0.56	-0.48	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
KIRP	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-8.96	6.44e-17	1.71e-13	-0.59	-0.48	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
KIRP	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	8.96	6.45e-17	1.71e-13	0.53	0.48	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
KIRP	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	8.96	6.45e-17	1.71e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	8.96	6.45e-17	1.71e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	8.96	6.45e-17	1.71e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	8.96	6.45e-17	1.71e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
KIRP	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-8.95	6.47e-17	1.72e-13	-0.62	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
KIRP	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-8.95	6.47e-17	1.72e-13	-0.59	-0.48	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-8.95	6.47e-17	1.72e-13	-0.59	-0.48	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-8.95	6.47e-17	1.72e-13	-0.59	-0.48	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-8.95	6.47e-17	1.72e-13	-0.59	-0.48	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-8.95	6.47e-17	1.72e-13	-0.59	-0.48	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
KIRP	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	8.95	6.48e-17	1.72e-13	0.54	0.48	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
KIRP	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	8.95	6.51e-17	1.73e-13	0.53	0.48	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	8.95	6.51e-17	1.73e-13	0.53	0.48	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
KIRP	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8.95	6.58e-17	1.74e-13	-0.59	-0.48	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
KIRP	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.95	6.64e-17	1.76e-13	0.54	0.48	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
KIRP	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	8.95	6.66e-17	1.76e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	8.95	6.66e-17	1.76e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	8.95	6.66e-17	1.76e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	8.95	6.66e-17	1.76e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
KIRP	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	8.95	6.71e-17	1.78e-13	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
KIRP	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-8.95	6.72e-17	1.78e-13	-0.55	-0.48	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-8.95	6.72e-17	1.78e-13	-0.55	-0.48	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
KIRP	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	8.95	6.72e-17	1.78e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	8.95	6.72e-17	1.78e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	8.95	6.72e-17	1.78e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
KIRP	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	8.95	6.73e-17	1.78e-13	0.57	0.48	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	8.95	6.73e-17	1.78e-13	0.57	0.48	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
KIRP	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	8.95	6.76e-17	1.79e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	8.95	6.76e-17	1.79e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	8.95	6.76e-17	1.79e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	8.95	6.76e-17	1.79e-13	0.78	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
KIRP	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.95	6.79e-17	1.79e-13	0.53	0.48	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.95	6.79e-17	1.79e-13	0.53	0.48	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
KIRP	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-8.95	6.83e-17	1.8e-13	-0.86	-0.48	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
KIRP	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	8.95	6.92e-17	1.83e-13	0.68	0.48	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
KIRP	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-8.94	6.93e-17	1.83e-13	-0.62	-0.48	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
KIRP	cis	rs67311347	1	rs4973989	ENSG00000230274.1	PGAM1P3	8.94	7.01e-17	1.85e-13	0.5	0.48	Renal cell carcinoma;	chr3:40410052	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs12634013	ENSG00000230274.1	PGAM1P3	8.94	7.01e-17	1.85e-13	0.5	0.48	Renal cell carcinoma;	chr3:40410897	chr3:40322715~40323279:-
KIRP	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-8.94	7.03e-17	1.85e-13	-0.63	-0.48	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-8.94	7.03e-17	1.85e-13	-0.63	-0.48	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-8.94	7.03e-17	1.85e-13	-0.63	-0.48	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-8.94	7.03e-17	1.85e-13	-0.63	-0.48	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
KIRP	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	8.94	7.04e-17	1.86e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-8.94	7.11e-17	1.87e-13	-0.63	-0.48	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
KIRP	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-8.94	7.12e-17	1.88e-13	-0.66	-0.48	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
KIRP	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	8.94	7.18e-17	1.89e-13	0.54	0.48	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
KIRP	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	8.94	7.28e-17	1.92e-13	0.55	0.48	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
KIRP	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	8.94	7.35e-17	1.93e-13	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
KIRP	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-8.94	7.39e-17	1.94e-13	-0.65	-0.48	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
KIRP	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	8.94	7.41e-17	1.95e-13	0.59	0.48	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
KIRP	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	8.93	7.5e-17	1.97e-13	0.54	0.48	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
KIRP	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	8.93	7.59e-17	1.99e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	8.93	7.59e-17	1.99e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	8.93	7.59e-17	1.99e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
KIRP	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	8.93	7.59e-17	1.99e-13	0.86	0.48	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
KIRP	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	8.93	7.71e-17	2.02e-13	0.55	0.48	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	8.93	7.77e-17	2.03e-13	0.54	0.48	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
KIRP	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	8.93	7.78e-17	2.03e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
KIRP	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	8.93	7.78e-17	2.04e-13	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
KIRP	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	8.93	7.82e-17	2.05e-13	0.55	0.48	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
KIRP	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-8.93	7.89e-17	2.06e-13	-0.41	-0.48	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
KIRP	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-8.92	8.14e-17	2.13e-13	-0.59	-0.48	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
KIRP	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	8.92	8.15e-17	2.13e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	8.92	8.15e-17	2.13e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
KIRP	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-8.92	8.16e-17	2.13e-13	-0.54	-0.48	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-8.92	8.16e-17	2.13e-13	-0.54	-0.48	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
KIRP	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	8.92	8.23e-17	2.15e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	8.92	8.23e-17	2.15e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	8.92	8.23e-17	2.15e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	8.92	8.23e-17	2.15e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-8.92	8.23e-17	2.15e-13	-0.63	-0.48	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-8.92	8.23e-17	2.15e-13	-0.63	-0.48	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
KIRP	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	8.92	8.36e-17	2.18e-13	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
KIRP	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-8.92	8.37e-17	2.18e-13	-0.47	-0.48	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
KIRP	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	8.92	8.37e-17	2.18e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	8.92	8.37e-17	2.18e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.92	8.42e-17	2.2e-13	0.54	0.48	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
KIRP	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-8.91	8.55e-17	2.23e-13	-0.42	-0.48	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
KIRP	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	8.91	8.6e-17	2.24e-13	0.72	0.48	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
KIRP	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	8.91	8.61e-17	2.24e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
KIRP	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	8.91	8.62e-17	2.25e-13	0.55	0.48	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
KIRP	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	8.91	8.63e-17	2.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	8.91	8.63e-17	2.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	8.91	8.63e-17	2.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
KIRP	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	8.91	8.66e-17	2.25e-13	0.54	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
KIRP	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	8.91	8.7e-17	2.27e-13	0.61	0.48	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-8.91	8.71e-17	2.27e-13	-0.54	-0.48	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	8.91	8.77e-17	2.28e-13	0.55	0.48	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
KIRP	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	8.91	8.78e-17	2.28e-13	0.56	0.48	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-8.91	8.79e-17	2.29e-13	-0.61	-0.48	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
KIRP	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-8.91	8.81e-17	2.29e-13	-0.51	-0.48	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
KIRP	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	8.91	8.88e-17	2.31e-13	0.6	0.48	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
KIRP	cis	rs2698530	0.554	rs10496110	ENSG00000225889.6	AC074289.1	-8.91	8.94e-17	2.33e-13	-0.44	-0.48	Iron status biomarkers;	chr2:64223221	chr2:64143239~64252859:+
KIRP	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	8.91	8.98e-17	2.33e-13	0.6	0.48	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
KIRP	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	8.91	9.05e-17	2.35e-13	0.53	0.48	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
KIRP	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	8.91	9.06e-17	2.35e-13	0.64	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
KIRP	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	8.91	9.08e-17	2.36e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	8.9	9.17e-17	2.38e-13	0.55	0.48	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	8.9	9.17e-17	2.38e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	8.9	9.17e-17	2.38e-13	0.55	0.48	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	8.9	9.22e-17	2.39e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	8.9	9.22e-17	2.39e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	8.9	9.22e-17	2.39e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	8.9	9.22e-17	2.39e-13	0.55	0.48	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	8.9	9.22e-17	2.39e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	8.9	9.28e-17	2.4e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	8.9	9.31e-17	2.41e-13	0.55	0.48	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
KIRP	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-8.9	9.33e-17	2.42e-13	-0.41	-0.48	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
KIRP	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	8.9	9.38e-17	2.43e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
KIRP	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-8.9	9.4e-17	2.43e-13	-0.47	-0.48	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
KIRP	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	8.9	9.44e-17	2.44e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	8.9	9.48e-17	2.45e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
KIRP	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-8.9	9.5e-17	2.46e-13	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
KIRP	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	8.9	9.54e-17	2.47e-13	0.53	0.48	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
KIRP	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	8.9	9.54e-17	2.47e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	8.9	9.56e-17	2.47e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	8.9	9.56e-17	2.47e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	8.9	9.56e-17	2.47e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	8.9	9.59e-17	2.48e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	8.9	9.64e-17	2.49e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	8.9	9.64e-17	2.49e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	8.9	9.64e-17	2.49e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	8.9	9.64e-17	2.49e-13	0.56	0.48	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	8.9	9.64e-17	2.49e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
KIRP	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-8.9	9.7e-17	2.5e-13	-0.54	-0.48	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-8.9	9.7e-17	2.5e-13	-0.54	-0.48	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	8.9	9.7e-17	2.5e-13	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
KIRP	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-8.9	9.71e-17	2.51e-13	-0.53	-0.48	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	8.9	9.75e-17	2.52e-13	0.55	0.48	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	8.9	9.75e-17	2.52e-13	0.55	0.48	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
KIRP	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-8.9	9.79e-17	2.53e-13	-0.62	-0.48	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
KIRP	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	8.89	9.81e-17	2.53e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	8.89	9.81e-17	2.53e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	8.89	9.81e-17	2.53e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
KIRP	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	8.89	9.83e-17	2.53e-13	0.37	0.48	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
KIRP	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-8.89	9.84e-17	2.54e-13	-0.46	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
KIRP	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-8.89	9.86e-17	2.54e-13	-0.42	-0.48	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
KIRP	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-8.89	9.87e-17	2.55e-13	-0.51	-0.48	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
KIRP	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	8.89	9.91e-17	2.55e-13	0.54	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
KIRP	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	8.89	9.93e-17	2.56e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	8.89	9.93e-17	2.56e-13	0.54	0.48	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
KIRP	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	8.89	9.94e-17	2.56e-13	0.56	0.48	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
KIRP	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-8.89	9.94e-17	2.56e-13	-0.51	-0.48	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
KIRP	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	8.89	9.98e-17	2.57e-13	0.58	0.48	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	8.89	9.99e-17	2.57e-13	0.55	0.48	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	8.89	9.99e-17	2.57e-13	0.55	0.48	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
KIRP	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	8.89	1e-16	2.57e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	8.89	1e-16	2.57e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	8.89	1e-16	2.57e-13	0.55	0.48	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
KIRP	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	8.89	1e-16	2.58e-13	0.44	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
KIRP	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	8.89	1e-16	2.58e-13	0.68	0.48	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
KIRP	cis	rs9326248	0.569	rs473172	ENSG00000254851.1	RP11-109L13.1	-8.89	1.01e-16	2.6e-13	-0.89	-0.48	Blood protein levels;	chr11:116937254	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	8.89	1.02e-16	2.62e-13	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
KIRP	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	8.89	1.02e-16	2.62e-13	0.68	0.48	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
KIRP	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	8.89	1.02e-16	2.63e-13	0.87	0.48	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
KIRP	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-8.89	1.04e-16	2.67e-13	-0.37	-0.48	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
KIRP	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-8.89	1.04e-16	2.67e-13	-0.39	-0.48	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-8.89	1.04e-16	2.67e-13	-0.39	-0.48	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
KIRP	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	8.88	1.05e-16	2.71e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	8.88	1.05e-16	2.71e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	8.88	1.05e-16	2.71e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	8.88	1.07e-16	2.73e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
KIRP	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	8.88	1.08e-16	2.76e-13	0.6	0.48	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
KIRP	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	8.88	1.08e-16	2.76e-13	0.54	0.48	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
KIRP	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-8.88	1.1e-16	2.81e-13	-0.39	-0.48	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
KIRP	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-8.88	1.1e-16	2.82e-13	-0.46	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-8.88	1.1e-16	2.82e-13	-0.46	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
KIRP	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	8.88	1.1e-16	2.83e-13	0.56	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	8.88	1.11e-16	2.84e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
KIRP	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-8.88	1.11e-16	2.84e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
KIRP	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-8.88	1.11e-16	2.84e-13	-0.52	-0.48	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
KIRP	cis	rs9322193	0.923	rs9322225	ENSG00000216906.2	RP11-350J20.9	8.88	1.12e-16	2.85e-13	0.61	0.48	Lung cancer;	chr6:149863746	chr6:149904243~149906418:+
KIRP	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-8.88	1.12e-16	2.86e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-8.88	1.12e-16	2.86e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
KIRP	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-8.88	1.12e-16	2.86e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
KIRP	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-8.88	1.12e-16	2.86e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
KIRP	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	8.88	1.12e-16	2.86e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
KIRP	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-8.87	1.13e-16	2.88e-13	-0.58	-0.48	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
KIRP	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	8.87	1.13e-16	2.89e-13	0.56	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
KIRP	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-8.87	1.13e-16	2.89e-13	-0.35	-0.48	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
KIRP	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-8.87	1.14e-16	2.9e-13	-0.54	-0.48	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
KIRP	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-8.87	1.14e-16	2.91e-13	-0.56	-0.48	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
KIRP	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-8.87	1.15e-16	2.94e-13	-0.51	-0.48	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
KIRP	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.87	1.16e-16	2.96e-13	0.6	0.48	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
KIRP	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	8.87	1.17e-16	2.98e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	8.87	1.17e-16	2.98e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	8.87	1.17e-16	2.98e-13	0.56	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	8.87	1.17e-16	2.98e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	8.87	1.17e-16	2.98e-13	0.56	0.48	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
KIRP	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	8.87	1.17e-16	2.99e-13	0.51	0.48	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
KIRP	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-8.87	1.18e-16	3e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
KIRP	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	8.87	1.18e-16	3e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
KIRP	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	8.86	1.24e-16	3.15e-13	0.71	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
KIRP	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	8.86	1.25e-16	3.17e-13	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	8.86	1.25e-16	3.17e-13	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
KIRP	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-8.86	1.26e-16	3.19e-13	-0.51	-0.48	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
KIRP	cis	rs67311347	1	rs17078813	ENSG00000230274.1	PGAM1P3	8.86	1.27e-16	3.22e-13	0.48	0.48	Renal cell carcinoma;	chr3:40392671	chr3:40322715~40323279:-
KIRP	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	8.86	1.27e-16	3.22e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
KIRP	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-8.86	1.28e-16	3.25e-13	-0.51	-0.48	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-8.86	1.28e-16	3.25e-13	-0.51	-0.48	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
KIRP	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	8.86	1.29e-16	3.26e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
KIRP	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-8.85	1.3e-16	3.29e-13	-0.38	-0.48	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
KIRP	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-8.85	1.33e-16	3.37e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
KIRP	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-8.85	1.33e-16	3.37e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
KIRP	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-8.85	1.34e-16	3.38e-13	-0.42	-0.48	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
KIRP	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	8.85	1.34e-16	3.39e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
KIRP	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	8.85	1.35e-16	3.42e-13	0.53	0.48	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
KIRP	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-8.85	1.35e-16	3.43e-13	-0.55	-0.48	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
KIRP	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-8.85	1.36e-16	3.43e-13	-0.41	-0.48	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
KIRP	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-8.85	1.37e-16	3.45e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
KIRP	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-8.85	1.37e-16	3.46e-13	-0.53	-0.48	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-8.85	1.37e-16	3.46e-13	-0.53	-0.48	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
KIRP	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-8.85	1.37e-16	3.46e-13	-0.53	-0.48	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
KIRP	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-8.84	1.38e-16	3.5e-13	-0.6	-0.48	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
KIRP	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-8.84	1.38e-16	3.5e-13	-0.54	-0.48	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
KIRP	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-8.84	1.4e-16	3.53e-13	-0.38	-0.48	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
KIRP	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.59e-13	-0.54	-0.48	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.59e-13	-0.54	-0.48	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.59e-13	-0.54	-0.48	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.59e-13	-0.54	-0.48	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.59e-13	-0.54	-0.48	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
KIRP	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	8.84	1.43e-16	3.6e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
KIRP	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-8.84	1.43e-16	3.62e-13	-0.54	-0.48	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
KIRP	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	8.84	1.44e-16	3.62e-13	0.54	0.48	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	8.84	1.44e-16	3.62e-13	0.65	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
KIRP	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-8.84	1.45e-16	3.65e-13	-0.54	-0.48	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
KIRP	cis	rs67311347	0.956	rs9817233	ENSG00000230274.1	PGAM1P3	8.84	1.46e-16	3.68e-13	0.49	0.48	Renal cell carcinoma;	chr3:40384127	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9817142	ENSG00000230274.1	PGAM1P3	8.84	1.46e-16	3.68e-13	0.49	0.48	Renal cell carcinoma;	chr3:40384283	chr3:40322715~40323279:-
KIRP	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	8.84	1.46e-16	3.69e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	8.84	1.47e-16	3.69e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
KIRP	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-8.84	1.48e-16	3.72e-13	-0.58	-0.48	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
KIRP	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-8.83	1.49e-16	3.75e-13	-0.62	-0.48	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-8.83	1.49e-16	3.75e-13	-0.62	-0.48	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
KIRP	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	8.83	1.53e-16	3.84e-13	0.58	0.48	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
KIRP	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	8.83	1.53e-16	3.84e-13	0.55	0.48	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-8.83	1.54e-16	3.86e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-8.83	1.54e-16	3.86e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-8.83	1.55e-16	3.9e-13	-0.55	-0.48	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
KIRP	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	8.83	1.56e-16	3.91e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
KIRP	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	8.83	1.57e-16	3.94e-13	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	8.83	1.57e-16	3.94e-13	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
KIRP	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	8.83	1.58e-16	3.95e-13	0.55	0.48	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	8.83	1.58e-16	3.95e-13	0.55	0.48	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
KIRP	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	8.83	1.58e-16	3.96e-13	0.53	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	8.82	1.6e-16	4.01e-13	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
KIRP	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	8.82	1.6e-16	4.01e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	8.82	1.6e-16	4.01e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	8.82	1.64e-16	4.11e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	8.82	1.65e-16	4.13e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	8.82	1.66e-16	4.14e-13	0.55	0.48	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
KIRP	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-8.82	1.68e-16	4.19e-13	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-8.82	1.68e-16	4.19e-13	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
KIRP	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	8.82	1.68e-16	4.19e-13	0.53	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
KIRP	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	8.81	1.7e-16	4.25e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
KIRP	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-8.81	1.71e-16	4.28e-13	-0.55	-0.48	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-8.81	1.73e-16	4.3e-13	-0.54	-0.48	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-8.81	1.73e-16	4.3e-13	-0.54	-0.48	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-8.81	1.73e-16	4.3e-13	-0.54	-0.48	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-8.81	1.73e-16	4.3e-13	-0.54	-0.48	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-8.81	1.73e-16	4.3e-13	-0.54	-0.48	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
KIRP	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-8.81	1.76e-16	4.39e-13	-0.65	-0.48	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
KIRP	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-8.81	1.77e-16	4.42e-13	-0.62	-0.48	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
KIRP	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.81	1.79e-16	4.45e-13	0.6	0.48	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
KIRP	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.81	1.79e-16	4.45e-13	0.6	0.48	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
KIRP	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-8.81	1.8e-16	4.47e-13	-0.59	-0.48	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
KIRP	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	8.81	1.81e-16	4.51e-13	0.54	0.48	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	8.81	1.81e-16	4.51e-13	0.54	0.48	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
KIRP	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-8.81	1.82e-16	4.52e-13	-0.56	-0.48	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
KIRP	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-8.81	1.82e-16	4.52e-13	-0.56	-0.48	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
KIRP	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-8.81	1.82e-16	4.52e-13	-0.56	-0.48	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
KIRP	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	8.8	1.83e-16	4.54e-13	0.56	0.48	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-8.8	1.83e-16	4.54e-13	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
KIRP	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	8.8	1.84e-16	4.56e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	8.8	1.84e-16	4.56e-13	0.56	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	8.8	1.85e-16	4.59e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	8.8	1.85e-16	4.59e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	8.8	1.85e-16	4.59e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
KIRP	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	8.8	1.87e-16	4.63e-13	0.67	0.48	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
KIRP	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-8.8	1.87e-16	4.63e-13	-0.54	-0.48	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
KIRP	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	8.8	1.87e-16	4.63e-13	0.55	0.48	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
KIRP	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	8.8	1.87e-16	4.65e-13	0.53	0.48	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
KIRP	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-8.8	1.88e-16	4.66e-13	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
KIRP	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	8.8	1.89e-16	4.67e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	8.8	1.89e-16	4.67e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
KIRP	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-8.8	1.89e-16	4.67e-13	-0.5	-0.48	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
KIRP	cis	rs67311347	1	rs11720360	ENSG00000230274.1	PGAM1P3	8.8	1.89e-16	4.68e-13	0.49	0.48	Renal cell carcinoma;	chr3:40406906	chr3:40322715~40323279:-
KIRP	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	8.8	1.9e-16	4.69e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
KIRP	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	8.8	1.91e-16	4.7e-13	0.67	0.48	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
KIRP	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-8.8	1.91e-16	4.71e-13	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
KIRP	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	8.8	1.92e-16	4.73e-13	0.56	0.48	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
KIRP	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-8.8	1.93e-16	4.76e-13	-0.51	-0.48	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	8.8	1.93e-16	4.76e-13	0.59	0.48	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	8.8	1.93e-16	4.77e-13	0.6	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
KIRP	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8.8	1.94e-16	4.77e-13	0.58	0.48	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
KIRP	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	8.8	1.94e-16	4.79e-13	0.58	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
KIRP	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-8.8	1.95e-16	4.8e-13	-0.65	-0.48	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
KIRP	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	8.79	1.96e-16	4.82e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
KIRP	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-8.79	1.96e-16	4.83e-13	-0.57	-0.48	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-8.79	1.96e-16	4.83e-13	-0.57	-0.48	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-8.79	1.96e-16	4.83e-13	-0.57	-0.48	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
KIRP	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	8.79	1.97e-16	4.86e-13	0.42	0.48	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
KIRP	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-8.79	1.98e-16	4.87e-13	-0.39	-0.48	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
KIRP	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-8.79	2.03e-16	4.99e-13	-0.56	-0.48	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
KIRP	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	8.79	2.03e-16	4.99e-13	0.6	0.48	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
KIRP	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-8.79	2.05e-16	5.05e-13	-0.56	-0.48	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-8.79	2.05e-16	5.05e-13	-0.56	-0.48	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
KIRP	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-8.79	2.06e-16	5.06e-13	-0.54	-0.48	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-8.79	2.06e-16	5.06e-13	-0.54	-0.48	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
KIRP	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	8.79	2.06e-16	5.06e-13	0.52	0.48	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	8.79	2.07e-16	5.09e-13	0.57	0.48	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
KIRP	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	8.79	2.08e-16	5.11e-13	0.54	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	8.79	2.08e-16	5.11e-13	0.54	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	8.79	2.08e-16	5.11e-13	0.54	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
KIRP	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	8.79	2.08e-16	5.11e-13	0.56	0.48	Height;	chr11:118737823	chr11:118688039~118690600:-
KIRP	cis	rs67311347	1	rs73078163	ENSG00000230274.1	PGAM1P3	8.78	2.1e-16	5.14e-13	0.49	0.48	Renal cell carcinoma;	chr3:40438467	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs73078123	ENSG00000230274.1	PGAM1P3	8.78	2.13e-16	5.21e-13	0.49	0.48	Renal cell carcinoma;	chr3:40417472	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs4973998	ENSG00000230274.1	PGAM1P3	8.78	2.13e-16	5.21e-13	0.49	0.48	Renal cell carcinoma;	chr3:40418861	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs73078162	ENSG00000230274.1	PGAM1P3	8.78	2.13e-16	5.21e-13	0.49	0.48	Renal cell carcinoma;	chr3:40435618	chr3:40322715~40323279:-
KIRP	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	8.78	2.14e-16	5.25e-13	0.55	0.48	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
KIRP	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	8.78	2.15e-16	5.27e-13	0.61	0.48	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
KIRP	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	8.78	2.17e-16	5.31e-13	0.67	0.48	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	8.78	2.17e-16	5.31e-13	0.67	0.48	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
KIRP	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	8.78	2.17e-16	5.32e-13	0.6	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
KIRP	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	8.78	2.17e-16	5.32e-13	0.6	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
KIRP	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	8.78	2.21e-16	5.42e-13	0.52	0.48	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
KIRP	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	8.78	2.22e-16	5.42e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	8.78	2.23e-16	5.44e-13	0.55	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
KIRP	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-8.77	2.26e-16	5.52e-13	-0.58	-0.48	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-8.77	2.28e-16	5.55e-13	-0.54	-0.48	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
KIRP	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-8.77	2.29e-16	5.59e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-8.77	2.29e-16	5.59e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-8.77	2.3e-16	5.6e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-8.77	2.3e-16	5.6e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
KIRP	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	8.77	2.31e-16	5.63e-13	0.86	0.48	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
KIRP	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	8.77	2.32e-16	5.64e-13	0.52	0.48	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
KIRP	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	8.77	2.32e-16	5.64e-13	0.52	0.48	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
KIRP	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	8.77	2.32e-16	5.64e-13	0.52	0.48	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	8.77	2.32e-16	5.64e-13	0.52	0.48	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
KIRP	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	8.77	2.32e-16	5.64e-13	0.52	0.48	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
KIRP	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-8.77	2.34e-16	5.69e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-8.77	2.34e-16	5.69e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-8.77	2.34e-16	5.69e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-8.77	2.34e-16	5.69e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
KIRP	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-8.77	2.36e-16	5.73e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
KIRP	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-8.76	2.4e-16	5.83e-13	-0.57	-0.48	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
KIRP	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.76	2.41e-16	5.84e-13	0.81	0.48	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
KIRP	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-8.76	2.42e-16	5.87e-13	-0.53	-0.48	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-8.76	2.42e-16	5.87e-13	-0.53	-0.48	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-8.76	2.42e-16	5.87e-13	-0.53	-0.48	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
KIRP	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-8.76	2.42e-16	5.88e-13	-0.58	-0.48	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
KIRP	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-8.76	2.43e-16	5.89e-13	-0.67	-0.48	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
KIRP	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	8.76	2.45e-16	5.93e-13	0.55	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	8.76	2.45e-16	5.93e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
KIRP	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-8.76	2.47e-16	5.98e-13	-0.36	-0.48	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
KIRP	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-8.76	2.47e-16	5.99e-13	-0.56	-0.48	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
KIRP	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	8.76	2.49e-16	6.02e-13	0.64	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
KIRP	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-8.76	2.5e-16	6.04e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
KIRP	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-8.76	2.5e-16	6.04e-13	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
KIRP	cis	rs67311347	1	rs9854493	ENSG00000230274.1	PGAM1P3	8.76	2.53e-16	6.1e-13	0.49	0.48	Renal cell carcinoma;	chr3:40382131	chr3:40322715~40323279:-
KIRP	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	8.76	2.54e-16	6.13e-13	0.53	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
KIRP	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-8.76	2.55e-16	6.14e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
KIRP	cis	rs2698530	0.77	rs1426710	ENSG00000225889.6	AC074289.1	-8.76	2.56e-16	6.17e-13	-0.47	-0.48	Iron status biomarkers;	chr2:64274541	chr2:64143239~64252859:+
KIRP	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-8.75	2.57e-16	6.2e-13	-0.54	-0.48	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
KIRP	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	8.75	2.59e-16	6.23e-13	0.65	0.48	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
KIRP	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-8.75	2.61e-16	6.27e-13	-0.48	-0.48	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
KIRP	cis	rs5760092	0.842	rs5760103	ENSG00000273295.1	AP000350.5	8.75	2.64e-16	6.35e-13	0.61	0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23901432~23907068:-
KIRP	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	8.75	2.65e-16	6.36e-13	0.62	0.48	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	8.75	2.65e-16	6.36e-13	0.62	0.48	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	8.75	2.65e-16	6.36e-13	0.62	0.48	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
KIRP	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-8.75	2.66e-16	6.39e-13	-0.45	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
KIRP	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-8.75	2.67e-16	6.41e-13	-0.58	-0.48	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-8.75	2.67e-16	6.41e-13	-0.58	-0.48	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
KIRP	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-8.74	2.76e-16	6.61e-13	-0.5	-0.48	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
KIRP	cis	rs67311347	1	rs9822644	ENSG00000230274.1	PGAM1P3	8.74	2.76e-16	6.62e-13	0.49	0.48	Renal cell carcinoma;	chr3:40385118	chr3:40322715~40323279:-
KIRP	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-8.74	2.76e-16	6.62e-13	-0.46	-0.48	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
KIRP	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	8.74	2.77e-16	6.65e-13	0.86	0.48	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	8.74	2.77e-16	6.65e-13	0.86	0.48	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
KIRP	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	8.74	2.78e-16	6.66e-13	0.56	0.48	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
KIRP	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-8.74	2.8e-16	6.7e-13	-0.61	-0.48	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
KIRP	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-8.74	2.83e-16	6.77e-13	-0.58	-0.48	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
KIRP	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	8.74	2.83e-16	6.77e-13	0.54	0.48	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
KIRP	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	8.74	2.88e-16	6.88e-13	0.54	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
KIRP	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	8.74	2.91e-16	6.94e-13	0.58	0.47	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
KIRP	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	8.74	2.93e-16	6.98e-13	0.38	0.47	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
KIRP	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	8.74	2.93e-16	7e-13	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
KIRP	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	8.73	2.95e-16	7.04e-13	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
KIRP	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	8.73	2.96e-16	7.07e-13	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	8.73	2.96e-16	7.07e-13	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	8.73	2.96e-16	7.07e-13	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	8.73	2.96e-16	7.07e-13	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	8.73	2.97e-16	7.08e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	8.73	2.97e-16	7.08e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	8.73	2.97e-16	7.08e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
KIRP	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	8.73	2.97e-16	7.09e-13	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
KIRP	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-8.73	2.98e-16	7.09e-13	-0.53	-0.47	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
KIRP	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	8.73	3.09e-16	7.36e-13	0.45	0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
KIRP	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-8.73	3.1e-16	7.38e-13	-0.5	-0.47	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
KIRP	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	8.72	3.18e-16	7.56e-13	0.68	0.47	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
KIRP	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	8.72	3.19e-16	7.59e-13	0.59	0.47	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
KIRP	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	8.72	3.19e-16	7.59e-13	0.62	0.47	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
KIRP	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	8.72	3.22e-16	7.66e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	8.72	3.22e-16	7.66e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
KIRP	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	8.72	3.23e-16	7.67e-13	0.61	0.47	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
KIRP	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	8.72	3.25e-16	7.71e-13	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
KIRP	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-8.72	3.28e-16	7.8e-13	-0.58	-0.47	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
KIRP	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	8.72	3.3e-16	7.84e-13	0.59	0.47	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	8.72	3.3e-16	7.84e-13	0.59	0.47	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
KIRP	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	8.72	3.31e-16	7.86e-13	0.61	0.47	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
KIRP	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-8.72	3.33e-16	7.89e-13	-0.58	-0.47	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
KIRP	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	8.72	3.34e-16	7.92e-13	0.52	0.47	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
KIRP	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	8.72	3.34e-16	7.93e-13	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
KIRP	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-8.71	3.39e-16	8.04e-13	-0.62	-0.47	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-8.71	3.39e-16	8.04e-13	-0.62	-0.47	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
KIRP	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-8.71	3.39e-16	8.04e-13	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
KIRP	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-8.71	3.4e-16	8.05e-13	-0.62	-0.47	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
KIRP	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	8.71	3.46e-16	8.2e-13	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
KIRP	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-8.71	3.53e-16	8.36e-13	-0.63	-0.47	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
KIRP	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-8.71	3.54e-16	8.37e-13	-0.48	-0.47	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-8.71	3.54e-16	8.37e-13	-0.48	-0.47	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
KIRP	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	8.71	3.58e-16	8.48e-13	0.56	0.47	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
KIRP	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	8.7	3.65e-16	8.62e-13	0.55	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
KIRP	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	8.7	3.66e-16	8.65e-13	0.37	0.47	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	8.7	3.67e-16	8.66e-13	0.58	0.47	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
KIRP	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	8.7	3.72e-16	8.78e-13	0.52	0.47	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
KIRP	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	8.7	3.76e-16	8.87e-13	0.61	0.47	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
KIRP	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	8.7	3.77e-16	8.9e-13	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
KIRP	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	8.7	3.79e-16	8.91e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.7	3.86e-16	9.07e-13	0.64	0.47	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
KIRP	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-8.7	3.87e-16	9.1e-13	-0.59	-0.47	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
KIRP	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	8.69	3.88e-16	9.11e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
KIRP	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	8.69	3.88e-16	9.12e-13	0.69	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
KIRP	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	8.69	3.89e-16	9.15e-13	0.66	0.47	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
KIRP	cis	rs4356975	0.83	rs6600868	ENSG00000248763.2	RP13-644M16.5	-8.69	3.92e-16	9.21e-13	-0.51	-0.47	Obesity-related traits;	chr4:69075923	chr4:69066395~69069888:+
KIRP	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	8.69	3.95e-16	9.26e-13	0.72	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
KIRP	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	8.69	3.96e-16	9.28e-13	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
KIRP	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	8.69	3.98e-16	9.35e-13	0.62	0.47	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
KIRP	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-8.69	3.99e-16	9.36e-13	-0.54	-0.47	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-8.69	3.99e-16	9.36e-13	-0.54	-0.47	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
KIRP	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-8.69	4e-16	9.39e-13	-0.54	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
KIRP	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-8.69	4.01e-16	9.4e-13	-0.54	-0.47	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
KIRP	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	8.69	4.01e-16	9.4e-13	0.51	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
KIRP	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	8.69	4.03e-16	9.44e-13	0.67	0.47	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
KIRP	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	8.69	4.04e-16	9.46e-13	0.53	0.47	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
KIRP	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-8.69	4.05e-16	9.49e-13	-0.52	-0.47	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	8.69	4.09e-16	9.58e-13	0.59	0.47	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
KIRP	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-8.69	4.09e-16	9.6e-13	-0.5	-0.47	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
KIRP	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	8.69	4.13e-16	9.67e-13	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
KIRP	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-8.69	4.13e-16	9.67e-13	-0.58	-0.47	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
KIRP	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	8.69	4.14e-16	9.69e-13	0.55	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	8.69	4.14e-16	9.69e-13	0.55	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	8.69	4.14e-16	9.69e-13	0.55	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-8.68	4.16e-16	9.74e-13	-0.53	-0.47	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
KIRP	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-8.68	4.19e-16	9.82e-13	-0.57	-0.47	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
KIRP	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-8.68	4.2e-16	9.82e-13	-0.5	-0.47	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
KIRP	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	8.68	4.27e-16	1e-12	0.57	0.47	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
KIRP	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	8.68	4.27e-16	1e-12	0.53	0.47	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
KIRP	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-8.68	4.28e-16	1e-12	-0.38	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
KIRP	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	8.68	4.3e-16	1.01e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	8.68	4.3e-16	1.01e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	8.68	4.3e-16	1.01e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
KIRP	cis	rs67311347	1	rs2085115	ENSG00000230274.1	PGAM1P3	8.68	4.3e-16	1.01e-12	0.49	0.47	Renal cell carcinoma;	chr3:40456049	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs28707772	ENSG00000230274.1	PGAM1P3	8.68	4.3e-16	1.01e-12	0.49	0.47	Renal cell carcinoma;	chr3:40463175	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs73080126	ENSG00000230274.1	PGAM1P3	8.68	4.3e-16	1.01e-12	0.49	0.47	Renal cell carcinoma;	chr3:40467662	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs28871903	ENSG00000230274.1	PGAM1P3	8.68	4.3e-16	1.01e-12	0.49	0.47	Renal cell carcinoma;	chr3:40469603	chr3:40322715~40323279:-
KIRP	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	8.68	4.31e-16	1.01e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	8.68	4.31e-16	1.01e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
KIRP	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	8.68	4.35e-16	1.02e-12	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
KIRP	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-8.68	4.4e-16	1.03e-12	-0.64	-0.47	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
KIRP	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	8.68	4.4e-16	1.03e-12	0.86	0.47	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	8.68	4.4e-16	1.03e-12	0.86	0.47	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
KIRP	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-8.68	4.43e-16	1.03e-12	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
KIRP	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-8.68	4.43e-16	1.03e-12	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
KIRP	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	8.67	4.46e-16	1.04e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
KIRP	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	8.67	4.47e-16	1.04e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	8.67	4.48e-16	1.05e-12	0.56	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
KIRP	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	8.67	4.53e-16	1.06e-12	0.55	0.47	Height;	chr11:118760944	chr11:118688039~118690600:-
KIRP	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	8.67	4.53e-16	1.06e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-8.67	4.55e-16	1.06e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
KIRP	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	8.67	4.55e-16	1.06e-12	0.51	0.47	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	8.67	4.61e-16	1.07e-12	0.52	0.47	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
KIRP	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-8.67	4.63e-16	1.08e-12	-0.46	-0.47	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
KIRP	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-8.67	4.64e-16	1.08e-12	-0.5	-0.47	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
KIRP	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-8.67	4.66e-16	1.08e-12	-0.64	-0.47	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
KIRP	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	8.67	4.68e-16	1.09e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
KIRP	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	8.67	4.68e-16	1.09e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
KIRP	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	8.67	4.71e-16	1.1e-12	0.56	0.47	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
KIRP	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.67	4.74e-16	1.1e-12	0.54	0.47	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
KIRP	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	8.67	4.75e-16	1.11e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-8.66	4.76e-16	1.11e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
KIRP	cis	rs4356975	0.932	rs4694610	ENSG00000250696.4	RP11-704M14.1	8.66	4.76e-16	1.11e-12	0.46	0.47	Obesity-related traits;	chr4:69079224	chr4:69182100~69216766:+
KIRP	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	8.66	4.77e-16	1.11e-12	0.54	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
KIRP	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	8.66	4.77e-16	1.11e-12	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
KIRP	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-8.66	4.8e-16	1.12e-12	-0.57	-0.47	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-8.66	4.8e-16	1.12e-12	-0.57	-0.47	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-8.66	4.8e-16	1.12e-12	-0.57	-0.47	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-8.66	4.8e-16	1.12e-12	-0.57	-0.47	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
KIRP	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-8.66	4.82e-16	1.12e-12	-0.46	-0.47	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
KIRP	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-8.66	4.82e-16	1.12e-12	-0.57	-0.47	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
KIRP	cis	rs67311347	1	rs1004655	ENSG00000230274.1	PGAM1P3	8.66	4.89e-16	1.13e-12	0.49	0.47	Renal cell carcinoma;	chr3:40448518	chr3:40322715~40323279:-
KIRP	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-8.66	4.9e-16	1.14e-12	-0.57	-0.47	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-8.66	4.9e-16	1.14e-12	-0.57	-0.47	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
KIRP	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-8.66	4.95e-16	1.15e-12	-0.4	-0.47	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
KIRP	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-8.66	4.95e-16	1.15e-12	-0.58	-0.47	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
KIRP	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	8.66	4.99e-16	1.16e-12	0.58	0.47	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
KIRP	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-8.66	5e-16	1.16e-12	-0.57	-0.47	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
KIRP	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	8.66	5.03e-16	1.17e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
KIRP	cis	rs67311347	1	rs56303661	ENSG00000230274.1	PGAM1P3	8.66	5.05e-16	1.17e-12	0.49	0.47	Renal cell carcinoma;	chr3:40479287	chr3:40322715~40323279:-
KIRP	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-8.66	5.07e-16	1.18e-12	-0.4	-0.47	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-8.66	5.07e-16	1.18e-12	-0.4	-0.47	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
KIRP	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-8.66	5.07e-16	1.18e-12	-0.4	-0.47	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-8.66	5.07e-16	1.18e-12	-0.4	-0.47	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
KIRP	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	8.65	5.22e-16	1.21e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
KIRP	cis	rs4356975	0.83	rs7693166	ENSG00000248763.2	RP13-644M16.5	8.65	5.24e-16	1.21e-12	0.51	0.47	Obesity-related traits;	chr4:69044866	chr4:69066395~69069888:+
KIRP	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	8.65	5.38e-16	1.24e-12	0.53	0.47	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
KIRP	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-8.65	5.45e-16	1.26e-12	-0.54	-0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.64	5.45e-16	1.26e-12	0.53	0.47	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
KIRP	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	8.64	5.5e-16	1.27e-12	0.66	0.47	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	8.64	5.5e-16	1.27e-12	0.66	0.47	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
KIRP	cis	rs4356975	0.83	rs4413468	ENSG00000248763.2	RP13-644M16.5	-8.64	5.51e-16	1.27e-12	-0.5	-0.47	Obesity-related traits;	chr4:69061845	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.798	rs4694588	ENSG00000248763.2	RP13-644M16.5	8.64	5.54e-16	1.28e-12	0.51	0.47	Obesity-related traits;	chr4:69044664	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs6422321	ENSG00000248763.2	RP13-644M16.5	8.64	5.54e-16	1.28e-12	0.51	0.47	Obesity-related traits;	chr4:69044911	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.768	rs4518318	ENSG00000248763.2	RP13-644M16.5	8.64	5.54e-16	1.28e-12	0.51	0.47	Obesity-related traits;	chr4:69045479	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs4351079	ENSG00000248763.2	RP13-644M16.5	8.64	5.54e-16	1.28e-12	0.51	0.47	Obesity-related traits;	chr4:69045631	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.798	rs4607293	ENSG00000248763.2	RP13-644M16.5	8.64	5.54e-16	1.28e-12	0.51	0.47	Obesity-related traits;	chr4:69045714	chr4:69066395~69069888:+
KIRP	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	8.64	5.59e-16	1.29e-12	0.61	0.47	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
KIRP	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-8.64	5.62e-16	1.3e-12	-0.42	-0.47	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
KIRP	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-8.64	5.67e-16	1.31e-12	-0.64	-0.47	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
KIRP	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-8.64	5.7e-16	1.31e-12	-0.58	-0.47	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
KIRP	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-8.64	5.71e-16	1.31e-12	-0.56	-0.47	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	8.64	5.71e-16	1.31e-12	0.63	0.47	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
KIRP	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	8.64	5.75e-16	1.32e-12	0.59	0.47	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	8.64	5.75e-16	1.32e-12	0.59	0.47	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
KIRP	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	8.63	5.85e-16	1.35e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
KIRP	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-8.63	5.86e-16	1.35e-12	-0.48	-0.47	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
KIRP	cis	rs67311347	1	rs12630072	ENSG00000230274.1	PGAM1P3	8.63	5.91e-16	1.36e-12	0.49	0.47	Renal cell carcinoma;	chr3:40475699	chr3:40322715~40323279:-
KIRP	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	8.63	5.96e-16	1.37e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
KIRP	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	8.63	5.97e-16	1.37e-12	0.55	0.47	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
KIRP	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-8.63	5.97e-16	1.37e-12	-0.5	-0.47	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
KIRP	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	8.63	5.99e-16	1.38e-12	0.55	0.47	Height;	chr11:118747911	chr11:118688039~118690600:-
KIRP	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	8.63	6.03e-16	1.39e-12	0.64	0.47	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
KIRP	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	8.63	6.05e-16	1.39e-12	0.59	0.47	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
KIRP	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	8.63	6.09e-16	1.4e-12	0.6	0.47	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
KIRP	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-8.63	6.09e-16	1.4e-12	-0.59	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
KIRP	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-8.63	6.12e-16	1.4e-12	-0.5	-0.47	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
KIRP	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-8.63	6.14e-16	1.41e-12	-0.59	-0.47	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
KIRP	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	8.63	6.17e-16	1.42e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
KIRP	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	8.63	6.21e-16	1.43e-12	0.53	0.47	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
KIRP	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	8.63	6.21e-16	1.43e-12	0.62	0.47	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
KIRP	cis	rs67311347	1	rs56291770	ENSG00000230274.1	PGAM1P3	8.62	6.26e-16	1.44e-12	0.49	0.47	Renal cell carcinoma;	chr3:40473879	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.932	rs12648830	ENSG00000250696.4	RP11-704M14.1	-8.62	6.27e-16	1.44e-12	-0.46	-0.47	Obesity-related traits;	chr4:69075436	chr4:69182100~69216766:+
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	8.62	6.32e-16	1.45e-12	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
KIRP	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	8.62	6.32e-16	1.45e-12	0.57	0.47	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
KIRP	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	8.62	6.34e-16	1.45e-12	0.64	0.47	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	8.62	6.34e-16	1.45e-12	0.64	0.47	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
KIRP	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	8.62	6.37e-16	1.46e-12	0.56	0.47	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
KIRP	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-8.62	6.41e-16	1.47e-12	-0.57	-0.47	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
KIRP	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-8.62	6.45e-16	1.48e-12	-0.4	-0.47	Height;	chr11:118760944	chr11:118791254~118793137:+
KIRP	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-8.62	6.51e-16	1.49e-12	-0.54	-0.47	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
KIRP	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	8.62	6.54e-16	1.5e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
KIRP	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	8.62	6.56e-16	1.5e-12	0.63	0.47	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
KIRP	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	8.62	6.58e-16	1.51e-12	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
KIRP	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	8.62	6.64e-16	1.52e-12	0.39	0.47	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
KIRP	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	8.62	6.67e-16	1.53e-12	0.55	0.47	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
KIRP	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	8.61	6.69e-16	1.53e-12	0.52	0.47	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
KIRP	cis	rs67311347	1	rs12488805	ENSG00000230274.1	PGAM1P3	8.61	6.7e-16	1.53e-12	0.49	0.47	Renal cell carcinoma;	chr3:40381378	chr3:40322715~40323279:-
KIRP	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-8.61	6.71e-16	1.53e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
KIRP	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-8.61	6.73e-16	1.54e-12	-0.38	-0.47	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
KIRP	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	8.61	6.81e-16	1.56e-12	0.54	0.47	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
KIRP	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-8.61	6.85e-16	1.56e-12	-0.57	-0.47	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
KIRP	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	8.61	6.88e-16	1.57e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
KIRP	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	8.61	6.94e-16	1.58e-12	0.59	0.47	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
KIRP	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-8.61	6.98e-16	1.59e-12	-0.62	-0.47	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-8.61	7.02e-16	1.6e-12	-0.62	-0.47	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
KIRP	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	8.61	7.02e-16	1.6e-12	0.6	0.47	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
KIRP	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	8.61	7.04e-16	1.61e-12	0.6	0.47	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
KIRP	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	8.61	7.05e-16	1.61e-12	0.59	0.47	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
KIRP	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-8.61	7.11e-16	1.62e-12	-0.52	-0.47	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
KIRP	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	8.61	7.13e-16	1.62e-12	0.55	0.47	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
KIRP	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	8.61	7.14e-16	1.63e-12	0.45	0.47	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
KIRP	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	8.6	7.18e-16	1.64e-12	0.56	0.47	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
KIRP	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-8.6	7.19e-16	1.64e-12	-0.5	-0.47	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
KIRP	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	8.6	7.19e-16	1.64e-12	0.54	0.47	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
KIRP	cis	rs67311347	0.955	rs73078170	ENSG00000230274.1	PGAM1P3	8.6	7.26e-16	1.65e-12	0.5	0.47	Renal cell carcinoma;	chr3:40442456	chr3:40322715~40323279:-
KIRP	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-8.6	7.26e-16	1.65e-12	-0.53	-0.47	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
KIRP	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	8.6	7.33e-16	1.67e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
KIRP	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	8.6	7.33e-16	1.67e-12	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
KIRP	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-8.6	7.38e-16	1.68e-12	-0.46	-0.47	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
KIRP	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	8.6	7.42e-16	1.69e-12	0.6	0.47	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
KIRP	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	8.6	7.45e-16	1.69e-12	0.54	0.47	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	8.6	7.45e-16	1.69e-12	0.54	0.47	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
KIRP	cis	rs4356975	0.932	rs7662632	ENSG00000248763.2	RP13-644M16.5	-8.6	7.51e-16	1.71e-12	-0.52	-0.47	Obesity-related traits;	chr4:69062256	chr4:69066395~69069888:+
KIRP	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-8.6	7.6e-16	1.73e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
KIRP	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	8.59	7.7e-16	1.75e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	8.59	7.7e-16	1.75e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	8.59	7.79e-16	1.77e-12	0.54	0.47	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	8.59	7.79e-16	1.77e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-8.59	7.82e-16	1.77e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
KIRP	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-8.59	7.83e-16	1.77e-12	-0.59	-0.47	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
KIRP	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	8.59	7.89e-16	1.79e-12	0.53	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
KIRP	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-8.59	7.9e-16	1.79e-12	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
KIRP	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	8.59	8.09e-16	1.83e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
KIRP	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-8.59	8.1e-16	1.83e-12	-0.65	-0.47	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
KIRP	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-8.59	8.11e-16	1.84e-12	-0.57	-0.47	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-8.59	8.11e-16	1.84e-12	-0.57	-0.47	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-8.59	8.11e-16	1.84e-12	-0.57	-0.47	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-8.59	8.11e-16	1.84e-12	-0.57	-0.47	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
KIRP	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	8.59	8.17e-16	1.85e-12	0.74	0.47	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
KIRP	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-8.58	8.22e-16	1.86e-12	-0.57	-0.47	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
KIRP	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	8.58	8.29e-16	1.87e-12	0.52	0.47	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
KIRP	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-8.58	8.34e-16	1.88e-12	-0.54	-0.47	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-8.58	8.34e-16	1.88e-12	-0.54	-0.47	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
KIRP	cis	rs1005277	0.54	rs1814077	ENSG00000151963.4	RP11-775A3.1	-8.58	8.55e-16	1.93e-12	-0.52	-0.47	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:37883594~37884109:+
KIRP	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	8.58	8.57e-16	1.93e-12	0.6	0.47	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
KIRP	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-8.58	8.59e-16	1.94e-12	-0.57	-0.47	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
KIRP	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	8.58	8.63e-16	1.95e-12	0.52	0.47	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
KIRP	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	8.58	8.65e-16	1.95e-12	0.54	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
KIRP	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	8.58	8.67e-16	1.96e-12	0.61	0.47	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.795	rs4694599	ENSG00000248763.2	RP13-644M16.5	-8.58	8.69e-16	1.96e-12	-0.5	-0.47	Obesity-related traits;	chr4:69070858	chr4:69066395~69069888:+
KIRP	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	8.58	8.75e-16	1.97e-12	0.57	0.47	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
KIRP	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	8.57	8.8e-16	1.98e-12	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
KIRP	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-8.57	8.81e-16	1.98e-12	-0.38	-0.47	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
KIRP	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-8.57	8.91e-16	2e-12	-0.49	-0.47	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
KIRP	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-8.57	8.93e-16	2.01e-12	-0.56	-0.47	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
KIRP	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-8.57	9e-16	2.02e-12	-0.5	-0.47	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
KIRP	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-8.57	9.03e-16	2.03e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
KIRP	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-8.57	9.1e-16	2.05e-12	-0.57	-0.47	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
KIRP	cis	rs4356975	0.83	rs7666894	ENSG00000248763.2	RP13-644M16.5	-8.57	9.21e-16	2.07e-12	-0.5	-0.47	Obesity-related traits;	chr4:69078780	chr4:69066395~69069888:+
KIRP	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-8.57	9.36e-16	2.1e-12	-0.42	-0.47	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
KIRP	cis	rs4356975	0.83	rs57386454	ENSG00000248763.2	RP13-644M16.5	-8.56	9.48e-16	2.13e-12	-0.5	-0.47	Obesity-related traits;	chr4:69052968	chr4:69066395~69069888:+
KIRP	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	8.56	9.53e-16	2.14e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	8.56	9.56e-16	2.14e-12	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
KIRP	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-8.56	9.56e-16	2.14e-12	-0.49	-0.47	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
KIRP	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	8.56	9.62e-16	2.16e-12	0.58	0.47	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
KIRP	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-8.56	9.66e-16	2.16e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
KIRP	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-8.56	9.66e-16	2.16e-12	-0.56	-0.47	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
KIRP	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	8.56	9.68e-16	2.17e-12	0.52	0.47	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
KIRP	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-8.56	9.92e-16	2.22e-12	-0.38	-0.47	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
KIRP	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	8.56	9.97e-16	2.23e-12	0.59	0.47	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
KIRP	cis	rs4356975	0.83	rs72851338	ENSG00000248763.2	RP13-644M16.5	-8.56	1e-15	2.24e-12	-0.5	-0.47	Obesity-related traits;	chr4:69052555	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs60212682	ENSG00000248763.2	RP13-644M16.5	-8.56	1e-15	2.24e-12	-0.5	-0.47	Obesity-related traits;	chr4:69052849	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs72851348	ENSG00000248763.2	RP13-644M16.5	-8.56	1e-15	2.24e-12	-0.5	-0.47	Obesity-related traits;	chr4:69054305	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs6422322	ENSG00000248763.2	RP13-644M16.5	-8.56	1e-15	2.24e-12	-0.5	-0.47	Obesity-related traits;	chr4:69055571	chr4:69066395~69069888:+
KIRP	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-8.55	1.01e-15	2.25e-12	-0.49	-0.47	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
KIRP	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	8.55	1.02e-15	2.27e-12	0.52	0.47	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
KIRP	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	8.55	1.02e-15	2.29e-12	0.39	0.47	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
KIRP	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	8.55	1.03e-15	2.29e-12	0.4	0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
KIRP	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	8.55	1.04e-15	2.32e-12	0.58	0.47	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
KIRP	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-8.55	1.05e-15	2.34e-12	-0.56	-0.47	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
KIRP	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	8.55	1.07e-15	2.38e-12	0.56	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
KIRP	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-8.55	1.07e-15	2.38e-12	-0.57	-0.47	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
KIRP	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-8.54	1.08e-15	2.4e-12	-0.57	-0.47	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
KIRP	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	8.54	1.08e-15	2.41e-12	0.49	0.47	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
KIRP	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	8.54	1.09e-15	2.43e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	8.54	1.09e-15	2.43e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	8.54	1.09e-15	2.43e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
KIRP	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	8.54	1.1e-15	2.45e-12	0.64	0.47	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
KIRP	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-8.54	1.1e-15	2.45e-12	-0.6	-0.47	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	8.54	1.1e-15	2.46e-12	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
KIRP	cis	rs4356975	0.83	rs4422474	ENSG00000248763.2	RP13-644M16.5	-8.54	1.11e-15	2.46e-12	-0.5	-0.47	Obesity-related traits;	chr4:69051322	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs4377650	ENSG00000248763.2	RP13-644M16.5	-8.54	1.11e-15	2.46e-12	-0.5	-0.47	Obesity-related traits;	chr4:69051355	chr4:69066395~69069888:+
KIRP	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	8.54	1.11e-15	2.48e-12	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
KIRP	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	8.54	1.12e-15	2.48e-12	0.59	0.47	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
KIRP	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-8.54	1.12e-15	2.49e-12	-0.56	-0.47	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
KIRP	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	8.54	1.12e-15	2.5e-12	0.66	0.47	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
KIRP	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	8.54	1.13e-15	2.5e-12	0.53	0.47	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
KIRP	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-8.54	1.13e-15	2.51e-12	-0.55	-0.47	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
KIRP	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	8.54	1.13e-15	2.52e-12	0.59	0.47	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
KIRP	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-8.54	1.14e-15	2.52e-12	-0.54	-0.47	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-8.54	1.14e-15	2.52e-12	-0.54	-0.47	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
KIRP	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	8.54	1.14e-15	2.52e-12	0.54	0.47	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
KIRP	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-8.54	1.14e-15	2.53e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
KIRP	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	8.54	1.14e-15	2.53e-12	0.54	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
KIRP	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	8.54	1.14e-15	2.54e-12	0.65	0.47	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-8.54	1.15e-15	2.55e-12	-0.56	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
KIRP	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	8.54	1.15e-15	2.55e-12	0.58	0.47	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
KIRP	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-8.53	1.16e-15	2.57e-12	-0.57	-0.47	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
KIRP	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-8.53	1.16e-15	2.57e-12	-0.57	-0.47	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
KIRP	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	8.53	1.16e-15	2.57e-12	0.58	0.47	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
KIRP	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	8.53	1.16e-15	2.57e-12	0.58	0.47	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
KIRP	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-8.53	1.16e-15	2.58e-12	-0.52	-0.47	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
KIRP	cis	rs67311347	1	rs7634375	ENSG00000230274.1	PGAM1P3	8.53	1.17e-15	2.59e-12	0.47	0.47	Renal cell carcinoma;	chr3:40390455	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.83	rs3922514	ENSG00000248763.2	RP13-644M16.5	-8.53	1.17e-15	2.59e-12	-0.5	-0.47	Obesity-related traits;	chr4:69060905	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs28775401	ENSG00000248763.2	RP13-644M16.5	-8.53	1.17e-15	2.59e-12	-0.5	-0.47	Obesity-related traits;	chr4:69060999	chr4:69066395~69069888:+
KIRP	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-8.53	1.18e-15	2.61e-12	-0.37	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
KIRP	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	8.53	1.18e-15	2.61e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	8.53	1.18e-15	2.61e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	8.53	1.18e-15	2.61e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
KIRP	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-8.53	1.18e-15	2.62e-12	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
KIRP	cis	rs4356975	0.83	rs10012215	ENSG00000248763.2	RP13-644M16.5	-8.53	1.18e-15	2.62e-12	-0.5	-0.47	Obesity-related traits;	chr4:69048448	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs10012240	ENSG00000248763.2	RP13-644M16.5	-8.53	1.18e-15	2.62e-12	-0.5	-0.47	Obesity-related traits;	chr4:69048519	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs10012607	ENSG00000248763.2	RP13-644M16.5	-8.53	1.18e-15	2.62e-12	-0.5	-0.47	Obesity-related traits;	chr4:69048866	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs7435274	ENSG00000248763.2	RP13-644M16.5	-8.53	1.18e-15	2.62e-12	-0.5	-0.47	Obesity-related traits;	chr4:69050281	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs7438808	ENSG00000248763.2	RP13-644M16.5	-8.53	1.18e-15	2.62e-12	-0.5	-0.47	Obesity-related traits;	chr4:69050666	chr4:69066395~69069888:+
KIRP	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-8.53	1.19e-15	2.62e-12	-0.61	-0.47	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
KIRP	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	8.53	1.19e-15	2.63e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	8.53	1.19e-15	2.63e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
KIRP	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-8.53	1.19e-15	2.63e-12	-0.57	-0.47	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
KIRP	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	8.53	1.2e-15	2.65e-12	0.51	0.47	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
KIRP	cis	rs67311347	1	rs17078941	ENSG00000230274.1	PGAM1P3	-8.53	1.2e-15	2.65e-12	-0.48	-0.47	Renal cell carcinoma;	chr3:40409397	chr3:40322715~40323279:-
KIRP	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-8.53	1.2e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-8.53	1.21e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-8.53	1.21e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-8.53	1.21e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-8.53	1.21e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-8.53	1.21e-15	2.67e-12	-0.57	-0.47	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
KIRP	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	8.53	1.21e-15	2.68e-12	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
KIRP	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-8.52	1.23e-15	2.72e-12	-0.45	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
KIRP	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-8.52	1.24e-15	2.74e-12	-0.67	-0.47	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
KIRP	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-8.52	1.24e-15	2.74e-12	-0.45	-0.47	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
KIRP	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-8.52	1.25e-15	2.76e-12	-0.53	-0.47	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
KIRP	cis	rs1005277	0.54	rs1987431	ENSG00000151963.4	RP11-775A3.1	-8.52	1.25e-15	2.77e-12	-0.51	-0.47	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:37883594~37884109:+
KIRP	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	8.52	1.25e-15	2.77e-12	0.6	0.47	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
KIRP	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	8.52	1.25e-15	2.77e-12	0.52	0.47	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
KIRP	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	8.52	1.27e-15	2.81e-12	0.54	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
KIRP	cis	rs67311347	1	rs1047855	ENSG00000230274.1	PGAM1P3	-8.52	1.28e-15	2.82e-12	-0.47	-0.47	Renal cell carcinoma;	chr3:40427405	chr3:40322715~40323279:-
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	8.52	1.28e-15	2.83e-12	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
KIRP	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8.52	1.29e-15	2.84e-12	-0.51	-0.47	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-8.52	1.29e-15	2.85e-12	-0.57	-0.47	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
KIRP	cis	rs67311347	0.826	rs9863679	ENSG00000230274.1	PGAM1P3	8.52	1.3e-15	2.86e-12	0.47	0.47	Renal cell carcinoma;	chr3:40398123	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.911	rs9863737	ENSG00000230274.1	PGAM1P3	8.52	1.3e-15	2.86e-12	0.47	0.47	Renal cell carcinoma;	chr3:40398345	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.932	rs60814050	ENSG00000248763.2	RP13-644M16.5	-8.52	1.31e-15	2.89e-12	-0.52	-0.47	Obesity-related traits;	chr4:69063770	chr4:69066395~69069888:+
KIRP	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-8.52	1.31e-15	2.89e-12	-0.52	-0.47	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
KIRP	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	8.51	1.32e-15	2.9e-12	0.53	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	8.51	1.32e-15	2.9e-12	0.53	0.47	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
KIRP	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	8.51	1.32e-15	2.91e-12	0.59	0.47	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
KIRP	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	8.51	1.34e-15	2.95e-12	0.59	0.47	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
KIRP	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	8.51	1.34e-15	2.95e-12	0.54	0.47	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
KIRP	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	8.51	1.36e-15	2.98e-12	0.55	0.47	Height;	chr11:118746590	chr11:118688039~118690600:-
KIRP	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-8.51	1.36e-15	2.99e-12	-0.41	-0.47	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
KIRP	cis	rs4356975	0.932	rs12648830	ENSG00000248763.2	RP13-644M16.5	8.51	1.37e-15	3e-12	0.51	0.47	Obesity-related traits;	chr4:69075436	chr4:69066395~69069888:+
KIRP	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-8.51	1.37e-15	3.02e-12	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
KIRP	cis	rs67311347	1	rs9875245	ENSG00000230274.1	PGAM1P3	8.51	1.38e-15	3.03e-12	0.47	0.47	Renal cell carcinoma;	chr3:40400789	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs954589	ENSG00000230274.1	PGAM1P3	8.51	1.38e-15	3.03e-12	0.47	0.47	Renal cell carcinoma;	chr3:40403054	chr3:40322715~40323279:-
KIRP	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-8.51	1.38e-15	3.04e-12	-0.59	-0.47	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
KIRP	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-8.51	1.39e-15	3.07e-12	-0.57	-0.47	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-8.51	1.39e-15	3.07e-12	-0.57	-0.47	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
KIRP	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-8.51	1.41e-15	3.09e-12	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
KIRP	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	8.5	1.41e-15	3.1e-12	0.53	0.47	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
KIRP	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	8.5	1.41e-15	3.1e-12	0.51	0.47	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
KIRP	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	8.5	1.42e-15	3.11e-12	0.61	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	8.5	1.42e-15	3.11e-12	0.61	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.932	rs4694610	ENSG00000248763.2	RP13-644M16.5	-8.5	1.43e-15	3.13e-12	-0.51	-0.47	Obesity-related traits;	chr4:69079224	chr4:69066395~69069888:+
KIRP	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-8.5	1.44e-15	3.17e-12	-0.58	-0.46	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
KIRP	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	8.5	1.44e-15	3.17e-12	0.53	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
KIRP	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-8.5	1.45e-15	3.18e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
KIRP	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-8.5	1.46e-15	3.2e-12	-0.52	-0.46	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
KIRP	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-8.5	1.46e-15	3.2e-12	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
KIRP	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-8.5	1.46e-15	3.21e-12	-0.49	-0.46	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
KIRP	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-8.5	1.47e-15	3.22e-12	-0.57	-0.46	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
KIRP	cis	rs1005277	0.522	rs11011343	ENSG00000151963.4	RP11-775A3.1	-8.5	1.47e-15	3.23e-12	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.522	rs7090858	ENSG00000151963.4	RP11-775A3.1	8.5	1.47e-15	3.23e-12	0.52	0.46	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:37883594~37884109:+
KIRP	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	8.5	1.48e-15	3.24e-12	0.6	0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
KIRP	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	8.5	1.48e-15	3.24e-12	0.44	0.46	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
KIRP	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	8.5	1.48e-15	3.25e-12	0.52	0.46	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
KIRP	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	8.5	1.49e-15	3.26e-12	0.63	0.46	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
KIRP	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	8.5	1.5e-15	3.28e-12	0.58	0.46	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
KIRP	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	8.5	1.5e-15	3.3e-12	0.55	0.46	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
KIRP	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	8.5	1.5e-15	3.3e-12	0.53	0.46	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	8.5	1.5e-15	3.3e-12	0.53	0.46	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
KIRP	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-8.49	1.51e-15	3.32e-12	-0.39	-0.46	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-8.49	1.51e-15	3.32e-12	-0.39	-0.46	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
KIRP	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	8.49	1.52e-15	3.32e-12	0.49	0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
KIRP	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	8.49	1.52e-15	3.33e-12	0.52	0.46	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
KIRP	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	8.49	1.53e-15	3.34e-12	0.45	0.46	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
KIRP	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-8.49	1.53e-15	3.35e-12	-0.53	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
KIRP	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	8.49	1.53e-15	3.35e-12	0.59	0.46	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-8.49	1.53e-15	3.35e-12	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
KIRP	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	8.49	1.53e-15	3.36e-12	0.52	0.46	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
KIRP	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	8.49	1.54e-15	3.36e-12	0.49	0.46	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
KIRP	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	8.49	1.54e-15	3.38e-12	0.53	0.46	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	8.49	1.54e-15	3.38e-12	0.53	0.46	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
KIRP	cis	rs4356975	0.83	rs4481286	ENSG00000248763.2	RP13-644M16.5	-8.49	1.55e-15	3.39e-12	-0.49	-0.46	Obesity-related traits;	chr4:69056631	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs4583828	ENSG00000248763.2	RP13-644M16.5	-8.49	1.55e-15	3.39e-12	-0.49	-0.46	Obesity-related traits;	chr4:69056669	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs4235113	ENSG00000248763.2	RP13-644M16.5	-8.49	1.55e-15	3.39e-12	-0.49	-0.46	Obesity-related traits;	chr4:69056739	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.83	rs4235114	ENSG00000248763.2	RP13-644M16.5	-8.49	1.55e-15	3.39e-12	-0.49	-0.46	Obesity-related traits;	chr4:69056953	chr4:69066395~69069888:+
KIRP	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	8.49	1.56e-15	3.41e-12	0.72	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
KIRP	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	8.49	1.56e-15	3.42e-12	0.53	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
KIRP	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	8.49	1.58e-15	3.44e-12	0.78	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
KIRP	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-8.49	1.58e-15	3.44e-12	-0.4	-0.46	Height;	chr11:118746590	chr11:118791254~118793137:+
KIRP	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	8.49	1.59e-15	3.47e-12	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
KIRP	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-8.49	1.59e-15	3.48e-12	-0.62	-0.46	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
KIRP	cis	rs755249	0.583	rs61779328	ENSG00000237624.1	OXCT2P1	8.49	1.6e-15	3.5e-12	0.78	0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39514956~39516490:+
KIRP	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-8.48	1.64e-15	3.57e-12	-0.56	-0.46	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
KIRP	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-8.48	1.64e-15	3.58e-12	-0.67	-0.46	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-8.48	1.64e-15	3.58e-12	-0.67	-0.46	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-8.48	1.64e-15	3.58e-12	-0.67	-0.46	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
KIRP	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	8.48	1.64e-15	3.59e-12	0.68	0.46	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
KIRP	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-8.48	1.66e-15	3.61e-12	-0.54	-0.46	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
KIRP	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	8.48	1.67e-15	3.63e-12	0.52	0.46	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
KIRP	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.48	1.67e-15	3.64e-12	0.53	0.46	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
KIRP	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-8.48	1.69e-15	3.68e-12	-0.45	-0.46	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-8.48	1.69e-15	3.68e-12	-0.45	-0.46	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-8.48	1.69e-15	3.68e-12	-0.45	-0.46	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
KIRP	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-8.48	1.69e-15	3.68e-12	-0.48	-0.46	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
KIRP	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-8.48	1.7e-15	3.7e-12	-0.55	-0.46	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-8.48	1.7e-15	3.7e-12	-0.55	-0.46	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
KIRP	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	8.48	1.7e-15	3.71e-12	0.45	0.46	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
KIRP	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	8.48	1.71e-15	3.73e-12	0.53	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
KIRP	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-8.48	1.71e-15	3.73e-12	-0.4	-0.46	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
KIRP	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	8.48	1.71e-15	3.73e-12	0.53	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
KIRP	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	8.47	1.72e-15	3.76e-12	0.54	0.46	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
KIRP	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	8.47	1.73e-15	3.76e-12	0.58	0.46	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
KIRP	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	8.47	1.73e-15	3.76e-12	0.63	0.46	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
KIRP	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	8.47	1.74e-15	3.78e-12	0.53	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
KIRP	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-8.47	1.75e-15	3.81e-12	-0.37	-0.46	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
KIRP	cis	rs67311347	1	rs73076046	ENSG00000230274.1	PGAM1P3	8.47	1.76e-15	3.82e-12	0.48	0.46	Renal cell carcinoma;	chr3:40406233	chr3:40322715~40323279:-
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000273295.1	AP000350.5	8.47	1.76e-15	3.83e-12	0.58	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23901432~23907068:-
KIRP	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-8.47	1.76e-15	3.83e-12	-0.57	-0.46	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
KIRP	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-8.47	1.76e-15	3.83e-12	-0.58	-0.46	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
KIRP	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-8.47	1.77e-15	3.84e-12	-0.52	-0.46	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
KIRP	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-8.47	1.77e-15	3.85e-12	-0.52	-0.46	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-8.47	1.77e-15	3.85e-12	-0.52	-0.46	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
KIRP	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-8.47	1.77e-15	3.85e-12	-0.55	-0.46	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-8.47	1.77e-15	3.85e-12	-0.55	-0.46	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-8.47	1.77e-15	3.85e-12	-0.55	-0.46	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-8.47	1.77e-15	3.85e-12	-0.55	-0.46	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-8.47	1.77e-15	3.85e-12	-0.55	-0.46	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
KIRP	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-8.47	1.78e-15	3.86e-12	-0.87	-0.46	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
KIRP	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	8.47	1.78e-15	3.87e-12	0.44	0.46	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
KIRP	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-8.47	1.78e-15	3.87e-12	-0.37	-0.46	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
KIRP	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-8.47	1.79e-15	3.9e-12	-0.57	-0.46	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
KIRP	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-8.47	1.81e-15	3.92e-12	-0.55	-0.46	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-8.47	1.81e-15	3.92e-12	-0.55	-0.46	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-8.47	1.81e-15	3.92e-12	-0.55	-0.46	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	8.47	1.81e-15	3.93e-12	0.64	0.46	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
KIRP	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-8.47	1.81e-15	3.93e-12	-0.53	-0.46	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
KIRP	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-8.47	1.81e-15	3.93e-12	-0.59	-0.46	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	8.47	1.81e-15	3.93e-12	0.61	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
KIRP	cis	rs67311347	1	rs12494022	ENSG00000230274.1	PGAM1P3	8.47	1.81e-15	3.94e-12	0.48	0.46	Renal cell carcinoma;	chr3:40385161	chr3:40322715~40323279:-
KIRP	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	8.47	1.84e-15	3.99e-12	0.54	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
KIRP	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-8.46	1.86e-15	4.04e-12	-0.37	-0.46	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
KIRP	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-8.46	1.86e-15	4.04e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
KIRP	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	8.46	1.87e-15	4.05e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
KIRP	cis	rs67311347	1	rs12108041	ENSG00000230274.1	PGAM1P3	8.46	1.87e-15	4.05e-12	0.46	0.46	Renal cell carcinoma;	chr3:40446044	chr3:40322715~40323279:-
KIRP	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-8.46	1.88e-15	4.08e-12	-0.39	-0.46	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
KIRP	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-8.46	1.9e-15	4.12e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
KIRP	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	8.46	1.91e-15	4.14e-12	0.53	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
KIRP	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	8.46	1.95e-15	4.21e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
KIRP	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	8.46	1.95e-15	4.21e-12	0.64	0.46	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
KIRP	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-8.46	1.95e-15	4.21e-12	-0.57	-0.46	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-8.46	1.95e-15	4.21e-12	-0.57	-0.46	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-8.46	1.95e-15	4.21e-12	-0.57	-0.46	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-8.46	1.95e-15	4.21e-12	-0.57	-0.46	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
KIRP	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-8.46	1.95e-15	4.22e-12	-0.55	-0.46	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
KIRP	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	8.45	1.97e-15	4.27e-12	0.51	0.46	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
KIRP	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-8.45	1.99e-15	4.31e-12	-0.56	-0.46	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
KIRP	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	8.45	1.99e-15	4.31e-12	0.73	0.46	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	8.45	1.99e-15	4.31e-12	0.73	0.46	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	8.45	1.99e-15	4.31e-12	0.73	0.46	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	8.45	1.99e-15	4.31e-12	0.73	0.46	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	8.45	1.99e-15	4.31e-12	0.73	0.46	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
KIRP	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-8.45	2.01e-15	4.35e-12	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-8.45	2.01e-15	4.35e-12	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-8.45	2.01e-15	4.35e-12	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
KIRP	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	8.45	2.01e-15	4.35e-12	0.49	0.46	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
KIRP	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-8.45	2.02e-15	4.36e-12	-0.57	-0.46	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-8.45	2.02e-15	4.36e-12	-0.57	-0.46	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
KIRP	cis	rs67311347	1	rs11706148	ENSG00000230274.1	PGAM1P3	8.45	2.03e-15	4.38e-12	0.48	0.46	Renal cell carcinoma;	chr3:40365752	chr3:40322715~40323279:-
KIRP	cis	rs755249	0.833	rs61779313	ENSG00000237624.1	OXCT2P1	8.45	2.04e-15	4.39e-12	0.72	0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39514956~39516490:+
KIRP	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-8.45	2.06e-15	4.44e-12	-0.49	-0.46	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
KIRP	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-8.45	2.06e-15	4.45e-12	-0.55	-0.46	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
KIRP	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.45	2.06e-15	4.45e-12	-0.56	-0.46	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
KIRP	cis	rs1005277	0.54	rs2145487	ENSG00000151963.4	RP11-775A3.1	-8.45	2.07e-15	4.46e-12	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.54	rs4934907	ENSG00000151963.4	RP11-775A3.1	-8.45	2.07e-15	4.46e-12	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.54	rs11011351	ENSG00000151963.4	RP11-775A3.1	-8.45	2.07e-15	4.46e-12	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:37883594~37884109:+
KIRP	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-8.45	2.07e-15	4.46e-12	-0.57	-0.46	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-8.45	2.09e-15	4.51e-12	-0.57	-0.46	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
KIRP	cis	rs1005277	0.522	rs1208767	ENSG00000151963.4	RP11-775A3.1	-8.45	2.1e-15	4.53e-12	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:37883594~37884109:+
KIRP	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	8.45	2.11e-15	4.54e-12	0.51	0.46	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
KIRP	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	8.44	2.11e-15	4.55e-12	0.78	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
KIRP	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	8.44	2.11e-15	4.55e-12	0.58	0.46	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
KIRP	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.52	-0.46	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
KIRP	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.12e-15	4.55e-12	-0.47	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
KIRP	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-8.44	2.12e-15	4.56e-12	-0.39	-0.46	Height;	chr11:118737823	chr11:118791254~118793137:+
KIRP	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	8.44	2.13e-15	4.57e-12	0.39	0.46	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
KIRP	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-8.44	2.13e-15	4.59e-12	-0.61	-0.46	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
KIRP	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	8.44	2.15e-15	4.63e-12	0.58	0.46	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	8.44	2.15e-15	4.63e-12	0.58	0.46	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	8.44	2.15e-15	4.63e-12	0.58	0.46	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
KIRP	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-8.44	2.17e-15	4.66e-12	-0.57	-0.46	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
KIRP	cis	rs755249	0.874	rs61779310	ENSG00000237624.1	OXCT2P1	8.44	2.17e-15	4.67e-12	0.71	0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39514956~39516490:+
KIRP	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-8.44	2.2e-15	4.72e-12	-0.53	-0.46	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
KIRP	cis	rs11647589	0.689	rs12599141	ENSG00000260762.1	ACSM5P1	8.44	2.2e-15	4.73e-12	0.48	0.46	Blood metabolite levels;	chr16:20440775	chr16:20586550~20607107:-
KIRP	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	8.44	2.21e-15	4.73e-12	0.66	0.46	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
KIRP	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-8.44	2.21e-15	4.73e-12	-0.61	-0.46	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
KIRP	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	8.44	2.21e-15	4.74e-12	0.44	0.46	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	8.44	2.21e-15	4.74e-12	0.44	0.46	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
KIRP	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	8.44	2.21e-15	4.75e-12	0.65	0.46	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
KIRP	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-8.44	2.22e-15	4.75e-12	-0.37	-0.46	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
KIRP	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	8.44	2.22e-15	4.76e-12	0.54	0.46	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
KIRP	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	8.44	2.24e-15	4.8e-12	0.54	0.46	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
KIRP	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	8.44	2.24e-15	4.8e-12	0.54	0.46	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
KIRP	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	8.43	2.27e-15	4.85e-12	0.5	0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
KIRP	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-8.43	2.27e-15	4.86e-12	-0.66	-0.46	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-8.43	2.27e-15	4.86e-12	-0.66	-0.46	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
KIRP	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	8.43	2.28e-15	4.88e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	8.43	2.28e-15	4.88e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
KIRP	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	8.43	2.29e-15	4.89e-12	0.57	0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
KIRP	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	8.43	2.31e-15	4.93e-12	0.45	0.46	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
KIRP	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-8.43	2.31e-15	4.94e-12	-0.66	-0.46	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
KIRP	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-8.43	2.31e-15	4.94e-12	-0.39	-0.46	Height;	chr11:118747911	chr11:118791254~118793137:+
KIRP	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	8.43	2.31e-15	4.95e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
KIRP	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	8.43	2.32e-15	4.95e-12	0.51	0.46	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
KIRP	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-8.43	2.34e-15	5e-12	-0.49	-0.46	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
KIRP	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-8.43	2.35e-15	5.02e-12	-0.57	-0.46	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-8.43	2.35e-15	5.02e-12	-0.57	-0.46	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-8.43	2.35e-15	5.02e-12	-0.57	-0.46	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
KIRP	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-8.43	2.37e-15	5.05e-12	-0.51	-0.46	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
KIRP	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	8.43	2.37e-15	5.06e-12	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
KIRP	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	8.43	2.4e-15	5.12e-12	0.53	0.46	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
KIRP	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	8.42	2.42e-15	5.17e-12	0.53	0.46	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
KIRP	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	8.42	2.44e-15	5.21e-12	0.6	0.46	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
KIRP	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	8.42	2.46e-15	5.23e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
KIRP	cis	rs4356975	0.932	rs4694604	ENSG00000248763.2	RP13-644M16.5	-8.42	2.46e-15	5.25e-12	-0.51	-0.46	Obesity-related traits;	chr4:69072745	chr4:69066395~69069888:+
KIRP	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-8.42	2.49e-15	5.3e-12	-0.57	-0.46	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
KIRP	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	8.42	2.49e-15	5.3e-12	0.72	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
KIRP	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	8.42	2.51e-15	5.35e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-8.42	2.53e-15	5.39e-12	-0.38	-0.46	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-8.42	2.53e-15	5.39e-12	-0.38	-0.46	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
KIRP	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	8.42	2.56e-15	5.44e-12	0.53	0.46	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	8.42	2.56e-15	5.44e-12	0.53	0.46	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
KIRP	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-8.42	2.56e-15	5.45e-12	-0.54	-0.46	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
KIRP	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	8.41	2.59e-15	5.51e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
KIRP	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	8.41	2.59e-15	5.51e-12	0.64	0.46	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
KIRP	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	8.41	2.59e-15	5.51e-12	0.72	0.46	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	8.41	2.63e-15	5.59e-12	0.61	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
KIRP	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-8.41	2.64e-15	5.6e-12	-0.58	-0.46	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
KIRP	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	8.41	2.64e-15	5.61e-12	0.53	0.46	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
KIRP	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	8.41	2.64e-15	5.61e-12	0.53	0.46	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
KIRP	cis	rs1005277	0.522	rs9417256	ENSG00000151963.4	RP11-775A3.1	-8.41	2.68e-15	5.69e-12	-0.5	-0.46	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:37883594~37884109:+
KIRP	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-8.41	2.73e-15	5.79e-12	-0.93	-0.46	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
KIRP	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-8.41	2.74e-15	5.81e-12	-0.56	-0.46	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
KIRP	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-8.41	2.75e-15	5.81e-12	-0.57	-0.46	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
KIRP	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-8.41	2.75e-15	5.81e-12	-0.48	-0.46	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-8.41	2.75e-15	5.82e-12	-0.48	-0.46	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
KIRP	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	8.41	2.75e-15	5.82e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
KIRP	cis	rs11603023	0.569	rs573905	ENSG00000255239.1	AP002954.6	8.41	2.76e-15	5.83e-12	0.54	0.46	Cholesterol, total;	chr11:118701558	chr11:118688039~118690600:-
KIRP	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-8.4	2.76e-15	5.84e-12	-0.55	-0.46	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-8.4	2.76e-15	5.84e-12	-0.38	-0.46	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-8.4	2.77e-15	5.86e-12	-0.57	-0.46	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
KIRP	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-8.4	2.77e-15	5.86e-12	-0.55	-0.46	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
KIRP	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-8.4	2.77e-15	5.86e-12	-0.57	-0.46	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-8.4	2.81e-15	5.94e-12	-0.37	-0.46	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-8.4	2.82e-15	5.95e-12	-0.37	-0.46	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	8.4	2.82e-15	5.95e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	8.4	2.82e-15	5.95e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	8.4	2.82e-15	5.95e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	8.4	2.82e-15	5.95e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	8.4	2.82e-15	5.95e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
KIRP	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	8.4	2.84e-15	5.98e-12	0.44	0.46	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
KIRP	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	8.4	2.84e-15	5.98e-12	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
KIRP	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-8.4	2.85e-15	6e-12	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
KIRP	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-8.4	2.86e-15	6.01e-12	-0.57	-0.46	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
KIRP	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.4	2.9e-15	6.08e-12	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
KIRP	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	8.4	2.91e-15	6.11e-12	0.6	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
KIRP	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	8.4	2.92e-15	6.13e-12	0.52	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
KIRP	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	8.4	2.94e-15	6.17e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	8.4	2.94e-15	6.17e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
KIRP	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	8.4	2.95e-15	6.18e-12	0.51	0.46	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
KIRP	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	8.4	2.95e-15	6.18e-12	0.51	0.46	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
KIRP	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-8.39	2.96e-15	6.2e-12	-0.49	-0.46	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
KIRP	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-8.39	2.97e-15	6.24e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-8.39	2.97e-15	6.24e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-8.39	2.97e-15	6.24e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-8.39	2.97e-15	6.24e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
KIRP	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-8.39	2.98e-15	6.26e-12	-0.35	-0.46	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
KIRP	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-8.39	3.02e-15	6.33e-12	-0.48	-0.46	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
KIRP	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-8.39	3.02e-15	6.33e-12	-0.48	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
KIRP	cis	rs67311347	1	rs4571217	ENSG00000230274.1	PGAM1P3	8.39	3.03e-15	6.34e-12	0.46	0.46	Renal cell carcinoma;	chr3:40480482	chr3:40322715~40323279:-
KIRP	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	8.39	3.03e-15	6.35e-12	0.53	0.46	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	8.39	3.03e-15	6.35e-12	0.53	0.46	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
KIRP	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-8.39	3.04e-15	6.36e-12	-0.57	-0.46	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
KIRP	cis	rs4356975	0.83	rs6600865	ENSG00000248763.2	RP13-644M16.5	-8.39	3.05e-15	6.37e-12	-0.49	-0.46	Obesity-related traits;	chr4:69057904	chr4:69066395~69069888:+
KIRP	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-8.39	3.1e-15	6.48e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
KIRP	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	8.39	3.1e-15	6.49e-12	0.71	0.46	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	8.39	3.1e-15	6.49e-12	0.71	0.46	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	8.39	3.1e-15	6.49e-12	0.71	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
KIRP	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-8.39	3.12e-15	6.52e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
KIRP	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-8.39	3.13e-15	6.53e-12	-0.39	-0.46	Height;	chr11:118742526	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-8.39	3.13e-15	6.54e-12	-0.51	-0.46	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
KIRP	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-8.39	3.16e-15	6.59e-12	-0.48	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
KIRP	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-8.39	3.16e-15	6.59e-12	-0.48	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
KIRP	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-8.39	3.16e-15	6.59e-12	-0.48	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
KIRP	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.38	3.16e-15	6.6e-12	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
KIRP	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	8.38	3.22e-15	6.72e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
KIRP	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-8.38	3.24e-15	6.75e-12	-0.39	-0.46	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
KIRP	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	8.38	3.25e-15	6.77e-12	0.51	0.46	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
KIRP	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	8.38	3.25e-15	6.77e-12	0.51	0.46	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
KIRP	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-8.38	3.27e-15	6.8e-12	-0.38	-0.46	Height;	chr11:118764443	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	8.38	3.27e-15	6.8e-12	0.53	0.46	Height;	chr11:118781100	chr11:118688039~118690600:-
KIRP	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-8.38	3.27e-15	6.82e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-8.38	3.27e-15	6.82e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-8.38	3.27e-15	6.82e-12	-0.61	-0.46	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
KIRP	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	8.38	3.27e-15	6.82e-12	0.37	0.46	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
KIRP	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	8.38	3.28e-15	6.83e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
KIRP	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-8.38	3.28e-15	6.83e-12	-0.66	-0.46	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
KIRP	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-8.38	3.3e-15	6.86e-12	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
KIRP	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	8.38	3.31e-15	6.89e-12	0.57	0.46	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
KIRP	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	8.38	3.34e-15	6.95e-12	0.53	0.46	Height;	chr11:118737916	chr11:118688039~118690600:-
KIRP	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	8.38	3.35e-15	6.96e-12	0.6	0.46	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
KIRP	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	8.38	3.36e-15	6.98e-12	0.5	0.46	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
KIRP	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	8.37	3.38e-15	7.02e-12	0.44	0.46	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	8.37	3.38e-15	7.02e-12	0.44	0.46	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	8.37	3.38e-15	7.02e-12	0.44	0.46	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-8.37	3.39e-15	7.05e-12	-0.44	-0.46	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	8.37	3.4e-15	7.05e-12	0.44	0.46	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	8.37	3.4e-15	7.05e-12	0.44	0.46	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	8.37	3.4e-15	7.05e-12	0.44	0.46	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
KIRP	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-8.37	3.4e-15	7.05e-12	-0.65	-0.46	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-8.37	3.4e-15	7.05e-12	-0.65	-0.46	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
KIRP	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	8.37	3.4e-15	7.05e-12	0.71	0.46	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
KIRP	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	8.37	3.4e-15	7.06e-12	0.53	0.46	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
KIRP	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-8.37	3.4e-15	7.06e-12	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-8.37	3.4e-15	7.06e-12	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
KIRP	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	8.37	3.41e-15	7.07e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
KIRP	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-8.37	3.44e-15	7.14e-12	-0.54	-0.46	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
KIRP	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	8.37	3.46e-15	7.17e-12	0.38	0.46	Height;	chr11:118758322	chr11:118791254~118793137:+
KIRP	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	8.37	3.47e-15	7.19e-12	0.45	0.46	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
KIRP	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-8.37	3.51e-15	7.27e-12	-0.86	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
KIRP	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	8.37	3.53e-15	7.33e-12	0.5	0.46	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
KIRP	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	8.37	3.55e-15	7.35e-12	0.52	0.46	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
KIRP	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-8.37	3.56e-15	7.37e-12	-0.57	-0.46	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-8.37	3.56e-15	7.37e-12	-0.57	-0.46	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
KIRP	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	8.37	3.56e-15	7.38e-12	0.58	0.46	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
KIRP	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-8.37	3.57e-15	7.4e-12	-0.38	-0.46	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-8.37	3.59e-15	7.44e-12	-0.54	-0.46	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
KIRP	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-8.37	3.6e-15	7.46e-12	-0.38	-0.46	Height;	chr11:118761813	chr11:118791254~118793137:+
KIRP	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	8.36	3.63e-15	7.51e-12	0.61	0.46	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
KIRP	cis	rs1005277	0.522	rs289649	ENSG00000151963.4	RP11-775A3.1	-8.36	3.65e-15	7.57e-12	-0.5	-0.46	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:37883594~37884109:+
KIRP	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-8.36	3.75e-15	7.76e-12	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
KIRP	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	8.36	3.76e-15	7.79e-12	0.77	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
KIRP	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-8.36	3.79e-15	7.84e-12	-0.65	-0.46	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
KIRP	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-8.36	3.8e-15	7.85e-12	-0.38	-0.46	Height;	chr11:118773873	chr11:118791254~118793137:+
KIRP	cis	rs832187	0.64	rs704367	ENSG00000280620.1	SCAANT1	-8.36	3.81e-15	7.88e-12	-0.5	-0.46	Schizophrenia;	chr3:63883101	chr3:63911518~63911772:-
KIRP	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-8.36	3.81e-15	7.88e-12	-0.38	-0.46	Height;	chr11:118781100	chr11:118791254~118793137:+
KIRP	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-8.36	3.82e-15	7.9e-12	-0.62	-0.46	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
KIRP	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	8.36	3.83e-15	7.92e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
KIRP	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	8.36	3.85e-15	7.95e-12	0.6	0.46	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
KIRP	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	8.36	3.85e-15	7.95e-12	0.51	0.46	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
KIRP	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	8.36	3.85e-15	7.96e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	8.36	3.85e-15	7.96e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	8.36	3.85e-15	7.96e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	8.36	3.85e-15	7.96e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
KIRP	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-8.35	3.88e-15	8.01e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
KIRP	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-8.35	3.88e-15	8.01e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
KIRP	cis	rs4356975	0.932	rs4694607	ENSG00000248763.2	RP13-644M16.5	-8.35	3.89e-15	8.03e-12	-0.51	-0.46	Obesity-related traits;	chr4:69073025	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs4410590	ENSG00000248763.2	RP13-644M16.5	-8.35	3.89e-15	8.03e-12	-0.51	-0.46	Obesity-related traits;	chr4:69073381	chr4:69066395~69069888:+
KIRP	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	8.35	3.9e-15	8.04e-12	0.44	0.46	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
KIRP	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-8.35	3.98e-15	8.19e-12	-0.51	-0.46	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
KIRP	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-8.35	3.98e-15	8.19e-12	-0.51	-0.46	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
KIRP	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-8.35	3.98e-15	8.19e-12	-0.51	-0.46	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
KIRP	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	8.35	3.98e-15	8.19e-12	0.57	0.46	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
KIRP	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	8.35	3.99e-15	8.21e-12	0.55	0.46	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
KIRP	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-8.35	3.99e-15	8.22e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-8.35	3.99e-15	8.22e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-8.35	3.99e-15	8.22e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
KIRP	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	8.35	3.99e-15	8.22e-12	0.5	0.46	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
KIRP	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	8.35	4e-15	8.24e-12	0.44	0.46	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
KIRP	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-8.35	4.01e-15	8.24e-12	-0.52	-0.46	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
KIRP	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-8.35	4.02e-15	8.26e-12	-0.65	-0.46	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
KIRP	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	8.35	4.02e-15	8.27e-12	0.52	0.46	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
KIRP	cis	rs4936099	0.646	rs4937514	ENSG00000175773.11	RP11-121M22.1	8.35	4.06e-15	8.35e-12	0.45	0.46	Optic cup area;Vertical cup-disc ratio;	chr11:130394620	chr11:130314993~130403657:+
KIRP	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-8.35	4.08e-15	8.38e-12	-0.41	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
KIRP	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-8.35	4.09e-15	8.41e-12	-0.59	-0.46	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
KIRP	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	8.35	4.1e-15	8.42e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	8.35	4.1e-15	8.42e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
KIRP	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-8.35	4.1e-15	8.42e-12	-0.55	-0.46	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	8.35	4.11e-15	8.44e-12	0.41	0.46	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.791	rs9612520	ENSG00000206090.4	AP000350.7	8.34	4.14e-15	8.49e-12	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23939998~23942798:+
KIRP	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	8.34	4.15e-15	8.51e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	8.34	4.18e-15	8.57e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	8.34	4.18e-15	8.57e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	8.34	4.18e-15	8.57e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
KIRP	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	8.34	4.19e-15	8.58e-12	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
KIRP	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-8.34	4.2e-15	8.62e-12	-0.65	-0.46	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
KIRP	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-8.34	4.22e-15	8.66e-12	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	8.34	4.24e-15	8.68e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
KIRP	cis	rs4356975	1	rs4356975	ENSG00000250696.4	RP11-704M14.1	8.34	4.28e-15	8.76e-12	0.46	0.46	Obesity-related traits;	chr4:69106745	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	8.34	4.36e-15	8.92e-12	0.54	0.46	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
KIRP	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-8.34	4.4e-15	9e-12	-0.55	-0.46	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
KIRP	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.34	4.4e-15	9e-12	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.34	4.4e-15	9e-12	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
KIRP	cis	rs4356975	0.932	rs7657426	ENSG00000248763.2	RP13-644M16.5	-8.34	4.4e-15	9.01e-12	-0.51	-0.46	Obesity-related traits;	chr4:69079291	chr4:69066395~69069888:+
KIRP	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-8.33	4.42e-15	9.03e-12	-0.38	-0.46	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
KIRP	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	8.33	4.42e-15	9.03e-12	0.65	0.46	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	8.33	4.42e-15	9.03e-12	0.65	0.46	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	8.33	4.42e-15	9.03e-12	0.65	0.46	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	8.33	4.42e-15	9.03e-12	0.65	0.46	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
KIRP	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-8.33	4.45e-15	9.09e-12	-0.38	-0.46	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
KIRP	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-8.33	4.45e-15	9.1e-12	-0.57	-0.46	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
KIRP	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-8.33	4.46e-15	9.12e-12	-0.56	-0.46	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
KIRP	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	8.33	4.47e-15	9.14e-12	0.57	0.46	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	8.33	4.47e-15	9.14e-12	0.57	0.46	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	8.33	4.47e-15	9.14e-12	0.57	0.46	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
KIRP	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	8.33	4.53e-15	9.2e-12	0.73	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
KIRP	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	8.33	4.54e-15	9.22e-12	0.57	0.46	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
KIRP	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-8.33	4.55e-15	9.25e-12	-0.51	-0.46	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
KIRP	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	8.33	4.56e-15	9.26e-12	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
KIRP	cis	rs4356975	0.932	rs4694159	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69068460	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4694597	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69068643	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs4694160	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69068755	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs7439419	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069090	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7658748	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069219	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs7687336	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069397	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs7659138	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069420	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7674600	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069614	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs72501227	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69069866	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4694602	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69070955	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4400060	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69071215	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4400061	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69071281	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4446390	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69071328	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7434389	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69071698	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.896	rs58496756	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69072070	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.899	rs7687725	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69072229	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4516791	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69072402	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4694605	ENSG00000248763.2	RP13-644M16.5	-8.33	4.56e-15	9.26e-12	-0.51	-0.46	Obesity-related traits;	chr4:69072777	chr4:69066395~69069888:+
KIRP	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	8.33	4.56e-15	9.26e-12	0.53	0.46	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
KIRP	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-8.33	4.57e-15	9.26e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
KIRP	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-8.33	4.59e-15	9.3e-12	-0.54	-0.46	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
KIRP	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-8.33	4.6e-15	9.32e-12	-0.51	-0.46	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
KIRP	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-8.33	4.61e-15	9.33e-12	-0.48	-0.46	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
KIRP	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	8.33	4.64e-15	9.4e-12	0.51	0.46	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
KIRP	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	8.33	4.65e-15	9.42e-12	0.52	0.46	Height;	chr11:118791319	chr11:118688039~118690600:-
KIRP	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-8.33	4.69e-15	9.49e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-8.33	4.69e-15	9.49e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-8.33	4.69e-15	9.49e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
KIRP	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	8.33	4.69e-15	9.49e-12	0.52	0.46	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
KIRP	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	8.33	4.71e-15	9.53e-12	0.52	0.46	Height;	chr11:118786602	chr11:118688039~118690600:-
KIRP	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	8.33	4.71e-15	9.53e-12	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
KIRP	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-8.32	4.73e-15	9.57e-12	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
KIRP	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	8.32	4.75e-15	9.6e-12	0.62	0.46	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
KIRP	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	8.32	4.75e-15	9.6e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
KIRP	cis	rs4356975	0.932	rs4611997	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69073429	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7436912	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69074077	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7654272	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69074144	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs6600867	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69074157	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs72852416	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69075085	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.806	rs12648808	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69075351	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.867	rs6600869	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69075937	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.836	rs6600870	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69075944	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7442394	ENSG00000248763.2	RP13-644M16.5	-8.32	4.76e-15	9.61e-12	-0.5	-0.46	Obesity-related traits;	chr4:69076309	chr4:69066395~69069888:+
KIRP	cis	rs67311347	0.955	rs11711994	ENSG00000230274.1	PGAM1P3	8.32	4.8e-15	9.68e-12	0.47	0.46	Renal cell carcinoma;	chr3:40349595	chr3:40322715~40323279:-
KIRP	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-8.32	4.84e-15	9.76e-12	-0.55	-0.46	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
KIRP	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-8.32	4.86e-15	9.79e-12	-0.57	-0.46	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
KIRP	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-8.32	4.86e-15	9.8e-12	-0.73	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
KIRP	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-8.32	4.88e-15	9.83e-12	-0.52	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
KIRP	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-8.32	4.9e-15	9.87e-12	-0.55	-0.46	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
KIRP	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	8.32	4.91e-15	9.89e-12	0.53	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
KIRP	cis	rs4356975	0.932	rs56879009	ENSG00000248763.2	RP13-644M16.5	-8.32	4.92e-15	9.91e-12	-0.51	-0.46	Obesity-related traits;	chr4:69079589	chr4:69066395~69069888:+
KIRP	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	8.32	4.93e-15	9.93e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
KIRP	cis	rs67311347	1	rs9822909	ENSG00000230274.1	PGAM1P3	8.32	4.93e-15	9.94e-12	0.49	0.46	Renal cell carcinoma;	chr3:40415593	chr3:40322715~40323279:-
KIRP	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-8.32	4.94e-15	9.95e-12	-0.52	-0.46	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
KIRP	cis	rs11647589	0.815	rs7194852	ENSG00000260762.1	ACSM5P1	8.32	4.95e-15	9.98e-12	0.47	0.46	Blood metabolite levels;	chr16:20461954	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.906	rs6416611	ENSG00000260762.1	ACSM5P1	8.32	5.01e-15	1.01e-11	0.48	0.46	Blood metabolite levels;	chr16:20459768	chr16:20586550~20607107:-
KIRP	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	8.32	5.01e-15	1.01e-11	0.52	0.46	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	8.32	5.01e-15	1.01e-11	0.52	0.46	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	8.32	5.01e-15	1.01e-11	0.52	0.46	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	8.32	5.01e-15	1.01e-11	0.52	0.46	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
KIRP	cis	rs4356975	0.599	rs7660019	ENSG00000248763.2	RP13-644M16.5	-8.31	5.05e-15	1.02e-11	-0.5	-0.46	Obesity-related traits;	chr4:69072135	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.574	rs7660021	ENSG00000248763.2	RP13-644M16.5	-8.31	5.05e-15	1.02e-11	-0.5	-0.46	Obesity-related traits;	chr4:69072143	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.549	rs7687692	ENSG00000248763.2	RP13-644M16.5	-8.31	5.05e-15	1.02e-11	-0.5	-0.46	Obesity-related traits;	chr4:69072154	chr4:69066395~69069888:+
KIRP	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	8.31	5.07e-15	1.02e-11	0.55	0.46	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
KIRP	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-8.31	5.1e-15	1.03e-11	-0.54	-0.46	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
KIRP	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	8.31	5.15e-15	1.03e-11	0.57	0.46	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
KIRP	cis	rs4356975	0.899	rs4412058	ENSG00000248763.2	RP13-644M16.5	-8.31	5.17e-15	1.04e-11	-0.5	-0.46	Obesity-related traits;	chr4:69073715	chr4:69066395~69069888:+
KIRP	cis	rs11647589	0.815	rs11646536	ENSG00000260762.1	ACSM5P1	8.31	5.21e-15	1.05e-11	0.48	0.46	Blood metabolite levels;	chr16:20462274	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.723	rs9937581	ENSG00000260762.1	ACSM5P1	8.31	5.21e-15	1.05e-11	0.48	0.46	Blood metabolite levels;	chr16:20462581	chr16:20586550~20607107:-
KIRP	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-8.31	5.21e-15	1.05e-11	-0.56	-0.46	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
KIRP	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	8.31	5.23e-15	1.05e-11	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	8.31	5.23e-15	1.05e-11	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
KIRP	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	8.31	5.25e-15	1.05e-11	0.52	0.46	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
KIRP	cis	rs4356975	0.932	rs7692377	ENSG00000248763.2	RP13-644M16.5	-8.31	5.27e-15	1.06e-11	-0.5	-0.46	Obesity-related traits;	chr4:69078113	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs61612343	ENSG00000248763.2	RP13-644M16.5	-8.31	5.27e-15	1.06e-11	-0.5	-0.46	Obesity-related traits;	chr4:69078247	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7679418	ENSG00000248763.2	RP13-644M16.5	-8.31	5.27e-15	1.06e-11	-0.5	-0.46	Obesity-related traits;	chr4:69078533	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7680156	ENSG00000248763.2	RP13-644M16.5	-8.31	5.27e-15	1.06e-11	-0.5	-0.46	Obesity-related traits;	chr4:69078868	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs7698430	ENSG00000248763.2	RP13-644M16.5	-8.31	5.27e-15	1.06e-11	-0.5	-0.46	Obesity-related traits;	chr4:69078897	chr4:69066395~69069888:+
KIRP	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	8.31	5.3e-15	1.06e-11	0.52	0.46	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
KIRP	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	8.31	5.32e-15	1.07e-11	0.61	0.46	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
KIRP	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-8.31	5.33e-15	1.07e-11	-0.52	-0.46	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-8.31	5.33e-15	1.07e-11	-0.54	-0.46	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
KIRP	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-8.31	5.34e-15	1.07e-11	-0.53	-0.46	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
KIRP	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	8.31	5.35e-15	1.07e-11	0.73	0.46	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
KIRP	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-8.31	5.37e-15	1.08e-11	-0.58	-0.46	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
KIRP	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-8.3	5.4e-15	1.08e-11	-0.53	-0.46	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
KIRP	cis	rs71007656	1	rs71007656	ENSG00000151963.4	RP11-775A3.1	-8.3	5.4e-15	1.08e-11	-0.5	-0.46	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:37883594~37884109:+
KIRP	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	8.3	5.42e-15	1.08e-11	0.65	0.46	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
KIRP	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-8.3	5.46e-15	1.09e-11	-0.53	-0.46	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-8.3	5.47e-15	1.1e-11	-0.37	-0.46	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
KIRP	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-8.3	5.48e-15	1.1e-11	-0.44	-0.46	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
KIRP	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	8.3	5.51e-15	1.1e-11	0.52	0.46	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	8.3	5.51e-15	1.1e-11	0.52	0.46	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	8.3	5.51e-15	1.1e-11	0.52	0.46	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
KIRP	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	8.3	5.52e-15	1.1e-11	0.53	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
KIRP	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.3	5.52e-15	1.1e-11	0.52	0.46	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
KIRP	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-8.3	5.57e-15	1.11e-11	-0.56	-0.46	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
KIRP	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-8.3	5.57e-15	1.11e-11	-0.85	-0.46	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-8.3	5.57e-15	1.11e-11	-0.85	-0.46	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-8.3	5.57e-15	1.11e-11	-0.85	-0.46	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
KIRP	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-8.3	5.57e-15	1.11e-11	-0.85	-0.46	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
KIRP	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-8.3	5.66e-15	1.13e-11	-0.52	-0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
KIRP	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-8.3	5.66e-15	1.13e-11	-0.38	-0.46	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
KIRP	cis	rs4356975	0.932	rs4694611	ENSG00000248763.2	RP13-644M16.5	-8.3	5.68e-15	1.13e-11	-0.5	-0.46	Obesity-related traits;	chr4:69079387	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.932	rs4694612	ENSG00000248763.2	RP13-644M16.5	-8.3	5.68e-15	1.13e-11	-0.5	-0.46	Obesity-related traits;	chr4:69079446	chr4:69066395~69069888:+
KIRP	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	8.3	5.69e-15	1.14e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	8.3	5.69e-15	1.14e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
KIRP	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-8.3	5.74e-15	1.15e-11	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
KIRP	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-8.29	5.77e-15	1.15e-11	-0.49	-0.46	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
KIRP	cis	rs2980439	0.729	rs2955585	ENSG00000253981.4	ALG1L13P	8.29	5.77e-15	1.15e-11	0.38	0.46	Neuroticism;	chr8:8235989	chr8:8236003~8244667:-
KIRP	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	8.29	5.79e-15	1.15e-11	0.44	0.46	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
KIRP	cis	rs1005277	0.522	rs200943	ENSG00000151963.4	RP11-775A3.1	-8.29	5.86e-15	1.17e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:37883594~37884109:+
KIRP	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-8.29	5.86e-15	1.17e-11	-0.57	-0.46	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
KIRP	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-8.29	5.86e-15	1.17e-11	-0.57	-0.46	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
KIRP	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-8.29	5.87e-15	1.17e-11	-0.49	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
KIRP	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	8.29	5.92e-15	1.18e-11	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
KIRP	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	8.29	5.94e-15	1.18e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
KIRP	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	8.29	5.95e-15	1.19e-11	0.53	0.46	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
KIRP	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	8.29	5.96e-15	1.19e-11	0.38	0.46	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
KIRP	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-8.29	5.99e-15	1.19e-11	-0.57	-0.46	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
KIRP	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-8.29	6.02e-15	1.2e-11	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	8.29	6.05e-15	1.2e-11	0.68	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	8.29	6.05e-15	1.2e-11	0.68	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
KIRP	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	8.29	6.08e-15	1.21e-11	0.38	0.46	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
KIRP	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	8.29	6.08e-15	1.21e-11	0.73	0.46	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
KIRP	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-8.29	6.15e-15	1.22e-11	-0.6	-0.46	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
KIRP	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-8.28	6.17e-15	1.23e-11	-0.36	-0.46	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
KIRP	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	8.28	6.21e-15	1.24e-11	0.54	0.46	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
KIRP	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-8.28	6.26e-15	1.25e-11	-0.38	-0.46	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-8.28	6.26e-15	1.25e-11	-0.38	-0.46	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
KIRP	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	8.28	6.3e-15	1.25e-11	0.59	0.46	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
KIRP	cis	rs1005277	0.505	rs200935	ENSG00000151963.4	RP11-775A3.1	-8.28	6.3e-15	1.25e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.505	rs200936	ENSG00000151963.4	RP11-775A3.1	-8.28	6.3e-15	1.25e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.505	rs200937	ENSG00000151963.4	RP11-775A3.1	-8.28	6.3e-15	1.25e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.505	rs200939	ENSG00000151963.4	RP11-775A3.1	-8.28	6.3e-15	1.25e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:37883594~37884109:+
KIRP	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-8.28	6.35e-15	1.26e-11	-0.52	-0.46	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
KIRP	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-8.28	6.38e-15	1.27e-11	-0.63	-0.46	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
KIRP	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	8.28	6.39e-15	1.27e-11	0.51	0.46	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
KIRP	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	8.28	6.39e-15	1.27e-11	0.52	0.46	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
KIRP	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-8.28	6.4e-15	1.27e-11	-0.51	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-8.28	6.4e-15	1.27e-11	-0.51	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
KIRP	cis	rs4356975	0.83	rs7438033	ENSG00000248763.2	RP13-644M16.5	8.28	6.4e-15	1.27e-11	0.47	0.46	Obesity-related traits;	chr4:69059343	chr4:69066395~69069888:+
KIRP	cis	rs832187	0.704	rs704364	ENSG00000280620.1	SCAANT1	-8.28	6.42e-15	1.27e-11	-0.5	-0.46	Schizophrenia;	chr3:63889058	chr3:63911518~63911772:-
KIRP	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	8.28	6.45e-15	1.28e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	8.28	6.45e-15	1.28e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	8.28	6.45e-15	1.28e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	8.28	6.45e-15	1.28e-11	0.52	0.46	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
KIRP	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	8.28	6.49e-15	1.29e-11	0.58	0.46	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
KIRP	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	8.28	6.51e-15	1.29e-11	0.59	0.46	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
KIRP	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-8.28	6.51e-15	1.29e-11	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
KIRP	cis	rs1005277	0.505	rs200910	ENSG00000151963.4	RP11-775A3.1	-8.28	6.52e-15	1.29e-11	-0.52	-0.46	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:37883594~37884109:+
KIRP	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-8.27	6.69e-15	1.33e-11	-0.57	-0.46	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
KIRP	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	8.27	6.69e-15	1.33e-11	0.56	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	8.27	6.72e-15	1.33e-11	0.53	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
KIRP	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	8.27	6.74e-15	1.33e-11	0.53	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
KIRP	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-8.27	6.75e-15	1.34e-11	-0.52	-0.46	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
KIRP	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-8.27	6.76e-15	1.34e-11	-0.49	-0.46	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	8.27	6.76e-15	1.34e-11	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
KIRP	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	8.27	6.78e-15	1.34e-11	0.49	0.45	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
KIRP	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-8.27	6.8e-15	1.35e-11	-0.84	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
KIRP	cis	rs67311347	1	rs2276870	ENSG00000230274.1	PGAM1P3	-8.27	6.89e-15	1.36e-11	-0.44	-0.45	Renal cell carcinoma;	chr3:40457691	chr3:40322715~40323279:-
KIRP	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	8.27	6.89e-15	1.36e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
KIRP	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	8.27	6.89e-15	1.36e-11	0.5	0.45	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
KIRP	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-8.27	6.95e-15	1.37e-11	-0.54	-0.45	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
KIRP	cis	rs67311347	1	rs17078916	ENSG00000230274.1	PGAM1P3	8.27	7e-15	1.38e-11	0.47	0.45	Renal cell carcinoma;	chr3:40403947	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-8.27	7.01e-15	1.39e-11	-0.58	-0.45	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
KIRP	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.27	7.02e-15	1.39e-11	-0.64	-0.45	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
KIRP	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-8.27	7.03e-15	1.39e-11	-0.88	-0.45	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-8.26	7.04e-15	1.39e-11	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
KIRP	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	8.26	7.12e-15	1.41e-11	0.64	0.45	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
KIRP	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-8.26	7.26e-15	1.43e-11	-0.56	-0.45	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
KIRP	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	8.26	7.3e-15	1.44e-11	0.52	0.45	Height;	chr11:118749988	chr11:118688039~118690600:-
KIRP	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	8.26	7.35e-15	1.45e-11	0.56	0.45	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
KIRP	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	8.26	7.37e-15	1.45e-11	0.47	0.45	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
KIRP	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-8.26	7.39e-15	1.46e-11	-0.54	-0.45	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-8.26	7.39e-15	1.46e-11	-0.38	-0.45	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
KIRP	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	8.26	7.4e-15	1.46e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
KIRP	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-8.26	7.43e-15	1.46e-11	-0.52	-0.45	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
KIRP	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-8.26	7.46e-15	1.47e-11	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
KIRP	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-8.26	7.46e-15	1.47e-11	-0.36	-0.45	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
KIRP	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	8.26	7.48e-15	1.48e-11	0.52	0.45	Height;	chr11:118764443	chr11:118688039~118690600:-
KIRP	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-8.25	7.58e-15	1.49e-11	-0.56	-0.45	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
KIRP	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	8.25	7.61e-15	1.5e-11	0.49	0.45	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
KIRP	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	8.25	7.65e-15	1.51e-11	0.51	0.45	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
KIRP	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	8.25	7.65e-15	1.51e-11	0.51	0.45	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
KIRP	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-8.25	7.67e-15	1.51e-11	-0.51	-0.45	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-8.25	7.69e-15	1.51e-11	-0.54	-0.45	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-8.25	7.69e-15	1.51e-11	-0.54	-0.45	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-8.25	7.69e-15	1.51e-11	-0.54	-0.45	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
KIRP	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	8.25	7.7e-15	1.52e-11	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	8.25	7.7e-15	1.52e-11	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
KIRP	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-8.25	7.71e-15	1.52e-11	-0.51	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
KIRP	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	8.25	7.72e-15	1.52e-11	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	8.25	7.72e-15	1.52e-11	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	8.25	7.72e-15	1.52e-11	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	8.25	7.72e-15	1.52e-11	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
KIRP	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-8.25	7.74e-15	1.52e-11	-0.55	-0.45	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
KIRP	cis	rs67311347	1	rs11714032	ENSG00000230274.1	PGAM1P3	8.25	7.75e-15	1.52e-11	0.47	0.45	Renal cell carcinoma;	chr3:40390114	chr3:40322715~40323279:-
KIRP	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-8.25	7.77e-15	1.53e-11	-0.56	-0.45	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
KIRP	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-8.25	7.78e-15	1.53e-11	-0.37	-0.45	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
KIRP	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	8.25	7.82e-15	1.54e-11	0.51	0.45	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
KIRP	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	8.25	7.84e-15	1.54e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
KIRP	cis	rs1005277	0.522	rs289648	ENSG00000151963.4	RP11-775A3.1	-8.25	7.86e-15	1.54e-11	-0.49	-0.45	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:37883594~37884109:+
KIRP	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	8.25	7.9e-15	1.55e-11	0.55	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
KIRP	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	8.25	7.92e-15	1.56e-11	0.58	0.45	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
KIRP	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-8.25	8.02e-15	1.58e-11	-0.65	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
KIRP	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-8.24	8.07e-15	1.58e-11	-0.64	-0.45	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
KIRP	cis	rs1005277	0.505	rs1208689	ENSG00000151963.4	RP11-775A3.1	-8.24	8.08e-15	1.59e-11	-0.52	-0.45	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:37883594~37884109:+
KIRP	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	8.24	8.11e-15	1.59e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
KIRP	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	8.24	8.14e-15	1.6e-11	0.39	0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
KIRP	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-8.24	8.18e-15	1.6e-11	-0.53	-0.45	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
KIRP	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-8.24	8.2e-15	1.61e-11	-0.38	-0.45	Height;	chr11:118737916	chr11:118791254~118793137:+
KIRP	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-8.24	8.27e-15	1.62e-11	-0.58	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
KIRP	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	8.24	8.29e-15	1.63e-11	0.57	0.45	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
KIRP	cis	rs67311347	1	rs4128740	ENSG00000230274.1	PGAM1P3	8.24	8.33e-15	1.63e-11	0.46	0.45	Renal cell carcinoma;	chr3:40478041	chr3:40322715~40323279:-
KIRP	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-8.24	8.4e-15	1.65e-11	-0.89	-0.45	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-8.24	8.4e-15	1.65e-11	-0.89	-0.45	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
KIRP	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-8.24	8.43e-15	1.65e-11	-0.56	-0.45	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
KIRP	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-8.24	8.58e-15	1.68e-11	-0.37	-0.45	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
KIRP	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	8.23	8.59e-15	1.68e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	8.23	8.59e-15	1.68e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	8.23	8.59e-15	1.68e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	8.23	8.59e-15	1.68e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
KIRP	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-8.23	8.68e-15	1.7e-11	-0.59	-0.45	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
KIRP	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	8.23	8.74e-15	1.71e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
KIRP	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	8.23	8.78e-15	1.72e-11	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
KIRP	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-8.23	8.9e-15	1.74e-11	-0.39	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
KIRP	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-8.23	8.9e-15	1.74e-11	-0.39	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
KIRP	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-8.23	8.9e-15	1.74e-11	-0.52	-0.45	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
KIRP	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-8.23	8.9e-15	1.74e-11	-0.36	-0.45	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
KIRP	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-8.23	8.96e-15	1.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-8.23	8.96e-15	1.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-8.23	8.96e-15	1.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-8.23	8.96e-15	1.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
KIRP	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	8.23	8.99e-15	1.76e-11	0.52	0.45	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
KIRP	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	8.23	9.01e-15	1.76e-11	0.52	0.45	Height;	chr11:118773873	chr11:118688039~118690600:-
KIRP	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	8.23	9.05e-15	1.77e-11	0.28	0.45	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
KIRP	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	8.23	9.08e-15	1.77e-11	0.52	0.45	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
KIRP	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	8.23	9.1e-15	1.78e-11	0.52	0.45	Height;	chr11:118761813	chr11:118688039~118690600:-
KIRP	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-8.23	9.15e-15	1.79e-11	-0.44	-0.45	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
KIRP	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-8.22	9.2e-15	1.79e-11	-0.52	-0.45	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-8.22	9.2e-15	1.79e-11	-0.52	-0.45	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-8.22	9.22e-15	1.8e-11	-0.55	-0.45	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
KIRP	cis	rs1005277	0.505	rs10827835	ENSG00000151963.4	RP11-775A3.1	8.22	9.23e-15	1.8e-11	0.53	0.45	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:37883594~37884109:+
KIRP	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-8.22	9.26e-15	1.8e-11	-0.52	-0.45	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
KIRP	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	8.22	9.29e-15	1.81e-11	0.71	0.45	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	8.22	9.29e-15	1.81e-11	0.71	0.45	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	8.22	9.29e-15	1.81e-11	0.71	0.45	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	8.22	9.29e-15	1.81e-11	0.71	0.45	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	8.22	9.29e-15	1.81e-11	0.71	0.45	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
KIRP	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-8.22	9.31e-15	1.81e-11	-0.48	-0.45	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
KIRP	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-8.22	9.33e-15	1.82e-11	-0.55	-0.45	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
KIRP	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	8.22	9.38e-15	1.83e-11	0.53	0.45	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
KIRP	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	8.22	9.47e-15	1.84e-11	0.47	0.45	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
KIRP	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	8.22	9.5e-15	1.85e-11	0.53	0.45	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
KIRP	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	8.22	9.55e-15	1.86e-11	0.51	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
KIRP	cis	rs4356975	1	rs4356975	ENSG00000248763.2	RP13-644M16.5	-8.22	9.56e-15	1.86e-11	-0.51	-0.45	Obesity-related traits;	chr4:69106745	chr4:69066395~69069888:+
KIRP	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-8.22	9.66e-15	1.88e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-8.22	9.66e-15	1.88e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
KIRP	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-8.22	9.69e-15	1.88e-11	-0.66	-0.45	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
KIRP	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	8.22	9.7e-15	1.88e-11	0.85	0.45	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
KIRP	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-8.22	9.71e-15	1.89e-11	-0.52	-0.45	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
KIRP	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-8.22	9.72e-15	1.89e-11	-1.01	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
KIRP	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-8.22	9.74e-15	1.89e-11	-0.52	-0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
KIRP	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-8.21	9.81e-15	1.91e-11	-0.5	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
KIRP	cis	rs67311347	1	rs73076035	ENSG00000230274.1	PGAM1P3	8.21	9.86e-15	1.91e-11	0.47	0.45	Renal cell carcinoma;	chr3:40398390	chr3:40322715~40323279:-
KIRP	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-8.21	9.99e-15	1.94e-11	-0.84	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
KIRP	cis	rs9371601	0.798	rs550685	ENSG00000226193.1	RP3-398G3.5	8.21	1e-14	1.94e-11	0.51	0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152397356	chr6:152402398~152404966:+
KIRP	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-8.21	1.01e-14	1.95e-11	-0.48	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
KIRP	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-8.21	1.01e-14	1.96e-11	-0.53	-0.45	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
KIRP	cis	rs9371601	0.859	rs1203233	ENSG00000226193.1	RP3-398G3.5	8.21	1.01e-14	1.96e-11	0.5	0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393471	chr6:152402398~152404966:+
KIRP	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-8.21	1.01e-14	1.96e-11	-0.38	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
KIRP	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-8.21	1.01e-14	1.96e-11	-0.38	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
KIRP	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-8.21	1.01e-14	1.96e-11	-0.38	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
KIRP	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-8.21	1.01e-14	1.97e-11	-0.52	-0.45	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
KIRP	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-8.21	1.02e-14	1.98e-11	-0.69	-0.45	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
KIRP	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-8.21	1.02e-14	1.98e-11	-0.66	-0.45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
KIRP	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	8.21	1.03e-14	2e-11	0.51	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
KIRP	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	8.21	1.03e-14	2e-11	0.5	0.45	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
KIRP	cis	rs1005277	0.522	rs1208684	ENSG00000151963.4	RP11-775A3.1	-8.21	1.04e-14	2.01e-11	-0.51	-0.45	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:37883594~37884109:+
KIRP	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-8.21	1.04e-14	2.01e-11	-0.67	-0.45	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
KIRP	cis	rs4356975	0.932	rs72852450	ENSG00000248763.2	RP13-644M16.5	-8.21	1.04e-14	2.01e-11	-0.5	-0.45	Obesity-related traits;	chr4:69079704	chr4:69066395~69069888:+
KIRP	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-8.21	1.04e-14	2.02e-11	-0.38	-0.45	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
KIRP	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-8.21	1.04e-14	2.02e-11	-0.52	-0.45	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
KIRP	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-8.21	1.04e-14	2.02e-11	-0.49	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
KIRP	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-8.21	1.05e-14	2.03e-11	-0.5	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
KIRP	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	8.2	1.05e-14	2.03e-11	0.71	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
KIRP	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-8.2	1.05e-14	2.04e-11	-0.37	-0.45	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
KIRP	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.2	1.06e-14	2.06e-11	0.38	0.45	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
KIRP	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-8.2	1.06e-14	2.06e-11	-0.38	-0.45	Height;	chr11:118749988	chr11:118791254~118793137:+
KIRP	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	8.2	1.08e-14	2.09e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
KIRP	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	8.2	1.09e-14	2.11e-11	0.54	0.45	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
KIRP	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-8.2	1.1e-14	2.13e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-8.2	1.1e-14	2.13e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-8.2	1.1e-14	2.13e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-8.2	1.1e-14	2.13e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	8.2	1.11e-14	2.13e-11	0.72	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	8.2	1.11e-14	2.13e-11	0.72	0.45	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	8.2	1.11e-14	2.13e-11	0.72	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
KIRP	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-8.2	1.11e-14	2.14e-11	-0.66	-0.45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
KIRP	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	8.19	1.12e-14	2.16e-11	0.52	0.45	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
KIRP	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	8.19	1.12e-14	2.16e-11	0.5	0.45	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
KIRP	cis	rs9371601	0.859	rs214980	ENSG00000226193.1	RP3-398G3.5	-8.19	1.12e-14	2.17e-11	-0.49	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152411483	chr6:152402398~152404966:+
KIRP	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-8.19	1.13e-14	2.17e-11	-0.46	-0.45	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
KIRP	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	8.19	1.13e-14	2.19e-11	0.58	0.45	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
KIRP	cis	rs1005277	0.505	rs719569	ENSG00000151963.4	RP11-775A3.1	8.19	1.13e-14	2.19e-11	0.52	0.45	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:37883594~37884109:+
KIRP	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.14e-14	2.19e-11	-0.51	-0.45	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.14e-14	2.19e-11	-0.51	-0.45	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.14e-14	2.19e-11	-0.51	-0.45	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
KIRP	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-8.19	1.14e-14	2.21e-11	-0.37	-0.45	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
KIRP	cis	rs9371601	0.667	rs214979	ENSG00000226193.1	RP3-398G3.5	-8.19	1.15e-14	2.22e-11	-0.49	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152410425	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs169975	ENSG00000226193.1	RP3-398G3.5	-8.19	1.15e-14	2.22e-11	-0.49	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152410486	chr6:152402398~152404966:+
KIRP	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	8.19	1.16e-14	2.23e-11	0.53	0.45	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
KIRP	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-8.19	1.16e-14	2.24e-11	-0.38	-0.45	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
KIRP	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	8.19	1.17e-14	2.24e-11	0.46	0.45	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
KIRP	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-8.19	1.17e-14	2.25e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-8.19	1.17e-14	2.25e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
KIRP	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	8.19	1.18e-14	2.27e-11	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
KIRP	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.18e-14	2.27e-11	-0.46	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
KIRP	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-8.19	1.19e-14	2.29e-11	-0.46	-0.45	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
KIRP	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.19	1.19e-14	2.3e-11	0.49	0.45	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.19	1.19e-14	2.3e-11	0.51	0.45	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
KIRP	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	8.18	1.2e-14	2.3e-11	0.5	0.45	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
KIRP	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-8.18	1.21e-14	2.32e-11	-0.38	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
KIRP	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-8.18	1.22e-14	2.34e-11	-0.52	-0.45	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
KIRP	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	8.18	1.22e-14	2.34e-11	0.28	0.45	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
KIRP	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-8.18	1.22e-14	2.34e-11	-0.55	-0.45	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
KIRP	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.18	1.23e-14	2.36e-11	0.5	0.45	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
KIRP	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-8.18	1.23e-14	2.36e-11	-0.56	-0.45	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
KIRP	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	8.18	1.23e-14	2.36e-11	0.7	0.45	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	8.18	1.23e-14	2.36e-11	0.7	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	8.18	1.23e-14	2.36e-11	0.7	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	8.18	1.23e-14	2.36e-11	0.7	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
KIRP	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-8.18	1.23e-14	2.37e-11	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
KIRP	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-8.18	1.24e-14	2.37e-11	-0.68	-0.45	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
KIRP	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	8.18	1.24e-14	2.38e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
KIRP	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-8.18	1.24e-14	2.38e-11	-0.37	-0.45	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
KIRP	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.18	1.24e-14	2.38e-11	0.8	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
KIRP	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-8.18	1.25e-14	2.39e-11	-0.52	-0.45	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
KIRP	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-8.18	1.25e-14	2.4e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
KIRP	cis	rs9371601	0.859	rs214944	ENSG00000226193.1	RP3-398G3.5	8.18	1.26e-14	2.41e-11	0.5	0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152391617	chr6:152402398~152404966:+
KIRP	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	8.18	1.27e-14	2.44e-11	0.28	0.45	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
KIRP	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-8.17	1.29e-14	2.46e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
KIRP	cis	rs1061377	0.862	rs12508577	ENSG00000249207.1	RP11-360F5.1	-8.17	1.29e-14	2.47e-11	-0.48	-0.45	Uric acid levels;	chr4:39107779	chr4:39112677~39126818:-
KIRP	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-8.17	1.3e-14	2.48e-11	-0.52	-0.45	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
KIRP	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	8.17	1.3e-14	2.49e-11	0.42	0.45	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
KIRP	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
KIRP	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-8.17	1.31e-14	2.5e-11	-0.48	-0.45	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
KIRP	cis	rs11647589	0.784	rs1910803	ENSG00000260762.1	ACSM5P1	8.17	1.31e-14	2.5e-11	0.47	0.45	Blood metabolite levels;	chr16:20464412	chr16:20586550~20607107:-
KIRP	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.17	1.32e-14	2.52e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
KIRP	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-8.17	1.32e-14	2.53e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-8.17	1.33e-14	2.53e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-8.17	1.33e-14	2.53e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-8.17	1.33e-14	2.53e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
KIRP	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-8.17	1.33e-14	2.55e-11	-0.37	-0.45	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
KIRP	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-8.17	1.34e-14	2.56e-11	-0.54	-0.45	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
KIRP	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	8.17	1.34e-14	2.56e-11	0.28	0.45	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
KIRP	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	8.17	1.35e-14	2.57e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
KIRP	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-8.17	1.35e-14	2.57e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
KIRP	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	8.17	1.35e-14	2.57e-11	0.51	0.45	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
KIRP	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-8.17	1.35e-14	2.58e-11	-0.85	-0.45	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
KIRP	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	8.17	1.35e-14	2.58e-11	0.71	0.45	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	8.17	1.35e-14	2.58e-11	0.52	0.45	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
KIRP	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.17	1.36e-14	2.6e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
KIRP	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	8.16	1.37e-14	2.61e-11	0.57	0.45	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
KIRP	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-8.16	1.39e-14	2.65e-11	-0.51	-0.45	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
KIRP	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	8.16	1.39e-14	2.65e-11	0.51	0.45	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
KIRP	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-8.16	1.39e-14	2.66e-11	-0.46	-0.45	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
KIRP	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-8.16	1.4e-14	2.67e-11	-0.37	-0.45	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	8.16	1.4e-14	2.67e-11	0.54	0.45	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.16	1.4e-14	2.67e-11	-0.52	-0.45	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
KIRP	cis	rs1005277	0.522	rs289650	ENSG00000151963.4	RP11-775A3.1	-8.16	1.41e-14	2.69e-11	-0.48	-0.45	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:37883594~37884109:+
KIRP	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-8.16	1.42e-14	2.7e-11	-0.54	-0.45	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-8.16	1.43e-14	2.72e-11	-0.37	-0.45	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
KIRP	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-8.16	1.43e-14	2.72e-11	-0.57	-0.45	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
KIRP	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	8.16	1.43e-14	2.73e-11	0.59	0.45	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
KIRP	cis	rs1005277	0.522	rs1208681	ENSG00000151963.4	RP11-775A3.1	-8.16	1.43e-14	2.73e-11	-0.5	-0.45	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:37883594~37884109:+
KIRP	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-8.16	1.45e-14	2.75e-11	-0.55	-0.45	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
KIRP	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	8.16	1.45e-14	2.76e-11	0.49	0.45	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
KIRP	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	8.16	1.45e-14	2.76e-11	0.49	0.45	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
KIRP	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-8.16	1.45e-14	2.77e-11	-0.84	-0.45	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
KIRP	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	8.16	1.45e-14	2.77e-11	0.46	0.45	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
KIRP	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	8.16	1.45e-14	2.77e-11	0.43	0.45	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
KIRP	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-8.15	1.46e-14	2.78e-11	-0.52	-0.45	Height;	chr11:118758322	chr11:118688039~118690600:-
KIRP	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-8.15	1.46e-14	2.79e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
KIRP	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-8.15	1.47e-14	2.8e-11	-0.54	-0.45	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
KIRP	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	8.15	1.47e-14	2.8e-11	0.28	0.45	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	8.15	1.47e-14	2.8e-11	0.28	0.45	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	8.15	1.47e-14	2.8e-11	0.28	0.45	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	8.15	1.47e-14	2.8e-11	0.28	0.45	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	8.15	1.47e-14	2.8e-11	0.28	0.45	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
KIRP	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	8.15	1.5e-14	2.84e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	8.15	1.5e-14	2.84e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
KIRP	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	8.15	1.51e-14	2.86e-11	0.51	0.45	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	8.15	1.51e-14	2.86e-11	0.51	0.45	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	8.15	1.51e-14	2.86e-11	0.51	0.45	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	8.15	1.51e-14	2.86e-11	0.51	0.45	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
KIRP	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	8.15	1.51e-14	2.88e-11	0.57	0.45	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
KIRP	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-8.15	1.54e-14	2.92e-11	-0.52	-0.45	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-8.15	1.54e-14	2.92e-11	-0.54	-0.45	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
KIRP	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-8.15	1.54e-14	2.93e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
KIRP	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-8.15	1.55e-14	2.93e-11	-0.53	-0.45	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
KIRP	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-8.15	1.55e-14	2.93e-11	-0.87	-0.45	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
KIRP	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-8.15	1.55e-14	2.93e-11	-0.87	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-8.15	1.55e-14	2.93e-11	-0.87	-0.45	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
KIRP	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
KIRP	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
KIRP	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	8.15	1.55e-14	2.93e-11	0.49	0.45	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
KIRP	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	8.15	1.55e-14	2.95e-11	0.51	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	8.15	1.55e-14	2.95e-11	0.51	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	8.14	1.57e-14	2.98e-11	0.39	0.45	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-8.14	1.57e-14	2.98e-11	-0.37	-0.45	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-8.14	1.58e-14	2.99e-11	-0.54	-0.45	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
KIRP	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.14	1.59e-14	3.02e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
KIRP	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	8.14	1.59e-14	3.02e-11	0.55	0.45	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
KIRP	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	8.14	1.6e-14	3.03e-11	0.51	0.45	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	8.14	1.6e-14	3.03e-11	0.51	0.45	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	8.14	1.6e-14	3.03e-11	0.51	0.45	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
KIRP	cis	rs755249	0.917	rs61779330	ENSG00000237624.1	OXCT2P1	8.14	1.6e-14	3.03e-11	0.73	0.45	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.876	rs72662001	ENSG00000237624.1	OXCT2P1	8.14	1.6e-14	3.03e-11	0.73	0.45	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.917	rs72663503	ENSG00000237624.1	OXCT2P1	8.14	1.6e-14	3.03e-11	0.73	0.45	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.917	rs61779331	ENSG00000237624.1	OXCT2P1	8.14	1.6e-14	3.03e-11	0.73	0.45	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39514956~39516490:+
KIRP	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-8.14	1.61e-14	3.05e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
KIRP	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-8.14	1.61e-14	3.05e-11	-0.85	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
KIRP	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-8.14	1.62e-14	3.06e-11	-0.51	-0.45	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
KIRP	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-8.14	1.62e-14	3.07e-11	-0.65	-0.45	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
KIRP	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-8.14	1.62e-14	3.07e-11	-0.57	-0.45	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
KIRP	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	8.14	1.63e-14	3.08e-11	0.6	0.45	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
KIRP	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	8.14	1.63e-14	3.08e-11	0.51	0.45	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	8.14	1.63e-14	3.08e-11	0.39	0.45	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-8.14	1.63e-14	3.09e-11	-0.37	-0.45	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
KIRP	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.14	1.65e-14	3.11e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
KIRP	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-8.14	1.65e-14	3.12e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
KIRP	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	8.14	1.66e-14	3.13e-11	0.51	0.45	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
KIRP	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	8.13	1.67e-14	3.15e-11	0.52	0.45	Height;	chr11:118742526	chr11:118688039~118690600:-
KIRP	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	8.13	1.67e-14	3.15e-11	0.5	0.45	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
KIRP	cis	rs1005277	0.54	rs289638	ENSG00000151963.4	RP11-775A3.1	-8.13	1.67e-14	3.16e-11	-0.49	-0.45	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:37883594~37884109:+
KIRP	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	8.13	1.67e-14	3.16e-11	0.42	0.45	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	8.13	1.67e-14	3.16e-11	0.42	0.45	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
KIRP	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-8.13	1.69e-14	3.19e-11	-0.47	-0.45	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
KIRP	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-8.13	1.69e-14	3.19e-11	-0.38	-0.45	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
KIRP	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	8.13	1.7e-14	3.2e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	8.13	1.7e-14	3.2e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
KIRP	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	8.13	1.7e-14	3.21e-11	0.71	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
KIRP	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-8.13	1.7e-14	3.21e-11	-0.52	-0.45	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
KIRP	cis	rs1005277	0.54	rs7903942	ENSG00000151963.4	RP11-775A3.1	8.13	1.7e-14	3.22e-11	0.49	0.45	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:37883594~37884109:+
KIRP	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	8.13	1.72e-14	3.25e-11	0.37	0.45	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
KIRP	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-8.13	1.73e-14	3.26e-11	-0.51	-0.45	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
KIRP	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-8.13	1.73e-14	3.26e-11	-0.48	-0.45	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
KIRP	cis	rs11647589	0.636	rs7186805	ENSG00000260762.1	ACSM5P1	8.13	1.73e-14	3.26e-11	0.47	0.45	Blood metabolite levels;	chr16:20465841	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.636	rs7186307	ENSG00000260762.1	ACSM5P1	8.13	1.73e-14	3.26e-11	0.47	0.45	Blood metabolite levels;	chr16:20465843	chr16:20586550~20607107:-
KIRP	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	8.13	1.73e-14	3.26e-11	0.4	0.45	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
KIRP	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	8.13	1.73e-14	3.27e-11	0.38	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
KIRP	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	8.13	1.74e-14	3.29e-11	0.59	0.45	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
KIRP	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	8.13	1.75e-14	3.3e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
KIRP	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	8.13	1.76e-14	3.31e-11	0.37	0.45	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	8.13	1.76e-14	3.31e-11	0.37	0.45	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	8.13	1.76e-14	3.31e-11	0.37	0.45	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	8.13	1.76e-14	3.31e-11	0.37	0.45	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	8.13	1.76e-14	3.31e-11	0.37	0.45	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
KIRP	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-8.13	1.77e-14	3.33e-11	-0.59	-0.45	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
KIRP	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	8.13	1.77e-14	3.33e-11	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
KIRP	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-8.13	1.77e-14	3.33e-11	-0.52	-0.45	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
KIRP	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	8.13	1.77e-14	3.33e-11	0.51	0.45	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
KIRP	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	8.13	1.77e-14	3.34e-11	0.5	0.45	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
KIRP	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-8.12	1.78e-14	3.36e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-8.12	1.78e-14	3.36e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-8.12	1.78e-14	3.36e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-8.12	1.78e-14	3.36e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
KIRP	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	8.12	1.81e-14	3.4e-11	0.59	0.45	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-8.12	1.81e-14	3.4e-11	-0.5	-0.45	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
KIRP	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-8.12	1.81e-14	3.4e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-8.12	1.81e-14	3.4e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-8.12	1.81e-14	3.4e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-8.12	1.81e-14	3.4e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
KIRP	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	8.12	1.83e-14	3.44e-11	0.37	0.45	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	8.12	1.83e-14	3.44e-11	0.37	0.45	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
KIRP	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	8.12	1.83e-14	3.44e-11	0.37	0.45	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
KIRP	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	8.12	1.84e-14	3.45e-11	0.62	0.45	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
KIRP	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	8.12	1.84e-14	3.46e-11	0.7	0.45	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
KIRP	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-8.12	1.84e-14	3.46e-11	-0.46	-0.45	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-8.12	1.84e-14	3.46e-11	-0.46	-0.45	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-8.12	1.84e-14	3.46e-11	-0.46	-0.45	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-8.12	1.84e-14	3.46e-11	-0.46	-0.45	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
KIRP	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-8.12	1.84e-14	3.46e-11	-0.54	-0.45	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
KIRP	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	8.12	1.85e-14	3.47e-11	0.49	0.45	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
KIRP	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-8.12	1.85e-14	3.48e-11	-0.56	-0.45	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
KIRP	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	8.12	1.86e-14	3.49e-11	0.52	0.45	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
KIRP	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	8.12	1.87e-14	3.51e-11	0.52	0.45	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
KIRP	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	8.12	1.88e-14	3.53e-11	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
KIRP	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-8.11	1.9e-14	3.56e-11	-0.65	-0.45	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-8.11	1.9e-14	3.56e-11	-0.65	-0.45	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
KIRP	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	8.11	1.9e-14	3.56e-11	0.57	0.45	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
KIRP	cis	rs453301	0.653	rs7853	ENSG00000253981.4	ALG1L13P	8.11	1.9e-14	3.57e-11	0.36	0.45	Joint mobility (Beighton score);	chr8:9033304	chr8:8236003~8244667:-
KIRP	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	8.11	1.9e-14	3.57e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
KIRP	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-8.11	1.9e-14	3.57e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
KIRP	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	8.11	1.91e-14	3.58e-11	0.42	0.45	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	8.11	1.91e-14	3.58e-11	0.42	0.45	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
KIRP	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	8.11	1.95e-14	3.65e-11	0.49	0.45	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
KIRP	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-8.11	1.96e-14	3.66e-11	-0.86	-0.45	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
KIRP	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-8.11	1.96e-14	3.67e-11	-0.59	-0.45	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
KIRP	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	8.11	1.96e-14	3.67e-11	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
KIRP	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-8.11	1.97e-14	3.69e-11	-0.56	-0.45	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
KIRP	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.11	1.97e-14	3.69e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
KIRP	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	8.11	1.97e-14	3.69e-11	0.51	0.45	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
KIRP	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-8.11	1.98e-14	3.7e-11	-0.52	-0.45	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-8.11	1.98e-14	3.7e-11	-0.52	-0.45	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-8.11	1.98e-14	3.7e-11	-0.52	-0.45	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
KIRP	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	8.11	1.98e-14	3.71e-11	0.58	0.45	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
KIRP	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-8.11	2e-14	3.73e-11	-0.38	-0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
KIRP	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	8.11	2.01e-14	3.76e-11	0.63	0.45	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
KIRP	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-8.11	2.02e-14	3.77e-11	-0.37	-0.45	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
KIRP	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-8.1	2.03e-14	3.79e-11	-0.42	-0.45	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
KIRP	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-8.1	2.05e-14	3.82e-11	-0.43	-0.45	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
KIRP	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	8.1	2.05e-14	3.83e-11	0.55	0.45	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
KIRP	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-8.1	2.05e-14	3.83e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-8.1	2.05e-14	3.83e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
KIRP	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-8.1	2.09e-14	3.9e-11	-0.89	-0.45	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
KIRP	cis	rs9371601	0.859	rs214943	ENSG00000226193.1	RP3-398G3.5	-8.1	2.1e-14	3.91e-11	-0.5	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152390260	chr6:152402398~152404966:+
KIRP	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	8.1	2.11e-14	3.94e-11	0.67	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
KIRP	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-8.1	2.11e-14	3.94e-11	-0.48	-0.45	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
KIRP	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-8.1	2.15e-14	4e-11	-0.49	-0.45	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
KIRP	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-8.1	2.15e-14	4.01e-11	-0.55	-0.45	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
KIRP	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-8.09	2.2e-14	4.1e-11	-0.59	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
KIRP	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	8.09	2.21e-14	4.11e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	8.09	2.21e-14	4.11e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
KIRP	cis	rs9371601	0.798	rs214954	ENSG00000226193.1	RP3-398G3.5	-8.09	2.21e-14	4.12e-11	-0.48	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152405062	chr6:152402398~152404966:+
KIRP	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-8.09	2.22e-14	4.13e-11	-0.51	-0.45	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
KIRP	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-8.09	2.22e-14	4.13e-11	-0.53	-0.45	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
KIRP	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-8.09	2.23e-14	4.14e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-8.09	2.23e-14	4.14e-11	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
KIRP	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-8.09	2.24e-14	4.15e-11	-0.38	-0.45	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
KIRP	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-8.09	2.24e-14	4.15e-11	-0.51	-0.45	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
KIRP	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	8.09	2.26e-14	4.2e-11	0.9	0.45	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
KIRP	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-8.09	2.27e-14	4.2e-11	-0.68	-0.45	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
KIRP	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-8.09	2.29e-14	4.24e-11	-0.64	-0.45	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
KIRP	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-8.09	2.3e-14	4.26e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	8.09	2.3e-14	4.26e-11	0.53	0.45	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
KIRP	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-8.09	2.3e-14	4.27e-11	-0.47	-0.45	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
KIRP	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	8.08	2.32e-14	4.29e-11	0.64	0.45	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
KIRP	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	8.08	2.32e-14	4.3e-11	0.88	0.45	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
KIRP	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	8.08	2.33e-14	4.31e-11	0.53	0.45	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
KIRP	cis	rs1005277	0.522	rs289647	ENSG00000151963.4	RP11-775A3.1	-8.08	2.34e-14	4.33e-11	-0.49	-0.45	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:37883594~37884109:+
KIRP	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	8.08	2.34e-14	4.34e-11	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
KIRP	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	8.08	2.35e-14	4.34e-11	0.45	0.45	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
KIRP	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-8.08	2.36e-14	4.36e-11	-0.48	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
KIRP	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	8.08	2.36e-14	4.36e-11	0.54	0.45	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
KIRP	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-8.08	2.37e-14	4.38e-11	-0.48	-0.45	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8.08	2.38e-14	4.39e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8.08	2.38e-14	4.39e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8.08	2.38e-14	4.39e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8.08	2.38e-14	4.39e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8.08	2.38e-14	4.39e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
KIRP	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-8.08	2.38e-14	4.39e-11	-0.37	-0.45	Height;	chr11:118791319	chr11:118791254~118793137:+
KIRP	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-8.08	2.38e-14	4.4e-11	-0.52	-0.45	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
KIRP	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	8.08	2.41e-14	4.45e-11	0.55	0.45	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
KIRP	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-8.08	2.42e-14	4.46e-11	-0.64	-0.45	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
KIRP	cis	rs453301	0.653	rs11784393	ENSG00000253981.4	ALG1L13P	8.08	2.42e-14	4.46e-11	0.36	0.45	Joint mobility (Beighton score);	chr8:9045624	chr8:8236003~8244667:-
KIRP	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-8.08	2.42e-14	4.46e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
KIRP	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	8.07	2.47e-14	4.55e-11	0.4	0.45	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	8.07	2.47e-14	4.55e-11	0.4	0.45	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.07	2.47e-14	4.56e-11	0.5	0.45	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.07	2.47e-14	4.56e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
KIRP	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	8.07	2.48e-14	4.57e-11	0.55	0.45	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
KIRP	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-8.07	2.5e-14	4.6e-11	-0.59	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
KIRP	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-8.07	2.5e-14	4.61e-11	-0.65	-0.45	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
KIRP	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.07	2.53e-14	4.66e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.07	2.53e-14	4.66e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.07	2.53e-14	4.66e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.07	2.53e-14	4.66e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
KIRP	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	8.07	2.53e-14	4.66e-11	0.49	0.45	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
KIRP	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-8.07	2.54e-14	4.68e-11	-0.43	-0.45	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
KIRP	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.07	2.54e-14	4.68e-11	0.79	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
KIRP	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	8.07	2.54e-14	4.68e-11	0.64	0.45	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
KIRP	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	8.07	2.55e-14	4.69e-11	0.49	0.45	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
KIRP	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	8.07	2.55e-14	4.7e-11	0.57	0.45	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
KIRP	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-8.07	2.56e-14	4.7e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.07	2.56e-14	4.7e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.07	2.56e-14	4.7e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.07	2.56e-14	4.7e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
KIRP	cis	rs1005277	0.522	rs9418276	ENSG00000151963.4	RP11-775A3.1	-8.07	2.56e-14	4.71e-11	-0.49	-0.45	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.522	rs7072977	ENSG00000151963.4	RP11-775A3.1	-8.07	2.56e-14	4.71e-11	-0.49	-0.45	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:37883594~37884109:+
KIRP	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-8.07	2.56e-14	4.71e-11	-0.4	-0.45	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
KIRP	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-8.07	2.57e-14	4.72e-11	-0.55	-0.45	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
KIRP	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	8.07	2.59e-14	4.74e-11	0.49	0.45	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
KIRP	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-8.07	2.6e-14	4.77e-11	-0.51	-0.45	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
KIRP	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.07	2.6e-14	4.77e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
KIRP	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-8.07	2.63e-14	4.81e-11	-0.6	-0.45	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
KIRP	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.06	2.65e-14	4.85e-11	0.83	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
KIRP	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-8.06	2.65e-14	4.86e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
KIRP	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	8.06	2.66e-14	4.87e-11	0.54	0.45	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	8.06	2.66e-14	4.88e-11	0.39	0.45	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	8.06	2.66e-14	4.88e-11	0.39	0.45	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	8.06	2.66e-14	4.88e-11	0.39	0.45	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
KIRP	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-8.06	2.7e-14	4.94e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
KIRP	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.06	2.71e-14	4.95e-11	-0.5	-0.45	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
KIRP	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-8.06	2.71e-14	4.96e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-8.06	2.71e-14	4.96e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-8.06	2.71e-14	4.96e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-8.06	2.71e-14	4.96e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
KIRP	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-8.06	2.72e-14	4.97e-11	-0.53	-0.45	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
KIRP	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-8.06	2.75e-14	5.02e-11	-0.37	-0.45	Height;	chr11:118786602	chr11:118791254~118793137:+
KIRP	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	8.06	2.76e-14	5.03e-11	0.7	0.45	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
KIRP	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-8.06	2.77e-14	5.06e-11	-0.48	-0.45	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
KIRP	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-8.06	2.78e-14	5.08e-11	-0.65	-0.45	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
KIRP	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	8.06	2.79e-14	5.09e-11	0.59	0.45	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
KIRP	cis	rs9371601	0.859	rs214951	ENSG00000226193.1	RP3-398G3.5	-8.06	2.79e-14	5.09e-11	-0.49	-0.45	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152399894	chr6:152402398~152404966:+
KIRP	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-8.06	2.8e-14	5.1e-11	-0.64	-0.45	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
KIRP	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	8.06	2.8e-14	5.1e-11	0.38	0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
KIRP	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-8.06	2.8e-14	5.1e-11	-0.65	-0.45	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
KIRP	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-8.06	2.81e-14	5.13e-11	-0.58	-0.45	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
KIRP	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	8.05	2.83e-14	5.15e-11	0.37	0.45	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
KIRP	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-8.05	2.84e-14	5.15e-11	-0.51	-0.45	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
KIRP	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	8.05	2.85e-14	5.18e-11	0.69	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
KIRP	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-8.05	2.87e-14	5.21e-11	-0.64	-0.45	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
KIRP	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-8.05	2.89e-14	5.24e-11	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
KIRP	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	8.05	2.89e-14	5.25e-11	0.47	0.45	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
KIRP	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	8.05	2.91e-14	5.28e-11	0.5	0.45	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
KIRP	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-8.05	2.93e-14	5.31e-11	-0.52	-0.45	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
KIRP	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	8.05	2.93e-14	5.31e-11	0.49	0.45	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
KIRP	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	8.05	2.93e-14	5.32e-11	0.52	0.45	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
KIRP	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	8.05	2.94e-14	5.33e-11	0.4	0.45	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	8.05	2.94e-14	5.33e-11	0.4	0.45	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	8.05	2.94e-14	5.33e-11	0.4	0.45	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
KIRP	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	8.05	2.95e-14	5.34e-11	0.51	0.45	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
KIRP	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	8.05	2.95e-14	5.34e-11	0.43	0.45	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
KIRP	cis	rs67311347	1	rs73080137	ENSG00000230274.1	PGAM1P3	8.05	2.95e-14	5.34e-11	0.43	0.45	Renal cell carcinoma;	chr3:40474921	chr3:40322715~40323279:-
KIRP	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	8.05	2.97e-14	5.37e-11	0.59	0.45	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
KIRP	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-8.05	2.98e-14	5.39e-11	-0.42	-0.45	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
KIRP	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-8.05	2.98e-14	5.39e-11	-0.42	-0.45	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
KIRP	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	8.05	2.98e-14	5.39e-11	0.46	0.45	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
KIRP	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	8.05	2.98e-14	5.4e-11	0.39	0.45	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
KIRP	cis	rs944002	1	rs2297067	ENSG00000259444.1	RP11-736N17.8	-8.05	2.99e-14	5.42e-11	-0.48	-0.45	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100448	chr14:103094723~103098885:+
KIRP	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	8.04	3e-14	5.43e-11	0.54	0.45	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
KIRP	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	8.04	3e-14	5.43e-11	0.4	0.45	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-8.04	3.03e-14	5.48e-11	-0.4	-0.45	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
KIRP	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	8.04	3.04e-14	5.49e-11	0.5	0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	8.04	3.04e-14	5.49e-11	0.5	0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	8.04	3.04e-14	5.49e-11	0.5	0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	8.04	3.04e-14	5.49e-11	0.5	0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
KIRP	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	8.04	3.04e-14	5.49e-11	0.5	0.45	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
KIRP	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-8.04	3.04e-14	5.49e-11	-0.37	-0.45	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-8.04	3.04e-14	5.49e-11	-0.37	-0.45	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-8.04	3.04e-14	5.49e-11	-0.37	-0.45	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
KIRP	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	8.04	3.05e-14	5.51e-11	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
KIRP	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-8.04	3.05e-14	5.51e-11	-0.63	-0.44	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
KIRP	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-8.04	3.05e-14	5.52e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
KIRP	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-8.04	3.07e-14	5.55e-11	-0.87	-0.44	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
KIRP	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-8.04	3.08e-14	5.56e-11	-0.68	-0.44	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
KIRP	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	8.04	3.08e-14	5.57e-11	0.64	0.44	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
KIRP	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-8.04	3.11e-14	5.62e-11	-0.65	-0.44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
KIRP	cis	rs755249	1	rs12037222	ENSG00000237624.1	OXCT2P1	8.04	3.12e-14	5.64e-11	0.73	0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39514956~39516490:+
KIRP	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.04	3.13e-14	5.66e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
KIRP	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-8.04	3.15e-14	5.68e-11	-0.57	-0.44	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
KIRP	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	8.04	3.16e-14	5.7e-11	0.64	0.44	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
KIRP	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-8.04	3.16e-14	5.7e-11	-0.58	-0.44	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-8.04	3.16e-14	5.7e-11	-0.58	-0.44	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
KIRP	cis	rs832187	0.64	rs56293138	ENSG00000280620.1	SCAANT1	8.04	3.17e-14	5.72e-11	0.5	0.44	Schizophrenia;	chr3:63903259	chr3:63911518~63911772:-
KIRP	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-8.04	3.17e-14	5.72e-11	-0.47	-0.44	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
KIRP	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	8.03	3.21e-14	5.79e-11	0.5	0.44	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	8.03	3.21e-14	5.79e-11	0.5	0.44	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
KIRP	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-8.03	3.23e-14	5.81e-11	-0.52	-0.44	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
KIRP	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	8.03	3.23e-14	5.83e-11	0.46	0.44	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
KIRP	cis	rs7714584	1	rs76872831	ENSG00000197083.10	ZNF300P1	8.03	3.27e-14	5.88e-11	0.96	0.44	Crohn's disease;	chr5:150791997	chr5:150930645~150946289:-
KIRP	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-8.03	3.27e-14	5.89e-11	-0.48	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
KIRP	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	8.03	3.28e-14	5.9e-11	0.4	0.44	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
KIRP	cis	rs7714584	1	rs57406211	ENSG00000197083.10	ZNF300P1	8.03	3.29e-14	5.93e-11	0.96	0.44	Crohn's disease;	chr5:150791404	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs79442859	ENSG00000197083.10	ZNF300P1	8.03	3.29e-14	5.93e-11	0.96	0.44	Crohn's disease;	chr5:150791648	chr5:150930645~150946289:-
KIRP	cis	rs9371601	0.859	rs214945	ENSG00000226193.1	RP3-398G3.5	-8.03	3.3e-14	5.93e-11	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152391770	chr6:152402398~152404966:+
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-8.03	3.3e-14	5.95e-11	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
KIRP	cis	rs1005277	0.505	rs200931	ENSG00000151963.4	RP11-775A3.1	-8.03	3.35e-14	6.02e-11	-0.51	-0.44	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:37883594~37884109:+
KIRP	cis	rs9371601	0.798	rs214987	ENSG00000226193.1	RP3-398G3.5	8.03	3.38e-14	6.08e-11	0.48	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152412458	chr6:152402398~152404966:+
KIRP	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-8.03	3.38e-14	6.09e-11	-0.51	-0.44	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
KIRP	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-8.03	3.39e-14	6.09e-11	-0.48	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
KIRP	cis	rs832187	0.813	rs704369	ENSG00000280620.1	SCAANT1	-8.03	3.41e-14	6.12e-11	-0.49	-0.44	Schizophrenia;	chr3:63882595	chr3:63911518~63911772:-
KIRP	cis	rs832187	0.813	rs704368	ENSG00000280620.1	SCAANT1	-8.03	3.41e-14	6.12e-11	-0.49	-0.44	Schizophrenia;	chr3:63882661	chr3:63911518~63911772:-
KIRP	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	8.02	3.43e-14	6.17e-11	0.4	0.44	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
KIRP	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	8.02	3.44e-14	6.18e-11	0.52	0.44	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
KIRP	cis	rs17082664	0.571	rs1489586	ENSG00000226193.1	RP3-398G3.5	-8.02	3.46e-14	6.22e-11	-0.65	-0.44	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152411122	chr6:152402398~152404966:+
KIRP	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-8.02	3.47e-14	6.23e-11	-0.85	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-8.02	3.49e-14	6.26e-11	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
KIRP	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	8.02	3.5e-14	6.28e-11	0.42	0.44	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
KIRP	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	8.02	3.53e-14	6.33e-11	0.43	0.44	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
KIRP	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	8.02	3.55e-14	6.37e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
KIRP	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-8.02	3.55e-14	6.37e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
KIRP	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	8.02	3.56e-14	6.38e-11	0.39	0.44	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
KIRP	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	8.02	3.57e-14	6.4e-11	0.46	0.44	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
KIRP	cis	rs4356975	0.932	rs4694607	ENSG00000250696.4	RP11-704M14.1	8.02	3.58e-14	6.41e-11	0.44	0.44	Obesity-related traits;	chr4:69073025	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs4410590	ENSG00000250696.4	RP11-704M14.1	8.02	3.58e-14	6.41e-11	0.44	0.44	Obesity-related traits;	chr4:69073381	chr4:69182100~69216766:+
KIRP	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-8.02	3.59e-14	6.43e-11	-0.59	-0.44	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
KIRP	cis	rs11647589	0.689	rs8045136	ENSG00000260762.1	ACSM5P1	-8.02	3.61e-14	6.46e-11	-0.46	-0.44	Blood metabolite levels;	chr16:20442599	chr16:20586550~20607107:-
KIRP	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-8.02	3.61e-14	6.47e-11	-0.58	-0.44	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
KIRP	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	8.02	3.64e-14	6.52e-11	0.49	0.44	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
KIRP	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	8.02	3.65e-14	6.53e-11	0.39	0.44	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	8.02	3.65e-14	6.53e-11	0.39	0.44	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
KIRP	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	8.02	3.65e-14	6.53e-11	0.87	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
KIRP	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-8.02	3.65e-14	6.54e-11	-0.39	-0.44	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-8.02	3.65e-14	6.54e-11	-0.39	-0.44	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-8.02	3.65e-14	6.54e-11	-0.39	-0.44	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
KIRP	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-8.01	3.69e-14	6.61e-11	-0.56	-0.44	QT interval;	chr16:28857143	chr16:28700294~28701540:-
KIRP	cis	rs67311347	1	rs2276871	ENSG00000230274.1	PGAM1P3	8.01	3.7e-14	6.62e-11	0.42	0.44	Renal cell carcinoma;	chr3:40457782	chr3:40322715~40323279:-
KIRP	cis	rs1005277	0.577	rs4934906	ENSG00000151963.4	RP11-775A3.1	-8.01	3.72e-14	6.65e-11	-0.5	-0.44	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37883594~37884109:+
KIRP	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-8.01	3.73e-14	6.67e-11	-0.88	-0.44	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
KIRP	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-8.01	3.73e-14	6.68e-11	-0.6	-0.44	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
KIRP	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-8.01	3.74e-14	6.69e-11	-0.48	-0.44	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
KIRP	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
KIRP	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-8.01	3.75e-14	6.71e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
KIRP	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	8.01	3.79e-14	6.76e-11	0.51	0.44	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	8.01	3.82e-14	6.82e-11	0.39	0.44	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
KIRP	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-8.01	3.84e-14	6.86e-11	-0.62	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
KIRP	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	8.01	3.88e-14	6.93e-11	0.49	0.44	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
KIRP	cis	rs755249	1	rs4660303	ENSG00000237624.1	OXCT2P1	8.01	3.89e-14	6.93e-11	0.72	0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39514956~39516490:+
KIRP	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	8.01	3.9e-14	6.95e-11	0.43	0.44	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	8.01	3.9e-14	6.95e-11	0.43	0.44	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	8.01	3.9e-14	6.95e-11	0.43	0.44	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
KIRP	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	8	3.91e-14	6.97e-11	0.43	0.44	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
KIRP	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	8	3.91e-14	6.97e-11	0.64	0.44	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
KIRP	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	8	3.94e-14	7.03e-11	0.81	0.44	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
KIRP	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	8	3.96e-14	7.06e-11	0.53	0.44	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
KIRP	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-8	3.97e-14	7.07e-11	-0.49	-0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
KIRP	cis	rs4356975	0.899	rs4412058	ENSG00000250696.4	RP11-704M14.1	8	3.97e-14	7.07e-11	0.43	0.44	Obesity-related traits;	chr4:69073715	chr4:69182100~69216766:+
KIRP	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	8	3.98e-14	7.08e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
KIRP	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-8	3.98e-14	7.09e-11	-0.53	-0.44	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
KIRP	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8	4e-14	7.11e-11	0.36	0.44	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
KIRP	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-8	4e-14	7.13e-11	-0.58	-0.44	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
KIRP	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	8	4.01e-14	7.14e-11	0.28	0.44	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
KIRP	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-8	4.01e-14	7.14e-11	-0.38	-0.44	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
KIRP	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	8	4.03e-14	7.17e-11	0.5	0.44	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	8	4.03e-14	7.17e-11	0.5	0.44	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
KIRP	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-8	4.04e-14	7.18e-11	-0.5	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
KIRP	cis	rs67311347	1	rs11539046	ENSG00000230274.1	PGAM1P3	-8	4.04e-14	7.18e-11	-0.43	-0.44	Renal cell carcinoma;	chr3:40462318	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs12633431	ENSG00000230274.1	PGAM1P3	-8	4.04e-14	7.18e-11	-0.43	-0.44	Renal cell carcinoma;	chr3:40464249	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.956	rs6771527	ENSG00000230274.1	PGAM1P3	-8	4.04e-14	7.18e-11	-0.43	-0.44	Renal cell carcinoma;	chr3:40465057	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.955	rs6782746	ENSG00000230274.1	PGAM1P3	-8	4.04e-14	7.18e-11	-0.43	-0.44	Renal cell carcinoma;	chr3:40469101	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs7628247	ENSG00000230274.1	PGAM1P3	-8	4.04e-14	7.18e-11	-0.43	-0.44	Renal cell carcinoma;	chr3:40471191	chr3:40322715~40323279:-
KIRP	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	8	4.04e-14	7.18e-11	0.58	0.44	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-8	4.05e-14	7.2e-11	-0.4	-0.44	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8	4.06e-14	7.21e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8	4.06e-14	7.21e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8	4.06e-14	7.21e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8	4.06e-14	7.21e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8	4.06e-14	7.21e-11	-0.49	-0.44	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	8	4.06e-14	7.22e-11	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
KIRP	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-8	4.06e-14	7.22e-11	-0.39	-0.44	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
KIRP	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	8	4.08e-14	7.24e-11	0.71	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
KIRP	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8	4.11e-14	7.29e-11	0.58	0.44	Height;	chr6:109407238	chr6:109382795~109383666:+
KIRP	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	8	4.12e-14	7.32e-11	0.54	0.44	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
KIRP	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-8	4.13e-14	7.33e-11	-0.35	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
KIRP	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	7.99	4.17e-14	7.4e-11	0.5	0.44	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
KIRP	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	7.99	4.18e-14	7.42e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
KIRP	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	7.99	4.19e-14	7.43e-11	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	7.99	4.19e-14	7.43e-11	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	7.99	4.19e-14	7.43e-11	0.75	0.44	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
KIRP	cis	rs4356975	0.692	rs7691361	ENSG00000248763.2	RP13-644M16.5	-7.99	4.21e-14	7.46e-11	-0.49	-0.44	Obesity-related traits;	chr4:69077628	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.72	rs7691362	ENSG00000248763.2	RP13-644M16.5	-7.99	4.21e-14	7.46e-11	-0.49	-0.44	Obesity-related traits;	chr4:69077631	chr4:69066395~69069888:+
KIRP	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	7.99	4.24e-14	7.51e-11	0.87	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
KIRP	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-7.99	4.25e-14	7.54e-11	-0.51	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
KIRP	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	7.99	4.27e-14	7.57e-11	0.68	0.44	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
KIRP	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	7.99	4.3e-14	7.62e-11	0.39	0.44	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-7.99	4.31e-14	7.63e-11	-0.51	-0.44	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
KIRP	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	7.99	4.31e-14	7.63e-11	0.4	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
KIRP	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-7.99	4.34e-14	7.68e-11	-0.47	-0.44	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
KIRP	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-7.99	4.35e-14	7.7e-11	-0.43	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
KIRP	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-7.99	4.35e-14	7.7e-11	-0.49	-0.44	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
KIRP	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	7.99	4.37e-14	7.72e-11	0.46	0.44	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
KIRP	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	7.99	4.37e-14	7.73e-11	0.33	0.44	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
KIRP	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	7.99	4.39e-14	7.76e-11	0.49	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
KIRP	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-7.99	4.39e-14	7.77e-11	-0.59	-0.44	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
KIRP	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-7.99	4.41e-14	7.79e-11	-0.55	-0.44	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
KIRP	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-7.99	4.41e-14	7.79e-11	-0.49	-0.44	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
KIRP	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.99	4.41e-14	7.8e-11	0.51	0.44	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
KIRP	cis	rs9371601	0.859	rs548400	ENSG00000226193.1	RP3-398G3.5	-7.98	4.45e-14	7.86e-11	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152429882	chr6:152402398~152404966:+
KIRP	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	7.98	4.46e-14	7.87e-11	0.7	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
KIRP	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-7.98	4.46e-14	7.88e-11	-0.47	-0.44	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
KIRP	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-7.98	4.46e-14	7.88e-11	-0.86	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
KIRP	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	7.98	4.46e-14	7.89e-11	0.51	0.44	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
KIRP	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-7.98	4.48e-14	7.91e-11	-0.5	-0.44	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
KIRP	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	7.98	4.5e-14	7.94e-11	0.49	0.44	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
KIRP	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	7.98	4.5e-14	7.94e-11	0.49	0.44	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
KIRP	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-7.98	4.5e-14	7.94e-11	-0.85	-0.44	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
KIRP	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-7.98	4.5e-14	7.94e-11	-0.85	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
KIRP	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-7.98	4.51e-14	7.95e-11	-0.48	-0.44	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
KIRP	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	7.98	4.52e-14	7.98e-11	0.54	0.44	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
KIRP	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	7.98	4.53e-14	7.99e-11	0.37	0.44	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	7.98	4.53e-14	7.99e-11	0.37	0.44	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-7.98	4.56e-14	8.04e-11	-0.5	-0.44	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
KIRP	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	7.98	4.57e-14	8.06e-11	0.63	0.44	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	7.98	4.57e-14	8.06e-11	0.63	0.44	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	7.98	4.57e-14	8.06e-11	0.63	0.44	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
KIRP	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-7.98	4.57e-14	8.06e-11	-0.59	-0.44	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
KIRP	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	7.98	4.58e-14	8.08e-11	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	7.98	4.58e-14	8.08e-11	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
KIRP	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-7.98	4.58e-14	8.08e-11	-0.86	-0.44	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
KIRP	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	7.98	4.59e-14	8.09e-11	0.51	0.44	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
KIRP	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	7.98	4.59e-14	8.09e-11	0.51	0.44	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
KIRP	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.98	4.59e-14	8.09e-11	0.51	0.44	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
KIRP	cis	rs9371601	0.859	rs488673	ENSG00000226193.1	RP3-398G3.5	-7.98	4.59e-14	8.09e-11	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152398467	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs492904	ENSG00000226193.1	RP3-398G3.5	-7.98	4.59e-14	8.09e-11	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152399059	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs490448	ENSG00000226193.1	RP3-398G3.5	-7.98	4.59e-14	8.09e-11	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152399276	chr6:152402398~152404966:+
KIRP	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-7.98	4.6e-14	8.11e-11	-0.51	-0.44	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
KIRP	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	7.98	4.61e-14	8.11e-11	0.65	0.44	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
KIRP	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	7.98	4.63e-14	8.16e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
KIRP	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	7.98	4.63e-14	8.16e-11	0.56	0.44	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
KIRP	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	7.98	4.63e-14	8.16e-11	0.37	0.44	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	7.98	4.63e-14	8.16e-11	0.37	0.44	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	7.98	4.63e-14	8.16e-11	0.37	0.44	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	7.98	4.63e-14	8.16e-11	0.37	0.44	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
KIRP	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-7.98	4.65e-14	8.18e-11	-0.46	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
KIRP	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	7.98	4.66e-14	8.2e-11	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	7.98	4.66e-14	8.2e-11	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
KIRP	cis	rs4356975	0.932	rs4611997	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69073429	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7436912	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69074077	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7654272	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69074144	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs6600867	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69074157	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs72852416	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69075085	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.806	rs12648808	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69075351	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.867	rs6600869	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69075937	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.836	rs6600870	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69075944	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7442394	ENSG00000250696.4	RP11-704M14.1	7.98	4.66e-14	8.2e-11	0.43	0.44	Obesity-related traits;	chr4:69076309	chr4:69182100~69216766:+
KIRP	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	7.98	4.68e-14	8.22e-11	0.51	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	7.98	4.68e-14	8.22e-11	0.51	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	7.98	4.68e-14	8.22e-11	0.51	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
KIRP	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-7.98	4.68e-14	8.22e-11	-0.48	-0.44	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-7.98	4.68e-14	8.22e-11	-0.48	-0.44	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
KIRP	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-7.98	4.68e-14	8.23e-11	-0.66	-0.44	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
KIRP	cis	rs11155671	0.53	rs9371504	ENSG00000268592.3	RAET1E-AS1	7.98	4.69e-14	8.24e-11	0.59	0.44	Testicular germ cell tumor;	chr6:149862944	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs9371505	ENSG00000268592.3	RAET1E-AS1	7.98	4.69e-14	8.24e-11	0.59	0.44	Testicular germ cell tumor;	chr6:149863012	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	7.98	4.71e-14	8.28e-11	0.37	0.44	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
KIRP	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-7.98	4.72e-14	8.29e-11	-0.55	-0.44	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
KIRP	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	7.98	4.73e-14	8.3e-11	0.43	0.44	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
KIRP	cis	rs4356975	0.599	rs7660019	ENSG00000250696.4	RP11-704M14.1	7.97	4.75e-14	8.34e-11	0.43	0.44	Obesity-related traits;	chr4:69072135	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.574	rs7660021	ENSG00000250696.4	RP11-704M14.1	7.97	4.75e-14	8.34e-11	0.43	0.44	Obesity-related traits;	chr4:69072143	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.549	rs7687692	ENSG00000250696.4	RP11-704M14.1	7.97	4.75e-14	8.34e-11	0.43	0.44	Obesity-related traits;	chr4:69072154	chr4:69182100~69216766:+
KIRP	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-7.97	4.77e-14	8.37e-11	-0.35	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
KIRP	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-7.97	4.83e-14	8.47e-11	-0.53	-0.44	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.932	rs7692377	ENSG00000250696.4	RP11-704M14.1	7.97	4.83e-14	8.47e-11	0.43	0.44	Obesity-related traits;	chr4:69078113	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs61612343	ENSG00000250696.4	RP11-704M14.1	7.97	4.83e-14	8.47e-11	0.43	0.44	Obesity-related traits;	chr4:69078247	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7679418	ENSG00000250696.4	RP11-704M14.1	7.97	4.83e-14	8.47e-11	0.43	0.44	Obesity-related traits;	chr4:69078533	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7680156	ENSG00000250696.4	RP11-704M14.1	7.97	4.83e-14	8.47e-11	0.43	0.44	Obesity-related traits;	chr4:69078868	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7698430	ENSG00000250696.4	RP11-704M14.1	7.97	4.83e-14	8.47e-11	0.43	0.44	Obesity-related traits;	chr4:69078897	chr4:69182100~69216766:+
KIRP	cis	rs7672749	0.73	rs7667813	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87862025	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs57195379	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87862860	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.643	rs72877193	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87863625	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs17013352	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87864677	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs17013355	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867091	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs4334720	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867772	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs1870963	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867882	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs17013369	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87868465	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs68078763	ENSG00000249973.2	CHCHD2P7	7.97	4.85e-14	8.49e-11	0.89	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87868787	chr4:87785920~87786371:-
KIRP	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-7.97	4.86e-14	8.51e-11	-0.59	-0.44	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
KIRP	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-7.97	4.87e-14	8.52e-11	-0.46	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
KIRP	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	7.97	4.87e-14	8.52e-11	0.66	0.44	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
KIRP	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-7.97	4.87e-14	8.52e-11	-0.52	-0.44	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
KIRP	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-7.97	4.89e-14	8.55e-11	-0.64	-0.44	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
KIRP	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	7.97	4.9e-14	8.58e-11	0.58	0.44	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
KIRP	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-7.97	4.91e-14	8.58e-11	-0.48	-0.44	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-7.97	4.91e-14	8.58e-11	-0.48	-0.44	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-7.97	4.91e-14	8.58e-11	-0.48	-0.44	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
KIRP	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	7.97	4.91e-14	8.59e-11	0.28	0.44	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
KIRP	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	7.97	4.91e-14	8.59e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	7.97	4.93e-14	8.63e-11	0.39	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
KIRP	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	7.97	4.94e-14	8.65e-11	0.28	0.44	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
KIRP	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-7.97	4.95e-14	8.66e-11	-0.37	-0.44	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
KIRP	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	7.97	4.97e-14	8.69e-11	0.59	0.44	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
KIRP	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	7.97	4.99e-14	8.73e-11	0.89	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
KIRP	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	7.97	5e-14	8.74e-11	0.81	0.44	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
KIRP	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-7.97	5.01e-14	8.76e-11	-0.48	-0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
KIRP	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	7.97	5.02e-14	8.76e-11	0.27	0.44	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
KIRP	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.97	5.04e-14	8.8e-11	0.39	0.44	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-7.97	5.06e-14	8.83e-11	-0.36	-0.44	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
KIRP	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	7.96	5.08e-14	8.86e-11	0.4	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	7.96	5.08e-14	8.86e-11	0.4	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
KIRP	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-7.96	5.1e-14	8.9e-11	-0.43	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
KIRP	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-7.96	5.1e-14	8.9e-11	-0.5	-0.44	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
KIRP	cis	rs4356975	0.932	rs4694611	ENSG00000250696.4	RP11-704M14.1	7.96	5.11e-14	8.9e-11	0.43	0.44	Obesity-related traits;	chr4:69079387	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4694612	ENSG00000250696.4	RP11-704M14.1	7.96	5.11e-14	8.9e-11	0.43	0.44	Obesity-related traits;	chr4:69079446	chr4:69182100~69216766:+
KIRP	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.96	5.11e-14	8.9e-11	0.57	0.44	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
KIRP	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	7.96	5.12e-14	8.92e-11	0.49	0.44	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
KIRP	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-7.96	5.13e-14	8.94e-11	-0.57	-0.44	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
KIRP	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	7.96	5.13e-14	8.94e-11	0.5	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
KIRP	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	7.96	5.15e-14	8.97e-11	0.43	0.44	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
KIRP	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	7.96	5.16e-14	8.99e-11	0.5	0.44	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
KIRP	cis	rs9399135	0.627	rs6930223	ENSG00000232876.1	CTA-212D2.2	-7.96	5.23e-14	9.11e-11	-0.53	-0.44	Red blood cell count;	chr6:135103065	chr6:135055033~135060550:+
KIRP	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	7.96	5.28e-14	9.18e-11	0.29	0.44	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	7.96	5.28e-14	9.18e-11	0.29	0.44	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
KIRP	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-7.96	5.29e-14	9.2e-11	-0.49	-0.44	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
KIRP	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	7.96	5.32e-14	9.26e-11	0.46	0.44	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
KIRP	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	7.96	5.32e-14	9.26e-11	0.46	0.44	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
KIRP	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	7.96	5.32e-14	9.26e-11	0.46	0.44	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
KIRP	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	7.96	5.32e-14	9.26e-11	0.46	0.44	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
KIRP	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	7.96	5.34e-14	9.28e-11	0.54	0.44	QT interval;	chr16:28860645	chr16:28700294~28701540:-
KIRP	cis	rs453301	0.653	rs7005133	ENSG00000253981.4	ALG1L13P	7.96	5.4e-14	9.38e-11	0.35	0.44	Joint mobility (Beighton score);	chr8:9043712	chr8:8236003~8244667:-
KIRP	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	7.95	5.44e-14	9.45e-11	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
KIRP	cis	rs453301	0.598	rs2921383	ENSG00000253981.4	ALG1L13P	7.95	5.47e-14	9.49e-11	0.36	0.44	Joint mobility (Beighton score);	chr8:9034711	chr8:8236003~8244667:-
KIRP	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-7.95	5.47e-14	9.5e-11	-0.63	-0.44	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
KIRP	cis	rs4356975	0.932	rs4694159	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69068460	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4694597	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69068643	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs4694160	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69068755	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs7439419	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069090	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7658748	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069219	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs7687336	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069397	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs7659138	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069420	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7674600	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069614	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs72501227	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69069866	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4694602	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69070955	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4400060	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69071215	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4400061	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69071281	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4446390	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69071328	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs7434389	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69071698	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.896	rs58496756	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69072070	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.899	rs7687725	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69072229	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4516791	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69072402	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs4694605	ENSG00000250696.4	RP11-704M14.1	7.95	5.49e-14	9.53e-11	0.43	0.44	Obesity-related traits;	chr4:69072777	chr4:69182100~69216766:+
KIRP	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	7.95	5.51e-14	9.55e-11	0.5	0.44	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
KIRP	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-7.95	5.53e-14	9.59e-11	-0.63	-0.44	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-7.95	5.53e-14	9.59e-11	-0.63	-0.44	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
KIRP	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	7.95	5.55e-14	9.63e-11	0.8	0.44	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
KIRP	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	7.95	5.56e-14	9.63e-11	0.63	0.44	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
KIRP	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	7.95	5.57e-14	9.65e-11	0.55	0.44	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
KIRP	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	7.95	5.57e-14	9.66e-11	0.45	0.44	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-7.95	5.63e-14	9.75e-11	-0.37	-0.44	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.95	5.71e-14	9.88e-11	0.4	0.44	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
KIRP	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	7.95	5.72e-14	9.91e-11	0.55	0.44	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
KIRP	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-7.94	5.78e-14	9.99e-11	-0.85	-0.44	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-7.94	5.78e-14	9.99e-11	-0.85	-0.44	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
KIRP	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	7.94	5.87e-14	1.02e-10	0.28	0.44	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
KIRP	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	7.94	5.88e-14	1.02e-10	0.55	0.44	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-7.94	5.91e-14	1.02e-10	-0.37	-0.44	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-7.94	5.91e-14	1.02e-10	-0.37	-0.44	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-7.94	5.91e-14	1.02e-10	-0.37	-0.44	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-7.94	5.91e-14	1.02e-10	-0.37	-0.44	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
KIRP	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	7.94	5.93e-14	1.02e-10	0.55	0.44	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	7.94	5.93e-14	1.02e-10	0.55	0.44	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
KIRP	cis	rs4356975	0.932	rs4694604	ENSG00000250696.4	RP11-704M14.1	7.94	5.93e-14	1.02e-10	0.43	0.44	Obesity-related traits;	chr4:69072745	chr4:69182100~69216766:+
KIRP	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.94	5.95e-14	1.03e-10	0.39	0.44	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
KIRP	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.94	5.99e-14	1.03e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.94	5.99e-14	1.03e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
KIRP	cis	rs832187	1	rs832187	ENSG00000280620.1	SCAANT1	-7.94	6e-14	1.04e-10	-0.47	-0.44	Schizophrenia;	chr3:63847374	chr3:63911518~63911772:-
KIRP	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-7.94	6e-14	1.04e-10	-0.53	-0.44	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
KIRP	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	7.94	6.01e-14	1.04e-10	0.51	0.44	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
KIRP	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	7.94	6.02e-14	1.04e-10	0.28	0.44	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
KIRP	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-7.94	6.03e-14	1.04e-10	-0.55	-0.44	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
KIRP	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-7.94	6.03e-14	1.04e-10	-0.37	-0.44	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
KIRP	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	7.94	6.05e-14	1.04e-10	0.45	0.44	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
KIRP	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	7.94	6.06e-14	1.05e-10	0.49	0.44	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
KIRP	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-7.94	6.06e-14	1.05e-10	-0.36	-0.44	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
KIRP	cis	rs9371601	0.859	rs522437	ENSG00000226193.1	RP3-398G3.5	-7.94	6.1e-14	1.05e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152398083	chr6:152402398~152404966:+
KIRP	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	7.94	6.13e-14	1.06e-10	0.89	0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
KIRP	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	7.94	6.15e-14	1.06e-10	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
KIRP	cis	rs2698530	0.535	rs2254856	ENSG00000225889.6	AC074289.1	-7.93	6.16e-14	1.06e-10	-0.4	-0.44	Iron status biomarkers;	chr2:64260559	chr2:64143239~64252859:+
KIRP	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-7.93	6.18e-14	1.07e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-7.93	6.18e-14	1.07e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-7.93	6.18e-14	1.07e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	7.93	6.19e-14	1.07e-10	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
KIRP	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-7.93	6.21e-14	1.07e-10	-0.37	-0.44	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
KIRP	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-7.93	6.23e-14	1.07e-10	-0.37	-0.44	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-7.93	6.23e-14	1.07e-10	-0.37	-0.44	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-7.93	6.23e-14	1.07e-10	-0.37	-0.44	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	7.93	6.23e-14	1.07e-10	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	7.93	6.23e-14	1.07e-10	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
KIRP	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	7.93	6.24e-14	1.07e-10	0.49	0.44	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
KIRP	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-7.93	6.27e-14	1.08e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-7.93	6.27e-14	1.08e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
KIRP	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	7.93	6.28e-14	1.08e-10	0.39	0.44	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
KIRP	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-7.93	6.3e-14	1.08e-10	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
KIRP	cis	rs67311347	1	rs6801859	ENSG00000230274.1	PGAM1P3	-7.93	6.38e-14	1.1e-10	-0.42	-0.44	Renal cell carcinoma;	chr3:40451727	chr3:40322715~40323279:-
KIRP	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-7.93	6.38e-14	1.1e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-7.93	6.38e-14	1.1e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-7.93	6.38e-14	1.1e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
KIRP	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	7.93	6.41e-14	1.1e-10	0.35	0.44	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
KIRP	cis	rs4356975	0.932	rs56879009	ENSG00000250696.4	RP11-704M14.1	7.93	6.41e-14	1.1e-10	0.43	0.44	Obesity-related traits;	chr4:69079589	chr4:69182100~69216766:+
KIRP	cis	rs7672749	0.73	rs6822777	ENSG00000249973.2	CHCHD2P7	-7.93	6.42e-14	1.1e-10	-0.88	-0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87870243	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.643	rs11728139	ENSG00000249973.2	CHCHD2P7	7.93	6.42e-14	1.1e-10	0.88	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87871286	chr4:87785920~87786371:-
KIRP	cis	rs7672749	1	rs11724215	ENSG00000249973.2	CHCHD2P7	7.93	6.42e-14	1.1e-10	0.88	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87880479	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs6820909	ENSG00000249973.2	CHCHD2P7	7.93	6.42e-14	1.1e-10	0.88	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87882542	chr4:87785920~87786371:-
KIRP	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.93	6.45e-14	1.11e-10	-0.38	-0.44	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
KIRP	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	7.93	6.45e-14	1.11e-10	0.46	0.44	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
KIRP	cis	rs9371601	0.798	rs214952	ENSG00000226193.1	RP3-398G3.5	-7.93	6.46e-14	1.11e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152401580	chr6:152402398~152404966:+
KIRP	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	7.93	6.49e-14	1.11e-10	0.5	0.44	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
KIRP	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	7.93	6.51e-14	1.12e-10	0.56	0.44	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
KIRP	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-7.92	6.57e-14	1.13e-10	-0.45	-0.44	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
KIRP	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-7.92	6.58e-14	1.13e-10	-0.85	-0.44	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
KIRP	cis	rs1005277	0.505	rs7099777	ENSG00000151963.4	RP11-775A3.1	7.92	6.6e-14	1.13e-10	0.51	0.44	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.505	rs7917943	ENSG00000151963.4	RP11-775A3.1	7.92	6.6e-14	1.13e-10	0.51	0.44	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:37883594~37884109:+
KIRP	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-7.92	6.6e-14	1.13e-10	-0.85	-0.44	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-7.92	6.6e-14	1.13e-10	-0.85	-0.44	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
KIRP	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-7.92	6.61e-14	1.13e-10	-0.39	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
KIRP	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-7.92	6.62e-14	1.14e-10	-0.55	-0.44	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
KIRP	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.92	6.64e-14	1.14e-10	0.48	0.44	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.92	6.64e-14	1.14e-10	0.48	0.44	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
KIRP	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	7.92	6.74e-14	1.15e-10	0.51	0.44	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
KIRP	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-7.92	6.76e-14	1.16e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
KIRP	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	7.92	6.77e-14	1.16e-10	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	7.92	6.77e-14	1.16e-10	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	7.92	6.77e-14	1.16e-10	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
KIRP	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.92	6.77e-14	1.16e-10	0.39	0.44	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.92	6.77e-14	1.16e-10	0.39	0.44	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.92	6.77e-14	1.16e-10	0.39	0.44	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
KIRP	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	7.92	6.77e-14	1.16e-10	0.56	0.44	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
KIRP	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.92	6.81e-14	1.16e-10	-0.47	-0.44	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
KIRP	cis	rs11647589	0.678	rs7198521	ENSG00000260762.1	ACSM5P1	7.92	6.81e-14	1.17e-10	0.5	0.44	Blood metabolite levels;	chr16:20441382	chr16:20586550~20607107:-
KIRP	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-7.92	6.83e-14	1.17e-10	-0.56	-0.44	QT interval;	chr16:28824579	chr16:28700294~28701540:-
KIRP	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	7.92	6.84e-14	1.17e-10	0.5	0.44	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
KIRP	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	7.92	6.85e-14	1.17e-10	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	7.92	6.85e-14	1.17e-10	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
KIRP	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	7.92	6.85e-14	1.17e-10	0.45	0.44	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-7.92	6.96e-14	1.19e-10	-0.37	-0.44	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-7.92	6.96e-14	1.19e-10	-0.37	-0.44	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
KIRP	cis	rs4578769	0.55	rs4800435	ENSG00000266850.1	RP11-370A5.1	7.92	6.99e-14	1.19e-10	0.52	0.44	Eosinophil percentage of white cells;	chr18:22862923	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs12966840	ENSG00000266850.1	RP11-370A5.1	-7.92	6.99e-14	1.19e-10	-0.52	-0.44	Eosinophil percentage of white cells;	chr18:22856911	chr18:22723491~22907721:-
KIRP	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	7.92	7e-14	1.2e-10	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	7.91	7.01e-14	1.2e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
KIRP	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	7.91	7.07e-14	1.21e-10	0.45	0.44	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
KIRP	cis	rs11647589	0.678	rs6497489	ENSG00000260762.1	ACSM5P1	7.91	7.08e-14	1.21e-10	0.46	0.44	Blood metabolite levels;	chr16:20460042	chr16:20586550~20607107:-
KIRP	cis	rs67311347	1	rs7628796	ENSG00000230274.1	PGAM1P3	-7.91	7.09e-14	1.21e-10	-0.42	-0.44	Renal cell carcinoma;	chr3:40465841	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.91	rs7651204	ENSG00000230274.1	PGAM1P3	-7.91	7.09e-14	1.21e-10	-0.42	-0.44	Renal cell carcinoma;	chr3:40471344	chr3:40322715~40323279:-
KIRP	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-7.91	7.12e-14	1.21e-10	-0.36	-0.44	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-7.91	7.12e-14	1.21e-10	-0.36	-0.44	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-7.91	7.12e-14	1.21e-10	-0.36	-0.44	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-7.91	7.12e-14	1.21e-10	-0.36	-0.44	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
KIRP	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-7.91	7.13e-14	1.22e-10	-0.55	-0.44	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
KIRP	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	7.91	7.15e-14	1.22e-10	0.49	0.44	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
KIRP	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-7.91	7.17e-14	1.22e-10	-0.37	-0.44	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
KIRP	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-7.91	7.21e-14	1.23e-10	-0.45	-0.44	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
KIRP	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-7.91	7.21e-14	1.23e-10	-0.45	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
KIRP	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	7.91	7.24e-14	1.23e-10	0.57	0.44	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
KIRP	cis	rs4356975	0.932	rs60814050	ENSG00000250696.4	RP11-704M14.1	7.91	7.3e-14	1.24e-10	0.43	0.44	Obesity-related traits;	chr4:69063770	chr4:69182100~69216766:+
KIRP	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	7.91	7.3e-14	1.24e-10	0.28	0.44	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	7.91	7.3e-14	1.24e-10	0.28	0.44	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	7.91	7.3e-14	1.24e-10	0.28	0.44	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
KIRP	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-7.91	7.31e-14	1.24e-10	-0.37	-0.44	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
KIRP	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	7.91	7.31e-14	1.24e-10	0.57	0.44	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
KIRP	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	7.91	7.38e-14	1.26e-10	0.28	0.44	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
KIRP	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-7.91	7.41e-14	1.26e-10	-0.48	-0.44	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
KIRP	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-7.9	7.5e-14	1.27e-10	-0.56	-0.44	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	7.9	7.51e-14	1.27e-10	0.58	0.44	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.51e-14	1.27e-10	-0.36	-0.44	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	7.9	7.51e-14	1.27e-10	0.36	0.44	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	7.9	7.51e-14	1.27e-10	0.36	0.44	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.52e-14	1.28e-10	-0.36	-0.44	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
KIRP	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-7.9	7.53e-14	1.28e-10	-0.86	-0.44	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
KIRP	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-7.9	7.63e-14	1.29e-10	-0.49	-0.44	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
KIRP	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-7.9	7.63e-14	1.29e-10	-0.54	-0.44	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
KIRP	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	7.9	7.64e-14	1.3e-10	0.55	0.44	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
KIRP	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	7.9	7.67e-14	1.3e-10	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	7.9	7.7e-14	1.3e-10	0.49	0.44	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
KIRP	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.9	7.72e-14	1.31e-10	0.48	0.44	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
KIRP	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-7.9	7.72e-14	1.31e-10	-0.48	-0.44	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
KIRP	cis	rs7672749	0.643	rs7690494	ENSG00000249973.2	CHCHD2P7	7.9	7.72e-14	1.31e-10	0.88	0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87879387	chr4:87785920~87786371:-
KIRP	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	7.9	7.81e-14	1.32e-10	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
KIRP	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-7.9	7.81e-14	1.32e-10	-0.54	-0.44	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-7.9	7.88e-14	1.33e-10	-0.59	-0.44	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-7.9	7.88e-14	1.33e-10	-0.59	-0.44	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	7.9	7.88e-14	1.33e-10	0.39	0.44	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
KIRP	cis	rs9371601	0.742	rs214947	ENSG00000226193.1	RP3-398G3.5	-7.9	7.92e-14	1.34e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152392712	chr6:152402398~152404966:+
KIRP	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	7.9	7.93e-14	1.34e-10	0.39	0.44	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-7.9	7.93e-14	1.34e-10	-0.46	-0.44	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
KIRP	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-7.9	7.94e-14	1.34e-10	-0.56	-0.44	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
KIRP	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-7.9	7.97e-14	1.35e-10	-0.48	-0.44	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
KIRP	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.89	7.99e-14	1.35e-10	-0.47	-0.44	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
KIRP	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	7.89	8.12e-14	1.37e-10	0.28	0.44	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	7.89	8.12e-14	1.37e-10	0.28	0.44	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
KIRP	cis	rs11647589	0.834	rs1394677	ENSG00000260762.1	ACSM5P1	7.89	8.16e-14	1.38e-10	0.45	0.44	Blood metabolite levels;	chr16:20478195	chr16:20586550~20607107:-
KIRP	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.89	8.17e-14	1.38e-10	0.66	0.44	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
KIRP	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.89	8.17e-14	1.38e-10	-0.49	-0.44	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7.89	8.17e-14	1.38e-10	-0.49	-0.44	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
KIRP	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-7.89	8.18e-14	1.38e-10	-0.52	-0.44	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
KIRP	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-7.89	8.18e-14	1.38e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
KIRP	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	7.89	8.19e-14	1.38e-10	0.35	0.44	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	7.89	8.19e-14	1.38e-10	0.35	0.44	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
KIRP	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-7.89	8.25e-14	1.39e-10	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
KIRP	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	7.89	8.28e-14	1.4e-10	0.51	0.44	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
KIRP	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	7.89	8.31e-14	1.4e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
KIRP	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	7.89	8.33e-14	1.41e-10	0.54	0.44	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	7.89	8.33e-14	1.41e-10	0.54	0.44	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
KIRP	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.89	8.33e-14	1.41e-10	-0.47	-0.44	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.89	8.33e-14	1.41e-10	-0.47	-0.44	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
KIRP	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	7.89	8.37e-14	1.41e-10	0.49	0.44	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
KIRP	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	7.89	8.37e-14	1.41e-10	0.49	0.44	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	7.89	8.38e-14	1.41e-10	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
KIRP	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.89	8.38e-14	1.41e-10	0.39	0.44	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	7.89	8.4e-14	1.42e-10	0.36	0.44	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
KIRP	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-7.89	8.41e-14	1.42e-10	-0.48	-0.44	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
KIRP	cis	rs4356975	0.932	rs7662632	ENSG00000250696.4	RP11-704M14.1	7.89	8.5e-14	1.43e-10	0.43	0.44	Obesity-related traits;	chr4:69062256	chr4:69182100~69216766:+
KIRP	cis	rs11647589	0.834	rs2271061	ENSG00000260762.1	ACSM5P1	7.88	8.55e-14	1.44e-10	0.45	0.44	Blood metabolite levels;	chr16:20471429	chr16:20586550~20607107:-
KIRP	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-7.88	8.56e-14	1.44e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-7.88	8.56e-14	1.44e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
KIRP	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-7.88	8.56e-14	1.44e-10	-0.51	-0.44	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
KIRP	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	7.88	8.57e-14	1.44e-10	0.56	0.44	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
KIRP	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	7.88	8.58e-14	1.45e-10	0.5	0.44	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
KIRP	cis	rs9371601	0.892	rs549720	ENSG00000226193.1	RP3-398G3.5	-7.88	8.61e-14	1.45e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152397456	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs548985	ENSG00000226193.1	RP3-398G3.5	-7.88	8.61e-14	1.45e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152397479	chr6:152402398~152404966:+
KIRP	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-7.88	8.62e-14	1.45e-10	-0.36	-0.44	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
KIRP	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	7.88	8.66e-14	1.46e-10	0.37	0.44	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
KIRP	cis	rs11647589	0.834	rs6497491	ENSG00000260762.1	ACSM5P1	7.88	8.67e-14	1.46e-10	0.45	0.44	Blood metabolite levels;	chr16:20468691	chr16:20586550~20607107:-
KIRP	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-7.88	8.69e-14	1.46e-10	-0.56	-0.44	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
KIRP	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	7.88	8.71e-14	1.46e-10	0.5	0.44	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
KIRP	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	7.88	8.71e-14	1.46e-10	0.58	0.44	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
KIRP	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	7.88	8.73e-14	1.47e-10	0.52	0.44	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
KIRP	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-7.88	8.76e-14	1.47e-10	-0.36	-0.44	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
KIRP	cis	rs4356975	0.692	rs7691361	ENSG00000250696.4	RP11-704M14.1	7.88	8.78e-14	1.48e-10	0.43	0.44	Obesity-related traits;	chr4:69077628	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.72	rs7691362	ENSG00000250696.4	RP11-704M14.1	7.88	8.78e-14	1.48e-10	0.43	0.44	Obesity-related traits;	chr4:69077631	chr4:69182100~69216766:+
KIRP	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	7.88	8.8e-14	1.48e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	7.88	8.81e-14	1.48e-10	0.37	0.44	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	7.88	8.83e-14	1.48e-10	0.38	0.44	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
KIRP	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.88	8.92e-14	1.5e-10	0.41	0.44	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.88	8.92e-14	1.5e-10	0.41	0.44	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.88	8.92e-14	1.5e-10	0.41	0.44	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
KIRP	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	7.88	8.93e-14	1.5e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	7.88	8.93e-14	1.5e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	7.88	8.93e-14	1.5e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	7.88	8.93e-14	1.5e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
KIRP	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.88	9e-14	1.51e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
KIRP	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	7.88	9.05e-14	1.52e-10	0.46	0.44	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
KIRP	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	7.88	9.06e-14	1.52e-10	0.53	0.44	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
KIRP	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	7.87	9.15e-14	1.53e-10	0.5	0.44	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	7.87	9.15e-14	1.53e-10	0.5	0.44	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
KIRP	cis	rs11647589	0.834	rs1827711	ENSG00000260762.1	ACSM5P1	7.87	9.2e-14	1.54e-10	0.44	0.44	Blood metabolite levels;	chr16:20471046	chr16:20586550~20607107:-
KIRP	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-7.87	9.23e-14	1.55e-10	-0.47	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
KIRP	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	7.87	9.25e-14	1.55e-10	0.57	0.44	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
KIRP	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-7.87	9.37e-14	1.57e-10	-0.35	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
KIRP	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	7.87	9.42e-14	1.58e-10	0.43	0.44	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
KIRP	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-7.87	9.46e-14	1.58e-10	-0.63	-0.44	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
KIRP	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	7.87	9.47e-14	1.58e-10	0.48	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	7.87	9.47e-14	1.58e-10	0.48	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	7.87	9.47e-14	1.58e-10	0.48	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
KIRP	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	7.87	9.47e-14	1.58e-10	0.59	0.44	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
KIRP	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-7.87	9.51e-14	1.59e-10	-0.55	-0.44	QT interval;	chr16:28877088	chr16:28700294~28701540:-
KIRP	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	7.87	9.51e-14	1.59e-10	0.35	0.44	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
KIRP	cis	rs453301	0.624	rs2979265	ENSG00000253981.4	ALG1L13P	7.87	9.52e-14	1.59e-10	0.36	0.44	Joint mobility (Beighton score);	chr8:9001207	chr8:8236003~8244667:-
KIRP	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	7.87	9.53e-14	1.59e-10	0.46	0.44	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
KIRP	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	7.87	9.53e-14	1.59e-10	0.46	0.44	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
KIRP	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	7.87	9.54e-14	1.59e-10	0.46	0.44	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
KIRP	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	7.87	9.66e-14	1.61e-10	0.5	0.44	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
KIRP	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	7.87	9.67e-14	1.61e-10	0.28	0.44	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
KIRP	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	7.87	9.68e-14	1.62e-10	0.49	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	7.86	9.69e-14	1.62e-10	0.37	0.44	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
KIRP	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	7.86	9.69e-14	1.62e-10	0.57	0.44	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
KIRP	cis	rs11079159	0.606	rs876720	ENSG00000263096.1	RP11-515O17.2	-7.86	9.78e-14	1.63e-10	-0.52	-0.44	QRS duration;	chr17:55289154	chr17:55271504~55273653:-
KIRP	cis	rs453301	0.598	rs10104303	ENSG00000253981.4	ALG1L13P	7.86	9.79e-14	1.63e-10	0.34	0.44	Joint mobility (Beighton score);	chr8:8977018	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-7.86	9.81e-14	1.64e-10	-0.37	-0.44	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-7.86	9.81e-14	1.64e-10	-0.37	-0.44	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-7.86	9.81e-14	1.64e-10	-0.37	-0.44	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
KIRP	cis	rs11647589	0.834	rs2271060	ENSG00000260762.1	ACSM5P1	7.86	9.81e-14	1.64e-10	0.45	0.44	Blood metabolite levels;	chr16:20471301	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.552	rs1632600	ENSG00000260762.1	ACSM5P1	7.86	9.81e-14	1.64e-10	0.45	0.44	Blood metabolite levels;	chr16:20476182	chr16:20586550~20607107:-
KIRP	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	7.86	9.84e-14	1.64e-10	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
KIRP	cis	rs944002	0.857	rs77071436	ENSG00000259444.1	RP11-736N17.8	7.86	9.86e-14	1.64e-10	0.49	0.44	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102644	chr14:103094723~103098885:+
KIRP	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-7.86	9.88e-14	1.65e-10	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	7.86	9.91e-14	1.65e-10	0.37	0.44	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	7.86	9.91e-14	1.65e-10	0.37	0.44	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	7.86	9.91e-14	1.65e-10	0.37	0.44	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	7.86	9.91e-14	1.65e-10	0.37	0.44	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
KIRP	cis	rs526231	0.584	rs246914	ENSG00000175749.11	EIF3KP1	7.86	9.97e-14	1.66e-10	0.62	0.44	Primary biliary cholangitis;	chr5:103223706	chr5:103032376~103033031:+
KIRP	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.86	1e-13	1.67e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.86	1e-13	1.67e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
KIRP	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-7.86	1e-13	1.67e-10	-0.52	-0.44	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
KIRP	cis	rs9322193	0.923	rs9322225	ENSG00000268592.3	RAET1E-AS1	7.86	1.01e-13	1.67e-10	0.6	0.44	Lung cancer;	chr6:149863746	chr6:149863494~149919507:+
KIRP	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-7.86	1.01e-13	1.68e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
KIRP	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-7.86	1.01e-13	1.69e-10	-0.59	-0.44	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-7.86	1.02e-13	1.7e-10	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-7.86	1.02e-13	1.7e-10	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-7.86	1.02e-13	1.7e-10	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
KIRP	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	7.86	1.02e-13	1.7e-10	0.53	0.44	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
KIRP	cis	rs11647589	0.834	rs1700801	ENSG00000260762.1	ACSM5P1	7.86	1.02e-13	1.7e-10	0.45	0.44	Blood metabolite levels;	chr16:20474158	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.834	rs1354577	ENSG00000260762.1	ACSM5P1	7.86	1.02e-13	1.7e-10	0.45	0.44	Blood metabolite levels;	chr16:20474341	chr16:20586550~20607107:-
KIRP	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-7.85	1.04e-13	1.73e-10	-0.48	-0.44	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
KIRP	cis	rs4356975	0.932	rs72852450	ENSG00000250696.4	RP11-704M14.1	7.85	1.04e-13	1.73e-10	0.43	0.44	Obesity-related traits;	chr4:69079704	chr4:69182100~69216766:+
KIRP	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-7.85	1.04e-13	1.73e-10	-0.48	-0.44	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
KIRP	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	7.85	1.05e-13	1.74e-10	0.46	0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
KIRP	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-7.85	1.05e-13	1.74e-10	-0.51	-0.44	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-7.85	1.05e-13	1.74e-10	-0.51	-0.44	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-7.85	1.05e-13	1.74e-10	-0.51	-0.44	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
KIRP	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-7.85	1.05e-13	1.74e-10	-0.58	-0.44	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
KIRP	cis	rs9371601	0.819	rs214946	ENSG00000226193.1	RP3-398G3.5	-7.85	1.05e-13	1.75e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152392677	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs20585	ENSG00000226193.1	RP3-398G3.5	-7.85	1.05e-13	1.75e-10	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393311	chr6:152402398~152404966:+
KIRP	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	7.85	1.05e-13	1.75e-10	0.36	0.44	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	7.85	1.06e-13	1.76e-10	0.5	0.44	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
KIRP	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	7.85	1.06e-13	1.76e-10	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
KIRP	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-7.85	1.06e-13	1.76e-10	-0.62	-0.44	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
KIRP	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-7.85	1.08e-13	1.78e-10	-0.84	-0.44	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
KIRP	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-7.85	1.08e-13	1.78e-10	-0.84	-0.44	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
KIRP	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	7.85	1.08e-13	1.8e-10	0.52	0.44	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
KIRP	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-7.85	1.09e-13	1.8e-10	-0.48	-0.44	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
KIRP	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	7.85	1.1e-13	1.82e-10	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
KIRP	cis	rs67311347	1	rs9874499	ENSG00000230274.1	PGAM1P3	7.84	1.1e-13	1.83e-10	0.43	0.44	Renal cell carcinoma;	chr3:40400417	chr3:40322715~40323279:-
KIRP	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	7.84	1.11e-13	1.83e-10	0.28	0.44	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
KIRP	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	7.84	1.11e-13	1.83e-10	0.35	0.44	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	7.84	1.11e-13	1.83e-10	0.35	0.44	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-7.84	1.11e-13	1.83e-10	-0.37	-0.44	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	7.84	1.11e-13	1.84e-10	0.36	0.44	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	7.84	1.11e-13	1.84e-10	0.36	0.44	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	7.84	1.11e-13	1.84e-10	0.36	0.44	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	7.84	1.11e-13	1.84e-10	0.36	0.44	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	7.84	1.11e-13	1.84e-10	0.36	0.44	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
KIRP	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	7.84	1.12e-13	1.85e-10	0.46	0.44	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
KIRP	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-7.84	1.12e-13	1.86e-10	-0.58	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
KIRP	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-7.84	1.14e-13	1.87e-10	-0.35	-0.44	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
KIRP	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-7.84	1.14e-13	1.88e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-7.84	1.14e-13	1.88e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-7.84	1.14e-13	1.88e-10	-0.42	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
KIRP	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	7.84	1.14e-13	1.88e-10	0.63	0.44	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
KIRP	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	7.84	1.14e-13	1.89e-10	0.59	0.44	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
KIRP	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	7.84	1.15e-13	1.89e-10	0.42	0.44	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
KIRP	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-7.84	1.15e-13	1.9e-10	-0.39	-0.44	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
KIRP	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-7.84	1.16e-13	1.92e-10	-0.5	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
KIRP	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-7.84	1.17e-13	1.92e-10	-0.49	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
KIRP	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	7.83	1.18e-13	1.94e-10	0.81	0.44	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
KIRP	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-7.83	1.18e-13	1.95e-10	-0.55	-0.44	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-7.83	1.18e-13	1.95e-10	-0.55	-0.44	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
KIRP	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	7.83	1.19e-13	1.95e-10	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
KIRP	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	7.83	1.19e-13	1.96e-10	0.58	0.44	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
KIRP	cis	rs9371601	0.859	rs1738438	ENSG00000226193.1	RP3-398G3.5	-7.83	1.2e-13	1.97e-10	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152426727	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.828	rs492233	ENSG00000226193.1	RP3-398G3.5	-7.83	1.2e-13	1.97e-10	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152431177	chr6:152402398~152404966:+
KIRP	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-7.83	1.2e-13	1.97e-10	-0.49	-0.44	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-7.83	1.2e-13	1.97e-10	-0.4	-0.44	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-7.83	1.2e-13	1.97e-10	-0.4	-0.44	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
KIRP	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	7.83	1.21e-13	1.98e-10	0.46	0.44	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
KIRP	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	7.83	1.21e-13	1.99e-10	0.54	0.44	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
KIRP	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-7.83	1.22e-13	2e-10	-0.49	-0.44	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
KIRP	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	7.83	1.23e-13	2.01e-10	0.52	0.44	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	7.83	1.23e-13	2.02e-10	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	7.83	1.23e-13	2.02e-10	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
KIRP	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	7.83	1.23e-13	2.02e-10	0.46	0.44	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
KIRP	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	7.83	1.24e-13	2.03e-10	0.57	0.44	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
KIRP	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	7.83	1.24e-13	2.04e-10	0.34	0.44	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
KIRP	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.83	1.25e-13	2.04e-10	-0.48	-0.44	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
KIRP	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	7.83	1.25e-13	2.04e-10	0.49	0.44	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
KIRP	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	7.82	1.25e-13	2.06e-10	0.49	0.44	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
KIRP	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-7.82	1.26e-13	2.06e-10	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
KIRP	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-7.82	1.27e-13	2.08e-10	-0.49	-0.44	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
KIRP	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.82	1.27e-13	2.08e-10	-0.47	-0.44	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.82	1.27e-13	2.08e-10	-0.47	-0.44	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
KIRP	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	7.82	1.27e-13	2.08e-10	0.46	0.44	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	7.82	1.27e-13	2.08e-10	0.46	0.44	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-7.82	1.27e-13	2.08e-10	-0.37	-0.44	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-7.82	1.27e-13	2.08e-10	-0.37	-0.44	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-7.82	1.27e-13	2.08e-10	-0.37	-0.44	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
KIRP	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	7.82	1.28e-13	2.09e-10	0.48	0.44	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
KIRP	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	7.82	1.29e-13	2.11e-10	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
KIRP	cis	rs755249	1	rs755249	ENSG00000237624.1	OXCT2P1	7.82	1.29e-13	2.12e-10	0.69	0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39514956~39516490:+
KIRP	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	7.82	1.3e-13	2.13e-10	0.67	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	7.82	1.3e-13	2.13e-10	0.67	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	7.82	1.3e-13	2.13e-10	0.67	0.43	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	7.82	1.3e-13	2.13e-10	0.68	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-7.82	1.31e-13	2.14e-10	-0.52	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
KIRP	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-7.82	1.32e-13	2.15e-10	-0.34	-0.43	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
KIRP	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	7.82	1.32e-13	2.16e-10	0.59	0.43	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
KIRP	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-7.82	1.33e-13	2.16e-10	-0.36	-0.43	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
KIRP	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	7.82	1.33e-13	2.17e-10	0.46	0.43	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	7.82	1.33e-13	2.17e-10	0.46	0.43	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
KIRP	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	7.82	1.34e-13	2.18e-10	0.35	0.43	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	7.81	1.34e-13	2.18e-10	0.37	0.43	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
KIRP	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	7.81	1.34e-13	2.18e-10	0.42	0.43	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
KIRP	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	7.81	1.34e-13	2.18e-10	0.42	0.43	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
KIRP	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	7.81	1.34e-13	2.18e-10	0.42	0.43	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
KIRP	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	7.81	1.34e-13	2.19e-10	0.62	0.43	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
KIRP	cis	rs11647589	0.642	rs7193826	ENSG00000260762.1	ACSM5P1	7.81	1.34e-13	2.19e-10	0.45	0.43	Blood metabolite levels;	chr16:20467260	chr16:20586550~20607107:-
KIRP	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.81	1.35e-13	2.19e-10	-0.48	-0.43	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
KIRP	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-7.81	1.35e-13	2.2e-10	-0.84	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
KIRP	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	7.81	1.35e-13	2.21e-10	0.64	0.43	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
KIRP	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	7.81	1.35e-13	2.21e-10	0.49	0.43	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
KIRP	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	7.81	1.35e-13	2.21e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	7.81	1.35e-13	2.21e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	7.81	1.35e-13	2.21e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	7.81	1.35e-13	2.21e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	7.81	1.35e-13	2.21e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	7.81	1.36e-13	2.21e-10	0.37	0.43	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	7.81	1.36e-13	2.21e-10	0.37	0.43	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
KIRP	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-7.81	1.36e-13	2.22e-10	-0.44	-0.43	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
KIRP	cis	rs4356975	0.932	rs7657426	ENSG00000250696.4	RP11-704M14.1	7.81	1.37e-13	2.23e-10	0.43	0.43	Obesity-related traits;	chr4:69079291	chr4:69182100~69216766:+
KIRP	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-7.81	1.37e-13	2.23e-10	-0.37	-0.43	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	7.81	1.37e-13	2.24e-10	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
KIRP	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.81	1.37e-13	2.24e-10	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
KIRP	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.81	1.38e-13	2.25e-10	-0.48	-0.43	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.81	1.38e-13	2.25e-10	-0.48	-0.43	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
KIRP	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-7.81	1.39e-13	2.25e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-7.81	1.39e-13	2.25e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
KIRP	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	7.81	1.39e-13	2.26e-10	0.57	0.43	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
KIRP	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-7.81	1.39e-13	2.26e-10	-0.43	-0.43	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
KIRP	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-7.81	1.39e-13	2.27e-10	-0.37	-0.43	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	7.81	1.4e-13	2.27e-10	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
KIRP	cis	rs9371601	0.798	rs127196	ENSG00000226193.1	RP3-398G3.5	-7.81	1.4e-13	2.28e-10	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152406196	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs2746418	ENSG00000226193.1	RP3-398G3.5	-7.81	1.4e-13	2.28e-10	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152407458	chr6:152402398~152404966:+
KIRP	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.81	1.4e-13	2.28e-10	-0.62	-0.43	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
KIRP	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-7.81	1.4e-13	2.28e-10	-0.36	-0.43	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-7.81	1.4e-13	2.28e-10	-0.36	-0.43	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	7.81	1.41e-13	2.28e-10	0.37	0.43	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	7.81	1.41e-13	2.28e-10	0.37	0.43	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
KIRP	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	7.81	1.41e-13	2.28e-10	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
KIRP	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.81	1.41e-13	2.28e-10	-0.46	-0.43	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
KIRP	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	7.81	1.42e-13	2.31e-10	0.57	0.43	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
KIRP	cis	rs9371601	0.859	rs473101	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152396063	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.819	rs551900	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152396182	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs550070	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152396370	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs550065	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152396372	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.78	rs551681	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152397227	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs549981	ENSG00000226193.1	RP3-398G3.5	-7.8	1.43e-13	2.32e-10	-0.49	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152397370	chr6:152402398~152404966:+
KIRP	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	7.8	1.43e-13	2.32e-10	0.49	0.43	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
KIRP	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	7.8	1.43e-13	2.32e-10	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
KIRP	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	7.8	1.43e-13	2.32e-10	0.36	0.43	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
KIRP	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	7.8	1.43e-13	2.32e-10	0.5	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
KIRP	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	7.8	1.45e-13	2.35e-10	0.5	0.43	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
KIRP	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-7.8	1.46e-13	2.37e-10	-0.53	-0.43	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
KIRP	cis	rs9371601	0.798	rs544125	ENSG00000226193.1	RP3-398G3.5	-7.8	1.46e-13	2.37e-10	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152407641	chr6:152402398~152404966:+
KIRP	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	7.8	1.46e-13	2.37e-10	0.62	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
KIRP	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	7.8	1.47e-13	2.37e-10	0.94	0.43	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	7.8	1.47e-13	2.37e-10	0.94	0.43	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	7.8	1.47e-13	2.37e-10	0.94	0.43	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	7.8	1.47e-13	2.37e-10	0.94	0.43	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	7.8	1.47e-13	2.37e-10	0.94	0.43	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
KIRP	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	7.8	1.47e-13	2.37e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
KIRP	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	7.8	1.48e-13	2.39e-10	0.37	0.43	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-7.8	1.48e-13	2.39e-10	-0.4	-0.43	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-7.8	1.49e-13	2.4e-10	-0.37	-0.43	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-7.8	1.49e-13	2.4e-10	-0.37	-0.43	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-7.8	1.49e-13	2.4e-10	-0.37	-0.43	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
KIRP	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	7.8	1.5e-13	2.42e-10	0.45	0.43	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
KIRP	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	7.8	1.5e-13	2.42e-10	0.49	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	7.8	1.5e-13	2.42e-10	0.49	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
KIRP	cis	rs4578769	0.569	rs4800431	ENSG00000266850.1	RP11-370A5.1	7.8	1.5e-13	2.43e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22803499	chr18:22723491~22907721:-
KIRP	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	7.8	1.51e-13	2.43e-10	0.46	0.43	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
KIRP	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.8	1.51e-13	2.44e-10	-0.54	-0.43	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
KIRP	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	7.8	1.52e-13	2.45e-10	0.54	0.43	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
KIRP	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-7.79	1.52e-13	2.46e-10	-0.61	-0.43	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
KIRP	cis	rs4578769	0.569	rs1597239	ENSG00000266850.1	RP11-370A5.1	7.79	1.52e-13	2.46e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22805673	chr18:22723491~22907721:-
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	7.79	1.54e-13	2.48e-10	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
KIRP	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	7.79	1.54e-13	2.48e-10	0.49	0.43	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
KIRP	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	7.79	1.55e-13	2.5e-10	0.47	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
KIRP	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-7.79	1.55e-13	2.5e-10	-0.56	-0.43	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
KIRP	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	7.79	1.55e-13	2.5e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
KIRP	cis	rs755249	0.959	rs72663520	ENSG00000237624.1	OXCT2P1	7.79	1.55e-13	2.5e-10	0.68	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39514956~39516490:+
KIRP	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	7.79	1.56e-13	2.52e-10	0.42	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
KIRP	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	7.79	1.57e-13	2.53e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	7.79	1.57e-13	2.53e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	7.79	1.57e-13	2.53e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
KIRP	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	7.79	1.58e-13	2.54e-10	0.49	0.43	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
KIRP	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-7.79	1.58e-13	2.54e-10	-0.5	-0.43	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
KIRP	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-7.79	1.58e-13	2.54e-10	-0.36	-0.43	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	7.79	1.58e-13	2.54e-10	0.36	0.43	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-7.79	1.59e-13	2.55e-10	-0.36	-0.43	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
KIRP	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	7.79	1.59e-13	2.56e-10	0.6	0.43	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
KIRP	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	7.79	1.6e-13	2.57e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
KIRP	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	7.79	1.6e-13	2.58e-10	0.56	0.43	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
KIRP	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-7.79	1.61e-13	2.58e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
KIRP	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-7.79	1.62e-13	2.6e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
KIRP	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
KIRP	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-7.79	1.62e-13	2.6e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
KIRP	cis	rs9371601	0.859	rs544098	ENSG00000226193.1	RP3-398G3.5	-7.79	1.62e-13	2.6e-10	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152407625	chr6:152402398~152404966:+
KIRP	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-7.78	1.63e-13	2.61e-10	-0.64	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
KIRP	cis	rs4578769	0.55	rs9949333	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22815080	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs9962620	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22815811	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs4800433	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22816691	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs11082155	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22824527	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs4289091	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22825856	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.589	rs12606787	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22830392	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs12956367	ENSG00000266850.1	RP11-370A5.1	7.78	1.63e-13	2.62e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22833742	chr18:22723491~22907721:-
KIRP	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-7.78	1.64e-13	2.62e-10	-0.36	-0.43	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
KIRP	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-7.78	1.64e-13	2.63e-10	-0.39	-0.43	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
KIRP	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-7.78	1.64e-13	2.63e-10	-0.39	-0.43	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
KIRP	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-7.78	1.64e-13	2.63e-10	-0.39	-0.43	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
KIRP	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-7.78	1.64e-13	2.64e-10	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	7.78	1.64e-13	2.64e-10	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	7.78	1.64e-13	2.64e-10	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-7.78	1.66e-13	2.66e-10	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
KIRP	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-7.78	1.67e-13	2.68e-10	-0.42	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
KIRP	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	7.78	1.69e-13	2.7e-10	0.36	0.43	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
KIRP	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-7.78	1.69e-13	2.71e-10	-0.37	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
KIRP	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	7.78	1.69e-13	2.71e-10	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
KIRP	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	7.78	1.7e-13	2.72e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	7.78	1.7e-13	2.72e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
KIRP	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	7.78	1.7e-13	2.73e-10	0.44	0.43	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	7.78	1.7e-13	2.73e-10	0.44	0.43	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
KIRP	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	7.78	1.71e-13	2.73e-10	0.28	0.43	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
KIRP	cis	rs11647589	0.834	rs1910802	ENSG00000260762.1	ACSM5P1	7.78	1.71e-13	2.73e-10	0.46	0.43	Blood metabolite levels;	chr16:20464245	chr16:20586550~20607107:-
KIRP	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-7.78	1.71e-13	2.73e-10	-0.81	-0.43	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
KIRP	cis	rs67311347	1	rs11914297	ENSG00000230274.1	PGAM1P3	7.78	1.72e-13	2.75e-10	0.43	0.43	Renal cell carcinoma;	chr3:40368579	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.955	rs12487955	ENSG00000230274.1	PGAM1P3	7.78	1.72e-13	2.75e-10	0.43	0.43	Renal cell carcinoma;	chr3:40371362	chr3:40322715~40323279:-
KIRP	cis	rs9371601	0.859	rs578359	ENSG00000226193.1	RP3-398G3.5	-7.78	1.72e-13	2.75e-10	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152396569	chr6:152402398~152404966:+
KIRP	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	7.78	1.72e-13	2.75e-10	0.58	0.43	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
KIRP	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	7.78	1.72e-13	2.76e-10	0.49	0.43	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
KIRP	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	7.77	1.74e-13	2.77e-10	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
KIRP	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-7.77	1.74e-13	2.78e-10	-0.57	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
KIRP	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-7.77	1.75e-13	2.8e-10	-0.43	-0.43	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
KIRP	cis	rs67311347	1	rs66841330	ENSG00000230274.1	PGAM1P3	7.77	1.76e-13	2.81e-10	0.44	0.43	Renal cell carcinoma;	chr3:40489632	chr3:40322715~40323279:-
KIRP	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-7.77	1.76e-13	2.81e-10	-0.37	-0.43	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-7.77	1.76e-13	2.81e-10	-0.37	-0.43	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
KIRP	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	7.77	1.77e-13	2.82e-10	0.42	0.43	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
KIRP	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-7.77	1.77e-13	2.83e-10	-0.53	-0.43	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
KIRP	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-7.77	1.78e-13	2.83e-10	-0.47	-0.43	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
KIRP	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	7.77	1.78e-13	2.83e-10	0.48	0.43	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
KIRP	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-7.77	1.78e-13	2.84e-10	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
KIRP	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	7.77	1.81e-13	2.89e-10	0.44	0.43	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
KIRP	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-7.77	1.82e-13	2.89e-10	-0.46	-0.43	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
KIRP	cis	rs4578769	0.569	rs1448769	ENSG00000266850.1	RP11-370A5.1	7.77	1.82e-13	2.89e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22838322	chr18:22723491~22907721:-
KIRP	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	7.77	1.82e-13	2.9e-10	0.55	0.43	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
KIRP	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-7.77	1.83e-13	2.91e-10	-0.53	-0.43	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
KIRP	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-7.77	1.83e-13	2.91e-10	-0.49	-0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
KIRP	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.77	1.84e-13	2.92e-10	0.47	0.43	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.76	1.85e-13	2.94e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.76	1.85e-13	2.94e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
KIRP	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	7.76	1.86e-13	2.96e-10	0.89	0.43	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
KIRP	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	7.76	1.87e-13	2.98e-10	0.53	0.43	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
KIRP	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	7.76	1.87e-13	2.98e-10	0.56	0.43	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
KIRP	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.76	1.87e-13	2.98e-10	0.48	0.43	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
KIRP	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-7.76	1.87e-13	2.98e-10	-0.36	-0.43	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
KIRP	cis	rs11647589	0.642	rs1532842	ENSG00000260762.1	ACSM5P1	7.76	1.88e-13	2.98e-10	0.45	0.43	Blood metabolite levels;	chr16:20468067	chr16:20586550~20607107:-
KIRP	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-7.76	1.88e-13	2.98e-10	-0.58	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
KIRP	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	7.76	1.88e-13	2.98e-10	0.42	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
KIRP	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.76	1.89e-13	3e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
KIRP	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.76	1.89e-13	3e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
KIRP	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-7.76	1.9e-13	3.01e-10	-0.36	-0.43	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
KIRP	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-7.76	1.91e-13	3.02e-10	-0.54	-0.43	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
KIRP	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-7.76	1.91e-13	3.03e-10	-0.57	-0.43	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
KIRP	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-7.76	1.92e-13	3.04e-10	-0.63	-0.43	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
KIRP	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	7.76	1.92e-13	3.04e-10	0.56	0.43	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
KIRP	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	7.76	1.93e-13	3.05e-10	0.49	0.43	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	7.76	1.93e-13	3.05e-10	0.49	0.43	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	7.76	1.93e-13	3.05e-10	0.49	0.43	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
KIRP	cis	rs1005277	0.505	rs13503	ENSG00000151963.4	RP11-775A3.1	7.76	1.96e-13	3.1e-10	0.5	0.43	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:37883594~37884109:+
KIRP	cis	rs12962334	0.57	rs4800434	ENSG00000266850.1	RP11-370A5.1	7.76	1.96e-13	3.1e-10	0.52	0.43	Breast cancer;	chr18:22848311	chr18:22723491~22907721:-
KIRP	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	7.75	1.97e-13	3.11e-10	0.52	0.43	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
KIRP	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-7.75	1.97e-13	3.12e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
KIRP	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-7.75	1.98e-13	3.12e-10	-0.81	-0.43	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
KIRP	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	7.75	1.98e-13	3.13e-10	0.46	0.43	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	7.75	1.98e-13	3.13e-10	0.46	0.43	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	7.75	1.98e-13	3.13e-10	0.46	0.43	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
KIRP	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	7.75	1.98e-13	3.14e-10	0.49	0.43	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
KIRP	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-7.75	1.99e-13	3.15e-10	-0.46	-0.43	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
KIRP	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-7.75	2e-13	3.16e-10	-0.57	-0.43	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
KIRP	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	7.75	2e-13	3.16e-10	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
KIRP	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-7.75	2e-13	3.16e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
KIRP	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	7.75	2e-13	3.17e-10	0.54	0.43	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	7.75	2e-13	3.17e-10	0.54	0.43	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
KIRP	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-7.75	2.02e-13	3.19e-10	-0.59	-0.43	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
KIRP	cis	rs755249	0.876	rs61781391	ENSG00000237624.1	OXCT2P1	7.75	2.02e-13	3.19e-10	0.71	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39514956~39516490:+
KIRP	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-7.75	2.02e-13	3.2e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
KIRP	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-7.75	2.03e-13	3.2e-10	-0.39	-0.43	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
KIRP	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-7.75	2.03e-13	3.21e-10	-0.37	-0.43	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
KIRP	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	7.75	2.06e-13	3.25e-10	0.48	0.43	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
KIRP	cis	rs71403859	0.685	rs12927044	ENSG00000260886.1	TAT-AS1	7.75	2.07e-13	3.26e-10	0.96	0.43	Post bronchodilator FEV1;	chr16:71896202	chr16:71565789~71578187:+
KIRP	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-7.75	2.07e-13	3.26e-10	-0.38	-0.43	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
KIRP	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	7.75	2.07e-13	3.27e-10	0.49	0.43	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
KIRP	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	7.75	2.08e-13	3.28e-10	0.57	0.43	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
KIRP	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	7.75	2.08e-13	3.28e-10	0.56	0.43	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
KIRP	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-7.75	2.08e-13	3.28e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-7.74	2.11e-13	3.33e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-7.74	2.11e-13	3.33e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
KIRP	cis	rs4578769	0.55	rs9961760	ENSG00000266850.1	RP11-370A5.1	7.74	2.13e-13	3.36e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:23021545	chr18:22723491~22907721:-
KIRP	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	7.74	2.14e-13	3.37e-10	0.36	0.43	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-7.74	2.15e-13	3.39e-10	-0.38	-0.43	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
KIRP	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-7.74	2.16e-13	3.39e-10	-0.57	-0.43	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
KIRP	cis	rs9371601	0.798	rs544863	ENSG00000226193.1	RP3-398G3.5	7.74	2.16e-13	3.4e-10	0.46	0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152407679	chr6:152402398~152404966:+
KIRP	cis	rs11647589	0.641	rs1394676	ENSG00000260762.1	ACSM5P1	7.74	2.17e-13	3.42e-10	0.44	0.43	Blood metabolite levels;	chr16:20477880	chr16:20586550~20607107:-
KIRP	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	7.74	2.19e-13	3.44e-10	0.37	0.43	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
KIRP	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	7.74	2.19e-13	3.45e-10	0.52	0.43	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
KIRP	cis	rs67311347	0.911	rs58282210	ENSG00000230274.1	PGAM1P3	7.74	2.2e-13	3.46e-10	0.43	0.43	Renal cell carcinoma;	chr3:40376452	chr3:40322715~40323279:-
KIRP	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	7.74	2.2e-13	3.46e-10	0.84	0.43	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	7.74	2.2e-13	3.46e-10	0.84	0.43	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
KIRP	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-7.74	2.21e-13	3.48e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-7.74	2.21e-13	3.48e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-7.74	2.21e-13	3.48e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
KIRP	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	7.74	2.23e-13	3.5e-10	0.61	0.43	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
KIRP	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-7.74	2.23e-13	3.5e-10	-0.48	-0.43	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
KIRP	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.74	2.23e-13	3.51e-10	0.49	0.43	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
KIRP	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	7.73	2.24e-13	3.52e-10	0.61	0.43	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
KIRP	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-7.73	2.24e-13	3.52e-10	-0.46	-0.43	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
KIRP	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-7.73	2.24e-13	3.52e-10	-0.36	-0.43	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-7.73	2.24e-13	3.52e-10	-0.36	-0.43	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
KIRP	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-7.73	2.24e-13	3.53e-10	-0.48	-0.43	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
KIRP	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-7.73	2.25e-13	3.53e-10	-0.4	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
KIRP	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	7.73	2.26e-13	3.55e-10	0.88	0.43	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
KIRP	cis	rs755249	0.761	rs61781390	ENSG00000237624.1	OXCT2P1	7.73	2.26e-13	3.55e-10	0.71	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39514956~39516490:+
KIRP	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-7.73	2.26e-13	3.55e-10	-0.49	-0.43	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
KIRP	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	7.73	2.27e-13	3.56e-10	0.58	0.43	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
KIRP	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-7.73	2.27e-13	3.56e-10	-0.55	-0.43	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
KIRP	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-7.73	2.28e-13	3.58e-10	-0.51	-0.43	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-7.73	2.28e-13	3.58e-10	-0.51	-0.43	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
KIRP	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-7.73	2.29e-13	3.59e-10	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
KIRP	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	7.73	2.29e-13	3.59e-10	0.58	0.43	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
KIRP	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.73	2.29e-13	3.6e-10	-0.46	-0.43	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
KIRP	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	7.73	2.3e-13	3.61e-10	0.55	0.43	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
KIRP	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.73	2.3e-13	3.61e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
KIRP	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	7.73	2.32e-13	3.63e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
KIRP	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	7.73	2.32e-13	3.63e-10	0.68	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
KIRP	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-7.73	2.32e-13	3.64e-10	-0.48	-0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-7.73	2.32e-13	3.64e-10	-0.48	-0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
KIRP	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	7.73	2.33e-13	3.64e-10	0.33	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
KIRP	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	7.73	2.33e-13	3.65e-10	0.36	0.43	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
KIRP	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-7.73	2.33e-13	3.65e-10	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
KIRP	cis	rs67311347	0.955	rs4974067	ENSG00000230274.1	PGAM1P3	7.73	2.34e-13	3.67e-10	0.42	0.43	Renal cell carcinoma;	chr3:40333060	chr3:40322715~40323279:-
KIRP	cis	rs7115242	0.699	rs17174502	ENSG00000254851.1	RP11-109L13.1	7.73	2.35e-13	3.67e-10	0.9	0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116888939	chr11:117135528~117138582:+
KIRP	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	7.73	2.37e-13	3.7e-10	0.57	0.43	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
KIRP	cis	rs1005277	0.505	rs7069702	ENSG00000151963.4	RP11-775A3.1	7.73	2.37e-13	3.71e-10	0.49	0.43	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:37883594~37884109:+
KIRP	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-7.73	2.38e-13	3.71e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
KIRP	cis	rs453301	0.653	rs1562211	ENSG00000253981.4	ALG1L13P	-7.73	2.38e-13	3.71e-10	-0.35	-0.43	Joint mobility (Beighton score);	chr8:9044914	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-7.72	2.39e-13	3.73e-10	-0.36	-0.43	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-7.72	2.39e-13	3.74e-10	-0.46	-0.43	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
KIRP	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-7.72	2.4e-13	3.74e-10	-0.37	-0.43	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
KIRP	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-7.72	2.41e-13	3.76e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-7.72	2.41e-13	3.76e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-7.72	2.41e-13	3.76e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-7.72	2.41e-13	3.76e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
KIRP	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	7.72	2.41e-13	3.76e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
KIRP	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	7.72	2.42e-13	3.77e-10	0.43	0.43	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
KIRP	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	7.72	2.44e-13	3.8e-10	0.54	0.43	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
KIRP	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-7.72	2.45e-13	3.81e-10	-0.36	-0.43	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-7.72	2.45e-13	3.81e-10	-0.36	-0.43	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-7.72	2.45e-13	3.81e-10	-0.36	-0.43	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-7.72	2.45e-13	3.81e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
KIRP	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-7.72	2.45e-13	3.82e-10	-0.43	-0.43	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
KIRP	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-7.72	2.46e-13	3.83e-10	-0.37	-0.43	Height;	chr11:118808920	chr11:118791254~118793137:+
KIRP	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	7.72	2.47e-13	3.84e-10	0.73	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
KIRP	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-7.72	2.47e-13	3.84e-10	-0.5	-0.43	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
KIRP	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	7.72	2.47e-13	3.85e-10	0.49	0.43	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-7.72	2.49e-13	3.86e-10	-0.37	-0.43	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-7.72	2.49e-13	3.88e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	7.72	2.5e-13	3.88e-10	0.39	0.43	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	7.72	2.5e-13	3.88e-10	0.39	0.43	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	7.72	2.5e-13	3.88e-10	0.39	0.43	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	7.72	2.5e-13	3.88e-10	0.39	0.43	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	7.72	2.5e-13	3.88e-10	0.39	0.43	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
KIRP	cis	rs4578769	0.55	rs8087501	ENSG00000266850.1	RP11-370A5.1	7.72	2.5e-13	3.88e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22970711	chr18:22723491~22907721:-
KIRP	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-7.72	2.51e-13	3.89e-10	-0.59	-0.43	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
KIRP	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-7.72	2.51e-13	3.9e-10	-0.36	-0.43	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
KIRP	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-7.72	2.52e-13	3.91e-10	-0.37	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
KIRP	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	7.72	2.52e-13	3.91e-10	0.6	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
KIRP	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-7.72	2.53e-13	3.92e-10	-0.34	-0.43	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
KIRP	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	7.72	2.53e-13	3.93e-10	0.39	0.43	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
KIRP	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	7.71	2.54e-13	3.94e-10	0.33	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
KIRP	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	7.71	2.56e-13	3.97e-10	0.46	0.43	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
KIRP	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	7.71	2.58e-13	4e-10	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	7.71	2.58e-13	4e-10	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	7.71	2.58e-13	4e-10	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	7.71	2.58e-13	4e-10	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
KIRP	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-7.71	2.58e-13	4e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
KIRP	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	7.71	2.58e-13	4e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	7.71	2.58e-13	4e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
KIRP	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	7.71	2.59e-13	4.01e-10	0.49	0.43	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
KIRP	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-7.71	2.59e-13	4.01e-10	-0.57	-0.43	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
KIRP	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-7.71	2.61e-13	4.03e-10	-0.43	-0.43	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-7.71	2.61e-13	4.03e-10	-0.43	-0.43	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
KIRP	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	7.71	2.61e-13	4.04e-10	0.49	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
KIRP	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-7.71	2.61e-13	4.04e-10	-0.56	-0.43	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
KIRP	cis	rs12962334	0.508	rs9966036	ENSG00000266850.1	RP11-370A5.1	7.71	2.62e-13	4.05e-10	0.53	0.43	Breast cancer;	chr18:22936105	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs12964830	ENSG00000266850.1	RP11-370A5.1	7.71	2.62e-13	4.05e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22938970	chr18:22723491~22907721:-
KIRP	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-7.71	2.63e-13	4.07e-10	-0.48	-0.43	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
KIRP	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-7.71	2.63e-13	4.07e-10	-0.36	-0.43	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-7.71	2.63e-13	4.07e-10	-0.36	-0.43	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-7.71	2.63e-13	4.07e-10	-0.36	-0.43	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
KIRP	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-7.71	2.63e-13	4.07e-10	-0.62	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
KIRP	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	7.71	2.63e-13	4.08e-10	0.45	0.43	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
KIRP	cis	rs4578769	0.55	rs12966925	ENSG00000266850.1	RP11-370A5.1	7.71	2.64e-13	4.08e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22953734	chr18:22723491~22907721:-
KIRP	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-7.71	2.65e-13	4.1e-10	-0.36	-0.43	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-7.71	2.66e-13	4.11e-10	-0.36	-0.43	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-7.71	2.66e-13	4.11e-10	-0.49	-0.43	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
KIRP	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-7.71	2.67e-13	4.12e-10	-0.5	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
KIRP	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-7.71	2.67e-13	4.13e-10	-0.65	-0.43	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
KIRP	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-7.71	2.68e-13	4.13e-10	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
KIRP	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	7.71	2.68e-13	4.14e-10	0.5	0.43	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
KIRP	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-7.71	2.69e-13	4.15e-10	-0.55	-0.43	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
KIRP	cis	rs7672749	0.73	rs61064865	ENSG00000249973.2	CHCHD2P7	7.71	2.69e-13	4.16e-10	0.86	0.43	TB-LM or TBLH-BMD (pleiotropy);	chr4:87873356	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs6532027	ENSG00000249973.2	CHCHD2P7	7.71	2.69e-13	4.16e-10	0.86	0.43	TB-LM or TBLH-BMD (pleiotropy);	chr4:87875291	chr4:87785920~87786371:-
KIRP	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-7.71	2.7e-13	4.18e-10	-0.62	-0.43	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
KIRP	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-7.7	2.72e-13	4.19e-10	-0.36	-0.43	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
KIRP	cis	rs4578769	0.55	rs12954377	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22940862	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs9957690	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22942697	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs12956837	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22946865	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.513	rs9953640	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22947856	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs4800442	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22958337	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs9953479	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22962644	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs12971230	ENSG00000266850.1	RP11-370A5.1	7.7	2.72e-13	4.21e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22962987	chr18:22723491~22907721:-
KIRP	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-7.7	2.72e-13	4.21e-10	-0.45	-0.43	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-7.7	2.72e-13	4.21e-10	-0.45	-0.43	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
KIRP	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-7.7	2.73e-13	4.22e-10	-0.54	-0.43	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
KIRP	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	7.7	2.74e-13	4.22e-10	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
KIRP	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-7.7	2.74e-13	4.23e-10	-0.48	-0.43	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
KIRP	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	7.7	2.74e-13	4.23e-10	0.48	0.43	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
KIRP	cis	rs4578769	0.55	rs11082182	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22872136	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.531	rs11082183	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22872137	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs12605806	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22882093	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.531	rs4616385	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22895327	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.524	rs9956919	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22896538	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs12958551	ENSG00000266850.1	RP11-370A5.1	7.7	2.76e-13	4.25e-10	0.51	0.43	Eosinophil percentage of white cells;	chr18:22897885	chr18:22723491~22907721:-
KIRP	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	7.7	2.76e-13	4.26e-10	0.46	0.43	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
KIRP	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-7.7	2.77e-13	4.26e-10	-0.36	-0.43	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-7.7	2.77e-13	4.26e-10	-0.36	-0.43	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-7.7	2.77e-13	4.26e-10	-0.36	-0.43	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
KIRP	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	7.7	2.78e-13	4.28e-10	0.61	0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-7.7	2.78e-13	4.28e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-7.7	2.78e-13	4.28e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-7.7	2.78e-13	4.28e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-7.7	2.78e-13	4.28e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-7.7	2.78e-13	4.28e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
KIRP	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	7.7	2.8e-13	4.31e-10	0.55	0.43	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
KIRP	cis	rs4578769	0.531	rs9957103	ENSG00000266850.1	RP11-370A5.1	7.7	2.8e-13	4.32e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22870172	chr18:22723491~22907721:-
KIRP	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	7.7	2.84e-13	4.36e-10	0.46	0.43	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
KIRP	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-7.7	2.84e-13	4.37e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
KIRP	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	7.7	2.87e-13	4.41e-10	0.52	0.43	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
KIRP	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	7.69	2.9e-13	4.44e-10	0.53	0.43	Migraine;	chr16:75350086	chr16:75379818~75381260:-
KIRP	cis	rs17361889	0.727	rs62440406	ENSG00000224683.1	RPL36AP29	7.69	2.9e-13	4.45e-10	0.51	0.43	Pediatric bone mineral content (hip);	chr7:16245394	chr7:16208945~16209265:+
KIRP	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	7.69	2.9e-13	4.45e-10	0.55	0.43	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
KIRP	cis	rs1005277	0.522	rs289645	ENSG00000151963.4	RP11-775A3.1	-7.69	2.91e-13	4.46e-10	-0.46	-0.43	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:37883594~37884109:+
KIRP	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-7.69	2.92e-13	4.47e-10	-0.36	-0.43	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
KIRP	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-7.69	2.92e-13	4.48e-10	-0.66	-0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
KIRP	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-7.69	2.93e-13	4.49e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-7.69	2.93e-13	4.5e-10	-0.39	-0.43	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-7.69	2.93e-13	4.5e-10	-0.39	-0.43	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-7.69	2.93e-13	4.5e-10	-0.39	-0.43	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-7.69	2.93e-13	4.5e-10	-0.39	-0.43	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
KIRP	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	7.69	2.95e-13	4.51e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
KIRP	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-7.69	2.95e-13	4.51e-10	-0.48	-0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
KIRP	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-7.69	2.95e-13	4.51e-10	-0.57	-0.43	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-7.69	2.95e-13	4.51e-10	-0.57	-0.43	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-7.69	2.95e-13	4.51e-10	-0.57	-0.43	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	7.69	2.95e-13	4.51e-10	0.57	0.43	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
KIRP	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	7.69	2.95e-13	4.52e-10	0.42	0.43	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
KIRP	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-7.69	2.96e-13	4.52e-10	-0.59	-0.43	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
KIRP	cis	rs4578769	0.55	rs9945620	ENSG00000266850.1	RP11-370A5.1	7.69	2.96e-13	4.53e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22997367	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs2305886	ENSG00000266850.1	RP11-370A5.1	7.69	2.96e-13	4.53e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22997493	chr18:22723491~22907721:-
KIRP	cis	rs12962334	0.555	rs9959556	ENSG00000266850.1	RP11-370A5.1	7.69	2.96e-13	4.53e-10	0.53	0.43	Breast cancer;	chr18:23011982	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.531	rs4800443	ENSG00000266850.1	RP11-370A5.1	7.69	2.96e-13	4.53e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:23015139	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs4635434	ENSG00000266850.1	RP11-370A5.1	-7.69	2.96e-13	4.53e-10	-0.53	-0.43	Eosinophil percentage of white cells;	chr18:22996032	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs4471804	ENSG00000266850.1	RP11-370A5.1	-7.69	2.96e-13	4.53e-10	-0.53	-0.43	Eosinophil percentage of white cells;	chr18:22996218	chr18:22723491~22907721:-
KIRP	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.54e-10	0.44	0.43	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.54e-10	0.44	0.43	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.54e-10	0.44	0.43	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.55e-10	0.44	0.43	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.55e-10	0.44	0.43	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	7.69	2.97e-13	4.55e-10	0.44	0.43	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
KIRP	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	7.69	2.98e-13	4.56e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
KIRP	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	7.69	2.99e-13	4.57e-10	0.58	0.43	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
KIRP	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-7.69	3e-13	4.59e-10	-0.36	-0.43	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-7.69	3e-13	4.59e-10	-0.36	-0.43	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-7.69	3e-13	4.59e-10	-0.36	-0.43	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-7.69	3e-13	4.59e-10	-0.36	-0.43	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-7.69	3.01e-13	4.6e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-7.69	3.01e-13	4.6e-10	-0.5	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
KIRP	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	7.69	3.02e-13	4.61e-10	0.55	0.43	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
KIRP	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.69	3.02e-13	4.61e-10	0.43	0.43	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
KIRP	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	7.69	3.02e-13	4.61e-10	0.79	0.43	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
KIRP	cis	rs4578769	0.55	rs9951410	ENSG00000266850.1	RP11-370A5.1	7.69	3.06e-13	4.68e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22964944	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.505	rs9951982	ENSG00000266850.1	RP11-370A5.1	7.69	3.06e-13	4.68e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22965607	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.513	rs34623893	ENSG00000266850.1	RP11-370A5.1	7.69	3.06e-13	4.68e-10	0.53	0.43	Eosinophil percentage of white cells;	chr18:22967224	chr18:22723491~22907721:-
KIRP	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	7.69	3.07e-13	4.68e-10	0.85	0.43	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
KIRP	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	7.68	3.11e-13	4.74e-10	0.52	0.43	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
KIRP	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	7.68	3.11e-13	4.74e-10	0.45	0.43	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
KIRP	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-7.68	3.13e-13	4.76e-10	-0.36	-0.43	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
KIRP	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-7.68	3.13e-13	4.76e-10	-0.49	-0.43	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
KIRP	cis	rs7672749	0.73	rs72877143	ENSG00000249973.2	CHCHD2P7	7.68	3.14e-13	4.78e-10	0.87	0.43	TB-LM or TBLH-BMD (pleiotropy);	chr4:87856263	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.73	rs66747117	ENSG00000249973.2	CHCHD2P7	7.68	3.14e-13	4.78e-10	0.87	0.43	TB-LM or TBLH-BMD (pleiotropy);	chr4:87857347	chr4:87785920~87786371:-
KIRP	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	7.68	3.14e-13	4.79e-10	0.36	0.43	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
KIRP	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	7.68	3.15e-13	4.8e-10	0.35	0.43	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
KIRP	cis	rs893363	0.517	rs6445606	ENSG00000271916.1	RP11-884K10.6	-7.68	3.18e-13	4.84e-10	-0.43	-0.43	Axial length;	chr3:53822023	chr3:53797764~53798019:-
KIRP	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	7.68	3.19e-13	4.85e-10	0.56	0.43	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
KIRP	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-7.68	3.19e-13	4.86e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-7.68	3.19e-13	4.86e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-7.68	3.19e-13	4.86e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-7.68	3.19e-13	4.86e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
KIRP	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-7.68	3.2e-13	4.86e-10	-0.49	-0.43	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
KIRP	cis	rs7672749	0.73	rs7696460	ENSG00000249973.2	CHCHD2P7	7.68	3.2e-13	4.86e-10	0.86	0.43	TB-LM or TBLH-BMD (pleiotropy);	chr4:87855784	chr4:87785920~87786371:-
KIRP	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	7.68	3.2e-13	4.86e-10	0.49	0.43	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
KIRP	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	7.68	3.2e-13	4.86e-10	0.49	0.43	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
KIRP	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	7.68	3.21e-13	4.88e-10	0.48	0.43	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
KIRP	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	7.68	3.21e-13	4.88e-10	0.34	0.43	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
KIRP	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	7.68	3.21e-13	4.88e-10	0.45	0.43	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	7.68	3.21e-13	4.88e-10	0.45	0.43	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
KIRP	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	7.68	3.22e-13	4.89e-10	0.46	0.43	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
KIRP	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-7.68	3.22e-13	4.89e-10	-0.32	-0.43	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
KIRP	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-7.68	3.23e-13	4.9e-10	-0.85	-0.43	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
KIRP	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-7.68	3.24e-13	4.92e-10	-0.36	-0.43	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
KIRP	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	7.68	3.24e-13	4.92e-10	0.48	0.43	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
KIRP	cis	rs4356975	0.899	rs7677996	ENSG00000248763.2	RP13-644M16.5	-7.68	3.25e-13	4.94e-10	-0.47	-0.43	Obesity-related traits;	chr4:69075473	chr4:69066395~69069888:+
KIRP	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	7.68	3.26e-13	4.95e-10	0.53	0.43	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
KIRP	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-7.68	3.26e-13	4.95e-10	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
KIRP	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	7.67	3.29e-13	5e-10	0.5	0.43	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
KIRP	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	7.67	3.32e-13	5.03e-10	0.35	0.43	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
KIRP	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-7.67	3.32e-13	5.03e-10	-0.36	-0.43	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
KIRP	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-7.67	3.32e-13	5.04e-10	-0.55	-0.43	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-7.67	3.33e-13	5.05e-10	-0.36	-0.43	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
KIRP	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	7.67	3.34e-13	5.07e-10	0.44	0.43	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
KIRP	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	7.67	3.35e-13	5.09e-10	0.5	0.43	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
KIRP	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	7.67	3.39e-13	5.13e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
KIRP	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-7.67	3.39e-13	5.13e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	7.67	3.39e-13	5.14e-10	0.5	0.43	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
KIRP	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	7.67	3.41e-13	5.16e-10	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
KIRP	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-7.67	3.44e-13	5.21e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
KIRP	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	7.67	3.46e-13	5.23e-10	0.52	0.43	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
KIRP	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	7.67	3.46e-13	5.23e-10	0.53	0.43	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
KIRP	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	7.67	3.47e-13	5.25e-10	0.45	0.43	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
KIRP	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	7.67	3.47e-13	5.25e-10	0.49	0.43	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
KIRP	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	7.67	3.48e-13	5.26e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
KIRP	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	7.67	3.48e-13	5.27e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
KIRP	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	7.66	3.5e-13	5.29e-10	0.56	0.43	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
KIRP	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	7.66	3.51e-13	5.31e-10	0.35	0.43	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
KIRP	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.66	3.51e-13	5.31e-10	-0.37	-0.43	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	7.66	3.51e-13	5.31e-10	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
KIRP	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	7.66	3.53e-13	5.33e-10	0.5	0.43	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	7.66	3.53e-13	5.33e-10	0.5	0.43	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
KIRP	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	7.66	3.54e-13	5.34e-10	0.49	0.43	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
KIRP	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	7.66	3.56e-13	5.37e-10	0.44	0.43	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
KIRP	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	7.66	3.59e-13	5.43e-10	0.34	0.43	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
KIRP	cis	rs755249	1	rs76841360	ENSG00000237624.1	OXCT2P1	7.66	3.6e-13	5.43e-10	0.69	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39514956~39516490:+
KIRP	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-7.66	3.6e-13	5.44e-10	-0.34	-0.43	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
KIRP	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-7.66	3.61e-13	5.46e-10	-0.54	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
KIRP	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	7.66	3.62e-13	5.47e-10	0.28	0.43	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
KIRP	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.66	3.62e-13	5.47e-10	0.55	0.43	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7.66	3.62e-13	5.47e-10	0.55	0.43	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
KIRP	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	7.66	3.63e-13	5.47e-10	0.5	0.43	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	7.66	3.63e-13	5.47e-10	0.5	0.43	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	7.66	3.63e-13	5.47e-10	0.5	0.43	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-7.66	3.64e-13	5.49e-10	-0.36	-0.43	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	7.66	3.64e-13	5.5e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	7.66	3.64e-13	5.5e-10	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
KIRP	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-7.66	3.66e-13	5.52e-10	-0.39	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
KIRP	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	7.66	3.67e-13	5.53e-10	0.48	0.43	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
KIRP	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	7.66	3.67e-13	5.53e-10	0.48	0.43	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
KIRP	cis	rs832187	0.704	rs3774720	ENSG00000280620.1	SCAANT1	7.66	3.69e-13	5.56e-10	0.48	0.43	Schizophrenia;	chr3:63966089	chr3:63911518~63911772:-
KIRP	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-7.66	3.7e-13	5.59e-10	-0.36	-0.43	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
KIRP	cis	rs4356975	0.899	rs7677996	ENSG00000250696.4	RP11-704M14.1	7.66	3.71e-13	5.6e-10	0.42	0.43	Obesity-related traits;	chr4:69075473	chr4:69182100~69216766:+
KIRP	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-7.65	3.73e-13	5.62e-10	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
KIRP	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	7.65	3.74e-13	5.64e-10	0.45	0.43	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
KIRP	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	7.65	3.75e-13	5.65e-10	0.56	0.43	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
KIRP	cis	rs11079159	0.606	rs4239192	ENSG00000263096.1	RP11-515O17.2	7.65	3.76e-13	5.66e-10	0.5	0.43	QRS duration;	chr17:55299143	chr17:55271504~55273653:-
KIRP	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	7.65	3.76e-13	5.66e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	7.65	3.76e-13	5.66e-10	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
KIRP	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-7.65	3.77e-13	5.68e-10	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
KIRP	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	7.65	3.79e-13	5.7e-10	0.57	0.43	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
KIRP	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-7.65	3.79e-13	5.7e-10	-0.54	-0.43	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
KIRP	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.65	3.8e-13	5.73e-10	-0.49	-0.43	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
KIRP	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	7.65	3.82e-13	5.75e-10	0.5	0.43	Height;	chr11:118808920	chr11:118688039~118690600:-
KIRP	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	7.65	3.82e-13	5.75e-10	0.42	0.43	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
KIRP	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.65	3.84e-13	5.78e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
KIRP	cis	rs2283792	0.792	rs151680	ENSG00000228050.1	TOP3BP1	7.65	3.86e-13	5.8e-10	0.47	0.43	Multiple sclerosis;	chr22:21918869	chr22:22223187~22224566:-
KIRP	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	7.65	3.86e-13	5.81e-10	0.94	0.43	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	7.65	3.86e-13	5.81e-10	0.94	0.43	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	7.65	3.86e-13	5.81e-10	0.94	0.43	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
KIRP	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	7.65	3.86e-13	5.81e-10	0.5	0.43	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
KIRP	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-7.65	3.87e-13	5.83e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-7.65	3.87e-13	5.83e-10	-0.39	-0.43	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
KIRP	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.65	3.88e-13	5.84e-10	-0.47	-0.43	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.65	3.88e-13	5.84e-10	0.47	0.43	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
KIRP	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.65	3.89e-13	5.84e-10	-0.34	-0.43	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
KIRP	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	7.65	3.89e-13	5.85e-10	0.55	0.43	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
KIRP	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	7.65	3.91e-13	5.87e-10	0.48	0.43	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
KIRP	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7.65	3.92e-13	5.9e-10	-0.42	-0.43	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
KIRP	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-7.65	3.93e-13	5.91e-10	-0.5	-0.43	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
KIRP	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-7.65	3.94e-13	5.93e-10	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
KIRP	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	7.65	3.95e-13	5.93e-10	0.55	0.43	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
KIRP	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-7.65	3.96e-13	5.95e-10	-0.54	-0.43	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-7.65	3.96e-13	5.95e-10	-0.54	-0.43	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
KIRP	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	7.64	3.97e-13	5.96e-10	0.52	0.43	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
KIRP	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-7.64	4.01e-13	6.02e-10	-0.54	-0.43	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
KIRP	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	7.64	4.03e-13	6.06e-10	0.34	0.43	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
KIRP	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	7.64	4.06e-13	6.1e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	7.64	4.06e-13	6.1e-10	0.47	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
KIRP	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	7.64	4.07e-13	6.11e-10	0.48	0.43	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
KIRP	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	7.64	4.08e-13	6.13e-10	0.55	0.43	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
KIRP	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	7.64	4.1e-13	6.16e-10	0.54	0.43	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
KIRP	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-7.64	4.12e-13	6.17e-10	-0.51	-0.43	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
KIRP	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-7.64	4.15e-13	6.22e-10	-0.31	-0.43	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-7.64	4.15e-13	6.22e-10	-0.31	-0.43	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
KIRP	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	7.64	4.16e-13	6.23e-10	0.41	0.43	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	7.64	4.16e-13	6.23e-10	0.41	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
KIRP	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-7.64	4.16e-13	6.23e-10	-0.36	-0.43	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-7.64	4.16e-13	6.23e-10	-0.36	-0.43	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
KIRP	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	7.64	4.18e-13	6.26e-10	0.5	0.43	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
KIRP	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-7.64	4.18e-13	6.27e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-7.64	4.18e-13	6.27e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-7.64	4.18e-13	6.27e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-7.64	4.18e-13	6.27e-10	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-7.64	4.19e-13	6.27e-10	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
KIRP	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-7.64	4.19e-13	6.28e-10	-0.48	-0.43	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
KIRP	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	7.64	4.22e-13	6.31e-10	0.33	0.43	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
KIRP	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-7.63	4.24e-13	6.35e-10	-0.47	-0.43	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
KIRP	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-7.63	4.24e-13	6.35e-10	-0.49	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
KIRP	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-7.63	4.25e-13	6.35e-10	-0.45	-0.43	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
KIRP	cis	rs832187	0.594	rs832197	ENSG00000280620.1	SCAANT1	-7.63	4.25e-13	6.36e-10	-0.48	-0.43	Schizophrenia;	chr3:63898616	chr3:63911518~63911772:-
KIRP	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	7.63	4.27e-13	6.38e-10	0.55	0.43	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
KIRP	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-7.63	4.28e-13	6.4e-10	-0.48	-0.43	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
KIRP	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-7.63	4.28e-13	6.4e-10	-0.31	-0.43	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
KIRP	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-7.63	4.29e-13	6.41e-10	-0.54	-0.43	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-7.63	4.29e-13	6.41e-10	-0.54	-0.43	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-7.63	4.29e-13	6.41e-10	-0.54	-0.43	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
KIRP	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	7.63	4.29e-13	6.42e-10	0.48	0.43	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	7.63	4.31e-13	6.44e-10	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
KIRP	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	7.63	4.31e-13	6.45e-10	0.48	0.43	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	7.63	4.31e-13	6.45e-10	0.48	0.43	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	7.63	4.32e-13	6.46e-10	0.38	0.43	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
KIRP	cis	rs4578769	0.55	rs12958492	ENSG00000266850.1	RP11-370A5.1	7.63	4.35e-13	6.5e-10	0.52	0.43	Eosinophil percentage of white cells;	chr18:22988974	chr18:22723491~22907721:-
KIRP	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	7.63	4.35e-13	6.5e-10	0.57	0.43	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
KIRP	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-7.63	4.37e-13	6.52e-10	-0.5	-0.43	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
KIRP	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-7.63	4.38e-13	6.54e-10	-0.55	-0.43	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
KIRP	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-7.63	4.4e-13	6.56e-10	-0.54	-0.43	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
KIRP	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	7.63	4.4e-13	6.56e-10	0.55	0.43	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
KIRP	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-7.63	4.42e-13	6.59e-10	-0.41	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
KIRP	cis	rs755249	0.917	rs61781392	ENSG00000237624.1	OXCT2P1	7.63	4.43e-13	6.61e-10	0.7	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.917	rs61232586	ENSG00000237624.1	OXCT2P1	7.63	4.43e-13	6.61e-10	0.7	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.917	rs61781393	ENSG00000237624.1	OXCT2P1	7.63	4.43e-13	6.61e-10	0.7	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39514956~39516490:+
KIRP	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-7.63	4.43e-13	6.61e-10	-0.36	-0.43	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
KIRP	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-7.63	4.45e-13	6.63e-10	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
KIRP	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-7.63	4.47e-13	6.67e-10	-0.48	-0.43	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
KIRP	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	7.63	4.48e-13	6.68e-10	0.45	0.43	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
KIRP	cis	rs832187	0.813	rs704370	ENSG00000280620.1	SCAANT1	-7.63	4.49e-13	6.69e-10	-0.47	-0.43	Schizophrenia;	chr3:63882574	chr3:63911518~63911772:-
KIRP	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-7.62	4.51e-13	6.72e-10	-0.38	-0.43	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-7.62	4.51e-13	6.72e-10	-0.38	-0.43	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
KIRP	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-7.62	4.53e-13	6.76e-10	-0.44	-0.43	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
KIRP	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	7.62	4.54e-13	6.76e-10	0.36	0.43	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
KIRP	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.62	4.55e-13	6.78e-10	-0.46	-0.43	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
KIRP	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-7.62	4.57e-13	6.8e-10	-0.36	-0.43	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
KIRP	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	7.62	4.57e-13	6.81e-10	0.44	0.43	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
KIRP	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	7.62	4.59e-13	6.83e-10	0.32	0.43	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
KIRP	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	7.62	4.62e-13	6.87e-10	0.36	0.43	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
KIRP	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	7.62	4.63e-13	6.9e-10	0.54	0.43	Depression;	chr6:28314871	chr6:28943877~28944537:+
KIRP	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	7.62	4.64e-13	6.91e-10	0.67	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	7.62	4.65e-13	6.91e-10	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
KIRP	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	7.62	4.65e-13	6.91e-10	0.55	0.43	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
KIRP	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	7.62	4.66e-13	6.92e-10	0.48	0.43	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
KIRP	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	7.62	4.66e-13	6.94e-10	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	7.62	4.66e-13	6.94e-10	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	7.62	4.66e-13	6.94e-10	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
KIRP	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-7.62	4.69e-13	6.98e-10	-0.34	-0.43	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
KIRP	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-7.62	4.7e-13	6.99e-10	-0.37	-0.43	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
KIRP	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-7.62	4.7e-13	6.99e-10	-0.31	-0.43	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
KIRP	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	7.62	4.72e-13	7.01e-10	0.46	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
KIRP	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-7.62	4.74e-13	7.04e-10	-0.31	-0.43	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
KIRP	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-7.62	4.74e-13	7.04e-10	-0.31	-0.43	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
KIRP	cis	rs944002	1	rs62006947	ENSG00000259444.1	RP11-736N17.8	7.62	4.76e-13	7.07e-10	0.47	0.43	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099033	chr14:103094723~103098885:+
KIRP	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	7.62	4.76e-13	7.07e-10	0.41	0.43	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
KIRP	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	7.61	4.84e-13	7.17e-10	0.56	0.43	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
KIRP	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	7.61	4.84e-13	7.19e-10	0.48	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	7.61	4.84e-13	7.19e-10	0.48	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
KIRP	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	7.61	4.84e-13	7.19e-10	0.54	0.43	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
KIRP	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	7.61	4.85e-13	7.19e-10	0.44	0.43	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
KIRP	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	7.61	4.89e-13	7.25e-10	0.48	0.43	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
KIRP	cis	rs11079159	0.5	rs7223165	ENSG00000263096.1	RP11-515O17.2	7.61	4.9e-13	7.27e-10	0.52	0.43	QRS duration;	chr17:55286477	chr17:55271504~55273653:-
KIRP	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-7.61	4.95e-13	7.34e-10	-0.56	-0.43	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
KIRP	cis	rs2980439	0.783	rs2948305	ENSG00000253981.4	ALG1L13P	7.61	5.01e-13	7.42e-10	0.36	0.43	Neuroticism;	chr8:8241055	chr8:8236003~8244667:-
KIRP	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-7.61	5.01e-13	7.42e-10	-0.55	-0.43	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
KIRP	cis	rs1005277	0.505	rs10827836	ENSG00000151963.4	RP11-775A3.1	7.61	5.03e-13	7.45e-10	0.49	0.43	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:37883594~37884109:+
KIRP	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-7.61	5.03e-13	7.45e-10	-0.62	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
KIRP	cis	rs67311347	1	rs1454497	ENSG00000230274.1	PGAM1P3	-7.61	5.04e-13	7.46e-10	-0.41	-0.43	Renal cell carcinoma;	chr3:40454835	chr3:40322715~40323279:-
KIRP	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	7.61	5.06e-13	7.48e-10	0.77	0.43	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
KIRP	cis	rs950027	0.62	rs1145089	ENSG00000259433.2	CTD-2651B20.4	-7.61	5.07e-13	7.5e-10	-0.36	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45330209~45332634:-
KIRP	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	7.61	5.07e-13	7.51e-10	0.72	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	7.61	5.07e-13	7.51e-10	0.72	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	7.61	5.07e-13	7.51e-10	0.72	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	7.61	5.07e-13	7.51e-10	0.72	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
KIRP	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	7.61	5.08e-13	7.51e-10	0.28	0.43	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	7.61	5.08e-13	7.51e-10	0.28	0.43	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
KIRP	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-7.61	5.1e-13	7.54e-10	-0.57	-0.43	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
KIRP	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-7.61	5.11e-13	7.55e-10	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
KIRP	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-7.61	5.11e-13	7.55e-10	-0.44	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
KIRP	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	7.6	5.12e-13	7.57e-10	0.46	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
KIRP	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.6	5.12e-13	7.57e-10	0.35	0.43	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
KIRP	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	7.6	5.15e-13	7.61e-10	0.37	0.43	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
KIRP	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	7.6	5.17e-13	7.64e-10	0.55	0.43	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
KIRP	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	7.6	5.21e-13	7.7e-10	0.56	0.43	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	7.6	5.21e-13	7.7e-10	0.56	0.43	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
KIRP	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-7.6	5.25e-13	7.75e-10	-0.54	-0.43	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
KIRP	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-7.6	5.27e-13	7.78e-10	-0.43	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
KIRP	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-7.6	5.28e-13	7.8e-10	-0.61	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
KIRP	cis	rs4936099	0.766	rs10894192	ENSG00000175773.11	RP11-121M22.1	7.6	5.29e-13	7.81e-10	0.42	0.42	Optic cup area;Vertical cup-disc ratio;	chr11:130396222	chr11:130314993~130403657:+
KIRP	cis	rs950027	0.62	rs2453533	ENSG00000259433.2	CTD-2651B20.4	-7.6	5.29e-13	7.81e-10	-0.36	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45330209~45332634:-
KIRP	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-7.6	5.29e-13	7.82e-10	-0.54	-0.42	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
KIRP	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-7.6	5.31e-13	7.84e-10	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
KIRP	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-7.6	5.31e-13	7.84e-10	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
KIRP	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-7.6	5.32e-13	7.85e-10	-0.5	-0.42	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
KIRP	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-7.6	5.32e-13	7.85e-10	-0.5	-0.42	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
KIRP	cis	rs4578769	0.55	rs4474794	ENSG00000266850.1	RP11-370A5.1	7.6	5.36e-13	7.9e-10	0.52	0.42	Eosinophil percentage of white cells;	chr18:22987010	chr18:22723491~22907721:-
KIRP	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-7.6	5.38e-13	7.93e-10	-0.35	-0.42	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-7.6	5.4e-13	7.96e-10	-0.46	-0.42	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
KIRP	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	7.6	5.42e-13	7.98e-10	0.58	0.42	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
KIRP	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-7.6	5.42e-13	7.98e-10	-0.45	-0.42	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
KIRP	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-7.59	5.45e-13	8.03e-10	-0.55	-0.42	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
KIRP	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	7.59	5.49e-13	8.09e-10	0.45	0.42	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
KIRP	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-7.59	5.51e-13	8.11e-10	-0.62	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-7.59	5.51e-13	8.11e-10	-0.62	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-7.59	5.51e-13	8.11e-10	-0.62	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-7.59	5.51e-13	8.11e-10	-0.62	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
KIRP	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-7.59	5.52e-13	8.13e-10	-0.52	-0.42	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
KIRP	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-7.59	5.52e-13	8.13e-10	-0.52	-0.42	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
KIRP	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	7.59	5.56e-13	8.18e-10	0.7	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
KIRP	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	7.59	5.57e-13	8.19e-10	0.54	0.42	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
KIRP	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	7.59	5.58e-13	8.2e-10	0.34	0.42	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
KIRP	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	7.59	5.61e-13	8.24e-10	0.36	0.42	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	7.59	5.61e-13	8.24e-10	0.36	0.42	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	7.59	5.61e-13	8.24e-10	0.36	0.42	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	7.59	5.61e-13	8.24e-10	0.36	0.42	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
KIRP	cis	rs67311347	1	rs9849992	ENSG00000230274.1	PGAM1P3	7.59	5.61e-13	8.24e-10	0.42	0.42	Renal cell carcinoma;	chr3:40360649	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs11715214	ENSG00000230274.1	PGAM1P3	7.59	5.61e-13	8.24e-10	0.42	0.42	Renal cell carcinoma;	chr3:40361513	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9860162	ENSG00000230274.1	PGAM1P3	7.59	5.61e-13	8.24e-10	0.42	0.42	Renal cell carcinoma;	chr3:40362384	chr3:40322715~40323279:-
KIRP	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-7.59	5.61e-13	8.24e-10	-0.38	-0.42	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-7.59	5.61e-13	8.24e-10	-0.38	-0.42	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
KIRP	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-7.59	5.62e-13	8.26e-10	-0.37	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
KIRP	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	7.59	5.66e-13	8.32e-10	0.44	0.42	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
KIRP	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-7.59	5.67e-13	8.32e-10	-0.35	-0.42	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
KIRP	cis	rs11079159	0.628	rs884303	ENSG00000263096.1	RP11-515O17.2	7.59	5.67e-13	8.33e-10	0.51	0.42	QRS duration;	chr17:55289939	chr17:55271504~55273653:-
KIRP	cis	rs11079159	0.628	rs884301	ENSG00000263096.1	RP11-515O17.2	7.59	5.67e-13	8.33e-10	0.51	0.42	QRS duration;	chr17:55290103	chr17:55271504~55273653:-
KIRP	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	7.59	5.69e-13	8.35e-10	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
KIRP	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	7.59	5.74e-13	8.43e-10	0.36	0.42	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
KIRP	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	7.58	5.83e-13	8.54e-10	0.55	0.42	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
KIRP	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-7.58	5.92e-13	8.67e-10	-0.31	-0.42	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
KIRP	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-7.58	5.92e-13	8.67e-10	-0.31	-0.42	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
KIRP	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	7.58	5.93e-13	8.68e-10	0.52	0.42	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
KIRP	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	7.58	5.93e-13	8.68e-10	0.52	0.42	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	7.58	5.97e-13	8.74e-10	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
KIRP	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	7.58	5.99e-13	8.77e-10	0.45	0.42	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
KIRP	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-7.58	6.01e-13	8.79e-10	-0.54	-0.42	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
KIRP	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-7.58	6.03e-13	8.82e-10	-0.49	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
KIRP	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-7.58	6.03e-13	8.82e-10	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
KIRP	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	7.58	6.04e-13	8.83e-10	0.48	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	7.58	6.04e-13	8.83e-10	0.48	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
KIRP	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-7.58	6.05e-13	8.85e-10	-0.51	-0.42	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
KIRP	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-7.58	6.06e-13	8.86e-10	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
KIRP	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	7.58	6.07e-13	8.88e-10	0.72	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	7.58	6.07e-13	8.88e-10	0.72	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	7.58	6.07e-13	8.88e-10	0.72	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
KIRP	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	7.58	6.09e-13	8.91e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
KIRP	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	7.58	6.09e-13	8.91e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
KIRP	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	7.58	6.09e-13	8.91e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	7.58	6.09e-13	8.91e-10	0.34	0.42	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
KIRP	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	7.58	6.09e-13	8.91e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-7.58	6.12e-13	8.94e-10	-0.49	-0.42	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-7.58	6.12e-13	8.94e-10	-0.49	-0.42	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-7.58	6.12e-13	8.94e-10	-0.49	-0.42	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	7.58	6.14e-13	8.97e-10	0.49	0.42	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	7.58	6.14e-13	8.97e-10	0.49	0.42	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
KIRP	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-7.57	6.2e-13	9.05e-10	-0.38	-0.42	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
KIRP	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.57	6.25e-13	9.12e-10	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
KIRP	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	7.57	6.27e-13	9.15e-10	0.47	0.42	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
KIRP	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-7.57	6.37e-13	9.3e-10	-0.46	-0.42	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-7.57	6.37e-13	9.3e-10	-0.46	-0.42	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-7.57	6.37e-13	9.3e-10	-0.46	-0.42	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
KIRP	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	7.57	6.37e-13	9.3e-10	0.61	0.42	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
KIRP	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	7.57	6.41e-13	9.34e-10	0.54	0.42	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
KIRP	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	7.57	6.47e-13	9.43e-10	0.27	0.42	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
KIRP	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	7.57	6.48e-13	9.45e-10	0.42	0.42	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
KIRP	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-7.57	6.52e-13	9.5e-10	-0.52	-0.42	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
KIRP	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-7.57	6.52e-13	9.5e-10	-0.31	-0.42	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-7.57	6.52e-13	9.5e-10	-0.31	-0.42	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-7.57	6.52e-13	9.5e-10	-0.31	-0.42	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	7.57	6.52e-13	9.5e-10	0.31	0.42	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
KIRP	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-7.57	6.52e-13	9.5e-10	-0.31	-0.42	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
KIRP	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-7.56	6.59e-13	9.6e-10	-0.49	-0.42	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
KIRP	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	7.56	6.62e-13	9.64e-10	0.27	0.42	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
KIRP	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	7.56	6.63e-13	9.65e-10	0.44	0.42	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
KIRP	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-7.56	6.63e-13	9.66e-10	-0.44	-0.42	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
KIRP	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-7.56	6.67e-13	9.71e-10	-0.44	-0.42	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
KIRP	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	7.56	6.68e-13	9.73e-10	0.47	0.42	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
KIRP	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	7.56	6.71e-13	9.76e-10	0.58	0.42	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	7.56	6.77e-13	9.84e-10	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
KIRP	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	7.56	6.77e-13	9.84e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
KIRP	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	7.56	6.77e-13	9.84e-10	0.34	0.42	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
KIRP	cis	rs4578769	0.569	rs3851822	ENSG00000266850.1	RP11-370A5.1	-7.56	6.79e-13	9.87e-10	-0.5	-0.42	Eosinophil percentage of white cells;	chr18:22882829	chr18:22723491~22907721:-
KIRP	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	7.56	6.8e-13	9.89e-10	0.77	0.42	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
KIRP	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-7.56	6.84e-13	9.94e-10	-0.54	-0.42	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-7.56	6.84e-13	9.94e-10	-0.54	-0.42	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
KIRP	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	7.56	6.85e-13	9.95e-10	0.41	0.42	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	7.56	6.85e-13	9.95e-10	0.41	0.42	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	7.56	6.85e-13	9.95e-10	0.41	0.42	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
KIRP	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	7.56	6.87e-13	9.98e-10	0.36	0.42	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
KIRP	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	7.56	6.88e-13	1e-09	0.57	0.42	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
KIRP	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	7.56	6.89e-13	1e-09	0.32	0.42	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
KIRP	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	7.56	6.9e-13	1e-09	0.45	0.42	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
KIRP	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-7.56	6.9e-13	1e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-7.56	6.9e-13	1e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-7.56	6.93e-13	1.01e-09	-0.49	-0.42	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-7.56	6.93e-13	1.01e-09	-0.49	-0.42	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-7.56	6.93e-13	1.01e-09	-0.49	-0.42	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
KIRP	cis	rs17082664	0.79	rs6935362	ENSG00000226193.1	RP3-398G3.5	-7.56	7e-13	1.02e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152432119	chr6:152402398~152404966:+
KIRP	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	7.55	7.02e-13	1.02e-09	0.55	0.42	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
KIRP	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	7.55	7.05e-13	1.02e-09	0.49	0.42	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
KIRP	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-7.55	7.14e-13	1.04e-09	-0.37	-0.42	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
KIRP	cis	rs4578769	0.531	rs9951973	ENSG00000266850.1	RP11-370A5.1	-7.55	7.15e-13	1.04e-09	-0.52	-0.42	Eosinophil percentage of white cells;	chr18:22974353	chr18:22723491~22907721:-
KIRP	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	7.55	7.17e-13	1.04e-09	0.55	0.42	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	7.55	7.17e-13	1.04e-09	0.55	0.42	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	7.55	7.17e-13	1.04e-09	0.55	0.42	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
KIRP	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	7.55	7.28e-13	1.05e-09	0.49	0.42	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	7.55	7.28e-13	1.05e-09	0.49	0.42	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	7.55	7.28e-13	1.05e-09	0.49	0.42	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	7.55	7.28e-13	1.05e-09	0.49	0.42	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
KIRP	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	7.55	7.3e-13	1.06e-09	0.41	0.42	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	7.55	7.3e-13	1.06e-09	0.41	0.42	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	7.55	7.3e-13	1.06e-09	0.41	0.42	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	7.55	7.3e-13	1.06e-09	0.41	0.42	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	7.55	7.3e-13	1.06e-09	0.41	0.42	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
KIRP	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-7.55	7.33e-13	1.06e-09	-0.66	-0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
KIRP	cis	rs8081395	0.502	rs12947232	ENSG00000266992.1	DHX40P1	-7.55	7.37e-13	1.07e-09	-0.48	-0.42	White blood cell count;	chr17:59714483	chr17:59976009~60002384:-
KIRP	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-7.55	7.38e-13	1.07e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
KIRP	cis	rs67311347	0.911	rs6776044	ENSG00000230274.1	PGAM1P3	7.55	7.38e-13	1.07e-09	0.42	0.42	Renal cell carcinoma;	chr3:40336012	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-7.55	7.43e-13	1.07e-09	-0.56	-0.42	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
KIRP	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-7.55	7.44e-13	1.07e-09	-0.41	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
KIRP	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	7.55	7.45e-13	1.08e-09	0.57	0.42	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-7.55	7.45e-13	1.08e-09	-0.57	-0.42	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
KIRP	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	7.54	7.49e-13	1.08e-09	0.53	0.42	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
KIRP	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	7.54	7.5e-13	1.08e-09	0.57	0.42	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
KIRP	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-7.54	7.5e-13	1.08e-09	-0.54	-0.42	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
KIRP	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	7.54	7.57e-13	1.09e-09	0.54	0.42	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
KIRP	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	7.54	7.63e-13	1.1e-09	0.36	0.42	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	7.54	7.63e-13	1.1e-09	0.36	0.42	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	7.54	7.63e-13	1.1e-09	0.36	0.42	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	7.54	7.63e-13	1.1e-09	0.36	0.42	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
KIRP	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	7.54	7.65e-13	1.1e-09	0.58	0.42	Height;	chr6:109391084	chr6:109382795~109383666:+
KIRP	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-7.54	7.66e-13	1.1e-09	-0.61	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
KIRP	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	7.54	7.69e-13	1.11e-09	0.38	0.42	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
KIRP	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	7.54	7.72e-13	1.11e-09	0.55	0.42	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	7.54	7.72e-13	1.11e-09	0.55	0.42	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	7.54	7.72e-13	1.11e-09	0.55	0.42	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	7.54	7.72e-13	1.11e-09	0.55	0.42	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
KIRP	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	7.54	7.76e-13	1.12e-09	0.84	0.42	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	7.54	7.76e-13	1.12e-09	0.84	0.42	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
KIRP	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-7.54	7.77e-13	1.12e-09	-0.4	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
KIRP	cis	rs1005277	0.683	rs7923868	ENSG00000151963.4	RP11-775A3.1	-7.54	7.82e-13	1.12e-09	-0.47	-0.42	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:37883594~37884109:+
KIRP	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-7.54	7.85e-13	1.13e-09	-0.42	-0.42	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
KIRP	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.54	7.86e-13	1.13e-09	0.51	0.42	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
KIRP	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	7.54	7.92e-13	1.14e-09	0.66	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	7.54	7.92e-13	1.14e-09	0.66	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
KIRP	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	7.54	7.92e-13	1.14e-09	0.66	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
KIRP	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	7.54	7.92e-13	1.14e-09	0.66	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
KIRP	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-7.54	7.92e-13	1.14e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
KIRP	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	7.54	7.92e-13	1.14e-09	0.39	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
KIRP	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	7.54	7.93e-13	1.14e-09	0.54	0.42	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-7.54	7.93e-13	1.14e-09	-0.54	-0.42	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
KIRP	cis	rs4578769	0.55	rs11082225	ENSG00000266850.1	RP11-370A5.1	7.53	8e-13	1.15e-09	0.52	0.42	Eosinophil percentage of white cells;	chr18:22963794	chr18:22723491~22907721:-
KIRP	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-7.53	8.06e-13	1.16e-09	-0.35	-0.42	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
KIRP	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	7.53	8.06e-13	1.16e-09	0.56	0.42	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
KIRP	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	7.53	8.12e-13	1.17e-09	0.44	0.42	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
KIRP	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-7.53	8.18e-13	1.17e-09	-0.37	-0.42	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.53	8.19e-13	1.18e-09	-0.35	-0.42	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
KIRP	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-7.53	8.19e-13	1.18e-09	-0.75	-0.42	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
KIRP	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	7.53	8.2e-13	1.18e-09	0.45	0.42	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	7.53	8.21e-13	1.18e-09	0.49	0.42	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
KIRP	cis	rs4638749	0.588	rs13401731	ENSG00000225328.1	AC019100.3	-7.53	8.22e-13	1.18e-09	-0.52	-0.42	Blood pressure;	chr2:108268884	chr2:108167748~108217841:-
KIRP	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	7.53	8.23e-13	1.18e-09	0.42	0.42	Axial length;	chr3:53815483	chr3:53797764~53798019:-
KIRP	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-7.53	8.23e-13	1.18e-09	-0.35	-0.42	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
KIRP	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	7.53	8.23e-13	1.18e-09	0.44	0.42	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
KIRP	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-7.53	8.24e-13	1.18e-09	-0.38	-0.42	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
KIRP	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	7.53	8.27e-13	1.19e-09	0.55	0.42	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
KIRP	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	7.53	8.3e-13	1.19e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
KIRP	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	7.53	8.32e-13	1.19e-09	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
KIRP	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-7.53	8.33e-13	1.19e-09	-0.54	-0.42	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
KIRP	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-7.53	8.35e-13	1.2e-09	-0.39	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-7.53	8.35e-13	1.2e-09	-0.39	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
KIRP	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	7.53	8.41e-13	1.21e-09	0.48	0.42	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
KIRP	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-7.53	8.41e-13	1.21e-09	-0.56	-0.42	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
KIRP	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	7.53	8.44e-13	1.21e-09	0.4	0.42	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
KIRP	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	7.53	8.46e-13	1.21e-09	0.81	0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
KIRP	cis	rs67311347	1	rs962847	ENSG00000230274.1	PGAM1P3	-7.52	8.47e-13	1.21e-09	-0.41	-0.42	Renal cell carcinoma;	chr3:40453665	chr3:40322715~40323279:-
KIRP	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-7.52	8.47e-13	1.21e-09	-0.52	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
KIRP	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.52	8.49e-13	1.22e-09	0.45	0.42	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
KIRP	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-7.52	8.5e-13	1.22e-09	-0.39	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
KIRP	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	7.52	8.51e-13	1.22e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
KIRP	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-7.52	8.56e-13	1.22e-09	-0.48	-0.42	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
KIRP	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	7.52	8.57e-13	1.23e-09	0.49	0.42	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
KIRP	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	7.52	8.57e-13	1.23e-09	0.36	0.42	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
KIRP	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-7.52	8.57e-13	1.23e-09	-0.54	-0.42	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-7.52	8.57e-13	1.23e-09	-0.54	-0.42	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
KIRP	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-7.52	8.58e-13	1.23e-09	-0.34	-0.42	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
KIRP	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-7.52	8.59e-13	1.23e-09	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
KIRP	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	7.52	8.6e-13	1.23e-09	0.48	0.42	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
KIRP	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	7.52	8.63e-13	1.23e-09	0.48	0.42	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
KIRP	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	7.52	8.64e-13	1.23e-09	0.57	0.42	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
KIRP	cis	rs67311347	0.868	rs10865895	ENSG00000230274.1	PGAM1P3	7.52	8.66e-13	1.24e-09	0.41	0.42	Renal cell carcinoma;	chr3:40337186	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-7.52	8.69e-13	1.24e-09	-0.54	-0.42	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	7.52	8.71e-13	1.24e-09	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	7.52	8.71e-13	1.24e-09	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
KIRP	cis	rs4578769	0.55	rs6507452	ENSG00000266850.1	RP11-370A5.1	7.52	8.75e-13	1.25e-09	0.53	0.42	Eosinophil percentage of white cells;	chr18:23032275	chr18:22723491~22907721:-
KIRP	cis	rs12962334	0.555	rs9954649	ENSG00000266850.1	RP11-370A5.1	7.52	8.75e-13	1.25e-09	0.53	0.42	Breast cancer;	chr18:23033307	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.505	rs9946743	ENSG00000266850.1	RP11-370A5.1	7.52	8.75e-13	1.25e-09	0.53	0.42	Eosinophil percentage of white cells;	chr18:23033394	chr18:22723491~22907721:-
KIRP	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	7.52	8.81e-13	1.26e-09	0.57	0.42	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
KIRP	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-7.52	8.82e-13	1.26e-09	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
KIRP	cis	rs67311347	0.955	rs6764102	ENSG00000230274.1	PGAM1P3	7.52	8.82e-13	1.26e-09	0.42	0.42	Renal cell carcinoma;	chr3:40336662	chr3:40322715~40323279:-
KIRP	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-7.52	8.89e-13	1.27e-09	-0.46	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
KIRP	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	7.52	8.89e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	7.52	8.89e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	7.52	8.89e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	7.52	8.89e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	7.52	8.89e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
KIRP	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-7.52	8.9e-13	1.27e-09	-0.67	-0.42	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
KIRP	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	7.52	8.91e-13	1.27e-09	0.57	0.42	Height;	chr6:109374782	chr6:109382795~109383666:+
KIRP	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-7.52	8.92e-13	1.27e-09	-0.51	-0.42	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	7.52	8.94e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	7.52	8.94e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	7.52	8.94e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	7.52	8.94e-13	1.27e-09	0.54	0.42	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
KIRP	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	7.52	8.95e-13	1.28e-09	0.45	0.42	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
KIRP	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	7.52	8.95e-13	1.28e-09	0.83	0.42	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
KIRP	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-7.52	8.96e-13	1.28e-09	-0.31	-0.42	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
KIRP	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	7.52	8.97e-13	1.28e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	7.52	8.97e-13	1.28e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
KIRP	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	7.52	8.99e-13	1.28e-09	0.54	0.42	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
KIRP	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-7.51	9.02e-13	1.29e-09	-0.64	-0.42	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
KIRP	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	7.51	9.03e-13	1.29e-09	0.38	0.42	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
KIRP	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-7.51	9.04e-13	1.29e-09	-0.44	-0.42	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
KIRP	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-7.51	9.04e-13	1.29e-09	-0.55	-0.42	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
KIRP	cis	rs67311347	1	rs73080138	ENSG00000230274.1	PGAM1P3	7.51	9.07e-13	1.29e-09	0.41	0.42	Renal cell carcinoma;	chr3:40474926	chr3:40322715~40323279:-
KIRP	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-7.51	9.1e-13	1.3e-09	-0.44	-0.42	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
KIRP	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	7.51	9.13e-13	1.3e-09	0.5	0.42	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
KIRP	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-7.51	9.13e-13	1.3e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
KIRP	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	7.51	9.14e-13	1.3e-09	0.53	0.42	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
KIRP	cis	rs950027	0.62	rs2461700	ENSG00000259433.2	CTD-2651B20.4	-7.51	9.18e-13	1.31e-09	-0.36	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45330209~45332634:-
KIRP	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.51	9.18e-13	1.31e-09	-0.37	-0.42	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
KIRP	cis	rs11647589	0.834	rs9806821	ENSG00000260762.1	ACSM5P1	7.51	9.18e-13	1.31e-09	0.43	0.42	Blood metabolite levels;	chr16:20473857	chr16:20586550~20607107:-
KIRP	cis	rs950027	0.62	rs35861938	ENSG00000259433.2	CTD-2651B20.4	-7.51	9.24e-13	1.31e-09	-0.36	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45330209~45332634:-
KIRP	cis	rs4578769	0.569	rs9951157	ENSG00000266850.1	RP11-370A5.1	7.51	9.26e-13	1.32e-09	0.5	0.42	Eosinophil percentage of white cells;	chr18:22974173	chr18:22723491~22907721:-
KIRP	cis	rs950027	0.596	rs2467865	ENSG00000259433.2	CTD-2651B20.4	-7.51	9.27e-13	1.32e-09	-0.36	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45330209~45332634:-
KIRP	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-7.51	9.3e-13	1.32e-09	-0.45	-0.42	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-7.51	9.3e-13	1.32e-09	-0.45	-0.42	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
KIRP	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-7.51	9.43e-13	1.34e-09	-0.47	-0.42	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
KIRP	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	7.51	9.48e-13	1.35e-09	0.41	0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
KIRP	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	7.51	9.5e-13	1.35e-09	0.56	0.42	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
KIRP	cis	rs67311347	1	rs7641495	ENSG00000230274.1	PGAM1P3	-7.51	9.54e-13	1.35e-09	-0.4	-0.42	Renal cell carcinoma;	chr3:40453199	chr3:40322715~40323279:-
KIRP	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-7.51	9.54e-13	1.35e-09	-0.44	-0.42	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
KIRP	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	7.5	9.61e-13	1.36e-09	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
KIRP	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-7.5	9.64e-13	1.37e-09	-0.46	-0.42	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
KIRP	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-7.5	9.65e-13	1.37e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-7.5	9.66e-13	1.37e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-7.5	9.66e-13	1.37e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
KIRP	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	7.5	9.78e-13	1.39e-09	0.4	0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	7.5	9.78e-13	1.39e-09	0.4	0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
KIRP	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	7.5	9.78e-13	1.39e-09	0.35	0.42	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
KIRP	cis	rs67311347	1	rs17078511	ENSG00000230274.1	PGAM1P3	7.5	9.8e-13	1.39e-09	0.41	0.42	Renal cell carcinoma;	chr3:40354763	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9865348	ENSG00000230274.1	PGAM1P3	7.5	9.8e-13	1.39e-09	0.41	0.42	Renal cell carcinoma;	chr3:40356167	chr3:40322715~40323279:-
KIRP	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	7.5	9.82e-13	1.39e-09	0.47	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
KIRP	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	7.5	9.83e-13	1.39e-09	0.35	0.42	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
KIRP	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	7.5	9.84e-13	1.39e-09	0.44	0.42	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
KIRP	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	7.5	9.88e-13	1.4e-09	0.47	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	7.5	9.88e-13	1.4e-09	0.47	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
KIRP	cis	rs453301	0.624	rs6987558	ENSG00000253981.4	ALG1L13P	7.5	9.95e-13	1.41e-09	0.33	0.42	Joint mobility (Beighton score);	chr8:9005011	chr8:8236003~8244667:-
KIRP	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-7.5	9.95e-13	1.41e-09	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
KIRP	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	7.5	9.96e-13	1.41e-09	0.37	0.42	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
KIRP	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-7.5	9.99e-13	1.41e-09	-0.44	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-7.5	9.99e-13	1.41e-09	-0.44	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
KIRP	cis	rs67311347	0.955	rs4974068	ENSG00000230274.1	PGAM1P3	7.5	1e-12	1.42e-09	0.41	0.42	Renal cell carcinoma;	chr3:40335438	chr3:40322715~40323279:-
KIRP	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-7.5	1.01e-12	1.42e-09	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
KIRP	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	7.5	1.01e-12	1.42e-09	0.44	0.42	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
KIRP	cis	rs9371601	0.798	rs553642	ENSG00000226193.1	RP3-398G3.5	-7.5	1.01e-12	1.43e-09	-0.45	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152430423	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs525210	ENSG00000226193.1	RP3-398G3.5	-7.5	1.01e-12	1.43e-09	-0.45	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152431189	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs521514	ENSG00000226193.1	RP3-398G3.5	-7.5	1.01e-12	1.43e-09	-0.45	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152431613	chr6:152402398~152404966:+
KIRP	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	7.5	1.02e-12	1.43e-09	0.49	0.42	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
KIRP	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-7.5	1.02e-12	1.43e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
KIRP	cis	rs893363	0.594	rs12676	ENSG00000271916.1	RP11-884K10.6	-7.5	1.02e-12	1.43e-09	-0.43	-0.42	Axial length;	chr3:53823776	chr3:53797764~53798019:-
KIRP	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	7.5	1.02e-12	1.44e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
KIRP	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	7.5	1.02e-12	1.44e-09	0.65	0.42	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
KIRP	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	7.49	1.03e-12	1.45e-09	0.34	0.42	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
KIRP	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	7.49	1.03e-12	1.45e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
KIRP	cis	rs67311347	0.955	rs9821036	ENSG00000230274.1	PGAM1P3	7.49	1.04e-12	1.46e-09	0.41	0.42	Renal cell carcinoma;	chr3:40337516	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.869	rs9832311	ENSG00000230274.1	PGAM1P3	7.49	1.04e-12	1.46e-09	0.41	0.42	Renal cell carcinoma;	chr3:40339831	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	7.49	1.04e-12	1.47e-09	0.52	0.42	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
KIRP	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-7.49	1.04e-12	1.47e-09	-0.44	-0.42	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
KIRP	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-7.49	1.04e-12	1.47e-09	-0.47	-0.42	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
KIRP	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	7.49	1.05e-12	1.47e-09	0.5	0.42	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-7.49	1.05e-12	1.48e-09	-0.52	-0.42	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	7.49	1.06e-12	1.49e-09	0.35	0.42	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	7.49	1.06e-12	1.49e-09	0.35	0.42	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
KIRP	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	7.49	1.06e-12	1.49e-09	0.38	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
KIRP	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-7.49	1.06e-12	1.49e-09	-0.35	-0.42	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
KIRP	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	7.49	1.06e-12	1.49e-09	0.54	0.42	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	7.49	1.07e-12	1.5e-09	0.53	0.42	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
KIRP	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	7.49	1.08e-12	1.51e-09	0.54	0.42	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	7.49	1.08e-12	1.51e-09	0.54	0.42	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
KIRP	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	7.49	1.08e-12	1.52e-09	0.6	0.42	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
KIRP	cis	rs950027	0.62	rs1049518	ENSG00000259433.2	CTD-2651B20.4	-7.49	1.09e-12	1.52e-09	-0.35	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45330209~45332634:-
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	7.49	1.09e-12	1.52e-09	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
KIRP	cis	rs67311347	0.956	rs4974029	ENSG00000230274.1	PGAM1P3	7.49	1.09e-12	1.53e-09	0.4	0.42	Renal cell carcinoma;	chr3:40479827	chr3:40322715~40323279:-
KIRP	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.48	1.09e-12	1.53e-09	0.45	0.42	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
KIRP	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	7.48	1.1e-12	1.54e-09	0.69	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	7.48	1.1e-12	1.54e-09	0.57	0.42	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
KIRP	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-7.48	1.1e-12	1.54e-09	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
KIRP	cis	rs11155671	0.53	rs9371504	ENSG00000231760.4	RP11-350J20.5	7.48	1.1e-12	1.54e-09	0.49	0.42	Testicular germ cell tumor;	chr6:149862944	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs9371505	ENSG00000231760.4	RP11-350J20.5	7.48	1.1e-12	1.54e-09	0.49	0.42	Testicular germ cell tumor;	chr6:149863012	chr6:149796151~149826294:-
KIRP	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-7.48	1.11e-12	1.56e-09	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-7.48	1.11e-12	1.56e-09	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-7.48	1.11e-12	1.56e-09	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-7.48	1.11e-12	1.56e-09	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	7.48	1.12e-12	1.57e-09	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
KIRP	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	7.48	1.12e-12	1.57e-09	0.5	0.42	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
KIRP	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	7.48	1.12e-12	1.57e-09	0.58	0.42	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	7.48	1.12e-12	1.57e-09	0.58	0.42	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
KIRP	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-7.48	1.13e-12	1.58e-09	-0.64	-0.42	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-7.48	1.13e-12	1.58e-09	-0.64	-0.42	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-7.48	1.13e-12	1.58e-09	-0.64	-0.42	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
KIRP	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	7.48	1.13e-12	1.58e-09	0.53	0.42	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
KIRP	cis	rs7301826	0.504	rs11061164	ENSG00000256250.1	RP11-989F5.1	-7.48	1.13e-12	1.59e-09	-0.43	-0.42	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810606~130812438:+
KIRP	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	7.48	1.14e-12	1.59e-09	0.57	0.42	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
KIRP	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	7.48	1.14e-12	1.59e-09	0.34	0.42	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
KIRP	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-7.48	1.14e-12	1.6e-09	-0.47	-0.42	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
KIRP	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	7.48	1.14e-12	1.6e-09	0.54	0.42	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
KIRP	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-7.48	1.15e-12	1.6e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
KIRP	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	7.48	1.15e-12	1.6e-09	0.43	0.42	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
KIRP	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	7.48	1.15e-12	1.61e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
KIRP	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	7.48	1.15e-12	1.61e-09	0.48	0.42	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
KIRP	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-7.48	1.15e-12	1.61e-09	-0.52	-0.42	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
KIRP	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	7.48	1.16e-12	1.62e-09	0.49	0.42	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
KIRP	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-7.48	1.16e-12	1.62e-09	-0.31	-0.42	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
KIRP	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-7.47	1.16e-12	1.62e-09	-0.55	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
KIRP	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	7.47	1.16e-12	1.62e-09	0.57	0.42	Height;	chr6:109367528	chr6:109382795~109383666:+
KIRP	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-7.47	1.16e-12	1.62e-09	-0.56	-0.42	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
KIRP	cis	rs755249	0.687	rs41264487	ENSG00000237624.1	OXCT2P1	7.47	1.16e-12	1.62e-09	0.7	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571682	chr1:39514956~39516490:+
KIRP	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	7.47	1.17e-12	1.63e-09	0.54	0.42	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
KIRP	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	7.47	1.17e-12	1.63e-09	0.49	0.42	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	7.47	1.17e-12	1.63e-09	0.49	0.42	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	7.47	1.17e-12	1.63e-09	0.49	0.42	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
KIRP	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	7.47	1.18e-12	1.65e-09	0.46	0.42	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
KIRP	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	7.47	1.18e-12	1.65e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
KIRP	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	7.47	1.19e-12	1.66e-09	0.45	0.42	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	7.47	1.19e-12	1.66e-09	0.45	0.42	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	7.47	1.19e-12	1.66e-09	0.45	0.42	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	7.47	1.19e-12	1.66e-09	0.45	0.42	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
KIRP	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	7.47	1.2e-12	1.68e-09	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
KIRP	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-7.47	1.2e-12	1.68e-09	-0.53	-0.42	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
KIRP	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	7.47	1.2e-12	1.68e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	7.47	1.2e-12	1.68e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
KIRP	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	7.47	1.21e-12	1.68e-09	0.5	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
KIRP	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-7.47	1.21e-12	1.68e-09	-0.46	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
KIRP	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	7.47	1.21e-12	1.69e-09	0.45	0.42	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
KIRP	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	7.47	1.22e-12	1.69e-09	0.48	0.42	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
KIRP	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	7.47	1.22e-12	1.69e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	7.47	1.22e-12	1.69e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
KIRP	cis	rs11647589	0.553	rs7195201	ENSG00000260762.1	ACSM5P1	7.47	1.22e-12	1.7e-09	0.43	0.42	Blood metabolite levels;	chr16:20467280	chr16:20586550~20607107:-
KIRP	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	7.47	1.22e-12	1.7e-09	0.45	0.42	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-7.47	1.22e-12	1.7e-09	-0.54	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
KIRP	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-7.47	1.23e-12	1.7e-09	-0.54	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
KIRP	cis	rs17082664	0.79	rs6909684	ENSG00000226193.1	RP3-398G3.5	-7.47	1.23e-12	1.71e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152424998	chr6:152402398~152404966:+
KIRP	cis	rs17082664	0.79	rs9479314	ENSG00000226193.1	RP3-398G3.5	-7.47	1.23e-12	1.71e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152426186	chr6:152402398~152404966:+
KIRP	cis	rs17082664	0.79	rs17082676	ENSG00000226193.1	RP3-398G3.5	-7.47	1.23e-12	1.71e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152435059	chr6:152402398~152404966:+
KIRP	cis	rs17082664	0.85	rs7769359	ENSG00000226193.1	RP3-398G3.5	-7.47	1.23e-12	1.71e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152435358	chr6:152402398~152404966:+
KIRP	cis	rs17082664	0.79	rs9479316	ENSG00000226193.1	RP3-398G3.5	-7.47	1.23e-12	1.71e-09	-0.63	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152436898	chr6:152402398~152404966:+
KIRP	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-7.47	1.23e-12	1.72e-09	-0.37	-0.42	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	7.47	1.23e-12	1.72e-09	0.49	0.42	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	7.46	1.24e-12	1.72e-09	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
KIRP	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	7.46	1.24e-12	1.72e-09	0.54	0.42	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
KIRP	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	7.46	1.24e-12	1.73e-09	0.47	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
KIRP	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-7.46	1.25e-12	1.73e-09	-0.52	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
KIRP	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	7.46	1.25e-12	1.74e-09	0.45	0.42	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
KIRP	cis	rs1005277	0.522	rs289643	ENSG00000151963.4	RP11-775A3.1	-7.46	1.26e-12	1.75e-09	-0.45	-0.42	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:37883594~37884109:+
KIRP	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-7.46	1.26e-12	1.75e-09	-0.37	-0.42	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
KIRP	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-7.46	1.26e-12	1.75e-09	-0.38	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
KIRP	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-7.46	1.27e-12	1.76e-09	-0.53	-0.42	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	7.46	1.27e-12	1.76e-09	0.49	0.42	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	7.46	1.27e-12	1.76e-09	0.49	0.42	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	7.46	1.27e-12	1.76e-09	0.49	0.42	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
KIRP	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	7.46	1.28e-12	1.77e-09	0.5	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
KIRP	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-7.46	1.28e-12	1.78e-09	-0.35	-0.42	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
KIRP	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-7.46	1.28e-12	1.78e-09	-0.72	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
KIRP	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	7.46	1.29e-12	1.79e-09	0.46	0.42	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
KIRP	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	7.46	1.3e-12	1.79e-09	0.32	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
KIRP	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	7.46	1.3e-12	1.8e-09	0.44	0.42	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
KIRP	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-7.46	1.3e-12	1.8e-09	-0.52	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
KIRP	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.31e-12	1.81e-09	-0.37	-0.42	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.31e-12	1.81e-09	-0.37	-0.42	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.31e-12	1.81e-09	-0.37	-0.42	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.31e-12	1.81e-09	-0.37	-0.42	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
KIRP	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	7.46	1.31e-12	1.81e-09	0.54	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
KIRP	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.46	1.31e-12	1.81e-09	-0.35	-0.42	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
KIRP	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	7.46	1.31e-12	1.81e-09	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	7.46	1.31e-12	1.81e-09	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
KIRP	cis	rs11647589	0.784	rs1700804	ENSG00000260762.1	ACSM5P1	-7.46	1.31e-12	1.81e-09	-0.43	-0.42	Blood metabolite levels;	chr16:20477047	chr16:20586550~20607107:-
KIRP	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	7.45	1.32e-12	1.82e-09	0.57	0.42	Height;	chr6:109368704	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-7.45	1.32e-12	1.82e-09	-0.49	-0.42	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
KIRP	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-7.45	1.33e-12	1.84e-09	-0.53	-0.42	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
KIRP	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	7.45	1.33e-12	1.85e-09	0.54	0.42	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-7.45	1.33e-12	1.85e-09	-0.49	-0.42	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
KIRP	cis	rs17082664	0.79	rs12661143	ENSG00000226193.1	RP3-398G3.5	-7.45	1.34e-12	1.85e-09	-0.62	-0.42	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152431125	chr6:152402398~152404966:+
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-7.45	1.34e-12	1.85e-09	-0.54	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
KIRP	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-7.45	1.34e-12	1.86e-09	-0.38	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-7.45	1.34e-12	1.86e-09	-0.38	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
KIRP	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	7.45	1.34e-12	1.86e-09	0.45	0.42	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
KIRP	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-7.45	1.35e-12	1.86e-09	-0.46	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
KIRP	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-7.45	1.35e-12	1.87e-09	-0.51	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
KIRP	cis	rs4578769	0.55	rs930909	ENSG00000266850.1	RP11-370A5.1	7.45	1.35e-12	1.87e-09	0.5	0.42	Eosinophil percentage of white cells;	chr18:22976361	chr18:22723491~22907721:-
KIRP	cis	rs893363	0.517	rs9836592	ENSG00000271916.1	RP11-884K10.6	-7.45	1.35e-12	1.87e-09	-0.42	-0.42	Axial length;	chr3:53821056	chr3:53797764~53798019:-
KIRP	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-7.45	1.36e-12	1.87e-09	-0.34	-0.42	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
KIRP	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	7.45	1.36e-12	1.88e-09	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
KIRP	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	7.45	1.36e-12	1.88e-09	0.52	0.42	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
KIRP	cis	rs67311347	0.911	rs6775936	ENSG00000230274.1	PGAM1P3	7.45	1.38e-12	1.91e-09	0.41	0.42	Renal cell carcinoma;	chr3:40335908	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	7.45	1.39e-12	1.91e-09	0.48	0.42	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
KIRP	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	7.45	1.4e-12	1.92e-09	0.42	0.42	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
KIRP	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-7.45	1.4e-12	1.92e-09	-0.34	-0.42	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
KIRP	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.45	1.4e-12	1.93e-09	0.45	0.42	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
KIRP	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	7.44	1.4e-12	1.93e-09	0.51	0.42	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	7.44	1.4e-12	1.93e-09	0.51	0.42	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
KIRP	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-7.44	1.4e-12	1.94e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
KIRP	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-7.44	1.42e-12	1.96e-09	-0.45	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
KIRP	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-7.44	1.42e-12	1.96e-09	-0.49	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
KIRP	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-7.44	1.42e-12	1.96e-09	-0.49	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
KIRP	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-7.44	1.42e-12	1.96e-09	-0.49	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
KIRP	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-7.44	1.43e-12	1.97e-09	-0.54	-0.42	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
KIRP	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	7.44	1.43e-12	1.97e-09	0.58	0.42	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
KIRP	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	7.44	1.44e-12	1.98e-09	0.43	0.42	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
KIRP	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	7.44	1.44e-12	1.98e-09	0.5	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
KIRP	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	7.44	1.45e-12	1.99e-09	0.43	0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
KIRP	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	7.44	1.46e-12	2.01e-09	0.35	0.42	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
KIRP	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	7.44	1.46e-12	2.01e-09	0.34	0.42	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
KIRP	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	7.44	1.48e-12	2.03e-09	0.38	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
KIRP	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-7.44	1.48e-12	2.04e-09	-0.37	-0.42	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
KIRP	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	7.44	1.49e-12	2.04e-09	0.78	0.42	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
KIRP	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-7.44	1.49e-12	2.04e-09	-0.48	-0.42	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
KIRP	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-7.43	1.5e-12	2.05e-09	-0.43	-0.42	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
KIRP	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-7.43	1.5e-12	2.06e-09	-0.54	-0.42	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
KIRP	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	7.43	1.5e-12	2.07e-09	0.54	0.42	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
KIRP	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	7.43	1.51e-12	2.07e-09	0.56	0.42	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
KIRP	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	7.43	1.52e-12	2.08e-09	0.38	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
KIRP	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-7.43	1.53e-12	2.1e-09	-0.35	-0.42	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	7.43	1.53e-12	2.1e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
KIRP	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.43	1.54e-12	2.11e-09	0.57	0.42	Height;	chr6:109357369	chr6:109382795~109383666:+
KIRP	cis	rs4578769	0.55	rs4517887	ENSG00000266850.1	RP11-370A5.1	-7.43	1.55e-12	2.12e-09	-0.51	-0.42	Eosinophil percentage of white cells;	chr18:22994715	chr18:22723491~22907721:-
KIRP	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	7.43	1.55e-12	2.12e-09	0.57	0.42	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
KIRP	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	7.43	1.55e-12	2.13e-09	0.44	0.42	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
KIRP	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	7.43	1.57e-12	2.14e-09	0.55	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
KIRP	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	7.43	1.57e-12	2.14e-09	0.47	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
KIRP	cis	rs9371601	0.798	rs214941	ENSG00000226193.1	RP3-398G3.5	-7.43	1.57e-12	2.15e-09	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152389729	chr6:152402398~152404966:+
KIRP	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	7.43	1.58e-12	2.16e-09	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
KIRP	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	7.43	1.58e-12	2.16e-09	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
KIRP	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	7.42	1.59e-12	2.17e-09	0.54	0.42	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	7.42	1.59e-12	2.17e-09	0.54	0.42	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	7.42	1.59e-12	2.17e-09	0.54	0.42	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	7.42	1.59e-12	2.17e-09	0.54	0.42	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
KIRP	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.42	1.59e-12	2.17e-09	0.51	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
KIRP	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-7.42	1.59e-12	2.18e-09	-0.54	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
KIRP	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-7.42	1.6e-12	2.19e-09	-0.3	-0.42	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
KIRP	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	7.42	1.6e-12	2.19e-09	0.33	0.42	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
KIRP	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	7.42	1.6e-12	2.19e-09	0.41	0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
KIRP	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	7.42	1.61e-12	2.2e-09	0.48	0.42	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	7.42	1.61e-12	2.2e-09	0.48	0.42	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	7.42	1.61e-12	2.2e-09	0.48	0.42	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
KIRP	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-7.42	1.62e-12	2.21e-09	-0.47	-0.42	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
KIRP	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-7.42	1.62e-12	2.21e-09	-0.45	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
KIRP	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-7.42	1.62e-12	2.22e-09	-0.39	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
KIRP	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	7.42	1.63e-12	2.22e-09	0.28	0.42	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
KIRP	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-7.42	1.64e-12	2.24e-09	-0.31	-0.42	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
KIRP	cis	rs453301	0.598	rs1025395	ENSG00000253981.4	ALG1L13P	7.42	1.65e-12	2.25e-09	0.33	0.42	Joint mobility (Beighton score);	chr8:8979093	chr8:8236003~8244667:-
KIRP	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.42	1.65e-12	2.26e-09	0.51	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
KIRP	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	7.42	1.66e-12	2.26e-09	0.55	0.42	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-7.42	1.66e-12	2.27e-09	-0.35	-0.42	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
KIRP	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	7.42	1.67e-12	2.28e-09	0.56	0.42	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
KIRP	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.42	1.67e-12	2.28e-09	0.45	0.42	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
KIRP	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	7.42	1.67e-12	2.28e-09	0.48	0.42	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-7.42	1.68e-12	2.29e-09	-0.56	-0.42	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
KIRP	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	7.42	1.68e-12	2.29e-09	0.41	0.42	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
KIRP	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	7.42	1.68e-12	2.3e-09	0.44	0.42	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
KIRP	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.41	1.69e-12	2.31e-09	-0.37	-0.42	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
KIRP	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-7.41	1.7e-12	2.31e-09	-0.47	-0.42	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-7.41	1.7e-12	2.32e-09	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
KIRP	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-7.41	1.72e-12	2.33e-09	-0.42	-0.42	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
KIRP	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	7.41	1.74e-12	2.36e-09	0.48	0.42	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
KIRP	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	7.41	1.75e-12	2.37e-09	0.44	0.42	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
KIRP	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-7.41	1.76e-12	2.39e-09	-0.37	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
KIRP	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	7.41	1.76e-12	2.39e-09	0.46	0.42	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
KIRP	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.41	1.77e-12	2.4e-09	0.51	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
KIRP	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	7.41	1.77e-12	2.41e-09	0.79	0.42	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
KIRP	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	7.41	1.79e-12	2.42e-09	0.38	0.42	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.41	1.79e-12	2.42e-09	0.38	0.42	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	7.4	1.8e-12	2.44e-09	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
KIRP	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-7.4	1.8e-12	2.44e-09	-0.67	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
KIRP	cis	rs755249	0.687	rs17343290	ENSG00000237624.1	OXCT2P1	7.4	1.81e-12	2.45e-09	0.72	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622371	chr1:39514956~39516490:+
KIRP	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-7.4	1.81e-12	2.46e-09	-0.56	-0.42	Height;	chr6:109432968	chr6:109382795~109383666:+
KIRP	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	7.4	1.81e-12	2.46e-09	0.55	0.42	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
KIRP	cis	rs7301826	0.504	rs11061164	ENSG00000256299.1	RP11-989F5.3	-7.4	1.82e-12	2.47e-09	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810821~130812622:-
KIRP	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	7.4	1.83e-12	2.47e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
KIRP	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	7.4	1.83e-12	2.48e-09	0.48	0.42	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
KIRP	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	7.4	1.83e-12	2.48e-09	0.46	0.42	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
KIRP	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	7.4	1.84e-12	2.49e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
KIRP	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	7.4	1.84e-12	2.49e-09	0.55	0.42	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
KIRP	cis	rs6993244	1	rs6993244	ENSG00000253981.4	ALG1L13P	7.4	1.85e-12	2.5e-09	0.33	0.42	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8236003~8244667:-
KIRP	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-7.4	1.86e-12	2.51e-09	-0.57	-0.42	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
KIRP	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-7.4	1.87e-12	2.53e-09	-0.52	-0.42	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
KIRP	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-7.4	1.87e-12	2.53e-09	-0.3	-0.42	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
KIRP	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	7.4	1.87e-12	2.53e-09	0.46	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
KIRP	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-7.4	1.87e-12	2.53e-09	-0.44	-0.42	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
KIRP	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	7.4	1.88e-12	2.54e-09	0.35	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
KIRP	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-7.4	1.88e-12	2.54e-09	-0.54	-0.42	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
KIRP	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	7.4	1.9e-12	2.56e-09	0.53	0.42	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
KIRP	cis	rs755249	0.687	rs72663521	ENSG00000237624.1	OXCT2P1	7.4	1.9e-12	2.57e-09	0.7	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540231	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.687	rs41270829	ENSG00000237624.1	OXCT2P1	7.4	1.9e-12	2.57e-09	0.7	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546018	chr1:39514956~39516490:+
KIRP	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	7.4	1.91e-12	2.58e-09	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
KIRP	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	7.4	1.91e-12	2.58e-09	0.53	0.42	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-7.39	1.91e-12	2.58e-09	-0.37	-0.42	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-7.39	1.91e-12	2.58e-09	-0.42	-0.42	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
KIRP	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	7.39	1.91e-12	2.58e-09	0.47	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
KIRP	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	7.39	1.92e-12	2.59e-09	0.55	0.42	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
KIRP	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-7.39	1.94e-12	2.61e-09	-0.43	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
KIRP	cis	rs950027	0.62	rs2467862	ENSG00000259433.2	CTD-2651B20.4	-7.39	1.94e-12	2.62e-09	-0.35	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45330209~45332634:-
KIRP	cis	rs950027	0.62	rs1145093	ENSG00000259433.2	CTD-2651B20.4	-7.39	1.94e-12	2.62e-09	-0.35	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45330209~45332634:-
KIRP	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-7.39	1.94e-12	2.62e-09	-0.62	-0.42	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-7.39	1.94e-12	2.62e-09	-0.62	-0.42	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
KIRP	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	7.39	1.95e-12	2.63e-09	0.47	0.42	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	7.39	1.95e-12	2.63e-09	0.47	0.42	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
KIRP	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-7.39	1.96e-12	2.64e-09	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
KIRP	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	7.39	1.98e-12	2.67e-09	0.55	0.42	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
KIRP	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	7.39	1.98e-12	2.67e-09	0.53	0.42	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
KIRP	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-7.39	1.99e-12	2.68e-09	-0.47	-0.42	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
KIRP	cis	rs4578769	0.569	rs11659166	ENSG00000266850.1	RP11-370A5.1	7.39	1.99e-12	2.68e-09	0.51	0.42	Eosinophil percentage of white cells;	chr18:22926143	chr18:22723491~22907721:-
KIRP	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	7.39	2e-12	2.7e-09	0.47	0.42	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
KIRP	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	7.39	2e-12	2.7e-09	0.45	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	7.39	2.02e-12	2.72e-09	0.48	0.42	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
KIRP	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-7.39	2.02e-12	2.72e-09	-0.38	-0.42	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
KIRP	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	7.39	2.03e-12	2.73e-09	0.49	0.42	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
KIRP	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	7.39	2.03e-12	2.73e-09	0.33	0.42	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	7.39	2.03e-12	2.73e-09	0.33	0.42	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
KIRP	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.39	2.03e-12	2.73e-09	0.54	0.42	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
KIRP	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-7.39	2.03e-12	2.73e-09	-0.45	-0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
KIRP	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	7.38	2.04e-12	2.74e-09	0.38	0.42	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
KIRP	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-7.38	2.06e-12	2.77e-09	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
KIRP	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	7.38	2.07e-12	2.79e-09	0.52	0.41	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
KIRP	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	7.38	2.08e-12	2.79e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	7.38	2.08e-12	2.79e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	7.38	2.08e-12	2.79e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
KIRP	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-7.38	2.08e-12	2.79e-09	-0.47	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
KIRP	cis	rs4578769	0.531	rs12964304	ENSG00000266850.1	RP11-370A5.1	7.38	2.08e-12	2.8e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22928641	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.531	rs12968784	ENSG00000266850.1	RP11-370A5.1	7.38	2.08e-12	2.8e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22928645	chr18:22723491~22907721:-
KIRP	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-7.38	2.08e-12	2.8e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-7.38	2.08e-12	2.8e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
KIRP	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	7.38	2.09e-12	2.8e-09	0.47	0.41	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	7.38	2.09e-12	2.8e-09	0.47	0.41	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
KIRP	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
KIRP	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-7.38	2.09e-12	2.81e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
KIRP	cis	rs11647589	0.911	rs9923452	ENSG00000260762.1	ACSM5P1	7.38	2.09e-12	2.81e-09	0.44	0.41	Blood metabolite levels;	chr16:20457882	chr16:20586550~20607107:-
KIRP	cis	rs11647589	0.911	rs71373192	ENSG00000260762.1	ACSM5P1	7.38	2.09e-12	2.81e-09	0.44	0.41	Blood metabolite levels;	chr16:20458840	chr16:20586550~20607107:-
KIRP	cis	rs4578769	0.55	rs721578	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22922719	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs7229422	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22923157	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.589	rs9964726	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22925516	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs9958831	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22926050	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs12957183	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22927124	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs9948922	ENSG00000266850.1	RP11-370A5.1	7.38	2.09e-12	2.81e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22930198	chr18:22723491~22907721:-
KIRP	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	7.38	2.1e-12	2.81e-09	0.48	0.41	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
KIRP	cis	rs67311347	1	rs13095055	ENSG00000230274.1	PGAM1P3	-7.38	2.1e-12	2.82e-09	-0.4	-0.41	Renal cell carcinoma;	chr3:40464175	chr3:40322715~40323279:-
KIRP	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-7.38	2.1e-12	2.82e-09	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
KIRP	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	7.38	2.11e-12	2.83e-09	0.45	0.41	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
KIRP	cis	rs950027	0.62	rs1153862	ENSG00000259433.2	CTD-2651B20.4	-7.38	2.11e-12	2.84e-09	-0.35	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45330209~45332634:-
KIRP	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	7.38	2.14e-12	2.87e-09	0.53	0.41	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
KIRP	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.38	2.14e-12	2.87e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
KIRP	cis	rs4578769	0.55	rs8092358	ENSG00000266850.1	RP11-370A5.1	7.38	2.14e-12	2.87e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22911835	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs1379805	ENSG00000266850.1	RP11-370A5.1	7.38	2.14e-12	2.87e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22914589	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs1031652	ENSG00000266850.1	RP11-370A5.1	7.38	2.14e-12	2.87e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22916035	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs9967326	ENSG00000266850.1	RP11-370A5.1	7.38	2.14e-12	2.87e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22916787	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.569	rs9946660	ENSG00000266850.1	RP11-370A5.1	7.38	2.14e-12	2.87e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22917007	chr18:22723491~22907721:-
KIRP	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-7.38	2.15e-12	2.88e-09	-0.4	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
KIRP	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	7.38	2.15e-12	2.88e-09	0.78	0.41	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
KIRP	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	7.37	2.17e-12	2.91e-09	0.44	0.41	Depression;	chr6:28314871	chr6:28176188~28176674:+
KIRP	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	7.37	2.18e-12	2.92e-09	0.43	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
KIRP	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	7.37	2.18e-12	2.92e-09	0.43	0.41	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
KIRP	cis	rs4578769	0.569	rs12960915	ENSG00000266850.1	RP11-370A5.1	7.37	2.19e-12	2.93e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22924013	chr18:22723491~22907721:-
KIRP	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	7.37	2.19e-12	2.93e-09	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	7.37	2.19e-12	2.93e-09	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
KIRP	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-7.37	2.2e-12	2.94e-09	-0.43	-0.41	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
KIRP	cis	rs4638749	0.734	rs6722745	ENSG00000225328.1	AC019100.3	7.37	2.2e-12	2.95e-09	0.52	0.41	Blood pressure;	chr2:108258788	chr2:108167748~108217841:-
KIRP	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	7.37	2.22e-12	2.97e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
KIRP	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	7.37	2.23e-12	2.99e-09	0.55	0.41	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	7.37	2.23e-12	2.99e-09	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	7.37	2.23e-12	2.99e-09	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	7.37	2.24e-12	3e-09	0.5	0.41	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
KIRP	cis	rs11647589	0.834	rs9933872	ENSG00000260762.1	ACSM5P1	7.37	2.25e-12	3.01e-09	0.44	0.41	Blood metabolite levels;	chr16:20473849	chr16:20586550~20607107:-
KIRP	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-7.37	2.25e-12	3.01e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
KIRP	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	7.37	2.26e-12	3.02e-09	0.57	0.41	Height;	chr6:109738751	chr6:109382795~109383666:+
KIRP	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	7.37	2.27e-12	3.02e-09	0.56	0.41	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
KIRP	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	7.37	2.27e-12	3.02e-09	0.43	0.41	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
KIRP	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	7.37	2.27e-12	3.03e-09	0.78	0.41	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
KIRP	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-7.37	2.27e-12	3.03e-09	-0.35	-0.41	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
KIRP	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-7.37	2.28e-12	3.03e-09	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
KIRP	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-7.37	2.28e-12	3.03e-09	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
KIRP	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-7.37	2.28e-12	3.03e-09	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
KIRP	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-7.37	2.28e-12	3.03e-09	-0.5	-0.41	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
KIRP	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	7.37	2.28e-12	3.04e-09	0.53	0.41	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
KIRP	cis	rs4578769	0.569	rs8094359	ENSG00000266850.1	RP11-370A5.1	7.37	2.28e-12	3.04e-09	0.5	0.41	Eosinophil percentage of white cells;	chr18:22907743	chr18:22723491~22907721:-
KIRP	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	7.37	2.29e-12	3.05e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-7.37	2.29e-12	3.05e-09	-0.59	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
KIRP	cis	rs9371601	0.859	rs214942	ENSG00000226193.1	RP3-398G3.5	-7.37	2.29e-12	3.05e-09	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152389867	chr6:152402398~152404966:+
KIRP	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	7.36	2.31e-12	3.07e-09	0.47	0.41	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
KIRP	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	7.36	2.31e-12	3.08e-09	0.57	0.41	Height;	chr6:109424139	chr6:109382795~109383666:+
KIRP	cis	rs4578769	0.55	rs11082258	ENSG00000266850.1	RP11-370A5.1	7.36	2.32e-12	3.08e-09	0.52	0.41	Eosinophil percentage of white cells;	chr18:23037401	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.55	rs4280358	ENSG00000266850.1	RP11-370A5.1	7.36	2.32e-12	3.08e-09	0.52	0.41	Eosinophil percentage of white cells;	chr18:23037844	chr18:22723491~22907721:-
KIRP	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-7.36	2.33e-12	3.1e-09	-0.52	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
KIRP	cis	rs4578769	0.569	rs4800438	ENSG00000266850.1	RP11-370A5.1	7.36	2.34e-12	3.11e-09	0.51	0.41	Eosinophil percentage of white cells;	chr18:22920482	chr18:22723491~22907721:-
KIRP	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-7.36	2.37e-12	3.14e-09	-0.34	-0.41	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
KIRP	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-7.36	2.37e-12	3.14e-09	-0.55	-0.41	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
KIRP	cis	rs2749592	0.55	rs7917262	ENSG00000151963.4	RP11-775A3.1	7.36	2.38e-12	3.15e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:37883594~37884109:+
KIRP	cis	rs2749592	0.55	rs9733309	ENSG00000151963.4	RP11-775A3.1	7.36	2.38e-12	3.15e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:37883594~37884109:+
KIRP	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-7.36	2.39e-12	3.17e-09	-0.37	-0.41	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-7.36	2.39e-12	3.17e-09	-0.37	-0.41	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
KIRP	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-7.36	2.39e-12	3.17e-09	-0.6	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
KIRP	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-7.36	2.39e-12	3.17e-09	-0.45	-0.41	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
KIRP	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-7.36	2.4e-12	3.18e-09	-0.37	-0.41	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
KIRP	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	7.36	2.4e-12	3.18e-09	0.48	0.41	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
KIRP	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-7.36	2.4e-12	3.19e-09	-0.33	-0.41	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
KIRP	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	7.36	2.42e-12	3.21e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
KIRP	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-7.36	2.44e-12	3.22e-09	-0.37	-0.41	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
KIRP	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	7.36	2.44e-12	3.23e-09	0.48	0.41	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	7.36	2.45e-12	3.24e-09	0.49	0.41	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
KIRP	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.36	2.45e-12	3.24e-09	-0.48	-0.41	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	7.36	2.45e-12	3.24e-09	0.52	0.41	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	7.36	2.45e-12	3.24e-09	0.52	0.41	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
KIRP	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-7.35	2.46e-12	3.25e-09	-0.52	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
KIRP	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	7.35	2.46e-12	3.26e-09	0.62	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
KIRP	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	7.35	2.47e-12	3.27e-09	0.39	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
KIRP	cis	rs950027	0.62	rs1719246	ENSG00000259433.2	CTD-2651B20.4	-7.35	2.48e-12	3.28e-09	-0.35	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45330209~45332634:-
KIRP	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-7.35	2.49e-12	3.29e-09	-0.49	-0.41	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
KIRP	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	7.35	2.5e-12	3.3e-09	0.73	0.41	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
KIRP	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	7.35	2.5e-12	3.3e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
KIRP	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	7.35	2.5e-12	3.31e-09	0.56	0.41	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
KIRP	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-7.35	2.5e-12	3.31e-09	-0.53	-0.41	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
KIRP	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.35	2.51e-12	3.32e-09	0.44	0.41	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
KIRP	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	7.35	2.51e-12	3.32e-09	0.52	0.41	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
KIRP	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-7.35	2.52e-12	3.33e-09	-0.36	-0.41	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
KIRP	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	7.35	2.53e-12	3.34e-09	0.32	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
KIRP	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	7.35	2.53e-12	3.34e-09	0.42	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
KIRP	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	7.35	2.53e-12	3.34e-09	0.34	0.41	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-7.35	2.54e-12	3.35e-09	-0.34	-0.41	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
KIRP	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	7.35	2.55e-12	3.37e-09	0.38	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
KIRP	cis	rs950027	0.62	rs1153860	ENSG00000259433.2	CTD-2651B20.4	7.35	2.56e-12	3.38e-09	0.35	0.41	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45330209~45332634:-
KIRP	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.35	2.58e-12	3.4e-09	-0.36	-0.41	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
KIRP	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-7.35	2.58e-12	3.41e-09	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
KIRP	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	7.35	2.6e-12	3.43e-09	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
KIRP	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	7.35	2.6e-12	3.43e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	7.35	2.6e-12	3.43e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
KIRP	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-7.35	2.61e-12	3.44e-09	-0.44	-0.41	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-7.35	2.61e-12	3.44e-09	-0.44	-0.41	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	7.34	2.61e-12	3.44e-09	0.48	0.41	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	7.34	2.63e-12	3.46e-09	0.56	0.41	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-7.34	2.63e-12	3.47e-09	-0.49	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
KIRP	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	7.34	2.65e-12	3.49e-09	0.56	0.41	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
KIRP	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	7.34	2.65e-12	3.49e-09	0.51	0.41	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	7.34	2.65e-12	3.49e-09	0.51	0.41	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
KIRP	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	7.34	2.65e-12	3.49e-09	0.47	0.41	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
KIRP	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-7.34	2.66e-12	3.5e-09	-0.47	-0.41	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
KIRP	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-7.34	2.66e-12	3.5e-09	-0.53	-0.41	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	7.34	2.66e-12	3.5e-09	0.53	0.41	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	7.34	2.66e-12	3.5e-09	0.53	0.41	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	7.34	2.66e-12	3.5e-09	0.53	0.41	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
KIRP	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	7.34	2.67e-12	3.52e-09	0.32	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
KIRP	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	7.34	2.69e-12	3.54e-09	0.53	0.41	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
KIRP	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	7.34	2.69e-12	3.54e-09	0.52	0.41	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
KIRP	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	7.34	2.7e-12	3.55e-09	0.41	0.41	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
KIRP	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	7.34	2.7e-12	3.55e-09	0.52	0.41	Height;	chr11:118856460	chr11:118688039~118690600:-
KIRP	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	7.34	2.7e-12	3.55e-09	0.52	0.41	Height;	chr11:118856623	chr11:118688039~118690600:-
KIRP	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	7.34	2.7e-12	3.55e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	7.34	2.7e-12	3.55e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
KIRP	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	7.34	2.71e-12	3.56e-09	0.45	0.41	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
KIRP	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	7.34	2.71e-12	3.56e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
KIRP	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	7.34	2.72e-12	3.57e-09	0.53	0.41	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
KIRP	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	7.34	2.73e-12	3.58e-09	0.47	0.41	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	7.34	2.73e-12	3.58e-09	0.47	0.41	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
KIRP	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	7.34	2.73e-12	3.58e-09	0.44	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
KIRP	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	7.34	2.74e-12	3.59e-09	0.38	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	7.34	2.74e-12	3.59e-09	0.38	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	7.34	2.74e-12	3.6e-09	0.35	0.41	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-7.34	2.75e-12	3.61e-09	-0.36	-0.41	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	7.34	2.75e-12	3.61e-09	0.35	0.41	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
KIRP	cis	rs2749592	0.55	rs7081464	ENSG00000151963.4	RP11-775A3.1	7.34	2.77e-12	3.63e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:37883594~37884109:+
KIRP	cis	rs755249	0.958	rs17264866	ENSG00000237624.1	OXCT2P1	7.33	2.78e-12	3.65e-09	0.65	0.41	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39514956~39516490:+
KIRP	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-7.33	2.79e-12	3.66e-09	-0.44	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
KIRP	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	7.33	2.8e-12	3.66e-09	0.5	0.41	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
KIRP	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	7.33	2.8e-12	3.66e-09	0.58	0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
KIRP	cis	rs7829975	0.517	rs12542733	ENSG00000253981.4	ALG1L13P	-7.33	2.84e-12	3.72e-09	-0.31	-0.41	Mood instability;	chr8:8967348	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-7.33	2.86e-12	3.75e-09	-0.53	-0.41	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
KIRP	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-7.33	2.88e-12	3.77e-09	-0.49	-0.41	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
KIRP	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-7.33	2.89e-12	3.77e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-7.33	2.89e-12	3.77e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-7.33	2.89e-12	3.77e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-7.33	2.89e-12	3.77e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
KIRP	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-7.33	2.89e-12	3.78e-09	-0.36	-0.41	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-7.33	2.89e-12	3.78e-09	-0.36	-0.41	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
KIRP	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-7.33	2.89e-12	3.78e-09	-0.31	-0.41	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
KIRP	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	7.33	2.9e-12	3.79e-09	0.5	0.41	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.923	rs9322225	ENSG00000223701.3	RAET1E-AS1	7.33	2.91e-12	3.81e-09	0.49	0.41	Lung cancer;	chr6:149863746	chr6:149884431~149919508:+
KIRP	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	7.32	2.96e-12	3.86e-09	0.47	0.41	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
KIRP	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-7.32	2.98e-12	3.88e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
KIRP	cis	rs4578769	0.55	rs9956087	ENSG00000266850.1	RP11-370A5.1	7.32	2.98e-12	3.89e-09	0.52	0.41	Eosinophil percentage of white cells;	chr18:23030538	chr18:22723491~22907721:-
KIRP	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	7.32	2.99e-12	3.9e-09	0.51	0.41	Height;	chr11:118857611	chr11:118688039~118690600:-
KIRP	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	7.32	3e-12	3.91e-09	0.41	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
KIRP	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	7.32	3.01e-12	3.93e-09	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
KIRP	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	7.32	3.02e-12	3.94e-09	0.41	0.41	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	7.32	3.02e-12	3.94e-09	0.41	0.41	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
KIRP	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-7.32	3.03e-12	3.95e-09	-0.48	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
KIRP	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.32	3.03e-12	3.95e-09	-0.35	-0.41	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
KIRP	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	7.32	3.04e-12	3.96e-09	0.48	0.41	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
KIRP	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-7.32	3.05e-12	3.97e-09	-0.37	-0.41	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
KIRP	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-7.32	3.05e-12	3.98e-09	-0.46	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
KIRP	cis	rs67311347	1	rs7633809	ENSG00000230274.1	PGAM1P3	-7.32	3.05e-12	3.98e-09	-0.4	-0.41	Renal cell carcinoma;	chr3:40476246	chr3:40322715~40323279:-
KIRP	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-7.32	3.06e-12	3.99e-09	-0.3	-0.41	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
KIRP	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	7.32	3.07e-12	4e-09	0.45	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
KIRP	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	7.32	3.07e-12	4e-09	0.47	0.41	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
KIRP	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	7.32	3.07e-12	4e-09	0.34	0.41	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
KIRP	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	7.32	3.07e-12	4e-09	0.45	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
KIRP	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-7.32	3.07e-12	4e-09	-0.47	-0.41	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
KIRP	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-7.32	3.07e-12	4e-09	-0.55	-0.41	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
KIRP	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	7.32	3.08e-12	4.01e-09	0.56	0.41	Height;	chr6:109440234	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	7.32	3.08e-12	4.01e-09	0.56	0.41	Height;	chr6:109443332	chr6:109382795~109383666:+
KIRP	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	7.32	3.08e-12	4.01e-09	0.5	0.41	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	7.32	3.08e-12	4.01e-09	0.5	0.41	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
KIRP	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-7.32	3.09e-12	4.03e-09	-0.29	-0.41	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
KIRP	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-7.32	3.1e-12	4.03e-09	-0.71	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
KIRP	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	7.32	3.1e-12	4.03e-09	0.55	0.41	Height;	chr6:109424122	chr6:109382795~109383666:+
KIRP	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	7.32	3.11e-12	4.05e-09	0.34	0.41	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
KIRP	cis	rs4356975	0.842	rs6600899	ENSG00000248763.2	RP13-644M16.5	-7.32	3.12e-12	4.06e-09	-0.46	-0.41	Obesity-related traits;	chr4:69132295	chr4:69066395~69069888:+
KIRP	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-7.32	3.12e-12	4.06e-09	-0.4	-0.41	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
KIRP	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	7.32	3.13e-12	4.08e-09	0.43	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
KIRP	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-7.31	3.14e-12	4.09e-09	-0.44	-0.41	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
KIRP	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-7.31	3.14e-12	4.09e-09	-0.46	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-7.31	3.15e-12	4.09e-09	-0.44	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-7.31	3.15e-12	4.09e-09	-0.44	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
KIRP	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-7.31	3.15e-12	4.09e-09	-0.46	-0.41	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
KIRP	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	7.31	3.16e-12	4.11e-09	0.38	0.41	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
KIRP	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	7.31	3.17e-12	4.12e-09	0.57	0.41	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
KIRP	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	7.31	3.17e-12	4.13e-09	0.42	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
KIRP	cis	rs17361889	0.613	rs4721484	ENSG00000224683.1	RPL36AP29	7.31	3.18e-12	4.13e-09	0.48	0.41	Pediatric bone mineral content (hip);	chr7:16242778	chr7:16208945~16209265:+
KIRP	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	7.31	3.18e-12	4.13e-09	0.37	0.41	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
KIRP	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	7.31	3.19e-12	4.14e-09	0.35	0.41	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	7.31	3.19e-12	4.14e-09	0.35	0.41	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-7.31	3.19e-12	4.14e-09	-0.34	-0.41	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
KIRP	cis	rs950027	0.584	rs1145086	ENSG00000259433.2	CTD-2651B20.4	-7.31	3.2e-12	4.15e-09	-0.35	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45330209~45332634:-
KIRP	cis	rs950027	0.62	rs1153857	ENSG00000259433.2	CTD-2651B20.4	-7.31	3.2e-12	4.15e-09	-0.35	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45330209~45332634:-
KIRP	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-7.31	3.2e-12	4.16e-09	-0.37	-0.41	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-7.31	3.2e-12	4.16e-09	-0.37	-0.41	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
KIRP	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	7.31	3.21e-12	4.16e-09	0.56	0.41	Height;	chr6:109732518	chr6:109382795~109383666:+
KIRP	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	7.31	3.21e-12	4.17e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.31	3.21e-12	4.17e-09	0.37	0.41	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.31	3.21e-12	4.17e-09	0.37	0.41	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
KIRP	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	7.31	3.23e-12	4.2e-09	0.51	0.41	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
KIRP	cis	rs2749592	0.531	rs994804	ENSG00000151963.4	RP11-775A3.1	7.31	3.26e-12	4.23e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:37883594~37884109:+
KIRP	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	7.31	3.28e-12	4.25e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	7.31	3.28e-12	4.25e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-7.31	3.28e-12	4.25e-09	-0.45	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
KIRP	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	7.31	3.29e-12	4.27e-09	0.43	0.41	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
KIRP	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-7.31	3.32e-12	4.3e-09	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	7.3	3.34e-12	4.34e-09	0.52	0.41	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
KIRP	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	7.3	3.36e-12	4.35e-09	0.79	0.41	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
KIRP	cis	rs4578769	0.505	rs4405649	ENSG00000266850.1	RP11-370A5.1	7.3	3.37e-12	4.36e-09	0.52	0.41	Eosinophil percentage of white cells;	chr18:23007590	chr18:22723491~22907721:-
KIRP	cis	rs9963862	1	rs9963862	ENSG00000266850.1	RP11-370A5.1	7.3	3.37e-12	4.36e-09	0.52	0.41	Late-onset myasthenia gravis;	chr18:23007948	chr18:22723491~22907721:-
KIRP	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	7.3	3.37e-12	4.36e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	7.3	3.37e-12	4.36e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	7.3	3.37e-12	4.36e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	7.3	3.37e-12	4.36e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
KIRP	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	7.3	3.38e-12	4.38e-09	0.43	0.41	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
KIRP	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	7.3	3.38e-12	4.38e-09	0.43	0.41	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
KIRP	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	7.3	3.38e-12	4.38e-09	0.49	0.41	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
KIRP	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-7.3	3.39e-12	4.38e-09	-0.54	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
KIRP	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	7.3	3.39e-12	4.38e-09	0.5	0.41	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
KIRP	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.3	3.42e-12	4.42e-09	0.43	0.41	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
KIRP	cis	rs2749592	0.55	rs4934881	ENSG00000151963.4	RP11-775A3.1	7.3	3.43e-12	4.44e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:37883594~37884109:+
KIRP	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-7.3	3.43e-12	4.44e-09	-0.94	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
KIRP	cis	rs4578769	0.569	rs12605341	ENSG00000266850.1	RP11-370A5.1	-7.3	3.45e-12	4.46e-09	-0.5	-0.41	Eosinophil percentage of white cells;	chr18:22803011	chr18:22723491~22907721:-
KIRP	cis	rs9371601	0.798	rs215004	ENSG00000226193.1	RP3-398G3.5	-7.3	3.45e-12	4.46e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152437157	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.798	rs215003	ENSG00000226193.1	RP3-398G3.5	-7.3	3.45e-12	4.46e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152437389	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.758	rs215002	ENSG00000226193.1	RP3-398G3.5	-7.3	3.45e-12	4.46e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152437455	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.828	rs215000	ENSG00000226193.1	RP3-398G3.5	-7.3	3.45e-12	4.46e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152440016	chr6:152402398~152404966:+
KIRP	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	7.3	3.45e-12	4.47e-09	0.44	0.41	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
KIRP	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	7.3	3.46e-12	4.47e-09	0.46	0.41	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
KIRP	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	7.3	3.48e-12	4.5e-09	0.43	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
KIRP	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-7.3	3.49e-12	4.51e-09	-0.51	-0.41	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
KIRP	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	7.3	3.51e-12	4.53e-09	0.34	0.41	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
KIRP	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-7.3	3.51e-12	4.53e-09	-0.57	-0.41	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
KIRP	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-7.3	3.52e-12	4.55e-09	-0.55	-0.41	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
KIRP	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-7.29	3.55e-12	4.59e-09	-0.36	-0.41	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-7.29	3.56e-12	4.6e-09	-0.37	-0.41	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	7.29	3.58e-12	4.62e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
KIRP	cis	rs11079159	0.565	rs4794563	ENSG00000263096.1	RP11-515O17.2	7.29	3.58e-12	4.62e-09	0.5	0.41	QRS duration;	chr17:55304524	chr17:55271504~55273653:-
KIRP	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	7.29	3.62e-12	4.67e-09	0.37	0.41	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
KIRP	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-7.29	3.62e-12	4.67e-09	-0.54	-0.41	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	7.29	3.64e-12	4.69e-09	0.54	0.41	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
KIRP	cis	rs9371601	0.859	rs214981	ENSG00000226193.1	RP3-398G3.5	-7.29	3.64e-12	4.69e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152411579	chr6:152402398~152404966:+
KIRP	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	7.29	3.64e-12	4.7e-09	0.55	0.41	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	7.29	3.64e-12	4.7e-09	0.55	0.41	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
KIRP	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-7.29	3.66e-12	4.71e-09	-0.54	-0.41	QT interval;	chr16:28845498	chr16:28700294~28701540:-
KIRP	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.29	3.66e-12	4.72e-09	0.42	0.41	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
KIRP	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-7.29	3.67e-12	4.73e-09	-0.4	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
KIRP	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	7.29	3.67e-12	4.73e-09	0.55	0.41	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
KIRP	cis	rs11079159	0.606	rs4239193	ENSG00000263096.1	RP11-515O17.2	7.29	3.7e-12	4.77e-09	0.5	0.41	QRS duration;	chr17:55299163	chr17:55271504~55273653:-
KIRP	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-7.29	3.71e-12	4.77e-09	-0.36	-0.41	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
KIRP	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-7.29	3.71e-12	4.77e-09	-0.6	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
KIRP	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	7.29	3.71e-12	4.78e-09	0.77	0.41	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
KIRP	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-7.29	3.71e-12	4.78e-09	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
KIRP	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-7.29	3.72e-12	4.79e-09	-0.34	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
KIRP	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	7.29	3.72e-12	4.79e-09	0.76	0.41	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
KIRP	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	7.29	3.73e-12	4.79e-09	0.37	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
KIRP	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-7.29	3.73e-12	4.8e-09	-0.53	-0.41	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
KIRP	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-7.29	3.75e-12	4.82e-09	-0.45	-0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
KIRP	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	7.29	3.76e-12	4.83e-09	0.53	0.41	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	7.29	3.76e-12	4.83e-09	0.53	0.41	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
KIRP	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	7.29	3.76e-12	4.83e-09	0.53	0.41	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
KIRP	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-7.29	3.77e-12	4.84e-09	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	7.29	3.77e-12	4.84e-09	0.36	0.41	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-7.29	3.77e-12	4.84e-09	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
KIRP	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	7.29	3.77e-12	4.84e-09	0.53	0.41	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
KIRP	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	7.29	3.78e-12	4.85e-09	0.47	0.41	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
KIRP	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	7.28	3.78e-12	4.86e-09	0.78	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
KIRP	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	7.28	3.78e-12	4.86e-09	0.64	0.41	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
KIRP	cis	rs9371601	0.819	rs215005	ENSG00000226193.1	RP3-398G3.5	-7.28	3.79e-12	4.86e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152436485	chr6:152402398~152404966:+
KIRP	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	7.28	3.79e-12	4.86e-09	0.52	0.41	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
KIRP	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-7.28	3.79e-12	4.87e-09	-0.32	-0.41	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
KIRP	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-7.28	3.79e-12	4.87e-09	-0.32	-0.41	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
KIRP	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-7.28	3.8e-12	4.87e-09	-0.39	-0.41	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-7.28	3.8e-12	4.87e-09	-0.39	-0.41	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-7.28	3.8e-12	4.87e-09	-0.39	-0.41	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
KIRP	cis	rs34779708	0.733	rs60616028	ENSG00000230534.5	RP11-297A16.2	7.28	3.8e-12	4.88e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35098006~35127020:-
KIRP	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	7.28	3.8e-12	4.88e-09	0.32	0.41	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
KIRP	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	7.28	3.81e-12	4.89e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
KIRP	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-7.28	3.84e-12	4.93e-09	-0.34	-0.41	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-7.28	3.84e-12	4.93e-09	-0.34	-0.41	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-7.28	3.84e-12	4.93e-09	-0.34	-0.41	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
KIRP	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-7.28	3.86e-12	4.95e-09	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	7.28	3.87e-12	4.96e-09	0.37	0.41	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
KIRP	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-7.28	3.87e-12	4.96e-09	-0.51	-0.41	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
KIRP	cis	rs17082664	0.85	rs12526147	ENSG00000226193.1	RP3-398G3.5	-7.28	3.9e-12	4.99e-09	-0.57	-0.41	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152444066	chr6:152402398~152404966:+
KIRP	cis	rs12962334	0.568	rs2034932	ENSG00000266850.1	RP11-370A5.1	7.28	3.9e-12	5e-09	0.5	0.41	Breast cancer;	chr18:22918727	chr18:22723491~22907721:-
KIRP	cis	rs5760092	0.842	rs5751763	ENSG00000225282.1	AP000350.6	7.28	3.9e-12	5e-09	0.53	0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23926900~23929574:+
KIRP	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-7.28	3.9e-12	5e-09	-0.34	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
KIRP	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	7.28	3.92e-12	5.02e-09	0.56	0.41	Height;	chr6:109738307	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	7.28	3.93e-12	5.04e-09	0.48	0.41	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-7.28	3.94e-12	5.04e-09	-0.48	-0.41	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
KIRP	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-7.28	3.98e-12	5.09e-09	-0.65	-0.41	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
KIRP	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	7.28	3.98e-12	5.1e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	7.28	3.98e-12	5.1e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
KIRP	cis	rs4578769	0.55	rs9953702	ENSG00000266850.1	RP11-370A5.1	7.28	3.99e-12	5.1e-09	0.49	0.41	Eosinophil percentage of white cells;	chr18:22971001	chr18:22723491~22907721:-
KIRP	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-7.28	3.99e-12	5.1e-09	-0.33	-0.41	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-7.28	3.99e-12	5.1e-09	-0.33	-0.41	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
KIRP	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	7.28	4e-12	5.12e-09	0.46	0.41	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
KIRP	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	7.28	4e-12	5.12e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	7.27	4.04e-12	5.16e-09	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
KIRP	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	7.27	4.08e-12	5.21e-09	0.5	0.41	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	7.27	4.08e-12	5.21e-09	0.5	0.41	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
KIRP	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-7.27	4.08e-12	5.21e-09	-0.44	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
KIRP	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.22e-09	0.52	0.41	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	7.27	4.09e-12	5.23e-09	0.53	0.41	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
KIRP	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	7.27	4.1e-12	5.23e-09	0.47	0.41	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	7.27	4.1e-12	5.23e-09	0.47	0.41	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	7.27	4.1e-12	5.23e-09	0.47	0.41	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.27	4.11e-12	5.25e-09	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
KIRP	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	7.27	4.11e-12	5.25e-09	0.47	0.41	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
KIRP	cis	rs4578769	0.55	rs7237400	ENSG00000266850.1	RP11-370A5.1	7.27	4.12e-12	5.25e-09	0.5	0.41	Eosinophil percentage of white cells;	chr18:22986533	chr18:22723491~22907721:-
KIRP	cis	rs11647589	0.834	rs4603548	ENSG00000260762.1	ACSM5P1	7.27	4.12e-12	5.26e-09	0.42	0.41	Blood metabolite levels;	chr16:20472639	chr16:20586550~20607107:-
KIRP	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	7.27	4.13e-12	5.27e-09	0.46	0.41	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
KIRP	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-7.27	4.15e-12	5.29e-09	-0.47	-0.41	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-7.27	4.17e-12	5.32e-09	-0.46	-0.41	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
KIRP	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.27	4.19e-12	5.34e-09	0.55	0.41	Height;	chr6:109634847	chr6:109382795~109383666:+
KIRP	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	7.27	4.19e-12	5.35e-09	0.5	0.41	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
KIRP	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	7.27	4.25e-12	5.42e-09	0.3	0.41	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
KIRP	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	7.27	4.26e-12	5.42e-09	0.56	0.41	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
KIRP	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	7.27	4.27e-12	5.43e-09	0.5	0.41	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
KIRP	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	7.26	4.28e-12	5.45e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
KIRP	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	7.26	4.3e-12	5.47e-09	0.89	0.41	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
KIRP	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-7.26	4.3e-12	5.48e-09	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
KIRP	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	7.26	4.31e-12	5.48e-09	0.4	0.41	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	7.26	4.32e-12	5.5e-09	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
KIRP	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-7.26	4.33e-12	5.51e-09	-0.46	-0.41	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
KIRP	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-7.26	4.33e-12	5.51e-09	-0.36	-0.41	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
KIRP	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-7.26	4.36e-12	5.54e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
KIRP	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-7.26	4.36e-12	5.54e-09	-0.38	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
KIRP	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-7.26	4.36e-12	5.54e-09	-0.34	-0.41	Height;	chr11:118703185	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-7.26	4.36e-12	5.54e-09	-0.34	-0.41	Height;	chr11:118703207	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-7.26	4.36e-12	5.54e-09	-0.34	-0.41	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-7.26	4.36e-12	5.54e-09	-0.34	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
KIRP	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-7.26	4.37e-12	5.55e-09	-0.52	-0.41	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	7.26	4.38e-12	5.56e-09	0.37	0.41	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
KIRP	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	7.26	4.39e-12	5.58e-09	0.75	0.41	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
KIRP	cis	rs453301	0.624	rs2915251	ENSG00000253981.4	ALG1L13P	7.26	4.4e-12	5.59e-09	0.32	0.41	Joint mobility (Beighton score);	chr8:9009901	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	7.26	4.41e-12	5.59e-09	0.5	0.41	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
KIRP	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	7.26	4.41e-12	5.59e-09	0.34	0.41	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
KIRP	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	7.26	4.41e-12	5.6e-09	0.48	0.41	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
KIRP	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	7.26	4.42e-12	5.6e-09	0.56	0.41	Height;	chr6:109741670	chr6:109382795~109383666:+
KIRP	cis	rs453301	0.624	rs2288671	ENSG00000253981.4	ALG1L13P	7.26	4.45e-12	5.65e-09	0.31	0.41	Joint mobility (Beighton score);	chr8:9003384	chr8:8236003~8244667:-
KIRP	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-7.26	4.45e-12	5.65e-09	-0.5	-0.41	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	7.26	4.46e-12	5.66e-09	0.56	0.41	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-7.26	4.5e-12	5.71e-09	-0.36	-0.41	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
KIRP	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	7.26	4.52e-12	5.72e-09	0.47	0.41	Height;	chr11:118809363	chr11:118688039~118690600:-
KIRP	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-7.26	4.53e-12	5.75e-09	-0.62	-0.41	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
KIRP	cis	rs9371601	0.859	rs214978	ENSG00000226193.1	RP3-398G3.5	-7.26	4.54e-12	5.75e-09	-0.44	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152410263	chr6:152402398~152404966:+
KIRP	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-7.25	4.55e-12	5.76e-09	-0.48	-0.41	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
KIRP	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	7.25	4.55e-12	5.76e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
KIRP	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-7.25	4.58e-12	5.8e-09	-0.33	-0.41	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
KIRP	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-7.25	4.59e-12	5.81e-09	-0.34	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
KIRP	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	7.25	4.59e-12	5.81e-09	0.43	0.41	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
KIRP	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	7.25	4.6e-12	5.82e-09	0.43	0.41	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
KIRP	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	7.25	4.61e-12	5.83e-09	0.3	0.41	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
KIRP	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-7.25	4.63e-12	5.85e-09	-0.49	-0.41	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
KIRP	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-7.25	4.63e-12	5.86e-09	-0.52	-0.41	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
KIRP	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-7.25	4.64e-12	5.86e-09	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-7.25	4.64e-12	5.86e-09	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-7.25	4.64e-12	5.86e-09	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
KIRP	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	7.25	4.65e-12	5.88e-09	0.44	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
KIRP	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	7.25	4.66e-12	5.89e-09	0.55	0.41	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
KIRP	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	7.25	4.7e-12	5.94e-09	0.46	0.41	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
KIRP	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	7.25	4.7e-12	5.94e-09	0.27	0.41	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
KIRP	cis	rs2749592	0.55	rs12255038	ENSG00000151963.4	RP11-775A3.1	7.25	4.71e-12	5.95e-09	0.44	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:37883594~37884109:+
KIRP	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	7.25	4.71e-12	5.95e-09	0.45	0.41	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
KIRP	cis	rs67311347	0.713	rs73073505	ENSG00000230274.1	PGAM1P3	7.25	4.71e-12	5.95e-09	0.41	0.41	Renal cell carcinoma;	chr3:40269202	chr3:40322715~40323279:-
KIRP	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-7.25	4.72e-12	5.97e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-7.25	4.72e-12	5.97e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-7.25	4.72e-12	5.97e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-7.25	4.72e-12	5.97e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
KIRP	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-7.25	4.72e-12	5.97e-09	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
KIRP	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-7.25	4.74e-12	5.98e-09	-0.46	-0.41	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-7.25	4.74e-12	5.98e-09	-0.46	-0.41	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
KIRP	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	7.25	4.74e-12	5.98e-09	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	7.25	4.74e-12	5.98e-09	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
KIRP	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-7.25	4.76e-12	6e-09	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
KIRP	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	7.25	4.76e-12	6.01e-09	0.52	0.41	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
KIRP	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	7.25	4.76e-12	6.01e-09	0.52	0.41	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
KIRP	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	7.25	4.77e-12	6.01e-09	0.46	0.41	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
KIRP	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	7.25	4.78e-12	6.03e-09	0.33	0.41	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
KIRP	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	7.24	4.84e-12	6.1e-09	0.46	0.41	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
KIRP	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	7.24	4.85e-12	6.1e-09	0.45	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
KIRP	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	7.24	4.85e-12	6.11e-09	0.43	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
KIRP	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	7.24	4.85e-12	6.11e-09	0.83	0.41	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
KIRP	cis	rs67311347	0.956	rs7640228	ENSG00000230274.1	PGAM1P3	-7.24	4.86e-12	6.12e-09	-0.39	-0.41	Renal cell carcinoma;	chr3:40474699	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.697	rs66666893	ENSG00000248763.2	RP13-644M16.5	-7.24	4.87e-12	6.13e-09	-0.45	-0.41	Obesity-related traits;	chr4:69133393	chr4:69066395~69069888:+
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	7.24	4.88e-12	6.14e-09	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
KIRP	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	7.24	4.89e-12	6.16e-09	0.71	0.41	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
KIRP	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-7.24	4.91e-12	6.18e-09	-0.54	-0.41	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
KIRP	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-7.24	4.92e-12	6.19e-09	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
KIRP	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	7.24	4.94e-12	6.21e-09	0.29	0.41	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	7.24	4.94e-12	6.21e-09	0.29	0.41	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
KIRP	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-7.24	4.95e-12	6.22e-09	-0.5	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
KIRP	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	7.24	4.95e-12	6.22e-09	0.46	0.41	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
KIRP	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-7.24	4.97e-12	6.25e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
KIRP	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	7.24	4.98e-12	6.26e-09	0.44	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	7.24	4.98e-12	6.26e-09	0.44	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	7.24	4.98e-12	6.26e-09	0.44	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
KIRP	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-7.24	4.98e-12	6.26e-09	-0.34	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
KIRP	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-7.24	4.99e-12	6.28e-09	-0.42	-0.41	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
KIRP	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.24	5.04e-12	6.33e-09	0.29	0.41	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
KIRP	cis	rs17082664	0.688	rs761408	ENSG00000226193.1	RP3-398G3.5	-7.24	5.08e-12	6.38e-09	-0.52	-0.41	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152415677	chr6:152402398~152404966:+
KIRP	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	7.24	5.09e-12	6.39e-09	0.5	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
KIRP	cis	rs67311347	1	rs9882171	ENSG00000230274.1	PGAM1P3	7.24	5.11e-12	6.42e-09	0.39	0.41	Renal cell carcinoma;	chr3:40477330	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	7.24	5.12e-12	6.42e-09	0.5	0.41	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
KIRP	cis	rs11647589	0.834	rs1505100	ENSG00000260762.1	ACSM5P1	-7.23	5.14e-12	6.45e-09	-0.41	-0.41	Blood metabolite levels;	chr16:20470350	chr16:20586550~20607107:-
KIRP	cis	rs67311347	0.956	rs9822870	ENSG00000230274.1	PGAM1P3	-7.23	5.15e-12	6.45e-09	-0.39	-0.41	Renal cell carcinoma;	chr3:40473399	chr3:40322715~40323279:-
KIRP	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	7.23	5.18e-12	6.5e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	7.23	5.18e-12	6.5e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	7.23	5.18e-12	6.5e-09	0.33	0.41	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
KIRP	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	7.23	5.19e-12	6.5e-09	0.34	0.41	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
KIRP	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.23	5.19e-12	6.5e-09	0.44	0.41	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
KIRP	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	7.23	5.2e-12	6.51e-09	0.27	0.41	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	7.23	5.2e-12	6.51e-09	0.27	0.41	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	7.23	5.2e-12	6.51e-09	0.27	0.41	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
KIRP	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-7.23	5.2e-12	6.52e-09	-0.51	-0.41	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
KIRP	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	7.23	5.23e-12	6.55e-09	0.37	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
KIRP	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	7.23	5.24e-12	6.56e-09	0.47	0.41	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
KIRP	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-7.23	5.24e-12	6.56e-09	-0.54	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
KIRP	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	7.23	5.24e-12	6.57e-09	0.4	0.41	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
KIRP	cis	rs4356975	0.83	rs6600868	ENSG00000250696.4	RP11-704M14.1	7.23	5.25e-12	6.57e-09	0.39	0.41	Obesity-related traits;	chr4:69075923	chr4:69182100~69216766:+
KIRP	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	7.23	5.28e-12	6.6e-09	0.37	0.41	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
KIRP	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-7.23	5.29e-12	6.62e-09	-0.48	-0.41	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-7.23	5.29e-12	6.62e-09	-0.48	-0.41	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
KIRP	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	7.23	5.32e-12	6.65e-09	0.39	0.41	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
KIRP	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-7.23	5.33e-12	6.67e-09	-0.48	-0.41	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
KIRP	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	7.23	5.34e-12	6.67e-09	0.49	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
KIRP	cis	rs1529102	1	rs1529102	ENSG00000225889.6	AC074289.1	-7.23	5.34e-12	6.68e-09	-0.36	-0.41	Breast size;	chr2:64268493	chr2:64143239~64252859:+
KIRP	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-7.23	5.35e-12	6.69e-09	-0.46	-0.41	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
KIRP	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-7.23	5.35e-12	6.69e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
KIRP	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	7.23	5.35e-12	6.7e-09	0.27	0.41	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
KIRP	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	7.23	5.36e-12	6.7e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	7.23	5.36e-12	6.7e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
KIRP	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	7.23	5.36e-12	6.71e-09	0.51	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
KIRP	cis	rs4578769	0.569	rs12955131	ENSG00000266850.1	RP11-370A5.1	-7.23	5.37e-12	6.71e-09	-0.48	-0.41	Eosinophil percentage of white cells;	chr18:22900424	chr18:22723491~22907721:-
KIRP	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	7.23	5.38e-12	6.73e-09	0.49	0.41	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
KIRP	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	7.23	5.39e-12	6.74e-09	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
KIRP	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-7.23	5.4e-12	6.75e-09	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
KIRP	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.23	5.41e-12	6.76e-09	0.29	0.41	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
KIRP	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-7.23	5.42e-12	6.77e-09	-0.46	-0.41	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
KIRP	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	7.23	5.42e-12	6.77e-09	0.77	0.41	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	7.23	5.42e-12	6.77e-09	0.77	0.41	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
KIRP	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	7.23	5.43e-12	6.78e-09	0.44	0.41	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	7.23	5.44e-12	6.8e-09	0.48	0.41	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
KIRP	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	7.23	5.46e-12	6.82e-09	0.51	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
KIRP	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-7.22	5.48e-12	6.85e-09	-0.45	-0.41	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
KIRP	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	7.22	5.49e-12	6.85e-09	0.43	0.41	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
KIRP	cis	rs67311347	1	rs13073003	ENSG00000230274.1	PGAM1P3	-7.22	5.49e-12	6.86e-09	-0.39	-0.41	Renal cell carcinoma;	chr3:40462835	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs6801185	ENSG00000230274.1	PGAM1P3	-7.22	5.49e-12	6.86e-09	-0.39	-0.41	Renal cell carcinoma;	chr3:40463569	chr3:40322715~40323279:-
KIRP	cis	rs755249	1	rs17513135	ENSG00000237624.1	OXCT2P1	7.22	5.53e-12	6.9e-09	0.63	0.41	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39514956~39516490:+
KIRP	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-7.22	5.54e-12	6.91e-09	-0.5	-0.41	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-7.22	5.54e-12	6.92e-09	-0.5	-0.41	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-7.22	5.55e-12	6.93e-09	-0.51	-0.41	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
KIRP	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-7.22	5.56e-12	6.94e-09	-0.47	-0.41	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
KIRP	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	7.22	5.69e-12	7.09e-09	0.3	0.41	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
KIRP	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	7.22	5.69e-12	7.1e-09	0.35	0.41	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	7.22	5.69e-12	7.1e-09	0.35	0.41	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
KIRP	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-7.22	5.71e-12	7.12e-09	-0.47	-0.41	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
KIRP	cis	rs950027	0.62	rs1617984	ENSG00000259433.2	CTD-2651B20.4	-7.22	5.74e-12	7.15e-09	-0.35	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45330209~45332634:-
KIRP	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	7.22	5.74e-12	7.15e-09	0.51	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
KIRP	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-7.22	5.75e-12	7.16e-09	-0.32	-0.41	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
KIRP	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	7.22	5.77e-12	7.19e-09	0.46	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
KIRP	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	7.21	5.82e-12	7.24e-09	0.45	0.41	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
KIRP	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-7.21	5.83e-12	7.25e-09	-0.44	-0.41	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
KIRP	cis	rs4578769	0.55	rs4473296	ENSG00000266850.1	RP11-370A5.1	-7.21	5.83e-12	7.26e-09	-0.49	-0.41	Eosinophil percentage of white cells;	chr18:22986421	chr18:22723491~22907721:-
KIRP	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-7.21	5.84e-12	7.26e-09	-0.56	-0.41	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
KIRP	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	7.21	5.85e-12	7.28e-09	0.49	0.41	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
KIRP	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-7.21	5.87e-12	7.31e-09	-0.53	-0.41	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
KIRP	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-7.21	5.92e-12	7.35e-09	-0.48	-0.41	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
KIRP	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-7.21	5.93e-12	7.37e-09	-0.52	-0.41	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
KIRP	cis	rs1529102	0.899	rs1358624	ENSG00000225889.6	AC074289.1	7.21	5.97e-12	7.41e-09	0.34	0.41	Breast size;	chr2:64259365	chr2:64143239~64252859:+
KIRP	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-7.21	5.98e-12	7.42e-09	-0.55	-0.41	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
KIRP	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-7.21	5.98e-12	7.43e-09	-0.67	-0.41	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
KIRP	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-7.21	6e-12	7.45e-09	-0.31	-0.41	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
KIRP	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-7.21	6.01e-12	7.46e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
KIRP	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-7.21	6.02e-12	7.47e-09	-0.34	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
KIRP	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	7.21	6.04e-12	7.5e-09	0.55	0.41	Height;	chr6:109358652	chr6:109382795~109383666:+
KIRP	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-7.21	6.06e-12	7.52e-09	-0.45	-0.41	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
KIRP	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-7.21	6.08e-12	7.54e-09	-0.58	-0.41	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
KIRP	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.21	6.15e-12	7.62e-09	-0.36	-0.41	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
KIRP	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	7.21	6.16e-12	7.63e-09	0.37	0.41	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
KIRP	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	7.2	6.2e-12	7.68e-09	0.54	0.41	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
KIRP	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-7.2	6.22e-12	7.71e-09	-0.54	-0.41	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
KIRP	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-7.2	6.22e-12	7.71e-09	-0.48	-0.41	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
KIRP	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-7.2	6.23e-12	7.71e-09	-0.36	-0.41	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
KIRP	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-7.2	6.25e-12	7.74e-09	-0.46	-0.41	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
KIRP	cis	rs11155671	0.53	rs9371504	ENSG00000223701.3	RAET1E-AS1	7.2	6.26e-12	7.74e-09	0.47	0.41	Testicular germ cell tumor;	chr6:149862944	chr6:149884431~149919508:+
KIRP	cis	rs11155671	0.53	rs9371505	ENSG00000223701.3	RAET1E-AS1	7.2	6.26e-12	7.74e-09	0.47	0.41	Testicular germ cell tumor;	chr6:149863012	chr6:149884431~149919508:+
KIRP	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-7.2	6.26e-12	7.75e-09	-0.44	-0.41	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
KIRP	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-7.2	6.27e-12	7.75e-09	-0.35	-0.41	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
KIRP	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	7.2	6.3e-12	7.79e-09	0.38	0.41	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
KIRP	cis	rs950027	0.62	rs1153855	ENSG00000259433.2	CTD-2651B20.4	-7.2	6.31e-12	7.81e-09	-0.34	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45330209~45332634:-
KIRP	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-7.2	6.32e-12	7.81e-09	-0.47	-0.41	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
KIRP	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-7.2	6.33e-12	7.83e-09	-0.46	-0.41	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
KIRP	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	7.2	6.4e-12	7.91e-09	0.47	0.41	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	7.2	6.4e-12	7.91e-09	0.47	0.41	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	7.2	6.4e-12	7.91e-09	0.47	0.41	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
KIRP	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	7.2	6.4e-12	7.91e-09	0.46	0.41	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
KIRP	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	7.2	6.42e-12	7.94e-09	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
KIRP	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-7.2	6.43e-12	7.94e-09	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
KIRP	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-7.2	6.44e-12	7.96e-09	-0.45	-0.41	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	7.2	6.51e-12	8.03e-09	0.5	0.41	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
KIRP	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-7.2	6.51e-12	8.04e-09	-0.39	-0.41	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
KIRP	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-7.2	6.51e-12	8.04e-09	-0.41	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
KIRP	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	7.19	6.57e-12	8.11e-09	0.3	0.41	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	7.19	6.58e-12	8.12e-09	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
KIRP	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	7.19	6.59e-12	8.13e-09	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	7.19	6.59e-12	8.13e-09	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
KIRP	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	7.19	6.6e-12	8.14e-09	0.6	0.41	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
KIRP	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-7.19	6.6e-12	8.15e-09	-0.54	-0.41	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
KIRP	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	7.19	6.64e-12	8.19e-09	0.46	0.41	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
KIRP	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-7.19	6.68e-12	8.22e-09	-0.46	-0.41	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-7.19	6.68e-12	8.22e-09	-0.46	-0.41	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
KIRP	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.19	6.68e-12	8.23e-09	0.55	0.41	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
KIRP	cis	rs17082664	0.79	rs9479313	ENSG00000226193.1	RP3-398G3.5	7.19	6.71e-12	8.26e-09	0.54	0.41	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152423615	chr6:152402398~152404966:+
KIRP	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	7.19	6.71e-12	8.26e-09	0.83	0.41	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
KIRP	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.19	6.72e-12	8.27e-09	0.33	0.41	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
KIRP	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-7.19	6.73e-12	8.29e-09	-0.54	-0.41	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
KIRP	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-7.19	6.74e-12	8.3e-09	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
KIRP	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-7.19	6.77e-12	8.34e-09	-0.33	-0.41	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	7.19	6.81e-12	8.38e-09	0.5	0.41	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
KIRP	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	7.19	6.81e-12	8.38e-09	0.57	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
KIRP	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-7.19	6.82e-12	8.4e-09	-0.5	-0.41	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
KIRP	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-7.19	6.83e-12	8.4e-09	-0.47	-0.41	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
KIRP	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	7.19	6.9e-12	8.49e-09	0.51	0.41	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
KIRP	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	7.19	6.91e-12	8.5e-09	0.83	0.41	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
KIRP	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-7.19	6.92e-12	8.51e-09	-0.42	-0.41	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
KIRP	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	7.19	6.95e-12	8.54e-09	0.31	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
KIRP	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-7.19	6.95e-12	8.55e-09	-0.44	-0.41	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
KIRP	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	7.19	6.96e-12	8.56e-09	0.85	0.41	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
KIRP	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	7.18	6.99e-12	8.59e-09	0.52	0.41	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
KIRP	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	7.18	6.99e-12	8.59e-09	0.37	0.41	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	7.18	6.99e-12	8.59e-09	0.37	0.41	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
KIRP	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-7.18	7e-12	8.6e-09	-0.38	-0.41	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
KIRP	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	7.18	7.05e-12	8.66e-09	0.55	0.41	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	7.18	7.05e-12	8.66e-09	0.55	0.41	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
KIRP	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-7.18	7.06e-12	8.67e-09	-0.43	-0.41	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
KIRP	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-7.18	7.07e-12	8.68e-09	-0.55	-0.41	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-7.18	7.08e-12	8.7e-09	-0.35	-0.41	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	7.18	7.08e-12	8.7e-09	0.3	0.41	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
KIRP	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	7.18	7.08e-12	8.7e-09	0.51	0.41	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
KIRP	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	7.18	7.09e-12	8.71e-09	0.34	0.41	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
KIRP	cis	rs4638749	0.588	rs13401731	ENSG00000231221.1	AC023672.2	-7.18	7.1e-12	8.72e-09	-0.49	-0.41	Blood pressure;	chr2:108268884	chr2:108049200~108052755:-
KIRP	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	7.18	7.11e-12	8.73e-09	0.48	0.41	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
KIRP	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-7.18	7.12e-12	8.74e-09	-0.54	-0.41	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
KIRP	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-7.18	7.12e-12	8.74e-09	-0.44	-0.41	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-7.18	7.13e-12	8.75e-09	-0.47	-0.41	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-7.18	7.13e-12	8.75e-09	-0.47	-0.41	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-7.18	7.13e-12	8.75e-09	-0.47	-0.41	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-7.18	7.13e-12	8.75e-09	-0.47	-0.41	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
KIRP	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	7.18	7.14e-12	8.76e-09	0.54	0.41	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
KIRP	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-7.18	7.19e-12	8.82e-09	-0.45	-0.41	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-7.18	7.19e-12	8.82e-09	-0.45	-0.41	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
KIRP	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	7.18	7.22e-12	8.85e-09	0.42	0.41	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
KIRP	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	7.18	7.24e-12	8.88e-09	0.5	0.41	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
KIRP	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	7.18	7.28e-12	8.92e-09	0.27	0.41	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
KIRP	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	7.18	7.3e-12	8.94e-09	0.42	0.41	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
KIRP	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-7.18	7.35e-12	9e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-7.18	7.35e-12	9e-09	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
KIRP	cis	rs2749592	0.55	rs10764135	ENSG00000151963.4	RP11-775A3.1	7.18	7.37e-12	9.02e-09	0.43	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:37883594~37884109:+
KIRP	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	7.18	7.38e-12	9.02e-09	0.27	0.41	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	7.18	7.38e-12	9.02e-09	0.27	0.41	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
KIRP	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	7.18	7.39e-12	9.04e-09	0.54	0.41	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
KIRP	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-7.18	7.4e-12	9.05e-09	-0.56	-0.41	Height;	chr6:109731677	chr6:109382795~109383666:+
KIRP	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	7.18	7.4e-12	9.05e-09	0.47	0.41	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	7.18	7.4e-12	9.05e-09	0.47	0.41	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	7.18	7.4e-12	9.05e-09	0.47	0.41	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
KIRP	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.18	7.4e-12	9.05e-09	-0.28	-0.41	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
KIRP	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	7.18	7.42e-12	9.06e-09	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
KIRP	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	7.17	7.54e-12	9.2e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
KIRP	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-7.17	7.55e-12	9.22e-09	-0.41	-0.41	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
KIRP	cis	rs2749592	0.531	rs10764134	ENSG00000151963.4	RP11-775A3.1	7.17	7.56e-12	9.22e-09	0.43	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:37883594~37884109:+
KIRP	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	7.17	7.58e-12	9.25e-09	0.39	0.41	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
KIRP	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.17	7.6e-12	9.27e-09	0.43	0.41	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
KIRP	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	7.17	7.67e-12	9.35e-09	0.39	0.4	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
KIRP	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-7.17	7.7e-12	9.38e-09	-0.33	-0.4	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
KIRP	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-7.17	7.7e-12	9.39e-09	-0.47	-0.4	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-7.17	7.7e-12	9.39e-09	-0.47	-0.4	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-7.17	7.7e-12	9.39e-09	-0.47	-0.4	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
KIRP	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	7.17	7.73e-12	9.43e-09	0.45	0.4	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
KIRP	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	7.17	7.74e-12	9.44e-09	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
KIRP	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	7.17	7.76e-12	9.46e-09	0.74	0.4	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
KIRP	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-7.17	7.78e-12	9.48e-09	-0.36	-0.4	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
KIRP	cis	rs9322193	0.923	rs9322225	ENSG00000231760.4	RP11-350J20.5	7.17	7.81e-12	9.52e-09	0.49	0.4	Lung cancer;	chr6:149863746	chr6:149796151~149826294:-
KIRP	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-7.17	7.82e-12	9.53e-09	-0.44	-0.4	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
KIRP	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-7.17	7.85e-12	9.56e-09	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-7.17	7.85e-12	9.56e-09	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
KIRP	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.16	7.9e-12	9.62e-09	0.26	0.4	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
KIRP	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-7.16	7.9e-12	9.62e-09	-0.38	-0.4	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
KIRP	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-7.16	7.92e-12	9.64e-09	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
KIRP	cis	rs4356975	0.697	rs5002700	ENSG00000248763.2	RP13-644M16.5	-7.16	7.97e-12	9.7e-09	-0.44	-0.4	Obesity-related traits;	chr4:69155637	chr4:69066395~69069888:+
KIRP	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	7.16	7.99e-12	9.72e-09	0.3	0.4	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
KIRP	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	7.16	8e-12	9.73e-09	0.8	0.4	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
KIRP	cis	rs7829975	0.582	rs6982832	ENSG00000253981.4	ALG1L13P	-7.16	8.03e-12	9.76e-09	-0.31	-0.4	Mood instability;	chr8:8934707	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.582	rs6983150	ENSG00000253981.4	ALG1L13P	-7.16	8.03e-12	9.76e-09	-0.31	-0.4	Mood instability;	chr8:8934916	chr8:8236003~8244667:-
KIRP	cis	rs950027	0.62	rs1145076	ENSG00000259433.2	CTD-2651B20.4	-7.16	8.05e-12	9.79e-09	-0.34	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45330209~45332634:-
KIRP	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	7.16	8.06e-12	9.8e-09	0.27	0.4	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
KIRP	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	7.16	8.07e-12	9.81e-09	0.32	0.4	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
KIRP	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-7.16	8.08e-12	9.82e-09	-0.43	-0.4	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
KIRP	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-7.16	8.08e-12	9.82e-09	-0.45	-0.4	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
KIRP	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.16	8.14e-12	9.89e-09	0.37	0.4	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
KIRP	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.16	8.14e-12	9.89e-09	-0.4	-0.4	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.16	8.14e-12	9.89e-09	-0.4	-0.4	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
KIRP	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-7.16	8.15e-12	9.89e-09	-0.45	-0.4	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
KIRP	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-7.16	8.16e-12	9.91e-09	-0.54	-0.4	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
KIRP	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-7.16	8.17e-12	9.92e-09	-0.52	-0.4	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
KIRP	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-7.16	8.23e-12	9.99e-09	-0.45	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
KIRP	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	7.16	8.27e-12	1e-08	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
KIRP	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	7.16	8.3e-12	1.01e-08	0.48	0.4	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
KIRP	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-7.16	8.33e-12	1.01e-08	-0.47	-0.4	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
KIRP	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	7.16	8.35e-12	1.01e-08	0.54	0.4	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
KIRP	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	7.16	8.36e-12	1.01e-08	0.37	0.4	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	7.16	8.36e-12	1.01e-08	0.37	0.4	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	7.16	8.36e-12	1.01e-08	0.37	0.4	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.16	8.36e-12	1.01e-08	0.52	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
KIRP	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	7.15	8.4e-12	1.02e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
KIRP	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-7.15	8.41e-12	1.02e-08	-0.45	-0.4	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-7.15	8.41e-12	1.02e-08	-0.45	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
KIRP	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	7.15	8.46e-12	1.02e-08	0.59	0.4	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
KIRP	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	7.15	8.46e-12	1.02e-08	0.42	0.4	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
KIRP	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	7.15	8.5e-12	1.03e-08	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	7.15	8.5e-12	1.03e-08	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
KIRP	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-7.15	8.53e-12	1.03e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-7.15	8.53e-12	1.03e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-7.15	8.53e-12	1.03e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-7.15	8.66e-12	1.05e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
KIRP	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-7.15	8.77e-12	1.06e-08	-0.52	-0.4	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	7.15	8.77e-12	1.06e-08	0.51	0.4	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
KIRP	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	7.15	8.79e-12	1.06e-08	0.44	0.4	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
KIRP	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-7.15	8.83e-12	1.07e-08	-0.4	-0.4	Axial length;	chr3:53813767	chr3:53797764~53798019:-
KIRP	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-7.15	8.88e-12	1.07e-08	-0.39	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
KIRP	cis	rs17082664	0.85	rs2281369	ENSG00000226193.1	RP3-398G3.5	-7.15	8.89e-12	1.07e-08	-0.62	-0.4	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152403191	chr6:152402398~152404966:+
KIRP	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-7.15	8.91e-12	1.08e-08	-0.49	-0.4	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
KIRP	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-7.15	8.91e-12	1.08e-08	-0.52	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
KIRP	cis	rs67311347	0.577	rs1317217	ENSG00000230274.1	PGAM1P3	7.15	8.91e-12	1.08e-08	0.4	0.4	Renal cell carcinoma;	chr3:40230206	chr3:40322715~40323279:-
KIRP	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	7.14	8.92e-12	1.08e-08	0.59	0.4	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
KIRP	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-7.14	8.93e-12	1.08e-08	-0.59	-0.4	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
KIRP	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-7.14	8.95e-12	1.08e-08	-0.49	-0.4	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
KIRP	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-7.14	9e-12	1.09e-08	-0.43	-0.4	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-7.14	9e-12	1.09e-08	-0.43	-0.4	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-7.14	9e-12	1.09e-08	-0.43	-0.4	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
KIRP	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	7.14	9.09e-12	1.1e-08	0.54	0.4	Height;	chr6:109351795	chr6:109382795~109383666:+
KIRP	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	7.14	9.1e-12	1.1e-08	0.51	0.4	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
KIRP	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-7.14	9.12e-12	1.1e-08	-0.7	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
KIRP	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	7.14	9.13e-12	1.1e-08	0.46	0.4	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
KIRP	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-7.14	9.22e-12	1.11e-08	-0.45	-0.4	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
KIRP	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
KIRP	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	7.14	9.29e-12	1.12e-08	0.47	0.4	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
KIRP	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-7.14	9.38e-12	1.13e-08	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
KIRP	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-7.14	9.38e-12	1.13e-08	-0.44	-0.4	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
KIRP	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	7.14	9.4e-12	1.13e-08	0.46	0.4	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
KIRP	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-7.14	9.43e-12	1.13e-08	-0.36	-0.4	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
KIRP	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-7.14	9.45e-12	1.14e-08	-0.47	-0.4	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
KIRP	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-7.13	9.47e-12	1.14e-08	-0.33	-0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
KIRP	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	7.13	9.52e-12	1.14e-08	0.59	0.4	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
KIRP	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	7.13	9.59e-12	1.15e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
KIRP	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-7.13	9.63e-12	1.16e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
KIRP	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-7.13	9.63e-12	1.16e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
KIRP	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	7.13	9.64e-12	1.16e-08	0.37	0.4	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
KIRP	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	7.13	9.72e-12	1.17e-08	0.51	0.4	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	7.13	9.72e-12	1.17e-08	0.51	0.4	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	7.13	9.72e-12	1.17e-08	0.51	0.4	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
KIRP	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	7.13	9.73e-12	1.17e-08	0.44	0.4	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
KIRP	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	7.13	9.74e-12	1.17e-08	0.34	0.4	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
KIRP	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-7.13	9.77e-12	1.17e-08	-0.52	-0.4	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
KIRP	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	7.13	9.78e-12	1.17e-08	0.33	0.4	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
KIRP	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-7.13	9.81e-12	1.18e-08	-0.46	-0.4	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
KIRP	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	7.13	9.82e-12	1.18e-08	0.47	0.4	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
KIRP	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	7.13	9.83e-12	1.18e-08	0.46	0.4	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
KIRP	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-7.13	9.86e-12	1.18e-08	-0.35	-0.4	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
KIRP	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-7.13	9.86e-12	1.18e-08	-0.35	-0.4	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
KIRP	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-7.13	9.89e-12	1.19e-08	-0.51	-0.4	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
KIRP	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-7.13	9.9e-12	1.19e-08	-0.51	-0.4	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	7.13	9.9e-12	1.19e-08	0.51	0.4	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	7.13	9.9e-12	1.19e-08	0.51	0.4	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	7.13	9.9e-12	1.19e-08	0.51	0.4	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
KIRP	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	7.13	9.92e-12	1.19e-08	0.5	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
KIRP	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	7.13	9.95e-12	1.19e-08	0.52	0.4	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	7.13	9.95e-12	1.19e-08	0.52	0.4	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-7.13	9.95e-12	1.19e-08	-0.37	-0.4	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
KIRP	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	7.13	9.95e-12	1.19e-08	0.58	0.4	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
KIRP	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-7.13	9.98e-12	1.2e-08	-0.48	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
KIRP	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	7.12	1.01e-11	1.21e-08	0.44	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
KIRP	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	7.12	1.01e-11	1.21e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	7.12	1.01e-11	1.21e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
KIRP	cis	rs11647589	0.651	rs6497485	ENSG00000260762.1	ACSM5P1	7.12	1.02e-11	1.22e-08	0.39	0.4	Blood metabolite levels;	chr16:20428511	chr16:20586550~20607107:-
KIRP	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	7.12	1.02e-11	1.23e-08	0.39	0.4	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
KIRP	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	7.12	1.03e-11	1.23e-08	0.55	0.4	Height;	chr6:109454233	chr6:109382795~109383666:+
KIRP	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-7.12	1.03e-11	1.23e-08	-0.61	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
KIRP	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-7.12	1.03e-11	1.23e-08	-0.35	-0.4	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-7.12	1.03e-11	1.23e-08	-0.35	-0.4	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
KIRP	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-7.12	1.03e-11	1.23e-08	-0.49	-0.4	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	7.12	1.03e-11	1.24e-08	0.49	0.4	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	7.12	1.03e-11	1.24e-08	0.49	0.4	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	7.12	1.03e-11	1.24e-08	0.49	0.4	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
KIRP	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	7.12	1.04e-11	1.24e-08	0.45	0.4	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
KIRP	cis	rs11650106	0.529	rs35391268	ENSG00000266992.1	DHX40P1	-7.12	1.04e-11	1.24e-08	-0.45	-0.4	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:59976009~60002384:-
KIRP	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	7.12	1.04e-11	1.24e-08	0.53	0.4	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.649	rs59421013	ENSG00000248763.2	RP13-644M16.5	-7.12	1.04e-11	1.25e-08	-0.43	-0.4	Obesity-related traits;	chr4:69149131	chr4:69066395~69069888:+
KIRP	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	7.12	1.04e-11	1.25e-08	0.45	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
KIRP	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-7.12	1.05e-11	1.25e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-7.12	1.05e-11	1.25e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-7.12	1.05e-11	1.25e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-7.12	1.05e-11	1.25e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
KIRP	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	7.12	1.05e-11	1.26e-08	0.49	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
KIRP	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-7.12	1.06e-11	1.26e-08	-0.46	-0.4	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
KIRP	cis	rs4578769	0.569	rs12326874	ENSG00000266850.1	RP11-370A5.1	7.12	1.06e-11	1.27e-08	0.49	0.4	Eosinophil percentage of white cells;	chr18:22926670	chr18:22723491~22907721:-
KIRP	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	7.12	1.06e-11	1.27e-08	0.36	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
KIRP	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-7.12	1.06e-11	1.27e-08	-0.46	-0.4	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
KIRP	cis	rs7115242	0.699	rs72645459	ENSG00000254851.1	RP11-109L13.1	7.12	1.06e-11	1.27e-08	0.85	0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891441	chr11:117135528~117138582:+
KIRP	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-7.12	1.07e-11	1.27e-08	-0.61	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
KIRP	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	7.12	1.07e-11	1.27e-08	0.48	0.4	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
KIRP	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	7.11	1.07e-11	1.28e-08	0.4	0.4	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
KIRP	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-7.11	1.07e-11	1.28e-08	-0.33	-0.4	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
KIRP	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-7.11	1.09e-11	1.29e-08	-0.36	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
KIRP	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-7.11	1.09e-11	1.3e-08	-0.55	-0.4	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
KIRP	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-7.11	1.09e-11	1.3e-08	-0.4	-0.4	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
KIRP	cis	rs4578769	0.531	rs12969559	ENSG00000266850.1	RP11-370A5.1	7.11	1.09e-11	1.3e-08	0.49	0.4	Eosinophil percentage of white cells;	chr18:22913702	chr18:22723491~22907721:-
KIRP	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-7.11	1.1e-11	1.31e-08	-0.48	-0.4	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
KIRP	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	7.11	1.1e-11	1.31e-08	0.44	0.4	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
KIRP	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	7.11	1.1e-11	1.31e-08	0.55	0.4	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	7.11	1.1e-11	1.31e-08	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
KIRP	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-7.11	1.1e-11	1.31e-08	-0.85	-0.4	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
KIRP	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-7.11	1.1e-11	1.31e-08	-0.44	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
KIRP	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.11	1.12e-11	1.33e-08	0.54	0.4	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.11	1.12e-11	1.33e-08	0.54	0.4	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-7.11	1.12e-11	1.33e-08	-0.35	-0.4	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
KIRP	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	7.11	1.12e-11	1.34e-08	0.54	0.4	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
KIRP	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-7.11	1.13e-11	1.34e-08	-0.47	-0.4	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
KIRP	cis	rs832187	0.679	rs9879045	ENSG00000280620.1	SCAANT1	7.11	1.13e-11	1.35e-08	0.45	0.4	Schizophrenia;	chr3:64016249	chr3:63911518~63911772:-
KIRP	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	7.11	1.14e-11	1.35e-08	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
KIRP	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	7.1	1.14e-11	1.35e-08	0.47	0.4	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
KIRP	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-7.1	1.14e-11	1.36e-08	-0.36	-0.4	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
KIRP	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-7.1	1.14e-11	1.36e-08	-0.53	-0.4	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-7.1	1.14e-11	1.36e-08	-0.53	-0.4	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
KIRP	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	7.1	1.15e-11	1.36e-08	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
KIRP	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-7.1	1.15e-11	1.37e-08	-0.46	-0.4	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-7.1	1.15e-11	1.37e-08	-0.46	-0.4	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
KIRP	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-7.1	1.15e-11	1.37e-08	-0.48	-0.4	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
KIRP	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	7.1	1.16e-11	1.37e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
KIRP	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-7.1	1.16e-11	1.38e-08	-0.52	-0.4	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-7.1	1.17e-11	1.39e-08	-0.47	-0.4	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
KIRP	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	7.1	1.18e-11	1.39e-08	0.27	0.4	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
KIRP	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-7.1	1.18e-11	1.4e-08	-0.48	-0.4	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
KIRP	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-7.1	1.18e-11	1.4e-08	-0.47	-0.4	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
KIRP	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	7.1	1.18e-11	1.4e-08	0.57	0.4	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
KIRP	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-7.1	1.19e-11	1.41e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
KIRP	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	7.1	1.2e-11	1.41e-08	0.49	0.4	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	7.1	1.2e-11	1.41e-08	0.49	0.4	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	7.1	1.2e-11	1.41e-08	0.49	0.4	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
KIRP	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	7.1	1.2e-11	1.42e-08	0.37	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
KIRP	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	7.09	1.21e-11	1.43e-08	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
KIRP	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	7.09	1.21e-11	1.43e-08	0.41	0.4	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
KIRP	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-7.09	1.21e-11	1.43e-08	-0.41	-0.4	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
KIRP	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	7.09	1.21e-11	1.44e-08	0.49	0.4	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
KIRP	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	7.09	1.22e-11	1.44e-08	0.5	0.4	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
KIRP	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-7.09	1.22e-11	1.44e-08	-0.39	-0.4	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
KIRP	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.09	1.22e-11	1.44e-08	0.27	0.4	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
KIRP	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	7.09	1.22e-11	1.45e-08	0.39	0.4	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
KIRP	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	7.09	1.23e-11	1.45e-08	0.51	0.4	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
KIRP	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	7.09	1.23e-11	1.45e-08	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	7.09	1.23e-11	1.45e-08	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	7.09	1.23e-11	1.45e-08	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
KIRP	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-7.09	1.23e-11	1.45e-08	-0.29	-0.4	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
KIRP	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-7.09	1.24e-11	1.46e-08	-0.48	-0.4	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-7.09	1.24e-11	1.46e-08	-0.48	-0.4	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-7.09	1.24e-11	1.47e-08	-0.47	-0.4	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
KIRP	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	7.09	1.24e-11	1.47e-08	0.53	0.4	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
KIRP	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-7.09	1.25e-11	1.47e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-7.09	1.25e-11	1.47e-08	-0.38	-0.4	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-7.09	1.26e-11	1.48e-08	-0.34	-0.4	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
KIRP	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	7.09	1.26e-11	1.49e-08	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
KIRP	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-7.09	1.28e-11	1.51e-08	-0.35	-0.4	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
KIRP	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-7.08	1.28e-11	1.51e-08	-0.46	-0.4	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
KIRP	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	7.08	1.29e-11	1.52e-08	0.45	0.4	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
KIRP	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-7.08	1.29e-11	1.52e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-7.08	1.29e-11	1.52e-08	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
KIRP	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	7.08	1.3e-11	1.53e-08	0.51	0.4	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	7.08	1.3e-11	1.53e-08	0.51	0.4	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
KIRP	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	7.08	1.3e-11	1.53e-08	0.46	0.4	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
KIRP	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.08	1.3e-11	1.53e-08	0.55	0.4	Height;	chr6:109546439	chr6:109382795~109383666:+
KIRP	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.08	1.3e-11	1.53e-08	0.55	0.4	Height;	chr6:109551060	chr6:109382795~109383666:+
KIRP	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-7.08	1.3e-11	1.54e-08	-0.44	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
KIRP	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-7.08	1.31e-11	1.54e-08	-0.39	-0.4	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-7.08	1.31e-11	1.54e-08	-0.39	-0.4	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
KIRP	cis	rs453301	0.624	rs4841083	ENSG00000253981.4	ALG1L13P	7.08	1.31e-11	1.54e-08	0.32	0.4	Joint mobility (Beighton score);	chr8:9012918	chr8:8236003~8244667:-
KIRP	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-7.08	1.32e-11	1.55e-08	-0.45	-0.4	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
KIRP	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	7.08	1.32e-11	1.55e-08	0.55	0.4	Height;	chr6:109739615	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	7.08	1.32e-11	1.55e-08	0.55	0.4	Height;	chr6:109740895	chr6:109382795~109383666:+
KIRP	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-7.08	1.32e-11	1.56e-08	-0.52	-0.4	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
KIRP	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	7.08	1.33e-11	1.56e-08	0.43	0.4	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
KIRP	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	7.08	1.34e-11	1.57e-08	0.46	0.4	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-7.08	1.34e-11	1.57e-08	-0.53	-0.4	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
KIRP	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-7.08	1.34e-11	1.58e-08	-0.39	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
KIRP	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-7.08	1.34e-11	1.58e-08	-0.33	-0.4	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-7.08	1.34e-11	1.58e-08	-0.33	-0.4	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	7.08	1.34e-11	1.58e-08	0.37	0.4	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
KIRP	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	7.08	1.34e-11	1.58e-08	0.54	0.4	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
KIRP	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	7.08	1.35e-11	1.59e-08	0.49	0.4	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
KIRP	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-7.08	1.35e-11	1.59e-08	-0.4	-0.4	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
KIRP	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-7.08	1.35e-11	1.59e-08	-0.42	-0.4	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
KIRP	cis	rs950027	0.62	rs1719245	ENSG00000259433.2	CTD-2651B20.4	-7.08	1.36e-11	1.59e-08	-0.34	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45330209~45332634:-
KIRP	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-7.08	1.36e-11	1.6e-08	-0.46	-0.4	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
KIRP	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-7.08	1.36e-11	1.6e-08	-0.33	-0.4	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
KIRP	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-7.07	1.37e-11	1.61e-08	-0.35	-0.4	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-7.07	1.38e-11	1.61e-08	-0.45	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
KIRP	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	7.07	1.38e-11	1.61e-08	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
KIRP	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-7.07	1.38e-11	1.62e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
KIRP	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-7.07	1.38e-11	1.62e-08	-0.5	-0.4	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
KIRP	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-7.07	1.38e-11	1.62e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
KIRP	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	7.07	1.39e-11	1.63e-08	0.52	0.4	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	7.07	1.39e-11	1.63e-08	0.52	0.4	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	7.07	1.39e-11	1.63e-08	0.52	0.4	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
KIRP	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	7.07	1.39e-11	1.63e-08	0.45	0.4	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
KIRP	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-7.07	1.4e-11	1.64e-08	-0.46	-0.4	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-7.07	1.4e-11	1.64e-08	-0.46	-0.4	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
KIRP	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.07	1.4e-11	1.64e-08	-0.36	-0.4	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
KIRP	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-7.07	1.41e-11	1.65e-08	-0.48	-0.4	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
KIRP	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	7.07	1.41e-11	1.65e-08	0.5	0.4	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
KIRP	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-7.07	1.41e-11	1.65e-08	-0.35	-0.4	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
KIRP	cis	rs4356975	0.83	rs7666894	ENSG00000250696.4	RP11-704M14.1	7.07	1.41e-11	1.66e-08	0.38	0.4	Obesity-related traits;	chr4:69078780	chr4:69182100~69216766:+
KIRP	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	7.07	1.43e-11	1.67e-08	0.4	0.4	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
KIRP	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	7.07	1.43e-11	1.67e-08	0.55	0.4	Height;	chr6:109715504	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	7.07	1.43e-11	1.67e-08	0.55	0.4	Height;	chr6:109715560	chr6:109382795~109383666:+
KIRP	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-7.07	1.43e-11	1.67e-08	-0.44	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
KIRP	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-7.07	1.43e-11	1.67e-08	-0.44	-0.4	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
KIRP	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	7.07	1.43e-11	1.68e-08	0.49	0.4	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-7.07	1.43e-11	1.68e-08	-0.46	-0.4	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-7.07	1.43e-11	1.68e-08	-0.46	-0.4	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-7.07	1.43e-11	1.68e-08	-0.46	-0.4	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-7.07	1.43e-11	1.68e-08	-0.46	-0.4	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
KIRP	cis	rs7829975	0.617	rs4841072	ENSG00000253981.4	ALG1L13P	-7.07	1.43e-11	1.68e-08	-0.31	-0.4	Mood instability;	chr8:8933743	chr8:8236003~8244667:-
KIRP	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	7.07	1.43e-11	1.68e-08	0.44	0.4	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	7.07	1.43e-11	1.68e-08	0.44	0.4	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	7.07	1.43e-11	1.68e-08	0.44	0.4	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
KIRP	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	7.07	1.43e-11	1.68e-08	0.56	0.4	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	7.07	1.43e-11	1.68e-08	0.56	0.4	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
KIRP	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	7.07	1.44e-11	1.69e-08	0.39	0.4	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	7.07	1.45e-11	1.69e-08	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
KIRP	cis	rs453301	0.624	rs2979256	ENSG00000253981.4	ALG1L13P	7.07	1.45e-11	1.69e-08	0.32	0.4	Joint mobility (Beighton score);	chr8:9014200	chr8:8236003~8244667:-
KIRP	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	7.06	1.45e-11	1.69e-08	0.56	0.4	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
KIRP	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	7.06	1.46e-11	1.7e-08	0.46	0.4	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
KIRP	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-7.06	1.46e-11	1.7e-08	-0.45	-0.4	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
KIRP	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-7.06	1.46e-11	1.7e-08	-0.45	-0.4	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
KIRP	cis	rs11647589	0.684	rs12051080	ENSG00000260762.1	ACSM5P1	7.06	1.46e-11	1.7e-08	0.39	0.4	Blood metabolite levels;	chr16:20428968	chr16:20586550~20607107:-
KIRP	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	7.06	1.48e-11	1.73e-08	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	7.06	1.48e-11	1.73e-08	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	7.06	1.48e-11	1.73e-08	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
KIRP	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	7.06	1.49e-11	1.74e-08	0.33	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	7.06	1.49e-11	1.74e-08	0.33	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	7.06	1.49e-11	1.74e-08	0.33	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
KIRP	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	7.06	1.49e-11	1.74e-08	0.56	0.4	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	7.06	1.49e-11	1.74e-08	0.56	0.4	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	7.06	1.49e-11	1.74e-08	0.56	0.4	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
KIRP	cis	rs17082664	0.688	rs2092602	ENSG00000226193.1	RP3-398G3.5	-7.06	1.5e-11	1.75e-08	-0.51	-0.4	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152415957	chr6:152402398~152404966:+
KIRP	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-7.06	1.51e-11	1.76e-08	-0.47	-0.4	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
KIRP	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-7.06	1.51e-11	1.77e-08	-0.35	-0.4	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
KIRP	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-7.06	1.52e-11	1.77e-08	-0.46	-0.4	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
KIRP	cis	rs67311347	0.869	rs7646899	ENSG00000230274.1	PGAM1P3	7.06	1.52e-11	1.77e-08	0.4	0.4	Renal cell carcinoma;	chr3:40325491	chr3:40322715~40323279:-
KIRP	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	7.06	1.53e-11	1.78e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
KIRP	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	7.06	1.54e-11	1.79e-08	0.41	0.4	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
KIRP	cis	rs67311347	0.869	rs6790495	ENSG00000230274.1	PGAM1P3	7.05	1.54e-11	1.8e-08	0.4	0.4	Renal cell carcinoma;	chr3:40325279	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.795	rs4694599	ENSG00000250696.4	RP11-704M14.1	7.05	1.55e-11	1.81e-08	0.38	0.4	Obesity-related traits;	chr4:69070858	chr4:69182100~69216766:+
KIRP	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-7.05	1.56e-11	1.81e-08	-0.35	-0.4	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
KIRP	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	7.05	1.56e-11	1.82e-08	0.56	0.4	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
KIRP	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-7.05	1.56e-11	1.82e-08	-0.44	-0.4	Temperament;	chr17:14075460	chr17:14024514~14025488:+
KIRP	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-7.05	1.57e-11	1.83e-08	-0.49	-0.4	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
KIRP	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-7.05	1.58e-11	1.83e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
KIRP	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-7.05	1.58e-11	1.84e-08	-0.4	-0.4	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
KIRP	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-7.05	1.59e-11	1.85e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-7.05	1.59e-11	1.85e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-7.05	1.59e-11	1.85e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
KIRP	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-7.05	1.59e-11	1.85e-08	-0.47	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
KIRP	cis	rs4638749	0.677	rs7594896	ENSG00000225328.1	AC019100.3	-7.05	1.6e-11	1.86e-08	-0.47	-0.4	Blood pressure;	chr2:108219046	chr2:108167748~108217841:-
KIRP	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-7.05	1.6e-11	1.86e-08	-0.44	-0.4	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
KIRP	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	7.05	1.62e-11	1.88e-08	0.54	0.4	Height;	chr6:109706514	chr6:109382795~109383666:+
KIRP	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-7.05	1.62e-11	1.89e-08	-0.53	-0.4	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-7.05	1.63e-11	1.89e-08	-0.53	-0.4	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-7.05	1.63e-11	1.89e-08	-0.53	-0.4	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
KIRP	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	7.05	1.63e-11	1.89e-08	0.27	0.4	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	7.05	1.63e-11	1.89e-08	0.27	0.4	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	7.05	1.63e-11	1.89e-08	0.27	0.4	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
KIRP	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	7.04	1.65e-11	1.91e-08	0.49	0.4	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	7.04	1.65e-11	1.91e-08	0.49	0.4	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
KIRP	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	7.04	1.65e-11	1.91e-08	0.54	0.4	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
KIRP	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109558247	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109564443	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109571489	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109576414	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109584789	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109588639	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.04	1.65e-11	1.91e-08	0.54	0.4	Height;	chr6:109589051	chr6:109382795~109383666:+
KIRP	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	7.04	1.65e-11	1.91e-08	0.45	0.4	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-7.04	1.65e-11	1.92e-08	-0.52	-0.4	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
KIRP	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-7.04	1.66e-11	1.92e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
KIRP	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	7.04	1.66e-11	1.92e-08	0.53	0.4	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	7.04	1.66e-11	1.92e-08	0.53	0.4	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	7.04	1.66e-11	1.92e-08	0.53	0.4	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	7.04	1.66e-11	1.92e-08	0.53	0.4	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
KIRP	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	7.04	1.66e-11	1.93e-08	0.33	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
KIRP	cis	rs7829975	0.606	rs6601274	ENSG00000253893.2	FAM85B	7.04	1.67e-11	1.93e-08	0.51	0.4	Mood instability;	chr8:8941549	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-7.04	1.67e-11	1.93e-08	-0.49	-0.4	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
KIRP	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	7.04	1.67e-11	1.94e-08	0.47	0.4	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
KIRP	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	7.04	1.67e-11	1.94e-08	0.47	0.4	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
KIRP	cis	rs2486288	0.539	rs2433601	ENSG00000259433.2	CTD-2651B20.4	-7.04	1.68e-11	1.94e-08	-0.34	-0.4	Glomerular filtration rate;	chr15:45424227	chr15:45330209~45332634:-
KIRP	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-7.04	1.68e-11	1.94e-08	-0.51	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
KIRP	cis	rs2749592	0.513	rs1208708	ENSG00000151963.4	RP11-775A3.1	-7.04	1.69e-11	1.95e-08	-0.46	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37883594~37884109:+
KIRP	cis	rs4356975	0.697	rs6849081	ENSG00000248763.2	RP13-644M16.5	-7.04	1.69e-11	1.96e-08	-0.43	-0.4	Obesity-related traits;	chr4:69144840	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.697	rs58039330	ENSG00000248763.2	RP13-644M16.5	-7.04	1.69e-11	1.96e-08	-0.43	-0.4	Obesity-related traits;	chr4:69149529	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.66	rs60567038	ENSG00000248763.2	RP13-644M16.5	-7.04	1.69e-11	1.96e-08	-0.43	-0.4	Obesity-related traits;	chr4:69150135	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.697	rs58366569	ENSG00000248763.2	RP13-644M16.5	-7.04	1.69e-11	1.96e-08	-0.43	-0.4	Obesity-related traits;	chr4:69150626	chr4:69066395~69069888:+
KIRP	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	7.04	1.69e-11	1.96e-08	0.48	0.4	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
KIRP	cis	rs4638749	0.627	rs6542753	ENSG00000225328.1	AC019100.3	-7.04	1.7e-11	1.96e-08	-0.48	-0.4	Blood pressure;	chr2:108199396	chr2:108167748~108217841:-
KIRP	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-7.04	1.7e-11	1.97e-08	-0.53	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
KIRP	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	7.04	1.71e-11	1.98e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
KIRP	cis	rs7672749	1	rs72879198	ENSG00000249973.2	CHCHD2P7	7.04	1.71e-11	1.98e-08	0.77	0.4	TB-LM or TBLH-BMD (pleiotropy);	chr4:87883468	chr4:87785920~87786371:-
KIRP	cis	rs7672749	1	rs66735573	ENSG00000249973.2	CHCHD2P7	7.04	1.71e-11	1.98e-08	0.77	0.4	TB-LM or TBLH-BMD (pleiotropy);	chr4:87883746	chr4:87785920~87786371:-
KIRP	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	7.04	1.71e-11	1.98e-08	0.36	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
KIRP	cis	rs2749592	0.505	rs7915670	ENSG00000151963.4	RP11-775A3.1	7.04	1.71e-11	1.98e-08	0.42	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:37883594~37884109:+
KIRP	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	7.04	1.72e-11	1.99e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	7.04	1.72e-11	1.99e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	7.04	1.72e-11	1.99e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
KIRP	cis	rs7829975	0.606	rs7837026	ENSG00000253893.2	FAM85B	7.04	1.72e-11	1.99e-08	0.52	0.4	Mood instability;	chr8:8944182	chr8:8167819~8226614:-
KIRP	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	7.04	1.73e-11	1.99e-08	0.5	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
KIRP	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	7.04	1.73e-11	2e-08	0.47	0.4	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
KIRP	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-7.04	1.73e-11	2e-08	-0.6	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
KIRP	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	7.04	1.74e-11	2e-08	0.52	0.4	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
KIRP	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	7.03	1.74e-11	2.01e-08	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
KIRP	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-7.03	1.74e-11	2.01e-08	-0.46	-0.4	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-7.03	1.74e-11	2.01e-08	-0.46	-0.4	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-7.03	1.74e-11	2.01e-08	-0.46	-0.4	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-7.03	1.74e-11	2.01e-08	-0.46	-0.4	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-7.03	1.74e-11	2.01e-08	-0.46	-0.4	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	7.03	1.75e-11	2.02e-08	0.46	0.4	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
KIRP	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	7.03	1.75e-11	2.02e-08	0.55	0.4	Height;	chr6:109747119	chr6:109382795~109383666:+
KIRP	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	7.03	1.75e-11	2.02e-08	0.55	0.4	Height;	chr6:109747411	chr6:109382795~109383666:+
KIRP	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	7.03	1.75e-11	2.02e-08	0.55	0.4	Height;	chr6:109748819	chr6:109382795~109383666:+
KIRP	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	7.03	1.75e-11	2.02e-08	0.55	0.4	Height;	chr6:109749564	chr6:109382795~109383666:+
KIRP	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	7.03	1.75e-11	2.02e-08	0.55	0.4	Height;	chr6:109763331	chr6:109382795~109383666:+
KIRP	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-7.03	1.75e-11	2.02e-08	-0.35	-0.4	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
KIRP	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	7.03	1.76e-11	2.03e-08	0.44	0.4	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
KIRP	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	7.03	1.76e-11	2.03e-08	0.55	0.4	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	7.03	1.76e-11	2.03e-08	0.55	0.4	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	7.03	1.76e-11	2.03e-08	0.55	0.4	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	7.03	1.76e-11	2.03e-08	0.55	0.4	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	7.03	1.76e-11	2.03e-08	0.55	0.4	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
KIRP	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-7.03	1.76e-11	2.03e-08	-0.38	-0.4	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
KIRP	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	7.03	1.77e-11	2.04e-08	0.87	0.4	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
KIRP	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	7.03	1.77e-11	2.04e-08	0.46	0.4	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	7.03	1.77e-11	2.04e-08	0.46	0.4	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
KIRP	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-7.03	1.78e-11	2.05e-08	-0.93	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
KIRP	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	7.03	1.78e-11	2.05e-08	0.43	0.4	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
KIRP	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	7.03	1.78e-11	2.05e-08	0.43	0.4	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
KIRP	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	7.03	1.78e-11	2.05e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	7.03	1.79e-11	2.07e-08	0.36	0.4	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
KIRP	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-7.03	1.8e-11	2.08e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
KIRP	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-7.03	1.81e-11	2.09e-08	-0.45	-0.4	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
KIRP	cis	rs13423976	0.631	rs4566347	ENSG00000231367.4	AC016995.3	7.03	1.82e-11	2.09e-08	0.51	0.4	Gut microbiome composition (summer);	chr2:38515498	chr2:38406719~38515740:-
KIRP	cis	rs13423976	0.572	rs11893988	ENSG00000231367.4	AC016995.3	7.03	1.82e-11	2.09e-08	0.51	0.4	Gut microbiome composition (summer);	chr2:38515630	chr2:38406719~38515740:-
KIRP	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	7.03	1.82e-11	2.1e-08	0.34	0.4	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
KIRP	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	7.03	1.82e-11	2.1e-08	0.59	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
KIRP	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	7.03	1.83e-11	2.11e-08	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
KIRP	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-7.03	1.83e-11	2.11e-08	-0.45	-0.4	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
KIRP	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	7.03	1.83e-11	2.11e-08	0.42	0.4	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	7.03	1.83e-11	2.11e-08	0.42	0.4	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
KIRP	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-7.03	1.84e-11	2.11e-08	-0.46	-0.4	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
KIRP	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	7.03	1.84e-11	2.12e-08	0.51	0.4	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
KIRP	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	7.03	1.84e-11	2.12e-08	0.33	0.4	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
KIRP	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	7.02	1.85e-11	2.13e-08	0.5	0.4	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	7.02	1.86e-11	2.13e-08	0.46	0.4	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-7.02	1.86e-11	2.14e-08	-0.53	-0.4	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
KIRP	cis	rs5760092	0.842	rs5760103	ENSG00000225282.1	AP000350.6	7.02	1.86e-11	2.14e-08	0.53	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23926900~23929574:+
KIRP	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	7.02	1.86e-11	2.14e-08	0.41	0.4	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
KIRP	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	7.02	1.86e-11	2.14e-08	0.58	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
KIRP	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.02	1.87e-11	2.15e-08	0.55	0.4	Height;	chr6:109586733	chr6:109382795~109383666:+
KIRP	cis	rs62344088	0.744	rs76038312	ENSG00000277812.1	AC021087.1	7.02	1.87e-11	2.15e-08	1.03	0.4	Asthma (childhood onset);	chr5:228890	chr5:262769~262881:+
KIRP	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	7.02	1.87e-11	2.15e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
KIRP	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	7.02	1.87e-11	2.15e-08	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
KIRP	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	7.02	1.87e-11	2.15e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
KIRP	cis	rs67311347	0.822	rs11709089	ENSG00000230274.1	PGAM1P3	7.02	1.87e-11	2.15e-08	0.4	0.4	Renal cell carcinoma;	chr3:40309993	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.866	rs9826419	ENSG00000230274.1	PGAM1P3	7.02	1.87e-11	2.15e-08	0.4	0.4	Renal cell carcinoma;	chr3:40310560	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.866	rs3214006	ENSG00000230274.1	PGAM1P3	7.02	1.87e-11	2.15e-08	0.4	0.4	Renal cell carcinoma;	chr3:40310643	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.866	rs56331709	ENSG00000230274.1	PGAM1P3	7.02	1.87e-11	2.15e-08	0.4	0.4	Renal cell carcinoma;	chr3:40315067	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.824	rs73073561	ENSG00000230274.1	PGAM1P3	7.02	1.87e-11	2.15e-08	0.4	0.4	Renal cell carcinoma;	chr3:40315807	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	7.02	1.88e-11	2.16e-08	0.47	0.4	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
KIRP	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	7.02	1.88e-11	2.16e-08	0.41	0.4	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-7.02	1.9e-11	2.18e-08	-0.46	-0.4	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	7.02	1.9e-11	2.18e-08	0.46	0.4	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
KIRP	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-7.02	1.9e-11	2.18e-08	-0.46	-0.4	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
KIRP	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-7.02	1.9e-11	2.18e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
KIRP	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	7.02	1.9e-11	2.18e-08	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
KIRP	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	7.02	1.9e-11	2.18e-08	0.66	0.4	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	7.02	1.9e-11	2.18e-08	0.66	0.4	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	7.02	1.9e-11	2.18e-08	0.66	0.4	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	7.02	1.9e-11	2.18e-08	0.66	0.4	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	7.02	1.9e-11	2.18e-08	0.66	0.4	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
KIRP	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	7.02	1.91e-11	2.19e-08	0.53	0.4	Height;	chr6:109405536	chr6:109382795~109383666:+
KIRP	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	7.02	1.91e-11	2.19e-08	0.52	0.4	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
KIRP	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.02	1.91e-11	2.2e-08	0.55	0.4	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
KIRP	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	7.02	1.92e-11	2.2e-08	0.56	0.4	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	7.02	1.92e-11	2.2e-08	0.56	0.4	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
KIRP	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-7.02	1.93e-11	2.21e-08	-0.53	-0.4	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
KIRP	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	7.02	1.93e-11	2.21e-08	0.65	0.4	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
KIRP	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	7.02	1.93e-11	2.21e-08	0.53	0.4	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
KIRP	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	7.02	1.94e-11	2.22e-08	0.54	0.4	Height;	chr6:109706740	chr6:109382795~109383666:+
KIRP	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	7.02	1.95e-11	2.24e-08	0.33	0.4	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
KIRP	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	7.02	1.95e-11	2.24e-08	0.38	0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
KIRP	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	7.01	1.96e-11	2.25e-08	0.46	0.4	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
KIRP	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-7.01	1.97e-11	2.25e-08	-0.51	-0.4	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
KIRP	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-7.01	1.98e-11	2.27e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
KIRP	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-7.01	1.98e-11	2.27e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
KIRP	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-7.01	1.98e-11	2.27e-08	-0.37	-0.4	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
KIRP	cis	rs4638749	0.654	rs6761157	ENSG00000225328.1	AC019100.3	-7.01	1.98e-11	2.27e-08	-0.48	-0.4	Blood pressure;	chr2:108200429	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs13398290	ENSG00000225328.1	AC019100.3	-7.01	1.98e-11	2.27e-08	-0.48	-0.4	Blood pressure;	chr2:108217397	chr2:108167748~108217841:-
KIRP	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-7.01	1.98e-11	2.27e-08	-0.4	-0.4	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
KIRP	cis	rs9371601	0.828	rs214996	ENSG00000226193.1	RP3-398G3.5	-7.01	1.98e-11	2.27e-08	-0.43	-0.4	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152441520	chr6:152402398~152404966:+
KIRP	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-7.01	1.98e-11	2.27e-08	-0.51	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
KIRP	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	7.01	1.99e-11	2.28e-08	0.47	0.4	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
KIRP	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	7.01	1.99e-11	2.28e-08	0.3	0.4	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
KIRP	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-7.01	2e-11	2.29e-08	-0.47	-0.4	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
KIRP	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	7.01	2e-11	2.29e-08	0.42	0.4	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
KIRP	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-7.01	2e-11	2.29e-08	-0.43	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
KIRP	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	7.01	2e-11	2.29e-08	0.32	0.4	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
KIRP	cis	rs7672749	1	rs11733405	ENSG00000249973.2	CHCHD2P7	7.01	2.03e-11	2.32e-08	0.76	0.4	TB-LM or TBLH-BMD (pleiotropy);	chr4:87877498	chr4:87785920~87786371:-
KIRP	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-7.01	2.03e-11	2.33e-08	-0.29	-0.4	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	7.01	2.04e-11	2.33e-08	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
KIRP	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	7.01	2.04e-11	2.34e-08	0.3	0.4	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
KIRP	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	7.01	2.04e-11	2.34e-08	0.53	0.4	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
KIRP	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-7.01	2.05e-11	2.34e-08	-0.4	-0.4	Axial length;	chr3:53813381	chr3:53797764~53798019:-
KIRP	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	7.01	2.05e-11	2.34e-08	0.51	0.4	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	7.01	2.05e-11	2.34e-08	0.51	0.4	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	7.01	2.06e-11	2.35e-08	0.46	0.4	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
KIRP	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-7.01	2.06e-11	2.35e-08	-0.5	-0.4	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
KIRP	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	7.01	2.07e-11	2.36e-08	0.55	0.4	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
KIRP	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	7.01	2.07e-11	2.36e-08	0.46	0.4	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	7.01	2.07e-11	2.36e-08	0.46	0.4	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
KIRP	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-7	2.08e-11	2.38e-08	-0.44	-0.4	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
KIRP	cis	rs4578769	0.513	rs2034933	ENSG00000266850.1	RP11-370A5.1	7	2.08e-11	2.38e-08	0.48	0.4	Eosinophil percentage of white cells;	chr18:22918788	chr18:22723491~22907721:-
KIRP	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-7	2.08e-11	2.38e-08	-0.46	-0.4	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
KIRP	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	7	2.09e-11	2.38e-08	0.35	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
KIRP	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7	2.09e-11	2.38e-08	0.33	0.4	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
KIRP	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	7	2.09e-11	2.39e-08	0.51	0.4	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
KIRP	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-7	2.12e-11	2.41e-08	-0.35	-0.4	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
KIRP	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	7	2.12e-11	2.41e-08	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
KIRP	cis	rs17082664	0.688	rs7738528	ENSG00000226193.1	RP3-398G3.5	-7	2.12e-11	2.41e-08	-0.51	-0.4	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152417200	chr6:152402398~152404966:+
KIRP	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	7	2.12e-11	2.42e-08	0.56	0.4	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
KIRP	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	7	2.12e-11	2.42e-08	0.4	0.4	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
KIRP	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	7	2.12e-11	2.42e-08	0.4	0.4	Breast size;	chr12:9232939	chr12:9277235~9313241:+
KIRP	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7	2.13e-11	2.43e-08	0.43	0.4	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
KIRP	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	7	2.13e-11	2.43e-08	0.33	0.4	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	7	2.13e-11	2.43e-08	0.33	0.4	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	7	2.14e-11	2.44e-08	0.37	0.4	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	7	2.14e-11	2.44e-08	0.46	0.4	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	7	2.14e-11	2.44e-08	0.46	0.4	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	7	2.14e-11	2.44e-08	0.46	0.4	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-7	2.14e-11	2.44e-08	-0.51	-0.4	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
KIRP	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-7	2.15e-11	2.45e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
KIRP	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	7	2.16e-11	2.46e-08	0.5	0.4	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
KIRP	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-7	2.17e-11	2.46e-08	-0.44	-0.4	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
KIRP	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-7	2.17e-11	2.47e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
KIRP	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	7	2.17e-11	2.47e-08	0.76	0.4	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
KIRP	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	7	2.17e-11	2.47e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
KIRP	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	7	2.19e-11	2.49e-08	0.47	0.4	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
KIRP	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	7	2.2e-11	2.5e-08	0.51	0.4	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
KIRP	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.56	0.4	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-7	2.2e-11	2.5e-08	-0.56	-0.4	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
KIRP	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	7	2.2e-11	2.5e-08	0.44	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
KIRP	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	7	2.2e-11	2.5e-08	0.53	0.4	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
KIRP	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	6.99	2.21e-11	2.51e-08	0.49	0.4	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
KIRP	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	6.99	2.21e-11	2.51e-08	0.47	0.4	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
KIRP	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	6.99	2.22e-11	2.51e-08	0.43	0.4	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
KIRP	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-6.99	2.22e-11	2.52e-08	-0.31	-0.4	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
KIRP	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-6.99	2.22e-11	2.52e-08	-0.91	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
KIRP	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-6.99	2.23e-11	2.53e-08	-0.27	-0.4	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
KIRP	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	6.99	2.23e-11	2.53e-08	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
KIRP	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	6.99	2.23e-11	2.53e-08	0.49	0.4	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
KIRP	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	6.99	2.23e-11	2.53e-08	0.5	0.4	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
KIRP	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	6.99	2.24e-11	2.54e-08	0.35	0.4	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
KIRP	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	6.99	2.24e-11	2.54e-08	0.71	0.4	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
KIRP	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.99	2.25e-11	2.55e-08	0.33	0.4	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
KIRP	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-6.99	2.26e-11	2.57e-08	-0.39	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
KIRP	cis	rs4638749	0.677	rs12329189	ENSG00000225328.1	AC019100.3	-6.99	2.27e-11	2.57e-08	-0.47	-0.4	Blood pressure;	chr2:108196399	chr2:108167748~108217841:-
KIRP	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-6.99	2.27e-11	2.58e-08	-0.61	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
KIRP	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-6.99	2.27e-11	2.58e-08	-0.39	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	6.99	2.28e-11	2.59e-08	0.38	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
KIRP	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-6.99	2.28e-11	2.59e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
KIRP	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	6.99	2.28e-11	2.59e-08	0.54	0.4	Height;	chr6:109592105	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	6.99	2.28e-11	2.59e-08	0.54	0.4	Height;	chr6:109608105	chr6:109382795~109383666:+
KIRP	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-6.99	2.29e-11	2.59e-08	-0.3	-0.4	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
KIRP	cis	rs1930961	0.558	rs5996951	ENSG00000272977.1	CTA-390C10.10	-6.99	2.3e-11	2.6e-08	-0.54	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25476218~25479971:+
KIRP	cis	rs1476679	0.927	rs2405442	ENSG00000078319.8	PMS2P1	6.99	2.3e-11	2.6e-08	0.52	0.4	Alzheimer's disease (late onset);	chr7:100373690	chr7:100320992~100341908:-
KIRP	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	6.99	2.31e-11	2.61e-08	0.27	0.4	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	6.99	2.31e-11	2.61e-08	0.27	0.4	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	6.99	2.31e-11	2.61e-08	0.27	0.4	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	6.99	2.31e-11	2.61e-08	0.27	0.4	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
KIRP	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-6.99	2.31e-11	2.61e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
KIRP	cis	rs950027	0.595	rs2486288	ENSG00000259433.2	CTD-2651B20.4	-6.99	2.31e-11	2.62e-08	-0.33	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45330209~45332634:-
KIRP	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	6.99	2.32e-11	2.63e-08	0.46	0.4	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
KIRP	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	6.99	2.33e-11	2.64e-08	0.52	0.4	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
KIRP	cis	rs950027	0.596	rs2467853	ENSG00000259433.2	CTD-2651B20.4	-6.99	2.33e-11	2.64e-08	-0.33	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45330209~45332634:-
KIRP	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	6.99	2.34e-11	2.65e-08	0.4	0.4	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-6.99	2.34e-11	2.65e-08	-0.4	-0.4	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-6.98	2.35e-11	2.65e-08	-0.37	-0.4	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
KIRP	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-6.98	2.35e-11	2.65e-08	-0.43	-0.4	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
KIRP	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	6.98	2.35e-11	2.66e-08	0.52	0.4	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
KIRP	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-6.98	2.36e-11	2.67e-08	-0.42	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
KIRP	cis	rs2921073	0.51	rs2976944	ENSG00000253893.2	FAM85B	-6.98	2.37e-11	2.67e-08	-0.53	-0.4	Parkinson's disease;	chr8:8413404	chr8:8167819~8226614:-
KIRP	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-6.98	2.37e-11	2.68e-08	-0.51	-0.4	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
KIRP	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-6.98	2.37e-11	2.68e-08	-0.52	-0.4	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	6.98	2.37e-11	2.68e-08	0.46	0.4	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	6.98	2.37e-11	2.68e-08	0.46	0.4	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
KIRP	cis	rs67311347	0.577	rs2887951	ENSG00000230274.1	PGAM1P3	6.98	2.38e-11	2.68e-08	0.38	0.4	Renal cell carcinoma;	chr3:40240613	chr3:40322715~40323279:-
KIRP	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	6.98	2.38e-11	2.69e-08	0.53	0.4	Height;	chr6:109447092	chr6:109382795~109383666:+
KIRP	cis	rs950027	0.62	rs2486274	ENSG00000259433.2	CTD-2651B20.4	-6.98	2.39e-11	2.7e-08	-0.33	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45330209~45332634:-
KIRP	cis	rs950027	0.62	rs1145080	ENSG00000259433.2	CTD-2651B20.4	-6.98	2.39e-11	2.7e-08	-0.33	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45330209~45332634:-
KIRP	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-6.98	2.39e-11	2.7e-08	-0.56	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
KIRP	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-6.98	2.39e-11	2.7e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-6.98	2.39e-11	2.7e-08	-0.37	-0.4	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
KIRP	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	6.98	2.4e-11	2.71e-08	0.56	0.4	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
KIRP	cis	rs4356975	0.83	rs3922514	ENSG00000250696.4	RP11-704M14.1	6.98	2.4e-11	2.71e-08	0.37	0.4	Obesity-related traits;	chr4:69060905	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs28775401	ENSG00000250696.4	RP11-704M14.1	6.98	2.4e-11	2.71e-08	0.37	0.4	Obesity-related traits;	chr4:69060999	chr4:69182100~69216766:+
KIRP	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-6.98	2.41e-11	2.72e-08	-0.56	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
KIRP	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-6.98	2.41e-11	2.72e-08	-0.55	-0.4	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	6.98	2.43e-11	2.73e-08	0.46	0.4	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	6.98	2.43e-11	2.74e-08	0.54	0.4	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
KIRP	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-6.98	2.43e-11	2.74e-08	-0.4	-0.4	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
KIRP	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-6.98	2.44e-11	2.75e-08	-0.45	-0.4	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
KIRP	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-6.98	2.45e-11	2.75e-08	-0.41	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
KIRP	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-6.98	2.45e-11	2.76e-08	-0.46	-0.4	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.98	2.45e-11	2.76e-08	0.37	0.4	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
KIRP	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.98	2.45e-11	2.76e-08	-0.33	-0.4	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
KIRP	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-6.98	2.46e-11	2.77e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-6.98	2.46e-11	2.77e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-6.98	2.46e-11	2.77e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-6.98	2.46e-11	2.77e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-6.98	2.46e-11	2.77e-08	-0.59	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
KIRP	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-6.98	2.46e-11	2.77e-08	-0.6	-0.4	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
KIRP	cis	rs7672749	1	rs7672749	ENSG00000249973.2	CHCHD2P7	6.98	2.48e-11	2.79e-08	0.75	0.4	TB-LM or TBLH-BMD (pleiotropy);	chr4:87877132	chr4:87785920~87786371:-
KIRP	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-6.98	2.48e-11	2.79e-08	-0.48	-0.4	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-6.98	2.48e-11	2.79e-08	-0.48	-0.4	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
KIRP	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	6.98	2.48e-11	2.79e-08	0.3	0.4	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
KIRP	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-6.98	2.48e-11	2.8e-08	-0.58	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
KIRP	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-6.98	2.49e-11	2.8e-08	-0.61	-0.4	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	6.97	2.49e-11	2.8e-08	0.48	0.4	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	6.97	2.49e-11	2.8e-08	0.48	0.4	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
KIRP	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	6.97	2.5e-11	2.81e-08	0.6	0.4	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
KIRP	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-6.97	2.52e-11	2.84e-08	-0.44	-0.4	Migraine;	chr4:56852029	chr4:56960927~56961373:-
KIRP	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	6.97	2.53e-11	2.84e-08	0.31	0.4	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
KIRP	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	6.97	2.53e-11	2.84e-08	0.58	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
KIRP	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	6.97	2.53e-11	2.84e-08	0.52	0.4	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
KIRP	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-6.97	2.55e-11	2.86e-08	-0.35	-0.4	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
KIRP	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-6.97	2.56e-11	2.87e-08	-0.35	-0.4	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
KIRP	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-6.97	2.57e-11	2.88e-08	-0.48	-0.4	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	6.97	2.57e-11	2.89e-08	0.52	0.4	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
KIRP	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	6.97	2.57e-11	2.89e-08	0.4	0.4	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-6.97	2.57e-11	2.89e-08	-0.4	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
KIRP	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	6.97	2.58e-11	2.9e-08	0.65	0.4	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
KIRP	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	6.97	2.59e-11	2.9e-08	0.46	0.4	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
KIRP	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.97	2.59e-11	2.91e-08	0.46	0.4	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
KIRP	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-6.97	2.61e-11	2.93e-08	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
KIRP	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-6.97	2.61e-11	2.93e-08	-0.52	-0.4	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-6.97	2.61e-11	2.93e-08	-0.52	-0.4	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-6.97	2.61e-11	2.93e-08	-0.52	-0.4	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	6.97	2.61e-11	2.93e-08	0.46	0.4	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	6.97	2.61e-11	2.93e-08	0.46	0.4	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	6.97	2.61e-11	2.93e-08	0.46	0.4	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	6.97	2.61e-11	2.93e-08	0.46	0.4	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	6.97	2.63e-11	2.95e-08	0.46	0.4	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
KIRP	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	6.97	2.64e-11	2.96e-08	0.51	0.4	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
KIRP	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	6.96	2.66e-11	2.98e-08	0.59	0.4	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
KIRP	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	6.96	2.66e-11	2.98e-08	0.51	0.4	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	6.96	2.66e-11	2.98e-08	0.51	0.4	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	6.96	2.66e-11	2.98e-08	0.46	0.4	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	6.96	2.66e-11	2.98e-08	0.46	0.4	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	6.96	2.66e-11	2.98e-08	0.46	0.4	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
KIRP	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	6.96	2.67e-11	2.99e-08	0.45	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
KIRP	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	6.96	2.67e-11	2.99e-08	0.31	0.4	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
KIRP	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	6.96	2.68e-11	3e-08	0.34	0.4	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
KIRP	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	6.96	2.68e-11	3.01e-08	0.42	0.4	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
KIRP	cis	rs832187	0.64	rs831692	ENSG00000280620.1	SCAANT1	6.96	2.69e-11	3.01e-08	0.44	0.4	Schizophrenia;	chr3:64018307	chr3:63911518~63911772:-
KIRP	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	6.96	2.69e-11	3.01e-08	0.81	0.4	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
KIRP	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	6.96	2.69e-11	3.01e-08	0.54	0.4	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
KIRP	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	6.96	2.7e-11	3.02e-08	0.33	0.4	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
KIRP	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-6.96	2.7e-11	3.02e-08	-0.44	-0.4	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
KIRP	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-6.96	2.7e-11	3.02e-08	-0.52	-0.4	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
KIRP	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-6.96	2.71e-11	3.03e-08	-0.41	-0.4	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
KIRP	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	6.96	2.71e-11	3.03e-08	0.46	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
KIRP	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	6.96	2.71e-11	3.04e-08	0.54	0.4	Height;	chr6:109526846	chr6:109382795~109383666:+
KIRP	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-6.96	2.72e-11	3.04e-08	-0.38	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
KIRP	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	6.96	2.72e-11	3.04e-08	0.27	0.4	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
KIRP	cis	rs4660214	0.627	rs16837533	ENSG00000237624.1	OXCT2P1	6.96	2.73e-11	3.05e-08	0.71	0.4	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39514956~39516490:+
KIRP	cis	rs7829975	0.606	rs6422352	ENSG00000253981.4	ALG1L13P	-6.96	2.74e-11	3.07e-08	-0.31	-0.39	Mood instability;	chr8:8936683	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-6.96	2.74e-11	3.07e-08	-0.31	-0.39	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
KIRP	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	6.96	2.75e-11	3.08e-08	0.5	0.39	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
KIRP	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	6.96	2.76e-11	3.09e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
KIRP	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	6.96	2.76e-11	3.09e-08	0.46	0.39	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	6.96	2.76e-11	3.09e-08	0.46	0.39	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	6.96	2.76e-11	3.09e-08	0.46	0.39	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	6.96	2.76e-11	3.09e-08	0.46	0.39	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
KIRP	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.96	2.77e-11	3.09e-08	-0.53	-0.39	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
KIRP	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-6.96	2.77e-11	3.1e-08	-0.57	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
KIRP	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	6.96	2.77e-11	3.1e-08	0.45	0.39	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
KIRP	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-6.96	2.78e-11	3.11e-08	-0.49	-0.39	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
KIRP	cis	rs832187	0.704	rs832195	ENSG00000280620.1	SCAANT1	-6.96	2.78e-11	3.11e-08	-0.46	-0.39	Schizophrenia;	chr3:63878936	chr3:63911518~63911772:-
KIRP	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	6.96	2.79e-11	3.12e-08	0.9	0.39	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
KIRP	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-6.95	2.82e-11	3.15e-08	-0.44	-0.39	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-6.95	2.82e-11	3.15e-08	-0.44	-0.39	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
KIRP	cis	rs7829975	0.542	rs7844374	ENSG00000253893.2	FAM85B	6.95	2.82e-11	3.15e-08	0.5	0.39	Mood instability;	chr8:8941174	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	6.95	2.85e-11	3.18e-08	0.47	0.39	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
KIRP	cis	rs4356975	0.545	rs11249525	ENSG00000250696.4	RP11-704M14.1	6.95	2.85e-11	3.18e-08	0.37	0.39	Obesity-related traits;	chr4:69080923	chr4:69182100~69216766:+
KIRP	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	6.95	2.85e-11	3.18e-08	0.44	0.39	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
KIRP	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	6.95	2.85e-11	3.18e-08	0.5	0.39	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
KIRP	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-6.95	2.86e-11	3.19e-08	-0.34	-0.39	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
KIRP	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	6.95	2.86e-11	3.19e-08	0.41	0.39	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
KIRP	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	6.95	2.87e-11	3.2e-08	0.34	0.39	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
KIRP	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	6.95	2.87e-11	3.2e-08	0.29	0.39	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
KIRP	cis	rs4356975	0.563	rs4443355	ENSG00000250696.4	RP11-704M14.1	6.95	2.89e-11	3.22e-08	0.37	0.39	Obesity-related traits;	chr4:69083026	chr4:69182100~69216766:+
KIRP	cis	rs1930961	0.558	rs12160908	ENSG00000272977.1	CTA-390C10.10	-6.95	2.89e-11	3.23e-08	-0.54	-0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25476218~25479971:+
KIRP	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-6.95	2.9e-11	3.23e-08	-0.33	-0.39	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
KIRP	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	6.95	2.92e-11	3.26e-08	0.54	0.39	Height;	chr6:109518783	chr6:109382795~109383666:+
KIRP	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	6.95	2.93e-11	3.26e-08	0.5	0.39	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	6.95	2.93e-11	3.26e-08	0.5	0.39	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
KIRP	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	6.95	2.93e-11	3.26e-08	0.5	0.39	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
KIRP	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	6.95	2.96e-11	3.3e-08	0.45	0.39	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
KIRP	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-6.95	2.96e-11	3.3e-08	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
KIRP	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	6.95	2.97e-11	3.31e-08	0.3	0.39	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
KIRP	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	6.95	2.97e-11	3.31e-08	0.44	0.39	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
KIRP	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-6.95	2.97e-11	3.31e-08	-0.48	-0.39	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
KIRP	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-6.94	2.98e-11	3.32e-08	-0.59	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
KIRP	cis	rs67311347	0.577	rs11129870	ENSG00000230274.1	PGAM1P3	6.94	2.98e-11	3.32e-08	0.38	0.39	Renal cell carcinoma;	chr3:40218915	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-6.94	2.99e-11	3.33e-08	-0.49	-0.39	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
KIRP	cis	rs4638749	0.677	rs7370742	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108198929	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs9631035	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108202460	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.651	rs13385677	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108209696	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10203004	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108210079	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs34449318	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108210766	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs6713634	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108211451	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10189396	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108213181	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs2100407	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108213732	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs7568919	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108215920	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs1522021	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108216807	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.627	rs1522020	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108216890	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs6757761	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108218386	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs7595399	ENSG00000225328.1	AC019100.3	-6.94	3e-11	3.33e-08	-0.47	-0.39	Blood pressure;	chr2:108219487	chr2:108167748~108217841:-
KIRP	cis	rs11647589	0.735	rs2221448	ENSG00000260762.1	ACSM5P1	6.94	3.01e-11	3.34e-08	0.43	0.39	Blood metabolite levels;	chr16:20473548	chr16:20586550~20607107:-
KIRP	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	6.94	3.01e-11	3.35e-08	0.42	0.39	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	6.94	3.01e-11	3.35e-08	0.42	0.39	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	6.94	3.01e-11	3.35e-08	0.42	0.39	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	6.94	3.01e-11	3.35e-08	0.42	0.39	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	6.94	3.01e-11	3.35e-08	0.42	0.39	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
KIRP	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	6.94	3.02e-11	3.36e-08	0.42	0.39	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
KIRP	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	6.94	3.03e-11	3.37e-08	0.3	0.39	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
KIRP	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	6.94	3.04e-11	3.38e-08	0.45	0.39	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
KIRP	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	6.94	3.04e-11	3.38e-08	0.48	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	6.94	3.04e-11	3.38e-08	0.48	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
KIRP	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	6.94	3.05e-11	3.39e-08	0.46	0.39	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
KIRP	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-6.94	3.05e-11	3.39e-08	-0.41	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
KIRP	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	6.94	3.06e-11	3.39e-08	0.45	0.39	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	6.94	3.06e-11	3.39e-08	0.45	0.39	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
KIRP	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-6.94	3.07e-11	3.4e-08	-0.42	-0.39	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
KIRP	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	6.94	3.07e-11	3.41e-08	0.5	0.39	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
KIRP	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-6.94	3.08e-11	3.42e-08	-0.38	-0.39	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-6.94	3.08e-11	3.42e-08	-0.38	-0.39	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
KIRP	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	6.94	3.08e-11	3.42e-08	0.66	0.39	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	6.94	3.08e-11	3.42e-08	0.66	0.39	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	6.94	3.08e-11	3.42e-08	0.66	0.39	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
KIRP	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-6.94	3.11e-11	3.45e-08	-0.49	-0.39	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
KIRP	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	6.94	3.11e-11	3.45e-08	0.54	0.39	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
KIRP	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-6.94	3.11e-11	3.45e-08	-0.33	-0.39	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
KIRP	cis	rs4443100	0.874	rs5996454	ENSG00000221069.1	AC000029.1	6.94	3.12e-11	3.45e-08	0.46	0.39	Serum parathyroid hormone levels;	chr22:23037029	chr22:23136620~23136710:+
KIRP	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	6.94	3.12e-11	3.46e-08	0.5	0.39	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
KIRP	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	6.94	3.14e-11	3.48e-08	0.54	0.39	Height;	chr6:109676091	chr6:109382795~109383666:+
KIRP	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	6.94	3.14e-11	3.48e-08	0.54	0.39	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
KIRP	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	6.94	3.15e-11	3.49e-08	0.53	0.39	Height;	chr6:109465777	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	6.94	3.15e-11	3.49e-08	0.54	0.39	Height;	chr6:109533040	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	6.94	3.15e-11	3.49e-08	0.54	0.39	Height;	chr6:109534269	chr6:109382795~109383666:+
KIRP	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-6.94	3.16e-11	3.5e-08	-0.5	-0.39	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-6.94	3.16e-11	3.5e-08	-0.48	-0.39	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
KIRP	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	6.94	3.16e-11	3.5e-08	0.28	0.39	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
KIRP	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	6.93	3.17e-11	3.51e-08	0.52	0.39	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
KIRP	cis	rs11647589	0.688	rs28556968	ENSG00000260762.1	ACSM5P1	6.93	3.17e-11	3.51e-08	0.43	0.39	Blood metabolite levels;	chr16:20469357	chr16:20586550~20607107:-
KIRP	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	6.93	3.18e-11	3.52e-08	0.49	0.39	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
KIRP	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	6.93	3.2e-11	3.55e-08	0.62	0.39	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
KIRP	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	6.93	3.24e-11	3.58e-08	0.46	0.39	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	6.93	3.24e-11	3.58e-08	0.46	0.39	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	6.93	3.24e-11	3.58e-08	0.46	0.39	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-6.93	3.24e-11	3.59e-08	-0.51	-0.39	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
KIRP	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	6.93	3.25e-11	3.59e-08	0.44	0.39	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
KIRP	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-6.93	3.25e-11	3.6e-08	-0.4	-0.39	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-6.93	3.25e-11	3.6e-08	-0.4	-0.39	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
KIRP	cis	rs67311347	0.866	rs1454491	ENSG00000230274.1	PGAM1P3	6.93	3.25e-11	3.6e-08	0.4	0.39	Renal cell carcinoma;	chr3:40311156	chr3:40322715~40323279:-
KIRP	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	6.93	3.25e-11	3.6e-08	0.47	0.39	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	6.93	3.25e-11	3.6e-08	0.47	0.39	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
KIRP	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	6.93	3.25e-11	3.6e-08	0.47	0.39	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
KIRP	cis	rs4638749	0.501	rs9653451	ENSG00000225328.1	AC019100.3	-6.93	3.26e-11	3.6e-08	-0.46	-0.39	Blood pressure;	chr2:108165402	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs12712014	ENSG00000225328.1	AC019100.3	6.93	3.26e-11	3.61e-08	0.46	0.39	Blood pressure;	chr2:108195588	chr2:108167748~108217841:-
KIRP	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-6.93	3.27e-11	3.61e-08	-0.38	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-6.93	3.27e-11	3.61e-08	-0.38	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-6.93	3.27e-11	3.61e-08	-0.38	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
KIRP	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-6.93	3.27e-11	3.61e-08	-0.46	-0.39	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
KIRP	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	6.93	3.27e-11	3.62e-08	0.49	0.39	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
KIRP	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	6.93	3.28e-11	3.63e-08	0.6	0.39	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
KIRP	cis	rs4356975	0.563	rs7442453	ENSG00000250696.4	RP11-704M14.1	6.93	3.29e-11	3.63e-08	0.38	0.39	Obesity-related traits;	chr4:69103462	chr4:69182100~69216766:+
KIRP	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-6.93	3.29e-11	3.63e-08	-0.49	-0.39	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	6.93	3.29e-11	3.63e-08	0.52	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
KIRP	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	6.93	3.31e-11	3.65e-08	0.51	0.39	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
KIRP	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	6.93	3.31e-11	3.65e-08	0.47	0.39	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
KIRP	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-6.93	3.31e-11	3.65e-08	-0.46	-0.39	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
KIRP	cis	rs67311347	0.577	rs11712626	ENSG00000230274.1	PGAM1P3	6.93	3.31e-11	3.66e-08	0.38	0.39	Renal cell carcinoma;	chr3:40218436	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.506	rs55962832	ENSG00000230274.1	PGAM1P3	6.93	3.32e-11	3.66e-08	0.38	0.39	Renal cell carcinoma;	chr3:40202960	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-6.93	3.32e-11	3.67e-08	-0.46	-0.39	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
KIRP	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-6.93	3.33e-11	3.67e-08	-0.41	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
KIRP	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	6.93	3.33e-11	3.68e-08	0.3	0.39	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
KIRP	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	6.93	3.33e-11	3.68e-08	0.45	0.39	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
KIRP	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-6.93	3.34e-11	3.68e-08	-0.6	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
KIRP	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-6.93	3.34e-11	3.69e-08	-0.51	-0.39	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
KIRP	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-6.93	3.34e-11	3.69e-08	-0.35	-0.39	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
KIRP	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	6.93	3.35e-11	3.69e-08	0.49	0.39	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
KIRP	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	6.93	3.35e-11	3.7e-08	0.46	0.39	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
KIRP	cis	rs9371601	0.859	rs177330	ENSG00000226193.1	RP3-398G3.5	-6.92	3.37e-11	3.72e-08	-0.44	-0.39	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152401093	chr6:152402398~152404966:+
KIRP	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-6.92	3.38e-11	3.73e-08	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
KIRP	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-6.92	3.39e-11	3.74e-08	-0.51	-0.39	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-6.92	3.39e-11	3.74e-08	-0.51	-0.39	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
KIRP	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-6.92	3.39e-11	3.74e-08	-0.36	-0.39	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
KIRP	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	6.92	3.4e-11	3.75e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
KIRP	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-6.92	3.42e-11	3.77e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-6.92	3.42e-11	3.77e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-6.92	3.42e-11	3.77e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-6.92	3.42e-11	3.77e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
KIRP	cis	rs4638749	0.501	rs9917180	ENSG00000225328.1	AC019100.3	6.92	3.45e-11	3.8e-08	0.47	0.39	Blood pressure;	chr2:108131189	chr2:108167748~108217841:-
KIRP	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	6.92	3.45e-11	3.8e-08	0.43	0.39	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
KIRP	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-6.92	3.46e-11	3.81e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-6.92	3.47e-11	3.82e-08	-0.35	-0.39	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
KIRP	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-6.92	3.49e-11	3.84e-08	-0.79	-0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
KIRP	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-6.92	3.49e-11	3.84e-08	-0.45	-0.39	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
KIRP	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	6.92	3.49e-11	3.84e-08	0.36	0.39	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
KIRP	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	6.92	3.49e-11	3.84e-08	0.36	0.39	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
KIRP	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-6.92	3.5e-11	3.86e-08	-0.45	-0.39	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
KIRP	cis	rs4638749	0.677	rs13414687	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108189789	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs13389470	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108189845	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10185270	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108222236	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs4396668	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108223908	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs6741222	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108224626	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs4676186	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108226184	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs12712017	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108227100	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs2198471	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108227613	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs2219081	ENSG00000225328.1	AC019100.3	-6.92	3.52e-11	3.88e-08	-0.47	-0.39	Blood pressure;	chr2:108227894	chr2:108167748~108217841:-
KIRP	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-6.92	3.53e-11	3.88e-08	-0.45	-0.39	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
KIRP	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-6.92	3.53e-11	3.89e-08	-0.43	-0.39	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
KIRP	cis	rs9371601	0.859	rs215001	ENSG00000226193.1	RP3-398G3.5	-6.92	3.54e-11	3.89e-08	-0.42	-0.39	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152439771	chr6:152402398~152404966:+
KIRP	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	6.92	3.55e-11	3.91e-08	0.51	0.39	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
KIRP	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	6.92	3.56e-11	3.91e-08	0.46	0.39	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
KIRP	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	6.92	3.56e-11	3.91e-08	0.43	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
KIRP	cis	rs2980439	0.729	rs2955585	ENSG00000253893.2	FAM85B	-6.92	3.56e-11	3.91e-08	-0.52	-0.39	Neuroticism;	chr8:8235989	chr8:8167819~8226614:-
KIRP	cis	rs67311347	0.577	rs1880763	ENSG00000230274.1	PGAM1P3	-6.92	3.56e-11	3.92e-08	-0.38	-0.39	Renal cell carcinoma;	chr3:40241764	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	6.91	3.57e-11	3.92e-08	0.49	0.39	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	6.91	3.57e-11	3.92e-08	0.49	0.39	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
KIRP	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-6.91	3.58e-11	3.93e-08	-0.36	-0.39	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
KIRP	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-6.91	3.59e-11	3.94e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
KIRP	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-6.91	3.6e-11	3.95e-08	-0.45	-0.39	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
KIRP	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-6.91	3.6e-11	3.96e-08	-0.56	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
KIRP	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	6.91	3.6e-11	3.96e-08	0.28	0.39	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
KIRP	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-6.91	3.61e-11	3.96e-08	-0.52	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
KIRP	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-6.91	3.61e-11	3.96e-08	-0.52	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
KIRP	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	6.91	3.61e-11	3.96e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	6.91	3.61e-11	3.96e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	6.91	3.61e-11	3.96e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
KIRP	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	6.91	3.62e-11	3.97e-08	0.46	0.39	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
KIRP	cis	rs950027	0.62	rs1346267	ENSG00000259433.2	CTD-2651B20.4	-6.91	3.62e-11	3.98e-08	-0.33	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45330209~45332634:-
KIRP	cis	rs4660214	0.671	rs72637904	ENSG00000237624.1	OXCT2P1	6.91	3.63e-11	3.98e-08	0.7	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39514956~39516490:+
KIRP	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	6.91	3.64e-11	3.99e-08	0.49	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
KIRP	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	6.91	3.64e-11	4e-08	0.57	0.39	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
KIRP	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-6.91	3.64e-11	4e-08	-0.47	-0.39	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
KIRP	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-6.91	3.65e-11	4e-08	-0.46	-0.39	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
KIRP	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	6.91	3.65e-11	4e-08	0.57	0.39	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
KIRP	cis	rs950027	0.62	rs1426932	ENSG00000259433.2	CTD-2651B20.4	-6.91	3.7e-11	4.05e-08	-0.33	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45330209~45332634:-
KIRP	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	6.91	3.7e-11	4.05e-08	0.79	0.39	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
KIRP	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	6.91	3.71e-11	4.06e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
KIRP	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-6.91	3.71e-11	4.06e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
KIRP	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	6.91	3.72e-11	4.07e-08	0.45	0.39	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	6.91	3.72e-11	4.07e-08	0.45	0.39	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
KIRP	cis	rs755249	0.517	rs66880209	ENSG00000237624.1	OXCT2P1	6.91	3.75e-11	4.1e-08	0.7	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39514956~39516490:+
KIRP	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	6.91	3.75e-11	4.11e-08	0.59	0.39	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
KIRP	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-6.91	3.75e-11	4.11e-08	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
KIRP	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-6.91	3.75e-11	4.11e-08	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
KIRP	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-6.91	3.77e-11	4.12e-08	-0.33	-0.39	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-6.91	3.77e-11	4.12e-08	-0.33	-0.39	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
KIRP	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-6.91	3.77e-11	4.12e-08	-0.47	-0.39	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
KIRP	cis	rs4356975	0.563	rs7439152	ENSG00000250696.4	RP11-704M14.1	6.91	3.77e-11	4.13e-08	0.37	0.39	Obesity-related traits;	chr4:69103288	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7375178	ENSG00000250696.4	RP11-704M14.1	6.91	3.77e-11	4.13e-08	0.37	0.39	Obesity-related traits;	chr4:69103961	chr4:69182100~69216766:+
KIRP	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-6.91	3.78e-11	4.13e-08	-0.41	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
KIRP	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-6.9	3.79e-11	4.14e-08	-0.43	-0.39	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	6.9	3.82e-11	4.18e-08	0.49	0.39	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	6.9	3.82e-11	4.18e-08	0.46	0.39	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
KIRP	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-6.9	3.83e-11	4.19e-08	-0.41	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
KIRP	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-6.9	3.85e-11	4.2e-08	-0.45	-0.39	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-6.9	3.85e-11	4.2e-08	-0.45	-0.39	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-6.9	3.85e-11	4.21e-08	-0.35	-0.39	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
KIRP	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	6.9	3.89e-11	4.24e-08	0.39	0.39	Height;	chr3:53082835	chr3:53064283~53065091:-
KIRP	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	6.9	3.91e-11	4.27e-08	0.52	0.39	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
KIRP	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	6.9	3.92e-11	4.28e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	6.9	3.92e-11	4.28e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-6.9	3.92e-11	4.28e-08	-0.44	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
KIRP	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-6.9	3.98e-11	4.34e-08	-0.39	-0.39	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
KIRP	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-6.9	3.99e-11	4.36e-08	-0.47	-0.39	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
KIRP	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-6.9	4e-11	4.36e-08	-0.54	-0.39	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
KIRP	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	6.9	4e-11	4.36e-08	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	6.9	4e-11	4.36e-08	0.45	0.39	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	6.9	4e-11	4.36e-08	0.45	0.39	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
KIRP	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.9	4e-11	4.36e-08	-0.44	-0.39	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
KIRP	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	6.9	4.01e-11	4.37e-08	0.44	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
KIRP	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.89	4.03e-11	4.4e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
KIRP	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-6.89	4.04e-11	4.4e-08	-0.4	-0.39	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
KIRP	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	6.89	4.04e-11	4.41e-08	0.45	0.39	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-6.89	4.05e-11	4.41e-08	-0.46	-0.39	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
KIRP	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	6.89	4.05e-11	4.41e-08	0.61	0.39	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	6.89	4.05e-11	4.41e-08	0.59	0.39	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
KIRP	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-6.89	4.08e-11	4.44e-08	-0.5	-0.39	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
KIRP	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.89	4.08e-11	4.44e-08	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
KIRP	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	6.89	4.08e-11	4.44e-08	0.28	0.39	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
KIRP	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	6.89	4.08e-11	4.45e-08	0.53	0.39	Height;	chr6:109690255	chr6:109382795~109383666:+
KIRP	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	6.89	4.08e-11	4.45e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	6.89	4.08e-11	4.45e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	6.89	4.08e-11	4.45e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	6.89	4.08e-11	4.45e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	6.89	4.08e-11	4.45e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
KIRP	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-6.89	4.12e-11	4.48e-08	-0.49	-0.39	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
KIRP	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-6.89	4.13e-11	4.5e-08	-0.44	-0.39	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
KIRP	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-6.89	4.13e-11	4.5e-08	-0.44	-0.39	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
KIRP	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-6.89	4.14e-11	4.5e-08	-0.51	-0.39	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
KIRP	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-6.89	4.14e-11	4.51e-08	-0.57	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
KIRP	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-6.89	4.14e-11	4.51e-08	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
KIRP	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	6.89	4.16e-11	4.53e-08	0.53	0.39	Height;	chr6:109462738	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	6.89	4.16e-11	4.53e-08	0.53	0.39	Height;	chr6:109464011	chr6:109382795~109383666:+
KIRP	cis	rs4638749	0.677	rs6711297	ENSG00000225328.1	AC019100.3	-6.89	4.17e-11	4.53e-08	-0.47	-0.39	Blood pressure;	chr2:108201901	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs6755598	ENSG00000225328.1	AC019100.3	-6.89	4.17e-11	4.53e-08	-0.47	-0.39	Blood pressure;	chr2:108211218	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10185601	ENSG00000225328.1	AC019100.3	-6.89	4.17e-11	4.53e-08	-0.47	-0.39	Blood pressure;	chr2:108211822	chr2:108167748~108217841:-
KIRP	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	6.89	4.18e-11	4.55e-08	0.45	0.39	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
KIRP	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	6.89	4.2e-11	4.57e-08	0.41	0.39	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
KIRP	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-6.89	4.22e-11	4.59e-08	-0.65	-0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
KIRP	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-6.89	4.24e-11	4.6e-08	-0.45	-0.39	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-6.89	4.24e-11	4.6e-08	-0.45	-0.39	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-6.89	4.24e-11	4.6e-08	-0.45	-0.39	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-6.89	4.24e-11	4.6e-08	-0.45	-0.39	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
KIRP	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-6.89	4.25e-11	4.62e-08	-0.52	-0.39	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
KIRP	cis	rs4638749	0.734	rs4676191	ENSG00000225328.1	AC019100.3	-6.88	4.28e-11	4.65e-08	-0.48	-0.39	Blood pressure;	chr2:108244786	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.734	rs35184015	ENSG00000225328.1	AC019100.3	-6.88	4.28e-11	4.65e-08	-0.48	-0.39	Blood pressure;	chr2:108254084	chr2:108167748~108217841:-
KIRP	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-6.88	4.29e-11	4.66e-08	-0.51	-0.39	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	6.88	4.3e-11	4.66e-08	0.31	0.39	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
KIRP	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	6.88	4.3e-11	4.67e-08	0.31	0.39	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
KIRP	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	6.88	4.3e-11	4.67e-08	0.55	0.39	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
KIRP	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-6.88	4.3e-11	4.67e-08	-0.51	-0.39	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
KIRP	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-6.88	4.3e-11	4.67e-08	-0.37	-0.39	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-6.88	4.3e-11	4.67e-08	-0.37	-0.39	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
KIRP	cis	rs4356975	0.563	rs6600885	ENSG00000250696.4	RP11-704M14.1	6.88	4.3e-11	4.67e-08	0.37	0.39	Obesity-related traits;	chr4:69103949	chr4:69182100~69216766:+
KIRP	cis	rs7829975	0.606	rs7837026	ENSG00000253981.4	ALG1L13P	-6.88	4.31e-11	4.67e-08	-0.32	-0.39	Mood instability;	chr8:8944182	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	6.88	4.32e-11	4.68e-08	0.47	0.39	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
KIRP	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.88	4.34e-11	4.71e-08	-0.45	-0.39	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
KIRP	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-6.88	4.35e-11	4.72e-08	-0.51	-0.39	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	6.88	4.36e-11	4.73e-08	0.45	0.39	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	6.88	4.38e-11	4.74e-08	0.54	0.39	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
KIRP	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	6.88	4.38e-11	4.75e-08	0.33	0.39	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
KIRP	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-6.88	4.38e-11	4.75e-08	-0.34	-0.39	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
KIRP	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-6.88	4.39e-11	4.76e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
KIRP	cis	rs116095464	1	rs3777237	ENSG00000277812.1	AC021087.1	6.88	4.39e-11	4.76e-08	0.98	0.39	Breast cancer;	chr5:307526	chr5:262769~262881:+
KIRP	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	6.88	4.4e-11	4.77e-08	0.36	0.39	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
KIRP	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	6.88	4.4e-11	4.77e-08	0.52	0.39	Height;	chr6:109383239	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	6.88	4.4e-11	4.77e-08	0.52	0.39	Height;	chr6:109383248	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	6.88	4.4e-11	4.77e-08	0.52	0.39	Height;	chr6:109358227	chr6:109382795~109383666:+
KIRP	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-6.88	4.42e-11	4.79e-08	-0.5	-0.39	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
KIRP	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	6.88	4.43e-11	4.8e-08	0.4	0.39	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
KIRP	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.88	4.44e-11	4.81e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.88	4.44e-11	4.81e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.88	4.44e-11	4.81e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
KIRP	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	6.88	4.44e-11	4.81e-08	0.28	0.39	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
KIRP	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	6.88	4.45e-11	4.82e-08	0.48	0.39	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
KIRP	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	6.88	4.46e-11	4.83e-08	0.44	0.39	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
KIRP	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-6.88	4.48e-11	4.85e-08	-0.46	-0.39	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
KIRP	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	6.88	4.48e-11	4.85e-08	0.45	0.39	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
KIRP	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-6.88	4.48e-11	4.85e-08	-0.42	-0.39	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
KIRP	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-6.88	4.48e-11	4.85e-08	-0.42	-0.39	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
KIRP	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	6.88	4.48e-11	4.85e-08	0.43	0.39	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
KIRP	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	6.88	4.48e-11	4.85e-08	0.33	0.39	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
KIRP	cis	rs453301	0.522	rs1964356	ENSG00000253981.4	ALG1L13P	6.88	4.5e-11	4.86e-08	0.33	0.39	Joint mobility (Beighton score);	chr8:8995760	chr8:8236003~8244667:-
KIRP	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	6.88	4.51e-11	4.88e-08	0.28	0.39	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
KIRP	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	6.87	4.54e-11	4.91e-08	0.53	0.39	Height;	chr6:109470427	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	6.87	4.54e-11	4.91e-08	0.53	0.39	Height;	chr6:109470900	chr6:109382795~109383666:+
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-6.87	4.54e-11	4.91e-08	-0.51	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
KIRP	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	6.87	4.55e-11	4.92e-08	0.46	0.39	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
KIRP	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-6.87	4.55e-11	4.92e-08	-0.34	-0.39	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
KIRP	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	6.87	4.55e-11	4.92e-08	0.52	0.39	Height;	chr6:109424305	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	6.87	4.55e-11	4.92e-08	0.52	0.39	Height;	chr6:109425054	chr6:109382795~109383666:+
KIRP	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-6.87	4.55e-11	4.92e-08	-0.45	-0.39	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
KIRP	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	6.87	4.57e-11	4.94e-08	0.49	0.39	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	6.87	4.57e-11	4.94e-08	0.49	0.39	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
KIRP	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	6.87	4.59e-11	4.96e-08	0.53	0.39	Height;	chr6:109693890	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	6.87	4.59e-11	4.96e-08	0.53	0.39	Height;	chr6:109694672	chr6:109382795~109383666:+
KIRP	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-6.87	4.59e-11	4.96e-08	-0.4	-0.39	Axial length;	chr3:53814645	chr3:53797764~53798019:-
KIRP	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	6.87	4.6e-11	4.97e-08	0.48	0.39	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
KIRP	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	6.87	4.61e-11	4.98e-08	0.52	0.39	Height;	chr6:109354092	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	6.87	4.63e-11	5.01e-08	0.45	0.39	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	6.87	4.63e-11	5.01e-08	0.45	0.39	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
KIRP	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-6.87	4.64e-11	5.01e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
KIRP	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
KIRP	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-6.87	4.64e-11	5.01e-08	-0.5	-0.39	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
KIRP	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	6.87	4.64e-11	5.01e-08	0.3	0.39	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
KIRP	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-6.87	4.67e-11	5.04e-08	-0.59	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
KIRP	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	6.87	4.67e-11	5.04e-08	0.52	0.39	Height;	chr6:109426518	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	6.87	4.67e-11	5.04e-08	0.52	0.39	Height;	chr6:109427644	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	6.87	4.67e-11	5.04e-08	0.52	0.39	Height;	chr6:109430292	chr6:109382795~109383666:+
KIRP	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-6.87	4.67e-11	5.04e-08	-0.35	-0.39	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
KIRP	cis	rs4356975	0.583	rs4632729	ENSG00000250696.4	RP11-704M14.1	6.87	4.68e-11	5.05e-08	0.37	0.39	Obesity-related traits;	chr4:69080286	chr4:69182100~69216766:+
KIRP	cis	rs4638749	0.603	rs34153365	ENSG00000225328.1	AC019100.3	-6.87	4.69e-11	5.06e-08	-0.46	-0.39	Blood pressure;	chr2:108230127	chr2:108167748~108217841:-
KIRP	cis	rs4356975	0.83	rs4413468	ENSG00000250696.4	RP11-704M14.1	6.87	4.69e-11	5.06e-08	0.37	0.39	Obesity-related traits;	chr4:69061845	chr4:69182100~69216766:+
KIRP	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-6.87	4.69e-11	5.06e-08	-0.39	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
KIRP	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-6.87	4.74e-11	5.11e-08	-0.53	-0.39	Height;	chr6:109501793	chr6:109382795~109383666:+
KIRP	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-6.86	4.81e-11	5.18e-08	-0.51	-0.39	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
KIRP	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	6.86	4.81e-11	5.18e-08	0.54	0.39	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
KIRP	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	6.86	4.82e-11	5.19e-08	0.47	0.39	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
KIRP	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-6.86	4.83e-11	5.21e-08	-0.49	-0.39	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
KIRP	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	6.86	4.85e-11	5.23e-08	0.51	0.39	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
KIRP	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.86	4.86e-11	5.23e-08	-0.53	-0.39	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
KIRP	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-6.86	4.86e-11	5.24e-08	-0.4	-0.39	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	6.86	4.87e-11	5.24e-08	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
KIRP	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-6.86	4.88e-11	5.25e-08	-0.42	-0.39	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
KIRP	cis	rs67311347	1	rs11129876	ENSG00000230274.1	PGAM1P3	-6.86	4.89e-11	5.26e-08	-0.38	-0.39	Renal cell carcinoma;	chr3:40360145	chr3:40322715~40323279:-
KIRP	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-6.86	4.89e-11	5.26e-08	-0.35	-0.39	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
KIRP	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-6.86	4.89e-11	5.26e-08	-0.35	-0.39	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
KIRP	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-6.86	4.9e-11	5.27e-08	-0.45	-0.39	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-6.86	4.9e-11	5.27e-08	-0.45	-0.39	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
KIRP	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	6.86	4.94e-11	5.32e-08	0.48	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
KIRP	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	6.86	4.95e-11	5.33e-08	0.46	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
KIRP	cis	rs7829975	0.617	rs4841071	ENSG00000253981.4	ALG1L13P	6.86	4.96e-11	5.34e-08	0.31	0.39	Mood instability;	chr8:8933634	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	6.86	4.97e-11	5.34e-08	0.52	0.39	Height;	chr6:109347707	chr6:109382795~109383666:+
KIRP	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	6.86	4.97e-11	5.34e-08	0.32	0.39	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
KIRP	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	6.86	4.99e-11	5.37e-08	0.32	0.39	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
KIRP	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-6.86	4.99e-11	5.37e-08	-0.52	-0.39	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
KIRP	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	6.86	5.01e-11	5.38e-08	0.26	0.39	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	6.86	5.01e-11	5.38e-08	0.26	0.39	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	6.86	5.01e-11	5.38e-08	0.26	0.39	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
KIRP	cis	rs1529102	0.844	rs2698533	ENSG00000225889.6	AC074289.1	-6.86	5.01e-11	5.38e-08	-0.35	-0.39	Breast size;	chr2:64271271	chr2:64143239~64252859:+
KIRP	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.86	5.02e-11	5.4e-08	-0.33	-0.39	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
KIRP	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	6.86	5.03e-11	5.41e-08	0.5	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
KIRP	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-6.86	5.03e-11	5.41e-08	-0.58	-0.39	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-6.86	5.04e-11	5.42e-08	-0.5	-0.39	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
KIRP	cis	rs4660214	0.627	rs61779282	ENSG00000237624.1	OXCT2P1	6.86	5.04e-11	5.42e-08	0.7	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39514956~39516490:+
KIRP	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-6.86	5.07e-11	5.45e-08	-0.55	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
KIRP	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-6.86	5.09e-11	5.47e-08	-0.32	-0.39	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
KIRP	cis	rs4638749	0.677	rs6755078	ENSG00000225328.1	AC019100.3	-6.85	5.1e-11	5.47e-08	-0.46	-0.39	Blood pressure;	chr2:108201814	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs13423385	ENSG00000225328.1	AC019100.3	-6.85	5.1e-11	5.47e-08	-0.46	-0.39	Blood pressure;	chr2:108209979	chr2:108167748~108217841:-
KIRP	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-6.85	5.1e-11	5.48e-08	-0.38	-0.39	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
KIRP	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	6.85	5.1e-11	5.48e-08	0.29	0.39	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
KIRP	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	6.85	5.1e-11	5.48e-08	0.46	0.39	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
KIRP	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-6.85	5.11e-11	5.48e-08	-0.46	-0.39	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
KIRP	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	6.85	5.11e-11	5.48e-08	0.48	0.39	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
KIRP	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	6.85	5.14e-11	5.52e-08	0.41	0.39	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
KIRP	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	6.85	5.15e-11	5.52e-08	0.51	0.39	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	6.85	5.15e-11	5.52e-08	0.51	0.39	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	6.85	5.15e-11	5.52e-08	0.51	0.39	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
KIRP	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	6.85	5.15e-11	5.53e-08	0.42	0.39	Temperament;	chr17:14068990	chr17:14024514~14025488:+
KIRP	cis	rs1964356	0.967	rs2953802	ENSG00000253981.4	ALG1L13P	6.85	5.16e-11	5.54e-08	0.32	0.39	Mean corpuscular volume;	chr8:8994371	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-6.85	5.16e-11	5.54e-08	-0.49	-0.39	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
KIRP	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	6.85	5.16e-11	5.54e-08	0.44	0.39	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
KIRP	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	6.85	5.18e-11	5.55e-08	0.49	0.39	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
KIRP	cis	rs4356975	0.83	rs6600865	ENSG00000250696.4	RP11-704M14.1	6.85	5.18e-11	5.56e-08	0.37	0.39	Obesity-related traits;	chr4:69057904	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	6.85	5.19e-11	5.56e-08	0.47	0.39	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	6.85	5.19e-11	5.56e-08	0.47	0.39	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
KIRP	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-6.85	5.19e-11	5.56e-08	-0.42	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
KIRP	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-6.85	5.19e-11	5.56e-08	-0.42	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
KIRP	cis	rs79349575	0.594	rs1985785	ENSG00000248278.1	SUMO2P17	6.85	5.19e-11	5.56e-08	0.44	0.39	Type 2 diabetes;	chr17:48890426	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.685	rs1124829	ENSG00000248278.1	SUMO2P17	6.85	5.19e-11	5.56e-08	0.44	0.39	Type 2 diabetes;	chr17:48890435	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.721	rs1008834	ENSG00000248278.1	SUMO2P17	6.85	5.19e-11	5.56e-08	0.44	0.39	Type 2 diabetes;	chr17:48890646	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.721	rs9904645	ENSG00000248278.1	SUMO2P17	6.85	5.19e-11	5.56e-08	0.44	0.39	Type 2 diabetes;	chr17:48892303	chr17:48874860~48908983:-
KIRP	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-6.85	5.25e-11	5.62e-08	-0.35	-0.39	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
KIRP	cis	rs7829975	0.591	rs12677543	ENSG00000253981.4	ALG1L13P	6.85	5.25e-11	5.62e-08	0.3	0.39	Mood instability;	chr8:8786764	chr8:8236003~8244667:-
KIRP	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	6.85	5.26e-11	5.63e-08	0.53	0.39	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
KIRP	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	6.85	5.26e-11	5.63e-08	0.53	0.39	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
KIRP	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	6.85	5.26e-11	5.63e-08	0.52	0.39	Height;	chr6:109346560	chr6:109382795~109383666:+
KIRP	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	6.85	5.26e-11	5.63e-08	0.46	0.39	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
KIRP	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-6.85	5.26e-11	5.64e-08	-0.5	-0.39	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
KIRP	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	6.85	5.28e-11	5.65e-08	0.52	0.39	Height;	chr6:109375548	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	6.85	5.29e-11	5.66e-08	0.53	0.39	Height;	chr6:109634150	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	6.85	5.29e-11	5.66e-08	0.53	0.39	Height;	chr6:109640141	chr6:109382795~109383666:+
KIRP	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	6.85	5.32e-11	5.69e-08	0.3	0.39	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	6.85	5.32e-11	5.69e-08	0.3	0.39	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
KIRP	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-6.85	5.34e-11	5.71e-08	-0.38	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
KIRP	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-6.85	5.34e-11	5.71e-08	-0.45	-0.39	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
KIRP	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	6.85	5.35e-11	5.72e-08	0.26	0.39	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
KIRP	cis	rs72634501	0.574	rs111623477	ENSG00000237624.1	OXCT2P1	6.85	5.36e-11	5.72e-08	0.7	0.39	HDL cholesterol;	chr1:39345533	chr1:39514956~39516490:+
KIRP	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-6.85	5.36e-11	5.73e-08	-0.42	-0.39	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
KIRP	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-6.84	5.41e-11	5.78e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-6.84	5.41e-11	5.78e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
KIRP	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-6.84	5.43e-11	5.79e-08	-0.51	-0.39	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
KIRP	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-6.84	5.43e-11	5.8e-08	-0.44	-0.39	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
KIRP	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	6.84	5.44e-11	5.81e-08	0.31	0.39	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
KIRP	cis	rs4638749	0.501	rs13391411	ENSG00000225328.1	AC019100.3	-6.84	5.46e-11	5.83e-08	-0.45	-0.39	Blood pressure;	chr2:108172597	chr2:108167748~108217841:-
KIRP	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	6.84	5.48e-11	5.85e-08	0.48	0.39	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	6.84	5.48e-11	5.85e-08	0.48	0.39	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-6.84	5.52e-11	5.89e-08	-0.42	-0.39	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
KIRP	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-6.84	5.52e-11	5.89e-08	-0.48	-0.39	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
KIRP	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-6.84	5.53e-11	5.89e-08	-0.45	-0.39	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
KIRP	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	6.84	5.53e-11	5.9e-08	0.5	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
KIRP	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	6.84	5.54e-11	5.9e-08	0.54	0.39	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
KIRP	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	6.84	5.54e-11	5.9e-08	0.54	0.39	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
KIRP	cis	rs755249	0.567	rs72661940	ENSG00000237624.1	OXCT2P1	6.84	5.55e-11	5.91e-08	0.64	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39514956~39516490:+
KIRP	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.84	5.57e-11	5.94e-08	0.43	0.39	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
KIRP	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-6.84	5.58e-11	5.95e-08	-0.42	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
KIRP	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	6.84	5.6e-11	5.97e-08	0.28	0.39	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
KIRP	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-6.84	5.6e-11	5.97e-08	-0.44	-0.39	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
KIRP	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-6.84	5.61e-11	5.98e-08	-0.35	-0.39	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
KIRP	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-6.84	5.61e-11	5.98e-08	-0.45	-0.39	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-6.84	5.61e-11	5.98e-08	-0.45	-0.39	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-6.84	5.61e-11	5.98e-08	-0.45	-0.39	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
KIRP	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-6.84	5.61e-11	5.98e-08	-0.45	-0.39	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
KIRP	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-6.84	5.61e-11	5.98e-08	-0.41	-0.39	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
KIRP	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	6.84	5.62e-11	5.98e-08	0.5	0.39	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
KIRP	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-6.84	5.64e-11	6.01e-08	-0.45	-0.39	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
KIRP	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.84	5.65e-11	6.01e-08	-0.45	-0.39	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
KIRP	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-6.84	5.66e-11	6.03e-08	-0.37	-0.39	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
KIRP	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-6.84	5.68e-11	6.04e-08	-0.45	-0.39	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
KIRP	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	6.84	5.69e-11	6.05e-08	0.45	0.39	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	6.84	5.69e-11	6.05e-08	0.45	0.39	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	6.84	5.69e-11	6.06e-08	0.48	0.39	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
KIRP	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-6.84	5.7e-11	6.06e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
KIRP	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	6.84	5.7e-11	6.07e-08	0.62	0.39	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
KIRP	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-6.84	5.71e-11	6.07e-08	-0.51	-0.39	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
KIRP	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	6.84	5.73e-11	6.09e-08	0.47	0.39	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
KIRP	cis	rs4660214	0.671	rs16826012	ENSG00000237624.1	OXCT2P1	-6.83	5.76e-11	6.12e-08	-0.68	-0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39514956~39516490:+
KIRP	cis	rs12188164	1	rs34453673	ENSG00000221990.4	EXOC3-AS1	6.83	5.77e-11	6.13e-08	0.37	0.39	Cystic fibrosis severity;	chr5:434607	chr5:441498~443160:-
KIRP	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	6.83	5.78e-11	6.15e-08	0.3	0.39	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
KIRP	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-6.83	5.79e-11	6.15e-08	-0.41	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
KIRP	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-6.83	5.81e-11	6.18e-08	-0.42	-0.39	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-6.83	5.81e-11	6.18e-08	-0.42	-0.39	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
KIRP	cis	rs7672749	0.73	rs17013324	ENSG00000249973.2	CHCHD2P7	6.83	5.82e-11	6.19e-08	0.77	0.39	TB-LM or TBLH-BMD (pleiotropy);	chr4:87850762	chr4:87785920~87786371:-
KIRP	cis	rs67311347	1	rs6762251	ENSG00000230274.1	PGAM1P3	-6.83	5.84e-11	6.21e-08	-0.38	-0.39	Renal cell carcinoma;	chr3:40489645	chr3:40322715~40323279:-
KIRP	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	6.83	5.84e-11	6.21e-08	0.4	0.39	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
KIRP	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	6.83	5.84e-11	6.21e-08	0.47	0.39	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	6.83	5.84e-11	6.21e-08	0.47	0.39	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
KIRP	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-6.83	5.86e-11	6.23e-08	-0.42	-0.39	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
KIRP	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-6.83	5.86e-11	6.23e-08	-0.42	-0.39	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
KIRP	cis	rs4660214	0.671	rs72661956	ENSG00000237624.1	OXCT2P1	6.83	5.87e-11	6.23e-08	0.69	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.671	rs16826068	ENSG00000237624.1	OXCT2P1	6.83	5.87e-11	6.23e-08	0.69	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39514956~39516490:+
KIRP	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-6.83	5.89e-11	6.25e-08	-0.42	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
KIRP	cis	rs71386933	0.509	rs34400689	ENSG00000260886.1	TAT-AS1	6.83	5.92e-11	6.28e-08	0.76	0.39	Post bronchodilator FEV1;	chr16:71969555	chr16:71565789~71578187:+
KIRP	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	6.83	5.94e-11	6.3e-08	0.36	0.39	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
KIRP	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	6.83	5.96e-11	6.32e-08	0.57	0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
KIRP	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	6.83	6e-11	6.36e-08	0.59	0.39	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
KIRP	cis	rs4638749	0.677	rs13022268	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108220864	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs13023102	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108221207	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10208945	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108222137	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs12611470	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108222893	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.627	rs4676185	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108225452	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10174695	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108225708	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs4676187	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108226480	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs10190865	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108227168	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.677	rs998186	ENSG00000225328.1	AC019100.3	-6.83	6.01e-11	6.37e-08	-0.46	-0.39	Blood pressure;	chr2:108227781	chr2:108167748~108217841:-
KIRP	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-6.83	6.01e-11	6.37e-08	-0.42	-0.39	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
KIRP	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	6.83	6.02e-11	6.38e-08	0.3	0.39	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
KIRP	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-6.83	6.02e-11	6.38e-08	-0.38	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
KIRP	cis	rs4356975	0.83	rs72851338	ENSG00000250696.4	RP11-704M14.1	6.83	6.06e-11	6.42e-08	0.37	0.39	Obesity-related traits;	chr4:69052555	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs60212682	ENSG00000250696.4	RP11-704M14.1	6.83	6.06e-11	6.42e-08	0.37	0.39	Obesity-related traits;	chr4:69052849	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs72851348	ENSG00000250696.4	RP11-704M14.1	6.83	6.06e-11	6.42e-08	0.37	0.39	Obesity-related traits;	chr4:69054305	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs6422322	ENSG00000250696.4	RP11-704M14.1	6.83	6.06e-11	6.42e-08	0.37	0.39	Obesity-related traits;	chr4:69055571	chr4:69182100~69216766:+
KIRP	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	6.83	6.07e-11	6.42e-08	0.49	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
KIRP	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-6.83	6.07e-11	6.43e-08	-0.43	-0.39	Migraine;	chr4:56853383	chr4:56960927~56961373:-
KIRP	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	6.83	6.08e-11	6.44e-08	0.45	0.39	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
KIRP	cis	rs950027	0.62	rs1145084	ENSG00000259433.2	CTD-2651B20.4	-6.82	6.1e-11	6.46e-08	-0.33	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45330209~45332634:-
KIRP	cis	rs4356975	0.83	rs4422474	ENSG00000250696.4	RP11-704M14.1	6.82	6.11e-11	6.46e-08	0.37	0.39	Obesity-related traits;	chr4:69051322	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs4377650	ENSG00000250696.4	RP11-704M14.1	6.82	6.11e-11	6.46e-08	0.37	0.39	Obesity-related traits;	chr4:69051355	chr4:69182100~69216766:+
KIRP	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	6.82	6.13e-11	6.48e-08	0.38	0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
KIRP	cis	rs2439831	0.85	rs67541383	ENSG00000249839.1	AC011330.5	-6.82	6.15e-11	6.51e-08	-0.65	-0.39	Lung cancer in ever smokers;	chr15:43880350	chr15:43663654~43684339:-
KIRP	cis	rs67311347	1	rs1119179	ENSG00000230274.1	PGAM1P3	-6.82	6.16e-11	6.51e-08	-0.38	-0.39	Renal cell carcinoma;	chr3:40383438	chr3:40322715~40323279:-
KIRP	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	6.82	6.16e-11	6.51e-08	0.47	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
KIRP	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-6.82	6.16e-11	6.52e-08	-0.42	-0.39	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-6.82	6.16e-11	6.52e-08	-0.42	-0.39	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
KIRP	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	6.82	6.17e-11	6.52e-08	0.52	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
KIRP	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-6.82	6.17e-11	6.53e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-6.82	6.17e-11	6.53e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
KIRP	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-6.82	6.18e-11	6.53e-08	-0.46	-0.39	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-6.82	6.19e-11	6.54e-08	-0.52	-0.39	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
KIRP	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-6.82	6.21e-11	6.56e-08	-0.56	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
KIRP	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-6.82	6.21e-11	6.56e-08	-0.46	-0.39	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
KIRP	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-6.82	6.22e-11	6.57e-08	-0.3	-0.39	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
KIRP	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.82	6.22e-11	6.58e-08	0.42	0.39	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
KIRP	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-6.82	6.23e-11	6.58e-08	-0.53	-0.39	Height;	chr6:109636120	chr6:109382795~109383666:+
KIRP	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-6.82	6.24e-11	6.59e-08	-0.46	-0.39	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
KIRP	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-6.82	6.24e-11	6.59e-08	-0.5	-0.39	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
KIRP	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	6.82	6.25e-11	6.6e-08	0.3	0.39	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	6.82	6.28e-11	6.63e-08	0.46	0.39	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
KIRP	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-6.82	6.3e-11	6.65e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-6.82	6.3e-11	6.65e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
KIRP	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	6.82	6.33e-11	6.68e-08	0.55	0.39	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
KIRP	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-6.82	6.33e-11	6.68e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
KIRP	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	6.82	6.34e-11	6.69e-08	0.53	0.39	Height;	chr6:109498586	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	6.82	6.34e-11	6.69e-08	0.53	0.39	Height;	chr6:109499759	chr6:109382795~109383666:+
KIRP	cis	rs4660214	0.671	rs17491275	ENSG00000237624.1	OXCT2P1	6.82	6.34e-11	6.69e-08	0.7	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39514956~39516490:+
KIRP	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-6.82	6.35e-11	6.7e-08	-0.45	-0.39	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
KIRP	cis	rs12188164	1	rs56104584	ENSG00000221990.4	EXOC3-AS1	6.82	6.39e-11	6.74e-08	0.37	0.39	Cystic fibrosis severity;	chr5:437427	chr5:441498~443160:-
KIRP	cis	rs12188164	1	rs55842567	ENSG00000221990.4	EXOC3-AS1	6.82	6.39e-11	6.74e-08	0.37	0.39	Cystic fibrosis severity;	chr5:437471	chr5:441498~443160:-
KIRP	cis	rs12188164	1	rs56042615	ENSG00000221990.4	EXOC3-AS1	6.82	6.39e-11	6.74e-08	0.37	0.39	Cystic fibrosis severity;	chr5:437552	chr5:441498~443160:-
KIRP	cis	rs12188164	1	rs34847072	ENSG00000221990.4	EXOC3-AS1	6.82	6.39e-11	6.74e-08	0.37	0.39	Cystic fibrosis severity;	chr5:437747	chr5:441498~443160:-
KIRP	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	6.82	6.4e-11	6.75e-08	0.47	0.39	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
KIRP	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	6.82	6.42e-11	6.76e-08	0.41	0.39	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	6.82	6.42e-11	6.76e-08	0.41	0.39	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
KIRP	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-6.82	6.42e-11	6.77e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-6.82	6.42e-11	6.77e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-6.82	6.42e-11	6.77e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-6.82	6.42e-11	6.77e-08	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
KIRP	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-6.82	6.44e-11	6.78e-08	-0.42	-0.39	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
KIRP	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	6.82	6.44e-11	6.79e-08	0.27	0.39	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
KIRP	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	6.82	6.46e-11	6.8e-08	0.45	0.39	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
KIRP	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-6.81	6.46e-11	6.81e-08	-0.51	-0.39	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
KIRP	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-6.81	6.46e-11	6.81e-08	-0.28	-0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
KIRP	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-6.81	6.47e-11	6.82e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
KIRP	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.81	6.48e-11	6.83e-08	0.44	0.39	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
KIRP	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.81	6.49e-11	6.84e-08	0.32	0.39	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.81	6.49e-11	6.84e-08	0.32	0.39	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
KIRP	cis	rs79349575	0.87	rs12941262	ENSG00000248278.1	SUMO2P17	6.81	6.49e-11	6.84e-08	0.44	0.39	Type 2 diabetes;	chr17:48889675	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.778	rs12950328	ENSG00000248278.1	SUMO2P17	6.81	6.49e-11	6.84e-08	0.44	0.39	Type 2 diabetes;	chr17:48889699	chr17:48874860~48908983:-
KIRP	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	6.81	6.5e-11	6.84e-08	0.32	0.39	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
KIRP	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-6.81	6.52e-11	6.86e-08	-0.41	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
KIRP	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	6.81	6.53e-11	6.87e-08	0.3	0.39	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
KIRP	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	6.81	6.58e-11	6.92e-08	0.5	0.39	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
KIRP	cis	rs67311347	0.503	rs11719968	ENSG00000230274.1	PGAM1P3	6.81	6.58e-11	6.92e-08	0.38	0.39	Renal cell carcinoma;	chr3:40200109	chr3:40322715~40323279:-
KIRP	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-6.81	6.6e-11	6.94e-08	-0.32	-0.39	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
KIRP	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	6.81	6.62e-11	6.96e-08	0.47	0.39	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
KIRP	cis	rs4356975	0.83	rs57386454	ENSG00000250696.4	RP11-704M14.1	6.81	6.64e-11	6.98e-08	0.37	0.39	Obesity-related traits;	chr4:69052968	chr4:69182100~69216766:+
KIRP	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-6.81	6.65e-11	6.99e-08	-0.51	-0.39	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
KIRP	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	6.81	6.65e-11	6.99e-08	0.47	0.39	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	6.81	6.65e-11	6.99e-08	0.47	0.39	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	6.81	6.65e-11	6.99e-08	0.47	0.39	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	6.81	6.65e-11	6.99e-08	0.47	0.39	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
KIRP	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	6.81	6.66e-11	7e-08	0.28	0.39	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
KIRP	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	6.81	6.67e-11	7.01e-08	0.45	0.39	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	6.81	6.67e-11	7.01e-08	0.45	0.39	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
KIRP	cis	rs4638749	0.677	rs10454132	ENSG00000225328.1	AC019100.3	-6.81	6.69e-11	7.03e-08	-0.46	-0.39	Blood pressure;	chr2:108211655	chr2:108167748~108217841:-
KIRP	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-6.81	6.69e-11	7.03e-08	-0.39	-0.39	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
KIRP	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	6.81	6.71e-11	7.05e-08	0.5	0.39	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
KIRP	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	6.81	6.73e-11	7.06e-08	0.3	0.39	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
KIRP	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-6.81	6.73e-11	7.07e-08	-0.42	-0.39	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
KIRP	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	6.81	6.74e-11	7.08e-08	0.48	0.39	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
KIRP	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	6.81	6.75e-11	7.08e-08	0.55	0.39	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
KIRP	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-6.81	6.78e-11	7.12e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
KIRP	cis	rs7829975	0.711	rs4481596	ENSG00000253981.4	ALG1L13P	6.81	6.79e-11	7.12e-08	0.3	0.39	Mood instability;	chr8:8846820	chr8:8236003~8244667:-
KIRP	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-6.81	6.79e-11	7.13e-08	-0.42	-0.39	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
KIRP	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	6.81	6.81e-11	7.15e-08	0.4	0.39	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
KIRP	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-6.81	6.82e-11	7.15e-08	-0.39	-0.39	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
KIRP	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-6.81	6.83e-11	7.16e-08	-0.43	-0.39	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
KIRP	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-6.81	6.83e-11	7.17e-08	-0.41	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
KIRP	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	6.81	6.84e-11	7.17e-08	0.47	0.39	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
KIRP	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	6.8	6.85e-11	7.18e-08	0.52	0.39	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-6.8	6.85e-11	7.18e-08	-0.52	-0.39	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	6.8	6.85e-11	7.18e-08	0.52	0.39	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
KIRP	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	6.8	6.85e-11	7.19e-08	0.44	0.39	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
KIRP	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	6.8	6.89e-11	7.22e-08	0.27	0.39	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
KIRP	cis	rs67311347	0.866	rs11712426	ENSG00000230274.1	PGAM1P3	6.8	6.89e-11	7.22e-08	0.39	0.39	Renal cell carcinoma;	chr3:40288831	chr3:40322715~40323279:-
KIRP	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	6.8	6.91e-11	7.24e-08	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
KIRP	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	6.8	6.91e-11	7.24e-08	0.53	0.39	Height;	chr6:109501402	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	6.8	6.91e-11	7.24e-08	0.53	0.39	Height;	chr6:109501429	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	6.8	6.91e-11	7.24e-08	0.53	0.39	Height;	chr6:109503623	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	6.8	6.91e-11	7.24e-08	0.53	0.39	Height;	chr6:109507271	chr6:109382795~109383666:+
KIRP	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	6.8	6.93e-11	7.26e-08	0.45	0.39	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
KIRP	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-6.8	6.94e-11	7.27e-08	-0.51	-0.39	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
KIRP	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-6.8	6.95e-11	7.28e-08	-0.29	-0.39	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
KIRP	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-6.8	6.96e-11	7.29e-08	-0.29	-0.39	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
KIRP	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.8	6.97e-11	7.3e-08	0.33	0.39	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
KIRP	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	6.8	6.97e-11	7.3e-08	0.54	0.39	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
KIRP	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-6.8	6.98e-11	7.31e-08	-0.41	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
KIRP	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	6.8	6.98e-11	7.31e-08	0.52	0.39	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
KIRP	cis	rs11647589	0.641	rs9922446	ENSG00000260762.1	ACSM5P1	6.8	6.98e-11	7.31e-08	0.41	0.39	Blood metabolite levels;	chr16:20470093	chr16:20586550~20607107:-
KIRP	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	6.8	7e-11	7.32e-08	0.48	0.39	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
KIRP	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	6.8	7.01e-11	7.33e-08	0.28	0.39	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
KIRP	cis	rs4356975	0.583	rs62296935	ENSG00000250696.4	RP11-704M14.1	6.8	7.03e-11	7.36e-08	0.36	0.39	Obesity-related traits;	chr4:69082878	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs62296936	ENSG00000250696.4	RP11-704M14.1	6.8	7.03e-11	7.36e-08	0.36	0.39	Obesity-related traits;	chr4:69082903	chr4:69182100~69216766:+
KIRP	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	6.8	7.05e-11	7.38e-08	0.52	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
KIRP	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	6.8	7.05e-11	7.38e-08	0.4	0.39	Breast size;	chr12:9220132	chr12:9277235~9313241:+
KIRP	cis	rs4356975	0.545	rs11249526	ENSG00000250696.4	RP11-704M14.1	6.8	7.07e-11	7.4e-08	0.36	0.39	Obesity-related traits;	chr4:69080934	chr4:69182100~69216766:+
KIRP	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-6.8	7.07e-11	7.4e-08	-0.41	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
KIRP	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	6.8	7.09e-11	7.42e-08	0.58	0.39	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
KIRP	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	6.8	7.11e-11	7.43e-08	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	6.8	7.11e-11	7.43e-08	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	6.8	7.11e-11	7.43e-08	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	6.8	7.11e-11	7.43e-08	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
KIRP	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	6.8	7.11e-11	7.44e-08	0.4	0.39	Breast size;	chr12:9219433	chr12:9277235~9313241:+
KIRP	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	6.8	7.12e-11	7.44e-08	0.46	0.39	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
KIRP	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-6.8	7.13e-11	7.45e-08	-0.35	-0.39	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
KIRP	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	6.8	7.14e-11	7.46e-08	0.45	0.39	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	6.8	7.14e-11	7.46e-08	0.47	0.39	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	6.8	7.16e-11	7.48e-08	0.47	0.39	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
KIRP	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-6.8	7.17e-11	7.49e-08	-0.35	-0.39	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
KIRP	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	6.8	7.17e-11	7.49e-08	0.36	0.39	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
KIRP	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	6.8	7.18e-11	7.5e-08	0.49	0.39	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
KIRP	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	6.8	7.19e-11	7.51e-08	0.64	0.39	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
KIRP	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-6.8	7.21e-11	7.53e-08	-0.45	-0.39	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
KIRP	cis	rs4356975	0.545	rs11249524	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69080653	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.602	rs7674851	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69081113	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7679550	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69081187	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4478248	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69081498	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7680709	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69081745	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.527	rs12643840	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69082245	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4131317	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69083280	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4540108	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69083614	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs4640729	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69083642	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4522933	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69083780	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs11937683	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69084102	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7659306	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69084560	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4454000	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69084853	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4273534	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69084927	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs4642304	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69085832	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4446391	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69086364	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7437174	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69086885	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6422324	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69087385	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600874	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69087695	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6843382	ENSG00000250696.4	RP11-704M14.1	6.8	7.21e-11	7.53e-08	0.36	0.39	Obesity-related traits;	chr4:69087884	chr4:69182100~69216766:+
KIRP	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-6.8	7.22e-11	7.53e-08	-0.5	-0.39	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
KIRP	cis	rs4638749	0.734	rs6542756	ENSG00000225328.1	AC019100.3	-6.8	7.26e-11	7.58e-08	-0.48	-0.39	Blood pressure;	chr2:108249173	chr2:108167748~108217841:-
KIRP	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	6.8	7.26e-11	7.58e-08	0.52	0.39	Height;	chr6:109360263	chr6:109382795~109383666:+
KIRP	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-6.8	7.27e-11	7.58e-08	-0.38	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
KIRP	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	6.79	7.28e-11	7.6e-08	0.33	0.39	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
KIRP	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-6.79	7.3e-11	7.61e-08	-0.42	-0.39	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	6.79	7.31e-11	7.62e-08	0.43	0.39	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
KIRP	cis	rs4638749	0.501	rs6733637	ENSG00000225328.1	AC019100.3	-6.79	7.32e-11	7.63e-08	-0.45	-0.39	Blood pressure;	chr2:108188108	chr2:108167748~108217841:-
KIRP	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-6.79	7.33e-11	7.64e-08	-0.34	-0.39	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
KIRP	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-6.79	7.33e-11	7.64e-08	-0.34	-0.39	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
KIRP	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-6.79	7.35e-11	7.65e-08	-0.49	-0.39	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
KIRP	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	6.79	7.35e-11	7.66e-08	0.6	0.39	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
KIRP	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-6.79	7.37e-11	7.68e-08	-0.39	-0.39	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
KIRP	cis	rs11647589	0.687	rs12598584	ENSG00000260762.1	ACSM5P1	-6.79	7.4e-11	7.71e-08	-0.41	-0.39	Blood metabolite levels;	chr16:20476785	chr16:20586550~20607107:-
KIRP	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-6.79	7.4e-11	7.71e-08	-0.32	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
KIRP	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-6.79	7.43e-11	7.74e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
KIRP	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	6.79	7.44e-11	7.75e-08	0.32	0.39	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
KIRP	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	6.79	7.45e-11	7.76e-08	0.47	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
KIRP	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	6.79	7.48e-11	7.79e-08	0.47	0.39	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
KIRP	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-6.79	7.49e-11	7.79e-08	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
KIRP	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	6.79	7.49e-11	7.8e-08	0.32	0.39	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
KIRP	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	6.79	7.49e-11	7.8e-08	0.45	0.39	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
KIRP	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	6.79	7.5e-11	7.81e-08	0.54	0.39	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
KIRP	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-6.79	7.51e-11	7.81e-08	-0.59	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-6.79	7.51e-11	7.81e-08	-0.59	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
KIRP	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	6.79	7.52e-11	7.82e-08	0.47	0.39	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
KIRP	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	6.79	7.53e-11	7.83e-08	0.53	0.39	Height;	chr6:109642186	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	6.79	7.53e-11	7.83e-08	0.53	0.39	Height;	chr6:109646187	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	6.79	7.53e-11	7.83e-08	0.53	0.39	Height;	chr6:109652694	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	6.79	7.53e-11	7.83e-08	0.53	0.39	Height;	chr6:109655791	chr6:109382795~109383666:+
KIRP	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-6.79	7.54e-11	7.84e-08	-0.29	-0.39	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
KIRP	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	6.79	7.57e-11	7.87e-08	0.45	0.39	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
KIRP	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-6.79	7.58e-11	7.88e-08	-0.49	-0.39	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
KIRP	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-6.79	7.58e-11	7.88e-08	-0.29	-0.39	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
KIRP	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	6.79	7.58e-11	7.88e-08	0.55	0.39	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
KIRP	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	6.79	7.58e-11	7.88e-08	0.55	0.39	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
KIRP	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	6.79	7.58e-11	7.88e-08	0.55	0.39	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
KIRP	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-6.79	7.59e-11	7.89e-08	-0.4	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
KIRP	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-6.79	7.59e-11	7.89e-08	-0.59	-0.39	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	6.79	7.61e-11	7.91e-08	0.47	0.39	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
KIRP	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	6.79	7.64e-11	7.94e-08	0.4	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
KIRP	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-6.79	7.67e-11	7.97e-08	-0.34	-0.39	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-6.79	7.68e-11	7.98e-08	-0.34	-0.39	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
KIRP	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-6.79	7.7e-11	8e-08	-0.42	-0.39	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	6.78	7.74e-11	8.04e-08	0.51	0.39	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	6.78	7.74e-11	8.04e-08	0.51	0.39	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	6.78	7.75e-11	8.04e-08	0.52	0.39	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
KIRP	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	6.78	7.76e-11	8.06e-08	0.49	0.39	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
KIRP	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	6.78	7.77e-11	8.07e-08	0.47	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
KIRP	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	6.78	7.78e-11	8.07e-08	0.54	0.39	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
KIRP	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	6.78	7.78e-11	8.08e-08	0.4	0.39	Breast size;	chr12:9220266	chr12:9277235~9313241:+
KIRP	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-6.78	7.84e-11	8.13e-08	-0.5	-0.39	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	6.78	7.84e-11	8.14e-08	0.47	0.39	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
KIRP	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-6.78	7.87e-11	8.16e-08	-0.3	-0.39	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
KIRP	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	6.78	7.88e-11	8.17e-08	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
KIRP	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	6.78	7.89e-11	8.18e-08	0.51	0.39	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
KIRP	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-6.78	7.92e-11	8.21e-08	-0.38	-0.39	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
KIRP	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-6.78	7.95e-11	8.24e-08	-0.45	-0.39	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
KIRP	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-6.78	7.97e-11	8.26e-08	-0.31	-0.39	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
KIRP	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	6.78	7.98e-11	8.27e-08	0.51	0.39	Height;	chr6:109383848	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-6.78	7.98e-11	8.27e-08	-0.35	-0.39	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
KIRP	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-6.78	7.99e-11	8.28e-08	-0.46	-0.39	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
KIRP	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-6.78	7.99e-11	8.28e-08	-0.42	-0.39	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	6.78	8e-11	8.29e-08	0.48	0.39	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
KIRP	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.78	8.01e-11	8.29e-08	0.43	0.39	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
KIRP	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-6.78	8.01e-11	8.3e-08	-0.35	-0.39	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
KIRP	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	6.78	8.02e-11	8.3e-08	0.43	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
KIRP	cis	rs67311347	0.635	rs73071706	ENSG00000230274.1	PGAM1P3	6.78	8.05e-11	8.34e-08	0.37	0.39	Renal cell carcinoma;	chr3:40246699	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.668	rs73071710	ENSG00000230274.1	PGAM1P3	6.78	8.05e-11	8.34e-08	0.37	0.39	Renal cell carcinoma;	chr3:40247096	chr3:40322715~40323279:-
KIRP	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-6.78	8.05e-11	8.34e-08	-0.44	-0.39	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
KIRP	cis	rs832187	0.615	rs9875198	ENSG00000280620.1	SCAANT1	6.78	8.07e-11	8.36e-08	0.44	0.39	Schizophrenia;	chr3:64010239	chr3:63911518~63911772:-
KIRP	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	6.78	8.08e-11	8.37e-08	0.41	0.39	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
KIRP	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-6.78	8.1e-11	8.39e-08	-0.53	-0.39	Height;	chr6:109531713	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-6.78	8.11e-11	8.4e-08	-0.31	-0.39	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	6.78	8.13e-11	8.41e-08	0.48	0.39	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
KIRP	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.78	8.15e-11	8.44e-08	0.33	0.39	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
KIRP	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-6.78	8.16e-11	8.44e-08	-0.44	-0.39	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
KIRP	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	6.78	8.16e-11	8.44e-08	0.66	0.39	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	6.78	8.16e-11	8.44e-08	0.66	0.39	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
KIRP	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-6.78	8.16e-11	8.44e-08	-0.42	-0.39	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-6.78	8.16e-11	8.44e-08	-0.42	-0.39	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-6.78	8.16e-11	8.44e-08	-0.42	-0.39	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
KIRP	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-6.78	8.16e-11	8.44e-08	-0.47	-0.39	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
KIRP	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-6.78	8.17e-11	8.45e-08	-0.29	-0.39	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-6.78	8.17e-11	8.45e-08	-0.29	-0.39	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
KIRP	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-6.78	8.17e-11	8.45e-08	-0.29	-0.39	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
KIRP	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	6.77	8.17e-11	8.45e-08	0.45	0.39	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
KIRP	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	6.77	8.18e-11	8.46e-08	0.27	0.39	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	6.77	8.18e-11	8.46e-08	0.27	0.39	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
KIRP	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-6.77	8.18e-11	8.46e-08	-0.34	-0.39	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
KIRP	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-6.77	8.18e-11	8.46e-08	-0.34	-0.39	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
KIRP	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-6.77	8.2e-11	8.48e-08	-0.46	-0.39	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
KIRP	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-6.77	8.23e-11	8.5e-08	-0.41	-0.39	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
KIRP	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109382188	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109384807	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109390638	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109391534	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109392096	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	6.77	8.25e-11	8.53e-08	0.51	0.39	Height;	chr6:109393881	chr6:109382795~109383666:+
KIRP	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-6.77	8.33e-11	8.6e-08	-0.6	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-6.77	8.33e-11	8.6e-08	-0.6	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
KIRP	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	6.77	8.34e-11	8.61e-08	0.48	0.39	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
KIRP	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	6.77	8.35e-11	8.62e-08	0.43	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
KIRP	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	6.77	8.37e-11	8.64e-08	0.51	0.39	Height;	chr6:109402736	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	6.77	8.37e-11	8.64e-08	0.51	0.39	Height;	chr6:109403734	chr6:109382795~109383666:+
KIRP	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-6.77	8.38e-11	8.65e-08	-0.51	-0.39	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-6.77	8.38e-11	8.65e-08	-0.51	-0.39	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
KIRP	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.77	8.38e-11	8.65e-08	0.44	0.39	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
KIRP	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	6.77	8.4e-11	8.67e-08	0.4	0.39	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
KIRP	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	6.77	8.4e-11	8.67e-08	0.4	0.39	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
KIRP	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-6.77	8.41e-11	8.68e-08	-0.5	-0.39	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
KIRP	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	6.77	8.41e-11	8.68e-08	0.31	0.39	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
KIRP	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-6.77	8.42e-11	8.69e-08	-0.48	-0.39	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
KIRP	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-6.77	8.46e-11	8.72e-08	-0.39	-0.39	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
KIRP	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	6.77	8.47e-11	8.73e-08	0.29	0.39	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
KIRP	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-6.77	8.47e-11	8.73e-08	-0.5	-0.39	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-6.77	8.47e-11	8.73e-08	-0.5	-0.39	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
KIRP	cis	rs4936099	0.931	rs7936928	ENSG00000175773.11	RP11-121M22.1	6.77	8.47e-11	8.73e-08	0.38	0.39	Optic cup area;Vertical cup-disc ratio;	chr11:130409273	chr11:130314993~130403657:+
KIRP	cis	rs950027	0.62	rs1617634	ENSG00000259433.2	CTD-2651B20.4	-6.77	8.48e-11	8.75e-08	-0.33	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45330209~45332634:-
KIRP	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	6.77	8.49e-11	8.75e-08	0.48	0.39	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
KIRP	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	6.77	8.5e-11	8.76e-08	0.51	0.39	Height;	chr6:109390116	chr6:109382795~109383666:+
KIRP	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	6.77	8.51e-11	8.77e-08	0.51	0.39	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
KIRP	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	6.77	8.53e-11	8.79e-08	0.44	0.39	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
KIRP	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	6.77	8.56e-11	8.82e-08	0.46	0.39	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
KIRP	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-6.77	8.57e-11	8.83e-08	-0.46	-0.39	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
KIRP	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	6.77	8.59e-11	8.84e-08	0.53	0.39	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
KIRP	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-6.77	8.59e-11	8.85e-08	-0.42	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
KIRP	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-6.77	8.61e-11	8.87e-08	-0.42	-0.39	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
KIRP	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	6.77	8.62e-11	8.88e-08	0.52	0.39	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	6.77	8.64e-11	8.89e-08	0.44	0.39	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
KIRP	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	6.77	8.64e-11	8.9e-08	0.64	0.39	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
KIRP	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-6.77	8.67e-11	8.92e-08	-0.34	-0.39	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
KIRP	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	6.77	8.67e-11	8.92e-08	0.61	0.39	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	6.77	8.67e-11	8.92e-08	0.61	0.39	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
KIRP	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	6.76	8.67e-11	8.92e-08	0.55	0.39	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
KIRP	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	6.76	8.67e-11	8.92e-08	0.55	0.39	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
KIRP	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-6.76	8.69e-11	8.94e-08	-0.31	-0.39	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
KIRP	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	6.76	8.7e-11	8.95e-08	0.38	0.39	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
KIRP	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	6.76	8.71e-11	8.96e-08	0.55	0.39	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
KIRP	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-6.76	8.75e-11	8.99e-08	-0.43	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
KIRP	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-6.76	8.76e-11	9.01e-08	-0.45	-0.39	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-6.76	8.76e-11	9.01e-08	-0.45	-0.39	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
KIRP	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	6.76	8.78e-11	9.02e-08	0.48	0.39	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	6.76	8.78e-11	9.02e-08	0.48	0.39	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
KIRP	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-6.76	8.78e-11	9.02e-08	-0.34	-0.39	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
KIRP	cis	rs17082664	0.79	rs7742641	ENSG00000226193.1	RP3-398G3.5	-6.76	8.82e-11	9.06e-08	-0.61	-0.39	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152399189	chr6:152402398~152404966:+
KIRP	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-6.76	8.82e-11	9.06e-08	-0.48	-0.39	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
KIRP	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.76	8.84e-11	9.07e-08	0.51	0.39	Height;	chr6:109490935	chr6:109382795~109383666:+
KIRP	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-6.76	8.86e-11	9.09e-08	-0.42	-0.39	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
KIRP	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	6.76	8.94e-11	9.17e-08	0.85	0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
KIRP	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-6.76	9.01e-11	9.23e-08	-0.52	-0.39	Height;	chr6:109497253	chr6:109382795~109383666:+
KIRP	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-6.76	9.02e-11	9.24e-08	-0.46	-0.39	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.83	rs4481286	ENSG00000250696.4	RP11-704M14.1	6.76	9.03e-11	9.25e-08	0.36	0.39	Obesity-related traits;	chr4:69056631	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs4583828	ENSG00000250696.4	RP11-704M14.1	6.76	9.03e-11	9.25e-08	0.36	0.39	Obesity-related traits;	chr4:69056669	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs4235113	ENSG00000250696.4	RP11-704M14.1	6.76	9.03e-11	9.25e-08	0.36	0.39	Obesity-related traits;	chr4:69056739	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs4235114	ENSG00000250696.4	RP11-704M14.1	6.76	9.03e-11	9.25e-08	0.36	0.39	Obesity-related traits;	chr4:69056953	chr4:69182100~69216766:+
KIRP	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-6.76	9.06e-11	9.28e-08	-0.28	-0.39	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
KIRP	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-6.76	9.06e-11	9.28e-08	-0.39	-0.39	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
KIRP	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	6.76	9.08e-11	9.3e-08	0.44	0.39	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
KIRP	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-6.76	9.09e-11	9.31e-08	-0.46	-0.39	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-6.76	9.09e-11	9.31e-08	-0.46	-0.39	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-6.76	9.09e-11	9.31e-08	-0.46	-0.39	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
KIRP	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	6.76	9.09e-11	9.31e-08	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
KIRP	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-6.76	9.1e-11	9.31e-08	-0.38	-0.39	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
KIRP	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-6.76	9.1e-11	9.31e-08	-0.45	-0.39	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-6.76	9.12e-11	9.34e-08	-0.46	-0.39	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-6.76	9.12e-11	9.34e-08	-0.46	-0.39	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
KIRP	cis	rs7829975	0.539	rs71537846	ENSG00000253893.2	FAM85B	6.76	9.13e-11	9.34e-08	0.52	0.39	Mood instability;	chr8:8684610	chr8:8167819~8226614:-
KIRP	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-6.76	9.16e-11	9.37e-08	-0.35	-0.39	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
KIRP	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-6.76	9.16e-11	9.37e-08	-0.41	-0.39	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
KIRP	cis	rs67311347	0.955	rs73080163	ENSG00000230274.1	PGAM1P3	6.76	9.19e-11	9.4e-08	0.38	0.39	Renal cell carcinoma;	chr3:40491570	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs73080165	ENSG00000230274.1	PGAM1P3	6.76	9.19e-11	9.4e-08	0.38	0.39	Renal cell carcinoma;	chr3:40491571	chr3:40322715~40323279:-
KIRP	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-6.75	9.23e-11	9.43e-08	-0.44	-0.39	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
KIRP	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.75	9.23e-11	9.44e-08	0.44	0.39	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
KIRP	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-6.75	9.24e-11	9.44e-08	-0.35	-0.39	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
KIRP	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	6.75	9.24e-11	9.44e-08	0.44	0.39	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
KIRP	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-6.75	9.26e-11	9.46e-08	-0.47	-0.39	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	6.75	9.27e-11	9.47e-08	0.46	0.39	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	6.75	9.27e-11	9.47e-08	0.46	0.39	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
KIRP	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-6.75	9.29e-11	9.49e-08	-0.45	-0.39	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
KIRP	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-6.75	9.29e-11	9.49e-08	-0.45	-0.39	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
KIRP	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	6.75	9.3e-11	9.5e-08	0.52	0.39	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
KIRP	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	6.75	9.3e-11	9.5e-08	0.52	0.39	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
KIRP	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	6.75	9.31e-11	9.5e-08	0.42	0.39	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
KIRP	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	6.75	9.35e-11	9.55e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
KIRP	cis	rs4638749	0.677	rs1563111	ENSG00000225328.1	AC019100.3	-6.75	9.39e-11	9.58e-08	-0.46	-0.38	Blood pressure;	chr2:108229261	chr2:108167748~108217841:-
KIRP	cis	rs9371601	0.819	rs214949	ENSG00000226193.1	RP3-398G3.5	-6.75	9.4e-11	9.6e-08	-0.42	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152386790	chr6:152402398~152404966:+
KIRP	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-6.75	9.41e-11	9.6e-08	-0.53	-0.38	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
KIRP	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-6.75	9.41e-11	9.6e-08	-0.53	-0.38	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
KIRP	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-6.75	9.41e-11	9.6e-08	-0.41	-0.38	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
KIRP	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	6.75	9.42e-11	9.61e-08	0.44	0.38	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
KIRP	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-6.75	9.43e-11	9.62e-08	-0.32	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
KIRP	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	6.75	9.45e-11	9.64e-08	0.46	0.38	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
KIRP	cis	rs4356975	0.563	rs6858558	ENSG00000250696.4	RP11-704M14.1	6.75	9.47e-11	9.65e-08	0.37	0.38	Obesity-related traits;	chr4:69103825	chr4:69182100~69216766:+
KIRP	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-6.75	9.48e-11	9.67e-08	-0.4	-0.38	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
KIRP	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-6.75	9.49e-11	9.67e-08	-0.32	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
KIRP	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	6.75	9.51e-11	9.7e-08	0.45	0.38	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
KIRP	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	6.75	9.52e-11	9.7e-08	0.51	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
KIRP	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-6.75	9.54e-11	9.72e-08	-0.48	-0.38	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
KIRP	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.75	9.55e-11	9.73e-08	-0.45	-0.38	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.75	9.55e-11	9.73e-08	-0.45	-0.38	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
KIRP	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	6.75	9.57e-11	9.75e-08	0.45	0.38	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
KIRP	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-6.75	9.58e-11	9.76e-08	-0.44	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
KIRP	cis	rs4356975	0.522	rs6600888	ENSG00000250696.4	RP11-704M14.1	6.75	9.58e-11	9.76e-08	0.37	0.38	Obesity-related traits;	chr4:69104141	chr4:69182100~69216766:+
KIRP	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	6.75	9.61e-11	9.79e-08	0.42	0.38	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
KIRP	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	6.75	9.63e-11	9.81e-08	0.41	0.38	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
KIRP	cis	rs4443100	0.916	rs2078726	ENSG00000221069.1	AC000029.1	6.75	9.68e-11	9.86e-08	0.46	0.38	Serum parathyroid hormone levels;	chr22:23040303	chr22:23136620~23136710:+
KIRP	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-6.75	9.7e-11	9.88e-08	-0.49	-0.38	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
KIRP	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.75	9.71e-11	9.89e-08	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.75	9.71e-11	9.89e-08	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
KIRP	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	6.75	9.73e-11	9.9e-08	0.42	0.38	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
KIRP	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	6.75	9.73e-11	9.9e-08	0.43	0.38	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
KIRP	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	6.75	9.74e-11	9.91e-08	0.64	0.38	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
KIRP	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-6.74	9.77e-11	9.94e-08	-0.58	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
KIRP	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-6.74	9.86e-11	1e-07	-0.35	-0.38	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-6.74	9.88e-11	1e-07	-0.35	-0.38	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	6.74	9.89e-11	1.01e-07	0.51	0.38	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	6.74	9.89e-11	1.01e-07	0.51	0.38	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
KIRP	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	6.74	9.91e-11	1.01e-07	0.49	0.38	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
KIRP	cis	rs9371601	0.892	rs214969	ENSG00000226193.1	RP3-398G3.5	-6.74	9.93e-11	1.01e-07	-0.42	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152455196	chr6:152402398~152404966:+
KIRP	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	6.74	9.94e-11	1.01e-07	0.43	0.38	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
KIRP	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	6.74	9.96e-11	1.01e-07	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
KIRP	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	6.74	9.96e-11	1.01e-07	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
KIRP	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	6.74	9.96e-11	1.01e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
KIRP	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-6.74	9.99e-11	1.01e-07	-0.31	-0.38	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
KIRP	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	6.74	1e-10	1.01e-07	0.26	0.38	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
KIRP	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	6.74	1e-10	1.02e-07	0.48	0.38	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
KIRP	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-6.74	1e-10	1.02e-07	-0.51	-0.38	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
KIRP	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-6.74	1e-10	1.02e-07	-0.44	-0.38	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
KIRP	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.74	1.01e-10	1.02e-07	-0.45	-0.38	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.74	1.01e-10	1.02e-07	-0.45	-0.38	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
KIRP	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	6.74	1.01e-10	1.03e-07	0.45	0.38	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
KIRP	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-6.74	1.01e-10	1.03e-07	-0.51	-0.38	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	6.74	1.01e-10	1.03e-07	0.51	0.38	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	6.74	1.01e-10	1.03e-07	0.51	0.38	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
KIRP	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	6.74	1.01e-10	1.03e-07	0.48	0.38	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
KIRP	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	6.74	1.02e-10	1.03e-07	0.28	0.38	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
KIRP	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	6.74	1.02e-10	1.03e-07	0.29	0.38	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
KIRP	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	6.74	1.02e-10	1.04e-07	0.42	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
KIRP	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	6.74	1.02e-10	1.04e-07	0.51	0.38	Height;	chr6:109409679	chr6:109382795~109383666:+
KIRP	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	6.74	1.02e-10	1.04e-07	0.5	0.38	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
KIRP	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-6.74	1.02e-10	1.04e-07	-0.47	-0.38	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
KIRP	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	6.74	1.03e-10	1.04e-07	0.51	0.38	Height;	chr6:109498751	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	6.74	1.03e-10	1.04e-07	0.51	0.38	Height;	chr6:109500687	chr6:109382795~109383666:+
KIRP	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	6.74	1.03e-10	1.04e-07	0.49	0.38	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
KIRP	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-6.74	1.03e-10	1.04e-07	-0.42	-0.38	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
KIRP	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	6.74	1.03e-10	1.04e-07	0.42	0.38	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
KIRP	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	6.74	1.03e-10	1.04e-07	0.46	0.38	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
KIRP	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	6.74	1.03e-10	1.04e-07	0.47	0.38	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
KIRP	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-6.74	1.03e-10	1.04e-07	-0.54	-0.38	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
KIRP	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	6.74	1.03e-10	1.04e-07	0.54	0.38	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
KIRP	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	6.74	1.03e-10	1.04e-07	0.51	0.38	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
KIRP	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-6.74	1.03e-10	1.04e-07	-0.47	-0.38	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
KIRP	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	6.74	1.03e-10	1.04e-07	0.52	0.38	Height;	chr6:109618620	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	6.74	1.03e-10	1.04e-07	0.52	0.38	Height;	chr6:109620772	chr6:109382795~109383666:+
KIRP	cis	rs4356975	0.563	rs11932131	ENSG00000250696.4	RP11-704M14.1	6.74	1.03e-10	1.04e-07	0.36	0.38	Obesity-related traits;	chr4:69083829	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs35297888	ENSG00000250696.4	RP11-704M14.1	6.74	1.03e-10	1.04e-07	0.36	0.38	Obesity-related traits;	chr4:69083855	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs35749478	ENSG00000250696.4	RP11-704M14.1	6.74	1.03e-10	1.04e-07	0.36	0.38	Obesity-related traits;	chr4:69083862	chr4:69182100~69216766:+
KIRP	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	6.73	1.04e-10	1.05e-07	0.51	0.38	Height;	chr6:109476101	chr6:109382795~109383666:+
KIRP	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-6.73	1.04e-10	1.05e-07	-0.42	-0.38	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-6.73	1.04e-10	1.05e-07	-0.42	-0.38	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
KIRP	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-6.73	1.04e-10	1.05e-07	-0.4	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-6.73	1.04e-10	1.05e-07	-0.4	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
KIRP	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	6.73	1.04e-10	1.05e-07	0.3	0.38	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
KIRP	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-6.73	1.04e-10	1.05e-07	-0.45	-0.38	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
KIRP	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	6.73	1.04e-10	1.06e-07	0.69	0.38	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
KIRP	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-6.73	1.05e-10	1.06e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-6.73	1.05e-10	1.06e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	6.73	1.05e-10	1.06e-07	0.46	0.38	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	6.73	1.05e-10	1.06e-07	0.46	0.38	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
KIRP	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-6.73	1.05e-10	1.06e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
KIRP	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	6.73	1.05e-10	1.06e-07	0.39	0.38	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
KIRP	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	6.73	1.06e-10	1.07e-07	0.51	0.38	Height;	chr6:109361200	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	6.73	1.06e-10	1.07e-07	0.51	0.38	Height;	chr6:109367335	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	6.73	1.06e-10	1.07e-07	0.51	0.38	Height;	chr6:109368228	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	6.73	1.06e-10	1.07e-07	0.51	0.38	Height;	chr6:109370741	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	6.73	1.06e-10	1.07e-07	0.51	0.38	Height;	chr6:109371524	chr6:109382795~109383666:+
KIRP	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-6.73	1.06e-10	1.07e-07	-0.4	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
KIRP	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.73	1.06e-10	1.07e-07	-0.33	-0.38	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
KIRP	cis	rs4356975	0.563	rs12506962	ENSG00000250696.4	RP11-704M14.1	6.73	1.06e-10	1.07e-07	0.36	0.38	Obesity-related traits;	chr4:69100306	chr4:69182100~69216766:+
KIRP	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	6.73	1.06e-10	1.07e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	6.73	1.06e-10	1.07e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	6.73	1.06e-10	1.07e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	6.73	1.06e-10	1.07e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
KIRP	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	6.73	1.07e-10	1.08e-07	0.48	0.38	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	6.73	1.07e-10	1.08e-07	0.48	0.38	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	6.73	1.07e-10	1.08e-07	0.48	0.38	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
KIRP	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	6.73	1.07e-10	1.08e-07	0.54	0.38	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
KIRP	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	6.73	1.07e-10	1.08e-07	0.51	0.38	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
KIRP	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-6.73	1.08e-10	1.08e-07	-0.51	-0.38	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-6.73	1.08e-10	1.09e-07	-0.45	-0.38	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	6.73	1.08e-10	1.09e-07	0.51	0.38	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
KIRP	cis	rs7916697	0.628	rs10998036	ENSG00000233590.1	RP11-153K11.3	6.73	1.08e-10	1.09e-07	0.47	0.38	Optic disc area;	chr10:68256921	chr10:68233251~68242379:-
KIRP	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	6.73	1.08e-10	1.09e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	6.73	1.08e-10	1.09e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
KIRP	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-6.73	1.08e-10	1.09e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
KIRP	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-6.73	1.09e-10	1.1e-07	-0.49	-0.38	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	6.73	1.09e-10	1.1e-07	0.51	0.38	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	6.73	1.09e-10	1.1e-07	0.51	0.38	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
KIRP	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	6.73	1.09e-10	1.1e-07	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
KIRP	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-6.72	1.1e-10	1.1e-07	-0.36	-0.38	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
KIRP	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	6.72	1.1e-10	1.1e-07	0.38	0.38	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
KIRP	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-6.72	1.1e-10	1.11e-07	-0.36	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
KIRP	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	6.72	1.11e-10	1.11e-07	0.52	0.38	Height;	chr6:109494237	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	6.72	1.11e-10	1.11e-07	0.52	0.38	Height;	chr6:109496073	chr6:109382795~109383666:+
KIRP	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	6.72	1.11e-10	1.11e-07	0.45	0.38	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
KIRP	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.72	1.11e-10	1.11e-07	-0.35	-0.38	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
KIRP	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-6.72	1.11e-10	1.11e-07	-0.44	-0.38	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
KIRP	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	6.72	1.11e-10	1.11e-07	0.42	0.38	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
KIRP	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	6.72	1.11e-10	1.12e-07	0.51	0.38	Height;	chr6:109507364	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	6.72	1.11e-10	1.12e-07	0.51	0.38	Height;	chr6:109507366	chr6:109382795~109383666:+
KIRP	cis	rs4443100	0.916	rs6003482	ENSG00000221069.1	AC000029.1	6.72	1.11e-10	1.12e-07	0.45	0.38	Serum parathyroid hormone levels;	chr22:23037185	chr22:23136620~23136710:+
KIRP	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	6.72	1.11e-10	1.12e-07	0.5	0.38	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	6.72	1.11e-10	1.12e-07	0.5	0.38	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
KIRP	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-6.72	1.11e-10	1.12e-07	-0.47	-0.38	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
KIRP	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	6.72	1.11e-10	1.12e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
KIRP	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	6.72	1.11e-10	1.12e-07	0.51	0.38	Height;	chr6:109397362	chr6:109382795~109383666:+
KIRP	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	6.72	1.11e-10	1.12e-07	0.41	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	6.72	1.11e-10	1.12e-07	0.41	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
KIRP	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	6.72	1.11e-10	1.12e-07	0.29	0.38	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	6.72	1.12e-10	1.12e-07	0.47	0.38	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
KIRP	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-6.72	1.12e-10	1.12e-07	-0.38	-0.38	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
KIRP	cis	rs950027	0.549	rs11636114	ENSG00000259433.2	CTD-2651B20.4	-6.72	1.12e-10	1.13e-07	-0.34	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45330209~45332634:-
KIRP	cis	rs7474896	0.559	rs10740949	ENSG00000151963.4	RP11-775A3.1	-6.72	1.13e-10	1.13e-07	-0.47	-0.38	Obesity (extreme);	chr10:37689507	chr10:37883594~37884109:+
KIRP	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	6.72	1.13e-10	1.13e-07	0.35	0.38	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
KIRP	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	6.72	1.13e-10	1.13e-07	0.35	0.38	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
KIRP	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-6.72	1.13e-10	1.14e-07	-0.42	-0.38	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	6.72	1.13e-10	1.14e-07	0.44	0.38	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
KIRP	cis	rs4638749	0.677	rs7570544	ENSG00000225328.1	AC019100.3	-6.72	1.13e-10	1.14e-07	-0.45	-0.38	Blood pressure;	chr2:108231681	chr2:108167748~108217841:-
KIRP	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	6.72	1.14e-10	1.14e-07	0.52	0.38	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.563	rs7657423	ENSG00000250696.4	RP11-704M14.1	-6.72	1.14e-10	1.14e-07	-0.37	-0.38	Obesity-related traits;	chr4:69090196	chr4:69182100~69216766:+
KIRP	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-6.72	1.14e-10	1.14e-07	-0.41	-0.38	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-6.72	1.14e-10	1.14e-07	-0.41	-0.38	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
KIRP	cis	rs4356975	0.563	rs6600886	ENSG00000250696.4	RP11-704M14.1	6.72	1.14e-10	1.15e-07	0.37	0.38	Obesity-related traits;	chr4:69104017	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600887	ENSG00000250696.4	RP11-704M14.1	6.72	1.14e-10	1.15e-07	0.37	0.38	Obesity-related traits;	chr4:69104070	chr4:69182100~69216766:+
KIRP	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-6.72	1.14e-10	1.15e-07	-0.45	-0.38	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
KIRP	cis	rs4356975	0.522	rs56388229	ENSG00000250696.4	RP11-704M14.1	6.72	1.14e-10	1.15e-07	0.36	0.38	Obesity-related traits;	chr4:69100940	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	6.72	1.15e-10	1.16e-07	0.51	0.38	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
KIRP	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-6.72	1.15e-10	1.16e-07	-0.5	-0.38	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
KIRP	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	6.72	1.15e-10	1.16e-07	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
KIRP	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	6.72	1.16e-10	1.16e-07	0.49	0.38	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
KIRP	cis	rs2698530	0.535	rs2114432	ENSG00000225889.6	AC074289.1	-6.72	1.16e-10	1.16e-07	-0.34	-0.38	Iron status biomarkers;	chr2:64258678	chr2:64143239~64252859:+
KIRP	cis	rs950027	0.549	rs12909409	ENSG00000259433.2	CTD-2651B20.4	6.72	1.16e-10	1.16e-07	0.34	0.38	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45330209~45332634:-
KIRP	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-6.71	1.17e-10	1.17e-07	-0.33	-0.38	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
KIRP	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	6.71	1.17e-10	1.17e-07	0.47	0.38	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
KIRP	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-6.71	1.17e-10	1.18e-07	-0.43	-0.38	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-6.71	1.17e-10	1.18e-07	-0.43	-0.38	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
KIRP	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	6.71	1.17e-10	1.18e-07	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	6.71	1.17e-10	1.18e-07	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
KIRP	cis	rs2765539	1	rs7525637	ENSG00000231365.4	RP11-418J17.1	-6.71	1.17e-10	1.18e-07	-0.41	-0.38	Waist-hip ratio;	chr1:119000848	chr1:119140396~119275973:+
KIRP	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	6.71	1.17e-10	1.18e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
KIRP	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-6.71	1.18e-10	1.18e-07	-0.45	-0.38	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
KIRP	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	6.71	1.18e-10	1.18e-07	0.68	0.38	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
KIRP	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.71	1.18e-10	1.19e-07	-0.43	-0.38	Migraine;	chr4:56850720	chr4:56960927~56961373:-
KIRP	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-6.71	1.19e-10	1.19e-07	-0.44	-0.38	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
KIRP	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-6.71	1.19e-10	1.19e-07	-0.53	-0.38	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
KIRP	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	6.71	1.19e-10	1.19e-07	0.43	0.38	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
KIRP	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-6.71	1.19e-10	1.19e-07	-0.44	-0.38	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
KIRP	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-6.71	1.19e-10	1.19e-07	-0.32	-0.38	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-6.71	1.19e-10	1.19e-07	-0.32	-0.38	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-6.71	1.19e-10	1.19e-07	-0.32	-0.38	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
KIRP	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	6.71	1.2e-10	1.2e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
KIRP	cis	rs4356975	0.83	rs7438033	ENSG00000250696.4	RP11-704M14.1	-6.71	1.2e-10	1.2e-07	-0.35	-0.38	Obesity-related traits;	chr4:69059343	chr4:69182100~69216766:+
KIRP	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-6.71	1.2e-10	1.2e-07	-0.46	-0.38	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
KIRP	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.71	1.2e-10	1.2e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
KIRP	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-6.71	1.2e-10	1.2e-07	-0.37	-0.38	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
KIRP	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-6.71	1.2e-10	1.2e-07	-0.31	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
KIRP	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	6.71	1.2e-10	1.2e-07	0.33	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	6.71	1.2e-10	1.2e-07	0.33	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
KIRP	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-6.71	1.2e-10	1.2e-07	-0.49	-0.38	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
KIRP	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-6.71	1.21e-10	1.2e-07	-0.31	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
KIRP	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-6.71	1.21e-10	1.21e-07	-0.45	-0.38	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
KIRP	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-6.71	1.21e-10	1.21e-07	-0.45	-0.38	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
KIRP	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-6.71	1.21e-10	1.21e-07	-0.45	-0.38	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
KIRP	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-6.71	1.21e-10	1.21e-07	-0.45	-0.38	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
KIRP	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	6.71	1.21e-10	1.21e-07	0.47	0.38	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
KIRP	cis	rs116095464	0.85	rs62330058	ENSG00000277812.1	AC021087.1	6.71	1.21e-10	1.21e-07	1.02	0.38	Breast cancer;	chr5:343449	chr5:262769~262881:+
KIRP	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	6.71	1.21e-10	1.21e-07	0.46	0.38	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
KIRP	cis	rs4356975	0.563	rs7438135	ENSG00000250696.4	RP11-704M14.1	6.71	1.21e-10	1.21e-07	0.36	0.38	Obesity-related traits;	chr4:69095621	chr4:69182100~69216766:+
KIRP	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	6.71	1.21e-10	1.21e-07	0.33	0.38	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
KIRP	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-6.71	1.22e-10	1.21e-07	-0.31	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
KIRP	cis	rs9322193	0.887	rs4870139	ENSG00000268592.3	RAET1E-AS1	6.71	1.22e-10	1.22e-07	0.51	0.38	Lung cancer;	chr6:149575182	chr6:149863494~149919507:+
KIRP	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-6.71	1.22e-10	1.22e-07	-0.45	-0.38	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
KIRP	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-6.71	1.22e-10	1.22e-07	-0.32	-0.38	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
KIRP	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-6.71	1.23e-10	1.23e-07	-0.45	-0.38	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
KIRP	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-6.71	1.23e-10	1.23e-07	-0.43	-0.38	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
KIRP	cis	rs17082664	0.79	rs6915736	ENSG00000226193.1	RP3-398G3.5	-6.71	1.23e-10	1.23e-07	-0.51	-0.38	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152440963	chr6:152402398~152404966:+
KIRP	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.71	1.23e-10	1.23e-07	-0.42	-0.38	Migraine;	chr4:56851192	chr4:56960927~56961373:-
KIRP	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	6.71	1.23e-10	1.23e-07	0.64	0.38	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
KIRP	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-6.7	1.23e-10	1.23e-07	-0.36	-0.38	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
KIRP	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-6.7	1.24e-10	1.24e-07	-0.3	-0.38	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
KIRP	cis	rs4718428	0.705	rs4718430	ENSG00000226824.5	RP4-756H11.3	-6.7	1.24e-10	1.24e-07	-0.53	-0.38	Corneal structure;	chr7:66967037	chr7:66654538~66669855:+
KIRP	cis	rs755249	0.73	rs3916164	ENSG00000237624.1	OXCT2P1	6.7	1.24e-10	1.24e-07	0.52	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39604267	chr1:39514956~39516490:+
KIRP	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-6.7	1.24e-10	1.24e-07	-0.48	-0.38	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
KIRP	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	6.7	1.25e-10	1.24e-07	0.49	0.38	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
KIRP	cis	rs1964356	0.967	rs17701675	ENSG00000253981.4	ALG1L13P	-6.7	1.25e-10	1.25e-07	-0.31	-0.38	Mean corpuscular volume;	chr8:8993123	chr8:8236003~8244667:-
KIRP	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-6.7	1.26e-10	1.26e-07	-0.46	-0.38	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
KIRP	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-6.7	1.26e-10	1.26e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-6.7	1.26e-10	1.26e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-6.7	1.26e-10	1.26e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-6.7	1.26e-10	1.26e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
KIRP	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.7	1.27e-10	1.26e-07	-0.48	-0.38	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
KIRP	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-6.7	1.27e-10	1.26e-07	-0.62	-0.38	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
KIRP	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.7	1.27e-10	1.27e-07	0.39	0.38	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
KIRP	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-6.7	1.27e-10	1.27e-07	-0.44	-0.38	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	6.7	1.28e-10	1.27e-07	0.51	0.38	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
KIRP	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	6.7	1.28e-10	1.27e-07	0.41	0.38	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
KIRP	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	6.7	1.28e-10	1.27e-07	0.28	0.38	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
KIRP	cis	rs755249	0.565	rs3768320	ENSG00000237624.1	OXCT2P1	-6.7	1.28e-10	1.28e-07	-0.48	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	6.7	1.29e-10	1.28e-07	0.47	0.38	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
KIRP	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-6.7	1.29e-10	1.28e-07	-0.59	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
KIRP	cis	rs2625529	0.586	rs59975112	ENSG00000260037.4	CTD-2524L6.3	6.7	1.29e-10	1.28e-07	0.29	0.38	Red blood cell count;	chr15:72131369	chr15:71818396~71823384:+
KIRP	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-6.7	1.29e-10	1.28e-07	-0.41	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
KIRP	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-6.7	1.29e-10	1.28e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
KIRP	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	6.7	1.29e-10	1.28e-07	0.47	0.38	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
KIRP	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	6.7	1.29e-10	1.28e-07	0.5	0.38	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-6.7	1.3e-10	1.29e-07	-0.35	-0.38	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-6.7	1.3e-10	1.29e-07	-0.35	-0.38	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	6.7	1.3e-10	1.29e-07	0.51	0.38	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	6.7	1.3e-10	1.29e-07	0.45	0.38	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	6.7	1.3e-10	1.29e-07	0.45	0.38	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	6.7	1.3e-10	1.29e-07	0.45	0.38	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
KIRP	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-6.7	1.3e-10	1.29e-07	-0.55	-0.38	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
KIRP	cis	rs4638749	0.677	rs7581595	ENSG00000225328.1	AC019100.3	-6.69	1.31e-10	1.3e-07	-0.45	-0.38	Blood pressure;	chr2:108231429	chr2:108167748~108217841:-
KIRP	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-6.69	1.31e-10	1.3e-07	-0.42	-0.38	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
KIRP	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	6.69	1.31e-10	1.3e-07	0.41	0.38	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
KIRP	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	6.69	1.32e-10	1.31e-07	0.41	0.38	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
KIRP	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.69	1.32e-10	1.31e-07	0.48	0.38	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
KIRP	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-6.69	1.32e-10	1.31e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-6.69	1.32e-10	1.31e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
KIRP	cis	rs2625529	0.556	rs55679065	ENSG00000260037.4	CTD-2524L6.3	6.69	1.32e-10	1.31e-07	0.29	0.38	Red blood cell count;	chr15:72141054	chr15:71818396~71823384:+
KIRP	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	6.69	1.32e-10	1.31e-07	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
KIRP	cis	rs4356975	0.563	rs4694171	ENSG00000250696.4	RP11-704M14.1	6.69	1.32e-10	1.31e-07	0.36	0.38	Obesity-related traits;	chr4:69088579	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600891	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69105878	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs7693957	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106078	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7698846	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106278	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12513195	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106368	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4541594	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106554	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.583	rs4351080	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106601	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4356974	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69106696	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs5013211	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107059	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4292394	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107231	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4337789	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107326	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4521414	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107807	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4314345	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107922	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4588522	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107949	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4364327	ENSG00000250696.4	RP11-704M14.1	6.69	1.33e-10	1.32e-07	0.37	0.38	Obesity-related traits;	chr4:69107974	chr4:69182100~69216766:+
KIRP	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	6.69	1.34e-10	1.32e-07	0.52	0.38	Height;	chr6:109672088	chr6:109382795~109383666:+
KIRP	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-6.69	1.35e-10	1.33e-07	-0.41	-0.38	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
KIRP	cis	rs755249	0.762	rs1775654	ENSG00000237624.1	OXCT2P1	6.69	1.35e-10	1.33e-07	0.54	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39514956~39516490:+
KIRP	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	6.69	1.35e-10	1.33e-07	0.48	0.38	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
KIRP	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	6.69	1.35e-10	1.33e-07	0.44	0.38	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
KIRP	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	6.69	1.35e-10	1.34e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	6.69	1.35e-10	1.34e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
KIRP	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	6.69	1.35e-10	1.34e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
KIRP	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	6.69	1.35e-10	1.34e-07	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
KIRP	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	6.69	1.36e-10	1.34e-07	0.44	0.38	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
KIRP	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-6.69	1.37e-10	1.35e-07	-0.41	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
KIRP	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	6.69	1.37e-10	1.36e-07	0.44	0.38	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
KIRP	cis	rs67311347	1	rs9835219	ENSG00000230274.1	PGAM1P3	6.69	1.37e-10	1.36e-07	0.37	0.38	Renal cell carcinoma;	chr3:40382602	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs7642552	ENSG00000230274.1	PGAM1P3	6.69	1.37e-10	1.36e-07	0.37	0.38	Renal cell carcinoma;	chr3:40383325	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	6.69	1.38e-10	1.36e-07	0.51	0.38	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
KIRP	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	6.69	1.38e-10	1.37e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
KIRP	cis	rs79349575	0.783	rs15563	ENSG00000248278.1	SUMO2P17	6.68	1.39e-10	1.37e-07	0.42	0.38	Type 2 diabetes;	chr17:48927831	chr17:48874860~48908983:-
KIRP	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	6.68	1.39e-10	1.37e-07	0.41	0.38	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
KIRP	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	6.68	1.39e-10	1.37e-07	0.41	0.38	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
KIRP	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-6.68	1.39e-10	1.37e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
KIRP	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	6.68	1.39e-10	1.37e-07	0.31	0.38	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
KIRP	cis	rs17082664	0.688	rs6557219	ENSG00000226193.1	RP3-398G3.5	-6.68	1.39e-10	1.38e-07	-0.5	-0.38	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152422313	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	6.68	1.4e-10	1.38e-07	0.51	0.38	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
KIRP	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	6.68	1.4e-10	1.38e-07	0.41	0.38	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
KIRP	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.68	1.4e-10	1.38e-07	0.32	0.38	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
KIRP	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	6.68	1.4e-10	1.38e-07	0.34	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
KIRP	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	6.68	1.4e-10	1.38e-07	0.44	0.38	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	6.68	1.4e-10	1.38e-07	0.44	0.38	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
KIRP	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	6.68	1.4e-10	1.38e-07	0.59	0.38	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
KIRP	cis	rs67311347	1	rs67680017	ENSG00000230274.1	PGAM1P3	6.68	1.4e-10	1.39e-07	0.37	0.38	Renal cell carcinoma;	chr3:40491673	chr3:40322715~40323279:-
KIRP	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6.68	1.41e-10	1.39e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
KIRP	cis	rs4356975	0.563	rs7698645	ENSG00000250696.4	RP11-704M14.1	6.68	1.41e-10	1.39e-07	0.37	0.38	Obesity-related traits;	chr4:69106192	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.932	rs12648830	ENSG00000196472.4	RP13-644M16.4	-6.68	1.41e-10	1.39e-07	-0.43	-0.38	Obesity-related traits;	chr4:69075436	chr4:69181660~69182372:+
KIRP	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-6.68	1.41e-10	1.39e-07	-0.35	-0.38	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
KIRP	cis	rs4128705	0.959	rs72880827	ENSG00000249049.1	RP11-763F8.1	6.68	1.41e-10	1.39e-07	0.34	0.38	Amyotrophic lateral sclerosis (sporadic);	chr4:91358919	chr4:91319034~91325306:-
KIRP	cis	rs4356975	0.563	rs4538548	ENSG00000250696.4	RP11-704M14.1	6.68	1.41e-10	1.39e-07	0.36	0.38	Obesity-related traits;	chr4:69094951	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600883	ENSG00000250696.4	RP11-704M14.1	6.68	1.41e-10	1.39e-07	0.36	0.38	Obesity-related traits;	chr4:69094953	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.798	rs4694588	ENSG00000250696.4	RP11-704M14.1	-6.68	1.42e-10	1.4e-07	-0.37	-0.38	Obesity-related traits;	chr4:69044664	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs6422321	ENSG00000250696.4	RP11-704M14.1	-6.68	1.42e-10	1.4e-07	-0.37	-0.38	Obesity-related traits;	chr4:69044911	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.768	rs4518318	ENSG00000250696.4	RP11-704M14.1	-6.68	1.42e-10	1.4e-07	-0.37	-0.38	Obesity-related traits;	chr4:69045479	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs4351079	ENSG00000250696.4	RP11-704M14.1	-6.68	1.42e-10	1.4e-07	-0.37	-0.38	Obesity-related traits;	chr4:69045631	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.798	rs4607293	ENSG00000250696.4	RP11-704M14.1	-6.68	1.42e-10	1.4e-07	-0.37	-0.38	Obesity-related traits;	chr4:69045714	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7676472	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69090226	chr4:69182100~69216766:+
KIRP	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Migraine;	chr4:56852087	chr4:56960927~56961373:-
KIRP	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-6.68	1.42e-10	1.4e-07	-0.42	-0.38	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
KIRP	cis	rs4356975	0.563	rs11249527	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69089267	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6846298	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69089278	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs11249528	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69089337	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs55757747	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69089919	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs56217918	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69089925	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7663584	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69090392	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600876	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69091212	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.583	rs6600877	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69091505	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600878	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69092618	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.583	rs6819757	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69092946	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs57216626	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69093105	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs59415892	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69093191	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs62296942	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69093401	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7437039	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69093758	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7439792	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69093881	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs62296944	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69094492	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600879	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69094669	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600880	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69094762	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4455491	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69095215	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs11940220	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69095222	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs11940316	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69095409	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7662029	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69096194	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7668258	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69096360	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs12647681	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69097442	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12647682	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69097450	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs58544196	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69097740	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7439326	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69098462	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7438244	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69098491	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7441750	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69098803	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7441774	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69098836	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs7434332	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69099141	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4293848	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69099784	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12512526	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69100700	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.522	rs34386959	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69100837	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs55834557	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69100876	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs34318523	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69101135	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.583	rs34630750	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69101208	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12508257	ENSG00000250696.4	RP11-704M14.1	6.68	1.42e-10	1.4e-07	0.36	0.38	Obesity-related traits;	chr4:69101921	chr4:69182100~69216766:+
KIRP	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.68	1.43e-10	1.41e-07	0.41	0.38	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
KIRP	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	6.68	1.43e-10	1.41e-07	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
KIRP	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	6.68	1.43e-10	1.41e-07	0.41	0.38	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
KIRP	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.68	1.44e-10	1.42e-07	-0.38	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
KIRP	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-6.68	1.45e-10	1.43e-07	-0.44	-0.38	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
KIRP	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	6.68	1.45e-10	1.43e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
KIRP	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	6.68	1.45e-10	1.43e-07	0.51	0.38	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
KIRP	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.68	1.45e-10	1.43e-07	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
KIRP	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-6.68	1.46e-10	1.43e-07	-0.32	-0.38	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
KIRP	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	6.68	1.46e-10	1.44e-07	0.35	0.38	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
KIRP	cis	rs453301	0.564	rs28649568	ENSG00000253981.4	ALG1L13P	-6.68	1.46e-10	1.44e-07	-0.29	-0.38	Joint mobility (Beighton score);	chr8:9102161	chr8:8236003~8244667:-
KIRP	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-6.68	1.47e-10	1.44e-07	-0.33	-0.38	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
KIRP	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-6.67	1.47e-10	1.44e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
KIRP	cis	rs7474896	0.583	rs4934898	ENSG00000151963.4	RP11-775A3.1	-6.67	1.47e-10	1.45e-07	-0.48	-0.38	Obesity (extreme);	chr10:37701467	chr10:37883594~37884109:+
KIRP	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	6.67	1.47e-10	1.45e-07	0.54	0.38	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
KIRP	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	6.67	1.47e-10	1.45e-07	0.46	0.38	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	6.67	1.47e-10	1.45e-07	0.45	0.38	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	6.67	1.47e-10	1.45e-07	0.45	0.38	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	6.67	1.47e-10	1.45e-07	0.45	0.38	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
KIRP	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	6.67	1.47e-10	1.45e-07	0.41	0.38	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
KIRP	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-6.67	1.48e-10	1.45e-07	-0.45	-0.38	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
KIRP	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-6.67	1.48e-10	1.45e-07	-0.29	-0.38	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
KIRP	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-6.67	1.48e-10	1.45e-07	-0.29	-0.38	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
KIRP	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	6.67	1.48e-10	1.45e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
KIRP	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-6.67	1.49e-10	1.46e-07	-0.4	-0.38	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
KIRP	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-6.67	1.49e-10	1.46e-07	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
KIRP	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.67	1.49e-10	1.46e-07	0.32	0.38	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
KIRP	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	6.67	1.49e-10	1.47e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	6.67	1.49e-10	1.47e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	6.67	1.49e-10	1.47e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
KIRP	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-6.67	1.5e-10	1.47e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
KIRP	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	6.67	1.5e-10	1.47e-07	0.43	0.38	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
KIRP	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-6.67	1.5e-10	1.48e-07	-0.46	-0.38	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
KIRP	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28147378	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28147406	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28148143	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28149979	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28152885	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28153120	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28154567	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28156691	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28158424	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28159056	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28159666	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28159843	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28159925	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28159932	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28162053	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28162598	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28163375	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28163759	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28164580	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28164825	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28164948	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28165025	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28165528	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28168434	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28169019	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28169249	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28169676	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28169755	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28169791	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28170075	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28173770	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28174809	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28175233	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-6.67	1.51e-10	1.48e-07	-0.46	-0.38	Depression;	chr6:28176973	chr6:28115628~28116551:+
KIRP	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-6.67	1.51e-10	1.48e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	6.67	1.51e-10	1.48e-07	0.49	0.38	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
KIRP	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-6.67	1.51e-10	1.48e-07	-0.32	-0.38	Height;	chr11:118809363	chr11:118791254~118793137:+
KIRP	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	6.67	1.51e-10	1.48e-07	0.28	0.38	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
KIRP	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-6.67	1.51e-10	1.48e-07	-0.5	-0.38	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-6.67	1.52e-10	1.49e-07	-0.5	-0.38	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
KIRP	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-6.67	1.53e-10	1.5e-07	-0.47	-0.38	Depression;	chr6:28145952	chr6:28115628~28116551:+
KIRP	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	6.67	1.53e-10	1.5e-07	0.33	0.38	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
KIRP	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-6.67	1.54e-10	1.51e-07	-0.48	-0.38	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
KIRP	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	6.67	1.54e-10	1.51e-07	0.5	0.38	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
KIRP	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-6.67	1.54e-10	1.51e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
KIRP	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	6.67	1.55e-10	1.51e-07	0.39	0.38	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
KIRP	cis	rs4356975	0.83	rs7693166	ENSG00000250696.4	RP11-704M14.1	-6.67	1.55e-10	1.52e-07	-0.36	-0.38	Obesity-related traits;	chr4:69044866	chr4:69182100~69216766:+
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	6.67	1.55e-10	1.52e-07	0.5	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	6.67	1.55e-10	1.52e-07	0.5	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	6.67	1.55e-10	1.52e-07	0.5	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
KIRP	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	6.66	1.56e-10	1.53e-07	0.48	0.38	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-6.66	1.57e-10	1.53e-07	-0.32	-0.38	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-6.66	1.57e-10	1.53e-07	-0.32	-0.38	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-6.66	1.57e-10	1.53e-07	-0.32	-0.38	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-6.66	1.57e-10	1.53e-07	-0.32	-0.38	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
KIRP	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-6.66	1.57e-10	1.54e-07	-0.5	-0.38	Height;	chr6:109360458	chr6:109382795~109383666:+
KIRP	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	6.66	1.58e-10	1.55e-07	0.42	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
KIRP	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-6.66	1.58e-10	1.55e-07	-0.45	-0.38	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
KIRP	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-6.66	1.58e-10	1.55e-07	-0.45	-0.38	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
KIRP	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-6.66	1.58e-10	1.55e-07	-0.45	-0.38	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
KIRP	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	6.66	1.58e-10	1.55e-07	0.39	0.38	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
KIRP	cis	rs4356975	0.503	rs11938761	ENSG00000250696.4	RP11-704M14.1	6.66	1.58e-10	1.55e-07	0.36	0.38	Obesity-related traits;	chr4:69083992	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.545	rs11935886	ENSG00000250696.4	RP11-704M14.1	6.66	1.58e-10	1.55e-07	0.36	0.38	Obesity-related traits;	chr4:69083994	chr4:69182100~69216766:+
KIRP	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-6.66	1.59e-10	1.55e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
KIRP	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-6.66	1.6e-10	1.56e-07	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
KIRP	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-6.66	1.6e-10	1.56e-07	-0.48	-0.38	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
KIRP	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-6.66	1.6e-10	1.57e-07	-0.28	-0.38	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
KIRP	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	6.66	1.61e-10	1.57e-07	0.54	0.38	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	6.66	1.61e-10	1.58e-07	0.47	0.38	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
KIRP	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-6.66	1.62e-10	1.58e-07	-0.33	-0.38	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
KIRP	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	6.66	1.62e-10	1.58e-07	0.48	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
KIRP	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	6.66	1.62e-10	1.58e-07	0.5	0.38	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
KIRP	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	6.66	1.62e-10	1.58e-07	0.5	0.38	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
KIRP	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-6.66	1.63e-10	1.59e-07	-0.41	-0.38	Migraine;	chr4:56940917	chr4:56960927~56961373:-
KIRP	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	6.66	1.63e-10	1.59e-07	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
KIRP	cis	rs755249	0.532	rs2296173	ENSG00000237624.1	OXCT2P1	6.66	1.63e-10	1.6e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39514956~39516490:+
KIRP	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	6.66	1.64e-10	1.6e-07	0.28	0.38	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
KIRP	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	6.66	1.64e-10	1.6e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
KIRP	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-6.66	1.64e-10	1.6e-07	-0.47	-0.38	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
KIRP	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-6.66	1.65e-10	1.6e-07	-0.31	-0.38	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
KIRP	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-6.66	1.65e-10	1.61e-07	-0.44	-0.38	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
KIRP	cis	rs4638749	0.677	rs17035849	ENSG00000225328.1	AC019100.3	-6.65	1.65e-10	1.61e-07	-0.45	-0.38	Blood pressure;	chr2:108226137	chr2:108167748~108217841:-
KIRP	cis	rs67311347	0.824	rs59922539	ENSG00000230274.1	PGAM1P3	6.65	1.65e-10	1.61e-07	0.38	0.38	Renal cell carcinoma;	chr3:40295619	chr3:40322715~40323279:-
KIRP	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	6.65	1.65e-10	1.61e-07	0.49	0.38	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	6.65	1.66e-10	1.62e-07	0.46	0.38	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	6.65	1.66e-10	1.62e-07	0.46	0.38	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
KIRP	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	6.65	1.66e-10	1.62e-07	0.3	0.38	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
KIRP	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	6.65	1.66e-10	1.62e-07	0.3	0.38	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.65	1.67e-10	1.62e-07	-0.5	-0.38	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
KIRP	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-6.65	1.67e-10	1.62e-07	-0.43	-0.38	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
KIRP	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-6.65	1.68e-10	1.63e-07	-0.46	-0.38	Depression;	chr6:28151096	chr6:28115628~28116551:+
KIRP	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-6.65	1.68e-10	1.64e-07	-0.39	-0.38	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
KIRP	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-6.65	1.69e-10	1.64e-07	-0.32	-0.38	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
KIRP	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-6.65	1.69e-10	1.64e-07	-0.46	-0.38	Depression;	chr6:28180209	chr6:28115628~28116551:+
KIRP	cis	rs755249	0.567	rs112672438	ENSG00000237624.1	OXCT2P1	6.65	1.69e-10	1.64e-07	0.61	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs16825921	ENSG00000237624.1	OXCT2P1	6.65	1.69e-10	1.64e-07	0.61	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39514956~39516490:+
KIRP	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-6.65	1.69e-10	1.64e-07	-0.34	-0.38	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
KIRP	cis	rs7267979	0.868	rs6138550	ENSG00000274414.1	RP5-965G21.4	-6.65	1.69e-10	1.65e-07	-0.36	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	6.65	1.69e-10	1.65e-07	0.46	0.38	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
KIRP	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-6.65	1.7e-10	1.65e-07	-0.34	-0.38	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
KIRP	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	6.65	1.72e-10	1.67e-07	0.32	0.38	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
KIRP	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	1.68e-07	0.51	0.38	Height;	chr6:109494148	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	1.68e-07	0.51	0.38	Height;	chr6:109494760	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	1.68e-07	0.51	0.38	Height;	chr6:109495102	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	1.68e-07	0.51	0.38	Height;	chr6:109496680	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	1.68e-07	0.51	0.38	Height;	chr6:109497088	chr6:109382795~109383666:+
KIRP	cis	rs2698530	0.655	rs2698528	ENSG00000225889.6	AC074289.1	-6.65	1.73e-10	1.68e-07	-0.37	-0.38	Iron status biomarkers;	chr2:64274630	chr2:64143239~64252859:+
KIRP	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-6.65	1.73e-10	1.68e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-6.65	1.73e-10	1.68e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-6.65	1.73e-10	1.68e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-6.65	1.73e-10	1.68e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
KIRP	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	6.65	1.73e-10	1.68e-07	0.61	0.38	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
KIRP	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	6.65	1.74e-10	1.69e-07	0.46	0.38	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
KIRP	cis	rs950027	0.549	rs9920634	ENSG00000259433.2	CTD-2651B20.4	6.65	1.74e-10	1.69e-07	0.33	0.38	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45330209~45332634:-
KIRP	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-6.65	1.74e-10	1.69e-07	-0.35	-0.38	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
KIRP	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-6.65	1.74e-10	1.69e-07	-0.3	-0.38	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
KIRP	cis	rs755249	0.567	rs41270803	ENSG00000237624.1	OXCT2P1	6.65	1.74e-10	1.7e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs61783376	ENSG00000237624.1	OXCT2P1	6.65	1.74e-10	1.7e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39514956~39516490:+
KIRP	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-6.64	1.75e-10	1.7e-07	-0.5	-0.38	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
KIRP	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-6.64	1.75e-10	1.7e-07	-0.4	-0.38	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
KIRP	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-6.64	1.76e-10	1.71e-07	-0.28	-0.38	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
KIRP	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	6.64	1.76e-10	1.71e-07	0.45	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
KIRP	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-6.64	1.77e-10	1.71e-07	-0.3	-0.38	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-6.64	1.77e-10	1.71e-07	-0.3	-0.38	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
KIRP	cis	rs67311347	0.577	rs2371129	ENSG00000230274.1	PGAM1P3	-6.64	1.77e-10	1.72e-07	-0.36	-0.38	Renal cell carcinoma;	chr3:40206902	chr3:40322715~40323279:-
KIRP	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	6.64	1.77e-10	1.72e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
KIRP	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-6.64	1.77e-10	1.72e-07	-0.34	-0.38	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
KIRP	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-6.64	1.78e-10	1.72e-07	-0.29	-0.38	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
KIRP	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-6.64	1.78e-10	1.73e-07	-0.5	-0.38	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
KIRP	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	6.64	1.78e-10	1.73e-07	0.3	0.38	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
KIRP	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	6.64	1.79e-10	1.73e-07	0.41	0.38	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
KIRP	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	6.64	1.79e-10	1.74e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
KIRP	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-6.64	1.8e-10	1.75e-07	-0.33	-0.38	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
KIRP	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-6.64	1.8e-10	1.75e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
KIRP	cis	rs950027	0.62	rs872192	ENSG00000259433.2	CTD-2651B20.4	-6.64	1.8e-10	1.75e-07	-0.32	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45330209~45332634:-
KIRP	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	6.64	1.8e-10	1.75e-07	0.51	0.38	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
KIRP	cis	rs4578769	0.788	rs12962334	ENSG00000266850.1	RP11-370A5.1	6.64	1.8e-10	1.75e-07	0.46	0.38	Eosinophil percentage of white cells;	chr18:22897971	chr18:22723491~22907721:-
KIRP	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-6.64	1.82e-10	1.76e-07	-0.47	-0.38	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
KIRP	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-6.64	1.82e-10	1.76e-07	-0.29	-0.38	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
KIRP	cis	rs4128705	0.916	rs111784092	ENSG00000249049.1	RP11-763F8.1	6.64	1.82e-10	1.76e-07	0.34	0.38	Amyotrophic lateral sclerosis (sporadic);	chr4:91358847	chr4:91319034~91325306:-
KIRP	cis	rs4128705	0.959	rs75296179	ENSG00000249049.1	RP11-763F8.1	6.64	1.82e-10	1.76e-07	0.34	0.38	Amyotrophic lateral sclerosis (sporadic);	chr4:91358931	chr4:91319034~91325306:-
KIRP	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	6.64	1.82e-10	1.76e-07	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
KIRP	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	6.64	1.82e-10	1.77e-07	0.33	0.38	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
KIRP	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-6.64	1.83e-10	1.77e-07	-0.46	-0.38	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-6.64	1.83e-10	1.77e-07	-0.46	-0.38	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
KIRP	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-6.64	1.83e-10	1.77e-07	-0.79	-0.38	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
KIRP	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	6.64	1.83e-10	1.77e-07	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
KIRP	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	6.64	1.83e-10	1.78e-07	0.6	0.38	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	6.64	1.83e-10	1.78e-07	0.6	0.38	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	6.64	1.83e-10	1.78e-07	0.6	0.38	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
KIRP	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	6.64	1.84e-10	1.78e-07	0.44	0.38	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
KIRP	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.64	1.84e-10	1.78e-07	0.36	0.38	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
KIRP	cis	rs950027	0.549	rs2899375	ENSG00000259433.2	CTD-2651B20.4	6.64	1.84e-10	1.78e-07	0.33	0.38	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45330209~45332634:-
KIRP	cis	rs7474896	0.583	rs10764144	ENSG00000151963.4	RP11-775A3.1	-6.64	1.85e-10	1.79e-07	-0.47	-0.38	Obesity (extreme);	chr10:37686804	chr10:37883594~37884109:+
KIRP	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	6.63	1.85e-10	1.79e-07	0.3	0.38	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
KIRP	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.63	1.85e-10	1.79e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.63	1.85e-10	1.79e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
KIRP	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	6.63	1.85e-10	1.79e-07	0.53	0.38	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	6.63	1.86e-10	1.8e-07	0.49	0.38	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
KIRP	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-6.63	1.87e-10	1.8e-07	-0.41	-0.38	Migraine;	chr4:56937339	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-6.63	1.87e-10	1.8e-07	-0.41	-0.38	Migraine;	chr4:56943905	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-6.63	1.87e-10	1.8e-07	-0.41	-0.38	Migraine;	chr4:56950140	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-6.63	1.87e-10	1.8e-07	-0.41	-0.38	Migraine;	chr4:56956882	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-6.63	1.87e-10	1.8e-07	-0.41	-0.38	Migraine;	chr4:56957291	chr4:56960927~56961373:-
KIRP	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-6.63	1.87e-10	1.81e-07	-0.48	-0.38	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
KIRP	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.63	1.87e-10	1.81e-07	0.46	0.38	Height;	chr11:118854014	chr11:118688039~118690600:-
KIRP	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-6.63	1.88e-10	1.82e-07	-0.32	-0.38	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
KIRP	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	6.63	1.89e-10	1.83e-07	0.52	0.38	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
KIRP	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-6.63	1.89e-10	1.83e-07	-0.39	-0.38	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
KIRP	cis	rs2303759	0.958	rs1465697	ENSG00000268686.1	AC010524.2	-6.63	1.9e-10	1.84e-07	-0.51	-0.38	Multiple sclerosis;	chr19:49333989	chr19:49368705~49388081:-
KIRP	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-6.63	1.9e-10	1.84e-07	-0.33	-0.38	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
KIRP	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.63	1.91e-10	1.84e-07	-0.48	-0.38	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
KIRP	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	6.63	1.91e-10	1.85e-07	0.52	0.38	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
KIRP	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	6.63	1.91e-10	1.85e-07	0.36	0.38	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	6.63	1.91e-10	1.85e-07	0.36	0.38	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
KIRP	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	6.63	1.91e-10	1.85e-07	0.45	0.38	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
KIRP	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	6.63	1.91e-10	1.85e-07	0.51	0.38	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
KIRP	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	6.63	1.92e-10	1.85e-07	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
KIRP	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6.63	1.92e-10	1.86e-07	0.41	0.38	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
KIRP	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-6.63	1.94e-10	1.87e-07	-0.47	-0.38	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
KIRP	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-6.63	1.94e-10	1.87e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-6.63	1.94e-10	1.87e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
KIRP	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-6.63	1.94e-10	1.87e-07	-0.41	-0.38	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
KIRP	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	6.63	1.95e-10	1.88e-07	0.46	0.38	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
KIRP	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.63	1.95e-10	1.88e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.63	1.95e-10	1.88e-07	-0.44	-0.38	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
KIRP	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	6.63	1.96e-10	1.88e-07	0.33	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
KIRP	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	6.63	1.96e-10	1.88e-07	0.36	0.38	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
KIRP	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-6.63	1.96e-10	1.88e-07	-0.49	-0.38	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
KIRP	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	6.63	1.96e-10	1.88e-07	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
KIRP	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-6.63	1.96e-10	1.89e-07	-0.48	-0.38	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
KIRP	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-6.62	1.97e-10	1.89e-07	-0.77	-0.38	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
KIRP	cis	rs755249	0.567	rs61783378	ENSG00000237624.1	OXCT2P1	6.62	1.97e-10	1.9e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39514956~39516490:+
KIRP	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-6.62	1.98e-10	1.9e-07	-0.31	-0.38	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
KIRP	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	6.62	1.98e-10	1.9e-07	0.49	0.38	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
KIRP	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-6.62	1.98e-10	1.9e-07	-0.33	-0.38	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-6.62	1.98e-10	1.9e-07	-0.33	-0.38	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
KIRP	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	6.62	1.99e-10	1.91e-07	0.27	0.38	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
KIRP	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-6.62	1.99e-10	1.91e-07	-0.31	-0.38	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
KIRP	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	6.62	2e-10	1.92e-07	0.49	0.38	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
KIRP	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	6.62	2e-10	1.92e-07	0.41	0.38	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
KIRP	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	6.62	2.01e-10	1.93e-07	0.5	0.38	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	6.62	2.01e-10	1.93e-07	0.46	0.38	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
KIRP	cis	rs67311347	0.955	rs1129200	ENSG00000230274.1	PGAM1P3	6.62	2.01e-10	1.93e-07	0.37	0.38	Renal cell carcinoma;	chr3:40490766	chr3:40322715~40323279:-
KIRP	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-6.62	2.02e-10	1.94e-07	-0.48	-0.38	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
KIRP	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-6.62	2.03e-10	1.94e-07	-0.38	-0.38	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
KIRP	cis	rs4356975	0.563	rs4554144	ENSG00000250696.4	RP11-704M14.1	6.62	2.03e-10	1.94e-07	0.35	0.38	Obesity-related traits;	chr4:69094837	chr4:69182100~69216766:+
KIRP	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	6.62	2.03e-10	1.95e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
KIRP	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	6.62	2.03e-10	1.95e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
KIRP	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-6.62	2.05e-10	1.97e-07	-0.43	-0.38	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
KIRP	cis	rs67311347	0.956	rs12633446	ENSG00000230274.1	PGAM1P3	-6.62	2.05e-10	1.97e-07	-0.37	-0.38	Renal cell carcinoma;	chr3:40464170	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-6.62	2.05e-10	1.97e-07	-0.3	-0.38	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-6.62	2.06e-10	1.97e-07	-0.29	-0.38	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
KIRP	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-6.62	2.06e-10	1.98e-07	-0.59	-0.38	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.62	2.06e-10	1.98e-07	-0.59	-0.38	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
KIRP	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-6.62	2.06e-10	1.98e-07	-0.32	-0.38	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
KIRP	cis	rs7474896	0.609	rs11011336	ENSG00000151963.4	RP11-775A3.1	-6.62	2.06e-10	1.98e-07	-0.47	-0.38	Obesity (extreme);	chr10:37696388	chr10:37883594~37884109:+
KIRP	cis	rs67311347	0.713	rs9861194	ENSG00000230274.1	PGAM1P3	6.62	2.07e-10	1.98e-07	0.37	0.38	Renal cell carcinoma;	chr3:40267734	chr3:40322715~40323279:-
KIRP	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	6.62	2.07e-10	1.98e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	6.62	2.07e-10	1.98e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
KIRP	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	6.62	2.08e-10	1.99e-07	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
KIRP	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	6.61	2.08e-10	1.99e-07	0.51	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	6.61	2.08e-10	1.99e-07	0.51	0.38	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
KIRP	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	6.61	2.08e-10	1.99e-07	0.41	0.38	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
KIRP	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	6.61	2.08e-10	2e-07	0.3	0.38	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
KIRP	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-6.61	2.09e-10	2e-07	-0.43	-0.38	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
KIRP	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-6.61	2.09e-10	2e-07	-0.42	-0.38	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
KIRP	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-6.61	2.09e-10	2e-07	-0.45	-0.38	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
KIRP	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-6.61	2.09e-10	2e-07	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
KIRP	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	6.61	2.1e-10	2.01e-07	0.37	0.38	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
KIRP	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-6.61	2.11e-10	2.02e-07	-0.39	-0.38	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
KIRP	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.61	2.11e-10	2.02e-07	-0.5	-0.38	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
KIRP	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-6.61	2.11e-10	2.02e-07	-0.48	-0.38	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
KIRP	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.61	2.11e-10	2.02e-07	-0.48	-0.38	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
KIRP	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-6.61	2.12e-10	2.02e-07	-0.33	-0.38	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
KIRP	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	6.61	2.12e-10	2.02e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	6.61	2.12e-10	2.03e-07	0.51	0.38	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	6.61	2.12e-10	2.03e-07	0.51	0.38	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
KIRP	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	6.61	2.13e-10	2.03e-07	0.42	0.38	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
KIRP	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
KIRP	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
KIRP	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
KIRP	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	6.61	2.13e-10	2.04e-07	0.36	0.38	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
KIRP	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	6.61	2.13e-10	2.04e-07	0.4	0.38	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	6.61	2.13e-10	2.04e-07	0.4	0.38	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	6.61	2.13e-10	2.04e-07	0.4	0.38	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-6.61	2.13e-10	2.04e-07	-0.4	-0.38	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-6.61	2.13e-10	2.04e-07	-0.4	-0.38	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-6.61	2.13e-10	2.04e-07	-0.4	-0.38	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	6.61	2.14e-10	2.05e-07	0.4	0.38	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
KIRP	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-6.61	2.15e-10	2.05e-07	-0.44	-0.38	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
KIRP	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	6.61	2.15e-10	2.05e-07	0.39	0.38	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
KIRP	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-6.61	2.16e-10	2.06e-07	-0.46	-0.38	Depression;	chr6:28161802	chr6:28115628~28116551:+
KIRP	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-6.61	2.16e-10	2.07e-07	-0.43	-0.38	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
KIRP	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	6.61	2.17e-10	2.07e-07	0.37	0.38	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
KIRP	cis	rs7829975	0.681	rs2271342	ENSG00000253981.4	ALG1L13P	6.61	2.17e-10	2.07e-07	0.3	0.38	Mood instability;	chr8:8786428	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	6.61	2.17e-10	2.07e-07	0.47	0.38	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
KIRP	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	6.61	2.18e-10	2.08e-07	0.48	0.38	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
KIRP	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	6.61	2.18e-10	2.08e-07	0.48	0.38	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
KIRP	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-6.61	2.18e-10	2.08e-07	-0.46	-0.38	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-6.61	2.18e-10	2.08e-07	-0.46	-0.38	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-6.61	2.18e-10	2.08e-07	-0.46	-0.38	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-6.61	2.18e-10	2.08e-07	-0.46	-0.38	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
KIRP	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-6.61	2.19e-10	2.09e-07	-0.33	-0.38	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
KIRP	cis	rs2625529	0.652	rs2034879	ENSG00000260037.4	CTD-2524L6.3	-6.61	2.2e-10	2.09e-07	-0.29	-0.38	Red blood cell count;	chr15:72137648	chr15:71818396~71823384:+
KIRP	cis	rs7829975	0.542	rs7844374	ENSG00000253981.4	ALG1L13P	-6.61	2.2e-10	2.09e-07	-0.3	-0.38	Mood instability;	chr8:8941174	chr8:8236003~8244667:-
KIRP	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-6.6	2.21e-10	2.1e-07	-0.64	-0.38	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
KIRP	cis	rs7829975	0.606	rs6601274	ENSG00000253981.4	ALG1L13P	-6.6	2.21e-10	2.1e-07	-0.3	-0.38	Mood instability;	chr8:8941549	chr8:8236003~8244667:-
KIRP	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-6.6	2.21e-10	2.1e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
KIRP	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	6.6	2.21e-10	2.11e-07	0.45	0.38	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
KIRP	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	6.6	2.21e-10	2.11e-07	0.45	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
KIRP	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	6.6	2.21e-10	2.11e-07	0.36	0.38	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
KIRP	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	6.6	2.22e-10	2.11e-07	0.46	0.38	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
KIRP	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-6.6	2.22e-10	2.12e-07	-0.35	-0.38	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
KIRP	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-6.6	2.22e-10	2.12e-07	-0.47	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
KIRP	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-6.6	2.23e-10	2.12e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-6.6	2.23e-10	2.12e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-6.6	2.23e-10	2.12e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-6.6	2.23e-10	2.12e-07	-0.43	-0.38	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
KIRP	cis	rs4356975	0.527	rs62296943	ENSG00000250696.4	RP11-704M14.1	6.6	2.23e-10	2.12e-07	0.36	0.38	Obesity-related traits;	chr4:69093465	chr4:69182100~69216766:+
KIRP	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-6.6	2.24e-10	2.13e-07	-0.29	-0.38	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
KIRP	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	6.6	2.24e-10	2.13e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	6.6	2.24e-10	2.13e-07	0.45	0.38	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	6.6	2.24e-10	2.13e-07	0.45	0.38	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
KIRP	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-6.6	2.25e-10	2.14e-07	-0.45	-0.38	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
KIRP	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	6.6	2.25e-10	2.14e-07	0.28	0.38	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
KIRP	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	6.6	2.26e-10	2.15e-07	0.38	0.38	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
KIRP	cis	rs8062405	0.964	rs12448902	ENSG00000259982.1	CDC37P1	6.6	2.26e-10	2.15e-07	0.5	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859870	chr16:28700294~28701540:-
KIRP	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	6.6	2.26e-10	2.15e-07	0.37	0.38	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
KIRP	cis	rs755249	0.567	rs4660543	ENSG00000237624.1	OXCT2P1	6.6	2.26e-10	2.15e-07	0.62	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39514956~39516490:+
KIRP	cis	rs7672749	0.642	rs66814999	ENSG00000249973.2	CHCHD2P7	6.6	2.26e-10	2.15e-07	0.71	0.38	TB-LM or TBLH-BMD (pleiotropy);	chr4:87849949	chr4:87785920~87786371:-
KIRP	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	6.6	2.27e-10	2.16e-07	0.44	0.38	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
KIRP	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-6.6	2.27e-10	2.16e-07	-0.34	-0.38	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
KIRP	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	6.6	2.28e-10	2.16e-07	0.84	0.38	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
KIRP	cis	rs1529102	1	rs2433388	ENSG00000225889.6	AC074289.1	-6.6	2.29e-10	2.18e-07	-0.33	-0.38	Breast size;	chr2:64266485	chr2:64143239~64252859:+
KIRP	cis	rs755249	0.567	rs4660208	ENSG00000237624.1	OXCT2P1	6.6	2.3e-10	2.19e-07	0.59	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.565	rs9729677	ENSG00000237624.1	OXCT2P1	-6.6	2.31e-10	2.19e-07	-0.49	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	6.6	2.31e-10	2.19e-07	0.46	0.38	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
KIRP	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-6.6	2.31e-10	2.2e-07	-0.45	-0.38	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
KIRP	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	6.59	2.34e-10	2.22e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
KIRP	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-6.59	2.34e-10	2.22e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	6.59	2.34e-10	2.22e-07	0.45	0.38	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
KIRP	cis	rs17082664	0.688	rs6913500	ENSG00000226193.1	RP3-398G3.5	-6.59	2.35e-10	2.23e-07	-0.49	-0.38	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152422872	chr6:152402398~152404966:+
KIRP	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	6.59	2.35e-10	2.23e-07	0.37	0.38	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
KIRP	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-6.59	2.36e-10	2.23e-07	-0.46	-0.38	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
KIRP	cis	rs1476679	0.962	rs34995835	ENSG00000078319.8	PMS2P1	6.59	2.37e-10	2.25e-07	0.52	0.38	Alzheimer's disease (late onset);	chr7:100392741	chr7:100320992~100341908:-
KIRP	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-6.59	2.37e-10	2.25e-07	-0.32	-0.38	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
KIRP	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-6.59	2.37e-10	2.25e-07	-0.32	-0.38	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
KIRP	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-6.59	2.37e-10	2.25e-07	-0.51	-0.38	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	6.59	2.39e-10	2.26e-07	0.46	0.38	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
KIRP	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	6.59	2.39e-10	2.26e-07	0.44	0.38	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
KIRP	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	6.59	2.39e-10	2.26e-07	0.38	0.38	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
KIRP	cis	rs755249	0.567	rs4660214	ENSG00000237624.1	OXCT2P1	6.59	2.39e-10	2.26e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39514956~39516490:+
KIRP	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	6.59	2.39e-10	2.26e-07	0.53	0.38	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
KIRP	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	6.59	2.39e-10	2.27e-07	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	6.59	2.39e-10	2.27e-07	0.39	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
KIRP	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-6.59	2.4e-10	2.27e-07	-0.37	-0.38	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
KIRP	cis	rs35538253	0.522	rs12934297	ENSG00000260886.1	TAT-AS1	6.59	2.41e-10	2.28e-07	0.72	0.38	Post bronchodilator FEV1;	chr16:71988922	chr16:71565789~71578187:+
KIRP	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	6.59	2.41e-10	2.28e-07	0.35	0.38	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	6.59	2.41e-10	2.28e-07	0.35	0.38	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
KIRP	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-6.59	2.42e-10	2.29e-07	-0.33	-0.38	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
KIRP	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	6.59	2.42e-10	2.29e-07	0.54	0.38	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	6.59	2.42e-10	2.29e-07	0.54	0.38	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	6.59	2.42e-10	2.29e-07	0.46	0.38	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
KIRP	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-6.59	2.42e-10	2.29e-07	-0.32	-0.38	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
KIRP	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-6.59	2.42e-10	2.29e-07	-0.58	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
KIRP	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	6.59	2.42e-10	2.29e-07	0.41	0.38	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
KIRP	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-6.59	2.43e-10	2.3e-07	-0.37	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
KIRP	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-6.59	2.43e-10	2.3e-07	-0.28	-0.38	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
KIRP	cis	rs453301	0.631	rs7843369	ENSG00000253893.2	FAM85B	6.59	2.44e-10	2.31e-07	0.48	0.38	Joint mobility (Beighton score);	chr8:8940276	chr8:8167819~8226614:-
KIRP	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-6.59	2.45e-10	2.32e-07	-0.49	-0.38	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-6.59	2.45e-10	2.32e-07	-0.49	-0.38	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-6.59	2.45e-10	2.32e-07	-0.49	-0.38	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
KIRP	cis	rs7829975	0.514	rs2979139	ENSG00000253981.4	ALG1L13P	6.59	2.45e-10	2.32e-07	0.31	0.38	Mood instability;	chr8:8410803	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	6.59	2.46e-10	2.33e-07	0.46	0.38	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
KIRP	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.59	2.46e-10	2.33e-07	-0.31	-0.38	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	6.59	2.47e-10	2.34e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	6.59	2.47e-10	2.34e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	6.59	2.47e-10	2.34e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
KIRP	cis	rs8062405	0.508	rs9929088	ENSG00000259982.1	CDC37P1	-6.59	2.47e-10	2.34e-07	-0.47	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28700294~28701540:-
KIRP	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	6.59	2.47e-10	2.34e-07	0.5	0.38	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
KIRP	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-6.58	2.48e-10	2.34e-07	-0.28	-0.38	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
KIRP	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	6.58	2.49e-10	2.35e-07	0.51	0.38	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-6.58	2.49e-10	2.35e-07	-0.5	-0.38	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
KIRP	cis	rs9532669	0.926	rs4270044	ENSG00000239827.7	SUGT1P3	-6.58	2.49e-10	2.35e-07	-0.42	-0.38	Cervical cancer;	chr13:40877923	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs11147824	ENSG00000239827.7	SUGT1P3	-6.58	2.49e-10	2.35e-07	-0.42	-0.38	Cervical cancer;	chr13:40878183	chr13:40908159~40921774:-
KIRP	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	6.58	2.49e-10	2.35e-07	0.39	0.38	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
KIRP	cis	rs755249	0.567	rs61779309	ENSG00000237624.1	OXCT2P1	6.58	2.49e-10	2.36e-07	0.59	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39514956~39516490:+
KIRP	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	6.58	2.5e-10	2.36e-07	0.53	0.38	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	6.58	2.5e-10	2.36e-07	0.53	0.38	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	6.58	2.5e-10	2.36e-07	0.53	0.38	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
KIRP	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-6.58	2.51e-10	2.37e-07	-0.32	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
KIRP	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-6.58	2.51e-10	2.37e-07	-0.47	-0.38	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
KIRP	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	6.58	2.51e-10	2.37e-07	0.43	0.38	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
KIRP	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	6.58	2.52e-10	2.37e-07	0.28	0.38	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
KIRP	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	6.58	2.52e-10	2.38e-07	0.29	0.38	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
KIRP	cis	rs755249	0.567	rs16825939	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs16825942	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs67020650	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs72661925	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs72661927	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs4660546	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs2036463	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs2036464	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs905381	ENSG00000237624.1	OXCT2P1	6.58	2.53e-10	2.38e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39514956~39516490:+
KIRP	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	6.58	2.55e-10	2.41e-07	0.47	0.38	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
KIRP	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-6.58	2.56e-10	2.41e-07	-0.57	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
KIRP	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-6.58	2.56e-10	2.41e-07	-0.84	-0.38	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
KIRP	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-6.58	2.56e-10	2.41e-07	-0.49	-0.38	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-6.58	2.56e-10	2.41e-07	-0.49	-0.38	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
KIRP	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	6.58	2.56e-10	2.41e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
KIRP	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	6.58	2.57e-10	2.42e-07	0.28	0.38	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
KIRP	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	6.58	2.57e-10	2.42e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	6.58	2.57e-10	2.42e-07	0.44	0.38	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	6.58	2.57e-10	2.42e-07	0.44	0.38	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
KIRP	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	6.58	2.58e-10	2.43e-07	0.42	0.38	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
KIRP	cis	rs7474896	0.583	rs10827818	ENSG00000151963.4	RP11-775A3.1	-6.58	2.59e-10	2.44e-07	-0.48	-0.38	Obesity (extreme);	chr10:37711928	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.583	rs7071147	ENSG00000151963.4	RP11-775A3.1	-6.58	2.59e-10	2.44e-07	-0.48	-0.38	Obesity (extreme);	chr10:37714448	chr10:37883594~37884109:+
KIRP	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-6.58	2.6e-10	2.44e-07	-0.49	-0.38	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
KIRP	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-6.58	2.6e-10	2.44e-07	-0.41	-0.38	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
KIRP	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-6.58	2.6e-10	2.45e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-6.58	2.6e-10	2.45e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-6.58	2.6e-10	2.45e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-6.58	2.6e-10	2.45e-07	-0.34	-0.38	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	6.58	2.6e-10	2.45e-07	0.44	0.38	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
KIRP	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-6.58	2.6e-10	2.45e-07	-0.41	-0.38	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
KIRP	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	6.58	2.61e-10	2.46e-07	0.52	0.38	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
KIRP	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	6.57	2.62e-10	2.47e-07	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
KIRP	cis	rs79349575	0.783	rs4793992	ENSG00000248278.1	SUMO2P17	6.57	2.63e-10	2.47e-07	0.42	0.38	Type 2 diabetes;	chr17:48930845	chr17:48874860~48908983:-
KIRP	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-6.57	2.63e-10	2.47e-07	-0.48	-0.38	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
KIRP	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	6.57	2.63e-10	2.47e-07	0.39	0.38	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
KIRP	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-6.57	2.63e-10	2.47e-07	-0.39	-0.38	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
KIRP	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	6.57	2.63e-10	2.47e-07	0.49	0.38	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
KIRP	cis	rs755249	0.567	rs72637906	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs67886352	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs60323161	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs66727439	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs16826000	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs16826009	ENSG00000237624.1	OXCT2P1	6.57	2.63e-10	2.48e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	6.57	2.64e-10	2.48e-07	0.43	0.38	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
KIRP	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	6.57	2.64e-10	2.48e-07	0.29	0.38	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
KIRP	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	6.57	2.65e-10	2.49e-07	0.63	0.38	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
KIRP	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	6.57	2.65e-10	2.49e-07	0.37	0.38	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
KIRP	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-6.57	2.65e-10	2.49e-07	-0.41	-0.38	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
KIRP	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	6.57	2.67e-10	2.51e-07	0.45	0.38	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	6.57	2.67e-10	2.51e-07	0.31	0.38	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
KIRP	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-6.57	2.67e-10	2.51e-07	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
KIRP	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-6.57	2.69e-10	2.53e-07	-0.37	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-6.57	2.69e-10	2.53e-07	-0.37	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
KIRP	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-6.57	2.7e-10	2.53e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-6.57	2.7e-10	2.53e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	6.57	2.7e-10	2.53e-07	0.51	0.38	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	6.57	2.7e-10	2.53e-07	0.51	0.38	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	6.57	2.7e-10	2.53e-07	0.51	0.38	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
KIRP	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	6.57	2.72e-10	2.55e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
KIRP	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	6.57	2.72e-10	2.55e-07	0.47	0.38	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
KIRP	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	6.57	2.72e-10	2.55e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	6.57	2.72e-10	2.55e-07	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
KIRP	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-6.57	2.72e-10	2.55e-07	-0.57	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-6.57	2.72e-10	2.55e-07	-0.57	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
KIRP	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-6.57	2.72e-10	2.55e-07	-0.33	-0.38	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
KIRP	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	6.57	2.73e-10	2.56e-07	0.53	0.38	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
KIRP	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	6.57	2.73e-10	2.56e-07	0.5	0.38	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-6.57	2.73e-10	2.56e-07	-0.46	-0.38	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
KIRP	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	6.57	2.74e-10	2.56e-07	0.51	0.38	Height;	chr6:109506513	chr6:109382795~109383666:+
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	6.57	2.74e-10	2.56e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
KIRP	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-6.57	2.74e-10	2.56e-07	-0.38	-0.38	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
KIRP	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	6.57	2.74e-10	2.56e-07	0.36	0.38	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
KIRP	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-6.57	2.75e-10	2.57e-07	-0.48	-0.38	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.932	rs4694610	ENSG00000196472.4	RP13-644M16.4	6.57	2.75e-10	2.57e-07	0.42	0.38	Obesity-related traits;	chr4:69079224	chr4:69181660~69182372:+
KIRP	cis	rs9532669	0.926	rs6560963	ENSG00000239827.7	SUGT1P3	-6.57	2.75e-10	2.58e-07	-0.42	-0.38	Cervical cancer;	chr13:40871126	chr13:40908159~40921774:-
KIRP	cis	rs4356975	0.842	rs6600899	ENSG00000250696.4	RP11-704M14.1	6.57	2.76e-10	2.58e-07	0.37	0.38	Obesity-related traits;	chr4:69132295	chr4:69182100~69216766:+
KIRP	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	6.57	2.77e-10	2.59e-07	0.46	0.38	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
KIRP	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	6.57	2.77e-10	2.59e-07	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
KIRP	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	6.57	2.77e-10	2.59e-07	0.48	0.38	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
KIRP	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	6.57	2.78e-10	2.59e-07	0.44	0.38	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
KIRP	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	6.56	2.78e-10	2.6e-07	0.48	0.38	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
KIRP	cis	rs755249	0.567	rs16826038	ENSG00000237624.1	OXCT2P1	6.56	2.78e-10	2.6e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs61782157	ENSG00000237624.1	OXCT2P1	6.56	2.78e-10	2.6e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs4660636	ENSG00000237624.1	OXCT2P1	6.56	2.78e-10	2.6e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.83	rs10012215	ENSG00000250696.4	RP11-704M14.1	6.56	2.79e-10	2.6e-07	0.36	0.38	Obesity-related traits;	chr4:69048448	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs10012240	ENSG00000250696.4	RP11-704M14.1	6.56	2.79e-10	2.6e-07	0.36	0.38	Obesity-related traits;	chr4:69048519	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs10012607	ENSG00000250696.4	RP11-704M14.1	6.56	2.79e-10	2.6e-07	0.36	0.38	Obesity-related traits;	chr4:69048866	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs7435274	ENSG00000250696.4	RP11-704M14.1	6.56	2.79e-10	2.6e-07	0.36	0.38	Obesity-related traits;	chr4:69050281	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.83	rs7438808	ENSG00000250696.4	RP11-704M14.1	6.56	2.79e-10	2.6e-07	0.36	0.38	Obesity-related traits;	chr4:69050666	chr4:69182100~69216766:+
KIRP	cis	rs7829975	0.682	rs7013471	ENSG00000253981.4	ALG1L13P	-6.56	2.79e-10	2.61e-07	-0.29	-0.38	Mood instability;	chr8:8829815	chr8:8236003~8244667:-
KIRP	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-6.56	2.8e-10	2.61e-07	-0.48	-0.38	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
KIRP	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	6.56	2.82e-10	2.63e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	6.56	2.82e-10	2.63e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	6.56	2.82e-10	2.63e-07	0.39	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
KIRP	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.56	2.82e-10	2.63e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
KIRP	cis	rs2625529	0.586	rs11639282	ENSG00000260037.4	CTD-2524L6.3	6.56	2.82e-10	2.63e-07	0.28	0.38	Red blood cell count;	chr15:72142919	chr15:71818396~71823384:+
KIRP	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	6.56	2.83e-10	2.64e-07	0.49	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
KIRP	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	6.56	2.83e-10	2.64e-07	0.47	0.38	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	6.56	2.83e-10	2.64e-07	0.47	0.38	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
KIRP	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-6.56	2.83e-10	2.64e-07	-0.44	-0.38	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
KIRP	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	6.56	2.83e-10	2.64e-07	0.39	0.38	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
KIRP	cis	rs9371601	0.892	rs214976	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152451129	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214974	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152452470	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.926	rs70015	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152452824	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs70016	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152452853	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.852	rs70017	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152452862	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs70018	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152452898	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214973	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152453782	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs169974	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152454097	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.926	rs214970	ENSG00000226193.1	RP3-398G3.5	-6.56	2.84e-10	2.65e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152455043	chr6:152402398~152404966:+
KIRP	cis	rs453301	0.631	rs11779804	ENSG00000253893.2	FAM85B	6.56	2.84e-10	2.65e-07	0.48	0.38	Joint mobility (Beighton score);	chr8:8940442	chr8:8167819~8226614:-
KIRP	cis	rs2749592	0.918	rs1208653	ENSG00000151963.4	RP11-775A3.1	6.56	2.87e-10	2.67e-07	0.47	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:37883594~37884109:+
KIRP	cis	rs9532669	0.89	rs12865032	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40873801	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs34123829	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40873808	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4488324	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40873864	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4288867	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40873880	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4415896	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874001	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs4415897	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874035	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4389021	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874209	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.824	rs4628828	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874369	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.737	rs34354179	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874424	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9594445	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874859	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9594446	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40874863	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4402423	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875010	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs9532628	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875172	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532629	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875193	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7491149	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875216	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532630	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875472	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs4306385	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40875641	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4406939	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876108	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4628824	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876217	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532632	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876309	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532633	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876332	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532634	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876369	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532635	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876397	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs12428959	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40876638	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.895	rs4942009	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40877243	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4334153	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40877737	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4309270	ENSG00000239827.7	SUGT1P3	-6.56	2.87e-10	2.67e-07	-0.42	-0.38	Cervical cancer;	chr13:40877827	chr13:40908159~40921774:-
KIRP	cis	rs1799949	1	rs2271573	ENSG00000236383.6	LINC00854	-6.56	2.88e-10	2.68e-07	-0.31	-0.38	Menopause (age at onset);	chr17:43175604	chr17:43216941~43305976:-
KIRP	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-6.56	2.89e-10	2.68e-07	-0.42	-0.38	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
KIRP	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-6.56	2.9e-10	2.69e-07	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
KIRP	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-6.56	2.9e-10	2.69e-07	-0.45	-0.38	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
KIRP	cis	rs755249	0.567	rs3818806	ENSG00000237624.1	OXCT2P1	6.56	2.9e-10	2.69e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs41270799	ENSG00000237624.1	OXCT2P1	6.56	2.9e-10	2.69e-07	0.6	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39514956~39516490:+
KIRP	cis	rs72634501	0.54	rs16826036	ENSG00000237624.1	OXCT2P1	6.56	2.9e-10	2.69e-07	0.6	0.38	HDL cholesterol;	chr1:39292127	chr1:39514956~39516490:+
KIRP	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	6.56	2.91e-10	2.7e-07	0.42	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
KIRP	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-6.56	2.92e-10	2.71e-07	-0.39	-0.38	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
KIRP	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-6.56	2.92e-10	2.71e-07	-0.45	-0.38	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
KIRP	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-6.56	2.92e-10	2.71e-07	-0.26	-0.38	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
KIRP	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	6.56	2.92e-10	2.71e-07	0.38	0.38	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-6.56	2.92e-10	2.71e-07	-0.38	-0.38	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
KIRP	cis	rs4638749	0.677	rs7599646	ENSG00000225328.1	AC019100.3	6.56	2.92e-10	2.72e-07	0.43	0.38	Blood pressure;	chr2:108235887	chr2:108167748~108217841:-
KIRP	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	6.56	2.93e-10	2.72e-07	0.3	0.38	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
KIRP	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	6.56	2.93e-10	2.72e-07	0.41	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
KIRP	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	6.55	2.95e-10	2.74e-07	0.5	0.38	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
KIRP	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-6.55	2.95e-10	2.74e-07	-0.49	-0.38	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	6.55	2.96e-10	2.74e-07	0.48	0.38	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
KIRP	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	6.55	2.96e-10	2.75e-07	0.5	0.38	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
KIRP	cis	rs9371601	0.798	rs214997	ENSG00000226193.1	RP3-398G3.5	6.55	2.96e-10	2.75e-07	0.41	0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152441454	chr6:152402398~152404966:+
KIRP	cis	rs755249	0.567	rs61779306	ENSG00000237624.1	OXCT2P1	6.55	2.97e-10	2.75e-07	0.58	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.622	rs61287898	ENSG00000248763.2	RP13-644M16.5	-6.55	2.97e-10	2.75e-07	-0.41	-0.38	Obesity-related traits;	chr4:69167116	chr4:69066395~69069888:+
KIRP	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	6.55	2.97e-10	2.75e-07	0.43	0.38	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
KIRP	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-6.55	2.98e-10	2.77e-07	-0.46	-0.38	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
KIRP	cis	rs2625529	0.73	rs2957373	ENSG00000260037.4	CTD-2524L6.3	6.55	2.99e-10	2.77e-07	0.29	0.38	Red blood cell count;	chr15:72048588	chr15:71818396~71823384:+
KIRP	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	6.55	2.99e-10	2.77e-07	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
KIRP	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	6.55	2.99e-10	2.77e-07	0.28	0.38	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
KIRP	cis	rs453301	0.631	rs11780774	ENSG00000253893.2	FAM85B	6.55	2.99e-10	2.77e-07	0.49	0.38	Joint mobility (Beighton score);	chr8:8941601	chr8:8167819~8226614:-
KIRP	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-6.55	3e-10	2.78e-07	-0.52	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
KIRP	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	6.55	3.01e-10	2.78e-07	0.3	0.38	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
KIRP	cis	rs67311347	0.822	rs9826847	ENSG00000230274.1	PGAM1P3	6.55	3.01e-10	2.78e-07	0.38	0.38	Renal cell carcinoma;	chr3:40303821	chr3:40322715~40323279:-
KIRP	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-6.55	3.01e-10	2.78e-07	-0.45	-0.38	Depression;	chr6:28099759	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-6.55	3.01e-10	2.78e-07	-0.45	-0.38	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-6.55	3.01e-10	2.78e-07	-0.45	-0.38	Depression;	chr6:28100648	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-6.55	3.01e-10	2.78e-07	-0.45	-0.38	Depression;	chr6:28107222	chr6:28115628~28116551:+
KIRP	cis	rs9371601	0.892	rs214967	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152456684	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214965	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152457740	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs492921	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152457784	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214964	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152458185	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214963	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152458378	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs214962	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152458579	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.859	rs214961	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152460604	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs182480	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152461100	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs508931	ENSG00000226193.1	RP3-398G3.5	-6.55	3.02e-10	2.79e-07	-0.41	-0.38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152461171	chr6:152402398~152404966:+
KIRP	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-6.55	3.02e-10	2.79e-07	-0.31	-0.38	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
KIRP	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	6.55	3.02e-10	2.79e-07	0.4	0.38	Myopia;	chr6:28302807	chr6:28176188~28176674:+
KIRP	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-6.55	3.02e-10	2.79e-07	-0.33	-0.38	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
KIRP	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-6.55	3.02e-10	2.8e-07	-0.43	-0.38	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6.55	3.02e-10	2.8e-07	-0.43	-0.38	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6.55	3.02e-10	2.8e-07	-0.43	-0.38	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
KIRP	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.55	3.02e-10	2.8e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
KIRP	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.55	3.03e-10	2.8e-07	-0.33	-0.38	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
KIRP	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	6.55	3.03e-10	2.8e-07	0.43	0.38	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
KIRP	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-6.55	3.03e-10	2.81e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-6.55	3.03e-10	2.81e-07	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
KIRP	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-6.55	3.04e-10	2.81e-07	-0.37	-0.38	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
KIRP	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-6.55	3.04e-10	2.81e-07	-0.45	-0.38	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
KIRP	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-6.55	3.06e-10	2.83e-07	-0.45	-0.38	Depression;	chr6:28108492	chr6:28115628~28116551:+
KIRP	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	6.55	3.06e-10	2.83e-07	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	6.55	3.06e-10	2.83e-07	0.4	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
KIRP	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	6.55	3.07e-10	2.84e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	6.55	3.07e-10	2.84e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
KIRP	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	6.55	3.07e-10	2.84e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
KIRP	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-6.55	3.07e-10	2.84e-07	-0.47	-0.37	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
KIRP	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-6.55	3.07e-10	2.84e-07	-0.31	-0.37	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
KIRP	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-6.55	3.07e-10	2.84e-07	-0.58	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
KIRP	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	6.55	3.08e-10	2.84e-07	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
KIRP	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-6.55	3.08e-10	2.84e-07	-0.37	-0.37	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
KIRP	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	6.55	3.1e-10	2.86e-07	0.42	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	6.55	3.1e-10	2.86e-07	0.42	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	6.55	3.1e-10	2.86e-07	0.42	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
KIRP	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.55	3.1e-10	2.86e-07	-0.4	-0.37	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
KIRP	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	6.55	3.1e-10	2.86e-07	0.45	0.37	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
KIRP	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.55	3.11e-10	2.87e-07	0.4	0.37	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
KIRP	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	6.54	3.12e-10	2.88e-07	0.44	0.37	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	6.54	3.12e-10	2.88e-07	0.44	0.37	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	6.54	3.12e-10	2.88e-07	0.44	0.37	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	6.54	3.12e-10	2.88e-07	0.44	0.37	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
KIRP	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-6.54	3.12e-10	2.88e-07	-0.47	-0.37	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
KIRP	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	6.54	3.12e-10	2.88e-07	0.38	0.37	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
KIRP	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-6.54	3.13e-10	2.89e-07	-0.49	-0.37	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	6.54	3.14e-10	2.9e-07	0.44	0.37	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
KIRP	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	6.54	3.15e-10	2.91e-07	0.3	0.37	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
KIRP	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	6.54	3.15e-10	2.91e-07	0.47	0.37	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
KIRP	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	6.54	3.16e-10	2.91e-07	0.28	0.37	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
KIRP	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-6.54	3.16e-10	2.92e-07	-0.35	-0.37	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
KIRP	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-6.54	3.17e-10	2.92e-07	-0.43	-0.37	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
KIRP	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-6.54	3.17e-10	2.92e-07	-0.49	-0.37	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
KIRP	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-6.54	3.18e-10	2.94e-07	-0.4	-0.37	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
KIRP	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	6.54	3.19e-10	2.94e-07	0.44	0.37	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
KIRP	cis	rs2283792	0.776	rs9610458	ENSG00000228050.1	TOP3BP1	6.54	3.19e-10	2.94e-07	0.41	0.37	Multiple sclerosis;	chr22:21851064	chr22:22223187~22224566:-
KIRP	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.54	3.19e-10	2.94e-07	0.4	0.37	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
KIRP	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-6.54	3.2e-10	2.95e-07	-0.57	-0.37	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	6.54	3.2e-10	2.95e-07	0.5	0.37	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
KIRP	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-6.54	3.2e-10	2.95e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
KIRP	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	6.54	3.21e-10	2.96e-07	0.51	0.37	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
KIRP	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	6.54	3.21e-10	2.96e-07	0.36	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
KIRP	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	6.54	3.21e-10	2.96e-07	0.36	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
KIRP	cis	rs755249	0.701	rs1180342	ENSG00000237624.1	OXCT2P1	-6.54	3.22e-10	2.96e-07	-0.46	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39514956~39516490:+
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	6.54	3.23e-10	2.97e-07	0.49	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
KIRP	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	6.54	3.23e-10	2.97e-07	0.44	0.37	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	6.54	3.23e-10	2.97e-07	0.44	0.37	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
KIRP	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.54	3.24e-10	2.98e-07	0.31	0.37	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	6.54	3.25e-10	2.99e-07	0.5	0.37	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	6.54	3.25e-10	2.99e-07	0.5	0.37	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
KIRP	cis	rs755249	0.567	rs41270821	ENSG00000237624.1	OXCT2P1	6.54	3.25e-10	2.99e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs2296175	ENSG00000237624.1	OXCT2P1	6.54	3.25e-10	2.99e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39514956~39516490:+
KIRP	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	6.54	3.25e-10	2.99e-07	0.46	0.37	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
KIRP	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	6.54	3.26e-10	2.99e-07	0.45	0.37	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
KIRP	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-6.54	3.27e-10	3e-07	-0.49	-0.37	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
KIRP	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	6.54	3.27e-10	3e-07	0.31	0.37	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	6.54	3.27e-10	3.01e-07	0.43	0.37	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	6.54	3.27e-10	3.01e-07	0.43	0.37	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	6.54	3.27e-10	3.01e-07	0.43	0.37	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	6.54	3.27e-10	3.01e-07	0.43	0.37	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
KIRP	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-6.54	3.28e-10	3.01e-07	-0.38	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
KIRP	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	6.54	3.29e-10	3.02e-07	0.43	0.37	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
KIRP	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-6.54	3.3e-10	3.03e-07	-0.45	-0.37	Depression;	chr6:28104824	chr6:28115628~28116551:+
KIRP	cis	rs9532669	0.926	rs9532647	ENSG00000239827.7	SUGT1P3	-6.54	3.3e-10	3.03e-07	-0.42	-0.37	Cervical cancer;	chr13:40881799	chr13:40908159~40921774:-
KIRP	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-6.53	3.31e-10	3.03e-07	-0.5	-0.37	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
KIRP	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-6.53	3.31e-10	3.03e-07	-0.5	-0.37	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
KIRP	cis	rs9532669	0.89	rs9525420	ENSG00000239827.7	SUGT1P3	-6.53	3.33e-10	3.05e-07	-0.42	-0.37	Cervical cancer;	chr13:40882628	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7324383	ENSG00000239827.7	SUGT1P3	-6.53	3.33e-10	3.05e-07	-0.42	-0.37	Cervical cancer;	chr13:40882754	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532648	ENSG00000239827.7	SUGT1P3	-6.53	3.33e-10	3.05e-07	-0.42	-0.37	Cervical cancer;	chr13:40882795	chr13:40908159~40921774:-
KIRP	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	6.53	3.34e-10	3.06e-07	0.45	0.37	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
KIRP	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-6.53	3.34e-10	3.06e-07	-0.46	-0.37	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
KIRP	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	6.53	3.34e-10	3.06e-07	0.72	0.37	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
KIRP	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-6.53	3.35e-10	3.07e-07	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	6.53	3.36e-10	3.08e-07	0.46	0.37	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	6.53	3.36e-10	3.08e-07	0.46	0.37	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
KIRP	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-6.53	3.36e-10	3.08e-07	-0.45	-0.37	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
KIRP	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-6.53	3.37e-10	3.08e-07	-0.43	-0.37	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
KIRP	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	6.53	3.37e-10	3.09e-07	0.31	0.37	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
KIRP	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	6.53	3.37e-10	3.09e-07	0.35	0.37	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
KIRP	cis	rs950027	0.62	rs1145077	ENSG00000259433.2	CTD-2651B20.4	6.53	3.37e-10	3.09e-07	0.32	0.37	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45330209~45332634:-
KIRP	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-6.53	3.38e-10	3.09e-07	-0.32	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-6.53	3.38e-10	3.09e-07	-0.32	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
KIRP	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	6.53	3.38e-10	3.09e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	6.53	3.38e-10	3.09e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	6.53	3.38e-10	3.09e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	6.53	3.38e-10	3.09e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	6.53	3.38e-10	3.09e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
KIRP	cis	rs755249	0.567	rs4660603	ENSG00000237624.1	OXCT2P1	-6.53	3.39e-10	3.1e-07	-0.59	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39514956~39516490:+
KIRP	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-6.53	3.39e-10	3.1e-07	-0.48	-0.37	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
KIRP	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	6.53	3.4e-10	3.11e-07	0.31	0.37	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	6.53	3.4e-10	3.11e-07	0.31	0.37	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	6.53	3.4e-10	3.11e-07	0.44	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
KIRP	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-6.53	3.41e-10	3.12e-07	-0.34	-0.37	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
KIRP	cis	rs453301	0.509	rs7000323	ENSG00000253893.2	FAM85B	6.53	3.41e-10	3.12e-07	0.48	0.37	Joint mobility (Beighton score);	chr8:8934763	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	6.53	3.42e-10	3.12e-07	0.31	0.37	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	6.53	3.42e-10	3.12e-07	0.31	0.37	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	6.53	3.42e-10	3.12e-07	0.31	0.37	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	6.53	3.42e-10	3.12e-07	0.31	0.37	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	6.53	3.42e-10	3.12e-07	0.31	0.37	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
KIRP	cis	rs12962334	0.518	rs4800141	ENSG00000266850.1	RP11-370A5.1	6.53	3.42e-10	3.13e-07	0.45	0.37	Breast cancer;	chr18:22984312	chr18:22723491~22907721:-
KIRP	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-6.53	3.42e-10	3.13e-07	-0.47	-0.37	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
KIRP	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.53	3.43e-10	3.13e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
KIRP	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-6.53	3.43e-10	3.13e-07	-0.45	-0.37	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
KIRP	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-6.53	3.45e-10	3.15e-07	-0.49	-0.37	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
KIRP	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-6.53	3.45e-10	3.15e-07	-0.45	-0.37	Depression;	chr6:28070115	chr6:28115628~28116551:+
KIRP	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	6.53	3.45e-10	3.15e-07	0.5	0.37	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	6.53	3.45e-10	3.15e-07	0.5	0.37	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	6.53	3.45e-10	3.15e-07	0.5	0.37	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
KIRP	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-6.53	3.47e-10	3.16e-07	-0.46	-0.37	Depression;	chr6:28140454	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-6.53	3.47e-10	3.16e-07	-0.46	-0.37	Depression;	chr6:28141189	chr6:28115628~28116551:+
KIRP	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	6.53	3.47e-10	3.17e-07	0.43	0.37	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
KIRP	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-6.53	3.47e-10	3.17e-07	-0.47	-0.37	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
KIRP	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-6.53	3.48e-10	3.17e-07	-0.38	-0.37	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-6.53	3.48e-10	3.17e-07	-0.38	-0.37	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-6.53	3.48e-10	3.17e-07	-0.38	-0.37	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
KIRP	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-6.53	3.49e-10	3.19e-07	-0.43	-0.37	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-6.53	3.49e-10	3.19e-07	-0.43	-0.37	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-6.53	3.49e-10	3.19e-07	-0.43	-0.37	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
KIRP	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	6.52	3.5e-10	3.2e-07	0.49	0.37	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	6.52	3.5e-10	3.2e-07	0.49	0.37	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	6.52	3.5e-10	3.2e-07	0.49	0.37	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
KIRP	cis	rs1476679	1	rs34919929	ENSG00000078319.8	PMS2P1	6.52	3.51e-10	3.2e-07	0.49	0.37	Alzheimer's disease (late onset);	chr7:100414711	chr7:100320992~100341908:-
KIRP	cis	rs9532669	0.926	rs11147823	ENSG00000239827.7	SUGT1P3	6.52	3.51e-10	3.2e-07	0.42	0.37	Cervical cancer;	chr13:40878138	chr13:40908159~40921774:-
KIRP	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-6.52	3.52e-10	3.21e-07	-0.48	-0.37	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-6.52	3.52e-10	3.21e-07	-0.48	-0.37	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
KIRP	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-6.52	3.53e-10	3.21e-07	-0.46	-0.37	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
KIRP	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	6.52	3.53e-10	3.22e-07	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
KIRP	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-6.52	3.54e-10	3.23e-07	-0.48	-0.37	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
KIRP	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-6.52	3.54e-10	3.23e-07	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
KIRP	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-6.52	3.55e-10	3.23e-07	-0.45	-0.37	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
KIRP	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	6.52	3.55e-10	3.24e-07	0.47	0.37	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
KIRP	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	6.52	3.57e-10	3.25e-07	0.52	0.37	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
KIRP	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	6.52	3.57e-10	3.25e-07	0.45	0.37	Height;	chr11:118859432	chr11:118688039~118690600:-
KIRP	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	6.52	3.57e-10	3.25e-07	0.45	0.37	Height;	chr11:118860890	chr11:118688039~118690600:-
KIRP	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	6.52	3.57e-10	3.25e-07	0.45	0.37	Height;	chr11:118861053	chr11:118688039~118690600:-
KIRP	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-6.52	3.57e-10	3.25e-07	-0.54	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
KIRP	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	6.52	3.58e-10	3.26e-07	0.38	0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
KIRP	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-6.52	3.58e-10	3.26e-07	-0.28	-0.37	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
KIRP	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-6.52	3.59e-10	3.27e-07	-0.32	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-6.52	3.59e-10	3.27e-07	-0.32	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
KIRP	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	6.52	3.59e-10	3.27e-07	0.55	0.37	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
KIRP	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	6.52	3.6e-10	3.27e-07	0.5	0.37	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
KIRP	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	6.52	3.6e-10	3.28e-07	0.45	0.37	Height;	chr11:118855233	chr11:118688039~118690600:-
KIRP	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	6.52	3.6e-10	3.28e-07	0.45	0.37	Height;	chr11:118855938	chr11:118688039~118690600:-
KIRP	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	6.52	3.61e-10	3.28e-07	0.43	0.37	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	6.52	3.61e-10	3.28e-07	0.43	0.37	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
KIRP	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-6.52	3.61e-10	3.28e-07	-0.3	-0.37	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-6.52	3.61e-10	3.28e-07	-0.3	-0.37	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
KIRP	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	6.52	3.62e-10	3.29e-07	0.46	0.37	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
KIRP	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	6.52	3.62e-10	3.29e-07	0.31	0.37	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
KIRP	cis	rs9926296	0.509	rs2159113	ENSG00000260259.1	RP11-368I7.4	-6.52	3.62e-10	3.3e-07	-0.28	-0.37	Vitiligo;	chr16:89765675	chr16:89682620~89686569:-
KIRP	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.52	3.63e-10	3.3e-07	-0.33	-0.37	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
KIRP	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	6.52	3.64e-10	3.31e-07	0.6	0.37	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
KIRP	cis	rs755249	0.567	rs61779308	ENSG00000237624.1	OXCT2P1	6.52	3.64e-10	3.31e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39514956~39516490:+
KIRP	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28089816	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28090857	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28091439	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28091659	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28093966	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28094014	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28096077	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-6.52	3.64e-10	3.31e-07	-0.45	-0.37	Depression;	chr6:28096855	chr6:28115628~28116551:+
KIRP	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	6.52	3.64e-10	3.31e-07	0.28	0.37	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
KIRP	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	6.52	3.66e-10	3.32e-07	0.49	0.37	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
KIRP	cis	rs10916248	0.612	rs10916304	ENSG00000232628.4	RP11-365O16.3	6.52	3.67e-10	3.33e-07	0.55	0.37	QT interval (drug interaction);	chr1:224110166	chr1:224208747~224213279:-
KIRP	cis	rs755249	0.567	rs16826093	ENSG00000237624.1	OXCT2P1	6.52	3.67e-10	3.33e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs17264671	ENSG00000237624.1	OXCT2P1	6.52	3.67e-10	3.33e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs4660690	ENSG00000237624.1	OXCT2P1	6.52	3.67e-10	3.33e-07	0.59	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39514956~39516490:+
KIRP	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	6.52	3.69e-10	3.35e-07	0.4	0.37	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	6.52	3.69e-10	3.35e-07	0.4	0.37	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	6.52	3.69e-10	3.35e-07	0.4	0.37	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	6.52	3.69e-10	3.35e-07	0.4	0.37	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
KIRP	cis	rs4356975	0.932	rs4694607	ENSG00000196472.4	RP13-644M16.4	6.52	3.69e-10	3.35e-07	0.42	0.37	Obesity-related traits;	chr4:69073025	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs4410590	ENSG00000196472.4	RP13-644M16.4	6.52	3.69e-10	3.35e-07	0.42	0.37	Obesity-related traits;	chr4:69073381	chr4:69181660~69182372:+
KIRP	cis	rs4443100	0.916	rs2330335	ENSG00000221069.1	AC000029.1	6.52	3.69e-10	3.35e-07	0.46	0.37	Serum parathyroid hormone levels;	chr22:23040185	chr22:23136620~23136710:+
KIRP	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-6.52	3.7e-10	3.35e-07	-0.46	-0.37	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
KIRP	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	6.52	3.7e-10	3.36e-07	0.49	0.37	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	6.52	3.7e-10	3.36e-07	0.49	0.37	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
KIRP	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	6.52	3.7e-10	3.36e-07	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
KIRP	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	6.51	3.7e-10	3.36e-07	0.31	0.37	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
KIRP	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-6.51	3.72e-10	3.37e-07	-0.32	-0.37	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-6.51	3.72e-10	3.37e-07	-0.32	-0.37	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
KIRP	cis	rs79349575	0.783	rs903567	ENSG00000248278.1	SUMO2P17	6.51	3.72e-10	3.37e-07	0.42	0.37	Type 2 diabetes;	chr17:48902956	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62075818	ENSG00000248278.1	SUMO2P17	6.51	3.72e-10	3.37e-07	0.42	0.37	Type 2 diabetes;	chr17:48904965	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs9912829	ENSG00000248278.1	SUMO2P17	6.51	3.72e-10	3.37e-07	0.42	0.37	Type 2 diabetes;	chr17:48905387	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62075820	ENSG00000248278.1	SUMO2P17	6.51	3.72e-10	3.37e-07	0.42	0.37	Type 2 diabetes;	chr17:48905809	chr17:48874860~48908983:-
KIRP	cis	rs4356975	0.522	rs7679184	ENSG00000250696.4	RP11-704M14.1	6.51	3.72e-10	3.37e-07	0.35	0.37	Obesity-related traits;	chr4:69100212	chr4:69182100~69216766:+
KIRP	cis	rs79349575	0.783	rs28409394	ENSG00000248278.1	SUMO2P17	6.51	3.72e-10	3.38e-07	0.42	0.37	Type 2 diabetes;	chr17:48920756	chr17:48874860~48908983:-
KIRP	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-6.51	3.73e-10	3.38e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
KIRP	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	6.51	3.73e-10	3.39e-07	0.38	0.37	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	6.51	3.73e-10	3.39e-07	0.38	0.37	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	6.51	3.73e-10	3.39e-07	0.38	0.37	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	6.51	3.73e-10	3.39e-07	0.38	0.37	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
KIRP	cis	rs755249	0.567	rs1126313	ENSG00000237624.1	OXCT2P1	-6.51	3.76e-10	3.41e-07	-0.59	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39514956~39516490:+
KIRP	cis	rs9532669	0.926	rs9566582	ENSG00000239827.7	SUGT1P3	-6.51	3.76e-10	3.41e-07	-0.43	-0.37	Cervical cancer;	chr13:40852121	chr13:40908159~40921774:-
KIRP	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	6.51	3.77e-10	3.41e-07	0.44	0.37	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
KIRP	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-6.51	3.77e-10	3.41e-07	-0.29	-0.37	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
KIRP	cis	rs4356975	0.563	rs35402056	ENSG00000250696.4	RP11-704M14.1	6.51	3.78e-10	3.42e-07	0.36	0.37	Obesity-related traits;	chr4:69108549	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4694177	ENSG00000250696.4	RP11-704M14.1	6.51	3.78e-10	3.42e-07	0.36	0.37	Obesity-related traits;	chr4:69110141	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12642938	ENSG00000250696.4	RP11-704M14.1	6.51	3.78e-10	3.42e-07	0.36	0.37	Obesity-related traits;	chr4:69110499	chr4:69182100~69216766:+
KIRP	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	6.51	3.79e-10	3.43e-07	0.35	0.37	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
KIRP	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.51	3.79e-10	3.43e-07	-0.4	-0.37	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
KIRP	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-6.51	3.79e-10	3.43e-07	-0.44	-0.37	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
KIRP	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-6.51	3.79e-10	3.43e-07	-0.44	-0.37	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
KIRP	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	6.51	3.8e-10	3.44e-07	0.46	0.37	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
KIRP	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	6.51	3.81e-10	3.45e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	6.51	3.81e-10	3.45e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
KIRP	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	6.51	3.82e-10	3.46e-07	0.45	0.37	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
KIRP	cis	rs67311347	0.713	rs4974018	ENSG00000230274.1	PGAM1P3	6.51	3.83e-10	3.46e-07	0.37	0.37	Renal cell carcinoma;	chr3:40265928	chr3:40322715~40323279:-
KIRP	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-6.51	3.83e-10	3.46e-07	-0.37	-0.37	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
KIRP	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	6.51	3.83e-10	3.46e-07	0.45	0.37	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
KIRP	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	6.51	3.84e-10	3.47e-07	0.38	0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	6.51	3.84e-10	3.47e-07	0.38	0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
KIRP	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	6.51	3.85e-10	3.48e-07	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
KIRP	cis	rs867371	1	rs867370	ENSG00000255769.6	GOLGA2P10	6.51	3.86e-10	3.48e-07	0.4	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs867371	ENSG00000255769.6	GOLGA2P10	6.51	3.86e-10	3.48e-07	0.4	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472993~82513950:-
KIRP	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	6.51	3.86e-10	3.48e-07	0.31	0.37	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
KIRP	cis	rs67311347	0.524	rs11129869	ENSG00000230274.1	PGAM1P3	6.51	3.87e-10	3.49e-07	0.36	0.37	Renal cell carcinoma;	chr3:40218247	chr3:40322715~40323279:-
KIRP	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	6.51	3.88e-10	3.51e-07	0.35	0.37	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	6.51	3.89e-10	3.51e-07	0.31	0.37	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
KIRP	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28082231	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28082261	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28082984	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28083994	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28084025	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-6.51	3.89e-10	3.51e-07	-0.45	-0.37	Depression;	chr6:28085319	chr6:28115628~28116551:+
KIRP	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	6.51	3.9e-10	3.52e-07	0.42	0.37	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
KIRP	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	6.51	3.9e-10	3.52e-07	0.41	0.37	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
KIRP	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-6.51	3.91e-10	3.52e-07	-0.56	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
KIRP	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-6.51	3.91e-10	3.52e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-6.51	3.91e-10	3.52e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-6.51	3.91e-10	3.52e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
KIRP	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	6.51	3.91e-10	3.52e-07	0.29	0.37	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
KIRP	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	6.51	3.91e-10	3.53e-07	0.59	0.37	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	6.51	3.91e-10	3.53e-07	0.59	0.37	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
KIRP	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-6.5	3.92e-10	3.54e-07	-0.32	-0.37	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
KIRP	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	6.5	3.93e-10	3.54e-07	0.46	0.37	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
KIRP	cis	rs67311347	1	rs2276868	ENSG00000230274.1	PGAM1P3	-6.5	3.94e-10	3.55e-07	-0.36	-0.37	Renal cell carcinoma;	chr3:40457354	chr3:40322715~40323279:-
KIRP	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-6.5	3.95e-10	3.56e-07	-0.32	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
KIRP	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	6.5	3.95e-10	3.56e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
KIRP	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.5	3.95e-10	3.56e-07	-0.34	-0.37	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
KIRP	cis	rs79349575	0.715	rs55724082	ENSG00000248278.1	SUMO2P17	6.5	3.97e-10	3.57e-07	0.42	0.37	Type 2 diabetes;	chr17:48940517	chr17:48874860~48908983:-
KIRP	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	6.5	3.97e-10	3.57e-07	0.48	0.37	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
KIRP	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	6.5	3.97e-10	3.58e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
KIRP	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	6.5	3.97e-10	3.58e-07	0.29	0.37	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	6.5	3.98e-10	3.58e-07	0.45	0.37	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
KIRP	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	6.5	3.99e-10	3.59e-07	0.35	0.37	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
KIRP	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-6.5	3.99e-10	3.59e-07	-0.45	-0.37	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
KIRP	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-6.5	3.99e-10	3.59e-07	-0.47	-0.37	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
KIRP	cis	rs10916248	0.53	rs72753952	ENSG00000232628.4	RP11-365O16.3	6.5	3.99e-10	3.59e-07	0.55	0.37	QT interval (drug interaction);	chr1:224126348	chr1:224208747~224213279:-
KIRP	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	6.5	4e-10	3.6e-07	0.46	0.37	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
KIRP	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	6.5	4e-10	3.6e-07	0.28	0.37	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
KIRP	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.5	4.01e-10	3.61e-07	0.31	0.37	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
KIRP	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-6.5	4.01e-10	3.61e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
KIRP	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-6.5	4.03e-10	3.62e-07	-0.3	-0.37	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
KIRP	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	6.5	4.03e-10	3.63e-07	0.45	0.37	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
KIRP	cis	rs453301	0.631	rs4840376	ENSG00000253893.2	FAM85B	6.5	4.03e-10	3.63e-07	0.48	0.37	Joint mobility (Beighton score);	chr8:8944591	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.605	rs7843024	ENSG00000253893.2	FAM85B	6.5	4.04e-10	3.63e-07	0.48	0.37	Joint mobility (Beighton score);	chr8:8942466	chr8:8167819~8226614:-
KIRP	cis	rs4638749	0.677	rs1563112	ENSG00000225328.1	AC019100.3	-6.5	4.04e-10	3.63e-07	-0.45	-0.37	Blood pressure;	chr2:108234123	chr2:108167748~108217841:-
KIRP	cis	rs9532669	0.89	rs9525417	ENSG00000239827.7	SUGT1P3	-6.5	4.05e-10	3.64e-07	-0.42	-0.37	Cervical cancer;	chr13:40878431	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9532638	ENSG00000239827.7	SUGT1P3	-6.5	4.05e-10	3.64e-07	-0.42	-0.37	Cervical cancer;	chr13:40878471	chr13:40908159~40921774:-
KIRP	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-6.5	4.05e-10	3.64e-07	-0.48	-0.37	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
KIRP	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	6.5	4.05e-10	3.64e-07	0.56	0.37	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
KIRP	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-6.5	4.05e-10	3.64e-07	-0.52	-0.37	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
KIRP	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	6.5	4.05e-10	3.64e-07	0.49	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	6.5	4.05e-10	3.64e-07	0.49	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
KIRP	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-6.5	4.06e-10	3.64e-07	-0.43	-0.37	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
KIRP	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	6.5	4.06e-10	3.65e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	6.5	4.06e-10	3.65e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
KIRP	cis	rs7672749	0.73	rs7672924	ENSG00000249973.2	CHCHD2P7	6.5	4.06e-10	3.65e-07	0.7	0.37	TB-LM or TBLH-BMD (pleiotropy);	chr4:87847095	chr4:87785920~87786371:-
KIRP	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	6.5	4.07e-10	3.65e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
KIRP	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	6.5	4.07e-10	3.66e-07	0.5	0.37	Height;	chr6:109332929	chr6:109382795~109383666:+
KIRP	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	6.5	4.07e-10	3.66e-07	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
KIRP	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.5	4.1e-10	3.68e-07	0.54	0.37	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
KIRP	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-6.5	4.13e-10	3.7e-07	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
KIRP	cis	rs17082664	0.79	rs62426392	ENSG00000226193.1	RP3-398G3.5	-6.5	4.13e-10	3.71e-07	-0.59	-0.37	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152395084	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	6.5	4.14e-10	3.71e-07	0.44	0.37	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	6.5	4.14e-10	3.71e-07	0.44	0.37	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	6.5	4.14e-10	3.71e-07	0.44	0.37	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
KIRP	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-6.5	4.14e-10	3.72e-07	-0.33	-0.37	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
KIRP	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	6.5	4.14e-10	3.72e-07	0.43	0.37	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
KIRP	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-6.49	4.15e-10	3.73e-07	-0.38	-0.37	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
KIRP	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.49	4.16e-10	3.73e-07	-0.47	-0.37	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.49	4.16e-10	3.73e-07	-0.47	-0.37	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
KIRP	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	6.49	4.16e-10	3.73e-07	0.5	0.37	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	6.49	4.17e-10	3.74e-07	0.3	0.37	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	6.49	4.18e-10	3.75e-07	0.43	0.37	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
KIRP	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-6.49	4.18e-10	3.75e-07	-0.46	-0.37	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
KIRP	cis	rs79349575	0.749	rs8182364	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48940663	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.681	rs56080003	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48941687	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4793995	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48942037	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4793996	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48942235	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.715	rs4793997	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48942310	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4793998	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48942537	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.749	rs2270574	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48944908	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4794000	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48945393	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	6.49	4.18e-10	3.75e-07	0.42	0.37	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
KIRP	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	6.49	4.19e-10	3.75e-07	0.35	0.37	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
KIRP	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.49	4.19e-10	3.76e-07	-0.39	-0.37	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
KIRP	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	6.49	4.19e-10	3.76e-07	0.46	0.37	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
KIRP	cis	rs755249	0.529	rs4660732	ENSG00000237624.1	OXCT2P1	6.49	4.21e-10	3.77e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39514956~39516490:+
KIRP	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	6.49	4.22e-10	3.78e-07	0.3	0.37	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
KIRP	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-6.49	4.22e-10	3.78e-07	-0.34	-0.37	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
KIRP	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.49	4.22e-10	3.78e-07	-0.31	-0.37	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
KIRP	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	6.49	4.22e-10	3.78e-07	0.39	0.37	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
KIRP	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	6.49	4.23e-10	3.78e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
KIRP	cis	rs755249	0.567	rs72661961	ENSG00000237624.1	OXCT2P1	6.49	4.23e-10	3.78e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39514956~39516490:+
KIRP	cis	rs67311347	1	rs7648952	ENSG00000230274.1	PGAM1P3	-6.49	4.23e-10	3.78e-07	-0.36	-0.37	Renal cell carcinoma;	chr3:40415547	chr3:40322715~40323279:-
KIRP	cis	rs2625529	0.73	rs6494990	ENSG00000260037.4	CTD-2524L6.3	6.49	4.23e-10	3.79e-07	0.29	0.37	Red blood cell count;	chr15:72108733	chr15:71818396~71823384:+
KIRP	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-6.49	4.24e-10	3.79e-07	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	6.49	4.24e-10	3.79e-07	0.31	0.37	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
KIRP	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	6.49	4.25e-10	3.8e-07	0.31	0.37	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
KIRP	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-6.49	4.27e-10	3.82e-07	-0.3	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-6.49	4.27e-10	3.82e-07	-0.3	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-6.49	4.27e-10	3.82e-07	-0.3	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-6.49	4.27e-10	3.82e-07	-0.3	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
KIRP	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-6.49	4.28e-10	3.83e-07	-0.6	-0.37	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
KIRP	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	6.49	4.28e-10	3.83e-07	0.3	0.37	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
KIRP	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	6.49	4.29e-10	3.83e-07	0.42	0.37	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
KIRP	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	6.49	4.31e-10	3.85e-07	0.5	0.37	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
KIRP	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-6.49	4.31e-10	3.85e-07	-0.43	-0.37	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
KIRP	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-6.49	4.33e-10	3.87e-07	-0.28	-0.37	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
KIRP	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	6.49	4.34e-10	3.87e-07	0.3	0.37	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	6.49	4.34e-10	3.87e-07	0.46	0.37	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
KIRP	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-6.49	4.34e-10	3.87e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
KIRP	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	6.49	4.36e-10	3.89e-07	0.4	0.37	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
KIRP	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-6.49	4.36e-10	3.89e-07	-0.46	-0.37	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
KIRP	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-6.49	4.37e-10	3.89e-07	-0.37	-0.37	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
KIRP	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	6.49	4.37e-10	3.9e-07	0.45	0.37	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
KIRP	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	6.49	4.37e-10	3.9e-07	0.34	0.37	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
KIRP	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-6.49	4.38e-10	3.91e-07	-0.29	-0.37	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
KIRP	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	6.49	4.39e-10	3.92e-07	0.38	0.37	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-6.49	4.39e-10	3.92e-07	-0.38	-0.37	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-6.49	4.39e-10	3.92e-07	-0.38	-0.37	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
KIRP	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-6.48	4.4e-10	3.92e-07	-0.48	-0.37	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
KIRP	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	6.48	4.41e-10	3.93e-07	0.3	0.37	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
KIRP	cis	rs67311347	1	rs72861689	ENSG00000230274.1	PGAM1P3	6.48	4.42e-10	3.94e-07	0.36	0.37	Renal cell carcinoma;	chr3:40394399	chr3:40322715~40323279:-
KIRP	cis	rs832190	1	rs832190	ENSG00000280620.1	SCAANT1	-6.48	4.43e-10	3.95e-07	-0.42	-0.37	Schizophrenia;	chr3:63856953	chr3:63911518~63911772:-
KIRP	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	6.48	4.44e-10	3.96e-07	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
KIRP	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.48	4.44e-10	3.96e-07	-0.31	-0.37	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
KIRP	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	6.48	4.45e-10	3.96e-07	0.38	0.37	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	6.48	4.45e-10	3.96e-07	0.38	0.37	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	6.48	4.45e-10	3.96e-07	0.38	0.37	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
KIRP	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	6.48	4.45e-10	3.97e-07	0.3	0.37	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
KIRP	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-6.48	4.46e-10	3.97e-07	-0.45	-0.37	Depression;	chr6:28092227	chr6:28115628~28116551:+
KIRP	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-6.48	4.49e-10	4e-07	-0.49	-0.37	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
KIRP	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-6.48	4.49e-10	4e-07	-0.47	-0.37	Depression;	chr6:28135913	chr6:28115628~28116551:+
KIRP	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	6.48	4.5e-10	4.01e-07	0.67	0.37	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
KIRP	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	6.48	4.52e-10	4.02e-07	0.5	0.37	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	6.48	4.52e-10	4.02e-07	0.5	0.37	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	6.48	4.52e-10	4.02e-07	0.5	0.37	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
KIRP	cis	rs11647589	0.553	rs6497484	ENSG00000260762.1	ACSM5P1	6.48	4.52e-10	4.03e-07	0.36	0.37	Blood metabolite levels;	chr16:20428396	chr16:20586550~20607107:-
KIRP	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	6.48	4.55e-10	4.05e-07	0.8	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	6.48	4.56e-10	4.06e-07	0.46	0.37	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
KIRP	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-6.48	4.57e-10	4.06e-07	-0.39	-0.37	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-6.48	4.57e-10	4.06e-07	-0.39	-0.37	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-6.48	4.57e-10	4.06e-07	-0.39	-0.37	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
KIRP	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-6.48	4.57e-10	4.07e-07	-0.43	-0.37	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
KIRP	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-6.48	4.6e-10	4.09e-07	-0.5	-0.37	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.599	rs7660019	ENSG00000196472.4	RP13-644M16.4	6.48	4.6e-10	4.09e-07	0.42	0.37	Obesity-related traits;	chr4:69072135	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.574	rs7660021	ENSG00000196472.4	RP13-644M16.4	6.48	4.6e-10	4.09e-07	0.42	0.37	Obesity-related traits;	chr4:69072143	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.549	rs7687692	ENSG00000196472.4	RP13-644M16.4	6.48	4.6e-10	4.09e-07	0.42	0.37	Obesity-related traits;	chr4:69072154	chr4:69181660~69182372:+
KIRP	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	6.48	4.6e-10	4.09e-07	0.43	0.37	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
KIRP	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	6.48	4.6e-10	4.09e-07	0.42	0.37	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
KIRP	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	6.48	4.6e-10	4.09e-07	0.39	0.37	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
KIRP	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-6.48	4.61e-10	4.1e-07	-0.52	-0.37	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
KIRP	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-6.48	4.61e-10	4.1e-07	-0.52	-0.37	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
KIRP	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-6.47	4.66e-10	4.14e-07	-0.32	-0.37	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
KIRP	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	6.47	4.66e-10	4.14e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
KIRP	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.47	4.68e-10	4.16e-07	0.31	0.37	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
KIRP	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-6.47	4.68e-10	4.16e-07	-0.39	-0.37	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
KIRP	cis	rs9532669	0.926	rs9315789	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40852898	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.857	rs7327018	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40856376	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7327315	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40856383	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7327059	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40856458	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9594433	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40856935	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9525403	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40858292	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7318768	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40859140	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4942000	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40859979	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.7	rs9525406	ENSG00000239827.7	SUGT1P3	-6.47	4.69e-10	4.16e-07	-0.42	-0.37	Cervical cancer;	chr13:40860812	chr13:40908159~40921774:-
KIRP	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	6.47	4.7e-10	4.17e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
KIRP	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	6.47	4.7e-10	4.17e-07	0.42	0.37	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
KIRP	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.47	4.7e-10	4.17e-07	0.4	0.37	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
KIRP	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-6.47	4.71e-10	4.18e-07	-0.34	-0.37	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
KIRP	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	6.47	4.71e-10	4.18e-07	0.41	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
KIRP	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-6.47	4.71e-10	4.18e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
KIRP	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-6.47	4.71e-10	4.18e-07	-0.48	-0.37	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
KIRP	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.47	4.72e-10	4.19e-07	0.46	0.37	Depression;	chr6:28109824	chr6:28115628~28116551:+
KIRP	cis	rs34375054	0.687	rs35540170	ENSG00000279233.1	RP11-158L12.4	6.47	4.72e-10	4.19e-07	0.33	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125184576	chr12:125138245~125141711:+
KIRP	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	6.47	4.72e-10	4.19e-07	0.42	0.37	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
KIRP	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-6.47	4.73e-10	4.2e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
KIRP	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	6.47	4.75e-10	4.21e-07	0.49	0.37	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
KIRP	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.47	4.75e-10	4.21e-07	-0.4	-0.37	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
KIRP	cis	rs9532669	0.929	rs9532601	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40861086	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs12871420	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880034	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs12871735	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880169	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs12871895	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880189	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs12872288	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880268	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532640	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880628	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9532641	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880648	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532643	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880800	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs9532644	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880860	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532645	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880898	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532646	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40880989	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9525419	ENSG00000239827.7	SUGT1P3	-6.47	4.77e-10	4.23e-07	-0.42	-0.37	Cervical cancer;	chr13:40881047	chr13:40908159~40921774:-
KIRP	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-6.47	4.78e-10	4.23e-07	-0.33	-0.37	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
KIRP	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	6.47	4.78e-10	4.23e-07	0.46	0.37	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
KIRP	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	6.47	4.8e-10	4.25e-07	0.55	0.37	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
KIRP	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	6.47	4.81e-10	4.26e-07	0.39	0.37	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
KIRP	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	6.47	4.81e-10	4.26e-07	0.29	0.37	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
KIRP	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-6.47	4.82e-10	4.27e-07	-0.46	-0.37	Depression;	chr6:28141484	chr6:28115628~28116551:+
KIRP	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-6.47	4.82e-10	4.27e-07	-0.28	-0.37	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	6.47	4.82e-10	4.27e-07	0.28	0.37	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	6.47	4.82e-10	4.27e-07	0.28	0.37	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
KIRP	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	6.47	4.83e-10	4.27e-07	0.41	0.37	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
KIRP	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	6.47	4.83e-10	4.27e-07	0.41	0.37	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
KIRP	cis	rs755249	0.565	rs7539279	ENSG00000237624.1	OXCT2P1	-6.47	4.83e-10	4.28e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39514956~39516490:+
KIRP	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-6.47	4.83e-10	4.28e-07	-0.53	-0.37	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
KIRP	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	6.47	4.85e-10	4.29e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	6.47	4.85e-10	4.29e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	6.47	4.85e-10	4.29e-07	0.48	0.37	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
KIRP	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-6.47	4.85e-10	4.29e-07	-0.56	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
KIRP	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	6.47	4.85e-10	4.29e-07	0.3	0.37	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
KIRP	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-6.47	4.86e-10	4.3e-07	-0.31	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-6.47	4.86e-10	4.3e-07	-0.31	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
KIRP	cis	rs67311347	1	rs7617989	ENSG00000230274.1	PGAM1P3	-6.47	4.89e-10	4.32e-07	-0.36	-0.37	Renal cell carcinoma;	chr3:40470972	chr3:40322715~40323279:-
KIRP	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.32e-07	0.31	0.37	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	6.47	4.89e-10	4.33e-07	0.31	0.37	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
KIRP	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-6.47	4.9e-10	4.33e-07	-0.47	-0.37	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-6.47	4.9e-10	4.33e-07	-0.47	-0.37	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-6.47	4.9e-10	4.33e-07	-0.47	-0.37	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
KIRP	cis	rs2617170	0.922	rs2617149	ENSG00000245648.1	RP11-277P12.20	-6.47	4.92e-10	4.35e-07	-0.42	-0.37	Behcet's disease;	chr12:10375734	chr12:10363769~10398506:+
KIRP	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-6.46	4.93e-10	4.35e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
KIRP	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	6.46	4.94e-10	4.36e-07	0.39	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
KIRP	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-6.46	4.95e-10	4.38e-07	-0.48	-0.37	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
KIRP	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-6.46	4.99e-10	4.4e-07	-0.33	-0.37	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
KIRP	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	6.46	5e-10	4.41e-07	0.35	0.37	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
KIRP	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	6.46	5e-10	4.41e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
KIRP	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	6.46	5e-10	4.41e-07	0.41	0.37	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
KIRP	cis	rs4356975	0.899	rs4412058	ENSG00000196472.4	RP13-644M16.4	6.46	5e-10	4.41e-07	0.42	0.37	Obesity-related traits;	chr4:69073715	chr4:69181660~69182372:+
KIRP	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	6.46	5e-10	4.41e-07	0.44	0.37	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
KIRP	cis	rs9532669	0.926	rs7997536	ENSG00000239827.7	SUGT1P3	-6.46	5.01e-10	4.41e-07	-0.42	-0.37	Cervical cancer;	chr13:40878685	chr13:40908159~40921774:-
KIRP	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	6.46	5.05e-10	4.45e-07	0.44	0.37	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
KIRP	cis	rs7829975	0.514	rs2920983	ENSG00000253981.4	ALG1L13P	6.46	5.06e-10	4.46e-07	0.3	0.37	Mood instability;	chr8:8410553	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	6.46	5.06e-10	4.46e-07	0.29	0.37	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
KIRP	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	6.46	5.07e-10	4.47e-07	0.28	0.37	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
KIRP	cis	rs7474896	0.537	rs1208587	ENSG00000151963.4	RP11-775A3.1	6.46	5.09e-10	4.48e-07	0.48	0.37	Obesity (extreme);	chr10:37918831	chr10:37883594~37884109:+
KIRP	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	6.46	5.09e-10	4.48e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
KIRP	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-6.46	5.1e-10	4.49e-07	-0.43	-0.37	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
KIRP	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-6.46	5.1e-10	4.49e-07	-0.45	-0.37	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	6.46	5.1e-10	4.49e-07	0.45	0.37	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.46	5.1e-10	4.49e-07	0.31	0.37	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	6.46	5.11e-10	4.5e-07	0.31	0.37	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
KIRP	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-6.46	5.11e-10	4.5e-07	-0.45	-0.37	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
KIRP	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	6.46	5.11e-10	4.5e-07	0.43	0.37	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
KIRP	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.46	5.12e-10	4.51e-07	0.48	0.37	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
KIRP	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-6.46	5.13e-10	4.51e-07	-0.44	-0.37	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-6.46	5.15e-10	4.53e-07	-0.51	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
KIRP	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	6.46	5.15e-10	4.53e-07	0.59	0.37	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	6.46	5.15e-10	4.53e-07	0.59	0.37	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	6.46	5.15e-10	4.53e-07	0.59	0.37	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
KIRP	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-6.46	5.16e-10	4.53e-07	-0.41	-0.37	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
KIRP	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	6.46	5.16e-10	4.54e-07	0.4	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
KIRP	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-6.46	5.16e-10	4.54e-07	-0.33	-0.37	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
KIRP	cis	rs755249	0.545	rs12037073	ENSG00000237624.1	OXCT2P1	-6.46	5.17e-10	4.55e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	6.46	5.17e-10	4.55e-07	0.45	0.37	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
KIRP	cis	rs2625529	0.73	rs2957368	ENSG00000260037.4	CTD-2524L6.3	-6.46	5.2e-10	4.57e-07	-0.29	-0.37	Red blood cell count;	chr15:72037565	chr15:71818396~71823384:+
KIRP	cis	rs17082664	0.704	rs9322371	ENSG00000226193.1	RP3-398G3.5	-6.46	5.2e-10	4.57e-07	-0.59	-0.37	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152397214	chr6:152402398~152404966:+
KIRP	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-6.46	5.21e-10	4.57e-07	-0.43	-0.37	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
KIRP	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	6.46	5.21e-10	4.58e-07	0.31	0.37	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	6.46	5.21e-10	4.58e-07	0.31	0.37	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	6.46	5.21e-10	4.58e-07	0.31	0.37	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	6.46	5.21e-10	4.58e-07	0.31	0.37	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	6.46	5.21e-10	4.58e-07	0.31	0.37	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
KIRP	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-6.45	5.22e-10	4.58e-07	-0.45	-0.37	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-6.45	5.22e-10	4.58e-07	-0.45	-0.37	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	6.45	5.22e-10	4.58e-07	0.45	0.37	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
KIRP	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	6.45	5.23e-10	4.59e-07	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
KIRP	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.23e-10	4.59e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.23e-10	4.59e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
KIRP	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	6.45	5.23e-10	4.59e-07	0.46	0.37	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	6.45	5.24e-10	4.6e-07	0.47	0.37	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
KIRP	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	6.45	5.25e-10	4.61e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
KIRP	cis	rs67311347	1	rs112619360	ENSG00000230274.1	PGAM1P3	6.45	5.26e-10	4.61e-07	0.36	0.37	Renal cell carcinoma;	chr3:40391154	chr3:40322715~40323279:-
KIRP	cis	rs9532669	0.926	rs7997560	ENSG00000239827.7	SUGT1P3	-6.45	5.26e-10	4.62e-07	-0.42	-0.37	Cervical cancer;	chr13:40878723	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4600337	ENSG00000239827.7	SUGT1P3	-6.45	5.26e-10	4.62e-07	-0.42	-0.37	Cervical cancer;	chr13:40879564	chr13:40908159~40921774:-
KIRP	cis	rs4356975	0.932	rs4611997	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69073429	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7436912	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69074077	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7654272	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69074144	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs6600867	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69074157	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs72852416	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69075085	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.806	rs12648808	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69075351	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.867	rs6600869	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69075937	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.836	rs6600870	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69075944	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7442394	ENSG00000196472.4	RP13-644M16.4	6.45	5.26e-10	4.62e-07	0.42	0.37	Obesity-related traits;	chr4:69076309	chr4:69181660~69182372:+
KIRP	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.45	5.27e-10	4.62e-07	-0.47	-0.37	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
KIRP	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	6.45	5.28e-10	4.63e-07	0.45	0.37	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	6.45	5.28e-10	4.63e-07	0.31	0.37	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
KIRP	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	6.45	5.29e-10	4.64e-07	0.5	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
KIRP	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	6.45	5.29e-10	4.64e-07	0.46	0.37	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
KIRP	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-6.45	5.29e-10	4.64e-07	-0.51	-0.37	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
KIRP	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-6.45	5.29e-10	4.64e-07	-0.44	-0.37	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
KIRP	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	6.45	5.3e-10	4.65e-07	0.39	0.37	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
KIRP	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	6.45	5.31e-10	4.66e-07	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
KIRP	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.32e-10	4.66e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.32e-10	4.66e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
KIRP	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-6.45	5.32e-10	4.67e-07	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
KIRP	cis	rs2283792	0.935	rs5750113	ENSG00000228050.1	TOP3BP1	6.45	5.33e-10	4.67e-07	0.4	0.37	Multiple sclerosis;	chr22:21865784	chr22:22223187~22224566:-
KIRP	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.45	5.33e-10	4.67e-07	0.4	0.37	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
KIRP	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	6.45	5.34e-10	4.68e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
KIRP	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-6.45	5.35e-10	4.69e-07	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
KIRP	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.45	5.35e-10	4.69e-07	0.39	0.37	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
KIRP	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-6.45	5.36e-10	4.7e-07	-0.37	-0.37	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
KIRP	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	6.45	5.36e-10	4.7e-07	0.3	0.37	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
KIRP	cis	rs2625529	0.73	rs3759900	ENSG00000260037.4	CTD-2524L6.3	6.45	5.37e-10	4.7e-07	0.29	0.37	Red blood cell count;	chr15:72159486	chr15:71818396~71823384:+
KIRP	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.45	5.39e-10	4.72e-07	0.3	0.37	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
KIRP	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	6.45	5.4e-10	4.73e-07	0.46	0.37	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
KIRP	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-6.45	5.4e-10	4.73e-07	-0.42	-0.37	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-6.45	5.4e-10	4.73e-07	-0.42	-0.37	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
KIRP	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	6.45	5.41e-10	4.73e-07	0.58	0.37	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
KIRP	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-6.45	5.43e-10	4.75e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-6.45	5.43e-10	4.75e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-6.45	5.43e-10	4.75e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-6.45	5.43e-10	4.75e-07	-0.29	-0.37	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
KIRP	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-6.45	5.44e-10	4.76e-07	-0.38	-0.37	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
KIRP	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-6.45	5.44e-10	4.76e-07	-0.41	-0.37	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
KIRP	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	6.45	5.45e-10	4.77e-07	0.41	0.37	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
KIRP	cis	rs13423976	0.631	rs4670876	ENSG00000231367.4	AC016995.3	6.45	5.46e-10	4.78e-07	0.5	0.37	Gut microbiome composition (summer);	chr2:38508948	chr2:38406719~38515740:-
KIRP	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-6.45	5.48e-10	4.78e-07	-0.32	-0.37	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
KIRP	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-6.45	5.49e-10	4.79e-07	-0.42	-0.37	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
KIRP	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-6.45	5.49e-10	4.8e-07	-0.51	-0.37	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	6.45	5.49e-10	4.8e-07	0.43	0.37	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	6.45	5.49e-10	4.8e-07	0.43	0.37	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
KIRP	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-6.45	5.49e-10	4.8e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
KIRP	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	6.45	5.5e-10	4.81e-07	0.49	0.37	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
KIRP	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-6.45	5.51e-10	4.81e-07	-0.31	-0.37	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
KIRP	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	6.45	5.51e-10	4.81e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
KIRP	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	6.45	5.51e-10	4.81e-07	0.51	0.37	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
KIRP	cis	rs9532669	0.926	rs2183144	ENSG00000239827.7	SUGT1P3	6.45	5.51e-10	4.81e-07	0.41	0.37	Cervical cancer;	chr13:40862129	chr13:40908159~40921774:-
KIRP	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.45	5.51e-10	4.81e-07	0.4	0.37	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
KIRP	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-6.44	5.52e-10	4.82e-07	-0.39	-0.37	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
KIRP	cis	rs2439831	0.85	rs2957637	ENSG00000249839.1	AC011330.5	-6.44	5.54e-10	4.84e-07	-0.52	-0.37	Lung cancer in ever smokers;	chr15:43658920	chr15:43663654~43684339:-
KIRP	cis	rs453301	0.631	rs7843789	ENSG00000253893.2	FAM85B	6.44	5.54e-10	4.84e-07	0.48	0.37	Joint mobility (Beighton score);	chr8:8943051	chr8:8167819~8226614:-
KIRP	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	6.44	5.55e-10	4.84e-07	0.46	0.37	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
KIRP	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-6.44	5.55e-10	4.85e-07	-0.49	-0.37	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	6.44	5.56e-10	4.85e-07	0.3	0.37	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
KIRP	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-6.44	5.58e-10	4.86e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
KIRP	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.44	5.59e-10	4.87e-07	0.39	0.37	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
KIRP	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-6.44	5.59e-10	4.88e-07	-0.47	-0.37	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
KIRP	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-6.44	5.59e-10	4.88e-07	-0.32	-0.37	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
KIRP	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-6.44	5.59e-10	4.88e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
KIRP	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-6.44	5.59e-10	4.88e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
KIRP	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	6.44	5.6e-10	4.88e-07	0.3	0.37	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	6.44	5.6e-10	4.88e-07	0.3	0.37	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
KIRP	cis	rs2283792	0.967	rs5999823	ENSG00000228050.1	TOP3BP1	6.44	5.6e-10	4.88e-07	0.4	0.37	Multiple sclerosis;	chr22:21856587	chr22:22223187~22224566:-
KIRP	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-6.44	5.61e-10	4.89e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
KIRP	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.44	5.63e-10	4.9e-07	0.31	0.37	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
KIRP	cis	rs67311347	1	rs6762997	ENSG00000230274.1	PGAM1P3	6.44	5.63e-10	4.91e-07	0.36	0.37	Renal cell carcinoma;	chr3:40436660	chr3:40322715~40323279:-
KIRP	cis	rs755249	0.567	rs6668369	ENSG00000237624.1	OXCT2P1	6.44	5.64e-10	4.92e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs16826069	ENSG00000237624.1	OXCT2P1	6.44	5.66e-10	4.93e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39514956~39516490:+
KIRP	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	6.44	5.68e-10	4.94e-07	0.37	0.37	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	6.44	5.68e-10	4.94e-07	0.37	0.37	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	6.44	5.69e-10	4.96e-07	0.43	0.37	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
KIRP	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	6.44	5.7e-10	4.96e-07	0.33	0.37	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
KIRP	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	6.44	5.71e-10	4.97e-07	0.46	0.37	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
KIRP	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	6.44	5.71e-10	4.97e-07	0.42	0.37	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
KIRP	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-6.44	5.72e-10	4.98e-07	-0.48	-0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
KIRP	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	6.44	5.72e-10	4.98e-07	0.74	0.37	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
KIRP	cis	rs755249	0.567	rs67408364	ENSG00000237624.1	OXCT2P1	6.44	5.72e-10	4.98e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs66531516	ENSG00000237624.1	OXCT2P1	6.44	5.72e-10	4.98e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39514956~39516490:+
KIRP	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.44	5.73e-10	4.99e-07	-0.31	-0.37	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
KIRP	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-6.44	5.74e-10	4.99e-07	-0.41	-0.37	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
KIRP	cis	rs2625529	0.73	rs2957737	ENSG00000260037.4	CTD-2524L6.3	6.44	5.74e-10	4.99e-07	0.29	0.37	Red blood cell count;	chr15:71973069	chr15:71818396~71823384:+
KIRP	cis	rs67311347	1	rs1466236	ENSG00000230274.1	PGAM1P3	6.44	5.75e-10	5e-07	0.36	0.37	Renal cell carcinoma;	chr3:40420671	chr3:40322715~40323279:-
KIRP	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	6.44	5.75e-10	5e-07	0.31	0.37	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	6.44	5.75e-10	5e-07	0.31	0.37	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
KIRP	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	6.44	5.76e-10	5.01e-07	0.45	0.37	Depression;	chr6:28142370	chr6:28115628~28116551:+
KIRP	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	6.44	5.76e-10	5.01e-07	0.3	0.37	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
KIRP	cis	rs7267979	0.868	rs6138546	ENSG00000274414.1	RP5-965G21.4	-6.44	5.79e-10	5.03e-07	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25239007~25245229:-
KIRP	cis	rs7829975	0.572	rs28730413	ENSG00000253981.4	ALG1L13P	-6.44	5.8e-10	5.04e-07	-0.29	-0.37	Mood instability;	chr8:8937937	chr8:8236003~8244667:-
KIRP	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-6.44	5.8e-10	5.04e-07	-0.38	-0.37	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
KIRP	cis	rs79349575	0.777	rs28517720	ENSG00000248278.1	SUMO2P17	6.44	5.81e-10	5.05e-07	0.42	0.37	Type 2 diabetes;	chr17:48899394	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.756	rs2643361	ENSG00000248278.1	SUMO2P17	6.44	5.81e-10	5.05e-07	0.42	0.37	Type 2 diabetes;	chr17:48900100	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.749	rs2546491	ENSG00000248278.1	SUMO2P17	6.44	5.81e-10	5.05e-07	0.42	0.37	Type 2 diabetes;	chr17:48900554	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs962272	ENSG00000248278.1	SUMO2P17	6.44	5.81e-10	5.05e-07	0.42	0.37	Type 2 diabetes;	chr17:48900921	chr17:48874860~48908983:-
KIRP	cis	rs755249	0.567	rs41270807	ENSG00000237624.1	OXCT2P1	6.44	5.82e-10	5.06e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.53	rs16826087	ENSG00000237624.1	OXCT2P1	6.44	5.82e-10	5.06e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs3754346	ENSG00000237624.1	OXCT2P1	6.44	5.82e-10	5.06e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs41270811	ENSG00000237624.1	OXCT2P1	6.44	5.82e-10	5.06e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs61779274	ENSG00000237624.1	OXCT2P1	6.44	5.82e-10	5.06e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39514956~39516490:+
KIRP	cis	rs2625529	0.73	rs7177242	ENSG00000260037.4	CTD-2524L6.3	6.44	5.83e-10	5.07e-07	0.29	0.37	Red blood cell count;	chr15:71891773	chr15:71818396~71823384:+
KIRP	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	6.43	5.85e-10	5.08e-07	0.57	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
KIRP	cis	rs2625529	0.73	rs7403191	ENSG00000260037.4	CTD-2524L6.3	-6.43	5.86e-10	5.09e-07	-0.29	-0.37	Red blood cell count;	chr15:71868623	chr15:71818396~71823384:+
KIRP	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-6.43	5.86e-10	5.09e-07	-0.45	-0.37	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
KIRP	cis	rs67311347	1	rs56992941	ENSG00000230274.1	PGAM1P3	6.43	5.86e-10	5.09e-07	0.36	0.37	Renal cell carcinoma;	chr3:40430943	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs4974017	ENSG00000230274.1	PGAM1P3	6.43	5.86e-10	5.09e-07	0.36	0.37	Renal cell carcinoma;	chr3:40432028	chr3:40322715~40323279:-
KIRP	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-6.43	5.87e-10	5.1e-07	-0.29	-0.37	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-6.43	5.87e-10	5.1e-07	-0.29	-0.37	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-6.43	5.87e-10	5.1e-07	-0.29	-0.37	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
KIRP	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-6.43	5.89e-10	5.11e-07	-0.44	-0.37	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
KIRP	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-6.43	5.91e-10	5.13e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-6.43	5.91e-10	5.13e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-6.43	5.91e-10	5.13e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
KIRP	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-6.43	5.91e-10	5.13e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-6.43	5.91e-10	5.13e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-6.43	5.91e-10	5.13e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-6.43	5.91e-10	5.13e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
KIRP	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	6.43	5.92e-10	5.13e-07	0.39	0.37	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
KIRP	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28071237	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28071808	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28074687	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28076559	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28076704	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28078391	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28080757	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-6.43	5.93e-10	5.14e-07	-0.44	-0.37	Depression;	chr6:28080760	chr6:28115628~28116551:+
KIRP	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	6.43	5.94e-10	5.15e-07	0.27	0.37	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
KIRP	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	6.43	5.95e-10	5.16e-07	0.4	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
KIRP	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-6.43	5.95e-10	5.16e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
KIRP	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	6.43	5.96e-10	5.16e-07	0.27	0.37	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
KIRP	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-6.43	5.96e-10	5.17e-07	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
KIRP	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-6.43	5.97e-10	5.18e-07	-0.41	-0.37	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
KIRP	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	6.43	5.98e-10	5.19e-07	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
KIRP	cis	rs4356975	0.932	rs4694159	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69068460	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4694597	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69068643	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs4694160	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69068755	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs7439419	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069090	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7658748	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069219	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs7687336	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069397	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs7659138	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069420	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7674600	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069614	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs72501227	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69069866	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4694602	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69070955	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4400060	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69071215	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4400061	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69071281	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4446390	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69071328	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7434389	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69071698	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.896	rs58496756	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69072070	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.899	rs7687725	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69072229	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4516791	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69072402	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4694605	ENSG00000196472.4	RP13-644M16.4	6.43	6.01e-10	5.2e-07	0.42	0.37	Obesity-related traits;	chr4:69072777	chr4:69181660~69182372:+
KIRP	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-6.43	6.01e-10	5.21e-07	-0.63	-0.37	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
KIRP	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	6.43	6.02e-10	5.21e-07	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
KIRP	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-6.43	6.02e-10	5.21e-07	-0.47	-0.37	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
KIRP	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-6.43	6.02e-10	5.21e-07	-0.49	-0.37	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
KIRP	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-6.43	6.03e-10	5.22e-07	-0.37	-0.37	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
KIRP	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	6.43	6.04e-10	5.23e-07	0.77	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
KIRP	cis	rs2283792	0.812	rs240066	ENSG00000228050.1	TOP3BP1	-6.43	6.04e-10	5.23e-07	-0.45	-0.37	Multiple sclerosis;	chr22:21938623	chr22:22223187~22224566:-
KIRP	cis	rs748404	0.518	rs2927085	ENSG00000205771.5	CATSPER2P1	-6.43	6.05e-10	5.24e-07	-0.43	-0.37	Lung cancer;	chr15:43697332	chr15:43726918~43747094:-
KIRP	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-6.43	6.06e-10	5.25e-07	-0.43	-0.37	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
KIRP	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-6.43	6.06e-10	5.25e-07	-0.46	-0.37	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
KIRP	cis	rs17082664	1	rs17082664	ENSG00000226193.1	RP3-398G3.5	-6.43	6.1e-10	5.28e-07	-0.53	-0.37	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152417619	chr6:152402398~152404966:+
KIRP	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-6.43	6.11e-10	5.29e-07	-0.44	-0.37	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
KIRP	cis	rs7267979	0.903	rs6050481	ENSG00000274414.1	RP5-965G21.4	-6.43	6.12e-10	5.29e-07	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.834	rs6115100	ENSG00000274414.1	RP5-965G21.4	-6.43	6.12e-10	5.29e-07	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25239007~25245229:-
KIRP	cis	rs755249	0.567	rs113214136	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs3768302	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.532	rs17343193	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs61779300	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs2018212	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs4660751	ENSG00000237624.1	OXCT2P1	6.43	6.12e-10	5.29e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39514956~39516490:+
KIRP	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-6.43	6.12e-10	5.29e-07	-0.42	-0.37	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
KIRP	cis	rs4638749	0.677	rs12475343	ENSG00000225328.1	AC019100.3	-6.43	6.12e-10	5.29e-07	-0.45	-0.37	Blood pressure;	chr2:108234917	chr2:108167748~108217841:-
KIRP	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	6.43	6.13e-10	5.3e-07	0.45	0.37	Height;	chr11:118852670	chr11:118688039~118690600:-
KIRP	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-6.43	6.14e-10	5.3e-07	-0.43	-0.37	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
KIRP	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	6.43	6.14e-10	5.31e-07	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
KIRP	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	6.43	6.14e-10	5.31e-07	0.45	0.37	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
KIRP	cis	rs4128705	0.92	rs72880824	ENSG00000249049.1	RP11-763F8.1	6.43	6.15e-10	5.31e-07	0.33	0.37	Amyotrophic lateral sclerosis (sporadic);	chr4:91358643	chr4:91319034~91325306:-
KIRP	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-6.43	6.17e-10	5.33e-07	-0.3	-0.37	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
KIRP	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-6.43	6.17e-10	5.33e-07	-0.48	-0.37	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
KIRP	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-6.43	6.17e-10	5.33e-07	-0.48	-0.37	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	6.43	6.18e-10	5.34e-07	0.49	0.37	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
KIRP	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-6.42	6.21e-10	5.36e-07	-0.43	-0.37	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
KIRP	cis	rs755249	0.567	rs61779284	ENSG00000237624.1	OXCT2P1	6.42	6.24e-10	5.39e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39514956~39516490:+
KIRP	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-6.42	6.27e-10	5.41e-07	-0.37	-0.37	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
KIRP	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-6.42	6.27e-10	5.41e-07	-0.37	-0.37	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
KIRP	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-6.42	6.27e-10	5.41e-07	-0.45	-0.37	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
KIRP	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	6.42	6.3e-10	5.43e-07	0.45	0.37	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
KIRP	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	6.42	6.3e-10	5.43e-07	0.49	0.37	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
KIRP	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	6.42	6.31e-10	5.44e-07	0.3	0.37	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
KIRP	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-6.42	6.32e-10	5.44e-07	-0.28	-0.37	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
KIRP	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-6.42	6.33e-10	5.45e-07	-0.43	-0.37	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
KIRP	cis	rs2625529	0.73	rs982752	ENSG00000260037.4	CTD-2524L6.3	-6.42	6.33e-10	5.45e-07	-0.29	-0.37	Red blood cell count;	chr15:71853596	chr15:71818396~71823384:+
KIRP	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	6.42	6.33e-10	5.45e-07	0.43	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
KIRP	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	6.42	6.35e-10	5.47e-07	0.46	0.37	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
KIRP	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	6.42	6.36e-10	5.47e-07	0.42	0.37	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
KIRP	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.42	6.37e-10	5.48e-07	0.31	0.37	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	6.42	6.37e-10	5.48e-07	0.31	0.37	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
KIRP	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-6.42	6.37e-10	5.48e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
KIRP	cis	rs755249	0.567	rs3118014	ENSG00000237624.1	OXCT2P1	6.42	6.37e-10	5.48e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39514956~39516490:+
KIRP	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	6.42	6.38e-10	5.49e-07	0.33	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
KIRP	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	6.42	6.39e-10	5.5e-07	0.5	0.37	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
KIRP	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	6.42	6.4e-10	5.5e-07	0.37	0.37	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
KIRP	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-6.42	6.4e-10	5.51e-07	-0.3	-0.37	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
KIRP	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	6.42	6.42e-10	5.52e-07	0.59	0.37	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
KIRP	cis	rs7829975	0.514	rs2945873	ENSG00000253981.4	ALG1L13P	6.42	6.45e-10	5.55e-07	0.3	0.37	Mood instability;	chr8:8402935	chr8:8236003~8244667:-
KIRP	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-6.42	6.47e-10	5.57e-07	-0.48	-0.37	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-6.42	6.47e-10	5.57e-07	-0.29	-0.37	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
KIRP	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-6.42	6.48e-10	5.57e-07	-0.48	-0.37	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
KIRP	cis	rs2283792	0.765	rs9607241	ENSG00000224086.5	LL22NC03-86G7.1	-6.42	6.49e-10	5.58e-07	-0.3	-0.37	Multiple sclerosis;	chr22:21750584	chr22:21938293~21977632:+
KIRP	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-6.42	6.5e-10	5.59e-07	-0.45	-0.37	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
KIRP	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.42	6.5e-10	5.59e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
KIRP	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-6.42	6.5e-10	5.59e-07	-0.31	-0.37	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
KIRP	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-6.42	6.51e-10	5.59e-07	-0.31	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
KIRP	cis	rs79349575	0.749	rs519537	ENSG00000248278.1	SUMO2P17	6.42	6.53e-10	5.61e-07	0.42	0.37	Type 2 diabetes;	chr17:48893778	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs832410	ENSG00000248278.1	SUMO2P17	6.42	6.53e-10	5.61e-07	0.42	0.37	Type 2 diabetes;	chr17:48895503	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs318095	ENSG00000248278.1	SUMO2P17	6.42	6.53e-10	5.61e-07	0.42	0.37	Type 2 diabetes;	chr17:48897372	chr17:48874860~48908983:-
KIRP	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-6.42	6.53e-10	5.61e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
KIRP	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.42	6.53e-10	5.61e-07	0.44	0.37	Depression;	chr6:28167882	chr6:28115628~28116551:+
KIRP	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-6.42	6.53e-10	5.61e-07	-0.46	-0.37	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
KIRP	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-6.42	6.53e-10	5.61e-07	-0.37	-0.37	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
KIRP	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-6.42	6.54e-10	5.62e-07	-0.3	-0.37	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
KIRP	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-6.41	6.55e-10	5.62e-07	-0.37	-0.37	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
KIRP	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	6.41	6.55e-10	5.63e-07	0.47	0.37	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	6.41	6.55e-10	5.63e-07	0.47	0.37	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	6.41	6.55e-10	5.63e-07	0.47	0.37	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
KIRP	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	6.41	6.56e-10	5.64e-07	0.49	0.37	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
KIRP	cis	rs755249	0.565	rs722357	ENSG00000237624.1	OXCT2P1	-6.41	6.57e-10	5.64e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39514956~39516490:+
KIRP	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-6.41	6.57e-10	5.64e-07	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-6.41	6.57e-10	5.64e-07	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.41	6.57e-10	5.64e-07	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.41	6.57e-10	5.64e-07	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
KIRP	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-6.41	6.58e-10	5.65e-07	-0.44	-0.37	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
KIRP	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-6.41	6.58e-10	5.65e-07	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-6.41	6.58e-10	5.65e-07	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-6.41	6.58e-10	5.65e-07	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
KIRP	cis	rs2625529	0.503	rs7162299	ENSG00000260037.4	CTD-2524L6.3	6.41	6.59e-10	5.65e-07	0.29	0.37	Red blood cell count;	chr15:72121724	chr15:71818396~71823384:+
KIRP	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.41	6.6e-10	5.66e-07	-0.49	-0.37	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
KIRP	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	6.41	6.64e-10	5.7e-07	0.74	0.37	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
KIRP	cis	rs755249	0.567	rs61779285	ENSG00000237624.1	OXCT2P1	6.41	6.64e-10	5.7e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs3768301	ENSG00000237624.1	OXCT2P1	6.41	6.64e-10	5.7e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39514956~39516490:+
KIRP	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	6.41	6.65e-10	5.7e-07	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
KIRP	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-6.41	6.65e-10	5.7e-07	-0.38	-0.37	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
KIRP	cis	rs755249	0.532	rs61779277	ENSG00000237624.1	OXCT2P1	6.41	6.67e-10	5.72e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.532	rs61779278	ENSG00000237624.1	OXCT2P1	6.41	6.67e-10	5.72e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs2296172	ENSG00000237624.1	OXCT2P1	6.41	6.67e-10	5.72e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs61779279	ENSG00000237624.1	OXCT2P1	6.41	6.67e-10	5.72e-07	0.58	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	6.41	6.67e-10	5.72e-07	0.49	0.37	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	6.41	6.67e-10	5.72e-07	0.49	0.37	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	6.41	6.67e-10	5.72e-07	0.49	0.37	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	6.41	6.67e-10	5.72e-07	0.49	0.37	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	6.41	6.68e-10	5.72e-07	0.45	0.37	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
KIRP	cis	rs2283792	1	rs2283792	ENSG00000228050.1	TOP3BP1	6.41	6.68e-10	5.73e-07	0.4	0.37	Multiple sclerosis;	chr22:21776836	chr22:22223187~22224566:-
KIRP	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	6.41	6.68e-10	5.73e-07	0.3	0.37	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	6.41	6.68e-10	5.73e-07	0.31	0.37	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
KIRP	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	6.41	6.68e-10	5.73e-07	0.77	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	6.41	6.7e-10	5.74e-07	0.49	0.37	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	6.41	6.71e-10	5.75e-07	0.45	0.37	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
KIRP	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	6.41	6.73e-10	5.77e-07	0.28	0.37	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
KIRP	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-6.41	6.74e-10	5.77e-07	-0.45	-0.37	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
KIRP	cis	rs4356975	0.509	rs4587017	ENSG00000248763.2	RP13-644M16.5	-6.41	6.75e-10	5.78e-07	-0.4	-0.37	Obesity-related traits;	chr4:69081680	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.509	rs6422323	ENSG00000248763.2	RP13-644M16.5	-6.41	6.75e-10	5.78e-07	-0.4	-0.37	Obesity-related traits;	chr4:69087362	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.509	rs4694169	ENSG00000248763.2	RP13-644M16.5	-6.41	6.75e-10	5.78e-07	-0.4	-0.37	Obesity-related traits;	chr4:69088433	chr4:69066395~69069888:+
KIRP	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.41	6.75e-10	5.78e-07	0.31	0.37	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
KIRP	cis	rs2765539	1	rs2765539	ENSG00000231365.4	RP11-418J17.1	-6.41	6.75e-10	5.78e-07	-0.41	-0.37	Waist-hip ratio;	chr1:119006795	chr1:119140396~119275973:+
KIRP	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-6.41	6.75e-10	5.78e-07	-0.39	-0.37	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-6.41	6.75e-10	5.78e-07	-0.39	-0.37	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
KIRP	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	6.41	6.77e-10	5.8e-07	0.28	0.37	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
KIRP	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.41	6.79e-10	5.81e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
KIRP	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	6.41	6.8e-10	5.82e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
KIRP	cis	rs4356975	0.509	rs4458521	ENSG00000248763.2	RP13-644M16.5	-6.41	6.8e-10	5.82e-07	-0.4	-0.37	Obesity-related traits;	chr4:69086240	chr4:69066395~69069888:+
KIRP	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	6.41	6.82e-10	5.84e-07	0.41	0.37	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
KIRP	cis	rs755249	0.565	rs12138051	ENSG00000237624.1	OXCT2P1	-6.41	6.83e-10	5.84e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.564	rs6691194	ENSG00000237624.1	OXCT2P1	-6.41	6.83e-10	5.84e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39514956~39516490:+
KIRP	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-6.41	6.9e-10	5.9e-07	-0.51	-0.37	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-6.41	6.9e-10	5.9e-07	-0.51	-0.37	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-6.41	6.9e-10	5.9e-07	-0.51	-0.37	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
KIRP	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	6.41	6.91e-10	5.91e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
KIRP	cis	rs9532669	0.926	rs4941995	ENSG00000239827.7	SUGT1P3	-6.4	6.94e-10	5.93e-07	-0.42	-0.37	Cervical cancer;	chr13:40850117	chr13:40908159~40921774:-
KIRP	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-6.4	6.97e-10	5.95e-07	-0.32	-0.37	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
KIRP	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-6.4	6.97e-10	5.95e-07	-0.3	-0.37	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-6.4	6.97e-10	5.95e-07	-0.3	-0.37	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
KIRP	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-6.4	6.98e-10	5.96e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
KIRP	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-6.4	6.98e-10	5.96e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
KIRP	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-6.4	7.05e-10	6.01e-07	-0.5	-0.37	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
KIRP	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	6.4	7.07e-10	6.03e-07	0.64	0.37	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
KIRP	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	6.4	7.1e-10	6.05e-07	0.25	0.37	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
KIRP	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	6.4	7.11e-10	6.06e-07	0.31	0.37	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
KIRP	cis	rs79349575	0.783	rs318096	ENSG00000248278.1	SUMO2P17	6.4	7.11e-10	6.06e-07	0.42	0.37	Type 2 diabetes;	chr17:48898008	chr17:48874860~48908983:-
KIRP	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	6.4	7.13e-10	6.08e-07	0.29	0.37	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
KIRP	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-6.4	7.13e-10	6.08e-07	-0.49	-0.37	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
KIRP	cis	rs4356975	0.932	rs4694604	ENSG00000196472.4	RP13-644M16.4	6.4	7.16e-10	6.1e-07	0.42	0.37	Obesity-related traits;	chr4:69072745	chr4:69181660~69182372:+
KIRP	cis	rs4638749	0.734	rs6722745	ENSG00000231221.1	AC023672.2	6.4	7.16e-10	6.1e-07	0.45	0.37	Blood pressure;	chr2:108258788	chr2:108049200~108052755:-
KIRP	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.4	7.16e-10	6.1e-07	0.51	0.37	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
KIRP	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-6.4	7.17e-10	6.11e-07	-0.34	-0.37	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
KIRP	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-6.4	7.17e-10	6.11e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
KIRP	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	6.4	7.19e-10	6.13e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
KIRP	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-6.4	7.19e-10	6.13e-07	-0.77	-0.37	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
KIRP	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	6.4	7.2e-10	6.14e-07	0.27	0.37	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	6.4	7.22e-10	6.15e-07	0.53	0.37	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
KIRP	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-6.4	7.22e-10	6.15e-07	-0.31	-0.37	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
KIRP	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	6.4	7.22e-10	6.15e-07	0.88	0.37	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
KIRP	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	6.4	7.22e-10	6.15e-07	0.88	0.37	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
KIRP	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	6.4	7.22e-10	6.15e-07	0.88	0.37	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
KIRP	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	6.4	7.24e-10	6.17e-07	0.47	0.37	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	6.4	7.24e-10	6.17e-07	0.45	0.37	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
KIRP	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-6.4	7.26e-10	6.18e-07	-0.33	-0.37	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
KIRP	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-6.4	7.26e-10	6.18e-07	-0.28	-0.37	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
KIRP	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	6.4	7.28e-10	6.2e-07	0.37	0.37	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	6.4	7.28e-10	6.2e-07	0.37	0.37	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
KIRP	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	6.4	7.31e-10	6.22e-07	0.46	0.37	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
KIRP	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.4	7.31e-10	6.22e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.4	7.31e-10	6.22e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.4	7.31e-10	6.22e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
KIRP	cis	rs755249	0.567	rs61779275	ENSG00000237624.1	OXCT2P1	6.4	7.32e-10	6.23e-07	0.57	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39514956~39516490:+
KIRP	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	6.4	7.32e-10	6.23e-07	0.51	0.37	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
KIRP	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-6.39	7.34e-10	6.25e-07	-0.49	-0.37	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
KIRP	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-6.39	7.35e-10	6.25e-07	-0.73	-0.37	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
KIRP	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.39	7.37e-10	6.26e-07	0.44	0.37	Depression;	chr6:28086929	chr6:28115628~28116551:+
KIRP	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-6.39	7.37e-10	6.27e-07	-0.56	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
KIRP	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	6.39	7.37e-10	6.27e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	6.39	7.37e-10	6.27e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	6.39	7.37e-10	6.27e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	6.39	7.37e-10	6.27e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
KIRP	cis	rs950027	0.572	rs12910764	ENSG00000259433.2	CTD-2651B20.4	6.39	7.41e-10	6.3e-07	0.32	0.37	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45330209~45332634:-
KIRP	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-6.39	7.41e-10	6.3e-07	-0.48	-0.37	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	6.39	7.44e-10	6.32e-07	0.45	0.37	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
KIRP	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	6.39	7.45e-10	6.33e-07	0.31	0.37	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
KIRP	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-6.39	7.49e-10	6.36e-07	-0.42	-0.37	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
KIRP	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-6.39	7.49e-10	6.36e-07	-0.42	-0.37	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
KIRP	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	6.39	7.49e-10	6.36e-07	0.37	0.37	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
KIRP	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	6.39	7.51e-10	6.37e-07	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
KIRP	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-6.39	7.51e-10	6.37e-07	-0.37	-0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
KIRP	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	6.39	7.51e-10	6.37e-07	0.37	0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
KIRP	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.39	7.51e-10	6.37e-07	-0.46	-0.37	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
KIRP	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-6.39	7.52e-10	6.38e-07	-0.36	-0.37	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
KIRP	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	6.39	7.52e-10	6.38e-07	0.31	0.37	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
KIRP	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.39	7.53e-10	6.38e-07	0.34	0.37	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
KIRP	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	6.39	7.56e-10	6.4e-07	0.25	0.37	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
KIRP	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-6.39	7.56e-10	6.41e-07	-0.41	-0.37	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-6.39	7.56e-10	6.41e-07	-0.41	-0.37	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-6.39	7.57e-10	6.42e-07	-0.42	-0.37	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-6.39	7.57e-10	6.42e-07	-0.42	-0.37	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-6.39	7.57e-10	6.42e-07	-0.42	-0.37	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
KIRP	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	6.39	7.57e-10	6.42e-07	0.45	0.37	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
KIRP	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-6.39	7.59e-10	6.43e-07	-0.53	-0.37	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
KIRP	cis	rs79349575	0.783	rs62075838	ENSG00000248278.1	SUMO2P17	6.39	7.59e-10	6.43e-07	0.41	0.37	Type 2 diabetes;	chr17:48919070	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62075839	ENSG00000248278.1	SUMO2P17	6.39	7.59e-10	6.43e-07	0.41	0.37	Type 2 diabetes;	chr17:48919072	chr17:48874860~48908983:-
KIRP	cis	rs72634501	0.716	rs67062906	ENSG00000237624.1	OXCT2P1	6.39	7.6e-10	6.44e-07	0.58	0.37	HDL cholesterol;	chr1:39151018	chr1:39514956~39516490:+
KIRP	cis	rs2625529	0.652	rs8027164	ENSG00000260037.4	CTD-2524L6.3	6.39	7.61e-10	6.45e-07	0.29	0.37	Red blood cell count;	chr15:72115392	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2278987	ENSG00000260037.4	CTD-2524L6.3	6.39	7.61e-10	6.45e-07	0.29	0.37	Red blood cell count;	chr15:72117428	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.586	rs7175197	ENSG00000260037.4	CTD-2524L6.3	6.39	7.61e-10	6.45e-07	0.29	0.37	Red blood cell count;	chr15:72169307	chr15:71818396~71823384:+
KIRP	cis	rs755249	0.835	rs4660877	ENSG00000237624.1	OXCT2P1	6.39	7.62e-10	6.45e-07	0.57	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613574	chr1:39514956~39516490:+
KIRP	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-6.39	7.62e-10	6.46e-07	-0.34	-0.37	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
KIRP	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	6.39	7.62e-10	6.46e-07	0.45	0.37	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
KIRP	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	6.39	7.63e-10	6.47e-07	0.43	0.37	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
KIRP	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-6.39	7.64e-10	6.47e-07	-0.62	-0.37	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
KIRP	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	6.39	7.65e-10	6.48e-07	0.81	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
KIRP	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-6.39	7.65e-10	6.48e-07	-0.31	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
KIRP	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	6.39	7.67e-10	6.49e-07	0.53	0.37	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
KIRP	cis	rs4356975	0.932	rs7692377	ENSG00000196472.4	RP13-644M16.4	6.39	7.7e-10	6.51e-07	0.41	0.37	Obesity-related traits;	chr4:69078113	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs61612343	ENSG00000196472.4	RP13-644M16.4	6.39	7.7e-10	6.51e-07	0.41	0.37	Obesity-related traits;	chr4:69078247	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7679418	ENSG00000196472.4	RP13-644M16.4	6.39	7.7e-10	6.51e-07	0.41	0.37	Obesity-related traits;	chr4:69078533	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7680156	ENSG00000196472.4	RP13-644M16.4	6.39	7.7e-10	6.51e-07	0.41	0.37	Obesity-related traits;	chr4:69078868	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs7698430	ENSG00000196472.4	RP13-644M16.4	6.39	7.7e-10	6.51e-07	0.41	0.37	Obesity-related traits;	chr4:69078897	chr4:69181660~69182372:+
KIRP	cis	rs893363	0.539	rs3774614	ENSG00000271916.1	RP11-884K10.6	-6.39	7.7e-10	6.51e-07	-0.34	-0.37	Axial length;	chr3:53807437	chr3:53797764~53798019:-
KIRP	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	6.39	7.71e-10	6.52e-07	0.3	0.37	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	6.39	7.71e-10	6.52e-07	0.3	0.37	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	6.39	7.71e-10	6.52e-07	0.3	0.37	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
KIRP	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-6.39	7.72e-10	6.53e-07	-0.48	-0.37	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
KIRP	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-6.39	7.73e-10	6.54e-07	-0.42	-0.37	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-6.39	7.73e-10	6.54e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
KIRP	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-6.39	7.73e-10	6.54e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
KIRP	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-6.39	7.73e-10	6.54e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
KIRP	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-6.39	7.73e-10	6.54e-07	-0.36	-0.37	Height;	chr11:118703185	chr11:118704607~118750263:+
KIRP	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-6.39	7.73e-10	6.54e-07	-0.36	-0.37	Height;	chr11:118703207	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-6.39	7.73e-10	6.54e-07	-0.36	-0.37	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
KIRP	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-6.39	7.73e-10	6.54e-07	-0.36	-0.37	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
KIRP	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	6.39	7.74e-10	6.54e-07	0.3	0.37	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
KIRP	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	6.39	7.74e-10	6.55e-07	0.49	0.37	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
KIRP	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.38	7.76e-10	6.56e-07	0.31	0.37	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
KIRP	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-6.38	7.77e-10	6.57e-07	-0.42	-0.37	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
KIRP	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	6.38	7.78e-10	6.57e-07	0.48	0.37	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	6.38	7.78e-10	6.58e-07	0.44	0.37	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	6.38	7.78e-10	6.58e-07	0.44	0.37	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	6.38	7.78e-10	6.58e-07	0.44	0.37	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	6.38	7.78e-10	6.58e-07	0.44	0.37	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
KIRP	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	6.38	7.78e-10	6.58e-07	0.4	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
KIRP	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	6.38	7.79e-10	6.58e-07	0.5	0.37	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
KIRP	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	6.38	7.79e-10	6.58e-07	0.39	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
KIRP	cis	rs2625529	0.529	rs7183055	ENSG00000260037.4	CTD-2524L6.3	6.38	7.79e-10	6.58e-07	0.29	0.37	Red blood cell count;	chr15:72084707	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	6.38	7.79e-10	6.58e-07	0.46	0.37	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	6.38	7.79e-10	6.58e-07	0.46	0.37	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	6.38	7.79e-10	6.58e-07	0.46	0.37	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
KIRP	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	6.38	7.8e-10	6.59e-07	0.38	0.37	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
KIRP	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-6.38	7.81e-10	6.6e-07	-0.33	-0.37	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
KIRP	cis	rs4936099	0.897	rs11222084	ENSG00000175773.11	RP11-121M22.1	-6.38	7.82e-10	6.6e-07	-0.37	-0.37	Optic cup area;Vertical cup-disc ratio;	chr11:130403335	chr11:130314993~130403657:+
KIRP	cis	rs2439831	0.702	rs3784275	ENSG00000249839.1	AC011330.5	-6.38	7.83e-10	6.61e-07	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43799188	chr15:43663654~43684339:-
KIRP	cis	rs2625529	0.73	rs4777485	ENSG00000260037.4	CTD-2524L6.3	-6.38	7.84e-10	6.62e-07	-0.31	-0.37	Red blood cell count;	chr15:72097043	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2929518	ENSG00000260037.4	CTD-2524L6.3	6.38	7.84e-10	6.62e-07	0.29	0.37	Red blood cell count;	chr15:72040407	chr15:71818396~71823384:+
KIRP	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-6.38	7.85e-10	6.63e-07	-0.31	-0.37	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
KIRP	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-6.38	7.86e-10	6.63e-07	-0.43	-0.37	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
KIRP	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	6.38	7.86e-10	6.64e-07	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
KIRP	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-6.38	7.87e-10	6.64e-07	-0.45	-0.37	Depression;	chr6:28140307	chr6:28115628~28116551:+
KIRP	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	6.38	7.87e-10	6.64e-07	0.37	0.37	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
KIRP	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-6.38	7.88e-10	6.65e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
KIRP	cis	rs67311347	0.955	rs4973999	ENSG00000230274.1	PGAM1P3	6.38	7.9e-10	6.66e-07	0.35	0.37	Renal cell carcinoma;	chr3:40418892	chr3:40322715~40323279:-
KIRP	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.38	7.9e-10	6.67e-07	-0.31	-0.37	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
KIRP	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	6.38	7.94e-10	6.7e-07	0.47	0.37	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
KIRP	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	6.38	7.95e-10	6.7e-07	0.37	0.37	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	6.38	7.95e-10	6.7e-07	0.49	0.37	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
KIRP	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.38	7.97e-10	6.72e-07	-0.44	-0.37	Depression;	chr6:28091242	chr6:28115628~28116551:+
KIRP	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.38	7.97e-10	6.72e-07	-0.31	-0.37	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.38	7.97e-10	6.72e-07	-0.31	-0.37	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
KIRP	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-6.38	7.98e-10	6.73e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
KIRP	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	6.38	7.99e-10	6.73e-07	0.28	0.37	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
KIRP	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	6.38	8.02e-10	6.76e-07	0.41	0.37	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
KIRP	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-6.38	8.02e-10	6.76e-07	-0.41	-0.37	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
KIRP	cis	rs79349575	0.749	rs46521	ENSG00000248278.1	SUMO2P17	6.38	8.02e-10	6.76e-07	0.41	0.37	Type 2 diabetes;	chr17:48911167	chr17:48874860~48908983:-
KIRP	cis	rs13423976	0.663	rs7559097	ENSG00000231367.4	AC016995.3	-6.38	8.03e-10	6.76e-07	-0.48	-0.37	Gut microbiome composition (summer);	chr2:38517625	chr2:38406719~38515740:-
KIRP	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	6.38	8.03e-10	6.77e-07	0.25	0.37	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
KIRP	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	6.38	8.05e-10	6.78e-07	0.37	0.37	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
KIRP	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-6.38	8.05e-10	6.78e-07	-0.44	-0.37	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
KIRP	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-6.38	8.05e-10	6.78e-07	-0.28	-0.37	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
KIRP	cis	rs2749592	0.531	rs1208559	ENSG00000151963.4	RP11-775A3.1	6.38	8.06e-10	6.78e-07	0.44	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:37883594~37884109:+
KIRP	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-6.38	8.06e-10	6.78e-07	-0.5	-0.37	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
KIRP	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.38	8.06e-10	6.79e-07	-0.47	-0.37	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
KIRP	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-6.38	8.06e-10	6.79e-07	-0.3	-0.37	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
KIRP	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-6.38	8.06e-10	6.79e-07	-0.32	-0.37	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
KIRP	cis	rs9532669	0.926	rs8002809	ENSG00000239827.7	SUGT1P3	-6.38	8.07e-10	6.8e-07	-0.41	-0.37	Cervical cancer;	chr13:40872769	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.929	rs7982421	ENSG00000239827.7	SUGT1P3	-6.38	8.07e-10	6.8e-07	-0.41	-0.37	Cervical cancer;	chr13:40872776	chr13:40908159~40921774:-
KIRP	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	6.38	8.08e-10	6.81e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
KIRP	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.38	8.09e-10	6.81e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.38	8.09e-10	6.81e-07	-0.33	-0.37	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
KIRP	cis	rs13423976	0.586	rs12617556	ENSG00000231367.4	AC016995.3	6.38	8.1e-10	6.82e-07	0.49	0.37	Gut microbiome composition (summer);	chr2:38514972	chr2:38406719~38515740:-
KIRP	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	6.38	8.1e-10	6.82e-07	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
KIRP	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.38	8.11e-10	6.82e-07	-0.47	-0.37	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
KIRP	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	6.38	8.13e-10	6.84e-07	0.29	0.37	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
KIRP	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	6.38	8.14e-10	6.84e-07	0.3	0.37	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	6.38	8.14e-10	6.84e-07	0.3	0.37	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
KIRP	cis	rs4638749	0.501	rs9917181	ENSG00000225328.1	AC019100.3	-6.38	8.15e-10	6.86e-07	-0.43	-0.37	Blood pressure;	chr2:108131409	chr2:108167748~108217841:-
KIRP	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-6.38	8.16e-10	6.86e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
KIRP	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	6.38	8.17e-10	6.87e-07	0.46	0.37	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
KIRP	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-6.38	8.2e-10	6.89e-07	-0.3	-0.37	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
KIRP	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-6.38	8.2e-10	6.89e-07	-0.3	-0.37	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
KIRP	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-6.38	8.2e-10	6.89e-07	-0.3	-0.37	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
KIRP	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	6.38	8.2e-10	6.89e-07	0.44	0.37	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	6.38	8.2e-10	6.89e-07	0.44	0.37	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	6.38	8.2e-10	6.89e-07	0.44	0.37	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	6.38	8.2e-10	6.89e-07	0.44	0.37	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
KIRP	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	6.38	8.21e-10	6.9e-07	0.42	0.37	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
KIRP	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.37	8.22e-10	6.91e-07	-0.38	-0.37	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
KIRP	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-6.37	8.22e-10	6.91e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
KIRP	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-6.37	8.22e-10	6.91e-07	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
KIRP	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	6.37	8.24e-10	6.93e-07	0.5	0.37	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.932	rs72852450	ENSG00000196472.4	RP13-644M16.4	6.37	8.25e-10	6.93e-07	0.41	0.37	Obesity-related traits;	chr4:69079704	chr4:69181660~69182372:+
KIRP	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	6.37	8.26e-10	6.94e-07	0.37	0.37	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	6.37	8.27e-10	6.95e-07	0.44	0.37	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
KIRP	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	6.37	8.28e-10	6.96e-07	0.41	0.37	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
KIRP	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	6.37	8.28e-10	6.96e-07	0.45	0.37	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
KIRP	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-6.37	8.29e-10	6.97e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
KIRP	cis	rs13423976	0.6	rs2373404	ENSG00000231367.4	AC016995.3	6.37	8.29e-10	6.97e-07	0.48	0.37	Gut microbiome composition (summer);	chr2:38512959	chr2:38406719~38515740:-
KIRP	cis	rs13423976	0.631	rs2373405	ENSG00000231367.4	AC016995.3	6.37	8.29e-10	6.97e-07	0.48	0.37	Gut microbiome composition (summer);	chr2:38513072	chr2:38406719~38515740:-
KIRP	cis	rs13423976	0.546	rs10184164	ENSG00000231367.4	AC016995.3	6.37	8.29e-10	6.97e-07	0.48	0.37	Gut microbiome composition (summer);	chr2:38514411	chr2:38406719~38515740:-
KIRP	cis	rs9532669	0.89	rs35396630	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863135	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4942001	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863176	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4942003	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863270	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs4942004	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863598	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9315791	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863931	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.824	rs9315792	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40863951	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.684	rs7139788	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40864264	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7338617	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40870787	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.857	rs6560961	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40870878	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs6560962	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40870948	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs1055588	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40871306	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs3610	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40871334	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4942006	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40871862	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4942008	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40871989	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs2039118	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40872260	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4356347	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40872516	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7982346	ENSG00000239827.7	SUGT1P3	-6.37	8.3e-10	6.97e-07	-0.41	-0.37	Cervical cancer;	chr13:40873273	chr13:40908159~40921774:-
KIRP	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	6.37	8.3e-10	6.97e-07	0.3	0.37	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	6.37	8.3e-10	6.97e-07	0.3	0.37	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
KIRP	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-6.37	8.32e-10	6.98e-07	-0.3	-0.37	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
KIRP	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	6.37	8.32e-10	6.98e-07	0.3	0.37	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
KIRP	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	6.37	8.34e-10	7e-07	0.45	0.37	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	6.37	8.36e-10	7.01e-07	0.49	0.37	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
KIRP	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	6.37	8.36e-10	7.01e-07	0.54	0.37	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
KIRP	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-6.37	8.42e-10	7.06e-07	-0.62	-0.37	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
KIRP	cis	rs9532669	0.824	rs4941998	ENSG00000239827.7	SUGT1P3	-6.37	8.44e-10	7.07e-07	-0.41	-0.37	Cervical cancer;	chr13:40859901	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.75	rs9532598	ENSG00000239827.7	SUGT1P3	-6.37	8.44e-10	7.07e-07	-0.41	-0.37	Cervical cancer;	chr13:40860627	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.611	rs9532599	ENSG00000239827.7	SUGT1P3	-6.37	8.44e-10	7.07e-07	-0.41	-0.37	Cervical cancer;	chr13:40860633	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.571	rs9525405	ENSG00000239827.7	SUGT1P3	-6.37	8.44e-10	7.07e-07	-0.41	-0.37	Cervical cancer;	chr13:40860638	chr13:40908159~40921774:-
KIRP	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	6.37	8.45e-10	7.08e-07	0.38	0.37	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
KIRP	cis	rs9532669	0.857	rs9525427	ENSG00000239827.7	SUGT1P3	-6.37	8.47e-10	7.1e-07	-0.41	-0.37	Cervical cancer;	chr13:40918029	chr13:40908159~40921774:-
KIRP	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	6.37	8.48e-10	7.11e-07	0.59	0.37	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
KIRP	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	6.37	8.48e-10	7.11e-07	0.46	0.37	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
KIRP	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	6.37	8.49e-10	7.11e-07	0.59	0.37	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
KIRP	cis	rs10872587	0.555	rs2265470	ENSG00000235652.6	RP11-545I5.3	6.37	8.51e-10	7.12e-07	0.44	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145898096	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	6.37	8.51e-10	7.13e-07	0.43	0.37	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
KIRP	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-6.37	8.53e-10	7.14e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
KIRP	cis	rs67311347	1	rs7642906	ENSG00000230274.1	PGAM1P3	-6.37	8.54e-10	7.15e-07	-0.36	-0.37	Renal cell carcinoma;	chr3:40451142	chr3:40322715~40323279:-
KIRP	cis	rs755249	0.567	rs76111861	ENSG00000237624.1	OXCT2P1	6.37	8.55e-10	7.16e-07	0.57	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.567	rs72661965	ENSG00000237624.1	OXCT2P1	6.37	8.55e-10	7.16e-07	0.57	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39514956~39516490:+
KIRP	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-6.37	8.57e-10	7.17e-07	-0.33	-0.37	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
KIRP	cis	rs2749592	0.918	rs11011388	ENSG00000151963.4	RP11-775A3.1	6.37	8.58e-10	7.18e-07	0.46	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr10:37866282	chr10:37883594~37884109:+
KIRP	cis	rs2625529	0.652	rs2929532	ENSG00000260037.4	CTD-2524L6.3	6.37	8.58e-10	7.18e-07	0.29	0.37	Red blood cell count;	chr15:72052769	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.617	rs2957365	ENSG00000260037.4	CTD-2524L6.3	6.37	8.58e-10	7.18e-07	0.29	0.37	Red blood cell count;	chr15:72055765	chr15:71818396~71823384:+
KIRP	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-6.37	8.58e-10	7.18e-07	-0.59	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
KIRP	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-6.37	8.58e-10	7.18e-07	-0.45	-0.37	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
KIRP	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	6.37	8.59e-10	7.19e-07	0.43	0.37	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
KIRP	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	6.37	8.6e-10	7.19e-07	0.35	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
KIRP	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	6.37	8.6e-10	7.19e-07	0.35	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
KIRP	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	6.37	8.6e-10	7.19e-07	0.35	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
KIRP	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-6.37	8.62e-10	7.21e-07	-0.57	-0.37	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
KIRP	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	6.37	8.62e-10	7.21e-07	0.36	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.89	rs7333274	ENSG00000239827.7	SUGT1P3	-6.37	8.62e-10	7.21e-07	-0.41	-0.37	Cervical cancer;	chr13:40862531	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs2324737	ENSG00000239827.7	SUGT1P3	-6.37	8.62e-10	7.21e-07	-0.41	-0.37	Cervical cancer;	chr13:40862808	chr13:40908159~40921774:-
KIRP	cis	rs2281558	0.917	rs3787080	ENSG00000274414.1	RP5-965G21.4	-6.37	8.63e-10	7.22e-07	-0.43	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:25239007~25245229:-
KIRP	cis	rs2281558	1	rs2281558	ENSG00000274414.1	RP5-965G21.4	-6.37	8.63e-10	7.22e-07	-0.43	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:25239007~25245229:-
KIRP	cis	rs2283792	0.846	rs240051	ENSG00000228050.1	TOP3BP1	6.37	8.65e-10	7.24e-07	0.39	0.37	Multiple sclerosis;	chr22:21909763	chr22:22223187~22224566:-
KIRP	cis	rs2283792	0.846	rs240053	ENSG00000228050.1	TOP3BP1	6.37	8.65e-10	7.24e-07	0.39	0.37	Multiple sclerosis;	chr22:21911000	chr22:22223187~22224566:-
KIRP	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-6.37	8.67e-10	7.25e-07	-0.3	-0.37	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
KIRP	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	6.36	8.7e-10	7.27e-07	0.44	0.37	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.932	rs4694611	ENSG00000196472.4	RP13-644M16.4	6.36	8.71e-10	7.28e-07	0.41	0.37	Obesity-related traits;	chr4:69079387	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.932	rs4694612	ENSG00000196472.4	RP13-644M16.4	6.36	8.71e-10	7.28e-07	0.41	0.37	Obesity-related traits;	chr4:69079446	chr4:69181660~69182372:+
KIRP	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-6.36	8.72e-10	7.29e-07	-0.39	-0.37	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
KIRP	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-6.36	8.72e-10	7.29e-07	-0.39	-0.37	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
KIRP	cis	rs4356975	0.932	rs56879009	ENSG00000196472.4	RP13-644M16.4	6.36	8.73e-10	7.29e-07	0.41	0.37	Obesity-related traits;	chr4:69079589	chr4:69181660~69182372:+
KIRP	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-6.36	8.73e-10	7.29e-07	-0.38	-0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
KIRP	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	6.36	8.74e-10	7.3e-07	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	6.36	8.74e-10	7.3e-07	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
KIRP	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	6.36	8.74e-10	7.3e-07	0.3	0.37	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	6.36	8.74e-10	7.3e-07	0.3	0.37	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
KIRP	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-6.36	8.76e-10	7.31e-07	-0.48	-0.37	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
KIRP	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	6.36	8.77e-10	7.32e-07	0.3	0.37	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
KIRP	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-6.36	8.78e-10	7.33e-07	-0.33	-0.37	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
KIRP	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-6.36	8.79e-10	7.34e-07	-0.3	-0.37	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
KIRP	cis	rs7829975	0.774	rs35039922	ENSG00000253981.4	ALG1L13P	6.36	8.82e-10	7.36e-07	0.29	0.37	Mood instability;	chr8:8817815	chr8:8236003~8244667:-
KIRP	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	6.36	8.83e-10	7.37e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	6.36	8.83e-10	7.37e-07	0.51	0.37	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
KIRP	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	6.36	8.84e-10	7.37e-07	0.46	0.37	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
KIRP	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	6.36	8.85e-10	7.38e-07	0.45	0.37	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
KIRP	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-6.36	8.86e-10	7.39e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
KIRP	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-6.36	8.86e-10	7.39e-07	-0.4	-0.37	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
KIRP	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-6.36	8.87e-10	7.4e-07	-0.5	-0.37	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-6.36	8.87e-10	7.4e-07	-0.5	-0.37	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
KIRP	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	6.36	8.87e-10	7.4e-07	0.58	0.37	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
KIRP	cis	rs4356975	0.932	rs7662632	ENSG00000196472.4	RP13-644M16.4	6.36	8.87e-10	7.4e-07	0.42	0.37	Obesity-related traits;	chr4:69062256	chr4:69181660~69182372:+
KIRP	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	6.36	8.87e-10	7.4e-07	0.43	0.37	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
KIRP	cis	rs748404	0.578	rs2244746	ENSG00000249839.1	AC011330.5	-6.36	8.88e-10	7.4e-07	-0.39	-0.37	Lung cancer;	chr15:43402885	chr15:43663654~43684339:-
KIRP	cis	rs755249	0.588	rs2275767	ENSG00000237624.1	OXCT2P1	-6.36	8.88e-10	7.4e-07	-0.47	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39514956~39516490:+
KIRP	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	6.36	8.88e-10	7.41e-07	0.45	0.37	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	6.36	8.89e-10	7.41e-07	0.46	0.37	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
KIRP	cis	rs67311347	1	rs9332450	ENSG00000230274.1	PGAM1P3	-6.36	8.92e-10	7.43e-07	-0.35	-0.37	Renal cell carcinoma;	chr3:40416550	chr3:40322715~40323279:-
KIRP	cis	rs9371601	0.892	rs9397518	ENSG00000226193.1	RP3-398G3.5	-6.36	8.92e-10	7.44e-07	-0.4	-0.37	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152489586	chr6:152402398~152404966:+
KIRP	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	6.36	8.93e-10	7.45e-07	0.28	0.37	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	6.36	8.94e-10	7.45e-07	0.44	0.37	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
KIRP	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	6.36	8.94e-10	7.45e-07	0.39	0.37	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
KIRP	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	6.36	8.97e-10	7.48e-07	0.49	0.37	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
KIRP	cis	rs7474896	0.583	rs1208770	ENSG00000151963.4	RP11-775A3.1	-6.36	8.99e-10	7.49e-07	-0.48	-0.37	Obesity (extreme);	chr10:37755755	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.526	rs1742235	ENSG00000151963.4	RP11-775A3.1	-6.36	8.99e-10	7.49e-07	-0.48	-0.37	Obesity (extreme);	chr10:37763328	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.559	rs1208779	ENSG00000151963.4	RP11-775A3.1	-6.36	8.99e-10	7.49e-07	-0.48	-0.37	Obesity (extreme);	chr10:37788801	chr10:37883594~37884109:+
KIRP	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-6.36	8.99e-10	7.49e-07	-0.42	-0.37	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
KIRP	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-6.36	8.99e-10	7.49e-07	-0.3	-0.37	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
KIRP	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-6.36	9e-10	7.49e-07	-0.39	-0.37	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
KIRP	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-6.36	9.02e-10	7.51e-07	-0.29	-0.37	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
KIRP	cis	rs4356975	0.509	rs28375964	ENSG00000248763.2	RP13-644M16.5	-6.36	9.04e-10	7.53e-07	-0.39	-0.37	Obesity-related traits;	chr4:69098070	chr4:69066395~69069888:+
KIRP	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	6.36	9.05e-10	7.54e-07	0.38	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
KIRP	cis	rs2283792	0.935	rs2283794	ENSG00000228050.1	TOP3BP1	6.36	9.07e-10	7.55e-07	0.4	0.37	Multiple sclerosis;	chr22:21858180	chr22:22223187~22224566:-
KIRP	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	6.36	9.09e-10	7.57e-07	0.44	0.37	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
KIRP	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-6.36	9.11e-10	7.58e-07	-0.41	-0.37	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
KIRP	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	6.36	9.11e-10	7.58e-07	0.47	0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
KIRP	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	6.36	9.12e-10	7.59e-07	0.37	0.37	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
KIRP	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.36	9.13e-10	7.6e-07	0.49	0.37	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
KIRP	cis	rs67311347	0.955	rs60554147	ENSG00000230274.1	PGAM1P3	6.36	9.15e-10	7.61e-07	0.35	0.37	Renal cell carcinoma;	chr3:40431012	chr3:40322715~40323279:-
KIRP	cis	rs755249	0.565	rs2695324	ENSG00000237624.1	OXCT2P1	6.36	9.16e-10	7.62e-07	0.48	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39514956~39516490:+
KIRP	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-6.36	9.16e-10	7.62e-07	-0.45	-0.37	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
KIRP	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	6.36	9.16e-10	7.62e-07	0.54	0.37	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
KIRP	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-6.36	9.17e-10	7.63e-07	-0.31	-0.37	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
KIRP	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-6.36	9.19e-10	7.64e-07	-0.55	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
KIRP	cis	rs4638749	0.501	rs6733637	ENSG00000231221.1	AC023672.2	-6.35	9.21e-10	7.66e-07	-0.42	-0.37	Blood pressure;	chr2:108188108	chr2:108049200~108052755:-
KIRP	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	6.35	9.23e-10	7.67e-07	0.42	0.37	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	6.35	9.23e-10	7.67e-07	0.42	0.37	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	6.35	9.23e-10	7.67e-07	0.42	0.37	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	6.35	9.23e-10	7.67e-07	0.42	0.37	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	6.35	9.23e-10	7.67e-07	0.42	0.37	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
KIRP	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	6.35	9.23e-10	7.67e-07	0.38	0.37	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
KIRP	cis	rs4638749	0.501	rs12624041	ENSG00000225328.1	AC019100.3	-6.35	9.23e-10	7.67e-07	-0.44	-0.37	Blood pressure;	chr2:108147091	chr2:108167748~108217841:-
KIRP	cis	rs9532669	0.926	rs12428966	ENSG00000239827.7	SUGT1P3	-6.35	9.23e-10	7.67e-07	-0.41	-0.37	Cervical cancer;	chr13:40876552	chr13:40908159~40921774:-
KIRP	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	6.35	9.24e-10	7.68e-07	0.25	0.37	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	6.35	9.24e-10	7.68e-07	0.25	0.37	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
KIRP	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	6.35	9.25e-10	7.69e-07	0.44	0.37	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
KIRP	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-6.35	9.26e-10	7.7e-07	-0.3	-0.37	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-6.35	9.26e-10	7.7e-07	-0.3	-0.37	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-6.35	9.26e-10	7.7e-07	-0.3	-0.37	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	6.35	9.28e-10	7.71e-07	0.3	0.37	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	6.35	9.28e-10	7.71e-07	0.3	0.37	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
KIRP	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	6.35	9.29e-10	7.72e-07	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
KIRP	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-6.35	9.29e-10	7.72e-07	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
KIRP	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	6.35	9.29e-10	7.72e-07	0.38	0.37	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
KIRP	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	6.35	9.29e-10	7.72e-07	0.3	0.37	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
KIRP	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-6.35	9.32e-10	7.74e-07	-0.41	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
KIRP	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	6.35	9.33e-10	7.75e-07	0.38	0.37	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
KIRP	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-6.35	9.33e-10	7.75e-07	-0.4	-0.37	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
KIRP	cis	rs1005277	0.638	rs1005278	ENSG00000151963.4	RP11-775A3.1	6.35	9.37e-10	7.78e-07	0.46	0.37	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:37883594~37884109:+
KIRP	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-6.35	9.37e-10	7.78e-07	-0.39	-0.37	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
KIRP	cis	rs67311347	1	rs28434528	ENSG00000230274.1	PGAM1P3	6.35	9.4e-10	7.8e-07	0.35	0.37	Renal cell carcinoma;	chr3:40443402	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs11716675	ENSG00000230274.1	PGAM1P3	6.35	9.4e-10	7.8e-07	0.35	0.37	Renal cell carcinoma;	chr3:40443789	chr3:40322715~40323279:-
KIRP	cis	rs4356975	0.932	rs7657426	ENSG00000196472.4	RP13-644M16.4	6.35	9.4e-10	7.8e-07	0.41	0.37	Obesity-related traits;	chr4:69079291	chr4:69181660~69182372:+
KIRP	cis	rs9532669	0.889	rs6560964	ENSG00000239827.7	SUGT1P3	-6.35	9.4e-10	7.8e-07	-0.41	-0.37	Cervical cancer;	chr13:40871132	chr13:40908159~40921774:-
KIRP	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	6.35	9.42e-10	7.82e-07	0.37	0.37	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
KIRP	cis	rs9532669	0.926	rs4942005	ENSG00000239827.7	SUGT1P3	-6.35	9.45e-10	7.84e-07	-0.41	-0.37	Cervical cancer;	chr13:40871636	chr13:40908159~40921774:-
KIRP	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-6.35	9.46e-10	7.85e-07	-0.5	-0.37	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	6.35	9.46e-10	7.85e-07	0.48	0.37	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
KIRP	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.35	9.48e-10	7.86e-07	0.3	0.37	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-6.35	9.5e-10	7.87e-07	-0.3	-0.37	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
KIRP	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-6.35	9.5e-10	7.88e-07	-0.44	-0.37	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
KIRP	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-6.35	9.52e-10	7.89e-07	-0.42	-0.37	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
KIRP	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	6.35	9.52e-10	7.89e-07	0.45	0.37	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
KIRP	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-6.35	9.53e-10	7.9e-07	-0.32	-0.37	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
KIRP	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-6.35	9.55e-10	7.92e-07	-0.42	-0.37	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
KIRP	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-6.35	9.57e-10	7.93e-07	-0.4	-0.37	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
KIRP	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-6.35	9.6e-10	7.95e-07	-0.37	-0.37	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
KIRP	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	6.35	9.61e-10	7.96e-07	0.42	0.37	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
KIRP	cis	rs4356975	0.509	rs4309908	ENSG00000248763.2	RP13-644M16.5	-6.35	9.61e-10	7.96e-07	-0.38	-0.37	Obesity-related traits;	chr4:69086022	chr4:69066395~69069888:+
KIRP	cis	rs79349575	0.729	rs62075824	ENSG00000248278.1	SUMO2P17	6.35	9.62e-10	7.97e-07	0.41	0.37	Type 2 diabetes;	chr17:48909317	chr17:48874860~48908983:-
KIRP	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	6.35	9.63e-10	7.98e-07	0.6	0.37	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
KIRP	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	6.35	9.65e-10	7.99e-07	0.49	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
KIRP	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	6.35	9.67e-10	8e-07	0.28	0.37	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
KIRP	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	6.35	9.71e-10	8.03e-07	0.45	0.36	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
KIRP	cis	rs67311347	1	rs13324109	ENSG00000230274.1	PGAM1P3	6.35	9.71e-10	8.04e-07	0.35	0.36	Renal cell carcinoma;	chr3:40419276	chr3:40322715~40323279:-
KIRP	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-6.35	9.71e-10	8.04e-07	-0.4	-0.36	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
KIRP	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	6.34	9.79e-10	8.09e-07	0.44	0.36	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	6.34	9.79e-10	8.09e-07	0.44	0.36	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
KIRP	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.81e-10	8.11e-07	-0.31	-0.36	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
KIRP	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-6.34	9.81e-10	8.11e-07	-0.34	-0.36	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
KIRP	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	6.34	9.82e-10	8.12e-07	0.42	0.36	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
KIRP	cis	rs2283792	0.967	rs5749998	ENSG00000228050.1	TOP3BP1	6.34	9.84e-10	8.13e-07	0.4	0.36	Multiple sclerosis;	chr22:21808085	chr22:22223187~22224566:-
KIRP	cis	rs2283792	1	rs9607287	ENSG00000228050.1	TOP3BP1	6.34	9.84e-10	8.13e-07	0.4	0.36	Multiple sclerosis;	chr22:21809136	chr22:22223187~22224566:-
KIRP	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	6.34	9.9e-10	8.18e-07	0.38	0.36	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
KIRP	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.34	9.9e-10	8.18e-07	0.43	0.36	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
KIRP	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.34	9.94e-10	8.21e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
KIRP	cis	rs67311347	1	rs9874006	ENSG00000230274.1	PGAM1P3	6.34	9.94e-10	8.21e-07	0.35	0.36	Renal cell carcinoma;	chr3:40430105	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs34762643	ENSG00000230274.1	PGAM1P3	6.34	9.94e-10	8.21e-07	0.35	0.36	Renal cell carcinoma;	chr3:40433942	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9841335	ENSG00000230274.1	PGAM1P3	6.34	9.94e-10	8.21e-07	0.35	0.36	Renal cell carcinoma;	chr3:40434367	chr3:40322715~40323279:-
KIRP	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-6.34	9.94e-10	8.21e-07	-0.58	-0.36	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
KIRP	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-6.34	9.95e-10	8.22e-07	-0.31	-0.36	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
KIRP	cis	rs4638749	0.677	rs2378098	ENSG00000225328.1	AC019100.3	-6.34	9.95e-10	8.22e-07	-0.44	-0.36	Blood pressure;	chr2:108232925	chr2:108167748~108217841:-
KIRP	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	6.34	9.95e-10	8.22e-07	0.29	0.36	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
KIRP	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-6.34	9.97e-10	8.23e-07	-0.47	-0.36	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
KIRP	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.34	9.98e-10	8.24e-07	0.44	0.36	Depression;	chr6:28110525	chr6:28115628~28116551:+
KIRP	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-6.34	9.98e-10	8.24e-07	-0.42	-0.36	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
KIRP	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-6.34	1e-09	8.26e-07	-0.51	-0.36	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
KIRP	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-6.34	1e-09	8.26e-07	-0.3	-0.36	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
KIRP	cis	rs4356975	0.932	rs60814050	ENSG00000196472.4	RP13-644M16.4	6.34	1e-09	8.27e-07	0.41	0.36	Obesity-related traits;	chr4:69063770	chr4:69181660~69182372:+
KIRP	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-6.34	1e-09	8.28e-07	-0.31	-0.36	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
KIRP	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	6.34	1e-09	8.28e-07	0.4	0.36	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-6.34	1e-09	8.28e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
KIRP	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-6.34	1.01e-09	8.31e-07	-0.47	-0.36	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
KIRP	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-6.34	1.01e-09	8.32e-07	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-6.34	1.01e-09	8.32e-07	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-6.34	1.01e-09	8.32e-07	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
KIRP	cis	rs79349575	0.783	rs4294857	ENSG00000248278.1	SUMO2P17	6.34	1.01e-09	8.32e-07	0.41	0.36	Type 2 diabetes;	chr17:48906029	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs61576918	ENSG00000248278.1	SUMO2P17	6.34	1.01e-09	8.32e-07	0.41	0.36	Type 2 diabetes;	chr17:48908231	chr17:48874860~48908983:-
KIRP	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-6.34	1.01e-09	8.33e-07	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
KIRP	cis	rs950027	0.787	rs1153845	ENSG00000259433.2	CTD-2651B20.4	6.34	1.01e-09	8.34e-07	0.31	0.36	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45330209~45332634:-
KIRP	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.34	1.02e-09	8.37e-07	0.48	0.36	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
KIRP	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	6.34	1.02e-09	8.37e-07	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
KIRP	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	6.34	1.02e-09	8.39e-07	0.39	0.36	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
KIRP	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	6.34	1.02e-09	8.39e-07	0.39	0.36	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
KIRP	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	6.34	1.02e-09	8.39e-07	0.28	0.36	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
KIRP	cis	rs67311347	0.866	rs2371183	ENSG00000230274.1	PGAM1P3	-6.34	1.02e-09	8.41e-07	-0.35	-0.36	Renal cell carcinoma;	chr3:40292756	chr3:40322715~40323279:-
KIRP	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-6.34	1.02e-09	8.41e-07	-0.5	-0.36	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	6.34	1.02e-09	8.41e-07	0.44	0.36	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
KIRP	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	6.34	1.02e-09	8.43e-07	0.53	0.36	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
KIRP	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	6.34	1.03e-09	8.43e-07	0.28	0.36	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.628	rs1109618	ENSG00000253893.2	FAM85B	6.33	1.03e-09	8.46e-07	0.46	0.36	Mood instability;	chr8:8713854	chr8:8167819~8226614:-
KIRP	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	6.33	1.03e-09	8.47e-07	0.85	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
KIRP	cis	rs12682352	0.652	rs3789843	ENSG00000253981.4	ALG1L13P	6.33	1.03e-09	8.47e-07	0.29	0.36	Neuroticism;	chr8:8866747	chr8:8236003~8244667:-
KIRP	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	6.33	1.03e-09	8.47e-07	0.29	0.36	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
KIRP	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-6.33	1.03e-09	8.48e-07	-0.48	-0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
KIRP	cis	rs7829975	0.626	rs332040	ENSG00000253981.4	ALG1L13P	6.33	1.04e-09	8.51e-07	0.29	0.36	Mood instability;	chr8:8872978	chr8:8236003~8244667:-
KIRP	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-6.33	1.04e-09	8.52e-07	-0.32	-0.36	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
KIRP	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-6.33	1.04e-09	8.54e-07	-0.46	-0.36	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
KIRP	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.33	1.04e-09	8.55e-07	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
KIRP	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	6.33	1.04e-09	8.56e-07	0.44	0.36	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	6.33	1.04e-09	8.56e-07	0.44	0.36	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	6.33	1.04e-09	8.56e-07	0.44	0.36	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
KIRP	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-6.33	1.04e-09	8.56e-07	-0.55	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
KIRP	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-6.33	1.05e-09	8.6e-07	-0.3	-0.36	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
KIRP	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-6.33	1.05e-09	8.62e-07	-0.28	-0.36	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
KIRP	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	6.33	1.05e-09	8.63e-07	0.48	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
KIRP	cis	rs67311347	1	rs1466237	ENSG00000230274.1	PGAM1P3	6.33	1.05e-09	8.65e-07	0.35	0.36	Renal cell carcinoma;	chr3:40420535	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs11714912	ENSG00000230274.1	PGAM1P3	-6.33	1.06e-09	8.66e-07	-0.36	-0.36	Renal cell carcinoma;	chr3:40452574	chr3:40322715~40323279:-
KIRP	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	6.33	1.06e-09	8.67e-07	0.52	0.36	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
KIRP	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-6.33	1.06e-09	8.68e-07	-0.48	-0.36	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-6.33	1.06e-09	8.68e-07	-0.48	-0.36	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-6.33	1.06e-09	8.68e-07	-0.48	-0.36	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
KIRP	cis	rs17082664	0.79	rs9479307	ENSG00000226193.1	RP3-398G3.5	-6.33	1.06e-09	8.69e-07	-0.57	-0.36	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152389910	chr6:152402398~152404966:+
KIRP	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-6.33	1.06e-09	8.7e-07	-0.58	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
KIRP	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-6.33	1.06e-09	8.7e-07	-0.58	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
KIRP	cis	rs79349575	0.783	rs1994970	ENSG00000248278.1	SUMO2P17	-6.33	1.06e-09	8.7e-07	-0.41	-0.36	Type 2 diabetes;	chr17:48936765	chr17:48874860~48908983:-
KIRP	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.33	1.06e-09	8.71e-07	0.3	0.36	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
KIRP	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	6.33	1.06e-09	8.71e-07	0.5	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
KIRP	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-6.33	1.06e-09	8.71e-07	-0.37	-0.36	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
KIRP	cis	rs1476679	1	rs1476679	ENSG00000078319.8	PMS2P1	6.33	1.06e-09	8.72e-07	0.5	0.36	Alzheimer's disease (late onset);	chr7:100406823	chr7:100320992~100341908:-
KIRP	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-6.33	1.06e-09	8.72e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
KIRP	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	6.33	1.07e-09	8.73e-07	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
KIRP	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.33	1.07e-09	8.74e-07	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.33	1.07e-09	8.74e-07	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.33	1.07e-09	8.74e-07	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
KIRP	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	6.33	1.07e-09	8.74e-07	0.43	0.36	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
KIRP	cis	rs4443100	0.958	rs9608066	ENSG00000221069.1	AC000029.1	6.33	1.07e-09	8.74e-07	0.47	0.36	Serum parathyroid hormone levels;	chr22:23044992	chr22:23136620~23136710:+
KIRP	cis	rs4443100	0.917	rs725984	ENSG00000221069.1	AC000029.1	6.33	1.07e-09	8.74e-07	0.47	0.36	Serum parathyroid hormone levels;	chr22:23045462	chr22:23136620~23136710:+
KIRP	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.33	1.07e-09	8.75e-07	0.31	0.36	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
KIRP	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	6.33	1.07e-09	8.75e-07	0.51	0.36	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
KIRP	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	6.33	1.07e-09	8.78e-07	0.46	0.36	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	6.33	1.07e-09	8.78e-07	0.46	0.36	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
KIRP	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-6.33	1.07e-09	8.8e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-6.33	1.07e-09	8.8e-07	-0.4	-0.36	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
KIRP	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-6.33	1.08e-09	8.82e-07	-0.45	-0.36	Depression;	chr6:28143758	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-6.33	1.08e-09	8.82e-07	-0.45	-0.36	Depression;	chr6:28144784	chr6:28115628~28116551:+
KIRP	cis	rs308403	0.509	rs7690133	ENSG00000224786.1	CETN4P	6.33	1.08e-09	8.82e-07	0.4	0.36	Blood protein levels;	chr4:122752654	chr4:122730548~122732193:-
KIRP	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	6.33	1.08e-09	8.82e-07	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-6.33	1.08e-09	8.85e-07	-0.3	-0.36	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-6.33	1.08e-09	8.85e-07	-0.3	-0.36	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-6.33	1.08e-09	8.85e-07	-0.3	-0.36	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-6.33	1.08e-09	8.85e-07	-0.3	-0.36	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
KIRP	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-6.33	1.08e-09	8.86e-07	-0.29	-0.36	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
KIRP	cis	rs4638749	0.501	rs2378096	ENSG00000225328.1	AC019100.3	-6.33	1.08e-09	8.86e-07	-0.43	-0.36	Blood pressure;	chr2:108148575	chr2:108167748~108217841:-
KIRP	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	6.33	1.09e-09	8.88e-07	0.42	0.36	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
KIRP	cis	rs9371601	1	rs9371601	ENSG00000226193.1	RP3-398G3.5	6.32	1.09e-09	8.91e-07	0.39	0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152469438	chr6:152402398~152404966:+
KIRP	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	6.32	1.09e-09	8.92e-07	0.3	0.36	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
KIRP	cis	rs2625529	0.617	rs7175792	ENSG00000260037.4	CTD-2524L6.3	-6.32	1.09e-09	8.92e-07	-0.29	-0.36	Red blood cell count;	chr15:72139542	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs8023788	ENSG00000260037.4	CTD-2524L6.3	6.32	1.09e-09	8.92e-07	0.29	0.36	Red blood cell count;	chr15:72167506	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.617	rs8025939	ENSG00000260037.4	CTD-2524L6.3	6.32	1.09e-09	8.92e-07	0.29	0.36	Red blood cell count;	chr15:72167998	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	6.32	1.09e-09	8.94e-07	0.44	0.36	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
KIRP	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-6.32	1.1e-09	8.96e-07	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
KIRP	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-6.32	1.1e-09	8.98e-07	-0.33	-0.36	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
KIRP	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	6.32	1.1e-09	9.01e-07	0.48	0.36	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
KIRP	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	6.32	1.11e-09	9.03e-07	0.42	0.36	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
KIRP	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-6.32	1.11e-09	9.05e-07	-0.41	-0.36	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
KIRP	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-6.32	1.11e-09	9.09e-07	-0.3	-0.36	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
KIRP	cis	rs308403	0.509	rs309379	ENSG00000224786.1	CETN4P	6.32	1.12e-09	9.12e-07	0.4	0.36	Blood protein levels;	chr4:122750301	chr4:122730548~122732193:-
KIRP	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-6.32	1.12e-09	9.12e-07	-0.44	-0.36	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
KIRP	cis	rs9532669	0.926	rs7328139	ENSG00000239827.7	SUGT1P3	-6.32	1.12e-09	9.13e-07	-0.41	-0.36	Cervical cancer;	chr13:40862295	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7328145	ENSG00000239827.7	SUGT1P3	-6.32	1.12e-09	9.13e-07	-0.41	-0.36	Cervical cancer;	chr13:40862307	chr13:40908159~40921774:-
KIRP	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-6.32	1.12e-09	9.13e-07	-0.33	-0.36	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
KIRP	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-6.32	1.12e-09	9.13e-07	-0.33	-0.36	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
KIRP	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-6.32	1.12e-09	9.14e-07	-0.46	-0.36	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
KIRP	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6.32	1.12e-09	9.14e-07	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	6.32	1.12e-09	9.14e-07	0.54	0.36	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
KIRP	cis	rs79349575	0.783	rs9747646	ENSG00000248278.1	SUMO2P17	6.32	1.12e-09	9.16e-07	0.41	0.36	Type 2 diabetes;	chr17:48939520	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs62075852	ENSG00000248278.1	SUMO2P17	6.32	1.12e-09	9.16e-07	0.41	0.36	Type 2 diabetes;	chr17:48939814	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12601858	ENSG00000248278.1	SUMO2P17	6.32	1.12e-09	9.16e-07	0.41	0.36	Type 2 diabetes;	chr17:48940115	chr17:48874860~48908983:-
KIRP	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-6.32	1.13e-09	9.18e-07	-0.49	-0.36	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
KIRP	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.13e-09	9.2e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.13e-09	9.2e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
KIRP	cis	rs10793273	1	rs10793273	ENSG00000254675.1	RP11-7I15.4	-6.32	1.13e-09	9.2e-07	-0.43	-0.36	Pelvic organ prolapse;	chr11:78031549	chr11:78022933~78023721:+
KIRP	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-6.32	1.13e-09	9.22e-07	-0.39	-0.36	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
KIRP	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-6.32	1.13e-09	9.22e-07	-0.39	-0.36	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
KIRP	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	6.32	1.13e-09	9.22e-07	0.3	0.36	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
KIRP	cis	rs79349575	0.749	rs318093	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48911992	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.745	rs170319	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48914169	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs318090	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48914390	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.721	rs3744608	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48915871	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.651	rs4378658	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48916008	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12453374	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48917484	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12453394	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48917608	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.811	rs12601072	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48920636	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.749	rs58838744	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48921540	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.811	rs60708039	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48922011	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs55771415	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48922575	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs2088139	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48922748	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4793991	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48924439	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.715	rs62075844	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48925027	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.749	rs957557	ENSG00000248278.1	SUMO2P17	6.32	1.13e-09	9.24e-07	0.41	0.36	Type 2 diabetes;	chr17:48925859	chr17:48874860~48908983:-
KIRP	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-6.32	1.14e-09	9.26e-07	-0.39	-0.36	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-6.32	1.14e-09	9.26e-07	-0.39	-0.36	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-6.32	1.14e-09	9.26e-07	-0.39	-0.36	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
KIRP	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	6.32	1.14e-09	9.27e-07	0.62	0.36	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
KIRP	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-6.32	1.14e-09	9.27e-07	-0.33	-0.36	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
KIRP	cis	rs7267979	0.903	rs2474766	ENSG00000274414.1	RP5-965G21.4	-6.32	1.14e-09	9.28e-07	-0.34	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.903	rs2474769	ENSG00000274414.1	RP5-965G21.4	-6.32	1.14e-09	9.28e-07	-0.34	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25239007~25245229:-
KIRP	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-6.32	1.14e-09	9.28e-07	-0.49	-0.36	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-6.32	1.14e-09	9.28e-07	-0.49	-0.36	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
KIRP	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-6.32	1.14e-09	9.28e-07	-0.49	-0.36	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
KIRP	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	6.32	1.14e-09	9.29e-07	0.26	0.36	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
KIRP	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	6.32	1.14e-09	9.29e-07	0.46	0.36	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
KIRP	cis	rs6908034	0.607	rs112659166	ENSG00000228412.5	RP4-625H18.2	6.32	1.14e-09	9.29e-07	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs34109983	ENSG00000228412.5	RP4-625H18.2	6.32	1.14e-09	9.29e-07	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs73376680	ENSG00000228412.5	RP4-625H18.2	6.32	1.14e-09	9.29e-07	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs73376681	ENSG00000228412.5	RP4-625H18.2	6.32	1.14e-09	9.29e-07	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs80355837	ENSG00000228412.5	RP4-625H18.2	6.32	1.14e-09	9.29e-07	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19802164~19804752:-
KIRP	cis	rs79349575	0.783	rs4255820	ENSG00000248278.1	SUMO2P17	6.32	1.14e-09	9.29e-07	0.41	0.36	Type 2 diabetes;	chr17:48919221	chr17:48874860~48908983:-
KIRP	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-6.32	1.14e-09	9.3e-07	-0.48	-0.36	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
KIRP	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-6.32	1.15e-09	9.32e-07	-0.42	-0.36	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
KIRP	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-6.32	1.15e-09	9.33e-07	-0.37	-0.36	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
KIRP	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.32	1.15e-09	9.34e-07	-0.3	-0.36	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
KIRP	cis	rs2625529	0.73	rs1481861	ENSG00000260037.4	CTD-2524L6.3	6.32	1.15e-09	9.34e-07	0.29	0.36	Red blood cell count;	chr15:71947788	chr15:71818396~71823384:+
KIRP	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	6.32	1.15e-09	9.35e-07	0.47	0.36	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
KIRP	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-6.32	1.15e-09	9.35e-07	-0.43	-0.36	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-6.32	1.15e-09	9.35e-07	-0.43	-0.36	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
KIRP	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.15e-09	9.35e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.15e-09	9.35e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.15e-09	9.35e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-6.32	1.15e-09	9.35e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
KIRP	cis	rs7829975	0.572	rs28446104	ENSG00000253981.4	ALG1L13P	-6.32	1.15e-09	9.35e-07	-0.28	-0.36	Mood instability;	chr8:8938391	chr8:8236003~8244667:-
KIRP	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-6.31	1.15e-09	9.37e-07	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-6.31	1.15e-09	9.37e-07	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-6.31	1.15e-09	9.37e-07	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-6.31	1.15e-09	9.37e-07	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
KIRP	cis	rs832187	0.615	rs9865811	ENSG00000280620.1	SCAANT1	6.31	1.15e-09	9.37e-07	0.4	0.36	Schizophrenia;	chr3:64008829	chr3:63911518~63911772:-
KIRP	cis	rs4936099	0.965	rs3740888	ENSG00000175773.11	RP11-121M22.1	6.31	1.15e-09	9.37e-07	0.37	0.36	Optic cup area;Vertical cup-disc ratio;	chr11:130408315	chr11:130314993~130403657:+
KIRP	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-6.31	1.16e-09	9.39e-07	-0.51	-0.36	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
KIRP	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-6.31	1.16e-09	9.4e-07	-0.43	-0.36	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
KIRP	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	6.31	1.16e-09	9.4e-07	0.43	0.36	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
KIRP	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	6.31	1.16e-09	9.42e-07	0.3	0.36	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	6.31	1.16e-09	9.42e-07	0.3	0.36	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	6.31	1.16e-09	9.43e-07	0.42	0.36	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
KIRP	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	6.31	1.16e-09	9.43e-07	0.42	0.36	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
KIRP	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-6.31	1.16e-09	9.44e-07	-0.3	-0.36	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-6.31	1.16e-09	9.44e-07	-0.3	-0.36	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-6.31	1.16e-09	9.44e-07	-0.3	-0.36	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-6.31	1.16e-09	9.44e-07	-0.3	-0.36	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
KIRP	cis	rs67311347	1	rs9848083	ENSG00000230274.1	PGAM1P3	-6.31	1.16e-09	9.44e-07	-0.35	-0.36	Renal cell carcinoma;	chr3:40425488	chr3:40322715~40323279:-
KIRP	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	6.31	1.16e-09	9.45e-07	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
KIRP	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	6.31	1.17e-09	9.45e-07	0.36	0.36	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-6.31	1.17e-09	9.45e-07	-0.36	-0.36	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	6.31	1.17e-09	9.48e-07	0.43	0.36	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
KIRP	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	6.31	1.17e-09	9.49e-07	0.31	0.36	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
KIRP	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-6.31	1.17e-09	9.5e-07	-0.3	-0.36	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
KIRP	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	6.31	1.17e-09	9.51e-07	0.45	0.36	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
KIRP	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	6.31	1.18e-09	9.53e-07	0.39	0.36	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
KIRP	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-6.31	1.18e-09	9.56e-07	-0.42	-0.36	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
KIRP	cis	rs984222	0.538	rs1106529	ENSG00000231365.4	RP11-418J17.1	-6.31	1.18e-09	9.57e-07	-0.38	-0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118988874	chr1:119140396~119275973:+
KIRP	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-6.31	1.18e-09	9.58e-07	-0.37	-0.36	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-6.31	1.18e-09	9.58e-07	-0.37	-0.36	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
KIRP	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-6.31	1.18e-09	9.58e-07	-0.48	-0.36	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	6.31	1.18e-09	9.6e-07	0.49	0.36	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	6.31	1.18e-09	9.6e-07	0.49	0.36	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
KIRP	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-6.31	1.18e-09	9.6e-07	-0.49	-0.36	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
KIRP	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-6.31	1.18e-09	9.6e-07	-0.47	-0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	6.31	1.19e-09	9.64e-07	0.48	0.36	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
KIRP	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-6.31	1.2e-09	9.71e-07	-0.38	-0.36	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-6.31	1.2e-09	9.71e-07	-0.38	-0.36	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
KIRP	cis	rs755249	0.517	rs56809193	ENSG00000237624.1	OXCT2P1	6.31	1.2e-09	9.71e-07	0.64	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39143626	chr1:39514956~39516490:+
KIRP	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-6.31	1.2e-09	9.75e-07	-0.4	-0.36	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
KIRP	cis	rs79349575	0.749	rs1057902	ENSG00000248278.1	SUMO2P17	6.31	1.21e-09	9.75e-07	0.41	0.36	Type 2 diabetes;	chr17:48928226	chr17:48874860~48908983:-
KIRP	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-6.31	1.21e-09	9.75e-07	-0.42	-0.36	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
KIRP	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	6.31	1.21e-09	9.77e-07	0.45	0.36	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
KIRP	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	6.31	1.21e-09	9.77e-07	0.36	0.36	Height;	chr11:118758322	chr11:118704607~118750263:+
KIRP	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	6.31	1.21e-09	9.77e-07	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
KIRP	cis	rs950027	0.787	rs1547487	ENSG00000259433.2	CTD-2651B20.4	-6.31	1.21e-09	9.77e-07	-0.31	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45330209~45332634:-
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	6.31	1.21e-09	9.78e-07	0.46	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
KIRP	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	6.31	1.21e-09	9.79e-07	0.67	0.36	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
KIRP	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	6.31	1.21e-09	9.82e-07	0.28	0.36	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
KIRP	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	6.31	1.22e-09	9.83e-07	0.38	0.36	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
KIRP	cis	rs4638749	0.677	rs12712018	ENSG00000225328.1	AC019100.3	-6.3	1.22e-09	9.86e-07	-0.43	-0.36	Blood pressure;	chr2:108237049	chr2:108167748~108217841:-
KIRP	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	6.3	1.22e-09	9.87e-07	0.49	0.36	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
KIRP	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	6.3	1.22e-09	9.87e-07	0.27	0.36	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
KIRP	cis	rs79349575	0.749	rs12601672	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48929131	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs17635252	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48929588	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs56046215	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48931395	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs4399576	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48932473	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.687	rs12602179	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48932672	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs17708633	ENSG00000248278.1	SUMO2P17	6.3	1.23e-09	9.91e-07	0.41	0.36	Type 2 diabetes;	chr17:48934258	chr17:48874860~48908983:-
KIRP	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-6.3	1.23e-09	9.93e-07	-0.33	-0.36	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
KIRP	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	6.3	1.23e-09	9.93e-07	0.48	0.36	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
KIRP	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-6.3	1.23e-09	9.96e-07	-0.39	-0.36	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
KIRP	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-6.3	1.23e-09	9.96e-07	-0.3	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
KIRP	cis	rs308403	0.509	rs309382	ENSG00000224786.1	CETN4P	6.3	1.23e-09	9.96e-07	0.4	0.36	Blood protein levels;	chr4:122748617	chr4:122730548~122732193:-
KIRP	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-6.3	1.24e-09	9.99e-07	-0.51	-0.36	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
KIRP	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	6.3	1.24e-09	1e-06	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
KIRP	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	6.3	1.24e-09	1e-06	0.47	0.36	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
KIRP	cis	rs2625529	0.652	rs2957750	ENSG00000260037.4	CTD-2524L6.3	6.3	1.24e-09	1e-06	0.29	0.36	Red blood cell count;	chr15:72039917	chr15:71818396~71823384:+
KIRP	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	6.3	1.24e-09	1e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
KIRP	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	6.3	1.24e-09	1e-06	0.31	0.36	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
KIRP	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-6.3	1.25e-09	1.01e-06	-0.41	-0.36	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
KIRP	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	6.3	1.25e-09	1.01e-06	0.37	0.36	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
KIRP	cis	rs67311347	1	rs9968170	ENSG00000230274.1	PGAM1P3	-6.3	1.25e-09	1.01e-06	-0.36	-0.36	Renal cell carcinoma;	chr3:40452783	chr3:40322715~40323279:-
KIRP	cis	rs2765539	0.887	rs2765541	ENSG00000231365.4	RP11-418J17.1	-6.3	1.25e-09	1.01e-06	-0.4	-0.36	Waist-hip ratio;	chr1:119016034	chr1:119140396~119275973:+
KIRP	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	6.3	1.26e-09	1.01e-06	0.61	0.36	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
KIRP	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	6.3	1.26e-09	1.01e-06	0.44	0.36	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	6.3	1.26e-09	1.02e-06	0.45	0.36	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
KIRP	cis	rs13423976	0.6	rs35776111	ENSG00000231367.4	AC016995.3	6.3	1.26e-09	1.02e-06	0.48	0.36	Gut microbiome composition (summer);	chr2:38515087	chr2:38406719~38515740:-
KIRP	cis	rs7665090	0.623	rs227368	ENSG00000246560.2	RP11-10L12.4	-6.3	1.26e-09	1.02e-06	-0.43	-0.36	Primary biliary cholangitis;	chr4:102690688	chr4:102828055~102844075:+
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	6.3	1.27e-09	1.02e-06	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
KIRP	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-6.3	1.27e-09	1.02e-06	-0.42	-0.36	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	6.3	1.27e-09	1.02e-06	0.46	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
KIRP	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-6.3	1.27e-09	1.02e-06	-0.49	-0.36	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
KIRP	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-6.3	1.27e-09	1.03e-06	-0.33	-0.36	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
KIRP	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.3	1.28e-09	1.03e-06	-0.43	-0.36	Depression;	chr6:28079011	chr6:28115628~28116551:+
KIRP	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	6.3	1.28e-09	1.03e-06	0.49	0.36	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
KIRP	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	6.3	1.29e-09	1.03e-06	0.41	0.36	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
KIRP	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	6.3	1.29e-09	1.04e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	6.3	1.29e-09	1.04e-06	0.42	0.36	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
KIRP	cis	rs4443100	0.958	rs5996455	ENSG00000221069.1	AC000029.1	6.29	1.29e-09	1.04e-06	0.44	0.36	Serum parathyroid hormone levels;	chr22:23037078	chr22:23136620~23136710:+
KIRP	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28111382	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28111650	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28112175	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28113851	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28114487	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28114933	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28115743	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28116411	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28123153	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28124529	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-6.29	1.29e-09	1.04e-06	-0.44	-0.36	Depression;	chr6:28127577	chr6:28115628~28116551:+
KIRP	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	6.29	1.29e-09	1.04e-06	0.46	0.36	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
KIRP	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-6.29	1.3e-09	1.04e-06	-0.42	-0.36	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	6.29	1.3e-09	1.05e-06	0.48	0.36	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	6.29	1.3e-09	1.05e-06	0.48	0.36	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
KIRP	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-6.29	1.3e-09	1.05e-06	-0.39	-0.36	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	6.29	1.3e-09	1.05e-06	0.48	0.36	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
KIRP	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	6.29	1.3e-09	1.05e-06	0.39	0.36	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	6.29	1.3e-09	1.05e-06	0.39	0.36	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
KIRP	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.29	1.31e-09	1.05e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
KIRP	cis	rs67311347	1	rs4973997	ENSG00000230274.1	PGAM1P3	6.29	1.31e-09	1.06e-06	0.35	0.36	Renal cell carcinoma;	chr3:40418654	chr3:40322715~40323279:-
KIRP	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	6.29	1.32e-09	1.06e-06	0.39	0.36	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
KIRP	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	6.29	1.32e-09	1.06e-06	0.39	0.36	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
KIRP	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	6.29	1.32e-09	1.06e-06	0.38	0.36	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
KIRP	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-6.29	1.32e-09	1.06e-06	-0.46	-0.36	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
KIRP	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-6.29	1.32e-09	1.06e-06	-0.44	-0.36	Depression;	chr6:28131566	chr6:28115628~28116551:+
KIRP	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	6.29	1.33e-09	1.07e-06	0.52	0.36	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	6.29	1.33e-09	1.07e-06	0.52	0.36	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	6.29	1.33e-09	1.07e-06	0.52	0.36	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
KIRP	cis	rs17082664	0.688	rs62426960	ENSG00000226193.1	RP3-398G3.5	-6.29	1.33e-09	1.07e-06	-0.48	-0.36	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152417487	chr6:152402398~152404966:+
KIRP	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	6.29	1.33e-09	1.07e-06	0.29	0.36	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
KIRP	cis	rs2765539	0.701	rs10754391	ENSG00000231365.4	RP11-418J17.1	-6.29	1.33e-09	1.07e-06	-0.38	-0.36	Waist-hip ratio;	chr1:119087081	chr1:119140396~119275973:+
KIRP	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	6.29	1.33e-09	1.07e-06	0.42	0.36	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
KIRP	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	6.29	1.33e-09	1.07e-06	0.37	0.36	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
KIRP	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-6.29	1.33e-09	1.07e-06	-0.42	-0.36	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
KIRP	cis	rs4443100	0.792	rs9612223	ENSG00000221069.1	AC000029.1	6.29	1.33e-09	1.07e-06	0.5	0.36	Serum parathyroid hormone levels;	chr22:23046964	chr22:23136620~23136710:+
KIRP	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-6.29	1.33e-09	1.07e-06	-0.47	-0.36	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
KIRP	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.29	1.34e-09	1.07e-06	0.58	0.36	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
KIRP	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	6.29	1.35e-09	1.08e-06	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
KIRP	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	6.29	1.35e-09	1.08e-06	0.43	0.36	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
KIRP	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-6.29	1.35e-09	1.08e-06	-0.42	-0.36	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-6.29	1.35e-09	1.08e-06	-0.5	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
KIRP	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-6.29	1.35e-09	1.08e-06	-0.29	-0.36	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
KIRP	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-6.29	1.35e-09	1.09e-06	-0.47	-0.36	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
KIRP	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.29	1.36e-09	1.09e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
KIRP	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	6.29	1.36e-09	1.09e-06	0.58	0.36	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
KIRP	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	6.29	1.36e-09	1.09e-06	0.46	0.36	Height;	chr6:109471826	chr6:109382795~109383666:+
KIRP	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-6.29	1.36e-09	1.09e-06	-0.43	-0.36	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-6.29	1.36e-09	1.09e-06	-0.3	-0.36	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
KIRP	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	6.28	1.36e-09	1.09e-06	0.37	0.36	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	6.28	1.36e-09	1.09e-06	0.37	0.36	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	6.28	1.36e-09	1.09e-06	0.37	0.36	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	6.28	1.36e-09	1.09e-06	0.37	0.36	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	6.28	1.36e-09	1.09e-06	0.37	0.36	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
KIRP	cis	rs950027	0.549	rs11070452	ENSG00000259433.2	CTD-2651B20.4	6.28	1.37e-09	1.09e-06	0.32	0.36	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45330209~45332634:-
KIRP	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-6.28	1.37e-09	1.09e-06	-0.55	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
KIRP	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	6.28	1.37e-09	1.1e-06	0.43	0.36	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
KIRP	cis	rs755249	0.529	rs3768299	ENSG00000237624.1	OXCT2P1	6.28	1.37e-09	1.1e-06	0.57	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39514956~39516490:+
KIRP	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-6.28	1.37e-09	1.1e-06	-0.28	-0.36	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
KIRP	cis	rs67311347	0.955	rs6599100	ENSG00000230274.1	PGAM1P3	6.28	1.37e-09	1.1e-06	0.34	0.36	Renal cell carcinoma;	chr3:40405871	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	6.28	1.38e-09	1.1e-06	0.43	0.36	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
KIRP	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-6.28	1.38e-09	1.1e-06	-0.47	-0.36	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-6.28	1.38e-09	1.1e-06	-0.47	-0.36	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-6.28	1.38e-09	1.1e-06	-0.47	-0.36	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
KIRP	cis	rs4443100	0.874	rs6003483	ENSG00000221069.1	AC000029.1	6.28	1.38e-09	1.1e-06	0.44	0.36	Serum parathyroid hormone levels;	chr22:23037448	chr22:23136620~23136710:+
KIRP	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	6.28	1.38e-09	1.1e-06	0.43	0.36	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
KIRP	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	6.28	1.38e-09	1.11e-06	0.41	0.36	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
KIRP	cis	rs14165	0.62	rs6445605	ENSG00000271916.1	RP11-884K10.6	-6.28	1.38e-09	1.11e-06	-0.34	-0.36	Refractive error;	chr3:53808078	chr3:53797764~53798019:-
KIRP	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	6.28	1.38e-09	1.11e-06	0.5	0.36	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
KIRP	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	6.28	1.39e-09	1.11e-06	0.36	0.36	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
KIRP	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	6.28	1.39e-09	1.11e-06	0.36	0.36	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
KIRP	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-6.28	1.39e-09	1.11e-06	-0.36	-0.36	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
KIRP	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	6.28	1.4e-09	1.12e-06	0.3	0.36	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	6.28	1.4e-09	1.12e-06	0.3	0.36	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	6.28	1.4e-09	1.12e-06	0.3	0.36	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
KIRP	cis	rs1799949	1	rs16940	ENSG00000236383.6	LINC00854	-6.28	1.4e-09	1.12e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43093220	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs66499067	ENSG00000236383.6	LINC00854	-6.28	1.4e-09	1.12e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43096467	chr17:43216941~43305976:-
KIRP	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	6.28	1.41e-09	1.12e-06	0.41	0.36	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
KIRP	cis	rs7474896	0.559	rs2753880	ENSG00000151963.4	RP11-775A3.1	6.28	1.41e-09	1.12e-06	0.47	0.36	Obesity (extreme);	chr10:37884410	chr10:37883594~37884109:+
KIRP	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-6.28	1.41e-09	1.13e-06	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
KIRP	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	6.28	1.41e-09	1.13e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
KIRP	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-6.28	1.41e-09	1.13e-06	-0.45	-0.36	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
KIRP	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-6.28	1.42e-09	1.13e-06	-0.45	-0.36	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
KIRP	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-6.28	1.42e-09	1.13e-06	-0.49	-0.36	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
KIRP	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-6.28	1.42e-09	1.14e-06	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-6.28	1.42e-09	1.14e-06	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
KIRP	cis	rs2283792	1	rs3788332	ENSG00000228050.1	TOP3BP1	6.28	1.42e-09	1.14e-06	0.4	0.36	Multiple sclerosis;	chr22:21817278	chr22:22223187~22224566:-
KIRP	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-6.28	1.44e-09	1.15e-06	-0.25	-0.36	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
KIRP	cis	rs7474896	0.526	rs1208633	ENSG00000151963.4	RP11-775A3.1	6.28	1.44e-09	1.15e-06	0.47	0.36	Obesity (extreme);	chr10:37867945	chr10:37883594~37884109:+
KIRP	cis	rs950169	0.656	rs748455	ENSG00000275120.1	RP11-182J1.17	6.27	1.44e-09	1.15e-06	0.46	0.36	Schizophrenia;	chr15:84606344	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.544	rs12913702	ENSG00000275120.1	RP11-182J1.17	6.27	1.44e-09	1.15e-06	0.46	0.36	Schizophrenia;	chr15:84609953	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.509	rs71395455	ENSG00000275120.1	RP11-182J1.17	6.27	1.44e-09	1.15e-06	0.46	0.36	Schizophrenia;	chr15:84610573	chr15:84599434~84606463:-
KIRP	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	6.27	1.45e-09	1.15e-06	0.36	0.36	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
KIRP	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-6.27	1.45e-09	1.16e-06	-0.37	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
KIRP	cis	rs4356975	0.563	rs4327554	ENSG00000250696.4	RP11-704M14.1	-6.27	1.46e-09	1.16e-06	-0.34	-0.36	Obesity-related traits;	chr4:69120690	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600896	ENSG00000250696.4	RP11-704M14.1	6.27	1.46e-09	1.16e-06	0.34	0.36	Obesity-related traits;	chr4:69121000	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	6.27	1.46e-09	1.16e-06	0.44	0.36	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
KIRP	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	6.27	1.46e-09	1.16e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
KIRP	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	6.27	1.46e-09	1.16e-06	0.36	0.36	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
KIRP	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-6.27	1.47e-09	1.17e-06	-0.46	-0.36	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-6.27	1.47e-09	1.17e-06	-0.46	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
KIRP	cis	rs2617170	0.922	rs1600128	ENSG00000245648.1	RP11-277P12.20	6.27	1.47e-09	1.17e-06	0.41	0.36	Behcet's disease;	chr12:10383559	chr12:10363769~10398506:+
KIRP	cis	rs2617170	0.922	rs1904123	ENSG00000245648.1	RP11-277P12.20	6.27	1.47e-09	1.17e-06	0.41	0.36	Behcet's disease;	chr12:10385181	chr12:10363769~10398506:+
KIRP	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	6.27	1.47e-09	1.17e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	6.27	1.47e-09	1.17e-06	0.44	0.36	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
KIRP	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-6.27	1.48e-09	1.17e-06	-0.57	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
KIRP	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	6.27	1.48e-09	1.18e-06	0.48	0.36	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
KIRP	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	6.27	1.48e-09	1.18e-06	0.38	0.36	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
KIRP	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	6.27	1.48e-09	1.18e-06	0.56	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
KIRP	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-6.27	1.48e-09	1.18e-06	-0.39	-0.36	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
KIRP	cis	rs755249	0.53	rs4660475	ENSG00000237624.1	OXCT2P1	6.27	1.48e-09	1.18e-06	0.56	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.53	rs66848709	ENSG00000237624.1	OXCT2P1	6.27	1.48e-09	1.18e-06	0.56	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39514956~39516490:+
KIRP	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	6.27	1.48e-09	1.18e-06	0.36	0.36	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
KIRP	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	6.27	1.48e-09	1.18e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	6.27	1.48e-09	1.18e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.546	rs74514942	ENSG00000228412.5	RP4-625H18.2	6.27	1.48e-09	1.18e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs78402429	ENSG00000228412.5	RP4-625H18.2	6.27	1.48e-09	1.18e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19802164~19804752:-
KIRP	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	6.27	1.49e-09	1.18e-06	0.31	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	6.27	1.49e-09	1.18e-06	0.31	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
KIRP	cis	rs2283792	0.905	rs5755694	ENSG00000228050.1	TOP3BP1	6.27	1.49e-09	1.18e-06	0.4	0.36	Multiple sclerosis;	chr22:21846241	chr22:22223187~22224566:-
KIRP	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	6.27	1.49e-09	1.19e-06	0.38	0.36	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
KIRP	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-6.27	1.49e-09	1.19e-06	-0.42	-0.36	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
KIRP	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	6.27	1.49e-09	1.19e-06	0.41	0.36	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
KIRP	cis	rs9388451	0.839	rs3757217	ENSG00000237742.5	RP11-624M8.1	-6.27	1.5e-09	1.19e-06	-0.38	-0.36	Brugada syndrome;	chr6:125748490	chr6:125578558~125749190:-
KIRP	cis	rs9388451	0.869	rs7764016	ENSG00000237742.5	RP11-624M8.1	-6.27	1.5e-09	1.19e-06	-0.38	-0.36	Brugada syndrome;	chr6:125749643	chr6:125578558~125749190:-
KIRP	cis	rs9388451	0.839	rs1811852	ENSG00000237742.5	RP11-624M8.1	-6.27	1.5e-09	1.19e-06	-0.38	-0.36	Brugada syndrome;	chr6:125750429	chr6:125578558~125749190:-
KIRP	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	6.27	1.5e-09	1.19e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
KIRP	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-6.27	1.5e-09	1.19e-06	-0.32	-0.36	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
KIRP	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	6.27	1.5e-09	1.19e-06	0.48	0.36	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
KIRP	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.27	1.5e-09	1.19e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
KIRP	cis	rs4356975	0.563	rs6600897	ENSG00000250696.4	RP11-704M14.1	6.27	1.5e-09	1.19e-06	0.34	0.36	Obesity-related traits;	chr4:69121531	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4274916	ENSG00000250696.4	RP11-704M14.1	6.27	1.5e-09	1.19e-06	0.34	0.36	Obesity-related traits;	chr4:69122660	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	6.27	1.5e-09	1.19e-06	0.44	0.36	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	6.27	1.5e-09	1.19e-06	0.44	0.36	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
KIRP	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-6.27	1.51e-09	1.2e-06	-0.38	-0.36	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-6.27	1.51e-09	1.2e-06	-0.38	-0.36	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
KIRP	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-6.27	1.51e-09	1.2e-06	-0.38	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
KIRP	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	6.27	1.51e-09	1.2e-06	0.35	0.36	Height;	chr3:53073764	chr3:53064283~53065091:-
KIRP	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-6.27	1.51e-09	1.2e-06	-0.39	-0.36	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
KIRP	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	6.27	1.51e-09	1.2e-06	0.47	0.36	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
KIRP	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	6.27	1.51e-09	1.2e-06	0.32	0.36	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
KIRP	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	6.27	1.52e-09	1.2e-06	0.52	0.36	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
KIRP	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	6.27	1.52e-09	1.2e-06	0.52	0.36	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
KIRP	cis	rs9532669	0.926	rs4555012	ENSG00000239827.7	SUGT1P3	-6.27	1.52e-09	1.2e-06	-0.41	-0.36	Cervical cancer;	chr13:40879997	chr13:40908159~40921774:-
KIRP	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-6.27	1.52e-09	1.21e-06	-0.44	-0.36	Depression;	chr6:28133900	chr6:28115628~28116551:+
KIRP	cis	rs893363	0.623	rs877483	ENSG00000271916.1	RP11-884K10.6	6.27	1.52e-09	1.21e-06	0.31	0.36	Axial length;	chr3:53812714	chr3:53797764~53798019:-
KIRP	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	6.26	1.52e-09	1.21e-06	0.36	0.36	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
KIRP	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	6.26	1.52e-09	1.21e-06	0.31	0.36	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
KIRP	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	6.26	1.52e-09	1.21e-06	0.3	0.36	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	6.26	1.53e-09	1.21e-06	0.5	0.36	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-6.26	1.53e-09	1.21e-06	-0.32	-0.36	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
KIRP	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.26	1.53e-09	1.21e-06	0.37	0.36	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
KIRP	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-6.26	1.54e-09	1.22e-06	-0.28	-0.36	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
KIRP	cis	rs2283792	0.871	rs8136867	ENSG00000228050.1	TOP3BP1	6.26	1.55e-09	1.23e-06	0.39	0.36	Multiple sclerosis;	chr22:21850504	chr22:22223187~22224566:-
KIRP	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.26	1.55e-09	1.23e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
KIRP	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	6.26	1.55e-09	1.23e-06	0.43	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
KIRP	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	6.26	1.55e-09	1.23e-06	0.41	0.36	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
KIRP	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	6.26	1.55e-09	1.23e-06	0.41	0.36	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
KIRP	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	6.26	1.56e-09	1.23e-06	0.5	0.36	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
KIRP	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	6.26	1.56e-09	1.23e-06	0.43	0.36	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
KIRP	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-6.26	1.56e-09	1.23e-06	-0.45	-0.36	Depression;	chr6:28096845	chr6:28115628~28116551:+
KIRP	cis	rs4356975	0.509	rs4587017	ENSG00000250696.4	RP11-704M14.1	6.26	1.56e-09	1.23e-06	0.35	0.36	Obesity-related traits;	chr4:69081680	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.509	rs6422323	ENSG00000250696.4	RP11-704M14.1	6.26	1.56e-09	1.23e-06	0.35	0.36	Obesity-related traits;	chr4:69087362	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.509	rs4694169	ENSG00000250696.4	RP11-704M14.1	6.26	1.56e-09	1.23e-06	0.35	0.36	Obesity-related traits;	chr4:69088433	chr4:69182100~69216766:+
KIRP	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	6.26	1.56e-09	1.24e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	6.26	1.57e-09	1.24e-06	0.34	0.36	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
KIRP	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-6.26	1.57e-09	1.24e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
KIRP	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	6.26	1.57e-09	1.24e-06	0.41	0.36	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
KIRP	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-6.26	1.57e-09	1.24e-06	-0.47	-0.36	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
KIRP	cis	rs4638749	0.677	rs2219082	ENSG00000225328.1	AC019100.3	-6.26	1.57e-09	1.24e-06	-0.43	-0.36	Blood pressure;	chr2:108237726	chr2:108167748~108217841:-
KIRP	cis	rs9532669	0.89	rs11619117	ENSG00000239827.7	SUGT1P3	-6.26	1.57e-09	1.24e-06	-0.41	-0.36	Cervical cancer;	chr13:40880020	chr13:40908159~40921774:-
KIRP	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-6.26	1.57e-09	1.24e-06	-0.35	-0.36	Height;	chr11:118761813	chr11:118704607~118750263:+
KIRP	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-6.26	1.58e-09	1.25e-06	-0.29	-0.36	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
KIRP	cis	rs2921073	0.51	rs2976944	ENSG00000253981.4	ALG1L13P	6.26	1.58e-09	1.25e-06	0.3	0.36	Parkinson's disease;	chr8:8413404	chr8:8236003~8244667:-
KIRP	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-6.26	1.58e-09	1.25e-06	-0.37	-0.36	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
KIRP	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-6.26	1.58e-09	1.25e-06	-0.49	-0.36	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
KIRP	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	6.26	1.58e-09	1.25e-06	0.43	0.36	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	6.26	1.58e-09	1.25e-06	0.43	0.36	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
KIRP	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-6.26	1.59e-09	1.26e-06	-0.39	-0.36	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
KIRP	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-6.26	1.59e-09	1.26e-06	-0.29	-0.36	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
KIRP	cis	rs4443100	0.917	rs5996460	ENSG00000221069.1	AC000029.1	6.26	1.59e-09	1.26e-06	0.47	0.36	Serum parathyroid hormone levels;	chr22:23050912	chr22:23136620~23136710:+
KIRP	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	6.26	1.59e-09	1.26e-06	0.43	0.36	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
KIRP	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-6.26	1.6e-09	1.26e-06	-0.38	-0.36	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
KIRP	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	6.26	1.6e-09	1.26e-06	0.37	0.36	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
KIRP	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	6.26	1.6e-09	1.26e-06	0.27	0.36	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	6.26	1.6e-09	1.26e-06	0.27	0.36	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
KIRP	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.26	1.6e-09	1.27e-06	-0.45	-0.36	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
KIRP	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-6.26	1.61e-09	1.27e-06	-0.44	-0.36	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
KIRP	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	6.25	1.61e-09	1.27e-06	0.42	0.36	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
KIRP	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-6.25	1.61e-09	1.27e-06	-0.41	-0.36	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-6.25	1.61e-09	1.27e-06	-0.41	-0.36	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
KIRP	cis	rs2625529	0.652	rs2899776	ENSG00000260037.4	CTD-2524L6.3	6.25	1.62e-09	1.27e-06	0.28	0.36	Red blood cell count;	chr15:71976024	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs3759820	ENSG00000260037.4	CTD-2524L6.3	6.25	1.62e-09	1.27e-06	0.28	0.36	Red blood cell count;	chr15:72007690	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs12148078	ENSG00000260037.4	CTD-2524L6.3	6.25	1.62e-09	1.27e-06	0.28	0.36	Red blood cell count;	chr15:72008130	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	6.25	1.62e-09	1.28e-06	0.43	0.36	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
KIRP	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	6.25	1.62e-09	1.28e-06	0.31	0.36	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
KIRP	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-6.25	1.62e-09	1.28e-06	-0.3	-0.36	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
KIRP	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	6.25	1.62e-09	1.28e-06	0.33	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
KIRP	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-6.25	1.62e-09	1.28e-06	-0.46	-0.36	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	6.25	1.63e-09	1.28e-06	0.43	0.36	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	6.25	1.63e-09	1.28e-06	0.43	0.36	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	6.25	1.63e-09	1.28e-06	0.43	0.36	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
KIRP	cis	rs2765539	0.851	rs1891141	ENSG00000231365.4	RP11-418J17.1	-6.25	1.63e-09	1.28e-06	-0.39	-0.36	Waist-hip ratio;	chr1:119034787	chr1:119140396~119275973:+
KIRP	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	6.25	1.63e-09	1.28e-06	0.39	0.36	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
KIRP	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	6.25	1.63e-09	1.28e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
KIRP	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-6.25	1.63e-09	1.29e-06	-0.31	-0.36	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
KIRP	cis	rs2625529	0.59	rs8023703	ENSG00000260037.4	CTD-2524L6.3	6.25	1.63e-09	1.29e-06	0.29	0.36	Red blood cell count;	chr15:72211718	chr15:71818396~71823384:+
KIRP	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-6.25	1.64e-09	1.29e-06	-0.44	-0.36	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
KIRP	cis	rs4356975	0.509	rs4458521	ENSG00000250696.4	RP11-704M14.1	6.25	1.64e-09	1.29e-06	0.35	0.36	Obesity-related traits;	chr4:69086240	chr4:69182100~69216766:+
KIRP	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	6.25	1.64e-09	1.29e-06	0.56	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
KIRP	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-6.25	1.65e-09	1.3e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
KIRP	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	6.25	1.65e-09	1.3e-06	0.44	0.36	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
KIRP	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.25	1.65e-09	1.3e-06	0.38	0.36	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
KIRP	cis	rs2625529	0.526	rs8032222	ENSG00000260037.4	CTD-2524L6.3	6.25	1.65e-09	1.3e-06	0.28	0.36	Red blood cell count;	chr15:72186837	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	6.25	1.66e-09	1.3e-06	0.37	0.36	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
KIRP	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	6.25	1.66e-09	1.3e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	6.25	1.66e-09	1.3e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
KIRP	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	6.25	1.66e-09	1.3e-06	0.42	0.36	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
KIRP	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-6.25	1.66e-09	1.31e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
KIRP	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-6.25	1.66e-09	1.31e-06	-0.62	-0.36	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
KIRP	cis	rs67311347	1	rs6795475	ENSG00000230274.1	PGAM1P3	6.25	1.66e-09	1.31e-06	0.35	0.36	Renal cell carcinoma;	chr3:40447790	chr3:40322715~40323279:-
KIRP	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-6.25	1.67e-09	1.31e-06	-0.4	-0.36	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
KIRP	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	6.25	1.67e-09	1.31e-06	0.27	0.36	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
KIRP	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-6.25	1.67e-09	1.31e-06	-0.45	-0.36	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
KIRP	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	6.25	1.67e-09	1.31e-06	0.46	0.36	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
KIRP	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	6.25	1.68e-09	1.32e-06	0.38	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
KIRP	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	6.25	1.68e-09	1.32e-06	0.36	0.36	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
KIRP	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	6.25	1.68e-09	1.32e-06	0.35	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
KIRP	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-6.25	1.68e-09	1.32e-06	-0.47	-0.36	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
KIRP	cis	rs10872587	0.555	rs9497426	ENSG00000235652.6	RP11-545I5.3	-6.25	1.68e-09	1.32e-06	-0.43	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145913508	chr6:145799409~145886585:+
KIRP	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	6.25	1.68e-09	1.32e-06	0.26	0.36	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
KIRP	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-6.25	1.68e-09	1.32e-06	-0.47	-0.36	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
KIRP	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	6.25	1.69e-09	1.32e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	6.25	1.69e-09	1.32e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	6.25	1.69e-09	1.32e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
KIRP	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	6.25	1.69e-09	1.33e-06	0.29	0.36	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
KIRP	cis	rs4356975	0.509	rs28375964	ENSG00000250696.4	RP11-704M14.1	6.25	1.69e-09	1.33e-06	0.35	0.36	Obesity-related traits;	chr4:69098070	chr4:69182100~69216766:+
KIRP	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	6.25	1.69e-09	1.33e-06	0.41	0.36	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
KIRP	cis	rs12682352	0.652	rs3827806	ENSG00000253981.4	ALG1L13P	6.25	1.69e-09	1.33e-06	0.29	0.36	Neuroticism;	chr8:8866766	chr8:8236003~8244667:-
KIRP	cis	rs755249	0.588	rs6665948	ENSG00000237624.1	OXCT2P1	-6.25	1.7e-09	1.33e-06	-0.47	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39514956~39516490:+
KIRP	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-6.25	1.7e-09	1.33e-06	-0.36	-0.36	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-6.25	1.7e-09	1.33e-06	-0.36	-0.36	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-6.25	1.7e-09	1.33e-06	-0.36	-0.36	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-6.25	1.7e-09	1.33e-06	-0.36	-0.36	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-6.25	1.7e-09	1.33e-06	-0.36	-0.36	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
KIRP	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	6.25	1.7e-09	1.33e-06	0.5	0.36	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
KIRP	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	6.25	1.7e-09	1.33e-06	0.43	0.36	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
KIRP	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-6.24	1.7e-09	1.34e-06	-0.3	-0.36	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
KIRP	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	6.24	1.7e-09	1.34e-06	0.58	0.36	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
KIRP	cis	rs9388451	0.839	rs980014	ENSG00000237742.5	RP11-624M8.1	-6.24	1.71e-09	1.34e-06	-0.38	-0.36	Brugada syndrome;	chr6:125746855	chr6:125578558~125749190:-
KIRP	cis	rs9532669	0.926	rs9532657	ENSG00000239827.7	SUGT1P3	6.24	1.71e-09	1.34e-06	0.4	0.36	Cervical cancer;	chr13:40918208	chr13:40908159~40921774:-
KIRP	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	6.24	1.71e-09	1.34e-06	0.44	0.36	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	6.24	1.71e-09	1.34e-06	0.48	0.36	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
KIRP	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-6.24	1.72e-09	1.34e-06	-0.36	-0.36	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
KIRP	cis	rs67311347	1	rs951560	ENSG00000230274.1	PGAM1P3	6.24	1.72e-09	1.35e-06	0.34	0.36	Renal cell carcinoma;	chr3:40421980	chr3:40322715~40323279:-
KIRP	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-6.24	1.72e-09	1.35e-06	-0.3	-0.36	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
KIRP	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	6.24	1.72e-09	1.35e-06	0.44	0.36	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	6.24	1.72e-09	1.35e-06	0.44	0.36	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
KIRP	cis	rs2625529	0.652	rs28650442	ENSG00000260037.4	CTD-2524L6.3	-6.24	1.73e-09	1.36e-06	-0.28	-0.36	Red blood cell count;	chr15:71863104	chr15:71818396~71823384:+
KIRP	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-6.24	1.73e-09	1.36e-06	-0.43	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
KIRP	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	6.24	1.73e-09	1.36e-06	0.36	0.36	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	6.24	1.73e-09	1.36e-06	0.36	0.36	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
KIRP	cis	rs308403	0.509	rs309357	ENSG00000224786.1	CETN4P	6.24	1.74e-09	1.36e-06	0.39	0.36	Blood protein levels;	chr4:122732421	chr4:122730548~122732193:-
KIRP	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	6.24	1.74e-09	1.36e-06	0.48	0.36	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
KIRP	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	6.24	1.74e-09	1.36e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	6.24	1.75e-09	1.37e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	6.24	1.75e-09	1.37e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	6.24	1.75e-09	1.37e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
KIRP	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	6.24	1.75e-09	1.37e-06	0.39	0.36	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
KIRP	cis	rs67311347	1	rs6599094	ENSG00000230274.1	PGAM1P3	6.24	1.75e-09	1.37e-06	0.34	0.36	Renal cell carcinoma;	chr3:40358102	chr3:40322715~40323279:-
KIRP	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-6.24	1.76e-09	1.37e-06	-0.39	-0.36	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
KIRP	cis	rs308403	0.533	rs309377	ENSG00000224786.1	CETN4P	6.24	1.76e-09	1.37e-06	0.39	0.36	Blood protein levels;	chr4:122755198	chr4:122730548~122732193:-
KIRP	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-6.24	1.76e-09	1.38e-06	-0.38	-0.36	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
KIRP	cis	rs67311347	1	rs6599102	ENSG00000230274.1	PGAM1P3	6.24	1.76e-09	1.38e-06	0.34	0.36	Renal cell carcinoma;	chr3:40426915	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs12638199	ENSG00000230274.1	PGAM1P3	6.24	1.76e-09	1.38e-06	0.34	0.36	Renal cell carcinoma;	chr3:40433794	chr3:40322715~40323279:-
KIRP	cis	rs2765539	0.851	rs1409158	ENSG00000231365.4	RP11-418J17.1	6.24	1.76e-09	1.38e-06	0.38	0.36	Waist-hip ratio;	chr1:118996267	chr1:119140396~119275973:+
KIRP	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-6.24	1.77e-09	1.38e-06	-0.38	-0.36	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-6.24	1.77e-09	1.38e-06	-0.38	-0.36	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
KIRP	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-6.24	1.78e-09	1.39e-06	-0.37	-0.36	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
KIRP	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-6.24	1.78e-09	1.39e-06	-0.3	-0.36	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
KIRP	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-6.24	1.78e-09	1.39e-06	-0.3	-0.36	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
KIRP	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	6.24	1.78e-09	1.39e-06	0.61	0.36	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
KIRP	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	6.24	1.78e-09	1.39e-06	0.45	0.36	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
KIRP	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	6.24	1.79e-09	1.39e-06	0.44	0.36	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
KIRP	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.24	1.79e-09	1.4e-06	-0.35	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
KIRP	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-6.24	1.79e-09	1.4e-06	-0.35	-0.36	Height;	chr11:118764443	chr11:118704607~118750263:+
KIRP	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	6.24	1.79e-09	1.4e-06	0.37	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	6.24	1.79e-09	1.4e-06	0.37	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
KIRP	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-6.24	1.8e-09	1.4e-06	-0.44	-0.36	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
KIRP	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-6.24	1.8e-09	1.4e-06	-0.33	-0.36	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
KIRP	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	6.24	1.8e-09	1.4e-06	0.47	0.36	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
KIRP	cis	rs2283792	1	rs6518986	ENSG00000228050.1	TOP3BP1	6.24	1.8e-09	1.4e-06	0.39	0.36	Multiple sclerosis;	chr22:21831058	chr22:22223187~22224566:-
KIRP	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-6.23	1.8e-09	1.41e-06	-0.34	-0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
KIRP	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-6.23	1.81e-09	1.41e-06	-0.3	-0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
KIRP	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	6.23	1.81e-09	1.41e-06	0.33	0.36	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
KIRP	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	6.23	1.82e-09	1.42e-06	0.45	0.36	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
KIRP	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.23	1.82e-09	1.42e-06	-0.38	-0.36	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.23	1.82e-09	1.42e-06	-0.38	-0.36	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
KIRP	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-6.23	1.83e-09	1.43e-06	-0.29	-0.36	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
KIRP	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-6.23	1.83e-09	1.43e-06	-0.38	-0.36	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
KIRP	cis	rs2283792	1	rs1892846	ENSG00000228050.1	TOP3BP1	6.23	1.83e-09	1.43e-06	0.39	0.36	Multiple sclerosis;	chr22:21832190	chr22:22223187~22224566:-
KIRP	cis	rs2283792	1	rs1892848	ENSG00000228050.1	TOP3BP1	6.23	1.83e-09	1.43e-06	0.39	0.36	Multiple sclerosis;	chr22:21832273	chr22:22223187~22224566:-
KIRP	cis	rs2283792	1	rs5999750	ENSG00000228050.1	TOP3BP1	6.23	1.83e-09	1.43e-06	0.39	0.36	Multiple sclerosis;	chr22:21833720	chr22:22223187~22224566:-
KIRP	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-6.23	1.84e-09	1.43e-06	-0.3	-0.36	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
KIRP	cis	rs6908034	0.607	rs77791009	ENSG00000228412.5	RP4-625H18.2	6.23	1.84e-09	1.43e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19802164~19804752:-
KIRP	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.23	1.84e-09	1.43e-06	-0.39	-0.36	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
KIRP	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.23	1.84e-09	1.43e-06	0.47	0.36	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
KIRP	cis	rs7474896	0.559	rs1779075	ENSG00000151963.4	RP11-775A3.1	6.23	1.84e-09	1.43e-06	0.47	0.36	Obesity (extreme);	chr10:37878602	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.583	rs1735621	ENSG00000151963.4	RP11-775A3.1	6.23	1.84e-09	1.43e-06	0.47	0.36	Obesity (extreme);	chr10:37878795	chr10:37883594~37884109:+
KIRP	cis	rs79349575	0.811	rs1057897	ENSG00000248278.1	SUMO2P17	6.23	1.84e-09	1.43e-06	0.41	0.36	Type 2 diabetes;	chr17:48928147	chr17:48874860~48908983:-
KIRP	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-6.23	1.84e-09	1.44e-06	-0.47	-0.36	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	6.23	1.85e-09	1.44e-06	0.41	0.36	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	6.23	1.85e-09	1.44e-06	0.41	0.36	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
KIRP	cis	rs2765539	0.851	rs1409159	ENSG00000231365.4	RP11-418J17.1	-6.23	1.85e-09	1.44e-06	-0.38	-0.36	Waist-hip ratio;	chr1:118995810	chr1:119140396~119275973:+
KIRP	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-6.23	1.85e-09	1.44e-06	-0.3	-0.36	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
KIRP	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	6.23	1.85e-09	1.44e-06	0.41	0.36	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
KIRP	cis	rs748404	0.578	rs1058298	ENSG00000249839.1	AC011330.5	-6.23	1.85e-09	1.44e-06	-0.39	-0.36	Lung cancer;	chr15:43408732	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-6.23	1.86e-09	1.45e-06	-0.3	-0.36	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
KIRP	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	6.23	1.86e-09	1.45e-06	0.44	0.36	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
KIRP	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.86e-09	1.45e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.86e-09	1.45e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
KIRP	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28136698	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28136856	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28138363	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28138981	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28139012	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28139049	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28139876	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-6.23	1.86e-09	1.45e-06	-0.44	-0.36	Depression;	chr6:28139998	chr6:28115628~28116551:+
KIRP	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-6.23	1.86e-09	1.45e-06	-0.55	-0.36	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
KIRP	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	6.23	1.86e-09	1.45e-06	0.48	0.36	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
KIRP	cis	rs7829975	0.742	rs882462	ENSG00000253981.4	ALG1L13P	6.23	1.87e-09	1.45e-06	0.29	0.36	Mood instability;	chr8:8821020	chr8:8236003~8244667:-
KIRP	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-6.23	1.87e-09	1.45e-06	-0.48	-0.36	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-6.23	1.87e-09	1.45e-06	-0.48	-0.36	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-6.23	1.87e-09	1.46e-06	-0.46	-0.36	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
KIRP	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-6.23	1.88e-09	1.46e-06	-0.42	-0.36	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
KIRP	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.23	1.88e-09	1.46e-06	0.38	0.36	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
KIRP	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-6.23	1.89e-09	1.47e-06	-0.39	-0.36	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
KIRP	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	6.23	1.89e-09	1.47e-06	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
KIRP	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.23	1.9e-09	1.47e-06	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.23	1.9e-09	1.47e-06	-0.48	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
KIRP	cis	rs2439831	0.867	rs45585139	ENSG00000249839.1	AC011330.5	-6.23	1.9e-09	1.47e-06	-0.51	-0.36	Lung cancer in ever smokers;	chr15:43408229	chr15:43663654~43684339:-
KIRP	cis	rs9532669	0.926	rs2324742	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40919059	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.857	rs9594455	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40919452	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532659	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40920380	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9594457	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40920439	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9594458	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40920448	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9590562	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40920503	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs12857052	ENSG00000239827.7	SUGT1P3	-6.23	1.9e-09	1.48e-06	-0.4	-0.36	Cervical cancer;	chr13:40920831	chr13:40908159~40921774:-
KIRP	cis	rs6908034	0.607	rs79842087	ENSG00000228412.5	RP4-625H18.2	6.22	1.9e-09	1.48e-06	0.76	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821085	chr6:19802164~19804752:-
KIRP	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	6.22	1.9e-09	1.48e-06	0.32	0.36	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
KIRP	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	6.22	1.91e-09	1.48e-06	0.47	0.36	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	6.22	1.91e-09	1.48e-06	0.47	0.36	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	6.22	1.91e-09	1.48e-06	0.47	0.36	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	6.22	1.91e-09	1.48e-06	0.47	0.36	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
KIRP	cis	rs9371601	0.852	rs506181	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152461493	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs579464	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152461798	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6925067	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152462560	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs7762190	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152465612	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs7763343	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152465679	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6557226	ENSG00000226193.1	RP3-398G3.5	-6.22	1.91e-09	1.48e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152466549	chr6:152402398~152404966:+
KIRP	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	6.22	1.91e-09	1.48e-06	0.27	0.36	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
KIRP	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	6.22	1.91e-09	1.48e-06	0.37	0.36	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
KIRP	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	6.22	1.91e-09	1.48e-06	0.29	0.36	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-6.22	1.91e-09	1.48e-06	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
KIRP	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	6.22	1.92e-09	1.49e-06	0.34	0.36	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
KIRP	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-6.22	1.92e-09	1.49e-06	-0.49	-0.36	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
KIRP	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-6.22	1.92e-09	1.49e-06	-0.49	-0.36	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
KIRP	cis	rs6908034	0.607	rs78774173	ENSG00000228412.5	RP4-625H18.2	6.22	1.93e-09	1.49e-06	0.76	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19802164~19804752:-
KIRP	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	6.22	1.93e-09	1.49e-06	0.46	0.36	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
KIRP	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	6.22	1.93e-09	1.5e-06	0.47	0.36	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
KIRP	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	6.22	1.93e-09	1.5e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
KIRP	cis	rs9388451	0.874	rs9398787	ENSG00000237742.5	RP11-624M8.1	-6.22	1.94e-09	1.5e-06	-0.37	-0.36	Brugada syndrome;	chr6:125769462	chr6:125578558~125749190:-
KIRP	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-6.22	1.94e-09	1.51e-06	-0.41	-0.36	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
KIRP	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-6.22	1.94e-09	1.51e-06	-0.37	-0.36	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
KIRP	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	6.22	1.94e-09	1.51e-06	0.49	0.36	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
KIRP	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-6.22	1.94e-09	1.51e-06	-0.32	-0.36	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
KIRP	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	6.22	1.94e-09	1.51e-06	0.31	0.36	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
KIRP	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-6.22	1.95e-09	1.51e-06	-0.36	-0.36	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
KIRP	cis	rs597539	0.69	rs659465	ENSG00000250508.1	RP11-757G1.6	-6.22	1.96e-09	1.51e-06	-0.55	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68851496	chr11:68870664~68874542:+
KIRP	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-6.22	1.96e-09	1.52e-06	-0.39	-0.36	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
KIRP	cis	rs4356975	0.692	rs7691361	ENSG00000196472.4	RP13-644M16.4	6.22	1.96e-09	1.52e-06	0.41	0.36	Obesity-related traits;	chr4:69077628	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.72	rs7691362	ENSG00000196472.4	RP13-644M16.4	6.22	1.96e-09	1.52e-06	0.41	0.36	Obesity-related traits;	chr4:69077631	chr4:69181660~69182372:+
KIRP	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-6.22	1.98e-09	1.53e-06	-0.49	-0.36	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
KIRP	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	6.22	1.98e-09	1.53e-06	0.43	0.36	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
KIRP	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-6.22	1.98e-09	1.53e-06	-0.41	-0.36	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
KIRP	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-6.22	1.99e-09	1.54e-06	-0.39	-0.36	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
KIRP	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	6.22	1.99e-09	1.54e-06	0.47	0.36	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
KIRP	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	6.22	1.99e-09	1.54e-06	0.77	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
KIRP	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-6.22	1.99e-09	1.54e-06	-0.32	-0.36	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
KIRP	cis	rs6085948	0.861	rs2224055	ENSG00000238102.1	RP11-19D2.1	-6.22	1.99e-09	1.54e-06	-0.44	-0.36	Interleukin-10 levels;	chr20:7253521	chr20:7256580~7258214:-
KIRP	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	6.22	2e-09	1.55e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
KIRP	cis	rs9371601	0.892	rs4574653	ENSG00000226193.1	RP3-398G3.5	-6.22	2e-09	1.55e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152486056	chr6:152402398~152404966:+
KIRP	cis	rs712022	0.935	rs2286810	ENSG00000246225.5	RP11-17A1.3	6.22	2e-09	1.55e-06	0.4	0.36	Dialysis-related mortality;	chr11:22829863	chr11:22829380~22945393:+
KIRP	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-6.22	2.01e-09	1.55e-06	-0.57	-0.36	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	6.22	2.01e-09	1.55e-06	0.47	0.36	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
KIRP	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.22	2.01e-09	1.55e-06	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	6.22	2.01e-09	1.55e-06	0.41	0.36	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	6.22	2.01e-09	1.55e-06	0.43	0.36	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
KIRP	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	6.21	2.02e-09	1.56e-06	0.36	0.36	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	6.21	2.02e-09	1.56e-06	0.47	0.36	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
KIRP	cis	rs67311347	1	rs7631893	ENSG00000230274.1	PGAM1P3	6.21	2.03e-09	1.57e-06	0.35	0.36	Renal cell carcinoma;	chr3:40399378	chr3:40322715~40323279:-
KIRP	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	6.21	2.03e-09	1.57e-06	0.41	0.36	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
KIRP	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-6.21	2.03e-09	1.57e-06	-0.35	-0.36	Height;	chr11:118786602	chr11:118704607~118750263:+
KIRP	cis	rs755249	0.565	rs4660846	ENSG00000237624.1	OXCT2P1	-6.21	2.03e-09	1.57e-06	-0.45	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39514956~39516490:+
KIRP	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	6.21	2.03e-09	1.57e-06	0.47	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
KIRP	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	6.21	2.03e-09	1.57e-06	0.27	0.36	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
KIRP	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	6.21	2.03e-09	1.57e-06	0.32	0.36	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
KIRP	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	6.21	2.04e-09	1.57e-06	0.47	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
KIRP	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	6.21	2.04e-09	1.57e-06	0.41	0.36	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
KIRP	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	6.21	2.04e-09	1.57e-06	0.39	0.36	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
KIRP	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	6.21	2.04e-09	1.58e-06	0.42	0.36	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
KIRP	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-6.21	2.05e-09	1.58e-06	-0.28	-0.36	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
KIRP	cis	rs2765539	0.701	rs4659148	ENSG00000231365.4	RP11-418J17.1	-6.21	2.05e-09	1.58e-06	-0.38	-0.36	Waist-hip ratio;	chr1:119104071	chr1:119140396~119275973:+
KIRP	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	6.21	2.05e-09	1.58e-06	0.37	0.36	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	6.21	2.05e-09	1.58e-06	0.37	0.36	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
KIRP	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-6.21	2.05e-09	1.58e-06	-0.38	-0.36	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
KIRP	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-6.21	2.06e-09	1.59e-06	-0.44	-0.36	Depression;	chr6:28137418	chr6:28115628~28116551:+
KIRP	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	6.21	2.06e-09	1.59e-06	0.25	0.36	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
KIRP	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-6.21	2.06e-09	1.59e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-6.21	2.06e-09	1.59e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-6.21	2.06e-09	1.59e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-6.21	2.06e-09	1.59e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-6.21	2.06e-09	1.59e-06	-0.47	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
KIRP	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-6.21	2.06e-09	1.59e-06	-0.43	-0.36	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-6.21	2.06e-09	1.59e-06	-0.43	-0.36	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-6.21	2.06e-09	1.59e-06	-0.43	-0.36	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
KIRP	cis	rs10256972	0.616	rs3802141	ENSG00000229043.2	AC091729.9	-6.21	2.07e-09	1.59e-06	-0.28	-0.36	Endometriosis;Longevity;	chr7:1091720	chr7:1160374~1165267:+
KIRP	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	6.21	2.07e-09	1.6e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
KIRP	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-6.21	2.08e-09	1.6e-06	-0.35	-0.36	Height;	chr11:118773873	chr11:118704607~118750263:+
KIRP	cis	rs7267979	0.833	rs6138556	ENSG00000274414.1	RP5-965G21.4	-6.21	2.09e-09	1.61e-06	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	6.21	2.09e-09	1.61e-06	0.48	0.36	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	6.21	2.09e-09	1.61e-06	0.31	0.36	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
KIRP	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-6.21	2.09e-09	1.61e-06	-0.36	-0.36	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
KIRP	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	6.21	2.1e-09	1.62e-06	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
KIRP	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	6.21	2.1e-09	1.62e-06	0.42	0.36	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
KIRP	cis	rs4638749	0.734	rs4676191	ENSG00000231221.1	AC023672.2	-6.21	2.11e-09	1.62e-06	-0.43	-0.36	Blood pressure;	chr2:108244786	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.734	rs35184015	ENSG00000231221.1	AC023672.2	-6.21	2.11e-09	1.62e-06	-0.43	-0.36	Blood pressure;	chr2:108254084	chr2:108049200~108052755:-
KIRP	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	6.21	2.11e-09	1.62e-06	0.68	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
KIRP	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.21	2.11e-09	1.62e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
KIRP	cis	rs9532669	0.963	rs9315794	ENSG00000239827.7	SUGT1P3	-6.21	2.11e-09	1.62e-06	-0.4	-0.36	Cervical cancer;	chr13:40939489	chr13:40908159~40921774:-
KIRP	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-6.21	2.11e-09	1.62e-06	-0.37	-0.36	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
KIRP	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	6.21	2.11e-09	1.62e-06	0.41	0.36	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
KIRP	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	6.21	2.11e-09	1.62e-06	0.28	0.36	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
KIRP	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	6.21	2.11e-09	1.63e-06	0.28	0.36	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	6.21	2.12e-09	1.63e-06	0.48	0.36	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
KIRP	cis	rs9388451	0.874	rs13209968	ENSG00000237742.5	RP11-624M8.1	-6.21	2.12e-09	1.63e-06	-0.37	-0.36	Brugada syndrome;	chr6:125768139	chr6:125578558~125749190:-
KIRP	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-6.21	2.12e-09	1.63e-06	-0.41	-0.36	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
KIRP	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-6.21	2.13e-09	1.64e-06	-0.36	-0.36	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
KIRP	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	6.2	2.13e-09	1.64e-06	0.61	0.36	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	6.2	2.13e-09	1.64e-06	0.61	0.36	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	6.2	2.13e-09	1.64e-06	0.61	0.36	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
KIRP	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-6.2	2.13e-09	1.64e-06	-0.4	-0.36	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
KIRP	cis	rs950027	0.787	rs2433616	ENSG00000259433.2	CTD-2651B20.4	-6.2	2.13e-09	1.64e-06	-0.3	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45330209~45332634:-
KIRP	cis	rs4356975	1	rs4356975	ENSG00000196472.4	RP13-644M16.4	6.2	2.13e-09	1.64e-06	0.41	0.36	Obesity-related traits;	chr4:69106745	chr4:69181660~69182372:+
KIRP	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-6.2	2.14e-09	1.64e-06	-0.32	-0.36	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
KIRP	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	6.2	2.14e-09	1.65e-06	0.3	0.36	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
KIRP	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-6.2	2.14e-09	1.65e-06	-0.45	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-6.2	2.14e-09	1.65e-06	-0.45	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-6.2	2.14e-09	1.65e-06	-0.45	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-6.2	2.14e-09	1.65e-06	-0.45	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
KIRP	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-6.2	2.15e-09	1.65e-06	-0.41	-0.36	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-6.2	2.15e-09	1.65e-06	-0.41	-0.36	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
KIRP	cis	rs9532669	0.926	rs9532654	ENSG00000239827.7	SUGT1P3	-6.2	2.15e-09	1.65e-06	-0.4	-0.36	Cervical cancer;	chr13:40909812	chr13:40908159~40921774:-
KIRP	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	6.2	2.16e-09	1.66e-06	0.43	0.36	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
KIRP	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	6.2	2.16e-09	1.66e-06	0.36	0.36	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
KIRP	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	6.2	2.16e-09	1.66e-06	0.37	0.36	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
KIRP	cis	rs2625529	0.652	rs2957736	ENSG00000260037.4	CTD-2524L6.3	6.2	2.16e-09	1.66e-06	0.28	0.36	Red blood cell count;	chr15:71973003	chr15:71818396~71823384:+
KIRP	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-6.2	2.16e-09	1.66e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
KIRP	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-6.2	2.16e-09	1.66e-06	-0.3	-0.36	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
KIRP	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-6.2	2.17e-09	1.67e-06	-0.44	-0.36	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
KIRP	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	6.2	2.17e-09	1.67e-06	0.41	0.36	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
KIRP	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-6.2	2.17e-09	1.67e-06	-0.3	-0.36	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
KIRP	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	6.2	2.18e-09	1.67e-06	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
KIRP	cis	rs2283792	1	rs5999515	ENSG00000228050.1	TOP3BP1	-6.2	2.18e-09	1.68e-06	-0.38	-0.36	Multiple sclerosis;	chr22:21790812	chr22:22223187~22224566:-
KIRP	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.2	2.2e-09	1.69e-06	-0.39	-0.36	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
KIRP	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	6.2	2.21e-09	1.69e-06	0.36	0.36	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
KIRP	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.2	2.21e-09	1.69e-06	0.94	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.2	2.21e-09	1.69e-06	0.94	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	6.2	2.21e-09	1.69e-06	0.94	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	6.2	2.21e-09	1.69e-06	0.94	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
KIRP	cis	rs6085948	0.861	rs6054847	ENSG00000238102.1	RP11-19D2.1	-6.2	2.21e-09	1.7e-06	-0.42	-0.36	Interleukin-10 levels;	chr20:7249794	chr20:7256580~7258214:-
KIRP	cis	rs6085948	0.861	rs11908494	ENSG00000238102.1	RP11-19D2.1	-6.2	2.21e-09	1.7e-06	-0.42	-0.36	Interleukin-10 levels;	chr20:7250266	chr20:7256580~7258214:-
KIRP	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	6.2	2.21e-09	1.7e-06	0.44	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
KIRP	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	6.2	2.21e-09	1.7e-06	0.44	0.36	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
KIRP	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	6.2	2.21e-09	1.7e-06	0.36	0.36	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
KIRP	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-6.2	2.22e-09	1.7e-06	-0.5	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
KIRP	cis	rs4443100	0.916	rs9612218	ENSG00000221069.1	AC000029.1	6.2	2.22e-09	1.7e-06	0.44	0.36	Serum parathyroid hormone levels;	chr22:23039637	chr22:23136620~23136710:+
KIRP	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.2	2.22e-09	1.7e-06	0.38	0.36	Depression;	chr6:28273214	chr6:28176188~28176674:+
KIRP	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.2	2.22e-09	1.7e-06	0.38	0.36	Depression;	chr6:28273215	chr6:28176188~28176674:+
KIRP	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-6.2	2.23e-09	1.71e-06	-0.29	-0.36	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	6.2	2.23e-09	1.71e-06	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
KIRP	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-6.2	2.23e-09	1.71e-06	-0.49	-0.36	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
KIRP	cis	rs67311347	0.911	rs6773917	ENSG00000230274.1	PGAM1P3	6.2	2.23e-09	1.71e-06	0.34	0.36	Renal cell carcinoma;	chr3:40427763	chr3:40322715~40323279:-
KIRP	cis	rs755249	0.567	rs16825887	ENSG00000237624.1	OXCT2P1	-6.2	2.23e-09	1.71e-06	-0.56	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39514956~39516490:+
KIRP	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	6.2	2.23e-09	1.71e-06	0.77	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	6.2	2.23e-09	1.71e-06	0.77	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
KIRP	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-6.2	2.24e-09	1.71e-06	-0.38	-0.36	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
KIRP	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	6.2	2.24e-09	1.72e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
KIRP	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	6.2	2.24e-09	1.72e-06	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
KIRP	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-6.2	2.25e-09	1.72e-06	-0.44	-0.36	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
KIRP	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	6.19	2.25e-09	1.73e-06	0.39	0.36	Breast size;	chr12:9232743	chr12:9277235~9313241:+
KIRP	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	6.19	2.26e-09	1.73e-06	0.67	0.36	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	6.19	2.26e-09	1.73e-06	0.71	0.36	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
KIRP	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-6.19	2.27e-09	1.74e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
KIRP	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	6.19	2.28e-09	1.74e-06	0.41	0.36	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
KIRP	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	6.19	2.28e-09	1.75e-06	0.45	0.36	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
KIRP	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	6.19	2.28e-09	1.75e-06	0.35	0.36	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
KIRP	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-6.19	2.3e-09	1.76e-06	-0.48	-0.36	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
KIRP	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	6.19	2.3e-09	1.76e-06	0.46	0.36	Myopia;	chr6:28302807	chr6:28943877~28944537:+
KIRP	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	6.19	2.3e-09	1.76e-06	0.5	0.36	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
KIRP	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-6.19	2.31e-09	1.76e-06	-0.38	-0.36	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
KIRP	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.19	2.31e-09	1.77e-06	-0.38	-0.36	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.19	2.31e-09	1.77e-06	-0.38	-0.36	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
KIRP	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-6.19	2.31e-09	1.77e-06	-0.47	-0.36	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
KIRP	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-6.19	2.31e-09	1.77e-06	-0.43	-0.36	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
KIRP	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-6.19	2.31e-09	1.77e-06	-0.3	-0.36	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
KIRP	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	6.19	2.31e-09	1.77e-06	0.58	0.36	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	6.19	2.31e-09	1.77e-06	0.58	0.36	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	6.19	2.31e-09	1.77e-06	0.58	0.36	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	6.19	2.31e-09	1.77e-06	0.58	0.36	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	6.19	2.31e-09	1.77e-06	0.58	0.36	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
KIRP	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	6.19	2.32e-09	1.77e-06	0.35	0.36	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000225282.1	AP000350.6	6.19	2.32e-09	1.77e-06	0.47	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23926900~23929574:+
KIRP	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-6.19	2.32e-09	1.77e-06	-0.37	-0.36	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
KIRP	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	6.19	2.32e-09	1.77e-06	0.45	0.36	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
KIRP	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.19	2.32e-09	1.77e-06	-0.38	-0.36	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
KIRP	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	6.19	2.33e-09	1.78e-06	0.46	0.36	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
KIRP	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-6.19	2.33e-09	1.78e-06	-0.37	-0.36	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
KIRP	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-6.19	2.33e-09	1.78e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
KIRP	cis	rs4443100	0.916	rs6003484	ENSG00000221069.1	AC000029.1	6.19	2.33e-09	1.78e-06	0.42	0.36	Serum parathyroid hormone levels;	chr22:23037808	chr22:23136620~23136710:+
KIRP	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	6.19	2.33e-09	1.78e-06	0.31	0.36	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
KIRP	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	6.19	2.34e-09	1.78e-06	0.25	0.36	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	6.19	2.34e-09	1.78e-06	0.25	0.36	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
KIRP	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	6.19	2.34e-09	1.78e-06	0.25	0.36	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
KIRP	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-6.19	2.34e-09	1.78e-06	-0.45	-0.36	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
KIRP	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-6.19	2.35e-09	1.8e-06	-0.29	-0.36	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
KIRP	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-6.19	2.36e-09	1.8e-06	-0.34	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-6.19	2.36e-09	1.8e-06	-0.34	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
KIRP	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.19	2.36e-09	1.8e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
KIRP	cis	rs4356975	0.563	rs7685151	ENSG00000250696.4	RP11-704M14.1	6.19	2.37e-09	1.81e-06	0.34	0.36	Obesity-related traits;	chr4:69114055	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.583	rs11936822	ENSG00000250696.4	RP11-704M14.1	6.19	2.37e-09	1.81e-06	0.34	0.36	Obesity-related traits;	chr4:69114229	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs34814736	ENSG00000250696.4	RP11-704M14.1	6.19	2.37e-09	1.81e-06	0.34	0.36	Obesity-related traits;	chr4:69114760	chr4:69182100~69216766:+
KIRP	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	6.19	2.37e-09	1.81e-06	0.61	0.36	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	6.19	2.37e-09	1.81e-06	0.61	0.36	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
KIRP	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-6.18	2.37e-09	1.81e-06	-0.35	-0.36	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
KIRP	cis	rs1799949	1	rs11654731	ENSG00000236383.6	LINC00854	-6.18	2.38e-09	1.81e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43174923	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs11651623	ENSG00000236383.6	LINC00854	-6.18	2.38e-09	1.81e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43177830	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs11657883	ENSG00000236383.6	LINC00854	-6.18	2.38e-09	1.81e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43178007	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs11656945	ENSG00000236383.6	LINC00854	-6.18	2.38e-09	1.81e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43178248	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12944430	ENSG00000236383.6	LINC00854	-6.18	2.38e-09	1.81e-06	-0.29	-0.36	Menopause (age at onset);	chr17:43178803	chr17:43216941~43305976:-
KIRP	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	6.18	2.38e-09	1.81e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	6.18	2.38e-09	1.81e-06	0.44	0.36	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	6.18	2.38e-09	1.81e-06	0.44	0.36	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
KIRP	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	6.18	2.38e-09	1.81e-06	0.34	0.36	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
KIRP	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-6.18	2.38e-09	1.81e-06	-0.45	-0.36	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
KIRP	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	6.18	2.38e-09	1.81e-06	0.36	0.36	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
KIRP	cis	rs7829975	0.777	rs6989926	ENSG00000253893.2	FAM85B	6.18	2.4e-09	1.83e-06	0.45	0.36	Mood instability;	chr8:8689803	chr8:8167819~8226614:-
KIRP	cis	rs67311347	1	rs7625736	ENSG00000230274.1	PGAM1P3	-6.18	2.4e-09	1.83e-06	-0.35	-0.36	Renal cell carcinoma;	chr3:40399854	chr3:40322715~40323279:-
KIRP	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	6.18	2.4e-09	1.83e-06	0.27	0.36	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
KIRP	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	6.18	2.41e-09	1.84e-06	0.95	0.36	Breast cancer;	chr5:349183	chr5:262769~262881:+
KIRP	cis	rs9371601	0.892	rs7755437	ENSG00000226193.1	RP3-398G3.5	-6.18	2.41e-09	1.84e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152474721	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs9383995	ENSG00000226193.1	RP3-398G3.5	-6.18	2.41e-09	1.84e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152475473	chr6:152402398~152404966:+
KIRP	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	6.18	2.41e-09	1.84e-06	0.48	0.36	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	6.18	2.42e-09	1.84e-06	0.3	0.36	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	6.18	2.42e-09	1.84e-06	0.3	0.36	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	6.18	2.43e-09	1.85e-06	0.48	0.36	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.622	rs61287898	ENSG00000250696.4	RP11-704M14.1	6.18	2.44e-09	1.85e-06	0.35	0.36	Obesity-related traits;	chr4:69167116	chr4:69182100~69216766:+
KIRP	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	6.18	2.44e-09	1.86e-06	0.41	0.36	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	6.18	2.44e-09	1.86e-06	0.41	0.36	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	6.18	2.44e-09	1.86e-06	0.41	0.36	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
KIRP	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-6.18	2.44e-09	1.86e-06	-0.35	-0.36	Height;	chr11:118791319	chr11:118704607~118750263:+
KIRP	cis	rs9532669	0.89	rs9532593	ENSG00000239827.7	SUGT1P3	-6.18	2.45e-09	1.86e-06	-0.4	-0.36	Cervical cancer;	chr13:40847717	chr13:40908159~40921774:-
KIRP	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	6.18	2.45e-09	1.86e-06	0.45	0.36	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
KIRP	cis	rs4356975	0.563	rs7658752	ENSG00000250696.4	RP11-704M14.1	6.18	2.45e-09	1.86e-06	0.34	0.36	Obesity-related traits;	chr4:69112350	chr4:69182100~69216766:+
KIRP	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-6.18	2.45e-09	1.86e-06	-0.39	-0.36	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
KIRP	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.18	2.45e-09	1.86e-06	0.52	0.36	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
KIRP	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.18	2.45e-09	1.86e-06	0.38	0.36	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
KIRP	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	6.18	2.46e-09	1.87e-06	0.47	0.36	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	6.18	2.46e-09	1.87e-06	0.47	0.36	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
KIRP	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-6.18	2.46e-09	1.87e-06	-0.32	-0.36	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
KIRP	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	2.46e-09	1.87e-06	-0.29	-0.36	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
KIRP	cis	rs4443100	1	rs4443100	ENSG00000221069.1	AC000029.1	6.18	2.46e-09	1.87e-06	0.45	0.36	Serum parathyroid hormone levels;	chr22:23030688	chr22:23136620~23136710:+
KIRP	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-6.18	2.46e-09	1.87e-06	-0.3	-0.36	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
KIRP	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	6.18	2.47e-09	1.88e-06	0.49	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
KIRP	cis	rs9402743	0.632	rs9389329	ENSG00000231028.7	LINC00271	6.18	2.47e-09	1.88e-06	0.32	0.36	Systemic lupus erythematosus;	chr6:135777966	chr6:135497801~135716055:+
KIRP	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	6.18	2.48e-09	1.88e-06	0.42	0.36	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	6.18	2.49e-09	1.89e-06	0.42	0.36	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
KIRP	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	6.18	2.49e-09	1.89e-06	0.31	0.36	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
KIRP	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	6.18	2.49e-09	1.89e-06	0.42	0.36	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
KIRP	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	6.18	2.49e-09	1.89e-06	0.46	0.36	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
KIRP	cis	rs4356975	0.563	rs11933459	ENSG00000250696.4	RP11-704M14.1	6.18	2.49e-09	1.89e-06	0.34	0.36	Obesity-related traits;	chr4:69116045	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs6600895	ENSG00000250696.4	RP11-704M14.1	6.18	2.49e-09	1.89e-06	0.34	0.36	Obesity-related traits;	chr4:69117694	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs4508963	ENSG00000250696.4	RP11-704M14.1	6.18	2.49e-09	1.89e-06	0.34	0.36	Obesity-related traits;	chr4:69118770	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs12505466	ENSG00000250696.4	RP11-704M14.1	6.18	2.49e-09	1.89e-06	0.34	0.36	Obesity-related traits;	chr4:69119944	chr4:69182100~69216766:+
KIRP	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.18	2.49e-09	1.89e-06	0.3	0.36	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
KIRP	cis	rs4638749	0.501	rs9917180	ENSG00000231221.1	AC023672.2	6.18	2.5e-09	1.89e-06	0.42	0.36	Blood pressure;	chr2:108131189	chr2:108049200~108052755:-
KIRP	cis	rs308403	0.509	rs1849430	ENSG00000224786.1	CETN4P	6.18	2.5e-09	1.9e-06	0.4	0.36	Blood protein levels;	chr4:122753546	chr4:122730548~122732193:-
KIRP	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-6.17	2.51e-09	1.91e-06	-0.32	-0.36	Height;	chr11:118857611	chr11:118791254~118793137:+
KIRP	cis	rs9532669	0.889	rs9549302	ENSG00000239827.7	SUGT1P3	-6.17	2.51e-09	1.91e-06	-0.41	-0.36	Cervical cancer;	chr13:40843278	chr13:40908159~40921774:-
KIRP	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	6.17	2.51e-09	1.91e-06	0.43	0.36	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
KIRP	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	6.17	2.52e-09	1.91e-06	0.4	0.36	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
KIRP	cis	rs2765539	0.851	rs1325939	ENSG00000231365.4	RP11-418J17.1	6.17	2.52e-09	1.91e-06	0.39	0.36	Waist-hip ratio;	chr1:119041345	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	6.17	2.52e-09	1.91e-06	0.41	0.36	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	6.17	2.52e-09	1.91e-06	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
KIRP	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	6.17	2.53e-09	1.92e-06	0.36	0.36	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
KIRP	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	6.17	2.53e-09	1.92e-06	0.36	0.36	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
KIRP	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	6.17	2.53e-09	1.92e-06	0.36	0.36	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
KIRP	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	6.17	2.53e-09	1.92e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
KIRP	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	6.17	2.53e-09	1.92e-06	0.27	0.36	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
KIRP	cis	rs6908034	0.607	rs75060331	ENSG00000228412.5	RP4-625H18.2	6.17	2.54e-09	1.93e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs77753186	ENSG00000228412.5	RP4-625H18.2	6.17	2.54e-09	1.93e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs79162793	ENSG00000228412.5	RP4-625H18.2	6.17	2.54e-09	1.93e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs76245225	ENSG00000228412.5	RP4-625H18.2	6.17	2.54e-09	1.93e-06	0.69	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19802164~19804752:-
KIRP	cis	rs1560104	0.536	rs11075131	ENSG00000274834.1	CTD-3037G24.5	6.17	2.55e-09	1.93e-06	0.4	0.36	Obesity-related traits;	chr16:12623130	chr16:12614451~12614852:+
KIRP	cis	rs7474896	0.537	rs2749589	ENSG00000151963.4	RP11-775A3.1	6.17	2.55e-09	1.93e-06	0.48	0.36	Obesity (extreme);	chr10:37977942	chr10:37883594~37884109:+
KIRP	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-6.17	2.55e-09	1.93e-06	-0.41	-0.36	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
KIRP	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	6.17	2.55e-09	1.93e-06	0.4	0.36	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	6.17	2.57e-09	1.95e-06	0.41	0.36	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	6.17	2.57e-09	1.95e-06	0.41	0.36	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
KIRP	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	6.17	2.58e-09	1.95e-06	0.37	0.36	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
KIRP	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-6.17	2.58e-09	1.95e-06	-0.44	-0.36	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
KIRP	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	6.17	2.58e-09	1.95e-06	0.43	0.36	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	6.17	2.58e-09	1.95e-06	0.43	0.36	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
KIRP	cis	rs4356975	0.563	rs6851533	ENSG00000250696.4	RP11-704M14.1	6.17	2.59e-09	1.96e-06	0.34	0.36	Obesity-related traits;	chr4:69113032	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.563	rs7666195	ENSG00000250696.4	RP11-704M14.1	6.17	2.59e-09	1.96e-06	0.34	0.36	Obesity-related traits;	chr4:69113765	chr4:69182100~69216766:+
KIRP	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	6.17	2.59e-09	1.96e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
KIRP	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-6.17	2.59e-09	1.96e-06	-0.27	-0.36	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
KIRP	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	6.17	2.59e-09	1.96e-06	0.41	0.36	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
KIRP	cis	rs2283792	0.935	rs8141851	ENSG00000228050.1	TOP3BP1	6.17	2.59e-09	1.96e-06	0.39	0.36	Multiple sclerosis;	chr22:21812161	chr22:22223187~22224566:-
KIRP	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	6.17	2.6e-09	1.96e-06	0.34	0.36	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
KIRP	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	6.17	2.6e-09	1.97e-06	0.43	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
KIRP	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	6.17	2.6e-09	1.97e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	6.17	2.6e-09	1.97e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	6.17	2.6e-09	1.97e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	6.17	2.6e-09	1.97e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	6.17	2.6e-09	1.97e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
KIRP	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-6.17	2.61e-09	1.97e-06	-0.41	-0.36	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
KIRP	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	6.17	2.61e-09	1.97e-06	0.41	0.36	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
KIRP	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-6.17	2.61e-09	1.98e-06	-0.36	-0.36	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
KIRP	cis	rs2625529	0.586	rs7170456	ENSG00000260037.4	CTD-2524L6.3	6.17	2.62e-09	1.98e-06	0.28	0.36	Red blood cell count;	chr15:72177605	chr15:71818396~71823384:+
KIRP	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.17	2.63e-09	1.99e-06	-0.37	-0.36	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
KIRP	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-6.17	2.63e-09	1.99e-06	-0.5	-0.36	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
KIRP	cis	rs755249	0.53	rs4660443	ENSG00000237624.1	OXCT2P1	6.17	2.63e-09	1.99e-06	0.57	0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39514956~39516490:+
KIRP	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	6.17	2.63e-09	1.99e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
KIRP	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	6.17	2.64e-09	1.99e-06	0.41	0.36	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
KIRP	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	6.17	2.64e-09	2e-06	0.55	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
KIRP	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	6.17	2.65e-09	2e-06	0.58	0.36	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	6.17	2.65e-09	2e-06	0.6	0.36	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
KIRP	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	6.17	2.65e-09	2e-06	0.31	0.36	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
KIRP	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	6.16	2.66e-09	2.01e-06	0.38	0.36	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
KIRP	cis	rs67311347	1	rs977652	ENSG00000230274.1	PGAM1P3	6.16	2.66e-09	2.01e-06	0.35	0.36	Renal cell carcinoma;	chr3:40437678	chr3:40322715~40323279:-
KIRP	cis	rs4852324	0.536	rs6721042	ENSG00000217702.2	RP11-287D1.4	6.16	2.66e-09	2.01e-06	0.66	0.36	Systemic lupus erythematosus;	chr2:73990156	chr2:74130583~74135395:+
KIRP	cis	rs2625529	0.73	rs8182011	ENSG00000260037.4	CTD-2524L6.3	6.16	2.67e-09	2.01e-06	0.29	0.36	Red blood cell count;	chr15:72097607	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	6.16	2.67e-09	2.02e-06	0.37	0.36	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	6.16	2.67e-09	2.02e-06	0.5	0.36	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
KIRP	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	6.16	2.68e-09	2.02e-06	0.27	0.36	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
KIRP	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	6.16	2.68e-09	2.02e-06	0.44	0.36	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
KIRP	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-6.16	2.68e-09	2.02e-06	-0.38	-0.36	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-6.16	2.68e-09	2.02e-06	-0.38	-0.36	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-6.16	2.68e-09	2.02e-06	-0.38	-0.36	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
KIRP	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.16	2.68e-09	2.02e-06	0.4	0.36	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
KIRP	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	6.16	2.68e-09	2.02e-06	0.41	0.36	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
KIRP	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-6.16	2.7e-09	2.03e-06	-0.27	-0.36	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
KIRP	cis	rs4443100	0.755	rs6003465	ENSG00000221069.1	AC000029.1	6.16	2.7e-09	2.04e-06	0.43	0.36	Serum parathyroid hormone levels;	chr22:23023333	chr22:23136620~23136710:+
KIRP	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	6.16	2.7e-09	2.04e-06	0.36	0.36	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
KIRP	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	6.16	2.71e-09	2.04e-06	0.26	0.36	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
KIRP	cis	rs4356975	0.563	rs6600893	ENSG00000250696.4	RP11-704M14.1	6.16	2.71e-09	2.04e-06	0.34	0.36	Obesity-related traits;	chr4:69113183	chr4:69182100~69216766:+
KIRP	cis	rs9388451	0.839	rs3966775	ENSG00000237742.5	RP11-624M8.1	-6.16	2.71e-09	2.04e-06	-0.37	-0.36	Brugada syndrome;	chr6:125746509	chr6:125578558~125749190:-
KIRP	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	6.16	2.72e-09	2.05e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	6.16	2.72e-09	2.05e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
KIRP	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-6.16	2.73e-09	2.05e-06	-0.35	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
KIRP	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	6.16	2.73e-09	2.06e-06	0.36	0.36	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
KIRP	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-6.16	2.73e-09	2.06e-06	-0.35	-0.36	Height;	chr11:118737916	chr11:118704607~118750263:+
KIRP	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	6.16	2.73e-09	2.06e-06	0.25	0.36	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
KIRP	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-6.16	2.74e-09	2.06e-06	-0.43	-0.36	Depression;	chr6:28110254	chr6:28115628~28116551:+
KIRP	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-6.16	2.74e-09	2.06e-06	-0.49	-0.36	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
KIRP	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.74e-09	2.06e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
KIRP	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.16	2.74e-09	2.07e-06	0.38	0.36	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
KIRP	cis	rs9371601	0.892	rs4304177	ENSG00000226193.1	RP3-398G3.5	-6.16	2.75e-09	2.07e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152468534	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs7771568	ENSG00000226193.1	RP3-398G3.5	-6.16	2.75e-09	2.07e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152470413	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs4318888	ENSG00000226193.1	RP3-398G3.5	-6.16	2.75e-09	2.07e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152471078	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.668	rs4343926	ENSG00000226193.1	RP3-398G3.5	-6.16	2.75e-09	2.07e-06	-0.39	-0.36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152472440	chr6:152402398~152404966:+
KIRP	cis	rs4638749	0.501	rs6708539	ENSG00000225328.1	AC019100.3	-6.16	2.75e-09	2.07e-06	-0.42	-0.36	Blood pressure;	chr2:108128586	chr2:108167748~108217841:-
KIRP	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	6.16	2.75e-09	2.07e-06	0.34	0.36	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
KIRP	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	6.16	2.75e-09	2.07e-06	0.45	0.36	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
KIRP	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	6.16	2.76e-09	2.08e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
KIRP	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-6.16	2.77e-09	2.08e-06	-0.61	-0.36	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
KIRP	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-6.16	2.77e-09	2.08e-06	-0.61	-0.36	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
KIRP	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	6.16	2.77e-09	2.08e-06	0.36	0.36	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
KIRP	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	6.16	2.77e-09	2.09e-06	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-6.16	2.77e-09	2.09e-06	-0.47	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
KIRP	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	6.16	2.78e-09	2.09e-06	0.44	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	6.16	2.78e-09	2.09e-06	0.44	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	6.16	2.78e-09	2.09e-06	0.44	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
KIRP	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-6.16	2.78e-09	2.09e-06	-0.38	-0.36	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	6.16	2.78e-09	2.09e-06	0.46	0.36	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
KIRP	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-6.16	2.78e-09	2.09e-06	-0.36	-0.36	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
KIRP	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	6.16	2.79e-09	2.09e-06	0.47	0.36	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	6.16	2.79e-09	2.09e-06	0.47	0.36	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
KIRP	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-6.16	2.79e-09	2.1e-06	-0.45	-0.36	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
KIRP	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	6.16	2.8e-09	2.1e-06	0.47	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
KIRP	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-6.16	2.8e-09	2.1e-06	-0.43	-0.36	Depression;	chr6:28126588	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-6.16	2.8e-09	2.1e-06	-0.43	-0.36	Depression;	chr6:28126953	chr6:28115628~28116551:+
KIRP	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.8e-09	2.1e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.8e-09	2.1e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.8e-09	2.1e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.8e-09	2.1e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.16	2.8e-09	2.1e-06	-0.32	-0.36	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
KIRP	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.16	2.8e-09	2.1e-06	0.35	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
KIRP	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-6.16	2.8e-09	2.1e-06	-0.29	-0.36	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
KIRP	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	6.15	2.81e-09	2.11e-06	0.36	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
KIRP	cis	rs2625529	0.689	rs12161990	ENSG00000260037.4	CTD-2524L6.3	6.15	2.81e-09	2.11e-06	0.28	0.36	Red blood cell count;	chr15:71910099	chr15:71818396~71823384:+
KIRP	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	6.15	2.81e-09	2.11e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
KIRP	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	6.15	2.82e-09	2.12e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	6.15	2.82e-09	2.12e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
KIRP	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	6.15	2.82e-09	2.12e-06	0.5	0.36	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
KIRP	cis	rs6908034	0.607	rs75110577	ENSG00000228412.5	RP4-625H18.2	6.15	2.83e-09	2.12e-06	0.68	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs79406203	ENSG00000228412.5	RP4-625H18.2	6.15	2.83e-09	2.12e-06	0.68	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19802164~19804752:-
KIRP	cis	rs67311347	1	rs9829800	ENSG00000230274.1	PGAM1P3	6.15	2.83e-09	2.12e-06	0.34	0.36	Renal cell carcinoma;	chr3:40402436	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	6.15	2.83e-09	2.12e-06	0.43	0.36	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	6.15	2.83e-09	2.12e-06	0.43	0.36	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
KIRP	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-6.15	2.83e-09	2.13e-06	-0.46	-0.36	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
KIRP	cis	rs453301	0.538	rs7830804	ENSG00000253981.4	ALG1L13P	-6.15	2.83e-09	2.13e-06	-0.29	-0.36	Joint mobility (Beighton score);	chr8:9113252	chr8:8236003~8244667:-
KIRP	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-6.15	2.84e-09	2.13e-06	-0.42	-0.36	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
KIRP	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	6.15	2.84e-09	2.13e-06	0.38	0.36	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
KIRP	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-6.15	2.85e-09	2.14e-06	-0.36	-0.36	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-6.15	2.85e-09	2.14e-06	-0.36	-0.36	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
KIRP	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-6.15	2.85e-09	2.14e-06	-0.39	-0.36	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
KIRP	cis	rs4852324	0.536	rs17009553	ENSG00000217702.2	RP11-287D1.4	-6.15	2.86e-09	2.14e-06	-0.74	-0.36	Systemic lupus erythematosus;	chr2:73992908	chr2:74130583~74135395:+
KIRP	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	6.15	2.86e-09	2.14e-06	0.35	0.36	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
KIRP	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-6.15	2.86e-09	2.15e-06	-0.32	-0.36	Height;	chr11:118856460	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-6.15	2.86e-09	2.15e-06	-0.32	-0.36	Height;	chr11:118856623	chr11:118791254~118793137:+
KIRP	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.15	2.87e-09	2.15e-06	-0.37	-0.36	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
KIRP	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-6.15	2.87e-09	2.15e-06	-0.43	-0.36	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
KIRP	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	6.15	2.88e-09	2.16e-06	0.44	0.36	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	6.15	2.88e-09	2.16e-06	0.44	0.36	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
KIRP	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	6.15	2.88e-09	2.16e-06	0.25	0.36	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
KIRP	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	6.15	2.88e-09	2.16e-06	0.25	0.36	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
KIRP	cis	rs4638749	0.734	rs6542756	ENSG00000231221.1	AC023672.2	-6.15	2.89e-09	2.17e-06	-0.43	-0.36	Blood pressure;	chr2:108249173	chr2:108049200~108052755:-
KIRP	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	6.15	2.91e-09	2.18e-06	0.43	0.36	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	6.15	2.91e-09	2.18e-06	0.41	0.36	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
KIRP	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	6.15	2.92e-09	2.18e-06	0.35	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
KIRP	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.15	2.92e-09	2.18e-06	-0.52	-0.36	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
KIRP	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	6.15	2.92e-09	2.18e-06	0.37	0.36	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
KIRP	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	6.15	2.92e-09	2.18e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	6.15	2.92e-09	2.18e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	6.15	2.92e-09	2.18e-06	0.42	0.36	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
KIRP	cis	rs12188164	0.686	rs72711365	ENSG00000221990.4	EXOC3-AS1	6.15	2.92e-09	2.19e-06	0.35	0.36	Cystic fibrosis severity;	chr5:416557	chr5:441498~443160:-
KIRP	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	6.15	2.92e-09	2.19e-06	0.4	0.36	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
KIRP	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	6.15	2.92e-09	2.19e-06	0.35	0.36	Breast size;	chr12:9228263	chr12:9277235~9313241:+
KIRP	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-6.15	2.93e-09	2.19e-06	-0.39	-0.36	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
KIRP	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-6.15	2.93e-09	2.19e-06	-0.38	-0.36	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
KIRP	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-6.15	2.93e-09	2.19e-06	-0.36	-0.36	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	6.15	2.93e-09	2.19e-06	0.47	0.36	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	6.15	2.94e-09	2.2e-06	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
KIRP	cis	rs67311347	1	rs4973898	ENSG00000230274.1	PGAM1P3	-6.15	2.94e-09	2.2e-06	-0.34	-0.35	Renal cell carcinoma;	chr3:40418041	chr3:40322715~40323279:-
KIRP	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	6.15	2.94e-09	2.2e-06	0.32	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	6.15	2.94e-09	2.2e-06	0.32	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
KIRP	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	6.15	2.96e-09	2.21e-06	0.41	0.35	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
KIRP	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-6.14	2.96e-09	2.21e-06	-0.35	-0.35	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
KIRP	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-6.14	2.96e-09	2.22e-06	-0.46	-0.35	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
KIRP	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	6.14	2.97e-09	2.22e-06	0.62	0.35	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
KIRP	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.14	2.97e-09	2.22e-06	-0.32	-0.35	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
KIRP	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	6.14	2.98e-09	2.22e-06	0.27	0.35	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
KIRP	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.14	2.98e-09	2.23e-06	-0.54	-0.35	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
KIRP	cis	rs4356975	0.697	rs6849081	ENSG00000250696.4	RP11-704M14.1	6.14	2.98e-09	2.23e-06	0.34	0.35	Obesity-related traits;	chr4:69144840	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.697	rs58039330	ENSG00000250696.4	RP11-704M14.1	6.14	2.98e-09	2.23e-06	0.34	0.35	Obesity-related traits;	chr4:69149529	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.66	rs60567038	ENSG00000250696.4	RP11-704M14.1	6.14	2.98e-09	2.23e-06	0.34	0.35	Obesity-related traits;	chr4:69150135	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.697	rs58366569	ENSG00000250696.4	RP11-704M14.1	6.14	2.98e-09	2.23e-06	0.34	0.35	Obesity-related traits;	chr4:69150626	chr4:69182100~69216766:+
KIRP	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-6.14	2.98e-09	2.23e-06	-0.39	-0.35	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-6.14	2.98e-09	2.23e-06	-0.39	-0.35	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-6.14	2.98e-09	2.23e-06	-0.39	-0.35	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-6.14	2.98e-09	2.23e-06	-0.39	-0.35	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-6.14	2.98e-09	2.23e-06	-0.39	-0.35	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
KIRP	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	6.14	2.98e-09	2.23e-06	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
KIRP	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	6.14	2.98e-09	2.23e-06	0.43	0.35	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
KIRP	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	6.14	2.99e-09	2.23e-06	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
KIRP	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-6.14	2.99e-09	2.23e-06	-0.33	-0.35	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
KIRP	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	6.14	2.99e-09	2.23e-06	0.43	0.35	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	6.14	2.99e-09	2.24e-06	0.41	0.35	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
KIRP	cis	rs308403	0.509	rs7690409	ENSG00000224786.1	CETN4P	6.14	3e-09	2.24e-06	0.39	0.35	Blood protein levels;	chr4:122745602	chr4:122730548~122732193:-
KIRP	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-6.14	3e-09	2.24e-06	-0.36	-0.35	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
KIRP	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	6.14	3e-09	2.24e-06	0.3	0.35	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
KIRP	cis	rs1560104	0.709	rs9806858	ENSG00000274834.1	CTD-3037G24.5	-6.14	3e-09	2.24e-06	-0.41	-0.35	Obesity-related traits;	chr16:12610564	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.709	rs2217271	ENSG00000274834.1	CTD-3037G24.5	-6.14	3e-09	2.24e-06	-0.41	-0.35	Obesity-related traits;	chr16:12610623	chr16:12614451~12614852:+
KIRP	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-6.14	3.01e-09	2.24e-06	-0.48	-0.35	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
KIRP	cis	rs2625529	0.652	rs7497104	ENSG00000260037.4	CTD-2524L6.3	-6.14	3.01e-09	2.25e-06	-0.28	-0.35	Red blood cell count;	chr15:71861659	chr15:71818396~71823384:+
KIRP	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	6.14	3.01e-09	2.25e-06	0.25	0.35	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
KIRP	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	6.14	3.02e-09	2.25e-06	0.35	0.35	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	6.14	3.02e-09	2.25e-06	0.35	0.35	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	6.14	3.02e-09	2.25e-06	0.35	0.35	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	6.14	3.02e-09	2.25e-06	0.35	0.35	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	6.14	3.02e-09	2.25e-06	0.35	0.35	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
KIRP	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-6.14	3.02e-09	2.25e-06	-0.54	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
KIRP	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.14	3.02e-09	2.25e-06	-0.32	-0.35	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.14	3.02e-09	2.25e-06	-0.32	-0.35	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
KIRP	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.14	3.03e-09	2.26e-06	0.4	0.35	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
KIRP	cis	rs1560104	0.536	rs34480785	ENSG00000274834.1	CTD-3037G24.5	6.14	3.03e-09	2.26e-06	0.4	0.35	Obesity-related traits;	chr16:12624032	chr16:12614451~12614852:+
KIRP	cis	rs4356975	0.509	rs4371688	ENSG00000248763.2	RP13-644M16.5	-6.14	3.04e-09	2.27e-06	-0.38	-0.35	Obesity-related traits;	chr4:69124323	chr4:69066395~69069888:+
KIRP	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-6.14	3.04e-09	2.27e-06	-0.37	-0.35	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
KIRP	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-6.14	3.05e-09	2.27e-06	-0.5	-0.35	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	6.14	3.05e-09	2.28e-06	0.42	0.35	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
KIRP	cis	rs4578769	0.691	rs28594790	ENSG00000266850.1	RP11-370A5.1	-6.14	3.05e-09	2.28e-06	-0.46	-0.35	Eosinophil percentage of white cells;	chr18:22985463	chr18:22723491~22907721:-
KIRP	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-6.14	3.06e-09	2.28e-06	-0.38	-0.35	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	6.14	3.07e-09	2.29e-06	0.49	0.35	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
KIRP	cis	rs7170668	1	rs7170668	ENSG00000258489.3	RP11-398J10.2	-6.14	3.07e-09	2.29e-06	-0.41	-0.35	Motion sickness;	chr15:95470914	chr15:95463592~95493770:-
KIRP	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	6.14	3.07e-09	2.29e-06	0.36	0.35	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
KIRP	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	6.14	3.07e-09	2.29e-06	0.48	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
KIRP	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	6.14	3.07e-09	2.29e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	6.14	3.07e-09	2.29e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
KIRP	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	6.14	3.08e-09	2.29e-06	0.47	0.35	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
KIRP	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-6.14	3.08e-09	2.29e-06	-0.38	-0.35	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
KIRP	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-6.14	3.08e-09	2.3e-06	-0.51	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
KIRP	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	6.14	3.09e-09	2.3e-06	0.46	0.35	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
KIRP	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.14	3.09e-09	2.3e-06	0.42	0.35	Depression;	chr6:28200948	chr6:28115628~28116551:+
KIRP	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.14	3.09e-09	2.3e-06	-0.38	-0.35	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.14	3.09e-09	2.3e-06	-0.38	-0.35	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
KIRP	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	6.14	3.1e-09	2.3e-06	0.44	0.35	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
KIRP	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-6.14	3.11e-09	2.31e-06	-0.43	-0.35	Depression;	chr6:28113616	chr6:28115628~28116551:+
KIRP	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-6.14	3.11e-09	2.31e-06	-0.42	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
KIRP	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-6.14	3.11e-09	2.32e-06	-0.4	-0.35	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
KIRP	cis	rs1799949	1	rs1973646	ENSG00000236383.6	LINC00854	-6.14	3.11e-09	2.32e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43158478	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793215	ENSG00000236383.6	LINC00854	-6.14	3.11e-09	2.32e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43166915	chr17:43216941~43305976:-
KIRP	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	6.14	3.12e-09	2.32e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	6.14	3.12e-09	2.32e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
KIRP	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.14	3.12e-09	2.32e-06	-0.47	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
KIRP	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-6.14	3.13e-09	2.32e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
KIRP	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-6.14	3.13e-09	2.33e-06	-0.38	-0.35	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
KIRP	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-6.13	3.14e-09	2.33e-06	-0.42	-0.35	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
KIRP	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	6.13	3.14e-09	2.34e-06	0.26	0.35	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
KIRP	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	6.13	3.15e-09	2.34e-06	0.37	0.35	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
KIRP	cis	rs2625529	0.618	rs6494992	ENSG00000260037.4	CTD-2524L6.3	6.13	3.16e-09	2.35e-06	0.27	0.35	Red blood cell count;	chr15:72128409	chr15:71818396~71823384:+
KIRP	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	6.13	3.17e-09	2.35e-06	0.38	0.35	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	6.13	3.17e-09	2.35e-06	0.38	0.35	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	6.13	3.17e-09	2.35e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
KIRP	cis	rs1560104	0.597	rs4781300	ENSG00000274834.1	CTD-3037G24.5	6.13	3.17e-09	2.35e-06	0.39	0.35	Obesity-related traits;	chr16:12613866	chr16:12614451~12614852:+
KIRP	cis	rs4356975	0.509	rs5014975	ENSG00000250696.4	RP11-704M14.1	6.13	3.17e-09	2.35e-06	0.34	0.35	Obesity-related traits;	chr4:69130244	chr4:69182100~69216766:+
KIRP	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-6.13	3.17e-09	2.35e-06	-0.26	-0.35	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
KIRP	cis	rs4936099	1	rs4936099	ENSG00000175773.11	RP11-121M22.1	6.13	3.17e-09	2.36e-06	0.36	0.35	Optic cup area;Vertical cup-disc ratio;	chr11:130410830	chr11:130314993~130403657:+
KIRP	cis	rs9371601	0.852	rs1949962	ENSG00000226193.1	RP3-398G3.5	-6.13	3.17e-09	2.36e-06	-0.39	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152502203	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	6.13	3.17e-09	2.36e-06	0.43	0.35	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
KIRP	cis	rs1799949	1	rs8176318	ENSG00000236383.6	LINC00854	-6.13	3.18e-09	2.36e-06	-0.26	-0.35	Menopause (age at onset);	chr17:43045257	chr17:43216941~43305976:-
KIRP	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	6.13	3.18e-09	2.36e-06	0.4	0.35	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	6.13	3.18e-09	2.36e-06	0.4	0.35	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
KIRP	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	6.13	3.18e-09	2.36e-06	0.45	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	6.13	3.18e-09	2.36e-06	0.45	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
KIRP	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	6.13	3.18e-09	2.36e-06	0.35	0.35	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
KIRP	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.13	3.19e-09	2.37e-06	-0.38	-0.35	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
KIRP	cis	rs6085948	0.861	rs6054849	ENSG00000238102.1	RP11-19D2.1	-6.13	3.19e-09	2.37e-06	-0.42	-0.35	Interleukin-10 levels;	chr20:7251460	chr20:7256580~7258214:-
KIRP	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	6.13	3.2e-09	2.38e-06	0.39	0.35	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
KIRP	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	6.13	3.2e-09	2.38e-06	0.39	0.35	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
KIRP	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.13	3.2e-09	2.38e-06	-0.38	-0.35	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.13	3.2e-09	2.38e-06	-0.38	-0.35	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.13	3.2e-09	2.38e-06	-0.38	-0.35	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.13	3.2e-09	2.38e-06	-0.38	-0.35	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
KIRP	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-6.13	3.21e-09	2.38e-06	-0.5	-0.35	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
KIRP	cis	rs9532669	0.963	rs7989303	ENSG00000239827.7	SUGT1P3	-6.13	3.21e-09	2.38e-06	-0.4	-0.35	Cervical cancer;	chr13:40950087	chr13:40908159~40921774:-
KIRP	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	6.13	3.22e-09	2.39e-06	0.6	0.35	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
KIRP	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-6.13	3.23e-09	2.39e-06	-0.38	-0.35	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-6.13	3.23e-09	2.4e-06	-0.45	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
KIRP	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-6.13	3.25e-09	2.41e-06	-0.32	-0.35	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
KIRP	cis	rs755249	0.53	rs1472662	ENSG00000237624.1	OXCT2P1	6.13	3.25e-09	2.41e-06	0.57	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39514956~39516490:+
KIRP	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	6.13	3.26e-09	2.41e-06	0.4	0.35	Height;	chr4:55361200	chr4:55363971~55395847:-
KIRP	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	6.13	3.26e-09	2.41e-06	0.48	0.35	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	6.13	3.26e-09	2.41e-06	0.48	0.35	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	6.13	3.26e-09	2.41e-06	0.48	0.35	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
KIRP	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-6.13	3.26e-09	2.41e-06	-0.47	-0.35	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-6.13	3.26e-09	2.41e-06	-0.47	-0.35	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	6.13	3.26e-09	2.41e-06	0.48	0.35	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
KIRP	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	6.13	3.26e-09	2.41e-06	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
KIRP	cis	rs755249	0.546	rs7533743	ENSG00000237624.1	OXCT2P1	-6.13	3.26e-09	2.42e-06	-0.46	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.565	rs7555699	ENSG00000237624.1	OXCT2P1	-6.13	3.26e-09	2.42e-06	-0.46	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.565	rs1809697	ENSG00000237624.1	OXCT2P1	-6.13	3.26e-09	2.42e-06	-0.46	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39514956~39516490:+
KIRP	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-6.13	3.27e-09	2.42e-06	-0.4	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
KIRP	cis	rs2625529	0.652	rs11634608	ENSG00000260037.4	CTD-2524L6.3	6.13	3.27e-09	2.42e-06	0.28	0.35	Red blood cell count;	chr15:71963377	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2957734	ENSG00000260037.4	CTD-2524L6.3	6.13	3.27e-09	2.42e-06	0.28	0.35	Red blood cell count;	chr15:71969044	chr15:71818396~71823384:+
KIRP	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.13	3.27e-09	2.42e-06	-0.46	-0.35	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
KIRP	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	6.13	3.27e-09	2.42e-06	0.37	0.35	Breast size;	chr12:9209254	chr12:9277235~9313241:+
KIRP	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	6.13	3.27e-09	2.42e-06	0.37	0.35	Breast size;	chr12:9209471	chr12:9277235~9313241:+
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	6.13	3.28e-09	2.43e-06	0.46	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
KIRP	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-6.13	3.29e-09	2.43e-06	-0.41	-0.35	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
KIRP	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.13	3.29e-09	2.44e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
KIRP	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-6.13	3.29e-09	2.44e-06	-0.32	-0.35	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs67060599	ENSG00000236383.6	LINC00854	-6.13	3.3e-09	2.44e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43103085	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176133	ENSG00000236383.6	LINC00854	-6.13	3.3e-09	2.44e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43105441	chr17:43216941~43305976:-
KIRP	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	6.13	3.3e-09	2.44e-06	0.41	0.35	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	6.13	3.3e-09	2.44e-06	0.41	0.35	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	6.13	3.3e-09	2.44e-06	0.41	0.35	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	6.13	3.3e-09	2.44e-06	0.41	0.35	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
KIRP	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	6.13	3.3e-09	2.44e-06	0.64	0.35	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
KIRP	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	6.12	3.31e-09	2.45e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	6.12	3.31e-09	2.45e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
KIRP	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-6.12	3.31e-09	2.45e-06	-0.4	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
KIRP	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	6.12	3.31e-09	2.45e-06	0.35	0.35	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
KIRP	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.12	3.31e-09	2.45e-06	0.4	0.35	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
KIRP	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-6.12	3.32e-09	2.45e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
KIRP	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-6.12	3.32e-09	2.45e-06	-0.38	-0.35	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
KIRP	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	6.12	3.32e-09	2.46e-06	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
KIRP	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	6.12	3.32e-09	2.46e-06	0.93	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	6.12	3.33e-09	2.46e-06	0.46	0.35	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	6.12	3.33e-09	2.46e-06	0.46	0.35	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
KIRP	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-6.12	3.33e-09	2.46e-06	-0.32	-0.35	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
KIRP	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-6.12	3.33e-09	2.46e-06	-0.3	-0.35	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
KIRP	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.12	3.33e-09	2.46e-06	-0.4	-0.35	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
KIRP	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	6.12	3.33e-09	2.46e-06	0.51	0.35	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
KIRP	cis	rs79349575	0.756	rs3848460	ENSG00000248278.1	SUMO2P17	-6.12	3.34e-09	2.47e-06	-0.41	-0.35	Type 2 diabetes;	chr17:48969752	chr17:48874860~48908983:-
KIRP	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.12	3.34e-09	2.47e-06	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
KIRP	cis	rs2283792	1	rs5999521	ENSG00000228050.1	TOP3BP1	6.12	3.35e-09	2.47e-06	0.38	0.35	Multiple sclerosis;	chr22:21792110	chr22:22223187~22224566:-
KIRP	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-6.12	3.35e-09	2.47e-06	-0.36	-0.35	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
KIRP	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-6.12	3.35e-09	2.48e-06	-0.48	-0.35	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
KIRP	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-6.12	3.35e-09	2.48e-06	-0.44	-0.35	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
KIRP	cis	rs2625529	0.73	rs2929528	ENSG00000260037.4	CTD-2524L6.3	6.12	3.36e-09	2.48e-06	0.28	0.35	Red blood cell count;	chr15:71976996	chr15:71818396~71823384:+
KIRP	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-6.12	3.36e-09	2.48e-06	-0.4	-0.35	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
KIRP	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	6.12	3.36e-09	2.48e-06	0.41	0.35	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	6.12	3.36e-09	2.48e-06	0.41	0.35	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	6.12	3.36e-09	2.48e-06	0.41	0.35	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
KIRP	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	6.12	3.36e-09	2.48e-06	0.38	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
KIRP	cis	rs2617170	0.732	rs2734423	ENSG00000245648.1	RP11-277P12.20	6.12	3.37e-09	2.49e-06	0.42	0.35	Behcet's disease;	chr12:10429008	chr12:10363769~10398506:+
KIRP	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-6.12	3.38e-09	2.5e-06	-0.36	-0.35	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
KIRP	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-6.12	3.39e-09	2.5e-06	-0.3	-0.35	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
KIRP	cis	rs7267979	0.903	rs6115101	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.868	rs6107019	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.868	rs6138553	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.903	rs6115109	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.833	rs4619688	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.903	rs6115118	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.903	rs1118963	ENSG00000274414.1	RP5-965G21.4	-6.12	3.39e-09	2.5e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25239007~25245229:-
KIRP	cis	rs4443100	0.958	rs13057385	ENSG00000221069.1	AC000029.1	6.12	3.39e-09	2.5e-06	0.48	0.35	Serum parathyroid hormone levels;	chr22:23038778	chr22:23136620~23136710:+
KIRP	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	6.12	3.39e-09	2.5e-06	0.45	0.35	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
KIRP	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	6.12	3.4e-09	2.51e-06	0.36	0.35	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
KIRP	cis	rs9532669	0.853	rs9315795	ENSG00000239827.7	SUGT1P3	-6.12	3.41e-09	2.51e-06	-0.4	-0.35	Cervical cancer;	chr13:40943382	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs3764056	ENSG00000239827.7	SUGT1P3	-6.12	3.41e-09	2.51e-06	-0.4	-0.35	Cervical cancer;	chr13:40943849	chr13:40908159~40921774:-
KIRP	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	6.12	3.41e-09	2.51e-06	0.26	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
KIRP	cis	rs6908034	0.607	rs12526109	ENSG00000228412.5	RP4-625H18.2	6.12	3.41e-09	2.51e-06	0.69	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19802164~19804752:-
KIRP	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	6.12	3.42e-09	2.52e-06	0.48	0.35	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
KIRP	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	6.12	3.42e-09	2.52e-06	0.39	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
KIRP	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	6.12	3.42e-09	2.52e-06	0.36	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
KIRP	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	6.12	3.42e-09	2.52e-06	0.44	0.35	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
KIRP	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-6.12	3.43e-09	2.53e-06	-0.36	-0.35	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
KIRP	cis	rs9371601	0.859	rs527021	ENSG00000226193.1	RP3-398G3.5	-6.12	3.43e-09	2.53e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152447059	chr6:152402398~152404966:+
KIRP	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-6.12	3.43e-09	2.53e-06	-0.36	-0.35	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
KIRP	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-6.12	3.44e-09	2.53e-06	-0.36	-0.35	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
KIRP	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	6.12	3.44e-09	2.54e-06	0.41	0.35	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
KIRP	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	6.12	3.44e-09	2.54e-06	0.26	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
KIRP	cis	rs4356975	0.697	rs5002700	ENSG00000250696.4	RP11-704M14.1	6.12	3.45e-09	2.54e-06	0.34	0.35	Obesity-related traits;	chr4:69155637	chr4:69182100~69216766:+
KIRP	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	6.12	3.45e-09	2.54e-06	0.36	0.35	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	6.12	3.45e-09	2.54e-06	0.36	0.35	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	6.12	3.45e-09	2.54e-06	0.36	0.35	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	6.12	3.45e-09	2.54e-06	0.36	0.35	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	6.12	3.45e-09	2.54e-06	0.48	0.35	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	6.12	3.46e-09	2.55e-06	0.41	0.35	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
KIRP	cis	rs2921073	0.51	rs2976945	ENSG00000253981.4	ALG1L13P	6.12	3.47e-09	2.55e-06	0.29	0.35	Parkinson's disease;	chr8:8413361	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	6.12	3.47e-09	2.56e-06	0.42	0.35	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	6.12	3.47e-09	2.56e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	6.12	3.47e-09	2.56e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
KIRP	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-6.12	3.47e-09	2.56e-06	-0.34	-0.35	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
KIRP	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	6.12	3.48e-09	2.57e-06	0.3	0.35	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
KIRP	cis	rs6908034	0.505	rs77880623	ENSG00000228412.5	RP4-625H18.2	6.12	3.49e-09	2.57e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19802164~19804752:-
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	6.12	3.49e-09	2.57e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
KIRP	cis	rs7474896	0.559	rs1735641	ENSG00000151963.4	RP11-775A3.1	6.12	3.49e-09	2.57e-06	0.47	0.35	Obesity (extreme);	chr10:37895924	chr10:37883594~37884109:+
KIRP	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-6.11	3.51e-09	2.58e-06	-0.49	-0.35	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
KIRP	cis	rs4443100	0.77	rs2330334	ENSG00000221069.1	AC000029.1	6.11	3.51e-09	2.58e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23021714	chr22:23136620~23136710:+
KIRP	cis	rs6908034	0.607	rs74559916	ENSG00000228412.5	RP4-625H18.2	6.11	3.51e-09	2.58e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.505	rs76391302	ENSG00000228412.5	RP4-625H18.2	6.11	3.51e-09	2.58e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19802164~19804752:-
KIRP	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	6.11	3.53e-09	2.59e-06	0.47	0.35	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
KIRP	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-6.11	3.53e-09	2.59e-06	-0.35	-0.35	Height;	chr11:118749988	chr11:118704607~118750263:+
KIRP	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-6.11	3.53e-09	2.59e-06	-0.33	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
KIRP	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-6.11	3.53e-09	2.6e-06	-0.51	-0.35	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
KIRP	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	6.11	3.53e-09	2.6e-06	0.36	0.35	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
KIRP	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.11	3.54e-09	2.6e-06	-0.47	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
KIRP	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-6.11	3.54e-09	2.6e-06	-0.36	-0.35	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
KIRP	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-6.11	3.54e-09	2.6e-06	-0.37	-0.35	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
KIRP	cis	rs893363	0.522	rs2241807	ENSG00000271916.1	RP11-884K10.6	-6.11	3.55e-09	2.61e-06	-0.33	-0.35	Axial length;	chr3:53823131	chr3:53797764~53798019:-
KIRP	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-6.11	3.56e-09	2.61e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-6.11	3.56e-09	2.61e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-6.11	3.56e-09	2.61e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
KIRP	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-6.11	3.56e-09	2.61e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
KIRP	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-6.11	3.56e-09	2.61e-06	-0.47	-0.35	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
KIRP	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	6.11	3.56e-09	2.62e-06	0.3	0.35	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
KIRP	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	6.11	3.57e-09	2.62e-06	0.34	0.35	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
KIRP	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	6.11	3.57e-09	2.62e-06	0.34	0.35	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
KIRP	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	6.11	3.57e-09	2.62e-06	0.32	0.35	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
KIRP	cis	rs4356975	0.509	rs4309908	ENSG00000250696.4	RP11-704M14.1	6.11	3.57e-09	2.62e-06	0.33	0.35	Obesity-related traits;	chr4:69086022	chr4:69182100~69216766:+
KIRP	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-6.11	3.57e-09	2.62e-06	-0.36	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
KIRP	cis	rs6496932	1	rs34434405	ENSG00000218052.5	ADAMTS7P4	6.11	3.57e-09	2.62e-06	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85255369~85330334:-
KIRP	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	6.11	3.58e-09	2.63e-06	0.42	0.35	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	6.11	3.58e-09	2.63e-06	0.42	0.35	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
KIRP	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	6.11	3.58e-09	2.63e-06	0.39	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
KIRP	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-6.11	3.58e-09	2.63e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
KIRP	cis	rs1560104	0.597	rs11075126	ENSG00000274834.1	CTD-3037G24.5	6.11	3.58e-09	2.63e-06	0.39	0.35	Obesity-related traits;	chr16:12613117	chr16:12614451~12614852:+
KIRP	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	6.11	3.59e-09	2.63e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	6.11	3.59e-09	2.63e-06	0.42	0.35	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
KIRP	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	6.11	3.59e-09	2.64e-06	0.37	0.35	Breast size;	chr12:9206399	chr12:9277235~9313241:+
KIRP	cis	rs4356975	0.509	rs10006452	ENSG00000248763.2	RP13-644M16.5	-6.11	3.59e-09	2.64e-06	-0.38	-0.35	Obesity-related traits;	chr4:69112090	chr4:69066395~69069888:+
KIRP	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
KIRP	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	6.11	3.6e-09	2.64e-06	0.38	0.35	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
KIRP	cis	rs9371601	0.892	rs6557227	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152466775	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6557228	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152467033	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6902037	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152468905	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6904183	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152469315	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs9371599	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152469357	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs6908747	ENSG00000226193.1	RP3-398G3.5	-6.11	3.6e-09	2.64e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152469486	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs7756410	ENSG00000226193.1	RP3-398G3.5	6.11	3.6e-09	2.64e-06	0.38	0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152468062	chr6:152402398~152404966:+
KIRP	cis	rs12188164	0.686	rs56279338	ENSG00000221990.4	EXOC3-AS1	6.11	3.6e-09	2.64e-06	0.35	0.35	Cystic fibrosis severity;	chr5:416003	chr5:441498~443160:-
KIRP	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-6.11	3.6e-09	2.64e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
KIRP	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-6.11	3.6e-09	2.64e-06	-0.46	-0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-6.11	3.6e-09	2.64e-06	-0.46	-0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
KIRP	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	6.11	3.61e-09	2.65e-06	0.83	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
KIRP	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	6.11	3.61e-09	2.65e-06	0.83	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
KIRP	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	6.11	3.61e-09	2.65e-06	0.83	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
KIRP	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-6.11	3.61e-09	2.65e-06	-0.49	-0.35	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
KIRP	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	6.11	3.62e-09	2.65e-06	0.61	0.35	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
KIRP	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-6.11	3.62e-09	2.65e-06	-0.3	-0.35	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
KIRP	cis	rs7267979	0.903	rs6107015	ENSG00000274414.1	RP5-965G21.4	-6.11	3.62e-09	2.65e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25239007~25245229:-
KIRP	cis	rs7829975	0.755	rs3789849	ENSG00000253981.4	ALG1L13P	6.11	3.63e-09	2.66e-06	0.27	0.35	Mood instability;	chr8:8829544	chr8:8236003~8244667:-
KIRP	cis	rs308403	0.532	rs309386	ENSG00000224786.1	CETN4P	6.11	3.63e-09	2.66e-06	0.38	0.35	Blood protein levels;	chr4:122744836	chr4:122730548~122732193:-
KIRP	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-6.11	3.63e-09	2.66e-06	-0.57	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
KIRP	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-6.11	3.64e-09	2.66e-06	-0.36	-0.35	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
KIRP	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-6.11	3.64e-09	2.67e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
KIRP	cis	rs308403	0.509	rs309376	ENSG00000224786.1	CETN4P	6.11	3.65e-09	2.67e-06	0.39	0.35	Blood protein levels;	chr4:122759036	chr4:122730548~122732193:-
KIRP	cis	rs1799949	0.93	rs3092987	ENSG00000236383.6	LINC00854	-6.11	3.65e-09	2.67e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43070706	chr17:43216941~43305976:-
KIRP	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.11	3.65e-09	2.68e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
KIRP	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	6.11	3.65e-09	2.68e-06	0.42	0.35	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
KIRP	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-6.11	3.65e-09	2.68e-06	-0.38	-0.35	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
KIRP	cis	rs9532669	0.963	rs4941391	ENSG00000239827.7	SUGT1P3	-6.11	3.66e-09	2.68e-06	-0.39	-0.35	Cervical cancer;	chr13:40939787	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs4343141	ENSG00000239827.7	SUGT1P3	-6.11	3.66e-09	2.68e-06	-0.39	-0.35	Cervical cancer;	chr13:40940497	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs3887418	ENSG00000239827.7	SUGT1P3	-6.11	3.66e-09	2.68e-06	-0.39	-0.35	Cervical cancer;	chr13:40940560	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs1056820	ENSG00000239827.7	SUGT1P3	-6.11	3.66e-09	2.68e-06	-0.39	-0.35	Cervical cancer;	chr13:40941150	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532678	ENSG00000239827.7	SUGT1P3	-6.11	3.66e-09	2.68e-06	-0.39	-0.35	Cervical cancer;	chr13:40941862	chr13:40908159~40921774:-
KIRP	cis	rs2283792	0.967	rs11704205	ENSG00000228050.1	TOP3BP1	6.11	3.66e-09	2.68e-06	0.38	0.35	Multiple sclerosis;	chr22:21790964	chr22:22223187~22224566:-
KIRP	cis	rs755249	0.614	rs10888798	ENSG00000237624.1	OXCT2P1	-6.11	3.66e-09	2.68e-06	-0.46	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39514956~39516490:+
KIRP	cis	rs7474896	0.537	rs2505255	ENSG00000151963.4	RP11-775A3.1	-6.11	3.66e-09	2.68e-06	-0.44	-0.35	Obesity (extreme);	chr10:38070714	chr10:37883594~37884109:+
KIRP	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-6.11	3.68e-09	2.69e-06	-0.47	-0.35	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
KIRP	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	6.11	3.68e-09	2.69e-06	0.41	0.35	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
KIRP	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	6.11	3.69e-09	2.7e-06	0.83	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
KIRP	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	6.11	3.69e-09	2.7e-06	0.83	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
KIRP	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.1	3.69e-09	2.7e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.1	3.69e-09	2.7e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.1	3.69e-09	2.7e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
KIRP	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-6.1	3.69e-09	2.7e-06	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
KIRP	cis	rs9926296	0.585	rs6500441	ENSG00000260259.1	RP11-368I7.4	-6.1	3.7e-09	2.71e-06	-0.24	-0.35	Vitiligo;	chr16:89762261	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	6.1	3.7e-09	2.71e-06	0.41	0.35	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
KIRP	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-6.1	3.71e-09	2.71e-06	-0.4	-0.35	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
KIRP	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-6.1	3.71e-09	2.71e-06	-0.24	-0.35	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
KIRP	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.1	3.71e-09	2.71e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
KIRP	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	6.1	3.71e-09	2.71e-06	0.36	0.35	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
KIRP	cis	rs4356975	0.527	rs4694645	ENSG00000250696.4	RP11-704M14.1	6.1	3.72e-09	2.72e-06	0.33	0.35	Obesity-related traits;	chr4:69127200	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.527	rs60423649	ENSG00000250696.4	RP11-704M14.1	6.1	3.72e-09	2.72e-06	0.33	0.35	Obesity-related traits;	chr4:69127952	chr4:69182100~69216766:+
KIRP	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	6.1	3.72e-09	2.72e-06	0.4	0.35	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
KIRP	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	6.1	3.72e-09	2.72e-06	0.4	0.35	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
KIRP	cis	rs712022	0.967	rs10766971	ENSG00000246225.5	RP11-17A1.3	-6.1	3.73e-09	2.72e-06	-0.39	-0.35	Dialysis-related mortality;	chr11:22832005	chr11:22829380~22945393:+
KIRP	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-6.1	3.73e-09	2.72e-06	-0.4	-0.35	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
KIRP	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.1	3.73e-09	2.73e-06	-0.47	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
KIRP	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	6.1	3.74e-09	2.73e-06	0.62	0.35	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
KIRP	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	6.1	3.75e-09	2.74e-06	0.52	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
KIRP	cis	rs9322193	0.887	rs4870139	ENSG00000223701.3	RAET1E-AS1	6.1	3.75e-09	2.74e-06	0.41	0.35	Lung cancer;	chr6:149575182	chr6:149884431~149919508:+
KIRP	cis	rs755249	0.565	rs7539261	ENSG00000237624.1	OXCT2P1	-6.1	3.76e-09	2.75e-06	-0.45	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39514956~39516490:+
KIRP	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-6.1	3.77e-09	2.76e-06	-0.4	-0.35	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
KIRP	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-6.1	3.77e-09	2.76e-06	-0.4	-0.35	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
KIRP	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	6.1	3.78e-09	2.76e-06	0.49	0.35	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	6.1	3.78e-09	2.76e-06	0.44	0.35	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
KIRP	cis	rs6085948	0.861	rs6085955	ENSG00000238102.1	RP11-19D2.1	-6.1	3.78e-09	2.76e-06	-0.45	-0.35	Interleukin-10 levels;	chr20:7258347	chr20:7256580~7258214:-
KIRP	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-6.1	3.78e-09	2.76e-06	-0.38	-0.35	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
KIRP	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	6.1	3.78e-09	2.76e-06	0.4	0.35	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
KIRP	cis	rs1799949	1	rs8176269	ENSG00000236383.6	LINC00854	-6.1	3.79e-09	2.76e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43061609	chr17:43216941~43305976:-
KIRP	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	6.1	3.79e-09	2.77e-06	0.3	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	6.1	3.79e-09	2.77e-06	0.3	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
KIRP	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-6.1	3.79e-09	2.77e-06	-0.25	-0.35	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-6.1	3.79e-09	2.77e-06	-0.25	-0.35	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
KIRP	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	6.1	3.8e-09	2.77e-06	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
KIRP	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.1	3.8e-09	2.77e-06	-0.43	-0.35	Depression;	chr6:28184805	chr6:28115628~28116551:+
KIRP	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	6.1	3.8e-09	2.78e-06	0.38	0.35	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
KIRP	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	6.1	3.81e-09	2.78e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
KIRP	cis	rs1799949	1	rs16941	ENSG00000236383.6	LINC00854	-6.1	3.82e-09	2.78e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43092418	chr17:43216941~43305976:-
KIRP	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-6.1	3.84e-09	2.8e-06	-0.37	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-6.1	3.84e-09	2.8e-06	-0.37	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
KIRP	cis	rs4443100	0.726	rs5996449	ENSG00000221069.1	AC000029.1	6.1	3.85e-09	2.81e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23023133	chr22:23136620~23136710:+
KIRP	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	6.1	3.86e-09	2.81e-06	0.34	0.35	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
KIRP	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	6.1	3.86e-09	2.81e-06	0.34	0.35	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
KIRP	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	6.1	3.86e-09	2.81e-06	0.34	0.35	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
KIRP	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	6.1	3.86e-09	2.81e-06	0.34	0.35	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
KIRP	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	6.1	3.86e-09	2.82e-06	0.36	0.35	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
KIRP	cis	rs7267979	0.873	rs6115093	ENSG00000274414.1	RP5-965G21.4	-6.1	3.87e-09	2.82e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25239007~25245229:-
KIRP	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	6.1	3.87e-09	2.82e-06	0.59	0.35	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
KIRP	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-6.1	3.87e-09	2.82e-06	-0.36	-0.35	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-6.1	3.87e-09	2.82e-06	-0.36	-0.35	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-6.1	3.87e-09	2.82e-06	-0.36	-0.35	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-6.1	3.87e-09	2.82e-06	-0.36	-0.35	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-6.1	3.87e-09	2.82e-06	-0.36	-0.35	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
KIRP	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	6.1	3.87e-09	2.82e-06	0.33	0.35	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
KIRP	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-6.1	3.87e-09	2.82e-06	-0.41	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	6.1	3.87e-09	2.82e-06	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	6.1	3.87e-09	2.82e-06	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
KIRP	cis	rs11079159	0.837	rs4794559	ENSG00000263096.1	RP11-515O17.2	6.1	3.88e-09	2.82e-06	0.55	0.35	QRS duration;	chr17:55286939	chr17:55271504~55273653:-
KIRP	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	6.1	3.88e-09	2.82e-06	0.37	0.35	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
KIRP	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-6.1	3.88e-09	2.82e-06	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
KIRP	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-6.09	3.9e-09	2.84e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-6.09	3.9e-09	2.84e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-6.09	3.9e-09	2.84e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-6.09	3.9e-09	2.84e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
KIRP	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.09	3.91e-09	2.85e-06	-0.38	-0.35	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.09	3.91e-09	2.85e-06	-0.38	-0.35	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.09	3.91e-09	2.85e-06	-0.38	-0.35	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.09	3.91e-09	2.85e-06	-0.38	-0.35	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.09	3.91e-09	2.85e-06	-0.38	-0.35	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
KIRP	cis	rs755249	0.53	rs112205225	ENSG00000237624.1	OXCT2P1	6.09	3.92e-09	2.85e-06	0.58	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39514956~39516490:+
KIRP	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	6.09	3.92e-09	2.85e-06	0.48	0.35	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
KIRP	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
KIRP	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
KIRP	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	6.09	3.93e-09	2.86e-06	0.53	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
KIRP	cis	rs1799949	0.55	rs2343818	ENSG00000236383.6	LINC00854	-6.09	3.93e-09	2.86e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43332406	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.526	rs4352088	ENSG00000236383.6	LINC00854	-6.09	3.93e-09	2.86e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43337311	chr17:43216941~43305976:-
KIRP	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-6.09	3.94e-09	2.86e-06	-0.37	-0.35	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
KIRP	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	6.09	3.94e-09	2.87e-06	0.4	0.35	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
KIRP	cis	rs1799949	1	rs1060915	ENSG00000236383.6	LINC00854	-6.09	3.94e-09	2.87e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43082453	chr17:43216941~43305976:-
KIRP	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.09	3.95e-09	2.87e-06	-0.38	-0.35	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
KIRP	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-6.09	3.95e-09	2.87e-06	-0.47	-0.35	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
KIRP	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	6.09	3.95e-09	2.87e-06	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
KIRP	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	6.09	3.95e-09	2.87e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
KIRP	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	6.09	3.95e-09	2.87e-06	0.27	0.35	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
KIRP	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	6.09	3.96e-09	2.88e-06	0.48	0.35	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-6.09	3.96e-09	2.88e-06	-0.42	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
KIRP	cis	rs4356975	0.83	rs7438033	ENSG00000196472.4	RP13-644M16.4	-6.09	3.97e-09	2.88e-06	-0.37	-0.35	Obesity-related traits;	chr4:69059343	chr4:69181660~69182372:+
KIRP	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-6.09	3.97e-09	2.89e-06	-0.35	-0.35	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
KIRP	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	6.09	3.98e-09	2.89e-06	0.37	0.35	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13084194	ENSG00000180385.7	EMC3-AS1	6.09	3.98e-09	2.89e-06	0.37	0.35	Alzheimer's disease;	chr3:9989808	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13099507	ENSG00000180385.7	EMC3-AS1	6.09	3.98e-09	2.89e-06	0.37	0.35	Alzheimer's disease;	chr3:9989919	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs55962400	ENSG00000180385.7	EMC3-AS1	6.09	3.98e-09	2.89e-06	0.37	0.35	Alzheimer's disease;	chr3:10002773	chr3:9986893~10006990:+
KIRP	cis	rs2980439	0.517	rs17594093	ENSG00000253893.2	FAM85B	6.09	3.98e-09	2.89e-06	0.5	0.35	Neuroticism;	chr8:8248884	chr8:8167819~8226614:-
KIRP	cis	rs4356975	0.899	rs7677996	ENSG00000196472.4	RP13-644M16.4	6.09	3.98e-09	2.89e-06	0.4	0.35	Obesity-related traits;	chr4:69075473	chr4:69181660~69182372:+
KIRP	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	6.09	3.99e-09	2.89e-06	0.4	0.35	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	6.09	3.99e-09	2.89e-06	0.4	0.35	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
KIRP	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-6.09	3.99e-09	2.9e-06	-0.31	-0.35	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
KIRP	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.09	3.99e-09	2.9e-06	-0.44	-0.35	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.09	3.99e-09	2.9e-06	-0.44	-0.35	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
KIRP	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	6.09	3.99e-09	2.9e-06	0.28	0.35	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
KIRP	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-6.09	3.99e-09	2.9e-06	-0.43	-0.35	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-6.09	3.99e-09	2.9e-06	-0.43	-0.35	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
KIRP	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-6.09	3.99e-09	2.9e-06	-0.41	-0.35	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
KIRP	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	6.09	3.99e-09	2.9e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	6.09	3.99e-09	2.9e-06	0.29	0.35	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
KIRP	cis	rs7829975	0.774	rs11775523	ENSG00000253981.4	ALG1L13P	6.09	3.99e-09	2.9e-06	0.28	0.35	Mood instability;	chr8:8821666	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.774	rs1039915	ENSG00000253981.4	ALG1L13P	6.09	3.99e-09	2.9e-06	0.28	0.35	Mood instability;	chr8:8822104	chr8:8236003~8244667:-
KIRP	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-6.09	4e-09	2.9e-06	-0.66	-0.35	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	6.09	4e-09	2.9e-06	0.4	0.35	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	6.09	4e-09	2.9e-06	0.4	0.35	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
KIRP	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.09	4.01e-09	2.91e-06	0.54	0.35	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
KIRP	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-6.09	4.02e-09	2.92e-06	-0.49	-0.35	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
KIRP	cis	rs2625529	0.652	rs9302260	ENSG00000260037.4	CTD-2524L6.3	6.09	4.02e-09	2.92e-06	0.28	0.35	Red blood cell count;	chr15:71882270	chr15:71818396~71823384:+
KIRP	cis	rs832187	0.615	rs2037119	ENSG00000280620.1	SCAANT1	6.09	4.02e-09	2.92e-06	0.39	0.35	Schizophrenia;	chr3:64009203	chr3:63911518~63911772:-
KIRP	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	-6.09	4.02e-09	2.92e-06	-0.28	-0.35	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
KIRP	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-6.09	4.02e-09	2.92e-06	-0.32	-0.35	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
KIRP	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	6.09	4.03e-09	2.92e-06	0.4	0.35	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
KIRP	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-6.09	4.04e-09	2.93e-06	-0.37	-0.35	Height;	chr3:53093751	chr3:53064283~53065091:-
KIRP	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	6.09	4.04e-09	2.93e-06	0.44	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
KIRP	cis	rs9371601	0.926	rs12202199	ENSG00000226193.1	RP3-398G3.5	-6.09	4.04e-09	2.93e-06	-0.39	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152497080	chr6:152402398~152404966:+
KIRP	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	6.09	4.05e-09	2.93e-06	0.29	0.35	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
KIRP	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	6.09	4.07e-09	2.95e-06	0.36	0.35	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-6.09	4.08e-09	2.96e-06	-0.47	-0.35	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
KIRP	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-6.09	4.08e-09	2.96e-06	-0.4	-0.35	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
KIRP	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-6.09	4.09e-09	2.96e-06	-0.48	-0.35	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-6.09	4.09e-09	2.96e-06	-0.48	-0.35	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-6.09	4.09e-09	2.96e-06	-0.48	-0.35	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
KIRP	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	6.09	4.09e-09	2.96e-06	0.4	0.35	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
KIRP	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	6.09	4.1e-09	2.97e-06	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
KIRP	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-6.09	4.1e-09	2.97e-06	-0.38	-0.35	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
KIRP	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-6.09	4.11e-09	2.98e-06	-0.36	-0.35	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
KIRP	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	6.09	4.11e-09	2.98e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	6.08	4.12e-09	2.98e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
KIRP	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	6.08	4.12e-09	2.98e-06	0.4	0.35	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
KIRP	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	6.08	4.12e-09	2.98e-06	0.45	0.35	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
KIRP	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-6.08	4.14e-09	2.99e-06	-0.4	-0.35	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
KIRP	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-6.08	4.14e-09	2.99e-06	-0.36	-0.35	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-6.08	4.14e-09	2.99e-06	-0.29	-0.35	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
KIRP	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	6.08	4.14e-09	3e-06	0.59	0.35	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-6.08	4.15e-09	3e-06	-0.38	-0.35	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-6.08	4.15e-09	3e-06	-0.38	-0.35	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-6.08	4.15e-09	3e-06	-0.38	-0.35	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-6.08	4.15e-09	3e-06	-0.38	-0.35	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-6.08	4.15e-09	3e-06	-0.38	-0.35	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
KIRP	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-6.08	4.15e-09	3e-06	-0.55	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
KIRP	cis	rs2625529	0.824	rs2415121	ENSG00000260037.4	CTD-2524L6.3	-6.08	4.15e-09	3e-06	-0.28	-0.35	Red blood cell count;	chr15:71841677	chr15:71818396~71823384:+
KIRP	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	6.08	4.15e-09	3e-06	0.28	0.35	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	6.08	4.15e-09	3e-06	0.46	0.35	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
KIRP	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-6.08	4.16e-09	3e-06	-0.3	-0.35	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
KIRP	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	6.08	4.17e-09	3.01e-06	0.46	0.35	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	6.08	4.17e-09	3.01e-06	0.46	0.35	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
KIRP	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-6.08	4.17e-09	3.01e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
KIRP	cis	rs4356203	0.933	rs12801545	ENSG00000272034.1	SNORD14A	6.08	4.17e-09	3.01e-06	0.32	0.35	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17074654~17074744:-
KIRP	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-6.08	4.18e-09	3.02e-06	-0.36	-0.35	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-6.08	4.18e-09	3.02e-06	-0.36	-0.35	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-6.08	4.18e-09	3.02e-06	-0.36	-0.35	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-6.08	4.18e-09	3.02e-06	-0.36	-0.35	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-6.08	4.18e-09	3.02e-06	-0.36	-0.35	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
KIRP	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-6.08	4.19e-09	3.02e-06	-0.36	-0.35	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
KIRP	cis	rs7267979	0.706	rs6138542	ENSG00000274414.1	RP5-965G21.4	-6.08	4.19e-09	3.03e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	6.08	4.19e-09	3.03e-06	0.36	0.35	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	6.08	4.19e-09	3.03e-06	0.36	0.35	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
KIRP	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	6.08	4.19e-09	3.03e-06	0.4	0.35	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
KIRP	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	6.08	4.19e-09	3.03e-06	0.43	0.35	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
KIRP	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.08	4.19e-09	3.03e-06	0.38	0.35	Depression;	chr6:28363475	chr6:28176188~28176674:+
KIRP	cis	rs4356975	0.563	rs4535394	ENSG00000250696.4	RP11-704M14.1	-6.08	4.2e-09	3.03e-06	-0.33	-0.35	Obesity-related traits;	chr4:69122735	chr4:69182100~69216766:+
KIRP	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-6.08	4.2e-09	3.03e-06	-0.35	-0.35	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
KIRP	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.08	4.2e-09	3.03e-06	-0.48	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
KIRP	cis	rs2486288	0.656	rs9921035	ENSG00000259433.2	CTD-2651B20.4	6.08	4.22e-09	3.05e-06	0.3	0.35	Glomerular filtration rate;	chr15:45254462	chr15:45330209~45332634:-
KIRP	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.08	4.22e-09	3.05e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.08	4.22e-09	3.05e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.08	4.22e-09	3.05e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
KIRP	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-6.08	4.23e-09	3.05e-06	-0.36	-0.35	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-6.08	4.23e-09	3.05e-06	-0.36	-0.35	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
KIRP	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-6.08	4.23e-09	3.05e-06	-0.31	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
KIRP	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.08	4.23e-09	3.06e-06	-0.3	-0.35	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
KIRP	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	6.08	4.24e-09	3.06e-06	0.46	0.35	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
KIRP	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-6.08	4.24e-09	3.06e-06	-0.29	-0.35	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
KIRP	cis	rs308403	0.509	rs10016979	ENSG00000224786.1	CETN4P	6.08	4.24e-09	3.06e-06	0.39	0.35	Blood protein levels;	chr4:122752037	chr4:122730548~122732193:-
KIRP	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-6.08	4.25e-09	3.07e-06	-0.6	-0.35	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
KIRP	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	6.08	4.26e-09	3.07e-06	0.34	0.35	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
KIRP	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-6.08	4.27e-09	3.08e-06	-0.44	-0.35	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
KIRP	cis	rs1799949	1	rs8176202	ENSG00000236383.6	LINC00854	-6.08	4.29e-09	3.09e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43078211	chr17:43216941~43305976:-
KIRP	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.08	4.29e-09	3.1e-06	-0.4	-0.35	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
KIRP	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	6.08	4.3e-09	3.1e-06	0.29	0.35	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
KIRP	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.08	4.3e-09	3.1e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.08	4.3e-09	3.1e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	6.08	4.3e-09	3.1e-06	0.45	0.35	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
KIRP	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	6.08	4.31e-09	3.11e-06	0.3	0.35	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
KIRP	cis	rs308403	0.509	rs13117125	ENSG00000224786.1	CETN4P	6.08	4.31e-09	3.11e-06	0.38	0.35	Blood protein levels;	chr4:122749669	chr4:122730548~122732193:-
KIRP	cis	rs4638749	0.501	rs750523	ENSG00000225328.1	AC019100.3	-6.08	4.32e-09	3.11e-06	-0.42	-0.35	Blood pressure;	chr2:108129765	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs1872594	ENSG00000225328.1	AC019100.3	-6.08	4.32e-09	3.11e-06	-0.42	-0.35	Blood pressure;	chr2:108130357	chr2:108167748~108217841:-
KIRP	cis	rs2625529	0.617	rs2306576	ENSG00000260037.4	CTD-2524L6.3	6.08	4.32e-09	3.11e-06	0.27	0.35	Red blood cell count;	chr15:71878345	chr15:71818396~71823384:+
KIRP	cis	rs4356203	1	rs4356203	ENSG00000272034.1	SNORD14A	6.08	4.33e-09	3.12e-06	0.32	0.35	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17074654~17074744:-
KIRP	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	6.08	4.33e-09	3.12e-06	0.37	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
KIRP	cis	rs7474896	0.537	rs2749588	ENSG00000151963.4	RP11-775A3.1	-6.08	4.34e-09	3.13e-06	-0.46	-0.35	Obesity (extreme);	chr10:37980529	chr10:37883594~37884109:+
KIRP	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.07	4.35e-09	3.13e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
KIRP	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-6.07	4.38e-09	3.15e-06	-0.37	-0.35	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
KIRP	cis	rs1799949	1	rs8176265	ENSG00000236383.6	LINC00854	-6.07	4.38e-09	3.15e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43061979	chr17:43216941~43305976:-
KIRP	cis	rs71403859	0.554	rs12920245	ENSG00000260886.1	TAT-AS1	6.07	4.38e-09	3.15e-06	0.83	0.35	Post bronchodilator FEV1;	chr16:71995170	chr16:71565789~71578187:+
KIRP	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	6.07	4.4e-09	3.16e-06	0.37	0.35	Breast size;	chr12:9205627	chr12:9277235~9313241:+
KIRP	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.07	4.41e-09	3.17e-06	-0.5	-0.35	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
KIRP	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	6.07	4.42e-09	3.18e-06	0.36	0.35	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
KIRP	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	6.07	4.45e-09	3.2e-06	0.47	0.35	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	6.07	4.45e-09	3.2e-06	0.47	0.35	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-6.07	4.45e-09	3.2e-06	-0.35	-0.35	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
KIRP	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-6.07	4.47e-09	3.21e-06	-0.52	-0.35	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
KIRP	cis	rs1799949	0.965	rs34633610	ENSG00000236383.6	LINC00854	-6.07	4.47e-09	3.21e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43342017	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs11654051	ENSG00000236383.6	LINC00854	-6.07	4.47e-09	3.21e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43342288	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs56729776	ENSG00000236383.6	LINC00854	-6.07	4.47e-09	3.21e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43344763	chr17:43216941~43305976:-
KIRP	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	6.07	4.47e-09	3.21e-06	0.33	0.35	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
KIRP	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-6.07	4.47e-09	3.21e-06	-0.36	-0.35	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
KIRP	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	6.07	4.47e-09	3.21e-06	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
KIRP	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	6.07	4.47e-09	3.21e-06	0.44	0.35	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	6.07	4.48e-09	3.21e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
KIRP	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	6.07	4.48e-09	3.22e-06	0.47	0.35	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
KIRP	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-6.07	4.48e-09	3.22e-06	-0.31	-0.35	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
KIRP	cis	rs4638749	0.501	rs13421955	ENSG00000225328.1	AC019100.3	-6.07	4.49e-09	3.22e-06	-0.42	-0.35	Blood pressure;	chr2:108131620	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs2101357	ENSG00000225328.1	AC019100.3	-6.07	4.49e-09	3.22e-06	-0.42	-0.35	Blood pressure;	chr2:108132518	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs2171181	ENSG00000225328.1	AC019100.3	-6.07	4.49e-09	3.22e-06	-0.42	-0.35	Blood pressure;	chr2:108133935	chr2:108167748~108217841:-
KIRP	cis	rs712022	1	rs6483880	ENSG00000246225.5	RP11-17A1.3	6.07	4.49e-09	3.22e-06	0.4	0.35	Dialysis-related mortality;	chr11:22831194	chr11:22829380~22945393:+
KIRP	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	6.07	4.49e-09	3.22e-06	0.41	0.35	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
KIRP	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	6.07	4.49e-09	3.22e-06	0.41	0.35	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
KIRP	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	6.07	4.5e-09	3.23e-06	0.48	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
KIRP	cis	rs1799949	0.965	rs11658499	ENSG00000236383.6	LINC00854	-6.07	4.5e-09	3.23e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43182732	chr17:43216941~43305976:-
KIRP	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	6.07	4.51e-09	3.23e-06	0.3	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
KIRP	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	6.07	4.51e-09	3.24e-06	0.34	0.35	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
KIRP	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	6.07	4.51e-09	3.24e-06	0.39	0.35	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
KIRP	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	6.07	4.51e-09	3.24e-06	0.33	0.35	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
KIRP	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-6.07	4.52e-09	3.24e-06	-0.36	-0.35	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-6.07	4.52e-09	3.24e-06	-0.36	-0.35	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-6.07	4.52e-09	3.24e-06	-0.36	-0.35	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-6.07	4.52e-09	3.24e-06	-0.36	-0.35	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	6.07	4.52e-09	3.24e-06	0.36	0.35	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
KIRP	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	6.07	4.52e-09	3.24e-06	0.42	0.35	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
KIRP	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-6.07	4.53e-09	3.25e-06	-0.34	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
KIRP	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-6.07	4.53e-09	3.25e-06	-0.37	-0.35	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
KIRP	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	6.07	4.55e-09	3.26e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
KIRP	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	6.07	4.56e-09	3.27e-06	0.45	0.35	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
KIRP	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-6.07	4.56e-09	3.27e-06	-0.36	-0.35	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
KIRP	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-6.07	4.57e-09	3.27e-06	-0.37	-0.35	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
KIRP	cis	rs7474896	0.583	rs10740950	ENSG00000151963.4	RP11-775A3.1	-6.07	4.57e-09	3.27e-06	-0.46	-0.35	Obesity (extreme);	chr10:37714568	chr10:37883594~37884109:+
KIRP	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-6.07	4.57e-09	3.27e-06	-0.39	-0.35	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
KIRP	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	6.07	4.58e-09	3.28e-06	0.47	0.35	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	6.07	4.58e-09	3.28e-06	0.47	0.35	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
KIRP	cis	rs1799949	0.93	rs8176194	ENSG00000236383.6	LINC00854	-6.07	4.58e-09	3.28e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43079204	chr17:43216941~43305976:-
KIRP	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-6.07	4.59e-09	3.28e-06	-0.49	-0.35	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	6.07	4.59e-09	3.28e-06	0.49	0.35	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	6.07	4.59e-09	3.28e-06	0.49	0.35	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	6.07	4.59e-09	3.28e-06	0.49	0.35	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
KIRP	cis	rs2625529	0.938	rs2625530	ENSG00000260037.4	CTD-2524L6.3	-6.07	4.59e-09	3.28e-06	-0.32	-0.35	Red blood cell count;	chr15:71833693	chr15:71818396~71823384:+
KIRP	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	6.06	4.59e-09	3.29e-06	0.4	0.35	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	6.06	4.59e-09	3.29e-06	0.46	0.35	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
KIRP	cis	rs4578769	0.531	rs768793	ENSG00000266850.1	RP11-370A5.1	6.06	4.59e-09	3.29e-06	0.42	0.35	Eosinophil percentage of white cells;	chr18:22976640	chr18:22723491~22907721:-
KIRP	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	6.06	4.6e-09	3.29e-06	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
KIRP	cis	rs1799949	1	rs9646417	ENSG00000236383.6	LINC00854	-6.06	4.6e-09	3.29e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43346885	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1545764	ENSG00000236383.6	LINC00854	-6.06	4.6e-09	3.29e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43347197	chr17:43216941~43305976:-
KIRP	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	6.06	4.6e-09	3.29e-06	0.38	0.35	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
KIRP	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.06	4.61e-09	3.3e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	6.06	4.61e-09	3.3e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
KIRP	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	6.06	4.62e-09	3.3e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	6.06	4.62e-09	3.3e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	6.06	4.62e-09	3.3e-06	0.35	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-6.06	4.62e-09	3.3e-06	-0.36	-0.35	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
KIRP	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-6.06	4.62e-09	3.3e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
KIRP	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-6.06	4.63e-09	3.31e-06	-0.47	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
KIRP	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	6.06	4.63e-09	3.31e-06	0.4	0.35	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
KIRP	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	6.06	4.63e-09	3.31e-06	0.4	0.35	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
KIRP	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	6.06	4.64e-09	3.31e-06	0.33	0.35	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
KIRP	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-6.06	4.66e-09	3.33e-06	-0.36	-0.35	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
KIRP	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-6.06	4.67e-09	3.33e-06	-0.45	-0.35	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.775	rs4777466	ENSG00000260037.4	CTD-2524L6.3	-6.06	4.67e-09	3.33e-06	-0.28	-0.35	Red blood cell count;	chr15:71844531	chr15:71818396~71823384:+
KIRP	cis	rs712022	1	rs10833824	ENSG00000246225.5	RP11-17A1.3	-6.06	4.67e-09	3.34e-06	-0.39	-0.35	Dialysis-related mortality;	chr11:22825939	chr11:22829380~22945393:+
KIRP	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-6.06	4.67e-09	3.34e-06	-0.29	-0.35	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-6.06	4.67e-09	3.34e-06	-0.29	-0.35	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-6.06	4.67e-09	3.34e-06	-0.29	-0.35	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
KIRP	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-6.06	4.68e-09	3.34e-06	-0.42	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
KIRP	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	6.06	4.69e-09	3.35e-06	0.36	0.35	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	6.06	4.69e-09	3.35e-06	0.36	0.35	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	6.06	4.69e-09	3.35e-06	0.36	0.35	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	6.06	4.69e-09	3.35e-06	0.36	0.35	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
KIRP	cis	rs1799949	1	rs8176242	ENSG00000236383.6	LINC00854	-6.06	4.69e-09	3.35e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43065857	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176273	ENSG00000236383.6	LINC00854	-6.06	4.69e-09	3.35e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43059636	chr17:43216941~43305976:-
KIRP	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	6.06	4.71e-09	3.36e-06	0.37	0.35	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
KIRP	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	6.06	4.71e-09	3.36e-06	0.42	0.35	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
KIRP	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-6.06	4.72e-09	3.37e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
KIRP	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-6.06	4.73e-09	3.37e-06	-0.47	-0.35	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
KIRP	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	6.06	4.73e-09	3.38e-06	0.41	0.35	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	6.06	4.73e-09	3.38e-06	0.41	0.35	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
KIRP	cis	rs4443100	0.77	rs876101	ENSG00000221069.1	AC000029.1	6.06	4.74e-09	3.38e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23022202	chr22:23136620~23136710:+
KIRP	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	6.06	4.75e-09	3.39e-06	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
KIRP	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	6.06	4.76e-09	3.39e-06	0.47	0.35	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
KIRP	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	6.06	4.77e-09	3.4e-06	0.3	0.35	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
KIRP	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-6.06	4.77e-09	3.4e-06	-0.34	-0.35	Height;	chr3:53074760	chr3:53064283~53065091:-
KIRP	cis	rs7267979	0.966	rs6050611	ENSG00000274414.1	RP5-965G21.4	-6.06	4.77e-09	3.4e-06	-0.33	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	6.06	4.77e-09	3.4e-06	0.45	0.35	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
KIRP	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
KIRP	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-6.06	4.77e-09	3.4e-06	-0.48	-0.35	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
KIRP	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	6.06	4.78e-09	3.41e-06	0.46	0.35	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	6.06	4.78e-09	3.41e-06	0.46	0.35	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
KIRP	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	6.06	4.78e-09	3.41e-06	0.4	0.35	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
KIRP	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	6.06	4.78e-09	3.41e-06	0.4	0.35	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
KIRP	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	6.06	4.78e-09	3.41e-06	0.4	0.35	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
KIRP	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	6.06	4.78e-09	3.41e-06	0.4	0.35	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
KIRP	cis	rs6908034	0.607	rs73376650	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs112599867	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs73376651	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs73376655	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs73376657	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs74573060	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs113592672	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs113894708	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.546	rs73376662	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs12529148	ENSG00000228412.5	RP4-625H18.2	6.06	4.81e-09	3.42e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19802164~19804752:-
KIRP	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-6.06	4.81e-09	3.43e-06	-0.35	-0.35	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
KIRP	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-6.06	4.82e-09	3.43e-06	-0.38	-0.35	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
KIRP	cis	rs9371601	0.852	rs6915547	ENSG00000226193.1	RP3-398G3.5	-6.06	4.82e-09	3.43e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152478823	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs9383622	ENSG00000226193.1	RP3-398G3.5	-6.06	4.82e-09	3.43e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152479781	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.852	rs9371252	ENSG00000226193.1	RP3-398G3.5	-6.06	4.82e-09	3.43e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152479795	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs11155853	ENSG00000226193.1	RP3-398G3.5	-6.06	4.82e-09	3.43e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152480231	chr6:152402398~152404966:+
KIRP	cis	rs710913	0.774	rs2695319	ENSG00000237624.1	OXCT2P1	6.06	4.82e-09	3.43e-06	0.45	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39514956~39516490:+
KIRP	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	6.06	4.83e-09	3.44e-06	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
KIRP	cis	rs7829975	0.511	rs2955578	ENSG00000253981.4	ALG1L13P	6.06	4.83e-09	3.44e-06	0.3	0.35	Mood instability;	chr8:8279561	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-6.06	4.84e-09	3.44e-06	-0.36	-0.35	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
KIRP	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	6.06	4.84e-09	3.44e-06	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	6.06	4.84e-09	3.44e-06	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
KIRP	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-6.06	4.84e-09	3.45e-06	-0.36	-0.35	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
KIRP	cis	rs9371601	0.892	rs7775384	ENSG00000226193.1	RP3-398G3.5	-6.06	4.84e-09	3.45e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152476416	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.892	rs1554782	ENSG00000226193.1	RP3-398G3.5	-6.06	4.84e-09	3.45e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152476844	chr6:152402398~152404966:+
KIRP	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	6.05	4.85e-09	3.45e-06	0.26	0.35	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
KIRP	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.05	4.85e-09	3.45e-06	0.54	0.35	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.05	4.85e-09	3.45e-06	0.54	0.35	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	6.05	4.86e-09	3.46e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	6.05	4.86e-09	3.46e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	6.05	4.86e-09	3.46e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
KIRP	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-6.05	4.87e-09	3.46e-06	-0.41	-0.35	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	6.05	4.87e-09	3.46e-06	0.48	0.35	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
KIRP	cis	rs1799949	1	rs33946455	ENSG00000236383.6	LINC00854	-6.05	4.87e-09	3.47e-06	-0.29	-0.35	Menopause (age at onset);	chr17:43169829	chr17:43216941~43305976:-
KIRP	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	6.05	4.88e-09	3.47e-06	0.36	0.35	Height;	chr3:53085313	chr3:53064283~53065091:-
KIRP	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-6.05	4.89e-09	3.47e-06	-0.49	-0.35	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
KIRP	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-6.05	4.89e-09	3.48e-06	-0.41	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
KIRP	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	6.05	4.9e-09	3.48e-06	0.82	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
KIRP	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	6.05	4.91e-09	3.49e-06	0.4	0.35	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	6.05	4.93e-09	3.5e-06	0.46	0.35	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
KIRP	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-6.05	4.94e-09	3.51e-06	-0.35	-0.35	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
KIRP	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	6.05	4.94e-09	3.51e-06	0.46	0.35	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
KIRP	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-6.05	4.96e-09	3.52e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
KIRP	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	6.05	4.96e-09	3.52e-06	0.55	0.35	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	6.05	4.96e-09	3.52e-06	0.55	0.35	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
KIRP	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-6.05	4.97e-09	3.53e-06	-0.41	-0.35	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
KIRP	cis	rs932287	0.58	rs10743098	ENSG00000254860.4	TMEM9B-AS1	-6.05	4.97e-09	3.53e-06	-0.39	-0.35	Colonoscopy-negative controls vs population controls;	chr11:9038003	chr11:8964675~8977527:+
KIRP	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.05	4.98e-09	3.53e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
KIRP	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	6.05	4.98e-09	3.54e-06	0.45	0.35	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
KIRP	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	6.05	4.99e-09	3.54e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
KIRP	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-6.05	4.99e-09	3.54e-06	-0.38	-0.35	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
KIRP	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	6.05	5.01e-09	3.55e-06	0.35	0.35	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	6.05	5.01e-09	3.55e-06	0.35	0.35	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	6.05	5.01e-09	3.55e-06	0.35	0.35	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	6.05	5.01e-09	3.55e-06	0.35	0.35	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
KIRP	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	6.05	5.02e-09	3.56e-06	0.4	0.35	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
KIRP	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-6.05	5.02e-09	3.56e-06	-0.45	-0.35	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-6.05	5.02e-09	3.56e-06	-0.45	-0.35	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	6.05	5.03e-09	3.56e-06	0.36	0.35	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
KIRP	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	6.05	5.03e-09	3.57e-06	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
KIRP	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-6.05	5.03e-09	3.57e-06	-0.46	-0.35	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
KIRP	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-6.05	5.03e-09	3.57e-06	-0.46	-0.35	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
KIRP	cis	rs1560104	0.597	rs4781299	ENSG00000274834.1	CTD-3037G24.5	6.05	5.03e-09	3.57e-06	0.39	0.35	Obesity-related traits;	chr16:12613756	chr16:12614451~12614852:+
KIRP	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-6.05	5.04e-09	3.57e-06	-0.43	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
KIRP	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-6.05	5.04e-09	3.57e-06	-0.43	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
KIRP	cis	rs2625529	0.73	rs1481860	ENSG00000260037.4	CTD-2524L6.3	6.05	5.04e-09	3.58e-06	0.27	0.35	Red blood cell count;	chr15:71949516	chr15:71818396~71823384:+
KIRP	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	6.05	5.04e-09	3.58e-06	0.35	0.35	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
KIRP	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.05	5.05e-09	3.58e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
KIRP	cis	rs4356975	0.563	rs7442453	ENSG00000196472.4	RP13-644M16.4	6.05	5.06e-09	3.58e-06	0.38	0.35	Obesity-related traits;	chr4:69103462	chr4:69181660~69182372:+
KIRP	cis	rs9371601	0.892	rs9397512	ENSG00000226193.1	RP3-398G3.5	-6.05	5.06e-09	3.59e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152484754	chr6:152402398~152404966:+
KIRP	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	6.05	5.08e-09	3.6e-06	0.36	0.35	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
KIRP	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	6.05	5.08e-09	3.6e-06	0.47	0.35	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
KIRP	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-6.05	5.08e-09	3.6e-06	-0.31	-0.35	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
KIRP	cis	rs2625529	0.617	rs13858	ENSG00000260037.4	CTD-2524L6.3	-6.05	5.09e-09	3.6e-06	-0.28	-0.35	Red blood cell count;	chr15:72140803	chr15:71818396~71823384:+
KIRP	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-6.05	5.09e-09	3.6e-06	-0.35	-0.35	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-6.05	5.09e-09	3.6e-06	-0.35	-0.35	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
KIRP	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	6.05	5.11e-09	3.62e-06	0.4	0.35	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
KIRP	cis	rs3121446	1	rs2354550	ENSG00000229654.1	RP1-60O19.2	6.05	5.12e-09	3.62e-06	0.37	0.35	Daytime sleep phenotypes;	chr6:106694068	chr6:106695535~106699994:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	6.04	5.12e-09	3.62e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
KIRP	cis	rs2749592	0.918	rs4934590	ENSG00000151963.4	RP11-775A3.1	6.04	5.13e-09	3.63e-06	0.44	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr10:37588641	chr10:37883594~37884109:+
KIRP	cis	rs6908034	0.607	rs62404179	ENSG00000228412.5	RP4-625H18.2	6.04	5.13e-09	3.63e-06	0.68	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19802164~19804752:-
KIRP	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	6.04	5.13e-09	3.63e-06	0.27	0.35	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
KIRP	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-6.04	5.13e-09	3.63e-06	-0.4	-0.35	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
KIRP	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	6.04	5.16e-09	3.65e-06	0.41	0.35	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
KIRP	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	6.04	5.16e-09	3.65e-06	0.41	0.35	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
KIRP	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-6.04	5.17e-09	3.66e-06	-0.39	-0.35	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
KIRP	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-6.04	5.17e-09	3.66e-06	-0.35	-0.35	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
KIRP	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	6.04	5.19e-09	3.67e-06	0.36	0.35	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
KIRP	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.04	5.2e-09	3.67e-06	0.42	0.35	Depression;	chr6:28187640	chr6:28115628~28116551:+
KIRP	cis	rs7474896	0.537	rs2472149	ENSG00000151963.4	RP11-775A3.1	6.04	5.2e-09	3.68e-06	0.46	0.35	Obesity (extreme);	chr10:37973268	chr10:37883594~37884109:+
KIRP	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	6.04	5.21e-09	3.68e-06	0.49	0.35	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
KIRP	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	6.04	5.21e-09	3.68e-06	0.33	0.35	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
KIRP	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	6.04	5.21e-09	3.69e-06	0.48	0.35	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
KIRP	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	6.04	5.22e-09	3.69e-06	0.38	0.35	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
KIRP	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	6.04	5.24e-09	3.7e-06	0.39	0.35	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
KIRP	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.04	5.25e-09	3.71e-06	0.54	0.35	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
KIRP	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	6.04	5.25e-09	3.71e-06	0.32	0.35	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
KIRP	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-6.04	5.25e-09	3.71e-06	-0.49	-0.35	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
KIRP	cis	rs4443100	0.77	rs9612214	ENSG00000221069.1	AC000029.1	6.04	5.25e-09	3.71e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23025318	chr22:23136620~23136710:+
KIRP	cis	rs4356975	0.563	rs7439152	ENSG00000196472.4	RP13-644M16.4	6.04	5.27e-09	3.72e-06	0.38	0.35	Obesity-related traits;	chr4:69103288	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7375178	ENSG00000196472.4	RP13-644M16.4	6.04	5.27e-09	3.72e-06	0.38	0.35	Obesity-related traits;	chr4:69103961	chr4:69181660~69182372:+
KIRP	cis	rs4443100	0.77	rs882513	ENSG00000221069.1	AC000029.1	6.04	5.27e-09	3.72e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23021552	chr22:23136620~23136710:+
KIRP	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-6.04	5.27e-09	3.72e-06	-0.35	-0.35	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
KIRP	cis	rs2625529	0.689	rs2957742	ENSG00000260037.4	CTD-2524L6.3	6.04	5.28e-09	3.73e-06	0.27	0.35	Red blood cell count;	chr15:72010553	chr15:71818396~71823384:+
KIRP	cis	rs7267979	0.903	rs6132819	ENSG00000274414.1	RP5-965G21.4	-6.04	5.28e-09	3.73e-06	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25239007~25245229:-
KIRP	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-6.04	5.29e-09	3.74e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-6.04	5.29e-09	3.74e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
KIRP	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	6.04	5.33e-09	3.76e-06	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
KIRP	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	6.04	5.35e-09	3.77e-06	0.33	0.35	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
KIRP	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	6.04	5.35e-09	3.77e-06	0.4	0.35	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
KIRP	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-6.04	5.36e-09	3.78e-06	-0.37	-0.35	Height;	chr3:53084188	chr3:53064283~53065091:-
KIRP	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	6.04	5.36e-09	3.78e-06	0.36	0.35	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
KIRP	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-6.04	5.37e-09	3.79e-06	-0.43	-0.35	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
KIRP	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-6.04	5.38e-09	3.79e-06	-0.33	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	6.04	5.38e-09	3.79e-06	0.44	0.35	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
KIRP	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	6.04	5.39e-09	3.8e-06	0.34	0.35	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
KIRP	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-6.04	5.4e-09	3.81e-06	-0.35	-0.35	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-6.04	5.4e-09	3.81e-06	-0.35	-0.35	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-6.04	5.4e-09	3.81e-06	-0.35	-0.35	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
KIRP	cis	rs1799949	0.965	rs11650132	ENSG00000236383.6	LINC00854	-6.03	5.41e-09	3.81e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43174070	chr17:43216941~43305976:-
KIRP	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-6.03	5.41e-09	3.81e-06	-0.44	-0.35	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
KIRP	cis	rs2625529	0.689	rs12898728	ENSG00000260037.4	CTD-2524L6.3	-6.03	5.42e-09	3.82e-06	-0.28	-0.35	Red blood cell count;	chr15:71820512	chr15:71818396~71823384:+
KIRP	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-6.03	5.43e-09	3.82e-06	-0.48	-0.35	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
KIRP	cis	rs7569084	0.687	rs11675538	ENSG00000237979.1	AC007389.1	6.03	5.43e-09	3.82e-06	0.4	0.35	Sum eosinophil basophil counts;	chr2:65459327	chr2:65500993~65502138:-
KIRP	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-6.03	5.43e-09	3.82e-06	-0.46	-0.35	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
KIRP	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-6.03	5.43e-09	3.83e-06	-0.28	-0.35	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
KIRP	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	6.03	5.44e-09	3.83e-06	0.26	0.35	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
KIRP	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	6.03	5.45e-09	3.84e-06	0.44	0.35	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	6.03	5.45e-09	3.84e-06	0.44	0.35	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
KIRP	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-6.03	5.45e-09	3.84e-06	-0.3	-0.35	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
KIRP	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	6.03	5.46e-09	3.84e-06	0.45	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
KIRP	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-6.03	5.47e-09	3.85e-06	-0.36	-0.35	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-6.03	5.47e-09	3.85e-06	-0.36	-0.35	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
KIRP	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	6.03	5.47e-09	3.85e-06	0.37	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
KIRP	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-6.03	5.47e-09	3.85e-06	-0.3	-0.35	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-6.03	5.47e-09	3.85e-06	-0.3	-0.35	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
KIRP	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	6.03	5.47e-09	3.85e-06	0.48	0.35	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
KIRP	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	6.03	5.47e-09	3.85e-06	0.38	0.35	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
KIRP	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	6.03	5.48e-09	3.86e-06	0.49	0.35	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
KIRP	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	6.03	5.48e-09	3.86e-06	0.38	0.35	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
KIRP	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.03	5.5e-09	3.87e-06	-0.35	-0.35	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
KIRP	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	6.03	5.5e-09	3.87e-06	0.48	0.35	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
KIRP	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	6.03	5.5e-09	3.87e-06	0.3	0.35	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	6.03	5.5e-09	3.87e-06	0.3	0.35	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
KIRP	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	6.03	5.51e-09	3.87e-06	0.4	0.35	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
KIRP	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-6.03	5.54e-09	3.89e-06	-0.29	-0.35	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
KIRP	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	6.03	5.55e-09	3.9e-06	0.35	0.35	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
KIRP	cis	rs67311347	0.956	rs13066971	ENSG00000230274.1	PGAM1P3	-6.03	5.55e-09	3.9e-06	-0.34	-0.35	Renal cell carcinoma;	chr3:40421019	chr3:40322715~40323279:-
KIRP	cis	rs9926296	0.632	rs72807526	ENSG00000260259.1	RP11-368I7.4	6.03	5.56e-09	3.9e-06	0.28	0.35	Vitiligo;	chr16:89709538	chr16:89682620~89686569:-
KIRP	cis	rs1799949	1	rs11653460	ENSG00000236383.6	LINC00854	-6.03	5.57e-09	3.91e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43179289	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs11650913	ENSG00000236383.6	LINC00854	-6.03	5.57e-09	3.91e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43179580	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12936831	ENSG00000236383.6	LINC00854	-6.03	5.57e-09	3.91e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43179799	chr17:43216941~43305976:-
KIRP	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	6.03	5.57e-09	3.92e-06	0.45	0.35	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
KIRP	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-6.03	5.6e-09	3.93e-06	-0.47	-0.35	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
KIRP	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.03	5.61e-09	3.94e-06	0.38	0.35	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.03	5.61e-09	3.94e-06	0.38	0.35	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.03	5.61e-09	3.94e-06	0.38	0.35	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.03	5.61e-09	3.94e-06	0.38	0.35	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.03	5.61e-09	3.94e-06	0.38	0.35	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
KIRP	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-6.03	5.61e-09	3.94e-06	-0.35	-0.35	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-6.03	5.62e-09	3.94e-06	-0.35	-0.35	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
KIRP	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-6.03	5.64e-09	3.95e-06	-0.4	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
KIRP	cis	rs1799949	1	rs9646412	ENSG00000236383.6	LINC00854	-6.03	5.64e-09	3.95e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43348525	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793231	ENSG00000236383.6	LINC00854	-6.03	5.64e-09	3.95e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43350101	chr17:43216941~43305976:-
KIRP	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	6.03	5.65e-09	3.96e-06	0.35	0.35	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
KIRP	cis	rs7474896	0.583	rs12776092	ENSG00000151963.4	RP11-775A3.1	-6.03	5.66e-09	3.96e-06	-0.45	-0.35	Obesity (extreme);	chr10:37726867	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.583	rs11011347	ENSG00000151963.4	RP11-775A3.1	-6.03	5.66e-09	3.96e-06	-0.45	-0.35	Obesity (extreme);	chr10:37730336	chr10:37883594~37884109:+
KIRP	cis	rs4638749	0.501	rs1385957	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108138648	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs1486194	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108139435	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs1486193	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108139569	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs2129145	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108141866	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs2220261	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108142429	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs6715622	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108142916	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs1003018	ENSG00000225328.1	AC019100.3	-6.03	5.66e-09	3.97e-06	-0.42	-0.35	Blood pressure;	chr2:108144466	chr2:108167748~108217841:-
KIRP	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	6.03	5.69e-09	3.98e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
KIRP	cis	rs7474896	0.583	rs11011341	ENSG00000151963.4	RP11-775A3.1	-6.03	5.69e-09	3.98e-06	-0.45	-0.35	Obesity (extreme);	chr10:37709572	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.609	rs1830612	ENSG00000151963.4	RP11-775A3.1	-6.03	5.69e-09	3.98e-06	-0.45	-0.35	Obesity (extreme);	chr10:37710955	chr10:37883594~37884109:+
KIRP	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	6.03	5.7e-09	3.98e-06	0.38	0.35	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
KIRP	cis	rs2976388	0.556	rs2572876	ENSG00000253741.1	CTD-2292P10.4	6.03	5.7e-09	3.98e-06	0.44	0.35	Urinary tract infection frequency;	chr8:142749181	chr8:142702252~142726973:-
KIRP	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	6.03	5.7e-09	3.99e-06	0.42	0.35	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
KIRP	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	6.02	5.71e-09	3.99e-06	0.41	0.35	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
KIRP	cis	rs9371601	0.859	rs214993	ENSG00000226193.1	RP3-398G3.5	-6.02	5.72e-09	4e-06	-0.37	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152445051	chr6:152402398~152404966:+
KIRP	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-6.02	5.72e-09	4e-06	-0.44	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
KIRP	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-6.02	5.73e-09	4e-06	-0.31	-0.35	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
KIRP	cis	rs1799949	1	rs2037075	ENSG00000236383.6	LINC00854	-6.02	5.73e-09	4.01e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43153809	chr17:43216941~43305976:-
KIRP	cis	rs6908034	0.556	rs113071446	ENSG00000228412.5	RP4-625H18.2	6.02	5.74e-09	4.01e-06	0.66	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19802164~19804752:-
KIRP	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	6.02	5.76e-09	4.02e-06	0.43	0.35	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
KIRP	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	6.02	5.76e-09	4.02e-06	0.4	0.35	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
KIRP	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-6.02	5.76e-09	4.03e-06	-0.78	-0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
KIRP	cis	rs2439831	0.717	rs2447198	ENSG00000249839.1	AC011330.5	-6.02	5.77e-09	4.03e-06	-0.47	-0.35	Lung cancer in ever smokers;	chr15:43602920	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	6.02	5.78e-09	4.04e-06	0.3	0.35	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
KIRP	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-6.02	5.78e-09	4.04e-06	-0.37	-0.35	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
KIRP	cis	rs755249	0.509	rs710913	ENSG00000237624.1	OXCT2P1	-6.02	5.79e-09	4.05e-06	-0.45	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39514956~39516490:+
KIRP	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	6.02	5.81e-09	4.06e-06	0.41	0.35	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
KIRP	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-6.02	5.83e-09	4.07e-06	-0.41	-0.35	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
KIRP	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	5.84e-09	4.08e-06	-0.29	-0.35	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
KIRP	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.02	5.86e-09	4.09e-06	-0.49	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
KIRP	cis	rs4443100	0.958	rs9620213	ENSG00000221069.1	AC000029.1	6.02	5.88e-09	4.1e-06	0.49	0.35	Serum parathyroid hormone levels;	chr22:23053233	chr22:23136620~23136710:+
KIRP	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	6.02	5.88e-09	4.1e-06	0.4	0.35	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	6.02	5.88e-09	4.1e-06	0.29	0.35	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
KIRP	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	6.02	5.89e-09	4.11e-06	0.26	0.35	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
KIRP	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-6.02	5.9e-09	4.11e-06	-0.35	-0.35	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
KIRP	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-6.02	5.9e-09	4.12e-06	-0.45	-0.35	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
KIRP	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	6.02	5.91e-09	4.12e-06	0.34	0.35	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	6.02	5.91e-09	4.12e-06	0.34	0.35	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
KIRP	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-6.02	5.91e-09	4.12e-06	-0.4	-0.35	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
KIRP	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	6.02	5.91e-09	4.12e-06	0.46	0.35	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.527	rs57102579	ENSG00000250696.4	RP11-704M14.1	6.02	5.92e-09	4.13e-06	0.33	0.35	Obesity-related traits;	chr4:69125476	chr4:69182100~69216766:+
KIRP	cis	rs4356975	0.527	rs4385139	ENSG00000250696.4	RP11-704M14.1	6.02	5.92e-09	4.13e-06	0.33	0.35	Obesity-related traits;	chr4:69125911	chr4:69182100~69216766:+
KIRP	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-6.02	5.94e-09	4.14e-06	-0.49	-0.35	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
KIRP	cis	rs308403	0.509	rs1849431	ENSG00000224786.1	CETN4P	6.02	5.94e-09	4.14e-06	0.39	0.35	Blood protein levels;	chr4:122753607	chr4:122730548~122732193:-
KIRP	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	6.02	5.96e-09	4.15e-06	0.35	0.35	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	6.02	5.96e-09	4.15e-06	0.35	0.35	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
KIRP	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-6.02	5.96e-09	4.15e-06	-0.5	-0.35	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
KIRP	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-6.02	5.96e-09	4.15e-06	-0.34	-0.35	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
KIRP	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
KIRP	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	6.02	5.97e-09	4.15e-06	0.4	0.35	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-6.02	5.97e-09	4.15e-06	-0.4	-0.35	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
KIRP	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-6.02	5.97e-09	4.16e-06	-0.36	-0.35	Temperament;	chr17:14007232	chr17:14024514~14025488:+
KIRP	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	6.02	5.98e-09	4.16e-06	0.41	0.35	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
KIRP	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	6.02	5.98e-09	4.16e-06	0.29	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
KIRP	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	6.02	5.98e-09	4.16e-06	0.29	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
KIRP	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-6.02	6e-09	4.17e-06	-0.48	-0.35	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
KIRP	cis	rs2283792	1	rs13943	ENSG00000228050.1	TOP3BP1	6.02	6.01e-09	4.18e-06	0.37	0.35	Multiple sclerosis;	chr22:21761913	chr22:22223187~22224566:-
KIRP	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	6.02	6.01e-09	4.18e-06	0.33	0.35	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	6.02	6.01e-09	4.18e-06	0.33	0.35	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
KIRP	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-6.01	6.05e-09	4.2e-06	-0.48	-0.35	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
KIRP	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-6.01	6.05e-09	4.2e-06	-0.47	-0.35	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
KIRP	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	6.01	6.05e-09	4.21e-06	0.45	0.35	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
KIRP	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-6.01	6.08e-09	4.22e-06	-0.35	-0.35	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
KIRP	cis	rs72634501	0.716	rs67637163	ENSG00000237624.1	OXCT2P1	6.01	6.08e-09	4.22e-06	0.57	0.35	HDL cholesterol;	chr1:39110949	chr1:39514956~39516490:+
KIRP	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.01	6.08e-09	4.22e-06	-0.45	-0.35	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
KIRP	cis	rs755249	0.761	rs3768321	ENSG00000237624.1	OXCT2P1	6.01	6.08e-09	4.22e-06	0.6	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39514956~39516490:+
KIRP	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	6.01	6.1e-09	4.23e-06	0.35	0.35	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
KIRP	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	6.01	6.1e-09	4.23e-06	0.43	0.35	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
KIRP	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-6.01	6.11e-09	4.24e-06	-0.4	-0.35	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
KIRP	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-6.01	6.11e-09	4.24e-06	-0.4	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
KIRP	cis	rs9532669	0.963	rs3736953	ENSG00000239827.7	SUGT1P3	-6.01	6.11e-09	4.24e-06	-0.39	-0.35	Cervical cancer;	chr13:40951450	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7322399	ENSG00000239827.7	SUGT1P3	-6.01	6.11e-09	4.24e-06	-0.39	-0.35	Cervical cancer;	chr13:40952511	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs7322097	ENSG00000239827.7	SUGT1P3	-6.01	6.11e-09	4.24e-06	-0.39	-0.35	Cervical cancer;	chr13:40952513	chr13:40908159~40921774:-
KIRP	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	6.01	6.12e-09	4.24e-06	0.36	0.35	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
KIRP	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	6.01	6.13e-09	4.25e-06	0.34	0.35	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
KIRP	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-6.01	6.13e-09	4.25e-06	-0.31	-0.35	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
KIRP	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-6.01	6.13e-09	4.25e-06	-0.45	-0.35	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
KIRP	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	6.01	6.14e-09	4.26e-06	0.35	0.35	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
KIRP	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-6.01	6.14e-09	4.26e-06	-0.37	-0.35	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-6.01	6.14e-09	4.26e-06	-0.37	-0.35	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
KIRP	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-6.01	6.14e-09	4.26e-06	-0.42	-0.35	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-6.01	6.14e-09	4.26e-06	-0.42	-0.35	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
KIRP	cis	rs4356975	0.697	rs66666893	ENSG00000250696.4	RP11-704M14.1	6.01	6.16e-09	4.27e-06	0.34	0.35	Obesity-related traits;	chr4:69133393	chr4:69182100~69216766:+
KIRP	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	6.01	6.16e-09	4.27e-06	0.33	0.35	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
KIRP	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	6.01	6.16e-09	4.27e-06	0.59	0.35	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
KIRP	cis	rs6908034	0.66	rs111509549	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.6	rs79733895	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.66	rs111231540	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.556	rs77486465	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.607	rs112824001	ENSG00000228412.5	RP4-625H18.2	6.01	6.17e-09	4.27e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19802164~19804752:-
KIRP	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	6.01	6.18e-09	4.28e-06	0.28	0.35	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
KIRP	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	6.01	6.19e-09	4.29e-06	0.46	0.35	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
KIRP	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	6.01	6.19e-09	4.29e-06	0.44	0.35	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
KIRP	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	6.01	6.2e-09	4.29e-06	0.37	0.35	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
KIRP	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	6.01	6.21e-09	4.29e-06	0.3	0.35	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
KIRP	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-6.01	6.21e-09	4.3e-06	-0.25	-0.35	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-6.01	6.21e-09	4.3e-06	-0.25	-0.35	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
KIRP	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	6.01	6.22e-09	4.3e-06	0.52	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
KIRP	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-6.01	6.22e-09	4.3e-06	-0.43	-0.35	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
KIRP	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	6.01	6.23e-09	4.31e-06	0.46	0.35	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
KIRP	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	6.01	6.24e-09	4.31e-06	0.4	0.35	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	6.01	6.24e-09	4.31e-06	0.4	0.35	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	6.01	6.24e-09	4.31e-06	0.4	0.35	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	6.01	6.24e-09	4.31e-06	0.4	0.35	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
KIRP	cis	rs1799949	0.965	rs35521261	ENSG00000236383.6	LINC00854	-6.01	6.24e-09	4.32e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43161595	chr17:43216941~43305976:-
KIRP	cis	rs4936099	0.931	rs4936098	ENSG00000175773.11	RP11-121M22.1	-6.01	6.26e-09	4.33e-06	-0.34	-0.35	Optic cup area;Vertical cup-disc ratio;	chr11:130410772	chr11:130314993~130403657:+
KIRP	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-6.01	6.26e-09	4.33e-06	-0.29	-0.35	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
KIRP	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	6.01	6.27e-09	4.33e-06	0.3	0.35	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
KIRP	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-6.01	6.28e-09	4.34e-06	-0.38	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
KIRP	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-6.01	6.28e-09	4.34e-06	-0.29	-0.35	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
KIRP	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-6.01	6.29e-09	4.34e-06	-0.3	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
KIRP	cis	rs4638749	0.501	rs1486192	ENSG00000225328.1	AC019100.3	6.01	6.29e-09	4.35e-06	0.42	0.35	Blood pressure;	chr2:108134594	chr2:108167748~108217841:-
KIRP	cis	rs2625529	0.73	rs2957725	ENSG00000260037.4	CTD-2524L6.3	6.01	6.3e-09	4.35e-06	0.27	0.35	Red blood cell count;	chr15:71955864	chr15:71818396~71823384:+
KIRP	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	6.01	6.3e-09	4.35e-06	0.42	0.35	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	6.01	6.3e-09	4.35e-06	0.42	0.35	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
KIRP	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-6.01	6.31e-09	4.36e-06	-0.34	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
KIRP	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-6.01	6.33e-09	4.37e-06	-0.29	-0.35	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
KIRP	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-6.01	6.35e-09	4.38e-06	-0.29	-0.35	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
KIRP	cis	rs4443100	0.77	rs6003472	ENSG00000221069.1	AC000029.1	6.01	6.36e-09	4.39e-06	0.47	0.35	Serum parathyroid hormone levels;	chr22:23027658	chr22:23136620~23136710:+
KIRP	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	6	6.37e-09	4.4e-06	0.42	0.35	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
KIRP	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	6	6.37e-09	4.4e-06	0.47	0.35	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	6	6.37e-09	4.4e-06	0.52	0.35	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
KIRP	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	6	6.39e-09	4.41e-06	0.27	0.35	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
KIRP	cis	rs1552244	0.832	rs61056817	ENSG00000180385.7	EMC3-AS1	6	6.39e-09	4.41e-06	0.37	0.35	Alzheimer's disease;	chr3:9985957	chr3:9986893~10006990:+
KIRP	cis	rs67311347	1	rs4973878	ENSG00000230274.1	PGAM1P3	6	6.4e-09	4.41e-06	0.33	0.35	Renal cell carcinoma;	chr3:40366074	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs4246666	ENSG00000230274.1	PGAM1P3	6	6.4e-09	4.41e-06	0.33	0.35	Renal cell carcinoma;	chr3:40366179	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs2887995	ENSG00000230274.1	PGAM1P3	6	6.4e-09	4.41e-06	0.33	0.35	Renal cell carcinoma;	chr3:40367538	chr3:40322715~40323279:-
KIRP	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	6	6.4e-09	4.41e-06	0.41	0.35	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	6	6.4e-09	4.41e-06	0.41	0.35	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
KIRP	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	6	6.4e-09	4.42e-06	0.35	0.35	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
KIRP	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	6	6.42e-09	4.43e-06	0.49	0.35	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
KIRP	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	6	6.43e-09	4.43e-06	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
KIRP	cis	rs4852324	0.536	rs71418714	ENSG00000217702.2	RP11-287D1.4	6	6.43e-09	4.44e-06	0.73	0.35	Systemic lupus erythematosus;	chr2:73992759	chr2:74130583~74135395:+
KIRP	cis	rs4356975	0.649	rs59421013	ENSG00000250696.4	RP11-704M14.1	6	6.44e-09	4.44e-06	0.33	0.35	Obesity-related traits;	chr4:69149131	chr4:69182100~69216766:+
KIRP	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	6	6.45e-09	4.45e-06	0.29	0.35	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
KIRP	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-6	6.46e-09	4.46e-06	-0.35	-0.35	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
KIRP	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	6	6.46e-09	4.46e-06	0.42	0.35	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
KIRP	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	6	6.47e-09	4.46e-06	0.39	0.35	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
KIRP	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-6	6.48e-09	4.47e-06	-0.3	-0.35	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	6	6.49e-09	4.47e-06	0.35	0.35	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
KIRP	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	6	6.49e-09	4.47e-06	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
KIRP	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	6	6.49e-09	4.47e-06	0.46	0.35	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
KIRP	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	6	6.5e-09	4.48e-06	0.29	0.35	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
KIRP	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	6	6.51e-09	4.48e-06	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
KIRP	cis	rs2625529	0.73	rs6494975	ENSG00000260037.4	CTD-2524L6.3	6	6.51e-09	4.48e-06	0.27	0.35	Red blood cell count;	chr15:71885484	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-6	6.52e-09	4.49e-06	-0.34	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
KIRP	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	6	6.52e-09	4.49e-06	0.41	0.35	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
KIRP	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	6	6.53e-09	4.5e-06	0.29	0.35	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
KIRP	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-6	6.54e-09	4.5e-06	-0.39	-0.35	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
KIRP	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6	6.54e-09	4.5e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
KIRP	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	6	6.56e-09	4.51e-06	0.36	0.35	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	6	6.56e-09	4.51e-06	0.36	0.35	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	6	6.56e-09	4.51e-06	0.36	0.35	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
KIRP	cis	rs2486288	0.656	rs11639420	ENSG00000259433.2	CTD-2651B20.4	6	6.58e-09	4.53e-06	0.3	0.35	Glomerular filtration rate;	chr15:45267070	chr15:45330209~45332634:-
KIRP	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6	6.59e-09	4.53e-06	0.38	0.35	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6	6.59e-09	4.53e-06	0.38	0.35	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6	6.59e-09	4.53e-06	0.38	0.35	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6	6.59e-09	4.53e-06	0.38	0.35	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
KIRP	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-6	6.59e-09	4.54e-06	-0.47	-0.35	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
KIRP	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	6	6.6e-09	4.54e-06	0.37	0.35	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
KIRP	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-6	6.6e-09	4.54e-06	-0.43	-0.35	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
KIRP	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	6	6.6e-09	4.54e-06	0.42	0.35	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
KIRP	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-6	6.62e-09	4.55e-06	-0.33	-0.35	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
KIRP	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	6	6.64e-09	4.57e-06	0.41	0.35	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	6	6.67e-09	4.58e-06	0.33	0.35	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
KIRP	cis	rs712022	1	rs2286809	ENSG00000246225.5	RP11-17A1.3	6	6.68e-09	4.59e-06	0.39	0.35	Dialysis-related mortality;	chr11:22829909	chr11:22829380~22945393:+
KIRP	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-6	6.68e-09	4.59e-06	-0.35	-0.35	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
KIRP	cis	rs2283792	1	rs3810610	ENSG00000228050.1	TOP3BP1	6	6.69e-09	4.6e-06	0.37	0.35	Multiple sclerosis;	chr22:21761209	chr22:22223187~22224566:-
KIRP	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-6	6.69e-09	4.6e-06	-0.35	-0.35	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-6	6.69e-09	4.6e-06	-0.35	-0.35	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
KIRP	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-6	6.69e-09	4.6e-06	-0.33	-0.35	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
KIRP	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	6	6.71e-09	4.61e-06	0.37	0.35	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
KIRP	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	6	6.71e-09	4.61e-06	0.44	0.35	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
KIRP	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-5.99	6.72e-09	4.62e-06	-0.44	-0.35	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
KIRP	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-5.99	6.72e-09	4.62e-06	-0.39	-0.35	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
KIRP	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	5.99	6.74e-09	4.63e-06	0.29	0.35	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	5.99	6.74e-09	4.63e-06	0.29	0.35	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	5.99	6.75e-09	4.63e-06	0.29	0.35	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	5.99	6.75e-09	4.63e-06	0.29	0.35	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
KIRP	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-5.99	6.75e-09	4.63e-06	-0.43	-0.35	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
KIRP	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-5.99	6.76e-09	4.64e-06	-0.37	-0.35	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	5.99	6.77e-09	4.64e-06	0.29	0.35	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
KIRP	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	5.99	6.78e-09	4.65e-06	0.43	0.35	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	5.99	6.78e-09	4.65e-06	0.36	0.35	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-5.99	6.8e-09	4.67e-06	-0.29	-0.35	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-5.99	6.8e-09	4.67e-06	-0.29	-0.35	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-5.99	6.8e-09	4.67e-06	-0.29	-0.35	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	5.99	6.82e-09	4.68e-06	0.29	0.35	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
KIRP	cis	rs67311347	0.544	rs9833640	ENSG00000230274.1	PGAM1P3	5.99	6.82e-09	4.68e-06	0.35	0.35	Renal cell carcinoma;	chr3:40313450	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.544	rs6762121	ENSG00000230274.1	PGAM1P3	5.99	6.82e-09	4.68e-06	0.35	0.35	Renal cell carcinoma;	chr3:40313822	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.544	rs6787516	ENSG00000230274.1	PGAM1P3	5.99	6.82e-09	4.68e-06	0.35	0.35	Renal cell carcinoma;	chr3:40314125	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.524	rs7649168	ENSG00000230274.1	PGAM1P3	5.99	6.82e-09	4.68e-06	0.35	0.35	Renal cell carcinoma;	chr3:40314667	chr3:40322715~40323279:-
KIRP	cis	rs2911132	0.62	rs1065407	ENSG00000248734.2	CTD-2260A17.1	5.99	6.82e-09	4.68e-06	0.33	0.35	Urate levels (BMI interaction);	chr5:96776379	chr5:96784777~96785999:+
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	5.99	6.83e-09	4.68e-06	0.29	0.35	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
KIRP	cis	rs2625529	0.73	rs12912771	ENSG00000260037.4	CTD-2524L6.3	-5.99	6.83e-09	4.68e-06	-0.27	-0.35	Red blood cell count;	chr15:71870587	chr15:71818396~71823384:+
KIRP	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	5.99	6.83e-09	4.69e-06	0.36	0.35	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
KIRP	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-5.99	6.83e-09	4.69e-06	-0.48	-0.35	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-5.99	6.83e-09	4.69e-06	-0.48	-0.35	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
KIRP	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-5.99	6.83e-09	4.69e-06	-0.48	-0.35	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
KIRP	cis	rs7474896	0.583	rs10827817	ENSG00000151963.4	RP11-775A3.1	-5.99	6.85e-09	4.69e-06	-0.44	-0.35	Obesity (extreme);	chr10:37709046	chr10:37883594~37884109:+
KIRP	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-5.99	6.86e-09	4.71e-06	-0.49	-0.35	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
KIRP	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	5.99	6.87e-09	4.71e-06	0.31	0.35	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
KIRP	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	5.99	6.87e-09	4.71e-06	0.31	0.35	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
KIRP	cis	rs67311347	0.955	rs11719205	ENSG00000230274.1	PGAM1P3	5.99	6.87e-09	4.71e-06	0.33	0.35	Renal cell carcinoma;	chr3:40375767	chr3:40322715~40323279:-
KIRP	cis	rs2617170	0.961	rs11053802	ENSG00000245648.1	RP11-277P12.20	5.99	6.89e-09	4.72e-06	0.41	0.35	Behcet's disease;	chr12:10444608	chr12:10363769~10398506:+
KIRP	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-5.99	6.89e-09	4.72e-06	-0.35	-0.35	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
KIRP	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	5.99	6.9e-09	4.73e-06	0.28	0.35	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
KIRP	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-5.99	6.91e-09	4.74e-06	-0.28	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
KIRP	cis	rs1799949	0.86	rs8176279	ENSG00000236383.6	LINC00854	-5.99	6.91e-09	4.74e-06	-0.26	-0.35	Menopause (age at onset);	chr17:43058379	chr17:43216941~43305976:-
KIRP	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-5.99	6.91e-09	4.74e-06	-0.37	-0.35	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-5.99	6.91e-09	4.74e-06	-0.37	-0.35	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
KIRP	cis	rs1560104	0.597	rs4781297	ENSG00000274834.1	CTD-3037G24.5	5.99	6.92e-09	4.74e-06	0.38	0.35	Obesity-related traits;	chr16:12613347	chr16:12614451~12614852:+
KIRP	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.99	6.93e-09	4.75e-06	-0.39	-0.35	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
KIRP	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	5.99	6.94e-09	4.75e-06	0.39	0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
KIRP	cis	rs2749592	1	rs2749592	ENSG00000151963.4	RP11-775A3.1	-5.99	6.94e-09	4.75e-06	-0.43	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr10:37969914	chr10:37883594~37884109:+
KIRP	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-5.99	6.94e-09	4.76e-06	-0.46	-0.35	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
KIRP	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	5.99	6.96e-09	4.76e-06	0.57	0.35	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
KIRP	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-5.99	6.97e-09	4.77e-06	-0.39	-0.35	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
KIRP	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	5.99	6.99e-09	4.79e-06	0.47	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
KIRP	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-5.99	7e-09	4.79e-06	-0.33	-0.35	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
KIRP	cis	rs4638749	0.627	rs6542753	ENSG00000231221.1	AC023672.2	-5.99	7.03e-09	4.81e-06	-0.41	-0.35	Blood pressure;	chr2:108199396	chr2:108049200~108052755:-
KIRP	cis	rs308403	0.509	rs6811183	ENSG00000224786.1	CETN4P	5.99	7.03e-09	4.81e-06	0.38	0.35	Blood protein levels;	chr4:122750396	chr4:122730548~122732193:-
KIRP	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-5.99	7.03e-09	4.81e-06	-0.36	-0.35	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-5.99	7.03e-09	4.81e-06	-0.36	-0.35	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-5.99	7.03e-09	4.81e-06	-0.36	-0.35	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
KIRP	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	5.99	7.03e-09	4.81e-06	0.45	0.35	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
KIRP	cis	rs308403	0.533	rs12644866	ENSG00000224786.1	CETN4P	5.99	7.04e-09	4.82e-06	0.38	0.35	Blood protein levels;	chr4:122746449	chr4:122730548~122732193:-
KIRP	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.99	7.05e-09	4.82e-06	-0.28	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
KIRP	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.99	7.05e-09	4.82e-06	-0.36	-0.35	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
KIRP	cis	rs712022	1	rs7112397	ENSG00000246225.5	RP11-17A1.3	5.99	7.05e-09	4.82e-06	0.39	0.35	Dialysis-related mortality;	chr11:22833070	chr11:22829380~22945393:+
KIRP	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	5.99	7.06e-09	4.83e-06	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
KIRP	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	5.99	7.07e-09	4.83e-06	0.45	0.35	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
KIRP	cis	rs2625529	0.775	rs16956273	ENSG00000260037.4	CTD-2524L6.3	-5.99	7.07e-09	4.84e-06	-0.27	-0.35	Red blood cell count;	chr15:71824761	chr15:71818396~71823384:+
KIRP	cis	rs7474896	0.559	rs2738185	ENSG00000151963.4	RP11-775A3.1	5.98	7.09e-09	4.85e-06	0.44	0.35	Obesity (extreme);	chr10:37958808	chr10:37883594~37884109:+
KIRP	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	5.98	7.1e-09	4.86e-06	0.4	0.35	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
KIRP	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	5.98	7.13e-09	4.88e-06	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
KIRP	cis	rs1560104	0.675	rs9927256	ENSG00000274834.1	CTD-3037G24.5	-5.98	7.13e-09	4.88e-06	-0.4	-0.35	Obesity-related traits;	chr16:12611158	chr16:12614451~12614852:+
KIRP	cis	rs2625529	0.878	rs2929511	ENSG00000260037.4	CTD-2524L6.3	5.98	7.14e-09	4.88e-06	0.27	0.35	Red blood cell count;	chr15:71939341	chr15:71818396~71823384:+
KIRP	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	5.98	7.14e-09	4.88e-06	0.36	0.35	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	5.98	7.14e-09	4.88e-06	0.36	0.35	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	5.98	7.14e-09	4.88e-06	0.36	0.35	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-5.98	7.15e-09	4.89e-06	-0.35	-0.35	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
KIRP	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	5.98	7.17e-09	4.9e-06	0.32	0.35	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
KIRP	cis	rs6085948	0.861	rs6077169	ENSG00000238102.1	RP11-19D2.1	-5.98	7.17e-09	4.9e-06	-0.46	-0.35	Interleukin-10 levels;	chr20:7267815	chr20:7256580~7258214:-
KIRP	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-5.98	7.19e-09	4.91e-06	-0.41	-0.35	Depression;	chr6:28201380	chr6:28115628~28116551:+
KIRP	cis	rs6085948	0.861	rs8121934	ENSG00000238102.1	RP11-19D2.1	-5.98	7.19e-09	4.91e-06	-0.45	-0.35	Interleukin-10 levels;	chr20:7263706	chr20:7256580~7258214:-
KIRP	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	5.98	7.2e-09	4.92e-06	0.52	0.35	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
KIRP	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	5.98	7.2e-09	4.92e-06	0.48	0.35	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
KIRP	cis	rs7569084	0.64	rs11126039	ENSG00000237979.1	AC007389.1	5.98	7.21e-09	4.93e-06	0.4	0.35	Sum eosinophil basophil counts;	chr2:65457953	chr2:65500993~65502138:-
KIRP	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	5.98	7.21e-09	4.93e-06	0.35	0.35	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
KIRP	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	5.98	7.22e-09	4.93e-06	0.39	0.35	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
KIRP	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	5.98	7.22e-09	4.93e-06	0.26	0.35	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
KIRP	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	5.98	7.23e-09	4.94e-06	0.41	0.35	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
KIRP	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-5.98	7.23e-09	4.94e-06	-0.38	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-5.98	7.23e-09	4.94e-06	-0.38	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
KIRP	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-5.98	7.27e-09	4.96e-06	-0.3	-0.35	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-5.98	7.28e-09	4.97e-06	-0.3	-0.35	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-5.98	7.28e-09	4.97e-06	-0.3	-0.35	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-5.98	7.28e-09	4.97e-06	-0.3	-0.35	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-5.98	7.28e-09	4.97e-06	-0.3	-0.35	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
KIRP	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-5.98	7.28e-09	4.97e-06	-0.4	-0.35	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
KIRP	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-5.98	7.29e-09	4.98e-06	-0.29	-0.35	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
KIRP	cis	rs9371601	0.892	rs9371254	ENSG00000226193.1	RP3-398G3.5	-5.98	7.29e-09	4.98e-06	-0.38	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152488638	chr6:152402398~152404966:+
KIRP	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-5.98	7.29e-09	4.98e-06	-0.34	-0.35	Height;	chr11:118781100	chr11:118704607~118750263:+
KIRP	cis	rs2765539	0.572	rs2361274	ENSG00000231365.4	RP11-418J17.1	-5.98	7.31e-09	4.99e-06	-0.39	-0.35	Waist-hip ratio;	chr1:119062604	chr1:119140396~119275973:+
KIRP	cis	rs7474896	0.559	rs1735629	ENSG00000151963.4	RP11-775A3.1	5.98	7.32e-09	4.99e-06	0.46	0.35	Obesity (extreme);	chr10:37889381	chr10:37883594~37884109:+
KIRP	cis	rs4638749	0.501	rs2378096	ENSG00000231221.1	AC023672.2	-5.98	7.33e-09	5e-06	-0.4	-0.35	Blood pressure;	chr2:108148575	chr2:108049200~108052755:-
KIRP	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-5.98	7.33e-09	5e-06	-0.35	-0.35	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
KIRP	cis	rs4638749	0.501	rs2378095	ENSG00000225328.1	AC019100.3	-5.98	7.33e-09	5e-06	-0.41	-0.35	Blood pressure;	chr2:108148443	chr2:108167748~108217841:-
KIRP	cis	rs9371601	0.859	rs502268	ENSG00000226193.1	RP3-398G3.5	-5.98	7.34e-09	5.01e-06	-0.37	-0.35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152447661	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	5.98	7.35e-09	5.01e-06	0.43	0.35	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
KIRP	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-5.98	7.35e-09	5.01e-06	-0.45	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
KIRP	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	5.98	7.36e-09	5.02e-06	0.61	0.35	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	5.98	7.37e-09	5.02e-06	0.41	0.35	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
KIRP	cis	rs1799949	1	rs33926631	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43152446	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1960605	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43153380	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs2037076	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43153866	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs12950779	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43154506	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.929	rs12937015	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43155456	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4340367	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43155755	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4792981	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43156257	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.896	rs33933393	ENSG00000236383.6	LINC00854	-5.98	7.37e-09	5.02e-06	-0.28	-0.35	Menopause (age at onset);	chr17:43165415	chr17:43216941~43305976:-
KIRP	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-5.98	7.37e-09	5.02e-06	-0.36	-0.35	Breast size;	chr12:9209187	chr12:9277235~9313241:+
KIRP	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	5.98	7.37e-09	5.02e-06	0.32	0.35	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
KIRP	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	5.98	7.38e-09	5.03e-06	0.4	0.35	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
KIRP	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	5.98	7.4e-09	5.04e-06	0.54	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
KIRP	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	5.98	7.42e-09	5.05e-06	0.54	0.35	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
KIRP	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-5.98	7.42e-09	5.05e-06	-0.45	-0.35	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-5.98	7.42e-09	5.05e-06	-0.45	-0.35	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-5.98	7.42e-09	5.05e-06	-0.45	-0.35	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	5.98	7.42e-09	5.05e-06	0.36	0.35	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	5.98	7.42e-09	5.05e-06	0.36	0.35	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	5.98	7.42e-09	5.05e-06	0.36	0.35	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
KIRP	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	5.98	7.42e-09	5.05e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
KIRP	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-5.98	7.43e-09	5.05e-06	-0.38	-0.35	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-5.98	7.43e-09	5.05e-06	-0.38	-0.35	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	5.98	7.43e-09	5.06e-06	0.47	0.35	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
KIRP	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	5.98	7.43e-09	5.06e-06	0.46	0.35	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
KIRP	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	5.98	7.47e-09	5.08e-06	0.4	0.35	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
KIRP	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	5.97	7.49e-09	5.09e-06	0.34	0.35	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
KIRP	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	5.97	7.51e-09	5.1e-06	0.34	0.35	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
KIRP	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	5.97	7.52e-09	5.11e-06	0.36	0.35	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
KIRP	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-5.97	7.53e-09	5.11e-06	-0.3	-0.35	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-5.97	7.53e-09	5.11e-06	-0.3	-0.35	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
KIRP	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	5.97	7.54e-09	5.12e-06	0.43	0.35	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
KIRP	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	5.97	7.55e-09	5.12e-06	0.29	0.35	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
KIRP	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	5.97	7.55e-09	5.13e-06	0.45	0.35	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
KIRP	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	5.97	7.55e-09	5.13e-06	0.4	0.35	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
KIRP	cis	rs7170668	0.839	rs12595031	ENSG00000258489.3	RP11-398J10.2	5.97	7.56e-09	5.13e-06	0.4	0.35	Motion sickness;	chr15:95480826	chr15:95463592~95493770:-
KIRP	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	5.97	7.56e-09	5.13e-06	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
KIRP	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	5.97	7.57e-09	5.14e-06	0.44	0.35	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
KIRP	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-5.97	7.57e-09	5.14e-06	-0.46	-0.35	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
KIRP	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-5.97	7.59e-09	5.15e-06	-0.35	-0.35	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
KIRP	cis	rs2283792	0.967	rs743409	ENSG00000228050.1	TOP3BP1	5.97	7.6e-09	5.16e-06	0.37	0.35	Multiple sclerosis;	chr22:21774926	chr22:22223187~22224566:-
KIRP	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-5.97	7.6e-09	5.16e-06	-0.34	-0.35	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
KIRP	cis	rs7569084	0.687	rs7577452	ENSG00000237979.1	AC007389.1	5.97	7.6e-09	5.16e-06	0.4	0.35	Sum eosinophil basophil counts;	chr2:65456694	chr2:65500993~65502138:-
KIRP	cis	rs2273156	1	rs17102904	ENSG00000226677.3	IGBP1P1	5.97	7.61e-09	5.16e-06	0.36	0.35	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971843	chr14:34939324~34940332:+
KIRP	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-5.97	7.63e-09	5.17e-06	-0.39	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
KIRP	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	5.97	7.63e-09	5.17e-06	0.3	0.35	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
KIRP	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-5.97	7.64e-09	5.18e-06	-0.29	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
KIRP	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-5.97	7.65e-09	5.19e-06	-0.35	-0.35	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-5.97	7.65e-09	5.19e-06	-0.35	-0.35	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
KIRP	cis	rs2486288	0.656	rs10519018	ENSG00000259433.2	CTD-2651B20.4	5.97	7.65e-09	5.19e-06	0.3	0.35	Glomerular filtration rate;	chr15:45257067	chr15:45330209~45332634:-
KIRP	cis	rs11148252	0.535	rs11616459	ENSG00000235660.1	LINC00345	-5.97	7.66e-09	5.2e-06	-0.39	-0.35	Lewy body disease;	chr13:52502265	chr13:52484161~52484680:-
KIRP	cis	rs12936587	0.568	rs4925062	ENSG00000223979.2	SMCR2	5.97	7.66e-09	5.2e-06	0.33	0.35	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17647452	chr17:17674026~17677688:-
KIRP	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.97	7.67e-09	5.2e-06	0.33	0.35	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
KIRP	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-5.97	7.67e-09	5.2e-06	-0.33	-0.35	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
KIRP	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	5.97	7.67e-09	5.2e-06	0.45	0.35	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
KIRP	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-5.97	7.68e-09	5.21e-06	-0.75	-0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
KIRP	cis	rs2625529	0.652	rs2957740	ENSG00000260037.4	CTD-2524L6.3	5.97	7.69e-09	5.21e-06	0.27	0.35	Red blood cell count;	chr15:72015350	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs7182776	ENSG00000260037.4	CTD-2524L6.3	5.97	7.69e-09	5.21e-06	0.28	0.35	Red blood cell count;	chr15:72170490	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-5.97	7.7e-09	5.22e-06	-0.29	-0.35	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
KIRP	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-5.97	7.7e-09	5.22e-06	-0.29	-0.35	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
KIRP	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-5.97	7.7e-09	5.22e-06	-0.49	-0.35	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
KIRP	cis	rs1200821	0.535	rs1208783	ENSG00000151963.4	RP11-775A3.1	-5.97	7.71e-09	5.22e-06	-0.38	-0.35	Hemostatic factors and hematological phenotypes;	chr10:37478539	chr10:37883594~37884109:+
KIRP	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-5.97	7.71e-09	5.22e-06	-0.35	-0.35	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-5.97	7.71e-09	5.22e-06	-0.35	-0.35	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
KIRP	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-5.97	7.71e-09	5.22e-06	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
KIRP	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	5.97	7.73e-09	5.24e-06	0.46	0.35	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
KIRP	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-5.97	7.73e-09	5.24e-06	-0.36	-0.35	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
KIRP	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-5.97	7.73e-09	5.24e-06	-0.4	-0.35	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
KIRP	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-5.97	7.74e-09	5.25e-06	-0.41	-0.35	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-5.97	7.74e-09	5.25e-06	-0.41	-0.35	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-5.97	7.74e-09	5.25e-06	-0.41	-0.35	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-5.97	7.74e-09	5.25e-06	-0.41	-0.35	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-5.97	7.74e-09	5.25e-06	-0.41	-0.35	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
KIRP	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	5.97	7.75e-09	5.25e-06	0.45	0.35	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
KIRP	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	5.97	7.75e-09	5.25e-06	0.41	0.35	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
KIRP	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	5.97	7.77e-09	5.26e-06	0.48	0.35	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
KIRP	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-5.97	7.77e-09	5.27e-06	-0.33	-0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
KIRP	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	5.97	7.78e-09	5.27e-06	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
KIRP	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	5.97	7.78e-09	5.27e-06	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
KIRP	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	5.97	7.8e-09	5.28e-06	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
KIRP	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	5.97	7.8e-09	5.28e-06	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
KIRP	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	5.97	7.82e-09	5.3e-06	0.39	0.35	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	5.97	7.82e-09	5.3e-06	0.39	0.35	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
KIRP	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	5.97	7.83e-09	5.3e-06	0.48	0.35	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
KIRP	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-5.97	7.84e-09	5.3e-06	-0.41	-0.35	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
KIRP	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	5.97	7.85e-09	5.31e-06	0.35	0.35	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	5.97	7.85e-09	5.31e-06	0.35	0.35	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
KIRP	cis	rs755249	0.567	rs1537817	ENSG00000237624.1	OXCT2P1	-5.97	7.86e-09	5.32e-06	-0.53	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39514956~39516490:+
KIRP	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	5.97	7.87e-09	5.32e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
KIRP	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	5.97	7.87e-09	5.32e-06	0.35	0.35	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
KIRP	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-5.97	7.88e-09	5.33e-06	-0.39	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
KIRP	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	5.97	7.88e-09	5.33e-06	0.85	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
KIRP	cis	rs4936099	0.897	rs6590455	ENSG00000175773.11	RP11-121M22.1	5.97	7.88e-09	5.33e-06	0.35	0.35	Optic cup area;Vertical cup-disc ratio;	chr11:130406532	chr11:130314993~130403657:+
KIRP	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	5.97	7.89e-09	5.33e-06	0.28	0.35	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
KIRP	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	5.97	7.89e-09	5.33e-06	0.34	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-5.97	7.89e-09	5.33e-06	-0.34	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	5.96	7.91e-09	5.34e-06	0.34	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
KIRP	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	5.96	7.91e-09	5.35e-06	0.38	0.35	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
KIRP	cis	rs11773103	0.708	rs55825235	ENSG00000224046.1	AC005076.5	5.96	7.92e-09	5.35e-06	0.43	0.35	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87151423~87152420:-
KIRP	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	5.96	7.92e-09	5.35e-06	0.41	0.35	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
KIRP	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	5.96	7.92e-09	5.35e-06	0.34	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
KIRP	cis	rs710913	0.816	rs1180341	ENSG00000237624.1	OXCT2P1	-5.96	7.92e-09	5.35e-06	-0.41	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39514956~39516490:+
KIRP	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	5.96	7.92e-09	5.35e-06	0.34	0.35	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
KIRP	cis	rs2625529	0.652	rs2899775	ENSG00000260037.4	CTD-2524L6.3	5.96	7.93e-09	5.36e-06	0.27	0.35	Red blood cell count;	chr15:71976013	chr15:71818396~71823384:+
KIRP	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	5.96	7.94e-09	5.37e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
KIRP	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	5.96	7.95e-09	5.37e-06	0.35	0.35	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
KIRP	cis	rs7665090	0.967	rs228611	ENSG00000246560.2	RP11-10L12.4	-5.96	7.97e-09	5.38e-06	-0.41	-0.35	Primary biliary cholangitis;	chr4:102640552	chr4:102828055~102844075:+
KIRP	cis	rs4638749	0.654	rs6761157	ENSG00000231221.1	AC023672.2	-5.96	7.98e-09	5.39e-06	-0.41	-0.35	Blood pressure;	chr2:108200429	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs13398290	ENSG00000231221.1	AC023672.2	-5.96	7.98e-09	5.39e-06	-0.41	-0.35	Blood pressure;	chr2:108217397	chr2:108049200~108052755:-
KIRP	cis	rs2551802	0.615	rs17395735	ENSG00000226363.3	HAGLROS	-5.96	7.99e-09	5.39e-06	-0.47	-0.35	Motion sickness;	chr2:176203052	chr2:176177717~176179008:+
KIRP	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	5.96	7.99e-09	5.39e-06	0.54	0.35	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
KIRP	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	5.96	8e-09	5.4e-06	0.47	0.35	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	5.96	8e-09	5.4e-06	0.47	0.35	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
KIRP	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	5.96	8.01e-09	5.4e-06	0.8	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	5.96	8.01e-09	5.4e-06	0.29	0.35	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
KIRP	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-5.96	8.02e-09	5.41e-06	-0.44	-0.35	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
KIRP	cis	rs79040073	0.637	rs11630318	ENSG00000259531.2	RP11-295H24.3	-5.96	8.05e-09	5.43e-06	-0.47	-0.35	Lung cancer in ever smokers;	chr15:49312606	chr15:49365124~49366685:-
KIRP	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-5.96	8.05e-09	5.43e-06	-0.44	-0.35	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
KIRP	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	5.96	8.05e-09	5.43e-06	0.39	0.35	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
KIRP	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-5.96	8.06e-09	5.44e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
KIRP	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-5.96	8.06e-09	5.44e-06	-0.31	-0.35	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
KIRP	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	5.96	8.06e-09	5.44e-06	0.36	0.35	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
KIRP	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	5.96	8.08e-09	5.45e-06	0.24	0.35	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
KIRP	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	5.96	8.1e-09	5.46e-06	0.32	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
KIRP	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-5.96	8.1e-09	5.46e-06	-0.37	-0.35	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-5.96	8.11e-09	5.47e-06	-0.38	-0.35	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
KIRP	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	5.96	8.13e-09	5.48e-06	0.41	0.35	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
KIRP	cis	rs2625529	0.689	rs4526973	ENSG00000260037.4	CTD-2524L6.3	-5.96	8.13e-09	5.48e-06	-0.27	-0.35	Red blood cell count;	chr15:71846378	chr15:71818396~71823384:+
KIRP	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	5.96	8.14e-09	5.49e-06	0.35	0.35	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
KIRP	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-5.96	8.14e-09	5.49e-06	-0.37	-0.35	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
KIRP	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-5.96	8.18e-09	5.51e-06	-0.38	-0.35	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
KIRP	cis	rs831571	0.955	rs35839	ENSG00000280620.1	SCAANT1	5.96	8.18e-09	5.51e-06	0.48	0.35	Type 2 diabetes;	chr3:64027741	chr3:63911518~63911772:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.96	8.18e-09	5.51e-06	0.29	0.35	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
KIRP	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	5.96	8.19e-09	5.52e-06	0.34	0.35	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
KIRP	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	5.96	8.2e-09	5.52e-06	0.41	0.35	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
KIRP	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	5.96	8.24e-09	5.55e-06	0.45	0.35	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
KIRP	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	5.96	8.24e-09	5.55e-06	0.45	0.35	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
KIRP	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	5.96	8.24e-09	5.55e-06	0.45	0.35	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
KIRP	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-5.96	8.24e-09	5.55e-06	-0.27	-0.35	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
KIRP	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-5.96	8.24e-09	5.55e-06	-0.44	-0.35	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
KIRP	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	5.96	8.25e-09	5.55e-06	0.36	0.35	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	5.96	8.25e-09	5.55e-06	0.36	0.35	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	5.96	8.25e-09	5.55e-06	0.36	0.35	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
KIRP	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-5.96	8.27e-09	5.57e-06	-0.39	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
KIRP	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-5.96	8.27e-09	5.57e-06	-0.25	-0.35	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	5.96	8.29e-09	5.58e-06	0.45	0.35	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
KIRP	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-5.96	8.3e-09	5.58e-06	-0.39	-0.35	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	5.96	8.3e-09	5.58e-06	0.46	0.35	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
KIRP	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	5.96	8.32e-09	5.59e-06	0.27	0.35	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
KIRP	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-5.95	8.35e-09	5.61e-06	-0.51	-0.35	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
KIRP	cis	rs67311347	1	rs10510708	ENSG00000230274.1	PGAM1P3	5.95	8.38e-09	5.63e-06	0.33	0.35	Renal cell carcinoma;	chr3:40363279	chr3:40322715~40323279:-
KIRP	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	5.95	8.39e-09	5.64e-06	0.67	0.35	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
KIRP	cis	rs7474896	0.526	rs1208716	ENSG00000151963.4	RP11-775A3.1	-5.95	8.39e-09	5.64e-06	-0.46	-0.35	Obesity (extreme);	chr10:37800345	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.559	rs1212108	ENSG00000151963.4	RP11-775A3.1	-5.95	8.39e-09	5.64e-06	-0.46	-0.35	Obesity (extreme);	chr10:37805394	chr10:37883594~37884109:+
KIRP	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	5.95	8.39e-09	5.64e-06	0.51	0.35	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
KIRP	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	5.95	8.39e-09	5.64e-06	0.3	0.35	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
KIRP	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	5.95	8.41e-09	5.66e-06	0.45	0.35	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	5.95	8.41e-09	5.66e-06	0.45	0.35	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	5.95	8.41e-09	5.66e-06	0.45	0.35	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
KIRP	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	5.95	8.42e-09	5.66e-06	0.45	0.35	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
KIRP	cis	rs1200821	0.529	rs2475206	ENSG00000151963.4	RP11-775A3.1	5.95	8.45e-09	5.68e-06	0.39	0.35	Hemostatic factors and hematological phenotypes;	chr10:37513604	chr10:37883594~37884109:+
KIRP	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-5.95	8.45e-09	5.68e-06	-0.44	-0.35	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
KIRP	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-5.95	8.45e-09	5.68e-06	-0.44	-0.35	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
KIRP	cis	rs7170668	1	rs10162686	ENSG00000258489.3	RP11-398J10.2	-5.95	8.46e-09	5.68e-06	-0.39	-0.35	Motion sickness;	chr15:95471854	chr15:95463592~95493770:-
KIRP	cis	rs4852324	0.536	rs13387174	ENSG00000217702.2	RP11-287D1.4	5.95	8.46e-09	5.68e-06	0.71	0.35	Systemic lupus erythematosus;	chr2:73979558	chr2:74130583~74135395:+
KIRP	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	5.95	8.47e-09	5.69e-06	0.41	0.35	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
KIRP	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-5.95	8.47e-09	5.69e-06	-0.43	-0.35	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
KIRP	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	5.95	8.5e-09	5.71e-06	0.45	0.35	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
KIRP	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-5.95	8.53e-09	5.73e-06	-0.49	-0.35	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
KIRP	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-5.95	8.53e-09	5.73e-06	-0.26	-0.35	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
KIRP	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	8.58e-09	5.76e-06	-0.29	-0.34	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
KIRP	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-5.95	8.61e-09	5.78e-06	-0.4	-0.34	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
KIRP	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-5.95	8.61e-09	5.78e-06	-0.38	-0.34	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
KIRP	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-5.95	8.62e-09	5.78e-06	-0.35	-0.34	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	5.95	8.63e-09	5.79e-06	0.45	0.34	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
KIRP	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-5.95	8.64e-09	5.8e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-5.95	8.64e-09	5.8e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
KIRP	cis	rs9926296	0.744	rs352939	ENSG00000260259.1	RP11-368I7.4	5.95	8.64e-09	5.8e-06	0.25	0.34	Vitiligo;	chr16:89643970	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	5.95	8.65e-09	5.8e-06	0.46	0.34	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
KIRP	cis	rs12908161	0.959	rs17534709	ENSG00000275120.1	RP11-182J1.17	5.95	8.65e-09	5.81e-06	0.45	0.34	Schizophrenia;	chr15:84771166	chr15:84599434~84606463:-
KIRP	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	5.95	8.66e-09	5.81e-06	0.35	0.34	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
KIRP	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-5.95	8.67e-09	5.82e-06	-0.26	-0.34	Height;	chr20:35190180	chr20:35201747~35203288:-
KIRP	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-5.95	8.69e-09	5.83e-06	-0.31	-0.34	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
KIRP	cis	rs1560104	0.718	rs36003824	ENSG00000274834.1	CTD-3037G24.5	-5.95	8.72e-09	5.85e-06	-0.4	-0.34	Obesity-related traits;	chr16:12611781	chr16:12614451~12614852:+
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	5.95	8.73e-09	5.85e-06	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
KIRP	cis	rs4638749	0.501	rs3919943	ENSG00000225328.1	AC019100.3	-5.95	8.73e-09	5.85e-06	-0.41	-0.34	Blood pressure;	chr2:108142409	chr2:108167748~108217841:-
KIRP	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-5.95	8.73e-09	5.86e-06	-0.43	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
KIRP	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	5.95	8.75e-09	5.87e-06	0.41	0.34	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.627	rs12902661	ENSG00000260037.4	CTD-2524L6.3	-5.95	8.76e-09	5.87e-06	-0.3	-0.34	Red blood cell count;	chr15:72187817	chr15:71818396~71823384:+
KIRP	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	5.95	8.77e-09	5.88e-06	0.41	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
KIRP	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	5.95	8.78e-09	5.89e-06	0.3	0.34	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
KIRP	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-5.95	8.79e-09	5.89e-06	-0.31	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
KIRP	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	5.95	8.79e-09	5.89e-06	0.35	0.34	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	5.95	8.79e-09	5.89e-06	0.35	0.34	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
KIRP	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-5.95	8.79e-09	5.89e-06	-0.36	-0.34	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
KIRP	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	5.94	8.81e-09	5.9e-06	0.34	0.34	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	5.94	8.81e-09	5.9e-06	0.34	0.34	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
KIRP	cis	rs2625529	0.824	rs11072346	ENSG00000260037.4	CTD-2524L6.3	-5.94	8.81e-09	5.9e-06	-0.3	-0.34	Red blood cell count;	chr15:72108093	chr15:71818396~71823384:+
KIRP	cis	rs7267979	0.934	rs2261115	ENSG00000274414.1	RP5-965G21.4	-5.94	8.85e-09	5.93e-06	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2261747	ENSG00000274414.1	RP5-965G21.4	-5.94	8.85e-09	5.93e-06	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25239007~25245229:-
KIRP	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	5.94	8.85e-09	5.93e-06	0.29	0.34	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
KIRP	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-5.94	8.85e-09	5.93e-06	-0.35	-0.34	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
KIRP	cis	rs453301	0.579	rs10096850	ENSG00000253893.2	FAM85B	5.94	8.87e-09	5.94e-06	0.45	0.34	Joint mobility (Beighton score);	chr8:8940712	chr8:8167819~8226614:-
KIRP	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-5.94	8.88e-09	5.94e-06	-0.38	-0.34	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
KIRP	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	5.94	8.89e-09	5.95e-06	0.32	0.34	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
KIRP	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	5.94	8.91e-09	5.97e-06	0.48	0.34	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
KIRP	cis	rs1552244	0.832	rs66597916	ENSG00000180385.7	EMC3-AS1	5.94	8.91e-09	5.97e-06	0.41	0.34	Alzheimer's disease;	chr3:10153723	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.832	rs115415687	ENSG00000180385.7	EMC3-AS1	5.94	8.91e-09	5.97e-06	0.41	0.34	Alzheimer's disease;	chr3:10154020	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.832	rs67145301	ENSG00000180385.7	EMC3-AS1	5.94	8.91e-09	5.97e-06	0.41	0.34	Alzheimer's disease;	chr3:10155630	chr3:9986893~10006990:+
KIRP	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-5.94	8.92e-09	5.97e-06	-0.44	-0.34	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
KIRP	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-5.94	8.94e-09	5.99e-06	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
KIRP	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	5.94	8.95e-09	5.99e-06	0.4	0.34	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
KIRP	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	5.94	8.96e-09	5.99e-06	0.4	0.34	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
KIRP	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-5.94	8.96e-09	6e-06	-0.43	-0.34	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
KIRP	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-5.94	8.96e-09	6e-06	-0.43	-0.34	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
KIRP	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-5.94	8.98e-09	6.01e-06	-0.38	-0.34	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-5.94	8.98e-09	6.01e-06	-0.38	-0.34	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
KIRP	cis	rs12188164	0.554	rs72711364	ENSG00000221990.4	EXOC3-AS1	5.94	8.98e-09	6.01e-06	0.34	0.34	Cystic fibrosis severity;	chr5:415208	chr5:441498~443160:-
KIRP	cis	rs4356975	0.563	rs6858558	ENSG00000196472.4	RP13-644M16.4	5.94	8.99e-09	6.01e-06	0.38	0.34	Obesity-related traits;	chr4:69103825	chr4:69181660~69182372:+
KIRP	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	5.94	8.99e-09	6.01e-06	0.29	0.34	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	5.94	8.99e-09	6.01e-06	0.29	0.34	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	5.94	8.99e-09	6.01e-06	0.29	0.34	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	5.94	8.99e-09	6.01e-06	0.29	0.34	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	5.94	8.99e-09	6.01e-06	0.29	0.34	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
KIRP	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	5.94	9.03e-09	6.04e-06	0.3	0.34	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
KIRP	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	5.94	9.04e-09	6.04e-06	0.38	0.34	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
KIRP	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	5.94	9.04e-09	6.04e-06	0.48	0.34	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	5.94	9.08e-09	6.07e-06	0.45	0.34	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
KIRP	cis	rs4936099	0.828	rs747249	ENSG00000175773.11	RP11-121M22.1	5.94	9.08e-09	6.07e-06	0.34	0.34	Optic cup area;Vertical cup-disc ratio;	chr11:130401752	chr11:130314993~130403657:+
KIRP	cis	rs9371601	0.852	rs2623970	ENSG00000226193.1	RP3-398G3.5	-5.94	9.09e-09	6.07e-06	-0.38	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152513359	chr6:152402398~152404966:+
KIRP	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	5.94	9.09e-09	6.08e-06	0.42	0.34	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
KIRP	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	5.94	9.1e-09	6.08e-06	0.35	0.34	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	5.94	9.1e-09	6.08e-06	0.35	0.34	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
KIRP	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	5.94	9.12e-09	6.09e-06	0.35	0.34	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
KIRP	cis	rs2625529	0.617	rs2929509	ENSG00000260037.4	CTD-2524L6.3	5.94	9.13e-09	6.09e-06	0.27	0.34	Red blood cell count;	chr15:71946931	chr15:71818396~71823384:+
KIRP	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-5.94	9.13e-09	6.09e-06	-0.36	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-5.94	9.13e-09	6.09e-06	-0.36	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
KIRP	cis	rs4638749	0.501	rs4322804	ENSG00000225328.1	AC019100.3	-5.94	9.14e-09	6.1e-06	-0.42	-0.34	Blood pressure;	chr2:108128483	chr2:108167748~108217841:-
KIRP	cis	rs4638749	0.501	rs9917181	ENSG00000231221.1	AC023672.2	-5.94	9.14e-09	6.1e-06	-0.4	-0.34	Blood pressure;	chr2:108131409	chr2:108049200~108052755:-
KIRP	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	5.94	9.15e-09	6.1e-06	0.3	0.34	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
KIRP	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	5.94	9.16e-09	6.11e-06	0.48	0.34	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
KIRP	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	5.94	9.16e-09	6.11e-06	0.48	0.34	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
KIRP	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-5.94	9.2e-09	6.14e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
KIRP	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-5.94	9.2e-09	6.14e-06	-0.39	-0.34	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
KIRP	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-5.94	9.2e-09	6.14e-06	-0.35	-0.34	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
KIRP	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	5.94	9.21e-09	6.14e-06	0.44	0.34	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
KIRP	cis	rs13423976	0.631	rs11888984	ENSG00000231367.4	AC016995.3	-5.94	9.26e-09	6.17e-06	-0.45	-0.34	Gut microbiome composition (summer);	chr2:38517250	chr2:38406719~38515740:-
KIRP	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	5.94	9.26e-09	6.17e-06	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	5.94	9.27e-09	6.17e-06	0.29	0.34	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
KIRP	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-5.93	9.29e-09	6.18e-06	-0.42	-0.34	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
KIRP	cis	rs7829975	0.774	rs57312668	ENSG00000253981.4	ALG1L13P	5.93	9.3e-09	6.19e-06	0.27	0.34	Mood instability;	chr8:8822967	chr8:8236003~8244667:-
KIRP	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-5.93	9.31e-09	6.2e-06	-0.47	-0.34	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
KIRP	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-5.93	9.31e-09	6.2e-06	-0.48	-0.34	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.563	rs6600885	ENSG00000196472.4	RP13-644M16.4	5.93	9.32e-09	6.21e-06	0.38	0.34	Obesity-related traits;	chr4:69103949	chr4:69181660~69182372:+
KIRP	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	5.93	9.33e-09	6.21e-06	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
KIRP	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-5.93	9.33e-09	6.21e-06	-0.3	-0.34	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
KIRP	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.93	9.33e-09	6.21e-06	-0.47	-0.34	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
KIRP	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-5.93	9.34e-09	6.21e-06	-0.37	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
KIRP	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	5.93	9.34e-09	6.21e-06	0.35	0.34	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
KIRP	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-5.93	9.34e-09	6.22e-06	-0.29	-0.34	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
KIRP	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-5.93	9.34e-09	6.22e-06	-0.39	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
KIRP	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-5.93	9.35e-09	6.22e-06	-0.47	-0.34	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
KIRP	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-5.93	9.35e-09	6.22e-06	-0.41	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
KIRP	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-5.93	9.37e-09	6.23e-06	-0.3	-0.34	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-5.93	9.37e-09	6.23e-06	-0.3	-0.34	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
KIRP	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-5.93	9.4e-09	6.25e-06	-0.39	-0.34	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
KIRP	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-5.93	9.44e-09	6.27e-06	-0.3	-0.34	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
KIRP	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	5.93	9.44e-09	6.27e-06	0.45	0.34	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
KIRP	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	5.93	9.44e-09	6.28e-06	0.45	0.34	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
KIRP	cis	rs9371601	0.892	rs9397106	ENSG00000226193.1	RP3-398G3.5	-5.93	9.44e-09	6.28e-06	-0.38	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152488392	chr6:152402398~152404966:+
KIRP	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-5.93	9.45e-09	6.28e-06	-0.41	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
KIRP	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	5.93	9.45e-09	6.28e-06	0.29	0.34	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
KIRP	cis	rs4356975	0.842	rs6600899	ENSG00000196472.4	RP13-644M16.4	5.93	9.46e-09	6.29e-06	0.39	0.34	Obesity-related traits;	chr4:69132295	chr4:69181660~69182372:+
KIRP	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-5.93	9.48e-09	6.3e-06	-0.35	-0.34	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
KIRP	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-5.93	9.48e-09	6.3e-06	-0.35	-0.34	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-5.93	9.5e-09	6.31e-06	-0.35	-0.34	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
KIRP	cis	rs2486288	0.656	rs12908581	ENSG00000259433.2	CTD-2651B20.4	5.93	9.5e-09	6.31e-06	0.3	0.34	Glomerular filtration rate;	chr15:45256437	chr15:45330209~45332634:-
KIRP	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	5.93	9.51e-09	6.32e-06	0.56	0.34	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
KIRP	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	5.93	9.52e-09	6.32e-06	0.35	0.34	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
KIRP	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-5.93	9.53e-09	6.33e-06	-0.4	-0.34	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
KIRP	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-5.93	9.54e-09	6.34e-06	-0.42	-0.34	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
KIRP	cis	rs7474896	0.537	rs1779068	ENSG00000151963.4	RP11-775A3.1	5.93	9.55e-09	6.34e-06	0.45	0.34	Obesity (extreme);	chr10:37961857	chr10:37883594~37884109:+
KIRP	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-5.93	9.57e-09	6.35e-06	-0.35	-0.34	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-5.93	9.57e-09	6.35e-06	-0.35	-0.34	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-5.93	9.57e-09	6.35e-06	-0.35	-0.34	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
KIRP	cis	rs1799949	1	rs11653231	ENSG00000236383.6	LINC00854	-5.93	9.59e-09	6.36e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43179443	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1399323	ENSG00000236383.6	LINC00854	-5.93	9.59e-09	6.36e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43180313	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs35954893	ENSG00000236383.6	LINC00854	-5.93	9.59e-09	6.36e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43181769	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs4445938	ENSG00000236383.6	LINC00854	-5.93	9.59e-09	6.36e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43185883	chr17:43216941~43305976:-
KIRP	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	5.93	9.6e-09	6.37e-06	0.56	0.34	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
KIRP	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-5.93	9.6e-09	6.37e-06	-0.43	-0.34	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
KIRP	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	5.93	9.63e-09	6.39e-06	0.38	0.34	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
KIRP	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	5.93	9.64e-09	6.39e-06	0.44	0.34	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
KIRP	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-5.93	9.64e-09	6.39e-06	-0.3	-0.34	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
KIRP	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	5.93	9.65e-09	6.4e-06	0.39	0.34	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
KIRP	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	5.93	9.65e-09	6.4e-06	0.39	0.34	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
KIRP	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	5.93	9.67e-09	6.41e-06	0.75	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
KIRP	cis	rs950169	0.922	rs11638445	ENSG00000275120.1	RP11-182J1.17	5.93	9.68e-09	6.41e-06	0.47	0.34	Schizophrenia;	chr15:84594463	chr15:84599434~84606463:-
KIRP	cis	rs2273156	1	rs761506	ENSG00000226677.3	IGBP1P1	5.93	9.7e-09	6.43e-06	0.35	0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:34947974	chr14:34939324~34940332:+
KIRP	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	5.93	9.7e-09	6.43e-06	0.29	0.34	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
KIRP	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-5.93	9.72e-09	6.44e-06	-0.35	-0.34	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	5.93	9.73e-09	6.45e-06	0.35	0.34	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	5.93	9.73e-09	6.45e-06	0.35	0.34	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	5.93	9.73e-09	6.45e-06	0.35	0.34	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
KIRP	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	5.93	9.73e-09	6.45e-06	0.92	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
KIRP	cis	rs7404843	0.789	rs222909	ENSG00000263335.1	AF001548.5	5.93	9.73e-09	6.45e-06	0.49	0.34	Testicular germ cell tumor;	chr16:15405432	chr16:15726674~15732993:+
KIRP	cis	rs79349575	0.756	rs937301	ENSG00000248278.1	SUMO2P17	-5.93	9.74e-09	6.45e-06	-0.4	-0.34	Type 2 diabetes;	chr17:48968914	chr17:48874860~48908983:-
KIRP	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-5.93	9.76e-09	6.46e-06	-0.44	-0.34	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
KIRP	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	5.93	9.76e-09	6.46e-06	0.45	0.34	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
KIRP	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	5.93	9.78e-09	6.48e-06	0.75	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
KIRP	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	5.93	9.79e-09	6.48e-06	0.78	0.34	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
KIRP	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	5.92	9.79e-09	6.49e-06	0.38	0.34	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
KIRP	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	5.92	9.81e-09	6.5e-06	0.27	0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
KIRP	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	5.92	9.81e-09	6.5e-06	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	5.92	9.81e-09	6.5e-06	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
KIRP	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-5.92	9.83e-09	6.51e-06	-0.45	-0.34	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
KIRP	cis	rs2625529	0.617	rs8557	ENSG00000260037.4	CTD-2524L6.3	-5.92	9.85e-09	6.52e-06	-0.27	-0.34	Red blood cell count;	chr15:71823392	chr15:71818396~71823384:+
KIRP	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	5.92	9.87e-09	6.53e-06	0.27	0.34	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
KIRP	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	5.92	9.87e-09	6.54e-06	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
KIRP	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-5.92	9.89e-09	6.55e-06	-0.3	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
KIRP	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	5.92	9.9e-09	6.55e-06	0.4	0.34	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
KIRP	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	5.92	9.92e-09	6.56e-06	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
KIRP	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-5.92	9.94e-09	6.58e-06	-0.38	-0.34	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
KIRP	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-5.92	9.95e-09	6.58e-06	-0.36	-0.34	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
KIRP	cis	rs308403	0.509	rs13122636	ENSG00000224786.1	CETN4P	5.92	9.96e-09	6.58e-06	0.37	0.34	Blood protein levels;	chr4:122749890	chr4:122730548~122732193:-
KIRP	cis	rs710913	0.717	rs2243761	ENSG00000237624.1	OXCT2P1	-5.92	9.98e-09	6.6e-06	-0.41	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39514956~39516490:+
KIRP	cis	rs7267979	0.966	rs2151144	ENSG00000274414.1	RP5-965G21.4	5.92	9.99e-09	6.6e-06	0.33	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25239007~25245229:-
KIRP	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-5.92	9.99e-09	6.61e-06	-0.43	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
KIRP	cis	rs2625529	0.775	rs35673773	ENSG00000260037.4	CTD-2524L6.3	-5.92	1e-08	6.61e-06	-0.3	-0.34	Red blood cell count;	chr15:72107545	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12592044	ENSG00000260037.4	CTD-2524L6.3	-5.92	1e-08	6.61e-06	-0.3	-0.34	Red blood cell count;	chr15:72126774	chr15:71818396~71823384:+
KIRP	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	5.92	1e-08	6.61e-06	0.54	0.34	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	5.92	1e-08	6.61e-06	0.54	0.34	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
KIRP	cis	rs6085948	1	rs6077170	ENSG00000238102.1	RP11-19D2.1	5.92	1e-08	6.62e-06	0.42	0.34	Interleukin-10 levels;	chr20:7268888	chr20:7256580~7258214:-
KIRP	cis	rs7829975	0.744	rs2409092	ENSG00000253981.4	ALG1L13P	5.92	1e-08	6.62e-06	0.27	0.34	Mood instability;	chr8:8824682	chr8:8236003~8244667:-
KIRP	cis	rs1799949	1	rs2271574	ENSG00000236383.6	LINC00854	-5.92	1.01e-08	6.65e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43175631	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs33994002	ENSG00000236383.6	LINC00854	-5.92	1.01e-08	6.65e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43176801	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs33920795	ENSG00000236383.6	LINC00854	-5.92	1.01e-08	6.65e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43176993	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs33918839	ENSG00000236383.6	LINC00854	-5.92	1.01e-08	6.65e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43177155	chr17:43216941~43305976:-
KIRP	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	5.92	1.01e-08	6.66e-06	0.56	0.34	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
KIRP	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	5.92	1.01e-08	6.66e-06	0.39	0.34	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
KIRP	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-5.92	1.01e-08	6.67e-06	-0.39	-0.34	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-5.92	1.01e-08	6.67e-06	-0.29	-0.34	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
KIRP	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	5.92	1.01e-08	6.68e-06	0.53	0.34	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
KIRP	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.92	1.01e-08	6.69e-06	-0.39	-0.34	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
KIRP	cis	rs7474896	0.537	rs2749586	ENSG00000151963.4	RP11-775A3.1	5.92	1.01e-08	6.7e-06	0.44	0.34	Obesity (extreme);	chr10:37981286	chr10:37883594~37884109:+
KIRP	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	5.92	1.02e-08	6.73e-06	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
KIRP	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-5.92	1.02e-08	6.73e-06	-0.34	-0.34	Height;	chr11:118742526	chr11:118704607~118750263:+
KIRP	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-5.92	1.02e-08	6.74e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-5.92	1.02e-08	6.74e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
KIRP	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	5.92	1.02e-08	6.74e-06	0.33	0.34	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
KIRP	cis	rs2008905	1	rs2008905	ENSG00000272034.1	SNORD14A	5.92	1.02e-08	6.74e-06	0.31	0.34	Schizophrenia;	chr11:17163076	chr11:17074654~17074744:-
KIRP	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-5.92	1.02e-08	6.75e-06	-0.23	-0.34	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
KIRP	cis	rs9371601	0.892	rs7759578	ENSG00000226193.1	RP3-398G3.5	-5.92	1.02e-08	6.75e-06	-0.38	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152480979	chr6:152402398~152404966:+
KIRP	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-5.92	1.02e-08	6.75e-06	-0.48	-0.34	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-5.92	1.02e-08	6.75e-06	-0.48	-0.34	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-5.92	1.02e-08	6.75e-06	-0.48	-0.34	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
KIRP	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	5.92	1.02e-08	6.75e-06	0.41	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
KIRP	cis	rs79349575	0.783	rs12603969	ENSG00000248278.1	SUMO2P17	5.92	1.02e-08	6.76e-06	0.39	0.34	Type 2 diabetes;	chr17:48957057	chr17:48874860~48908983:-
KIRP	cis	rs79349575	0.783	rs12601955	ENSG00000248278.1	SUMO2P17	5.92	1.02e-08	6.76e-06	0.39	0.34	Type 2 diabetes;	chr17:48957058	chr17:48874860~48908983:-
KIRP	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	5.92	1.02e-08	6.76e-06	0.34	0.34	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
KIRP	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	5.92	1.03e-08	6.77e-06	0.35	0.34	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
KIRP	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-5.92	1.03e-08	6.77e-06	-0.29	-0.34	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
KIRP	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	5.92	1.03e-08	6.77e-06	0.56	0.34	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
KIRP	cis	rs4273100	1	rs57433322	ENSG00000228157.4	AC007952.5	5.92	1.03e-08	6.78e-06	0.65	0.34	Schizophrenia;	chr17:19238269	chr17:19092974~19096837:+
KIRP	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	5.92	1.03e-08	6.78e-06	0.39	0.34	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	5.92	1.03e-08	6.78e-06	0.39	0.34	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	5.92	1.03e-08	6.78e-06	0.39	0.34	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	5.92	1.03e-08	6.78e-06	0.39	0.34	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	5.92	1.03e-08	6.78e-06	0.39	0.34	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
KIRP	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	5.92	1.03e-08	6.8e-06	0.26	0.34	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
KIRP	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-5.92	1.03e-08	6.8e-06	-0.45	-0.34	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-5.92	1.03e-08	6.81e-06	-0.42	-0.34	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
KIRP	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-5.91	1.04e-08	6.83e-06	-0.35	-0.34	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
KIRP	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-5.91	1.04e-08	6.83e-06	-0.52	-0.34	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
KIRP	cis	rs308403	0.509	rs9990804	ENSG00000224786.1	CETN4P	5.91	1.04e-08	6.83e-06	0.38	0.34	Blood protein levels;	chr4:122750829	chr4:122730548~122732193:-
KIRP	cis	rs4443100	0.958	rs11090217	ENSG00000221069.1	AC000029.1	5.91	1.04e-08	6.87e-06	0.46	0.34	Serum parathyroid hormone levels;	chr22:23036329	chr22:23136620~23136710:+
KIRP	cis	rs2283792	0.967	rs5755099	ENSG00000228050.1	TOP3BP1	5.91	1.04e-08	6.87e-06	0.37	0.34	Multiple sclerosis;	chr22:21770751	chr22:22223187~22224566:-
KIRP	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-5.91	1.04e-08	6.87e-06	-0.36	-0.34	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
KIRP	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	5.91	1.05e-08	6.89e-06	0.39	0.34	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	5.91	1.05e-08	6.9e-06	0.45	0.34	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	5.91	1.05e-08	6.9e-06	0.45	0.34	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
KIRP	cis	rs2486288	0.656	rs2413768	ENSG00000259433.2	CTD-2651B20.4	5.91	1.05e-08	6.9e-06	0.3	0.34	Glomerular filtration rate;	chr15:45269786	chr15:45330209~45332634:-
KIRP	cis	rs7170668	0.93	rs4984581	ENSG00000258489.3	RP11-398J10.2	-5.91	1.05e-08	6.9e-06	-0.39	-0.34	Motion sickness;	chr15:95472992	chr15:95463592~95493770:-
KIRP	cis	rs7170668	0.93	rs12910890	ENSG00000258489.3	RP11-398J10.2	-5.91	1.05e-08	6.9e-06	-0.39	-0.34	Motion sickness;	chr15:95473444	chr15:95463592~95493770:-
KIRP	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-5.91	1.05e-08	6.91e-06	-0.43	-0.34	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
KIRP	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	5.91	1.05e-08	6.92e-06	0.46	0.34	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	5.91	1.05e-08	6.92e-06	0.46	0.34	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
KIRP	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-5.91	1.05e-08	6.93e-06	-0.39	-0.34	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
KIRP	cis	rs2625529	0.824	rs7172309	ENSG00000260037.4	CTD-2524L6.3	-5.91	1.05e-08	6.93e-06	-0.3	-0.34	Red blood cell count;	chr15:72092142	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12901886	ENSG00000260037.4	CTD-2524L6.3	-5.91	1.05e-08	6.93e-06	-0.3	-0.34	Red blood cell count;	chr15:72115728	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2957735	ENSG00000260037.4	CTD-2524L6.3	5.91	1.06e-08	6.95e-06	0.27	0.34	Red blood cell count;	chr15:71972832	chr15:71818396~71823384:+
KIRP	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-5.91	1.06e-08	6.97e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
KIRP	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	5.91	1.06e-08	6.97e-06	0.42	0.34	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	5.91	1.06e-08	6.97e-06	0.29	0.34	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	5.91	1.06e-08	6.97e-06	0.29	0.34	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	5.91	1.06e-08	6.97e-06	0.29	0.34	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
KIRP	cis	rs7474896	0.559	rs1208645	ENSG00000151963.4	RP11-775A3.1	5.91	1.06e-08	6.98e-06	0.44	0.34	Obesity (extreme);	chr10:37843159	chr10:37883594~37884109:+
KIRP	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-5.91	1.06e-08	6.99e-06	-0.33	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
KIRP	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-5.91	1.06e-08	6.99e-06	-0.48	-0.34	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
KIRP	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	5.91	1.06e-08	7e-06	0.33	0.34	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
KIRP	cis	rs6085948	1	rs1033603	ENSG00000238102.1	RP11-19D2.1	5.91	1.07e-08	7.01e-06	0.41	0.34	Interleukin-10 levels;	chr20:7267540	chr20:7256580~7258214:-
KIRP	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	5.91	1.07e-08	7.01e-06	0.3	0.34	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
KIRP	cis	rs1560104	0.709	rs7194367	ENSG00000274834.1	CTD-3037G24.5	-5.91	1.07e-08	7.02e-06	-0.42	-0.34	Obesity-related traits;	chr16:12604376	chr16:12614451~12614852:+
KIRP	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	5.91	1.07e-08	7.02e-06	0.39	0.34	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
KIRP	cis	rs7474896	0.515	rs675628	ENSG00000151963.4	RP11-775A3.1	5.91	1.07e-08	7.02e-06	0.44	0.34	Obesity (extreme);	chr10:38016403	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.515	rs594594	ENSG00000151963.4	RP11-775A3.1	5.91	1.07e-08	7.02e-06	0.44	0.34	Obesity (extreme);	chr10:38018795	chr10:37883594~37884109:+
KIRP	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	5.91	1.07e-08	7.02e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	5.91	1.07e-08	7.02e-06	0.39	0.34	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
KIRP	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-5.91	1.07e-08	7.02e-06	-0.33	-0.34	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
KIRP	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-5.91	1.07e-08	7.03e-06	-0.64	-0.34	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
KIRP	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	5.91	1.07e-08	7.03e-06	0.27	0.34	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
KIRP	cis	rs6740462	1	rs6740462	ENSG00000204929.10	AC074391.1	-5.91	1.07e-08	7.04e-06	-0.52	-0.34	Inflammatory bowel disease;Crohn's disease;	chr2:65440138	chr2:65436711~66084639:+
KIRP	cis	rs2486288	0.656	rs11632419	ENSG00000259433.2	CTD-2651B20.4	5.91	1.07e-08	7.04e-06	0.3	0.34	Glomerular filtration rate;	chr15:45265258	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs2271438	ENSG00000259433.2	CTD-2651B20.4	5.91	1.07e-08	7.04e-06	0.3	0.34	Glomerular filtration rate;	chr15:45265270	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11854365	ENSG00000259433.2	CTD-2651B20.4	5.91	1.07e-08	7.04e-06	0.3	0.34	Glomerular filtration rate;	chr15:45265885	chr15:45330209~45332634:-
KIRP	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	5.91	1.07e-08	7.04e-06	0.26	0.34	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
KIRP	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	5.91	1.07e-08	7.04e-06	0.44	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
KIRP	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	5.91	1.07e-08	7.05e-06	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
KIRP	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	5.91	1.07e-08	7.05e-06	0.44	0.34	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
KIRP	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-5.91	1.07e-08	7.06e-06	-0.29	-0.34	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
KIRP	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-5.91	1.07e-08	7.06e-06	-0.47	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
KIRP	cis	rs67311347	1	rs2305522	ENSG00000230274.1	PGAM1P3	5.91	1.08e-08	7.06e-06	0.33	0.34	Renal cell carcinoma;	chr3:40387867	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs7636719	ENSG00000230274.1	PGAM1P3	5.91	1.08e-08	7.06e-06	0.33	0.34	Renal cell carcinoma;	chr3:40390593	chr3:40322715~40323279:-
KIRP	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-5.91	1.08e-08	7.09e-06	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
KIRP	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	5.91	1.08e-08	7.11e-06	0.43	0.34	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
KIRP	cis	rs6908034	0.607	rs77386860	ENSG00000228412.5	RP4-625H18.2	5.91	1.08e-08	7.11e-06	0.65	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19802164~19804752:-
KIRP	cis	rs12936587	0.583	rs9783803	ENSG00000223979.2	SMCR2	5.91	1.08e-08	7.12e-06	0.33	0.34	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17649583	chr17:17674026~17677688:-
KIRP	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	5.91	1.08e-08	7.12e-06	0.27	0.34	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
KIRP	cis	rs9828933	0.808	rs3733125	ENSG00000280620.1	SCAANT1	5.91	1.08e-08	7.12e-06	0.64	0.34	Type 2 diabetes;	chr3:63995959	chr3:63911518~63911772:-
KIRP	cis	rs2625529	0.526	rs8040828	ENSG00000260037.4	CTD-2524L6.3	5.91	1.09e-08	7.13e-06	0.27	0.34	Red blood cell count;	chr15:72200438	chr15:71818396~71823384:+
KIRP	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-5.91	1.09e-08	7.13e-06	-0.35	-0.34	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
KIRP	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	5.91	1.09e-08	7.13e-06	0.5	0.34	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
KIRP	cis	rs7474896	0.583	rs34185758	ENSG00000151963.4	RP11-775A3.1	-5.91	1.09e-08	7.13e-06	-0.47	-0.34	Obesity (extreme);	chr10:37701926	chr10:37883594~37884109:+
KIRP	cis	rs67311347	0.956	rs11714871	ENSG00000230274.1	PGAM1P3	5.91	1.09e-08	7.14e-06	0.33	0.34	Renal cell carcinoma;	chr3:40387447	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs2305521	ENSG00000230274.1	PGAM1P3	5.91	1.09e-08	7.14e-06	0.33	0.34	Renal cell carcinoma;	chr3:40387692	chr3:40322715~40323279:-
KIRP	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-5.91	1.09e-08	7.14e-06	-0.32	-0.34	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
KIRP	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.9	1.09e-08	7.16e-06	0.39	0.34	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
KIRP	cis	rs1799949	1	rs8074136	ENSG00000236383.6	LINC00854	-5.9	1.09e-08	7.17e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43190296	chr17:43216941~43305976:-
KIRP	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	5.9	1.09e-08	7.17e-06	0.29	0.34	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	5.9	1.1e-08	7.21e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
KIRP	cis	rs67311347	1	rs9842564	ENSG00000230274.1	PGAM1P3	-5.9	1.1e-08	7.23e-06	-0.33	-0.34	Renal cell carcinoma;	chr3:40364319	chr3:40322715~40323279:-
KIRP	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	5.9	1.1e-08	7.23e-06	0.35	0.34	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
KIRP	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-5.9	1.11e-08	7.24e-06	-0.3	-0.34	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
KIRP	cis	rs2625529	0.689	rs8178	ENSG00000260037.4	CTD-2524L6.3	-5.9	1.11e-08	7.25e-06	-0.27	-0.34	Red blood cell count;	chr15:71822406	chr15:71818396~71823384:+
KIRP	cis	rs853679	0.723	rs1736904	ENSG00000204709.4	LINC01556	5.9	1.11e-08	7.28e-06	0.47	0.34	Depression;	chr6:28251492	chr6:28943877~28944537:+
KIRP	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	5.9	1.11e-08	7.28e-06	0.29	0.34	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
KIRP	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	5.9	1.11e-08	7.29e-06	0.46	0.34	Height;	chr6:109458989	chr6:109382795~109383666:+
KIRP	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	5.9	1.11e-08	7.29e-06	0.56	0.34	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
KIRP	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	5.9	1.11e-08	7.29e-06	0.41	0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
KIRP	cis	rs9388451	0.839	rs9401845	ENSG00000237742.5	RP11-624M8.1	-5.9	1.12e-08	7.3e-06	-0.36	-0.34	Brugada syndrome;	chr6:125782972	chr6:125578558~125749190:-
KIRP	cis	rs9388451	0.805	rs1028481	ENSG00000237742.5	RP11-624M8.1	-5.9	1.12e-08	7.3e-06	-0.36	-0.34	Brugada syndrome;	chr6:125785427	chr6:125578558~125749190:-
KIRP	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-5.9	1.12e-08	7.33e-06	-0.44	-0.34	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
KIRP	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	5.9	1.12e-08	7.33e-06	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
KIRP	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-5.9	1.12e-08	7.33e-06	-0.35	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
KIRP	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-5.9	1.12e-08	7.33e-06	-0.46	-0.34	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
KIRP	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	5.9	1.12e-08	7.35e-06	0.39	0.34	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	5.9	1.13e-08	7.36e-06	0.29	0.34	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	5.9	1.13e-08	7.36e-06	0.29	0.34	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
KIRP	cis	rs2625529	0.652	rs2929525	ENSG00000260037.4	CTD-2524L6.3	5.9	1.13e-08	7.36e-06	0.27	0.34	Red blood cell count;	chr15:71995515	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-5.9	1.13e-08	7.36e-06	-0.29	-0.34	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
KIRP	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	5.9	1.13e-08	7.37e-06	0.36	0.34	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
KIRP	cis	rs2765539	0.887	rs1325933	ENSG00000231365.4	RP11-418J17.1	-5.9	1.13e-08	7.37e-06	-0.39	-0.34	Waist-hip ratio;	chr1:119013136	chr1:119140396~119275973:+
KIRP	cis	rs453301	0.658	rs6983877	ENSG00000253981.4	ALG1L13P	-5.9	1.13e-08	7.37e-06	-0.27	-0.34	Joint mobility (Beighton score);	chr8:9047129	chr8:8236003~8244667:-
KIRP	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-5.9	1.13e-08	7.37e-06	-0.29	-0.34	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
KIRP	cis	rs9532669	0.926	rs4454835	ENSG00000239827.7	SUGT1P3	-5.9	1.13e-08	7.38e-06	-0.38	-0.34	Cervical cancer;	chr13:40928978	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs1571116	ENSG00000239827.7	SUGT1P3	-5.9	1.13e-08	7.38e-06	-0.38	-0.34	Cervical cancer;	chr13:40929765	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs9532673	ENSG00000239827.7	SUGT1P3	-5.9	1.13e-08	7.38e-06	-0.38	-0.34	Cervical cancer;	chr13:40930412	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9532676	ENSG00000239827.7	SUGT1P3	-5.9	1.13e-08	7.38e-06	-0.38	-0.34	Cervical cancer;	chr13:40935626	chr13:40908159~40921774:-
KIRP	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	5.9	1.13e-08	7.38e-06	0.29	0.34	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	5.9	1.13e-08	7.38e-06	0.29	0.34	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
KIRP	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	5.9	1.13e-08	7.38e-06	0.33	0.34	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	5.9	1.13e-08	7.38e-06	0.33	0.34	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	5.9	1.13e-08	7.38e-06	0.33	0.34	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
KIRP	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	5.9	1.13e-08	7.38e-06	0.46	0.34	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
KIRP	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	5.9	1.13e-08	7.39e-06	0.41	0.34	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
KIRP	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-5.9	1.13e-08	7.39e-06	-0.48	-0.34	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
KIRP	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-5.9	1.13e-08	7.4e-06	-0.3	-0.34	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
KIRP	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	5.9	1.13e-08	7.41e-06	0.39	0.34	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
KIRP	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	5.9	1.14e-08	7.41e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
KIRP	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-5.9	1.14e-08	7.43e-06	-0.48	-0.34	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
KIRP	cis	rs453301	0.658	rs12114954	ENSG00000253981.4	ALG1L13P	-5.9	1.14e-08	7.43e-06	-0.27	-0.34	Joint mobility (Beighton score);	chr8:9047352	chr8:8236003~8244667:-
KIRP	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	5.9	1.14e-08	7.43e-06	0.3	0.34	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
KIRP	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-5.9	1.14e-08	7.43e-06	-0.43	-0.34	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	5.9	1.14e-08	7.44e-06	0.45	0.34	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
KIRP	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	5.9	1.14e-08	7.44e-06	0.35	0.34	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
KIRP	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	5.9	1.14e-08	7.44e-06	0.39	0.34	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
KIRP	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	5.9	1.14e-08	7.44e-06	0.29	0.34	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
KIRP	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-5.9	1.14e-08	7.45e-06	-0.47	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
KIRP	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	5.9	1.14e-08	7.46e-06	0.35	0.34	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
KIRP	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	5.9	1.15e-08	7.48e-06	0.45	0.34	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	5.9	1.15e-08	7.48e-06	0.29	0.34	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	5.9	1.15e-08	7.48e-06	0.29	0.34	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	5.9	1.15e-08	7.48e-06	0.29	0.34	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
KIRP	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-5.9	1.15e-08	7.49e-06	-0.49	-0.34	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
KIRP	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	5.9	1.15e-08	7.49e-06	0.34	0.34	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	5.9	1.15e-08	7.49e-06	0.34	0.34	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
KIRP	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-5.89	1.15e-08	7.5e-06	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-5.89	1.15e-08	7.5e-06	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
KIRP	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-5.89	1.15e-08	7.51e-06	-0.41	-0.34	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
KIRP	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.89	1.15e-08	7.51e-06	0.48	0.34	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	5.89	1.15e-08	7.51e-06	0.29	0.34	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
KIRP	cis	rs1560104	0.576	rs11640886	ENSG00000274834.1	CTD-3037G24.5	5.89	1.15e-08	7.52e-06	0.38	0.34	Obesity-related traits;	chr16:12615377	chr16:12614451~12614852:+
KIRP	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-5.89	1.15e-08	7.53e-06	-0.29	-0.34	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
KIRP	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-5.89	1.16e-08	7.54e-06	-0.43	-0.34	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
KIRP	cis	rs710913	0.738	rs1180347	ENSG00000237624.1	OXCT2P1	-5.89	1.16e-08	7.57e-06	-0.4	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39514956~39516490:+
KIRP	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-5.89	1.16e-08	7.58e-06	-0.3	-0.34	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
KIRP	cis	rs9595908	0.714	rs1018800	ENSG00000212293.1	SNORA16	5.89	1.17e-08	7.62e-06	0.33	0.34	Body mass index;	chr13:32624039	chr13:32420390~32420516:-
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	5.89	1.17e-08	7.62e-06	0.29	0.34	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	5.89	1.17e-08	7.62e-06	0.29	0.34	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
KIRP	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	5.89	1.17e-08	7.62e-06	0.32	0.34	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
KIRP	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	5.89	1.17e-08	7.65e-06	0.29	0.34	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
KIRP	cis	rs6480314	0.542	rs7079054	ENSG00000233590.1	RP11-153K11.3	-5.89	1.18e-08	7.66e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68266404	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs12570281	ENSG00000233590.1	RP11-153K11.3	-5.89	1.18e-08	7.66e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68267237	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs61854813	ENSG00000233590.1	RP11-153K11.3	-5.89	1.18e-08	7.66e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68267464	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs61854814	ENSG00000233590.1	RP11-153K11.3	-5.89	1.18e-08	7.66e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68267639	chr10:68233251~68242379:-
KIRP	cis	rs9371601	0.852	rs214994	ENSG00000226193.1	RP3-398G3.5	-5.89	1.18e-08	7.66e-06	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152445007	chr6:152402398~152404966:+
KIRP	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-5.89	1.18e-08	7.66e-06	-0.48	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
KIRP	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	5.89	1.18e-08	7.67e-06	0.63	0.34	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
KIRP	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.67e-06	0.45	0.34	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	7.68e-06	0.45	0.34	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
KIRP	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-5.89	1.18e-08	7.68e-06	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
KIRP	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-5.89	1.18e-08	7.69e-06	-0.48	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
KIRP	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	5.89	1.19e-08	7.71e-06	0.4	0.34	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
KIRP	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-5.89	1.19e-08	7.73e-06	-0.47	-0.34	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
KIRP	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	5.89	1.19e-08	7.73e-06	0.44	0.34	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
KIRP	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-5.89	1.19e-08	7.74e-06	-0.33	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	5.89	1.19e-08	7.76e-06	0.28	0.34	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-5.89	1.19e-08	7.77e-06	-0.35	-0.34	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
KIRP	cis	rs1799949	0.965	rs8176087	ENSG00000236383.6	LINC00854	-5.89	1.2e-08	7.78e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43118649	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs34942571	ENSG00000236383.6	LINC00854	-5.89	1.2e-08	7.78e-06	-0.28	-0.34	Menopause (age at onset);	chr17:43121362	chr17:43216941~43305976:-
KIRP	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	5.89	1.2e-08	7.78e-06	0.35	0.34	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-5.89	1.2e-08	7.79e-06	-0.29	-0.34	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-5.89	1.2e-08	7.79e-06	-0.29	-0.34	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	5.89	1.2e-08	7.79e-06	0.41	0.34	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
KIRP	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-5.89	1.2e-08	7.79e-06	-0.3	-0.34	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
KIRP	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-5.89	1.2e-08	7.79e-06	-0.38	-0.34	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
KIRP	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-5.89	1.2e-08	7.8e-06	-0.4	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
KIRP	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-5.89	1.2e-08	7.8e-06	-0.38	-0.34	Migraine;	chr4:56879851	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-5.89	1.2e-08	7.8e-06	-0.38	-0.34	Migraine;	chr4:56880007	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-5.89	1.2e-08	7.8e-06	-0.38	-0.34	Migraine;	chr4:56880190	chr4:56960927~56961373:-
KIRP	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-5.89	1.2e-08	7.8e-06	-0.38	-0.34	Migraine;	chr4:56880659	chr4:56960927~56961373:-
KIRP	cis	rs9371601	0.892	rs7755453	ENSG00000226193.1	RP3-398G3.5	-5.89	1.2e-08	7.82e-06	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152484231	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	5.89	1.2e-08	7.83e-06	0.45	0.34	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
KIRP	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-5.89	1.21e-08	7.83e-06	-0.32	-0.34	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
KIRP	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	5.89	1.21e-08	7.84e-06	0.39	0.34	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-5.89	1.21e-08	7.85e-06	-0.39	-0.34	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-5.89	1.21e-08	7.85e-06	-0.29	-0.34	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
KIRP	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	5.89	1.21e-08	7.87e-06	0.26	0.34	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-5.89	1.21e-08	7.87e-06	-0.29	-0.34	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-5.89	1.21e-08	7.87e-06	-0.29	-0.34	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
KIRP	cis	rs1560104	0.549	rs7201160	ENSG00000274834.1	CTD-3037G24.5	5.88	1.21e-08	7.88e-06	0.38	0.34	Obesity-related traits;	chr16:12614022	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.576	rs7202727	ENSG00000274834.1	CTD-3037G24.5	5.88	1.21e-08	7.88e-06	0.38	0.34	Obesity-related traits;	chr16:12614087	chr16:12614451~12614852:+
KIRP	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	5.88	1.22e-08	7.89e-06	0.79	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	5.88	1.22e-08	7.89e-06	0.79	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	5.88	1.22e-08	7.89e-06	0.79	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
KIRP	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-5.88	1.22e-08	7.89e-06	-0.24	-0.34	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
KIRP	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-5.88	1.22e-08	7.89e-06	-0.41	-0.34	Depression;	chr6:28206179	chr6:28115628~28116551:+
KIRP	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	5.88	1.22e-08	7.9e-06	0.45	0.34	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
KIRP	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	5.88	1.22e-08	7.91e-06	0.45	0.34	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
KIRP	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	5.88	1.22e-08	7.91e-06	0.39	0.34	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
KIRP	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	5.88	1.22e-08	7.92e-06	0.45	0.34	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	5.88	1.22e-08	7.92e-06	0.45	0.34	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	5.88	1.22e-08	7.92e-06	0.42	0.34	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	5.88	1.22e-08	7.93e-06	0.39	0.34	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
KIRP	cis	rs6480314	0.542	rs7476012	ENSG00000233590.1	RP11-153K11.3	-5.88	1.22e-08	7.93e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68259950	chr10:68233251~68242379:-
KIRP	cis	rs4638749	0.677	rs6711297	ENSG00000231221.1	AC023672.2	-5.88	1.22e-08	7.94e-06	-0.4	-0.34	Blood pressure;	chr2:108201901	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs6755598	ENSG00000231221.1	AC023672.2	-5.88	1.22e-08	7.94e-06	-0.4	-0.34	Blood pressure;	chr2:108211218	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10185601	ENSG00000231221.1	AC023672.2	-5.88	1.22e-08	7.94e-06	-0.4	-0.34	Blood pressure;	chr2:108211822	chr2:108049200~108052755:-
KIRP	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	5.88	1.23e-08	7.96e-06	0.63	0.34	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
KIRP	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	5.88	1.23e-08	7.96e-06	0.42	0.34	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
KIRP	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-5.88	1.23e-08	7.97e-06	-0.45	-0.34	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
KIRP	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	5.88	1.23e-08	7.98e-06	0.47	0.34	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
KIRP	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	5.88	1.23e-08	7.98e-06	0.62	0.34	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	5.88	1.23e-08	8e-06	0.41	0.34	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	5.88	1.23e-08	8e-06	0.35	0.34	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
KIRP	cis	rs67311347	0.91	rs7617361	ENSG00000230274.1	PGAM1P3	5.88	1.23e-08	8e-06	0.32	0.34	Renal cell carcinoma;	chr3:40331768	chr3:40322715~40323279:-
KIRP	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	5.88	1.24e-08	8.01e-06	0.61	0.34	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
KIRP	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	5.88	1.24e-08	8.02e-06	0.3	0.34	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
KIRP	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-5.88	1.24e-08	8.02e-06	-0.34	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
KIRP	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	5.88	1.24e-08	8.03e-06	0.43	0.34	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
KIRP	cis	rs4128705	0.958	rs1830354	ENSG00000249049.1	RP11-763F8.1	5.88	1.24e-08	8.03e-06	0.29	0.34	Amyotrophic lateral sclerosis (sporadic);	chr4:91359191	chr4:91319034~91325306:-
KIRP	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-5.88	1.24e-08	8.04e-06	-0.26	-0.34	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
KIRP	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-5.88	1.24e-08	8.04e-06	-0.49	-0.34	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
KIRP	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-5.88	1.24e-08	8.04e-06	-0.36	-0.34	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
KIRP	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	5.88	1.24e-08	8.06e-06	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
KIRP	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-5.88	1.24e-08	8.06e-06	-0.37	-0.34	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
KIRP	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-5.88	1.25e-08	8.1e-06	-0.29	-0.34	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
KIRP	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	5.88	1.25e-08	8.1e-06	0.29	0.34	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
KIRP	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-5.88	1.25e-08	8.1e-06	-0.37	-0.34	Height;	chr3:53097932	chr3:53064283~53065091:-
KIRP	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	5.88	1.25e-08	8.12e-06	0.42	0.34	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	5.88	1.26e-08	8.13e-06	0.28	0.34	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
KIRP	cis	rs67311347	0.911	rs9849224	ENSG00000230274.1	PGAM1P3	5.88	1.26e-08	8.13e-06	0.32	0.34	Renal cell carcinoma;	chr3:40351071	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs2168111	ENSG00000230274.1	PGAM1P3	5.88	1.26e-08	8.13e-06	0.32	0.34	Renal cell carcinoma;	chr3:40353834	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs9834052	ENSG00000230274.1	PGAM1P3	5.88	1.26e-08	8.13e-06	0.32	0.34	Renal cell carcinoma;	chr3:40357569	chr3:40322715~40323279:-
KIRP	cis	rs67311347	1	rs7612015	ENSG00000230274.1	PGAM1P3	5.88	1.26e-08	8.13e-06	0.32	0.34	Renal cell carcinoma;	chr3:40358483	chr3:40322715~40323279:-
KIRP	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-5.88	1.26e-08	8.14e-06	-0.34	-0.34	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
KIRP	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-5.88	1.26e-08	8.16e-06	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
KIRP	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	5.88	1.27e-08	8.2e-06	0.34	0.34	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
KIRP	cis	rs4443100	0.837	rs6003490	ENSG00000221069.1	AC000029.1	5.88	1.27e-08	8.21e-06	0.47	0.34	Serum parathyroid hormone levels;	chr22:23046267	chr22:23136620~23136710:+
KIRP	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-5.88	1.27e-08	8.21e-06	-0.28	-0.34	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
KIRP	cis	rs9371601	0.961	rs4331993	ENSG00000226193.1	RP3-398G3.5	-5.88	1.27e-08	8.21e-06	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152472437	chr6:152402398~152404966:+
KIRP	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	5.88	1.27e-08	8.22e-06	0.45	0.34	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	5.88	1.27e-08	8.22e-06	0.45	0.34	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
KIRP	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	5.88	1.27e-08	8.24e-06	0.77	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	5.88	1.27e-08	8.24e-06	0.77	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-5.88	1.27e-08	8.24e-06	-0.77	-0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
KIRP	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-5.88	1.28e-08	8.25e-06	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
KIRP	cis	rs1799949	0.773	rs2137990	ENSG00000236383.6	LINC00854	5.88	1.28e-08	8.26e-06	0.25	0.34	Menopause (age at onset);	chr17:43165879	chr17:43216941~43305976:-
KIRP	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-5.88	1.28e-08	8.26e-06	-0.34	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
KIRP	cis	rs7404843	0.925	rs72774861	ENSG00000263335.1	AF001548.5	5.88	1.28e-08	8.26e-06	0.49	0.34	Testicular germ cell tumor;	chr16:15415777	chr16:15726674~15732993:+
KIRP	cis	rs2283792	0.967	rs3810609	ENSG00000228050.1	TOP3BP1	5.87	1.28e-08	8.27e-06	0.37	0.34	Multiple sclerosis;	chr22:21758513	chr22:22223187~22224566:-
KIRP	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	5.87	1.28e-08	8.27e-06	0.45	0.34	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
KIRP	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-5.87	1.28e-08	8.27e-06	-0.35	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
KIRP	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	5.87	1.28e-08	8.27e-06	0.53	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
KIRP	cis	rs9928842	0.882	rs8048956	ENSG00000280152.1	RP11-331F4.5	-5.87	1.28e-08	8.28e-06	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr16:75221068	chr16:75245994~75250077:-
KIRP	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.87	1.28e-08	8.29e-06	-0.44	-0.34	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.87	1.28e-08	8.29e-06	-0.44	-0.34	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.87	1.28e-08	8.29e-06	-0.44	-0.34	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
KIRP	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.87	1.29e-08	8.3e-06	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
KIRP	cis	rs13423976	0.631	rs7582463	ENSG00000231367.4	AC016995.3	-5.87	1.29e-08	8.31e-06	-0.45	-0.34	Gut microbiome composition (summer);	chr2:38511226	chr2:38406719~38515740:-
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	5.87	1.29e-08	8.32e-06	0.29	0.34	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
KIRP	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-5.87	1.29e-08	8.32e-06	-0.41	-0.34	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
KIRP	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-5.87	1.29e-08	8.32e-06	-0.41	-0.34	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
KIRP	cis	rs710913	0.816	rs1727098	ENSG00000237624.1	OXCT2P1	-5.87	1.29e-08	8.32e-06	-0.4	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39514956~39516490:+
KIRP	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	5.87	1.29e-08	8.33e-06	0.37	0.34	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
KIRP	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.87	1.29e-08	8.34e-06	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
KIRP	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-5.87	1.29e-08	8.34e-06	-0.35	-0.34	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
KIRP	cis	rs7267979	1	rs6050559	ENSG00000274414.1	RP5-965G21.4	-5.87	1.29e-08	8.34e-06	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25239007~25245229:-
KIRP	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.87	1.3e-08	8.37e-06	0.26	0.34	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
KIRP	cis	rs2273156	0.929	rs12894820	ENSG00000226677.3	IGBP1P1	5.87	1.3e-08	8.39e-06	0.36	0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966319	chr14:34939324~34940332:+
KIRP	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-5.87	1.3e-08	8.4e-06	-0.43	-0.34	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
KIRP	cis	rs7267979	0.966	rs910996	ENSG00000274414.1	RP5-965G21.4	-5.87	1.3e-08	8.41e-06	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25239007~25245229:-
KIRP	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-5.87	1.31e-08	8.41e-06	-0.44	-0.34	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
KIRP	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	5.87	1.31e-08	8.42e-06	0.3	0.34	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	5.87	1.31e-08	8.42e-06	0.3	0.34	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
KIRP	cis	rs4273100	1	rs16960158	ENSG00000228157.4	AC007952.5	5.87	1.31e-08	8.42e-06	0.61	0.34	Schizophrenia;	chr17:19259739	chr17:19092974~19096837:+
KIRP	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	5.87	1.31e-08	8.42e-06	0.39	0.34	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
KIRP	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-5.87	1.31e-08	8.45e-06	-0.4	-0.34	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
KIRP	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-5.87	1.31e-08	8.46e-06	-0.34	-0.34	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
KIRP	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	5.87	1.32e-08	8.47e-06	0.48	0.34	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
KIRP	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-5.87	1.32e-08	8.47e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-5.87	1.32e-08	8.47e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
KIRP	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-5.87	1.32e-08	8.47e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
KIRP	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-5.87	1.32e-08	8.48e-06	-0.49	-0.34	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
KIRP	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-5.87	1.32e-08	8.48e-06	-0.46	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
KIRP	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	5.87	1.32e-08	8.48e-06	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
KIRP	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	5.87	1.32e-08	8.5e-06	0.3	0.34	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
KIRP	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	5.87	1.32e-08	8.5e-06	0.41	0.34	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	5.87	1.32e-08	8.5e-06	0.41	0.34	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
KIRP	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	5.87	1.32e-08	8.5e-06	0.29	0.34	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	5.87	1.32e-08	8.5e-06	0.29	0.34	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	5.87	1.32e-08	8.5e-06	0.29	0.34	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
KIRP	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	5.87	1.32e-08	8.51e-06	0.38	0.34	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
KIRP	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	5.87	1.32e-08	8.52e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
KIRP	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-5.87	1.33e-08	8.52e-06	-0.4	-0.34	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
KIRP	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-5.87	1.33e-08	8.52e-06	-0.4	-0.34	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
KIRP	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.53e-06	0.44	0.34	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
KIRP	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-5.87	1.33e-08	8.54e-06	-0.36	-0.34	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
KIRP	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
KIRP	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.55e-06	0.45	0.34	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
KIRP	cis	rs755249	0.883	rs12035330	ENSG00000237624.1	OXCT2P1	5.87	1.33e-08	8.55e-06	0.52	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39514956~39516490:+
KIRP	cis	rs7170668	0.93	rs12911974	ENSG00000258489.3	RP11-398J10.2	-5.87	1.33e-08	8.56e-06	-0.38	-0.34	Motion sickness;	chr15:95473420	chr15:95463592~95493770:-
KIRP	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	5.87	1.33e-08	8.56e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	5.87	1.33e-08	8.56e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	5.87	1.33e-08	8.56e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	5.87	1.33e-08	8.56e-06	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
KIRP	cis	rs7474896	0.515	rs688608	ENSG00000151963.4	RP11-775A3.1	5.87	1.33e-08	8.56e-06	0.49	0.34	Obesity (extreme);	chr10:38042696	chr10:37883594~37884109:+
KIRP	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.57e-06	0.45	0.34	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	5.87	1.33e-08	8.57e-06	0.45	0.34	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
KIRP	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	5.87	1.34e-08	8.59e-06	0.3	0.34	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
KIRP	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	5.87	1.34e-08	8.59e-06	0.29	0.34	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-5.87	1.34e-08	8.59e-06	-0.35	-0.34	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
KIRP	cis	rs4356975	0.83	rs6600868	ENSG00000196472.4	RP13-644M16.4	5.87	1.34e-08	8.59e-06	0.37	0.34	Obesity-related traits;	chr4:69075923	chr4:69181660~69182372:+
KIRP	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	5.87	1.34e-08	8.59e-06	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
KIRP	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-5.87	1.34e-08	8.6e-06	-0.34	-0.34	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
KIRP	cis	rs7474896	0.583	rs12783272	ENSG00000151963.4	RP11-775A3.1	-5.87	1.34e-08	8.6e-06	-0.47	-0.34	Obesity (extreme);	chr10:37735957	chr10:37883594~37884109:+
KIRP	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	5.87	1.34e-08	8.61e-06	0.45	0.34	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
KIRP	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	5.87	1.34e-08	8.63e-06	0.47	0.34	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
KIRP	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	5.87	1.34e-08	8.63e-06	0.48	0.34	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-5.87	1.34e-08	8.63e-06	-0.48	-0.34	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
KIRP	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	5.87	1.35e-08	8.65e-06	0.31	0.34	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
KIRP	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	5.87	1.35e-08	8.65e-06	0.4	0.34	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	5.87	1.35e-08	8.65e-06	0.45	0.34	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-5.87	1.35e-08	8.66e-06	-0.29	-0.34	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
KIRP	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-5.86	1.35e-08	8.67e-06	-0.43	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
KIRP	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	5.86	1.35e-08	8.69e-06	0.41	0.34	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
KIRP	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-5.86	1.36e-08	8.71e-06	-0.29	-0.34	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
KIRP	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-5.86	1.36e-08	8.71e-06	-0.29	-0.34	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
KIRP	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	5.86	1.36e-08	8.71e-06	0.4	0.34	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
KIRP	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	5.86	1.36e-08	8.71e-06	0.38	0.34	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
KIRP	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	5.86	1.36e-08	8.73e-06	0.66	0.34	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
KIRP	cis	rs2625529	0.652	rs11072350	ENSG00000260037.4	CTD-2524L6.3	5.86	1.37e-08	8.77e-06	0.26	0.34	Red blood cell count;	chr15:72172268	chr15:71818396~71823384:+
KIRP	cis	rs7474896	0.559	rs1208560	ENSG00000151963.4	RP11-775A3.1	5.86	1.37e-08	8.77e-06	0.43	0.34	Obesity (extreme);	chr10:37932690	chr10:37883594~37884109:+
KIRP	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	5.86	1.37e-08	8.77e-06	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
KIRP	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	5.86	1.37e-08	8.78e-06	0.4	0.34	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
KIRP	cis	rs2273156	1	rs60803103	ENSG00000226677.3	IGBP1P1	-5.86	1.37e-08	8.78e-06	-0.36	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:34944847	chr14:34939324~34940332:+
KIRP	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-5.86	1.37e-08	8.79e-06	-0.36	-0.34	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
KIRP	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	5.86	1.37e-08	8.79e-06	0.29	0.34	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	5.86	1.37e-08	8.79e-06	0.29	0.34	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	5.86	1.37e-08	8.79e-06	0.29	0.34	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
KIRP	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	5.86	1.37e-08	8.8e-06	0.44	0.34	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	5.86	1.37e-08	8.8e-06	0.44	0.34	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
KIRP	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	5.86	1.38e-08	8.81e-06	0.38	0.34	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
KIRP	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-5.86	1.38e-08	8.81e-06	-0.37	-0.34	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
KIRP	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-5.86	1.38e-08	8.82e-06	-0.47	-0.34	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
KIRP	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	5.86	1.38e-08	8.83e-06	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
KIRP	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-5.86	1.38e-08	8.86e-06	-0.46	-0.34	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
KIRP	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-5.86	1.39e-08	8.88e-06	-0.71	-0.34	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
KIRP	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	5.86	1.39e-08	8.89e-06	0.3	0.34	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
KIRP	cis	rs2283792	0.967	rs5999550	ENSG00000228050.1	TOP3BP1	5.86	1.39e-08	8.89e-06	0.37	0.34	Multiple sclerosis;	chr22:21796997	chr22:22223187~22224566:-
KIRP	cis	rs2283792	1	rs2266967	ENSG00000228050.1	TOP3BP1	5.86	1.39e-08	8.89e-06	0.37	0.34	Multiple sclerosis;	chr22:21802500	chr22:22223187~22224566:-
KIRP	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-5.86	1.39e-08	8.9e-06	-0.28	-0.34	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
KIRP	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	5.86	1.39e-08	8.9e-06	0.63	0.34	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
KIRP	cis	rs7747960	1	rs62427036	ENSG00000226193.1	RP3-398G3.5	-5.86	1.39e-08	8.9e-06	-0.53	-0.34	Bipolar disorder;	chr6:152454328	chr6:152402398~152404966:+
KIRP	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	5.86	1.39e-08	8.91e-06	0.37	0.34	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
KIRP	cis	rs7829975	0.539	rs883647	ENSG00000253893.2	FAM85B	5.86	1.39e-08	8.91e-06	0.43	0.34	Mood instability;	chr8:8712214	chr8:8167819~8226614:-
KIRP	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	5.86	1.39e-08	8.92e-06	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	5.86	1.39e-08	8.92e-06	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	5.86	1.39e-08	8.92e-06	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-5.86	1.4e-08	8.94e-06	-0.45	-0.34	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
KIRP	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-5.86	1.4e-08	8.95e-06	-0.48	-0.34	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-5.86	1.4e-08	8.95e-06	-0.43	-0.34	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
KIRP	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	5.86	1.4e-08	8.96e-06	0.39	0.34	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
KIRP	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-5.86	1.4e-08	8.97e-06	-0.46	-0.34	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
KIRP	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-5.86	1.4e-08	8.97e-06	-0.45	-0.34	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
KIRP	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-5.86	1.4e-08	8.97e-06	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-5.86	1.4e-08	8.97e-06	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-5.86	1.4e-08	8.97e-06	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-5.86	1.4e-08	8.97e-06	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
KIRP	cis	rs950169	0.922	rs17531523	ENSG00000275120.1	RP11-182J1.17	5.86	1.4e-08	8.97e-06	0.45	0.34	Schizophrenia;	chr15:84589218	chr15:84599434~84606463:-
KIRP	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-5.86	1.4e-08	8.97e-06	-0.37	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
KIRP	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	5.86	1.41e-08	8.98e-06	0.53	0.34	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
KIRP	cis	rs2617170	0.961	rs2617171	ENSG00000245648.1	RP11-277P12.20	5.86	1.41e-08	8.99e-06	0.4	0.34	Behcet's disease;	chr12:10408680	chr12:10363769~10398506:+
KIRP	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-5.86	1.41e-08	9e-06	-0.35	-0.34	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-5.86	1.41e-08	9e-06	-0.35	-0.34	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
KIRP	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-5.86	1.41e-08	9.02e-06	-0.37	-0.34	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
KIRP	cis	rs2842992	0.747	rs4709378	ENSG00000237927.1	RP3-393E18.2	-5.86	1.41e-08	9.02e-06	-0.49	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159806403	chr6:159586955~159589169:-
KIRP	cis	rs2625529	0.878	rs4777478	ENSG00000260037.4	CTD-2524L6.3	-5.86	1.41e-08	9.03e-06	-0.29	-0.34	Red blood cell count;	chr15:71986744	chr15:71818396~71823384:+
KIRP	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-5.86	1.42e-08	9.04e-06	-0.42	-0.34	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
KIRP	cis	rs62388641	0.636	rs35412353	ENSG00000272279.1	RP11-157J24.2	5.86	1.42e-08	9.04e-06	0.58	0.34	Daytime sleep phenotypes;	chr6:1529209	chr6:1528364~1528911:-
KIRP	cis	rs755249	0.642	rs28788506	ENSG00000237624.1	OXCT2P1	5.86	1.42e-08	9.04e-06	0.45	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39514956~39516490:+
KIRP	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-5.86	1.42e-08	9.06e-06	-0.43	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
KIRP	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	5.86	1.42e-08	9.07e-06	0.37	0.34	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
KIRP	cis	rs712022	1	rs11026804	ENSG00000246225.5	RP11-17A1.3	5.85	1.42e-08	9.08e-06	0.38	0.34	Dialysis-related mortality;	chr11:22820036	chr11:22829380~22945393:+
KIRP	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	5.85	1.42e-08	9.08e-06	0.39	0.34	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
KIRP	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	5.85	1.43e-08	9.09e-06	0.41	0.34	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
KIRP	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-5.85	1.43e-08	9.09e-06	-0.29	-0.34	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
KIRP	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	5.85	1.43e-08	9.11e-06	0.92	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
KIRP	cis	rs1799949	1	rs3092988	ENSG00000236383.6	LINC00854	-5.85	1.43e-08	9.12e-06	-0.27	-0.34	Menopause (age at onset);	chr17:43049685	chr17:43216941~43305976:-
KIRP	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-5.85	1.43e-08	9.14e-06	-0.41	-0.34	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
KIRP	cis	rs7569084	0.687	rs12614851	ENSG00000237979.1	AC007389.1	5.85	1.43e-08	9.14e-06	0.4	0.34	Sum eosinophil basophil counts;	chr2:65458050	chr2:65500993~65502138:-
KIRP	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.44e-08	9.17e-06	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.44e-08	9.17e-06	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.44e-08	9.17e-06	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.44e-08	9.17e-06	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.44e-08	9.17e-06	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
KIRP	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-5.85	1.44e-08	9.2e-06	-0.27	-0.34	Monocyte count;	chr11:307036	chr11:318640~325631:+
KIRP	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-5.85	1.44e-08	9.2e-06	-0.29	-0.34	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
KIRP	cis	rs1061377	0.585	rs2163271	ENSG00000249207.1	RP11-360F5.1	-5.85	1.45e-08	9.21e-06	-0.35	-0.34	Uric acid levels;	chr4:39076525	chr4:39112677~39126818:-
KIRP	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-5.85	1.45e-08	9.21e-06	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
KIRP	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-5.85	1.45e-08	9.22e-06	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
KIRP	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-5.85	1.45e-08	9.22e-06	-0.26	-0.34	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
KIRP	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	5.85	1.45e-08	9.23e-06	0.3	0.34	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	5.85	1.45e-08	9.24e-06	0.35	0.34	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	5.85	1.45e-08	9.24e-06	0.35	0.34	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	5.85	1.45e-08	9.24e-06	0.35	0.34	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
KIRP	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	5.85	1.46e-08	9.27e-06	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
KIRP	cis	rs897984	0.684	rs6950	ENSG00000275263.1	RP11-1072A3.4	5.85	1.46e-08	9.27e-06	0.35	0.34	Dementia with Lewy bodies;	chr16:30984348	chr16:30956872~30957199:-
KIRP	cis	rs2625529	0.668	rs12591313	ENSG00000260037.4	CTD-2524L6.3	-5.85	1.46e-08	9.27e-06	-0.3	-0.34	Red blood cell count;	chr15:72264405	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.668	rs12591338	ENSG00000260037.4	CTD-2524L6.3	-5.85	1.46e-08	9.27e-06	-0.3	-0.34	Red blood cell count;	chr15:72264506	chr15:71818396~71823384:+
KIRP	cis	rs79349575	0.756	rs62078385	ENSG00000248278.1	SUMO2P17	5.85	1.46e-08	9.28e-06	0.39	0.34	Type 2 diabetes;	chr17:48967647	chr17:48874860~48908983:-
KIRP	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-5.85	1.46e-08	9.3e-06	-0.35	-0.34	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
KIRP	cis	rs67311347	0.955	rs11717036	ENSG00000230274.1	PGAM1P3	-5.85	1.46e-08	9.31e-06	-0.33	-0.34	Renal cell carcinoma;	chr3:40338087	chr3:40322715~40323279:-
KIRP	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-5.85	1.47e-08	9.36e-06	-0.27	-0.34	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
KIRP	cis	rs116095464	1	rs10069360	ENSG00000277812.1	AC021087.1	5.85	1.47e-08	9.37e-06	0.77	0.34	Breast cancer;	chr5:351500	chr5:262769~262881:+
KIRP	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	5.85	1.47e-08	9.37e-06	0.57	0.34	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
KIRP	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	5.85	1.47e-08	9.38e-06	0.39	0.34	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
KIRP	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-5.85	1.47e-08	9.38e-06	-0.45	-0.34	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
KIRP	cis	rs79349575	0.655	rs62078384	ENSG00000248278.1	SUMO2P17	5.85	1.48e-08	9.38e-06	0.39	0.34	Type 2 diabetes;	chr17:48967101	chr17:48874860~48908983:-
KIRP	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-5.85	1.48e-08	9.39e-06	-0.37	-0.34	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
KIRP	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	5.85	1.48e-08	9.4e-06	0.36	0.34	Height;	chr3:53073584	chr3:53064283~53065091:-
KIRP	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-5.85	1.48e-08	9.4e-06	-0.34	-0.34	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-5.85	1.48e-08	9.42e-06	-0.54	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
KIRP	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-5.85	1.48e-08	9.42e-06	-0.44	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
KIRP	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	5.85	1.48e-08	9.43e-06	0.45	0.34	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
KIRP	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-5.85	1.48e-08	9.43e-06	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
KIRP	cis	rs710913	0.745	rs67563067	ENSG00000237624.1	OXCT2P1	-5.85	1.48e-08	9.44e-06	-0.41	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39514956~39516490:+
KIRP	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-5.85	1.48e-08	9.44e-06	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
KIRP	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-5.85	1.48e-08	9.44e-06	-0.3	-0.34	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
KIRP	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	5.85	1.49e-08	9.45e-06	0.4	0.34	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	5.85	1.49e-08	9.45e-06	0.4	0.34	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
KIRP	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	5.85	1.49e-08	9.47e-06	0.54	0.34	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
KIRP	cis	rs6908034	0.556	rs79028848	ENSG00000228412.5	RP4-625H18.2	5.85	1.49e-08	9.47e-06	0.67	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19802164~19804752:-
KIRP	cis	rs6908034	0.66	rs6918235	ENSG00000228412.5	RP4-625H18.2	5.85	1.49e-08	9.47e-06	0.67	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19802164~19804752:-
KIRP	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	5.85	1.49e-08	9.47e-06	0.34	0.34	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	5.85	1.49e-08	9.47e-06	0.34	0.34	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
KIRP	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	5.85	1.49e-08	9.48e-06	0.39	0.34	Height;	chr4:55457922	chr4:55363971~55395847:-
KIRP	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-5.85	1.49e-08	9.49e-06	-0.36	-0.34	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
KIRP	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-5.85	1.49e-08	9.49e-06	-0.34	-0.34	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
KIRP	cis	rs755249	0.669	rs4660311	ENSG00000237624.1	OXCT2P1	5.85	1.5e-08	9.5e-06	0.45	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39514956~39516490:+
KIRP	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	5.85	1.5e-08	9.5e-06	0.3	0.34	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
KIRP	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-5.85	1.5e-08	9.51e-06	-0.35	-0.34	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
KIRP	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-5.85	1.5e-08	9.51e-06	-0.41	-0.34	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
KIRP	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	5.85	1.5e-08	9.51e-06	0.29	0.34	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
KIRP	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	5.85	1.5e-08	9.53e-06	0.43	0.34	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
KIRP	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-5.84	1.5e-08	9.53e-06	-0.41	-0.34	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
KIRP	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	5.84	1.5e-08	9.54e-06	0.23	0.34	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
KIRP	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-5.84	1.51e-08	9.56e-06	-0.38	-0.34	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
KIRP	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	5.84	1.51e-08	9.58e-06	0.33	0.34	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
KIRP	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-5.84	1.52e-08	9.62e-06	-0.37	-0.34	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-5.84	1.52e-08	9.62e-06	-0.37	-0.34	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
KIRP	cis	rs72634501	0.622	rs4660416	ENSG00000237624.1	OXCT2P1	5.84	1.52e-08	9.62e-06	0.55	0.34	HDL cholesterol;	chr1:39113314	chr1:39514956~39516490:+
KIRP	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.62e-06	0.44	0.34	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.62e-06	0.44	0.34	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.62e-06	0.44	0.34	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.62e-06	0.44	0.34	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
KIRP	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	5.84	1.52e-08	9.64e-06	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
KIRP	cis	rs6480314	0.542	rs4592311	ENSG00000233590.1	RP11-153K11.3	-5.84	1.52e-08	9.65e-06	-0.53	-0.34	Optic nerve measurement (disc area);	chr10:68268492	chr10:68233251~68242379:-
KIRP	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	5.84	1.52e-08	9.66e-06	0.41	0.34	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
KIRP	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-5.84	1.52e-08	9.66e-06	-0.47	-0.34	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
KIRP	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.66e-06	0.43	0.34	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	5.84	1.52e-08	9.66e-06	0.43	0.34	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
KIRP	cis	rs4356975	0.509	rs5014975	ENSG00000196472.4	RP13-644M16.4	5.84	1.53e-08	9.68e-06	0.37	0.34	Obesity-related traits;	chr4:69130244	chr4:69181660~69182372:+
KIRP	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-5.84	1.53e-08	9.69e-06	-0.29	-0.34	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
KIRP	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-5.84	1.53e-08	9.7e-06	-0.38	-0.34	Migraine;	chr4:56879297	chr4:56960927~56961373:-
KIRP	cis	rs6908034	0.66	rs74795718	ENSG00000228412.5	RP4-625H18.2	5.84	1.53e-08	9.71e-06	0.67	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19802164~19804752:-
KIRP	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-5.84	1.53e-08	9.72e-06	-0.31	-0.34	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
KIRP	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	5.84	1.53e-08	9.72e-06	0.44	0.34	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
KIRP	cis	rs6908034	0.66	rs74457659	ENSG00000228412.5	RP4-625H18.2	5.84	1.54e-08	9.76e-06	0.66	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19802164~19804752:-
KIRP	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	5.84	1.54e-08	9.76e-06	0.35	0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
KIRP	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	5.84	1.54e-08	9.76e-06	0.39	0.34	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
KIRP	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	5.84	1.54e-08	9.77e-06	0.42	0.34	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	5.84	1.54e-08	9.77e-06	0.42	0.34	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	5.84	1.54e-08	9.77e-06	0.42	0.34	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
KIRP	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-5.84	1.54e-08	9.78e-06	-0.44	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
KIRP	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-5.84	1.55e-08	9.79e-06	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
KIRP	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	5.84	1.55e-08	9.79e-06	0.45	0.34	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
KIRP	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-5.84	1.55e-08	9.8e-06	-0.45	-0.34	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
KIRP	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	5.84	1.55e-08	9.8e-06	0.26	0.34	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
KIRP	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	5.84	1.55e-08	9.81e-06	0.51	0.34	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
KIRP	cis	rs2625529	0.526	rs10851850	ENSG00000260037.4	CTD-2524L6.3	5.84	1.55e-08	9.81e-06	0.27	0.34	Red blood cell count;	chr15:72194168	chr15:71818396~71823384:+
KIRP	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-5.84	1.55e-08	9.82e-06	-0.39	-0.34	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
KIRP	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-5.84	1.55e-08	9.82e-06	-0.4	-0.34	Depression;	chr6:28197321	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-5.84	1.55e-08	9.82e-06	-0.4	-0.34	Depression;	chr6:28197412	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-5.84	1.55e-08	9.82e-06	-0.4	-0.34	Depression;	chr6:28198669	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-5.84	1.55e-08	9.82e-06	-0.4	-0.34	Depression;	chr6:28205175	chr6:28115628~28116551:+
KIRP	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	5.84	1.55e-08	9.82e-06	0.4	0.34	Depression;	chr6:28199145	chr6:28115628~28116551:+
KIRP	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	5.84	1.55e-08	9.82e-06	0.26	0.34	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
KIRP	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-5.84	1.55e-08	9.83e-06	-0.37	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
KIRP	cis	rs4638749	0.677	rs7594896	ENSG00000231221.1	AC023672.2	-5.84	1.55e-08	9.83e-06	-0.39	-0.34	Blood pressure;	chr2:108219046	chr2:108049200~108052755:-
KIRP	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-5.84	1.55e-08	9.83e-06	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-5.84	1.55e-08	9.83e-06	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
KIRP	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.84	1.55e-08	9.83e-06	-0.45	-0.34	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
KIRP	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	5.84	1.55e-08	9.84e-06	0.34	0.34	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
KIRP	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-5.84	1.55e-08	9.84e-06	-0.4	-0.34	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
KIRP	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-5.84	1.56e-08	9.88e-06	-0.43	-0.34	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
KIRP	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-5.84	1.56e-08	9.88e-06	-0.37	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
KIRP	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-5.84	1.56e-08	9.9e-06	-0.37	-0.34	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
KIRP	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	5.84	1.57e-08	9.91e-06	0.44	0.34	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
KIRP	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	5.84	1.57e-08	9.93e-06	0.35	0.34	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	5.84	1.57e-08	9.93e-06	0.35	0.34	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
KIRP	cis	rs2625529	0.668	rs34487006	ENSG00000260037.4	CTD-2524L6.3	-5.84	1.57e-08	9.94e-06	-0.3	-0.34	Red blood cell count;	chr15:72170009	chr15:71818396~71823384:+
KIRP	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	5.84	1.57e-08	9.94e-06	0.37	0.34	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
KIRP	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-5.84	1.57e-08	9.95e-06	-0.45	-0.34	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-5.84	1.57e-08	9.95e-06	-0.45	-0.34	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
KIRP	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	5.84	1.57e-08	9.96e-06	0.42	0.34	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
KIRP	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-5.84	1.58e-08	9.97e-06	-0.3	-0.34	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
KIRP	cis	rs4356975	0.563	rs6600886	ENSG00000196472.4	RP13-644M16.4	5.84	1.58e-08	9.98e-06	0.37	0.34	Obesity-related traits;	chr4:69104017	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600887	ENSG00000196472.4	RP13-644M16.4	5.84	1.58e-08	9.98e-06	0.37	0.34	Obesity-related traits;	chr4:69104070	chr4:69181660~69182372:+
KIRP	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-5.84	1.58e-08	9.98e-06	-0.37	-0.34	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-5.84	1.58e-08	9.98e-06	-0.37	-0.34	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
KIRP	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	5.84	1.58e-08	9.99e-06	0.39	0.34	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
KIRP	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	5.84	1.58e-08	1e-05	0.38	0.34	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	5.84	1.58e-08	1e-05	0.38	0.34	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	5.83	1.58e-08	1e-05	0.45	0.34	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
KIRP	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	5.83	1.59e-08	1e-05	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	5.83	1.59e-08	1e-05	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
KIRP	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-5.83	1.59e-08	1e-05	-0.46	-0.34	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	5.83	1.59e-08	1e-05	0.44	0.34	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	5.83	1.59e-08	1e-05	0.44	0.34	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
KIRP	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-5.83	1.59e-08	1e-05	-0.45	-0.34	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
KIRP	cis	rs17082664	0.524	rs6935911	ENSG00000226193.1	RP3-398G3.5	-5.83	1.59e-08	1e-05	-0.47	-0.34	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152422934	chr6:152402398~152404966:+
KIRP	cis	rs2625529	0.761	rs3743224	ENSG00000260037.4	CTD-2524L6.3	-5.83	1.59e-08	1.01e-05	-0.3	-0.34	Red blood cell count;	chr15:72174458	chr15:71818396~71823384:+
KIRP	cis	rs4356975	0.545	rs11249525	ENSG00000196472.4	RP13-644M16.4	5.83	1.59e-08	1.01e-05	0.37	0.34	Obesity-related traits;	chr4:69080923	chr4:69181660~69182372:+
KIRP	cis	rs4443100	0.535	rs13055979	ENSG00000221069.1	AC000029.1	5.83	1.59e-08	1.01e-05	0.43	0.34	Serum parathyroid hormone levels;	chr22:23131898	chr22:23136620~23136710:+
KIRP	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-5.83	1.59e-08	1.01e-05	-0.26	-0.34	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
KIRP	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	5.83	1.59e-08	1.01e-05	0.4	0.34	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
KIRP	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-5.83	1.59e-08	1.01e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
KIRP	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
KIRP	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	5.83	1.6e-08	1.01e-05	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
KIRP	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	5.83	1.6e-08	1.01e-05	0.35	0.34	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	5.83	1.6e-08	1.01e-05	0.35	0.34	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	5.83	1.6e-08	1.01e-05	0.35	0.34	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	5.83	1.6e-08	1.01e-05	0.35	0.34	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	5.83	1.6e-08	1.01e-05	0.42	0.34	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
KIRP	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.83	1.6e-08	1.01e-05	-0.26	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
KIRP	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-5.83	1.6e-08	1.01e-05	-0.3	-0.34	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
KIRP	cis	rs9388451	0.839	rs4897157	ENSG00000237742.5	RP11-624M8.1	-5.83	1.6e-08	1.01e-05	-0.36	-0.34	Brugada syndrome;	chr6:125781835	chr6:125578558~125749190:-
KIRP	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	5.83	1.6e-08	1.01e-05	0.34	0.34	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	5.83	1.6e-08	1.01e-05	0.34	0.34	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
KIRP	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	5.83	1.6e-08	1.01e-05	0.26	0.34	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
KIRP	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	5.83	1.6e-08	1.01e-05	0.29	0.34	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-5.83	1.6e-08	1.01e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
KIRP	cis	rs2625529	0.824	rs7183749	ENSG00000260037.4	CTD-2524L6.3	-5.83	1.6e-08	1.01e-05	-0.29	-0.34	Red blood cell count;	chr15:72084937	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-5.83	1.61e-08	1.01e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
KIRP	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	5.83	1.61e-08	1.01e-05	0.4	0.34	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
KIRP	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	5.83	1.61e-08	1.01e-05	0.37	0.34	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
KIRP	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-5.83	1.61e-08	1.01e-05	-0.35	-0.34	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-5.83	1.61e-08	1.01e-05	-0.35	-0.34	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-5.83	1.61e-08	1.01e-05	-0.35	-0.34	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-5.83	1.61e-08	1.01e-05	-0.35	-0.34	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
KIRP	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-5.83	1.61e-08	1.01e-05	-0.34	-0.34	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-5.83	1.61e-08	1.01e-05	-0.34	-0.34	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
KIRP	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-5.83	1.61e-08	1.01e-05	-0.38	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
KIRP	cis	rs4356975	0.563	rs4443355	ENSG00000196472.4	RP13-644M16.4	5.83	1.61e-08	1.02e-05	0.37	0.34	Obesity-related traits;	chr4:69083026	chr4:69181660~69182372:+
KIRP	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-5.83	1.61e-08	1.02e-05	-0.41	-0.34	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
KIRP	cis	rs2625529	0.816	rs4777467	ENSG00000260037.4	CTD-2524L6.3	-5.83	1.62e-08	1.02e-05	-0.3	-0.34	Red blood cell count;	chr15:71846137	chr15:71818396~71823384:+
KIRP	cis	rs710913	0.738	rs755247	ENSG00000237624.1	OXCT2P1	-5.83	1.62e-08	1.02e-05	-0.4	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39514956~39516490:+
KIRP	cis	rs12682352	0.605	rs60707155	ENSG00000253981.4	ALG1L13P	5.83	1.62e-08	1.02e-05	0.29	0.34	Neuroticism;	chr8:8866905	chr8:8236003~8244667:-
KIRP	cis	rs2625529	0.73	rs2929527	ENSG00000260037.4	CTD-2524L6.3	5.83	1.62e-08	1.02e-05	0.26	0.34	Red blood cell count;	chr15:71989929	chr15:71818396~71823384:+
KIRP	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	5.83	1.62e-08	1.02e-05	0.42	0.34	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
KIRP	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	5.83	1.63e-08	1.02e-05	0.38	0.34	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	5.83	1.63e-08	1.02e-05	0.38	0.34	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
KIRP	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-5.83	1.63e-08	1.02e-05	-0.34	-0.34	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
KIRP	cis	rs1153858	1	rs1153858	ENSG00000259433.2	CTD-2651B20.4	5.83	1.63e-08	1.03e-05	0.3	0.34	Homoarginine levels;	chr15:45360505	chr15:45330209~45332634:-
KIRP	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	5.83	1.63e-08	1.03e-05	0.39	0.34	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
KIRP	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	5.83	1.63e-08	1.03e-05	0.44	0.34	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
KIRP	cis	rs2486288	0.656	rs7162022	ENSG00000259433.2	CTD-2651B20.4	5.83	1.63e-08	1.03e-05	0.29	0.34	Glomerular filtration rate;	chr15:45273055	chr15:45330209~45332634:-
KIRP	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-5.83	1.64e-08	1.03e-05	-0.45	-0.34	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-5.83	1.64e-08	1.03e-05	-0.45	-0.34	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-5.83	1.64e-08	1.03e-05	-0.45	-0.34	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	5.83	1.64e-08	1.03e-05	0.44	0.34	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
KIRP	cis	rs710913	0.717	rs11206377	ENSG00000237624.1	OXCT2P1	5.83	1.64e-08	1.03e-05	0.4	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39514956~39516490:+
KIRP	cis	rs2439831	0.867	rs3809481	ENSG00000249839.1	AC011330.5	-5.83	1.64e-08	1.03e-05	-0.48	-0.34	Lung cancer in ever smokers;	chr15:43370631	chr15:43663654~43684339:-
KIRP	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	5.83	1.64e-08	1.03e-05	0.4	0.34	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
KIRP	cis	rs2625529	0.938	rs4238447	ENSG00000260037.4	CTD-2524L6.3	-5.83	1.64e-08	1.03e-05	-0.3	-0.34	Red blood cell count;	chr15:71839539	chr15:71818396~71823384:+
KIRP	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-5.83	1.64e-08	1.03e-05	-0.44	-0.34	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	5.83	1.64e-08	1.03e-05	0.41	0.34	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
KIRP	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
KIRP	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-5.83	1.65e-08	1.04e-05	-0.28	-0.34	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-5.83	1.65e-08	1.04e-05	-0.28	-0.34	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
KIRP	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	5.83	1.65e-08	1.04e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
KIRP	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	5.83	1.65e-08	1.04e-05	0.85	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
KIRP	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-5.83	1.65e-08	1.04e-05	-0.29	-0.34	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
KIRP	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	5.83	1.65e-08	1.04e-05	0.46	0.34	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
KIRP	cis	rs6480314	0.542	rs17231644	ENSG00000233590.1	RP11-153K11.3	5.83	1.65e-08	1.04e-05	0.52	0.34	Optic nerve measurement (disc area);	chr10:68270301	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs10998044	ENSG00000233590.1	RP11-153K11.3	-5.83	1.65e-08	1.04e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68269508	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs36103935	ENSG00000233590.1	RP11-153K11.3	-5.83	1.65e-08	1.04e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68273171	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs61854829	ENSG00000233590.1	RP11-153K11.3	-5.83	1.65e-08	1.04e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68273286	chr10:68233251~68242379:-
KIRP	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-5.83	1.66e-08	1.04e-05	-0.28	-0.34	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
KIRP	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	5.83	1.66e-08	1.04e-05	0.29	0.34	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.28	0.34	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.29	0.34	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
KIRP	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	5.83	1.66e-08	1.04e-05	0.46	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	5.83	1.66e-08	1.04e-05	0.28	0.34	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	5.83	1.66e-08	1.05e-05	0.39	0.34	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
KIRP	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-5.83	1.67e-08	1.05e-05	-0.29	-0.34	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-5.83	1.67e-08	1.05e-05	-0.29	-0.34	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-5.83	1.67e-08	1.05e-05	-0.29	-0.34	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
KIRP	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	5.82	1.67e-08	1.05e-05	0.39	0.34	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
KIRP	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	5.82	1.67e-08	1.05e-05	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	5.82	1.68e-08	1.05e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
KIRP	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	5.82	1.68e-08	1.05e-05	0.5	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
KIRP	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	5.82	1.68e-08	1.05e-05	0.5	0.34	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
KIRP	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	5.82	1.68e-08	1.05e-05	0.5	0.34	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
KIRP	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	5.82	1.68e-08	1.05e-05	0.5	0.34	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
KIRP	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	5.82	1.68e-08	1.06e-05	0.28	0.34	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
KIRP	cis	rs6085948	1	rs4815987	ENSG00000238102.1	RP11-19D2.1	5.82	1.68e-08	1.06e-05	0.4	0.34	Interleukin-10 levels;	chr20:7259968	chr20:7256580~7258214:-
KIRP	cis	rs6085948	0.953	rs6117725	ENSG00000238102.1	RP11-19D2.1	5.82	1.68e-08	1.06e-05	0.4	0.34	Interleukin-10 levels;	chr20:7262362	chr20:7256580~7258214:-
KIRP	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-5.82	1.68e-08	1.06e-05	-0.25	-0.34	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
KIRP	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-5.82	1.68e-08	1.06e-05	-0.39	-0.34	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
KIRP	cis	rs11158026	0.757	rs8018800	ENSG00000258413.1	RP11-665C16.6	5.82	1.68e-08	1.06e-05	0.4	0.34	Parkinson's disease;	chr14:54986588	chr14:55262767~55272075:-
KIRP	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	5.82	1.68e-08	1.06e-05	0.76	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	5.82	1.68e-08	1.06e-05	0.41	0.34	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
KIRP	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	5.82	1.69e-08	1.06e-05	0.47	0.34	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
KIRP	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	5.82	1.69e-08	1.06e-05	0.47	0.34	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
KIRP	cis	rs2625529	0.652	rs8036307	ENSG00000260037.4	CTD-2524L6.3	5.82	1.69e-08	1.06e-05	0.26	0.34	Red blood cell count;	chr15:71882779	chr15:71818396~71823384:+
KIRP	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	5.82	1.69e-08	1.06e-05	0.46	0.34	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
KIRP	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	5.82	1.69e-08	1.06e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
KIRP	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-5.82	1.69e-08	1.06e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-5.82	1.69e-08	1.06e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
KIRP	cis	rs2625529	0.73	rs35713471	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.69e-08	1.06e-05	-0.29	-0.34	Red blood cell count;	chr15:72167630	chr15:71818396~71823384:+
KIRP	cis	rs79040073	0.637	rs17473568	ENSG00000259531.2	RP11-295H24.3	5.82	1.69e-08	1.06e-05	0.46	0.34	Lung cancer in ever smokers;	chr15:49149326	chr15:49365124~49366685:-
KIRP	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-5.82	1.69e-08	1.06e-05	-0.39	-0.34	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
KIRP	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-5.82	1.69e-08	1.06e-05	-0.27	-0.34	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
KIRP	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-5.82	1.7e-08	1.06e-05	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-5.82	1.7e-08	1.06e-05	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-5.82	1.7e-08	1.06e-05	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-5.82	1.7e-08	1.06e-05	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
KIRP	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	5.82	1.7e-08	1.06e-05	0.29	0.34	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
KIRP	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-5.82	1.7e-08	1.06e-05	-0.38	-0.34	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
KIRP	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	5.82	1.7e-08	1.06e-05	0.29	0.34	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	5.82	1.7e-08	1.06e-05	0.29	0.34	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
KIRP	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	5.82	1.7e-08	1.06e-05	0.42	0.34	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
KIRP	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	5.82	1.7e-08	1.06e-05	0.29	0.34	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
KIRP	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	5.82	1.7e-08	1.07e-05	0.46	0.34	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
KIRP	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	5.82	1.7e-08	1.07e-05	0.29	0.34	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
KIRP	cis	rs6085948	0.861	rs11907461	ENSG00000238102.1	RP11-19D2.1	-5.82	1.7e-08	1.07e-05	-0.43	-0.34	Interleukin-10 levels;	chr20:7251766	chr20:7256580~7258214:-
KIRP	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	5.82	1.71e-08	1.07e-05	0.41	0.34	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
KIRP	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-5.82	1.71e-08	1.07e-05	-0.36	-0.34	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-5.82	1.71e-08	1.07e-05	-0.46	-0.34	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.527	rs62296943	ENSG00000196472.4	RP13-644M16.4	5.82	1.71e-08	1.07e-05	0.37	0.34	Obesity-related traits;	chr4:69093465	chr4:69181660~69182372:+
KIRP	cis	rs755249	0.642	rs11206430	ENSG00000237624.1	OXCT2P1	5.82	1.71e-08	1.07e-05	0.45	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39514956~39516490:+
KIRP	cis	rs2625529	0.641	rs11852789	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:71973153	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12595228	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:71974874	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs10518979	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:71976645	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.775	rs4777477	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:71977271	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.668	rs12914070	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72041938	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4445848	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72062257	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4131630	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72063057	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs35167572	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72086619	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4776586	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72138162	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs55854204	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72140841	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.73	rs12908882	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72145231	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs16953769	ENSG00000260037.4	CTD-2524L6.3	-5.82	1.71e-08	1.07e-05	-0.29	-0.34	Red blood cell count;	chr15:72170984	chr15:71818396~71823384:+
KIRP	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-5.82	1.72e-08	1.08e-05	-0.46	-0.34	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	5.82	1.72e-08	1.08e-05	0.41	0.34	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
KIRP	cis	rs12554020	0.579	rs59326991	ENSG00000227603.1	RP11-165J3.6	5.82	1.72e-08	1.08e-05	0.55	0.34	Schizophrenia;	chr9:93473603	chr9:93435332~93437121:-
KIRP	cis	rs12280210	0.655	rs76169968	ENSG00000254851.1	RP11-109L13.1	5.82	1.72e-08	1.08e-05	0.71	0.34	Lobe attachment (rater-scored or self-reported);	chr11:117212250	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	5.82	1.72e-08	1.08e-05	0.79	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	5.82	1.72e-08	1.08e-05	0.79	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
KIRP	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	5.82	1.73e-08	1.08e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
KIRP	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	5.82	1.73e-08	1.08e-05	0.38	0.34	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
KIRP	cis	rs11158026	0.757	rs7157085	ENSG00000258413.1	RP11-665C16.6	-5.82	1.73e-08	1.08e-05	-0.4	-0.34	Parkinson's disease;	chr14:54978028	chr14:55262767~55272075:-
KIRP	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	5.82	1.73e-08	1.08e-05	0.29	0.34	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
KIRP	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	5.82	1.73e-08	1.09e-05	0.4	0.34	Depression;	chr6:28205232	chr6:28115628~28116551:+
KIRP	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-5.82	1.73e-08	1.09e-05	-0.46	-0.34	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-5.82	1.73e-08	1.09e-05	-0.46	-0.34	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-5.82	1.73e-08	1.09e-05	-0.46	-0.34	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-5.82	1.73e-08	1.09e-05	-0.46	-0.34	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
KIRP	cis	rs7672749	0.73	rs17013278	ENSG00000249973.2	CHCHD2P7	5.82	1.74e-08	1.09e-05	0.62	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87839550	chr4:87785920~87786371:-
KIRP	cis	rs9371601	0.811	rs6557229	ENSG00000226193.1	RP3-398G3.5	-5.82	1.74e-08	1.09e-05	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152474455	chr6:152402398~152404966:+
KIRP	cis	rs9371601	0.781	rs6557230	ENSG00000226193.1	RP3-398G3.5	-5.82	1.74e-08	1.09e-05	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152474457	chr6:152402398~152404966:+
KIRP	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	5.82	1.74e-08	1.09e-05	0.28	0.34	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
KIRP	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-5.82	1.74e-08	1.09e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-5.82	1.74e-08	1.09e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-5.82	1.74e-08	1.09e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
KIRP	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	5.82	1.74e-08	1.09e-05	0.4	0.34	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
KIRP	cis	rs7474896	0.515	rs2749582	ENSG00000151963.4	RP11-775A3.1	5.82	1.74e-08	1.09e-05	0.43	0.34	Obesity (extreme);	chr10:37986356	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.515	rs624359	ENSG00000151963.4	RP11-775A3.1	5.82	1.74e-08	1.09e-05	0.43	0.34	Obesity (extreme);	chr10:38010204	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.537	rs598857	ENSG00000151963.4	RP11-775A3.1	5.82	1.74e-08	1.09e-05	0.43	0.34	Obesity (extreme);	chr10:38013998	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.515	rs2738208	ENSG00000151963.4	RP11-775A3.1	5.82	1.74e-08	1.09e-05	0.43	0.34	Obesity (extreme);	chr10:38017200	chr10:37883594~37884109:+
KIRP	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	5.82	1.74e-08	1.09e-05	0.32	0.34	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
KIRP	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-5.82	1.74e-08	1.09e-05	-0.37	-0.34	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
KIRP	cis	rs4356975	0.522	rs6600888	ENSG00000196472.4	RP13-644M16.4	5.82	1.75e-08	1.09e-05	0.37	0.34	Obesity-related traits;	chr4:69104141	chr4:69181660~69182372:+
KIRP	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	5.82	1.75e-08	1.09e-05	0.39	0.34	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	5.82	1.75e-08	1.09e-05	0.39	0.34	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
KIRP	cis	rs2486288	0.656	rs11632920	ENSG00000259433.2	CTD-2651B20.4	5.82	1.75e-08	1.1e-05	0.29	0.34	Glomerular filtration rate;	chr15:45259066	chr15:45330209~45332634:-
KIRP	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-5.82	1.76e-08	1.1e-05	-0.29	-0.34	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
KIRP	cis	rs1552244	0.832	rs73024575	ENSG00000180385.7	EMC3-AS1	5.82	1.76e-08	1.1e-05	0.4	0.34	Alzheimer's disease;	chr3:10156516	chr3:9986893~10006990:+
KIRP	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-5.81	1.76e-08	1.1e-05	-0.41	-0.34	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
KIRP	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	5.81	1.76e-08	1.1e-05	0.29	0.34	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
KIRP	cis	rs1799949	1	rs8176145	ENSG00000236383.6	LINC00854	-5.81	1.76e-08	1.1e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43097077	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs8176140	ENSG00000236383.6	LINC00854	-5.81	1.76e-08	1.1e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43099629	chr17:43216941~43305976:-
KIRP	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	5.81	1.77e-08	1.11e-05	0.35	0.34	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	5.81	1.77e-08	1.11e-05	0.35	0.34	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	5.81	1.77e-08	1.11e-05	0.35	0.34	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
KIRP	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-5.81	1.77e-08	1.11e-05	-0.41	-0.34	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
KIRP	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-5.81	1.77e-08	1.11e-05	-0.29	-0.34	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-5.81	1.77e-08	1.11e-05	-0.29	-0.34	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-5.81	1.77e-08	1.11e-05	-0.29	-0.34	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
KIRP	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	5.81	1.77e-08	1.11e-05	0.42	0.34	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
KIRP	cis	rs79349575	0.594	rs62078375	ENSG00000248278.1	SUMO2P17	5.81	1.77e-08	1.11e-05	0.39	0.34	Type 2 diabetes;	chr17:48957612	chr17:48874860~48908983:-
KIRP	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	5.81	1.78e-08	1.11e-05	0.29	0.34	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
KIRP	cis	rs2976388	0.578	rs3736010	ENSG00000253741.1	CTD-2292P10.4	5.81	1.78e-08	1.11e-05	0.44	0.34	Urinary tract infection frequency;	chr8:142736085	chr8:142702252~142726973:-
KIRP	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	5.81	1.78e-08	1.11e-05	0.41	0.34	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
KIRP	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-5.81	1.78e-08	1.11e-05	-0.44	-0.34	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
KIRP	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	5.81	1.79e-08	1.12e-05	0.34	0.34	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
KIRP	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	5.81	1.79e-08	1.12e-05	0.31	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
KIRP	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-5.81	1.79e-08	1.12e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
KIRP	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	5.81	1.79e-08	1.12e-05	0.33	0.34	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
KIRP	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-5.81	1.79e-08	1.12e-05	-0.43	-0.34	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
KIRP	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-5.81	1.8e-08	1.12e-05	-0.36	-0.34	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
KIRP	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-5.81	1.8e-08	1.12e-05	-0.46	-0.34	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
KIRP	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	5.81	1.8e-08	1.12e-05	0.38	0.34	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
KIRP	cis	rs7224610	0.932	rs10852974	ENSG00000263096.1	RP11-515O17.2	5.81	1.81e-08	1.13e-05	0.45	0.34	Urate levels;	chr17:55295205	chr17:55271504~55273653:-
KIRP	cis	rs112521149	1	rs112521149	ENSG00000242349.4	NPPA-AS1	-5.81	1.81e-08	1.13e-05	-0.39	-0.34	Mean corpuscular volume;	chr1:11829758	chr1:11841017~11848079:+
KIRP	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	5.81	1.81e-08	1.13e-05	0.39	0.34	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
KIRP	cis	rs72634501	0.716	rs4660165	ENSG00000237624.1	OXCT2P1	-5.81	1.81e-08	1.13e-05	-0.54	-0.34	HDL cholesterol;	chr1:39112860	chr1:39514956~39516490:+
KIRP	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	5.81	1.81e-08	1.13e-05	0.26	0.34	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
KIRP	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	5.81	1.82e-08	1.13e-05	0.42	0.34	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	5.81	1.82e-08	1.13e-05	0.42	0.34	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
KIRP	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-5.81	1.82e-08	1.13e-05	-0.41	-0.34	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
KIRP	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-5.81	1.82e-08	1.14e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	5.81	1.82e-08	1.14e-05	0.39	0.34	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
KIRP	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-5.81	1.83e-08	1.14e-05	-0.35	-0.34	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-5.81	1.83e-08	1.14e-05	-0.35	-0.34	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-5.81	1.83e-08	1.14e-05	-0.35	-0.34	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-5.81	1.83e-08	1.14e-05	-0.35	-0.34	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
KIRP	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	5.81	1.83e-08	1.14e-05	0.23	0.34	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
KIRP	cis	rs7267979	1	rs6515651	ENSG00000274414.1	RP5-965G21.4	5.81	1.83e-08	1.14e-05	0.33	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2424716	ENSG00000274414.1	RP5-965G21.4	-5.81	1.83e-08	1.14e-05	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs761025	ENSG00000274414.1	RP5-965G21.4	-5.81	1.83e-08	1.14e-05	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050631	ENSG00000274414.1	RP5-965G21.4	-5.81	1.83e-08	1.14e-05	-0.33	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25239007~25245229:-
KIRP	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	5.81	1.83e-08	1.14e-05	0.29	0.34	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
KIRP	cis	rs67311347	0.955	rs6773383	ENSG00000230274.1	PGAM1P3	5.81	1.84e-08	1.14e-05	0.32	0.34	Renal cell carcinoma;	chr3:40335921	chr3:40322715~40323279:-
KIRP	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-5.81	1.84e-08	1.14e-05	-0.35	-0.34	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
KIRP	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-5.81	1.84e-08	1.14e-05	-0.27	-0.34	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
KIRP	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	5.81	1.84e-08	1.14e-05	0.4	0.34	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
KIRP	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-5.81	1.84e-08	1.14e-05	-0.28	-0.34	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
KIRP	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	5.81	1.85e-08	1.15e-05	0.4	0.34	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-5.81	1.85e-08	1.15e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-5.81	1.85e-08	1.15e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
KIRP	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-5.81	1.85e-08	1.15e-05	-0.48	-0.34	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
KIRP	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-5.81	1.85e-08	1.15e-05	-0.25	-0.34	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
KIRP	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	5.81	1.85e-08	1.15e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
KIRP	cis	rs2625529	0.668	rs8192431	ENSG00000260037.4	CTD-2524L6.3	-5.81	1.85e-08	1.15e-05	-0.3	-0.34	Red blood cell count;	chr15:72200011	chr15:71818396~71823384:+
KIRP	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-5.81	1.85e-08	1.15e-05	-0.35	-0.34	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
KIRP	cis	rs4356975	0.509	rs4371688	ENSG00000250696.4	RP11-704M14.1	5.8	1.86e-08	1.16e-05	0.32	0.34	Obesity-related traits;	chr4:69124323	chr4:69182100~69216766:+
KIRP	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	5.8	1.86e-08	1.16e-05	0.55	0.34	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
KIRP	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	5.8	1.86e-08	1.16e-05	0.4	0.34	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
KIRP	cis	rs1858037	0.867	rs4671660	ENSG00000281920.1	RP11-418H16.1	5.8	1.86e-08	1.16e-05	0.43	0.34	Rheumatoid arthritis;	chr2:65349302	chr2:65623272~65628424:+
KIRP	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-5.8	1.86e-08	1.16e-05	-0.34	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
KIRP	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-5.8	1.86e-08	1.16e-05	-0.38	-0.34	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
KIRP	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-5.8	1.86e-08	1.16e-05	-0.29	-0.34	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
KIRP	cis	rs1799949	1	rs2175957	ENSG00000236383.6	LINC00854	-5.8	1.87e-08	1.16e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43134805	chr17:43216941~43305976:-
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.8	1.87e-08	1.16e-05	0.29	0.34	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
KIRP	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-5.8	1.87e-08	1.16e-05	-0.27	-0.34	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	5.8	1.87e-08	1.16e-05	0.35	0.34	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	5.8	1.87e-08	1.16e-05	0.35	0.34	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	5.8	1.87e-08	1.16e-05	0.35	0.34	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
KIRP	cis	rs12050794	0.636	rs3759902	ENSG00000260037.4	CTD-2524L6.3	5.8	1.87e-08	1.16e-05	0.26	0.34	Metabolite levels (HVA/MHPG ratio);	chr15:72232933	chr15:71818396~71823384:+
KIRP	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-5.8	1.87e-08	1.16e-05	-0.3	-0.34	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
KIRP	cis	rs7569084	0.663	rs1437461	ENSG00000237979.1	AC007389.1	5.8	1.88e-08	1.17e-05	0.4	0.34	Sum eosinophil basophil counts;	chr2:65452578	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.687	rs7562559	ENSG00000237979.1	AC007389.1	5.8	1.88e-08	1.17e-05	0.4	0.34	Sum eosinophil basophil counts;	chr2:65452719	chr2:65500993~65502138:-
KIRP	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-5.8	1.88e-08	1.17e-05	-0.42	-0.34	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
KIRP	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	5.8	1.88e-08	1.17e-05	0.38	0.34	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
KIRP	cis	rs1799949	1	rs16942	ENSG00000236383.6	LINC00854	-5.8	1.88e-08	1.17e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43091983	chr17:43216941~43305976:-
KIRP	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-5.8	1.88e-08	1.17e-05	-0.29	-0.34	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
KIRP	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	5.8	1.88e-08	1.17e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
KIRP	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	5.8	1.88e-08	1.17e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
KIRP	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	5.8	1.88e-08	1.17e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
KIRP	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	5.8	1.89e-08	1.17e-05	0.29	0.34	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	5.8	1.89e-08	1.17e-05	0.29	0.34	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	5.8	1.89e-08	1.17e-05	0.29	0.34	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
KIRP	cis	rs2625529	0.668	rs8192386	ENSG00000260037.4	CTD-2524L6.3	5.8	1.89e-08	1.17e-05	0.29	0.34	Red blood cell count;	chr15:72220807	chr15:71818396~71823384:+
KIRP	cis	rs1560104	0.597	rs17227492	ENSG00000274834.1	CTD-3037G24.5	5.8	1.89e-08	1.17e-05	0.37	0.34	Obesity-related traits;	chr16:12620186	chr16:12614451~12614852:+
KIRP	cis	rs8067545	0.641	rs397969	ENSG00000270091.1	RP11-78O7.2	-5.8	1.89e-08	1.17e-05	-0.22	-0.34	Schizophrenia;	chr17:19900934	chr17:19896590~19897287:-
KIRP	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	5.8	1.89e-08	1.17e-05	0.42	0.34	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
KIRP	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-5.8	1.89e-08	1.17e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
KIRP	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	5.8	1.89e-08	1.17e-05	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	5.8	1.89e-08	1.17e-05	0.35	0.34	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	5.8	1.89e-08	1.17e-05	0.35	0.34	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	5.8	1.89e-08	1.17e-05	0.35	0.34	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	5.8	1.89e-08	1.17e-05	0.35	0.34	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	5.8	1.89e-08	1.17e-05	0.35	0.34	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-5.8	1.89e-08	1.18e-05	-0.34	-0.34	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
KIRP	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-5.8	1.9e-08	1.18e-05	-0.38	-0.34	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
KIRP	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	5.8	1.9e-08	1.18e-05	0.42	0.34	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
KIRP	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	5.8	1.91e-08	1.18e-05	0.27	0.34	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
KIRP	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-5.8	1.91e-08	1.18e-05	-0.3	-0.34	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
KIRP	cis	rs9640161	0.658	rs57888387	ENSG00000261305.1	RP4-584D14.7	5.8	1.91e-08	1.18e-05	0.46	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150307155	chr7:150341771~150342607:+
KIRP	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	5.8	1.91e-08	1.18e-05	0.56	0.34	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
KIRP	cis	rs1799949	0.93	rs35292991	ENSG00000236383.6	LINC00854	-5.8	1.91e-08	1.18e-05	-0.28	-0.34	Menopause (age at onset);	chr17:43181999	chr17:43216941~43305976:-
KIRP	cis	rs9913711	1	rs9913711	ENSG00000234899.8	SOX9-AS1	-5.8	1.91e-08	1.19e-05	-0.3	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr17:72102020	chr17:72034107~72237203:-
KIRP	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-5.8	1.91e-08	1.19e-05	-0.34	-0.34	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
KIRP	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	5.8	1.91e-08	1.19e-05	0.45	0.34	Height;	chr6:109407148	chr6:109382795~109383666:+
KIRP	cis	rs2625529	0.775	rs4777489	ENSG00000260037.4	CTD-2524L6.3	5.8	1.92e-08	1.19e-05	0.29	0.34	Red blood cell count;	chr15:72138093	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-5.8	1.92e-08	1.19e-05	-0.28	-0.34	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
KIRP	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-5.8	1.92e-08	1.19e-05	-0.41	-0.34	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-5.8	1.92e-08	1.19e-05	-0.41	-0.34	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-5.8	1.92e-08	1.19e-05	-0.41	-0.34	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
KIRP	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-5.8	1.92e-08	1.19e-05	-0.41	-0.34	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	5.8	1.92e-08	1.19e-05	0.44	0.34	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
KIRP	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-5.8	1.92e-08	1.19e-05	-0.44	-0.34	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-5.8	1.92e-08	1.19e-05	-0.44	-0.34	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
KIRP	cis	rs3892630	1	rs3892630	ENSG00000267475.1	CTD-2538C1.2	5.8	1.93e-08	1.19e-05	0.45	0.34	Red blood cell traits;	chr19:32690578	chr19:32687089~32691750:-
KIRP	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	5.8	1.93e-08	1.19e-05	0.33	0.34	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	5.8	1.93e-08	1.19e-05	0.33	0.34	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
KIRP	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-5.8	1.93e-08	1.19e-05	-0.28	-0.34	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
KIRP	cis	rs6480314	0.542	rs61854824	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68270438	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs12572954	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68270766	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs12572967	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68270873	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs12572960	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68270966	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs2241969	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68271253	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs61854825	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68271535	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs61854826	ENSG00000233590.1	RP11-153K11.3	-5.8	1.93e-08	1.19e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68271801	chr10:68233251~68242379:-
KIRP	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-5.8	1.93e-08	1.2e-05	-0.49	-0.34	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
KIRP	cis	rs2625529	0.775	rs4777484	ENSG00000260037.4	CTD-2524L6.3	-5.8	1.93e-08	1.2e-05	-0.29	-0.34	Red blood cell count;	chr15:72084202	chr15:71818396~71823384:+
KIRP	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	5.8	1.93e-08	1.2e-05	0.38	0.34	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.824	rs4411469	ENSG00000260037.4	CTD-2524L6.3	-5.8	1.93e-08	1.2e-05	-0.29	-0.34	Red blood cell count;	chr15:72129348	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	5.8	1.94e-08	1.2e-05	0.42	0.34	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
KIRP	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-5.8	1.94e-08	1.2e-05	-0.32	-0.34	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
KIRP	cis	rs7267979	0.873	rs6037062	ENSG00000274414.1	RP5-965G21.4	-5.8	1.94e-08	1.2e-05	-0.32	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-5.8	1.94e-08	1.2e-05	-0.28	-0.34	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
KIRP	cis	rs11158026	0.757	rs7159933	ENSG00000258413.1	RP11-665C16.6	-5.8	1.94e-08	1.2e-05	-0.4	-0.34	Parkinson's disease;	chr14:54974923	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	5.8	1.94e-08	1.2e-05	0.45	0.34	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-5.8	1.94e-08	1.2e-05	-0.28	-0.34	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-5.8	1.94e-08	1.2e-05	-0.28	-0.34	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
KIRP	cis	rs2625529	0.526	rs8031386	ENSG00000260037.4	CTD-2524L6.3	-5.8	1.95e-08	1.2e-05	-0.27	-0.34	Red blood cell count;	chr15:72216458	chr15:71818396~71823384:+
KIRP	cis	rs7569084	0.663	rs4671128	ENSG00000237979.1	AC007389.1	5.8	1.95e-08	1.2e-05	0.38	0.34	Sum eosinophil basophil counts;	chr2:65438130	chr2:65500993~65502138:-
KIRP	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-5.8	1.95e-08	1.2e-05	-0.48	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
KIRP	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	5.8	1.95e-08	1.21e-05	0.26	0.34	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	5.8	1.95e-08	1.21e-05	0.44	0.34	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	5.8	1.95e-08	1.21e-05	0.44	0.34	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
KIRP	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-5.8	1.95e-08	1.21e-05	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
KIRP	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.79	1.96e-08	1.21e-05	-0.37	-0.34	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
KIRP	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	5.79	1.96e-08	1.21e-05	0.44	0.34	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
KIRP	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-5.79	1.96e-08	1.21e-05	-0.39	-0.34	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
KIRP	cis	rs2625529	0.59	rs2607090	ENSG00000260037.4	CTD-2524L6.3	-5.79	1.96e-08	1.21e-05	-0.3	-0.34	Red blood cell count;	chr15:72203670	chr15:71818396~71823384:+
KIRP	cis	rs67311347	0.544	rs1454492	ENSG00000230274.1	PGAM1P3	5.79	1.96e-08	1.21e-05	0.34	0.34	Renal cell carcinoma;	chr3:40311393	chr3:40322715~40323279:-
KIRP	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5.79	1.96e-08	1.21e-05	0.28	0.34	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
KIRP	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5.79	1.96e-08	1.21e-05	0.26	0.34	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
KIRP	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	5.79	1.96e-08	1.21e-05	0.38	0.34	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
KIRP	cis	rs7267979	1	rs6050544	ENSG00000274414.1	RP5-965G21.4	5.79	1.96e-08	1.21e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs8125868	ENSG00000274414.1	RP5-965G21.4	5.79	1.96e-08	1.21e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25239007~25245229:-
KIRP	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	5.79	1.97e-08	1.21e-05	0.29	0.34	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
KIRP	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-5.79	1.97e-08	1.22e-05	-0.34	-0.34	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
KIRP	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	5.79	1.97e-08	1.22e-05	0.56	0.34	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
KIRP	cis	rs2749592	0.611	rs2505199	ENSG00000151963.4	RP11-775A3.1	-5.79	1.97e-08	1.22e-05	-0.39	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:37883594~37884109:+
KIRP	cis	rs2749592	0.588	rs2505192	ENSG00000151963.4	RP11-775A3.1	-5.79	1.97e-08	1.22e-05	-0.39	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:37883594~37884109:+
KIRP	cis	rs2278170	1	rs1292642	ENSG00000225101.4	OR52K3P	-5.79	1.97e-08	1.22e-05	-0.41	-0.34	Amyotrophic lateral sclerosis;	chr11:4455037	chr11:4474813~4475755:+
KIRP	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-5.79	1.98e-08	1.22e-05	-0.46	-0.34	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-5.79	1.98e-08	1.22e-05	-0.46	-0.34	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-5.79	1.98e-08	1.22e-05	-0.46	-0.34	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-5.79	1.98e-08	1.22e-05	-0.46	-0.34	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
KIRP	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-5.79	1.98e-08	1.22e-05	-0.29	-0.34	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
KIRP	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	5.79	1.98e-08	1.22e-05	0.38	0.34	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
KIRP	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-5.79	1.98e-08	1.22e-05	-0.41	-0.34	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
KIRP	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-5.79	1.98e-08	1.22e-05	-0.42	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
KIRP	cis	rs9532669	0.963	rs1056824	ENSG00000239827.7	SUGT1P3	-5.79	1.98e-08	1.22e-05	-0.38	-0.34	Cervical cancer;	chr13:40932748	chr13:40908159~40921774:-
KIRP	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	5.79	1.98e-08	1.22e-05	0.43	0.34	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
KIRP	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	5.79	1.99e-08	1.23e-05	0.41	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
KIRP	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	5.79	1.99e-08	1.23e-05	0.39	0.34	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
KIRP	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	5.79	1.99e-08	1.23e-05	0.78	0.34	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	5.79	1.99e-08	1.23e-05	0.42	0.34	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
KIRP	cis	rs6480314	0.542	rs61854809	ENSG00000233590.1	RP11-153K11.3	-5.79	1.99e-08	1.23e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68262847	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs61854810	ENSG00000233590.1	RP11-153K11.3	-5.79	1.99e-08	1.23e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68264139	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs61854811	ENSG00000233590.1	RP11-153K11.3	-5.79	1.99e-08	1.23e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68264474	chr10:68233251~68242379:-
KIRP	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-5.79	1.99e-08	1.23e-05	-0.48	-0.34	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
KIRP	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	5.79	1.99e-08	1.23e-05	0.39	0.34	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.689	rs10851847	ENSG00000260037.4	CTD-2524L6.3	-5.79	2e-08	1.23e-05	-0.27	-0.34	Red blood cell count;	chr15:71819419	chr15:71818396~71823384:+
KIRP	cis	rs6832769	0.925	rs11133383	ENSG00000272969.1	RP11-528I4.2	-5.79	2e-08	1.23e-05	-0.33	-0.34	Personality dimensions;	chr4:55450878	chr4:55547112~55547889:+
KIRP	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.79	2e-08	1.23e-05	-0.46	-0.34	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	5.79	2e-08	1.23e-05	0.41	0.34	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	5.79	2e-08	1.23e-05	0.41	0.34	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
KIRP	cis	rs1200821	0.535	rs1208784	ENSG00000151963.4	RP11-775A3.1	-5.79	2e-08	1.23e-05	-0.37	-0.34	Hemostatic factors and hematological phenotypes;	chr10:37479505	chr10:37883594~37884109:+
KIRP	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	5.79	2e-08	1.24e-05	0.28	0.34	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
KIRP	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-5.79	2e-08	1.24e-05	-0.41	-0.34	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
KIRP	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-5.79	2e-08	1.24e-05	-0.41	-0.34	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
KIRP	cis	rs7224610	1	rs7224610	ENSG00000263096.1	RP11-515O17.2	5.79	2.01e-08	1.24e-05	0.44	0.34	Urate levels;	chr17:55287427	chr17:55271504~55273653:-
KIRP	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-5.79	2.01e-08	1.24e-05	-0.35	-0.34	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	5.79	2.01e-08	1.24e-05	0.28	0.34	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
KIRP	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	5.79	2.01e-08	1.24e-05	0.45	0.34	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
KIRP	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-5.79	2.01e-08	1.24e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
KIRP	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	5.79	2.01e-08	1.24e-05	0.39	0.34	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-5.79	2.01e-08	1.24e-05	-0.44	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
KIRP	cis	rs7267979	1	rs6037095	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050562	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815407	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815408	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050566	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4813563	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6037103	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.934	rs4815423	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815424	ENSG00000274414.1	RP5-965G21.4	5.79	2.02e-08	1.24e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25239007~25245229:-
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	5.79	2.02e-08	1.24e-05	0.4	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	5.79	2.02e-08	1.24e-05	0.4	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
KIRP	cis	rs67311347	0.544	rs2278930	ENSG00000230274.1	PGAM1P3	5.79	2.02e-08	1.25e-05	0.34	0.34	Renal cell carcinoma;	chr3:40309601	chr3:40322715~40323279:-
KIRP	cis	rs6480314	0.542	rs17297383	ENSG00000233590.1	RP11-153K11.3	-5.79	2.03e-08	1.25e-05	-0.51	-0.34	Optic nerve measurement (disc area);	chr10:68269106	chr10:68233251~68242379:-
KIRP	cis	rs1799949	1	rs3950989	ENSG00000236383.6	LINC00854	-5.79	2.03e-08	1.25e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43085936	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs2070834	ENSG00000236383.6	LINC00854	-5.79	2.03e-08	1.25e-05	-0.27	-0.34	Menopause (age at onset);	chr17:43090268	chr17:43216941~43305976:-
KIRP	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	5.79	2.03e-08	1.25e-05	0.47	0.34	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
KIRP	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-5.79	2.04e-08	1.25e-05	-0.24	-0.34	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	5.79	2.04e-08	1.25e-05	0.28	0.34	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
KIRP	cis	rs1799949	0.931	rs9912203	ENSG00000236383.6	LINC00854	5.79	2.04e-08	1.25e-05	0.26	0.34	Menopause (age at onset);	chr17:43367777	chr17:43216941~43305976:-
KIRP	cis	rs2278170	1	rs9633906	ENSG00000225101.4	OR52K3P	-5.79	2.04e-08	1.26e-05	-0.42	-0.34	Amyotrophic lateral sclerosis;	chr11:4477120	chr11:4474813~4475755:+
KIRP	cis	rs9371601	0.892	rs9384000	ENSG00000226193.1	RP3-398G3.5	-5.79	2.04e-08	1.26e-05	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152492218	chr6:152402398~152404966:+
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.79	2.04e-08	1.26e-05	0.29	0.34	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
KIRP	cis	rs897984	0.762	rs4889599	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30957268	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.721	rs2305884	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30959420	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs11150601	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30966478	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs897986	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30969581	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.721	rs28360557	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30971939	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs7204459	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30972891	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs4889604	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30974673	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs12931046	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30975823	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.721	rs4889525	ENSG00000275263.1	RP11-1072A3.4	5.79	2.04e-08	1.26e-05	0.35	0.34	Dementia with Lewy bodies;	chr16:30978537	chr16:30956872~30957199:-
KIRP	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-5.79	2.05e-08	1.26e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
KIRP	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	5.79	2.05e-08	1.26e-05	0.28	0.34	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
KIRP	cis	rs2625529	0.878	rs16956302	ENSG00000260037.4	CTD-2524L6.3	-5.79	2.05e-08	1.26e-05	-0.3	-0.34	Red blood cell count;	chr15:71843902	chr15:71818396~71823384:+
KIRP	cis	rs75920871	0.589	rs4938342	ENSG00000254851.1	RP11-109L13.1	-5.79	2.05e-08	1.26e-05	-0.58	-0.34	Subjective well-being;	chr11:117132704	chr11:117135528~117138582:+
KIRP	cis	rs2625529	0.824	rs4238449	ENSG00000260037.4	CTD-2524L6.3	-5.79	2.05e-08	1.26e-05	-0.29	-0.34	Red blood cell count;	chr15:72129262	chr15:71818396~71823384:+
KIRP	cis	rs79040073	0.637	rs10519221	ENSG00000259531.2	RP11-295H24.3	5.79	2.05e-08	1.26e-05	0.46	0.34	Lung cancer in ever smokers;	chr15:49286377	chr15:49365124~49366685:-
KIRP	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.79	2.06e-08	1.27e-05	0.38	0.34	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
KIRP	cis	rs9371601	0.892	rs7774755	ENSG00000226193.1	RP3-398G3.5	-5.78	2.06e-08	1.27e-05	-0.37	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152498024	chr6:152402398~152404966:+
KIRP	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-5.78	2.06e-08	1.27e-05	-0.4	-0.34	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
KIRP	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.78	2.07e-08	1.27e-05	-0.42	-0.34	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
KIRP	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	5.78	2.08e-08	1.28e-05	0.47	0.34	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
KIRP	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-5.78	2.08e-08	1.28e-05	-0.39	-0.34	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
KIRP	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-5.78	2.08e-08	1.28e-05	-0.39	-0.34	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
KIRP	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	5.78	2.08e-08	1.28e-05	0.36	0.34	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
KIRP	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	5.78	2.08e-08	1.28e-05	0.45	0.34	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
KIRP	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-5.78	2.09e-08	1.28e-05	-0.36	-0.34	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-5.78	2.09e-08	1.28e-05	-0.36	-0.34	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-5.78	2.09e-08	1.28e-05	-0.36	-0.34	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-5.78	2.09e-08	1.28e-05	-0.36	-0.34	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-5.78	2.09e-08	1.28e-05	-0.36	-0.34	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
KIRP	cis	rs7747960	1	rs2295041	ENSG00000226193.1	RP3-398G3.5	5.78	2.09e-08	1.28e-05	0.51	0.34	Bipolar disorder;	chr6:152452059	chr6:152402398~152404966:+
KIRP	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-5.78	2.09e-08	1.28e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-5.78	2.09e-08	1.28e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
KIRP	cis	rs7586673	0.893	rs889925	ENSG00000235724.7	AC009299.2	-5.78	2.09e-08	1.28e-05	-0.4	-0.34	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161222785~161308303:-
KIRP	cis	rs7586673	0.93	rs2884364	ENSG00000235724.7	AC009299.2	-5.78	2.09e-08	1.28e-05	-0.4	-0.34	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161222785~161308303:-
KIRP	cis	rs2625529	0.938	rs4776579	ENSG00000260037.4	CTD-2524L6.3	-5.78	2.09e-08	1.28e-05	-0.27	-0.34	Red blood cell count;	chr15:71840267	chr15:71818396~71823384:+
KIRP	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-5.78	2.1e-08	1.29e-05	-0.34	-0.34	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
KIRP	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-5.78	2.1e-08	1.29e-05	-0.31	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	5.78	2.1e-08	1.29e-05	0.41	0.34	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.78	2.1e-08	1.29e-05	0.29	0.34	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
KIRP	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	5.78	2.1e-08	1.29e-05	0.33	0.34	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
KIRP	cis	rs7267979	1	rs2500443	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482928	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482930	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2500446	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482937	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2263204	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2500417	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482911	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2500436	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083856	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2482918	ENSG00000274414.1	RP5-965G21.4	5.78	2.11e-08	1.29e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25239007~25245229:-
KIRP	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-5.78	2.11e-08	1.29e-05	-0.52	-0.34	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
KIRP	cis	rs11158026	0.757	rs8019220	ENSG00000258413.1	RP11-665C16.6	-5.78	2.11e-08	1.29e-05	-0.4	-0.34	Parkinson's disease;	chr14:54986751	chr14:55262767~55272075:-
KIRP	cis	rs14165	0.67	rs2359133	ENSG00000271916.1	RP11-884K10.6	5.78	2.11e-08	1.29e-05	0.31	0.34	Refractive error;	chr3:53802715	chr3:53797764~53798019:-
KIRP	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-5.78	2.11e-08	1.29e-05	-0.34	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-5.78	2.12e-08	1.3e-05	-0.28	-0.34	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
KIRP	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-5.78	2.12e-08	1.3e-05	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
KIRP	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	5.78	2.12e-08	1.3e-05	0.44	0.34	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
KIRP	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-5.78	2.12e-08	1.3e-05	-0.43	-0.34	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
KIRP	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	5.78	2.12e-08	1.3e-05	0.28	0.34	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
KIRP	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-5.78	2.12e-08	1.3e-05	-0.24	-0.34	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
KIRP	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	5.78	2.12e-08	1.3e-05	0.43	0.34	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	5.78	2.12e-08	1.3e-05	0.43	0.34	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	5.78	2.12e-08	1.3e-05	0.43	0.34	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	5.78	2.12e-08	1.3e-05	0.43	0.34	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
KIRP	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	5.78	2.12e-08	1.3e-05	0.38	0.34	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
KIRP	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.78	2.13e-08	1.3e-05	-0.28	-0.34	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
KIRP	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	5.78	2.13e-08	1.3e-05	0.33	0.34	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	5.78	2.13e-08	1.3e-05	0.33	0.34	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
KIRP	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.78	2.13e-08	1.3e-05	0.69	0.34	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
KIRP	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	5.78	2.13e-08	1.3e-05	0.38	0.34	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	5.78	2.13e-08	1.3e-05	0.38	0.34	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
KIRP	cis	rs9532669	1	rs9532669	ENSG00000239827.7	SUGT1P3	-5.78	2.13e-08	1.3e-05	-0.37	-0.34	Cervical cancer;	chr13:40927414	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.927	rs9532670	ENSG00000239827.7	SUGT1P3	5.78	2.13e-08	1.3e-05	0.37	0.34	Cervical cancer;	chr13:40927691	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532671	ENSG00000239827.7	SUGT1P3	-5.78	2.13e-08	1.3e-05	-0.37	-0.34	Cervical cancer;	chr13:40927761	chr13:40908159~40921774:-
KIRP	cis	rs9913711	0.899	rs9913936	ENSG00000234899.8	SOX9-AS1	-5.78	2.13e-08	1.3e-05	-0.3	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr17:72078007	chr17:72034107~72237203:-
KIRP	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	5.78	2.13e-08	1.3e-05	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
KIRP	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	5.78	2.13e-08	1.3e-05	0.28	0.34	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
KIRP	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	5.78	2.13e-08	1.31e-05	0.26	0.34	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-5.78	2.13e-08	1.31e-05	-0.44	-0.34	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
KIRP	cis	rs7626444	1	rs2089979	ENSG00000272359.1	U4	-5.78	2.14e-08	1.31e-05	-0.38	-0.34	Monocyte count;	chr3:196774542	chr3:196747192~196747324:-
KIRP	cis	rs453301	0.682	rs2929308	ENSG00000253981.4	ALG1L13P	-5.78	2.14e-08	1.31e-05	-0.27	-0.34	Joint mobility (Beighton score);	chr8:9226611	chr8:8236003~8244667:-
KIRP	cis	rs6085948	0.817	rs17394645	ENSG00000238102.1	RP11-19D2.1	-5.78	2.14e-08	1.31e-05	-0.42	-0.34	Interleukin-10 levels;	chr20:7250193	chr20:7256580~7258214:-
KIRP	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-5.78	2.14e-08	1.31e-05	-0.29	-0.34	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
KIRP	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-5.78	2.14e-08	1.31e-05	-0.62	-0.34	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
KIRP	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	5.78	2.15e-08	1.31e-05	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	5.78	2.15e-08	1.31e-05	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	5.78	2.15e-08	1.31e-05	0.78	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	5.78	2.15e-08	1.31e-05	0.39	0.34	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
KIRP	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	5.78	2.15e-08	1.31e-05	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	5.78	2.15e-08	1.31e-05	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
KIRP	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-5.78	2.15e-08	1.32e-05	-0.24	-0.34	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
KIRP	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	5.78	2.15e-08	1.32e-05	0.63	0.34	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
KIRP	cis	rs2625529	0.824	rs16956452	ENSG00000260037.4	CTD-2524L6.3	-5.78	2.15e-08	1.32e-05	-0.29	-0.34	Red blood cell count;	chr15:71991751	chr15:71818396~71823384:+
KIRP	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	5.78	2.15e-08	1.32e-05	0.41	0.34	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
KIRP	cis	rs7569084	0.687	rs934731	ENSG00000237979.1	AC007389.1	5.78	2.16e-08	1.32e-05	0.38	0.34	Sum eosinophil basophil counts;	chr2:65456353	chr2:65500993~65502138:-
KIRP	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	5.78	2.16e-08	1.32e-05	0.47	0.34	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
KIRP	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-5.78	2.16e-08	1.32e-05	-0.27	-0.34	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
KIRP	cis	rs7474896	0.515	rs662928	ENSG00000151963.4	RP11-775A3.1	5.78	2.16e-08	1.32e-05	0.43	0.34	Obesity (extreme);	chr10:38027288	chr10:37883594~37884109:+
KIRP	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	5.78	2.16e-08	1.32e-05	0.34	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	5.78	2.16e-08	1.32e-05	0.38	0.34	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	5.78	2.16e-08	1.32e-05	0.38	0.34	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	5.78	2.16e-08	1.32e-05	0.38	0.34	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
KIRP	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-5.78	2.17e-08	1.32e-05	-0.34	-0.34	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
KIRP	cis	rs9388451	0.872	rs2008027	ENSG00000237742.5	RP11-624M8.1	-5.78	2.17e-08	1.32e-05	-0.35	-0.34	Brugada syndrome;	chr6:125731213	chr6:125578558~125749190:-
KIRP	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-5.78	2.17e-08	1.32e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-5.78	2.17e-08	1.32e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-5.78	2.17e-08	1.32e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-5.78	2.17e-08	1.32e-05	-0.46	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
KIRP	cis	rs2625529	0.761	rs8028532	ENSG00000260037.4	CTD-2524L6.3	-5.78	2.17e-08	1.33e-05	-0.29	-0.34	Red blood cell count;	chr15:72055713	chr15:71818396~71823384:+
KIRP	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-5.77	2.17e-08	1.33e-05	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
KIRP	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	5.77	2.18e-08	1.33e-05	0.39	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	5.77	2.18e-08	1.33e-05	0.39	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
KIRP	cis	rs2976388	0.556	rs4736300	ENSG00000253741.1	CTD-2292P10.4	5.77	2.18e-08	1.33e-05	0.44	0.34	Urinary tract infection frequency;	chr8:142747851	chr8:142702252~142726973:-
KIRP	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	5.77	2.18e-08	1.33e-05	0.35	0.34	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	5.77	2.18e-08	1.33e-05	0.35	0.34	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
KIRP	cis	rs9532669	0.963	rs1056835	ENSG00000239827.7	SUGT1P3	-5.77	2.18e-08	1.33e-05	-0.38	-0.34	Cervical cancer;	chr13:40932585	chr13:40908159~40921774:-
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	5.77	2.18e-08	1.33e-05	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
KIRP	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	5.77	2.19e-08	1.33e-05	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
KIRP	cis	rs79040073	0.637	rs73392249	ENSG00000259531.2	RP11-295H24.3	5.77	2.19e-08	1.33e-05	0.46	0.34	Lung cancer in ever smokers;	chr15:49224264	chr15:49365124~49366685:-
KIRP	cis	rs9402743	0.632	rs6570040	ENSG00000231028.7	LINC00271	-5.77	2.19e-08	1.34e-05	-0.3	-0.34	Systemic lupus erythematosus;	chr6:135779557	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs7754830	ENSG00000231028.7	LINC00271	-5.77	2.19e-08	1.34e-05	-0.3	-0.34	Systemic lupus erythematosus;	chr6:135779904	chr6:135497801~135716055:+
KIRP	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-5.77	2.19e-08	1.34e-05	-0.34	-0.34	Height;	chr11:118760944	chr11:118704607~118750263:+
KIRP	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	5.77	2.19e-08	1.34e-05	0.52	0.34	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
KIRP	cis	rs7569084	0.687	rs35839762	ENSG00000237979.1	AC007389.1	5.77	2.19e-08	1.34e-05	0.39	0.34	Sum eosinophil basophil counts;	chr2:65441318	chr2:65500993~65502138:-
KIRP	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-5.77	2.2e-08	1.34e-05	-0.36	-0.34	Height;	chr3:53094335	chr3:53064283~53065091:-
KIRP	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	5.77	2.2e-08	1.34e-05	0.34	0.34	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.77	2.2e-08	1.34e-05	0.29	0.34	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.77	2.2e-08	1.34e-05	0.29	0.34	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
KIRP	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	5.77	2.2e-08	1.34e-05	0.58	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
KIRP	cis	rs9532669	0.963	rs4600338	ENSG00000239827.7	SUGT1P3	-5.77	2.2e-08	1.34e-05	-0.37	-0.34	Cervical cancer;	chr13:40925175	chr13:40908159~40921774:-
KIRP	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-5.77	2.2e-08	1.34e-05	-0.36	-0.34	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-5.77	2.2e-08	1.34e-05	-0.36	-0.34	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
KIRP	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-5.77	2.2e-08	1.34e-05	-0.36	-0.34	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
KIRP	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	5.77	2.2e-08	1.34e-05	0.47	0.34	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
KIRP	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	5.77	2.21e-08	1.34e-05	0.25	0.34	Height;	chr20:35200390	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	5.77	2.21e-08	1.34e-05	0.25	0.34	Height;	chr20:35200671	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	5.77	2.21e-08	1.34e-05	0.25	0.34	Height;	chr20:35201180	chr20:35201747~35203288:-
KIRP	cis	rs12571093	0.803	rs17297418	ENSG00000233590.1	RP11-153K11.3	5.77	2.21e-08	1.34e-05	0.52	0.34	Optic nerve measurement (disc area);	chr10:68271894	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs1007848	ENSG00000233590.1	RP11-153K11.3	-5.77	2.21e-08	1.34e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68258549	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs61854807	ENSG00000233590.1	RP11-153K11.3	-5.77	2.21e-08	1.34e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68258948	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.616	rs12571093	ENSG00000233590.1	RP11-153K11.3	-5.77	2.21e-08	1.34e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68259614	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs2120902	ENSG00000233590.1	RP11-153K11.3	-5.77	2.21e-08	1.34e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68260465	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.773	rs4142047	ENSG00000233590.1	RP11-153K11.3	-5.77	2.21e-08	1.34e-05	-0.52	-0.34	Optic nerve measurement (disc area);	chr10:68261498	chr10:68233251~68242379:-
KIRP	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-5.77	2.21e-08	1.34e-05	-0.34	-0.34	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
KIRP	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-5.77	2.21e-08	1.35e-05	-0.38	-0.34	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
KIRP	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	5.77	2.21e-08	1.35e-05	0.48	0.34	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
KIRP	cis	rs7170668	0.93	rs6496111	ENSG00000258489.3	RP11-398J10.2	-5.77	2.22e-08	1.35e-05	-0.38	-0.34	Motion sickness;	chr15:95470466	chr15:95463592~95493770:-
KIRP	cis	rs7170668	0.896	rs6496112	ENSG00000258489.3	RP11-398J10.2	-5.77	2.22e-08	1.35e-05	-0.38	-0.34	Motion sickness;	chr15:95470513	chr15:95463592~95493770:-
KIRP	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-5.77	2.22e-08	1.35e-05	-0.32	-0.34	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
KIRP	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	5.77	2.22e-08	1.35e-05	0.35	0.34	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
KIRP	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-5.77	2.23e-08	1.35e-05	-0.36	-0.34	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
KIRP	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-5.77	2.23e-08	1.35e-05	-0.36	-0.34	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
KIRP	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-5.77	2.23e-08	1.36e-05	-0.39	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.77	2.23e-08	1.36e-05	0.29	0.34	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-5.77	2.23e-08	1.36e-05	-0.28	-0.34	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
KIRP	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-5.77	2.23e-08	1.36e-05	-0.34	-0.34	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
KIRP	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-5.77	2.24e-08	1.36e-05	-0.48	-0.34	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
KIRP	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	5.77	2.24e-08	1.36e-05	0.63	0.34	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
KIRP	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	5.77	2.24e-08	1.36e-05	0.35	0.34	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
KIRP	cis	rs2625529	0.938	rs4777464	ENSG00000260037.4	CTD-2524L6.3	-5.77	2.24e-08	1.37e-05	-0.27	-0.34	Red blood cell count;	chr15:71839422	chr15:71818396~71823384:+
KIRP	cis	rs79349575	0.721	rs2291725	ENSG00000248278.1	SUMO2P17	5.77	2.25e-08	1.37e-05	0.39	0.34	Type 2 diabetes;	chr17:48961770	chr17:48874860~48908983:-
KIRP	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	5.77	2.25e-08	1.37e-05	0.44	0.34	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
KIRP	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	5.77	2.25e-08	1.37e-05	0.3	0.34	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
KIRP	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-5.77	2.26e-08	1.37e-05	-0.35	-0.34	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
KIRP	cis	rs2273156	1	rs12050267	ENSG00000226677.3	IGBP1P1	-5.77	2.26e-08	1.38e-05	-0.35	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:34942222	chr14:34939324~34940332:+
KIRP	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-5.77	2.27e-08	1.38e-05	-0.37	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
KIRP	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-5.77	2.27e-08	1.38e-05	-0.51	-0.34	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-5.77	2.27e-08	1.38e-05	-0.51	-0.34	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
KIRP	cis	rs2617170	0.922	rs2250877	ENSG00000245648.1	RP11-277P12.20	5.77	2.27e-08	1.38e-05	0.38	0.34	Behcet's disease;	chr12:10393659	chr12:10363769~10398506:+
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.77	2.27e-08	1.38e-05	0.29	0.34	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
KIRP	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-5.77	2.28e-08	1.38e-05	-0.29	-0.34	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
KIRP	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	5.77	2.28e-08	1.38e-05	0.33	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
KIRP	cis	rs2617170	0.883	rs1351111	ENSG00000245648.1	RP11-277P12.20	5.77	2.28e-08	1.38e-05	0.4	0.34	Behcet's disease;	chr12:10402849	chr12:10363769~10398506:+
KIRP	cis	rs2625529	0.586	rs2306489	ENSG00000260037.4	CTD-2524L6.3	5.77	2.28e-08	1.38e-05	0.26	0.34	Red blood cell count;	chr15:71935130	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2957728	ENSG00000260037.4	CTD-2524L6.3	5.77	2.28e-08	1.38e-05	0.26	0.34	Red blood cell count;	chr15:71944091	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	5.77	2.28e-08	1.38e-05	0.46	0.34	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	5.77	2.28e-08	1.38e-05	0.44	0.34	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
KIRP	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-5.77	2.28e-08	1.38e-05	-0.4	-0.34	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
KIRP	cis	rs6452524	0.544	rs2126989	ENSG00000249664.1	CTD-2227C6.2	-5.77	2.28e-08	1.38e-05	-0.4	-0.34	Hypertension (SNP x SNP interaction);	chr5:83092120	chr5:83012285~83013109:-
KIRP	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-5.77	2.29e-08	1.39e-05	-0.27	-0.34	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	5.76	2.29e-08	1.39e-05	0.32	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
KIRP	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-5.76	2.29e-08	1.39e-05	-0.28	-0.34	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
KIRP	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-5.76	2.29e-08	1.39e-05	-0.61	-0.34	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
KIRP	cis	rs1799949	0.859	rs11657004	ENSG00000236383.6	LINC00854	-5.76	2.29e-08	1.39e-05	-0.26	-0.34	Menopause (age at onset);	chr17:43365383	chr17:43216941~43305976:-
KIRP	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-5.76	2.3e-08	1.4e-05	-0.34	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
KIRP	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	5.76	2.3e-08	1.4e-05	0.28	0.34	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
KIRP	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-5.76	2.3e-08	1.4e-05	-0.38	-0.34	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
KIRP	cis	rs4638749	0.677	rs12329189	ENSG00000231221.1	AC023672.2	-5.76	2.3e-08	1.4e-05	-0.39	-0.34	Blood pressure;	chr2:108196399	chr2:108049200~108052755:-
KIRP	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	5.76	2.31e-08	1.4e-05	0.28	0.34	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
KIRP	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	5.76	2.31e-08	1.4e-05	0.37	0.34	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
KIRP	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	5.76	2.32e-08	1.4e-05	0.44	0.34	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	5.76	2.32e-08	1.4e-05	0.44	0.34	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	5.76	2.32e-08	1.4e-05	0.44	0.34	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
KIRP	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-5.76	2.32e-08	1.4e-05	-0.38	-0.34	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
KIRP	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	5.76	2.32e-08	1.41e-05	0.45	0.34	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
KIRP	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-5.76	2.32e-08	1.41e-05	-0.53	-0.34	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
KIRP	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	5.76	2.32e-08	1.41e-05	0.42	0.34	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
KIRP	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-5.76	2.32e-08	1.41e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-5.76	2.32e-08	1.41e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
KIRP	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	5.76	2.32e-08	1.41e-05	0.36	0.34	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
KIRP	cis	rs4356975	0.583	rs4632729	ENSG00000196472.4	RP13-644M16.4	5.76	2.32e-08	1.41e-05	0.36	0.34	Obesity-related traits;	chr4:69080286	chr4:69181660~69182372:+
KIRP	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	5.76	2.33e-08	1.41e-05	0.44	0.34	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
KIRP	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-5.76	2.33e-08	1.41e-05	-0.32	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
KIRP	cis	rs2617170	0.961	rs1841957	ENSG00000245648.1	RP11-277P12.20	5.76	2.33e-08	1.41e-05	0.39	0.34	Behcet's disease;	chr12:10409426	chr12:10363769~10398506:+
KIRP	cis	rs710913	0.527	rs2004330	ENSG00000237624.1	OXCT2P1	-5.76	2.33e-08	1.41e-05	-0.41	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39498201	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.563	rs7698645	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106192	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600891	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69105878	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs7693957	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106078	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7698846	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106278	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12513195	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106368	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4541594	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106554	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.583	rs4351080	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106601	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4356974	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69106696	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs5013211	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107059	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4292394	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107231	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4337789	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107326	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4521414	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107807	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4314345	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107922	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4588522	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107949	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4364327	ENSG00000196472.4	RP13-644M16.4	5.76	2.33e-08	1.41e-05	0.37	0.34	Obesity-related traits;	chr4:69107974	chr4:69181660~69182372:+
KIRP	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-5.76	2.33e-08	1.41e-05	-0.41	-0.34	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	5.76	2.34e-08	1.42e-05	0.34	0.34	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
KIRP	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-5.76	2.34e-08	1.42e-05	-0.44	-0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
KIRP	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-5.76	2.34e-08	1.42e-05	-0.3	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-5.76	2.35e-08	1.42e-05	-0.26	-0.34	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
KIRP	cis	rs7267979	1	rs6083828	ENSG00000274414.1	RP5-965G21.4	5.76	2.35e-08	1.42e-05	0.32	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25239007~25245229:-
KIRP	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	5.76	2.35e-08	1.42e-05	0.44	0.34	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
KIRP	cis	rs6832769	0.89	rs564762	ENSG00000272969.1	RP11-528I4.2	5.76	2.35e-08	1.42e-05	0.32	0.34	Personality dimensions;	chr4:55418464	chr4:55547112~55547889:+
KIRP	cis	rs6085948	1	rs6085948	ENSG00000238102.1	RP11-19D2.1	5.76	2.35e-08	1.42e-05	0.4	0.34	Interleukin-10 levels;	chr20:7252703	chr20:7256580~7258214:-
KIRP	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	5.76	2.35e-08	1.42e-05	0.3	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
KIRP	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-5.76	2.36e-08	1.43e-05	-0.3	-0.34	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
KIRP	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	5.76	2.36e-08	1.43e-05	0.49	0.34	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
KIRP	cis	rs1858037	0.867	rs953312	ENSG00000281920.1	RP11-418H16.1	5.76	2.37e-08	1.43e-05	0.44	0.34	Rheumatoid arthritis;	chr2:65340556	chr2:65623272~65628424:+
KIRP	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	5.76	2.37e-08	1.43e-05	0.42	0.34	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
KIRP	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-5.76	2.37e-08	1.43e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
KIRP	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-5.76	2.38e-08	1.44e-05	-0.39	-0.34	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
KIRP	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-5.76	2.39e-08	1.44e-05	-0.47	-0.34	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
KIRP	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-5.76	2.39e-08	1.44e-05	-0.47	-0.34	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
KIRP	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-5.76	2.39e-08	1.44e-05	-0.47	-0.34	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
KIRP	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-5.76	2.39e-08	1.44e-05	-0.33	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
KIRP	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	5.76	2.39e-08	1.44e-05	0.42	0.34	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
KIRP	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	5.76	2.39e-08	1.44e-05	0.32	0.34	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
KIRP	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-5.76	2.39e-08	1.44e-05	-0.43	-0.34	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
KIRP	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	5.76	2.39e-08	1.44e-05	0.25	0.34	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
KIRP	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	5.76	2.39e-08	1.44e-05	0.28	0.34	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
KIRP	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-5.76	2.39e-08	1.45e-05	-0.29	-0.34	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
KIRP	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-5.76	2.39e-08	1.45e-05	-0.36	-0.34	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
KIRP	cis	rs7267979	0.903	rs6050482	ENSG00000274414.1	RP5-965G21.4	-5.76	2.4e-08	1.45e-05	-0.32	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-5.76	2.4e-08	1.45e-05	-0.43	-0.34	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
KIRP	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	5.76	2.4e-08	1.45e-05	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	5.76	2.4e-08	1.45e-05	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
KIRP	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	5.76	2.4e-08	1.45e-05	0.41	0.34	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
KIRP	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	5.76	2.41e-08	1.45e-05	0.4	0.34	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
KIRP	cis	rs2625529	0.652	rs2957745	ENSG00000260037.4	CTD-2524L6.3	5.76	2.41e-08	1.46e-05	0.26	0.34	Red blood cell count;	chr15:71995736	chr15:71818396~71823384:+
KIRP	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	5.76	2.41e-08	1.46e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
KIRP	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	5.76	2.41e-08	1.46e-05	0.4	0.34	Height;	chr4:55413708	chr4:55363971~55395847:-
KIRP	cis	rs67311347	0.955	rs2123999	ENSG00000230274.1	PGAM1P3	5.76	2.41e-08	1.46e-05	0.32	0.34	Renal cell carcinoma;	chr3:40337247	chr3:40322715~40323279:-
KIRP	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-5.75	2.41e-08	1.46e-05	-0.3	-0.33	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
KIRP	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-5.75	2.42e-08	1.46e-05	-0.37	-0.33	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
KIRP	cis	rs7474896	0.559	rs1024202	ENSG00000151963.4	RP11-775A3.1	5.75	2.42e-08	1.46e-05	0.45	0.33	Obesity (extreme);	chr10:37990049	chr10:37883594~37884109:+
KIRP	cis	rs7474896	0.537	rs1022449	ENSG00000151963.4	RP11-775A3.1	5.75	2.42e-08	1.46e-05	0.45	0.33	Obesity (extreme);	chr10:37990539	chr10:37883594~37884109:+
KIRP	cis	rs3121446	0.96	rs2354549	ENSG00000229654.1	RP1-60O19.2	5.75	2.43e-08	1.46e-05	0.34	0.33	Daytime sleep phenotypes;	chr6:106694448	chr6:106695535~106699994:+
KIRP	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	5.75	2.43e-08	1.46e-05	0.37	0.33	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
KIRP	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	5.75	2.43e-08	1.46e-05	0.38	0.33	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
KIRP	cis	rs9915657	0.803	rs12449851	ENSG00000234899.8	SOX9-AS1	5.75	2.43e-08	1.47e-05	0.27	0.33	Thyroid hormone levels;	chr17:72102861	chr17:72034107~72237203:-
KIRP	cis	rs7829975	0.774	rs1703982	ENSG00000253981.4	ALG1L13P	-5.75	2.43e-08	1.47e-05	-0.27	-0.33	Mood instability;	chr8:8740878	chr8:8236003~8244667:-
KIRP	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-5.75	2.43e-08	1.47e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
KIRP	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	5.75	2.43e-08	1.47e-05	0.35	0.33	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	5.75	2.44e-08	1.47e-05	0.44	0.33	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.563	rs3924192	ENSG00000250696.4	RP11-704M14.1	-5.75	2.44e-08	1.47e-05	-0.33	-0.33	Obesity-related traits;	chr4:69105246	chr4:69182100~69216766:+
KIRP	cis	rs1560104	0.5	rs11075127	ENSG00000274834.1	CTD-3037G24.5	5.75	2.44e-08	1.47e-05	0.37	0.33	Obesity-related traits;	chr16:12620700	chr16:12614451~12614852:+
KIRP	cis	rs1799949	0.931	rs34474989	ENSG00000236383.6	LINC00854	-5.75	2.44e-08	1.47e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43368042	chr17:43216941~43305976:-
KIRP	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	5.75	2.45e-08	1.48e-05	0.41	0.33	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
KIRP	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	5.75	2.45e-08	1.48e-05	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
KIRP	cis	rs1560104	0.597	rs4780468	ENSG00000274834.1	CTD-3037G24.5	5.75	2.46e-08	1.48e-05	0.37	0.33	Obesity-related traits;	chr16:12620390	chr16:12614451~12614852:+
KIRP	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-5.75	2.46e-08	1.48e-05	-0.37	-0.33	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
KIRP	cis	rs1858037	0.867	rs6727013	ENSG00000281920.1	RP11-418H16.1	5.75	2.46e-08	1.48e-05	0.44	0.33	Rheumatoid arthritis;	chr2:65331241	chr2:65623272~65628424:+
KIRP	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-5.75	2.46e-08	1.49e-05	-0.36	-0.33	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.75	2.47e-08	1.49e-05	0.29	0.33	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
KIRP	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-5.75	2.47e-08	1.49e-05	-0.28	-0.33	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
KIRP	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-5.75	2.47e-08	1.49e-05	-0.4	-0.33	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
KIRP	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	5.75	2.47e-08	1.49e-05	0.28	0.33	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
KIRP	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-5.75	2.47e-08	1.49e-05	-0.39	-0.33	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
KIRP	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-5.75	2.47e-08	1.49e-05	-0.37	-0.33	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
KIRP	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-5.75	2.48e-08	1.49e-05	-0.39	-0.33	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
KIRP	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	5.75	2.48e-08	1.5e-05	0.33	0.33	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	5.75	2.48e-08	1.5e-05	0.33	0.33	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	5.75	2.48e-08	1.5e-05	0.33	0.33	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
KIRP	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	5.75	2.48e-08	1.5e-05	0.3	0.33	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
KIRP	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	5.75	2.49e-08	1.5e-05	0.28	0.33	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	5.75	2.49e-08	1.5e-05	0.28	0.33	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	5.75	2.49e-08	1.5e-05	0.28	0.33	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
KIRP	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-5.75	2.49e-08	1.5e-05	-0.74	-0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
KIRP	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-5.75	2.49e-08	1.5e-05	-0.36	-0.33	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
KIRP	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-5.75	2.49e-08	1.5e-05	-0.36	-0.33	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
KIRP	cis	rs1200821	0.529	rs4934856	ENSG00000151963.4	RP11-775A3.1	5.75	2.49e-08	1.5e-05	0.38	0.33	Hemostatic factors and hematological phenotypes;	chr10:37518919	chr10:37883594~37884109:+
KIRP	cis	rs12050794	0.671	rs8192362	ENSG00000260037.4	CTD-2524L6.3	5.75	2.49e-08	1.5e-05	0.25	0.33	Metabolite levels (HVA/MHPG ratio);	chr15:72227517	chr15:71818396~71823384:+
KIRP	cis	rs12050794	0.671	rs2052713	ENSG00000260037.4	CTD-2524L6.3	5.75	2.49e-08	1.5e-05	0.25	0.33	Metabolite levels (HVA/MHPG ratio);	chr15:72228051	chr15:71818396~71823384:+
KIRP	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	5.75	2.5e-08	1.5e-05	0.41	0.33	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
KIRP	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	5.75	2.5e-08	1.51e-05	0.39	0.33	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
KIRP	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.75	2.5e-08	1.51e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.75	2.5e-08	1.51e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.75	2.5e-08	1.51e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.75	2.5e-08	1.51e-05	-0.26	-0.33	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
KIRP	cis	rs11647589	0.834	rs1700801	ENSG00000262995.1	CTD-2194A8.2	-5.75	2.5e-08	1.51e-05	-0.37	-0.33	Blood metabolite levels;	chr16:20474158	chr16:20440266~20447000:-
KIRP	cis	rs11647589	0.834	rs1354577	ENSG00000262995.1	CTD-2194A8.2	-5.75	2.5e-08	1.51e-05	-0.37	-0.33	Blood metabolite levels;	chr16:20474341	chr16:20440266~20447000:-
KIRP	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-5.75	2.51e-08	1.51e-05	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
KIRP	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	5.75	2.51e-08	1.51e-05	0.32	0.33	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
KIRP	cis	rs2625529	0.824	rs12902006	ENSG00000260037.4	CTD-2524L6.3	-5.75	2.51e-08	1.51e-05	-0.29	-0.33	Red blood cell count;	chr15:71960655	chr15:71818396~71823384:+
KIRP	cis	rs11158026	0.757	rs72715573	ENSG00000258413.1	RP11-665C16.6	-5.75	2.51e-08	1.51e-05	-0.4	-0.33	Parkinson's disease;	chr14:54992853	chr14:55262767~55272075:-
KIRP	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-5.75	2.51e-08	1.51e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	5.75	2.51e-08	1.51e-05	0.41	0.33	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
KIRP	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-5.75	2.51e-08	1.51e-05	-0.44	-0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
KIRP	cis	rs11158026	0.757	rs10150110	ENSG00000258413.1	RP11-665C16.6	-5.75	2.52e-08	1.51e-05	-0.4	-0.33	Parkinson's disease;	chr14:54995292	chr14:55262767~55272075:-
KIRP	cis	rs11158026	0.757	rs7153937	ENSG00000258413.1	RP11-665C16.6	-5.75	2.52e-08	1.51e-05	-0.4	-0.33	Parkinson's disease;	chr14:55004157	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	5.75	2.52e-08	1.51e-05	0.39	0.33	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	5.75	2.52e-08	1.51e-05	0.39	0.33	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
KIRP	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	5.75	2.52e-08	1.52e-05	0.36	0.33	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
KIRP	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	5.75	2.52e-08	1.52e-05	0.58	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
KIRP	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	5.75	2.52e-08	1.52e-05	0.58	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
KIRP	cis	rs453301	0.686	rs6601281	ENSG00000253981.4	ALG1L13P	-5.75	2.53e-08	1.52e-05	-0.27	-0.33	Joint mobility (Beighton score);	chr8:9053494	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.571	rs2929452	ENSG00000253981.4	ALG1L13P	-5.75	2.53e-08	1.52e-05	-0.27	-0.33	Joint mobility (Beighton score);	chr8:9226955	chr8:8236003~8244667:-
KIRP	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-5.75	2.53e-08	1.52e-05	-0.4	-0.33	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
KIRP	cis	rs9402743	0.597	rs9483879	ENSG00000231028.7	LINC00271	-5.75	2.53e-08	1.52e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135778024	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs9494383	ENSG00000231028.7	LINC00271	-5.75	2.53e-08	1.52e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135778026	chr6:135497801~135716055:+
KIRP	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-5.75	2.53e-08	1.52e-05	-0.37	-0.33	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
KIRP	cis	rs7569084	0.687	rs1370394	ENSG00000237979.1	AC007389.1	5.75	2.54e-08	1.52e-05	0.39	0.33	Sum eosinophil basophil counts;	chr2:65453176	chr2:65500993~65502138:-
KIRP	cis	rs9371601	0.892	rs9371603	ENSG00000226193.1	RP3-398G3.5	5.74	2.55e-08	1.53e-05	0.37	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152489495	chr6:152402398~152404966:+
KIRP	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	5.74	2.55e-08	1.53e-05	0.52	0.33	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
KIRP	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	5.74	2.55e-08	1.53e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
KIRP	cis	rs67311347	1	rs897117	ENSG00000230274.1	PGAM1P3	-5.74	2.55e-08	1.53e-05	-0.32	-0.33	Renal cell carcinoma;	chr3:40395803	chr3:40322715~40323279:-
KIRP	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-5.74	2.55e-08	1.53e-05	-0.27	-0.33	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
KIRP	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	5.74	2.56e-08	1.54e-05	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
KIRP	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-5.74	2.56e-08	1.54e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-5.74	2.56e-08	1.54e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
KIRP	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.74	2.56e-08	1.54e-05	-0.31	-0.33	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	5.74	2.56e-08	1.54e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
KIRP	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-5.74	2.56e-08	1.54e-05	-0.37	-0.33	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-5.74	2.56e-08	1.54e-05	-0.37	-0.33	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-5.74	2.56e-08	1.54e-05	-0.37	-0.33	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-5.74	2.56e-08	1.54e-05	-0.37	-0.33	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-5.74	2.56e-08	1.54e-05	-0.37	-0.33	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
KIRP	cis	rs1560104	0.518	rs11645483	ENSG00000274834.1	CTD-3037G24.5	5.74	2.56e-08	1.54e-05	0.38	0.33	Obesity-related traits;	chr16:12615400	chr16:12614451~12614852:+
KIRP	cis	rs2625529	0.938	rs2742323	ENSG00000260037.4	CTD-2524L6.3	5.74	2.57e-08	1.54e-05	0.29	0.33	Red blood cell count;	chr15:71824437	chr15:71818396~71823384:+
KIRP	cis	rs950169	0.881	rs72750843	ENSG00000275120.1	RP11-182J1.17	5.74	2.57e-08	1.54e-05	0.45	0.33	Schizophrenia;	chr15:84592552	chr15:84599434~84606463:-
KIRP	cis	rs2625529	0.824	rs12592364	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.58e-08	1.54e-05	-0.29	-0.33	Red blood cell count;	chr15:71992306	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.641	rs2035379	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.58e-08	1.54e-05	-0.29	-0.33	Red blood cell count;	chr15:72000861	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12595464	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.58e-08	1.54e-05	-0.29	-0.33	Red blood cell count;	chr15:72002057	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12916694	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.58e-08	1.54e-05	-0.29	-0.33	Red blood cell count;	chr15:72005799	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12593134	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.58e-08	1.54e-05	-0.29	-0.33	Red blood cell count;	chr15:72010666	chr15:71818396~71823384:+
KIRP	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-5.74	2.58e-08	1.55e-05	-0.41	-0.33	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
KIRP	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.74	2.58e-08	1.55e-05	0.41	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
KIRP	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-5.74	2.58e-08	1.55e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
KIRP	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	5.74	2.58e-08	1.55e-05	0.32	0.33	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
KIRP	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	5.74	2.58e-08	1.55e-05	0.32	0.33	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
KIRP	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-5.74	2.58e-08	1.55e-05	-0.28	-0.33	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
KIRP	cis	rs1799949	1	rs8176083	ENSG00000236383.6	LINC00854	-5.74	2.58e-08	1.55e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43123134	chr17:43216941~43305976:-
KIRP	cis	rs7474896	0.515	rs2505233	ENSG00000151963.4	RP11-775A3.1	-5.74	2.58e-08	1.55e-05	-0.43	-0.33	Obesity (extreme);	chr10:38051337	chr10:37883594~37884109:+
KIRP	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-5.74	2.59e-08	1.55e-05	-0.37	-0.33	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
KIRP	cis	rs2765539	0.701	rs12068932	ENSG00000231365.4	RP11-418J17.1	-5.74	2.6e-08	1.56e-05	-0.37	-0.33	Waist-hip ratio;	chr1:119113057	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	5.74	2.6e-08	1.56e-05	0.43	0.33	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	5.74	2.6e-08	1.56e-05	0.43	0.33	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
KIRP	cis	rs79040073	0.637	rs57749497	ENSG00000259531.2	RP11-295H24.3	5.74	2.6e-08	1.56e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49297661	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73394355	ENSG00000259531.2	RP11-295H24.3	5.74	2.6e-08	1.56e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49299893	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73394359	ENSG00000259531.2	RP11-295H24.3	5.74	2.6e-08	1.56e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49300941	chr15:49365124~49366685:-
KIRP	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	5.74	2.61e-08	1.56e-05	0.26	0.33	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
KIRP	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-5.74	2.61e-08	1.56e-05	-0.36	-0.33	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
KIRP	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-5.74	2.61e-08	1.56e-05	-0.37	-0.33	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
KIRP	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	5.74	2.61e-08	1.56e-05	0.38	0.33	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.74	2.61e-08	1.56e-05	0.38	0.33	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
KIRP	cis	rs947583	0.517	rs6935371	ENSG00000231028.7	LINC00271	-5.74	2.61e-08	1.56e-05	-0.29	-0.33	Phosphorus levels;	chr6:135779380	chr6:135497801~135716055:+
KIRP	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	5.74	2.61e-08	1.57e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
KIRP	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	5.74	2.61e-08	1.57e-05	0.37	0.33	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
KIRP	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	5.74	2.61e-08	1.57e-05	0.37	0.33	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
KIRP	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	5.74	2.62e-08	1.57e-05	0.44	0.33	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
KIRP	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	5.74	2.62e-08	1.57e-05	0.26	0.33	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
KIRP	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-5.74	2.62e-08	1.57e-05	-0.38	-0.33	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
KIRP	cis	rs2625529	0.627	rs11858015	ENSG00000260037.4	CTD-2524L6.3	-5.74	2.62e-08	1.57e-05	-0.29	-0.33	Red blood cell count;	chr15:72260151	chr15:71818396~71823384:+
KIRP	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	5.74	2.63e-08	1.57e-05	0.25	0.33	Height;	chr20:35198453	chr20:35201747~35203288:-
KIRP	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	5.74	2.63e-08	1.58e-05	0.42	0.33	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
KIRP	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	5.74	2.66e-08	1.59e-05	0.23	0.33	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
KIRP	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-5.74	2.66e-08	1.59e-05	-0.35	-0.33	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-5.74	2.66e-08	1.59e-05	-0.28	-0.33	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
KIRP	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-5.74	2.66e-08	1.59e-05	-0.28	-0.33	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-5.74	2.66e-08	1.59e-05	-0.28	-0.33	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
KIRP	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-5.74	2.67e-08	1.6e-05	-0.25	-0.33	Height;	chr20:35185886	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-5.74	2.67e-08	1.6e-05	-0.25	-0.33	Height;	chr20:35186641	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-5.74	2.67e-08	1.6e-05	-0.25	-0.33	Height;	chr20:35187574	chr20:35201747~35203288:-
KIRP	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	5.74	2.67e-08	1.6e-05	0.34	0.33	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
KIRP	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-5.74	2.67e-08	1.6e-05	-0.45	-0.33	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-5.74	2.67e-08	1.6e-05	-0.45	-0.33	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-5.74	2.67e-08	1.6e-05	-0.45	-0.33	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
KIRP	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-5.74	2.67e-08	1.6e-05	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
KIRP	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	5.74	2.68e-08	1.6e-05	0.35	0.33	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
KIRP	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	5.73	2.68e-08	1.6e-05	0.27	0.33	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	5.73	2.68e-08	1.6e-05	0.46	0.33	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
KIRP	cis	rs4356975	0.563	rs4327554	ENSG00000196472.4	RP13-644M16.4	-5.73	2.68e-08	1.61e-05	-0.36	-0.33	Obesity-related traits;	chr4:69120690	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600896	ENSG00000196472.4	RP13-644M16.4	5.73	2.68e-08	1.61e-05	0.36	0.33	Obesity-related traits;	chr4:69121000	chr4:69181660~69182372:+
KIRP	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	5.73	2.69e-08	1.61e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	5.73	2.69e-08	1.61e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-5.73	2.69e-08	1.61e-05	-0.37	-0.33	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
KIRP	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	5.73	2.69e-08	1.61e-05	0.26	0.33	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
KIRP	cis	rs2749592	0.611	rs176888	ENSG00000151963.4	RP11-775A3.1	-5.73	2.69e-08	1.61e-05	-0.38	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:37883594~37884109:+
KIRP	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	5.73	2.69e-08	1.61e-05	0.34	0.33	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
KIRP	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-5.73	2.7e-08	1.61e-05	-0.3	-0.33	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
KIRP	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-5.73	2.7e-08	1.61e-05	-0.3	-0.33	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
KIRP	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-5.73	2.7e-08	1.61e-05	-0.37	-0.33	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
KIRP	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	5.73	2.7e-08	1.61e-05	0.36	0.33	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
KIRP	cis	rs7474896	0.515	rs2738203	ENSG00000151963.4	RP11-775A3.1	5.73	2.7e-08	1.61e-05	0.48	0.33	Obesity (extreme);	chr10:37988668	chr10:37883594~37884109:+
KIRP	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	5.73	2.7e-08	1.61e-05	0.39	0.33	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-5.73	2.7e-08	1.61e-05	-0.25	-0.33	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
KIRP	cis	rs2765539	0.851	rs8928	ENSG00000231365.4	RP11-418J17.1	-5.73	2.7e-08	1.62e-05	-0.38	-0.33	Waist-hip ratio;	chr1:119031451	chr1:119140396~119275973:+
KIRP	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	5.73	2.71e-08	1.62e-05	0.4	0.33	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
KIRP	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-5.73	2.71e-08	1.62e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-5.73	2.71e-08	1.62e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-5.73	2.71e-08	1.62e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-5.73	2.71e-08	1.62e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
KIRP	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-5.73	2.71e-08	1.62e-05	-0.36	-0.33	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
KIRP	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-5.73	2.71e-08	1.62e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
KIRP	cis	rs2765539	0.74	rs10047100	ENSG00000231365.4	RP11-418J17.1	-5.73	2.72e-08	1.62e-05	-0.39	-0.33	Waist-hip ratio;	chr1:119077734	chr1:119140396~119275973:+
KIRP	cis	rs11158026	0.757	rs17128120	ENSG00000258413.1	RP11-665C16.6	-5.73	2.72e-08	1.62e-05	-0.4	-0.33	Parkinson's disease;	chr14:55007880	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.592	rs2878174	ENSG00000258413.1	RP11-665C16.6	-5.73	2.72e-08	1.62e-05	-0.39	-0.33	Protein biomarker;	chr14:55003906	chr14:55262767~55272075:-
KIRP	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-5.73	2.72e-08	1.63e-05	-0.38	-0.33	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
KIRP	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	5.73	2.73e-08	1.63e-05	0.35	0.33	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
KIRP	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-5.73	2.73e-08	1.63e-05	-0.4	-0.33	Depression;	chr6:28206812	chr6:28115628~28116551:+
KIRP	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-5.73	2.73e-08	1.63e-05	-0.46	-0.33	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-5.73	2.73e-08	1.63e-05	-0.46	-0.33	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
KIRP	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	5.73	2.73e-08	1.63e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	5.73	2.73e-08	1.63e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	5.73	2.73e-08	1.63e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
KIRP	cis	rs8067545	0.616	rs203470	ENSG00000270091.1	RP11-78O7.2	-5.73	2.73e-08	1.63e-05	-0.22	-0.33	Schizophrenia;	chr17:19955313	chr17:19896590~19897287:-
KIRP	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-5.73	2.74e-08	1.63e-05	-0.41	-0.33	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-5.73	2.74e-08	1.63e-05	-0.41	-0.33	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-5.73	2.74e-08	1.63e-05	-0.41	-0.33	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
KIRP	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	5.73	2.74e-08	1.63e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
KIRP	cis	rs2625529	0.59	rs12442886	ENSG00000260037.4	CTD-2524L6.3	5.73	2.74e-08	1.63e-05	0.27	0.33	Red blood cell count;	chr15:72181270	chr15:71818396~71823384:+
KIRP	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	5.73	2.74e-08	1.64e-05	0.41	0.33	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
KIRP	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	5.73	2.74e-08	1.64e-05	0.26	0.33	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	5.73	2.74e-08	1.64e-05	0.26	0.33	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-5.73	2.74e-08	1.64e-05	-0.26	-0.33	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-5.73	2.74e-08	1.64e-05	-0.26	-0.33	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-5.73	2.74e-08	1.64e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-5.73	2.74e-08	1.64e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-5.73	2.74e-08	1.64e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
KIRP	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-5.73	2.74e-08	1.64e-05	-0.46	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
KIRP	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	5.73	2.75e-08	1.64e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
KIRP	cis	rs79040073	0.637	rs73390360	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49171265	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73390362	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49172292	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.599	rs73390384	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49180905	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.6	rs57785991	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49188443	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs7177624	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49189515	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11635814	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49195028	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs78298181	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49213350	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73392236	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49216829	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.564	rs34606419	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49240390	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73394339	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49279601	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17397211	ENSG00000259531.2	RP11-295H24.3	5.73	2.75e-08	1.64e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49279746	chr15:49365124~49366685:-
KIRP	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	5.73	2.75e-08	1.64e-05	0.35	0.33	Height;	chr4:55363436	chr4:55363971~55395847:-
KIRP	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	5.73	2.76e-08	1.64e-05	0.43	0.33	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	5.73	2.76e-08	1.64e-05	0.43	0.33	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
KIRP	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	5.73	2.76e-08	1.65e-05	0.43	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
KIRP	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	5.73	2.76e-08	1.65e-05	0.41	0.33	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
KIRP	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-5.73	2.76e-08	1.65e-05	-0.3	-0.33	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
KIRP	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-5.73	2.76e-08	1.65e-05	-0.34	-0.33	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
KIRP	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	5.73	2.76e-08	1.65e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
KIRP	cis	rs4356975	0.563	rs6600897	ENSG00000196472.4	RP13-644M16.4	5.73	2.77e-08	1.65e-05	0.36	0.33	Obesity-related traits;	chr4:69121531	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4274916	ENSG00000196472.4	RP13-644M16.4	5.73	2.77e-08	1.65e-05	0.36	0.33	Obesity-related traits;	chr4:69122660	chr4:69181660~69182372:+
KIRP	cis	rs1560104	0.576	rs7186185	ENSG00000274834.1	CTD-3037G24.5	5.73	2.77e-08	1.65e-05	0.37	0.33	Obesity-related traits;	chr16:12614985	chr16:12614451~12614852:+
KIRP	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-5.73	2.77e-08	1.65e-05	-0.34	-0.33	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-5.73	2.77e-08	1.65e-05	-0.34	-0.33	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-5.73	2.77e-08	1.65e-05	-0.34	-0.33	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-5.73	2.77e-08	1.65e-05	-0.34	-0.33	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
KIRP	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-5.73	2.78e-08	1.66e-05	-0.31	-0.33	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
KIRP	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-5.73	2.78e-08	1.66e-05	-0.26	-0.33	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
KIRP	cis	rs77926410	0.604	rs11053801	ENSG00000245648.1	RP11-277P12.20	-5.73	2.78e-08	1.66e-05	-0.39	-0.33	Mean corpuscular volume;	chr12:10443518	chr12:10363769~10398506:+
KIRP	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	5.73	2.78e-08	1.66e-05	0.41	0.33	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	5.73	2.78e-08	1.66e-05	0.41	0.33	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	5.73	2.78e-08	1.66e-05	0.41	0.33	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	5.73	2.79e-08	1.66e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
KIRP	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-5.73	2.79e-08	1.66e-05	-0.33	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
KIRP	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-5.73	2.79e-08	1.66e-05	-0.3	-0.33	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
KIRP	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-5.73	2.8e-08	1.67e-05	-0.33	-0.33	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
KIRP	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-5.73	2.8e-08	1.67e-05	-0.36	-0.33	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-5.73	2.8e-08	1.67e-05	-0.36	-0.33	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-5.73	2.8e-08	1.67e-05	-0.36	-0.33	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
KIRP	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	5.73	2.8e-08	1.67e-05	0.9	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	5.73	2.8e-08	1.67e-05	0.9	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
KIRP	cis	rs2765539	0.74	rs12045196	ENSG00000231365.4	RP11-418J17.1	-5.73	2.8e-08	1.67e-05	-0.39	-0.33	Waist-hip ratio;	chr1:119077020	chr1:119140396~119275973:+
KIRP	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-5.73	2.8e-08	1.67e-05	-0.37	-0.33	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
KIRP	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-5.73	2.8e-08	1.67e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
KIRP	cis	rs79349575	0.756	rs4793605	ENSG00000248278.1	SUMO2P17	5.73	2.81e-08	1.67e-05	0.38	0.33	Type 2 diabetes;	chr17:48958507	chr17:48874860~48908983:-
KIRP	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-5.73	2.81e-08	1.67e-05	-0.34	-0.33	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
KIRP	cis	rs11864453	0.682	rs10852509	ENSG00000260886.1	TAT-AS1	5.73	2.82e-08	1.68e-05	0.46	0.33	Fibrinogen levels;	chr16:71992111	chr16:71565789~71578187:+
KIRP	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	5.73	2.82e-08	1.68e-05	0.57	0.33	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
KIRP	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	5.73	2.82e-08	1.68e-05	0.57	0.33	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
KIRP	cis	rs7569084	0.687	rs1437462	ENSG00000237979.1	AC007389.1	5.73	2.82e-08	1.68e-05	0.39	0.33	Sum eosinophil basophil counts;	chr2:65449559	chr2:65500993~65502138:-
KIRP	cis	rs4356975	0.583	rs4632729	ENSG00000248763.2	RP13-644M16.5	-5.73	2.82e-08	1.68e-05	-0.35	-0.33	Obesity-related traits;	chr4:69080286	chr4:69066395~69069888:+
KIRP	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	5.73	2.82e-08	1.68e-05	0.43	0.33	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	5.73	2.82e-08	1.68e-05	0.43	0.33	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	5.73	2.82e-08	1.68e-05	0.43	0.33	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
KIRP	cis	rs2486288	0.656	rs8037583	ENSG00000259433.2	CTD-2651B20.4	5.73	2.82e-08	1.68e-05	0.29	0.33	Glomerular filtration rate;	chr15:45254180	chr15:45330209~45332634:-
KIRP	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-5.73	2.82e-08	1.68e-05	-0.36	-0.33	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
KIRP	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	5.73	2.82e-08	1.68e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
KIRP	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
KIRP	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	5.73	2.82e-08	1.68e-05	0.41	0.33	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
KIRP	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	5.72	2.83e-08	1.68e-05	0.36	0.33	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
KIRP	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	5.72	2.83e-08	1.68e-05	0.3	0.33	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
KIRP	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	5.72	2.83e-08	1.68e-05	0.52	0.33	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
KIRP	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	5.72	2.83e-08	1.69e-05	0.41	0.33	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
KIRP	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-5.72	2.84e-08	1.69e-05	-0.37	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
KIRP	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-5.72	2.84e-08	1.69e-05	-0.43	-0.33	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
KIRP	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-5.72	2.84e-08	1.69e-05	-0.4	-0.33	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.72	2.84e-08	1.69e-05	0.28	0.33	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.72	2.84e-08	1.69e-05	0.28	0.33	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.72	2.84e-08	1.69e-05	0.28	0.33	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
KIRP	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	5.72	2.85e-08	1.69e-05	0.41	0.33	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	5.72	2.85e-08	1.69e-05	0.27	0.33	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
KIRP	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-5.72	2.85e-08	1.69e-05	-0.37	-0.33	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
KIRP	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	5.72	2.86e-08	1.7e-05	0.46	0.33	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
KIRP	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	5.72	2.86e-08	1.7e-05	0.29	0.33	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
KIRP	cis	rs6480314	0.542	rs4403687	ENSG00000233590.1	RP11-153K11.3	-5.72	2.86e-08	1.7e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68268295	chr10:68233251~68242379:-
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.72	2.87e-08	1.7e-05	0.28	0.33	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.72	2.87e-08	1.7e-05	0.28	0.33	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
KIRP	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.72	2.87e-08	1.7e-05	0.29	0.33	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
KIRP	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	5.72	2.87e-08	1.7e-05	0.42	0.33	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
KIRP	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	5.72	2.87e-08	1.7e-05	0.42	0.33	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
KIRP	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	5.72	2.87e-08	1.71e-05	0.4	0.33	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
KIRP	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	5.72	2.88e-08	1.71e-05	0.37	0.33	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
KIRP	cis	rs2439831	0.681	rs2278858	ENSG00000249839.1	AC011330.5	-5.72	2.88e-08	1.71e-05	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43340557	chr15:43663654~43684339:-
KIRP	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	5.72	2.88e-08	1.71e-05	0.44	0.33	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
KIRP	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-5.72	2.88e-08	1.71e-05	-0.34	-0.33	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
KIRP	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-5.72	2.88e-08	1.71e-05	-0.46	-0.33	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-5.72	2.88e-08	1.71e-05	-0.46	-0.33	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-5.72	2.88e-08	1.71e-05	-0.46	-0.33	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	5.72	2.89e-08	1.71e-05	0.45	0.33	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
KIRP	cis	rs6480314	0.542	rs79081413	ENSG00000233590.1	RP11-153K11.3	-5.72	2.89e-08	1.72e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68268746	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs17231630	ENSG00000233590.1	RP11-153K11.3	-5.72	2.89e-08	1.72e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68268960	chr10:68233251~68242379:-
KIRP	cis	rs2625529	0.529	rs1552133	ENSG00000260037.4	CTD-2524L6.3	5.72	2.9e-08	1.72e-05	0.26	0.33	Red blood cell count;	chr15:71940556	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.556	rs1552134	ENSG00000260037.4	CTD-2524L6.3	5.72	2.9e-08	1.72e-05	0.26	0.33	Red blood cell count;	chr15:71940557	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-5.72	2.9e-08	1.72e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-5.72	2.9e-08	1.72e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
KIRP	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	5.72	2.9e-08	1.72e-05	0.39	0.33	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-5.72	2.9e-08	1.72e-05	-0.27	-0.33	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
KIRP	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	5.72	2.9e-08	1.72e-05	0.26	0.33	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
KIRP	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	5.72	2.91e-08	1.72e-05	0.23	0.33	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
KIRP	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	5.72	2.91e-08	1.72e-05	0.28	0.33	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
KIRP	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-5.72	2.91e-08	1.72e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
KIRP	cis	rs2625529	0.668	rs72733369	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.91e-08	1.72e-05	-0.29	-0.33	Red blood cell count;	chr15:72274919	chr15:71818396~71823384:+
KIRP	cis	rs2976388	0.578	rs3758081	ENSG00000253741.1	CTD-2292P10.4	5.72	2.91e-08	1.73e-05	0.44	0.33	Urinary tract infection frequency;	chr8:142742955	chr8:142702252~142726973:-
KIRP	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	5.72	2.91e-08	1.73e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
KIRP	cis	rs2625529	0.824	rs4776581	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.92e-08	1.73e-05	-0.29	-0.33	Red blood cell count;	chr15:71914730	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4777470	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.92e-08	1.73e-05	-0.29	-0.33	Red blood cell count;	chr15:71915177	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.761	rs4776582	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.92e-08	1.73e-05	-0.29	-0.33	Red blood cell count;	chr15:71915179	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4777471	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.92e-08	1.73e-05	-0.29	-0.33	Red blood cell count;	chr15:71915463	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12906711	ENSG00000260037.4	CTD-2524L6.3	-5.72	2.92e-08	1.73e-05	-0.29	-0.33	Red blood cell count;	chr15:71922724	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-5.72	2.92e-08	1.73e-05	-0.33	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
KIRP	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-5.72	2.93e-08	1.73e-05	-0.33	-0.33	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
KIRP	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	5.72	2.94e-08	1.74e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
KIRP	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-5.72	2.94e-08	1.74e-05	-0.46	-0.33	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
KIRP	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	5.72	2.94e-08	1.74e-05	0.34	0.33	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
KIRP	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-5.72	2.94e-08	1.74e-05	-0.34	-0.33	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
KIRP	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-5.72	2.94e-08	1.74e-05	-0.34	-0.33	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
KIRP	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	5.72	2.94e-08	1.74e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.72	2.95e-08	1.74e-05	0.28	0.33	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.72	2.95e-08	1.74e-05	0.28	0.33	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
KIRP	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	5.72	2.95e-08	1.74e-05	0.31	0.33	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
KIRP	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	5.72	2.95e-08	1.74e-05	0.39	0.33	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
KIRP	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-5.72	2.95e-08	1.75e-05	-0.4	-0.33	Depression;	chr6:28193021	chr6:28115628~28116551:+
KIRP	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	5.72	2.95e-08	1.75e-05	0.41	0.33	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
KIRP	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	5.72	2.95e-08	1.75e-05	0.64	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
KIRP	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-5.72	2.96e-08	1.75e-05	-0.46	-0.33	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
KIRP	cis	rs1799949	1	rs8176234	ENSG00000236383.6	LINC00854	-5.72	2.96e-08	1.75e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43067763	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176233	ENSG00000236383.6	LINC00854	-5.72	2.96e-08	1.75e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43067787	chr17:43216941~43305976:-
KIRP	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	5.72	2.96e-08	1.75e-05	0.41	0.33	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
KIRP	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	5.72	2.96e-08	1.75e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-5.72	2.96e-08	1.75e-05	-0.35	-0.33	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
KIRP	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	5.72	2.96e-08	1.75e-05	0.34	0.33	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	5.72	2.96e-08	1.75e-05	0.34	0.33	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	5.72	2.96e-08	1.75e-05	0.34	0.33	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.72	2.97e-08	1.75e-05	0.28	0.33	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
KIRP	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-5.72	2.97e-08	1.75e-05	-0.34	-0.33	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
KIRP	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	5.72	2.97e-08	1.76e-05	0.43	0.33	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
KIRP	cis	rs710913	0.587	rs6690413	ENSG00000237624.1	OXCT2P1	5.72	2.98e-08	1.76e-05	0.42	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39514956~39516490:+
KIRP	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-5.71	2.98e-08	1.76e-05	-0.41	-0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
KIRP	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-5.71	2.98e-08	1.76e-05	-0.34	-0.33	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	5.71	2.98e-08	1.76e-05	0.34	0.33	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
KIRP	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	5.71	2.98e-08	1.76e-05	0.34	0.33	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
KIRP	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-5.71	2.98e-08	1.76e-05	-0.35	-0.33	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
KIRP	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	5.71	2.99e-08	1.76e-05	0.46	0.33	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
KIRP	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	5.71	2.99e-08	1.76e-05	0.39	0.33	Height;	chr4:55415153	chr4:55363971~55395847:-
KIRP	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	5.71	2.99e-08	1.77e-05	0.34	0.33	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
KIRP	cis	rs8067545	0.641	rs203466	ENSG00000270091.1	RP11-78O7.2	5.71	2.99e-08	1.77e-05	0.22	0.33	Schizophrenia;	chr17:19906640	chr17:19896590~19897287:-
KIRP	cis	rs7586673	0.964	rs34444368	ENSG00000235724.7	AC009299.2	-5.71	2.99e-08	1.77e-05	-0.41	-0.33	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161222785~161308303:-
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	5.71	2.99e-08	1.77e-05	0.26	0.33	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
KIRP	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	5.71	3e-08	1.77e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	5.71	3e-08	1.77e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	5.71	3e-08	1.77e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	5.71	3e-08	1.77e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	5.71	3e-08	1.77e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
KIRP	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-5.71	3e-08	1.77e-05	-0.34	-0.33	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
KIRP	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	5.71	3e-08	1.77e-05	0.35	0.33	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
KIRP	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	5.71	3.01e-08	1.78e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	5.71	3.01e-08	1.78e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	5.71	3.01e-08	1.78e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	5.71	3.01e-08	1.78e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	5.71	3.01e-08	1.78e-05	0.35	0.33	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
KIRP	cis	rs5758659	1	rs134900	ENSG00000205702.9	CYP2D7	5.71	3.01e-08	1.78e-05	0.24	0.33	Cognitive function;	chr22:42287337	chr22:42140203~42144577:-
KIRP	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	5.71	3.02e-08	1.78e-05	0.36	0.33	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
KIRP	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	5.71	3.02e-08	1.78e-05	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
KIRP	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-5.71	3.02e-08	1.78e-05	-0.36	-0.33	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
KIRP	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-5.71	3.02e-08	1.78e-05	-0.36	-0.33	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
KIRP	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-5.71	3.02e-08	1.78e-05	-0.29	-0.33	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-5.71	3.02e-08	1.78e-05	-0.29	-0.33	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-5.71	3.02e-08	1.78e-05	-0.29	-0.33	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
KIRP	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-5.71	3.03e-08	1.78e-05	-0.36	-0.33	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
KIRP	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	5.71	3.03e-08	1.79e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
KIRP	cis	rs1799949	1	rs8176126	ENSG00000236383.6	LINC00854	5.71	3.03e-08	1.79e-05	0.27	0.33	Menopause (age at onset);	chr17:43107032	chr17:43216941~43305976:-
KIRP	cis	rs2625529	0.504	rs11072349	ENSG00000260037.4	CTD-2524L6.3	5.71	3.03e-08	1.79e-05	0.26	0.33	Red blood cell count;	chr15:72172130	chr15:71818396~71823384:+
KIRP	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-5.71	3.03e-08	1.79e-05	-0.36	-0.33	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
KIRP	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	5.71	3.04e-08	1.79e-05	0.36	0.33	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
KIRP	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	5.71	3.04e-08	1.79e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	5.71	3.04e-08	1.79e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
KIRP	cis	rs7267979	1	rs4815404	ENSG00000274414.1	RP5-965G21.4	5.71	3.04e-08	1.79e-05	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083805	ENSG00000274414.1	RP5-965G21.4	5.71	3.04e-08	1.79e-05	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs7018	ENSG00000274414.1	RP5-965G21.4	-5.71	3.04e-08	1.79e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25239007~25245229:-
KIRP	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	5.71	3.05e-08	1.8e-05	0.43	0.33	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	5.71	3.05e-08	1.8e-05	0.41	0.33	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	5.71	3.05e-08	1.8e-05	0.41	0.33	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	5.71	3.05e-08	1.8e-05	0.41	0.33	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
KIRP	cis	rs10050311	1	rs10050311	ENSG00000251411.1	RP11-397E7.4	-5.71	3.06e-08	1.8e-05	-0.38	-0.33	Insulin-related traits;	chr4:86833266	chr4:86913266~86914817:-
KIRP	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	5.71	3.06e-08	1.8e-05	0.25	0.33	Height;	chr20:35190631	chr20:35201747~35203288:-
KIRP	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	5.71	3.06e-08	1.8e-05	0.38	0.33	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	5.71	3.06e-08	1.8e-05	0.38	0.33	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
KIRP	cis	rs72634501	0.716	rs2036465	ENSG00000237624.1	OXCT2P1	-5.71	3.06e-08	1.81e-05	-0.54	-0.33	HDL cholesterol;	chr1:39110310	chr1:39514956~39516490:+
KIRP	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	5.71	3.07e-08	1.81e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
KIRP	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-5.71	3.07e-08	1.81e-05	-0.37	-0.33	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
KIRP	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-5.71	3.07e-08	1.81e-05	-0.41	-0.33	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
KIRP	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	5.71	3.08e-08	1.81e-05	0.26	0.33	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
KIRP	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-5.71	3.08e-08	1.81e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
KIRP	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-5.71	3.08e-08	1.82e-05	-0.35	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
KIRP	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	5.71	3.08e-08	1.82e-05	0.32	0.33	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
KIRP	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	5.71	3.09e-08	1.82e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
KIRP	cis	rs7267979	0.966	rs4813557	ENSG00000274414.1	RP5-965G21.4	5.71	3.09e-08	1.82e-05	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25239007~25245229:-
KIRP	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-5.71	3.09e-08	1.82e-05	-0.37	-0.33	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-5.71	3.09e-08	1.82e-05	-0.37	-0.33	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-5.71	3.09e-08	1.82e-05	-0.37	-0.33	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
KIRP	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	5.71	3.09e-08	1.82e-05	0.26	0.33	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	5.71	3.09e-08	1.82e-05	0.25	0.33	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
KIRP	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	5.71	3.09e-08	1.82e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
KIRP	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-5.71	3.09e-08	1.82e-05	-0.31	-0.33	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
KIRP	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	5.71	3.1e-08	1.82e-05	0.34	0.33	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
KIRP	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	5.71	3.1e-08	1.82e-05	0.34	0.33	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
KIRP	cis	rs4638749	0.677	rs7370742	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108198929	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs9631035	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108202460	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.651	rs13385677	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108209696	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10203004	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108210079	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs34449318	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108210766	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs6713634	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108211451	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10189396	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108213181	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs2100407	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108213732	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs7568919	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108215920	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs1522021	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108216807	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.627	rs1522020	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108216890	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs6757761	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108218386	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs7595399	ENSG00000231221.1	AC023672.2	-5.71	3.1e-08	1.82e-05	-0.39	-0.33	Blood pressure;	chr2:108219487	chr2:108049200~108052755:-
KIRP	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-5.71	3.1e-08	1.82e-05	-0.67	-0.33	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
KIRP	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-5.71	3.1e-08	1.82e-05	-0.46	-0.33	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
KIRP	cis	rs1560104	0.536	rs12446050	ENSG00000274834.1	CTD-3037G24.5	-5.71	3.11e-08	1.83e-05	-0.37	-0.33	Obesity-related traits;	chr16:12621408	chr16:12614451~12614852:+
KIRP	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	5.71	3.11e-08	1.83e-05	0.28	0.33	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
KIRP	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	5.71	3.11e-08	1.83e-05	0.41	0.33	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
KIRP	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	5.71	3.11e-08	1.83e-05	0.38	0.33	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
KIRP	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	5.71	3.11e-08	1.83e-05	0.23	0.33	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
KIRP	cis	rs1799949	1	rs915945	ENSG00000236383.6	LINC00854	-5.71	3.11e-08	1.83e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43027847	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12944597	ENSG00000236383.6	LINC00854	-5.71	3.11e-08	1.83e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43035667	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12942277	ENSG00000236383.6	LINC00854	-5.71	3.11e-08	1.83e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43035957	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs34616041	ENSG00000236383.6	LINC00854	-5.71	3.11e-08	1.83e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43036769	chr17:43216941~43305976:-
KIRP	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	5.71	3.12e-08	1.83e-05	0.55	0.33	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
KIRP	cis	rs1799949	0.965	rs33961729	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43135907	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11657835	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43139936	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1135214	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43140306	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793212	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43150733	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs34534709	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43150923	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs34059614	ENSG00000236383.6	LINC00854	-5.71	3.12e-08	1.83e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43151054	chr17:43216941~43305976:-
KIRP	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-5.71	3.12e-08	1.83e-05	-0.32	-0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
KIRP	cis	rs897984	0.806	rs11150600	ENSG00000275263.1	RP11-1072A3.4	5.71	3.12e-08	1.83e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30929010	chr16:30956872~30957199:-
KIRP	cis	rs1560104	0.619	rs3829519	ENSG00000274834.1	CTD-3037G24.5	5.71	3.12e-08	1.83e-05	0.37	0.33	Obesity-related traits;	chr16:12614854	chr16:12614451~12614852:+
KIRP	cis	rs897984	0.762	rs1870293	ENSG00000275263.1	RP11-1072A3.4	5.71	3.12e-08	1.83e-05	0.36	0.33	Dementia with Lewy bodies;	chr16:30959620	chr16:30956872~30957199:-
KIRP	cis	rs67517081	1	rs67517081	ENSG00000275263.1	RP11-1072A3.4	5.71	3.12e-08	1.83e-05	0.36	0.33	Mean corpuscular hemoglobin;	chr16:30976060	chr16:30956872~30957199:-
KIRP	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-5.71	3.12e-08	1.83e-05	-0.39	-0.33	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
KIRP	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	5.71	3.12e-08	1.84e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
KIRP	cis	rs4638749	0.501	rs6708539	ENSG00000231221.1	AC023672.2	-5.71	3.13e-08	1.84e-05	-0.39	-0.33	Blood pressure;	chr2:108128586	chr2:108049200~108052755:-
KIRP	cis	rs61457372	0.545	rs9789073	ENSG00000264026.1	RP11-1124B17.1	5.71	3.13e-08	1.84e-05	0.35	0.33	Triptolide cytotoxicity;	chr17:72350476	chr17:72342940~72355136:+
KIRP	cis	rs7267979	1	rs7019	ENSG00000274414.1	RP5-965G21.4	-5.7	3.14e-08	1.84e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2424710	ENSG00000274414.1	RP5-965G21.4	-5.7	3.14e-08	1.84e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6115140	ENSG00000274414.1	RP5-965G21.4	-5.7	3.14e-08	1.84e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs1888997	ENSG00000274414.1	RP5-965G21.4	5.7	3.14e-08	1.84e-05	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs3002698	ENSG00000274414.1	RP5-965G21.4	5.7	3.14e-08	1.84e-05	0.32	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25239007~25245229:-
KIRP	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
KIRP	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-5.7	3.14e-08	1.84e-05	-0.45	-0.33	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
KIRP	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-5.7	3.14e-08	1.85e-05	-0.46	-0.33	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	5.7	3.14e-08	1.85e-05	0.38	0.33	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
KIRP	cis	rs9601248	0.756	rs7997134	ENSG00000227676.3	LINC01068	-5.7	3.17e-08	1.86e-05	-0.38	-0.33	Major depressive disorder;	chr13:79619594	chr13:79566727~79571436:+
KIRP	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	5.7	3.17e-08	1.86e-05	0.28	0.33	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
KIRP	cis	rs1799949	1	rs4793197	ENSG00000236383.6	LINC00854	-5.7	3.18e-08	1.86e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43079885	chr17:43216941~43305976:-
KIRP	cis	rs710913	0.717	rs2068473	ENSG00000237624.1	OXCT2P1	-5.7	3.18e-08	1.86e-05	-0.39	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39514956~39516490:+
KIRP	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-5.7	3.19e-08	1.86e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	5.7	3.19e-08	1.86e-05	0.4	0.33	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	5.7	3.19e-08	1.87e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
KIRP	cis	rs9915657	0.773	rs9896360	ENSG00000234899.8	SOX9-AS1	-5.7	3.19e-08	1.87e-05	-0.27	-0.33	Thyroid hormone levels;	chr17:72103328	chr17:72034107~72237203:-
KIRP	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	5.7	3.19e-08	1.87e-05	0.37	0.33	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
KIRP	cis	rs897984	0.806	rs9319588	ENSG00000275263.1	RP11-1072A3.4	5.7	3.2e-08	1.87e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30919662	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.77	rs12930657	ENSG00000275263.1	RP11-1072A3.4	5.7	3.2e-08	1.87e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30920647	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.77	rs3813020	ENSG00000275263.1	RP11-1072A3.4	5.7	3.2e-08	1.87e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30922754	chr16:30956872~30957199:-
KIRP	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-5.7	3.2e-08	1.87e-05	-0.36	-0.33	Height;	chr3:53064759	chr3:53064283~53065091:-
KIRP	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	5.7	3.2e-08	1.87e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	5.7	3.2e-08	1.87e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
KIRP	cis	rs7586673	0.93	rs7591506	ENSG00000235724.7	AC009299.2	-5.7	3.21e-08	1.88e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161222785~161308303:-
KIRP	cis	rs4638749	0.677	rs1563111	ENSG00000231221.1	AC023672.2	-5.7	3.21e-08	1.88e-05	-0.39	-0.33	Blood pressure;	chr2:108229261	chr2:108049200~108052755:-
KIRP	cis	rs9913711	0.868	rs7216619	ENSG00000234899.8	SOX9-AS1	-5.7	3.22e-08	1.88e-05	-0.29	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr17:72083567	chr17:72034107~72237203:-
KIRP	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	5.7	3.22e-08	1.88e-05	0.23	0.33	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
KIRP	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	5.7	3.22e-08	1.88e-05	0.23	0.33	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
KIRP	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	5.7	3.22e-08	1.88e-05	0.44	0.33	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
KIRP	cis	rs1799949	0.864	rs60309406	ENSG00000236383.6	LINC00854	-5.7	3.22e-08	1.88e-05	-0.28	-0.33	Menopause (age at onset);	chr17:43358297	chr17:43216941~43305976:-
KIRP	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.7	3.22e-08	1.88e-05	0.43	0.33	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	5.7	3.22e-08	1.88e-05	0.43	0.33	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	5.7	3.22e-08	1.88e-05	0.43	0.33	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	5.7	3.22e-08	1.88e-05	0.43	0.33	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
KIRP	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	5.7	3.23e-08	1.89e-05	0.52	0.33	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
KIRP	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	5.7	3.23e-08	1.89e-05	0.3	0.33	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
KIRP	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	5.7	3.23e-08	1.89e-05	0.59	0.33	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
KIRP	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	5.7	3.23e-08	1.89e-05	0.34	0.33	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
KIRP	cis	rs4356975	0.503	rs11938761	ENSG00000248763.2	RP13-644M16.5	-5.7	3.24e-08	1.89e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083992	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs11935886	ENSG00000248763.2	RP13-644M16.5	-5.7	3.24e-08	1.89e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083994	chr4:69066395~69069888:+
KIRP	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	5.7	3.24e-08	1.89e-05	0.42	0.33	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
KIRP	cis	rs7267979	1	rs7020	ENSG00000274414.1	RP5-965G21.4	-5.7	3.24e-08	1.9e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25239007~25245229:-
KIRP	cis	rs1200821	0.535	rs1938417	ENSG00000151963.4	RP11-775A3.1	5.7	3.25e-08	1.9e-05	0.36	0.33	Hemostatic factors and hematological phenotypes;	chr10:37398592	chr10:37883594~37884109:+
KIRP	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	5.7	3.25e-08	1.9e-05	0.36	0.33	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
KIRP	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	5.7	3.25e-08	1.9e-05	0.37	0.33	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
KIRP	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	5.7	3.25e-08	1.9e-05	0.44	0.33	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
KIRP	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	5.7	3.26e-08	1.9e-05	0.36	0.33	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
KIRP	cis	rs2948294	0.566	rs13274039	ENSG00000253981.4	ALG1L13P	5.7	3.26e-08	1.9e-05	0.3	0.33	Red cell distribution width;	chr8:8254137	chr8:8236003~8244667:-
KIRP	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-5.7	3.27e-08	1.91e-05	-0.38	-0.33	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
KIRP	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-5.7	3.27e-08	1.91e-05	-0.38	-0.33	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
KIRP	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-5.7	3.27e-08	1.91e-05	-0.41	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
KIRP	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	5.7	3.27e-08	1.91e-05	0.43	0.33	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
KIRP	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-5.7	3.28e-08	1.91e-05	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
KIRP	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	5.7	3.28e-08	1.91e-05	0.32	0.33	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
KIRP	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	5.7	3.28e-08	1.91e-05	0.28	0.33	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	5.7	3.28e-08	1.91e-05	0.28	0.33	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	5.7	3.28e-08	1.91e-05	0.28	0.33	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
KIRP	cis	rs4638749	0.677	rs13414687	ENSG00000231221.1	AC023672.2	-5.7	3.28e-08	1.91e-05	-0.39	-0.33	Blood pressure;	chr2:108189789	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs13389470	ENSG00000231221.1	AC023672.2	-5.7	3.28e-08	1.91e-05	-0.39	-0.33	Blood pressure;	chr2:108189845	chr2:108049200~108052755:-
KIRP	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-5.7	3.29e-08	1.92e-05	-0.34	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
KIRP	cis	rs2625529	0.824	rs2306488	ENSG00000260037.4	CTD-2524L6.3	-5.7	3.29e-08	1.92e-05	-0.29	-0.33	Red blood cell count;	chr15:71999774	chr15:71818396~71823384:+
KIRP	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	5.7	3.29e-08	1.92e-05	0.4	0.33	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
KIRP	cis	rs9915657	0.773	rs9912974	ENSG00000234899.8	SOX9-AS1	-5.7	3.29e-08	1.92e-05	-0.27	-0.33	Thyroid hormone levels;	chr17:72099822	chr17:72034107~72237203:-
KIRP	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	5.7	3.3e-08	1.92e-05	0.33	0.33	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	5.7	3.3e-08	1.92e-05	0.33	0.33	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	5.7	3.3e-08	1.92e-05	0.33	0.33	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
KIRP	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-5.7	3.3e-08	1.92e-05	-0.28	-0.33	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
KIRP	cis	rs78905543	0.967	rs4242388	ENSG00000253616.4	RP11-875O11.3	5.69	3.32e-08	1.93e-05	0.38	0.33	Mean corpuscular volume;	chr8:23075198	chr8:23071377~23074488:-
KIRP	cis	rs2765539	0.7	rs4659147	ENSG00000231365.4	RP11-418J17.1	-5.69	3.32e-08	1.93e-05	-0.37	-0.33	Waist-hip ratio;	chr1:119103412	chr1:119140396~119275973:+
KIRP	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-5.69	3.32e-08	1.94e-05	-0.45	-0.33	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
KIRP	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	5.69	3.33e-08	1.94e-05	0.37	0.33	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
KIRP	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-5.69	3.33e-08	1.94e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
KIRP	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-5.69	3.33e-08	1.94e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
KIRP	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-5.69	3.33e-08	1.94e-05	-0.36	-0.33	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
KIRP	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	5.69	3.33e-08	1.94e-05	0.28	0.33	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
KIRP	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	5.69	3.33e-08	1.94e-05	0.44	0.33	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
KIRP	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-5.69	3.33e-08	1.94e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
KIRP	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-5.69	3.34e-08	1.94e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-5.69	3.34e-08	1.94e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
KIRP	cis	rs1799949	0.965	rs9646413	ENSG00000236383.6	LINC00854	-5.69	3.34e-08	1.94e-05	-0.25	-0.33	Menopause (age at onset);	chr17:43348789	chr17:43216941~43305976:-
KIRP	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-5.69	3.34e-08	1.94e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-5.69	3.34e-08	1.94e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-5.69	3.34e-08	1.94e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
KIRP	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	5.69	3.34e-08	1.95e-05	0.42	0.33	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
KIRP	cis	rs2976388	0.556	rs10956985	ENSG00000253741.1	CTD-2292P10.4	5.69	3.34e-08	1.95e-05	0.43	0.33	Urinary tract infection frequency;	chr8:142737332	chr8:142702252~142726973:-
KIRP	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-5.69	3.35e-08	1.95e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
KIRP	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	5.69	3.35e-08	1.95e-05	0.34	0.33	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	5.69	3.35e-08	1.95e-05	0.34	0.33	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	5.69	3.35e-08	1.95e-05	0.34	0.33	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
KIRP	cis	rs7267979	0.933	rs1130694	ENSG00000274414.1	RP5-965G21.4	-5.69	3.35e-08	1.95e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25239007~25245229:-
KIRP	cis	rs1552244	0.882	rs55808392	ENSG00000180385.7	EMC3-AS1	5.69	3.36e-08	1.95e-05	0.33	0.33	Alzheimer's disease;	chr3:10012997	chr3:9986893~10006990:+
KIRP	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-5.69	3.36e-08	1.95e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-5.69	3.36e-08	1.95e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
KIRP	cis	rs7829975	0.502	rs11785183	ENSG00000253893.2	FAM85B	5.69	3.36e-08	1.95e-05	0.43	0.33	Mood instability;	chr8:8708447	chr8:8167819~8226614:-
KIRP	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	5.69	3.36e-08	1.95e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	5.69	3.36e-08	1.95e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	5.69	3.36e-08	1.95e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	5.69	3.36e-08	1.95e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
KIRP	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-5.69	3.36e-08	1.95e-05	-0.45	-0.33	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-5.69	3.36e-08	1.95e-05	-0.45	-0.33	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
KIRP	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-5.69	3.37e-08	1.96e-05	-0.47	-0.33	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
KIRP	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	5.69	3.37e-08	1.96e-05	0.43	0.33	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
KIRP	cis	rs2625529	0.652	rs2415128	ENSG00000260037.4	CTD-2524L6.3	5.69	3.37e-08	1.96e-05	0.26	0.33	Red blood cell count;	chr15:71898732	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	5.69	3.37e-08	1.96e-05	0.43	0.33	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
KIRP	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-5.69	3.37e-08	1.96e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
KIRP	cis	rs1799949	0.501	rs2343819	ENSG00000236383.6	LINC00854	-5.69	3.37e-08	1.96e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43332285	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.501	rs35399157	ENSG00000236383.6	LINC00854	-5.69	3.37e-08	1.96e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43334234	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.602	rs4600503	ENSG00000236383.6	LINC00854	-5.69	3.37e-08	1.96e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43336956	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.501	rs9675035	ENSG00000236383.6	LINC00854	-5.69	3.37e-08	1.96e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43337648	chr17:43216941~43305976:-
KIRP	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	5.69	3.37e-08	1.96e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
KIRP	cis	rs79040073	0.637	rs61442055	ENSG00000259531.2	RP11-295H24.3	5.69	3.38e-08	1.96e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49156901	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11632211	ENSG00000259531.2	RP11-295H24.3	5.69	3.38e-08	1.96e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49159178	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73390343	ENSG00000259531.2	RP11-295H24.3	5.69	3.38e-08	1.96e-05	0.46	0.33	Lung cancer in ever smokers;	chr15:49164026	chr15:49365124~49366685:-
KIRP	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-5.69	3.38e-08	1.97e-05	-0.3	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
KIRP	cis	rs2625529	0.762	rs1384007	ENSG00000260037.4	CTD-2524L6.3	-5.69	3.39e-08	1.97e-05	-0.29	-0.33	Red blood cell count;	chr15:71937193	chr15:71818396~71823384:+
KIRP	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	5.69	3.39e-08	1.97e-05	0.27	0.33	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
KIRP	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-5.69	3.39e-08	1.97e-05	-0.34	-0.33	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
KIRP	cis	rs3892630	0.878	rs8108621	ENSG00000267475.1	CTD-2538C1.2	-5.69	3.41e-08	1.98e-05	-0.45	-0.33	Red blood cell traits;	chr19:32692385	chr19:32687089~32691750:-
KIRP	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	5.69	3.41e-08	1.98e-05	0.45	0.33	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
KIRP	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-5.69	3.41e-08	1.98e-05	-0.28	-0.33	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
KIRP	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	5.69	3.41e-08	1.98e-05	0.25	0.33	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
KIRP	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-5.69	3.42e-08	1.99e-05	-0.28	-0.33	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
KIRP	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-5.69	3.42e-08	1.99e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	5.69	3.44e-08	2e-05	0.4	0.33	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
KIRP	cis	rs712022	1	rs1019217	ENSG00000246225.5	RP11-17A1.3	5.69	3.44e-08	2e-05	0.37	0.33	Dialysis-related mortality;	chr11:22821076	chr11:22829380~22945393:+
KIRP	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-5.69	3.44e-08	2e-05	-0.36	-0.33	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
KIRP	cis	rs9376098	0.734	rs7765438	ENSG00000232876.1	CTA-212D2.2	-5.69	3.45e-08	2e-05	-0.38	-0.33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135156199	chr6:135055033~135060550:+
KIRP	cis	rs7829975	0.658	rs907181	ENSG00000253981.4	ALG1L13P	5.69	3.45e-08	2e-05	0.25	0.33	Mood instability;	chr8:8845365	chr8:8236003~8244667:-
KIRP	cis	rs947583	0.955	rs927330	ENSG00000231028.7	LINC00271	5.69	3.45e-08	2e-05	0.3	0.33	Phosphorus levels;	chr6:135810618	chr6:135497801~135716055:+
KIRP	cis	rs1799949	1	rs8176120	ENSG00000236383.6	LINC00854	-5.69	3.45e-08	2e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43109216	chr17:43216941~43305976:-
KIRP	cis	rs8053891	0.507	rs10852510	ENSG00000260886.1	TAT-AS1	5.69	3.46e-08	2.01e-05	0.46	0.33	Coronary artery disease;	chr16:71992142	chr16:71565789~71578187:+
KIRP	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	5.69	3.46e-08	2.01e-05	0.31	0.33	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
KIRP	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	5.69	3.47e-08	2.01e-05	0.26	0.33	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
KIRP	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-5.69	3.47e-08	2.01e-05	-0.34	-0.33	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
KIRP	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	5.69	3.48e-08	2.02e-05	0.34	0.33	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
KIRP	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	5.69	3.48e-08	2.02e-05	0.41	0.33	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
KIRP	cis	rs1150668	0.768	rs1150709	ENSG00000204709.4	LINC01556	-5.69	3.48e-08	2.02e-05	-0.41	-0.33	Pubertal anthropometrics;	chr6:28239585	chr6:28943877~28944537:+
KIRP	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-5.68	3.49e-08	2.02e-05	-0.35	-0.33	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
KIRP	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	5.68	3.49e-08	2.02e-05	0.25	0.33	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
KIRP	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	5.68	3.5e-08	2.03e-05	0.31	0.33	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
KIRP	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-5.68	3.5e-08	2.03e-05	-0.25	-0.33	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
KIRP	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	5.68	3.5e-08	2.03e-05	0.41	0.33	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
KIRP	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-5.68	3.5e-08	2.03e-05	-0.24	-0.33	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
KIRP	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	5.68	3.51e-08	2.03e-05	0.42	0.33	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
KIRP	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-5.68	3.51e-08	2.03e-05	-0.33	-0.33	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
KIRP	cis	rs7267979	1	rs11087520	ENSG00000274414.1	RP5-965G21.4	-5.68	3.51e-08	2.04e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs398036	ENSG00000274414.1	RP5-965G21.4	-5.68	3.51e-08	2.04e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs397119	ENSG00000274414.1	RP5-965G21.4	-5.68	3.51e-08	2.04e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25239007~25245229:-
KIRP	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-5.68	3.51e-08	2.04e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
KIRP	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	5.68	3.51e-08	2.04e-05	0.46	0.33	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	5.68	3.51e-08	2.04e-05	0.46	0.33	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	5.68	3.51e-08	2.04e-05	0.46	0.33	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
KIRP	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-5.68	3.51e-08	2.04e-05	-0.3	-0.33	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
KIRP	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	5.68	3.51e-08	2.04e-05	0.72	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
KIRP	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	5.68	3.52e-08	2.04e-05	0.75	0.33	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
KIRP	cis	rs1799949	0.894	rs71367985	ENSG00000236383.6	LINC00854	-5.68	3.52e-08	2.04e-05	-0.25	-0.33	Menopause (age at onset);	chr17:43222443	chr17:43216941~43305976:-
KIRP	cis	rs2486288	0.656	rs2413774	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45257225	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs2413773	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45257244	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11637838	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258459	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11632724	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258593	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11632651	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258640	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11637920	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258707	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11632777	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258847	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11632778	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258858	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11632752	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45258942	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs12911186	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45259225	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs12915314	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45259293	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs8039138	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45259394	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs8039540	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45259644	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs8040185	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45259883	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs1060896	ENSG00000259433.2	CTD-2651B20.4	5.68	3.52e-08	2.04e-05	0.28	0.33	Glomerular filtration rate;	chr15:45262069	chr15:45330209~45332634:-
KIRP	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	5.68	3.52e-08	2.04e-05	0.37	0.33	Depression;	chr6:28407125	chr6:28176188~28176674:+
KIRP	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	5.68	3.52e-08	2.04e-05	0.42	0.33	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
KIRP	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-5.68	3.53e-08	2.04e-05	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
KIRP	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	5.68	3.53e-08	2.05e-05	0.34	0.33	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
KIRP	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-5.68	3.54e-08	2.05e-05	-0.37	-0.33	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
KIRP	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-5.68	3.54e-08	2.05e-05	-0.28	-0.33	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
KIRP	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-5.68	3.54e-08	2.05e-05	-0.44	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
KIRP	cis	rs6085948	0.861	rs6117729	ENSG00000238102.1	RP11-19D2.1	-5.68	3.55e-08	2.06e-05	-0.43	-0.33	Interleukin-10 levels;	chr20:7267542	chr20:7256580~7258214:-
KIRP	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-5.68	3.55e-08	2.06e-05	-0.38	-0.33	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
KIRP	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-5.68	3.55e-08	2.06e-05	-0.38	-0.33	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
KIRP	cis	rs710913	0.604	rs1180343	ENSG00000237624.1	OXCT2P1	-5.68	3.55e-08	2.06e-05	-0.39	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39514956~39516490:+
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	5.68	3.56e-08	2.06e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
KIRP	cis	rs2625529	0.824	rs12903484	ENSG00000260037.4	CTD-2524L6.3	-5.68	3.56e-08	2.06e-05	-0.28	-0.33	Red blood cell count;	chr15:72007140	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs4777480	ENSG00000260037.4	CTD-2524L6.3	-5.68	3.56e-08	2.06e-05	-0.28	-0.33	Red blood cell count;	chr15:72036656	chr15:71818396~71823384:+
KIRP	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	5.68	3.56e-08	2.06e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
KIRP	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-5.68	3.56e-08	2.06e-05	-0.28	-0.33	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
KIRP	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	5.68	3.57e-08	2.06e-05	0.38	0.33	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
KIRP	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	5.68	3.57e-08	2.06e-05	0.43	0.33	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
KIRP	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-5.68	3.57e-08	2.06e-05	-0.38	-0.33	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
KIRP	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.68	3.57e-08	2.07e-05	-0.28	-0.33	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.68	3.57e-08	2.07e-05	-0.28	-0.33	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
KIRP	cis	rs8053891	0.507	rs34150651	ENSG00000260886.1	TAT-AS1	5.68	3.57e-08	2.07e-05	0.46	0.33	Coronary artery disease;	chr16:71994213	chr16:71565789~71578187:+
KIRP	cis	rs8053891	0.507	rs66553600	ENSG00000260886.1	TAT-AS1	5.68	3.57e-08	2.07e-05	0.46	0.33	Coronary artery disease;	chr16:71994299	chr16:71565789~71578187:+
KIRP	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-5.68	3.57e-08	2.07e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-5.68	3.57e-08	2.07e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-5.68	3.57e-08	2.07e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
KIRP	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	5.68	3.58e-08	2.07e-05	0.58	0.33	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
KIRP	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	5.68	3.58e-08	2.07e-05	0.51	0.33	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
KIRP	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-5.68	3.59e-08	2.07e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-5.68	3.59e-08	2.07e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-5.68	3.59e-08	2.07e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-5.68	3.59e-08	2.07e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-5.68	3.59e-08	2.07e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
KIRP	cis	rs12908161	0.96	rs11633450	ENSG00000225151.9	GOLGA2P7	-5.68	3.6e-08	2.08e-05	-0.43	-0.33	Schizophrenia;	chr15:84764056	chr15:84199311~84230136:-
KIRP	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-5.68	3.6e-08	2.08e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
KIRP	cis	rs7267979	1	rs7267979	ENSG00000274414.1	RP5-965G21.4	-5.68	3.6e-08	2.08e-05	-0.31	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25239007~25245229:-
KIRP	cis	rs4356975	0.563	rs11932131	ENSG00000248763.2	RP13-644M16.5	-5.68	3.6e-08	2.08e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083829	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs35297888	ENSG00000248763.2	RP13-644M16.5	-5.68	3.6e-08	2.08e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083855	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs35749478	ENSG00000248763.2	RP13-644M16.5	-5.68	3.6e-08	2.08e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083862	chr4:69066395~69069888:+
KIRP	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	5.68	3.6e-08	2.08e-05	0.49	0.33	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
KIRP	cis	rs2617170	1	rs2617170	ENSG00000245648.1	RP11-277P12.20	-5.68	3.61e-08	2.09e-05	-0.38	-0.33	Behcet's disease;	chr12:10408358	chr12:10363769~10398506:+
KIRP	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	5.68	3.62e-08	2.09e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	5.68	3.62e-08	2.09e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
KIRP	cis	rs2283792	1	rs5749986	ENSG00000228050.1	TOP3BP1	-5.68	3.62e-08	2.09e-05	-0.35	-0.33	Multiple sclerosis;	chr22:21803372	chr22:22223187~22224566:-
KIRP	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-5.68	3.62e-08	2.09e-05	-0.34	-0.33	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
KIRP	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	5.68	3.62e-08	2.09e-05	0.34	0.33	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
KIRP	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	5.68	3.62e-08	2.09e-05	0.3	0.33	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	5.68	3.62e-08	2.09e-05	0.3	0.33	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
KIRP	cis	rs1799949	1	rs4793229	ENSG00000236383.6	LINC00854	5.68	3.63e-08	2.1e-05	0.27	0.33	Menopause (age at onset);	chr17:43340966	chr17:43216941~43305976:-
KIRP	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	5.68	3.63e-08	2.1e-05	0.35	0.33	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
KIRP	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-5.68	3.64e-08	2.1e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-5.68	3.64e-08	2.1e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-5.68	3.64e-08	2.1e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-5.68	3.64e-08	2.1e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
KIRP	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-5.68	3.64e-08	2.1e-05	-0.26	-0.33	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
KIRP	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	5.68	3.64e-08	2.1e-05	0.35	0.33	Height;	chr4:55387515	chr4:55363971~55395847:-
KIRP	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	5.68	3.64e-08	2.1e-05	0.56	0.33	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
KIRP	cis	rs6480314	0.542	rs61854816	ENSG00000233590.1	RP11-153K11.3	-5.68	3.64e-08	2.1e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68269051	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.542	rs10998045	ENSG00000233590.1	RP11-153K11.3	-5.68	3.64e-08	2.1e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68269626	chr10:68233251~68242379:-
KIRP	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-5.68	3.64e-08	2.1e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-5.68	3.64e-08	2.1e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-5.68	3.64e-08	2.1e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	5.68	3.65e-08	2.11e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
KIRP	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	5.68	3.65e-08	2.11e-05	0.43	0.33	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
KIRP	cis	rs4356975	0.509	rs10006452	ENSG00000250696.4	RP11-704M14.1	5.68	3.65e-08	2.11e-05	0.32	0.33	Obesity-related traits;	chr4:69112090	chr4:69182100~69216766:+
KIRP	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-5.68	3.66e-08	2.11e-05	-0.29	-0.33	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
KIRP	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	5.68	3.66e-08	2.11e-05	0.34	0.33	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
KIRP	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	5.68	3.67e-08	2.12e-05	0.43	0.33	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
KIRP	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-5.67	3.67e-08	2.12e-05	-0.35	-0.33	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
KIRP	cis	rs367615	0.918	rs115145487	ENSG00000249476.1	CTD-2587M2.1	5.67	3.67e-08	2.12e-05	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109552445	chr5:109237120~109326369:-
KIRP	cis	rs1858037	0.867	rs9789444	ENSG00000281920.1	RP11-418H16.1	5.67	3.68e-08	2.12e-05	0.43	0.33	Rheumatoid arthritis;	chr2:65342093	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.867	rs67817304	ENSG00000281920.1	RP11-418H16.1	5.67	3.68e-08	2.12e-05	0.43	0.33	Rheumatoid arthritis;	chr2:65346982	chr2:65623272~65628424:+
KIRP	cis	rs2625529	0.652	rs8028115	ENSG00000260037.4	CTD-2524L6.3	5.67	3.68e-08	2.12e-05	0.25	0.33	Red blood cell count;	chr15:72047162	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs8030815	ENSG00000260037.4	CTD-2524L6.3	5.67	3.68e-08	2.12e-05	0.25	0.33	Red blood cell count;	chr15:72110660	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	5.67	3.68e-08	2.12e-05	0.37	0.33	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.775	rs62023342	ENSG00000260037.4	CTD-2524L6.3	-5.67	3.68e-08	2.12e-05	-0.28	-0.33	Red blood cell count;	chr15:71868964	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.713	rs12903980	ENSG00000260037.4	CTD-2524L6.3	-5.67	3.68e-08	2.12e-05	-0.28	-0.33	Red blood cell count;	chr15:71873208	chr15:71818396~71823384:+
KIRP	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-5.67	3.69e-08	2.13e-05	-0.37	-0.33	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-5.67	3.69e-08	2.13e-05	-0.37	-0.33	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
KIRP	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	5.67	3.69e-08	2.13e-05	0.49	0.33	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
KIRP	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	5.67	3.71e-08	2.14e-05	0.25	0.33	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
KIRP	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-5.67	3.73e-08	2.15e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-5.67	3.73e-08	2.15e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-5.67	3.73e-08	2.15e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
KIRP	cis	rs7267979	1	rs2500432	ENSG00000274414.1	RP5-965G21.4	-5.67	3.73e-08	2.15e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25239007~25245229:-
KIRP	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-5.67	3.74e-08	2.15e-05	-0.43	-0.33	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
KIRP	cis	rs1799949	0.965	rs8176130	ENSG00000236383.6	LINC00854	-5.67	3.74e-08	2.16e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43106026	chr17:43216941~43305976:-
KIRP	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-5.67	3.75e-08	2.16e-05	-0.3	-0.33	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
KIRP	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	5.67	3.75e-08	2.16e-05	0.52	0.33	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
KIRP	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	5.67	3.75e-08	2.16e-05	0.37	0.33	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
KIRP	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	5.67	3.77e-08	2.17e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
KIRP	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-5.67	3.77e-08	2.17e-05	-0.34	-0.33	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-5.67	3.77e-08	2.17e-05	-0.34	-0.33	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
KIRP	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-5.67	3.77e-08	2.17e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
KIRP	cis	rs4638749	0.677	rs12712014	ENSG00000231221.1	AC023672.2	5.67	3.78e-08	2.17e-05	0.38	0.33	Blood pressure;	chr2:108195588	chr2:108049200~108052755:-
KIRP	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	5.67	3.78e-08	2.17e-05	0.4	0.33	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
KIRP	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-5.67	3.78e-08	2.17e-05	-0.35	-0.33	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-5.67	3.78e-08	2.17e-05	-0.35	-0.33	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
KIRP	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	5.67	3.79e-08	2.18e-05	0.43	0.33	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
KIRP	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-5.67	3.79e-08	2.18e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
KIRP	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	5.67	3.8e-08	2.18e-05	0.44	0.33	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
KIRP	cis	rs1560104	0.597	rs12708757	ENSG00000274834.1	CTD-3037G24.5	5.67	3.8e-08	2.19e-05	0.36	0.33	Obesity-related traits;	chr16:12616724	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.597	rs12708758	ENSG00000274834.1	CTD-3037G24.5	5.67	3.8e-08	2.19e-05	0.36	0.33	Obesity-related traits;	chr16:12616844	chr16:12614451~12614852:+
KIRP	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	5.67	3.8e-08	2.19e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	5.67	3.8e-08	2.19e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	5.67	3.8e-08	2.19e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	5.67	3.8e-08	2.19e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
KIRP	cis	rs4356975	0.527	rs4694645	ENSG00000196472.4	RP13-644M16.4	5.67	3.81e-08	2.19e-05	0.36	0.33	Obesity-related traits;	chr4:69127200	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.527	rs60423649	ENSG00000196472.4	RP13-644M16.4	5.67	3.81e-08	2.19e-05	0.36	0.33	Obesity-related traits;	chr4:69127952	chr4:69181660~69182372:+
KIRP	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-5.67	3.81e-08	2.19e-05	-0.41	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
KIRP	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	5.67	3.82e-08	2.19e-05	0.36	0.33	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
KIRP	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	5.67	3.82e-08	2.19e-05	0.36	0.33	Height;	chr3:53072864	chr3:53064283~53065091:-
KIRP	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	5.67	3.82e-08	2.19e-05	0.43	0.33	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	5.67	3.82e-08	2.19e-05	0.43	0.33	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
KIRP	cis	rs1799949	1	rs11649954	ENSG00000236383.6	LINC00854	-5.67	3.82e-08	2.2e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43342667	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1824889	ENSG00000236383.6	LINC00854	-5.67	3.82e-08	2.2e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43344508	chr17:43216941~43305976:-
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-5.67	3.82e-08	2.2e-05	-0.42	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
KIRP	cis	rs12050794	0.636	rs4506844	ENSG00000260037.4	CTD-2524L6.3	5.67	3.82e-08	2.2e-05	0.26	0.33	Metabolite levels (HVA/MHPG ratio);	chr15:72216797	chr15:71818396~71823384:+
KIRP	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	5.67	3.83e-08	2.2e-05	0.38	0.33	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
KIRP	cis	rs4638749	0.677	rs10185270	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108222236	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs4396668	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108223908	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs6741222	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108224626	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs4676186	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108226184	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs12712017	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108227100	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs2198471	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108227613	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs2219081	ENSG00000231221.1	AC023672.2	-5.67	3.83e-08	2.2e-05	-0.39	-0.33	Blood pressure;	chr2:108227894	chr2:108049200~108052755:-
KIRP	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-5.67	3.83e-08	2.2e-05	-0.34	-0.33	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
KIRP	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-5.67	3.84e-08	2.21e-05	-0.28	-0.33	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-5.67	3.84e-08	2.21e-05	-0.28	-0.33	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-5.67	3.84e-08	2.21e-05	-0.28	-0.33	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-5.67	3.84e-08	2.21e-05	-0.28	-0.33	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
KIRP	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.67	3.84e-08	2.21e-05	0.4	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
KIRP	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-5.67	3.84e-08	2.21e-05	-0.29	-0.33	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
KIRP	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-5.67	3.84e-08	2.21e-05	-0.29	-0.33	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
KIRP	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.67	3.84e-08	2.21e-05	-0.3	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
KIRP	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.67	3.84e-08	2.21e-05	-0.28	-0.33	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
KIRP	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-5.67	3.84e-08	2.21e-05	-0.41	-0.33	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
KIRP	cis	rs1552244	0.882	rs9312044	ENSG00000180385.7	EMC3-AS1	5.67	3.85e-08	2.21e-05	0.3	0.33	Alzheimer's disease;	chr3:9995797	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs6796419	ENSG00000180385.7	EMC3-AS1	5.67	3.85e-08	2.21e-05	0.3	0.33	Alzheimer's disease;	chr3:9999128	chr3:9986893~10006990:+
KIRP	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-5.66	3.87e-08	2.22e-05	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-5.66	3.87e-08	2.22e-05	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
KIRP	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	5.66	3.87e-08	2.22e-05	0.43	0.33	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
KIRP	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	5.66	3.87e-08	2.22e-05	0.52	0.33	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
KIRP	cis	rs1799949	0.894	rs36062488	ENSG00000236383.6	LINC00854	5.66	3.87e-08	2.22e-05	0.25	0.33	Menopause (age at onset);	chr17:43185455	chr17:43216941~43305976:-
KIRP	cis	rs4356975	0.563	rs7438135	ENSG00000196472.4	RP13-644M16.4	5.66	3.87e-08	2.22e-05	0.36	0.33	Obesity-related traits;	chr4:69095621	chr4:69181660~69182372:+
KIRP	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	5.66	3.87e-08	2.22e-05	0.38	0.33	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
KIRP	cis	rs4356975	0.545	rs11249524	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69080653	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.602	rs7674851	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69081113	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7679550	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69081187	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4478248	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69081498	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7680709	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69081745	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.527	rs12643840	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69082245	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4131317	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083280	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4540108	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083614	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs4640729	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083642	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4522933	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083780	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs11937683	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69084102	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7659306	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69084560	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4454000	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69084853	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4273534	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69084927	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs4642304	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69085832	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4446391	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69086364	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7437174	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69086885	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6422324	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69087385	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600874	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69087695	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6843382	ENSG00000248763.2	RP13-644M16.5	-5.66	3.88e-08	2.22e-05	-0.35	-0.33	Obesity-related traits;	chr4:69087884	chr4:69066395~69069888:+
KIRP	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-5.66	3.88e-08	2.22e-05	-0.41	-0.33	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
KIRP	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	5.66	3.88e-08	2.23e-05	0.43	0.33	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
KIRP	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	5.66	3.88e-08	2.23e-05	0.33	0.33	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
KIRP	cis	rs453301	0.686	rs3989373	ENSG00000253981.4	ALG1L13P	-5.66	3.89e-08	2.23e-05	-0.26	-0.33	Joint mobility (Beighton score);	chr8:9053798	chr8:8236003~8244667:-
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	5.66	3.89e-08	2.23e-05	0.43	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
KIRP	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	5.66	3.89e-08	2.23e-05	0.62	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
KIRP	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-5.66	3.91e-08	2.24e-05	-0.27	-0.33	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
KIRP	cis	rs4356975	0.545	rs11249526	ENSG00000248763.2	RP13-644M16.5	-5.66	3.91e-08	2.24e-05	-0.35	-0.33	Obesity-related traits;	chr4:69080934	chr4:69066395~69069888:+
KIRP	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	5.66	3.92e-08	2.25e-05	0.43	0.33	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	5.66	3.92e-08	2.25e-05	0.43	0.33	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.66	3.92e-08	2.25e-05	0.43	0.33	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5.66	3.92e-08	2.25e-05	0.43	0.33	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
KIRP	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	5.66	3.92e-08	2.25e-05	0.42	0.33	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
KIRP	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	5.66	3.93e-08	2.25e-05	0.39	0.33	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
KIRP	cis	rs1799949	1	rs35956818	ENSG00000236383.6	LINC00854	-5.66	3.93e-08	2.25e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43345617	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs4584865	ENSG00000236383.6	LINC00854	-5.66	3.93e-08	2.25e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43347551	chr17:43216941~43305976:-
KIRP	cis	rs2625529	0.818	rs16956241	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.93e-08	2.25e-05	-0.29	-0.33	Red blood cell count;	chr15:71819347	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.701	rs12911154	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71920312	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs7170754	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71926253	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs7170461	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71926258	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.701	rs62025574	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71943734	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.878	rs71395051	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71947448	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs11072339	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.94e-08	2.26e-05	-0.29	-0.33	Red blood cell count;	chr15:71954849	chr15:71818396~71823384:+
KIRP	cis	rs1799949	0.896	rs35908185	ENSG00000236383.6	LINC00854	-5.66	3.94e-08	2.26e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43103094	chr17:43216941~43305976:-
KIRP	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	5.66	3.95e-08	2.26e-05	0.37	0.33	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.66	3.95e-08	2.26e-05	-0.28	-0.33	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
KIRP	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-5.66	3.95e-08	2.26e-05	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
KIRP	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-5.66	3.96e-08	2.27e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
KIRP	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-5.66	3.96e-08	2.27e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
KIRP	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	5.66	3.97e-08	2.27e-05	0.38	0.33	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
KIRP	cis	rs7378815	0.685	rs290753	ENSG00000250787.1	HMGN1P17	5.66	3.97e-08	2.27e-05	0.32	0.33	Breast cancer;	chr5:56357443	chr5:56381781~56382075:+
KIRP	cis	rs2625529	0.824	rs16956328	ENSG00000260037.4	CTD-2524L6.3	-5.66	3.98e-08	2.28e-05	-0.28	-0.33	Red blood cell count;	chr15:71851514	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.652	rs2957361	ENSG00000260037.4	CTD-2524L6.3	5.66	3.98e-08	2.28e-05	0.25	0.33	Red blood cell count;	chr15:72052877	chr15:71818396~71823384:+
KIRP	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.66	3.99e-08	2.28e-05	-0.25	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
KIRP	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-5.66	3.99e-08	2.28e-05	-0.4	-0.33	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
KIRP	cis	rs1799949	1	rs8176220	ENSG00000236383.6	LINC00854	-5.66	3.99e-08	2.28e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43070445	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs1799966	ENSG00000236383.6	LINC00854	-5.66	3.99e-08	2.28e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43071077	chr17:43216941~43305976:-
KIRP	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	5.66	3.99e-08	2.28e-05	0.24	0.33	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
KIRP	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-5.66	3.99e-08	2.29e-05	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
KIRP	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-5.66	3.99e-08	2.29e-05	-0.41	-0.33	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
KIRP	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5.66	4e-08	2.29e-05	0.25	0.33	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5.66	4e-08	2.29e-05	0.25	0.33	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5.66	4e-08	2.29e-05	0.25	0.33	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
KIRP	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-5.66	4e-08	2.29e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-5.66	4e-08	2.29e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-5.66	4e-08	2.29e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-5.66	4e-08	2.29e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
KIRP	cis	rs9595908	0.869	rs9595948	ENSG00000212293.1	SNORA16	5.66	4e-08	2.29e-05	0.32	0.33	Body mass index;	chr13:32629519	chr13:32420390~32420516:-
KIRP	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	5.66	4.01e-08	2.29e-05	0.47	0.33	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
KIRP	cis	rs4356975	0.583	rs62296935	ENSG00000248763.2	RP13-644M16.5	-5.66	4.02e-08	2.3e-05	-0.35	-0.33	Obesity-related traits;	chr4:69082878	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs62296936	ENSG00000248763.2	RP13-644M16.5	-5.66	4.02e-08	2.3e-05	-0.35	-0.33	Obesity-related traits;	chr4:69082903	chr4:69066395~69069888:+
KIRP	cis	rs7170668	0.93	rs12899367	ENSG00000258489.3	RP11-398J10.2	-5.66	4.02e-08	2.3e-05	-0.38	-0.33	Motion sickness;	chr15:95469794	chr15:95463592~95493770:-
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000206090.4	AP000350.7	5.66	4.03e-08	2.3e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23939998~23942798:+
KIRP	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-5.66	4.03e-08	2.3e-05	-0.33	-0.33	Height;	chr11:118737823	chr11:118704607~118750263:+
KIRP	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-5.66	4.03e-08	2.3e-05	-0.26	-0.33	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-5.66	4.03e-08	2.3e-05	-0.26	-0.33	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
KIRP	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	5.66	4.03e-08	2.31e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	5.66	4.03e-08	2.31e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
KIRP	cis	rs79040073	0.637	rs3088333	ENSG00000259531.2	RP11-295H24.3	5.66	4.03e-08	2.31e-05	0.44	0.33	Lung cancer in ever smokers;	chr15:49140891	chr15:49365124~49366685:-
KIRP	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-5.66	4.04e-08	2.31e-05	-0.38	-0.33	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
KIRP	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-5.66	4.04e-08	2.31e-05	-0.33	-0.33	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
KIRP	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-5.66	4.04e-08	2.31e-05	-0.33	-0.33	Height;	chr11:118747911	chr11:118704607~118750263:+
KIRP	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-5.66	4.04e-08	2.31e-05	-0.33	-0.33	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	5.66	4.05e-08	2.31e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
KIRP	cis	rs1799949	1	rs11652332	ENSG00000236383.6	LINC00854	-5.66	4.05e-08	2.31e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43143472	chr17:43216941~43305976:-
KIRP	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-5.66	4.06e-08	2.32e-05	-0.28	-0.33	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	5.66	4.06e-08	2.32e-05	0.25	0.33	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
KIRP	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	5.66	4.06e-08	2.32e-05	0.32	0.33	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	5.65	4.07e-08	2.32e-05	0.42	0.33	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
KIRP	cis	rs1799949	0.965	rs4793233	ENSG00000236383.6	LINC00854	-5.65	4.07e-08	2.33e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43358069	chr17:43216941~43305976:-
KIRP	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-5.65	4.07e-08	2.33e-05	-0.37	-0.33	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
KIRP	cis	rs9532669	0.833	rs9532672	ENSG00000239827.7	SUGT1P3	-5.65	4.09e-08	2.34e-05	-0.36	-0.33	Cervical cancer;	chr13:40928285	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.963	rs7324625	ENSG00000239827.7	SUGT1P3	-5.65	4.09e-08	2.34e-05	-0.36	-0.33	Cervical cancer;	chr13:40928606	chr13:40908159~40921774:-
KIRP	cis	rs1528149	0.576	rs1881242	ENSG00000224683.1	RPL36AP29	-5.65	4.09e-08	2.34e-05	-0.39	-0.33	Sitting height ratio;	chr7:16073822	chr7:16208945~16209265:+
KIRP	cis	rs6085948	0.681	rs73087273	ENSG00000238102.1	RP11-19D2.1	-5.65	4.09e-08	2.34e-05	-0.42	-0.33	Interleukin-10 levels;	chr20:7248867	chr20:7256580~7258214:-
KIRP	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	5.65	4.09e-08	2.34e-05	0.33	0.33	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
KIRP	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-5.65	4.09e-08	2.34e-05	-0.42	-0.33	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-5.65	4.09e-08	2.34e-05	-0.42	-0.33	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-5.65	4.09e-08	2.34e-05	-0.42	-0.33	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
KIRP	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-5.65	4.1e-08	2.34e-05	-0.34	-0.33	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-5.65	4.1e-08	2.34e-05	-0.34	-0.33	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
KIRP	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-5.65	4.1e-08	2.34e-05	-0.42	-0.33	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
KIRP	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	5.65	4.1e-08	2.34e-05	0.38	0.33	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	5.65	4.1e-08	2.34e-05	0.27	0.33	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
KIRP	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	5.65	4.1e-08	2.34e-05	0.38	0.33	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
KIRP	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	5.65	4.11e-08	2.34e-05	0.53	0.33	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	5.65	4.11e-08	2.34e-05	0.53	0.33	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	5.65	4.11e-08	2.34e-05	0.53	0.33	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
KIRP	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	5.65	4.11e-08	2.35e-05	0.54	0.33	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
KIRP	cis	rs11647589	0.641	rs1394676	ENSG00000262995.1	CTD-2194A8.2	-5.65	4.11e-08	2.35e-05	-0.37	-0.33	Blood metabolite levels;	chr16:20477880	chr16:20440266~20447000:-
KIRP	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	5.65	4.12e-08	2.35e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	5.65	4.12e-08	2.35e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
KIRP	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	5.65	4.12e-08	2.35e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-5.65	4.12e-08	2.35e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
KIRP	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	5.65	4.12e-08	2.35e-05	0.32	0.33	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
KIRP	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-5.65	4.13e-08	2.35e-05	-0.29	-0.33	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
KIRP	cis	rs2625529	0.824	rs35112434	ENSG00000260037.4	CTD-2524L6.3	-5.65	4.13e-08	2.35e-05	-0.29	-0.33	Red blood cell count;	chr15:72155985	chr15:71818396~71823384:+
KIRP	cis	rs2765539	0.701	rs6671822	ENSG00000231365.4	RP11-418J17.1	-5.65	4.13e-08	2.36e-05	-0.37	-0.33	Waist-hip ratio;	chr1:119118898	chr1:119140396~119275973:+
KIRP	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	5.65	4.14e-08	2.36e-05	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
KIRP	cis	rs9388451	1	rs9388451	ENSG00000237742.5	RP11-624M8.1	-5.65	4.14e-08	2.36e-05	-0.35	-0.33	Brugada syndrome;	chr6:125769231	chr6:125578558~125749190:-
KIRP	cis	rs9532669	0.926	rs9532690	ENSG00000239827.7	SUGT1P3	-5.65	4.14e-08	2.36e-05	-0.37	-0.33	Cervical cancer;	chr13:40968654	chr13:40908159~40921774:-
KIRP	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	5.65	4.14e-08	2.36e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	5.65	4.14e-08	2.36e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	5.65	4.14e-08	2.36e-05	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
KIRP	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-5.65	4.14e-08	2.36e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
KIRP	cis	rs7267979	0.966	rs7270835	ENSG00000274414.1	RP5-965G21.4	-5.65	4.15e-08	2.36e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6115191	ENSG00000274414.1	RP5-965G21.4	-5.65	4.15e-08	2.36e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6107045	ENSG00000274414.1	RP5-965G21.4	-5.65	4.15e-08	2.36e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6107046	ENSG00000274414.1	RP5-965G21.4	-5.65	4.15e-08	2.36e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6107047	ENSG00000274414.1	RP5-965G21.4	-5.65	4.15e-08	2.36e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25239007~25245229:-
KIRP	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-5.65	4.15e-08	2.37e-05	-0.28	-0.33	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
KIRP	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	5.65	4.16e-08	2.37e-05	0.3	0.33	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
KIRP	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	5.65	4.16e-08	2.37e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
KIRP	cis	rs9388451	0.903	rs7758115	ENSG00000237742.5	RP11-624M8.1	-5.65	4.16e-08	2.37e-05	-0.34	-0.33	Brugada syndrome;	chr6:125740356	chr6:125578558~125749190:-
KIRP	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-5.65	4.16e-08	2.37e-05	-0.28	-0.33	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
KIRP	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	5.65	4.16e-08	2.37e-05	0.37	0.33	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
KIRP	cis	rs6832769	1	rs1522110	ENSG00000272969.1	RP11-528I4.2	5.65	4.17e-08	2.37e-05	0.32	0.33	Personality dimensions;	chr4:55514116	chr4:55547112~55547889:+
KIRP	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	5.65	4.17e-08	2.37e-05	0.41	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
KIRP	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-5.65	4.17e-08	2.38e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
KIRP	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-5.65	4.18e-08	2.38e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-5.65	4.18e-08	2.38e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-5.65	4.18e-08	2.38e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	5.65	4.18e-08	2.38e-05	0.29	0.33	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
KIRP	cis	rs4660214	0.756	rs11205823	ENSG00000237624.1	OXCT2P1	-5.65	4.19e-08	2.38e-05	-0.43	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39514956~39516490:+
KIRP	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-5.65	4.19e-08	2.39e-05	-0.37	-0.33	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-5.65	4.19e-08	2.39e-05	-0.37	-0.33	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-5.65	4.19e-08	2.39e-05	-0.37	-0.33	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
KIRP	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-5.65	4.2e-08	2.39e-05	-0.45	-0.33	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
KIRP	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-5.65	4.2e-08	2.39e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-5.65	4.2e-08	2.39e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-5.65	4.2e-08	2.39e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-5.65	4.2e-08	2.39e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
KIRP	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	5.65	4.2e-08	2.39e-05	0.33	0.33	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	5.65	4.2e-08	2.39e-05	0.37	0.33	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
KIRP	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-5.65	4.2e-08	2.39e-05	-0.29	-0.33	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
KIRP	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-5.65	4.21e-08	2.39e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-5.65	4.21e-08	2.39e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-5.65	4.21e-08	2.39e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-5.65	4.21e-08	2.39e-05	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
KIRP	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	5.65	4.21e-08	2.39e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
KIRP	cis	rs9926296	0.744	rs164749	ENSG00000260259.1	RP11-368I7.4	5.65	4.22e-08	2.4e-05	0.24	0.33	Vitiligo;	chr16:89641816	chr16:89682620~89686569:-
KIRP	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	5.65	4.22e-08	2.4e-05	0.37	0.33	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
KIRP	cis	rs79040073	0.637	rs73408143	ENSG00000259531.2	RP11-295H24.3	5.65	4.22e-08	2.4e-05	0.45	0.33	Lung cancer in ever smokers;	chr15:49126771	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17394970	ENSG00000259531.2	RP11-295H24.3	5.65	4.22e-08	2.4e-05	0.45	0.33	Lung cancer in ever smokers;	chr15:49145371	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11635455	ENSG00000259531.2	RP11-295H24.3	5.65	4.22e-08	2.4e-05	0.45	0.33	Lung cancer in ever smokers;	chr15:49147216	chr15:49365124~49366685:-
KIRP	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	5.65	4.23e-08	2.4e-05	0.27	0.33	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-5.65	4.23e-08	2.41e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-5.65	4.23e-08	2.41e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-5.65	4.24e-08	2.41e-05	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
KIRP	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-5.65	4.24e-08	2.41e-05	-0.41	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-5.65	4.25e-08	2.41e-05	-0.42	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
KIRP	cis	rs6480314	0.542	rs17231637	ENSG00000233590.1	RP11-153K11.3	5.65	4.26e-08	2.42e-05	0.52	0.33	Optic nerve measurement (disc area);	chr10:68270137	chr10:68233251~68242379:-
KIRP	cis	rs12571093	0.803	rs2241970	ENSG00000233590.1	RP11-153K11.3	5.65	4.26e-08	2.42e-05	0.52	0.33	Optic nerve measurement (disc area);	chr10:68271310	chr10:68233251~68242379:-
KIRP	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-5.65	4.26e-08	2.42e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
KIRP	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-5.65	4.26e-08	2.42e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
KIRP	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	5.65	4.26e-08	2.42e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
KIRP	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-5.65	4.26e-08	2.42e-05	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
KIRP	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-5.65	4.27e-08	2.42e-05	-0.41	-0.33	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
KIRP	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-5.65	4.27e-08	2.43e-05	-0.33	-0.33	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-5.65	4.27e-08	2.43e-05	-0.33	-0.33	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
KIRP	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-5.65	4.27e-08	2.43e-05	-0.33	-0.33	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
KIRP	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-5.65	4.27e-08	2.43e-05	-0.33	-0.33	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
KIRP	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	5.65	4.28e-08	2.43e-05	0.45	0.33	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
KIRP	cis	rs2625529	0.824	rs12899485	ENSG00000260037.4	CTD-2524L6.3	5.65	4.28e-08	2.43e-05	0.29	0.33	Red blood cell count;	chr15:71850874	chr15:71818396~71823384:+
KIRP	cis	rs1799949	1	rs35330014	ENSG00000236383.6	LINC00854	-5.65	4.28e-08	2.43e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43060530	chr17:43216941~43305976:-
KIRP	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-5.65	4.28e-08	2.43e-05	-0.45	-0.33	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
KIRP	cis	rs12460587	0.547	rs4566288	ENSG00000275055.1	CTC-471J1.11	-5.65	4.28e-08	2.43e-05	-0.27	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52092677	chr19:52049007~52049754:+
KIRP	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	5.65	4.29e-08	2.43e-05	0.54	0.33	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
KIRP	cis	rs2625529	0.652	rs2957724	ENSG00000260037.4	CTD-2524L6.3	5.64	4.29e-08	2.43e-05	0.25	0.33	Red blood cell count;	chr15:71956133	chr15:71818396~71823384:+
KIRP	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-5.64	4.29e-08	2.44e-05	-0.42	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
KIRP	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	5.64	4.29e-08	2.44e-05	0.32	0.33	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
KIRP	cis	rs897984	0.762	rs12930545	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30927490	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.806	rs10782001	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30931304	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.806	rs12928852	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30932667	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.806	rs4889571	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30937726	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.806	rs11640534	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30938194	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs7206511	ENSG00000275263.1	RP11-1072A3.4	5.64	4.3e-08	2.44e-05	0.35	0.33	Dementia with Lewy bodies;	chr16:30939031	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.806	rs1458202	ENSG00000275263.1	RP11-1072A3.4	-5.64	4.3e-08	2.44e-05	-0.35	-0.33	Dementia with Lewy bodies;	chr16:30941881	chr16:30956872~30957199:-
KIRP	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	5.64	4.31e-08	2.44e-05	0.44	0.33	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
KIRP	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-5.64	4.31e-08	2.44e-05	-0.23	-0.33	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
KIRP	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-5.64	4.31e-08	2.44e-05	-0.37	-0.33	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
KIRP	cis	rs7829975	0.502	rs7820738	ENSG00000253981.4	ALG1L13P	-5.64	4.32e-08	2.45e-05	-0.26	-0.33	Mood instability;	chr8:8845097	chr8:8236003~8244667:-
KIRP	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-5.64	4.34e-08	2.46e-05	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
KIRP	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-5.64	4.34e-08	2.46e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
KIRP	cis	rs2625529	0.617	rs3784313	ENSG00000260037.4	CTD-2524L6.3	5.64	4.34e-08	2.46e-05	0.26	0.33	Red blood cell count;	chr15:71895178	chr15:71818396~71823384:+
KIRP	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	5.64	4.35e-08	2.46e-05	0.42	0.33	Depression;	chr6:28363475	chr6:28943877~28944537:+
KIRP	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-5.64	4.35e-08	2.47e-05	-0.36	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
KIRP	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-5.64	4.36e-08	2.47e-05	-0.31	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	5.64	4.36e-08	2.47e-05	0.33	0.33	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
KIRP	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-5.64	4.36e-08	2.47e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-5.64	4.36e-08	2.47e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
KIRP	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	5.64	4.36e-08	2.48e-05	0.41	0.33	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
KIRP	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	5.64	4.37e-08	2.48e-05	0.63	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
KIRP	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-5.64	4.37e-08	2.48e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
KIRP	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-5.64	4.37e-08	2.48e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
KIRP	cis	rs897984	0.645	rs9938550	ENSG00000275263.1	RP11-1072A3.4	5.64	4.38e-08	2.48e-05	0.34	0.33	Dementia with Lewy bodies;	chr16:30987821	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.762	rs2305880	ENSG00000275263.1	RP11-1072A3.4	5.64	4.38e-08	2.48e-05	0.34	0.33	Dementia with Lewy bodies;	chr16:30988141	chr16:30956872~30957199:-
KIRP	cis	rs897984	0.759	rs13708	ENSG00000275263.1	RP11-1072A3.4	5.64	4.38e-08	2.48e-05	0.34	0.33	Dementia with Lewy bodies;	chr16:30989488	chr16:30956872~30957199:-
KIRP	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-5.64	4.39e-08	2.49e-05	-0.28	-0.33	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
KIRP	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	5.64	4.4e-08	2.49e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	5.64	4.4e-08	2.49e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	5.64	4.4e-08	2.49e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
KIRP	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	5.64	4.41e-08	2.5e-05	0.54	0.33	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	5.64	4.41e-08	2.5e-05	0.54	0.33	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
KIRP	cis	rs67311347	0.544	rs6804545	ENSG00000230274.1	PGAM1P3	5.64	4.41e-08	2.5e-05	0.34	0.33	Renal cell carcinoma;	chr3:40312549	chr3:40322715~40323279:-
KIRP	cis	rs1560104	0.709	rs2903042	ENSG00000274834.1	CTD-3037G24.5	-5.64	4.42e-08	2.5e-05	-0.39	-0.33	Obesity-related traits;	chr16:12604249	chr16:12614451~12614852:+
KIRP	cis	rs11158026	0.722	rs2840268	ENSG00000258413.1	RP11-665C16.6	-5.64	4.42e-08	2.5e-05	-0.39	-0.33	Parkinson's disease;	chr14:55005265	chr14:55262767~55272075:-
KIRP	cis	rs11158026	0.757	rs2183085	ENSG00000258413.1	RP11-665C16.6	-5.64	4.42e-08	2.5e-05	-0.39	-0.33	Parkinson's disease;	chr14:55005673	chr14:55262767~55272075:-
KIRP	cis	rs2486288	0.656	rs8039354	ENSG00000259433.2	CTD-2651B20.4	-5.64	4.43e-08	2.51e-05	-0.28	-0.33	Glomerular filtration rate;	chr15:45259558	chr15:45330209~45332634:-
KIRP	cis	rs4356975	0.527	rs62296943	ENSG00000248763.2	RP13-644M16.5	-5.64	4.43e-08	2.51e-05	-0.35	-0.33	Obesity-related traits;	chr4:69093465	chr4:69066395~69069888:+
KIRP	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	5.64	4.44e-08	2.51e-05	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	5.64	4.44e-08	2.51e-05	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	5.64	4.44e-08	2.51e-05	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
KIRP	cis	rs2625529	0.824	rs12917428	ENSG00000260037.4	CTD-2524L6.3	-5.64	4.45e-08	2.52e-05	-0.29	-0.33	Red blood cell count;	chr15:71929657	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.701	rs2306490	ENSG00000260037.4	CTD-2524L6.3	-5.64	4.45e-08	2.52e-05	-0.29	-0.33	Red blood cell count;	chr15:71935496	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-5.64	4.45e-08	2.52e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
KIRP	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-5.64	4.46e-08	2.52e-05	-0.44	-0.33	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
KIRP	cis	rs2749592	0.588	rs2504144	ENSG00000151963.4	RP11-775A3.1	-5.64	4.46e-08	2.53e-05	-0.38	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:37883594~37884109:+
KIRP	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-5.64	4.46e-08	2.53e-05	-0.28	-0.33	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
KIRP	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-5.64	4.46e-08	2.53e-05	-0.28	-0.33	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
KIRP	cis	rs2283792	1	rs5749806	ENSG00000228050.1	TOP3BP1	5.64	4.47e-08	2.53e-05	0.36	0.33	Multiple sclerosis;	chr22:21752329	chr22:22223187~22224566:-
KIRP	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-5.64	4.47e-08	2.53e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-5.64	4.47e-08	2.53e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
KIRP	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-5.64	4.47e-08	2.53e-05	-0.32	-0.33	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
KIRP	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	5.64	4.47e-08	2.53e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	5.64	4.47e-08	2.53e-05	0.26	0.33	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
KIRP	cis	rs4638749	0.677	rs1563112	ENSG00000231221.1	AC023672.2	-5.64	4.48e-08	2.53e-05	-0.39	-0.33	Blood pressure;	chr2:108234123	chr2:108049200~108052755:-
KIRP	cis	rs4356975	0.563	rs4443355	ENSG00000248763.2	RP13-644M16.5	-5.64	4.48e-08	2.54e-05	-0.35	-0.33	Obesity-related traits;	chr4:69083026	chr4:69066395~69069888:+
KIRP	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	5.64	4.49e-08	2.54e-05	0.4	0.33	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
KIRP	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	5.64	4.49e-08	2.54e-05	0.41	0.33	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
KIRP	cis	rs7829975	0.501	rs74345345	ENSG00000253893.2	FAM85B	5.64	4.49e-08	2.54e-05	0.42	0.33	Mood instability;	chr8:8720925	chr8:8167819~8226614:-
KIRP	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-5.64	4.49e-08	2.54e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
KIRP	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	5.64	4.5e-08	2.54e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
KIRP	cis	rs3121446	1	rs3127661	ENSG00000229654.1	RP1-60O19.2	5.64	4.5e-08	2.54e-05	0.34	0.33	Daytime sleep phenotypes;	chr6:106694052	chr6:106695535~106699994:+
KIRP	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-5.64	4.5e-08	2.55e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
KIRP	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	5.64	4.5e-08	2.55e-05	0.39	0.33	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
KIRP	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	5.64	4.51e-08	2.55e-05	0.75	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	5.64	4.51e-08	2.55e-05	0.41	0.33	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
KIRP	cis	rs2625529	0.824	rs1074330	ENSG00000260037.4	CTD-2524L6.3	-5.64	4.51e-08	2.55e-05	-0.28	-0.33	Red blood cell count;	chr15:71958400	chr15:71818396~71823384:+
KIRP	cis	rs5758659	1	rs134902	ENSG00000205702.9	CYP2D7	5.64	4.51e-08	2.55e-05	0.24	0.33	Cognitive function;	chr22:42287991	chr22:42140203~42144577:-
KIRP	cis	rs4356975	0.545	rs11249525	ENSG00000248763.2	RP13-644M16.5	-5.64	4.51e-08	2.55e-05	-0.35	-0.33	Obesity-related traits;	chr4:69080923	chr4:69066395~69069888:+
KIRP	cis	rs4638749	0.501	rs13391411	ENSG00000231221.1	AC023672.2	-5.64	4.51e-08	2.55e-05	-0.38	-0.33	Blood pressure;	chr2:108172597	chr2:108049200~108052755:-
KIRP	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	5.63	4.52e-08	2.55e-05	0.33	0.33	Height;	chr3:53091453	chr3:53064283~53065091:-
KIRP	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	5.63	4.52e-08	2.56e-05	0.33	0.33	Height;	chr14:75077486	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	5.63	4.52e-08	2.56e-05	0.33	0.33	Height;	chr14:75077767	chr14:75011269~75012851:-
KIRP	cis	rs1799949	0.965	rs8176161	ENSG00000236383.6	LINC00854	-5.63	4.52e-08	2.56e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43089373	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.894	rs8176160	ENSG00000236383.6	LINC00854	-5.63	4.52e-08	2.56e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43089486	chr17:43216941~43305976:-
KIRP	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-5.63	4.53e-08	2.56e-05	-0.35	-0.33	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
KIRP	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-5.63	4.54e-08	2.56e-05	-0.33	-0.33	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
KIRP	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-5.63	4.55e-08	2.57e-05	-0.25	-0.33	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
KIRP	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-5.63	4.56e-08	2.57e-05	-0.42	-0.33	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
KIRP	cis	rs7224610	0.966	rs3794748	ENSG00000263096.1	RP11-515O17.2	5.63	4.56e-08	2.57e-05	0.44	0.33	Urate levels;	chr17:55287811	chr17:55271504~55273653:-
KIRP	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	5.63	4.56e-08	2.58e-05	0.42	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	5.63	4.56e-08	2.58e-05	0.42	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
KIRP	cis	rs6480314	0.542	rs61854805	ENSG00000233590.1	RP11-153K11.3	-5.63	4.58e-08	2.58e-05	-0.51	-0.33	Optic nerve measurement (disc area);	chr10:68255826	chr10:68233251~68242379:-
KIRP	cis	rs4356975	0.545	rs11249526	ENSG00000196472.4	RP13-644M16.4	5.63	4.58e-08	2.58e-05	0.35	0.33	Obesity-related traits;	chr4:69080934	chr4:69181660~69182372:+
KIRP	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	5.63	4.58e-08	2.59e-05	0.24	0.33	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
KIRP	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-5.63	4.59e-08	2.59e-05	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
KIRP	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-5.63	4.6e-08	2.6e-05	-0.45	-0.33	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
KIRP	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	5.63	4.61e-08	2.6e-05	0.3	0.33	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	5.63	4.61e-08	2.6e-05	0.3	0.33	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
KIRP	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-5.63	4.61e-08	2.6e-05	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
KIRP	cis	rs2765539	0.772	rs2148150	ENSG00000231365.4	RP11-418J17.1	-5.63	4.61e-08	2.6e-05	-0.34	-0.33	Waist-hip ratio;	chr1:119029434	chr1:119140396~119275973:+
KIRP	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	5.63	4.62e-08	2.61e-05	0.33	0.33	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
KIRP	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-5.63	4.63e-08	2.61e-05	-0.41	-0.33	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-5.63	4.63e-08	2.61e-05	-0.41	-0.33	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
KIRP	cis	rs7829975	0.51	rs332037	ENSG00000253981.4	ALG1L13P	5.63	4.63e-08	2.61e-05	0.26	0.33	Mood instability;	chr8:8865165	chr8:8236003~8244667:-
KIRP	cis	rs1552244	0.882	rs7633769	ENSG00000180385.7	EMC3-AS1	5.63	4.64e-08	2.61e-05	0.3	0.33	Alzheimer's disease;	chr3:9978938	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.751	rs12715665	ENSG00000180385.7	EMC3-AS1	5.63	4.64e-08	2.61e-05	0.3	0.33	Alzheimer's disease;	chr3:9979917	chr3:9986893~10006990:+
KIRP	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	5.63	4.65e-08	2.62e-05	0.4	0.33	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
KIRP	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-5.63	4.65e-08	2.62e-05	-0.36	-0.33	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
KIRP	cis	rs7267979	0.866	rs2424698	ENSG00000274414.1	RP5-965G21.4	-5.63	4.65e-08	2.62e-05	-0.31	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25239007~25245229:-
KIRP	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-5.63	4.66e-08	2.62e-05	-0.4	-0.33	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
KIRP	cis	rs453301	0.507	rs2929306	ENSG00000253981.4	ALG1L13P	-5.63	4.66e-08	2.62e-05	-0.26	-0.33	Joint mobility (Beighton score);	chr8:9227399	chr8:8236003~8244667:-
KIRP	cis	rs4356975	0.545	rs11249524	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69080653	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.602	rs7674851	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69081113	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7679550	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69081187	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4478248	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69081498	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7680709	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69081745	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.527	rs12643840	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69082245	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4131317	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69083280	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4540108	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69083614	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs4640729	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69083642	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4522933	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69083780	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs11937683	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69084102	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7659306	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69084560	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4454000	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69084853	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4273534	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69084927	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs4642304	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69085832	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4446391	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69086364	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7437174	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69086885	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6422324	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69087385	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600874	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69087695	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6843382	ENSG00000196472.4	RP13-644M16.4	5.63	4.66e-08	2.62e-05	0.35	0.33	Obesity-related traits;	chr4:69087884	chr4:69181660~69182372:+
KIRP	cis	rs1799949	1	rs8070085	ENSG00000236383.6	LINC00854	5.63	4.66e-08	2.63e-05	0.26	0.33	Menopause (age at onset);	chr17:43189967	chr17:43216941~43305976:-
KIRP	cis	rs73198271	0.74	rs28521727	ENSG00000253981.4	ALG1L13P	-5.63	4.67e-08	2.63e-05	-0.28	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.74	rs28402110	ENSG00000253981.4	ALG1L13P	-5.63	4.67e-08	2.63e-05	-0.28	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.74	rs10098636	ENSG00000253981.4	ALG1L13P	-5.63	4.67e-08	2.63e-05	-0.28	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.74	rs10112989	ENSG00000253981.4	ALG1L13P	-5.63	4.67e-08	2.63e-05	-0.28	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.74	rs10113326	ENSG00000253981.4	ALG1L13P	-5.63	4.67e-08	2.63e-05	-0.28	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8236003~8244667:-
KIRP	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	5.63	4.67e-08	2.63e-05	0.39	0.33	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
KIRP	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	5.63	4.67e-08	2.63e-05	0.38	0.33	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
KIRP	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	5.63	4.68e-08	2.63e-05	0.25	0.33	Height;	chr20:35203478	chr20:35201747~35203288:-
KIRP	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-5.63	4.68e-08	2.64e-05	-0.45	-0.33	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
KIRP	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	5.63	4.68e-08	2.64e-05	0.28	0.33	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
KIRP	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	5.63	4.68e-08	2.64e-05	0.28	0.33	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
KIRP	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	5.63	4.68e-08	2.64e-05	0.28	0.33	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
KIRP	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	5.63	4.68e-08	2.64e-05	0.28	0.33	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
KIRP	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	5.63	4.68e-08	2.64e-05	0.28	0.33	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
KIRP	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	5.63	4.69e-08	2.64e-05	0.42	0.33	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
KIRP	cis	rs7404843	0.704	rs112251447	ENSG00000263335.1	AF001548.5	5.63	4.69e-08	2.64e-05	0.49	0.33	Testicular germ cell tumor;	chr16:15428015	chr16:15726674~15732993:+
KIRP	cis	rs2625529	0.627	rs1037680	ENSG00000260037.4	CTD-2524L6.3	-5.63	4.69e-08	2.64e-05	-0.29	-0.33	Red blood cell count;	chr15:72221978	chr15:71818396~71823384:+
KIRP	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	5.63	4.69e-08	2.64e-05	0.24	0.33	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
KIRP	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-5.63	4.7e-08	2.64e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-5.63	4.7e-08	2.64e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-5.63	4.7e-08	2.64e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
KIRP	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-5.63	4.7e-08	2.64e-05	-0.33	-0.33	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-5.63	4.7e-08	2.64e-05	-0.33	-0.33	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
KIRP	cis	rs11647589	0.834	rs2271060	ENSG00000262995.1	CTD-2194A8.2	-5.63	4.71e-08	2.65e-05	-0.36	-0.33	Blood metabolite levels;	chr16:20471301	chr16:20440266~20447000:-
KIRP	cis	rs11647589	0.552	rs1632600	ENSG00000262995.1	CTD-2194A8.2	-5.63	4.71e-08	2.65e-05	-0.36	-0.33	Blood metabolite levels;	chr16:20476182	chr16:20440266~20447000:-
KIRP	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-5.63	4.71e-08	2.65e-05	-0.49	-0.33	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
KIRP	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-5.63	4.71e-08	2.65e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
KIRP	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-5.63	4.71e-08	2.65e-05	-0.26	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
KIRP	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	5.63	4.72e-08	2.65e-05	0.24	0.33	Height;	chr20:35196485	chr20:35201747~35203288:-
KIRP	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-5.63	4.72e-08	2.65e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
KIRP	cis	rs80285556	0.85	rs55975323	ENSG00000161643.11	SIGLEC16	5.63	4.72e-08	2.66e-05	0.75	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50071686	chr19:49969673~49975814:+
KIRP	cis	rs1799949	0.965	rs1842147	ENSG00000236383.6	LINC00854	-5.63	4.73e-08	2.66e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43357824	chr17:43216941~43305976:-
KIRP	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.63	4.74e-08	2.66e-05	0.36	0.33	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
KIRP	cis	rs1799949	1	rs35070007	ENSG00000236383.6	LINC00854	5.63	4.74e-08	2.67e-05	0.25	0.33	Menopause (age at onset);	chr17:43164730	chr17:43216941~43305976:-
KIRP	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-5.63	4.75e-08	2.67e-05	-0.37	-0.33	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
KIRP	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	5.63	4.75e-08	2.67e-05	0.56	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
KIRP	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	5.63	4.75e-08	2.67e-05	0.3	0.33	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
KIRP	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	5.63	4.75e-08	2.67e-05	0.23	0.33	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
KIRP	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-5.62	4.76e-08	2.68e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
KIRP	cis	rs7267979	0.932	rs6037125	ENSG00000274414.1	RP5-965G21.4	-5.62	4.77e-08	2.68e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	5.62	4.77e-08	2.68e-05	0.37	0.33	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
KIRP	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-5.62	4.77e-08	2.68e-05	-0.28	-0.33	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
KIRP	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-5.62	4.77e-08	2.68e-05	-0.24	-0.33	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
KIRP	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	5.62	4.77e-08	2.68e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
KIRP	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	5.62	4.78e-08	2.69e-05	0.42	0.33	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	5.62	4.79e-08	2.69e-05	0.38	0.33	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	5.62	4.79e-08	2.69e-05	0.38	0.33	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	5.62	4.79e-08	2.69e-05	0.38	0.33	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
KIRP	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-5.62	4.81e-08	2.7e-05	-0.34	-0.33	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
KIRP	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	5.62	4.81e-08	2.7e-05	0.28	0.33	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
KIRP	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	5.62	4.81e-08	2.7e-05	0.31	0.33	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
KIRP	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	5.62	4.81e-08	2.7e-05	0.35	0.33	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
KIRP	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	5.62	4.81e-08	2.7e-05	0.47	0.33	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
KIRP	cis	rs7267979	0.706	rs6037069	ENSG00000274414.1	RP5-965G21.4	-5.62	4.82e-08	2.71e-05	-0.31	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25239007~25245229:-
KIRP	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-5.62	4.83e-08	2.71e-05	-0.24	-0.33	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
KIRP	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	5.62	4.83e-08	2.71e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
KIRP	cis	rs453301	0.657	rs36056437	ENSG00000253981.4	ALG1L13P	-5.62	4.84e-08	2.72e-05	-0.26	-0.33	Joint mobility (Beighton score);	chr8:8935355	chr8:8236003~8244667:-
KIRP	cis	rs1799949	0.965	rs8176193	ENSG00000236383.6	LINC00854	-5.62	4.84e-08	2.72e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43079499	chr17:43216941~43305976:-
KIRP	cis	rs12908161	0.92	rs35738019	ENSG00000275120.1	RP11-182J1.17	5.62	4.84e-08	2.72e-05	0.42	0.33	Schizophrenia;	chr15:84736979	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs34570071	ENSG00000275120.1	RP11-182J1.17	5.62	4.84e-08	2.72e-05	0.42	0.33	Schizophrenia;	chr15:84736981	chr15:84599434~84606463:-
KIRP	cis	rs4638749	0.501	rs1000173	ENSG00000225328.1	AC019100.3	-5.62	4.84e-08	2.72e-05	-0.4	-0.33	Blood pressure;	chr2:108146422	chr2:108167748~108217841:-
KIRP	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	5.62	4.84e-08	2.72e-05	0.32	0.33	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
KIRP	cis	rs1560104	0.556	rs59670495	ENSG00000274834.1	CTD-3037G24.5	5.62	4.85e-08	2.72e-05	0.37	0.33	Obesity-related traits;	chr16:12617241	chr16:12614451~12614852:+
KIRP	cis	rs9402743	0.632	rs2104133	ENSG00000231028.7	LINC00271	-5.62	4.85e-08	2.72e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135781149	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.597	rs9483880	ENSG00000231028.7	LINC00271	-5.62	4.85e-08	2.72e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135781474	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs4895458	ENSG00000231028.7	LINC00271	-5.62	4.85e-08	2.72e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135783235	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs4896178	ENSG00000231028.7	LINC00271	-5.62	4.85e-08	2.72e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135783957	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs7773035	ENSG00000231028.7	LINC00271	-5.62	4.85e-08	2.72e-05	-0.29	-0.33	Systemic lupus erythematosus;	chr6:135784743	chr6:135497801~135716055:+
KIRP	cis	rs831571	0.955	rs35837	ENSG00000280620.1	SCAANT1	5.62	4.86e-08	2.73e-05	0.45	0.33	Type 2 diabetes;	chr3:64027573	chr3:63911518~63911772:-
KIRP	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	5.62	4.86e-08	2.73e-05	0.39	0.33	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
KIRP	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	5.62	4.86e-08	2.73e-05	0.54	0.33	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
KIRP	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-5.62	4.88e-08	2.74e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
KIRP	cis	rs2486288	0.656	rs9921025	ENSG00000259433.2	CTD-2651B20.4	5.62	4.89e-08	2.74e-05	0.28	0.33	Glomerular filtration rate;	chr15:45254404	chr15:45330209~45332634:-
KIRP	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	5.62	4.89e-08	2.74e-05	0.38	0.33	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
KIRP	cis	rs4934494	1	rs4934494	ENSG00000232936.4	RP11-80H5.2	5.62	4.89e-08	2.74e-05	0.42	0.33	Red blood cell count;	chr10:89687662	chr10:89645282~89650667:+
KIRP	cis	rs1552244	0.882	rs9812006	ENSG00000180385.7	EMC3-AS1	5.62	4.89e-08	2.74e-05	0.3	0.33	Alzheimer's disease;	chr3:9980974	chr3:9986893~10006990:+
KIRP	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	5.62	4.89e-08	2.75e-05	0.35	0.33	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
KIRP	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-5.62	4.9e-08	2.75e-05	-0.46	-0.33	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
KIRP	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-5.62	4.9e-08	2.75e-05	-0.27	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
KIRP	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35175051	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35176148	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35176829	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35177782	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35179263	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35179488	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35179887	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35180449	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35182684	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-5.62	4.91e-08	2.75e-05	-0.24	-0.33	Height;	chr20:35183632	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	5.62	4.91e-08	2.75e-05	0.24	0.33	Height;	chr20:35177813	chr20:35201747~35203288:-
KIRP	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-5.62	4.91e-08	2.75e-05	-0.37	-0.33	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	5.62	4.92e-08	2.76e-05	0.25	0.33	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
KIRP	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	5.62	4.92e-08	2.76e-05	0.5	0.33	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
KIRP	cis	rs2734839	0.964	rs7122246	ENSG00000270179.1	RP11-159N11.4	-5.62	4.93e-08	2.76e-05	-0.29	-0.33	Information processing speed;	chr11:113433735	chr11:113368478~113369117:+
KIRP	cis	rs8067545	0.641	rs860335	ENSG00000270091.1	RP11-78O7.2	-5.62	4.93e-08	2.76e-05	-0.22	-0.33	Schizophrenia;	chr17:19934366	chr17:19896590~19897287:-
KIRP	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	5.62	4.93e-08	2.76e-05	0.33	0.33	Height;	chr14:75087658	chr14:75011269~75012851:-
KIRP	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-5.62	4.93e-08	2.76e-05	-0.45	-0.33	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-5.62	4.93e-08	2.76e-05	-0.45	-0.33	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-5.62	4.93e-08	2.76e-05	-0.45	-0.33	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-5.62	4.93e-08	2.76e-05	-0.45	-0.33	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
KIRP	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	5.62	4.93e-08	2.76e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	5.62	4.93e-08	2.76e-05	0.37	0.33	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
KIRP	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	5.62	4.94e-08	2.77e-05	0.39	0.33	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
KIRP	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-5.62	4.94e-08	2.77e-05	-0.3	-0.33	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
KIRP	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-5.62	4.95e-08	2.77e-05	-0.35	-0.33	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-5.62	4.95e-08	2.77e-05	-0.35	-0.33	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-5.62	4.95e-08	2.77e-05	-0.35	-0.33	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-5.62	4.95e-08	2.77e-05	-0.35	-0.33	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5.62	4.95e-08	2.77e-05	0.28	0.33	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
KIRP	cis	rs7829975	0.582	rs448231	ENSG00000253981.4	ALG1L13P	-5.62	4.95e-08	2.77e-05	-0.25	-0.33	Mood instability;	chr8:8932549	chr8:8236003~8244667:-
KIRP	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-5.62	4.95e-08	2.77e-05	-0.24	-0.33	Height;	chr20:35174686	chr20:35201747~35203288:-
KIRP	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.62	4.96e-08	2.78e-05	0.25	0.33	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
KIRP	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-5.62	4.96e-08	2.78e-05	-0.42	-0.33	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
KIRP	cis	rs11773103	0.786	rs73202985	ENSG00000224046.1	AC005076.5	5.62	4.96e-08	2.78e-05	0.47	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87126604	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.581	rs73202987	ENSG00000224046.1	AC005076.5	5.62	4.96e-08	2.78e-05	0.47	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87126637	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.786	rs73202988	ENSG00000224046.1	AC005076.5	5.62	4.96e-08	2.78e-05	0.47	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87127087	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.786	rs73202994	ENSG00000224046.1	AC005076.5	5.62	4.96e-08	2.78e-05	0.47	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87127312	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.786	rs73202997	ENSG00000224046.1	AC005076.5	5.62	4.96e-08	2.78e-05	0.47	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87127363	chr7:87151423~87152420:-
KIRP	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	5.62	4.96e-08	2.78e-05	0.25	0.33	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
KIRP	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	5.62	4.97e-08	2.78e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
KIRP	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-5.62	4.99e-08	2.79e-05	-0.42	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
KIRP	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	5.62	4.99e-08	2.79e-05	0.44	0.33	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	5.62	5e-08	2.8e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
KIRP	cis	rs4356975	0.583	rs62296935	ENSG00000196472.4	RP13-644M16.4	5.62	5e-08	2.8e-05	0.35	0.33	Obesity-related traits;	chr4:69082878	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs62296936	ENSG00000196472.4	RP13-644M16.4	5.62	5e-08	2.8e-05	0.35	0.33	Obesity-related traits;	chr4:69082903	chr4:69181660~69182372:+
KIRP	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	5.62	5.01e-08	2.8e-05	0.4	0.33	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
KIRP	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	5.62	5.01e-08	2.8e-05	0.4	0.33	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
KIRP	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-5.61	5.01e-08	2.8e-05	-0.32	-0.33	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
KIRP	cis	rs6832769	1	rs6832769	ENSG00000272969.1	RP11-528I4.2	5.61	5.01e-08	2.81e-05	0.32	0.33	Personality dimensions;	chr4:55432027	chr4:55547112~55547889:+
KIRP	cis	rs67311347	0.544	rs2887965	ENSG00000230274.1	PGAM1P3	-5.61	5.02e-08	2.81e-05	-0.32	-0.33	Renal cell carcinoma;	chr3:40292663	chr3:40322715~40323279:-
KIRP	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	5.61	5.02e-08	2.81e-05	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
KIRP	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	5.61	5.02e-08	2.81e-05	0.33	0.33	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
KIRP	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-5.61	5.02e-08	2.81e-05	-0.37	-0.33	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	5.61	5.03e-08	2.81e-05	0.25	0.33	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
KIRP	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	5.61	5.03e-08	2.81e-05	0.38	0.33	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	5.61	5.03e-08	2.81e-05	0.38	0.33	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	5.61	5.03e-08	2.81e-05	0.38	0.33	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
KIRP	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	5.61	5.04e-08	2.81e-05	0.42	0.33	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
KIRP	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	5.61	5.04e-08	2.82e-05	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
KIRP	cis	rs1799949	1	rs3092994	ENSG00000236383.6	LINC00854	-5.61	5.05e-08	2.82e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43063808	chr17:43216941~43305976:-
KIRP	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	5.61	5.05e-08	2.82e-05	0.44	0.33	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
KIRP	cis	rs7826238	0.526	rs876955	ENSG00000253981.4	ALG1L13P	5.61	5.06e-08	2.82e-05	0.28	0.33	Systolic blood pressure;	chr8:8453374	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	5.61	5.06e-08	2.83e-05	0.43	0.33	Height;	chr6:109370985	chr6:109382795~109383666:+
KIRP	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	5.61	5.06e-08	2.83e-05	0.43	0.33	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
KIRP	cis	rs2625529	0.761	rs972028	ENSG00000260037.4	CTD-2524L6.3	-5.61	5.07e-08	2.83e-05	-0.28	-0.33	Red blood cell count;	chr15:71880751	chr15:71818396~71823384:+
KIRP	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	5.61	5.08e-08	2.83e-05	0.44	0.33	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
KIRP	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-5.61	5.08e-08	2.84e-05	-0.24	-0.33	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
KIRP	cis	rs9601248	0.756	rs9601251	ENSG00000227676.3	LINC01068	-5.61	5.09e-08	2.84e-05	-0.38	-0.33	Major depressive disorder;	chr13:79615582	chr13:79566727~79571436:+
KIRP	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	5.61	5.09e-08	2.84e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
KIRP	cis	rs7267979	0.932	rs417130	ENSG00000274414.1	RP5-965G21.4	-5.61	5.09e-08	2.84e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs372678	ENSG00000274414.1	RP5-965G21.4	-5.61	5.09e-08	2.84e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25239007~25245229:-
KIRP	cis	rs2625529	0.761	rs16956444	ENSG00000260037.4	CTD-2524L6.3	-5.61	5.1e-08	2.84e-05	-0.28	-0.33	Red blood cell count;	chr15:71978894	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs12439900	ENSG00000260037.4	CTD-2524L6.3	-5.61	5.1e-08	2.84e-05	-0.28	-0.33	Red blood cell count;	chr15:72081299	chr15:71818396~71823384:+
KIRP	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	5.61	5.1e-08	2.85e-05	0.3	0.33	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
KIRP	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-5.61	5.1e-08	2.85e-05	-0.28	-0.33	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
KIRP	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	5.61	5.11e-08	2.85e-05	0.29	0.33	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-5.61	5.11e-08	2.85e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
KIRP	cis	rs11158026	0.757	rs8012152	ENSG00000258413.1	RP11-665C16.6	-5.61	5.12e-08	2.85e-05	-0.4	-0.33	Parkinson's disease;	chr14:54958849	chr14:55262767~55272075:-
KIRP	cis	rs7829975	0.523	rs9644774	ENSG00000253893.2	FAM85B	5.61	5.13e-08	2.86e-05	0.43	0.33	Mood instability;	chr8:8702322	chr8:8167819~8226614:-
KIRP	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	5.61	5.13e-08	2.86e-05	0.47	0.33	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
KIRP	cis	rs2625529	0.642	rs2200056	ENSG00000260037.4	CTD-2524L6.3	-5.61	5.15e-08	2.87e-05	-0.29	-0.33	Red blood cell count;	chr15:72010326	chr15:71818396~71823384:+
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	5.61	5.16e-08	2.88e-05	0.25	0.33	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
KIRP	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	5.61	5.16e-08	2.88e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	5.61	5.18e-08	2.89e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
KIRP	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-5.61	5.19e-08	2.89e-05	-0.37	-0.33	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
KIRP	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-5.61	5.2e-08	2.9e-05	-0.27	-0.33	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
KIRP	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	5.61	5.2e-08	2.9e-05	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
KIRP	cis	rs1799949	1	rs4793194	ENSG00000236383.6	LINC00854	-5.61	5.2e-08	2.9e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43066316	chr17:43216941~43305976:-
KIRP	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-5.61	5.22e-08	2.91e-05	-0.5	-0.33	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
KIRP	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	5.61	5.22e-08	2.91e-05	0.48	0.33	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
KIRP	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	5.61	5.22e-08	2.91e-05	0.3	0.33	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
KIRP	cis	rs11773103	0.786	rs6979269	ENSG00000224046.1	AC005076.5	5.61	5.23e-08	2.92e-05	0.45	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87125666	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.786	rs734607	ENSG00000224046.1	AC005076.5	5.61	5.23e-08	2.92e-05	0.45	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87125842	chr7:87151423~87152420:-
KIRP	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	5.61	5.23e-08	2.92e-05	0.44	0.33	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
KIRP	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-5.61	5.24e-08	2.92e-05	-0.37	-0.33	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
KIRP	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	5.61	5.24e-08	2.92e-05	0.34	0.33	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
KIRP	cis	rs7378815	0.685	rs290754	ENSG00000250787.1	HMGN1P17	-5.61	5.25e-08	2.92e-05	-0.32	-0.33	Breast cancer;	chr5:56357325	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs184105	ENSG00000250787.1	HMGN1P17	-5.61	5.25e-08	2.92e-05	-0.32	-0.33	Breast cancer;	chr5:56357764	chr5:56381781~56382075:+
KIRP	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	5.61	5.25e-08	2.92e-05	0.37	0.33	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
KIRP	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	5.61	5.25e-08	2.92e-05	0.45	0.33	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
KIRP	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	5.61	5.25e-08	2.92e-05	0.45	0.33	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
KIRP	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-5.61	5.25e-08	2.92e-05	-0.36	-0.33	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-5.61	5.25e-08	2.92e-05	-0.36	-0.33	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
KIRP	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	5.61	5.25e-08	2.93e-05	0.37	0.33	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
KIRP	cis	rs7378815	0.725	rs58958293	ENSG00000250787.1	HMGN1P17	-5.61	5.26e-08	2.93e-05	-0.32	-0.33	Breast cancer;	chr5:56357306	chr5:56381781~56382075:+
KIRP	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	5.61	5.27e-08	2.93e-05	0.6	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
KIRP	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	5.61	5.27e-08	2.93e-05	0.25	0.33	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
KIRP	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	5.61	5.27e-08	2.93e-05	0.44	0.33	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
KIRP	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	5.6	5.27e-08	2.94e-05	0.34	0.33	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
KIRP	cis	rs4638749	0.603	rs34153365	ENSG00000231221.1	AC023672.2	-5.6	5.29e-08	2.94e-05	-0.38	-0.33	Blood pressure;	chr2:108230127	chr2:108049200~108052755:-
KIRP	cis	rs2486288	0.656	rs11629807	ENSG00000259433.2	CTD-2651B20.4	5.6	5.31e-08	2.95e-05	0.28	0.33	Glomerular filtration rate;	chr15:45254839	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.587	rs12899942	ENSG00000259433.2	CTD-2651B20.4	5.6	5.31e-08	2.95e-05	0.28	0.33	Glomerular filtration rate;	chr15:45255082	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs12899058	ENSG00000259433.2	CTD-2651B20.4	5.6	5.31e-08	2.95e-05	0.28	0.33	Glomerular filtration rate;	chr15:45255126	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs12904150	ENSG00000259433.2	CTD-2651B20.4	5.6	5.31e-08	2.95e-05	0.28	0.33	Glomerular filtration rate;	chr15:45255407	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs9920290	ENSG00000259433.2	CTD-2651B20.4	5.6	5.31e-08	2.95e-05	0.28	0.33	Glomerular filtration rate;	chr15:45255837	chr15:45330209~45332634:-
KIRP	cis	rs28386778	0.787	rs2665827	ENSG00000240280.5	TCAM1P	-5.6	5.31e-08	2.95e-05	-0.41	-0.33	Prudent dietary pattern;	chr17:63883990	chr17:63849292~63864379:+
KIRP	cis	rs9302635	0.515	rs36033103	ENSG00000260886.1	TAT-AS1	5.6	5.32e-08	2.96e-05	0.77	0.33	Blood protein levels;	chr16:72108139	chr16:71565789~71578187:+
KIRP	cis	rs4128705	1	rs4128704	ENSG00000249049.1	RP11-763F8.1	5.6	5.32e-08	2.96e-05	0.29	0.33	Amyotrophic lateral sclerosis (sporadic);	chr4:91362540	chr4:91319034~91325306:-
KIRP	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	5.6	5.32e-08	2.96e-05	0.28	0.33	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	5.6	5.32e-08	2.96e-05	0.28	0.33	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
KIRP	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-5.6	5.33e-08	2.96e-05	-0.28	-0.33	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-5.6	5.33e-08	2.96e-05	-0.28	-0.33	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
KIRP	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	5.6	5.33e-08	2.97e-05	0.44	0.33	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
KIRP	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-5.6	5.35e-08	2.97e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
KIRP	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-5.6	5.35e-08	2.97e-05	-0.27	-0.33	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
KIRP	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-5.6	5.35e-08	2.97e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
KIRP	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-5.6	5.35e-08	2.97e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
KIRP	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	5.6	5.36e-08	2.98e-05	0.42	0.33	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	5.6	5.36e-08	2.98e-05	0.42	0.33	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
KIRP	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-5.6	5.37e-08	2.98e-05	-0.43	-0.33	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
KIRP	cis	rs2439831	0.85	rs544122	ENSG00000249839.1	AC011330.5	-5.6	5.37e-08	2.98e-05	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43483534	chr15:43663654~43684339:-
KIRP	cis	rs12908161	1	rs17600551	ENSG00000275120.1	RP11-182J1.17	5.6	5.37e-08	2.99e-05	0.42	0.33	Schizophrenia;	chr15:84776027	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs62019469	ENSG00000275120.1	RP11-182J1.17	5.6	5.37e-08	2.99e-05	0.42	0.33	Schizophrenia;	chr15:84777989	chr15:84599434~84606463:-
KIRP	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	5.6	5.38e-08	2.99e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
KIRP	cis	rs7378815	0.685	rs172354	ENSG00000250787.1	HMGN1P17	5.6	5.39e-08	3e-05	0.32	0.33	Breast cancer;	chr5:56355231	chr5:56381781~56382075:+
KIRP	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	5.6	5.4e-08	3e-05	0.34	0.33	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
KIRP	cis	rs1799949	0.965	rs4793234	ENSG00000236383.6	LINC00854	-5.6	5.41e-08	3e-05	-0.27	-0.33	Menopause (age at onset);	chr17:43358815	chr17:43216941~43305976:-
KIRP	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	5.6	5.41e-08	3e-05	0.54	0.33	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
KIRP	cis	rs7267979	0.932	rs2387891	ENSG00000274414.1	RP5-965G21.4	-5.6	5.41e-08	3e-05	-0.32	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25239007~25245229:-
KIRP	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-5.6	5.41e-08	3e-05	-0.27	-0.33	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
KIRP	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	5.6	5.41e-08	3.01e-05	0.33	0.33	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
KIRP	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-5.6	5.42e-08	3.01e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-5.6	5.42e-08	3.01e-05	-0.32	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	5.6	5.42e-08	3.01e-05	0.33	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	5.6	5.43e-08	3.01e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	5.6	5.43e-08	3.01e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
KIRP	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-5.6	5.43e-08	3.02e-05	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
KIRP	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-5.6	5.43e-08	3.02e-05	-0.44	-0.33	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
KIRP	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	5.6	5.44e-08	3.02e-05	0.36	0.33	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
KIRP	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	5.6	5.44e-08	3.02e-05	0.36	0.33	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
KIRP	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-5.6	5.45e-08	3.02e-05	-0.37	-0.33	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
KIRP	cis	rs755249	0.509	rs11206378	ENSG00000237624.1	OXCT2P1	-5.6	5.45e-08	3.03e-05	-0.4	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.563	rs11932131	ENSG00000196472.4	RP13-644M16.4	5.6	5.46e-08	3.03e-05	0.35	0.33	Obesity-related traits;	chr4:69083829	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs35297888	ENSG00000196472.4	RP13-644M16.4	5.6	5.46e-08	3.03e-05	0.35	0.33	Obesity-related traits;	chr4:69083855	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs35749478	ENSG00000196472.4	RP13-644M16.4	5.6	5.46e-08	3.03e-05	0.35	0.33	Obesity-related traits;	chr4:69083862	chr4:69181660~69182372:+
KIRP	cis	rs9987353	0.62	rs34455383	ENSG00000253893.2	FAM85B	5.6	5.46e-08	3.03e-05	0.46	0.33	Recombination measurement;	chr8:9208948	chr8:8167819~8226614:-
KIRP	cis	rs1552244	0.882	rs36006511	ENSG00000180385.7	EMC3-AS1	5.6	5.46e-08	3.03e-05	0.32	0.33	Alzheimer's disease;	chr3:10012507	chr3:9986893~10006990:+
KIRP	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-5.6	5.49e-08	3.05e-05	-0.43	-0.33	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
KIRP	cis	rs73198271	0.773	rs66618176	ENSG00000253981.4	ALG1L13P	-5.6	5.49e-08	3.05e-05	-0.27	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8236003~8244667:-
KIRP	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-5.6	5.49e-08	3.05e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
KIRP	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-5.6	5.49e-08	3.05e-05	-0.32	-0.33	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-5.6	5.49e-08	3.05e-05	-0.32	-0.33	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-5.6	5.49e-08	3.05e-05	-0.32	-0.33	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
KIRP	cis	rs28386778	0.966	rs2854206	ENSG00000240280.5	TCAM1P	-5.6	5.49e-08	3.05e-05	-0.41	-0.33	Prudent dietary pattern;	chr17:63869843	chr17:63849292~63864379:+
KIRP	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-5.6	5.49e-08	3.05e-05	-0.37	-0.33	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
KIRP	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-5.6	5.49e-08	3.05e-05	-0.37	-0.33	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
KIRP	cis	rs710913	0.618	rs12030495	ENSG00000237624.1	OXCT2P1	5.6	5.5e-08	3.05e-05	0.41	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39514956~39516490:+
KIRP	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-5.6	5.5e-08	3.05e-05	-0.27	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
KIRP	cis	rs4356975	0.563	rs4694171	ENSG00000248763.2	RP13-644M16.5	-5.6	5.51e-08	3.05e-05	-0.35	-0.33	Obesity-related traits;	chr4:69088579	chr4:69066395~69069888:+
KIRP	cis	rs2765539	0.781	rs6428790	ENSG00000231365.4	RP11-418J17.1	-5.6	5.51e-08	3.06e-05	-0.38	-0.33	Waist-hip ratio;	chr1:119063374	chr1:119140396~119275973:+
KIRP	cis	rs4356975	0.795	rs4694599	ENSG00000196472.4	RP13-644M16.4	5.6	5.51e-08	3.06e-05	0.35	0.33	Obesity-related traits;	chr4:69070858	chr4:69181660~69182372:+
KIRP	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-5.6	5.52e-08	3.06e-05	-0.29	-0.33	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
KIRP	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-5.6	5.52e-08	3.06e-05	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
KIRP	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	5.6	5.52e-08	3.06e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
KIRP	cis	rs897984	0.806	rs10782002	ENSG00000275263.1	RP11-1072A3.4	5.6	5.52e-08	3.06e-05	0.33	0.33	Dementia with Lewy bodies;	chr16:30935185	chr16:30956872~30957199:-
KIRP	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-5.6	5.53e-08	3.06e-05	-0.51	-0.33	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
KIRP	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	5.6	5.53e-08	3.07e-05	0.38	0.33	Height;	chr4:55566291	chr4:55363971~55395847:-
KIRP	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-5.6	5.53e-08	3.07e-05	-0.45	-0.33	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
KIRP	cis	rs4356975	0.697	rs6849081	ENSG00000196472.4	RP13-644M16.4	5.6	5.54e-08	3.07e-05	0.36	0.33	Obesity-related traits;	chr4:69144840	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.697	rs58039330	ENSG00000196472.4	RP13-644M16.4	5.6	5.54e-08	3.07e-05	0.36	0.33	Obesity-related traits;	chr4:69149529	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.66	rs60567038	ENSG00000196472.4	RP13-644M16.4	5.6	5.54e-08	3.07e-05	0.36	0.33	Obesity-related traits;	chr4:69150135	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.697	rs58366569	ENSG00000196472.4	RP13-644M16.4	5.6	5.54e-08	3.07e-05	0.36	0.33	Obesity-related traits;	chr4:69150626	chr4:69181660~69182372:+
KIRP	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	5.6	5.54e-08	3.07e-05	0.33	0.33	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
KIRP	cis	rs7267979	0.932	rs6107052	ENSG00000274414.1	RP5-965G21.4	-5.6	5.55e-08	3.07e-05	-0.31	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25239007~25245229:-
KIRP	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-5.59	5.55e-08	3.08e-05	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
KIRP	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-5.59	5.55e-08	3.08e-05	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
KIRP	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-5.59	5.55e-08	3.08e-05	-0.37	-0.33	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-5.59	5.55e-08	3.08e-05	-0.37	-0.33	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
KIRP	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-5.59	5.57e-08	3.09e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
KIRP	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	5.59	5.57e-08	3.09e-05	0.33	0.33	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
KIRP	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	5.59	5.58e-08	3.09e-05	0.92	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
KIRP	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-5.59	5.58e-08	3.09e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
KIRP	cis	rs1153858	1	rs1145091	ENSG00000259433.2	CTD-2651B20.4	-5.59	5.59e-08	3.1e-05	-0.29	-0.33	Homoarginine levels;	chr15:45357798	chr15:45330209~45332634:-
KIRP	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-5.59	5.61e-08	3.11e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
KIRP	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-5.59	5.61e-08	3.11e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
KIRP	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-5.59	5.61e-08	3.11e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
KIRP	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	5.59	5.61e-08	3.11e-05	0.52	0.33	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
KIRP	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.59	5.61e-08	3.11e-05	0.27	0.33	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
KIRP	cis	rs4356975	0.522	rs56388229	ENSG00000196472.4	RP13-644M16.4	5.59	5.61e-08	3.11e-05	0.35	0.33	Obesity-related traits;	chr4:69100940	chr4:69181660~69182372:+
KIRP	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-5.59	5.63e-08	3.12e-05	-0.33	-0.33	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
KIRP	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	5.59	5.64e-08	3.12e-05	0.38	0.33	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
KIRP	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	5.59	5.64e-08	3.12e-05	0.29	0.33	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
KIRP	cis	rs7829975	0.711	rs1039916	ENSG00000253981.4	ALG1L13P	5.59	5.65e-08	3.13e-05	0.26	0.33	Mood instability;	chr8:8828344	chr8:8236003~8244667:-
KIRP	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	5.59	5.65e-08	3.13e-05	0.3	0.33	Axial length;	chr3:53812897	chr3:53797764~53798019:-
KIRP	cis	rs4128705	0.958	rs72880830	ENSG00000249049.1	RP11-763F8.1	5.59	5.66e-08	3.13e-05	0.28	0.33	Amyotrophic lateral sclerosis (sporadic);	chr4:91359432	chr4:91319034~91325306:-
KIRP	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-5.59	5.67e-08	3.14e-05	-0.27	-0.33	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
KIRP	cis	rs4852324	0.536	rs13390332	ENSG00000217702.2	RP11-287D1.4	5.59	5.67e-08	3.14e-05	0.65	0.33	Systemic lupus erythematosus;	chr2:73980230	chr2:74130583~74135395:+
KIRP	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-5.59	5.68e-08	3.14e-05	-0.28	-0.33	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
KIRP	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	5.59	5.68e-08	3.14e-05	0.46	0.33	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
KIRP	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	5.59	5.69e-08	3.15e-05	0.39	0.33	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
KIRP	cis	rs71403859	0.541	rs73588051	ENSG00000260886.1	TAT-AS1	5.59	5.7e-08	3.15e-05	0.68	0.33	Post bronchodilator FEV1;	chr16:71354724	chr16:71565789~71578187:+
KIRP	cis	rs6453278	1	rs6453279	ENSG00000250802.5	ZBED3-AS1	-5.59	5.7e-08	3.16e-05	-0.37	-0.33	Autism;	chr5:77121249	chr5:77086740~77166909:+
KIRP	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	5.59	5.71e-08	3.16e-05	0.53	0.33	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
KIRP	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	5.59	5.71e-08	3.16e-05	0.53	0.33	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
KIRP	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	5.59	5.71e-08	3.16e-05	0.53	0.33	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
KIRP	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	5.59	5.71e-08	3.16e-05	0.53	0.33	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
KIRP	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	5.59	5.71e-08	3.16e-05	0.53	0.33	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
KIRP	cis	rs2625529	0.617	rs2415120	ENSG00000260037.4	CTD-2524L6.3	-5.59	5.71e-08	3.16e-05	-0.26	-0.33	Red blood cell count;	chr15:71813204	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	5.59	5.71e-08	3.16e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	5.59	5.71e-08	3.16e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	5.59	5.71e-08	3.16e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	5.59	5.71e-08	3.16e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-5.59	5.72e-08	3.16e-05	-0.34	-0.33	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
KIRP	cis	rs11773103	0.786	rs73203002	ENSG00000224046.1	AC005076.5	5.59	5.72e-08	3.16e-05	0.44	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87129584	chr7:87151423~87152420:-
KIRP	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	5.59	5.73e-08	3.17e-05	0.28	0.33	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
KIRP	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-5.59	5.73e-08	3.17e-05	-0.36	-0.33	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
KIRP	cis	rs4356975	0.563	rs35402056	ENSG00000196472.4	RP13-644M16.4	5.59	5.75e-08	3.17e-05	0.36	0.33	Obesity-related traits;	chr4:69108549	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4694177	ENSG00000196472.4	RP13-644M16.4	5.59	5.75e-08	3.17e-05	0.36	0.33	Obesity-related traits;	chr4:69110141	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12642938	ENSG00000196472.4	RP13-644M16.4	5.59	5.75e-08	3.17e-05	0.36	0.33	Obesity-related traits;	chr4:69110499	chr4:69181660~69182372:+
KIRP	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	5.59	5.75e-08	3.17e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
KIRP	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	5.59	5.75e-08	3.17e-05	0.44	0.33	Height;	chr6:109429207	chr6:109382795~109383666:+
KIRP	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	5.59	5.76e-08	3.18e-05	0.44	0.33	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
KIRP	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	5.59	5.78e-08	3.19e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	5.59	5.78e-08	3.19e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	5.59	5.78e-08	3.19e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	5.59	5.78e-08	3.19e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	5.59	5.78e-08	3.19e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
KIRP	cis	rs4356975	0.563	rs4538548	ENSG00000196472.4	RP13-644M16.4	5.59	5.78e-08	3.19e-05	0.35	0.33	Obesity-related traits;	chr4:69094951	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600883	ENSG00000196472.4	RP13-644M16.4	5.59	5.78e-08	3.19e-05	0.35	0.33	Obesity-related traits;	chr4:69094953	chr4:69181660~69182372:+
KIRP	cis	rs2749592	0.513	rs9417249	ENSG00000151963.4	RP11-775A3.1	5.59	5.78e-08	3.19e-05	0.38	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:37883594~37884109:+
KIRP	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	5.59	5.78e-08	3.19e-05	0.4	0.33	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
KIRP	cis	rs9926296	0.744	rs460879	ENSG00000260259.1	RP11-368I7.4	5.59	5.78e-08	3.19e-05	0.24	0.33	Vitiligo;	chr16:89646481	chr16:89682620~89686569:-
KIRP	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-5.59	5.78e-08	3.19e-05	-0.38	-0.33	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
KIRP	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	5.59	5.79e-08	3.19e-05	0.27	0.33	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
KIRP	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-5.59	5.79e-08	3.19e-05	-0.45	-0.33	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-5.59	5.79e-08	3.19e-05	-0.45	-0.33	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-5.59	5.79e-08	3.19e-05	-0.45	-0.33	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
KIRP	cis	rs2504916	0.712	rs2619276	ENSG00000230234.1	RP1-276N6.2	-5.59	5.79e-08	3.2e-05	-0.32	-0.33	Response to hepatitis C treatment;	chr6:160278502	chr6:160272617~160276130:+
KIRP	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-5.59	5.8e-08	3.2e-05	-0.28	-0.33	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
KIRP	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-5.59	5.8e-08	3.2e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
KIRP	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	5.59	5.81e-08	3.21e-05	0.35	0.33	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
KIRP	cis	rs4660214	0.614	rs6688708	ENSG00000237624.1	OXCT2P1	-5.59	5.81e-08	3.21e-05	-0.42	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.563	rs6600886	ENSG00000248763.2	RP13-644M16.5	-5.59	5.81e-08	3.21e-05	-0.35	-0.33	Obesity-related traits;	chr4:69104017	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600887	ENSG00000248763.2	RP13-644M16.5	-5.59	5.81e-08	3.21e-05	-0.35	-0.33	Obesity-related traits;	chr4:69104070	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs11249527	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69089267	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6846298	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69089278	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs11249528	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69089337	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs55757747	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69089919	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs56217918	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69089925	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7663584	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69090392	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600876	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69091212	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.583	rs6600877	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69091505	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600878	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69092618	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.583	rs6819757	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69092946	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs57216626	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69093105	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs59415892	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69093191	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs62296942	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69093401	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7437039	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69093758	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7439792	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69093881	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs62296944	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69094492	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600879	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69094669	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600880	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69094762	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4455491	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69095215	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs11940220	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69095222	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs11940316	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69095409	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7662029	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69096194	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7668258	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69096360	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs12647681	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69097442	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12647682	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69097450	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs58544196	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69097740	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7439326	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69098462	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7438244	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69098491	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7441750	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69098803	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7441774	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69098836	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs7434332	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69099141	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4293848	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69099784	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12512526	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69100700	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.522	rs34386959	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69100837	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs55834557	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69100876	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs34318523	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69101135	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.583	rs34630750	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69101208	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12508257	ENSG00000196472.4	RP13-644M16.4	5.59	5.82e-08	3.21e-05	0.35	0.33	Obesity-related traits;	chr4:69101921	chr4:69181660~69182372:+
KIRP	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	5.59	5.82e-08	3.21e-05	0.3	0.33	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
KIRP	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	5.59	5.83e-08	3.21e-05	0.32	0.33	Height;	chr14:75103590	chr14:75011269~75012851:-
KIRP	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	5.59	5.83e-08	3.22e-05	0.28	0.33	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
KIRP	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	5.59	5.83e-08	3.22e-05	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
KIRP	cis	rs2386661	1	rs2386661	ENSG00000228951.1	RP11-336A10.4	5.59	5.84e-08	3.22e-05	0.4	0.33	Breast cancer;	chr10:5628312	chr10:5616862~5618161:-
KIRP	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	5.59	5.84e-08	3.22e-05	0.4	0.33	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
KIRP	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-5.58	5.84e-08	3.22e-05	-0.31	-0.33	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
KIRP	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	5.58	5.85e-08	3.23e-05	0.37	0.33	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
KIRP	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	5.58	5.85e-08	3.23e-05	0.4	0.33	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
KIRP	cis	rs11773103	0.786	rs56365880	ENSG00000224046.1	AC005076.5	5.58	5.86e-08	3.23e-05	0.44	0.33	Bipolar disorder or major depressive disorder (combined);	chr7:87126354	chr7:87151423~87152420:-
KIRP	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	5.58	5.87e-08	3.23e-05	0.43	0.33	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
KIRP	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-5.58	5.87e-08	3.23e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
KIRP	cis	rs2273156	1	rs35106382	ENSG00000226677.3	IGBP1P1	-5.58	5.87e-08	3.24e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965085	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12894365	ENSG00000226677.3	IGBP1P1	-5.58	5.87e-08	3.24e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966185	chr14:34939324~34940332:+
KIRP	cis	rs4356975	0.697	rs5002700	ENSG00000196472.4	RP13-644M16.4	5.58	5.87e-08	3.24e-05	0.36	0.33	Obesity-related traits;	chr4:69155637	chr4:69181660~69182372:+
KIRP	cis	rs1552244	0.882	rs13075842	ENSG00000180385.7	EMC3-AS1	5.58	5.87e-08	3.24e-05	0.32	0.33	Alzheimer's disease;	chr3:10014129	chr3:9986893~10006990:+
KIRP	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-5.58	5.88e-08	3.24e-05	-0.24	-0.33	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
KIRP	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-5.58	5.89e-08	3.24e-05	-0.28	-0.33	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
KIRP	cis	rs4356975	0.563	rs7676472	ENSG00000196472.4	RP13-644M16.4	5.58	5.89e-08	3.24e-05	0.35	0.33	Obesity-related traits;	chr4:69090226	chr4:69181660~69182372:+
KIRP	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	5.58	5.89e-08	3.24e-05	0.77	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
KIRP	cis	rs6085948	0.953	rs6077166	ENSG00000238102.1	RP11-19D2.1	5.58	5.89e-08	3.24e-05	0.37	0.33	Interleukin-10 levels;	chr20:7252921	chr20:7256580~7258214:-
KIRP	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	5.58	5.91e-08	3.25e-05	0.38	0.33	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
KIRP	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	5.58	5.91e-08	3.25e-05	0.31	0.33	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
KIRP	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	5.58	5.92e-08	3.26e-05	0.31	0.33	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
KIRP	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	5.58	5.92e-08	3.26e-05	0.4	0.33	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
KIRP	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-5.58	5.92e-08	3.26e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
KIRP	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	5.58	5.92e-08	3.26e-05	0.4	0.33	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
KIRP	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-5.58	5.92e-08	3.26e-05	-0.42	-0.33	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
KIRP	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-5.58	5.93e-08	3.26e-05	-0.32	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
KIRP	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	5.58	5.93e-08	3.26e-05	0.29	0.33	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
KIRP	cis	rs2734839	0.964	rs4587762	ENSG00000270179.1	RP11-159N11.4	-5.58	5.93e-08	3.26e-05	-0.29	-0.33	Information processing speed;	chr11:113436171	chr11:113368478~113369117:+
KIRP	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	5.58	5.96e-08	3.28e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
KIRP	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-5.58	5.97e-08	3.29e-05	-0.41	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-5.58	5.97e-08	3.29e-05	-0.41	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
KIRP	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-5.58	5.98e-08	3.29e-05	-0.41	-0.33	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
KIRP	cis	rs7378815	0.685	rs397430	ENSG00000250787.1	HMGN1P17	-5.58	5.98e-08	3.29e-05	-0.31	-0.33	Breast cancer;	chr5:56358681	chr5:56381781~56382075:+
KIRP	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-5.58	5.99e-08	3.29e-05	-0.41	-0.33	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
KIRP	cis	rs67311347	0.544	rs2278927	ENSG00000230274.1	PGAM1P3	5.58	6e-08	3.3e-05	0.33	0.33	Renal cell carcinoma;	chr3:40308956	chr3:40322715~40323279:-
KIRP	cis	rs1560104	0.597	rs12162027	ENSG00000274834.1	CTD-3037G24.5	5.58	6.01e-08	3.3e-05	0.36	0.33	Obesity-related traits;	chr16:12616235	chr16:12614451~12614852:+
KIRP	cis	rs2273156	0.929	rs8017225	ENSG00000226677.3	IGBP1P1	-5.58	6.01e-08	3.3e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000843	chr14:34939324~34940332:+
KIRP	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	5.58	6.01e-08	3.3e-05	0.45	0.33	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	5.58	6.01e-08	3.3e-05	0.45	0.33	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
KIRP	cis	rs7569084	0.687	rs4671663	ENSG00000237979.1	AC007389.1	5.58	6.01e-08	3.3e-05	0.38	0.33	Sum eosinophil basophil counts;	chr2:65434400	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.687	rs11692813	ENSG00000237979.1	AC007389.1	5.58	6.01e-08	3.3e-05	0.38	0.33	Sum eosinophil basophil counts;	chr2:65435172	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.663	rs11126037	ENSG00000237979.1	AC007389.1	5.58	6.01e-08	3.3e-05	0.38	0.33	Sum eosinophil basophil counts;	chr2:65436024	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.687	rs11126038	ENSG00000237979.1	AC007389.1	5.58	6.01e-08	3.3e-05	0.38	0.33	Sum eosinophil basophil counts;	chr2:65436100	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.663	rs11694714	ENSG00000237979.1	AC007389.1	5.58	6.01e-08	3.3e-05	0.38	0.33	Sum eosinophil basophil counts;	chr2:65436802	chr2:65500993~65502138:-
KIRP	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	5.58	6.01e-08	3.3e-05	0.25	0.33	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
KIRP	cis	rs1061377	0.56	rs6531690	ENSG00000249207.1	RP11-360F5.1	-5.58	6.02e-08	3.31e-05	-0.34	-0.33	Uric acid levels;	chr4:39072583	chr4:39112677~39126818:-
KIRP	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	5.58	6.03e-08	3.31e-05	0.42	0.33	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	5.58	6.03e-08	3.31e-05	0.42	0.33	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	5.58	6.03e-08	3.31e-05	0.42	0.33	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
KIRP	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-5.58	6.04e-08	3.32e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
KIRP	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	5.58	6.04e-08	3.32e-05	0.27	0.33	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
KIRP	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-5.58	6.04e-08	3.32e-05	-0.27	-0.33	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-5.58	6.04e-08	3.32e-05	-0.27	-0.33	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs316306	ENSG00000224316.1	RP11-479O9.2	-5.58	6.04e-08	3.32e-05	-0.27	-0.33	Aortic root size;	chr7:66153687	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs2460427	ENSG00000224316.1	RP11-479O9.2	-5.58	6.04e-08	3.32e-05	-0.27	-0.33	Aortic root size;	chr7:66154218	chr7:65773620~65802067:+
KIRP	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	5.58	6.05e-08	3.32e-05	0.28	0.33	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
KIRP	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	5.58	6.05e-08	3.32e-05	0.36	0.33	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
KIRP	cis	rs11647589	0.834	rs2271061	ENSG00000262995.1	CTD-2194A8.2	-5.58	6.05e-08	3.33e-05	-0.36	-0.33	Blood metabolite levels;	chr16:20471429	chr16:20440266~20447000:-
KIRP	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	5.58	6.06e-08	3.33e-05	0.53	0.33	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
KIRP	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-5.58	6.06e-08	3.33e-05	-0.28	-0.33	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
KIRP	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-5.58	6.06e-08	3.33e-05	-0.28	-0.33	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
KIRP	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-5.58	6.07e-08	3.33e-05	-0.4	-0.33	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
KIRP	cis	rs453301	0.571	rs2929305	ENSG00000253981.4	ALG1L13P	-5.58	6.07e-08	3.34e-05	-0.26	-0.33	Joint mobility (Beighton score);	chr8:9227707	chr8:8236003~8244667:-
KIRP	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	5.58	6.08e-08	3.34e-05	0.52	0.33	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	5.58	6.08e-08	3.34e-05	0.52	0.33	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
KIRP	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	5.58	6.08e-08	3.34e-05	0.38	0.33	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
KIRP	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-5.58	6.08e-08	3.34e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
KIRP	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	5.58	6.09e-08	3.34e-05	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
KIRP	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	5.58	6.09e-08	3.34e-05	0.32	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	5.58	6.1e-08	3.35e-05	0.32	0.33	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
KIRP	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-5.58	6.1e-08	3.35e-05	-0.43	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
KIRP	cis	rs7224610	0.931	rs7223342	ENSG00000263096.1	RP11-515O17.2	5.58	6.11e-08	3.35e-05	0.44	0.33	Urate levels;	chr17:55292233	chr17:55271504~55273653:-
KIRP	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	5.58	6.11e-08	3.35e-05	0.43	0.33	Height;	chr6:109478720	chr6:109382795~109383666:+
KIRP	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-5.58	6.11e-08	3.35e-05	-0.41	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
KIRP	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	5.58	6.11e-08	3.35e-05	0.91	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	5.58	6.11e-08	3.35e-05	0.91	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	5.58	6.11e-08	3.35e-05	0.91	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
KIRP	cis	rs1799949	1	rs11651341	ENSG00000236383.6	LINC00854	-5.58	6.11e-08	3.36e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43350693	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs34572725	ENSG00000236383.6	LINC00854	-5.58	6.11e-08	3.36e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43351298	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4534897	ENSG00000236383.6	LINC00854	-5.58	6.11e-08	3.36e-05	-0.26	-0.33	Menopause (age at onset);	chr17:43354440	chr17:43216941~43305976:-
KIRP	cis	rs4356975	0.649	rs59421013	ENSG00000196472.4	RP13-644M16.4	5.58	6.12e-08	3.36e-05	0.36	0.33	Obesity-related traits;	chr4:69149131	chr4:69181660~69182372:+
KIRP	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-5.58	6.12e-08	3.36e-05	-0.38	-0.33	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
KIRP	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs67611618	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8523429	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	5.58	6.12e-08	3.36e-05	0.49	0.33	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
KIRP	cis	rs28386778	1	rs3020613	ENSG00000240280.5	TCAM1P	-5.58	6.13e-08	3.36e-05	-0.41	-0.33	Prudent dietary pattern;	chr17:63878623	chr17:63849292~63864379:+
KIRP	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	5.58	6.13e-08	3.37e-05	0.27	0.33	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
KIRP	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-5.58	6.14e-08	3.37e-05	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
KIRP	cis	rs77204473	0.744	rs12420361	ENSG00000254851.1	RP11-109L13.1	5.58	6.14e-08	3.37e-05	0.9	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117123072	chr11:117135528~117138582:+
KIRP	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	5.58	6.14e-08	3.37e-05	0.39	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
KIRP	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-5.57	6.15e-08	3.37e-05	-0.36	-0.33	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
KIRP	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	5.57	6.15e-08	3.37e-05	0.37	0.33	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
KIRP	cis	rs78905543	1	rs55804226	ENSG00000253616.4	RP11-875O11.3	5.57	6.16e-08	3.38e-05	0.37	0.33	Mean corpuscular volume;	chr8:23072158	chr8:23071377~23074488:-
KIRP	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	5.57	6.16e-08	3.38e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
KIRP	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-5.57	6.16e-08	3.38e-05	-0.27	-0.33	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
KIRP	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-5.57	6.16e-08	3.38e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
KIRP	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	5.57	6.16e-08	3.38e-05	0.46	0.33	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	5.57	6.16e-08	3.38e-05	0.46	0.33	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	5.57	6.16e-08	3.38e-05	0.46	0.33	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
KIRP	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	5.57	6.17e-08	3.38e-05	0.44	0.33	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
KIRP	cis	rs2273156	1	rs36008567	ENSG00000226677.3	IGBP1P1	-5.57	6.17e-08	3.38e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34951870	chr14:34939324~34940332:+
KIRP	cis	rs2273156	0.925	rs12890056	ENSG00000226677.3	IGBP1P1	-5.57	6.17e-08	3.38e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34952928	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12161905	ENSG00000226677.3	IGBP1P1	-5.57	6.17e-08	3.38e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953087	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12888272	ENSG00000226677.3	IGBP1P1	-5.57	6.17e-08	3.38e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34956396	chr14:34939324~34940332:+
KIRP	cis	rs8067545	0.641	rs4925060	ENSG00000270091.1	RP11-78O7.2	-5.57	6.17e-08	3.38e-05	-0.21	-0.33	Schizophrenia;	chr17:19959945	chr17:19896590~19897287:-
KIRP	cis	rs1552244	0.882	rs6443279	ENSG00000180385.7	EMC3-AS1	5.57	6.18e-08	3.39e-05	0.32	0.33	Alzheimer's disease;	chr3:10011915	chr3:9986893~10006990:+
KIRP	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-5.57	6.19e-08	3.39e-05	-0.42	-0.33	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	5.57	6.19e-08	3.39e-05	0.41	0.33	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
KIRP	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	5.57	6.2e-08	3.4e-05	0.31	0.33	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
KIRP	cis	rs897984	0.762	rs2054213	ENSG00000275263.1	RP11-1072A3.4	5.57	6.2e-08	3.4e-05	0.34	0.33	Dementia with Lewy bodies;	chr16:30960489	chr16:30956872~30957199:-
KIRP	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	5.57	6.2e-08	3.4e-05	0.44	0.33	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
KIRP	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	5.57	6.21e-08	3.4e-05	0.54	0.33	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
KIRP	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-5.57	6.21e-08	3.4e-05	-0.35	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-5.57	6.21e-08	3.4e-05	-0.35	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-5.57	6.21e-08	3.4e-05	-0.35	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
KIRP	cis	rs11158026	0.757	rs6572994	ENSG00000258413.1	RP11-665C16.6	-5.57	6.21e-08	3.4e-05	-0.39	-0.33	Parkinson's disease;	chr14:54960385	chr14:55262767~55272075:-
KIRP	cis	rs11647589	0.815	rs7194852	ENSG00000262995.1	CTD-2194A8.2	-5.57	6.23e-08	3.41e-05	-0.37	-0.33	Blood metabolite levels;	chr16:20461954	chr16:20440266~20447000:-
KIRP	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-5.57	6.23e-08	3.41e-05	-0.37	-0.33	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
KIRP	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	5.57	6.24e-08	3.42e-05	0.39	0.33	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
KIRP	cis	rs947583	0.955	rs7760254	ENSG00000231028.7	LINC00271	5.57	6.24e-08	3.42e-05	0.29	0.33	Phosphorus levels;	chr6:135811157	chr6:135497801~135716055:+
KIRP	cis	rs2625529	0.617	rs2128112	ENSG00000260037.4	CTD-2524L6.3	5.57	6.24e-08	3.42e-05	0.25	0.33	Red blood cell count;	chr15:71893945	chr15:71818396~71823384:+
KIRP	cis	rs2273156	1	rs56686328	ENSG00000226677.3	IGBP1P1	-5.57	6.26e-08	3.43e-05	-0.34	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:34988864	chr14:34939324~34940332:+
KIRP	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-5.57	6.26e-08	3.43e-05	-0.43	-0.33	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
KIRP	cis	rs2625529	0.591	rs7172158	ENSG00000260037.4	CTD-2524L6.3	5.57	6.27e-08	3.43e-05	0.26	0.33	Red blood cell count;	chr15:72112972	chr15:71818396~71823384:+
KIRP	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-5.57	6.27e-08	3.43e-05	-0.45	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
KIRP	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-5.57	6.27e-08	3.43e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-5.57	6.27e-08	3.43e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
KIRP	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-5.57	6.28e-08	3.43e-05	-0.35	-0.33	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
KIRP	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-5.57	6.28e-08	3.43e-05	-0.27	-0.33	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-5.57	6.28e-08	3.43e-05	-0.27	-0.33	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
KIRP	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.57	6.28e-08	3.43e-05	-0.36	-0.33	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
KIRP	cis	rs4356975	0.503	rs11938761	ENSG00000196472.4	RP13-644M16.4	5.57	6.28e-08	3.44e-05	0.35	0.33	Obesity-related traits;	chr4:69083992	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.545	rs11935886	ENSG00000196472.4	RP13-644M16.4	5.57	6.28e-08	3.44e-05	0.35	0.33	Obesity-related traits;	chr4:69083994	chr4:69181660~69182372:+
KIRP	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-5.57	6.28e-08	3.44e-05	-0.33	-0.33	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
KIRP	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	5.57	6.28e-08	3.44e-05	0.32	0.33	Height;	chr14:75066238	chr14:75011269~75012851:-
KIRP	cis	rs1153858	1	rs7169818	ENSG00000259433.2	CTD-2651B20.4	-5.57	6.3e-08	3.44e-05	-0.29	-0.33	Homoarginine levels;	chr15:45347993	chr15:45330209~45332634:-
KIRP	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-5.57	6.31e-08	3.45e-05	-0.28	-0.33	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
KIRP	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	5.57	6.31e-08	3.45e-05	0.41	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
KIRP	cis	rs2562456	0.55	rs4809143	ENSG00000268555.1	RP11-678G14.3	5.57	6.31e-08	3.45e-05	0.48	0.33	Pain;	chr19:21589926	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.583	rs4809144	ENSG00000268555.1	RP11-678G14.3	5.57	6.31e-08	3.45e-05	0.48	0.33	Pain;	chr19:21589928	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.652	rs62110214	ENSG00000268555.1	RP11-678G14.3	5.57	6.31e-08	3.45e-05	0.48	0.33	Pain;	chr19:21592406	chr19:21570822~21587322:-
KIRP	cis	rs2255336	0.938	rs60528788	ENSG00000245648.1	RP11-277P12.20	-5.57	6.32e-08	3.46e-05	-0.45	-0.33	Blood protein levels;	chr12:10444430	chr12:10363769~10398506:+
KIRP	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-5.57	6.32e-08	3.46e-05	-0.53	-0.33	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
KIRP	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	5.57	6.32e-08	3.46e-05	0.25	0.33	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
KIRP	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-5.57	6.32e-08	3.46e-05	-0.25	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
KIRP	cis	rs2299587	0.604	rs11203933	ENSG00000254054.2	RP11-156K13.3	5.57	6.33e-08	3.46e-05	0.38	0.33	Economic and political preferences;	chr8:18044401	chr8:17905756~17907887:+
KIRP	cis	rs2625529	0.668	rs34189331	ENSG00000260037.4	CTD-2524L6.3	-5.57	6.33e-08	3.46e-05	-0.28	-0.33	Red blood cell count;	chr15:72112232	chr15:71818396~71823384:+
KIRP	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.57	6.33e-08	3.46e-05	-0.36	-0.33	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
KIRP	cis	rs4356975	0.563	rs4554144	ENSG00000248763.2	RP13-644M16.5	-5.57	6.34e-08	3.47e-05	-0.34	-0.33	Obesity-related traits;	chr4:69094837	chr4:69066395~69069888:+
KIRP	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	5.57	6.35e-08	3.47e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
KIRP	cis	rs950169	0.922	rs11635505	ENSG00000275120.1	RP11-182J1.17	-5.57	6.35e-08	3.47e-05	-0.43	-0.33	Schizophrenia;	chr15:84553803	chr15:84599434~84606463:-
KIRP	cis	rs11158026	0.757	rs9285583	ENSG00000258413.1	RP11-665C16.6	-5.57	6.36e-08	3.47e-05	-0.39	-0.33	Parkinson's disease;	chr14:54964717	chr14:55262767~55272075:-
KIRP	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	5.57	6.37e-08	3.48e-05	0.34	0.33	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
KIRP	cis	rs8067545	0.641	rs1479129	ENSG00000270091.1	RP11-78O7.2	-5.57	6.37e-08	3.48e-05	-0.21	-0.33	Schizophrenia;	chr17:19942456	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.641	rs169412	ENSG00000270091.1	RP11-78O7.2	-5.57	6.37e-08	3.48e-05	-0.21	-0.33	Schizophrenia;	chr17:19948562	chr17:19896590~19897287:-
KIRP	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	5.57	6.38e-08	3.48e-05	0.7	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	5.57	6.38e-08	3.48e-05	0.7	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
KIRP	cis	rs4356975	0.527	rs57102579	ENSG00000196472.4	RP13-644M16.4	5.57	6.38e-08	3.48e-05	0.35	0.33	Obesity-related traits;	chr4:69125476	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.527	rs4385139	ENSG00000196472.4	RP13-644M16.4	5.57	6.38e-08	3.48e-05	0.35	0.33	Obesity-related traits;	chr4:69125911	chr4:69181660~69182372:+
KIRP	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	5.57	6.38e-08	3.49e-05	0.37	0.33	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
KIRP	cis	rs2625529	0.816	rs8025504	ENSG00000260037.4	CTD-2524L6.3	-5.57	6.39e-08	3.49e-05	-0.28	-0.33	Red blood cell count;	chr15:72002416	chr15:71818396~71823384:+
KIRP	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	5.57	6.39e-08	3.49e-05	0.4	0.33	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
KIRP	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-5.57	6.39e-08	3.49e-05	-0.35	-0.33	Height;	chr3:53070344	chr3:53064283~53065091:-
KIRP	cis	rs710913	0.717	rs1180349	ENSG00000237624.1	OXCT2P1	-5.57	6.4e-08	3.49e-05	-0.39	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39514956~39516490:+
KIRP	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-5.57	6.4e-08	3.49e-05	-0.41	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-5.57	6.4e-08	3.49e-05	-0.41	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
KIRP	cis	rs4356975	0.563	rs7685151	ENSG00000196472.4	RP13-644M16.4	5.57	6.41e-08	3.5e-05	0.35	0.33	Obesity-related traits;	chr4:69114055	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.583	rs11936822	ENSG00000196472.4	RP13-644M16.4	5.57	6.41e-08	3.5e-05	0.35	0.33	Obesity-related traits;	chr4:69114229	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs34814736	ENSG00000196472.4	RP13-644M16.4	5.57	6.41e-08	3.5e-05	0.35	0.33	Obesity-related traits;	chr4:69114760	chr4:69181660~69182372:+
KIRP	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	5.57	6.41e-08	3.5e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	5.57	6.41e-08	3.5e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	5.57	6.41e-08	3.5e-05	0.35	0.33	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
KIRP	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	5.57	6.41e-08	3.5e-05	0.36	0.33	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
KIRP	cis	rs3121446	0.889	rs3104041	ENSG00000229654.1	RP1-60O19.2	5.57	6.42e-08	3.5e-05	0.34	0.33	Daytime sleep phenotypes;	chr6:106693853	chr6:106695535~106699994:+
KIRP	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	5.57	6.44e-08	3.52e-05	0.26	0.33	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	5.57	6.44e-08	3.52e-05	0.26	0.33	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
KIRP	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-5.57	6.45e-08	3.52e-05	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
KIRP	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	5.57	6.45e-08	3.52e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	5.57	6.45e-08	3.52e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
KIRP	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	5.57	6.45e-08	3.52e-05	0.4	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
KIRP	cis	rs4934494	0.911	rs7098233	ENSG00000232936.4	RP11-80H5.2	-5.56	6.48e-08	3.53e-05	-0.42	-0.33	Red blood cell count;	chr10:89663111	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.911	rs7081788	ENSG00000232936.4	RP11-80H5.2	5.56	6.48e-08	3.53e-05	0.42	0.33	Red blood cell count;	chr10:89648999	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.911	rs34486602	ENSG00000232936.4	RP11-80H5.2	5.56	6.48e-08	3.53e-05	0.42	0.33	Red blood cell count;	chr10:89655895	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.911	rs6586213	ENSG00000232936.4	RP11-80H5.2	5.56	6.48e-08	3.53e-05	0.42	0.33	Red blood cell count;	chr10:89656327	chr10:89645282~89650667:+
KIRP	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-5.56	6.48e-08	3.53e-05	-0.34	-0.33	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
KIRP	cis	rs2486288	0.656	rs11629858	ENSG00000259433.2	CTD-2651B20.4	5.56	6.48e-08	3.53e-05	0.28	0.33	Glomerular filtration rate;	chr15:45254916	chr15:45330209~45332634:-
KIRP	cis	rs2486288	0.656	rs11629859	ENSG00000259433.2	CTD-2651B20.4	5.56	6.48e-08	3.53e-05	0.28	0.33	Glomerular filtration rate;	chr15:45254923	chr15:45330209~45332634:-
KIRP	cis	rs4356975	0.522	rs7679184	ENSG00000248763.2	RP13-644M16.5	-5.56	6.48e-08	3.53e-05	-0.34	-0.33	Obesity-related traits;	chr4:69100212	chr4:69066395~69069888:+
KIRP	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	5.56	6.48e-08	3.54e-05	0.43	0.33	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	5.56	6.48e-08	3.54e-05	0.43	0.33	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	5.56	6.48e-08	3.54e-05	0.43	0.33	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
KIRP	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-5.56	6.5e-08	3.54e-05	-0.45	-0.33	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
KIRP	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.56	6.5e-08	3.54e-05	0.37	0.33	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
KIRP	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-5.56	6.51e-08	3.55e-05	-0.27	-0.33	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
KIRP	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	5.56	6.52e-08	3.55e-05	0.36	0.33	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
KIRP	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	5.56	6.52e-08	3.55e-05	0.26	0.33	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
KIRP	cis	rs10916248	0.569	rs4654002	ENSG00000232628.4	RP11-365O16.3	5.56	6.54e-08	3.56e-05	0.36	0.33	QT interval (drug interaction);	chr1:224075680	chr1:224208747~224213279:-
KIRP	cis	rs713477	1	rs8010013	ENSG00000258413.1	RP11-665C16.6	5.56	6.54e-08	3.56e-05	0.41	0.33	Pediatric bone mineral content (femoral neck);	chr14:55418110	chr14:55262767~55272075:-
KIRP	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-5.56	6.54e-08	3.56e-05	-0.89	-0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
KIRP	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	5.56	6.55e-08	3.57e-05	0.42	0.33	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-5.56	6.55e-08	3.57e-05	-0.51	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
KIRP	cis	rs79040073	0.637	rs11632575	ENSG00000259531.2	RP11-295H24.3	5.56	6.56e-08	3.57e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49380758	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.594	rs59112977	ENSG00000259531.2	RP11-295H24.3	5.56	6.56e-08	3.57e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49382342	chr15:49365124~49366685:-
KIRP	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-5.56	6.57e-08	3.58e-05	-0.24	-0.32	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
KIRP	cis	rs12571093	0.803	rs61854839	ENSG00000233590.1	RP11-153K11.3	-5.56	6.58e-08	3.58e-05	-0.5	-0.32	Optic nerve measurement (disc area);	chr10:68284859	chr10:68233251~68242379:-
KIRP	cis	rs9388451	0.903	rs9388446	ENSG00000237742.5	RP11-624M8.1	-5.56	6.58e-08	3.58e-05	-0.34	-0.32	Brugada syndrome;	chr6:125743774	chr6:125578558~125749190:-
KIRP	cis	rs7829975	0.871	rs777709	ENSG00000253981.4	ALG1L13P	-5.56	6.59e-08	3.59e-05	-0.25	-0.32	Mood instability;	chr8:8726362	chr8:8236003~8244667:-
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	5.56	6.6e-08	3.59e-05	0.25	0.32	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	5.56	6.6e-08	3.59e-05	0.25	0.32	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	5.56	6.6e-08	3.59e-05	0.25	0.32	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	5.56	6.6e-08	3.59e-05	0.25	0.32	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	5.56	6.6e-08	3.59e-05	0.25	0.32	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
KIRP	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-5.56	6.6e-08	3.59e-05	-0.46	-0.32	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
KIRP	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-5.56	6.61e-08	3.6e-05	-0.38	-0.32	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
KIRP	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	5.56	6.62e-08	3.6e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
KIRP	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	5.56	6.62e-08	3.6e-05	0.36	0.32	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
KIRP	cis	rs2625529	0.526	rs55763892	ENSG00000260037.4	CTD-2524L6.3	5.56	6.64e-08	3.61e-05	0.26	0.32	Red blood cell count;	chr15:72247839	chr15:71818396~71823384:+
KIRP	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-5.56	6.65e-08	3.61e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
KIRP	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-5.56	6.65e-08	3.62e-05	-0.38	-0.32	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
KIRP	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-5.56	6.65e-08	3.62e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-5.56	6.65e-08	3.62e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
KIRP	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-5.56	6.66e-08	3.62e-05	-0.37	-0.32	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
KIRP	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	5.56	6.67e-08	3.63e-05	0.33	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
KIRP	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-5.56	6.68e-08	3.63e-05	-0.28	-0.32	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
KIRP	cis	rs7267979	0.873	rs7453	ENSG00000274414.1	RP5-965G21.4	-5.56	6.7e-08	3.64e-05	-0.3	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25239007~25245229:-
KIRP	cis	rs4638749	0.677	rs6755078	ENSG00000231221.1	AC023672.2	-5.56	6.7e-08	3.64e-05	-0.38	-0.32	Blood pressure;	chr2:108201814	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs13423385	ENSG00000231221.1	AC023672.2	-5.56	6.7e-08	3.64e-05	-0.38	-0.32	Blood pressure;	chr2:108209979	chr2:108049200~108052755:-
KIRP	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	5.56	6.7e-08	3.64e-05	0.31	0.32	Height;	chr4:55540912	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	5.56	6.7e-08	3.64e-05	0.31	0.32	Height;	chr4:55540972	chr4:55547112~55547889:+
KIRP	cis	rs4356975	0.563	rs11933459	ENSG00000196472.4	RP13-644M16.4	5.56	6.72e-08	3.65e-05	0.35	0.32	Obesity-related traits;	chr4:69116045	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs6600895	ENSG00000196472.4	RP13-644M16.4	5.56	6.72e-08	3.65e-05	0.35	0.32	Obesity-related traits;	chr4:69117694	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs4508963	ENSG00000196472.4	RP13-644M16.4	5.56	6.72e-08	3.65e-05	0.35	0.32	Obesity-related traits;	chr4:69118770	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs12505466	ENSG00000196472.4	RP13-644M16.4	5.56	6.72e-08	3.65e-05	0.35	0.32	Obesity-related traits;	chr4:69119944	chr4:69181660~69182372:+
KIRP	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-5.56	6.73e-08	3.66e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-5.56	6.73e-08	3.66e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
KIRP	cis	rs710913	0.691	rs1180351	ENSG00000237624.1	OXCT2P1	-5.56	6.74e-08	3.66e-05	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39514956~39516490:+
KIRP	cis	rs710913	0.717	rs1180352	ENSG00000237624.1	OXCT2P1	-5.56	6.74e-08	3.66e-05	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	5.56	6.75e-08	3.66e-05	0.38	0.32	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
KIRP	cis	rs12571093	0.773	rs61854802	ENSG00000233590.1	RP11-153K11.3	-5.56	6.75e-08	3.67e-05	-0.51	-0.32	Optic nerve measurement (disc area);	chr10:68249815	chr10:68233251~68242379:-
KIRP	cis	rs950169	0.922	rs11633534	ENSG00000275120.1	RP11-182J1.17	5.56	6.75e-08	3.67e-05	0.43	0.32	Schizophrenia;	chr15:84581411	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.65	rs12902052	ENSG00000275120.1	RP11-182J1.17	5.56	6.75e-08	3.67e-05	0.43	0.32	Schizophrenia;	chr15:84582607	chr15:84599434~84606463:-
KIRP	cis	rs11158026	0.757	rs7146285	ENSG00000258413.1	RP11-665C16.6	-5.56	6.76e-08	3.67e-05	-0.39	-0.32	Parkinson's disease;	chr14:54946151	chr14:55262767~55272075:-
KIRP	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	5.56	6.76e-08	3.67e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	5.56	6.76e-08	3.67e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	5.56	6.76e-08	3.67e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	5.56	6.76e-08	3.67e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	5.56	6.76e-08	3.67e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
KIRP	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	5.56	6.77e-08	3.67e-05	0.4	0.32	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
KIRP	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	5.56	6.77e-08	3.68e-05	0.36	0.32	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
KIRP	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-5.56	6.77e-08	3.68e-05	-0.44	-0.32	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
KIRP	cis	rs11079159	0.958	rs11656277	ENSG00000263096.1	RP11-515O17.2	5.56	6.78e-08	3.68e-05	0.47	0.32	QRS duration;	chr17:55293686	chr17:55271504~55273653:-
KIRP	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	5.56	6.8e-08	3.69e-05	0.32	0.32	Height;	chr14:74993858	chr14:75011269~75012851:-
KIRP	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	5.56	6.81e-08	3.69e-05	0.27	0.32	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
KIRP	cis	rs2486288	0.656	rs11854325	ENSG00000259433.2	CTD-2651B20.4	5.56	6.81e-08	3.7e-05	0.28	0.32	Glomerular filtration rate;	chr15:45256761	chr15:45330209~45332634:-
KIRP	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	5.55	6.82e-08	3.7e-05	0.25	0.32	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
KIRP	cis	rs28386778	1	rs2665851	ENSG00000240280.5	TCAM1P	-5.55	6.82e-08	3.7e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63879663	chr17:63849292~63864379:+
KIRP	cis	rs9388451	0.839	rs11154331	ENSG00000237742.5	RP11-624M8.1	-5.55	6.82e-08	3.7e-05	-0.34	-0.32	Brugada syndrome;	chr6:125790283	chr6:125578558~125749190:-
KIRP	cis	rs1153858	1	rs2467858	ENSG00000259433.2	CTD-2651B20.4	-5.55	6.82e-08	3.7e-05	-0.29	-0.32	Homoarginine levels;	chr15:45419294	chr15:45330209~45332634:-
KIRP	cis	rs763121	0.853	rs5750627	ENSG00000273076.1	RP3-508I15.22	5.55	6.83e-08	3.7e-05	0.3	0.32	Menopause (age at onset);	chr22:38586316	chr22:38743495~38743910:+
KIRP	cis	rs1479119	0.78	rs1479114	ENSG00000180861.8	LINC01559	-5.55	6.83e-08	3.7e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:13347305	chr12:13371089~13387167:-
KIRP	cis	rs1799949	1	rs11653069	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43131360	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs33988650	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43135863	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11656097	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43138596	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11658754	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43140722	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs33968979	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43145975	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12952790	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43147590	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12950607	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43147911	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11079056	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43148782	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12936816	ENSG00000236383.6	LINC00854	-5.55	6.83e-08	3.7e-05	-0.27	-0.32	Menopause (age at onset);	chr17:43149692	chr17:43216941~43305976:-
KIRP	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-5.55	6.84e-08	3.71e-05	-0.36	-0.32	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
KIRP	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	5.55	6.85e-08	3.72e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	5.55	6.85e-08	3.72e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	5.55	6.85e-08	3.72e-05	0.38	0.32	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
KIRP	cis	rs7829975	0.686	rs907180	ENSG00000253981.4	ALG1L13P	5.55	6.86e-08	3.72e-05	0.25	0.32	Mood instability;	chr8:8845317	chr8:8236003~8244667:-
KIRP	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-5.55	6.86e-08	3.72e-05	-0.33	-0.32	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-5.55	6.86e-08	3.72e-05	-0.33	-0.32	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
KIRP	cis	rs2439831	1	rs28628574	ENSG00000249839.1	AC011330.5	-5.55	6.86e-08	3.72e-05	-0.51	-0.32	Lung cancer in ever smokers;	chr15:43509840	chr15:43663654~43684339:-
KIRP	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	5.55	6.87e-08	3.72e-05	0.24	0.32	Height;	chr20:35197247	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	5.55	6.87e-08	3.72e-05	0.24	0.32	Height;	chr20:35197418	chr20:35201747~35203288:-
KIRP	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	5.55	6.87e-08	3.72e-05	0.24	0.32	Height;	chr20:35201339	chr20:35201747~35203288:-
KIRP	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-5.55	6.87e-08	3.72e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
KIRP	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-5.55	6.87e-08	3.72e-05	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-5.55	6.87e-08	3.72e-05	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	5.55	6.88e-08	3.73e-05	0.25	0.32	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
KIRP	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-5.55	6.88e-08	3.73e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-5.55	6.88e-08	3.73e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-5.55	6.88e-08	3.73e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
KIRP	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-5.55	6.89e-08	3.73e-05	-0.36	-0.32	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
KIRP	cis	rs2625529	0.617	rs62023343	ENSG00000260037.4	CTD-2524L6.3	5.55	6.89e-08	3.73e-05	0.25	0.32	Red blood cell count;	chr15:71882622	chr15:71818396~71823384:+
KIRP	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	5.55	6.9e-08	3.74e-05	0.36	0.32	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	5.55	6.9e-08	3.74e-05	0.25	0.32	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	5.55	6.9e-08	3.74e-05	0.25	0.32	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
KIRP	cis	rs984222	0.559	rs61807010	ENSG00000231365.4	RP11-418J17.1	5.55	6.91e-08	3.74e-05	0.3	0.32	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119200568	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	5.55	6.91e-08	3.74e-05	0.38	0.32	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
KIRP	cis	rs710913	0.745	rs1180334	ENSG00000237624.1	OXCT2P1	-5.55	6.91e-08	3.74e-05	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39514956~39516490:+
KIRP	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	5.55	6.91e-08	3.74e-05	0.4	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
KIRP	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	5.55	6.92e-08	3.75e-05	0.38	0.32	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
KIRP	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	5.55	6.92e-08	3.75e-05	0.36	0.32	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
KIRP	cis	rs763121	0.853	rs1013338	ENSG00000273076.1	RP3-508I15.22	5.55	6.93e-08	3.75e-05	0.3	0.32	Menopause (age at onset);	chr22:38578149	chr22:38743495~38743910:+
KIRP	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	5.55	6.93e-08	3.75e-05	0.24	0.32	Height;	chr20:35192965	chr20:35201747~35203288:-
KIRP	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-5.55	6.93e-08	3.75e-05	-0.28	-0.32	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	5.55	6.93e-08	3.75e-05	0.28	0.32	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
KIRP	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-5.55	6.93e-08	3.75e-05	-0.39	-0.32	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-5.55	6.93e-08	3.75e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-5.55	6.93e-08	3.75e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
KIRP	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	5.55	6.94e-08	3.76e-05	0.44	0.32	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	5.55	6.94e-08	3.76e-05	0.25	0.32	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
KIRP	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	5.55	6.95e-08	3.76e-05	0.38	0.32	Height;	chr4:55501955	chr4:55363971~55395847:-
KIRP	cis	rs7378815	0.685	rs290758	ENSG00000250787.1	HMGN1P17	-5.55	6.96e-08	3.77e-05	-0.32	-0.32	Breast cancer;	chr5:56356629	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs290757	ENSG00000250787.1	HMGN1P17	-5.55	6.96e-08	3.77e-05	-0.32	-0.32	Breast cancer;	chr5:56356661	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs290755	ENSG00000250787.1	HMGN1P17	-5.55	6.96e-08	3.77e-05	-0.32	-0.32	Breast cancer;	chr5:56357246	chr5:56381781~56382075:+
KIRP	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	5.55	6.96e-08	3.77e-05	0.37	0.32	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-5.55	6.96e-08	3.77e-05	-0.36	-0.32	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
KIRP	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-5.55	6.97e-08	3.77e-05	-0.26	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
KIRP	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	5.55	6.97e-08	3.77e-05	0.5	0.32	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
KIRP	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-5.55	6.97e-08	3.77e-05	-0.31	-0.32	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
KIRP	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	5.55	6.99e-08	3.78e-05	0.32	0.32	Height;	chr14:75142025	chr14:75011269~75012851:-
KIRP	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-5.55	6.99e-08	3.78e-05	-0.36	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
KIRP	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-5.55	7e-08	3.78e-05	-0.36	-0.32	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
KIRP	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-5.55	7e-08	3.79e-05	-0.4	-0.32	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
KIRP	cis	rs28386778	0.933	rs2665801	ENSG00000240280.5	TCAM1P	-5.55	7e-08	3.79e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63874740	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.901	rs2854194	ENSG00000240280.5	TCAM1P	-5.55	7e-08	3.79e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63874750	chr17:63849292~63864379:+
KIRP	cis	rs28386778	1	rs2665849	ENSG00000240280.5	TCAM1P	-5.55	7e-08	3.79e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63876310	chr17:63849292~63864379:+
KIRP	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-5.55	7.01e-08	3.79e-05	-0.45	-0.32	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
KIRP	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-5.55	7.02e-08	3.8e-05	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
KIRP	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	5.55	7.03e-08	3.8e-05	0.34	0.32	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
KIRP	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	5.55	7.03e-08	3.8e-05	0.35	0.32	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
KIRP	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	5.55	7.03e-08	3.8e-05	0.25	0.32	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
KIRP	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	5.55	7.03e-08	3.8e-05	0.42	0.32	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
KIRP	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	5.55	7.03e-08	3.8e-05	0.42	0.32	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
KIRP	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	5.55	7.03e-08	3.8e-05	0.42	0.32	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
KIRP	cis	rs2625529	0.761	rs11853268	ENSG00000260037.4	CTD-2524L6.3	-5.55	7.04e-08	3.8e-05	-0.28	-0.32	Red blood cell count;	chr15:71946632	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.824	rs11072338	ENSG00000260037.4	CTD-2524L6.3	-5.55	7.04e-08	3.8e-05	-0.28	-0.32	Red blood cell count;	chr15:71953106	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	5.55	7.04e-08	3.81e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	5.55	7.04e-08	3.81e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	5.55	7.04e-08	3.81e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
KIRP	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	5.55	7.05e-08	3.81e-05	0.42	0.32	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
KIRP	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	5.55	7.09e-08	3.83e-05	0.43	0.32	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
KIRP	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-5.55	7.1e-08	3.83e-05	-0.33	-0.32	Height;	chr11:118746590	chr11:118704607~118750263:+
KIRP	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	5.55	7.1e-08	3.83e-05	0.38	0.32	Height;	chr4:55401306	chr4:55363971~55395847:-
KIRP	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-5.55	7.1e-08	3.83e-05	-0.31	-0.32	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
KIRP	cis	rs2273156	1	rs17102923	ENSG00000226677.3	IGBP1P1	-5.55	7.1e-08	3.83e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34980633	chr14:34939324~34940332:+
KIRP	cis	rs2273156	0.929	rs34678475	ENSG00000226677.3	IGBP1P1	-5.55	7.1e-08	3.83e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34981897	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12890307	ENSG00000226677.3	IGBP1P1	-5.55	7.1e-08	3.83e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34982926	chr14:34939324~34940332:+
KIRP	cis	rs79040073	0.637	rs60594237	ENSG00000259531.2	RP11-295H24.3	5.55	7.1e-08	3.84e-05	0.45	0.32	Lung cancer in ever smokers;	chr15:49379916	chr15:49365124~49366685:-
KIRP	cis	rs4356975	0.83	rs7666894	ENSG00000196472.4	RP13-644M16.4	5.55	7.11e-08	3.84e-05	0.35	0.32	Obesity-related traits;	chr4:69078780	chr4:69181660~69182372:+
KIRP	cis	rs893363	0.559	rs893365	ENSG00000271916.1	RP11-884K10.6	-5.55	7.12e-08	3.85e-05	-0.3	-0.32	Axial length;	chr3:53807119	chr3:53797764~53798019:-
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	5.55	7.12e-08	3.85e-05	0.25	0.32	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	5.55	7.12e-08	3.85e-05	0.25	0.32	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
KIRP	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.55	7.12e-08	3.85e-05	-0.34	-0.32	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
KIRP	cis	rs2154427	0.872	rs10446070	ENSG00000238197.4	PAXBP1-AS1	5.55	7.13e-08	3.85e-05	0.46	0.32	Bilirubin levels;	chr21:32638314	chr21:32728115~32743122:+
KIRP	cis	rs13423976	1	rs13423976	ENSG00000231367.4	AC016995.3	-5.55	7.14e-08	3.86e-05	-0.44	-0.32	Gut microbiome composition (summer);	chr2:38518482	chr2:38406719~38515740:-
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	5.55	7.14e-08	3.86e-05	0.25	0.32	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
KIRP	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	5.55	7.15e-08	3.86e-05	0.32	0.32	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
KIRP	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	5.55	7.15e-08	3.86e-05	0.36	0.32	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
KIRP	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	5.55	7.16e-08	3.87e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	5.55	7.16e-08	3.87e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
KIRP	cis	rs9532669	0.963	rs4942012	ENSG00000239827.7	SUGT1P3	-5.54	7.17e-08	3.87e-05	-0.37	-0.32	Cervical cancer;	chr13:40939112	chr13:40908159~40921774:-
KIRP	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-5.54	7.17e-08	3.87e-05	-0.39	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
KIRP	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-5.54	7.19e-08	3.88e-05	-0.37	-0.32	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
KIRP	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	5.54	7.19e-08	3.88e-05	0.52	0.32	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
KIRP	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-5.54	7.2e-08	3.88e-05	-0.31	-0.32	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
KIRP	cis	rs1153858	0.945	rs2467854	ENSG00000259433.2	CTD-2651B20.4	-5.54	7.2e-08	3.89e-05	-0.29	-0.32	Homoarginine levels;	chr15:45409399	chr15:45330209~45332634:-
KIRP	cis	rs1153858	1	rs2461701	ENSG00000259433.2	CTD-2651B20.4	-5.54	7.2e-08	3.89e-05	-0.29	-0.32	Homoarginine levels;	chr15:45411193	chr15:45330209~45332634:-
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	5.54	7.2e-08	3.89e-05	0.25	0.32	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
KIRP	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-5.54	7.21e-08	3.89e-05	-0.41	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-5.54	7.21e-08	3.89e-05	-0.41	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-5.54	7.21e-08	3.89e-05	-0.41	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-5.54	7.21e-08	3.89e-05	-0.41	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
KIRP	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-5.54	7.21e-08	3.89e-05	-0.34	-0.32	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
KIRP	cis	rs7267979	1	rs453329	ENSG00000274414.1	RP5-965G21.4	-5.54	7.22e-08	3.89e-05	-0.32	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25239007~25245229:-
KIRP	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	5.54	7.22e-08	3.89e-05	0.44	0.32	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
KIRP	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-5.54	7.22e-08	3.9e-05	-0.36	-0.32	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
KIRP	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	5.54	7.24e-08	3.9e-05	0.29	0.32	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
KIRP	cis	rs8053891	0.507	rs12920844	ENSG00000260886.1	TAT-AS1	5.54	7.25e-08	3.91e-05	0.44	0.32	Coronary artery disease;	chr16:71995405	chr16:71565789~71578187:+
KIRP	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-5.54	7.25e-08	3.91e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
KIRP	cis	rs2273156	1	rs35797365	ENSG00000226677.3	IGBP1P1	-5.54	7.26e-08	3.92e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34983553	chr14:34939324~34940332:+
KIRP	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	5.54	7.26e-08	3.92e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	5.54	7.26e-08	3.92e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
KIRP	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-5.54	7.27e-08	3.92e-05	-0.39	-0.32	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
KIRP	cis	rs2486288	0.656	rs2413772	ENSG00000259433.2	CTD-2651B20.4	5.54	7.28e-08	3.92e-05	0.28	0.32	Glomerular filtration rate;	chr15:45257664	chr15:45330209~45332634:-
KIRP	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-5.54	7.29e-08	3.93e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-5.54	7.29e-08	3.93e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-5.54	7.29e-08	3.93e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	5.54	7.29e-08	3.93e-05	0.33	0.32	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-5.54	7.29e-08	3.93e-05	-0.33	-0.32	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
KIRP	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-5.54	7.3e-08	3.93e-05	-0.36	-0.32	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-5.54	7.3e-08	3.93e-05	-0.36	-0.32	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-5.54	7.3e-08	3.93e-05	-0.36	-0.32	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-5.54	7.3e-08	3.93e-05	-0.36	-0.32	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
KIRP	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.54	7.3e-08	3.93e-05	0.28	0.32	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
KIRP	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	5.54	7.3e-08	3.94e-05	0.53	0.32	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	5.54	7.3e-08	3.94e-05	0.53	0.32	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
KIRP	cis	rs4660214	0.666	rs7554206	ENSG00000237624.1	OXCT2P1	-5.54	7.31e-08	3.94e-05	-0.42	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39514956~39516490:+
KIRP	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.54	7.31e-08	3.94e-05	0.36	0.32	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
KIRP	cis	rs4443100	0.916	rs2078727	ENSG00000221069.1	AC000029.1	5.54	7.33e-08	3.95e-05	0.38	0.32	Serum parathyroid hormone levels;	chr22:23042844	chr22:23136620~23136710:+
KIRP	cis	rs4443100	0.916	rs2078728	ENSG00000221069.1	AC000029.1	5.54	7.33e-08	3.95e-05	0.38	0.32	Serum parathyroid hormone levels;	chr22:23042944	chr22:23136620~23136710:+
KIRP	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-5.54	7.33e-08	3.95e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-5.54	7.33e-08	3.95e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-5.54	7.33e-08	3.95e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
KIRP	cis	rs4638749	0.677	rs17035849	ENSG00000231221.1	AC023672.2	-5.54	7.33e-08	3.95e-05	-0.38	-0.32	Blood pressure;	chr2:108226137	chr2:108049200~108052755:-
KIRP	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	5.54	7.33e-08	3.95e-05	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
KIRP	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.54	7.33e-08	3.95e-05	0.39	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
KIRP	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	5.54	7.33e-08	3.95e-05	0.25	0.32	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
KIRP	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	5.54	7.34e-08	3.95e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
KIRP	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	5.54	7.35e-08	3.96e-05	0.42	0.32	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
KIRP	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-5.54	7.35e-08	3.96e-05	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-5.54	7.35e-08	3.96e-05	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-5.54	7.35e-08	3.96e-05	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
KIRP	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-5.54	7.35e-08	3.96e-05	-0.33	-0.32	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
KIRP	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	5.54	7.35e-08	3.96e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	5.54	7.35e-08	3.96e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	5.54	7.35e-08	3.96e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	5.54	7.35e-08	3.96e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	5.54	7.35e-08	3.96e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
KIRP	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-5.54	7.35e-08	3.96e-05	-0.32	-0.32	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
KIRP	cis	rs9402743	0.6	rs9376151	ENSG00000231028.7	LINC00271	-5.54	7.36e-08	3.96e-05	-0.29	-0.32	Systemic lupus erythematosus;	chr6:135789599	chr6:135497801~135716055:+
KIRP	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-5.54	7.36e-08	3.96e-05	-0.39	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
KIRP	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-5.54	7.36e-08	3.96e-05	-0.45	-0.32	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	5.54	7.37e-08	3.96e-05	0.37	0.32	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
KIRP	cis	rs8067545	0.616	rs203465	ENSG00000270091.1	RP11-78O7.2	-5.54	7.38e-08	3.97e-05	-0.21	-0.32	Schizophrenia;	chr17:19907407	chr17:19896590~19897287:-
KIRP	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	5.54	7.38e-08	3.97e-05	0.37	0.32	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
KIRP	cis	rs67311347	0.549	rs60249586	ENSG00000230274.1	PGAM1P3	5.54	7.38e-08	3.97e-05	0.31	0.32	Renal cell carcinoma;	chr3:40205168	chr3:40322715~40323279:-
KIRP	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-5.54	7.4e-08	3.98e-05	-0.33	-0.32	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
KIRP	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-5.54	7.42e-08	3.99e-05	-0.3	-0.32	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
KIRP	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-5.54	7.42e-08	3.99e-05	-0.35	-0.32	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
KIRP	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	5.54	7.42e-08	3.99e-05	0.21	0.32	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
KIRP	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	5.54	7.42e-08	3.99e-05	0.36	0.32	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
KIRP	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-5.54	7.43e-08	3.99e-05	-0.23	-0.32	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
KIRP	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	5.54	7.45e-08	4.01e-05	0.48	0.32	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
KIRP	cis	rs4356975	0.563	rs7658752	ENSG00000196472.4	RP13-644M16.4	5.54	7.46e-08	4.01e-05	0.35	0.32	Obesity-related traits;	chr4:69112350	chr4:69181660~69182372:+
KIRP	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-5.54	7.47e-08	4.01e-05	-0.36	-0.32	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
KIRP	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-5.54	7.48e-08	4.02e-05	-0.33	-0.32	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
KIRP	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-5.54	7.49e-08	4.02e-05	-0.41	-0.32	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
KIRP	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-5.54	7.49e-08	4.03e-05	-0.29	-0.32	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
KIRP	cis	rs2439831	1	rs2601014	ENSG00000249839.1	AC011330.5	-5.54	7.51e-08	4.03e-05	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43463815	chr15:43663654~43684339:-
KIRP	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-5.54	7.52e-08	4.04e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
KIRP	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-5.54	7.53e-08	4.04e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
KIRP	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-5.54	7.53e-08	4.04e-05	-0.24	-0.32	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
KIRP	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	5.54	7.54e-08	4.05e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
KIRP	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-5.54	7.55e-08	4.05e-05	-0.45	-0.32	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
KIRP	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-5.53	7.55e-08	4.05e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
KIRP	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	5.53	7.55e-08	4.06e-05	0.38	0.32	Height;	chr4:55482360	chr4:55363971~55395847:-
KIRP	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	5.53	7.56e-08	4.06e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
KIRP	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	5.53	7.57e-08	4.06e-05	0.37	0.32	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
KIRP	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-5.53	7.58e-08	4.07e-05	-0.34	-0.32	Temperament;	chr17:14046511	chr17:14024514~14025488:+
KIRP	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-5.53	7.58e-08	4.07e-05	-0.34	-0.32	Temperament;	chr17:14048649	chr17:14024514~14025488:+
KIRP	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
KIRP	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
KIRP	cis	rs881375	0.502	rs4837811	ENSG00000226752.6	PSMD5-AS1	-5.53	7.58e-08	4.07e-05	-0.37	-0.32	Rheumatoid arthritis;	chr9:121139316	chr9:120824828~120854385:+
KIRP	cis	rs2976388	0.669	rs2585135	ENSG00000253741.1	CTD-2292P10.4	5.53	7.58e-08	4.07e-05	0.36	0.32	Urinary tract infection frequency;	chr8:142732775	chr8:142702252~142726973:-
KIRP	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	5.53	7.58e-08	4.07e-05	0.29	0.32	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
KIRP	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	5.53	7.58e-08	4.07e-05	0.37	0.32	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
KIRP	cis	rs9915657	0.773	rs9894696	ENSG00000234899.8	SOX9-AS1	-5.53	7.59e-08	4.07e-05	-0.26	-0.32	Thyroid hormone levels;	chr17:72103346	chr17:72034107~72237203:-
KIRP	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	5.53	7.59e-08	4.07e-05	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
KIRP	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	5.53	7.59e-08	4.07e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
KIRP	cis	rs61457372	0.545	rs4793433	ENSG00000264026.1	RP11-1124B17.1	5.53	7.6e-08	4.07e-05	0.35	0.32	Triptolide cytotoxicity;	chr17:72351595	chr17:72342940~72355136:+
KIRP	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-5.53	7.6e-08	4.08e-05	-0.4	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
KIRP	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-5.53	7.6e-08	4.08e-05	-0.28	-0.32	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	5.53	7.6e-08	4.08e-05	0.28	0.32	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
KIRP	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	5.53	7.61e-08	4.08e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
KIRP	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	5.53	7.61e-08	4.08e-05	0.89	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
KIRP	cis	rs453301	0.686	rs17702602	ENSG00000253893.2	FAM85B	5.53	7.61e-08	4.08e-05	0.42	0.32	Joint mobility (Beighton score);	chr8:9051086	chr8:8167819~8226614:-
KIRP	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-5.53	7.62e-08	4.09e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-5.53	7.62e-08	4.09e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
KIRP	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.53	7.62e-08	4.09e-05	0.36	0.32	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
KIRP	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	5.53	7.63e-08	4.09e-05	0.45	0.32	Height;	chr6:109438349	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	5.53	7.63e-08	4.09e-05	0.45	0.32	Height;	chr6:109441033	chr6:109382795~109383666:+
KIRP	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-5.53	7.63e-08	4.09e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
KIRP	cis	rs9987353	0.519	rs13276350	ENSG00000253893.2	FAM85B	5.53	7.66e-08	4.1e-05	0.43	0.32	Recombination measurement;	chr8:9205647	chr8:8167819~8226614:-
KIRP	cis	rs12468226	0.623	rs12471811	ENSG00000273456.1	RP11-686O6.2	5.53	7.68e-08	4.12e-05	0.54	0.32	Urate levels;	chr2:202586164	chr2:202374932~202375604:-
KIRP	cis	rs496547	1	rs496547	ENSG00000278376.1	RP11-158I9.8	-5.53	7.68e-08	4.12e-05	-0.3	-0.32	Hip minimal joint space width;	chr11:118705754	chr11:118791254~118793137:+
KIRP	cis	rs9388451	0.772	rs1268064	ENSG00000237742.5	RP11-624M8.1	5.53	7.7e-08	4.12e-05	0.34	0.32	Brugada syndrome;	chr6:125721432	chr6:125578558~125749190:-
KIRP	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	5.53	7.7e-08	4.12e-05	0.52	0.32	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
KIRP	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-5.53	7.7e-08	4.12e-05	-0.36	-0.32	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
KIRP	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	5.53	7.7e-08	4.13e-05	0.33	0.32	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
KIRP	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	5.53	7.71e-08	4.13e-05	0.3	0.32	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
KIRP	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-5.53	7.72e-08	4.13e-05	-0.4	-0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
KIRP	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	5.53	7.73e-08	4.14e-05	0.3	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
KIRP	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	5.53	7.73e-08	4.14e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
KIRP	cis	rs11647589	0.834	rs1827711	ENSG00000262995.1	CTD-2194A8.2	-5.53	7.74e-08	4.14e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20471046	chr16:20440266~20447000:-
KIRP	cis	rs1858037	0.867	rs4671658	ENSG00000281920.1	RP11-418H16.1	-5.53	7.75e-08	4.15e-05	-0.42	-0.32	Rheumatoid arthritis;	chr2:65334258	chr2:65623272~65628424:+
KIRP	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-5.53	7.76e-08	4.16e-05	-0.29	-0.32	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
KIRP	cis	rs56205728	0.601	rs3784399	ENSG00000273855.1	RP11-133K1.12	-5.53	7.77e-08	4.16e-05	-0.31	-0.32	Schizophrenia;	chr15:40306093	chr15:40285468~40285909:-
KIRP	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-5.53	7.77e-08	4.16e-05	-0.38	-0.32	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
KIRP	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	5.53	7.78e-08	4.16e-05	0.4	0.32	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
KIRP	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	5.53	7.78e-08	4.16e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	5.53	7.78e-08	4.16e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	5.53	7.78e-08	4.16e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	5.53	7.78e-08	4.16e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
KIRP	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	5.53	7.79e-08	4.17e-05	0.33	0.32	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
KIRP	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	5.53	7.79e-08	4.17e-05	0.28	0.32	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
KIRP	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-5.53	7.8e-08	4.17e-05	-0.35	-0.32	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
KIRP	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-5.53	7.8e-08	4.17e-05	-0.35	-0.32	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
KIRP	cis	rs8067545	0.641	rs2108978	ENSG00000270091.1	RP11-78O7.2	-5.53	7.8e-08	4.17e-05	-0.21	-0.32	Schizophrenia;	chr17:19958145	chr17:19896590~19897287:-
KIRP	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-5.53	7.81e-08	4.18e-05	-0.37	-0.32	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
KIRP	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	5.53	7.81e-08	4.18e-05	0.26	0.32	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
KIRP	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	5.53	7.83e-08	4.19e-05	0.37	0.32	Migraine;	chr4:56881468	chr4:56960927~56961373:-
KIRP	cis	rs2625529	0.627	rs12898585	ENSG00000260037.4	CTD-2524L6.3	-5.53	7.85e-08	4.2e-05	-0.28	-0.32	Red blood cell count;	chr15:72181587	chr15:71818396~71823384:+
KIRP	cis	rs4356975	0.563	rs6851533	ENSG00000196472.4	RP13-644M16.4	5.53	7.85e-08	4.2e-05	0.35	0.32	Obesity-related traits;	chr4:69113032	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7666195	ENSG00000196472.4	RP13-644M16.4	5.53	7.85e-08	4.2e-05	0.35	0.32	Obesity-related traits;	chr4:69113765	chr4:69181660~69182372:+
KIRP	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-5.53	7.86e-08	4.2e-05	-0.31	-0.32	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
KIRP	cis	rs4934494	0.822	rs3962370	ENSG00000232936.4	RP11-80H5.2	5.53	7.86e-08	4.2e-05	0.41	0.32	Red blood cell count;	chr10:89777763	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs1590566	ENSG00000232936.4	RP11-80H5.2	5.53	7.86e-08	4.2e-05	0.41	0.32	Red blood cell count;	chr10:89778781	chr10:89645282~89650667:+
KIRP	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	5.53	7.86e-08	4.2e-05	0.87	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
KIRP	cis	rs2278170	1	rs9633900	ENSG00000225101.4	OR52K3P	-5.53	7.86e-08	4.2e-05	-0.4	-0.32	Amyotrophic lateral sclerosis;	chr11:4477088	chr11:4474813~4475755:+
KIRP	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-5.53	7.86e-08	4.2e-05	-0.46	-0.32	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
KIRP	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	5.53	7.87e-08	4.21e-05	0.3	0.32	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	5.53	7.87e-08	4.21e-05	0.3	0.32	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
KIRP	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	5.53	7.88e-08	4.21e-05	0.26	0.32	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	5.53	7.88e-08	4.21e-05	0.26	0.32	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	5.53	7.88e-08	4.21e-05	0.26	0.32	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	5.53	7.88e-08	4.21e-05	0.26	0.32	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
KIRP	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	5.53	7.88e-08	4.21e-05	0.26	0.32	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
KIRP	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-5.53	7.9e-08	4.22e-05	-0.36	-0.32	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
KIRP	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-5.53	7.9e-08	4.22e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	5.53	7.92e-08	4.23e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	5.53	7.92e-08	4.23e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	5.53	7.92e-08	4.23e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	5.53	7.92e-08	4.23e-05	0.42	0.32	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	5.53	7.92e-08	4.23e-05	0.42	0.32	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	5.53	7.92e-08	4.23e-05	0.42	0.32	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
KIRP	cis	rs1858037	0.867	rs1039765	ENSG00000281920.1	RP11-418H16.1	-5.53	7.93e-08	4.24e-05	-0.42	-0.32	Rheumatoid arthritis;	chr2:65387228	chr2:65623272~65628424:+
KIRP	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	5.53	7.93e-08	4.24e-05	0.42	0.32	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
KIRP	cis	rs7378815	0.685	rs444266	ENSG00000250787.1	HMGN1P17	-5.53	7.94e-08	4.24e-05	-0.31	-0.32	Breast cancer;	chr5:56357918	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs385605	ENSG00000250787.1	HMGN1P17	5.53	7.94e-08	4.24e-05	0.31	0.32	Breast cancer;	chr5:56358112	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs445095	ENSG00000250787.1	HMGN1P17	-5.53	7.94e-08	4.24e-05	-0.31	-0.32	Breast cancer;	chr5:56358242	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs382059	ENSG00000250787.1	HMGN1P17	-5.53	7.94e-08	4.24e-05	-0.31	-0.32	Breast cancer;	chr5:56358734	chr5:56381781~56382075:+
KIRP	cis	rs7378815	0.685	rs1278057	ENSG00000250787.1	HMGN1P17	-5.53	7.94e-08	4.24e-05	-0.31	-0.32	Breast cancer;	chr5:56359569	chr5:56381781~56382075:+
KIRP	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-5.53	7.94e-08	4.24e-05	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
KIRP	cis	rs28386778	0.966	rs2008053	ENSG00000240280.5	TCAM1P	-5.52	7.95e-08	4.24e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63877558	chr17:63849292~63864379:+
KIRP	cis	rs2625529	0.526	rs16956623	ENSG00000260037.4	CTD-2524L6.3	5.52	7.95e-08	4.24e-05	0.25	0.32	Red blood cell count;	chr15:72244354	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.667	rs16956381	ENSG00000260037.4	CTD-2524L6.3	-5.52	7.95e-08	4.25e-05	-0.28	-0.32	Red blood cell count;	chr15:71900896	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.775	rs12913042	ENSG00000260037.4	CTD-2524L6.3	-5.52	7.95e-08	4.25e-05	-0.28	-0.32	Red blood cell count;	chr15:71909968	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	5.52	7.96e-08	4.25e-05	0.43	0.32	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	5.52	7.96e-08	4.25e-05	0.43	0.32	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
KIRP	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	5.52	7.96e-08	4.25e-05	0.34	0.32	Height;	chr4:55370412	chr4:55363971~55395847:-
KIRP	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	5.52	7.96e-08	4.25e-05	0.42	0.32	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
KIRP	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	5.52	7.96e-08	4.25e-05	0.32	0.32	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
KIRP	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	5.52	8e-08	4.27e-05	0.29	0.32	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
KIRP	cis	rs1552244	0.882	rs13077641	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9981251	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13074282	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9983015	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs68080705	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9984059	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs67895180	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9984395	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs3755782	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9987621	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs17050699	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9995483	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	5.52	8e-08	4.27e-05	0.31	0.32	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
KIRP	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-5.52	8.01e-08	4.27e-05	-0.33	-0.32	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-5.52	8.01e-08	4.27e-05	-0.33	-0.32	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
KIRP	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	5.52	8.03e-08	4.28e-05	0.38	0.32	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
KIRP	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-5.52	8.03e-08	4.28e-05	-0.32	-0.32	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
KIRP	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-5.52	8.04e-08	4.29e-05	-0.31	-0.32	Height;	chr3:53085518	chr3:53064283~53065091:-
KIRP	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-5.52	8.04e-08	4.29e-05	-0.31	-0.32	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
KIRP	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-5.52	8.04e-08	4.29e-05	-0.31	-0.32	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
KIRP	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-5.52	8.04e-08	4.29e-05	-0.36	-0.32	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
KIRP	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-5.52	8.04e-08	4.29e-05	-0.37	-0.32	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
KIRP	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-5.52	8.06e-08	4.3e-05	-0.4	-0.32	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
KIRP	cis	rs7586673	0.866	rs747003	ENSG00000235724.7	AC009299.2	5.52	8.06e-08	4.3e-05	0.38	0.32	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161222785~161308303:-
KIRP	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-5.52	8.08e-08	4.31e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
KIRP	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-5.52	8.08e-08	4.31e-05	-0.36	-0.32	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
KIRP	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-5.52	8.08e-08	4.31e-05	-0.26	-0.32	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
KIRP	cis	rs2281558	0.876	rs6107025	ENSG00000274414.1	RP5-965G21.4	-5.52	8.09e-08	4.31e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:25239007~25245229:-
KIRP	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-5.52	8.09e-08	4.31e-05	-0.31	-0.32	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
KIRP	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-5.52	8.1e-08	4.31e-05	-0.37	-0.32	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
KIRP	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	5.52	8.1e-08	4.31e-05	0.33	0.32	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	5.52	8.1e-08	4.31e-05	0.33	0.32	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	5.52	8.1e-08	4.32e-05	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
KIRP	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	5.52	8.11e-08	4.32e-05	0.39	0.32	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
KIRP	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	5.52	8.11e-08	4.32e-05	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
KIRP	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	5.52	8.11e-08	4.32e-05	0.36	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
KIRP	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.52	8.13e-08	4.33e-05	-0.35	-0.32	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
KIRP	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-5.52	8.13e-08	4.33e-05	-0.33	-0.32	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
KIRP	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-5.52	8.13e-08	4.33e-05	-0.33	-0.32	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
KIRP	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	5.52	8.13e-08	4.33e-05	0.42	0.32	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
KIRP	cis	rs4356975	0.563	rs4694171	ENSG00000196472.4	RP13-644M16.4	5.52	8.13e-08	4.33e-05	0.35	0.32	Obesity-related traits;	chr4:69088579	chr4:69181660~69182372:+
KIRP	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	5.52	8.14e-08	4.33e-05	0.23	0.32	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
KIRP	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-5.52	8.14e-08	4.33e-05	-0.37	-0.32	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
KIRP	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-5.52	8.15e-08	4.34e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-5.52	8.15e-08	4.34e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
KIRP	cis	rs4356203	0.87	rs214919	ENSG00000272034.1	SNORD14A	-5.52	8.15e-08	4.34e-05	-0.27	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214916	ENSG00000272034.1	SNORD14A	-5.52	8.15e-08	4.34e-05	-0.27	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs2171615	ENSG00000272034.1	SNORD14A	-5.52	8.15e-08	4.34e-05	-0.27	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs10766381	ENSG00000272034.1	SNORD14A	-5.52	8.15e-08	4.34e-05	-0.27	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17074654~17074744:-
KIRP	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.52	8.16e-08	4.34e-05	-0.35	-0.32	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
KIRP	cis	rs897984	0.76	rs11076	ENSG00000275263.1	RP11-1072A3.4	5.52	8.16e-08	4.34e-05	0.34	0.32	Dementia with Lewy bodies;	chr16:30984207	chr16:30956872~30957199:-
KIRP	cis	rs1858037	0.867	rs876933	ENSG00000281920.1	RP11-418H16.1	5.52	8.17e-08	4.35e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65382303	chr2:65623272~65628424:+
KIRP	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	5.52	8.18e-08	4.36e-05	0.32	0.32	Height;	chr14:75124119	chr14:75011269~75012851:-
KIRP	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-5.52	8.19e-08	4.36e-05	-0.32	-0.32	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
KIRP	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-5.52	8.19e-08	4.36e-05	-0.28	-0.32	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
KIRP	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	5.52	8.2e-08	4.37e-05	0.4	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
KIRP	cis	rs4356975	0.563	rs6600893	ENSG00000196472.4	RP13-644M16.4	5.52	8.2e-08	4.37e-05	0.35	0.32	Obesity-related traits;	chr4:69113183	chr4:69181660~69182372:+
KIRP	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	5.52	8.21e-08	4.37e-05	0.37	0.32	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
KIRP	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	5.52	8.22e-08	4.37e-05	0.29	0.32	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
KIRP	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-5.52	8.22e-08	4.38e-05	-0.23	-0.32	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-5.52	8.22e-08	4.38e-05	-0.23	-0.32	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
KIRP	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-5.52	8.22e-08	4.38e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	5.52	8.23e-08	4.38e-05	0.36	0.32	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	5.52	8.23e-08	4.38e-05	0.36	0.32	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
KIRP	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-5.52	8.23e-08	4.38e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
KIRP	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.52	8.25e-08	4.39e-05	0.33	0.32	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
KIRP	cis	rs4927850	0.666	rs4927853	ENSG00000231464.1	AC024937.4	5.52	8.25e-08	4.39e-05	0.37	0.32	Pancreatic cancer;	chr3:196025182	chr3:195996738~195998233:+
KIRP	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	5.52	8.25e-08	4.39e-05	0.5	0.32	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
KIRP	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-5.52	8.25e-08	4.39e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
KIRP	cis	rs4638749	0.677	rs13022268	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108220864	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs13023102	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108221207	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10208945	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108222137	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs12611470	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108222893	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.627	rs4676185	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108225452	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10174695	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108225708	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs4676187	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108226480	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs10190865	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108227168	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.677	rs998186	ENSG00000231221.1	AC023672.2	-5.52	8.26e-08	4.39e-05	-0.38	-0.32	Blood pressure;	chr2:108227781	chr2:108049200~108052755:-
KIRP	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-5.52	8.28e-08	4.4e-05	-0.38	-0.32	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
KIRP	cis	rs8067545	0.641	rs203482	ENSG00000270091.1	RP11-78O7.2	-5.52	8.3e-08	4.41e-05	-0.21	-0.32	Schizophrenia;	chr17:19923897	chr17:19896590~19897287:-
KIRP	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	5.52	8.31e-08	4.42e-05	0.33	0.32	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
KIRP	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	5.52	8.31e-08	4.42e-05	0.37	0.32	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
KIRP	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	5.52	8.32e-08	4.42e-05	0.33	0.32	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	5.52	8.32e-08	4.42e-05	0.33	0.32	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	5.52	8.32e-08	4.42e-05	0.33	0.32	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
KIRP	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	5.52	8.32e-08	4.42e-05	0.38	0.32	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
KIRP	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	5.52	8.33e-08	4.43e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
KIRP	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	5.52	8.33e-08	4.43e-05	0.52	0.32	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
KIRP	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-5.52	8.33e-08	4.43e-05	-0.4	-0.32	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
KIRP	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-5.52	8.34e-08	4.43e-05	-0.28	-0.32	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-5.52	8.34e-08	4.43e-05	-0.28	-0.32	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-5.52	8.34e-08	4.43e-05	-0.28	-0.32	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-5.52	8.34e-08	4.43e-05	-0.28	-0.32	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
KIRP	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	5.52	8.35e-08	4.43e-05	0.36	0.32	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
KIRP	cis	rs2154427	0.655	rs844996	ENSG00000238197.4	PAXBP1-AS1	-5.51	8.37e-08	4.44e-05	-0.46	-0.32	Bilirubin levels;	chr21:32669216	chr21:32728115~32743122:+
KIRP	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	5.51	8.37e-08	4.44e-05	0.3	0.32	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
KIRP	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-5.51	8.38e-08	4.45e-05	-0.24	-0.32	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
KIRP	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	5.51	8.38e-08	4.45e-05	0.37	0.32	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
KIRP	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-5.51	8.38e-08	4.45e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-5.51	8.38e-08	4.45e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-5.51	8.38e-08	4.45e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
KIRP	cis	rs2273156	1	rs12893021	ENSG00000226677.3	IGBP1P1	-5.51	8.39e-08	4.45e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971474	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12895051	ENSG00000226677.3	IGBP1P1	-5.51	8.39e-08	4.45e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34974864	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs35090385	ENSG00000226677.3	IGBP1P1	-5.51	8.39e-08	4.45e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34975229	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs8019179	ENSG00000226677.3	IGBP1P1	-5.51	8.39e-08	4.45e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34978589	chr14:34939324~34940332:+
KIRP	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	5.51	8.39e-08	4.45e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
KIRP	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	5.51	8.4e-08	4.46e-05	0.39	0.32	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
KIRP	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-5.51	8.4e-08	4.46e-05	-0.38	-0.32	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
KIRP	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	5.51	8.41e-08	4.46e-05	0.31	0.32	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
KIRP	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	5.51	8.42e-08	4.47e-05	0.72	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
KIRP	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-5.51	8.42e-08	4.47e-05	-0.72	-0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
KIRP	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-5.51	8.43e-08	4.47e-05	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-5.51	8.43e-08	4.47e-05	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
KIRP	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-5.51	8.43e-08	4.47e-05	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
KIRP	cis	rs11079159	1	rs11079159	ENSG00000263096.1	RP11-515O17.2	5.51	8.45e-08	4.48e-05	0.46	0.32	QRS duration;	chr17:55296189	chr17:55271504~55273653:-
KIRP	cis	rs2976388	0.578	rs13263987	ENSG00000253741.1	CTD-2292P10.4	5.51	8.46e-08	4.49e-05	0.41	0.32	Urinary tract infection frequency;	chr8:142745969	chr8:142702252~142726973:-
KIRP	cis	rs2439831	0.681	rs2242067	ENSG00000249839.1	AC011330.5	-5.51	8.46e-08	4.49e-05	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43407105	chr15:43663654~43684339:-
KIRP	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	5.51	8.47e-08	4.49e-05	0.37	0.32	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
KIRP	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	5.51	8.47e-08	4.49e-05	0.27	0.32	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
KIRP	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-5.51	8.47e-08	4.49e-05	-0.47	-0.32	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-5.51	8.47e-08	4.49e-05	-0.47	-0.32	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
KIRP	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.51	8.49e-08	4.5e-05	0.36	0.32	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
KIRP	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-5.51	8.5e-08	4.5e-05	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
KIRP	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	5.51	8.5e-08	4.51e-05	0.37	0.32	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
KIRP	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	5.51	8.51e-08	4.51e-05	0.4	0.32	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
KIRP	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-5.51	8.51e-08	4.51e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
KIRP	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-5.51	8.51e-08	4.51e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
KIRP	cis	rs4356975	0.563	rs7439152	ENSG00000248763.2	RP13-644M16.5	-5.51	8.51e-08	4.51e-05	-0.34	-0.32	Obesity-related traits;	chr4:69103288	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7375178	ENSG00000248763.2	RP13-644M16.5	-5.51	8.51e-08	4.51e-05	-0.34	-0.32	Obesity-related traits;	chr4:69103961	chr4:69066395~69069888:+
KIRP	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-5.51	8.53e-08	4.52e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
KIRP	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-5.51	8.53e-08	4.52e-05	-0.4	-0.32	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
KIRP	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-5.51	8.54e-08	4.52e-05	-0.38	-0.32	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
KIRP	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	5.51	8.56e-08	4.54e-05	0.3	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
KIRP	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	5.51	8.57e-08	4.54e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73396235	ENSG00000259531.2	RP11-295H24.3	5.51	8.57e-08	4.54e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49346956	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73396238	ENSG00000259531.2	RP11-295H24.3	5.51	8.57e-08	4.54e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49347146	chr15:49365124~49366685:-
KIRP	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-5.51	8.58e-08	4.54e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
KIRP	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-5.51	8.58e-08	4.54e-05	-0.33	-0.32	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-5.51	8.58e-08	4.54e-05	-0.33	-0.32	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-5.51	8.58e-08	4.54e-05	-0.33	-0.32	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
KIRP	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.51	8.59e-08	4.55e-05	-0.27	-0.32	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
KIRP	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-5.51	8.6e-08	4.55e-05	-0.53	-0.32	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
KIRP	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	5.51	8.61e-08	4.56e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
KIRP	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	5.51	8.62e-08	4.56e-05	0.35	0.32	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
KIRP	cis	rs4934494	0.768	rs12771413	ENSG00000232936.4	RP11-80H5.2	-5.51	8.62e-08	4.56e-05	-0.48	-0.32	Red blood cell count;	chr10:89633010	chr10:89645282~89650667:+
KIRP	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	5.51	8.64e-08	4.57e-05	0.33	0.32	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	5.51	8.64e-08	4.57e-05	0.33	0.32	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
KIRP	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	5.51	8.64e-08	4.57e-05	0.4	0.32	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
KIRP	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	5.51	8.65e-08	4.58e-05	0.33	0.32	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	5.51	8.65e-08	4.58e-05	0.33	0.32	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	5.51	8.65e-08	4.58e-05	0.33	0.32	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
KIRP	cis	rs7299940	1	rs6486613	ENSG00000256250.1	RP11-989F5.1	5.51	8.66e-08	4.58e-05	0.32	0.32	Panic disorder;	chr12:130909133	chr12:130810606~130812438:+
KIRP	cis	rs1560104	0.675	rs8063669	ENSG00000274834.1	CTD-3037G24.5	-5.51	8.66e-08	4.58e-05	-0.38	-0.32	Obesity-related traits;	chr16:12603379	chr16:12614451~12614852:+
KIRP	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	5.51	8.67e-08	4.59e-05	0.25	0.32	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
KIRP	cis	rs2976388	0.578	rs4736324	ENSG00000253741.1	CTD-2292P10.4	5.51	8.68e-08	4.59e-05	0.39	0.32	Urinary tract infection frequency;	chr8:142749044	chr8:142702252~142726973:-
KIRP	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-5.51	8.71e-08	4.61e-05	-0.35	-0.32	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
KIRP	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	5.51	8.72e-08	4.61e-05	0.39	0.32	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
KIRP	cis	rs11647589	0.689	rs8045136	ENSG00000262995.1	CTD-2194A8.2	5.51	8.72e-08	4.61e-05	0.36	0.32	Blood metabolite levels;	chr16:20442599	chr16:20440266~20447000:-
KIRP	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.51	8.73e-08	4.62e-05	-0.35	-0.32	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
KIRP	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-5.51	8.73e-08	4.62e-05	-0.35	-0.32	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
KIRP	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-5.51	8.73e-08	4.62e-05	-0.44	-0.32	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
KIRP	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-5.51	8.74e-08	4.62e-05	-0.37	-0.32	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
KIRP	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-5.51	8.74e-08	4.62e-05	-0.28	-0.32	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
KIRP	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-5.51	8.75e-08	4.62e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-5.51	8.75e-08	4.62e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
KIRP	cis	rs9635231	1	rs9635231	ENSG00000258413.1	RP11-665C16.6	5.51	8.76e-08	4.63e-05	0.4	0.32	Pediatric bone mineral density (femoral neck);	chr14:55420985	chr14:55262767~55272075:-
KIRP	cis	rs453301	0.571	rs2929454	ENSG00000253981.4	ALG1L13P	-5.51	8.78e-08	4.64e-05	-0.26	-0.32	Joint mobility (Beighton score);	chr8:9226344	chr8:8236003~8244667:-
KIRP	cis	rs9532669	0.926	rs9525438	ENSG00000239827.7	SUGT1P3	-5.51	8.79e-08	4.65e-05	-0.36	-0.32	Cervical cancer;	chr13:40964123	chr13:40908159~40921774:-
KIRP	cis	rs4356975	0.563	rs6600897	ENSG00000248763.2	RP13-644M16.5	-5.51	8.79e-08	4.65e-05	-0.34	-0.32	Obesity-related traits;	chr4:69121531	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4274916	ENSG00000248763.2	RP13-644M16.5	-5.51	8.79e-08	4.65e-05	-0.34	-0.32	Obesity-related traits;	chr4:69122660	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4327554	ENSG00000248763.2	RP13-644M16.5	5.5	8.8e-08	4.65e-05	0.34	0.32	Obesity-related traits;	chr4:69120690	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600896	ENSG00000248763.2	RP13-644M16.5	-5.5	8.8e-08	4.65e-05	-0.34	-0.32	Obesity-related traits;	chr4:69121000	chr4:69066395~69069888:+
KIRP	cis	rs4638749	1	rs2219078	ENSG00000225328.1	AC019100.3	-5.5	8.8e-08	4.65e-05	-0.41	-0.32	Blood pressure;	chr2:108258742	chr2:108167748~108217841:-
KIRP	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	5.5	8.8e-08	4.65e-05	0.35	0.32	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
KIRP	cis	rs453301	0.686	rs17702602	ENSG00000253981.4	ALG1L13P	-5.5	8.81e-08	4.66e-05	-0.26	-0.32	Joint mobility (Beighton score);	chr8:9051086	chr8:8236003~8244667:-
KIRP	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	5.5	8.81e-08	4.66e-05	0.44	0.32	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
KIRP	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	5.5	8.81e-08	4.66e-05	0.37	0.32	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
KIRP	cis	rs2273156	1	rs2383688	ENSG00000226677.3	IGBP1P1	-5.5	8.81e-08	4.66e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934245	chr14:34939324~34940332:+
KIRP	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	5.5	8.83e-08	4.66e-05	0.52	0.32	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
KIRP	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	5.5	8.83e-08	4.66e-05	0.52	0.32	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	5.5	8.83e-08	4.66e-05	0.52	0.32	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	5.5	8.83e-08	4.66e-05	0.52	0.32	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
KIRP	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-5.5	8.84e-08	4.67e-05	-0.46	-0.32	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
KIRP	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-5.5	8.85e-08	4.67e-05	-0.44	-0.32	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
KIRP	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	5.5	8.86e-08	4.68e-05	0.34	0.32	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
KIRP	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.5	8.87e-08	4.68e-05	0.35	0.32	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
KIRP	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	5.5	8.87e-08	4.69e-05	0.32	0.32	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
KIRP	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-5.5	8.88e-08	4.69e-05	-0.35	-0.32	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
KIRP	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-5.5	8.89e-08	4.69e-05	-0.27	-0.32	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
KIRP	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	5.5	8.9e-08	4.7e-05	0.31	0.32	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
KIRP	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	5.5	8.9e-08	4.7e-05	0.33	0.32	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
KIRP	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	5.5	8.91e-08	4.7e-05	0.32	0.32	Height;	chr14:75135034	chr14:75011269~75012851:-
KIRP	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-5.5	8.93e-08	4.71e-05	-0.34	-0.32	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
KIRP	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-5.5	8.94e-08	4.72e-05	-0.38	-0.32	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
KIRP	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	5.5	8.96e-08	4.73e-05	0.32	0.32	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
KIRP	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	5.5	8.97e-08	4.73e-05	0.4	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
KIRP	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	5.5	8.98e-08	4.74e-05	0.42	0.32	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	5.5	8.98e-08	4.74e-05	0.42	0.32	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
KIRP	cis	rs7945705	0.967	rs10840147	ENSG00000254860.4	TMEM9B-AS1	-5.5	8.98e-08	4.74e-05	-0.36	-0.32	Hemoglobin concentration;	chr11:8899157	chr11:8964675~8977527:+
KIRP	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-5.5	9e-08	4.75e-05	-0.35	-0.32	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
KIRP	cis	rs1799949	0.965	rs799916	ENSG00000236383.6	LINC00854	5.5	9.01e-08	4.75e-05	0.22	0.32	Menopause (age at onset);	chr17:43091173	chr17:43216941~43305976:-
KIRP	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-5.5	9.02e-08	4.76e-05	-0.35	-0.32	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
KIRP	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-5.5	9.02e-08	4.76e-05	-0.41	-0.32	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
KIRP	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-5.5	9.03e-08	4.76e-05	-0.3	-0.32	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
KIRP	cis	rs4356975	0.563	rs4554144	ENSG00000196472.4	RP13-644M16.4	5.5	9.04e-08	4.77e-05	0.34	0.32	Obesity-related traits;	chr4:69094837	chr4:69181660~69182372:+
KIRP	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	5.5	9.04e-08	4.77e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
KIRP	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	5.5	9.05e-08	4.77e-05	0.3	0.32	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
KIRP	cis	rs4356975	0.522	rs6600888	ENSG00000248763.2	RP13-644M16.5	-5.5	9.07e-08	4.78e-05	-0.35	-0.32	Obesity-related traits;	chr4:69104141	chr4:69066395~69069888:+
KIRP	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	5.5	9.08e-08	4.79e-05	0.41	0.32	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	5.5	9.08e-08	4.79e-05	0.41	0.32	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
KIRP	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	5.5	9.09e-08	4.79e-05	0.88	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	5.5	9.09e-08	4.79e-05	0.88	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	5.5	9.09e-08	4.79e-05	0.88	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	5.5	9.09e-08	4.79e-05	0.88	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
KIRP	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	5.5	9.09e-08	4.79e-05	0.24	0.32	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
KIRP	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-5.5	9.13e-08	4.81e-05	-0.32	-0.32	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
KIRP	cis	rs4356975	0.563	rs7438135	ENSG00000248763.2	RP13-644M16.5	-5.5	9.14e-08	4.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69095621	chr4:69066395~69069888:+
KIRP	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	5.5	9.15e-08	4.82e-05	0.34	0.32	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
KIRP	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-5.5	9.15e-08	4.82e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
KIRP	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-5.5	9.16e-08	4.82e-05	-0.37	-0.32	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
KIRP	cis	rs7747960	0.901	rs7776345	ENSG00000226193.1	RP3-398G3.5	-5.5	9.18e-08	4.83e-05	-0.5	-0.32	Bipolar disorder;	chr6:152470816	chr6:152402398~152404966:+
KIRP	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	5.5	9.19e-08	4.84e-05	0.4	0.32	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
KIRP	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-5.5	9.19e-08	4.84e-05	-0.32	-0.32	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
KIRP	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	5.5	9.2e-08	4.84e-05	0.29	0.32	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
KIRP	cis	rs9388451	0.807	rs1268065	ENSG00000237742.5	RP11-624M8.1	5.5	9.24e-08	4.86e-05	0.34	0.32	Brugada syndrome;	chr6:125721637	chr6:125578558~125749190:-
KIRP	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-5.49	9.26e-08	4.87e-05	-0.37	-0.32	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
KIRP	cis	rs12908161	1	rs11637142	ENSG00000275120.1	RP11-182J1.17	5.49	9.26e-08	4.87e-05	0.41	0.32	Schizophrenia;	chr15:84752696	chr15:84599434~84606463:-
KIRP	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-5.49	9.27e-08	4.88e-05	-0.33	-0.32	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
KIRP	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-5.49	9.28e-08	4.88e-05	-0.44	-0.32	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
KIRP	cis	rs4443100	0.916	rs875602	ENSG00000221069.1	AC000029.1	5.49	9.3e-08	4.89e-05	0.39	0.32	Serum parathyroid hormone levels;	chr22:23053506	chr22:23136620~23136710:+
KIRP	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-5.49	9.31e-08	4.9e-05	-0.35	-0.32	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
KIRP	cis	rs4356975	0.563	rs12506962	ENSG00000196472.4	RP13-644M16.4	5.49	9.32e-08	4.9e-05	0.34	0.32	Obesity-related traits;	chr4:69100306	chr4:69181660~69182372:+
KIRP	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-5.49	9.32e-08	4.9e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.49	9.32e-08	4.9e-05	-0.24	-0.32	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.49	9.32e-08	4.9e-05	-0.24	-0.32	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
KIRP	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-5.49	9.35e-08	4.91e-05	-0.45	-0.32	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
KIRP	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-5.49	9.36e-08	4.92e-05	-0.28	-0.32	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
KIRP	cis	rs7586673	1	rs16845584	ENSG00000235724.7	AC009299.2	5.49	9.36e-08	4.92e-05	0.38	0.32	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161222785~161308303:-
KIRP	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-5.49	9.38e-08	4.93e-05	-0.41	-0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
KIRP	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	5.49	9.38e-08	4.93e-05	0.34	0.32	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
KIRP	cis	rs12449964	0.515	rs9899364	ENSG00000223979.2	SMCR2	5.49	9.38e-08	4.93e-05	0.31	0.32	Coronary artery disease or ischemic stroke;	chr17:17663798	chr17:17674026~17677688:-
KIRP	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	5.49	9.39e-08	4.94e-05	0.3	0.32	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
KIRP	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-5.49	9.43e-08	4.95e-05	-0.45	-0.32	Height;	chr6:109405874	chr6:109382795~109383666:+
KIRP	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-5.49	9.43e-08	4.96e-05	-0.47	-0.32	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
KIRP	cis	rs73198271	0.74	rs10094270	ENSG00000253981.4	ALG1L13P	-5.49	9.44e-08	4.96e-05	-0.27	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8236003~8244667:-
KIRP	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-5.49	9.45e-08	4.96e-05	-0.35	-0.32	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
KIRP	cis	rs2625529	0.824	rs4777475	ENSG00000260037.4	CTD-2524L6.3	-5.49	9.46e-08	4.97e-05	-0.28	-0.32	Red blood cell count;	chr15:71925865	chr15:71818396~71823384:+
KIRP	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-5.49	9.47e-08	4.97e-05	-0.45	-0.32	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
KIRP	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	5.49	9.47e-08	4.97e-05	0.45	0.32	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
KIRP	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	5.49	9.47e-08	4.97e-05	0.45	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
KIRP	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-5.49	9.48e-08	4.97e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-5.49	9.48e-08	4.97e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-5.49	9.48e-08	4.97e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
KIRP	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	5.49	9.48e-08	4.97e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
KIRP	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	5.49	9.49e-08	4.98e-05	0.25	0.32	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
KIRP	cis	rs9402743	0.632	rs9399161	ENSG00000231028.7	LINC00271	-5.49	9.5e-08	4.98e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135759326	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.597	rs9399162	ENSG00000231028.7	LINC00271	-5.49	9.5e-08	4.98e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135759368	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs6570031	ENSG00000231028.7	LINC00271	-5.49	9.5e-08	4.98e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135762018	chr6:135497801~135716055:+
KIRP	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	5.49	9.51e-08	4.99e-05	0.35	0.32	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
KIRP	cis	rs1560104	0.709	rs6498334	ENSG00000274834.1	CTD-3037G24.5	-5.49	9.52e-08	4.99e-05	-0.36	-0.32	Obesity-related traits;	chr16:12602789	chr16:12614451~12614852:+
KIRP	cis	rs79040073	0.637	rs73398223	ENSG00000259531.2	RP11-295H24.3	5.49	9.52e-08	4.99e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49379505	chr15:49365124~49366685:-
KIRP	cis	rs2273156	1	rs2383689	ENSG00000226677.3	IGBP1P1	-5.49	9.54e-08	5e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934814	chr14:34939324~34940332:+
KIRP	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	5.49	9.55e-08	5e-05	0.33	0.32	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
KIRP	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	5.49	9.55e-08	5e-05	0.33	0.32	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	5.49	9.55e-08	5e-05	0.33	0.32	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	5.49	9.55e-08	5e-05	0.33	0.32	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
KIRP	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-5.49	9.55e-08	5.01e-05	-0.31	-0.32	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
KIRP	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-5.49	9.55e-08	5.01e-05	-0.37	-0.32	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
KIRP	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-5.49	9.55e-08	5.01e-05	-0.37	-0.32	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
KIRP	cis	rs7170668	0.93	rs7170640	ENSG00000258489.3	RP11-398J10.2	-5.49	9.55e-08	5.01e-05	-0.37	-0.32	Motion sickness;	chr15:95470867	chr15:95463592~95493770:-
KIRP	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-5.49	9.56e-08	5.01e-05	-0.32	-0.32	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
KIRP	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	5.49	9.57e-08	5.02e-05	0.34	0.32	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
KIRP	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	5.49	9.57e-08	5.02e-05	0.24	0.32	Height;	chr20:35205344	chr20:35201747~35203288:-
KIRP	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs68153882	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9971426	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs35056669	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9972487	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs3732967	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9973753	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs3732966	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9974056	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13062917	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9975348	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.816	rs13076197	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9978089	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs34779351	ENSG00000180385.7	EMC3-AS1	5.49	9.59e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9980117	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	5.49	9.6e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	5.49	9.6e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	5.49	9.6e-08	5.02e-05	0.31	0.32	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
KIRP	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-5.49	9.6e-08	5.03e-05	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
KIRP	cis	rs2976388	0.578	rs34956412	ENSG00000253741.1	CTD-2292P10.4	5.49	9.61e-08	5.03e-05	0.42	0.32	Urinary tract infection frequency;	chr8:142740610	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.556	rs4736321	ENSG00000253741.1	CTD-2292P10.4	5.49	9.61e-08	5.03e-05	0.42	0.32	Urinary tract infection frequency;	chr8:142740776	chr8:142702252~142726973:-
KIRP	cis	rs6832769	0.961	rs1873092	ENSG00000272969.1	RP11-528I4.2	-5.49	9.61e-08	5.03e-05	-0.33	-0.32	Personality dimensions;	chr4:55578133	chr4:55547112~55547889:+
KIRP	cis	rs4638749	0.677	rs7570544	ENSG00000231221.1	AC023672.2	-5.49	9.62e-08	5.03e-05	-0.37	-0.32	Blood pressure;	chr2:108231681	chr2:108049200~108052755:-
KIRP	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-5.49	9.62e-08	5.03e-05	-0.34	-0.32	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-5.49	9.62e-08	5.03e-05	-0.34	-0.32	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
KIRP	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-5.49	9.62e-08	5.03e-05	-0.33	-0.32	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
KIRP	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-5.49	9.63e-08	5.04e-05	-0.5	-0.32	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
KIRP	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	5.49	9.63e-08	5.04e-05	0.34	0.32	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
KIRP	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	5.49	9.64e-08	5.04e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	5.49	9.66e-08	5.05e-05	0.42	0.32	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	5.49	9.66e-08	5.05e-05	0.42	0.32	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
KIRP	cis	rs453301	0.571	rs2929456	ENSG00000253981.4	ALG1L13P	-5.49	9.66e-08	5.05e-05	-0.26	-0.32	Joint mobility (Beighton score);	chr8:9225906	chr8:8236003~8244667:-
KIRP	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-5.49	9.66e-08	5.05e-05	-0.36	-0.32	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
KIRP	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	5.49	9.67e-08	5.06e-05	0.29	0.32	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
KIRP	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-5.49	9.67e-08	5.06e-05	-0.65	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
KIRP	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-5.49	9.68e-08	5.06e-05	-0.46	-0.32	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
KIRP	cis	rs4356203	0.905	rs2052188	ENSG00000272034.1	SNORD14A	5.49	9.69e-08	5.06e-05	0.27	0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17074654~17074744:-
KIRP	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-5.49	9.69e-08	5.07e-05	-0.34	-0.32	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	5.49	9.69e-08	5.07e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	5.49	9.69e-08	5.07e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
KIRP	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	5.49	9.69e-08	5.07e-05	0.34	0.32	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	5.49	9.69e-08	5.07e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
KIRP	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-5.49	9.69e-08	5.07e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-5.49	9.69e-08	5.07e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	5.49	9.73e-08	5.08e-05	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
KIRP	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-5.48	9.75e-08	5.1e-05	-0.3	-0.32	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
KIRP	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-5.48	9.76e-08	5.1e-05	-0.32	-0.32	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
KIRP	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-5.48	9.76e-08	5.1e-05	-0.29	-0.32	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
KIRP	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	5.48	9.77e-08	5.1e-05	0.29	0.32	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
KIRP	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-5.48	9.77e-08	5.1e-05	-0.35	-0.32	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
KIRP	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	5.48	9.78e-08	5.11e-05	0.34	0.32	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
KIRP	cis	rs4356975	0.522	rs7679184	ENSG00000196472.4	RP13-644M16.4	5.48	9.79e-08	5.11e-05	0.35	0.32	Obesity-related traits;	chr4:69100212	chr4:69181660~69182372:+
KIRP	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-5.48	9.79e-08	5.11e-05	-0.33	-0.32	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-5.48	9.79e-08	5.11e-05	-0.33	-0.32	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-5.48	9.79e-08	5.11e-05	-0.33	-0.32	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-5.48	9.79e-08	5.11e-05	-0.33	-0.32	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-5.48	9.79e-08	5.11e-05	-0.33	-0.32	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
KIRP	cis	rs7267979	0.932	rs928121	ENSG00000274414.1	RP5-965G21.4	-5.48	9.79e-08	5.11e-05	-0.31	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs4280527	ENSG00000274414.1	RP5-965G21.4	-5.48	9.79e-08	5.11e-05	-0.31	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25239007~25245229:-
KIRP	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	5.48	9.8e-08	5.11e-05	0.49	0.32	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
KIRP	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	5.48	9.8e-08	5.11e-05	0.49	0.32	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
KIRP	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	5.48	9.8e-08	5.11e-05	0.33	0.32	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	5.48	9.8e-08	5.11e-05	0.33	0.32	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
KIRP	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	5.48	9.8e-08	5.11e-05	0.37	0.32	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
KIRP	cis	rs4638749	0.677	rs12475343	ENSG00000231221.1	AC023672.2	-5.48	9.8e-08	5.12e-05	-0.38	-0.32	Blood pressure;	chr2:108234917	chr2:108049200~108052755:-
KIRP	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-5.48	9.82e-08	5.13e-05	-0.38	-0.32	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
KIRP	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	5.48	9.82e-08	5.13e-05	0.29	0.32	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
KIRP	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	5.48	9.83e-08	5.13e-05	0.45	0.32	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
KIRP	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-5.48	9.86e-08	5.15e-05	-0.33	-0.32	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
KIRP	cis	rs4578769	0.959	rs3851819	ENSG00000266850.1	RP11-370A5.1	5.48	9.87e-08	5.15e-05	0.41	0.32	Eosinophil percentage of white cells;	chr18:22881321	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.959	rs3851820	ENSG00000266850.1	RP11-370A5.1	5.48	9.87e-08	5.15e-05	0.41	0.32	Eosinophil percentage of white cells;	chr18:22881359	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.918	rs3851821	ENSG00000266850.1	RP11-370A5.1	5.48	9.87e-08	5.15e-05	0.41	0.32	Eosinophil percentage of white cells;	chr18:22882492	chr18:22723491~22907721:-
KIRP	cis	rs1560104	0.709	rs8063664	ENSG00000274834.1	CTD-3037G24.5	-5.48	9.87e-08	5.15e-05	-0.38	-0.32	Obesity-related traits;	chr16:12603354	chr16:12614451~12614852:+
KIRP	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	5.48	9.87e-08	5.15e-05	0.36	0.32	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
KIRP	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-5.48	9.88e-08	5.15e-05	-0.34	-0.32	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
KIRP	cis	rs2625529	0.824	rs2279283	ENSG00000260037.4	CTD-2524L6.3	-5.48	9.89e-08	5.16e-05	-0.28	-0.32	Red blood cell count;	chr15:71951325	chr15:71818396~71823384:+
KIRP	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-5.48	9.89e-08	5.16e-05	-0.28	-0.32	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
KIRP	cis	rs7378815	0.769	rs290761	ENSG00000250787.1	HMGN1P17	-5.48	9.89e-08	5.16e-05	-0.31	-0.32	Breast cancer;	chr5:56354364	chr5:56381781~56382075:+
KIRP	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	5.48	9.9e-08	5.16e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
KIRP	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-5.48	9.9e-08	5.17e-05	-0.34	-0.32	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
KIRP	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-5.48	9.91e-08	5.17e-05	-0.44	-0.32	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
KIRP	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-5.48	9.92e-08	5.17e-05	-0.31	-0.32	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
KIRP	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	5.48	9.94e-08	5.18e-05	0.35	0.32	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
KIRP	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	5.48	9.94e-08	5.18e-05	0.35	0.32	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
KIRP	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	5.48	9.94e-08	5.18e-05	0.35	0.32	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
KIRP	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-5.48	9.94e-08	5.18e-05	-0.32	-0.32	Height;	chr14:75203367	chr14:75011269~75012851:-
KIRP	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	5.48	9.95e-08	5.19e-05	0.27	0.32	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
KIRP	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	5.48	9.96e-08	5.19e-05	0.3	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
KIRP	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	5.48	9.99e-08	5.2e-05	0.4	0.32	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	5.48	9.99e-08	5.2e-05	0.4	0.32	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
KIRP	cis	rs2625529	0.59	rs2856929	ENSG00000260037.4	CTD-2524L6.3	-5.48	9.99e-08	5.21e-05	-0.28	-0.32	Red blood cell count;	chr15:72204421	chr15:71818396~71823384:+
KIRP	cis	rs2976388	0.533	rs12543368	ENSG00000253741.1	CTD-2292P10.4	5.48	9.99e-08	5.21e-05	0.41	0.32	Urinary tract infection frequency;	chr8:142738032	chr8:142702252~142726973:-
KIRP	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	5.48	9.99e-08	5.21e-05	0.47	0.32	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
KIRP	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-5.48	9.99e-08	5.21e-05	-0.45	-0.32	Height;	chr6:109444615	chr6:109382795~109383666:+
KIRP	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	5.48	1e-07	5.22e-05	0.43	0.32	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	5.48	1e-07	5.22e-05	0.43	0.32	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
KIRP	cis	rs28386778	0.901	rs2665855	ENSG00000240280.5	TCAM1P	-5.48	1e-07	5.22e-05	-0.4	-0.32	Prudent dietary pattern;	chr17:63887783	chr17:63849292~63864379:+
KIRP	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-5.48	1e-07	5.23e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-5.48	1e-07	5.23e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-5.48	1e-07	5.23e-05	-0.39	-0.32	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
KIRP	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	5.48	1e-07	5.23e-05	0.28	0.32	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
KIRP	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-5.48	1.01e-07	5.24e-05	-0.25	-0.32	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
KIRP	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.48	1.01e-07	5.24e-05	0.35	0.32	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
KIRP	cis	rs2976388	0.566	rs4736301	ENSG00000253741.1	CTD-2292P10.4	5.48	1.01e-07	5.24e-05	0.39	0.32	Urinary tract infection frequency;	chr8:142748081	chr8:142702252~142726973:-
KIRP	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-5.48	1.01e-07	5.25e-05	-0.29	-0.32	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
KIRP	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	5.48	1.01e-07	5.25e-05	0.51	0.32	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
KIRP	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	5.48	1.01e-07	5.25e-05	0.3	0.32	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
KIRP	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	5.48	1.01e-07	5.26e-05	0.34	0.32	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
KIRP	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	5.48	1.01e-07	5.26e-05	0.39	0.32	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
KIRP	cis	rs7786410	1	rs7786410	ENSG00000273720.1	RP11-613E4.4	5.48	1.01e-07	5.26e-05	0.51	0.32	Age-related hearing impairment;	chr7:55854630	chr7:55743073~55743457:+
KIRP	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	5.48	1.01e-07	5.27e-05	0.27	0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
KIRP	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	5.48	1.01e-07	5.27e-05	0.28	0.32	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
KIRP	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-5.48	1.01e-07	5.27e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
KIRP	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-5.48	1.01e-07	5.27e-05	-0.25	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
KIRP	cis	rs897984	0.806	rs8050588	ENSG00000275263.1	RP11-1072A3.4	-5.48	1.01e-07	5.27e-05	-0.34	-0.32	Dementia with Lewy bodies;	chr16:30926478	chr16:30956872~30957199:-
KIRP	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-5.48	1.01e-07	5.28e-05	-0.39	-0.32	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
KIRP	cis	rs6496932	0.663	rs7496211	ENSG00000218052.5	ADAMTS7P4	-5.48	1.01e-07	5.28e-05	-0.46	-0.32	Central corneal thickness;Corneal structure;	chr15:85379358	chr15:85255369~85330334:-
KIRP	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-5.48	1.02e-07	5.29e-05	-0.31	-0.32	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
KIRP	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	5.48	1.02e-07	5.3e-05	0.38	0.32	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-5.48	1.02e-07	5.3e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
KIRP	cis	rs11647589	0.689	rs12599141	ENSG00000262995.1	CTD-2194A8.2	-5.48	1.02e-07	5.3e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20440775	chr16:20440266~20447000:-
KIRP	cis	rs4356975	0.697	rs66666893	ENSG00000196472.4	RP13-644M16.4	5.48	1.02e-07	5.31e-05	0.36	0.32	Obesity-related traits;	chr4:69133393	chr4:69181660~69182372:+
KIRP	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-5.48	1.02e-07	5.32e-05	-0.41	-0.32	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
KIRP	cis	rs28386778	0.897	rs1877318	ENSG00000240280.5	TCAM1P	-5.48	1.02e-07	5.32e-05	-0.4	-0.32	Prudent dietary pattern;	chr17:63742600	chr17:63849292~63864379:+
KIRP	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	5.48	1.02e-07	5.32e-05	0.53	0.32	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
KIRP	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	5.48	1.02e-07	5.32e-05	0.53	0.32	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
KIRP	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	5.48	1.02e-07	5.33e-05	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
KIRP	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	5.47	1.02e-07	5.33e-05	0.33	0.32	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	5.47	1.02e-07	5.33e-05	0.33	0.32	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
KIRP	cis	rs713477	1	rs713477	ENSG00000258413.1	RP11-665C16.6	5.47	1.02e-07	5.33e-05	0.4	0.32	Pediatric bone mineral content (femoral neck);	chr14:55437708	chr14:55262767~55272075:-
KIRP	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-5.47	1.03e-07	5.33e-05	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
KIRP	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-5.47	1.03e-07	5.33e-05	-0.4	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
KIRP	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.47	1.03e-07	5.34e-05	-0.4	-0.32	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
KIRP	cis	rs2625529	0.59	rs3803471	ENSG00000260037.4	CTD-2524L6.3	-5.47	1.03e-07	5.34e-05	-0.28	-0.32	Red blood cell count;	chr15:72208445	chr15:71818396~71823384:+
KIRP	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	5.47	1.03e-07	5.34e-05	0.36	0.32	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
KIRP	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.47	1.03e-07	5.34e-05	-0.35	-0.32	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
KIRP	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	5.47	1.03e-07	5.35e-05	0.4	0.32	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
KIRP	cis	rs4963124	0.886	rs10902216	ENSG00000279672.1	CMB9-55F22.1	5.47	1.03e-07	5.35e-05	0.39	0.32	Proteinuria and chronic kidney disease;	chr11:739392	chr11:779617~780755:+
KIRP	cis	rs2625529	0.526	rs62022789	ENSG00000260037.4	CTD-2524L6.3	5.47	1.03e-07	5.35e-05	0.25	0.32	Red blood cell count;	chr15:72272151	chr15:71818396~71823384:+
KIRP	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-5.47	1.03e-07	5.36e-05	-0.35	-0.32	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-5.47	1.03e-07	5.36e-05	-0.35	-0.32	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
KIRP	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	5.47	1.04e-07	5.38e-05	0.28	0.32	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
KIRP	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	5.47	1.04e-07	5.38e-05	0.35	0.32	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	5.47	1.04e-07	5.38e-05	0.35	0.32	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
KIRP	cis	rs2625529	0.938	rs2723343	ENSG00000260037.4	CTD-2524L6.3	-5.47	1.04e-07	5.38e-05	-0.29	-0.32	Red blood cell count;	chr15:71815928	chr15:71818396~71823384:+
KIRP	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-5.47	1.04e-07	5.39e-05	-0.24	-0.32	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	5.47	1.04e-07	5.39e-05	0.39	0.32	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
KIRP	cis	rs1476679	0.927	rs2405442	ENSG00000281827.1	AC005071.4	5.47	1.04e-07	5.39e-05	0.27	0.32	Alzheimer's disease (late onset);	chr7:100373690	chr7:100344375~100344475:-
KIRP	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-5.47	1.04e-07	5.4e-05	-0.32	-0.32	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
KIRP	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-5.47	1.04e-07	5.41e-05	-0.28	-0.32	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
KIRP	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-5.47	1.04e-07	5.41e-05	-0.28	-0.32	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
KIRP	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	5.47	1.04e-07	5.41e-05	0.37	0.32	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
KIRP	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-5.47	1.04e-07	5.41e-05	-0.45	-0.32	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-5.47	1.04e-07	5.41e-05	-0.45	-0.32	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
KIRP	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-5.47	1.04e-07	5.41e-05	-0.26	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
KIRP	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-5.47	1.04e-07	5.42e-05	-0.42	-0.32	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
KIRP	cis	rs9926296	0.609	rs4785709	ENSG00000260259.1	RP11-368I7.4	5.47	1.04e-07	5.42e-05	0.27	0.32	Vitiligo;	chr16:89730257	chr16:89682620~89686569:-
KIRP	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-5.47	1.05e-07	5.43e-05	-0.34	-0.32	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
KIRP	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-5.47	1.05e-07	5.43e-05	-0.32	-0.32	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
KIRP	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	5.47	1.05e-07	5.43e-05	0.32	0.32	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
KIRP	cis	rs6832769	1	rs473005	ENSG00000272969.1	RP11-528I4.2	5.47	1.05e-07	5.44e-05	0.31	0.32	Personality dimensions;	chr4:55421958	chr4:55547112~55547889:+
KIRP	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	5.47	1.05e-07	5.44e-05	0.41	0.32	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
KIRP	cis	rs1858037	0.765	rs67404371	ENSG00000281920.1	RP11-418H16.1	5.47	1.05e-07	5.44e-05	0.41	0.32	Rheumatoid arthritis;	chr2:65370137	chr2:65623272~65628424:+
KIRP	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-5.47	1.05e-07	5.45e-05	-0.47	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
KIRP	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	5.47	1.05e-07	5.45e-05	0.42	0.32	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
KIRP	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	5.47	1.05e-07	5.46e-05	0.38	0.32	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
KIRP	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	5.47	1.05e-07	5.46e-05	0.35	0.32	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
KIRP	cis	rs7829975	0.807	rs519019	ENSG00000253981.4	ALG1L13P	-5.47	1.05e-07	5.46e-05	-0.25	-0.32	Mood instability;	chr8:8737594	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-5.47	1.05e-07	5.46e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	5.47	1.05e-07	5.47e-05	0.26	0.32	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
KIRP	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-5.47	1.05e-07	5.47e-05	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
KIRP	cis	rs4638749	0.501	rs12624041	ENSG00000231221.1	AC023672.2	-5.47	1.06e-07	5.47e-05	-0.38	-0.32	Blood pressure;	chr2:108147091	chr2:108049200~108052755:-
KIRP	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	5.47	1.06e-07	5.48e-05	0.42	0.32	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
KIRP	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	5.47	1.06e-07	5.49e-05	0.5	0.32	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
KIRP	cis	rs4356975	0.563	rs35402056	ENSG00000248763.2	RP13-644M16.5	-5.47	1.06e-07	5.49e-05	-0.35	-0.32	Obesity-related traits;	chr4:69108549	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4694177	ENSG00000248763.2	RP13-644M16.5	-5.47	1.06e-07	5.49e-05	-0.35	-0.32	Obesity-related traits;	chr4:69110141	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12642938	ENSG00000248763.2	RP13-644M16.5	-5.47	1.06e-07	5.49e-05	-0.35	-0.32	Obesity-related traits;	chr4:69110499	chr4:69066395~69069888:+
KIRP	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	5.47	1.06e-07	5.5e-05	0.32	0.32	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
KIRP	cis	rs6085948	0.861	rs6085947	ENSG00000238102.1	RP11-19D2.1	5.47	1.06e-07	5.5e-05	0.38	0.32	Interleukin-10 levels;	chr20:7252181	chr20:7256580~7258214:-
KIRP	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-5.47	1.06e-07	5.5e-05	-0.37	-0.32	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
KIRP	cis	rs79040073	0.637	rs8027094	ENSG00000259531.2	RP11-295H24.3	5.47	1.06e-07	5.5e-05	0.43	0.32	Lung cancer in ever smokers;	chr15:49388639	chr15:49365124~49366685:-
KIRP	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-5.47	1.06e-07	5.51e-05	-0.34	-0.32	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
KIRP	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	5.47	1.06e-07	5.51e-05	0.42	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
KIRP	cis	rs4443100	0.832	rs4434089	ENSG00000221069.1	AC000029.1	-5.47	1.06e-07	5.51e-05	-0.38	-0.32	Serum parathyroid hormone levels;	chr22:23041683	chr22:23136620~23136710:+
KIRP	cis	rs2976388	0.632	rs2585139	ENSG00000253741.1	CTD-2292P10.4	-5.47	1.06e-07	5.51e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142726757	chr8:142702252~142726973:-
KIRP	cis	rs1858037	0.867	rs72621551	ENSG00000281920.1	RP11-418H16.1	5.47	1.07e-07	5.52e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65388087	chr2:65623272~65628424:+
KIRP	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	5.47	1.07e-07	5.53e-05	0.39	0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
KIRP	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	5.47	1.07e-07	5.53e-05	0.3	0.32	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
KIRP	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	5.47	1.07e-07	5.53e-05	0.35	0.32	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
KIRP	cis	rs8067545	0.641	rs203450	ENSG00000270091.1	RP11-78O7.2	-5.47	1.07e-07	5.53e-05	-0.21	-0.32	Schizophrenia;	chr17:19919757	chr17:19896590~19897287:-
KIRP	cis	rs1858037	0.836	rs1396209	ENSG00000281920.1	RP11-418H16.1	5.47	1.07e-07	5.53e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65374100	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.867	rs2118305	ENSG00000281920.1	RP11-418H16.1	5.47	1.07e-07	5.53e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65378086	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.836	rs17475335	ENSG00000281920.1	RP11-418H16.1	5.47	1.07e-07	5.53e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65378646	chr2:65623272~65628424:+
KIRP	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-5.47	1.07e-07	5.54e-05	-0.34	-0.32	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
KIRP	cis	rs2273156	1	rs8014327	ENSG00000226677.3	IGBP1P1	-5.47	1.07e-07	5.54e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965530	chr14:34939324~34940332:+
KIRP	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-5.47	1.07e-07	5.54e-05	-0.28	-0.32	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
KIRP	cis	rs5758659	0.729	rs134866	ENSG00000205702.9	CYP2D7	5.47	1.07e-07	5.54e-05	0.25	0.32	Cognitive function;	chr22:42254657	chr22:42140203~42144577:-
KIRP	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-5.47	1.07e-07	5.54e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-5.47	1.07e-07	5.54e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-5.47	1.07e-07	5.54e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
KIRP	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-5.47	1.07e-07	5.54e-05	-0.31	-0.32	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
KIRP	cis	rs61457372	0.563	rs3744313	ENSG00000264026.1	RP11-1124B17.1	5.47	1.07e-07	5.54e-05	0.34	0.32	Triptolide cytotoxicity;	chr17:72361917	chr17:72342940~72355136:+
KIRP	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-5.47	1.07e-07	5.55e-05	-0.33	-0.32	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-5.47	1.07e-07	5.55e-05	-0.33	-0.32	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
KIRP	cis	rs8067545	0.641	rs203457	ENSG00000270091.1	RP11-78O7.2	5.47	1.07e-07	5.55e-05	0.21	0.32	Schizophrenia;	chr17:19915025	chr17:19896590~19897287:-
KIRP	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	5.47	1.07e-07	5.55e-05	0.4	0.32	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
KIRP	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-5.47	1.07e-07	5.55e-05	-0.34	-0.32	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
KIRP	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	5.47	1.07e-07	5.55e-05	0.32	0.32	Height;	chr14:75053362	chr14:75011269~75012851:-
KIRP	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-5.47	1.07e-07	5.55e-05	-0.44	-0.32	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
KIRP	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.47	1.07e-07	5.55e-05	0.35	0.32	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
KIRP	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	5.47	1.07e-07	5.56e-05	0.24	0.32	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
KIRP	cis	rs2625529	0.668	rs35206011	ENSG00000260037.4	CTD-2524L6.3	-5.47	1.07e-07	5.56e-05	-0.28	-0.32	Red blood cell count;	chr15:72247153	chr15:71818396~71823384:+
KIRP	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	5.47	1.07e-07	5.56e-05	0.32	0.32	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-5.47	1.07e-07	5.56e-05	-0.32	-0.32	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	5.47	1.07e-07	5.56e-05	0.32	0.32	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
KIRP	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-5.47	1.07e-07	5.56e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
KIRP	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	5.47	1.07e-07	5.56e-05	0.27	0.32	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
KIRP	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-5.47	1.08e-07	5.56e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
KIRP	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-5.47	1.08e-07	5.56e-05	-0.45	-0.32	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	5.46	1.08e-07	5.57e-05	0.43	0.32	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
KIRP	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-5.46	1.08e-07	5.58e-05	-0.32	-0.32	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
KIRP	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.46	1.08e-07	5.59e-05	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
KIRP	cis	rs78905543	1	rs11778166	ENSG00000253616.4	RP11-875O11.3	5.46	1.08e-07	5.59e-05	0.36	0.32	Mean corpuscular volume;	chr8:23071837	chr8:23071377~23074488:-
KIRP	cis	rs7211079	0.719	rs2289535	ENSG00000275479.1	RP11-334C17.6	5.46	1.08e-07	5.59e-05	0.25	0.32	Myocardial infarction;	chr17:80137650	chr17:80149627~80149798:+
KIRP	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	5.46	1.08e-07	5.6e-05	0.33	0.32	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
KIRP	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	5.46	1.08e-07	5.6e-05	0.26	0.32	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
KIRP	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	5.46	1.09e-07	5.62e-05	0.28	0.32	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
KIRP	cis	rs2625529	0.526	rs7183810	ENSG00000260037.4	CTD-2524L6.3	5.46	1.09e-07	5.62e-05	0.25	0.32	Red blood cell count;	chr15:72268117	chr15:71818396~71823384:+
KIRP	cis	rs9402743	0.632	rs9399166	ENSG00000231028.7	LINC00271	-5.46	1.09e-07	5.62e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135776762	chr6:135497801~135716055:+
KIRP	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	5.46	1.09e-07	5.62e-05	0.41	0.32	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
KIRP	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-5.46	1.09e-07	5.63e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
KIRP	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.46	1.09e-07	5.63e-05	-0.27	-0.32	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
KIRP	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	5.46	1.09e-07	5.64e-05	0.36	0.32	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
KIRP	cis	rs2976388	0.578	rs13254358	ENSG00000253741.1	CTD-2292P10.4	5.46	1.09e-07	5.64e-05	0.41	0.32	Urinary tract infection frequency;	chr8:142742458	chr8:142702252~142726973:-
KIRP	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-5.46	1.09e-07	5.65e-05	-0.33	-0.32	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
KIRP	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-5.46	1.09e-07	5.65e-05	-0.42	-0.32	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
KIRP	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	5.46	1.1e-07	5.66e-05	0.33	0.32	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
KIRP	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	5.46	1.1e-07	5.66e-05	0.33	0.32	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
KIRP	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	5.46	1.1e-07	5.66e-05	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
KIRP	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-5.46	1.1e-07	5.66e-05	-0.35	-0.32	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
KIRP	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	5.46	1.1e-07	5.66e-05	0.27	0.32	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
KIRP	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	5.46	1.1e-07	5.66e-05	0.27	0.32	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
KIRP	cis	rs638893	0.541	rs553188	ENSG00000278376.1	RP11-158I9.8	-5.46	1.1e-07	5.67e-05	-0.41	-0.32	Vitiligo;	chr11:118706053	chr11:118791254~118793137:+
KIRP	cis	rs638893	0.541	rs498912	ENSG00000278376.1	RP11-158I9.8	-5.46	1.1e-07	5.67e-05	-0.41	-0.32	Vitiligo;	chr11:118706288	chr11:118791254~118793137:+
KIRP	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-5.46	1.1e-07	5.67e-05	-0.3	-0.32	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
KIRP	cis	rs11647589	0.834	rs1394677	ENSG00000262995.1	CTD-2194A8.2	-5.46	1.1e-07	5.67e-05	-0.35	-0.32	Blood metabolite levels;	chr16:20478195	chr16:20440266~20447000:-
KIRP	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	5.46	1.1e-07	5.67e-05	0.39	0.32	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
KIRP	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-5.46	1.1e-07	5.68e-05	-0.29	-0.32	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
KIRP	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-5.46	1.1e-07	5.68e-05	-0.42	-0.32	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
KIRP	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	5.46	1.1e-07	5.68e-05	0.4	0.32	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
KIRP	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5.46	1.1e-07	5.68e-05	-0.31	-0.32	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
KIRP	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	5.46	1.1e-07	5.69e-05	0.38	0.32	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
KIRP	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	5.46	1.1e-07	5.69e-05	0.32	0.32	Height;	chr14:75059147	chr14:75011269~75012851:-
KIRP	cis	rs897984	0.647	rs8060857	ENSG00000275263.1	RP11-1072A3.4	5.46	1.1e-07	5.69e-05	0.33	0.32	Dementia with Lewy bodies;	chr16:30991399	chr16:30956872~30957199:-
KIRP	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-5.46	1.1e-07	5.69e-05	-0.34	-0.32	Height;	chr3:53080524	chr3:53064283~53065091:-
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.46	1.1e-07	5.7e-05	-0.27	-0.32	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.46	1.1e-07	5.7e-05	-0.27	-0.32	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
KIRP	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-5.46	1.11e-07	5.72e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-5.46	1.11e-07	5.72e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	5.46	1.11e-07	5.72e-05	0.32	0.32	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
KIRP	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.11e-07	5.72e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.11e-07	5.72e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.11e-07	5.72e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.11e-07	5.72e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.11e-07	5.72e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
KIRP	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-5.46	1.11e-07	5.74e-05	-0.34	-0.32	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
KIRP	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	5.46	1.11e-07	5.74e-05	0.36	0.32	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	5.46	1.11e-07	5.74e-05	0.36	0.32	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
KIRP	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	5.46	1.11e-07	5.74e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
KIRP	cis	rs8067545	0.641	rs203479	ENSG00000270091.1	RP11-78O7.2	-5.46	1.11e-07	5.74e-05	-0.21	-0.32	Schizophrenia;	chr17:19925998	chr17:19896590~19897287:-
KIRP	cis	rs11647589	0.642	rs1532842	ENSG00000262995.1	CTD-2194A8.2	-5.46	1.11e-07	5.74e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20468067	chr16:20440266~20447000:-
KIRP	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-5.46	1.11e-07	5.75e-05	-0.41	-0.32	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
KIRP	cis	rs875971	0.545	rs10950025	ENSG00000224316.1	RP11-479O9.2	5.46	1.11e-07	5.75e-05	0.27	0.32	Aortic root size;	chr7:66158946	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.52	rs12666485	ENSG00000224316.1	RP11-479O9.2	5.46	1.11e-07	5.75e-05	0.27	0.32	Aortic root size;	chr7:66160135	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs67688847	ENSG00000224316.1	RP11-479O9.2	5.46	1.11e-07	5.75e-05	0.27	0.32	Aortic root size;	chr7:66161064	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs7787063	ENSG00000224316.1	RP11-479O9.2	5.46	1.11e-07	5.75e-05	0.27	0.32	Aortic root size;	chr7:66164012	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs12673308	ENSG00000224316.1	RP11-479O9.2	5.46	1.11e-07	5.75e-05	0.27	0.32	Aortic root size;	chr7:66166374	chr7:65773620~65802067:+
KIRP	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	5.46	1.12e-07	5.75e-05	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
KIRP	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-5.46	1.12e-07	5.76e-05	-0.33	-0.32	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
KIRP	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-5.46	1.12e-07	5.76e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
KIRP	cis	rs4356975	0.563	rs4538548	ENSG00000248763.2	RP13-644M16.5	-5.46	1.12e-07	5.77e-05	-0.34	-0.32	Obesity-related traits;	chr4:69094951	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600883	ENSG00000248763.2	RP13-644M16.5	-5.46	1.12e-07	5.77e-05	-0.34	-0.32	Obesity-related traits;	chr4:69094953	chr4:69066395~69069888:+
KIRP	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-5.46	1.12e-07	5.78e-05	-0.35	-0.32	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-5.46	1.12e-07	5.78e-05	-0.35	-0.32	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
KIRP	cis	rs4356975	0.563	rs7676472	ENSG00000248763.2	RP13-644M16.5	-5.46	1.12e-07	5.78e-05	-0.34	-0.32	Obesity-related traits;	chr4:69090226	chr4:69066395~69069888:+
KIRP	cis	rs1560104	0.597	rs7187433	ENSG00000274834.1	CTD-3037G24.5	5.46	1.12e-07	5.78e-05	0.35	0.32	Obesity-related traits;	chr16:12615251	chr16:12614451~12614852:+
KIRP	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	5.46	1.12e-07	5.78e-05	0.29	0.32	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
KIRP	cis	rs1975197	0.515	rs2814723	ENSG00000225706.1	PTPRD-AS1	-5.46	1.12e-07	5.78e-05	-0.35	-0.32	Restless legs syndrome;	chr9:8846151	chr9:8858130~8862255:+
KIRP	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	5.46	1.12e-07	5.79e-05	0.35	0.32	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
KIRP	cis	rs2273156	1	rs12897044	ENSG00000226677.3	IGBP1P1	-5.46	1.12e-07	5.79e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953938	chr14:34939324~34940332:+
KIRP	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-5.46	1.12e-07	5.79e-05	-0.31	-0.32	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
KIRP	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	5.46	1.12e-07	5.79e-05	0.34	0.32	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
KIRP	cis	rs1560104	0.536	rs9933641	ENSG00000274834.1	CTD-3037G24.5	5.46	1.12e-07	5.79e-05	0.36	0.32	Obesity-related traits;	chr16:12615413	chr16:12614451~12614852:+
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.46	1.12e-07	5.79e-05	-0.27	-0.32	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.46	1.12e-07	5.79e-05	-0.27	-0.32	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
KIRP	cis	rs28386778	1	rs28386778	ENSG00000240280.5	TCAM1P	-5.46	1.13e-07	5.79e-05	-0.4	-0.32	Prudent dietary pattern;	chr17:63887455	chr17:63849292~63864379:+
KIRP	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-5.46	1.13e-07	5.8e-05	-0.43	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
KIRP	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	5.46	1.13e-07	5.8e-05	0.35	0.32	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
KIRP	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	5.46	1.13e-07	5.8e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
KIRP	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-5.46	1.13e-07	5.81e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
KIRP	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-5.46	1.13e-07	5.81e-05	-0.33	-0.32	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
KIRP	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-5.46	1.13e-07	5.81e-05	-0.44	-0.32	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
KIRP	cis	rs295490	0.688	rs184156	ENSG00000272656.1	RP11-219D15.3	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	PR interval in Tripanosoma cruzi seropositivity;	chr3:139519526	chr3:139349024~139349371:-
KIRP	cis	rs4356975	0.563	rs11249527	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69089267	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6846298	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69089278	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs11249528	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69089337	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs55757747	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69089919	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs56217918	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69089925	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7663584	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69090392	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600876	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69091212	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.583	rs6600877	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69091505	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600878	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69092618	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.583	rs6819757	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69092946	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs57216626	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69093105	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs59415892	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69093191	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs62296942	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69093401	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7437039	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69093758	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7439792	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69093881	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.545	rs62296944	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69094492	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600879	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69094669	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600880	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69094762	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4455491	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69095215	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs11940220	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69095222	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs11940316	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69095409	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7662029	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69096194	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7668258	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69096360	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs12647681	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69097442	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12647682	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69097450	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs58544196	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69097740	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7439326	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69098462	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7438244	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69098491	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7441750	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69098803	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7441774	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69098836	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs7434332	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69099141	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4293848	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69099784	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12512526	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69100700	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs34386959	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69100837	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs55834557	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69100876	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs34318523	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69101135	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.583	rs34630750	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69101208	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12508257	ENSG00000248763.2	RP13-644M16.5	-5.46	1.13e-07	5.81e-05	-0.34	-0.32	Obesity-related traits;	chr4:69101921	chr4:69066395~69069888:+
KIRP	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	5.46	1.13e-07	5.81e-05	0.35	0.32	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-5.46	1.13e-07	5.81e-05	-0.35	-0.32	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
KIRP	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-5.46	1.13e-07	5.81e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
KIRP	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	5.46	1.13e-07	5.81e-05	0.33	0.32	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
KIRP	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	5.46	1.13e-07	5.82e-05	0.71	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
KIRP	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	5.45	1.13e-07	5.83e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	5.45	1.13e-07	5.83e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
KIRP	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-5.45	1.13e-07	5.83e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-5.45	1.13e-07	5.83e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
KIRP	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-5.45	1.13e-07	5.83e-05	-0.3	-0.32	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
KIRP	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	5.45	1.14e-07	5.85e-05	0.26	0.32	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
KIRP	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	5.45	1.14e-07	5.85e-05	0.29	0.32	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
KIRP	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	5.45	1.14e-07	5.86e-05	0.36	0.32	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
KIRP	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	5.45	1.14e-07	5.86e-05	0.41	0.32	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
KIRP	cis	rs1799949	1	rs2292595	ENSG00000236383.6	LINC00854	-5.45	1.14e-07	5.86e-05	-0.26	-0.32	Menopause (age at onset);	chr17:43138657	chr17:43216941~43305976:-
KIRP	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	5.45	1.14e-07	5.86e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	5.45	1.14e-07	5.86e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	5.45	1.14e-07	5.86e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	5.45	1.14e-07	5.87e-05	0.25	0.32	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
KIRP	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	5.45	1.14e-07	5.87e-05	0.36	0.32	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	5.45	1.14e-07	5.87e-05	0.36	0.32	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	5.45	1.14e-07	5.87e-05	0.36	0.32	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
KIRP	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	5.45	1.14e-07	5.88e-05	0.31	0.32	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.688	rs7645137	ENSG00000180385.7	EMC3-AS1	5.45	1.14e-07	5.88e-05	0.31	0.32	Alzheimer's disease;	chr3:9978865	chr3:9986893~10006990:+
KIRP	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	5.45	1.15e-07	5.89e-05	0.28	0.32	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
KIRP	cis	rs7615952	1	rs7615952	ENSG00000250012.1	RP11-124N2.1	5.45	1.15e-07	5.89e-05	0.39	0.32	Blood pressure (smoking interaction);	chr3:125930560	chr3:126084220~126095349:+
KIRP	cis	rs1200821	0.529	rs2505707	ENSG00000151963.4	RP11-775A3.1	-5.45	1.15e-07	5.9e-05	-0.36	-0.32	Hemostatic factors and hematological phenotypes;	chr10:37512326	chr10:37883594~37884109:+
KIRP	cis	rs9532669	0.889	rs7333447	ENSG00000239827.7	SUGT1P3	-5.45	1.15e-07	5.9e-05	-0.37	-0.32	Cervical cancer;	chr13:40917586	chr13:40908159~40921774:-
KIRP	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	5.45	1.15e-07	5.9e-05	0.61	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
KIRP	cis	rs67311347	0.544	rs4974040	ENSG00000230274.1	PGAM1P3	5.45	1.15e-07	5.9e-05	0.32	0.32	Renal cell carcinoma;	chr3:40289568	chr3:40322715~40323279:-
KIRP	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-5.45	1.15e-07	5.91e-05	-0.44	-0.32	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
KIRP	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	5.45	1.15e-07	5.91e-05	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
KIRP	cis	rs1799949	0.602	rs8176199	ENSG00000279602.1	CTD-3014M21.1	-5.45	1.15e-07	5.92e-05	-0.32	-0.32	Menopause (age at onset);	chr17:43078507	chr17:43360041~43361361:-
KIRP	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	5.45	1.15e-07	5.92e-05	0.4	0.32	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
KIRP	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-5.45	1.15e-07	5.93e-05	-0.23	-0.32	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
KIRP	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	5.45	1.16e-07	5.93e-05	0.36	0.32	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
KIRP	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	5.45	1.16e-07	5.93e-05	0.37	0.32	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
KIRP	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	5.45	1.16e-07	5.93e-05	0.37	0.32	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
KIRP	cis	rs755249	0.51	rs582883	ENSG00000237624.1	OXCT2P1	5.45	1.16e-07	5.94e-05	0.42	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39514956~39516490:+
KIRP	cis	rs11647589	0.906	rs6416611	ENSG00000262995.1	CTD-2194A8.2	-5.45	1.16e-07	5.94e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20459768	chr16:20440266~20447000:-
KIRP	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-5.45	1.16e-07	5.94e-05	-0.4	-0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
KIRP	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-5.45	1.16e-07	5.94e-05	-0.4	-0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
KIRP	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	5.45	1.16e-07	5.95e-05	0.35	0.32	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
KIRP	cis	rs4601821	0.635	rs7114433	ENSG00000270179.1	RP11-159N11.4	-5.45	1.16e-07	5.96e-05	-0.29	-0.32	Alcoholic chronic pancreatitis;	chr11:113337376	chr11:113368478~113369117:+
KIRP	cis	rs9402743	0.632	rs7766804	ENSG00000231028.7	LINC00271	-5.45	1.16e-07	5.97e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135772118	chr6:135497801~135716055:+
KIRP	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-5.45	1.16e-07	5.97e-05	-0.28	-0.32	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
KIRP	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-5.45	1.16e-07	5.97e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
KIRP	cis	rs7747960	0.61	rs17545391	ENSG00000226193.1	RP3-398G3.5	-5.45	1.17e-07	5.98e-05	-0.46	-0.32	Bipolar disorder;	chr6:152514685	chr6:152402398~152404966:+
KIRP	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-5.45	1.17e-07	5.98e-05	-0.34	-0.32	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
KIRP	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-5.45	1.17e-07	5.99e-05	-0.4	-0.32	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
KIRP	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-5.45	1.17e-07	5.99e-05	-0.38	-0.32	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000206090.4	AP000350.7	-5.45	1.17e-07	5.99e-05	-0.39	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23939998~23942798:+
KIRP	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-5.45	1.17e-07	6e-05	-0.28	-0.32	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-5.45	1.17e-07	6e-05	-0.28	-0.32	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
KIRP	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	5.45	1.17e-07	6e-05	0.31	0.32	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
KIRP	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	5.45	1.17e-07	6.01e-05	0.44	0.32	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
KIRP	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	5.45	1.17e-07	6.02e-05	0.33	0.32	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	5.45	1.17e-07	6.02e-05	0.33	0.32	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	5.45	1.17e-07	6.02e-05	0.33	0.32	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	5.45	1.17e-07	6.02e-05	0.33	0.32	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	5.45	1.17e-07	6.02e-05	0.33	0.32	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
KIRP	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-5.45	1.17e-07	6.02e-05	-0.23	-0.32	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
KIRP	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	5.45	1.18e-07	6.03e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	5.45	1.18e-07	6.03e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	5.45	1.18e-07	6.03e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
KIRP	cis	rs4638749	0.501	rs3919943	ENSG00000231221.1	AC023672.2	-5.45	1.18e-07	6.03e-05	-0.38	-0.32	Blood pressure;	chr2:108142409	chr2:108049200~108052755:-
KIRP	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.45	1.18e-07	6.03e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
KIRP	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	5.45	1.18e-07	6.04e-05	0.29	0.32	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
KIRP	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	5.45	1.18e-07	6.04e-05	0.35	0.32	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
KIRP	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-5.45	1.18e-07	6.04e-05	-0.28	-0.32	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-5.45	1.18e-07	6.04e-05	-0.28	-0.32	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
KIRP	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	5.45	1.18e-07	6.04e-05	0.52	0.32	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
KIRP	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-5.45	1.18e-07	6.04e-05	-0.23	-0.32	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
KIRP	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-5.45	1.18e-07	6.05e-05	-0.39	-0.32	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
KIRP	cis	rs11085466	1	rs4399664	ENSG00000268555.1	RP11-678G14.3	5.45	1.18e-07	6.05e-05	0.42	0.32	Colorectal or endometrial cancer;	chr19:21595224	chr19:21570822~21587322:-
KIRP	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-5.45	1.18e-07	6.06e-05	-0.44	-0.32	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
KIRP	cis	rs4149423	1	rs4149420	ENSG00000225328.1	AC019100.3	-5.45	1.18e-07	6.06e-05	-0.42	-0.32	Lobe size;	chr2:108296634	chr2:108167748~108217841:-
KIRP	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	5.45	1.18e-07	6.06e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-5.45	1.18e-07	6.06e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-5.45	1.18e-07	6.06e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-5.45	1.18e-07	6.06e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
KIRP	cis	rs2734839	0.964	rs12364051	ENSG00000270179.1	RP11-159N11.4	-5.45	1.18e-07	6.06e-05	-0.28	-0.32	Information processing speed;	chr11:113434592	chr11:113368478~113369117:+
KIRP	cis	rs2273156	1	rs12897612	ENSG00000226677.3	IGBP1P1	-5.45	1.18e-07	6.06e-05	-0.34	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35001941	chr14:34939324~34940332:+
KIRP	cis	rs1560104	0.576	rs11645674	ENSG00000274834.1	CTD-3037G24.5	-5.45	1.18e-07	6.07e-05	-0.35	-0.32	Obesity-related traits;	chr16:12615117	chr16:12614451~12614852:+
KIRP	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	5.45	1.19e-07	6.07e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
KIRP	cis	rs7829975	0.545	rs13261926	ENSG00000253893.2	FAM85B	5.45	1.19e-07	6.07e-05	0.41	0.32	Mood instability;	chr8:8694100	chr8:8167819~8226614:-
KIRP	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	5.45	1.19e-07	6.07e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	5.45	1.19e-07	6.07e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	5.45	1.19e-07	6.07e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	5.45	1.19e-07	6.07e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	5.45	1.19e-07	6.07e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
KIRP	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	5.45	1.19e-07	6.08e-05	0.38	0.32	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
KIRP	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-5.45	1.19e-07	6.08e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
KIRP	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	5.45	1.19e-07	6.08e-05	0.33	0.32	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
KIRP	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-5.45	1.19e-07	6.1e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
KIRP	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	5.44	1.19e-07	6.1e-05	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
KIRP	cis	rs5758659	0.716	rs86669	ENSG00000205702.9	CYP2D7	5.44	1.2e-07	6.12e-05	0.25	0.32	Cognitive function;	chr22:42284794	chr22:42140203~42144577:-
KIRP	cis	rs6085948	1	rs6054856	ENSG00000238102.1	RP11-19D2.1	-5.44	1.2e-07	6.12e-05	-0.38	-0.32	Interleukin-10 levels;	chr20:7266592	chr20:7256580~7258214:-
KIRP	cis	rs8067545	0.641	rs203481	ENSG00000270091.1	RP11-78O7.2	-5.44	1.2e-07	6.12e-05	-0.21	-0.32	Schizophrenia;	chr17:19925415	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.616	rs203477	ENSG00000270091.1	RP11-78O7.2	-5.44	1.2e-07	6.12e-05	-0.21	-0.32	Schizophrenia;	chr17:19928506	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.641	rs850623	ENSG00000270091.1	RP11-78O7.2	-5.44	1.2e-07	6.12e-05	-0.21	-0.32	Schizophrenia;	chr17:19933817	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.641	rs119672	ENSG00000270091.1	RP11-78O7.2	-5.44	1.2e-07	6.12e-05	-0.21	-0.32	Schizophrenia;	chr17:19915288	chr17:19896590~19897287:-
KIRP	cis	rs7586673	1	rs7586673	ENSG00000235724.7	AC009299.2	-5.44	1.2e-07	6.12e-05	-0.37	-0.32	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161222785~161308303:-
KIRP	cis	rs6832769	1	rs28463765	ENSG00000272969.1	RP11-528I4.2	-5.44	1.2e-07	6.12e-05	-0.33	-0.32	Personality dimensions;	chr4:55546267	chr4:55547112~55547889:+
KIRP	cis	rs4638749	0.677	rs7581595	ENSG00000231221.1	AC023672.2	-5.44	1.2e-07	6.13e-05	-0.37	-0.32	Blood pressure;	chr2:108231429	chr2:108049200~108052755:-
KIRP	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-5.44	1.2e-07	6.13e-05	-0.28	-0.32	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
KIRP	cis	rs9595908	0.869	rs7998956	ENSG00000212293.1	SNORA16	5.44	1.2e-07	6.13e-05	0.3	0.32	Body mass index;	chr13:32622239	chr13:32420390~32420516:-
KIRP	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	5.44	1.2e-07	6.14e-05	0.36	0.32	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
KIRP	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	5.44	1.2e-07	6.14e-05	0.36	0.32	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
KIRP	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	5.44	1.2e-07	6.14e-05	0.33	0.32	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
KIRP	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	5.44	1.2e-07	6.14e-05	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
KIRP	cis	rs2281558	0.876	rs2274890	ENSG00000274414.1	RP5-965G21.4	-5.44	1.2e-07	6.15e-05	-0.36	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:25239007~25245229:-
KIRP	cis	rs6832769	0.857	rs28377791	ENSG00000272969.1	RP11-528I4.2	-5.44	1.2e-07	6.15e-05	-0.33	-0.32	Personality dimensions;	chr4:55607014	chr4:55547112~55547889:+
KIRP	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	5.44	1.2e-07	6.16e-05	0.38	0.32	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
KIRP	cis	rs962856	1	rs6722203	ENSG00000236780.4	AC078941.1	5.44	1.21e-07	6.17e-05	0.39	0.32	Pancreatic cancer;	chr2:67342061	chr2:67123357~67215319:-
KIRP	cis	rs4356975	0.522	rs56388229	ENSG00000248763.2	RP13-644M16.5	-5.44	1.21e-07	6.18e-05	-0.34	-0.32	Obesity-related traits;	chr4:69100940	chr4:69066395~69069888:+
KIRP	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	5.44	1.21e-07	6.18e-05	0.24	0.32	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
KIRP	cis	rs9388451	0.868	rs10457467	ENSG00000237742.5	RP11-624M8.1	-5.44	1.21e-07	6.19e-05	-0.34	-0.32	Brugada syndrome;	chr6:125724002	chr6:125578558~125749190:-
KIRP	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	5.44	1.21e-07	6.2e-05	0.38	0.32	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	5.44	1.21e-07	6.2e-05	0.38	0.32	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
KIRP	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-5.44	1.21e-07	6.21e-05	-0.5	-0.32	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
KIRP	cis	rs73198271	0.694	rs73201840	ENSG00000253981.4	ALG1L13P	-5.44	1.22e-07	6.21e-05	-0.27	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.694	rs113694763	ENSG00000253981.4	ALG1L13P	-5.44	1.22e-07	6.21e-05	-0.27	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.694	rs115037021	ENSG00000253981.4	ALG1L13P	-5.44	1.22e-07	6.21e-05	-0.27	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.694	rs114184516	ENSG00000253981.4	ALG1L13P	-5.44	1.22e-07	6.21e-05	-0.27	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8236003~8244667:-
KIRP	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-5.44	1.22e-07	6.22e-05	-0.35	-0.32	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
KIRP	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	5.44	1.22e-07	6.22e-05	0.3	0.32	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	5.44	1.22e-07	6.22e-05	0.3	0.32	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
KIRP	cis	rs6832769	1	rs4865010	ENSG00000272969.1	RP11-528I4.2	-5.44	1.22e-07	6.22e-05	-0.31	-0.32	Personality dimensions;	chr4:55548795	chr4:55547112~55547889:+
KIRP	cis	rs4638749	0.677	rs2378098	ENSG00000231221.1	AC023672.2	-5.44	1.22e-07	6.23e-05	-0.38	-0.32	Blood pressure;	chr2:108232925	chr2:108049200~108052755:-
KIRP	cis	rs710913	0.531	rs1180331	ENSG00000237624.1	OXCT2P1	-5.44	1.22e-07	6.23e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39514956~39516490:+
KIRP	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	5.44	1.22e-07	6.23e-05	0.47	0.32	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
KIRP	cis	rs2625529	0.938	rs8747	ENSG00000260037.4	CTD-2524L6.3	-5.44	1.22e-07	6.23e-05	-0.28	-0.32	Red blood cell count;	chr15:71823200	chr15:71818396~71823384:+
KIRP	cis	rs2625529	0.938	rs9120	ENSG00000260037.4	CTD-2524L6.3	-5.44	1.22e-07	6.23e-05	-0.28	-0.32	Red blood cell count;	chr15:71823422	chr15:71818396~71823384:+
KIRP	cis	rs7569084	0.687	rs1344891	ENSG00000237979.1	AC007389.1	5.44	1.22e-07	6.23e-05	0.36	0.32	Sum eosinophil basophil counts;	chr2:65458890	chr2:65500993~65502138:-
KIRP	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-5.44	1.22e-07	6.23e-05	-0.45	-0.32	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
KIRP	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	5.44	1.22e-07	6.23e-05	0.37	0.32	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	5.44	1.22e-07	6.23e-05	0.37	0.32	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
KIRP	cis	rs2976388	1	rs2717562	ENSG00000253741.1	CTD-2292P10.4	5.44	1.22e-07	6.24e-05	0.37	0.32	Urinary tract infection frequency;	chr8:142695250	chr8:142702252~142726973:-
KIRP	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	5.44	1.22e-07	6.25e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	5.44	1.22e-07	6.25e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-5.44	1.22e-07	6.25e-05	-0.36	-0.32	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
KIRP	cis	rs1858037	0.867	rs1553675	ENSG00000281920.1	RP11-418H16.1	-5.44	1.23e-07	6.27e-05	-0.41	-0.32	Rheumatoid arthritis;	chr2:65343173	chr2:65623272~65628424:+
KIRP	cis	rs11647589	0.834	rs6497491	ENSG00000262995.1	CTD-2194A8.2	-5.44	1.23e-07	6.27e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20468691	chr16:20440266~20447000:-
KIRP	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	5.44	1.23e-07	6.27e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
KIRP	cis	rs9402743	0.632	rs6570029	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135757894	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.665	rs6933507	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135760018	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.665	rs4896172	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135760664	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs4896173	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135762413	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs4896174	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135762421	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs4896175	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135762568	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs2093330	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135763534	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs2104132	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135763810	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.632	rs9389324	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.27e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135765375	chr6:135497801~135716055:+
KIRP	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	5.44	1.23e-07	6.28e-05	0.35	0.32	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
KIRP	cis	rs9402743	0.632	rs9399167	ENSG00000231028.7	LINC00271	-5.44	1.23e-07	6.28e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135792678	chr6:135497801~135716055:+
KIRP	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-5.44	1.23e-07	6.29e-05	-0.33	-0.32	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
KIRP	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	5.44	1.23e-07	6.29e-05	0.52	0.32	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
KIRP	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	5.44	1.23e-07	6.29e-05	0.4	0.32	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	5.44	1.23e-07	6.29e-05	0.4	0.32	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
KIRP	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-5.44	1.23e-07	6.29e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
KIRP	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-5.44	1.24e-07	6.3e-05	-0.41	-0.32	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-5.44	1.24e-07	6.3e-05	-0.37	-0.32	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
KIRP	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	5.44	1.24e-07	6.3e-05	0.37	0.32	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
KIRP	cis	rs2625529	0.824	rs2415130	ENSG00000260037.4	CTD-2524L6.3	-5.44	1.24e-07	6.3e-05	-0.28	-0.32	Red blood cell count;	chr15:71950213	chr15:71818396~71823384:+
KIRP	cis	rs9402743	0.632	rs6900101	ENSG00000231028.7	LINC00271	-5.44	1.24e-07	6.31e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135773766	chr6:135497801~135716055:+
KIRP	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	5.44	1.24e-07	6.31e-05	0.3	0.32	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	5.44	1.24e-07	6.31e-05	0.3	0.32	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	5.44	1.24e-07	6.31e-05	0.3	0.32	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
KIRP	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	5.44	1.24e-07	6.31e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	5.44	1.24e-07	6.32e-05	0.26	0.32	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
KIRP	cis	rs4638749	0.677	rs12712018	ENSG00000231221.1	AC023672.2	-5.44	1.24e-07	6.32e-05	-0.37	-0.32	Blood pressure;	chr2:108237049	chr2:108049200~108052755:-
KIRP	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	5.44	1.24e-07	6.33e-05	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
KIRP	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	5.44	1.24e-07	6.33e-05	0.52	0.32	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
KIRP	cis	rs9532669	0.926	rs2039119	ENSG00000239827.7	SUGT1P3	5.44	1.24e-07	6.34e-05	0.36	0.32	Cervical cancer;	chr13:40872432	chr13:40908159~40921774:-
KIRP	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	5.44	1.24e-07	6.34e-05	0.31	0.32	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
KIRP	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	5.44	1.24e-07	6.34e-05	0.31	0.32	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
KIRP	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-5.44	1.25e-07	6.34e-05	-0.44	-0.32	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
KIRP	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	5.44	1.25e-07	6.35e-05	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
KIRP	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	5.44	1.25e-07	6.35e-05	0.37	0.32	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
KIRP	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-5.44	1.25e-07	6.35e-05	-0.28	-0.32	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
KIRP	cis	rs1153858	1	rs2453541	ENSG00000259433.2	CTD-2651B20.4	-5.44	1.25e-07	6.36e-05	-0.28	-0.32	Homoarginine levels;	chr15:45353180	chr15:45330209~45332634:-
KIRP	cis	rs1153858	1	rs2461702	ENSG00000259433.2	CTD-2651B20.4	-5.44	1.25e-07	6.36e-05	-0.28	-0.32	Homoarginine levels;	chr15:45355229	chr15:45330209~45332634:-
KIRP	cis	rs2281558	0.833	rs55792313	ENSG00000274414.1	RP5-965G21.4	-5.44	1.25e-07	6.36e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:25239007~25245229:-
KIRP	cis	rs2281558	0.833	rs12480853	ENSG00000274414.1	RP5-965G21.4	-5.44	1.25e-07	6.36e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	5.44	1.25e-07	6.36e-05	0.42	0.32	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
KIRP	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	5.44	1.25e-07	6.36e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-5.44	1.25e-07	6.36e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
KIRP	cis	rs2483058	0.739	rs963893	ENSG00000261000.1	RP11-534L20.5	5.44	1.25e-07	6.37e-05	0.34	0.32	Cholesterol and Triglycerides;	chr1:206452351	chr1:206503948~206504456:+
KIRP	cis	rs453301	0.564	rs28649568	ENSG00000253893.2	FAM85B	5.44	1.25e-07	6.38e-05	0.39	0.32	Joint mobility (Beighton score);	chr8:9102161	chr8:8167819~8226614:-
KIRP	cis	rs1799949	1	rs35668327	ENSG00000236383.6	LINC00854	-5.43	1.25e-07	6.39e-05	-0.26	-0.32	Menopause (age at onset);	chr17:43121078	chr17:43216941~43305976:-
KIRP	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	5.43	1.26e-07	6.39e-05	0.39	0.32	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
KIRP	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.43	1.26e-07	6.39e-05	0.42	0.32	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
KIRP	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	5.43	1.26e-07	6.39e-05	0.39	0.32	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
KIRP	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	5.43	1.26e-07	6.4e-05	0.37	0.32	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
KIRP	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-5.43	1.26e-07	6.4e-05	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
KIRP	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-5.43	1.26e-07	6.4e-05	-0.23	-0.32	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
KIRP	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-5.43	1.26e-07	6.4e-05	-0.23	-0.32	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
KIRP	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-5.43	1.26e-07	6.4e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
KIRP	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
KIRP	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	5.43	1.26e-07	6.41e-05	0.33	0.32	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
KIRP	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-5.43	1.26e-07	6.41e-05	-0.41	-0.32	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
KIRP	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	5.43	1.26e-07	6.41e-05	0.3	0.32	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
KIRP	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	5.43	1.26e-07	6.42e-05	0.4	0.32	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
KIRP	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	5.43	1.26e-07	6.42e-05	0.25	0.32	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
KIRP	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-5.43	1.27e-07	6.44e-05	-0.24	-0.32	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
KIRP	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-5.43	1.27e-07	6.44e-05	-0.64	-0.32	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
KIRP	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-5.43	1.27e-07	6.44e-05	-0.39	-0.32	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
KIRP	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	5.43	1.27e-07	6.45e-05	0.36	0.32	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	5.43	1.27e-07	6.45e-05	0.36	0.32	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
KIRP	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	5.43	1.27e-07	6.46e-05	0.37	0.32	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	5.43	1.27e-07	6.46e-05	0.37	0.32	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	5.43	1.27e-07	6.46e-05	0.37	0.32	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	5.43	1.27e-07	6.46e-05	0.37	0.32	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	5.43	1.27e-07	6.46e-05	0.37	0.32	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
KIRP	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-5.43	1.27e-07	6.46e-05	-0.3	-0.32	Height;	chr4:55537550	chr4:55547112~55547889:+
KIRP	cis	rs1479119	0.621	rs1479115	ENSG00000180861.8	LINC01559	5.43	1.27e-07	6.47e-05	0.37	0.32	Intelligence (multi-trait analysis);	chr12:13347541	chr12:13371089~13387167:-
KIRP	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	5.43	1.27e-07	6.47e-05	0.31	0.32	Height;	chr14:75009368	chr14:75011269~75012851:-
KIRP	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	5.43	1.27e-07	6.47e-05	0.3	0.32	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	5.43	1.27e-07	6.47e-05	0.3	0.32	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
KIRP	cis	rs330048	0.525	rs10112237	ENSG00000253893.2	FAM85B	5.43	1.27e-07	6.47e-05	0.41	0.32	Systemic lupus erythematosus;	chr8:9215219	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	5.43	1.28e-07	6.48e-05	0.42	0.32	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
KIRP	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-5.43	1.28e-07	6.49e-05	-0.35	-0.32	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
KIRP	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	5.43	1.28e-07	6.49e-05	0.33	0.32	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
KIRP	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-5.43	1.28e-07	6.5e-05	-0.49	-0.32	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
KIRP	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	5.43	1.28e-07	6.5e-05	0.26	0.32	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
KIRP	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	5.43	1.28e-07	6.5e-05	0.4	0.32	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	5.43	1.28e-07	6.5e-05	0.4	0.32	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
KIRP	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	5.43	1.28e-07	6.5e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
KIRP	cis	rs4356975	0.563	rs6858558	ENSG00000248763.2	RP13-644M16.5	-5.43	1.28e-07	6.5e-05	-0.35	-0.32	Obesity-related traits;	chr4:69103825	chr4:69066395~69069888:+
KIRP	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	5.43	1.28e-07	6.52e-05	0.37	0.32	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
KIRP	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	5.43	1.28e-07	6.52e-05	0.61	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
KIRP	cis	rs9959145	1	rs9967026	ENSG00000267108.1	RP11-861E21.1	5.43	1.28e-07	6.52e-05	0.46	0.32	Immune response to smallpox vaccine (IL-6);	chr18:12566484	chr18:12432897~12437635:+
KIRP	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	5.43	1.29e-07	6.53e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-5.43	1.29e-07	6.53e-05	-0.38	-0.32	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
KIRP	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.43	1.29e-07	6.53e-05	-0.35	-0.32	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
KIRP	cis	rs4149423	1	rs12620050	ENSG00000225328.1	AC019100.3	-5.43	1.29e-07	6.53e-05	-0.42	-0.32	Lobe size;	chr2:108303342	chr2:108167748~108217841:-
KIRP	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	5.43	1.29e-07	6.54e-05	0.43	0.32	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
KIRP	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-5.43	1.29e-07	6.55e-05	-0.3	-0.32	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
KIRP	cis	rs79040073	0.637	rs73398250	ENSG00000259531.2	RP11-295H24.3	5.43	1.29e-07	6.56e-05	0.42	0.32	Lung cancer in ever smokers;	chr15:49404829	chr15:49365124~49366685:-
KIRP	cis	rs10504130	0.569	rs12681734	ENSG00000272024.1	RP11-546K22.3	-5.43	1.29e-07	6.56e-05	-0.37	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51950284~51950690:+
KIRP	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-5.43	1.3e-07	6.57e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
KIRP	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	5.43	1.3e-07	6.58e-05	0.39	0.32	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	5.43	1.3e-07	6.59e-05	0.37	0.32	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
KIRP	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	5.43	1.3e-07	6.59e-05	0.25	0.32	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
KIRP	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	5.43	1.3e-07	6.6e-05	0.32	0.32	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
KIRP	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-5.43	1.3e-07	6.6e-05	-0.31	-0.32	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
KIRP	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	5.43	1.3e-07	6.6e-05	0.26	0.32	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.43	1.3e-07	6.61e-05	-0.24	-0.32	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
KIRP	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	5.43	1.3e-07	6.61e-05	0.5	0.32	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
KIRP	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	5.43	1.31e-07	6.62e-05	0.39	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
KIRP	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	5.43	1.31e-07	6.62e-05	0.34	0.32	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	5.43	1.31e-07	6.62e-05	0.34	0.32	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
KIRP	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	5.43	1.31e-07	6.62e-05	0.34	0.32	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
KIRP	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	5.43	1.31e-07	6.62e-05	0.33	0.32	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
KIRP	cis	rs1005277	0.579	rs2008449	ENSG00000151963.4	RP11-775A3.1	5.43	1.31e-07	6.64e-05	0.37	0.32	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:37883594~37884109:+
KIRP	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-5.43	1.31e-07	6.64e-05	-0.38	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
KIRP	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	5.43	1.31e-07	6.65e-05	0.36	0.32	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	5.43	1.31e-07	6.65e-05	0.36	0.32	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	5.43	1.31e-07	6.65e-05	0.36	0.32	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
KIRP	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	5.43	1.32e-07	6.66e-05	0.24	0.32	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
KIRP	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	5.43	1.32e-07	6.66e-05	0.3	0.32	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
KIRP	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	5.43	1.32e-07	6.66e-05	0.51	0.32	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	5.43	1.32e-07	6.66e-05	0.51	0.32	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
KIRP	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	5.43	1.32e-07	6.67e-05	0.38	0.32	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
KIRP	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	5.43	1.32e-07	6.67e-05	0.36	0.32	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
KIRP	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-5.43	1.32e-07	6.67e-05	-0.45	-0.32	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
KIRP	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	5.43	1.32e-07	6.67e-05	0.34	0.32	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
KIRP	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-5.42	1.32e-07	6.68e-05	-0.29	-0.32	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
KIRP	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-5.42	1.32e-07	6.69e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
KIRP	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-5.42	1.32e-07	6.7e-05	-0.44	-0.32	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
KIRP	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	5.42	1.32e-07	6.7e-05	0.37	0.32	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
KIRP	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	5.42	1.32e-07	6.7e-05	0.28	0.32	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
KIRP	cis	rs11647589	0.642	rs7193826	ENSG00000262995.1	CTD-2194A8.2	-5.42	1.33e-07	6.71e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20467260	chr16:20440266~20447000:-
KIRP	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	5.42	1.33e-07	6.72e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
KIRP	cis	rs79040073	0.637	rs57252806	ENSG00000259531.2	RP11-295H24.3	5.42	1.33e-07	6.72e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49352188	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11633981	ENSG00000259531.2	RP11-295H24.3	5.42	1.33e-07	6.72e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49360903	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11633282	ENSG00000259531.2	RP11-295H24.3	5.42	1.33e-07	6.72e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49372472	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11638606	ENSG00000259531.2	RP11-295H24.3	5.42	1.33e-07	6.72e-05	0.44	0.32	Lung cancer in ever smokers;	chr15:49372564	chr15:49365124~49366685:-
KIRP	cis	rs1799949	1	rs8176103	ENSG00000236383.6	LINC00854	-5.42	1.33e-07	6.73e-05	-0.26	-0.32	Menopause (age at onset);	chr17:43115033	chr17:43216941~43305976:-
KIRP	cis	rs4356203	0.905	rs7946165	ENSG00000272034.1	SNORD14A	-5.42	1.33e-07	6.73e-05	-0.26	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17074654~17074744:-
KIRP	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	5.42	1.33e-07	6.73e-05	0.3	0.32	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	5.42	1.33e-07	6.73e-05	0.3	0.32	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
KIRP	cis	rs2281558	0.876	rs6115135	ENSG00000274414.1	RP5-965G21.4	-5.42	1.33e-07	6.73e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:25239007~25245229:-
KIRP	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-5.42	1.33e-07	6.73e-05	-0.26	-0.32	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
KIRP	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	5.42	1.33e-07	6.73e-05	0.33	0.32	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
KIRP	cis	rs12460587	0.568	rs8113376	ENSG00000275055.1	CTC-471J1.11	-5.42	1.33e-07	6.74e-05	-0.25	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090170	chr19:52049007~52049754:+
KIRP	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-5.42	1.34e-07	6.75e-05	-0.26	-0.32	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
KIRP	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-5.42	1.34e-07	6.76e-05	-0.36	-0.32	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
KIRP	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	-5.42	1.34e-07	6.76e-05	-0.24	-0.32	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
KIRP	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	-5.42	1.34e-07	6.76e-05	-0.24	-0.32	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
KIRP	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	5.42	1.34e-07	6.77e-05	0.4	0.32	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
KIRP	cis	rs7224610	0.898	rs4299205	ENSG00000263096.1	RP11-515O17.2	5.42	1.34e-07	6.77e-05	0.43	0.32	Urate levels;	chr17:55288785	chr17:55271504~55273653:-
KIRP	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	5.42	1.34e-07	6.78e-05	0.38	0.32	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
KIRP	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-5.42	1.34e-07	6.78e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
KIRP	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	5.42	1.34e-07	6.78e-05	0.42	0.32	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
KIRP	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-5.42	1.34e-07	6.79e-05	-0.31	-0.32	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
KIRP	cis	rs1799949	1	rs4793189	ENSG00000236383.6	LINC00854	-5.42	1.34e-07	6.79e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43038698	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11657053	ENSG00000236383.6	LINC00854	-5.42	1.34e-07	6.79e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43039112	chr17:43216941~43305976:-
KIRP	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	5.42	1.34e-07	6.79e-05	0.33	0.32	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
KIRP	cis	rs4149423	1	rs4149423	ENSG00000225328.1	AC019100.3	-5.42	1.34e-07	6.79e-05	-0.42	-0.32	Lobe size;	chr2:108299588	chr2:108167748~108217841:-
KIRP	cis	rs61457372	0.527	rs11077602	ENSG00000264026.1	RP11-1124B17.1	-5.42	1.35e-07	6.8e-05	-0.35	-0.32	Triptolide cytotoxicity;	chr17:72361389	chr17:72342940~72355136:+
KIRP	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-5.42	1.35e-07	6.8e-05	-0.32	-0.32	Height;	chr14:75178824	chr14:75011269~75012851:-
KIRP	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-5.42	1.35e-07	6.8e-05	-0.25	-0.32	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	5.42	1.35e-07	6.81e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	5.42	1.35e-07	6.81e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
KIRP	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-5.42	1.35e-07	6.82e-05	-0.52	-0.32	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
KIRP	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-5.42	1.35e-07	6.82e-05	-0.41	-0.32	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
KIRP	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	5.42	1.35e-07	6.83e-05	0.4	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
KIRP	cis	rs6832769	1	rs28572116	ENSG00000272969.1	RP11-528I4.2	-5.42	1.35e-07	6.84e-05	-0.32	-0.32	Personality dimensions;	chr4:55558177	chr4:55547112~55547889:+
KIRP	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	5.42	1.36e-07	6.85e-05	0.32	0.32	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
KIRP	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-5.42	1.36e-07	6.86e-05	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
KIRP	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.42	1.36e-07	6.86e-05	0.37	0.32	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
KIRP	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	5.42	1.36e-07	6.87e-05	0.24	0.32	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
KIRP	cis	rs67311347	0.544	rs7644181	ENSG00000230274.1	PGAM1P3	-5.42	1.36e-07	6.87e-05	-0.32	-0.32	Renal cell carcinoma;	chr3:40314174	chr3:40322715~40323279:-
KIRP	cis	rs7267979	0.808	rs84816	ENSG00000274414.1	RP5-965G21.4	-5.42	1.36e-07	6.87e-05	-0.31	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25239007~25245229:-
KIRP	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-5.42	1.36e-07	6.88e-05	-0.55	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
KIRP	cis	rs1552244	0.832	rs17050674	ENSG00000180385.7	EMC3-AS1	5.42	1.36e-07	6.89e-05	0.31	0.32	Alzheimer's disease;	chr3:9985574	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.765	rs17050675	ENSG00000180385.7	EMC3-AS1	5.42	1.36e-07	6.89e-05	0.31	0.32	Alzheimer's disease;	chr3:9986002	chr3:9986893~10006990:+
KIRP	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-5.42	1.37e-07	6.9e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
KIRP	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-5.42	1.37e-07	6.9e-05	-0.35	-0.32	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
KIRP	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	5.42	1.37e-07	6.9e-05	0.5	0.32	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
KIRP	cis	rs12682352	0.715	rs332039	ENSG00000253981.4	ALG1L13P	5.42	1.37e-07	6.91e-05	0.26	0.32	Neuroticism;	chr8:8866141	chr8:8236003~8244667:-
KIRP	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	5.42	1.37e-07	6.92e-05	0.38	0.32	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
KIRP	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	5.42	1.37e-07	6.93e-05	0.52	0.32	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
KIRP	cis	rs9402743	0.632	rs6570038	ENSG00000231028.7	LINC00271	-5.42	1.37e-07	6.93e-05	-0.28	-0.32	Systemic lupus erythematosus;	chr6:135775465	chr6:135497801~135716055:+
KIRP	cis	rs1799949	0.965	rs8176323	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43043694	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs8176322	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43043756	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12516	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43044391	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793190	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43048092	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176297	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43051308	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176296	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43051574	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793191	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43052360	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs4793192	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43052373	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176289	ENSG00000236383.6	LINC00854	-5.42	1.37e-07	6.93e-05	-0.25	-0.32	Menopause (age at onset);	chr17:43054039	chr17:43216941~43305976:-
KIRP	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	5.42	1.38e-07	6.93e-05	0.31	0.32	Height;	chr14:75005099	chr14:75011269~75012851:-
KIRP	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	5.42	1.38e-07	6.93e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
KIRP	cis	rs2281558	0.876	rs2281562	ENSG00000274414.1	RP5-965G21.4	-5.42	1.38e-07	6.94e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:25239007~25245229:-
KIRP	cis	rs11085466	1	rs73552468	ENSG00000268555.1	RP11-678G14.3	5.42	1.38e-07	6.95e-05	0.42	0.32	Colorectal or endometrial cancer;	chr19:21589295	chr19:21570822~21587322:-
KIRP	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	5.42	1.38e-07	6.95e-05	0.3	0.32	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
KIRP	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	5.42	1.38e-07	6.96e-05	0.39	0.32	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	5.42	1.38e-07	6.96e-05	0.39	0.32	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	5.42	1.38e-07	6.96e-05	0.39	0.32	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
KIRP	cis	rs2281558	0.837	rs56238023	ENSG00000274414.1	RP5-965G21.4	-5.42	1.38e-07	6.97e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:25239007~25245229:-
KIRP	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-5.42	1.38e-07	6.97e-05	-0.39	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
KIRP	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	5.42	1.39e-07	6.98e-05	0.28	0.32	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
KIRP	cis	rs1476679	0.83	rs6971558	ENSG00000078319.8	PMS2P1	5.42	1.39e-07	6.98e-05	0.44	0.32	Alzheimer's disease (late onset);	chr7:100482234	chr7:100320992~100341908:-
KIRP	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	5.41	1.39e-07	6.99e-05	0.33	0.32	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
KIRP	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-5.41	1.39e-07	6.99e-05	-0.36	-0.32	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
KIRP	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-5.41	1.39e-07	6.99e-05	-0.36	-0.32	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
KIRP	cis	rs8067545	0.641	rs203462	ENSG00000270091.1	RP11-78O7.2	-5.41	1.39e-07	6.99e-05	-0.21	-0.32	Schizophrenia;	chr17:19909228	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.641	rs203460	ENSG00000270091.1	RP11-78O7.2	-5.41	1.39e-07	6.99e-05	-0.21	-0.32	Schizophrenia;	chr17:19911973	chr17:19896590~19897287:-
KIRP	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-5.41	1.39e-07	7e-05	-0.55	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
KIRP	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-5.41	1.39e-07	7e-05	-0.55	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
KIRP	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-5.41	1.39e-07	7e-05	-0.46	-0.32	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
KIRP	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	5.41	1.4e-07	7.03e-05	0.32	0.32	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
KIRP	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	5.41	1.4e-07	7.04e-05	0.3	0.32	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
KIRP	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	5.41	1.4e-07	7.04e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	5.41	1.4e-07	7.04e-05	0.32	0.32	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	5.41	1.4e-07	7.04e-05	0.32	0.32	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	5.41	1.4e-07	7.04e-05	0.32	0.32	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	5.41	1.4e-07	7.04e-05	0.32	0.32	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
KIRP	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-5.41	1.4e-07	7.04e-05	-0.35	-0.32	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-5.41	1.4e-07	7.04e-05	-0.35	-0.32	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
KIRP	cis	rs11603023	1	rs11603023	ENSG00000255422.1	AP002954.4	-5.41	1.4e-07	7.05e-05	-0.32	-0.32	Cholesterol, total;	chr11:118615352	chr11:118704607~118750263:+
KIRP	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	5.41	1.4e-07	7.05e-05	0.29	0.32	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
KIRP	cis	rs6832769	0.961	rs13152650	ENSG00000272969.1	RP11-528I4.2	5.41	1.4e-07	7.05e-05	0.31	0.32	Personality dimensions;	chr4:55491691	chr4:55547112~55547889:+
KIRP	cis	rs710913	0.646	rs2695325	ENSG00000237624.1	OXCT2P1	5.41	1.4e-07	7.06e-05	0.39	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39607957	chr1:39514956~39516490:+
KIRP	cis	rs4356975	0.563	rs7685151	ENSG00000248763.2	RP13-644M16.5	-5.41	1.4e-07	7.06e-05	-0.34	-0.32	Obesity-related traits;	chr4:69114055	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.583	rs11936822	ENSG00000248763.2	RP13-644M16.5	-5.41	1.4e-07	7.06e-05	-0.34	-0.32	Obesity-related traits;	chr4:69114229	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs34814736	ENSG00000248763.2	RP13-644M16.5	-5.41	1.4e-07	7.06e-05	-0.34	-0.32	Obesity-related traits;	chr4:69114760	chr4:69066395~69069888:+
KIRP	cis	rs7726354	1	rs59536253	ENSG00000271828.1	CTD-2310F14.1	5.41	1.4e-07	7.07e-05	0.52	0.32	Breast cancer (early onset);	chr5:56973685	chr5:56927874~56929573:+
KIRP	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	5.41	1.41e-07	7.07e-05	0.32	0.32	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
KIRP	cis	rs1479119	0.681	rs10744022	ENSG00000180861.8	LINC01559	5.41	1.41e-07	7.08e-05	0.37	0.32	Intelligence (multi-trait analysis);	chr12:13349659	chr12:13371089~13387167:-
KIRP	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-5.41	1.41e-07	7.08e-05	-0.34	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
KIRP	cis	rs7474896	0.537	rs1208591	ENSG00000151963.4	RP11-775A3.1	-5.41	1.41e-07	7.09e-05	-0.41	-0.32	Obesity (extreme);	chr10:37923574	chr10:37883594~37884109:+
KIRP	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-5.41	1.41e-07	7.09e-05	-0.24	-0.32	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
KIRP	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-5.41	1.41e-07	7.09e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
KIRP	cis	rs881375	0.902	rs7021880	ENSG00000226752.6	PSMD5-AS1	5.41	1.42e-07	7.12e-05	0.39	0.32	Rheumatoid arthritis;	chr9:120911612	chr9:120824828~120854385:+
KIRP	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	5.41	1.42e-07	7.12e-05	0.32	0.32	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
KIRP	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	5.41	1.42e-07	7.12e-05	0.32	0.32	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
KIRP	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	5.41	1.42e-07	7.12e-05	0.32	0.32	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
KIRP	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	5.41	1.42e-07	7.12e-05	0.37	0.32	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	5.41	1.42e-07	7.13e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	5.41	1.42e-07	7.13e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	5.41	1.42e-07	7.13e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
KIRP	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	5.41	1.42e-07	7.13e-05	0.52	0.32	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
KIRP	cis	rs962856	1	rs962856	ENSG00000236780.4	AC078941.1	5.41	1.42e-07	7.13e-05	0.39	0.32	Pancreatic cancer;	chr2:67366671	chr2:67123357~67215319:-
KIRP	cis	rs2154427	0.872	rs80098814	ENSG00000238197.4	PAXBP1-AS1	5.41	1.42e-07	7.13e-05	0.45	0.32	Bilirubin levels;	chr21:32760691	chr21:32728115~32743122:+
KIRP	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-5.41	1.42e-07	7.15e-05	-0.33	-0.32	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
KIRP	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.41	1.42e-07	7.15e-05	0.27	0.32	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
KIRP	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	5.41	1.43e-07	7.17e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	5.41	1.43e-07	7.17e-05	0.33	0.32	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
KIRP	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-5.41	1.43e-07	7.17e-05	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
KIRP	cis	rs1153858	1	rs2467864	ENSG00000259433.2	CTD-2651B20.4	5.41	1.43e-07	7.17e-05	0.28	0.32	Homoarginine levels;	chr15:45348900	chr15:45330209~45332634:-
KIRP	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	5.41	1.43e-07	7.17e-05	0.23	0.32	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
KIRP	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	5.41	1.43e-07	7.18e-05	0.26	0.32	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
KIRP	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-5.41	1.43e-07	7.18e-05	-0.39	-0.32	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-5.41	1.43e-07	7.18e-05	-0.39	-0.32	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-5.41	1.43e-07	7.18e-05	-0.39	-0.32	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-5.41	1.43e-07	7.18e-05	-0.39	-0.32	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
KIRP	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-5.41	1.43e-07	7.18e-05	-0.23	-0.32	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
KIRP	cis	rs2625529	0.775	rs2723342	ENSG00000260037.4	CTD-2524L6.3	-5.41	1.43e-07	7.18e-05	-0.28	-0.32	Red blood cell count;	chr15:71815358	chr15:71818396~71823384:+
KIRP	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	5.41	1.43e-07	7.19e-05	0.4	0.32	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
KIRP	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-5.41	1.43e-07	7.19e-05	-0.36	-0.32	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
KIRP	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	5.41	1.43e-07	7.19e-05	0.52	0.32	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	5.41	1.43e-07	7.19e-05	0.52	0.32	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	5.41	1.43e-07	7.19e-05	0.52	0.32	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	5.41	1.43e-07	7.19e-05	0.52	0.32	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
KIRP	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	5.41	1.43e-07	7.2e-05	0.26	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
KIRP	cis	rs7586673	0.857	rs16845580	ENSG00000235724.7	AC009299.2	-5.41	1.44e-07	7.2e-05	-0.37	-0.32	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161222785~161308303:-
KIRP	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	5.41	1.44e-07	7.22e-05	0.3	0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
KIRP	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	5.41	1.44e-07	7.22e-05	0.3	0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
KIRP	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	5.41	1.44e-07	7.22e-05	0.3	0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
KIRP	cis	rs2273156	1	rs74046408	ENSG00000226677.3	IGBP1P1	-5.41	1.44e-07	7.22e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34997929	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs8017191	ENSG00000226677.3	IGBP1P1	-5.41	1.44e-07	7.22e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000785	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs36112862	ENSG00000226677.3	IGBP1P1	-5.41	1.44e-07	7.22e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35009227	chr14:34939324~34940332:+
KIRP	cis	rs4356975	0.563	rs11933459	ENSG00000248763.2	RP13-644M16.5	-5.41	1.44e-07	7.22e-05	-0.34	-0.32	Obesity-related traits;	chr4:69116045	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs6600895	ENSG00000248763.2	RP13-644M16.5	-5.41	1.44e-07	7.22e-05	-0.34	-0.32	Obesity-related traits;	chr4:69117694	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4508963	ENSG00000248763.2	RP13-644M16.5	-5.41	1.44e-07	7.22e-05	-0.34	-0.32	Obesity-related traits;	chr4:69118770	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12505466	ENSG00000248763.2	RP13-644M16.5	-5.41	1.44e-07	7.22e-05	-0.34	-0.32	Obesity-related traits;	chr4:69119944	chr4:69066395~69069888:+
KIRP	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	5.41	1.44e-07	7.22e-05	0.35	0.32	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
KIRP	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	5.41	1.44e-07	7.24e-05	0.38	0.32	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
KIRP	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-5.41	1.44e-07	7.24e-05	-0.37	-0.32	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
KIRP	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	5.41	1.44e-07	7.25e-05	0.39	0.32	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
KIRP	cis	rs2283792	1	rs2006893	ENSG00000228050.1	TOP3BP1	5.41	1.45e-07	7.25e-05	0.35	0.32	Multiple sclerosis;	chr22:21774389	chr22:22223187~22224566:-
KIRP	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	5.41	1.45e-07	7.25e-05	0.32	0.32	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
KIRP	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	5.41	1.45e-07	7.26e-05	0.7	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
KIRP	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	5.41	1.45e-07	7.26e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	5.41	1.45e-07	7.26e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	5.41	1.45e-07	7.26e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
KIRP	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	5.41	1.45e-07	7.26e-05	0.39	0.32	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
KIRP	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	5.41	1.45e-07	7.26e-05	0.32	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
KIRP	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	5.41	1.45e-07	7.26e-05	0.27	0.32	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
KIRP	cis	rs1858037	0.867	rs55945621	ENSG00000281920.1	RP11-418H16.1	5.41	1.45e-07	7.28e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65388220	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.867	rs964505	ENSG00000281920.1	RP11-418H16.1	5.41	1.45e-07	7.28e-05	0.42	0.32	Rheumatoid arthritis;	chr2:65396055	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.836	rs2576923	ENSG00000281920.1	RP11-418H16.1	-5.41	1.45e-07	7.28e-05	-0.42	-0.32	Rheumatoid arthritis;	chr2:65406750	chr2:65623272~65628424:+
KIRP	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	5.41	1.45e-07	7.28e-05	0.36	0.32	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
KIRP	cis	rs7829975	0.777	rs6989926	ENSG00000253981.4	ALG1L13P	-5.41	1.45e-07	7.29e-05	-0.25	-0.32	Mood instability;	chr8:8689803	chr8:8236003~8244667:-
KIRP	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-5.41	1.46e-07	7.3e-05	-0.31	-0.32	Height;	chr14:75204004	chr14:75011269~75012851:-
KIRP	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	5.41	1.46e-07	7.3e-05	0.37	0.32	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000250470.1	AP000351.3	5.41	1.46e-07	7.3e-05	0.5	0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23976904~23977585:-
KIRP	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-5.41	1.46e-07	7.3e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
KIRP	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	5.4	1.46e-07	7.31e-05	0.48	0.32	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	5.4	1.46e-07	7.31e-05	0.36	0.32	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	5.4	1.46e-07	7.31e-05	0.36	0.32	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
KIRP	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	5.4	1.46e-07	7.31e-05	0.25	0.32	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
KIRP	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	5.4	1.46e-07	7.32e-05	0.33	0.32	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
KIRP	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-5.4	1.46e-07	7.32e-05	-0.39	-0.32	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
KIRP	cis	rs712022	0.534	rs4567455	ENSG00000246225.5	RP11-17A1.3	-5.4	1.46e-07	7.33e-05	-0.36	-0.32	Dialysis-related mortality;	chr11:22841980	chr11:22829380~22945393:+
KIRP	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-5.4	1.46e-07	7.33e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-5.4	1.46e-07	7.33e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-5.4	1.46e-07	7.33e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
KIRP	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-5.4	1.47e-07	7.35e-05	-0.36	-0.32	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
KIRP	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	5.4	1.47e-07	7.35e-05	0.62	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
KIRP	cis	rs11647589	0.784	rs1700804	ENSG00000262995.1	CTD-2194A8.2	5.4	1.47e-07	7.36e-05	0.35	0.32	Blood metabolite levels;	chr16:20477047	chr16:20440266~20447000:-
KIRP	cis	rs9371601	0.892	rs7763880	ENSG00000226193.1	RP3-398G3.5	-5.4	1.47e-07	7.36e-05	-0.36	-0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152481162	chr6:152402398~152404966:+
KIRP	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.4	1.47e-07	7.36e-05	0.23	0.32	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
KIRP	cis	rs9915657	0.743	rs9894720	ENSG00000234899.8	SOX9-AS1	-5.4	1.47e-07	7.36e-05	-0.26	-0.32	Thyroid hormone levels;	chr17:72101466	chr17:72034107~72237203:-
KIRP	cis	rs713477	0.967	rs10483642	ENSG00000258413.1	RP11-665C16.6	-5.4	1.47e-07	7.36e-05	-0.39	-0.32	Pediatric bone mineral content (femoral neck);	chr14:55453742	chr14:55262767~55272075:-
KIRP	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-5.4	1.47e-07	7.37e-05	-0.35	-0.32	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
KIRP	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	5.4	1.47e-07	7.37e-05	0.28	0.32	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
KIRP	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-5.4	1.47e-07	7.37e-05	-0.44	-0.32	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
KIRP	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-5.4	1.47e-07	7.37e-05	-0.44	-0.32	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
KIRP	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	5.4	1.47e-07	7.38e-05	0.29	0.32	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
KIRP	cis	rs11773103	0.881	rs73204816	ENSG00000224046.1	AC005076.5	5.4	1.47e-07	7.38e-05	0.45	0.32	Bipolar disorder or major depressive disorder (combined);	chr7:87139556	chr7:87151423~87152420:-
KIRP	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	5.4	1.47e-07	7.38e-05	0.34	0.32	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
KIRP	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	5.4	1.48e-07	7.38e-05	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
KIRP	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	5.4	1.48e-07	7.38e-05	0.3	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
KIRP	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	5.4	1.48e-07	7.39e-05	0.4	0.32	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
KIRP	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	5.4	1.48e-07	7.39e-05	0.3	0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
KIRP	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	5.4	1.48e-07	7.4e-05	0.52	0.32	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	5.4	1.48e-07	7.4e-05	0.52	0.32	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
KIRP	cis	rs13113518	0.812	rs56055342	ENSG00000272969.1	RP11-528I4.2	5.4	1.48e-07	7.4e-05	0.31	0.32	Height;	chr4:55540928	chr4:55547112~55547889:+
KIRP	cis	rs8067545	0.641	rs203455	ENSG00000270091.1	RP11-78O7.2	-5.4	1.48e-07	7.41e-05	-0.21	-0.32	Schizophrenia;	chr17:19917872	chr17:19896590~19897287:-
KIRP	cis	rs9532669	0.926	rs9532691	ENSG00000239827.7	SUGT1P3	5.4	1.48e-07	7.41e-05	0.36	0.32	Cervical cancer;	chr13:40969358	chr13:40908159~40921774:-
KIRP	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	5.4	1.48e-07	7.41e-05	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
KIRP	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	5.4	1.48e-07	7.41e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
KIRP	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	5.4	1.48e-07	7.42e-05	0.34	0.32	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
KIRP	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	5.4	1.49e-07	7.43e-05	0.3	0.32	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
KIRP	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	5.4	1.49e-07	7.43e-05	0.34	0.32	Height;	chr4:55452921	chr4:55363971~55395847:-
KIRP	cis	rs1009647	1	rs1009647	ENSG00000258413.1	RP11-665C16.6	-5.4	1.49e-07	7.44e-05	-0.45	-0.32	Testicular germ cell tumor;	chr14:55413329	chr14:55262767~55272075:-
KIRP	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	5.4	1.49e-07	7.44e-05	0.39	0.32	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
KIRP	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	5.4	1.49e-07	7.44e-05	0.5	0.32	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
KIRP	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	5.4	1.49e-07	7.44e-05	0.37	0.32	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
KIRP	cis	rs8067545	0.641	rs203458	ENSG00000270091.1	RP11-78O7.2	-5.4	1.49e-07	7.45e-05	-0.21	-0.32	Schizophrenia;	chr17:19913585	chr17:19896590~19897287:-
KIRP	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-5.4	1.49e-07	7.45e-05	-0.48	-0.32	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
KIRP	cis	rs4660214	0.666	rs4660550	ENSG00000237624.1	OXCT2P1	-5.4	1.49e-07	7.45e-05	-0.41	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39514956~39516490:+
KIRP	cis	rs11158026	0.603	rs3783646	ENSG00000258413.1	RP11-665C16.6	-5.4	1.49e-07	7.45e-05	-0.4	-0.32	Parkinson's disease;	chr14:55005169	chr14:55262767~55272075:-
KIRP	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	5.4	1.49e-07	7.45e-05	0.3	0.32	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
KIRP	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	5.4	1.49e-07	7.46e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
KIRP	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	5.4	1.49e-07	7.46e-05	0.33	0.32	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	5.4	1.49e-07	7.46e-05	0.33	0.32	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	5.4	1.49e-07	7.46e-05	0.33	0.32	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
KIRP	cis	rs11647589	0.834	rs9933872	ENSG00000262995.1	CTD-2194A8.2	-5.4	1.49e-07	7.46e-05	-0.36	-0.32	Blood metabolite levels;	chr16:20473849	chr16:20440266~20447000:-
KIRP	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-5.4	1.49e-07	7.46e-05	-0.32	-0.32	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-5.4	1.49e-07	7.46e-05	-0.32	-0.32	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-5.4	1.49e-07	7.46e-05	-0.32	-0.32	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-5.4	1.49e-07	7.46e-05	-0.32	-0.32	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
KIRP	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-5.4	1.49e-07	7.46e-05	-0.41	-0.32	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
KIRP	cis	rs2625529	0.526	rs7179942	ENSG00000260037.4	CTD-2524L6.3	5.4	1.49e-07	7.47e-05	0.24	0.32	Red blood cell count;	chr15:72270733	chr15:71818396~71823384:+
KIRP	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-5.4	1.49e-07	7.47e-05	-0.39	-0.32	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
KIRP	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	5.4	1.5e-07	7.47e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
KIRP	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	5.4	1.5e-07	7.5e-05	0.2	0.32	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
KIRP	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-5.4	1.5e-07	7.5e-05	-0.43	-0.32	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
KIRP	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	5.4	1.5e-07	7.5e-05	0.37	0.32	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
KIRP	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	5.4	1.5e-07	7.51e-05	0.51	0.32	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
KIRP	cis	rs11079159	0.959	rs17817857	ENSG00000263096.1	RP11-515O17.2	5.4	1.5e-07	7.51e-05	0.43	0.32	QRS duration;	chr17:55299581	chr17:55271504~55273653:-
KIRP	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	-5.4	1.5e-07	7.51e-05	-0.24	-0.32	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
KIRP	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	5.4	1.51e-07	7.52e-05	0.3	0.32	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
KIRP	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	5.4	1.51e-07	7.52e-05	0.25	0.32	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
KIRP	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	5.4	1.51e-07	7.52e-05	0.33	0.32	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
KIRP	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	5.4	1.51e-07	7.52e-05	0.3	0.32	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
KIRP	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	5.4	1.51e-07	7.53e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
KIRP	cis	rs2273156	0.929	rs7144646	ENSG00000226677.3	IGBP1P1	-5.4	1.51e-07	7.54e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34985495	chr14:34939324~34940332:+
KIRP	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-5.4	1.51e-07	7.55e-05	-0.26	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
KIRP	cis	rs4356975	0.563	rs12506962	ENSG00000248763.2	RP13-644M16.5	-5.4	1.51e-07	7.55e-05	-0.33	-0.32	Obesity-related traits;	chr4:69100306	chr4:69066395~69069888:+
KIRP	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-5.4	1.51e-07	7.55e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
KIRP	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-5.4	1.51e-07	7.55e-05	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
KIRP	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	5.4	1.51e-07	7.55e-05	0.43	0.32	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
KIRP	cis	rs7586673	0.866	rs7579662	ENSG00000235724.7	AC009299.2	-5.4	1.51e-07	7.56e-05	-0.38	-0.32	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161222785~161308303:-
KIRP	cis	rs2273156	1	rs71421920	ENSG00000226677.3	IGBP1P1	-5.4	1.52e-07	7.57e-05	-0.33	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:34977539	chr14:34939324~34940332:+
KIRP	cis	rs2283792	0.73	rs2027790	ENSG00000228050.1	TOP3BP1	5.4	1.52e-07	7.57e-05	0.37	0.32	Multiple sclerosis;	chr22:21933592	chr22:22223187~22224566:-
KIRP	cis	rs4356975	0.563	rs7698645	ENSG00000248763.2	RP13-644M16.5	-5.4	1.52e-07	7.57e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106192	chr4:69066395~69069888:+
KIRP	cis	rs4356203	0.905	rs7930058	ENSG00000272034.1	SNORD14A	-5.4	1.52e-07	7.58e-05	-0.26	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs7927240	ENSG00000272034.1	SNORD14A	-5.4	1.52e-07	7.58e-05	-0.26	-0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17074654~17074744:-
KIRP	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	5.4	1.52e-07	7.59e-05	0.84	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
KIRP	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-5.4	1.52e-07	7.6e-05	-0.34	-0.32	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
KIRP	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-5.4	1.52e-07	7.6e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
KIRP	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	5.39	1.53e-07	7.64e-05	0.33	0.32	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
KIRP	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.39	1.53e-07	7.65e-05	-0.34	-0.32	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
KIRP	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	5.39	1.53e-07	7.65e-05	0.43	0.32	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
KIRP	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-5.39	1.54e-07	7.65e-05	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
KIRP	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	5.39	1.54e-07	7.66e-05	0.34	0.32	Height;	chr4:55508982	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	5.39	1.54e-07	7.66e-05	0.34	0.32	Height;	chr4:55509442	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	5.39	1.54e-07	7.66e-05	0.34	0.32	Height;	chr4:55510177	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	5.39	1.54e-07	7.66e-05	0.34	0.32	Height;	chr4:55542243	chr4:55363971~55395847:-
KIRP	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	5.39	1.54e-07	7.67e-05	0.44	0.32	Height;	chr6:109428824	chr6:109382795~109383666:+
KIRP	cis	rs12935418	0.616	rs77336552	ENSG00000261061.1	RP11-303E16.2	-5.39	1.54e-07	7.67e-05	-0.45	-0.32	Mean corpuscular volume;	chr16:80942989	chr16:81030770~81031485:+
KIRP	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	5.39	1.54e-07	7.67e-05	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
KIRP	cis	rs950169	0.922	rs11630760	ENSG00000275120.1	RP11-182J1.17	5.39	1.54e-07	7.68e-05	0.41	0.32	Schizophrenia;	chr15:84570106	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.887	rs71395453	ENSG00000275120.1	RP11-182J1.17	5.39	1.54e-07	7.68e-05	0.41	0.32	Schizophrenia;	chr15:84570259	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs11633075	ENSG00000275120.1	RP11-182J1.17	5.39	1.54e-07	7.68e-05	0.41	0.32	Schizophrenia;	chr15:84570741	chr15:84599434~84606463:-
KIRP	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	5.39	1.55e-07	7.7e-05	0.33	0.32	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
KIRP	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	5.39	1.55e-07	7.71e-05	0.37	0.32	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
KIRP	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-5.39	1.55e-07	7.71e-05	-0.54	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
KIRP	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-5.39	1.55e-07	7.72e-05	-0.24	-0.32	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
KIRP	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-5.39	1.55e-07	7.72e-05	-0.24	-0.32	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
KIRP	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	5.39	1.55e-07	7.72e-05	0.61	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
KIRP	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	5.39	1.55e-07	7.73e-05	0.36	0.32	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
KIRP	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-5.39	1.55e-07	7.73e-05	-0.43	-0.32	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
KIRP	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-5.39	1.55e-07	7.73e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-5.39	1.55e-07	7.73e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-5.39	1.55e-07	7.73e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
KIRP	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	5.39	1.56e-07	7.75e-05	0.64	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
KIRP	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	5.39	1.56e-07	7.76e-05	0.43	0.32	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	5.39	1.56e-07	7.76e-05	0.36	0.32	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
KIRP	cis	rs4638749	0.501	rs9653451	ENSG00000231221.1	AC023672.2	-5.39	1.56e-07	7.76e-05	-0.36	-0.32	Blood pressure;	chr2:108165402	chr2:108049200~108052755:-
KIRP	cis	rs2625529	0.712	rs2054601	ENSG00000260037.4	CTD-2524L6.3	-5.39	1.56e-07	7.77e-05	-0.27	-0.32	Red blood cell count;	chr15:71892627	chr15:71818396~71823384:+
KIRP	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	5.39	1.56e-07	7.77e-05	0.3	0.32	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
KIRP	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-5.39	1.56e-07	7.78e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
KIRP	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	5.39	1.56e-07	7.79e-05	0.52	0.32	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
KIRP	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-5.39	1.56e-07	7.79e-05	-0.44	-0.32	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
KIRP	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-5.39	1.57e-07	7.79e-05	-0.25	-0.32	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
KIRP	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	5.39	1.57e-07	7.8e-05	0.35	0.32	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
KIRP	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	5.39	1.57e-07	7.8e-05	0.35	0.32	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
KIRP	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-5.39	1.57e-07	7.8e-05	-0.34	-0.32	Temperament;	chr17:14013482	chr17:14024514~14025488:+
KIRP	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.39	1.57e-07	7.81e-05	0.29	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.39	1.57e-07	7.81e-05	0.29	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
KIRP	cis	rs1044826	0.642	rs2118981	ENSG00000178631.7	ACTG1P1	5.39	1.57e-07	7.82e-05	0.32	0.32	Obesity-related traits;	chr3:139460011	chr3:139493809~139494937:+
KIRP	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-5.39	1.57e-07	7.83e-05	-0.4	-0.32	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-5.39	1.57e-07	7.83e-05	-0.4	-0.32	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
KIRP	cis	rs710913	0.618	rs11206437	ENSG00000237624.1	OXCT2P1	5.39	1.57e-07	7.83e-05	0.39	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39514956~39516490:+
KIRP	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	5.39	1.57e-07	7.83e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	5.39	1.57e-07	7.83e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	5.39	1.57e-07	7.83e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	5.39	1.57e-07	7.83e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	5.39	1.57e-07	7.83e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
KIRP	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-5.39	1.58e-07	7.83e-05	-0.32	-0.32	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
KIRP	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-5.39	1.58e-07	7.85e-05	-0.51	-0.32	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
KIRP	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	5.39	1.58e-07	7.85e-05	0.35	0.32	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
KIRP	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
KIRP	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	5.39	1.58e-07	7.85e-05	0.33	0.32	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
KIRP	cis	rs2625529	0.713	rs16956634	ENSG00000260037.4	CTD-2524L6.3	5.39	1.58e-07	7.85e-05	0.28	0.32	Red blood cell count;	chr15:72259902	chr15:71818396~71823384:+
KIRP	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-5.39	1.58e-07	7.86e-05	-0.36	-0.32	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
KIRP	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-5.39	1.58e-07	7.87e-05	-0.46	-0.32	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
KIRP	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	5.39	1.59e-07	7.88e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	5.39	1.59e-07	7.88e-05	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
KIRP	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	5.39	1.59e-07	7.88e-05	0.48	0.32	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
KIRP	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	5.39	1.59e-07	7.88e-05	0.35	0.32	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
KIRP	cis	rs7170668	0.93	rs6496110	ENSG00000258489.3	RP11-398J10.2	5.39	1.59e-07	7.88e-05	0.36	0.32	Motion sickness;	chr15:95470378	chr15:95463592~95493770:-
KIRP	cis	rs2625529	0.652	rs1481862	ENSG00000260037.4	CTD-2524L6.3	5.39	1.59e-07	7.88e-05	0.24	0.32	Red blood cell count;	chr15:71953307	chr15:71818396~71823384:+
KIRP	cis	rs61457372	0.563	rs10852741	ENSG00000264026.1	RP11-1124B17.1	-5.39	1.59e-07	7.88e-05	-0.34	-0.32	Triptolide cytotoxicity;	chr17:72361878	chr17:72342940~72355136:+
KIRP	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-5.39	1.59e-07	7.88e-05	-0.28	-0.32	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
KIRP	cis	rs7688014	1	rs7688014	ENSG00000251288.2	RP11-10L12.2	-5.39	1.59e-07	7.89e-05	-0.38	-0.32	Schizophrenia;	chr4:103053903	chr4:102751401~102752641:+
KIRP	cis	rs875971	0.545	rs10950029	ENSG00000236529.1	RP13-254B10.1	5.39	1.59e-07	7.89e-05	0.28	0.32	Aortic root size;	chr7:66169334	chr7:65840212~65840596:+
KIRP	cis	rs11773103	0.881	rs56404754	ENSG00000224046.1	AC005076.5	5.39	1.59e-07	7.9e-05	0.44	0.32	Bipolar disorder or major depressive disorder (combined);	chr7:87137693	chr7:87151423~87152420:-
KIRP	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	5.39	1.59e-07	7.9e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	5.39	1.59e-07	7.9e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	5.39	1.59e-07	7.9e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	5.39	1.59e-07	7.9e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	5.39	1.59e-07	7.9e-05	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
KIRP	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-5.39	1.59e-07	7.91e-05	-0.28	-0.32	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
KIRP	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.92e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.92e-05	-0.27	-0.32	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
KIRP	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	5.39	1.6e-07	7.93e-05	0.32	0.32	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
KIRP	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-5.39	1.6e-07	7.93e-05	-0.22	-0.32	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
KIRP	cis	rs79349575	0.756	rs2291726	ENSG00000248278.1	SUMO2P17	-5.39	1.6e-07	7.93e-05	-0.37	-0.32	Type 2 diabetes;	chr17:48961892	chr17:48874860~48908983:-
KIRP	cis	rs4356203	0.905	rs11024158	ENSG00000272034.1	SNORD14A	5.39	1.6e-07	7.94e-05	0.27	0.32	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17074654~17074744:-
KIRP	cis	rs710913	0.557	rs1180320	ENSG00000237624.1	OXCT2P1	5.39	1.6e-07	7.94e-05	0.39	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39616330	chr1:39514956~39516490:+
KIRP	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-5.39	1.6e-07	7.94e-05	-0.23	-0.32	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
KIRP	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-5.39	1.6e-07	7.95e-05	-0.26	-0.32	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
KIRP	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	5.39	1.6e-07	7.95e-05	0.46	0.32	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
KIRP	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	5.39	1.6e-07	7.95e-05	0.4	0.32	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
KIRP	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-5.39	1.61e-07	7.96e-05	-0.34	-0.32	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
KIRP	cis	rs7829975	0.508	rs1594437	ENSG00000253981.4	ALG1L13P	5.39	1.61e-07	7.96e-05	0.24	0.32	Mood instability;	chr8:8968365	chr8:8236003~8244667:-
KIRP	cis	rs2976388	0.59	rs13254346	ENSG00000253741.1	CTD-2292P10.4	5.39	1.61e-07	7.96e-05	0.38	0.32	Urinary tract infection frequency;	chr8:142742445	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.59	rs3758082	ENSG00000253741.1	CTD-2292P10.4	5.39	1.61e-07	7.96e-05	0.38	0.32	Urinary tract infection frequency;	chr8:142743065	chr8:142702252~142726973:-
KIRP	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.39	1.61e-07	7.97e-05	0.37	0.32	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
KIRP	cis	rs9810089	0.692	rs589092	ENSG00000261758.1	RP11-102M11.2	-5.39	1.61e-07	7.98e-05	-0.31	-0.32	Gestational age at birth (child effect);	chr3:136260856	chr3:136752630~136755780:+
KIRP	cis	rs950169	0.84	rs2896002	ENSG00000275120.1	RP11-182J1.17	5.39	1.61e-07	7.98e-05	0.44	0.32	Schizophrenia;	chr15:84390423	chr15:84599434~84606463:-
KIRP	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-5.38	1.61e-07	7.99e-05	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
KIRP	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	5.38	1.62e-07	8.03e-05	0.33	0.32	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
KIRP	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	5.38	1.62e-07	8.03e-05	0.35	0.32	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
KIRP	cis	rs28386778	0.897	rs7212196	ENSG00000240280.5	TCAM1P	-5.38	1.62e-07	8.05e-05	-0.4	-0.32	Prudent dietary pattern;	chr17:63757621	chr17:63849292~63864379:+
KIRP	cis	rs11158026	0.603	rs4325453	ENSG00000258413.1	RP11-665C16.6	-5.38	1.62e-07	8.05e-05	-0.39	-0.32	Parkinson's disease;	chr14:54972600	chr14:55262767~55272075:-
KIRP	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-5.38	1.63e-07	8.05e-05	-0.35	-0.32	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
KIRP	cis	rs4356975	0.563	rs6600891	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69105878	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.522	rs7693957	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106078	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7698846	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106278	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs12513195	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106368	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4541594	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106554	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.583	rs4351080	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106601	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4356974	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69106696	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs5013211	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107059	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4292394	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107231	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4337789	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107326	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4521414	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107807	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4314345	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107922	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4588522	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107949	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs4364327	ENSG00000248763.2	RP13-644M16.5	-5.38	1.63e-07	8.08e-05	-0.34	-0.32	Obesity-related traits;	chr4:69107974	chr4:69066395~69069888:+
KIRP	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	5.38	1.63e-07	8.08e-05	0.36	0.32	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	5.38	1.63e-07	8.08e-05	0.36	0.32	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
KIRP	cis	rs2281558	0.876	rs12625157	ENSG00000274414.1	RP5-965G21.4	-5.38	1.63e-07	8.09e-05	-0.37	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	5.38	1.63e-07	8.09e-05	0.37	0.32	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	5.38	1.63e-07	8.09e-05	0.37	0.32	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
KIRP	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-5.38	1.64e-07	8.1e-05	-0.39	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
KIRP	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.38	1.64e-07	8.1e-05	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.38	1.64e-07	8.1e-05	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.38	1.64e-07	8.1e-05	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
KIRP	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-5.38	1.64e-07	8.11e-05	-0.36	-0.32	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
KIRP	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-5.38	1.64e-07	8.11e-05	-0.33	-0.32	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
KIRP	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	5.38	1.64e-07	8.12e-05	0.46	0.32	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
KIRP	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	5.38	1.64e-07	8.12e-05	0.32	0.32	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
KIRP	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-5.38	1.64e-07	8.13e-05	-0.54	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
KIRP	cis	rs79040073	0.637	rs8030457	ENSG00000259531.2	RP11-295H24.3	5.38	1.64e-07	8.13e-05	0.43	0.32	Lung cancer in ever smokers;	chr15:49392809	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.599	rs17477722	ENSG00000259531.2	RP11-295H24.3	5.38	1.64e-07	8.13e-05	0.43	0.32	Lung cancer in ever smokers;	chr15:49394220	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73398243	ENSG00000259531.2	RP11-295H24.3	5.38	1.64e-07	8.13e-05	0.43	0.32	Lung cancer in ever smokers;	chr15:49394344	chr15:49365124~49366685:-
KIRP	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	5.38	1.65e-07	8.14e-05	0.37	0.32	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
KIRP	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-5.38	1.65e-07	8.14e-05	-0.3	-0.32	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
KIRP	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	5.38	1.65e-07	8.15e-05	0.35	0.32	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	5.38	1.65e-07	8.15e-05	0.35	0.32	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
KIRP	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-5.38	1.65e-07	8.15e-05	-0.26	-0.32	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
KIRP	cis	rs3892630	0.588	rs28787932	ENSG00000267475.1	CTD-2538C1.2	-5.38	1.65e-07	8.15e-05	-0.4	-0.32	Red blood cell traits;	chr19:32735323	chr19:32687089~32691750:-
KIRP	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	5.38	1.65e-07	8.17e-05	0.31	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
KIRP	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	5.38	1.66e-07	8.18e-05	0.3	0.32	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
KIRP	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-5.38	1.66e-07	8.19e-05	-0.23	-0.32	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
KIRP	cis	rs6832769	1	rs726967	ENSG00000272969.1	RP11-528I4.2	-5.38	1.66e-07	8.19e-05	-0.33	-0.32	Personality dimensions;	chr4:55555546	chr4:55547112~55547889:+
KIRP	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	5.38	1.66e-07	8.19e-05	0.53	0.32	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
KIRP	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-5.38	1.66e-07	8.2e-05	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
KIRP	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
KIRP	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	5.38	1.66e-07	8.2e-05	0.74	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
KIRP	cis	rs3745672	1	rs9989684	ENSG00000219665.7	CTD-2006C1.2	-5.38	1.66e-07	8.2e-05	-0.71	-0.32	Multiple sclerosis;	chr19:11991467	chr19:11987617~12046275:+
KIRP	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-5.38	1.66e-07	8.2e-05	-0.32	-0.32	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
KIRP	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	5.38	1.66e-07	8.21e-05	0.31	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
KIRP	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-5.38	1.66e-07	8.22e-05	-0.43	-0.32	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
KIRP	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	5.38	1.67e-07	8.23e-05	0.36	0.32	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	5.38	1.67e-07	8.23e-05	0.35	0.32	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
KIRP	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-5.38	1.67e-07	8.24e-05	-0.31	-0.32	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
KIRP	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-5.38	1.67e-07	8.24e-05	-0.36	-0.32	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
KIRP	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	5.38	1.67e-07	8.26e-05	0.44	0.32	Height;	chr6:109446728	chr6:109382795~109383666:+
KIRP	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-5.38	1.68e-07	8.27e-05	-0.28	-0.32	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
KIRP	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	5.38	1.68e-07	8.27e-05	0.23	0.32	Height;	chr20:35192624	chr20:35201747~35203288:-
KIRP	cis	rs75920871	0.589	rs67201490	ENSG00000254851.1	RP11-109L13.1	-5.38	1.68e-07	8.27e-05	-0.54	-0.32	Subjective well-being;	chr11:117212288	chr11:117135528~117138582:+
KIRP	cis	rs75920871	0.64	rs4938357	ENSG00000254851.1	RP11-109L13.1	-5.38	1.68e-07	8.27e-05	-0.54	-0.32	Subjective well-being;	chr11:117213324	chr11:117135528~117138582:+
KIRP	cis	rs75920871	0.589	rs56081989	ENSG00000254851.1	RP11-109L13.1	-5.38	1.68e-07	8.27e-05	-0.54	-0.32	Subjective well-being;	chr11:117214589	chr11:117135528~117138582:+
KIRP	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	5.38	1.68e-07	8.29e-05	0.25	0.32	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
KIRP	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	5.38	1.68e-07	8.29e-05	0.25	0.32	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
KIRP	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	5.38	1.68e-07	8.29e-05	0.25	0.32	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
KIRP	cis	rs950169	0.887	rs3860265	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84390487	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.724	rs11632668	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84393989	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs34591918	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84396135	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.887	rs12903946	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84399732	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.887	rs62029593	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84400482	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.81	rs62029594	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84400554	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs62029596	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84400736	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs4081123	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84401537	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs62029599	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84401867	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.8	rs4099846	ENSG00000275120.1	RP11-182J1.17	5.38	1.68e-07	8.29e-05	0.44	0.32	Schizophrenia;	chr15:84402196	chr15:84599434~84606463:-
KIRP	cis	rs713477	0.845	rs4898863	ENSG00000258413.1	RP11-665C16.6	5.38	1.68e-07	8.29e-05	0.39	0.32	Pediatric bone mineral content (femoral neck);	chr14:55443566	chr14:55262767~55272075:-
KIRP	cis	rs4128705	0.958	rs2904380	ENSG00000249049.1	RP11-763F8.1	5.38	1.68e-07	8.3e-05	0.28	0.32	Amyotrophic lateral sclerosis (sporadic);	chr4:91361761	chr4:91319034~91325306:-
KIRP	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	5.38	1.68e-07	8.31e-05	0.25	0.32	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
KIRP	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-5.38	1.68e-07	8.31e-05	-0.24	-0.32	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
KIRP	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	5.38	1.68e-07	8.31e-05	0.44	0.32	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
KIRP	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.38	1.69e-07	8.33e-05	-0.39	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
KIRP	cis	rs2283792	0.765	rs34550586	ENSG00000228050.1	TOP3BP1	5.38	1.69e-07	8.33e-05	0.34	0.32	Multiple sclerosis;	chr22:21791345	chr22:22223187~22224566:-
KIRP	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.38	1.69e-07	8.33e-05	0.35	0.32	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
KIRP	cis	rs950169	0.922	rs12912934	ENSG00000275120.1	RP11-182J1.17	5.38	1.69e-07	8.33e-05	0.41	0.32	Schizophrenia;	chr15:84571216	chr15:84599434~84606463:-
KIRP	cis	rs9987353	0.544	rs2929470	ENSG00000253893.2	FAM85B	5.38	1.69e-07	8.34e-05	0.4	0.32	Recombination measurement;	chr8:9204980	chr8:8167819~8226614:-
KIRP	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-5.38	1.69e-07	8.35e-05	-0.34	-0.32	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
KIRP	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	5.38	1.69e-07	8.35e-05	0.77	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
KIRP	cis	rs67311347	0.544	rs9877105	ENSG00000230274.1	PGAM1P3	5.37	1.7e-07	8.37e-05	0.32	0.32	Renal cell carcinoma;	chr3:40291875	chr3:40322715~40323279:-
KIRP	cis	rs7569084	0.687	rs12993075	ENSG00000237979.1	AC007389.1	5.37	1.7e-07	8.37e-05	0.37	0.32	Sum eosinophil basophil counts;	chr2:65431010	chr2:65500993~65502138:-
KIRP	cis	rs4443100	0.916	rs6003494	ENSG00000221069.1	AC000029.1	5.37	1.7e-07	8.38e-05	0.38	0.32	Serum parathyroid hormone levels;	chr22:23057283	chr22:23136620~23136710:+
KIRP	cis	rs2976388	0.59	rs4736322	ENSG00000253741.1	CTD-2292P10.4	5.37	1.7e-07	8.38e-05	0.38	0.32	Urinary tract infection frequency;	chr8:142740790	chr8:142702252~142726973:-
KIRP	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	5.37	1.7e-07	8.39e-05	0.45	0.32	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
KIRP	cis	rs4356975	0.563	rs4535394	ENSG00000248763.2	RP13-644M16.5	5.37	1.7e-07	8.4e-05	0.33	0.32	Obesity-related traits;	chr4:69122735	chr4:69066395~69069888:+
KIRP	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	5.37	1.71e-07	8.4e-05	0.44	0.32	Height;	chr6:109423238	chr6:109382795~109383666:+
KIRP	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	5.37	1.71e-07	8.4e-05	0.36	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
KIRP	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-5.37	1.71e-07	8.41e-05	-0.36	-0.32	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
KIRP	cis	rs2976388	0.59	rs3736011	ENSG00000253741.1	CTD-2292P10.4	5.37	1.71e-07	8.42e-05	0.38	0.32	Urinary tract infection frequency;	chr8:142736371	chr8:142702252~142726973:-
KIRP	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	5.37	1.71e-07	8.42e-05	0.47	0.32	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
KIRP	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-5.37	1.71e-07	8.43e-05	-0.39	-0.32	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-5.37	1.71e-07	8.43e-05	-0.39	-0.32	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
KIRP	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-5.37	1.72e-07	8.45e-05	-0.3	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
KIRP	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.37	1.72e-07	8.46e-05	0.33	0.31	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
KIRP	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-5.37	1.72e-07	8.46e-05	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-5.37	1.72e-07	8.46e-05	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-5.37	1.72e-07	8.46e-05	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
KIRP	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-5.37	1.72e-07	8.47e-05	-0.33	-0.31	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
KIRP	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-5.37	1.72e-07	8.47e-05	-0.36	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-5.37	1.72e-07	8.47e-05	-0.36	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
KIRP	cis	rs28386778	0.897	rs2727330	ENSG00000240280.5	TCAM1P	5.37	1.72e-07	8.47e-05	0.39	0.31	Prudent dietary pattern;	chr17:63848138	chr17:63849292~63864379:+
KIRP	cis	rs67311347	0.544	rs6599088	ENSG00000230274.1	PGAM1P3	5.37	1.72e-07	8.47e-05	0.32	0.31	Renal cell carcinoma;	chr3:40287797	chr3:40322715~40323279:-
KIRP	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	5.37	1.72e-07	8.47e-05	0.28	0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
KIRP	cis	rs950169	0.84	rs62029595	ENSG00000275120.1	RP11-182J1.17	5.37	1.72e-07	8.47e-05	0.43	0.31	Schizophrenia;	chr15:84400603	chr15:84599434~84606463:-
KIRP	cis	rs4356975	0.563	rs6851533	ENSG00000248763.2	RP13-644M16.5	-5.37	1.72e-07	8.48e-05	-0.34	-0.31	Obesity-related traits;	chr4:69113032	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.563	rs7666195	ENSG00000248763.2	RP13-644M16.5	-5.37	1.72e-07	8.48e-05	-0.34	-0.31	Obesity-related traits;	chr4:69113765	chr4:69066395~69069888:+
KIRP	cis	rs4128705	1	rs12498254	ENSG00000249049.1	RP11-763F8.1	5.37	1.72e-07	8.49e-05	0.28	0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91361586	chr4:91319034~91325306:-
KIRP	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-5.37	1.73e-07	8.49e-05	-0.24	-0.31	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
KIRP	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-5.37	1.73e-07	8.5e-05	-0.3	-0.31	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
KIRP	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-5.37	1.73e-07	8.5e-05	-0.24	-0.31	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
KIRP	cis	rs4443100	0.631	rs13054904	ENSG00000221069.1	AC000029.1	-5.37	1.73e-07	8.51e-05	-0.42	-0.31	Serum parathyroid hormone levels;	chr22:23068739	chr22:23136620~23136710:+
KIRP	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-5.37	1.73e-07	8.52e-05	-0.35	-0.31	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-5.37	1.73e-07	8.52e-05	-0.35	-0.31	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
KIRP	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	5.37	1.73e-07	8.52e-05	0.47	0.31	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
KIRP	cis	rs61457372	0.509	rs12450251	ENSG00000264026.1	RP11-1124B17.1	-5.37	1.73e-07	8.52e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72351164	chr17:72342940~72355136:+
KIRP	cis	rs2278170	1	rs331534	ENSG00000225101.4	OR52K3P	-5.37	1.73e-07	8.52e-05	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4455850	chr11:4474813~4475755:+
KIRP	cis	rs2278170	1	rs2915038	ENSG00000225101.4	OR52K3P	-5.37	1.73e-07	8.52e-05	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4456509	chr11:4474813~4475755:+
KIRP	cis	rs2278170	0.961	rs331533	ENSG00000225101.4	OR52K3P	-5.37	1.73e-07	8.52e-05	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4456789	chr11:4474813~4475755:+
KIRP	cis	rs2278170	1	rs331525	ENSG00000225101.4	OR52K3P	-5.37	1.73e-07	8.52e-05	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4458605	chr11:4474813~4475755:+
KIRP	cis	rs1858037	0.867	rs67453645	ENSG00000281920.1	RP11-418H16.1	5.37	1.74e-07	8.53e-05	0.41	0.31	Rheumatoid arthritis;	chr2:65358908	chr2:65623272~65628424:+
KIRP	cis	rs1858037	0.867	rs57913336	ENSG00000281920.1	RP11-418H16.1	5.37	1.74e-07	8.53e-05	0.41	0.31	Rheumatoid arthritis;	chr2:65360485	chr2:65623272~65628424:+
KIRP	cis	rs1153858	1	rs1049508	ENSG00000259433.2	CTD-2651B20.4	-5.37	1.74e-07	8.53e-05	-0.28	-0.31	Homoarginine levels;	chr15:45361394	chr15:45330209~45332634:-
KIRP	cis	rs1153858	1	rs1145085	ENSG00000259433.2	CTD-2651B20.4	-5.37	1.74e-07	8.53e-05	-0.28	-0.31	Homoarginine levels;	chr15:45365606	chr15:45330209~45332634:-
KIRP	cis	rs1153858	1	rs1288775	ENSG00000259433.2	CTD-2651B20.4	-5.37	1.74e-07	8.53e-05	-0.28	-0.31	Homoarginine levels;	chr15:45369480	chr15:45330209~45332634:-
KIRP	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-5.37	1.74e-07	8.53e-05	-0.31	-0.31	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
KIRP	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-5.37	1.74e-07	8.55e-05	-0.4	-0.31	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
KIRP	cis	rs62388641	0.636	rs62388638	ENSG00000272279.1	RP11-157J24.2	5.37	1.74e-07	8.57e-05	0.54	0.31	Daytime sleep phenotypes;	chr6:1529224	chr6:1528364~1528911:-
KIRP	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	5.37	1.75e-07	8.58e-05	0.34	0.31	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
KIRP	cis	rs2976388	1	rs2572910	ENSG00000253741.1	CTD-2292P10.4	5.37	1.75e-07	8.59e-05	0.36	0.31	Urinary tract infection frequency;	chr8:142688717	chr8:142702252~142726973:-
KIRP	cis	rs728616	0.614	rs3934643	ENSG00000234382.2	RP11-40F6.1	-5.37	1.75e-07	8.59e-05	-0.39	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:80233664~80245367:+
KIRP	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-5.37	1.75e-07	8.59e-05	-0.34	-0.31	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
KIRP	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-5.37	1.75e-07	8.59e-05	-0.34	-0.31	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
KIRP	cis	rs79040073	0.636	rs74339964	ENSG00000259531.2	RP11-295H24.3	5.37	1.75e-07	8.59e-05	0.45	0.31	Lung cancer in ever smokers;	chr15:49329916	chr15:49365124~49366685:-
KIRP	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-5.37	1.75e-07	8.6e-05	-0.47	-0.31	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-5.37	1.75e-07	8.6e-05	-0.47	-0.31	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
KIRP	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	5.37	1.75e-07	8.6e-05	0.23	0.31	Height;	chr20:35194822	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	5.37	1.75e-07	8.6e-05	0.23	0.31	Height;	chr20:35201240	chr20:35201747~35203288:-
KIRP	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-5.37	1.75e-07	8.61e-05	-0.32	-0.31	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
KIRP	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55515292	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55518776	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55518922	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55520278	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55523835	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55524246	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55525589	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55525781	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	5.37	1.75e-07	8.61e-05	0.3	0.31	Height;	chr4:55526514	chr4:55547112~55547889:+
KIRP	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.37	1.75e-07	8.62e-05	-0.29	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
KIRP	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	5.37	1.76e-07	8.63e-05	0.34	0.31	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
KIRP	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	5.37	1.76e-07	8.63e-05	0.33	0.31	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
KIRP	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-5.37	1.76e-07	8.63e-05	-0.33	-0.31	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
KIRP	cis	rs79040073	0.637	rs112792737	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49198849	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.599	rs73394331	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49278236	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73394333	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49278719	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	5.37	1.76e-07	8.64e-05	0.44	0.31	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
KIRP	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	5.37	1.76e-07	8.64e-05	0.31	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
KIRP	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	5.37	1.76e-07	8.65e-05	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
KIRP	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	5.37	1.76e-07	8.65e-05	0.26	0.31	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
KIRP	cis	rs4356975	0.563	rs6600893	ENSG00000248763.2	RP13-644M16.5	-5.37	1.76e-07	8.65e-05	-0.34	-0.31	Obesity-related traits;	chr4:69113183	chr4:69066395~69069888:+
KIRP	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-5.37	1.76e-07	8.66e-05	-0.23	-0.31	Height;	chr20:35160450	chr20:35201747~35203288:-
KIRP	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	5.37	1.77e-07	8.66e-05	0.38	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
KIRP	cis	rs67311347	0.544	rs2123998	ENSG00000230274.1	PGAM1P3	-5.37	1.77e-07	8.67e-05	-0.3	-0.31	Renal cell carcinoma;	chr3:40317514	chr3:40322715~40323279:-
KIRP	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-5.37	1.77e-07	8.68e-05	-0.43	-0.31	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
KIRP	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	5.37	1.77e-07	8.68e-05	0.38	0.31	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
KIRP	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	5.37	1.77e-07	8.69e-05	0.4	0.31	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
KIRP	cis	rs7586673	0.93	rs6432667	ENSG00000235724.7	AC009299.2	-5.37	1.77e-07	8.7e-05	-0.37	-0.31	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161222785~161308303:-
KIRP	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-5.37	1.78e-07	8.71e-05	-0.38	-0.31	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
KIRP	cis	rs7267979	0.586	rs6037057	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.586	rs6050429	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.586	rs6050431	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.586	rs6050432	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25239007~25245229:-
KIRP	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	5.37	1.78e-07	8.73e-05	0.29	0.31	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
KIRP	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	5.37	1.78e-07	8.73e-05	0.29	0.31	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
KIRP	cis	rs7267979	0.586	rs6083776	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.586	rs1473695	ENSG00000274414.1	RP5-965G21.4	-5.37	1.78e-07	8.73e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25239007~25245229:-
KIRP	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	5.37	1.78e-07	8.73e-05	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
KIRP	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	5.36	1.78e-07	8.73e-05	0.4	0.31	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
KIRP	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	5.36	1.78e-07	8.74e-05	0.32	0.31	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
KIRP	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-5.36	1.78e-07	8.75e-05	-0.27	-0.31	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
KIRP	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	5.36	1.78e-07	8.75e-05	0.4	0.31	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
KIRP	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-5.36	1.79e-07	8.76e-05	-0.28	-0.31	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
KIRP	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-5.36	1.79e-07	8.76e-05	-0.28	-0.31	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	5.36	1.79e-07	8.77e-05	0.38	0.31	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	5.36	1.79e-07	8.77e-05	0.38	0.31	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
KIRP	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.36	1.79e-07	8.77e-05	0.37	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
KIRP	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-5.36	1.79e-07	8.77e-05	-0.42	-0.31	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
KIRP	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	5.36	1.79e-07	8.77e-05	0.46	0.31	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	5.36	1.79e-07	8.77e-05	0.46	0.31	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
KIRP	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	5.36	1.79e-07	8.78e-05	0.37	0.31	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
KIRP	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55531150	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55531218	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55534166	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55534180	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55534788	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55535489	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55536421	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55537080	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	5.36	1.79e-07	8.79e-05	0.3	0.31	Height;	chr4:55541259	chr4:55547112~55547889:+
KIRP	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-5.36	1.79e-07	8.8e-05	-0.37	-0.31	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
KIRP	cis	rs4443100	0.958	rs5996459	ENSG00000221069.1	AC000029.1	5.36	1.8e-07	8.8e-05	0.38	0.31	Serum parathyroid hormone levels;	chr22:23048953	chr22:23136620~23136710:+
KIRP	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-5.36	1.8e-07	8.8e-05	-0.32	-0.31	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	5.36	1.8e-07	8.8e-05	0.32	0.31	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
KIRP	cis	rs4356975	0.83	rs4413468	ENSG00000196472.4	RP13-644M16.4	5.36	1.8e-07	8.81e-05	0.34	0.31	Obesity-related traits;	chr4:69061845	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.563	rs7658752	ENSG00000248763.2	RP13-644M16.5	-5.36	1.8e-07	8.81e-05	-0.33	-0.31	Obesity-related traits;	chr4:69112350	chr4:69066395~69069888:+
KIRP	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	5.36	1.8e-07	8.82e-05	0.31	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
KIRP	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	5.36	1.8e-07	8.82e-05	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
KIRP	cis	rs2278170	1	rs331524	ENSG00000225101.4	OR52K3P	-5.36	1.8e-07	8.82e-05	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4458724	chr11:4474813~4475755:+
KIRP	cis	rs7225151	0.71	rs8077567	ENSG00000234327.6	AC012146.7	-5.36	1.8e-07	8.83e-05	-0.5	-0.31	Alzheimer's disease (late onset);	chr17:5286121	chr17:5111468~5115004:+
KIRP	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	5.36	1.8e-07	8.83e-05	0.44	0.31	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
KIRP	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	5.36	1.81e-07	8.85e-05	0.46	0.31	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
KIRP	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	5.36	1.81e-07	8.85e-05	0.52	0.31	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
KIRP	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	5.36	1.81e-07	8.85e-05	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
KIRP	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.36	1.81e-07	8.86e-05	0.32	0.31	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
KIRP	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-5.36	1.81e-07	8.86e-05	-0.37	-0.31	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
KIRP	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-5.36	1.81e-07	8.87e-05	-0.33	-0.31	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
KIRP	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-5.36	1.81e-07	8.87e-05	-0.34	-0.31	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
KIRP	cis	rs950169	0.887	rs220333	ENSG00000275120.1	RP11-182J1.17	5.36	1.81e-07	8.88e-05	0.41	0.31	Schizophrenia;	chr15:84547902	chr15:84599434~84606463:-
KIRP	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	5.36	1.82e-07	8.88e-05	0.48	0.31	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	5.36	1.82e-07	8.88e-05	0.48	0.31	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	5.36	1.82e-07	8.88e-05	0.48	0.31	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
KIRP	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.36	1.82e-07	8.9e-05	0.7	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
KIRP	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	5.36	1.82e-07	8.91e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	5.36	1.82e-07	8.91e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	5.36	1.82e-07	8.91e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
KIRP	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	5.36	1.82e-07	8.92e-05	0.59	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
KIRP	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	5.36	1.82e-07	8.92e-05	0.59	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
KIRP	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-5.36	1.82e-07	8.92e-05	-0.47	-0.31	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
KIRP	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	5.36	1.83e-07	8.93e-05	0.3	0.31	Height;	chr4:55538228	chr4:55547112~55547889:+
KIRP	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-5.36	1.83e-07	8.97e-05	-0.39	-0.31	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
KIRP	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-5.36	1.83e-07	8.97e-05	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
KIRP	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	5.36	1.84e-07	8.98e-05	0.5	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
KIRP	cis	rs11079159	0.651	rs2287223	ENSG00000263096.1	RP11-515O17.2	5.36	1.84e-07	8.98e-05	0.38	0.31	QRS duration;	chr17:55315491	chr17:55271504~55273653:-
KIRP	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	5.36	1.84e-07	8.98e-05	0.49	0.31	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	5.36	1.84e-07	8.99e-05	0.51	0.31	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
KIRP	cis	rs9595908	0.645	rs4942924	ENSG00000212293.1	SNORA16	5.36	1.84e-07	9e-05	0.3	0.31	Body mass index;	chr13:32806987	chr13:32420390~32420516:-
KIRP	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-5.36	1.84e-07	9e-05	-0.36	-0.31	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
KIRP	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	5.36	1.84e-07	9.01e-05	0.52	0.31	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	5.36	1.84e-07	9.01e-05	0.52	0.31	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	5.36	1.84e-07	9.01e-05	0.52	0.31	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	5.36	1.84e-07	9.01e-05	0.52	0.31	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
KIRP	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-5.36	1.85e-07	9.02e-05	-0.36	-0.31	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
KIRP	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-5.36	1.85e-07	9.02e-05	-0.41	-0.31	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
KIRP	cis	rs4660214	0.666	rs2256614	ENSG00000237624.1	OXCT2P1	5.36	1.85e-07	9.02e-05	0.4	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs596062	ENSG00000237624.1	OXCT2P1	5.36	1.85e-07	9.02e-05	0.4	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39514956~39516490:+
KIRP	cis	rs2504916	0.712	rs2774227	ENSG00000230234.1	RP1-276N6.2	-5.36	1.85e-07	9.03e-05	-0.31	-0.31	Response to hepatitis C treatment;	chr6:160278648	chr6:160272617~160276130:+
KIRP	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	5.36	1.85e-07	9.04e-05	0.48	0.31	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
KIRP	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	5.36	1.85e-07	9.04e-05	0.33	0.31	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
KIRP	cis	rs61457372	0.545	rs9788986	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350496	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs9788987	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350534	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs11077600	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350676	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs12451307	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350691	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs12451950	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350826	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.527	rs12451971	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350983	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs4793285	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72351298	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs4793286	ENSG00000264026.1	RP11-1124B17.1	-5.36	1.85e-07	9.06e-05	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72351541	chr17:72342940~72355136:+
KIRP	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-5.36	1.85e-07	9.06e-05	-0.36	-0.31	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
KIRP	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55436423	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55437438	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55452295	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55454900	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55454938	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55455102	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55486718	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55493557	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55495262	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	5.36	1.85e-07	9.06e-05	0.34	0.31	Height;	chr4:55502504	chr4:55363971~55395847:-
KIRP	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	5.36	1.86e-07	9.06e-05	0.36	0.31	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
KIRP	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-5.36	1.86e-07	9.06e-05	-0.34	-0.31	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
KIRP	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	5.36	1.86e-07	9.07e-05	0.41	0.31	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
KIRP	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	5.36	1.86e-07	9.07e-05	0.41	0.31	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	5.36	1.86e-07	9.07e-05	0.38	0.31	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	5.36	1.86e-07	9.07e-05	0.38	0.31	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
KIRP	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-5.36	1.86e-07	9.08e-05	-0.36	-0.31	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	5.36	1.86e-07	9.08e-05	0.36	0.31	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	5.36	1.86e-07	9.08e-05	0.36	0.31	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
KIRP	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	5.36	1.86e-07	9.08e-05	0.36	0.31	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
KIRP	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	5.36	1.86e-07	9.08e-05	0.37	0.31	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
KIRP	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	5.36	1.86e-07	9.09e-05	0.41	0.31	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
KIRP	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	5.36	1.86e-07	9.09e-05	0.34	0.31	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
KIRP	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	5.36	1.86e-07	9.09e-05	0.35	0.31	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
KIRP	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-5.36	1.86e-07	9.09e-05	-0.41	-0.31	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
KIRP	cis	rs7182621	0.509	rs12917012	ENSG00000259363.4	CTD-2054N24.2	-5.36	1.86e-07	9.1e-05	-0.36	-0.31	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99807023~99877148:+
KIRP	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-5.36	1.86e-07	9.1e-05	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-5.36	1.86e-07	9.1e-05	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
KIRP	cis	rs1799949	0.965	rs9897425	ENSG00000236383.6	LINC00854	-5.36	1.86e-07	9.1e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43352811	chr17:43216941~43305976:-
KIRP	cis	rs28386778	0.897	rs2584608	ENSG00000240280.5	TCAM1P	-5.36	1.87e-07	9.1e-05	-0.4	-0.31	Prudent dietary pattern;	chr17:63859350	chr17:63849292~63864379:+
KIRP	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-5.36	1.87e-07	9.11e-05	-0.34	-0.31	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
KIRP	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-5.36	1.87e-07	9.11e-05	-0.34	-0.31	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
KIRP	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	5.36	1.87e-07	9.12e-05	0.33	0.31	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
KIRP	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	5.36	1.87e-07	9.12e-05	0.51	0.31	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
KIRP	cis	rs4356975	0.563	rs3924192	ENSG00000196472.4	RP13-644M16.4	-5.36	1.87e-07	9.12e-05	-0.36	-0.31	Obesity-related traits;	chr4:69105246	chr4:69181660~69182372:+
KIRP	cis	rs4660214	0.666	rs2275186	ENSG00000237624.1	OXCT2P1	-5.35	1.87e-07	9.14e-05	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs12025847	ENSG00000237624.1	OXCT2P1	-5.35	1.87e-07	9.14e-05	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39514956~39516490:+
KIRP	cis	rs56804039	0.524	rs11783173	ENSG00000253893.2	FAM85B	5.35	1.87e-07	9.14e-05	0.49	0.31	Cervical cancer;	chr8:8505200	chr8:8167819~8226614:-
KIRP	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	5.35	1.87e-07	9.14e-05	0.33	0.31	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
KIRP	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-5.35	1.87e-07	9.14e-05	-0.42	-0.31	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
KIRP	cis	rs453301	0.624	rs7014430	ENSG00000253981.4	ALG1L13P	5.35	1.87e-07	9.14e-05	0.24	0.31	Joint mobility (Beighton score);	chr8:8970227	chr8:8236003~8244667:-
KIRP	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-5.35	1.88e-07	9.15e-05	-0.51	-0.31	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
KIRP	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-5.35	1.88e-07	9.15e-05	-0.36	-0.31	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
KIRP	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-5.35	1.88e-07	9.15e-05	-0.36	-0.31	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
KIRP	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	5.35	1.88e-07	9.16e-05	0.36	0.31	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
KIRP	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-5.35	1.88e-07	9.17e-05	-0.29	-0.31	Axial length;	chr3:53806638	chr3:53797764~53798019:-
KIRP	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	5.35	1.88e-07	9.17e-05	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
KIRP	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	5.35	1.88e-07	9.18e-05	0.38	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
KIRP	cis	rs2976388	1	rs2585179	ENSG00000253741.1	CTD-2292P10.4	5.35	1.88e-07	9.18e-05	0.36	0.31	Urinary tract infection frequency;	chr8:142692775	chr8:142702252~142726973:-
KIRP	cis	rs6832769	0.89	rs1522107	ENSG00000272969.1	RP11-528I4.2	5.35	1.88e-07	9.18e-05	0.31	0.31	Personality dimensions;	chr4:55514606	chr4:55547112~55547889:+
KIRP	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.35	1.88e-07	9.18e-05	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
KIRP	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	5.35	1.88e-07	9.18e-05	0.31	0.31	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
KIRP	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	5.35	1.88e-07	9.19e-05	0.35	0.31	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
KIRP	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-5.35	1.89e-07	9.2e-05	-0.34	-0.31	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
KIRP	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-5.35	1.89e-07	9.2e-05	-0.34	-0.31	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
KIRP	cis	rs5758659	0.679	rs134870	ENSG00000205702.9	CYP2D7	5.35	1.89e-07	9.2e-05	0.24	0.31	Cognitive function;	chr22:42256311	chr22:42140203~42144577:-
KIRP	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	5.35	1.89e-07	9.2e-05	0.32	0.31	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
KIRP	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	5.35	1.89e-07	9.2e-05	0.33	0.31	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
KIRP	cis	rs4356203	0.875	rs7939614	ENSG00000272034.1	SNORD14A	-5.35	1.89e-07	9.21e-05	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs9919600	ENSG00000272034.1	SNORD14A	-5.35	1.89e-07	9.21e-05	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs7939750	ENSG00000272034.1	SNORD14A	-5.35	1.89e-07	9.21e-05	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs9919540	ENSG00000272034.1	SNORD14A	-5.35	1.89e-07	9.21e-05	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17074654~17074744:-
KIRP	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-5.35	1.89e-07	9.21e-05	-0.35	-0.31	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
KIRP	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	5.35	1.89e-07	9.22e-05	0.29	0.31	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
KIRP	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-5.35	1.89e-07	9.22e-05	-0.46	-0.31	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
KIRP	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-5.35	1.9e-07	9.25e-05	-0.26	-0.31	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
KIRP	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-5.35	1.9e-07	9.26e-05	-0.36	-0.31	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
KIRP	cis	rs34375054	0.573	rs12823172	ENSG00000279233.1	RP11-158L12.4	5.35	1.9e-07	9.26e-05	0.3	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125161737	chr12:125138245~125141711:+
KIRP	cis	rs67311347	0.544	rs13098483	ENSG00000230274.1	PGAM1P3	5.35	1.9e-07	9.26e-05	0.31	0.31	Renal cell carcinoma;	chr3:40301252	chr3:40322715~40323279:-
KIRP	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	5.35	1.9e-07	9.26e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
KIRP	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-5.35	1.9e-07	9.26e-05	-0.35	-0.31	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
KIRP	cis	rs2439831	1	rs2256764	ENSG00000249839.1	AC011330.5	-5.35	1.9e-07	9.27e-05	-0.44	-0.31	Lung cancer in ever smokers;	chr15:43443565	chr15:43663654~43684339:-
KIRP	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	5.35	1.9e-07	9.27e-05	0.34	0.31	Height;	chr4:55483718	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	5.35	1.9e-07	9.27e-05	0.34	0.31	Height;	chr4:55544621	chr4:55363971~55395847:-
KIRP	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	5.35	1.9e-07	9.27e-05	0.32	0.31	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
KIRP	cis	rs8062405	0.964	rs12448902	ENSG00000251417.2	RP11-1348G14.4	-5.35	1.91e-07	9.28e-05	-0.27	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859870	chr16:28802743~28817828:+
KIRP	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-5.35	1.91e-07	9.28e-05	-0.41	-0.31	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
KIRP	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	5.35	1.91e-07	9.29e-05	0.34	0.31	Height;	chr4:55548666	chr4:55363971~55395847:-
KIRP	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	5.35	1.91e-07	9.29e-05	0.35	0.31	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
KIRP	cis	rs950169	0.922	rs11631096	ENSG00000275120.1	RP11-182J1.17	5.35	1.91e-07	9.3e-05	0.41	0.31	Schizophrenia;	chr15:84557698	chr15:84599434~84606463:-
KIRP	cis	rs1799949	1	rs2298862	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43024671	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs2298861	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43024814	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12944458	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43028755	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs36036395	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43029280	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs72829113	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43029818	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11653253	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43030645	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs12951869	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43035550	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11654452	ENSG00000236383.6	LINC00854	-5.35	1.91e-07	9.32e-05	-0.24	-0.31	Menopause (age at onset);	chr17:43037366	chr17:43216941~43305976:-
KIRP	cis	rs9595908	0.792	rs61947055	ENSG00000212293.1	SNORA16	5.35	1.92e-07	9.32e-05	0.3	0.31	Body mass index;	chr13:32614414	chr13:32420390~32420516:-
KIRP	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-5.35	1.92e-07	9.33e-05	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
KIRP	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-5.35	1.92e-07	9.33e-05	-0.6	-0.31	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
KIRP	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	5.35	1.92e-07	9.36e-05	0.35	0.31	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
KIRP	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	5.35	1.92e-07	9.36e-05	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
KIRP	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-5.35	1.92e-07	9.36e-05	-0.34	-0.31	Height;	chr3:53052712	chr3:53064283~53065091:-
KIRP	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.35	1.93e-07	9.36e-05	0.3	0.31	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
KIRP	cis	rs4660214	0.59	rs11205885	ENSG00000237624.1	OXCT2P1	-5.35	1.93e-07	9.37e-05	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39514956~39516490:+
KIRP	cis	rs7829975	0.667	rs1877119	ENSG00000253981.4	ALG1L13P	5.35	1.93e-07	9.38e-05	0.26	0.31	Mood instability;	chr8:8849687	chr8:8236003~8244667:-
KIRP	cis	rs2749592	0.725	rs9417245	ENSG00000151963.4	RP11-775A3.1	5.35	1.93e-07	9.38e-05	0.41	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr10:37537394	chr10:37883594~37884109:+
KIRP	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	5.35	1.93e-07	9.39e-05	0.39	0.31	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
KIRP	cis	rs12478296	1	rs11899408	ENSG00000261186.2	RP11-341N2.1	-5.35	1.93e-07	9.4e-05	-0.44	-0.31	Obesity-related traits;	chr2:242072479	chr2:242087351~242088457:-
KIRP	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-5.35	1.93e-07	9.4e-05	-0.34	-0.31	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
KIRP	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	5.35	1.94e-07	9.42e-05	0.36	0.31	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
KIRP	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	5.35	1.94e-07	9.42e-05	0.28	0.31	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
KIRP	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	5.35	1.94e-07	9.43e-05	0.37	0.31	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
KIRP	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-5.35	1.94e-07	9.43e-05	-0.39	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
KIRP	cis	rs7267979	1	rs2482927	ENSG00000274414.1	RP5-965G21.4	5.35	1.94e-07	9.44e-05	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25239007~25245229:-
KIRP	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	5.35	1.94e-07	9.45e-05	0.32	0.31	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
KIRP	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	5.35	1.94e-07	9.45e-05	0.3	0.31	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
KIRP	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-5.35	1.94e-07	9.45e-05	-0.51	-0.31	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-5.35	1.94e-07	9.45e-05	-0.51	-0.31	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
KIRP	cis	rs9959145	1	rs28815517	ENSG00000267108.1	RP11-861E21.1	5.35	1.94e-07	9.45e-05	0.44	0.31	Immune response to smallpox vaccine (IL-6);	chr18:12558747	chr18:12432897~12437635:+
KIRP	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	5.35	1.95e-07	9.46e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	5.35	1.95e-07	9.46e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	5.35	1.95e-07	9.46e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	5.35	1.95e-07	9.46e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
KIRP	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	5.35	1.95e-07	9.47e-05	0.37	0.31	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
KIRP	cis	rs2483058	0.767	rs2336939	ENSG00000261000.1	RP11-534L20.5	5.35	1.95e-07	9.47e-05	0.34	0.31	Cholesterol and Triglycerides;	chr1:206446827	chr1:206503948~206504456:+
KIRP	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-5.35	1.95e-07	9.47e-05	-0.4	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
KIRP	cis	rs4356203	0.905	rs10832743	ENSG00000272034.1	SNORD14A	-5.35	1.95e-07	9.47e-05	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17074654~17074744:-
KIRP	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-5.35	1.95e-07	9.47e-05	-0.43	-0.31	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
KIRP	cis	rs962856	0.964	rs1486135	ENSG00000236780.4	AC078941.1	5.35	1.95e-07	9.47e-05	0.39	0.31	Pancreatic cancer;	chr2:67369133	chr2:67123357~67215319:-
KIRP	cis	rs962856	0.633	rs6755775	ENSG00000236780.4	AC078941.1	5.35	1.95e-07	9.47e-05	0.39	0.31	Pancreatic cancer;	chr2:67371451	chr2:67123357~67215319:-
KIRP	cis	rs962856	1	rs6755797	ENSG00000236780.4	AC078941.1	5.35	1.95e-07	9.47e-05	0.39	0.31	Pancreatic cancer;	chr2:67371501	chr2:67123357~67215319:-
KIRP	cis	rs962856	1	rs6739392	ENSG00000236780.4	AC078941.1	5.35	1.95e-07	9.47e-05	0.39	0.31	Pancreatic cancer;	chr2:67374839	chr2:67123357~67215319:-
KIRP	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-5.35	1.95e-07	9.47e-05	-0.28	-0.31	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	5.35	1.95e-07	9.48e-05	0.37	0.31	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
KIRP	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	5.35	1.95e-07	9.49e-05	0.46	0.31	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
KIRP	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	5.35	1.96e-07	9.5e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	5.35	1.96e-07	9.5e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
KIRP	cis	rs911119	0.657	rs13039144	ENSG00000270001.1	RP11-218C14.8	-5.35	1.96e-07	9.5e-05	-0.4	-0.31	Chronic kidney disease;	chr20:23653118	chr20:23631826~23632316:-
KIRP	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	5.35	1.96e-07	9.52e-05	0.47	0.31	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	5.35	1.96e-07	9.52e-05	0.47	0.31	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	5.35	1.96e-07	9.52e-05	0.47	0.31	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	5.35	1.96e-07	9.52e-05	0.47	0.31	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
KIRP	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	5.35	1.97e-07	9.54e-05	0.3	0.31	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
KIRP	cis	rs4638749	0.677	rs10454132	ENSG00000231221.1	AC023672.2	-5.34	1.97e-07	9.55e-05	-0.37	-0.31	Blood pressure;	chr2:108211655	chr2:108049200~108052755:-
KIRP	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-5.34	1.97e-07	9.56e-05	-0.33	-0.31	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
KIRP	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-5.34	1.97e-07	9.56e-05	-0.26	-0.31	Height;	chr2:46640019	chr2:46668870~46670778:+
KIRP	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	5.34	1.97e-07	9.56e-05	0.31	0.31	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	5.34	1.97e-07	9.56e-05	0.31	0.31	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
KIRP	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-5.34	1.97e-07	9.56e-05	-0.32	-0.31	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-5.34	1.97e-07	9.56e-05	-0.32	-0.31	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-5.34	1.97e-07	9.56e-05	-0.32	-0.31	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
KIRP	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	5.34	1.97e-07	9.57e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	5.34	1.97e-07	9.57e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
KIRP	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-5.34	1.98e-07	9.58e-05	-0.3	-0.31	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
KIRP	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-5.34	1.98e-07	9.59e-05	-0.22	-0.31	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
KIRP	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	5.34	1.98e-07	9.6e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	5.34	1.98e-07	9.6e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	5.34	1.98e-07	9.6e-05	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
KIRP	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-5.34	1.98e-07	9.6e-05	-0.38	-0.31	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
KIRP	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-5.34	1.98e-07	9.6e-05	-0.27	-0.31	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
KIRP	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-5.34	1.99e-07	9.62e-05	-0.35	-0.31	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
KIRP	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	5.34	1.99e-07	9.62e-05	0.31	0.31	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
KIRP	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-5.34	1.99e-07	9.63e-05	-0.35	-0.31	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
KIRP	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-5.34	1.99e-07	9.63e-05	-0.28	-0.31	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
KIRP	cis	rs7267979	0.586	rs1007708	ENSG00000274414.1	RP5-965G21.4	-5.34	1.99e-07	9.64e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25239007~25245229:-
KIRP	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-5.34	1.99e-07	9.64e-05	-0.64	-0.31	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-5.34	1.99e-07	9.64e-05	-0.64	-0.31	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
KIRP	cis	rs7267979	0.586	rs1007707	ENSG00000274414.1	RP5-965G21.4	-5.34	2e-07	9.66e-05	-0.29	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25239007~25245229:-
KIRP	cis	rs11079159	0.959	rs4794562	ENSG00000263096.1	RP11-515O17.2	5.34	2e-07	9.66e-05	0.44	0.31	QRS duration;	chr17:55302450	chr17:55271504~55273653:-
KIRP	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	5.34	2e-07	9.67e-05	0.32	0.31	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
KIRP	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	5.34	2e-07	9.68e-05	0.44	0.31	Height;	chr6:109452743	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-5.34	2.01e-07	9.71e-05	-0.26	-0.31	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
KIRP	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-5.34	2.01e-07	9.72e-05	-0.35	-0.31	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
KIRP	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	5.34	2.01e-07	9.72e-05	0.33	0.31	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
KIRP	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	5.34	2.01e-07	9.72e-05	0.35	0.31	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
KIRP	cis	rs11773103	0.881	rs11978231	ENSG00000224046.1	AC005076.5	5.34	2.01e-07	9.72e-05	0.42	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87136444	chr7:87151423~87152420:-
KIRP	cis	rs962856	0.964	rs4671183	ENSG00000236780.4	AC078941.1	5.34	2.01e-07	9.73e-05	0.38	0.31	Pancreatic cancer;	chr2:67416545	chr2:67123357~67215319:-
KIRP	cis	rs7267979	0.702	rs449801	ENSG00000274973.1	RP13-401N8.7	-5.34	2.01e-07	9.73e-05	-0.33	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:25845497~25845862:+
KIRP	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-5.34	2.01e-07	9.74e-05	-0.32	-0.31	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
KIRP	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	5.34	2.02e-07	9.75e-05	0.39	0.31	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
KIRP	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	5.34	2.02e-07	9.76e-05	0.33	0.31	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
KIRP	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	5.34	2.02e-07	9.76e-05	0.25	0.31	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
KIRP	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	5.34	2.02e-07	9.77e-05	0.24	0.31	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
KIRP	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	5.34	2.02e-07	9.77e-05	0.41	0.31	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
KIRP	cis	rs1799949	0.587	rs1824890	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.77e-05	-0.31	-0.31	Menopause (age at onset);	chr17:43344536	chr17:43360041~43361361:-
KIRP	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	5.34	2.02e-07	9.77e-05	0.35	0.31	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
KIRP	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-5.34	2.02e-07	9.78e-05	-0.24	-0.31	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
KIRP	cis	rs8049040	0.564	rs310335	ENSG00000260886.1	TAT-AS1	5.34	2.02e-07	9.78e-05	0.4	0.31	Blood protein levels;	chr16:71540015	chr16:71565789~71578187:+
KIRP	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-5.34	2.02e-07	9.79e-05	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
KIRP	cis	rs1799949	1	rs11653069	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43131360	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs33988650	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43135863	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11656097	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43138596	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11658754	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43140722	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.93	rs33968979	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43145975	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs12952790	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43147590	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs12950607	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43147911	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11079056	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43148782	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs12936816	ENSG00000279602.1	CTD-3014M21.1	-5.34	2.02e-07	9.79e-05	-0.29	-0.31	Menopause (age at onset);	chr17:43149692	chr17:43360041~43361361:-
KIRP	cis	rs713477	1	rs10782426	ENSG00000258413.1	RP11-665C16.6	5.34	2.02e-07	9.79e-05	0.39	0.31	Pediatric bone mineral content (femoral neck);	chr14:55423984	chr14:55262767~55272075:-
KIRP	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	5.34	2.03e-07	9.8e-05	0.5	0.31	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-5.34	2.03e-07	9.8e-05	-0.5	-0.31	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
KIRP	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	5.34	2.03e-07	9.8e-05	0.33	0.31	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
KIRP	cis	rs453301	0.522	rs2929309	ENSG00000253981.4	ALG1L13P	-5.34	2.03e-07	9.82e-05	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9226261	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	5.34	2.03e-07	9.82e-05	0.43	0.31	Height;	chr6:109395761	chr6:109382795~109383666:+
KIRP	cis	rs4660214	0.666	rs1984143	ENSG00000237624.1	OXCT2P1	-5.34	2.03e-07	9.82e-05	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39514956~39516490:+
KIRP	cis	rs2483058	0.767	rs4127124	ENSG00000261000.1	RP11-534L20.5	5.34	2.04e-07	9.82e-05	0.34	0.31	Cholesterol and Triglycerides;	chr1:206451019	chr1:206503948~206504456:+
KIRP	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	5.34	2.04e-07	9.85e-05	0.32	0.31	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
KIRP	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	5.34	2.04e-07	9.86e-05	0.32	0.31	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
KIRP	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	5.34	2.04e-07	9.86e-05	0.34	0.31	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	5.34	2.04e-07	9.86e-05	0.34	0.31	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
KIRP	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	5.34	2.05e-07	9.87e-05	0.36	0.31	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
KIRP	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	5.34	2.05e-07	9.88e-05	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
KIRP	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	5.34	2.05e-07	9.88e-05	0.63	0.31	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
KIRP	cis	rs4578769	0.569	rs12966840	ENSG00000265943.1	RP11-739L10.1	-5.34	2.05e-07	9.89e-05	-0.39	-0.31	Eosinophil percentage of white cells;	chr18:22856911	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.55	rs4800435	ENSG00000265943.1	RP11-739L10.1	5.34	2.05e-07	9.89e-05	0.39	0.31	Eosinophil percentage of white cells;	chr18:22862923	chr18:22699481~22933764:-
KIRP	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-5.34	2.05e-07	9.9e-05	-0.3	-0.31	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
KIRP	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5.34	2.05e-07	9.9e-05	0.35	0.31	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
KIRP	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	5.34	2.05e-07	9.9e-05	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
KIRP	cis	rs3892630	0.588	rs7260037	ENSG00000267475.1	CTD-2538C1.2	-5.34	2.05e-07	9.91e-05	-0.4	-0.31	Red blood cell traits;	chr19:32751795	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.588	rs7245709	ENSG00000267475.1	CTD-2538C1.2	-5.34	2.05e-07	9.91e-05	-0.4	-0.31	Red blood cell traits;	chr19:32751849	chr19:32687089~32691750:-
KIRP	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	5.34	2.06e-07	9.91e-05	0.32	0.31	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-5.34	2.06e-07	9.93e-05	-0.36	-0.31	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
KIRP	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-5.34	2.06e-07	9.94e-05	-0.27	-0.31	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
KIRP	cis	rs713477	0.712	rs72717779	ENSG00000258413.1	RP11-665C16.6	5.33	2.07e-07	9.98e-05	0.4	0.31	Pediatric bone mineral content (femoral neck);	chr14:55426722	chr14:55262767~55272075:-
KIRP	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.33	2.07e-07	9.98e-05	0.32	0.31	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
KIRP	cis	rs9409565	0.502	rs509022	ENSG00000231806.2	PCAT7	5.33	2.07e-07	9.99e-05	0.38	0.31	Colorectal cancer (alcohol consumption interaction);	chr9:94566989	chr9:94555069~94568127:+
KIRP	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	5.33	2.07e-07	1e-04	0.3	0.31	Height;	chr4:55531811	chr4:55547112~55547889:+
KIRP	cis	rs7267979	1	rs2482931	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482940	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2027003	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2027004	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.934	rs2500399	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2500404	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2500405	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482941	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.903	rs2500423	ENSG00000274414.1	RP5-965G21.4	5.33	2.08e-07	1e-04	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25239007~25245229:-
KIRP	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	5.33	2.08e-07	1e-04	0.31	0.31	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
KIRP	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	5.33	2.08e-07	1e-04	0.36	0.31	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
KIRP	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-5.33	2.08e-07	1e-04	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-5.33	2.08e-07	1e-04	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-5.33	2.08e-07	1e-04	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
KIRP	cis	rs3745672	1	rs10409509	ENSG00000219665.7	CTD-2006C1.2	-5.33	2.08e-07	1e-04	-0.7	-0.31	Multiple sclerosis;	chr19:11987622	chr19:11987617~12046275:+
KIRP	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-5.33	2.08e-07	1e-04	-0.3	-0.31	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
KIRP	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-5.33	2.08e-07	1e-04	-0.37	-0.31	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
KIRP	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	5.33	2.09e-07	1e-04	0.43	0.31	Height;	chr6:109416225	chr6:109382795~109383666:+
KIRP	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-5.33	2.09e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
KIRP	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	5.33	2.09e-07	0.000101	0.33	0.31	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	5.33	2.09e-07	0.000101	0.33	0.31	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	5.33	2.09e-07	0.000101	0.33	0.31	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
KIRP	cis	rs2625529	0.526	rs11637611	ENSG00000260037.4	CTD-2524L6.3	5.33	2.09e-07	0.000101	0.24	0.31	Red blood cell count;	chr15:72259371	chr15:71818396~71823384:+
KIRP	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	5.33	2.09e-07	0.000101	0.33	0.31	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
KIRP	cis	rs4660214	0.666	rs3116398	ENSG00000237624.1	OXCT2P1	-5.33	2.1e-07	0.000101	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39514956~39516490:+
KIRP	cis	rs1479119	0.681	rs1479113	ENSG00000180861.8	LINC01559	5.33	2.1e-07	0.000101	0.36	0.31	Intelligence (multi-trait analysis);	chr12:13345046	chr12:13371089~13387167:-
KIRP	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	5.33	2.1e-07	0.000101	0.3	0.31	Height;	chr4:55515118	chr4:55547112~55547889:+
KIRP	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-5.33	2.1e-07	0.000101	-0.33	-0.31	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
KIRP	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-5.33	2.1e-07	0.000101	-0.26	-0.31	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
KIRP	cis	rs7170668	0.894	rs8036283	ENSG00000258489.3	RP11-398J10.2	5.33	2.1e-07	0.000101	0.37	0.31	Motion sickness;	chr15:95480382	chr15:95463592~95493770:-
KIRP	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	5.33	2.1e-07	0.000101	0.3	0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
KIRP	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	5.33	2.11e-07	0.000101	0.43	0.31	Height;	chr6:109414295	chr6:109382795~109383666:+
KIRP	cis	rs1044826	0.642	rs2071388	ENSG00000178631.7	ACTG1P1	-5.33	2.11e-07	0.000101	-0.33	-0.31	Obesity-related traits;	chr3:139517841	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs295482	ENSG00000178631.7	ACTG1P1	-5.33	2.11e-07	0.000101	-0.33	-0.31	Obesity-related traits;	chr3:139510422	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.692	rs184155	ENSG00000178631.7	ACTG1P1	-5.33	2.11e-07	0.000101	-0.33	-0.31	Obesity-related traits;	chr3:139510930	chr3:139493809~139494937:+
KIRP	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	5.33	2.11e-07	0.000101	0.49	0.31	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	5.33	2.11e-07	0.000101	0.49	0.31	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
KIRP	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	5.33	2.11e-07	0.000101	0.31	0.31	Height;	chr14:75112940	chr14:75011269~75012851:-
KIRP	cis	rs7829975	0.871	rs7829826	ENSG00000253981.4	ALG1L13P	-5.33	2.11e-07	0.000101	-0.24	-0.31	Mood instability;	chr8:8720610	chr8:8236003~8244667:-
KIRP	cis	rs1799949	0.965	rs8176198	ENSG00000236383.6	LINC00854	-5.33	2.11e-07	0.000101	-0.23	-0.31	Menopause (age at onset);	chr17:43078520	chr17:43216941~43305976:-
KIRP	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	5.33	2.11e-07	0.000101	0.34	0.31	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	5.33	2.11e-07	0.000101	0.34	0.31	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	5.33	2.11e-07	0.000101	0.34	0.31	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	5.33	2.11e-07	0.000101	0.34	0.31	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	5.33	2.11e-07	0.000101	0.34	0.31	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
KIRP	cis	rs1044826	0.642	rs295481	ENSG00000178631.7	ACTG1P1	5.33	2.11e-07	0.000102	0.33	0.31	Obesity-related traits;	chr3:139509969	chr3:139493809~139494937:+
KIRP	cis	rs4660214	0.666	rs2275188	ENSG00000237624.1	OXCT2P1	-5.33	2.11e-07	0.000102	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39514956~39516490:+
KIRP	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	5.33	2.11e-07	0.000102	0.33	0.31	Height;	chr4:55460485	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	5.33	2.11e-07	0.000102	0.33	0.31	Height;	chr4:55465165	chr4:55363971~55395847:-
KIRP	cis	rs2904804	0.641	rs2904802	ENSG00000224251.5	RP11-499O7.7	5.33	2.12e-07	0.000102	0.33	0.31	Economic and political preferences (immigration/crime);	chr10:4967172	chr10:4995488~4997380:+
KIRP	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-5.33	2.12e-07	0.000102	-0.28	-0.31	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
KIRP	cis	rs1799949	0.965	rs2236762	ENSG00000236383.6	LINC00854	-5.33	2.12e-07	0.000102	-0.23	-0.31	Menopause (age at onset);	chr17:43074658	chr17:43216941~43305976:-
KIRP	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	5.33	2.12e-07	0.000102	0.28	0.31	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
KIRP	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	5.33	2.12e-07	0.000102	0.35	0.31	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
KIRP	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	5.33	2.12e-07	0.000102	0.48	0.31	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
KIRP	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	5.33	2.12e-07	0.000102	0.4	0.31	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
KIRP	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	5.33	2.12e-07	0.000102	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
KIRP	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	5.33	2.12e-07	0.000102	0.3	0.31	Height;	chr14:75025993	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	5.33	2.12e-07	0.000102	0.3	0.31	Height;	chr14:75026029	chr14:75011269~75012851:-
KIRP	cis	rs11148252	0.74	rs7983971	ENSG00000278238.1	RP11-245D16.4	-5.33	2.12e-07	0.000102	-0.34	-0.31	Lewy body disease;	chr13:52216565	chr13:52454775~52455331:-
KIRP	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-5.33	2.12e-07	0.000102	-0.54	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
KIRP	cis	rs1479119	0.681	rs11055378	ENSG00000180861.8	LINC01559	5.33	2.13e-07	0.000102	0.37	0.31	Intelligence (multi-trait analysis);	chr12:13348295	chr12:13371089~13387167:-
KIRP	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	5.33	2.13e-07	0.000102	0.35	0.31	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
KIRP	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	5.33	2.13e-07	0.000102	0.29	0.31	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
KIRP	cis	rs962856	1	rs1032157	ENSG00000236780.4	AC078941.1	5.33	2.13e-07	0.000102	0.39	0.31	Pancreatic cancer;	chr2:67374684	chr2:67123357~67215319:-
KIRP	cis	rs713477	1	rs4901562	ENSG00000258413.1	RP11-665C16.6	5.33	2.13e-07	0.000102	0.4	0.31	Pediatric bone mineral content (femoral neck);	chr14:55434655	chr14:55262767~55272075:-
KIRP	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-5.33	2.13e-07	0.000102	-0.34	-0.31	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
KIRP	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-5.33	2.13e-07	0.000102	-0.32	-0.31	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-5.33	2.13e-07	0.000102	-0.32	-0.31	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-5.33	2.13e-07	0.000102	-0.32	-0.31	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
KIRP	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.33	2.13e-07	0.000102	-0.35	-0.31	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
KIRP	cis	rs61457372	0.545	rs12450702	ENSG00000264026.1	RP11-1124B17.1	-5.33	2.14e-07	0.000103	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72349288	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs12450736	ENSG00000264026.1	RP11-1124B17.1	-5.33	2.14e-07	0.000103	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72349399	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.545	rs2058064	ENSG00000264026.1	RP11-1124B17.1	-5.33	2.14e-07	0.000103	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72349736	chr17:72342940~72355136:+
KIRP	cis	rs9287719	0.649	rs12617968	ENSG00000234818.1	AC092687.5	5.33	2.14e-07	0.000103	0.68	0.31	Prostate cancer;	chr2:10581819	chr2:10589166~10604830:+
KIRP	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.33	2.14e-07	0.000103	0.35	0.31	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
KIRP	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	5.33	2.14e-07	0.000103	0.24	0.31	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
KIRP	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-5.33	2.14e-07	0.000103	-0.33	-0.31	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
KIRP	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-5.33	2.14e-07	0.000103	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
KIRP	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-5.33	2.14e-07	0.000103	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
KIRP	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	5.33	2.14e-07	0.000103	0.29	0.31	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
KIRP	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-5.33	2.14e-07	0.000103	-0.38	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-5.33	2.14e-07	0.000103	-0.38	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
KIRP	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	5.33	2.15e-07	0.000103	0.35	0.31	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
KIRP	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-5.33	2.15e-07	0.000103	-0.34	-0.31	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
KIRP	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.33	2.15e-07	0.000103	-0.23	-0.31	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
KIRP	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	5.33	2.15e-07	0.000103	0.35	0.31	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
KIRP	cis	rs73198271	0.74	rs1039911	ENSG00000253981.4	ALG1L13P	-5.33	2.15e-07	0.000103	-0.26	-0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8236003~8244667:-
KIRP	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-5.33	2.16e-07	0.000104	-0.35	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
KIRP	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	5.33	2.16e-07	0.000104	0.35	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
KIRP	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	5.33	2.16e-07	0.000104	0.36	0.31	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	5.33	2.16e-07	0.000104	0.36	0.31	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
KIRP	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	5.33	2.16e-07	0.000104	0.27	0.31	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
KIRP	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	5.33	2.16e-07	0.000104	0.48	0.31	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
KIRP	cis	rs1799949	0.965	rs33925201	ENSG00000279602.1	CTD-3014M21.1	-5.33	2.16e-07	0.000104	-0.28	-0.31	Menopause (age at onset);	chr17:43128665	chr17:43360041~43361361:-
KIRP	cis	rs75920871	0.764	rs17120347	ENSG00000254851.1	RP11-109L13.1	-5.33	2.17e-07	0.000104	-0.62	-0.31	Subjective well-being;	chr11:117125823	chr11:117135528~117138582:+
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-5.33	2.17e-07	0.000104	-0.37	-0.31	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
KIRP	cis	rs5758659	0.904	rs134877	ENSG00000205702.9	CYP2D7	5.33	2.17e-07	0.000104	0.24	0.31	Cognitive function;	chr22:42266365	chr22:42140203~42144577:-
KIRP	cis	rs5758659	0.935	rs134879	ENSG00000205702.9	CYP2D7	5.33	2.17e-07	0.000104	0.24	0.31	Cognitive function;	chr22:42268195	chr22:42140203~42144577:-
KIRP	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-5.33	2.17e-07	0.000104	-0.35	-0.31	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-5.33	2.17e-07	0.000104	-0.35	-0.31	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
KIRP	cis	rs4356975	0.563	rs6600885	ENSG00000248763.2	RP13-644M16.5	-5.33	2.17e-07	0.000104	-0.34	-0.31	Obesity-related traits;	chr4:69103949	chr4:69066395~69069888:+
KIRP	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-5.33	2.17e-07	0.000104	-0.45	-0.31	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
KIRP	cis	rs2625529	0.557	rs1000281	ENSG00000260037.4	CTD-2524L6.3	5.33	2.17e-07	0.000104	0.24	0.31	Red blood cell count;	chr15:72261081	chr15:71818396~71823384:+
KIRP	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-5.32	2.17e-07	0.000104	-0.23	-0.31	Height;	chr20:35157243	chr20:35201747~35203288:-
KIRP	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	5.32	2.17e-07	0.000104	0.61	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
KIRP	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	5.32	2.17e-07	0.000104	0.36	0.31	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
KIRP	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-5.32	2.17e-07	0.000104	-0.4	-0.31	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
KIRP	cis	rs9532669	0.926	rs11147831	ENSG00000239827.7	SUGT1P3	-5.32	2.18e-07	0.000104	-0.36	-0.31	Cervical cancer;	chr13:40978593	chr13:40908159~40921774:-
KIRP	cis	rs1075265	0.722	rs2287639	ENSG00000233266.1	HMGB1P31	5.32	2.18e-07	0.000104	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54138959	chr2:54051334~54051760:+
KIRP	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-5.32	2.18e-07	0.000104	-0.33	-0.31	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
KIRP	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.32	2.18e-07	0.000104	-0.23	-0.31	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
KIRP	cis	rs2299587	0.582	rs17515033	ENSG00000254054.2	RP11-156K13.3	5.32	2.18e-07	0.000104	0.36	0.31	Economic and political preferences;	chr8:18041009	chr8:17905756~17907887:+
KIRP	cis	rs1799949	1	rs2292595	ENSG00000279602.1	CTD-3014M21.1	-5.32	2.18e-07	0.000105	-0.29	-0.31	Menopause (age at onset);	chr17:43138657	chr17:43360041~43361361:-
KIRP	cis	rs11158026	0.603	rs59323730	ENSG00000258413.1	RP11-665C16.6	-5.32	2.18e-07	0.000105	-0.38	-0.31	Parkinson's disease;	chr14:54972357	chr14:55262767~55272075:-
KIRP	cis	rs11158026	0.603	rs11846514	ENSG00000258413.1	RP11-665C16.6	-5.32	2.18e-07	0.000105	-0.38	-0.31	Parkinson's disease;	chr14:54973622	chr14:55262767~55272075:-
KIRP	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-5.32	2.18e-07	0.000105	-0.22	-0.31	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
KIRP	cis	rs4356975	0.83	rs3922514	ENSG00000196472.4	RP13-644M16.4	5.32	2.18e-07	0.000105	0.34	0.31	Obesity-related traits;	chr4:69060905	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs28775401	ENSG00000196472.4	RP13-644M16.4	5.32	2.18e-07	0.000105	0.34	0.31	Obesity-related traits;	chr4:69060999	chr4:69181660~69182372:+
KIRP	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-5.32	2.19e-07	0.000105	-0.33	-0.31	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
KIRP	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	5.32	2.19e-07	0.000105	0.3	0.31	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
KIRP	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-5.32	2.19e-07	0.000105	-0.27	-0.31	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
KIRP	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-5.32	2.19e-07	0.000105	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
KIRP	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-5.32	2.19e-07	0.000105	-0.42	-0.31	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
KIRP	cis	rs4273100	1	rs868698	ENSG00000228157.4	AC007952.5	5.32	2.19e-07	0.000105	0.52	0.31	Schizophrenia;	chr17:19281898	chr17:19092974~19096837:+
KIRP	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	5.32	2.19e-07	0.000105	0.28	0.31	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
KIRP	cis	rs6832769	1	rs11133399	ENSG00000272969.1	RP11-528I4.2	-5.32	2.19e-07	0.000105	-0.33	-0.31	Personality dimensions;	chr4:55547664	chr4:55547112~55547889:+
KIRP	cis	rs7267979	1	rs2424713	ENSG00000274414.1	RP5-965G21.4	-5.32	2.19e-07	0.000105	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2387885	ENSG00000274414.1	RP5-965G21.4	5.32	2.19e-07	0.000105	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25239007~25245229:-
KIRP	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	5.32	2.2e-07	0.000105	0.42	0.31	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
KIRP	cis	rs4638749	0.501	rs750523	ENSG00000231221.1	AC023672.2	-5.32	2.2e-07	0.000105	-0.37	-0.31	Blood pressure;	chr2:108129765	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs1872594	ENSG00000231221.1	AC023672.2	-5.32	2.2e-07	0.000105	-0.37	-0.31	Blood pressure;	chr2:108130357	chr2:108049200~108052755:-
KIRP	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-5.32	2.2e-07	0.000105	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
KIRP	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-5.32	2.2e-07	0.000105	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
KIRP	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	5.32	2.2e-07	0.000105	0.36	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
KIRP	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	5.32	2.2e-07	0.000105	0.25	0.31	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
KIRP	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-5.32	2.2e-07	0.000105	-0.51	-0.31	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	5.32	2.2e-07	0.000105	0.51	0.31	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
KIRP	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-5.32	2.2e-07	0.000106	-0.53	-0.31	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
KIRP	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-5.32	2.21e-07	0.000106	-0.44	-0.31	Height;	chr6:109380015	chr6:109382795~109383666:+
KIRP	cis	rs67311347	0.544	rs9868700	ENSG00000230274.1	PGAM1P3	5.32	2.21e-07	0.000106	0.32	0.31	Renal cell carcinoma;	chr3:40303917	chr3:40322715~40323279:-
KIRP	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.32	2.21e-07	0.000106	-0.29	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
KIRP	cis	rs1560104	0.556	rs7188416	ENSG00000274834.1	CTD-3037G24.5	5.32	2.21e-07	0.000106	0.35	0.31	Obesity-related traits;	chr16:12615754	chr16:12614451~12614852:+
KIRP	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-5.32	2.22e-07	0.000106	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-5.32	2.22e-07	0.000106	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-5.32	2.22e-07	0.000106	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-5.32	2.22e-07	0.000106	-0.38	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
KIRP	cis	rs4356203	0.905	rs10832733	ENSG00000272034.1	SNORD14A	-5.32	2.22e-07	0.000106	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17074654~17074744:-
KIRP	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-5.32	2.22e-07	0.000106	-0.33	-0.31	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-5.32	2.22e-07	0.000106	-0.33	-0.31	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
KIRP	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	5.32	2.22e-07	0.000106	0.36	0.31	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
KIRP	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	5.32	2.22e-07	0.000106	0.36	0.31	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
KIRP	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-5.32	2.22e-07	0.000106	-0.33	-0.31	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-5.32	2.22e-07	0.000106	-0.33	-0.31	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
KIRP	cis	rs962856	0.822	rs1944911	ENSG00000236780.4	AC078941.1	5.32	2.22e-07	0.000106	0.38	0.31	Pancreatic cancer;	chr2:67420029	chr2:67123357~67215319:-
KIRP	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	5.32	2.22e-07	0.000106	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
KIRP	cis	rs6832769	1	rs28670674	ENSG00000272969.1	RP11-528I4.2	-5.32	2.23e-07	0.000106	-0.32	-0.31	Personality dimensions;	chr4:55540936	chr4:55547112~55547889:+
KIRP	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	5.32	2.23e-07	0.000106	0.24	0.31	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
KIRP	cis	rs2281558	0.837	rs67676850	ENSG00000274414.1	RP5-965G21.4	-5.32	2.23e-07	0.000107	-0.36	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:25239007~25245229:-
KIRP	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	5.32	2.23e-07	0.000107	0.27	0.31	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
KIRP	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	5.32	2.23e-07	0.000107	0.31	0.31	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
KIRP	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	5.32	2.23e-07	0.000107	0.51	0.31	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	5.32	2.23e-07	0.000107	0.51	0.31	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
KIRP	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	5.32	2.23e-07	0.000107	0.3	0.31	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
KIRP	cis	rs8067545	0.641	rs175922	ENSG00000270091.1	RP11-78O7.2	-5.32	2.24e-07	0.000107	-0.2	-0.31	Schizophrenia;	chr17:19922266	chr17:19896590~19897287:-
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-5.32	2.24e-07	0.000107	-0.37	-0.31	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
KIRP	cis	rs4660214	0.666	rs7553009	ENSG00000237624.1	OXCT2P1	-5.32	2.24e-07	0.000107	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs10493087	ENSG00000237624.1	OXCT2P1	-5.32	2.24e-07	0.000107	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs11205828	ENSG00000237624.1	OXCT2P1	-5.32	2.24e-07	0.000107	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39514956~39516490:+
KIRP	cis	rs11647589	0.815	rs11646536	ENSG00000262995.1	CTD-2194A8.2	-5.32	2.24e-07	0.000107	-0.36	-0.31	Blood metabolite levels;	chr16:20462274	chr16:20440266~20447000:-
KIRP	cis	rs11647589	0.723	rs9937581	ENSG00000262995.1	CTD-2194A8.2	-5.32	2.24e-07	0.000107	-0.36	-0.31	Blood metabolite levels;	chr16:20462581	chr16:20440266~20447000:-
KIRP	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-5.32	2.24e-07	0.000107	-0.3	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-5.32	2.24e-07	0.000107	-0.37	-0.31	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-5.32	2.24e-07	0.000107	-0.37	-0.31	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
KIRP	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	5.32	2.24e-07	0.000107	0.27	0.31	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
KIRP	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-5.32	2.24e-07	0.000107	-0.29	-0.31	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
KIRP	cis	rs6832769	1	rs6554286	ENSG00000272969.1	RP11-528I4.2	-5.32	2.25e-07	0.000107	-0.32	-0.31	Personality dimensions;	chr4:55534137	chr4:55547112~55547889:+
KIRP	cis	rs6840258	0.831	rs3775211	ENSG00000251411.1	RP11-397E7.4	-5.32	2.25e-07	0.000107	-0.31	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87117939	chr4:86913266~86914817:-
KIRP	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-5.32	2.25e-07	0.000107	-0.39	-0.31	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
KIRP	cis	rs295490	0.688	rs184157	ENSG00000272656.1	RP11-219D15.3	5.32	2.25e-07	0.000107	0.33	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139523324	chr3:139349024~139349371:-
KIRP	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	5.32	2.25e-07	0.000108	0.35	0.31	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
KIRP	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	5.32	2.25e-07	0.000108	0.36	0.31	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
KIRP	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	5.32	2.25e-07	0.000108	0.3	0.31	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	5.32	2.25e-07	0.000108	0.3	0.31	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
KIRP	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-5.32	2.25e-07	0.000108	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-5.32	2.25e-07	0.000108	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-5.32	2.25e-07	0.000108	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
KIRP	cis	rs11773103	0.881	rs73204817	ENSG00000224046.1	AC005076.5	5.32	2.26e-07	0.000108	0.42	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87140388	chr7:87151423~87152420:-
KIRP	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	5.32	2.26e-07	0.000108	0.3	0.31	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
KIRP	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	5.32	2.26e-07	0.000108	0.22	0.31	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
KIRP	cis	rs2562456	0.617	rs34203148	ENSG00000268555.1	RP11-678G14.3	5.32	2.26e-07	0.000108	0.44	0.31	Pain;	chr19:21590743	chr19:21570822~21587322:-
KIRP	cis	rs4356203	0.905	rs214940	ENSG00000272034.1	SNORD14A	-5.32	2.26e-07	0.000108	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17074654~17074744:-
KIRP	cis	rs10916248	1	rs10916248	ENSG00000232628.4	RP11-365O16.3	5.32	2.27e-07	0.000108	0.43	0.31	QT interval (drug interaction);	chr1:224068646	chr1:224208747~224213279:-
KIRP	cis	rs1799949	0.965	rs9911630	ENSG00000236383.6	LINC00854	-5.32	2.27e-07	0.000108	-0.23	-0.31	Menopause (age at onset);	chr17:43036325	chr17:43216941~43305976:-
KIRP	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	5.32	2.27e-07	0.000108	0.3	0.31	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
KIRP	cis	rs11773103	0.881	rs56226963	ENSG00000224046.1	AC005076.5	5.32	2.27e-07	0.000108	0.44	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87142615	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.881	rs56209936	ENSG00000224046.1	AC005076.5	5.32	2.27e-07	0.000108	0.44	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87142700	chr7:87151423~87152420:-
KIRP	cis	rs11773103	1	rs73204824	ENSG00000224046.1	AC005076.5	5.32	2.27e-07	0.000108	0.44	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87144095	chr7:87151423~87152420:-
KIRP	cis	rs11773103	0.881	rs73204825	ENSG00000224046.1	AC005076.5	5.32	2.27e-07	0.000108	0.44	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87144132	chr7:87151423~87152420:-
KIRP	cis	rs4638749	0.501	rs13421955	ENSG00000231221.1	AC023672.2	-5.32	2.27e-07	0.000108	-0.37	-0.31	Blood pressure;	chr2:108131620	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs2101357	ENSG00000231221.1	AC023672.2	-5.32	2.27e-07	0.000108	-0.37	-0.31	Blood pressure;	chr2:108132518	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs2171181	ENSG00000231221.1	AC023672.2	-5.32	2.27e-07	0.000108	-0.37	-0.31	Blood pressure;	chr2:108133935	chr2:108049200~108052755:-
KIRP	cis	rs61457372	0.545	rs12451994	ENSG00000264026.1	RP11-1124B17.1	-5.32	2.28e-07	0.000108	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72351096	chr17:72342940~72355136:+
KIRP	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-5.32	2.28e-07	0.000109	-0.32	-0.31	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
KIRP	cis	rs4660214	0.666	rs636083	ENSG00000237624.1	OXCT2P1	5.32	2.28e-07	0.000109	0.41	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39514956~39516490:+
KIRP	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-5.32	2.28e-07	0.000109	-0.27	-0.31	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
KIRP	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	5.32	2.28e-07	0.000109	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	5.32	2.28e-07	0.000109	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	5.32	2.28e-07	0.000109	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	5.32	2.28e-07	0.000109	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	5.32	2.28e-07	0.000109	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
KIRP	cis	rs8053891	0.507	rs12919469	ENSG00000260886.1	TAT-AS1	5.32	2.28e-07	0.000109	0.42	0.31	Coronary artery disease;	chr16:71994713	chr16:71565789~71578187:+
KIRP	cis	rs11079159	0.585	rs8079998	ENSG00000263096.1	RP11-515O17.2	5.31	2.28e-07	0.000109	0.37	0.31	QRS duration;	chr17:55308138	chr17:55271504~55273653:-
KIRP	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-5.31	2.28e-07	0.000109	-0.32	-0.31	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
KIRP	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	5.31	2.28e-07	0.000109	0.42	0.31	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	5.31	2.28e-07	0.000109	0.42	0.31	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
KIRP	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	5.31	2.29e-07	0.000109	0.44	0.31	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
KIRP	cis	rs7714584	1	rs59043558	ENSG00000197083.10	ZNF300P1	5.31	2.29e-07	0.000109	0.53	0.31	Crohn's disease;	chr5:150955100	chr5:150930645~150946289:-
KIRP	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	5.31	2.29e-07	0.000109	0.42	0.31	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
KIRP	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	5.31	2.29e-07	0.000109	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	5.31	2.29e-07	0.000109	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
KIRP	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	5.31	2.29e-07	0.000109	0.28	0.31	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
KIRP	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-5.31	2.29e-07	0.000109	-0.32	-0.31	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
KIRP	cis	rs2625529	0.824	rs12916951	ENSG00000260037.4	CTD-2524L6.3	-5.31	2.29e-07	0.000109	-0.26	-0.31	Red blood cell count;	chr15:71960157	chr15:71818396~71823384:+
KIRP	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-5.31	2.29e-07	0.000109	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
KIRP	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	5.31	2.29e-07	0.000109	0.23	0.31	Height;	chr20:35206707	chr20:35201747~35203288:-
KIRP	cis	rs8114671	0.967	rs2180568	ENSG00000269202.1	RP4-614O4.12	5.31	2.29e-07	0.000109	0.23	0.31	Height;	chr20:35206991	chr20:35201747~35203288:-
KIRP	cis	rs7267979	1	rs2500448	ENSG00000274414.1	RP5-965G21.4	5.31	2.29e-07	0.000109	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25239007~25245229:-
KIRP	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	5.31	2.29e-07	0.000109	0.48	0.31	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
KIRP	cis	rs2154427	0.872	rs76446596	ENSG00000238197.4	PAXBP1-AS1	5.31	2.3e-07	0.000109	0.42	0.31	Bilirubin levels;	chr21:32726080	chr21:32728115~32743122:+
KIRP	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
KIRP	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	5.31	2.3e-07	0.000109	0.5	0.31	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
KIRP	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-5.31	2.3e-07	0.00011	-0.3	-0.31	Height;	chr4:55514317	chr4:55547112~55547889:+
KIRP	cis	rs1560104	0.709	rs7200211	ENSG00000274834.1	CTD-3037G24.5	-5.31	2.3e-07	0.00011	-0.37	-0.31	Obesity-related traits;	chr16:12605083	chr16:12614451~12614852:+
KIRP	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-5.31	2.3e-07	0.00011	-0.26	-0.31	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
KIRP	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-5.31	2.3e-07	0.00011	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-5.31	2.3e-07	0.00011	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-5.31	2.3e-07	0.00011	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
KIRP	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	5.31	2.31e-07	0.00011	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
KIRP	cis	rs713477	1	rs8014526	ENSG00000258413.1	RP11-665C16.6	5.31	2.31e-07	0.00011	0.39	0.31	Pediatric bone mineral content (femoral neck);	chr14:55418336	chr14:55262767~55272075:-
KIRP	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	5.31	2.31e-07	0.00011	0.46	0.31	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
KIRP	cis	rs1858037	0.867	rs4671660	ENSG00000237979.1	AC007389.1	5.31	2.31e-07	0.00011	0.35	0.31	Rheumatoid arthritis;	chr2:65349302	chr2:65500993~65502138:-
KIRP	cis	rs12571093	0.656	rs3858147	ENSG00000233590.1	RP11-153K11.3	-5.31	2.32e-07	0.00011	-0.48	-0.31	Optic nerve measurement (disc area);	chr10:68253507	chr10:68233251~68242379:-
KIRP	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-5.31	2.32e-07	0.00011	-0.24	-0.31	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
KIRP	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	5.31	2.32e-07	0.00011	0.36	0.31	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
KIRP	cis	rs1560104	0.709	rs3919630	ENSG00000274834.1	CTD-3037G24.5	-5.31	2.32e-07	0.00011	-0.37	-0.31	Obesity-related traits;	chr16:12607086	chr16:12614451~12614852:+
KIRP	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	5.31	2.32e-07	0.00011	0.29	0.31	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	5.31	2.32e-07	0.00011	0.29	0.31	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
KIRP	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-5.31	2.32e-07	0.00011	-0.27	-0.31	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
KIRP	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-5.31	2.32e-07	0.00011	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
KIRP	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-5.31	2.32e-07	0.00011	-0.32	-0.31	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
KIRP	cis	rs962856	1	rs1601531	ENSG00000236780.4	AC078941.1	5.31	2.32e-07	0.00011	0.38	0.31	Pancreatic cancer;	chr2:67370972	chr2:67123357~67215319:-
KIRP	cis	rs4578769	0.918	rs8085287	ENSG00000266850.1	RP11-370A5.1	5.31	2.32e-07	0.00011	0.39	0.31	Eosinophil percentage of white cells;	chr18:22884208	chr18:22723491~22907721:-
KIRP	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-5.31	2.32e-07	0.00011	-0.31	-0.31	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
KIRP	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	5.31	2.32e-07	0.00011	0.34	0.31	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
KIRP	cis	rs2904804	0.641	rs4242782	ENSG00000224251.5	RP11-499O7.7	5.31	2.33e-07	0.000111	0.33	0.31	Economic and political preferences (immigration/crime);	chr10:4973950	chr10:4995488~4997380:+
KIRP	cis	rs2504916	0.68	rs2774229	ENSG00000230234.1	RP1-276N6.2	-5.31	2.33e-07	0.000111	-0.3	-0.31	Response to hepatitis C treatment;	chr6:160278356	chr6:160272617~160276130:+
KIRP	cis	rs2504916	0.712	rs2774228	ENSG00000230234.1	RP1-276N6.2	-5.31	2.33e-07	0.000111	-0.3	-0.31	Response to hepatitis C treatment;	chr6:160278367	chr6:160272617~160276130:+
KIRP	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-5.31	2.34e-07	0.000111	-0.41	-0.31	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
KIRP	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-5.31	2.34e-07	0.000111	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
KIRP	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-5.31	2.34e-07	0.000111	-0.26	-0.31	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-5.31	2.34e-07	0.000111	-0.26	-0.31	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
KIRP	cis	rs2976388	0.935	rs2978979	ENSG00000253741.1	CTD-2292P10.4	5.31	2.34e-07	0.000111	0.36	0.31	Urinary tract infection frequency;	chr8:142675868	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.935	rs2978980	ENSG00000253741.1	CTD-2292P10.4	5.31	2.34e-07	0.000111	0.36	0.31	Urinary tract infection frequency;	chr8:142676290	chr8:142702252~142726973:-
KIRP	cis	rs3745672	1	rs111626990	ENSG00000219665.7	CTD-2006C1.2	-5.31	2.34e-07	0.000111	-0.69	-0.31	Multiple sclerosis;	chr19:11994809	chr19:11987617~12046275:+
KIRP	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-5.31	2.34e-07	0.000111	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	5.31	2.34e-07	0.000111	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
KIRP	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	5.31	2.34e-07	0.000111	0.35	0.31	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
KIRP	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	5.31	2.35e-07	0.000111	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
KIRP	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-5.31	2.35e-07	0.000112	-0.27	-0.31	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
KIRP	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-5.31	2.35e-07	0.000112	-0.37	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
KIRP	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-5.31	2.35e-07	0.000112	-0.37	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
KIRP	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	5.31	2.35e-07	0.000112	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
KIRP	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-5.31	2.35e-07	0.000112	-0.26	-0.31	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
KIRP	cis	rs4356203	0.905	rs214937	ENSG00000272034.1	SNORD14A	5.31	2.36e-07	0.000112	0.26	0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.875	rs527810	ENSG00000272034.1	SNORD14A	-5.31	2.36e-07	0.000112	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs589319	ENSG00000272034.1	SNORD14A	-5.31	2.36e-07	0.000112	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs536628	ENSG00000272034.1	SNORD14A	-5.31	2.36e-07	0.000112	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17074654~17074744:-
KIRP	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	5.31	2.36e-07	0.000112	0.29	0.31	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
KIRP	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	5.31	2.36e-07	0.000112	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
KIRP	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-5.31	2.36e-07	0.000112	-0.23	-0.31	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
KIRP	cis	rs7378815	0.545	rs290764	ENSG00000250787.1	HMGN1P17	-5.31	2.37e-07	0.000112	-0.31	-0.31	Breast cancer;	chr5:56352295	chr5:56381781~56382075:+
KIRP	cis	rs9402743	0.597	rs34266043	ENSG00000231028.7	LINC00271	-5.31	2.37e-07	0.000112	-0.27	-0.31	Systemic lupus erythematosus;	chr6:135763663	chr6:135497801~135716055:+
KIRP	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	5.31	2.37e-07	0.000112	0.36	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
KIRP	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	5.31	2.37e-07	0.000113	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
KIRP	cis	rs28386778	0.829	rs1877317	ENSG00000240280.5	TCAM1P	-5.31	2.37e-07	0.000113	-0.41	-0.31	Prudent dietary pattern;	chr17:63699119	chr17:63849292~63864379:+
KIRP	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-5.31	2.37e-07	0.000113	-0.34	-0.31	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
KIRP	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-5.31	2.37e-07	0.000113	-0.26	-0.31	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
KIRP	cis	rs712022	0.537	rs4420266	ENSG00000246225.5	RP11-17A1.3	-5.31	2.38e-07	0.000113	-0.36	-0.31	Dialysis-related mortality;	chr11:22852637	chr11:22829380~22945393:+
KIRP	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-5.31	2.38e-07	0.000113	-0.51	-0.31	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
KIRP	cis	rs61457372	0.545	rs4514715	ENSG00000264026.1	RP11-1124B17.1	5.31	2.38e-07	0.000113	0.34	0.31	Triptolide cytotoxicity;	chr17:72349962	chr17:72342940~72355136:+
KIRP	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-5.31	2.38e-07	0.000113	-0.32	-0.31	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
KIRP	cis	rs4356203	0.905	rs11821773	ENSG00000272034.1	SNORD14A	-5.31	2.38e-07	0.000113	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17074654~17074744:-
KIRP	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-5.31	2.38e-07	0.000113	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-5.31	2.38e-07	0.000113	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-5.31	2.38e-07	0.000113	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-5.31	2.38e-07	0.000113	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
KIRP	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-5.31	2.38e-07	0.000113	-0.31	-0.31	Height;	chr14:75170656	chr14:75011269~75012851:-
KIRP	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	5.31	2.39e-07	0.000113	0.38	0.31	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	5.31	2.39e-07	0.000113	0.38	0.31	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	5.31	2.39e-07	0.000113	0.38	0.31	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	5.31	2.39e-07	0.000113	0.38	0.31	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
KIRP	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	5.31	2.39e-07	0.000113	0.36	0.31	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
KIRP	cis	rs728616	0.764	rs11201025	ENSG00000234382.2	RP11-40F6.1	-5.31	2.39e-07	0.000113	-0.39	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:80233664~80245367:+
KIRP	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	5.31	2.39e-07	0.000113	0.36	0.31	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
KIRP	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-5.31	2.39e-07	0.000113	-0.39	-0.31	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
KIRP	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	5.31	2.39e-07	0.000113	0.51	0.31	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
KIRP	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-5.31	2.39e-07	0.000113	-0.32	-0.31	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
KIRP	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	5.31	2.39e-07	0.000114	0.25	0.31	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
KIRP	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	5.31	2.4e-07	0.000114	0.43	0.31	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
KIRP	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-5.31	2.4e-07	0.000114	-0.39	-0.31	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
KIRP	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	5.31	2.4e-07	0.000114	0.36	0.31	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
KIRP	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	5.31	2.4e-07	0.000114	0.3	0.31	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
KIRP	cis	rs79040073	0.637	rs11634636	ENSG00000259531.2	RP11-295H24.3	5.3	2.4e-07	0.000114	0.44	0.31	Lung cancer in ever smokers;	chr15:49315407	chr15:49365124~49366685:-
KIRP	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-5.3	2.4e-07	0.000114	-0.33	-0.31	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
KIRP	cis	rs79349575	0.721	rs4794004	ENSG00000248278.1	SUMO2P17	5.3	2.4e-07	0.000114	0.35	0.31	Type 2 diabetes;	chr17:48961109	chr17:48874860~48908983:-
KIRP	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	5.3	2.41e-07	0.000114	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
KIRP	cis	rs2976388	0.556	rs4736323	ENSG00000253741.1	CTD-2292P10.4	5.3	2.41e-07	0.000114	0.4	0.31	Urinary tract infection frequency;	chr8:142748941	chr8:142702252~142726973:-
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000228039.3	KB-1125A3.10	5.3	2.41e-07	0.000114	0.48	0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23963780~23964374:+
KIRP	cis	rs11085466	1	rs2292986	ENSG00000268555.1	RP11-678G14.3	-5.3	2.41e-07	0.000114	-0.41	-0.31	Colorectal or endometrial cancer;	chr19:21593530	chr19:21570822~21587322:-
KIRP	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-5.3	2.42e-07	0.000115	-0.38	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
KIRP	cis	rs7829975	0.84	rs555617	ENSG00000253981.4	ALG1L13P	-5.3	2.42e-07	0.000115	-0.24	-0.31	Mood instability;	chr8:8735335	chr8:8236003~8244667:-
KIRP	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	5.3	2.43e-07	0.000115	0.31	0.31	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
KIRP	cis	rs28386778	1	rs2665810	ENSG00000240280.5	TCAM1P	-5.3	2.43e-07	0.000115	-0.37	-0.31	Prudent dietary pattern;	chr17:63892850	chr17:63849292~63864379:+
KIRP	cis	rs9659323	0.73	rs10802070	ENSG00000231365.4	RP11-418J17.1	-5.3	2.43e-07	0.000115	-0.28	-0.31	Body mass index;	chr1:118998863	chr1:119140396~119275973:+
KIRP	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	5.3	2.43e-07	0.000115	0.48	0.31	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
KIRP	cis	rs5758659	0.716	rs5758661	ENSG00000205702.9	CYP2D7	5.3	2.43e-07	0.000115	0.24	0.31	Cognitive function;	chr22:42228439	chr22:42140203~42144577:-
KIRP	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	5.3	2.43e-07	0.000115	0.47	0.31	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
KIRP	cis	rs950169	0.887	rs35986397	ENSG00000275120.1	RP11-182J1.17	5.3	2.43e-07	0.000115	0.43	0.31	Schizophrenia;	chr15:84400409	chr15:84599434~84606463:-
KIRP	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	5.3	2.44e-07	0.000115	0.29	0.31	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
KIRP	cis	rs308403	0.6	rs13135445	ENSG00000224786.1	CETN4P	5.3	2.44e-07	0.000115	0.43	0.31	Blood protein levels;	chr4:122743302	chr4:122730548~122732193:-
KIRP	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	5.3	2.44e-07	0.000115	0.38	0.31	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
KIRP	cis	rs9595908	0.832	rs9315172	ENSG00000212293.1	SNORA16	5.3	2.44e-07	0.000115	0.31	0.31	Body mass index;	chr13:32634035	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.832	rs9595976	ENSG00000212293.1	SNORA16	5.3	2.44e-07	0.000115	0.31	0.31	Body mass index;	chr13:32637910	chr13:32420390~32420516:-
KIRP	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	5.3	2.44e-07	0.000115	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
KIRP	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	5.3	2.44e-07	0.000115	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
KIRP	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-5.3	2.44e-07	0.000115	-0.39	-0.31	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
KIRP	cis	rs2976388	0.59	rs7828042	ENSG00000253741.1	CTD-2292P10.4	5.3	2.44e-07	0.000116	0.37	0.31	Urinary tract infection frequency;	chr8:142737965	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920282	ENSG00000253741.1	CTD-2292P10.4	5.3	2.44e-07	0.000116	0.36	0.31	Urinary tract infection frequency;	chr8:142676345	chr8:142702252~142726973:-
KIRP	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-5.3	2.45e-07	0.000116	-0.5	-0.31	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
KIRP	cis	rs67311347	0.544	rs9821440	ENSG00000230274.1	PGAM1P3	5.3	2.45e-07	0.000116	0.31	0.31	Renal cell carcinoma;	chr3:40300856	chr3:40322715~40323279:-
KIRP	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	5.3	2.45e-07	0.000116	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
KIRP	cis	rs6480314	0.636	rs61854797	ENSG00000233590.1	RP11-153K11.3	-5.3	2.46e-07	0.000116	-0.49	-0.31	Optic nerve measurement (disc area);	chr10:68245854	chr10:68233251~68242379:-
KIRP	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	5.3	2.46e-07	0.000116	0.33	0.31	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
KIRP	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	5.3	2.46e-07	0.000116	0.3	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
KIRP	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-5.3	2.46e-07	0.000116	-0.36	-0.31	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
KIRP	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-5.3	2.46e-07	0.000116	-0.29	-0.31	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
KIRP	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	5.3	2.46e-07	0.000116	0.34	0.31	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
KIRP	cis	rs1799949	1	rs11659028	ENSG00000236383.6	LINC00854	-5.3	2.46e-07	0.000116	-0.25	-0.31	Menopause (age at onset);	chr17:43043008	chr17:43216941~43305976:-
KIRP	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	5.3	2.46e-07	0.000116	0.32	0.31	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	5.3	2.46e-07	0.000116	0.32	0.31	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
KIRP	cis	rs6832769	0.925	rs4865018	ENSG00000272969.1	RP11-528I4.2	-5.3	2.46e-07	0.000116	-0.31	-0.31	Personality dimensions;	chr4:55591024	chr4:55547112~55547889:+
KIRP	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	5.3	2.46e-07	0.000116	0.29	0.31	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
KIRP	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	5.3	2.46e-07	0.000117	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
KIRP	cis	rs4852324	0.527	rs10166809	ENSG00000217702.2	RP11-287D1.4	5.3	2.46e-07	0.000117	0.46	0.31	Systemic lupus erythematosus;	chr2:73973913	chr2:74130583~74135395:+
KIRP	cis	rs7826238	0.526	rs876955	ENSG00000253893.2	FAM85B	-5.3	2.46e-07	0.000117	-0.43	-0.31	Systolic blood pressure;	chr8:8453374	chr8:8167819~8226614:-
KIRP	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	5.3	2.47e-07	0.000117	0.42	0.31	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
KIRP	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	5.3	2.47e-07	0.000117	0.29	0.31	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	5.3	2.47e-07	0.000117	0.29	0.31	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
KIRP	cis	rs4356203	0.905	rs7123301	ENSG00000272034.1	SNORD14A	-5.3	2.47e-07	0.000117	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs12286505	ENSG00000272034.1	SNORD14A	5.3	2.47e-07	0.000117	0.26	0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17074654~17074744:-
KIRP	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	5.3	2.47e-07	0.000117	0.26	0.31	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
KIRP	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	5.3	2.48e-07	0.000117	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
KIRP	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-5.3	2.48e-07	0.000117	-0.41	-0.31	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
KIRP	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-5.3	2.49e-07	0.000117	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-5.3	2.49e-07	0.000117	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
KIRP	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5.3	2.49e-07	0.000118	0.34	0.31	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
KIRP	cis	rs2299587	0.622	rs12334522	ENSG00000254054.2	RP11-156K13.3	5.3	2.49e-07	0.000118	0.37	0.31	Economic and political preferences;	chr8:18032264	chr8:17905756~17907887:+
KIRP	cis	rs893363	0.522	rs2241808	ENSG00000271916.1	RP11-884K10.6	-5.3	2.49e-07	0.000118	-0.29	-0.31	Axial length;	chr3:53822626	chr3:53797764~53798019:-
KIRP	cis	rs7267979	0.744	rs6050463	ENSG00000277938.1	RP5-965G21.3	5.3	2.49e-07	0.000118	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25229150~25231933:+
KIRP	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	5.3	2.49e-07	0.000118	0.32	0.31	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
KIRP	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-5.3	2.49e-07	0.000118	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
KIRP	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	5.3	2.49e-07	0.000118	0.34	0.31	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	5.3	2.49e-07	0.000118	0.34	0.31	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
KIRP	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-5.3	2.49e-07	0.000118	-0.5	-0.31	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
KIRP	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-5.3	2.5e-07	0.000118	-0.37	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
KIRP	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	5.3	2.5e-07	0.000118	0.4	0.31	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
KIRP	cis	rs28386778	0.742	rs3020617	ENSG00000240280.5	TCAM1P	-5.3	2.5e-07	0.000118	-0.4	-0.31	Prudent dietary pattern;	chr17:63869943	chr17:63849292~63864379:+
KIRP	cis	rs1858037	0.806	rs12612780	ENSG00000281920.1	RP11-418H16.1	5.3	2.5e-07	0.000118	0.4	0.31	Rheumatoid arthritis;	chr2:65355967	chr2:65623272~65628424:+
KIRP	cis	rs28386778	0.863	rs3760252	ENSG00000240280.5	TCAM1P	-5.3	2.5e-07	0.000118	-0.4	-0.31	Prudent dietary pattern;	chr17:63774826	chr17:63849292~63864379:+
KIRP	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-5.3	2.5e-07	0.000118	-0.29	-0.31	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
KIRP	cis	rs2154427	0.872	rs76474418	ENSG00000238197.4	PAXBP1-AS1	5.3	2.5e-07	0.000118	0.42	0.31	Bilirubin levels;	chr21:32677803	chr21:32728115~32743122:+
KIRP	cis	rs7267979	0.873	rs6083853	ENSG00000274414.1	RP5-965G21.4	5.3	2.5e-07	0.000118	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.934	rs2482913	ENSG00000274414.1	RP5-965G21.4	5.3	2.5e-07	0.000118	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25239007~25245229:-
KIRP	cis	rs4638749	0.677	rs7599646	ENSG00000231221.1	AC023672.2	5.3	2.5e-07	0.000118	0.35	0.31	Blood pressure;	chr2:108235887	chr2:108049200~108052755:-
KIRP	cis	rs7267979	0.899	rs6115213	ENSG00000274414.1	RP5-965G21.4	-5.3	2.51e-07	0.000118	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25239007~25245229:-
KIRP	cis	rs6840258	0.891	rs17012512	ENSG00000251411.1	RP11-397E7.4	-5.3	2.51e-07	0.000118	-0.3	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87146352	chr4:86913266~86914817:-
KIRP	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	5.3	2.51e-07	0.000118	0.33	0.31	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
KIRP	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-5.3	2.51e-07	0.000118	-0.49	-0.31	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
KIRP	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	5.3	2.51e-07	0.000118	0.36	0.31	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
KIRP	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	5.3	2.51e-07	0.000118	0.36	0.31	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
KIRP	cis	rs4356975	0.83	rs4481286	ENSG00000196472.4	RP13-644M16.4	5.3	2.51e-07	0.000119	0.34	0.31	Obesity-related traits;	chr4:69056631	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs4583828	ENSG00000196472.4	RP13-644M16.4	5.3	2.51e-07	0.000119	0.34	0.31	Obesity-related traits;	chr4:69056669	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs4235113	ENSG00000196472.4	RP13-644M16.4	5.3	2.51e-07	0.000119	0.34	0.31	Obesity-related traits;	chr4:69056739	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs4235114	ENSG00000196472.4	RP13-644M16.4	5.3	2.51e-07	0.000119	0.34	0.31	Obesity-related traits;	chr4:69056953	chr4:69181660~69182372:+
KIRP	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-5.3	2.51e-07	0.000119	-0.61	-0.31	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
KIRP	cis	rs962856	0.964	rs11890812	ENSG00000236780.4	AC078941.1	5.3	2.51e-07	0.000119	0.37	0.31	Pancreatic cancer;	chr2:67392883	chr2:67123357~67215319:-
KIRP	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	5.3	2.51e-07	0.000119	0.61	0.31	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
KIRP	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	5.3	2.52e-07	0.000119	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
KIRP	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-5.3	2.52e-07	0.000119	-0.28	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
KIRP	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	5.3	2.52e-07	0.000119	0.58	0.31	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
KIRP	cis	rs7809615	0.551	rs952319	ENSG00000244219.5	GS1-259H13.2	-5.3	2.52e-07	0.000119	-0.39	-0.31	Blood metabolite ratios;	chr7:99573826	chr7:99598066~99610813:+
KIRP	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-5.3	2.52e-07	0.000119	-0.25	-0.31	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
KIRP	cis	rs6832769	1	rs6837710	ENSG00000272969.1	RP11-528I4.2	5.29	2.52e-07	0.000119	0.32	0.31	Personality dimensions;	chr4:55508288	chr4:55547112~55547889:+
KIRP	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	5.29	2.53e-07	0.000119	0.32	0.31	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
KIRP	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-5.29	2.53e-07	0.000119	-0.44	-0.31	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
KIRP	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	5.29	2.53e-07	0.000119	0.41	0.31	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
KIRP	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	5.29	2.53e-07	0.000119	0.44	0.31	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
KIRP	cis	rs28386778	0.897	rs2727326	ENSG00000240280.5	TCAM1P	-5.29	2.53e-07	0.000119	-0.4	-0.31	Prudent dietary pattern;	chr17:63845656	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2727327	ENSG00000240280.5	TCAM1P	-5.29	2.53e-07	0.000119	-0.4	-0.31	Prudent dietary pattern;	chr17:63846062	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2727328	ENSG00000240280.5	TCAM1P	-5.29	2.53e-07	0.000119	-0.4	-0.31	Prudent dietary pattern;	chr17:63846204	chr17:63849292~63864379:+
KIRP	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	5.29	2.53e-07	0.000119	0.24	0.31	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
KIRP	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-5.29	2.53e-07	0.000119	-0.32	-0.31	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
KIRP	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-5.29	2.53e-07	0.000119	-0.3	-0.31	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
KIRP	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-5.29	2.54e-07	0.00012	-0.37	-0.31	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
KIRP	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	5.29	2.54e-07	0.00012	0.35	0.31	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
KIRP	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-5.29	2.54e-07	0.00012	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
KIRP	cis	rs6453278	0.961	rs6453277	ENSG00000250802.5	ZBED3-AS1	5.29	2.54e-07	0.00012	0.36	0.31	Autism;	chr5:77121056	chr5:77086740~77166909:+
KIRP	cis	rs6832769	1	rs59804446	ENSG00000272969.1	RP11-528I4.2	-5.29	2.54e-07	0.00012	-0.32	-0.31	Personality dimensions;	chr4:55563374	chr4:55547112~55547889:+
KIRP	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	5.29	2.54e-07	0.00012	0.37	0.31	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
KIRP	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-5.29	2.54e-07	0.00012	-0.26	-0.31	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-5.29	2.54e-07	0.00012	-0.26	-0.31	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
KIRP	cis	rs712022	0.534	rs4550218	ENSG00000246225.5	RP11-17A1.3	-5.29	2.54e-07	0.00012	-0.36	-0.31	Dialysis-related mortality;	chr11:22842112	chr11:22829380~22945393:+
KIRP	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-5.29	2.55e-07	0.00012	-0.33	-0.31	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
KIRP	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	5.29	2.55e-07	0.00012	0.37	0.31	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
KIRP	cis	rs2839627	0.638	rs7276320	ENSG00000225218.1	AP001628.6	-5.29	2.55e-07	0.00012	-0.29	-0.31	Information processing speed;	chr21:42849478	chr21:42831040~42836477:-
KIRP	cis	rs2976388	0.935	rs2920285	ENSG00000253741.1	CTD-2292P10.4	5.29	2.55e-07	0.00012	0.36	0.31	Urinary tract infection frequency;	chr8:142674800	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.935	rs2978978	ENSG00000253741.1	CTD-2292P10.4	5.29	2.55e-07	0.00012	0.36	0.31	Urinary tract infection frequency;	chr8:142675112	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.935	rs2920284	ENSG00000253741.1	CTD-2292P10.4	5.29	2.55e-07	0.00012	0.36	0.31	Urinary tract infection frequency;	chr8:142675501	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920283	ENSG00000253741.1	CTD-2292P10.4	5.29	2.55e-07	0.00012	0.36	0.31	Urinary tract infection frequency;	chr8:142675619	chr8:142702252~142726973:-
KIRP	cis	rs7267979	1	rs1888999	ENSG00000274414.1	RP5-965G21.4	-5.29	2.55e-07	0.00012	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25239007~25245229:-
KIRP	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.29	2.56e-07	0.000121	0.26	0.31	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
KIRP	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-5.29	2.56e-07	0.000121	-0.35	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
KIRP	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-5.29	2.57e-07	0.000121	-0.33	-0.31	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
KIRP	cis	rs2625529	0.526	rs11634622	ENSG00000260037.4	CTD-2524L6.3	5.29	2.57e-07	0.000121	0.24	0.31	Red blood cell count;	chr15:72269986	chr15:71818396~71823384:+
KIRP	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	5.29	2.57e-07	0.000121	0.46	0.31	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
KIRP	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	5.29	2.57e-07	0.000121	0.46	0.31	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
KIRP	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-5.29	2.57e-07	0.000121	-0.24	-0.31	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
KIRP	cis	rs7267979	0.816	rs6115094	ENSG00000277938.1	RP5-965G21.3	5.29	2.57e-07	0.000121	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25229150~25231933:+
KIRP	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	5.29	2.57e-07	0.000121	0.37	0.31	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
KIRP	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-5.29	2.57e-07	0.000121	-0.4	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
KIRP	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-5.29	2.58e-07	0.000121	-0.32	-0.31	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
KIRP	cis	rs4356975	0.622	rs61287898	ENSG00000196472.4	RP13-644M16.4	5.29	2.58e-07	0.000121	0.35	0.31	Obesity-related traits;	chr4:69167116	chr4:69181660~69182372:+
KIRP	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	5.29	2.58e-07	0.000121	0.38	0.31	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	5.29	2.58e-07	0.000121	0.38	0.31	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	5.29	2.58e-07	0.000121	0.38	0.31	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	5.29	2.58e-07	0.000121	0.38	0.31	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
KIRP	cis	rs2504916	0.712	rs2481058	ENSG00000230234.1	RP1-276N6.2	-5.29	2.58e-07	0.000121	-0.32	-0.31	Response to hepatitis C treatment;	chr6:160318204	chr6:160272617~160276130:+
KIRP	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-5.29	2.58e-07	0.000122	-0.38	-0.31	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
KIRP	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	5.29	2.58e-07	0.000122	0.5	0.31	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	5.29	2.58e-07	0.000122	0.5	0.31	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	5.29	2.58e-07	0.000122	0.5	0.31	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
KIRP	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	5.29	2.58e-07	0.000122	0.37	0.31	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	5.29	2.58e-07	0.000122	0.37	0.31	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
KIRP	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	5.29	2.58e-07	0.000122	0.5	0.31	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
KIRP	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-5.29	2.58e-07	0.000122	-0.34	-0.31	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
KIRP	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	5.29	2.59e-07	0.000122	0.35	0.31	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
KIRP	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	5.29	2.59e-07	0.000122	0.29	0.31	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	5.29	2.59e-07	0.000122	0.29	0.31	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	5.29	2.59e-07	0.000122	0.29	0.31	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	5.29	2.59e-07	0.000122	0.29	0.31	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
KIRP	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-5.29	2.59e-07	0.000122	-0.27	-0.31	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
KIRP	cis	rs11864453	0.793	rs7197869	ENSG00000260886.1	TAT-AS1	5.29	2.59e-07	0.000122	0.4	0.31	Fibrinogen levels;	chr16:72045453	chr16:71565789~71578187:+
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-5.29	2.59e-07	0.000122	-0.24	-0.31	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-5.29	2.59e-07	0.000122	-0.24	-0.31	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
KIRP	cis	rs2839627	0.638	rs73366794	ENSG00000225218.1	AP001628.6	5.29	2.59e-07	0.000122	0.31	0.31	Information processing speed;	chr21:42849070	chr21:42831040~42836477:-
KIRP	cis	rs11673344	0.504	rs11666786	ENSG00000226686.6	LINC01535	5.29	2.59e-07	0.000122	0.37	0.31	Obesity-related traits;	chr19:37133947	chr19:37251912~37265535:+
KIRP	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-5.29	2.59e-07	0.000122	-0.52	-0.31	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
KIRP	cis	rs947583	0.663	rs7765436	ENSG00000231028.7	LINC00271	-5.29	2.59e-07	0.000122	-0.29	-0.31	Phosphorus levels;	chr6:135804721	chr6:135497801~135716055:+
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-5.29	2.6e-07	0.000122	-0.24	-0.31	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-5.29	2.6e-07	0.000122	-0.24	-0.31	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
KIRP	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.29	2.6e-07	0.000122	-0.35	-0.31	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
KIRP	cis	rs7726354	1	rs73122135	ENSG00000271828.1	CTD-2310F14.1	5.29	2.6e-07	0.000122	0.52	0.31	Breast cancer (early onset);	chr5:56971481	chr5:56927874~56929573:+
KIRP	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-5.29	2.6e-07	0.000122	-0.5	-0.31	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
KIRP	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	5.29	2.6e-07	0.000122	0.28	0.31	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	5.29	2.6e-07	0.000122	0.28	0.31	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
KIRP	cis	rs79040073	0.51	rs111307556	ENSG00000259531.2	RP11-295H24.3	5.29	2.6e-07	0.000122	0.43	0.31	Lung cancer in ever smokers;	chr15:49339858	chr15:49365124~49366685:-
KIRP	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-5.29	2.6e-07	0.000122	-0.24	-0.31	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
KIRP	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-5.29	2.6e-07	0.000122	-0.34	-0.31	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
KIRP	cis	rs2273156	1	rs7153068	ENSG00000226677.3	IGBP1P1	-5.29	2.6e-07	0.000122	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:34990275	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12050447	ENSG00000226677.3	IGBP1P1	-5.29	2.6e-07	0.000122	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992759	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs7141293	ENSG00000226677.3	IGBP1P1	-5.29	2.6e-07	0.000122	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993704	chr14:34939324~34940332:+
KIRP	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	5.29	2.61e-07	0.000122	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
KIRP	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-5.29	2.61e-07	0.000123	-0.33	-0.31	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
KIRP	cis	rs79349575	0.715	rs11657238	ENSG00000248278.1	SUMO2P17	5.29	2.61e-07	0.000123	0.34	0.31	Type 2 diabetes;	chr17:48908272	chr17:48874860~48908983:-
KIRP	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	5.29	2.61e-07	0.000123	0.31	0.31	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
KIRP	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	5.29	2.61e-07	0.000123	0.49	0.31	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
KIRP	cis	rs4356203	0.905	rs35933265	ENSG00000272034.1	SNORD14A	-5.29	2.61e-07	0.000123	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17074654~17074744:-
KIRP	cis	rs453301	0.652	rs2043129	ENSG00000253981.4	ALG1L13P	5.29	2.61e-07	0.000123	0.24	0.31	Joint mobility (Beighton score);	chr8:8967994	chr8:8236003~8244667:-
KIRP	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-5.29	2.62e-07	0.000123	-0.28	-0.31	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
KIRP	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	5.29	2.62e-07	0.000123	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
KIRP	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	5.29	2.62e-07	0.000123	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	5.29	2.62e-07	0.000123	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	5.29	2.62e-07	0.000123	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	5.29	2.62e-07	0.000123	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
KIRP	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-5.29	2.62e-07	0.000123	-0.37	-0.31	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-5.29	2.62e-07	0.000123	-0.37	-0.31	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
KIRP	cis	rs2299587	0.932	rs11203929	ENSG00000254054.2	RP11-156K13.3	5.29	2.62e-07	0.000123	0.37	0.31	Economic and political preferences;	chr8:17962303	chr8:17905756~17907887:+
KIRP	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	5.29	2.62e-07	0.000123	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
KIRP	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	5.29	2.63e-07	0.000123	0.39	0.31	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
KIRP	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	5.29	2.63e-07	0.000123	0.37	0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
KIRP	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-5.29	2.63e-07	0.000123	-0.34	-0.31	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
KIRP	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-5.29	2.63e-07	0.000124	-0.49	-0.31	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
KIRP	cis	rs3892630	0.588	rs12610342	ENSG00000267475.1	CTD-2538C1.2	-5.29	2.64e-07	0.000124	-0.4	-0.31	Red blood cell traits;	chr19:32759784	chr19:32687089~32691750:-
KIRP	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	5.29	2.64e-07	0.000124	0.28	0.31	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
KIRP	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	5.29	2.64e-07	0.000124	0.34	0.31	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
KIRP	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-5.29	2.64e-07	0.000124	-0.32	-0.31	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
KIRP	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	5.29	2.64e-07	0.000124	0.46	0.31	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
KIRP	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-5.29	2.64e-07	0.000124	-0.27	-0.31	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
KIRP	cis	rs9595908	0.869	rs9591185	ENSG00000212293.1	SNORA16	5.29	2.65e-07	0.000124	0.29	0.31	Body mass index;	chr13:32627829	chr13:32420390~32420516:-
KIRP	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-5.29	2.65e-07	0.000124	-0.36	-0.31	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
KIRP	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-5.29	2.65e-07	0.000124	-0.36	-0.31	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
KIRP	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	5.28	2.65e-07	0.000124	0.37	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
KIRP	cis	rs11638352	1	rs2733221	ENSG00000205771.5	CATSPER2P1	5.28	2.66e-07	0.000125	0.62	0.31	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097672	chr15:43726918~43747094:-
KIRP	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-5.28	2.66e-07	0.000125	-0.58	-0.31	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-5.28	2.66e-07	0.000125	-0.58	-0.31	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-5.28	2.66e-07	0.000125	-0.58	-0.31	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.922	rs67804993	ENSG00000275120.1	RP11-182J1.17	5.28	2.67e-07	0.000125	0.41	0.31	Schizophrenia;	chr15:84560799	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs34117475	ENSG00000275120.1	RP11-182J1.17	5.28	2.67e-07	0.000125	0.41	0.31	Schizophrenia;	chr15:84565212	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs12915832	ENSG00000275120.1	RP11-182J1.17	5.28	2.67e-07	0.000125	0.41	0.31	Schizophrenia;	chr15:84568226	chr15:84599434~84606463:-
KIRP	cis	rs2483058	0.767	rs11120575	ENSG00000261000.1	RP11-534L20.5	5.28	2.67e-07	0.000125	0.34	0.31	Cholesterol and Triglycerides;	chr1:206453261	chr1:206503948~206504456:+
KIRP	cis	rs7829975	0.684	rs488904	ENSG00000253981.4	ALG1L13P	-5.28	2.67e-07	0.000125	-0.23	-0.31	Mood instability;	chr8:8730061	chr8:8236003~8244667:-
KIRP	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-5.28	2.67e-07	0.000125	-0.38	-0.31	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
KIRP	cis	rs2281558	0.833	rs6115202	ENSG00000274414.1	RP5-965G21.4	5.28	2.67e-07	0.000125	0.36	0.31	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:25239007~25245229:-
KIRP	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	5.28	2.67e-07	0.000125	0.29	0.31	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	5.28	2.67e-07	0.000125	0.29	0.31	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
KIRP	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.28	2.68e-07	0.000126	-0.43	-0.31	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
KIRP	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-5.28	2.68e-07	0.000126	-0.35	-0.31	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
KIRP	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	5.28	2.68e-07	0.000126	0.28	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
KIRP	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	5.28	2.68e-07	0.000126	0.39	0.31	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
KIRP	cis	rs7474896	0.583	rs11011346	ENSG00000151963.4	RP11-775A3.1	-5.28	2.68e-07	0.000126	-0.42	-0.31	Obesity (extreme);	chr10:37720555	chr10:37883594~37884109:+
KIRP	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-5.28	2.68e-07	0.000126	-0.27	-0.31	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
KIRP	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-5.28	2.68e-07	0.000126	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
KIRP	cis	rs4356203	0.875	rs680205	ENSG00000272034.1	SNORD14A	-5.28	2.68e-07	0.000126	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17074654~17074744:-
KIRP	cis	rs67311347	0.605	rs1880762	ENSG00000230274.1	PGAM1P3	5.28	2.68e-07	0.000126	0.29	0.31	Renal cell carcinoma;	chr3:40241724	chr3:40322715~40323279:-
KIRP	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-5.28	2.68e-07	0.000126	-0.32	-0.31	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-5.28	2.68e-07	0.000126	-0.32	-0.31	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-5.28	2.68e-07	0.000126	-0.32	-0.31	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
KIRP	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-5.28	2.69e-07	0.000126	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
KIRP	cis	rs1009647	0.592	rs1045004	ENSG00000258413.1	RP11-665C16.6	-5.28	2.69e-07	0.000126	-0.48	-0.31	Testicular germ cell tumor;	chr14:55353073	chr14:55262767~55272075:-
KIRP	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-5.28	2.69e-07	0.000126	-0.39	-0.31	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
KIRP	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	5.28	2.69e-07	0.000126	0.25	0.31	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	5.28	2.69e-07	0.000126	0.25	0.31	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
KIRP	cis	rs7267979	0.816	rs8115257	ENSG00000277938.1	RP5-965G21.3	5.28	2.69e-07	0.000126	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25229150~25231933:+
KIRP	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-5.28	2.69e-07	0.000126	-0.37	-0.31	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
KIRP	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	5.28	2.69e-07	0.000126	0.38	0.31	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
KIRP	cis	rs1200821	0.535	rs1208789	ENSG00000151963.4	RP11-775A3.1	-5.28	2.69e-07	0.000126	-0.35	-0.31	Hemostatic factors and hematological phenotypes;	chr10:37433544	chr10:37883594~37884109:+
KIRP	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-5.28	2.7e-07	0.000126	-0.3	-0.31	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
KIRP	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	5.28	2.7e-07	0.000126	0.38	0.31	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
KIRP	cis	rs6832769	1	rs6812042	ENSG00000272969.1	RP11-528I4.2	5.28	2.7e-07	0.000126	0.31	0.31	Personality dimensions;	chr4:55529912	chr4:55547112~55547889:+
KIRP	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-5.28	2.7e-07	0.000126	-0.4	-0.31	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
KIRP	cis	rs4927850	0.829	rs6768483	ENSG00000231464.1	AC024937.4	5.28	2.7e-07	0.000126	0.37	0.31	Pancreatic cancer;	chr3:196019092	chr3:195996738~195998233:+
KIRP	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	5.28	2.7e-07	0.000126	0.47	0.31	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
KIRP	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	5.28	2.7e-07	0.000127	0.31	0.31	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
KIRP	cis	rs4638749	0.953	rs4676033	ENSG00000225328.1	AC019100.3	-5.28	2.7e-07	0.000127	-0.4	-0.31	Blood pressure;	chr2:108252912	chr2:108167748~108217841:-
KIRP	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	5.28	2.7e-07	0.000127	0.8	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
KIRP	cis	rs875971	0.545	rs316328	ENSG00000224316.1	RP11-479O9.2	-5.28	2.7e-07	0.000127	-0.25	-0.31	Aortic root size;	chr7:66143851	chr7:65773620~65802067:+
KIRP	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-5.28	2.7e-07	0.000127	-0.27	-0.31	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
KIRP	cis	rs1044826	0.692	rs295484	ENSG00000178631.7	ACTG1P1	-5.28	2.7e-07	0.000127	-0.32	-0.31	Obesity-related traits;	chr3:139512940	chr3:139493809~139494937:+
KIRP	cis	rs28386778	0.897	rs968719	ENSG00000240280.5	TCAM1P	-5.28	2.7e-07	0.000127	-0.39	-0.31	Prudent dietary pattern;	chr17:63830911	chr17:63849292~63864379:+
KIRP	cis	rs11773103	0.881	rs11971310	ENSG00000224046.1	AC005076.5	5.28	2.71e-07	0.000127	0.42	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87136326	chr7:87151423~87152420:-
KIRP	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-5.28	2.71e-07	0.000127	-0.32	-0.31	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
KIRP	cis	rs7747960	0.706	rs9397519	ENSG00000226193.1	RP3-398G3.5	-5.28	2.71e-07	0.000127	-0.45	-0.31	Bipolar disorder;	chr6:152504942	chr6:152402398~152404966:+
KIRP	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	5.28	2.71e-07	0.000127	0.38	0.31	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
KIRP	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	5.28	2.71e-07	0.000127	0.38	0.31	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
KIRP	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	5.28	2.71e-07	0.000127	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	5.28	2.71e-07	0.000127	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
KIRP	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	5.28	2.71e-07	0.000127	0.34	0.31	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
KIRP	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-5.28	2.71e-07	0.000127	-0.23	-0.31	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
KIRP	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	5.28	2.71e-07	0.000127	0.46	0.31	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	5.28	2.71e-07	0.000127	0.46	0.31	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	5.28	2.71e-07	0.000127	0.46	0.31	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	5.28	2.71e-07	0.000127	0.46	0.31	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
KIRP	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	5.28	2.72e-07	0.000127	0.29	0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
KIRP	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-5.28	2.72e-07	0.000127	-0.33	-0.31	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
KIRP	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-5.28	2.72e-07	0.000127	-0.33	-0.31	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
KIRP	cis	rs79040073	0.637	rs113885253	ENSG00000259531.2	RP11-295H24.3	5.28	2.72e-07	0.000127	0.42	0.31	Lung cancer in ever smokers;	chr15:49402615	chr15:49365124~49366685:-
KIRP	cis	rs11976180	0.569	rs12703565	ENSG00000228960.5	OR2A9P	-5.28	2.73e-07	0.000127	-0.49	-0.31	Obesity-related traits;	chr7:144057308	chr7:144294480~144300934:+
KIRP	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-5.28	2.73e-07	0.000128	-0.37	-0.31	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
KIRP	cis	rs4356975	0.83	rs57386454	ENSG00000196472.4	RP13-644M16.4	5.28	2.73e-07	0.000128	0.34	0.31	Obesity-related traits;	chr4:69052968	chr4:69181660~69182372:+
KIRP	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	5.28	2.73e-07	0.000128	0.44	0.31	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
KIRP	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	5.28	2.74e-07	0.000128	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
KIRP	cis	rs4356203	0.818	rs214927	ENSG00000272034.1	SNORD14A	-5.28	2.74e-07	0.000128	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17074654~17074744:-
KIRP	cis	rs4660214	0.724	rs11205695	ENSG00000237624.1	OXCT2P1	-5.28	2.74e-07	0.000128	-0.41	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39514956~39516490:+
KIRP	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	5.28	2.74e-07	0.000128	0.33	0.31	Height;	chr4:55490176	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	5.28	2.74e-07	0.000128	0.33	0.31	Height;	chr4:55490228	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	5.28	2.74e-07	0.000128	0.33	0.31	Height;	chr4:55491150	chr4:55363971~55395847:-
KIRP	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.28	2.74e-07	0.000128	-0.35	-0.31	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
KIRP	cis	rs67311347	0.544	rs1902073	ENSG00000230274.1	PGAM1P3	5.28	2.74e-07	0.000128	0.31	0.31	Renal cell carcinoma;	chr3:40292006	chr3:40322715~40323279:-
KIRP	cis	rs2154427	0.872	rs80141393	ENSG00000238197.4	PAXBP1-AS1	5.28	2.74e-07	0.000128	0.43	0.31	Bilirubin levels;	chr21:32725993	chr21:32728115~32743122:+
KIRP	cis	rs3892630	0.612	rs10413282	ENSG00000267475.1	CTD-2538C1.2	-5.28	2.75e-07	0.000129	-0.38	-0.31	Red blood cell traits;	chr19:32691845	chr19:32687089~32691750:-
KIRP	cis	rs4356975	0.83	rs72851338	ENSG00000196472.4	RP13-644M16.4	5.28	2.76e-07	0.000129	0.34	0.31	Obesity-related traits;	chr4:69052555	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs60212682	ENSG00000196472.4	RP13-644M16.4	5.28	2.76e-07	0.000129	0.34	0.31	Obesity-related traits;	chr4:69052849	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs72851348	ENSG00000196472.4	RP13-644M16.4	5.28	2.76e-07	0.000129	0.34	0.31	Obesity-related traits;	chr4:69054305	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs6422322	ENSG00000196472.4	RP13-644M16.4	5.28	2.76e-07	0.000129	0.34	0.31	Obesity-related traits;	chr4:69055571	chr4:69181660~69182372:+
KIRP	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	5.28	2.76e-07	0.000129	0.26	0.31	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
KIRP	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	5.28	2.76e-07	0.000129	0.25	0.31	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
KIRP	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	5.28	2.76e-07	0.000129	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
KIRP	cis	rs10050311	0.932	rs4693784	ENSG00000251411.1	RP11-397E7.4	-5.28	2.76e-07	0.000129	-0.38	-0.31	Insulin-related traits;	chr4:86802935	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.932	rs2287147	ENSG00000251411.1	RP11-397E7.4	-5.28	2.76e-07	0.000129	-0.38	-0.31	Insulin-related traits;	chr4:86811330	chr4:86913266~86914817:-
KIRP	cis	rs2273156	1	rs7141292	ENSG00000226677.3	IGBP1P1	-5.28	2.77e-07	0.000129	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993700	chr14:34939324~34940332:+
KIRP	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	5.28	2.77e-07	0.000129	0.24	0.31	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
KIRP	cis	rs1799949	0.602	rs8176257	ENSG00000279602.1	CTD-3014M21.1	-5.28	2.77e-07	0.000129	-0.3	-0.31	Menopause (age at onset);	chr17:43064188	chr17:43360041~43361361:-
KIRP	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	5.28	2.77e-07	0.000129	0.25	0.31	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
KIRP	cis	rs73198271	0.74	rs1039910	ENSG00000253981.4	ALG1L13P	-5.28	2.77e-07	0.000129	-0.26	-0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8236003~8244667:-
KIRP	cis	rs9532669	0.926	rs9532693	ENSG00000239827.7	SUGT1P3	-5.28	2.77e-07	0.000129	-0.35	-0.31	Cervical cancer;	chr13:40980557	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs2324748	ENSG00000239827.7	SUGT1P3	-5.28	2.77e-07	0.000129	-0.35	-0.31	Cervical cancer;	chr13:40989452	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs4245311	ENSG00000239827.7	SUGT1P3	-5.28	2.77e-07	0.000129	-0.35	-0.31	Cervical cancer;	chr13:40990003	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs35073784	ENSG00000239827.7	SUGT1P3	-5.28	2.77e-07	0.000129	-0.35	-0.31	Cervical cancer;	chr13:40993428	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs9594473	ENSG00000239827.7	SUGT1P3	-5.28	2.77e-07	0.000129	-0.35	-0.31	Cervical cancer;	chr13:40997997	chr13:40908159~40921774:-
KIRP	cis	rs9595908	0.869	rs9595962	ENSG00000212293.1	SNORA16	5.28	2.78e-07	0.00013	0.29	0.31	Body mass index;	chr13:32634429	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.869	rs2320301	ENSG00000212293.1	SNORA16	5.28	2.78e-07	0.00013	0.29	0.31	Body mass index;	chr13:32635067	chr13:32420390~32420516:-
KIRP	cis	rs4638749	0.501	rs1385957	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108138648	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs1486194	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108139435	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs1486193	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108139569	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs2129145	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108141866	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs2220261	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108142429	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs6715622	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108142916	chr2:108049200~108052755:-
KIRP	cis	rs4638749	0.501	rs1003018	ENSG00000231221.1	AC023672.2	-5.28	2.78e-07	0.00013	-0.37	-0.31	Blood pressure;	chr2:108144466	chr2:108049200~108052755:-
KIRP	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	5.28	2.78e-07	0.00013	0.38	0.31	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
KIRP	cis	rs10050311	0.746	rs17420607	ENSG00000251411.1	RP11-397E7.4	-5.28	2.78e-07	0.00013	-0.36	-0.31	Insulin-related traits;	chr4:86749048	chr4:86913266~86914817:-
KIRP	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	5.27	2.78e-07	0.00013	0.34	0.31	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
KIRP	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-5.27	2.78e-07	0.00013	-0.64	-0.31	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-5.27	2.78e-07	0.00013	-0.64	-0.31	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-5.27	2.78e-07	0.00013	-0.64	-0.31	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-5.27	2.78e-07	0.00013	-0.64	-0.31	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-5.27	2.78e-07	0.00013	-0.64	-0.31	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
KIRP	cis	rs4128705	1	rs2870310	ENSG00000249049.1	RP11-763F8.1	-5.27	2.78e-07	0.00013	-0.27	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91361746	chr4:91319034~91325306:-
KIRP	cis	rs950169	0.922	rs12910334	ENSG00000275120.1	RP11-182J1.17	5.27	2.79e-07	0.00013	0.43	0.31	Schizophrenia;	chr15:84403620	chr15:84599434~84606463:-
KIRP	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-5.27	2.79e-07	0.00013	-0.41	-0.31	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
KIRP	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	5.27	2.8e-07	0.00013	0.31	0.31	Height;	chr14:75038305	chr14:75011269~75012851:-
KIRP	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	5.27	2.8e-07	0.00013	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
KIRP	cis	rs2273156	1	rs17102970	ENSG00000226677.3	IGBP1P1	-5.27	2.8e-07	0.00013	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011363	chr14:34939324~34940332:+
KIRP	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-5.27	2.8e-07	0.00013	-0.43	-0.31	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
KIRP	cis	rs79040073	0.637	rs78050772	ENSG00000259531.2	RP11-295H24.3	5.27	2.8e-07	0.000131	0.45	0.31	Lung cancer in ever smokers;	chr15:49286380	chr15:49365124~49366685:-
KIRP	cis	rs67311347	0.544	rs13062243	ENSG00000230274.1	PGAM1P3	5.27	2.8e-07	0.000131	0.31	0.31	Renal cell carcinoma;	chr3:40295298	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.544	rs12054197	ENSG00000230274.1	PGAM1P3	5.27	2.8e-07	0.000131	0.31	0.31	Renal cell carcinoma;	chr3:40296071	chr3:40322715~40323279:-
KIRP	cis	rs712022	0.534	rs4494299	ENSG00000246225.5	RP11-17A1.3	-5.27	2.81e-07	0.000131	-0.36	-0.31	Dialysis-related mortality;	chr11:22850686	chr11:22829380~22945393:+
KIRP	cis	rs712022	0.534	rs7927085	ENSG00000246225.5	RP11-17A1.3	-5.27	2.81e-07	0.000131	-0.36	-0.31	Dialysis-related mortality;	chr11:22852337	chr11:22829380~22945393:+
KIRP	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-5.27	2.81e-07	0.000131	-0.32	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
KIRP	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.27	2.81e-07	0.000131	0.37	0.31	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
KIRP	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-5.27	2.81e-07	0.000131	-0.26	-0.31	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
KIRP	cis	rs28386778	0.897	rs2665831	ENSG00000240280.5	TCAM1P	-5.27	2.81e-07	0.000131	-0.39	-0.31	Prudent dietary pattern;	chr17:63835032	chr17:63849292~63864379:+
KIRP	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-5.27	2.81e-07	0.000131	-0.3	-0.31	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
KIRP	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-5.27	2.81e-07	0.000131	-0.3	-0.31	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
KIRP	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	5.27	2.82e-07	0.000131	0.33	0.31	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
KIRP	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	5.27	2.82e-07	0.000131	0.24	0.31	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
KIRP	cis	rs11864453	0.793	rs7197453	ENSG00000260886.1	TAT-AS1	5.27	2.82e-07	0.000131	0.39	0.31	Fibrinogen levels;	chr16:72045228	chr16:71565789~71578187:+
KIRP	cis	rs4646450	0.838	rs10257758	ENSG00000244219.5	GS1-259H13.2	-5.27	2.82e-07	0.000131	-0.35	-0.31	Blood metabolite levels;	chr7:99591365	chr7:99598066~99610813:+
KIRP	cis	rs77741769	0.529	rs525425	ENSG00000277423.1	RP11-173P15.9	-5.27	2.82e-07	0.000131	-0.33	-0.31	Mean corpuscular volume;	chr12:120757822	chr12:120703867~120704282:+
KIRP	cis	rs9595908	0.832	rs13378546	ENSG00000212293.1	SNORA16	5.27	2.82e-07	0.000131	0.31	0.31	Body mass index;	chr13:32631522	chr13:32420390~32420516:-
KIRP	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-5.27	2.82e-07	0.000131	-0.64	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
KIRP	cis	rs67311347	0.544	rs9814779	ENSG00000230274.1	PGAM1P3	5.27	2.82e-07	0.000131	0.31	0.31	Renal cell carcinoma;	chr3:40298940	chr3:40322715~40323279:-
KIRP	cis	rs1560104	0.536	rs12708760	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617071	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.576	rs12708761	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617077	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.597	rs13338316	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617168	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.597	rs13333850	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617231	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.597	rs13334919	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617300	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.597	rs13338716	ENSG00000274834.1	CTD-3037G24.5	5.27	2.82e-07	0.000131	0.34	0.31	Obesity-related traits;	chr16:12617477	chr16:12614451~12614852:+
KIRP	cis	rs4356975	0.83	rs4422474	ENSG00000196472.4	RP13-644M16.4	5.27	2.83e-07	0.000132	0.34	0.31	Obesity-related traits;	chr4:69051322	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs4377650	ENSG00000196472.4	RP13-644M16.4	5.27	2.83e-07	0.000132	0.34	0.31	Obesity-related traits;	chr4:69051355	chr4:69181660~69182372:+
KIRP	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	5.27	2.83e-07	0.000132	0.26	0.31	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	5.27	2.83e-07	0.000132	0.26	0.31	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	5.27	2.83e-07	0.000132	0.26	0.31	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
KIRP	cis	rs9402743	0.632	rs9389330	ENSG00000231028.7	LINC00271	5.27	2.83e-07	0.000132	0.27	0.31	Systemic lupus erythematosus;	chr6:135787865	chr6:135497801~135716055:+
KIRP	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-5.27	2.83e-07	0.000132	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-5.27	2.83e-07	0.000132	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-5.27	2.83e-07	0.000132	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-5.27	2.83e-07	0.000132	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-5.27	2.83e-07	0.000132	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
KIRP	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-5.27	2.84e-07	0.000132	-0.26	-0.31	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
KIRP	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-5.27	2.84e-07	0.000132	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
KIRP	cis	rs308403	0.568	rs13101575	ENSG00000224786.1	CETN4P	5.27	2.84e-07	0.000132	0.45	0.31	Blood protein levels;	chr4:122696406	chr4:122730548~122732193:-
KIRP	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-5.27	2.84e-07	0.000132	-0.34	-0.31	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
KIRP	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	5.27	2.84e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
KIRP	cis	rs9595908	0.869	rs9591191	ENSG00000212293.1	SNORA16	5.27	2.85e-07	0.000132	0.29	0.31	Body mass index;	chr13:32633397	chr13:32420390~32420516:-
KIRP	cis	rs28386778	0.897	rs8066754	ENSG00000240280.5	TCAM1P	-5.27	2.85e-07	0.000132	-0.39	-0.31	Prudent dietary pattern;	chr17:63739230	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs3826341	ENSG00000240280.5	TCAM1P	-5.27	2.85e-07	0.000132	-0.39	-0.31	Prudent dietary pattern;	chr17:63741862	chr17:63849292~63864379:+
KIRP	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-5.27	2.85e-07	0.000132	-0.54	-0.31	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
KIRP	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	5.27	2.85e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	5.27	2.85e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	5.27	2.85e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	5.27	2.85e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	5.27	2.85e-07	0.000132	0.31	0.31	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
KIRP	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	5.27	2.85e-07	0.000133	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
KIRP	cis	rs4927850	0.794	rs13070153	ENSG00000231464.1	AC024937.4	5.27	2.85e-07	0.000133	0.37	0.31	Pancreatic cancer;	chr3:196014314	chr3:195996738~195998233:+
KIRP	cis	rs1799949	0.536	rs4793227	ENSG00000236383.6	LINC00854	-5.27	2.85e-07	0.000133	-0.24	-0.31	Menopause (age at onset);	chr17:43334882	chr17:43216941~43305976:-
KIRP	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-5.27	2.86e-07	0.000133	-0.4	-0.31	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
KIRP	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	5.27	2.86e-07	0.000133	0.33	0.31	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
KIRP	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	5.27	2.86e-07	0.000133	0.24	0.31	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
KIRP	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	5.27	2.86e-07	0.000133	0.37	0.31	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
KIRP	cis	rs7829975	0.811	rs7011229	ENSG00000253981.4	ALG1L13P	-5.27	2.86e-07	0.000133	-0.24	-0.31	Mood instability;	chr8:8685814	chr8:8236003~8244667:-
KIRP	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-5.27	2.87e-07	0.000133	-0.29	-0.31	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
KIRP	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-5.27	2.87e-07	0.000133	-0.31	-0.31	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
KIRP	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-5.27	2.87e-07	0.000133	-0.25	-0.31	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
KIRP	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	5.27	2.87e-07	0.000133	0.26	0.31	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
KIRP	cis	rs7267979	1	rs2500424	ENSG00000274414.1	RP5-965G21.4	5.27	2.87e-07	0.000133	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25239007~25245229:-
KIRP	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.27	2.87e-07	0.000133	-0.38	-0.31	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
KIRP	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-5.27	2.87e-07	0.000134	-0.24	-0.31	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
KIRP	cis	rs2273156	1	rs7145608	ENSG00000226677.3	IGBP1P1	-5.27	2.87e-07	0.000134	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:34994291	chr14:34939324~34940332:+
KIRP	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-5.27	2.88e-07	0.000134	-0.41	-0.31	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
KIRP	cis	rs875971	0.545	rs67397473	ENSG00000224316.1	RP11-479O9.2	5.27	2.88e-07	0.000134	0.26	0.31	Aortic root size;	chr7:66168318	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs10950027	ENSG00000224316.1	RP11-479O9.2	5.27	2.88e-07	0.000134	0.26	0.31	Aortic root size;	chr7:66169164	chr7:65773620~65802067:+
KIRP	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	5.27	2.88e-07	0.000134	0.52	0.31	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
KIRP	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-5.27	2.88e-07	0.000134	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
KIRP	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	5.27	2.88e-07	0.000134	0.26	0.31	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
KIRP	cis	rs2483058	0.767	rs10779631	ENSG00000261000.1	RP11-534L20.5	5.27	2.88e-07	0.000134	0.33	0.31	Cholesterol and Triglycerides;	chr1:206448943	chr1:206503948~206504456:+
KIRP	cis	rs2483058	0.739	rs3860302	ENSG00000261000.1	RP11-534L20.5	5.27	2.88e-07	0.000134	0.33	0.31	Cholesterol and Triglycerides;	chr1:206451299	chr1:206503948~206504456:+
KIRP	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-5.27	2.89e-07	0.000134	-0.35	-0.31	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
KIRP	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	5.27	2.89e-07	0.000134	0.42	0.31	Depression;	chr6:28407125	chr6:28943877~28944537:+
KIRP	cis	rs10050311	0.586	rs2054592	ENSG00000251411.1	RP11-397E7.4	-5.27	2.89e-07	0.000134	-0.36	-0.31	Insulin-related traits;	chr4:86752292	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.746	rs17454662	ENSG00000251411.1	RP11-397E7.4	-5.27	2.89e-07	0.000134	-0.36	-0.31	Insulin-related traits;	chr4:86752611	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.746	rs72665791	ENSG00000251411.1	RP11-397E7.4	-5.27	2.89e-07	0.000134	-0.36	-0.31	Insulin-related traits;	chr4:86757634	chr4:86913266~86914817:-
KIRP	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	5.27	2.9e-07	0.000135	0.37	0.31	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
KIRP	cis	rs2645288	1	rs2645288	ENSG00000231365.4	RP11-418J17.1	-5.27	2.9e-07	0.000135	-0.35	-0.31	Breast size;	chr1:118957860	chr1:119140396~119275973:+
KIRP	cis	rs2361718	0.5	rs8068856	ENSG00000275479.1	RP11-334C17.6	5.27	2.91e-07	0.000135	0.25	0.31	Yeast infection;	chr17:80126932	chr17:80149627~80149798:+
KIRP	cis	rs1479119	0.681	rs1382679	ENSG00000180861.8	LINC01559	5.27	2.91e-07	0.000135	0.36	0.31	Intelligence (multi-trait analysis);	chr12:13346347	chr12:13371089~13387167:-
KIRP	cis	rs79040073	0.637	rs111375880	ENSG00000259531.2	RP11-295H24.3	5.27	2.91e-07	0.000135	0.43	0.31	Lung cancer in ever smokers;	chr15:49120197	chr15:49365124~49366685:-
KIRP	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	5.27	2.91e-07	0.000135	0.38	0.31	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
KIRP	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-5.27	2.91e-07	0.000135	-0.33	-0.31	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
KIRP	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-5.27	2.91e-07	0.000135	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
KIRP	cis	rs2625529	0.689	rs12898868	ENSG00000260037.4	CTD-2524L6.3	5.27	2.91e-07	0.000135	0.24	0.31	Red blood cell count;	chr15:71820577	chr15:71818396~71823384:+
KIRP	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	5.27	2.92e-07	0.000135	0.4	0.31	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
KIRP	cis	rs4443100	0.916	rs8139695	ENSG00000221069.1	AC000029.1	-5.27	2.92e-07	0.000135	-0.41	-0.31	Serum parathyroid hormone levels;	chr22:23031726	chr22:23136620~23136710:+
KIRP	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-5.27	2.92e-07	0.000135	-0.41	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
KIRP	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-5.27	2.92e-07	0.000135	-0.41	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
KIRP	cis	rs4356203	0.905	rs6486354	ENSG00000272034.1	SNORD14A	-5.27	2.92e-07	0.000135	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17074654~17074744:-
KIRP	cis	rs79040073	0.637	rs73398272	ENSG00000259531.2	RP11-295H24.3	5.27	2.92e-07	0.000136	0.41	0.31	Lung cancer in ever smokers;	chr15:49416426	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs73398276	ENSG00000259531.2	RP11-295H24.3	5.27	2.92e-07	0.000136	0.41	0.31	Lung cancer in ever smokers;	chr15:49418782	chr15:49365124~49366685:-
KIRP	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-5.27	2.92e-07	0.000136	-0.31	-0.31	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-5.27	2.92e-07	0.000136	-0.31	-0.31	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
KIRP	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	5.26	2.92e-07	0.000136	0.33	0.31	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
KIRP	cis	rs7267979	0.657	rs6107073	ENSG00000274973.1	RP13-401N8.7	-5.26	2.93e-07	0.000136	-0.33	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:25845497~25845862:+
KIRP	cis	rs61457372	0.527	rs9902482	ENSG00000264026.1	RP11-1124B17.1	-5.26	2.93e-07	0.000136	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72360852	chr17:72342940~72355136:+
KIRP	cis	rs1560104	0.576	rs7186154	ENSG00000274834.1	CTD-3037G24.5	5.26	2.93e-07	0.000136	0.35	0.31	Obesity-related traits;	chr16:12615650	chr16:12614451~12614852:+
KIRP	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	5.26	2.93e-07	0.000136	0.31	0.31	Height;	chr14:75123410	chr14:75011269~75012851:-
KIRP	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	5.26	2.94e-07	0.000136	0.47	0.31	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	5.26	2.94e-07	0.000136	0.47	0.31	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	5.26	2.94e-07	0.000136	0.47	0.31	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	5.26	2.94e-07	0.000136	0.47	0.31	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	5.26	2.94e-07	0.000136	0.47	0.31	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
KIRP	cis	rs28386778	0.831	rs2584618	ENSG00000240280.5	TCAM1P	-5.26	2.94e-07	0.000136	-0.39	-0.31	Prudent dietary pattern;	chr17:63846251	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2665796	ENSG00000240280.5	TCAM1P	-5.26	2.94e-07	0.000136	-0.39	-0.31	Prudent dietary pattern;	chr17:63846356	chr17:63849292~63864379:+
KIRP	cis	rs4128705	1	rs10516892	ENSG00000249049.1	RP11-763F8.1	5.26	2.94e-07	0.000136	0.27	0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91362969	chr4:91319034~91325306:-
KIRP	cis	rs67311347	0.544	rs6769627	ENSG00000230274.1	PGAM1P3	5.26	2.94e-07	0.000136	0.31	0.31	Renal cell carcinoma;	chr3:40286354	chr3:40322715~40323279:-
KIRP	cis	rs2283792	1	rs6928	ENSG00000228050.1	TOP3BP1	5.26	2.94e-07	0.000136	0.33	0.31	Multiple sclerosis;	chr22:21760715	chr22:22223187~22224566:-
KIRP	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	5.26	2.94e-07	0.000136	0.34	0.31	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
KIRP	cis	rs4356203	0.87	rs214900	ENSG00000272034.1	SNORD14A	5.26	2.95e-07	0.000136	0.26	0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17074654~17074744:-
KIRP	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
KIRP	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	5.26	2.95e-07	0.000137	0.33	0.31	Height;	chr4:55573424	chr4:55363971~55395847:-
KIRP	cis	rs1552244	0.935	rs66493421	ENSG00000180385.7	EMC3-AS1	5.26	2.95e-07	0.000137	0.36	0.31	Alzheimer's disease;	chr3:10050885	chr3:9986893~10006990:+
KIRP	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-5.26	2.95e-07	0.000137	-0.26	-0.31	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
KIRP	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-5.26	2.96e-07	0.000137	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
KIRP	cis	rs4356203	0.875	rs11024136	ENSG00000272034.1	SNORD14A	-5.26	2.96e-07	0.000137	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17074654~17074744:-
KIRP	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	5.26	2.96e-07	0.000137	0.31	0.31	Height;	chr14:75045909	chr14:75011269~75012851:-
KIRP	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	5.26	2.97e-07	0.000137	0.23	0.31	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
KIRP	cis	rs28386778	0.897	rs1062791	ENSG00000240280.5	TCAM1P	-5.26	2.98e-07	0.000138	-0.4	-0.31	Prudent dietary pattern;	chr17:63819127	chr17:63849292~63864379:+
KIRP	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	5.26	2.98e-07	0.000138	0.46	0.31	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
KIRP	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-5.26	2.98e-07	0.000138	-0.27	-0.31	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
KIRP	cis	rs950169	0.922	rs2033284	ENSG00000275120.1	RP11-182J1.17	5.26	2.99e-07	0.000138	0.43	0.31	Schizophrenia;	chr15:84391575	chr15:84599434~84606463:-
KIRP	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	5.26	2.99e-07	0.000138	0.46	0.31	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
KIRP	cis	rs11647589	0.636	rs7186805	ENSG00000262995.1	CTD-2194A8.2	-5.26	2.99e-07	0.000138	-0.35	-0.31	Blood metabolite levels;	chr16:20465841	chr16:20440266~20447000:-
KIRP	cis	rs11647589	0.636	rs7186307	ENSG00000262995.1	CTD-2194A8.2	-5.26	2.99e-07	0.000138	-0.35	-0.31	Blood metabolite levels;	chr16:20465843	chr16:20440266~20447000:-
KIRP	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-5.26	2.99e-07	0.000138	-0.37	-0.31	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-5.26	2.99e-07	0.000138	-0.37	-0.31	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-5.26	2.99e-07	0.000138	-0.37	-0.31	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-5.26	2.99e-07	0.000138	-0.37	-0.31	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
KIRP	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-5.26	2.99e-07	0.000138	-0.4	-0.31	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
KIRP	cis	rs77204473	1	rs17120177	ENSG00000254851.1	RP11-109L13.1	5.26	2.99e-07	0.000138	0.8	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116956653	chr11:117135528~117138582:+
KIRP	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	5.26	3e-07	0.000139	0.38	0.31	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
KIRP	cis	rs9925964	0.748	rs11640961	ENSG00000232748.3	RP11-196G11.6	5.26	3e-07	0.000139	0.37	0.31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:31056460~31062803:+
KIRP	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	5.26	3e-07	0.000139	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
KIRP	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-5.26	3e-07	0.000139	-0.62	-0.31	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-5.26	3e-07	0.000139	-0.62	-0.31	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-5.26	3e-07	0.000139	-0.62	-0.31	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
KIRP	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	5.26	3e-07	0.000139	0.38	0.31	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
KIRP	cis	rs4934494	0.768	rs1409357	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89669719	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs17125834	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89673405	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs12571918	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89674920	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs12776306	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89676300	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs7078321	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89678341	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs34379399	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89683526	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs17126269	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89694974	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs768805	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89695448	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs12571268	ENSG00000232936.4	RP11-80H5.2	5.26	3e-07	0.000139	0.47	0.31	Red blood cell count;	chr10:89698830	chr10:89645282~89650667:+
KIRP	cis	rs4356975	0.83	rs6600865	ENSG00000196472.4	RP13-644M16.4	5.26	3e-07	0.000139	0.33	0.31	Obesity-related traits;	chr4:69057904	chr4:69181660~69182372:+
KIRP	cis	rs2283792	0.935	rs9610375	ENSG00000228050.1	TOP3BP1	5.26	3.01e-07	0.000139	0.35	0.31	Multiple sclerosis;	chr22:21832804	chr22:22223187~22224566:-
KIRP	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-5.26	3.01e-07	0.000139	-0.4	-0.31	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
KIRP	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	5.26	3.01e-07	0.000139	0.37	0.31	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
KIRP	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-5.26	3.01e-07	0.000139	-0.3	-0.31	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
KIRP	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-5.26	3.01e-07	0.000139	-0.3	-0.31	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
KIRP	cis	rs12908161	0.96	rs11633450	ENSG00000275120.1	RP11-182J1.17	5.26	3.02e-07	0.00014	0.4	0.31	Schizophrenia;	chr15:84764056	chr15:84599434~84606463:-
KIRP	cis	rs2273156	1	rs8018114	ENSG00000226677.3	IGBP1P1	-5.26	3.02e-07	0.00014	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000813	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12880809	ENSG00000226677.3	IGBP1P1	-5.26	3.02e-07	0.00014	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006450	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12880928	ENSG00000226677.3	IGBP1P1	-5.26	3.02e-07	0.00014	-0.33	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006472	chr14:34939324~34940332:+
KIRP	cis	rs10078	0.571	rs890977	ENSG00000221990.4	EXOC3-AS1	5.26	3.03e-07	0.00014	0.42	0.31	Fat distribution (HIV);	chr5:476795	chr5:441498~443160:-
KIRP	cis	rs453301	0.571	rs330057	ENSG00000253981.4	ALG1L13P	-5.26	3.03e-07	0.00014	-0.25	-0.31	Joint mobility (Beighton score);	chr8:9232283	chr8:8236003~8244667:-
KIRP	cis	rs9388451	0.807	rs1268070	ENSG00000237742.5	RP11-624M8.1	-5.26	3.03e-07	0.00014	-0.33	-0.31	Brugada syndrome;	chr6:125720018	chr6:125578558~125749190:-
KIRP	cis	rs1799949	1	rs8176109	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43113759	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.896	rs8176098	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43116189	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.896	rs8176086	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43122761	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.93	rs3765640	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43124230	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs8176077	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43124331	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs11655505	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43126360	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs4793204	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43127281	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs12947782	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43127865	chr17:43216941~43305976:-
KIRP	cis	rs1799949	1	rs33945274	ENSG00000236383.6	LINC00854	-5.26	3.03e-07	0.00014	-0.25	-0.31	Menopause (age at onset);	chr17:43128056	chr17:43216941~43305976:-
KIRP	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	5.26	3.03e-07	0.00014	0.53	0.31	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	5.26	3.03e-07	0.00014	0.53	0.31	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
KIRP	cis	rs11773103	0.881	rs73204813	ENSG00000224046.1	AC005076.5	5.26	3.03e-07	0.00014	0.42	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87137427	chr7:87151423~87152420:-
KIRP	cis	rs1479119	0.681	rs10772655	ENSG00000180861.8	LINC01559	5.26	3.04e-07	0.00014	0.36	0.31	Intelligence (multi-trait analysis);	chr12:13345447	chr12:13371089~13387167:-
KIRP	cis	rs12571093	0.773	rs3740588	ENSG00000233590.1	RP11-153K11.3	5.26	3.04e-07	0.00014	0.48	0.31	Optic nerve measurement (disc area);	chr10:68261079	chr10:68233251~68242379:-
KIRP	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-5.26	3.04e-07	0.00014	-0.41	-0.31	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
KIRP	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-5.26	3.04e-07	0.000141	-0.33	-0.31	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
KIRP	cis	rs4660214	0.614	rs1537815	ENSG00000237624.1	OXCT2P1	-5.26	3.05e-07	0.000141	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.789	rs1984142	ENSG00000237624.1	OXCT2P1	-5.26	3.05e-07	0.000141	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39514956~39516490:+
KIRP	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	5.26	3.05e-07	0.000141	0.41	0.31	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
KIRP	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	5.26	3.05e-07	0.000141	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
KIRP	cis	rs11148252	0.716	rs1887360	ENSG00000278238.1	RP11-245D16.4	-5.26	3.05e-07	0.000141	-0.34	-0.31	Lewy body disease;	chr13:52205031	chr13:52454775~52455331:-
KIRP	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	5.26	3.05e-07	0.000141	0.45	0.31	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
KIRP	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	5.26	3.05e-07	0.000141	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
KIRP	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	5.26	3.05e-07	0.000141	0.28	0.31	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
KIRP	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-5.26	3.05e-07	0.000141	-0.32	-0.31	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-5.26	3.06e-07	0.000141	-0.37	-0.31	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
KIRP	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-5.26	3.06e-07	0.000141	-0.34	-0.31	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-5.26	3.06e-07	0.000141	-0.34	-0.31	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
KIRP	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-5.26	3.06e-07	0.000141	-0.34	-0.31	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
KIRP	cis	rs1799949	1	rs11653231	ENSG00000279602.1	CTD-3014M21.1	-5.26	3.06e-07	0.000141	-0.29	-0.31	Menopause (age at onset);	chr17:43179443	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs1399323	ENSG00000279602.1	CTD-3014M21.1	-5.26	3.06e-07	0.000141	-0.29	-0.31	Menopause (age at onset);	chr17:43180313	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs35954893	ENSG00000279602.1	CTD-3014M21.1	-5.26	3.06e-07	0.000141	-0.29	-0.31	Menopause (age at onset);	chr17:43181769	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.93	rs4445938	ENSG00000279602.1	CTD-3014M21.1	-5.26	3.06e-07	0.000141	-0.29	-0.31	Menopause (age at onset);	chr17:43185883	chr17:43360041~43361361:-
KIRP	cis	rs7267979	1	rs884613	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs1888998	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2500433	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2482948	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2482919	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6037086	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2482923	ENSG00000274414.1	RP5-965G21.4	5.26	3.06e-07	0.000141	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258719	ENSG00000274414.1	RP5-965G21.4	-5.26	3.06e-07	0.000141	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.933	rs2424708	ENSG00000274414.1	RP5-965G21.4	-5.26	3.06e-07	0.000141	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-5.26	3.07e-07	0.000141	-0.37	-0.31	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
KIRP	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-5.26	3.07e-07	0.000141	-0.4	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
KIRP	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-5.26	3.07e-07	0.000142	-0.27	-0.31	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-5.26	3.07e-07	0.000142	-0.27	-0.31	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-5.26	3.07e-07	0.000142	-0.27	-0.31	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-5.26	3.07e-07	0.000142	-0.27	-0.31	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
KIRP	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	5.26	3.07e-07	0.000142	0.33	0.31	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
KIRP	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-5.25	3.08e-07	0.000142	-0.26	-0.31	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-5.25	3.08e-07	0.000142	-0.26	-0.31	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
KIRP	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-5.25	3.08e-07	0.000142	-0.32	-0.31	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
KIRP	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-5.25	3.08e-07	0.000142	-0.33	-0.31	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-5.25	3.08e-07	0.000142	-0.33	-0.31	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
KIRP	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-5.25	3.08e-07	0.000142	-0.35	-0.31	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
KIRP	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-5.25	3.08e-07	0.000142	-0.5	-0.31	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
KIRP	cis	rs950169	0.881	rs150965	ENSG00000275120.1	RP11-182J1.17	5.25	3.08e-07	0.000142	0.42	0.31	Schizophrenia;	chr15:84537296	chr15:84599434~84606463:-
KIRP	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	5.25	3.08e-07	0.000142	0.36	0.31	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
KIRP	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-5.25	3.08e-07	0.000142	-0.35	-0.31	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-5.25	3.08e-07	0.000142	-0.35	-0.31	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
KIRP	cis	rs7267979	0.932	rs433352	ENSG00000274414.1	RP5-965G21.4	5.25	3.08e-07	0.000142	0.29	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25239007~25245229:-
KIRP	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-5.25	3.09e-07	0.000142	-0.32	-0.31	Height;	chr3:53069965	chr3:53064283~53065091:-
KIRP	cis	rs7569084	0.687	rs6755006	ENSG00000237979.1	AC007389.1	-5.25	3.09e-07	0.000142	-0.36	-0.31	Sum eosinophil basophil counts;	chr2:65426008	chr2:65500993~65502138:-
KIRP	cis	rs7569084	0.687	rs6755128	ENSG00000237979.1	AC007389.1	-5.25	3.09e-07	0.000142	-0.36	-0.31	Sum eosinophil basophil counts;	chr2:65426065	chr2:65500993~65502138:-
KIRP	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	5.25	3.09e-07	0.000142	0.83	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
KIRP	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	5.25	3.09e-07	0.000142	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
KIRP	cis	rs11773103	0.881	rs73204826	ENSG00000224046.1	AC005076.5	5.25	3.09e-07	0.000142	0.43	0.31	Bipolar disorder or major depressive disorder (combined);	chr7:87144942	chr7:87151423~87152420:-
KIRP	cis	rs11085466	0.615	rs76695906	ENSG00000268555.1	RP11-678G14.3	5.25	3.09e-07	0.000142	0.41	0.31	Colorectal or endometrial cancer;	chr19:21583908	chr19:21570822~21587322:-
KIRP	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	5.25	3.09e-07	0.000142	0.31	0.31	Height;	chr14:75093260	chr14:75011269~75012851:-
KIRP	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.25	3.09e-07	0.000142	0.34	0.31	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
KIRP	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-5.25	3.09e-07	0.000143	-0.33	-0.31	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
KIRP	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	5.25	3.09e-07	0.000143	0.29	0.31	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
KIRP	cis	rs4356203	0.905	rs7396382	ENSG00000272034.1	SNORD14A	5.25	3.1e-07	0.000143	0.26	0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17074654~17074744:-
KIRP	cis	rs6496932	0.635	rs4356428	ENSG00000218052.5	ADAMTS7P4	-5.25	3.1e-07	0.000143	-0.45	-0.31	Central corneal thickness;Corneal structure;	chr15:85386349	chr15:85255369~85330334:-
KIRP	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	5.25	3.1e-07	0.000143	0.46	0.31	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
KIRP	cis	rs28386778	0.897	rs2584610	ENSG00000240280.5	TCAM1P	-5.25	3.1e-07	0.000143	-0.39	-0.31	Prudent dietary pattern;	chr17:63857423	chr17:63849292~63864379:+
KIRP	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.25	3.11e-07	0.000143	-0.26	-0.31	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
KIRP	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.25	3.11e-07	0.000143	0.44	0.31	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
KIRP	cis	rs984222	0.775	rs2645294	ENSG00000231365.4	RP11-418J17.1	-5.25	3.11e-07	0.000143	-0.28	-0.31	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119031964	chr1:119140396~119275973:+
KIRP	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-5.25	3.11e-07	0.000143	-0.33	-0.31	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-5.25	3.11e-07	0.000143	-0.33	-0.31	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
KIRP	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-5.25	3.11e-07	0.000143	-0.33	-0.31	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
KIRP	cis	rs4660214	0.724	rs7554301	ENSG00000237624.1	OXCT2P1	-5.25	3.12e-07	0.000143	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39514956~39516490:+
KIRP	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	5.25	3.12e-07	0.000144	0.33	0.31	Height;	chr4:55561053	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	5.25	3.12e-07	0.000144	0.33	0.31	Height;	chr4:55564241	chr4:55363971~55395847:-
KIRP	cis	rs2269497	0.59	rs2515955	ENSG00000199335.1	RNU6-204P	5.25	3.12e-07	0.000144	0.74	0.31	Tuberculosis;	chr4:3058663	chr4:3044101~3044207:+
KIRP	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-5.25	3.12e-07	0.000144	-0.36	-0.31	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
KIRP	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	5.25	3.12e-07	0.000144	0.28	0.31	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
KIRP	cis	rs7224610	0.702	rs3829578	ENSG00000263096.1	RP11-515O17.2	5.25	3.12e-07	0.000144	0.4	0.31	Urate levels;	chr17:55304149	chr17:55271504~55273653:-
KIRP	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-5.25	3.13e-07	0.000144	-0.35	-0.31	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
KIRP	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	5.25	3.13e-07	0.000144	0.26	0.31	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
KIRP	cis	rs13113518	1	rs13132420	ENSG00000272969.1	RP11-528I4.2	-5.25	3.13e-07	0.000144	-0.29	-0.31	Height;	chr4:55526646	chr4:55547112~55547889:+
KIRP	cis	rs7267979	1	rs2500418	ENSG00000274414.1	RP5-965G21.4	5.25	3.13e-07	0.000144	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25239007~25245229:-
KIRP	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	5.25	3.14e-07	0.000144	0.36	0.31	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
KIRP	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	5.25	3.14e-07	0.000144	0.48	0.31	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	5.25	3.14e-07	0.000144	0.48	0.31	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-5.25	3.14e-07	0.000145	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
KIRP	cis	rs11864453	1	rs7185407	ENSG00000260886.1	TAT-AS1	-5.25	3.14e-07	0.000145	-0.36	-0.31	Fibrinogen levels;	chr16:72001058	chr16:71565789~71578187:+
KIRP	cis	rs4578769	0.569	rs4800431	ENSG00000265943.1	RP11-739L10.1	5.25	3.14e-07	0.000145	0.39	0.31	Eosinophil percentage of white cells;	chr18:22803499	chr18:22699481~22933764:-
KIRP	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-5.25	3.14e-07	0.000145	-0.47	-0.31	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
KIRP	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs4638645	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63750989	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.805	rs9911714	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63751592	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs4968599	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63758632	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs67905415	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63763876	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs3744293	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63764428	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs6504184	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63765048	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs8081454	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63765286	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs58269663	ENSG00000240280.5	TCAM1P	-5.25	3.15e-07	0.000145	-0.39	-0.31	Prudent dietary pattern;	chr17:63765770	chr17:63849292~63864379:+
KIRP	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-5.25	3.15e-07	0.000145	-0.37	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
KIRP	cis	rs4356975	0.563	rs7657423	ENSG00000196472.4	RP13-644M16.4	-5.25	3.15e-07	0.000145	-0.34	-0.31	Obesity-related traits;	chr4:69090196	chr4:69181660~69182372:+
KIRP	cis	rs10246939	0.543	rs7786202	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141906099	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs7802271	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141909624	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.52	rs7782886	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141909958	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs994808	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141911091	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs7808421	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141911592	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs7789123	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141911699	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs11769089	ENSG00000228775.6	WEE2-AS1	5.25	3.15e-07	0.000145	0.33	0.31	Bitter taste perception;	chr7:141914310	chr7:141704338~141738346:-
KIRP	cis	rs713477	0.967	rs34652660	ENSG00000258413.1	RP11-665C16.6	5.25	3.15e-07	0.000145	0.39	0.31	Pediatric bone mineral content (femoral neck);	chr14:55452762	chr14:55262767~55272075:-
KIRP	cis	rs4356975	0.563	rs4535394	ENSG00000196472.4	RP13-644M16.4	-5.25	3.15e-07	0.000145	-0.33	-0.31	Obesity-related traits;	chr4:69122735	chr4:69181660~69182372:+
KIRP	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-5.25	3.15e-07	0.000145	-0.33	-0.31	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
KIRP	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-5.25	3.16e-07	0.000145	-0.27	-0.31	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
KIRP	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-5.25	3.16e-07	0.000145	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
KIRP	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	5.25	3.16e-07	0.000145	0.48	0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
KIRP	cis	rs4934494	0.635	rs12572869	ENSG00000232936.4	RP11-80H5.2	5.25	3.16e-07	0.000145	0.46	0.31	Red blood cell count;	chr10:89653611	chr10:89645282~89650667:+
KIRP	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-5.25	3.16e-07	0.000145	-0.63	-0.31	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
KIRP	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	5.25	3.17e-07	0.000145	0.38	0.31	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
KIRP	cis	rs2230624	1	rs76823085	ENSG00000242349.4	NPPA-AS1	-5.25	3.17e-07	0.000145	-0.55	-0.31	Mosquito bite size;	chr1:11823491	chr1:11841017~11848079:+
KIRP	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-5.25	3.17e-07	0.000145	-0.36	-0.31	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
KIRP	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	5.25	3.17e-07	0.000146	0.26	0.31	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
KIRP	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-5.25	3.17e-07	0.000146	-0.3	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
KIRP	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-5.25	3.17e-07	0.000146	-0.42	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
KIRP	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-5.25	3.17e-07	0.000146	-0.42	-0.31	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
KIRP	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	5.25	3.18e-07	0.000146	0.26	0.31	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	5.25	3.18e-07	0.000146	0.26	0.31	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	5.25	3.18e-07	0.000146	0.26	0.31	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	5.25	3.18e-07	0.000146	0.26	0.31	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	5.25	3.18e-07	0.000146	0.26	0.31	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
KIRP	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	5.25	3.18e-07	0.000146	0.33	0.31	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
KIRP	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-5.25	3.18e-07	0.000146	-0.3	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-5.25	3.18e-07	0.000146	-0.3	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
KIRP	cis	rs4578769	0.569	rs1597239	ENSG00000265943.1	RP11-739L10.1	5.25	3.18e-07	0.000146	0.39	0.31	Eosinophil percentage of white cells;	chr18:22805673	chr18:22699481~22933764:-
KIRP	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	-5.25	3.18e-07	0.000146	-0.24	-0.31	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
KIRP	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-5.25	3.19e-07	0.000146	-0.63	-0.31	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-5.25	3.19e-07	0.000146	-0.63	-0.31	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-5.25	3.19e-07	0.000146	-0.63	-0.31	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-5.25	3.19e-07	0.000146	-0.63	-0.31	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
KIRP	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	5.25	3.19e-07	0.000146	0.46	0.31	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	5.25	3.19e-07	0.000146	0.46	0.31	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	5.25	3.19e-07	0.000146	0.46	0.31	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
KIRP	cis	rs2154427	0.872	rs76549663	ENSG00000238197.4	PAXBP1-AS1	5.25	3.19e-07	0.000147	0.43	0.31	Bilirubin levels;	chr21:32727457	chr21:32728115~32743122:+
KIRP	cis	rs2154427	0.872	rs78882615	ENSG00000238197.4	PAXBP1-AS1	5.25	3.19e-07	0.000147	0.43	0.31	Bilirubin levels;	chr21:32728337	chr21:32728115~32743122:+
KIRP	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-5.25	3.19e-07	0.000147	-0.31	-0.31	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
KIRP	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-5.25	3.2e-07	0.000147	-0.33	-0.31	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
KIRP	cis	rs2946504	1	rs2946504	ENSG00000251468.2	RP11-369K16.1	-5.25	3.2e-07	0.000147	-0.42	-0.31	Type 2 diabetes;	chr8:12954071	chr8:12958387~12962200:+
KIRP	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	5.25	3.2e-07	0.000147	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
KIRP	cis	rs950169	0.92	rs11637666	ENSG00000259728.4	LINC00933	5.25	3.2e-07	0.000147	0.42	0.31	Schizophrenia;	chr15:84035122	chr15:84570649~84580175:+
KIRP	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-5.25	3.2e-07	0.000147	-0.25	-0.31	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
KIRP	cis	rs2976388	1	rs2294010	ENSG00000253741.1	CTD-2292P10.4	5.25	3.2e-07	0.000147	0.35	0.31	Urinary tract infection frequency;	chr8:142681012	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2978982	ENSG00000253741.1	CTD-2292P10.4	5.25	3.2e-07	0.000147	0.35	0.31	Urinary tract infection frequency;	chr8:142682072	chr8:142702252~142726973:-
KIRP	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	5.25	3.2e-07	0.000147	0.26	0.31	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
KIRP	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	5.25	3.2e-07	0.000147	0.36	0.31	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
KIRP	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	5.25	3.2e-07	0.000147	0.36	0.31	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
KIRP	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-5.25	3.21e-07	0.000147	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-5.25	3.21e-07	0.000147	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-5.25	3.21e-07	0.000147	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
KIRP	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	5.25	3.21e-07	0.000147	0.45	0.31	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
KIRP	cis	rs1552244	0.882	rs13100734	ENSG00000180385.7	EMC3-AS1	5.25	3.21e-07	0.000147	0.3	0.31	Alzheimer's disease;	chr3:9981194	chr3:9986893~10006990:+
KIRP	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-5.25	3.21e-07	0.000147	-0.36	-0.31	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
KIRP	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-5.25	3.21e-07	0.000147	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
KIRP	cis	rs10916248	0.788	rs7543027	ENSG00000232628.4	RP11-365O16.3	5.25	3.21e-07	0.000147	0.39	0.31	QT interval (drug interaction);	chr1:224072795	chr1:224208747~224213279:-
KIRP	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	5.25	3.21e-07	0.000147	0.35	0.31	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
KIRP	cis	rs7267979	0.932	rs6115214	ENSG00000274414.1	RP5-965G21.4	5.25	3.21e-07	0.000147	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25239007~25245229:-
KIRP	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	5.25	3.21e-07	0.000147	0.28	0.31	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
KIRP	cis	rs1858037	0.867	rs61226353	ENSG00000281920.1	RP11-418H16.1	5.25	3.21e-07	0.000147	0.4	0.31	Rheumatoid arthritis;	chr2:65363637	chr2:65623272~65628424:+
KIRP	cis	rs2043112	0.964	rs10461998	ENSG00000249911.1	LINC01265	5.25	3.22e-07	0.000147	0.36	0.31	Obesity-related traits;	chr5:38984695	chr5:38710367~38720273:-
KIRP	cis	rs2976388	1	rs2976392	ENSG00000253741.1	CTD-2292P10.4	5.25	3.22e-07	0.000147	0.35	0.31	Urinary tract infection frequency;	chr8:142681514	chr8:142702252~142726973:-
KIRP	cis	rs79040073	0.563	rs17479003	ENSG00000259531.2	RP11-295H24.3	5.25	3.22e-07	0.000148	0.41	0.31	Lung cancer in ever smokers;	chr15:49453223	chr15:49365124~49366685:-
KIRP	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	5.25	3.22e-07	0.000148	0.56	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
KIRP	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-5.25	3.22e-07	0.000148	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
KIRP	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-5.25	3.22e-07	0.000148	-0.35	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
KIRP	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	5.25	3.22e-07	0.000148	0.39	0.31	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	5.25	3.22e-07	0.000148	0.39	0.31	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
KIRP	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-5.24	3.23e-07	0.000148	-0.63	-0.31	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
KIRP	cis	rs1560104	0.597	rs881667	ENSG00000274834.1	CTD-3037G24.5	5.24	3.23e-07	0.000148	0.34	0.31	Obesity-related traits;	chr16:12618569	chr16:12614451~12614852:+
KIRP	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-5.24	3.23e-07	0.000148	-0.35	-0.31	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
KIRP	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-5.24	3.23e-07	0.000148	-0.35	-0.31	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-5.24	3.23e-07	0.000148	-0.35	-0.31	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-5.24	3.23e-07	0.000148	-0.35	-0.31	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
KIRP	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-5.24	3.23e-07	0.000148	-0.27	-0.31	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
KIRP	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	5.24	3.23e-07	0.000148	0.31	0.31	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
KIRP	cis	rs9925964	0.748	rs4889603	ENSG00000232748.3	RP11-196G11.6	-5.24	3.23e-07	0.000148	-0.37	-0.31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31056460~31062803:+
KIRP	cis	rs4660214	0.666	rs61783383	ENSG00000237624.1	OXCT2P1	-5.24	3.23e-07	0.000148	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs6704246	ENSG00000237624.1	OXCT2P1	-5.24	3.23e-07	0.000148	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs597311	ENSG00000237624.1	OXCT2P1	5.24	3.23e-07	0.000148	0.39	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.615	rs597708	ENSG00000237624.1	OXCT2P1	5.24	3.23e-07	0.000148	0.39	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs636156	ENSG00000237624.1	OXCT2P1	5.24	3.23e-07	0.000148	0.39	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.724	rs10888683	ENSG00000237624.1	OXCT2P1	5.24	3.23e-07	0.000148	0.4	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs2275187	ENSG00000237624.1	OXCT2P1	-5.24	3.23e-07	0.000148	-0.41	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39514956~39516490:+
KIRP	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-5.24	3.23e-07	0.000148	-0.31	-0.31	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
KIRP	cis	rs12050794	0.671	rs62022788	ENSG00000260037.4	CTD-2524L6.3	5.24	3.24e-07	0.000148	0.24	0.31	Metabolite levels (HVA/MHPG ratio);	chr15:72266985	chr15:71818396~71823384:+
KIRP	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-5.24	3.24e-07	0.000148	-0.37	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-5.24	3.24e-07	0.000148	-0.37	-0.31	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
KIRP	cis	rs10050311	0.932	rs72665795	ENSG00000251411.1	RP11-397E7.4	-5.24	3.24e-07	0.000148	-0.38	-0.31	Insulin-related traits;	chr4:86812000	chr4:86913266~86914817:-
KIRP	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	5.24	3.24e-07	0.000149	0.42	0.31	Height;	chr6:109340338	chr6:109382795~109383666:+
KIRP	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	5.24	3.25e-07	0.000149	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
KIRP	cis	rs875971	0.545	rs2707851	ENSG00000224316.1	RP11-479O9.2	-5.24	3.25e-07	0.000149	-0.25	-0.31	Aortic root size;	chr7:66624178	chr7:65773620~65802067:+
KIRP	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	5.24	3.25e-07	0.000149	0.26	0.31	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
KIRP	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-5.24	3.25e-07	0.000149	-0.42	-0.31	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
KIRP	cis	rs3745672	1	rs113790048	ENSG00000219665.7	CTD-2006C1.2	-5.24	3.26e-07	0.000149	-0.69	-0.31	Multiple sclerosis;	chr19:12013180	chr19:11987617~12046275:+
KIRP	cis	rs3745672	0.661	rs111970048	ENSG00000219665.7	CTD-2006C1.2	-5.24	3.26e-07	0.000149	-0.69	-0.31	Multiple sclerosis;	chr19:12013192	chr19:11987617~12046275:+
KIRP	cis	rs3745672	1	rs112074246	ENSG00000219665.7	CTD-2006C1.2	-5.24	3.26e-07	0.000149	-0.69	-0.31	Multiple sclerosis;	chr19:12017206	chr19:11987617~12046275:+
KIRP	cis	rs3745672	1	rs10420683	ENSG00000219665.7	CTD-2006C1.2	-5.24	3.26e-07	0.000149	-0.69	-0.31	Multiple sclerosis;	chr19:12022954	chr19:11987617~12046275:+
KIRP	cis	rs11673344	0.504	rs7252940	ENSG00000226686.6	LINC01535	5.24	3.26e-07	0.000149	0.37	0.31	Obesity-related traits;	chr19:37138589	chr19:37251912~37265535:+
KIRP	cis	rs5758659	1	rs134869	ENSG00000205702.9	CYP2D7	5.24	3.26e-07	0.000149	0.24	0.31	Cognitive function;	chr22:42256068	chr22:42140203~42144577:-
KIRP	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-5.24	3.26e-07	0.000149	-0.63	-0.31	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
KIRP	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	5.24	3.27e-07	0.00015	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
KIRP	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	5.24	3.27e-07	0.00015	0.29	0.31	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
KIRP	cis	rs11085466	1	rs75211977	ENSG00000268555.1	RP11-678G14.3	5.24	3.27e-07	0.00015	0.41	0.31	Colorectal or endometrial cancer;	chr19:21577399	chr19:21570822~21587322:-
KIRP	cis	rs11085466	0.948	rs76881507	ENSG00000268555.1	RP11-678G14.3	5.24	3.27e-07	0.00015	0.41	0.31	Colorectal or endometrial cancer;	chr19:21579387	chr19:21570822~21587322:-
KIRP	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	5.24	3.28e-07	0.00015	0.38	0.31	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
KIRP	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	5.24	3.29e-07	0.00015	0.38	0.31	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
KIRP	cis	rs7829975	0.533	rs1039917	ENSG00000253981.4	ALG1L13P	5.24	3.29e-07	0.000151	0.25	0.31	Mood instability;	chr8:8861340	chr8:8236003~8244667:-
KIRP	cis	rs4934494	0.768	rs12572608	ENSG00000232936.4	RP11-80H5.2	-5.24	3.29e-07	0.000151	-0.46	-0.31	Red blood cell count;	chr10:89647170	chr10:89645282~89650667:+
KIRP	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-5.24	3.29e-07	0.000151	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
KIRP	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	5.24	3.3e-07	0.000151	0.25	0.31	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
KIRP	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	5.24	3.3e-07	0.000151	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
KIRP	cis	rs28386778	0.897	rs8067102	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63771419	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs6504185	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63771432	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs8077013	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63773032	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.797	rs4968664	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63774006	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs9913323	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63774125	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs3760254	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63774391	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs9906247	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63779954	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs7221573	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63782030	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs7221853	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63782476	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs7207005	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63782995	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs896064	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63783572	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs2665841	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63783859	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584640	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63786128	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584639	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63786372	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2028567	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63837966	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs894413	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63838987	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs894414	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63839024	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs6504187	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63839739	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2859619	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63840326	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs8076760	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63843137	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs2665798	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63844037	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.799	rs2727322	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63844346	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2727323	ENSG00000240280.5	TCAM1P	-5.24	3.31e-07	0.000151	-0.39	-0.31	Prudent dietary pattern;	chr17:63844639	chr17:63849292~63864379:+
KIRP	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-5.24	3.32e-07	0.000151	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-5.24	3.32e-07	0.000151	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
KIRP	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.24	3.32e-07	0.000151	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
KIRP	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	5.24	3.32e-07	0.000151	0.37	0.31	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
KIRP	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	5.24	3.32e-07	0.000151	0.37	0.31	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
KIRP	cis	rs710913	0.618	rs6587	ENSG00000237624.1	OXCT2P1	5.24	3.32e-07	0.000151	0.38	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39514956~39516490:+
KIRP	cis	rs1044826	0.692	rs176987	ENSG00000178631.7	ACTG1P1	-5.24	3.32e-07	0.000152	-0.32	-0.31	Obesity-related traits;	chr3:139514159	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.692	rs188420	ENSG00000178631.7	ACTG1P1	-5.24	3.32e-07	0.000152	-0.32	-0.31	Obesity-related traits;	chr3:139515023	chr3:139493809~139494937:+
KIRP	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	5.24	3.33e-07	0.000152	0.49	0.31	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
KIRP	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-5.24	3.34e-07	0.000152	-0.56	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
KIRP	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-5.24	3.34e-07	0.000152	-0.49	-0.31	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
KIRP	cis	rs6480314	0.542	rs61854804	ENSG00000233590.1	RP11-153K11.3	-5.24	3.34e-07	0.000153	-0.47	-0.31	Optic nerve measurement (disc area);	chr10:68255819	chr10:68233251~68242379:-
KIRP	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	5.24	3.35e-07	0.000153	0.53	0.31	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	5.24	3.35e-07	0.000153	0.53	0.31	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
KIRP	cis	rs1479119	0.681	rs10734862	ENSG00000180861.8	LINC01559	5.24	3.35e-07	0.000153	0.36	0.31	Intelligence (multi-trait analysis);	chr12:13343403	chr12:13371089~13387167:-
KIRP	cis	rs1479119	0.681	rs7134400	ENSG00000180861.8	LINC01559	5.24	3.35e-07	0.000153	0.36	0.31	Intelligence (multi-trait analysis);	chr12:13343636	chr12:13371089~13387167:-
KIRP	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	5.24	3.35e-07	0.000153	0.29	0.31	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
KIRP	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	5.24	3.36e-07	0.000153	0.37	0.31	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
KIRP	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-5.24	3.36e-07	0.000153	-0.26	-0.31	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
KIRP	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	5.24	3.36e-07	0.000153	0.64	0.31	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
KIRP	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	5.24	3.36e-07	0.000153	0.39	0.31	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
KIRP	cis	rs2483058	0.767	rs11809494	ENSG00000261000.1	RP11-534L20.5	5.24	3.36e-07	0.000153	0.33	0.31	Cholesterol and Triglycerides;	chr1:206450521	chr1:206503948~206504456:+
KIRP	cis	rs1479119	0.681	rs1382680	ENSG00000180861.8	LINC01559	5.24	3.36e-07	0.000153	0.35	0.31	Intelligence (multi-trait analysis);	chr12:13346641	chr12:13371089~13387167:-
KIRP	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-5.24	3.36e-07	0.000153	-0.38	-0.31	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
KIRP	cis	rs7267979	1	rs6050573	ENSG00000274414.1	RP5-965G21.4	-5.24	3.37e-07	0.000153	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815411	ENSG00000274414.1	RP5-965G21.4	5.24	3.37e-07	0.000153	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25239007~25245229:-
KIRP	cis	rs1799949	1	rs8077486	ENSG00000236383.6	LINC00854	-5.24	3.37e-07	0.000154	-0.23	-0.31	Menopause (age at onset);	chr17:43060788	chr17:43216941~43305976:-
KIRP	cis	rs755249	0.508	rs12023553	ENSG00000237624.1	OXCT2P1	-5.24	3.37e-07	0.000154	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.694	rs16866216	ENSG00000237624.1	OXCT2P1	-5.24	3.37e-07	0.000154	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.724	rs10788933	ENSG00000237624.1	OXCT2P1	-5.24	3.37e-07	0.000154	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39514956~39516490:+
KIRP	cis	rs7267979	1	rs2482943	ENSG00000274414.1	RP5-965G21.4	5.24	3.37e-07	0.000154	0.3	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25239007~25245229:-
KIRP	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	5.24	3.37e-07	0.000154	0.71	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
KIRP	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	5.24	3.37e-07	0.000154	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
KIRP	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	5.24	3.37e-07	0.000154	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
KIRP	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	5.24	3.38e-07	0.000154	0.25	0.31	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
KIRP	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	5.24	3.38e-07	0.000154	0.49	0.31	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	5.24	3.38e-07	0.000154	0.49	0.31	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	5.24	3.38e-07	0.000154	0.49	0.31	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	5.24	3.38e-07	0.000154	0.49	0.31	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
KIRP	cis	rs1153858	1	rs2668747	ENSG00000259433.2	CTD-2651B20.4	-5.24	3.38e-07	0.000154	-0.27	-0.31	Homoarginine levels;	chr15:45325018	chr15:45330209~45332634:-
KIRP	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-5.24	3.38e-07	0.000154	-0.42	-0.31	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
KIRP	cis	rs17684571	0.872	rs13198597	ENSG00000231441.1	RP11-472M19.2	5.24	3.39e-07	0.000154	0.5	0.31	Schizophrenia;	chr6:56852929	chr6:56844002~56864078:+
KIRP	cis	rs1044826	0.642	rs432387	ENSG00000178631.7	ACTG1P1	-5.23	3.39e-07	0.000154	-0.32	-0.31	Obesity-related traits;	chr3:139513011	chr3:139493809~139494937:+
KIRP	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-5.23	3.39e-07	0.000154	-0.4	-0.31	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-5.23	3.39e-07	0.000154	-0.4	-0.31	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
KIRP	cis	rs4578769	0.55	rs9949333	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22815080	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs9962620	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22815811	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs4800433	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22816691	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs11082155	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22824527	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs4289091	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22825856	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.589	rs12606787	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22830392	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs12956367	ENSG00000265943.1	RP11-739L10.1	5.23	3.4e-07	0.000155	0.39	0.31	Eosinophil percentage of white cells;	chr18:22833742	chr18:22699481~22933764:-
KIRP	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	5.23	3.4e-07	0.000155	0.49	0.31	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
KIRP	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	5.23	3.4e-07	0.000155	0.34	0.31	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
KIRP	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
KIRP	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	5.23	3.4e-07	0.000155	0.26	0.31	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
KIRP	cis	rs1044826	0.692	rs169824	ENSG00000178631.7	ACTG1P1	-5.23	3.4e-07	0.000155	-0.32	-0.31	Obesity-related traits;	chr3:139516164	chr3:139493809~139494937:+
KIRP	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-5.23	3.4e-07	0.000155	-0.26	-0.31	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
KIRP	cis	rs4356975	0.527	rs57102579	ENSG00000248763.2	RP13-644M16.5	-5.23	3.4e-07	0.000155	-0.33	-0.31	Obesity-related traits;	chr4:69125476	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.527	rs4385139	ENSG00000248763.2	RP13-644M16.5	-5.23	3.4e-07	0.000155	-0.33	-0.31	Obesity-related traits;	chr4:69125911	chr4:69066395~69069888:+
KIRP	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	5.23	3.4e-07	0.000155	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	5.23	3.4e-07	0.000155	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-5.23	3.41e-07	0.000155	-0.23	-0.31	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
KIRP	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-5.23	3.41e-07	0.000155	-0.34	-0.31	Height;	chr5:36861889	chr5:36666214~36725195:-
KIRP	cis	rs58722170	0.659	rs55852308	ENSG00000232273.1	FTH1P1	5.23	3.41e-07	0.000155	0.41	0.31	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37612958	chr1:37544763~37545294:+
KIRP	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-5.23	3.41e-07	0.000155	-0.26	-0.31	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-5.23	3.41e-07	0.000155	-0.26	-0.31	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-5.23	3.41e-07	0.000155	-0.26	-0.31	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-5.23	3.41e-07	0.000155	-0.26	-0.31	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-5.23	3.41e-07	0.000155	-0.26	-0.31	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
KIRP	cis	rs10246939	0.543	rs11767119	ENSG00000228775.6	WEE2-AS1	5.23	3.41e-07	0.000155	0.33	0.31	Bitter taste perception;	chr7:141912316	chr7:141704338~141738346:-
KIRP	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	5.23	3.42e-07	0.000155	0.49	0.31	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
KIRP	cis	rs755249	0.508	rs6703800	ENSG00000237624.1	OXCT2P1	-5.23	3.42e-07	0.000155	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.724	rs12117785	ENSG00000237624.1	OXCT2P1	-5.23	3.42e-07	0.000155	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39514956~39516490:+
KIRP	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-5.23	3.42e-07	0.000156	-0.49	-0.31	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
KIRP	cis	rs41271473	0.526	rs56043220	ENSG00000212237.1	RNA5SP18	5.23	3.42e-07	0.000156	0.54	0.31	Chronic lymphocytic leukemia;	chr1:228647727	chr1:228647912~228648032:-
KIRP	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	5.23	3.43e-07	0.000156	0.49	0.31	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
KIRP	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-5.23	3.43e-07	0.000156	-0.33	-0.31	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
KIRP	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	5.23	3.43e-07	0.000156	0.34	0.31	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
KIRP	cis	rs6840258	0.943	rs10029915	ENSG00000251411.1	RP11-397E7.4	-5.23	3.43e-07	0.000156	-0.31	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87138465	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.891	rs66477840	ENSG00000251411.1	RP11-397E7.4	-5.23	3.43e-07	0.000156	-0.31	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87142207	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.891	rs10023056	ENSG00000251411.1	RP11-397E7.4	-5.23	3.43e-07	0.000156	-0.31	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87143314	chr4:86913266~86914817:-
KIRP	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-5.23	3.43e-07	0.000156	-0.4	-0.31	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
KIRP	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-5.23	3.43e-07	0.000156	-0.26	-0.31	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
KIRP	cis	rs4356203	0.846	rs1685932	ENSG00000272034.1	SNORD14A	-5.23	3.44e-07	0.000156	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17074654~17074744:-
KIRP	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-5.23	3.44e-07	0.000156	-0.25	-0.31	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
KIRP	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-5.23	3.44e-07	0.000156	-0.36	-0.31	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
KIRP	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	5.23	3.44e-07	0.000156	0.26	0.31	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
KIRP	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-5.23	3.45e-07	0.000157	-0.26	-0.31	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-5.23	3.45e-07	0.000157	-0.26	-0.31	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
KIRP	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-5.23	3.45e-07	0.000157	-0.32	-0.31	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
KIRP	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	5.23	3.45e-07	0.000157	0.29	0.31	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
KIRP	cis	rs453301	0.686	rs13252797	ENSG00000253981.4	ALG1L13P	5.23	3.45e-07	0.000157	0.23	0.31	Joint mobility (Beighton score);	chr8:9003920	chr8:8236003~8244667:-
KIRP	cis	rs11673344	0.504	rs7258360	ENSG00000226686.6	LINC01535	5.23	3.45e-07	0.000157	0.36	0.31	Obesity-related traits;	chr19:37115015	chr19:37251912~37265535:+
KIRP	cis	rs11992186	0.57	rs17628941	ENSG00000253981.4	ALG1L13P	-5.23	3.45e-07	0.000157	-0.24	-0.31	Neuroticism;	chr8:8730024	chr8:8236003~8244667:-
KIRP	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-5.23	3.46e-07	0.000157	-0.4	-0.31	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-5.23	3.46e-07	0.000157	-0.4	-0.31	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
KIRP	cis	rs1799949	0.931	rs34410138	ENSG00000236383.6	LINC00854	-5.23	3.46e-07	0.000157	-0.25	-0.31	Menopause (age at onset);	chr17:43127753	chr17:43216941~43305976:-
KIRP	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	5.23	3.46e-07	0.000157	0.33	0.31	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
KIRP	cis	rs6540731	0.754	rs2358452	ENSG00000229983.1	RP11-15I11.2	5.23	3.46e-07	0.000157	0.34	0.31	Intelligence (childhood);	chr1:212185707	chr1:212168207~212190259:+
KIRP	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	5.23	3.46e-07	0.000157	0.33	0.31	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
KIRP	cis	rs67311347	0.544	rs2278929	ENSG00000230274.1	PGAM1P3	-5.23	3.46e-07	0.000157	-0.31	-0.31	Renal cell carcinoma;	chr3:40309517	chr3:40322715~40323279:-
KIRP	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-5.23	3.46e-07	0.000157	-0.32	-0.31	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
KIRP	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.23	3.47e-07	0.000157	0.33	0.31	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
KIRP	cis	rs2439831	0.717	rs690170	ENSG00000205771.5	CATSPER2P1	-5.23	3.47e-07	0.000158	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43518224	chr15:43726918~43747094:-
KIRP	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-5.23	3.47e-07	0.000158	-0.37	-0.31	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
KIRP	cis	rs11647589	0.784	rs1910803	ENSG00000262995.1	CTD-2194A8.2	-5.23	3.47e-07	0.000158	-0.35	-0.31	Blood metabolite levels;	chr16:20464412	chr16:20440266~20447000:-
KIRP	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-5.23	3.47e-07	0.000158	-0.25	-0.31	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-5.23	3.47e-07	0.000158	-0.25	-0.31	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
KIRP	cis	rs11079159	1	rs876719	ENSG00000263096.1	RP11-515O17.2	5.23	3.47e-07	0.000158	0.46	0.31	QRS duration;	chr17:55289205	chr17:55271504~55273653:-
KIRP	cis	rs28386778	0.897	rs6504176	ENSG00000240280.5	TCAM1P	-5.23	3.48e-07	0.000158	-0.39	-0.31	Prudent dietary pattern;	chr17:63734560	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs6504180	ENSG00000240280.5	TCAM1P	-5.23	3.48e-07	0.000158	-0.39	-0.31	Prudent dietary pattern;	chr17:63735809	chr17:63849292~63864379:+
KIRP	cis	rs79040073	0.637	rs12913966	ENSG00000259531.2	RP11-295H24.3	5.23	3.48e-07	0.000158	0.44	0.31	Lung cancer in ever smokers;	chr15:49214290	chr15:49365124~49366685:-
KIRP	cis	rs8049040	0.586	rs13333985	ENSG00000260886.1	TAT-AS1	5.23	3.48e-07	0.000158	0.39	0.31	Blood protein levels;	chr16:71516950	chr16:71565789~71578187:+
KIRP	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	5.23	3.49e-07	0.000158	0.25	0.31	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
KIRP	cis	rs11647589	0.834	rs4603548	ENSG00000262995.1	CTD-2194A8.2	-5.23	3.49e-07	0.000158	-0.35	-0.31	Blood metabolite levels;	chr16:20472639	chr16:20440266~20447000:-
KIRP	cis	rs2625529	0.556	rs35603965	ENSG00000260037.4	CTD-2524L6.3	5.23	3.49e-07	0.000158	0.23	0.31	Red blood cell count;	chr15:72230702	chr15:71818396~71823384:+
KIRP	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	5.23	3.49e-07	0.000158	0.52	0.31	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
KIRP	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	5.23	3.49e-07	0.000159	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
KIRP	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-5.23	3.5e-07	0.000159	-0.42	-0.31	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
KIRP	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	5.23	3.5e-07	0.000159	0.39	0.31	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.933	rs2665804	ENSG00000240280.5	TCAM1P	-5.23	3.5e-07	0.000159	-0.37	-0.31	Prudent dietary pattern;	chr17:63874476	chr17:63849292~63864379:+
KIRP	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	5.23	3.5e-07	0.000159	0.46	0.31	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	5.23	3.5e-07	0.000159	0.46	0.31	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
KIRP	cis	rs1560104	0.584	rs12921820	ENSG00000274834.1	CTD-3037G24.5	-5.23	3.5e-07	0.000159	-0.37	-0.31	Obesity-related traits;	chr16:12606775	chr16:12614451~12614852:+
KIRP	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-5.23	3.51e-07	0.000159	-0.26	-0.31	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
KIRP	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	5.23	3.51e-07	0.000159	0.26	0.31	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
KIRP	cis	rs5758659	0.716	rs2143138	ENSG00000205702.9	CYP2D7	5.23	3.51e-07	0.000159	0.24	0.31	Cognitive function;	chr22:42222334	chr22:42140203~42144577:-
KIRP	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	5.23	3.51e-07	0.000159	0.29	0.31	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
KIRP	cis	rs4356203	0.905	rs7107283	ENSG00000272034.1	SNORD14A	5.23	3.52e-07	0.00016	0.26	0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17074654~17074744:-
KIRP	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-5.23	3.52e-07	0.00016	-0.4	-0.31	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-5.23	3.52e-07	0.00016	-0.4	-0.31	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-5.23	3.52e-07	0.00016	-0.4	-0.31	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-5.23	3.52e-07	0.00016	-0.4	-0.31	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
KIRP	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-5.23	3.54e-07	0.00016	-0.29	-0.31	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
KIRP	cis	rs9532669	0.963	rs9532662	ENSG00000239827.7	SUGT1P3	-5.23	3.54e-07	0.00016	-0.34	-0.31	Cervical cancer;	chr13:40926215	chr13:40908159~40921774:-
KIRP	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-5.23	3.54e-07	0.000161	-0.32	-0.31	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-5.23	3.54e-07	0.000161	-0.32	-0.31	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-5.23	3.54e-07	0.000161	-0.32	-0.31	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
KIRP	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-5.23	3.55e-07	0.000161	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
KIRP	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-5.23	3.55e-07	0.000161	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
KIRP	cis	rs710913	0.618	rs2310799	ENSG00000237624.1	OXCT2P1	5.23	3.55e-07	0.000161	0.38	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39600950	chr1:39514956~39516490:+
KIRP	cis	rs710913	0.614	rs6672296	ENSG00000237624.1	OXCT2P1	5.23	3.55e-07	0.000161	0.38	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39605116	chr1:39514956~39516490:+
KIRP	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-5.23	3.55e-07	0.000161	-0.32	-0.31	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
KIRP	cis	rs67311347	0.544	rs4974047	ENSG00000230274.1	PGAM1P3	5.23	3.55e-07	0.000161	0.31	0.31	Renal cell carcinoma;	chr3:40298162	chr3:40322715~40323279:-
KIRP	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	5.22	3.56e-07	0.000161	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
KIRP	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	5.22	3.56e-07	0.000161	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
KIRP	cis	rs11673344	0.504	rs8105065	ENSG00000226686.6	LINC01535	5.22	3.56e-07	0.000161	0.37	0.31	Obesity-related traits;	chr19:37141003	chr19:37251912~37265535:+
KIRP	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-5.22	3.56e-07	0.000161	-0.32	-0.31	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
KIRP	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	5.22	3.56e-07	0.000161	0.4	0.31	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
KIRP	cis	rs4660214	0.666	rs1180383	ENSG00000237624.1	OXCT2P1	5.22	3.57e-07	0.000162	0.39	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39514956~39516490:+
KIRP	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	5.22	3.57e-07	0.000162	0.35	0.31	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
KIRP	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	5.22	3.57e-07	0.000162	0.46	0.31	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
KIRP	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	5.22	3.57e-07	0.000162	0.38	0.31	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	5.22	3.57e-07	0.000162	0.38	0.31	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	5.22	3.57e-07	0.000162	0.38	0.31	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
KIRP	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-5.22	3.58e-07	0.000162	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
KIRP	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-5.22	3.58e-07	0.000162	-0.23	-0.31	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
KIRP	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	5.22	3.58e-07	0.000162	0.26	0.31	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
KIRP	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	5.22	3.58e-07	0.000162	0.49	0.31	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
KIRP	cis	rs962856	0.964	rs1552359	ENSG00000236780.4	AC078941.1	5.22	3.58e-07	0.000162	0.37	0.31	Pancreatic cancer;	chr2:67388297	chr2:67123357~67215319:-
KIRP	cis	rs962856	0.964	rs5022017	ENSG00000236780.4	AC078941.1	5.22	3.58e-07	0.000162	0.37	0.31	Pancreatic cancer;	chr2:67392045	chr2:67123357~67215319:-
KIRP	cis	rs28386778	0.897	rs2584617	ENSG00000240280.5	TCAM1P	-5.22	3.59e-07	0.000162	-0.39	-0.31	Prudent dietary pattern;	chr17:63847938	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584615	ENSG00000240280.5	TCAM1P	-5.22	3.59e-07	0.000162	-0.39	-0.31	Prudent dietary pattern;	chr17:63850414	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.865	rs2727276	ENSG00000240280.5	TCAM1P	-5.22	3.59e-07	0.000162	-0.39	-0.31	Prudent dietary pattern;	chr17:63852349	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs2727355	ENSG00000240280.5	TCAM1P	-5.22	3.59e-07	0.000162	-0.39	-0.31	Prudent dietary pattern;	chr17:63854430	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.799	rs2584612	ENSG00000240280.5	TCAM1P	-5.22	3.59e-07	0.000162	-0.39	-0.31	Prudent dietary pattern;	chr17:63854844	chr17:63849292~63864379:+
KIRP	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	5.22	3.59e-07	0.000162	0.42	0.31	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
KIRP	cis	rs748404	0.578	rs1058298	ENSG00000205771.5	CATSPER2P1	-5.22	3.59e-07	0.000162	-0.35	-0.31	Lung cancer;	chr15:43408732	chr15:43726918~43747094:-
KIRP	cis	rs2976388	0.935	rs2976384	ENSG00000253741.1	CTD-2292P10.4	5.22	3.59e-07	0.000163	0.35	0.31	Urinary tract infection frequency;	chr8:142671576	chr8:142702252~142726973:-
KIRP	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	5.22	3.59e-07	0.000163	0.3	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
KIRP	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	5.22	3.59e-07	0.000163	0.26	0.31	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	5.22	3.59e-07	0.000163	0.26	0.31	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
KIRP	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	5.22	3.59e-07	0.000163	0.35	0.31	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
KIRP	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	5.22	3.6e-07	0.000163	0.31	0.31	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
KIRP	cis	rs12358692	0.669	rs7068614	ENSG00000271046.1	RP11-138I18.2	-5.22	3.6e-07	0.000163	-0.35	-0.31	Alzheimer's disease;	chr10:11679478	chr10:11679675~11680514:+
KIRP	cis	rs79040073	0.637	rs77813839	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49172799	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs77965410	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49194450	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs75391491	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49210376	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs117582142	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49228624	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.565	rs11638515	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49233530	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.599	rs17396536	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49256871	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs78881953	ENSG00000259531.2	RP11-295H24.3	5.22	3.6e-07	0.000163	0.44	0.31	Lung cancer in ever smokers;	chr15:49269019	chr15:49365124~49366685:-
KIRP	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-5.22	3.6e-07	0.000163	-0.56	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
KIRP	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	5.22	3.6e-07	0.000163	0.34	0.31	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
KIRP	cis	rs2483058	0.515	rs2987936	ENSG00000261000.1	RP11-534L20.5	-5.22	3.61e-07	0.000163	-0.34	-0.31	Cholesterol and Triglycerides;	chr1:206432728	chr1:206503948~206504456:+
KIRP	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	5.22	3.61e-07	0.000163	0.28	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
KIRP	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	5.22	3.62e-07	0.000164	0.39	0.31	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
KIRP	cis	rs4638749	0.501	rs1486192	ENSG00000231221.1	AC023672.2	5.22	3.62e-07	0.000164	0.36	0.31	Blood pressure;	chr2:108134594	chr2:108049200~108052755:-
KIRP	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-5.22	3.62e-07	0.000164	-0.38	-0.31	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
KIRP	cis	rs58722170	0.659	rs61776209	ENSG00000232273.1	FTH1P1	5.22	3.62e-07	0.000164	0.41	0.31	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37624651	chr1:37544763~37545294:+
KIRP	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	5.22	3.62e-07	0.000164	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
KIRP	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	5.22	3.62e-07	0.000164	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
KIRP	cis	rs58722170	0.627	rs12039431	ENSG00000232273.1	FTH1P1	5.22	3.62e-07	0.000164	0.41	0.31	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37616450	chr1:37544763~37545294:+
KIRP	cis	rs58722170	0.627	rs12046650	ENSG00000232273.1	FTH1P1	5.22	3.62e-07	0.000164	0.41	0.31	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37616451	chr1:37544763~37545294:+
KIRP	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	5.22	3.63e-07	0.000164	0.32	0.31	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
KIRP	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	5.22	3.63e-07	0.000164	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
KIRP	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-5.22	3.63e-07	0.000164	-0.44	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
KIRP	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-5.22	3.63e-07	0.000164	-0.36	-0.31	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-5.22	3.63e-07	0.000164	-0.36	-0.31	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
KIRP	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-5.22	3.63e-07	0.000164	-0.32	-0.31	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
KIRP	cis	rs2839627	0.638	rs8133179	ENSG00000225218.1	AP001628.6	5.22	3.64e-07	0.000164	0.31	0.31	Information processing speed;	chr21:42852217	chr21:42831040~42836477:-
KIRP	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-5.22	3.64e-07	0.000164	-0.3	-0.31	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
KIRP	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	5.22	3.64e-07	0.000164	0.49	0.31	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	5.22	3.64e-07	0.000164	0.49	0.31	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
KIRP	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	5.22	3.64e-07	0.000164	0.49	0.31	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
KIRP	cis	rs2283792	0.73	rs2329884	ENSG00000228050.1	TOP3BP1	5.22	3.64e-07	0.000164	0.35	0.31	Multiple sclerosis;	chr22:21927890	chr22:22223187~22224566:-
KIRP	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-5.22	3.64e-07	0.000164	-0.29	-0.31	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
KIRP	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	5.22	3.64e-07	0.000165	0.45	0.31	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
KIRP	cis	rs8141529	0.956	rs469989	ENSG00000226471.5	CTA-292E10.6	5.22	3.65e-07	0.000165	0.33	0.31	Lymphocyte counts;	chr22:28907607	chr22:28800683~28848559:+
KIRP	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-5.22	3.65e-07	0.000165	-0.32	-0.31	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-5.22	3.65e-07	0.000165	-0.32	-0.31	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-5.22	3.65e-07	0.000165	-0.32	-0.31	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-5.22	3.65e-07	0.000165	-0.32	-0.31	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
KIRP	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	5.22	3.65e-07	0.000165	0.33	0.31	Height;	chr4:55529387	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	5.22	3.65e-07	0.000165	0.33	0.31	Height;	chr4:55529786	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	5.22	3.65e-07	0.000165	0.33	0.31	Height;	chr4:55532542	chr4:55363971~55395847:-
KIRP	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	5.22	3.65e-07	0.000165	0.35	0.31	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
KIRP	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-5.22	3.65e-07	0.000165	-0.34	-0.31	Temperament;	chr17:14018109	chr17:14024514~14025488:+
KIRP	cis	rs4927850	0.666	rs4927853	ENSG00000207650.1	MIR570	5.22	3.65e-07	0.000165	0.32	0.31	Pancreatic cancer;	chr3:196025182	chr3:195699401~195699497:+
KIRP	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-5.22	3.65e-07	0.000165	-0.4	-0.31	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
KIRP	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-5.22	3.66e-07	0.000165	-0.33	-0.31	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
KIRP	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-5.22	3.66e-07	0.000165	-0.38	-0.31	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
KIRP	cis	rs5758659	1	rs5751255	ENSG00000205702.9	CYP2D7	5.22	3.66e-07	0.000165	0.24	0.31	Cognitive function;	chr22:42252402	chr22:42140203~42144577:-
KIRP	cis	rs17684571	0.613	rs4587171	ENSG00000231441.1	RP11-472M19.2	5.22	3.66e-07	0.000165	0.46	0.31	Schizophrenia;	chr6:56805465	chr6:56844002~56864078:+
KIRP	cis	rs4578769	0.55	rs11082182	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22872136	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.531	rs11082183	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22872137	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs12605806	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22882093	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.531	rs4616385	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22895327	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.524	rs9956919	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22896538	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs12958551	ENSG00000265943.1	RP11-739L10.1	5.22	3.66e-07	0.000165	0.39	0.31	Eosinophil percentage of white cells;	chr18:22897885	chr18:22699481~22933764:-
KIRP	cis	rs755249	0.508	rs10888688	ENSG00000237624.1	OXCT2P1	-5.22	3.66e-07	0.000165	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39514956~39516490:+
KIRP	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-5.22	3.66e-07	0.000165	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
KIRP	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-5.22	3.66e-07	0.000165	-0.3	-0.31	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
KIRP	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	5.22	3.66e-07	0.000165	0.38	0.31	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
KIRP	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	5.22	3.66e-07	0.000165	0.38	0.31	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
KIRP	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	5.22	3.66e-07	0.000165	0.38	0.31	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
KIRP	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-5.22	3.66e-07	0.000165	-0.34	-0.31	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
KIRP	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	5.22	3.67e-07	0.000165	0.38	0.31	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
KIRP	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-5.22	3.67e-07	0.000166	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
KIRP	cis	rs41271473	0.526	rs10916337	ENSG00000212237.1	RNA5SP18	5.22	3.67e-07	0.000166	0.53	0.31	Chronic lymphocytic leukemia;	chr1:228527201	chr1:228647912~228648032:-
KIRP	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-5.22	3.67e-07	0.000166	-0.4	-0.31	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
KIRP	cis	rs7176527	0.5	rs895571	ENSG00000230373.7	GOLGA6L5P	5.22	3.68e-07	0.000166	0.28	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84507885~84516814:-
KIRP	cis	rs2483058	0.767	rs11579993	ENSG00000261000.1	RP11-534L20.5	5.22	3.68e-07	0.000166	0.33	0.31	Cholesterol and Triglycerides;	chr1:206445529	chr1:206503948~206504456:+
KIRP	cis	rs453301	0.522	rs2929455	ENSG00000253981.4	ALG1L13P	-5.22	3.69e-07	0.000166	-0.24	-0.31	Joint mobility (Beighton score);	chr8:9225923	chr8:8236003~8244667:-
KIRP	cis	rs4578769	0.569	rs1448769	ENSG00000265943.1	RP11-739L10.1	5.22	3.69e-07	0.000167	0.39	0.31	Eosinophil percentage of white cells;	chr18:22838322	chr18:22699481~22933764:-
KIRP	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	5.22	3.7e-07	0.000167	0.35	0.31	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
KIRP	cis	rs4128705	1	rs4128705	ENSG00000249049.1	RP11-763F8.1	5.22	3.7e-07	0.000167	0.27	0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91362620	chr4:91319034~91325306:-
KIRP	cis	rs4578769	0.55	rs6507452	ENSG00000265943.1	RP11-739L10.1	5.22	3.7e-07	0.000167	0.41	0.31	Eosinophil percentage of white cells;	chr18:23032275	chr18:22699481~22933764:-
KIRP	cis	rs12962334	0.555	rs9954649	ENSG00000265943.1	RP11-739L10.1	5.22	3.7e-07	0.000167	0.41	0.31	Breast cancer;	chr18:23033307	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.505	rs9946743	ENSG00000265943.1	RP11-739L10.1	5.22	3.7e-07	0.000167	0.41	0.31	Eosinophil percentage of white cells;	chr18:23033394	chr18:22699481~22933764:-
KIRP	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	5.22	3.7e-07	0.000167	0.34	0.31	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
KIRP	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-5.22	3.71e-07	0.000167	-0.39	-0.31	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
KIRP	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-5.22	3.71e-07	0.000167	-0.46	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
KIRP	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	5.22	3.72e-07	0.000167	0.49	0.31	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
KIRP	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	5.22	3.72e-07	0.000167	0.19	0.31	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
KIRP	cis	rs79040073	0.637	rs77408643	ENSG00000259531.2	RP11-295H24.3	5.22	3.72e-07	0.000168	0.44	0.31	Lung cancer in ever smokers;	chr15:49377226	chr15:49365124~49366685:-
KIRP	cis	rs7170668	0.831	rs8023322	ENSG00000258489.3	RP11-398J10.2	-5.22	3.72e-07	0.000168	-0.35	-0.31	Motion sickness;	chr15:95483744	chr15:95463592~95493770:-
KIRP	cis	rs13129231	0.92	rs17676840	ENSG00000206820.1	RNU1-138P	5.22	3.72e-07	0.000168	0.39	0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113439469	chr4:113420323~113420486:+
KIRP	cis	rs9987353	0.522	rs2929466	ENSG00000253893.2	FAM85B	5.22	3.72e-07	0.000168	0.4	0.31	Recombination measurement;	chr8:9206389	chr8:8167819~8226614:-
KIRP	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-5.22	3.72e-07	0.000168	-0.37	-0.31	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-5.22	3.72e-07	0.000168	-0.37	-0.31	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
KIRP	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-5.22	3.72e-07	0.000168	-0.44	-0.31	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
KIRP	cis	rs2278170	1	rs2566264	ENSG00000225101.4	OR52K3P	-5.22	3.73e-07	0.000168	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4460913	chr11:4474813~4475755:+
KIRP	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	5.22	3.73e-07	0.000168	0.3	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
KIRP	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-5.22	3.73e-07	0.000168	-0.42	-0.31	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
KIRP	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	5.21	3.74e-07	0.000168	0.49	0.31	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	5.21	3.74e-07	0.000168	0.49	0.31	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
KIRP	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	5.21	3.74e-07	0.000169	0.32	0.31	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
KIRP	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-5.21	3.75e-07	0.000169	-0.32	-0.31	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
KIRP	cis	rs28386778	0.897	rs2665832	ENSG00000240280.5	TCAM1P	-5.21	3.75e-07	0.000169	-0.39	-0.31	Prudent dietary pattern;	chr17:63834901	chr17:63849292~63864379:+
KIRP	cis	rs453301	0.631	rs28572014	ENSG00000253981.4	ALG1L13P	-5.21	3.75e-07	0.000169	-0.24	-0.31	Joint mobility (Beighton score);	chr8:8936097	chr8:8236003~8244667:-
KIRP	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	5.21	3.75e-07	0.000169	0.28	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
KIRP	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-5.21	3.76e-07	0.000169	-0.25	-0.31	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
KIRP	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-5.21	3.76e-07	0.000169	-0.3	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
KIRP	cis	rs79040073	0.637	rs61259878	ENSG00000259531.2	RP11-295H24.3	5.21	3.76e-07	0.000169	0.41	0.31	Lung cancer in ever smokers;	chr15:49432564	chr15:49365124~49366685:-
KIRP	cis	rs67311347	0.544	rs7644643	ENSG00000230274.1	PGAM1P3	-5.21	3.77e-07	0.00017	-0.31	-0.31	Renal cell carcinoma;	chr3:40308718	chr3:40322715~40323279:-
KIRP	cis	rs2976388	0.967	rs2978981	ENSG00000253741.1	CTD-2292P10.4	5.21	3.77e-07	0.00017	0.35	0.31	Urinary tract infection frequency;	chr8:142677719	chr8:142702252~142726973:-
KIRP	cis	rs910316	0.836	rs6574212	ENSG00000279594.1	RP11-950C14.10	-5.21	3.77e-07	0.00017	-0.31	-0.31	Height;	chr14:75204956	chr14:75011269~75012851:-
KIRP	cis	rs5751901	0.688	rs2017869	ENSG00000225098.1	BCRP1	5.21	3.77e-07	0.00017	0.33	0.31	Protein quantitative trait loci;	chr22:24601342	chr22:24259929~24263764:-
KIRP	cis	rs67311347	0.568	rs57287242	ENSG00000230274.1	PGAM1P3	5.21	3.77e-07	0.00017	0.31	0.31	Renal cell carcinoma;	chr3:40294047	chr3:40322715~40323279:-
KIRP	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	5.21	3.77e-07	0.00017	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
KIRP	cis	rs4638749	1	rs12472278	ENSG00000225328.1	AC019100.3	5.21	3.77e-07	0.00017	0.39	0.31	Blood pressure;	chr2:108256977	chr2:108167748~108217841:-
KIRP	cis	rs755249	0.51	rs599892	ENSG00000237624.1	OXCT2P1	5.21	3.77e-07	0.00017	0.4	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39514956~39516490:+
KIRP	cis	rs12962334	0.57	rs4800434	ENSG00000265943.1	RP11-739L10.1	5.21	3.77e-07	0.00017	0.39	0.31	Breast cancer;	chr18:22848311	chr18:22699481~22933764:-
KIRP	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	5.21	3.78e-07	0.00017	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
KIRP	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	5.21	3.78e-07	0.00017	0.51	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
KIRP	cis	rs2625529	0.607	rs2912231	ENSG00000260037.4	CTD-2524L6.3	-5.21	3.78e-07	0.00017	-0.25	-0.31	Red blood cell count;	chr15:72275616	chr15:71818396~71823384:+
KIRP	cis	rs2043112	1	rs13165709	ENSG00000249911.1	LINC01265	5.21	3.78e-07	0.00017	0.36	0.31	Obesity-related traits;	chr5:38971763	chr5:38710367~38720273:-
KIRP	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-5.21	3.78e-07	0.00017	-0.38	-0.31	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
KIRP	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	5.21	3.79e-07	0.00017	0.33	0.31	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
KIRP	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	5.21	3.79e-07	0.00017	0.32	0.31	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	5.21	3.79e-07	0.00017	0.32	0.31	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
KIRP	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	5.21	3.79e-07	0.000171	0.37	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
KIRP	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-5.21	3.8e-07	0.000171	-0.42	-0.31	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
KIRP	cis	rs61457372	0.545	rs9900137	ENSG00000264026.1	RP11-1124B17.1	-5.21	3.8e-07	0.000171	-0.34	-0.31	Triptolide cytotoxicity;	chr17:72350841	chr17:72342940~72355136:+
KIRP	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-5.21	3.8e-07	0.000171	-0.39	-0.31	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
KIRP	cis	rs2483058	0.767	rs61817176	ENSG00000261000.1	RP11-534L20.5	5.21	3.81e-07	0.000171	0.33	0.31	Cholesterol and Triglycerides;	chr1:206447682	chr1:206503948~206504456:+
KIRP	cis	rs4638749	0.501	rs2378095	ENSG00000231221.1	AC023672.2	-5.21	3.81e-07	0.000171	-0.36	-0.31	Blood pressure;	chr2:108148443	chr2:108049200~108052755:-
KIRP	cis	rs950169	0.922	rs11630507	ENSG00000275120.1	RP11-182J1.17	5.21	3.81e-07	0.000171	0.41	0.31	Schizophrenia;	chr15:84552494	chr15:84599434~84606463:-
KIRP	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	5.21	3.81e-07	0.000171	0.33	0.31	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
KIRP	cis	rs1799949	0.965	rs33925201	ENSG00000236383.6	LINC00854	-5.21	3.81e-07	0.000171	-0.24	-0.31	Menopause (age at onset);	chr17:43128665	chr17:43216941~43305976:-
KIRP	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	5.21	3.81e-07	0.000171	0.32	0.31	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
KIRP	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	5.21	3.81e-07	0.000171	0.32	0.31	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
KIRP	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	5.21	3.81e-07	0.000172	0.31	0.31	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	5.21	3.81e-07	0.000172	0.31	0.31	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	5.21	3.81e-07	0.000172	0.31	0.31	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	5.21	3.81e-07	0.000172	0.31	0.31	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
KIRP	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-5.21	3.82e-07	0.000172	-0.31	-0.31	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
KIRP	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	5.21	3.82e-07	0.000172	0.33	0.31	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
KIRP	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	5.21	3.82e-07	0.000172	0.37	0.31	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
KIRP	cis	rs4660214	0.666	rs950805	ENSG00000237624.1	OXCT2P1	-5.21	3.83e-07	0.000172	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39514956~39516490:+
KIRP	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	5.21	3.83e-07	0.000172	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	5.21	3.83e-07	0.000172	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	5.21	3.83e-07	0.000172	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	5.21	3.83e-07	0.000172	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	5.21	3.83e-07	0.000172	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
KIRP	cis	rs2562456	0.833	rs2650801	ENSG00000268555.1	RP11-678G14.3	5.21	3.83e-07	0.000172	0.42	0.31	Pain;	chr19:21452553	chr19:21570822~21587322:-
KIRP	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	5.21	3.83e-07	0.000172	0.34	0.31	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
KIRP	cis	rs11085466	1	rs75079001	ENSG00000268555.1	RP11-678G14.3	5.21	3.84e-07	0.000172	0.4	0.31	Colorectal or endometrial cancer;	chr19:21574573	chr19:21570822~21587322:-
KIRP	cis	rs11085466	0.948	rs11668453	ENSG00000268555.1	RP11-678G14.3	5.21	3.84e-07	0.000172	0.4	0.31	Colorectal or endometrial cancer;	chr19:21576555	chr19:21570822~21587322:-
KIRP	cis	rs875971	0.545	rs73378304	ENSG00000224316.1	RP11-479O9.2	5.21	3.84e-07	0.000173	0.25	0.31	Aortic root size;	chr7:66175760	chr7:65773620~65802067:+
KIRP	cis	rs7615952	0.599	rs2333408	ENSG00000241439.1	RP11-666A20.3	5.21	3.84e-07	0.000173	0.4	0.31	Blood pressure (smoking interaction);	chr3:126013255	chr3:125958556~125958817:+
KIRP	cis	rs28386778	0.897	rs2156903	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63859819	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2236737	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63860740	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2236736	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63860888	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584601	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63863617	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2854221	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63864085	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584642	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63865067	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2854213	ENSG00000240280.5	TCAM1P	-5.21	3.84e-07	0.000173	-0.39	-0.31	Prudent dietary pattern;	chr17:63868271	chr17:63849292~63864379:+
KIRP	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-5.21	3.85e-07	0.000173	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
KIRP	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	5.21	3.85e-07	0.000173	0.33	0.31	Height;	chr4:55540928	chr4:55363971~55395847:-
KIRP	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	5.21	3.85e-07	0.000173	0.49	0.31	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
KIRP	cis	rs453301	0.686	rs6987107	ENSG00000253981.4	ALG1L13P	-5.21	3.85e-07	0.000173	-0.23	-0.31	Joint mobility (Beighton score);	chr8:9036071	chr8:8236003~8244667:-
KIRP	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	5.21	3.85e-07	0.000173	0.47	0.31	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
KIRP	cis	rs4660214	0.568	rs6692769	ENSG00000237624.1	OXCT2P1	-5.21	3.85e-07	0.000173	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.614	rs11205802	ENSG00000237624.1	OXCT2P1	-5.21	3.85e-07	0.000173	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.614	rs10888715	ENSG00000237624.1	OXCT2P1	-5.21	3.85e-07	0.000173	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39514956~39516490:+
KIRP	cis	rs4356203	0.87	rs214922	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214921	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.811	rs214920	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214918	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214915	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214914	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.84	rs214911	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214910	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs214909	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs618331	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs7949699	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs10832745	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs11024204	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs10832747	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs10832748	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs10741724	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.783	rs7113964	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs11024208	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.678	rs1125737	ENSG00000272034.1	SNORD14A	-5.21	3.85e-07	0.000173	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17074654~17074744:-
KIRP	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	5.21	3.85e-07	0.000173	0.29	0.31	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
KIRP	cis	rs2278170	1	rs331523	ENSG00000225101.4	OR52K3P	-5.21	3.86e-07	0.000173	-0.37	-0.31	Amyotrophic lateral sclerosis;	chr11:4459001	chr11:4474813~4475755:+
KIRP	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	5.21	3.86e-07	0.000173	0.28	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
KIRP	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-5.21	3.86e-07	0.000173	-0.24	-0.31	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
KIRP	cis	rs7726354	1	rs73122138	ENSG00000271828.1	CTD-2310F14.1	5.21	3.86e-07	0.000173	0.47	0.31	Breast cancer (early onset);	chr5:56972122	chr5:56927874~56929573:+
KIRP	cis	rs4638749	0.501	rs4322804	ENSG00000231221.1	AC023672.2	-5.21	3.87e-07	0.000174	-0.37	-0.31	Blood pressure;	chr2:108128483	chr2:108049200~108052755:-
KIRP	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	5.21	3.87e-07	0.000174	0.46	0.31	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
KIRP	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-5.21	3.87e-07	0.000174	-0.29	-0.31	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-5.21	3.87e-07	0.000174	-0.29	-0.31	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-5.21	3.87e-07	0.000174	-0.29	-0.31	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-5.21	3.87e-07	0.000174	-0.29	-0.31	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-5.21	3.87e-07	0.000174	-0.29	-0.31	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
KIRP	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	5.21	3.87e-07	0.000174	0.45	0.31	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
KIRP	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-5.21	3.88e-07	0.000174	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
KIRP	cis	rs1552244	0.882	rs6443276	ENSG00000180385.7	EMC3-AS1	5.21	3.88e-07	0.000174	0.29	0.31	Alzheimer's disease;	chr3:9967221	chr3:9986893~10006990:+
KIRP	cis	rs42648	0.748	rs12673914	ENSG00000225498.1	AC002064.5	5.21	3.88e-07	0.000174	0.22	0.31	Homocysteine levels;	chr7:90314075	chr7:90312496~90322592:+
KIRP	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	5.21	3.88e-07	0.000174	0.29	0.31	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
KIRP	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-5.21	3.88e-07	0.000174	-0.3	-0.31	Height;	chr14:75023964	chr14:75011269~75012851:-
KIRP	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-5.21	3.89e-07	0.000174	-0.37	-0.31	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
KIRP	cis	rs1075265	0.901	rs7569743	ENSG00000233266.1	HMGB1P31	5.21	3.89e-07	0.000174	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54137806	chr2:54051334~54051760:+
KIRP	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-5.21	3.89e-07	0.000175	-0.34	-0.31	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
KIRP	cis	rs28386778	0.897	rs2854208	ENSG00000240280.5	TCAM1P	-5.21	3.89e-07	0.000175	-0.39	-0.31	Prudent dietary pattern;	chr17:63869525	chr17:63849292~63864379:+
KIRP	cis	rs1799949	1	rs2175957	ENSG00000279602.1	CTD-3014M21.1	-5.21	3.89e-07	0.000175	-0.28	-0.31	Menopause (age at onset);	chr17:43134805	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.929	rs799906	ENSG00000236383.6	LINC00854	-5.21	3.89e-07	0.000175	-0.23	-0.31	Menopause (age at onset);	chr17:43126099	chr17:43216941~43305976:-
KIRP	cis	rs1799949	0.965	rs799908	ENSG00000236383.6	LINC00854	-5.21	3.89e-07	0.000175	-0.23	-0.31	Menopause (age at onset);	chr17:43126899	chr17:43216941~43305976:-
KIRP	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-5.21	3.9e-07	0.000175	-0.34	-0.31	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
KIRP	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	5.21	3.9e-07	0.000175	0.35	0.31	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
KIRP	cis	rs11673344	0.504	rs4239587	ENSG00000226686.6	LINC01535	5.21	3.9e-07	0.000175	0.37	0.31	Obesity-related traits;	chr19:37136211	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs4805202	ENSG00000226686.6	LINC01535	5.21	3.9e-07	0.000175	0.37	0.31	Obesity-related traits;	chr19:37136499	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs4805203	ENSG00000226686.6	LINC01535	5.21	3.9e-07	0.000175	0.37	0.31	Obesity-related traits;	chr19:37136586	chr19:37251912~37265535:+
KIRP	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	5.21	3.9e-07	0.000175	0.43	0.31	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
KIRP	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55514802	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55516548	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55516744	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55517185	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55522229	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs13140173	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55527164	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs2035692	ENSG00000272969.1	RP11-528I4.2	5.21	3.9e-07	0.000175	0.3	0.31	Height;	chr4:55528801	chr4:55547112~55547889:+
KIRP	cis	rs4356975	0.527	rs4694645	ENSG00000248763.2	RP13-644M16.5	-5.21	3.9e-07	0.000175	-0.32	-0.31	Obesity-related traits;	chr4:69127200	chr4:69066395~69069888:+
KIRP	cis	rs4356975	0.527	rs60423649	ENSG00000248763.2	RP13-644M16.5	-5.21	3.9e-07	0.000175	-0.32	-0.31	Obesity-related traits;	chr4:69127952	chr4:69066395~69069888:+
KIRP	cis	rs911119	0.954	rs35966482	ENSG00000270001.1	RP11-218C14.8	-5.21	3.9e-07	0.000175	-0.37	-0.31	Chronic kidney disease;	chr20:23640079	chr20:23631826~23632316:-
KIRP	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-5.21	3.91e-07	0.000175	-0.33	-0.31	Temperament;	chr17:14003617	chr17:14024514~14025488:+
KIRP	cis	rs7267979	0.899	rs2104734	ENSG00000274414.1	RP5-965G21.4	-5.21	3.91e-07	0.000175	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25239007~25245229:-
KIRP	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-5.21	3.91e-07	0.000175	-0.39	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
KIRP	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	5.21	3.91e-07	0.000175	0.31	0.31	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-5.2	3.93e-07	0.000176	-0.36	-0.31	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
KIRP	cis	rs6560039	1	rs6560039	ENSG00000234460.1	XXyac-YM21GA2.4	5.2	3.93e-07	0.000176	0.41	0.31	Gait variability;	chr9:87860031	chr9:87864166~87866290:+
KIRP	cis	rs4601821	0.635	rs2303380	ENSG00000270179.1	RP11-159N11.4	-5.2	3.93e-07	0.000176	-0.28	-0.31	Alcoholic chronic pancreatitis;	chr11:113329987	chr11:113368478~113369117:+
KIRP	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	5.2	3.94e-07	0.000176	0.34	0.31	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
KIRP	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-5.2	3.94e-07	0.000176	-0.25	-0.31	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
KIRP	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	5.2	3.94e-07	0.000176	0.27	0.31	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
KIRP	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-5.2	3.94e-07	0.000176	-0.33	-0.31	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
KIRP	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-5.2	3.94e-07	0.000177	-0.24	-0.31	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
KIRP	cis	rs9915657	0.933	rs8075603	ENSG00000234899.8	SOX9-AS1	-5.2	3.94e-07	0.000177	-0.26	-0.31	Thyroid hormone levels;	chr17:72140692	chr17:72034107~72237203:-
KIRP	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-5.2	3.94e-07	0.000177	-0.32	-0.31	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
KIRP	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	5.2	3.94e-07	0.000177	0.26	0.31	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-5.2	3.95e-07	0.000177	-0.26	-0.31	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
KIRP	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	5.2	3.95e-07	0.000177	0.25	0.31	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
KIRP	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	5.2	3.96e-07	0.000177	0.38	0.31	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
KIRP	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-5.2	3.96e-07	0.000177	-0.25	-0.31	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-5.2	3.96e-07	0.000177	-0.25	-0.31	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-5.2	3.96e-07	0.000177	-0.25	-0.31	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
KIRP	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	5.2	3.96e-07	0.000177	0.44	0.31	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
KIRP	cis	rs2904804	0.688	rs6601881	ENSG00000224251.5	RP11-499O7.7	5.2	3.96e-07	0.000177	0.32	0.31	Economic and political preferences (immigration/crime);	chr10:4977409	chr10:4995488~4997380:+
KIRP	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	5.2	3.96e-07	0.000177	0.44	0.31	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
KIRP	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-5.2	3.97e-07	0.000178	-0.49	-0.31	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
KIRP	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	5.2	3.97e-07	0.000178	0.34	0.31	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
KIRP	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-5.2	3.97e-07	0.000178	-0.32	-0.31	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-5.2	3.97e-07	0.000178	-0.32	-0.31	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
KIRP	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	5.2	3.97e-07	0.000178	0.49	0.31	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
KIRP	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-5.2	3.97e-07	0.000178	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
KIRP	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-5.2	3.97e-07	0.000178	-0.24	-0.31	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
KIRP	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-5.2	3.98e-07	0.000178	-0.27	-0.31	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
KIRP	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	5.2	3.98e-07	0.000178	0.27	0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
KIRP	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-5.2	3.98e-07	0.000178	-0.23	-0.31	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
KIRP	cis	rs1858037	0.867	rs6727013	ENSG00000237979.1	AC007389.1	5.2	3.98e-07	0.000178	0.35	0.31	Rheumatoid arthritis;	chr2:65331241	chr2:65500993~65502138:-
KIRP	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	5.2	3.99e-07	0.000178	0.34	0.31	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
KIRP	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	5.2	3.99e-07	0.000178	0.34	0.31	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
KIRP	cis	rs8049040	0.521	rs12935725	ENSG00000260886.1	TAT-AS1	5.2	3.99e-07	0.000179	0.39	0.31	Blood protein levels;	chr16:71535485	chr16:71565789~71578187:+
KIRP	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.2	3.99e-07	0.000179	-0.33	-0.31	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
KIRP	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-5.2	3.99e-07	0.000179	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
KIRP	cis	rs79040073	0.637	rs77296528	ENSG00000259531.2	RP11-295H24.3	5.2	3.99e-07	0.000179	0.43	0.31	Lung cancer in ever smokers;	chr15:49381827	chr15:49365124~49366685:-
KIRP	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-5.2	4e-07	0.000179	-0.26	-0.31	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
KIRP	cis	rs28386778	0.897	rs2727290	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63817368	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs1062787	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63818644	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs1062788	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63818767	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs1062790	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63819095	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs894408	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63819454	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.799	rs2665836	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63820775	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs2727288	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63823837	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584627	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63824079	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs894407	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63824281	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs894406	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63824297	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs716880	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63825462	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584626	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63825819	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs2584625	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63826085	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584624	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63827186	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs2665834	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63827364	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2727287	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63827368	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2665833	ENSG00000240280.5	TCAM1P	-5.2	4e-07	0.000179	-0.39	-0.31	Prudent dietary pattern;	chr17:63829486	chr17:63849292~63864379:+
KIRP	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	5.2	4.02e-07	0.000179	0.31	0.31	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
KIRP	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	5.2	4.02e-07	0.000179	0.26	0.31	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
KIRP	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	5.2	4.02e-07	0.00018	0.44	0.31	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
KIRP	cis	rs2278170	1	rs9633905	ENSG00000225101.4	OR52K3P	5.2	4.02e-07	0.00018	0.39	0.31	Amyotrophic lateral sclerosis;	chr11:4475383	chr11:4474813~4475755:+
KIRP	cis	rs13113518	0.812	rs4507426	ENSG00000272969.1	RP11-528I4.2	5.2	4.02e-07	0.00018	0.3	0.31	Height;	chr4:55529387	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	5.2	4.02e-07	0.00018	0.3	0.31	Height;	chr4:55529786	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	5.2	4.02e-07	0.00018	0.3	0.31	Height;	chr4:55532542	chr4:55547112~55547889:+
KIRP	cis	rs4638749	1	rs2198463	ENSG00000225328.1	AC019100.3	-5.2	4.03e-07	0.00018	-0.39	-0.31	Blood pressure;	chr2:108258637	chr2:108167748~108217841:-
KIRP	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	5.2	4.03e-07	0.00018	0.32	0.31	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	5.2	4.03e-07	0.00018	0.32	0.31	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
KIRP	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	5.2	4.03e-07	0.00018	0.28	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
KIRP	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-5.2	4.03e-07	0.00018	-0.33	-0.31	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
KIRP	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55514802	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55516548	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55516744	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55517185	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55522229	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55527164	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	5.2	4.04e-07	0.00018	0.33	0.31	Height;	chr4:55528801	chr4:55363971~55395847:-
KIRP	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-5.2	4.04e-07	0.00018	-0.29	-0.31	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
KIRP	cis	rs7267979	1	rs6138572	ENSG00000274414.1	RP5-965G21.4	-5.2	4.04e-07	0.00018	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6138575	ENSG00000274414.1	RP5-965G21.4	-5.2	4.04e-07	0.00018	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs11087521	ENSG00000274414.1	RP5-965G21.4	-5.2	4.04e-07	0.00018	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25239007~25245229:-
KIRP	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	5.2	4.04e-07	0.00018	0.33	0.31	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
KIRP	cis	rs72634501	0.642	rs67452844	ENSG00000237624.1	OXCT2P1	5.2	4.04e-07	0.00018	0.46	0.31	HDL cholesterol;	chr1:39150610	chr1:39514956~39516490:+
KIRP	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	5.2	4.04e-07	0.00018	0.36	0.31	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
KIRP	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	5.2	4.04e-07	0.000181	0.26	0.31	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
KIRP	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-5.2	4.04e-07	0.000181	-0.32	-0.31	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
KIRP	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-5.2	4.05e-07	0.000181	-0.62	-0.31	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
KIRP	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	5.2	4.05e-07	0.000181	0.32	0.31	Height;	chr4:55561218	chr4:55363971~55395847:-
KIRP	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-5.2	4.05e-07	0.000181	-0.49	-0.31	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
KIRP	cis	rs56804039	0.895	rs11776995	ENSG00000253893.2	FAM85B	5.2	4.05e-07	0.000181	0.46	0.31	Cervical cancer;	chr8:8528037	chr8:8167819~8226614:-
KIRP	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-5.2	4.05e-07	0.000181	-0.36	-0.31	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
KIRP	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	5.2	4.06e-07	0.000181	0.35	0.31	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	5.2	4.06e-07	0.000181	0.35	0.31	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	5.2	4.06e-07	0.000181	0.35	0.31	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	5.2	4.06e-07	0.000181	0.35	0.31	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
KIRP	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	5.2	4.06e-07	0.000181	0.29	0.31	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
KIRP	cis	rs11158026	0.603	rs943914	ENSG00000258413.1	RP11-665C16.6	-5.2	4.06e-07	0.000181	-0.38	-0.31	Parkinson's disease;	chr14:54973350	chr14:55262767~55272075:-
KIRP	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-5.2	4.06e-07	0.000181	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-5.2	4.06e-07	0.000181	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
KIRP	cis	rs6832769	1	rs3805152	ENSG00000272969.1	RP11-528I4.2	5.2	4.06e-07	0.000181	0.32	0.31	Personality dimensions;	chr4:55493491	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs6824057	ENSG00000272969.1	RP11-528I4.2	5.2	4.06e-07	0.000181	0.32	0.31	Personality dimensions;	chr4:55501111	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs12646078	ENSG00000272969.1	RP11-528I4.2	5.2	4.06e-07	0.000181	0.32	0.31	Personality dimensions;	chr4:55502037	chr4:55547112~55547889:+
KIRP	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-5.2	4.06e-07	0.000181	-0.45	-0.31	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
KIRP	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-5.2	4.06e-07	0.000181	-0.45	-0.31	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
KIRP	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-5.2	4.06e-07	0.000181	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-5.2	4.06e-07	0.000181	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
KIRP	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-5.2	4.06e-07	0.000181	-0.29	-0.31	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-5.2	4.06e-07	0.000181	-0.29	-0.31	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
KIRP	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	5.2	4.06e-07	0.000181	0.34	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
KIRP	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	5.2	4.06e-07	0.000181	0.43	0.31	Height;	chr6:109430398	chr6:109382795~109383666:+
KIRP	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	5.2	4.07e-07	0.000182	0.32	0.31	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
KIRP	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	5.2	4.07e-07	0.000182	0.42	0.31	Height;	chr6:109449796	chr6:109382795~109383666:+
KIRP	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-5.2	4.07e-07	0.000182	-0.26	-0.31	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-5.2	4.07e-07	0.000182	-0.26	-0.31	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-5.2	4.07e-07	0.000182	-0.26	-0.31	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
KIRP	cis	rs79040073	0.679	rs76231511	ENSG00000259531.2	RP11-295H24.3	5.2	4.07e-07	0.000182	0.44	0.31	Lung cancer in ever smokers;	chr15:49222243	chr15:49365124~49366685:-
KIRP	cis	rs2154427	0.689	rs2833947	ENSG00000238197.4	PAXBP1-AS1	5.2	4.07e-07	0.000182	0.42	0.31	Bilirubin levels;	chr21:32752619	chr21:32728115~32743122:+
KIRP	cis	rs1153858	1	rs1145081	ENSG00000259433.2	CTD-2651B20.4	-5.2	4.08e-07	0.000182	-0.27	-0.31	Homoarginine levels;	chr15:45387469	chr15:45330209~45332634:-
KIRP	cis	rs1153858	0.943	rs1145079	ENSG00000259433.2	CTD-2651B20.4	-5.2	4.08e-07	0.000182	-0.27	-0.31	Homoarginine levels;	chr15:45389563	chr15:45330209~45332634:-
KIRP	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-5.2	4.08e-07	0.000182	-0.42	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
KIRP	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	5.2	4.08e-07	0.000182	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
KIRP	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	5.2	4.08e-07	0.000182	0.32	0.31	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
KIRP	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	5.2	4.08e-07	0.000182	0.32	0.31	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
KIRP	cis	rs3892630	0.588	rs8106748	ENSG00000267475.1	CTD-2538C1.2	-5.2	4.08e-07	0.000182	-0.39	-0.31	Red blood cell traits;	chr19:32791891	chr19:32687089~32691750:-
KIRP	cis	rs962856	1	rs6546294	ENSG00000236780.4	AC078941.1	5.2	4.08e-07	0.000182	0.37	0.31	Pancreatic cancer;	chr2:67335098	chr2:67123357~67215319:-
KIRP	cis	rs7267979	0.586	rs11087505	ENSG00000274414.1	RP5-965G21.4	-5.2	4.08e-07	0.000182	-0.28	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-5.2	4.09e-07	0.000182	-0.23	-0.31	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
KIRP	cis	rs3745672	1	rs112765800	ENSG00000219665.7	CTD-2006C1.2	-5.2	4.09e-07	0.000182	-0.68	-0.31	Multiple sclerosis;	chr19:12014530	chr19:11987617~12046275:+
KIRP	cis	rs763512	0.504	rs1051838	ENSG00000276054.1	RP11-378E13.3	5.2	4.09e-07	0.000182	0.44	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37510731	chr17:37386886~37387926:+
KIRP	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	5.2	4.1e-07	0.000183	0.44	0.31	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
KIRP	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	5.2	4.1e-07	0.000183	0.44	0.31	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
KIRP	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	5.2	4.1e-07	0.000183	0.44	0.31	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
KIRP	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	5.2	4.1e-07	0.000183	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
KIRP	cis	rs9402743	0.709	rs9373136	ENSG00000234084.1	RP3-388E23.2	-5.2	4.1e-07	0.000183	-0.26	-0.31	Systemic lupus erythematosus;	chr6:135617531	chr6:135301568~135307158:+
KIRP	cis	rs9402743	0.678	rs965191	ENSG00000234084.1	RP3-388E23.2	-5.2	4.1e-07	0.000183	-0.26	-0.31	Systemic lupus erythematosus;	chr6:135618363	chr6:135301568~135307158:+
KIRP	cis	rs7267979	0.586	rs6050439	ENSG00000274414.1	RP5-965G21.4	-5.2	4.1e-07	0.000183	-0.28	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25239007~25245229:-
KIRP	cis	rs10853057	0.85	rs62065479	ENSG00000214174.7	AMZ2P1	5.2	4.11e-07	0.000183	0.67	0.31	White matter microstructure (global fractional anisotropy);	chr17:65002593	chr17:64966550~64975576:-
KIRP	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	5.2	4.11e-07	0.000183	0.47	0.31	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
KIRP	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	5.2	4.11e-07	0.000183	0.32	0.31	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
KIRP	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-5.2	4.11e-07	0.000183	-0.34	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
KIRP	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	5.2	4.11e-07	0.000183	0.29	0.31	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
KIRP	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-5.2	4.11e-07	0.000183	-0.25	-0.31	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-5.2	4.11e-07	0.000183	-0.25	-0.31	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
KIRP	cis	rs6832769	1	rs9998146	ENSG00000272969.1	RP11-528I4.2	-5.2	4.12e-07	0.000183	-0.31	-0.31	Personality dimensions;	chr4:55531810	chr4:55547112~55547889:+
KIRP	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-5.2	4.12e-07	0.000183	-0.25	-0.31	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
KIRP	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	5.19	4.12e-07	0.000183	0.23	0.31	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
KIRP	cis	rs8059260	0.673	rs77240340	ENSG00000274038.1	RP11-66H6.4	-5.19	4.12e-07	0.000184	-0.54	-0.31	Alcohol consumption over the past year;	chr16:10945778	chr16:11056556~11057034:+
KIRP	cis	rs7267979	1	rs2257991	ENSG00000274414.1	RP5-965G21.4	5.19	4.12e-07	0.000184	0.29	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25239007~25245229:-
KIRP	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	5.19	4.13e-07	0.000184	0.29	0.31	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
KIRP	cis	rs9595908	0.869	rs9591189	ENSG00000212293.1	SNORA16	5.19	4.13e-07	0.000184	0.29	0.31	Body mass index;	chr13:32632514	chr13:32420390~32420516:-
KIRP	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-5.19	4.13e-07	0.000184	-0.48	-0.31	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
KIRP	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	5.19	4.13e-07	0.000184	0.37	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
KIRP	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	5.19	4.13e-07	0.000184	0.37	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
KIRP	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-5.19	4.13e-07	0.000184	-0.34	-0.31	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
KIRP	cis	rs4128705	0.876	rs4411947	ENSG00000249049.1	RP11-763F8.1	5.19	4.13e-07	0.000184	0.3	0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91395333	chr4:91319034~91325306:-
KIRP	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-5.19	4.13e-07	0.000184	-0.39	-0.31	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
KIRP	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	5.19	4.13e-07	0.000184	0.39	0.31	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
KIRP	cis	rs7615952	0.599	rs6438953	ENSG00000241439.1	RP11-666A20.3	5.19	4.13e-07	0.000184	0.38	0.31	Blood pressure (smoking interaction);	chr3:126006108	chr3:125958556~125958817:+
KIRP	cis	rs7615952	0.599	rs1044215	ENSG00000241439.1	RP11-666A20.3	5.19	4.13e-07	0.000184	0.38	0.31	Blood pressure (smoking interaction);	chr3:126006716	chr3:125958556~125958817:+
KIRP	cis	rs2625529	0.526	rs1035744	ENSG00000260037.4	CTD-2524L6.3	5.19	4.13e-07	0.000184	0.24	0.31	Red blood cell count;	chr15:72274274	chr15:71818396~71823384:+
KIRP	cis	rs712022	0.534	rs7940885	ENSG00000246225.5	RP11-17A1.3	-5.19	4.13e-07	0.000184	-0.36	-0.31	Dialysis-related mortality;	chr11:22839479	chr11:22829380~22945393:+
KIRP	cis	rs7267979	0.899	rs2179459	ENSG00000274414.1	RP5-965G21.4	-5.19	4.13e-07	0.000184	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs6115200	ENSG00000274414.1	RP5-965G21.4	-5.19	4.13e-07	0.000184	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs6138588	ENSG00000274414.1	RP5-965G21.4	-5.19	4.13e-07	0.000184	-0.3	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25239007~25245229:-
KIRP	cis	rs4356975	0.83	rs7693166	ENSG00000196472.4	RP13-644M16.4	-5.19	4.14e-07	0.000184	-0.34	-0.31	Obesity-related traits;	chr4:69044866	chr4:69181660~69182372:+
KIRP	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	5.19	4.14e-07	0.000184	0.34	0.31	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
KIRP	cis	rs9450351	0.744	rs2229524	ENSG00000203875.9	SNHG5	-5.19	4.14e-07	0.000184	-0.51	-0.31	Interferon gamma-induced protein 10 levels;	chr6:85489525	chr6:85660950~85678736:-
KIRP	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	5.19	4.14e-07	0.000185	0.5	0.31	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	5.19	4.14e-07	0.000185	0.5	0.31	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
KIRP	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	5.19	4.15e-07	0.000185	0.28	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
KIRP	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-5.19	4.16e-07	0.000185	-0.27	-0.31	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
KIRP	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	5.19	4.16e-07	0.000185	0.6	0.31	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-5.19	4.16e-07	0.000185	-0.6	-0.31	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
KIRP	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	5.19	4.16e-07	0.000185	0.23	0.31	Height;	chr20:35200735	chr20:35201747~35203288:-
KIRP	cis	rs454217	0.875	rs7958204	ENSG00000277851.1	RP11-756G20.1	5.19	4.16e-07	0.000185	0.38	0.31	Smoking quantity;	chr12:92323167	chr12:92247756~92363832:-
KIRP	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	5.19	4.16e-07	0.000185	0.38	0.31	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
KIRP	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	5.19	4.17e-07	0.000185	0.38	0.31	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
KIRP	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	5.19	4.17e-07	0.000185	0.38	0.31	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
KIRP	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-5.19	4.17e-07	0.000185	-0.26	-0.31	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
KIRP	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	5.19	4.17e-07	0.000186	0.5	0.31	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
KIRP	cis	rs2625529	0.526	rs6494997	ENSG00000260037.4	CTD-2524L6.3	5.19	4.18e-07	0.000186	0.23	0.31	Red blood cell count;	chr15:72268301	chr15:71818396~71823384:+
KIRP	cis	rs4356975	0.798	rs4694588	ENSG00000196472.4	RP13-644M16.4	-5.19	4.18e-07	0.000186	-0.34	-0.31	Obesity-related traits;	chr4:69044664	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs6422321	ENSG00000196472.4	RP13-644M16.4	-5.19	4.18e-07	0.000186	-0.34	-0.31	Obesity-related traits;	chr4:69044911	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.768	rs4518318	ENSG00000196472.4	RP13-644M16.4	-5.19	4.18e-07	0.000186	-0.34	-0.31	Obesity-related traits;	chr4:69045479	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs4351079	ENSG00000196472.4	RP13-644M16.4	-5.19	4.18e-07	0.000186	-0.34	-0.31	Obesity-related traits;	chr4:69045631	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.798	rs4607293	ENSG00000196472.4	RP13-644M16.4	-5.19	4.18e-07	0.000186	-0.34	-0.31	Obesity-related traits;	chr4:69045714	chr4:69181660~69182372:+
KIRP	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	5.19	4.18e-07	0.000186	0.3	0.31	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
KIRP	cis	rs4601821	0.583	rs1893696	ENSG00000270179.1	RP11-159N11.4	-5.19	4.18e-07	0.000186	-0.28	-0.31	Alcoholic chronic pancreatitis;	chr11:113335553	chr11:113368478~113369117:+
KIRP	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-5.19	4.18e-07	0.000186	-0.27	-0.31	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
KIRP	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	5.19	4.19e-07	0.000186	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
KIRP	cis	rs67311347	0.544	rs35112505	ENSG00000230274.1	PGAM1P3	5.19	4.19e-07	0.000186	0.31	0.31	Renal cell carcinoma;	chr3:40295584	chr3:40322715~40323279:-
KIRP	cis	rs67311347	0.544	rs67533651	ENSG00000230274.1	PGAM1P3	5.19	4.19e-07	0.000186	0.31	0.31	Renal cell carcinoma;	chr3:40296876	chr3:40322715~40323279:-
KIRP	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	5.19	4.19e-07	0.000186	0.31	0.31	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
KIRP	cis	rs4356203	0.905	rs11024159	ENSG00000272034.1	SNORD14A	-5.19	4.19e-07	0.000186	-0.26	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.87	rs603618	ENSG00000272034.1	SNORD14A	-5.19	4.19e-07	0.000186	-0.25	-0.31	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17074654~17074744:-
KIRP	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	5.19	4.19e-07	0.000186	0.37	0.31	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
KIRP	cis	rs947583	0.517	rs7764412	ENSG00000231028.7	LINC00271	-5.19	4.19e-07	0.000186	-0.27	-0.31	Phosphorus levels;	chr6:135787214	chr6:135497801~135716055:+
KIRP	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	5.19	4.2e-07	0.000187	0.39	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
KIRP	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-5.19	4.2e-07	0.000187	-0.34	-0.31	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
KIRP	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.19	4.21e-07	0.000187	-0.33	-0.31	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
KIRP	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.19	4.21e-07	0.000187	-0.33	-0.31	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
KIRP	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	5.19	4.21e-07	0.000187	0.3	0.31	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
KIRP	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-5.19	4.21e-07	0.000187	-0.25	-0.31	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
KIRP	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-5.19	4.21e-07	0.000187	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
KIRP	cis	rs964611	0.882	rs10851465	ENSG00000259488.2	RP11-154J22.1	5.19	4.22e-07	0.000187	0.28	0.31	Metabolite levels (Pyroglutamine);	chr15:48337687	chr15:48312353~48331856:-
KIRP	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	5.19	4.22e-07	0.000187	0.32	0.31	Height;	chr4:55407965	chr4:55363971~55395847:-
KIRP	cis	rs3745672	1	rs112315514	ENSG00000219665.7	CTD-2006C1.2	-5.19	4.22e-07	0.000188	-0.68	-0.31	Multiple sclerosis;	chr19:12002519	chr19:11987617~12046275:+
KIRP	cis	rs5758659	1	rs5758659	ENSG00000205702.9	CYP2D7	5.19	4.22e-07	0.000188	0.24	0.31	Cognitive function;	chr22:42225997	chr22:42140203~42144577:-
KIRP	cis	rs1799949	1	rs8176103	ENSG00000279602.1	CTD-3014M21.1	-5.19	4.22e-07	0.000188	-0.28	-0.31	Menopause (age at onset);	chr17:43115033	chr17:43360041~43361361:-
KIRP	cis	rs9601248	0.627	rs2876741	ENSG00000227676.3	LINC01068	-5.19	4.22e-07	0.000188	-0.37	-0.31	Major depressive disorder;	chr13:79612577	chr13:79566727~79571436:+
KIRP	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-5.19	4.23e-07	0.000188	-0.25	-0.31	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
KIRP	cis	rs73198271	0.74	rs10105920	ENSG00000253981.4	ALG1L13P	5.19	4.23e-07	0.000188	0.26	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	5.19	4.23e-07	0.000188	0.43	0.31	Height;	chr6:109375003	chr6:109382795~109383666:+
KIRP	cis	rs947583	0.913	rs2027516	ENSG00000231028.7	LINC00271	-5.19	4.23e-07	0.000188	-0.27	-0.31	Phosphorus levels;	chr6:135810750	chr6:135497801~135716055:+
KIRP	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.19	4.24e-07	0.000188	-0.39	-0.31	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
KIRP	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	5.19	4.24e-07	0.000188	0.29	0.31	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
KIRP	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-5.19	4.24e-07	0.000188	-0.23	-0.31	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
KIRP	cis	rs962856	1	rs979043	ENSG00000236780.4	AC078941.1	5.19	4.25e-07	0.000189	0.37	0.31	Pancreatic cancer;	chr2:67339149	chr2:67123357~67215319:-
KIRP	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	5.19	4.25e-07	0.000189	0.38	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
KIRP	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	5.19	4.25e-07	0.000189	0.31	0.31	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	5.19	4.25e-07	0.000189	0.31	0.31	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	5.19	4.25e-07	0.000189	0.31	0.31	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
KIRP	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	5.19	4.25e-07	0.000189	0.45	0.31	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
KIRP	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	5.19	4.25e-07	0.000189	0.36	0.31	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	5.19	4.25e-07	0.000189	0.36	0.31	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	5.19	4.26e-07	0.000189	0.36	0.31	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
KIRP	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	5.19	4.26e-07	0.000189	0.36	0.31	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
KIRP	cis	rs12050794	0.671	rs7179427	ENSG00000260037.4	CTD-2524L6.3	5.19	4.26e-07	0.000189	0.23	0.31	Metabolite levels (HVA/MHPG ratio);	chr15:72224480	chr15:71818396~71823384:+
KIRP	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	5.19	4.26e-07	0.000189	0.32	0.31	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
KIRP	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	5.19	4.26e-07	0.000189	0.33	0.31	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
KIRP	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	5.19	4.27e-07	0.000189	0.27	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
KIRP	cis	rs6569038	0.557	rs9374777	ENSG00000253194.1	RP11-351A11.1	-5.19	4.27e-07	0.000189	-0.37	-0.31	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119056334	chr6:118934785~119031541:+
KIRP	cis	rs2278170	1	rs331503	ENSG00000225101.4	OR52K3P	-5.19	4.28e-07	0.00019	-0.38	-0.31	Amyotrophic lateral sclerosis;	chr11:4473798	chr11:4474813~4475755:+
KIRP	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-5.19	4.28e-07	0.00019	-0.48	-0.31	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
KIRP	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	5.19	4.28e-07	0.00019	0.25	0.31	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
KIRP	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	5.19	4.29e-07	0.00019	0.31	0.31	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
KIRP	cis	rs9402743	0.634	rs9494306	ENSG00000234084.1	RP3-388E23.2	-5.19	4.29e-07	0.00019	-0.26	-0.31	Systemic lupus erythematosus;	chr6:135622823	chr6:135301568~135307158:+
KIRP	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-5.19	4.3e-07	0.00019	-0.25	-0.31	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-5.19	4.3e-07	0.00019	-0.25	-0.31	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-5.19	4.3e-07	0.00019	-0.25	-0.31	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
KIRP	cis	rs4660214	0.666	rs11205839	ENSG00000237624.1	OXCT2P1	-5.19	4.3e-07	0.00019	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39514956~39516490:+
KIRP	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	5.19	4.3e-07	0.000191	0.27	0.31	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-5.19	4.3e-07	0.000191	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
KIRP	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	5.19	4.3e-07	0.000191	0.51	0.31	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
KIRP	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	5.19	4.31e-07	0.000191	0.38	0.31	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
KIRP	cis	rs2625529	0.59	rs713048	ENSG00000260037.4	CTD-2524L6.3	-5.19	4.31e-07	0.000191	-0.26	-0.31	Red blood cell count;	chr15:72250743	chr15:71818396~71823384:+
KIRP	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	5.19	4.31e-07	0.000191	0.29	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	5.19	4.31e-07	0.000191	0.29	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
KIRP	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	5.19	4.31e-07	0.000191	0.31	0.31	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
KIRP	cis	rs1479119	0.681	rs1382681	ENSG00000180861.8	LINC01559	5.19	4.31e-07	0.000191	0.34	0.31	Intelligence (multi-trait analysis);	chr12:13346737	chr12:13371089~13387167:-
KIRP	cis	rs11148252	0.716	rs2760772	ENSG00000278238.1	RP11-245D16.4	-5.19	4.32e-07	0.000191	-0.33	-0.31	Lewy body disease;	chr13:52206238	chr13:52454775~52455331:-
KIRP	cis	rs7672749	0.63	rs1824701	ENSG00000249973.2	CHCHD2P7	-5.18	4.33e-07	0.000192	-0.48	-0.31	TB-LM or TBLH-BMD (pleiotropy);	chr4:87875690	chr4:87785920~87786371:-
KIRP	cis	rs58722170	0.659	rs12023270	ENSG00000232273.1	FTH1P1	-5.18	4.33e-07	0.000192	-0.4	-0.31	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37620906	chr1:37544763~37545294:+
KIRP	cis	rs67311347	0.544	rs7652439	ENSG00000230274.1	PGAM1P3	5.18	4.33e-07	0.000192	0.29	0.31	Renal cell carcinoma;	chr3:40308457	chr3:40322715~40323279:-
KIRP	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	5.18	4.33e-07	0.000192	0.38	0.31	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
KIRP	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	5.18	4.33e-07	0.000192	0.39	0.31	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	5.18	4.33e-07	0.000192	0.39	0.31	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
KIRP	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-5.18	4.35e-07	0.000193	-0.26	-0.3	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-5.18	4.35e-07	0.000193	-0.26	-0.3	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
KIRP	cis	rs8114671	0.869	rs2145559	ENSG00000269202.1	RP4-614O4.12	5.18	4.35e-07	0.000193	0.22	0.3	Height;	chr20:35063922	chr20:35201747~35203288:-
KIRP	cis	rs4443100	0.67	rs3788338	ENSG00000221069.1	AC000029.1	5.18	4.35e-07	0.000193	0.41	0.3	Serum parathyroid hormone levels;	chr22:23069879	chr22:23136620~23136710:+
KIRP	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	5.18	4.35e-07	0.000193	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
KIRP	cis	rs6832769	1	rs576779	ENSG00000272969.1	RP11-528I4.2	5.18	4.36e-07	0.000193	0.29	0.3	Personality dimensions;	chr4:55408140	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs480479	ENSG00000272969.1	RP11-528I4.2	5.18	4.36e-07	0.000193	0.29	0.3	Personality dimensions;	chr4:55408163	chr4:55547112~55547889:+
KIRP	cis	rs6453278	1	rs6453278	ENSG00000250802.5	ZBED3-AS1	5.18	4.36e-07	0.000193	0.34	0.3	Autism;	chr5:77121217	chr5:77086740~77166909:+
KIRP	cis	rs1799949	1	rs33946455	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.36e-07	0.000193	-0.29	-0.3	Menopause (age at onset);	chr17:43169829	chr17:43360041~43361361:-
KIRP	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-5.18	4.36e-07	0.000193	-0.31	-0.3	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
KIRP	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-5.18	4.36e-07	0.000193	-0.53	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
KIRP	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	5.18	4.36e-07	0.000193	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	5.18	4.36e-07	0.000193	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
KIRP	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-5.18	4.36e-07	0.000193	-0.33	-0.3	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
KIRP	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-5.18	4.36e-07	0.000193	-0.62	-0.3	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
KIRP	cis	rs713477	1	rs28604440	ENSG00000258413.1	RP11-665C16.6	5.18	4.37e-07	0.000193	0.37	0.3	Pediatric bone mineral content (femoral neck);	chr14:55444606	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	5.18	4.37e-07	0.000193	0.23	0.3	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	5.18	4.37e-07	0.000193	0.23	0.3	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
KIRP	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	5.18	4.37e-07	0.000193	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
KIRP	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	5.18	4.37e-07	0.000194	0.45	0.3	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
KIRP	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-5.18	4.37e-07	0.000194	-0.34	-0.3	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
KIRP	cis	rs5760092	0.755	rs3884794	ENSG00000231271.1	AP000350.8	5.18	4.37e-07	0.000194	0.44	0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23949918~23954042:+
KIRP	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	5.18	4.38e-07	0.000194	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
KIRP	cis	rs453301	0.631	rs7843369	ENSG00000253981.4	ALG1L13P	-5.18	4.38e-07	0.000194	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8940276	chr8:8236003~8244667:-
KIRP	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	5.18	4.38e-07	0.000194	0.37	0.3	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
KIRP	cis	rs7726354	1	rs2408651	ENSG00000271828.1	CTD-2310F14.1	5.18	4.38e-07	0.000194	0.46	0.3	Breast cancer (early onset);	chr5:56973164	chr5:56927874~56929573:+
KIRP	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-5.18	4.38e-07	0.000194	-0.37	-0.3	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
KIRP	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-5.18	4.38e-07	0.000194	-0.37	-0.3	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
KIRP	cis	rs7255436	1	rs7255436	ENSG00000269386.4	RAB11B-AS1	5.18	4.39e-07	0.000194	0.3	0.3	HDL cholesterol;	chr19:8368312	chr19:8374373~8390685:-
KIRP	cis	rs4934494	0.727	rs12572012	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89727892	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs3758388	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89729222	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs12783582	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89735210	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs2418929	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89741720	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs67827533	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89745626	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs1926139	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89753395	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs55823491	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89757598	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs12570750	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89761273	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs36019294	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89777822	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.636	rs34408087	ENSG00000232936.4	RP11-80H5.2	5.18	4.39e-07	0.000194	0.46	0.3	Red blood cell count;	chr10:89783794	chr10:89645282~89650667:+
KIRP	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	5.18	4.39e-07	0.000194	0.45	0.3	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	5.18	4.39e-07	0.000194	0.45	0.3	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
KIRP	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	5.18	4.39e-07	0.000194	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	5.18	4.39e-07	0.000194	0.23	0.3	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
KIRP	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-5.18	4.4e-07	0.000195	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
KIRP	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-5.18	4.4e-07	0.000195	-0.29	-0.3	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-5.18	4.4e-07	0.000195	-0.29	-0.3	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
KIRP	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	5.18	4.4e-07	0.000195	0.32	0.3	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
KIRP	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	5.18	4.4e-07	0.000195	0.32	0.3	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	5.18	4.4e-07	0.000195	0.32	0.3	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
KIRP	cis	rs6540731	0.728	rs12746096	ENSG00000229983.1	RP11-15I11.2	5.18	4.41e-07	0.000195	0.35	0.3	Intelligence (childhood);	chr1:212190424	chr1:212168207~212190259:+
KIRP	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-5.18	4.41e-07	0.000195	-0.26	-0.3	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-5.18	4.41e-07	0.000195	-0.26	-0.3	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-5.18	4.41e-07	0.000195	-0.26	-0.3	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
KIRP	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	5.18	4.41e-07	0.000195	0.24	0.3	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
KIRP	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	5.18	4.41e-07	0.000195	0.44	0.3	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
KIRP	cis	rs755249	0.508	rs624971	ENSG00000237624.1	OXCT2P1	5.18	4.41e-07	0.000195	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39514956~39516490:+
KIRP	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.18	4.43e-07	0.000196	-0.31	-0.3	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
KIRP	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-5.18	4.43e-07	0.000196	-0.2	-0.3	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
KIRP	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	5.18	4.43e-07	0.000196	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	5.18	4.43e-07	0.000196	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
KIRP	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-5.18	4.43e-07	0.000196	-0.32	-0.3	Temperament;	chr17:13999319	chr17:14024514~14025488:+
KIRP	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	5.18	4.43e-07	0.000196	0.33	0.3	Height;	chr4:55575856	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	5.18	4.43e-07	0.000196	0.33	0.3	Height;	chr4:55577294	chr4:55363971~55395847:-
KIRP	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	5.18	4.43e-07	0.000196	0.43	0.3	Height;	chr6:109380457	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	5.18	4.43e-07	0.000196	0.43	0.3	Height;	chr6:109380990	chr6:109382795~109383666:+
KIRP	cis	rs4356203	0.905	rs17472886	ENSG00000272034.1	SNORD14A	-5.18	4.44e-07	0.000196	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17074654~17074744:-
KIRP	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-5.18	4.44e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
KIRP	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	5.18	4.44e-07	0.000196	0.51	0.3	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	5.18	4.44e-07	0.000196	0.51	0.3	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
KIRP	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-5.18	4.44e-07	0.000196	-0.3	-0.3	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
KIRP	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-5.18	4.44e-07	0.000196	-0.26	-0.3	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
KIRP	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-5.18	4.44e-07	0.000196	-0.32	-0.3	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-5.18	4.44e-07	0.000196	-0.32	-0.3	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-5.18	4.44e-07	0.000196	-0.32	-0.3	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
KIRP	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-5.18	4.45e-07	0.000196	-0.26	-0.3	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
KIRP	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-5.18	4.45e-07	0.000196	-0.34	-0.3	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
KIRP	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	5.18	4.45e-07	0.000196	0.25	0.3	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
KIRP	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-5.18	4.46e-07	0.000197	-0.32	-0.3	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-5.18	4.46e-07	0.000197	-0.32	-0.3	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-5.18	4.46e-07	0.000197	-0.32	-0.3	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
KIRP	cis	rs35146811	0.7	rs866500	ENSG00000078319.8	PMS2P1	5.18	4.46e-07	0.000197	0.44	0.3	Coronary artery disease;	chr7:100242838	chr7:100320992~100341908:-
KIRP	cis	rs4356203	0.905	rs550667	ENSG00000272034.1	SNORD14A	-5.18	4.47e-07	0.000197	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs656623	ENSG00000272034.1	SNORD14A	-5.18	4.47e-07	0.000197	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17074654~17074744:-
KIRP	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	5.18	4.47e-07	0.000197	0.35	0.3	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	5.18	4.47e-07	0.000197	0.35	0.3	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
KIRP	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-5.18	4.47e-07	0.000197	-0.63	-0.3	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-5.18	4.47e-07	0.000197	-0.63	-0.3	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-5.18	4.47e-07	0.000197	-0.63	-0.3	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-5.18	4.47e-07	0.000197	-0.63	-0.3	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
KIRP	cis	rs1153858	1	rs1145074	ENSG00000259433.2	CTD-2651B20.4	-5.18	4.47e-07	0.000197	-0.27	-0.3	Homoarginine levels;	chr15:45411626	chr15:45330209~45332634:-
KIRP	cis	rs453301	0.631	rs11780774	ENSG00000253981.4	ALG1L13P	-5.18	4.48e-07	0.000197	-0.25	-0.3	Joint mobility (Beighton score);	chr8:8941601	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	5.18	4.48e-07	0.000197	0.42	0.3	Height;	chr6:109354040	chr6:109382795~109383666:+
KIRP	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-5.18	4.48e-07	0.000198	-0.24	-0.3	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	5.18	4.48e-07	0.000198	0.23	0.3	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
KIRP	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	5.18	4.48e-07	0.000198	0.33	0.3	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
KIRP	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-5.18	4.49e-07	0.000198	-0.57	-0.3	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
KIRP	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
KIRP	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
KIRP	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	5.18	4.49e-07	0.000198	0.34	0.3	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
KIRP	cis	rs6832769	0.961	rs11133382	ENSG00000272969.1	RP11-528I4.2	5.18	4.49e-07	0.000198	0.29	0.3	Personality dimensions;	chr4:55450813	chr4:55547112~55547889:+
KIRP	cis	rs6840258	0.891	rs1842685	ENSG00000251411.1	RP11-397E7.4	-5.18	4.49e-07	0.000198	-0.29	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87139680	chr4:86913266~86914817:-
KIRP	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	5.18	4.5e-07	0.000198	0.43	0.3	Height;	chr6:109382524	chr6:109382795~109383666:+
KIRP	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-5.18	4.5e-07	0.000198	-0.25	-0.3	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-5.18	4.5e-07	0.000198	-0.25	-0.3	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
KIRP	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	5.18	4.51e-07	0.000199	0.29	0.3	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
KIRP	cis	rs1799949	1	rs8176109	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43113759	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.896	rs8176098	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43116189	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.896	rs8176086	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43122761	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.93	rs3765640	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43124230	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs8176077	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43124331	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11655505	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43126360	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs4793204	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43127281	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs12947782	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43127865	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs33945274	ENSG00000279602.1	CTD-3014M21.1	-5.18	4.51e-07	0.000199	-0.28	-0.3	Menopause (age at onset);	chr17:43128056	chr17:43360041~43361361:-
KIRP	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-5.18	4.52e-07	0.000199	-0.26	-0.3	Height;	chr2:46627569	chr2:46668870~46670778:+
KIRP	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-5.18	4.52e-07	0.000199	-0.5	-0.3	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
KIRP	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	5.18	4.53e-07	0.000199	0.36	0.3	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	5.18	4.53e-07	0.000199	0.36	0.3	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
KIRP	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	5.18	4.53e-07	0.000199	0.45	0.3	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
KIRP	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	5.18	4.53e-07	0.000199	0.45	0.3	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
KIRP	cis	rs2283792	0.73	rs2083565	ENSG00000228050.1	TOP3BP1	5.18	4.53e-07	0.000199	0.35	0.3	Multiple sclerosis;	chr22:21929985	chr22:22223187~22224566:-
KIRP	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	5.18	4.53e-07	2e-04	0.44	0.3	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	5.18	4.53e-07	2e-04	0.44	0.3	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-5.18	4.53e-07	2e-04	-0.46	-0.3	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
KIRP	cis	rs1858037	0.867	rs953312	ENSG00000237979.1	AC007389.1	5.18	4.53e-07	2e-04	0.34	0.3	Rheumatoid arthritis;	chr2:65340556	chr2:65500993~65502138:-
KIRP	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	5.18	4.53e-07	2e-04	0.29	0.3	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
KIRP	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	5.18	4.53e-07	2e-04	0.29	0.3	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
KIRP	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-5.18	4.54e-07	2e-04	-0.6	-0.3	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-5.18	4.54e-07	2e-04	-0.6	-0.3	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-5.18	4.54e-07	2e-04	-0.6	-0.3	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
KIRP	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	5.18	4.54e-07	2e-04	0.34	0.3	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
KIRP	cis	rs10912872	0.672	rs7516677	ENSG00000225704.2	RP4-798A17.5	5.17	4.54e-07	2e-04	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171372697	chr1:171345089~171345320:+
KIRP	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	5.17	4.55e-07	2e-04	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-5.17	4.55e-07	2e-04	-0.36	-0.3	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
KIRP	cis	rs42648	0.633	rs11563909	ENSG00000225498.1	AC002064.5	5.17	4.55e-07	2e-04	0.22	0.3	Homocysteine levels;	chr7:90306390	chr7:90312496~90322592:+
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-5.17	4.55e-07	2e-04	-0.36	-0.3	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-5.17	4.55e-07	2e-04	-0.37	-0.3	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
KIRP	cis	rs7267979	0.966	rs2261795	ENSG00000274414.1	RP5-965G21.4	-5.17	4.55e-07	2e-04	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25239007~25245229:-
KIRP	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	5.17	4.55e-07	2e-04	0.29	0.3	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
KIRP	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-5.17	4.55e-07	0.000201	-0.25	-0.3	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
KIRP	cis	rs2976388	1	rs1045605	ENSG00000253741.1	CTD-2292P10.4	5.17	4.56e-07	0.000201	0.34	0.3	Urinary tract infection frequency;	chr8:142682683	chr8:142702252~142726973:-
KIRP	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-5.17	4.56e-07	0.000201	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
KIRP	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	5.17	4.56e-07	0.000201	0.36	0.3	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
KIRP	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	5.17	4.56e-07	0.000201	0.36	0.3	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
KIRP	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	5.17	4.56e-07	0.000201	0.24	0.3	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
KIRP	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	5.17	4.56e-07	0.000201	0.25	0.3	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
KIRP	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	5.17	4.56e-07	0.000201	0.36	0.3	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
KIRP	cis	rs11158026	0.757	rs56206440	ENSG00000258413.1	RP11-665C16.6	-5.17	4.57e-07	0.000201	-0.36	-0.3	Parkinson's disease;	chr14:54984168	chr14:55262767~55272075:-
KIRP	cis	rs41271473	0.526	rs28593014	ENSG00000212237.1	RNA5SP18	5.17	4.57e-07	0.000201	0.54	0.3	Chronic lymphocytic leukemia;	chr1:228555875	chr1:228647912~228648032:-
KIRP	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	5.17	4.57e-07	0.000201	0.36	0.3	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
KIRP	cis	rs1005277	0.579	rs2505248	ENSG00000151963.4	RP11-775A3.1	-5.17	4.57e-07	0.000201	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:37883594~37884109:+
KIRP	cis	rs2439831	1	rs689754	ENSG00000249839.1	AC011330.5	-5.17	4.58e-07	0.000202	-0.42	-0.3	Lung cancer in ever smokers;	chr15:43483697	chr15:43663654~43684339:-
KIRP	cis	rs2976388	1	rs2920298	ENSG00000253741.1	CTD-2292P10.4	5.17	4.59e-07	0.000202	0.34	0.3	Urinary tract infection frequency;	chr8:142681625	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920297	ENSG00000253741.1	CTD-2292P10.4	5.17	4.59e-07	0.000202	0.34	0.3	Urinary tract infection frequency;	chr8:142681665	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920296	ENSG00000253741.1	CTD-2292P10.4	5.17	4.59e-07	0.000202	0.34	0.3	Urinary tract infection frequency;	chr8:142681691	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs1045531	ENSG00000253741.1	CTD-2292P10.4	5.17	4.59e-07	0.000202	0.34	0.3	Urinary tract infection frequency;	chr8:142682129	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2976394	ENSG00000253741.1	CTD-2292P10.4	5.17	4.59e-07	0.000202	0.34	0.3	Urinary tract infection frequency;	chr8:142682204	chr8:142702252~142726973:-
KIRP	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	5.17	4.59e-07	0.000202	0.43	0.3	Height;	chr6:109384228	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	5.17	4.59e-07	0.000202	0.43	0.3	Height;	chr6:109385087	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	5.17	4.59e-07	0.000202	0.43	0.3	Height;	chr6:109387685	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	5.17	4.59e-07	0.000202	0.43	0.3	Height;	chr6:109388256	chr6:109382795~109383666:+
KIRP	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-5.17	4.59e-07	0.000202	-0.29	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
KIRP	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	5.17	4.59e-07	0.000202	0.3	0.3	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
KIRP	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-5.17	4.59e-07	0.000202	-0.61	-0.3	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
KIRP	cis	rs8067545	0.693	rs8066150	ENSG00000270091.1	RP11-78O7.2	-5.17	4.59e-07	0.000202	-0.2	-0.3	Schizophrenia;	chr17:19983635	chr17:19896590~19897287:-
KIRP	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	5.17	4.6e-07	0.000202	0.36	0.3	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
KIRP	cis	rs12908161	0.959	rs11637728	ENSG00000275120.1	RP11-182J1.17	5.17	4.6e-07	0.000202	0.39	0.3	Schizophrenia;	chr15:84660161	chr15:84599434~84606463:-
KIRP	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-5.17	4.6e-07	0.000202	-0.32	-0.3	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-5.17	4.6e-07	0.000202	-0.32	-0.3	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
KIRP	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	5.17	4.6e-07	0.000202	0.32	0.3	Height;	chr4:55587104	chr4:55363971~55395847:-
KIRP	cis	rs4660214	0.666	rs7538300	ENSG00000237624.1	OXCT2P1	-5.17	4.6e-07	0.000202	-0.4	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39514956~39516490:+
KIRP	cis	rs2154427	0.938	rs2833967	ENSG00000238197.4	PAXBP1-AS1	5.17	4.6e-07	0.000202	0.4	0.3	Bilirubin levels;	chr21:32818998	chr21:32728115~32743122:+
KIRP	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	5.17	4.61e-07	0.000202	0.33	0.3	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
KIRP	cis	rs79040073	0.637	rs79365293	ENSG00000259531.2	RP11-295H24.3	5.17	4.61e-07	0.000203	0.43	0.3	Lung cancer in ever smokers;	chr15:49402268	chr15:49365124~49366685:-
KIRP	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-5.17	4.61e-07	0.000203	-0.6	-0.3	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
KIRP	cis	rs453301	0.631	rs4840376	ENSG00000253981.4	ALG1L13P	-5.17	4.61e-07	0.000203	-0.25	-0.3	Joint mobility (Beighton score);	chr8:8944591	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	5.17	4.61e-07	0.000203	0.42	0.3	Height;	chr6:109469907	chr6:109382795~109383666:+
KIRP	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-5.17	4.61e-07	0.000203	-0.37	-0.3	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
KIRP	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	5.17	4.62e-07	0.000203	0.33	0.3	Height;	chr4:55578154	chr4:55363971~55395847:-
KIRP	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-5.17	4.62e-07	0.000203	-0.42	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
KIRP	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-5.17	4.62e-07	0.000203	-0.26	-0.3	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
KIRP	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	5.17	4.62e-07	0.000203	0.29	0.3	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
KIRP	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-5.17	4.63e-07	0.000204	-0.35	-0.3	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
KIRP	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	5.17	4.64e-07	0.000204	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
KIRP	cis	rs11673344	0.504	rs35579954	ENSG00000226686.6	LINC01535	5.17	4.64e-07	0.000204	0.37	0.3	Obesity-related traits;	chr19:37139308	chr19:37251912~37265535:+
KIRP	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-5.17	4.64e-07	0.000204	-0.23	-0.3	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
KIRP	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	5.17	4.64e-07	0.000204	0.27	0.3	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
KIRP	cis	rs2283792	0.715	rs55891647	ENSG00000228050.1	TOP3BP1	5.17	4.64e-07	0.000204	0.35	0.3	Multiple sclerosis;	chr22:21824198	chr22:22223187~22224566:-
KIRP	cis	rs10916248	0.569	rs7528514	ENSG00000232628.4	RP11-365O16.3	5.17	4.65e-07	0.000204	0.33	0.3	QT interval (drug interaction);	chr1:224077561	chr1:224208747~224213279:-
KIRP	cis	rs9388451	0.868	rs1268083	ENSG00000237742.5	RP11-624M8.1	5.17	4.65e-07	0.000204	0.32	0.3	Brugada syndrome;	chr6:125727894	chr6:125578558~125749190:-
KIRP	cis	rs984222	0.617	rs1891222	ENSG00000231365.4	RP11-418J17.1	-5.17	4.65e-07	0.000204	-0.28	-0.3	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119208379	chr1:119140396~119275973:+
KIRP	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	5.17	4.65e-07	0.000204	0.27	0.3	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
KIRP	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-5.17	4.66e-07	0.000205	-0.38	-0.3	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
KIRP	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	5.17	4.66e-07	0.000205	0.29	0.3	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
KIRP	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.17	4.67e-07	0.000205	0.32	0.3	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
KIRP	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	5.17	4.67e-07	0.000205	0.24	0.3	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
KIRP	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	5.17	4.67e-07	0.000205	0.33	0.3	Temperament;	chr17:13996939	chr17:14024514~14025488:+
KIRP	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	5.17	4.68e-07	0.000205	0.28	0.3	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
KIRP	cis	rs1479119	0.681	rs1382682	ENSG00000180861.8	LINC01559	5.17	4.68e-07	0.000205	0.35	0.3	Intelligence (multi-trait analysis);	chr12:13346797	chr12:13371089~13387167:-
KIRP	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	5.17	4.68e-07	0.000205	0.3	0.3	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
KIRP	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-5.17	4.68e-07	0.000205	-0.31	-0.3	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
KIRP	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-5.17	4.68e-07	0.000205	-0.37	-0.3	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
KIRP	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	5.17	4.69e-07	0.000206	0.26	0.3	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
KIRP	cis	rs2299587	0.643	rs6586680	ENSG00000254054.2	RP11-156K13.3	5.17	4.69e-07	0.000206	0.36	0.3	Economic and political preferences;	chr8:18033669	chr8:17905756~17907887:+
KIRP	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	5.17	4.69e-07	0.000206	0.29	0.3	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
KIRP	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-5.17	4.69e-07	0.000206	-0.3	-0.3	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
KIRP	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	5.17	4.69e-07	0.000206	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
KIRP	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-5.17	4.69e-07	0.000206	-0.3	-0.3	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
KIRP	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	5.17	4.69e-07	0.000206	0.36	0.3	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
KIRP	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-5.17	4.69e-07	0.000206	-0.24	-0.3	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
KIRP	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	5.17	4.69e-07	0.000206	0.34	0.3	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
KIRP	cis	rs4660214	0.789	rs1180375	ENSG00000237624.1	OXCT2P1	5.17	4.7e-07	0.000206	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39514956~39516490:+
KIRP	cis	rs763512	0.504	rs11652399	ENSG00000276054.1	RP11-378E13.3	5.17	4.7e-07	0.000206	0.43	0.3	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37509679	chr17:37386886~37387926:+
KIRP	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-5.17	4.7e-07	0.000206	-0.31	-0.3	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
KIRP	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	5.17	4.7e-07	0.000206	0.35	0.3	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
KIRP	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	5.17	4.7e-07	0.000206	0.35	0.3	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
KIRP	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	5.17	4.7e-07	0.000206	0.38	0.3	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
KIRP	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	5.17	4.7e-07	0.000206	0.25	0.3	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
KIRP	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-5.17	4.71e-07	0.000206	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
KIRP	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	5.17	4.71e-07	0.000206	0.28	0.3	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
KIRP	cis	rs2976388	0.967	rs2976395	ENSG00000253741.1	CTD-2292P10.4	5.17	4.71e-07	0.000206	0.35	0.3	Urinary tract infection frequency;	chr8:142682332	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs1045547	ENSG00000253741.1	CTD-2292P10.4	5.17	4.71e-07	0.000206	0.35	0.3	Urinary tract infection frequency;	chr8:142682339	chr8:142702252~142726973:-
KIRP	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	5.17	4.72e-07	0.000207	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
KIRP	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	5.17	4.72e-07	0.000207	0.42	0.3	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
KIRP	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	5.17	4.72e-07	0.000207	0.28	0.3	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	5.17	4.72e-07	0.000207	0.28	0.3	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	5.17	4.72e-07	0.000207	0.28	0.3	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	5.17	4.72e-07	0.000207	0.28	0.3	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	5.17	4.72e-07	0.000207	0.28	0.3	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
KIRP	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	5.17	4.73e-07	0.000207	0.32	0.3	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
KIRP	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	5.17	4.73e-07	0.000207	0.34	0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
KIRP	cis	rs2765539	0.59	rs4659137	ENSG00000231365.4	RP11-418J17.1	-5.17	4.73e-07	0.000207	-0.33	-0.3	Waist-hip ratio;	chr1:118978171	chr1:119140396~119275973:+
KIRP	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	5.17	4.74e-07	0.000208	0.45	0.3	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
KIRP	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	5.17	4.74e-07	0.000208	0.25	0.3	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
KIRP	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-5.17	4.74e-07	0.000208	-0.24	-0.3	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
KIRP	cis	rs755249	0.51	rs613511	ENSG00000237624.1	OXCT2P1	5.17	4.75e-07	0.000208	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs629093	ENSG00000237624.1	OXCT2P1	5.17	4.75e-07	0.000208	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs2490946	ENSG00000237624.1	OXCT2P1	5.17	4.75e-07	0.000208	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39514956~39516490:+
KIRP	cis	rs755249	0.51	rs1184716	ENSG00000237624.1	OXCT2P1	5.17	4.75e-07	0.000208	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39514956~39516490:+
KIRP	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	5.17	4.75e-07	0.000208	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
KIRP	cis	rs4443100	0.67	rs9612225	ENSG00000221069.1	AC000029.1	5.17	4.75e-07	0.000208	0.41	0.3	Serum parathyroid hormone levels;	chr22:23064441	chr22:23136620~23136710:+
KIRP	cis	rs4443100	0.67	rs13054331	ENSG00000221069.1	AC000029.1	5.17	4.75e-07	0.000208	0.41	0.3	Serum parathyroid hormone levels;	chr22:23064885	chr22:23136620~23136710:+
KIRP	cis	rs4443100	0.67	rs13056137	ENSG00000221069.1	AC000029.1	5.17	4.75e-07	0.000208	0.41	0.3	Serum parathyroid hormone levels;	chr22:23065083	chr22:23136620~23136710:+
KIRP	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-5.17	4.75e-07	0.000208	-0.36	-0.3	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
KIRP	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	5.17	4.76e-07	0.000209	0.32	0.3	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
KIRP	cis	rs5758659	1	rs5758677	ENSG00000205702.9	CYP2D7	5.16	4.77e-07	0.000209	0.23	0.3	Cognitive function;	chr22:42247033	chr22:42140203~42144577:-
KIRP	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-5.16	4.77e-07	0.000209	-0.32	-0.3	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-5.16	4.77e-07	0.000209	-0.32	-0.3	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-5.16	4.77e-07	0.000209	-0.32	-0.3	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-5.16	4.77e-07	0.000209	-0.32	-0.3	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-5.16	4.77e-07	0.000209	-0.32	-0.3	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
KIRP	cis	rs2976388	1	rs2294008	ENSG00000253741.1	CTD-2292P10.4	5.16	4.77e-07	0.000209	0.35	0.3	Urinary tract infection frequency;	chr8:142680513	chr8:142702252~142726973:-
KIRP	cis	rs5758659	0.904	rs5758653	ENSG00000205702.9	CYP2D7	5.16	4.77e-07	0.000209	0.23	0.3	Cognitive function;	chr22:42217479	chr22:42140203~42144577:-
KIRP	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-5.16	4.77e-07	0.000209	-0.42	-0.3	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
KIRP	cis	rs12530	0.715	rs2294314	ENSG00000241954.1	RP1-149A16.17	-5.16	4.78e-07	0.000209	-0.35	-0.3	IgG glycosylation;	chr22:32398616	chr22:32383786~32385631:+
KIRP	cis	rs8049040	0.609	rs16972805	ENSG00000260886.1	TAT-AS1	-5.16	4.78e-07	0.000209	-0.39	-0.3	Blood protein levels;	chr16:71444346	chr16:71565789~71578187:+
KIRP	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-5.16	4.79e-07	0.000209	-0.39	-0.3	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
KIRP	cis	rs8067545	0.667	rs7222403	ENSG00000270091.1	RP11-78O7.2	-5.16	4.79e-07	0.00021	-0.2	-0.3	Schizophrenia;	chr17:19975851	chr17:19896590~19897287:-
KIRP	cis	rs5758659	1	rs134873	ENSG00000205702.9	CYP2D7	5.16	4.79e-07	0.00021	0.23	0.3	Cognitive function;	chr22:42261560	chr22:42140203~42144577:-
KIRP	cis	rs2043112	0.964	rs13166875	ENSG00000249911.1	LINC01265	5.16	4.79e-07	0.00021	0.36	0.3	Obesity-related traits;	chr5:38996536	chr5:38710367~38720273:-
KIRP	cis	rs2734839	0.964	rs4938017	ENSG00000270179.1	RP11-159N11.4	5.16	4.79e-07	0.00021	0.27	0.3	Information processing speed;	chr11:113433207	chr11:113368478~113369117:+
KIRP	cis	rs7225151	0.522	rs78534596	ENSG00000234327.6	AC012146.7	-5.16	4.79e-07	0.00021	-0.46	-0.3	Alzheimer's disease (late onset);	chr17:5232065	chr17:5111468~5115004:+
KIRP	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	5.16	4.81e-07	0.00021	0.34	0.3	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
KIRP	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-5.16	4.81e-07	0.00021	-0.22	-0.3	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
KIRP	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-5.16	4.81e-07	0.00021	-0.27	-0.3	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
KIRP	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-5.16	4.82e-07	0.000211	-0.31	-0.3	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
KIRP	cis	rs2976388	1	rs10216533	ENSG00000253741.1	CTD-2292P10.4	5.16	4.82e-07	0.000211	0.35	0.3	Urinary tract infection frequency;	chr8:142682272	chr8:142702252~142726973:-
KIRP	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-5.16	4.82e-07	0.000211	-0.32	-0.3	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
KIRP	cis	rs28386778	0.863	rs2584637	ENSG00000240280.5	TCAM1P	-5.16	4.82e-07	0.000211	-0.39	-0.3	Prudent dietary pattern;	chr17:63865592	chr17:63849292~63864379:+
KIRP	cis	rs7255436	0.965	rs7254882	ENSG00000269386.4	RAB11B-AS1	5.16	4.83e-07	0.000211	0.29	0.3	HDL cholesterol;	chr19:8388938	chr19:8374373~8390685:-
KIRP	cis	rs28386778	0.897	rs1982400	ENSG00000240280.5	TCAM1P	-5.16	4.83e-07	0.000211	-0.39	-0.3	Prudent dietary pattern;	chr17:63716458	chr17:63849292~63864379:+
KIRP	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	5.16	4.84e-07	0.000211	0.31	0.3	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
KIRP	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	5.16	4.84e-07	0.000211	0.31	0.3	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
KIRP	cis	rs8067545	0.72	rs11204419	ENSG00000270091.1	RP11-78O7.2	-5.16	4.84e-07	0.000212	-0.2	-0.3	Schizophrenia;	chr17:19985684	chr17:19896590~19897287:-
KIRP	cis	rs8067545	0.72	rs11204420	ENSG00000270091.1	RP11-78O7.2	-5.16	4.84e-07	0.000212	-0.2	-0.3	Schizophrenia;	chr17:19985707	chr17:19896590~19897287:-
KIRP	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	5.16	4.85e-07	0.000212	0.3	0.3	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
KIRP	cis	rs9543976	1	rs55927305	ENSG00000261105.4	LMO7-AS1	-5.16	4.86e-07	0.000212	-0.53	-0.3	Diabetic retinopathy;	chr13:75561213	chr13:75604700~75635994:-
KIRP	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	5.16	4.86e-07	0.000212	0.4	0.3	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
KIRP	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	5.16	4.86e-07	0.000212	0.26	0.3	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
KIRP	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	5.16	4.86e-07	0.000212	0.46	0.3	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
KIRP	cis	rs8067545	0.641	rs1638525	ENSG00000270091.1	RP11-78O7.2	-5.16	4.86e-07	0.000212	-0.2	-0.3	Schizophrenia;	chr17:19945281	chr17:19896590~19897287:-
KIRP	cis	rs4934494	0.768	rs58163515	ENSG00000232936.4	RP11-80H5.2	5.16	4.87e-07	0.000213	0.46	0.3	Red blood cell count;	chr10:89637807	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs2094214	ENSG00000232936.4	RP11-80H5.2	5.16	4.87e-07	0.000213	0.46	0.3	Red blood cell count;	chr10:89649624	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs67111731	ENSG00000232936.4	RP11-80H5.2	5.16	4.87e-07	0.000213	0.46	0.3	Red blood cell count;	chr10:89659528	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.768	rs11330	ENSG00000232936.4	RP11-80H5.2	-5.16	4.87e-07	0.000213	-0.46	-0.3	Red blood cell count;	chr10:89634322	chr10:89645282~89650667:+
KIRP	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-5.16	4.87e-07	0.000213	-0.44	-0.3	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
KIRP	cis	rs4660214	0.666	rs663892	ENSG00000237624.1	OXCT2P1	5.16	4.87e-07	0.000213	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs1180384	ENSG00000237624.1	OXCT2P1	5.16	4.87e-07	0.000213	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs683135	ENSG00000237624.1	OXCT2P1	5.16	4.87e-07	0.000213	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39514956~39516490:+
KIRP	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	5.16	4.87e-07	0.000213	0.42	0.3	Height;	chr6:109352730	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	5.16	4.87e-07	0.000213	0.42	0.3	Height;	chr6:109353355	chr6:109382795~109383666:+
KIRP	cis	rs7829975	0.533	rs13274028	ENSG00000253981.4	ALG1L13P	5.16	4.88e-07	0.000213	0.25	0.3	Mood instability;	chr8:8871683	chr8:8236003~8244667:-
KIRP	cis	rs79040073	0.682	rs12592277	ENSG00000259531.2	RP11-295H24.3	5.16	4.88e-07	0.000213	0.39	0.3	Lung cancer in ever smokers;	chr15:49436562	chr15:49365124~49366685:-
KIRP	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	5.16	4.88e-07	0.000213	0.48	0.3	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
KIRP	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	5.16	4.88e-07	0.000213	0.24	0.3	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
KIRP	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	5.16	4.88e-07	0.000213	0.32	0.3	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
KIRP	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-5.16	4.88e-07	0.000213	-0.41	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
KIRP	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-5.16	4.89e-07	0.000214	-0.37	-0.3	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
KIRP	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-5.16	4.9e-07	0.000214	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
KIRP	cis	rs41271473	0.526	rs10916343	ENSG00000212237.1	RNA5SP18	5.16	4.9e-07	0.000214	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228540260	chr1:228647912~228648032:-
KIRP	cis	rs79040073	0.637	rs79979867	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49177261	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs80214300	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49180767	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs79723325	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49193423	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs77815234	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49193495	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs75691966	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49214743	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17476361	ENSG00000259531.2	RP11-295H24.3	5.16	4.9e-07	0.000214	0.44	0.3	Lung cancer in ever smokers;	chr15:49302255	chr15:49365124~49366685:-
KIRP	cis	rs10050311	0.932	rs17012072	ENSG00000251411.1	RP11-397E7.4	-5.16	4.9e-07	0.000214	-0.37	-0.3	Insulin-related traits;	chr4:86783816	chr4:86913266~86914817:-
KIRP	cis	rs10050311	0.932	rs17694112	ENSG00000251411.1	RP11-397E7.4	-5.16	4.9e-07	0.000214	-0.37	-0.3	Insulin-related traits;	chr4:86807523	chr4:86913266~86914817:-
KIRP	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-5.16	4.9e-07	0.000214	-0.34	-0.3	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
KIRP	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-5.16	4.91e-07	0.000214	-0.32	-0.3	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-5.16	4.91e-07	0.000214	-0.32	-0.3	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-5.16	4.91e-07	0.000214	-0.32	-0.3	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-5.16	4.91e-07	0.000214	-0.32	-0.3	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
KIRP	cis	rs4660214	0.666	rs663449	ENSG00000237624.1	OXCT2P1	5.16	4.92e-07	0.000215	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39514956~39516490:+
KIRP	cis	rs4934494	0.681	rs1129777	ENSG00000232936.4	RP11-80H5.2	5.16	4.92e-07	0.000215	0.46	0.3	Red blood cell count;	chr10:89709168	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs3824607	ENSG00000232936.4	RP11-80H5.2	5.16	4.92e-07	0.000215	0.46	0.3	Red blood cell count;	chr10:89711258	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.681	rs3740035	ENSG00000232936.4	RP11-80H5.2	5.16	4.92e-07	0.000215	0.46	0.3	Red blood cell count;	chr10:89716708	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.681	rs34591435	ENSG00000232936.4	RP11-80H5.2	5.16	4.92e-07	0.000215	0.46	0.3	Red blood cell count;	chr10:89721691	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.727	rs12783845	ENSG00000232936.4	RP11-80H5.2	5.16	4.92e-07	0.000215	0.46	0.3	Red blood cell count;	chr10:89722872	chr10:89645282~89650667:+
KIRP	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.39	-0.3	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.39	-0.3	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.39	-0.3	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.4	-0.3	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.4	-0.3	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-5.16	4.92e-07	0.000215	-0.4	-0.3	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
KIRP	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-5.16	4.93e-07	0.000215	-0.27	-0.3	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	5.16	4.93e-07	0.000215	0.27	0.3	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	5.16	4.93e-07	0.000215	0.27	0.3	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
KIRP	cis	rs7267979	0.586	rs6050445	ENSG00000274414.1	RP5-965G21.4	-5.16	4.93e-07	0.000215	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25239007~25245229:-
KIRP	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	5.16	4.93e-07	0.000215	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
KIRP	cis	rs4936099	0.531	rs7103349	ENSG00000175773.11	RP11-121M22.1	5.16	4.93e-07	0.000215	0.39	0.3	Optic cup area;Vertical cup-disc ratio;	chr11:130410618	chr11:130314993~130403657:+
KIRP	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-5.16	4.93e-07	0.000215	-0.26	-0.3	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
KIRP	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-5.16	4.93e-07	0.000215	-0.24	-0.3	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
KIRP	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-5.16	4.93e-07	0.000215	-0.24	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
KIRP	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	5.16	4.94e-07	0.000215	0.28	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
KIRP	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-5.16	4.94e-07	0.000215	-0.32	-0.3	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-5.16	4.94e-07	0.000215	-0.32	-0.3	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-5.16	4.94e-07	0.000216	-0.32	-0.3	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-5.16	4.94e-07	0.000216	-0.32	-0.3	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
KIRP	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	5.16	4.95e-07	0.000216	0.36	0.3	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
KIRP	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-5.16	4.95e-07	0.000216	-0.26	-0.3	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
KIRP	cis	rs2904804	0.58	rs10128163	ENSG00000224251.5	RP11-499O7.7	5.16	4.95e-07	0.000216	0.32	0.3	Economic and political preferences (immigration/crime);	chr10:4976520	chr10:4995488~4997380:+
KIRP	cis	rs897984	0.646	rs9938088	ENSG00000275263.1	RP11-1072A3.4	-5.16	4.96e-07	0.000216	-0.31	-0.3	Dementia with Lewy bodies;	chr16:30818683	chr16:30956872~30957199:-
KIRP	cis	rs9402743	0.64	rs9494384	ENSG00000231028.7	LINC00271	-5.16	4.96e-07	0.000216	-0.27	-0.3	Systemic lupus erythematosus;	chr6:135779072	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs6570041	ENSG00000231028.7	LINC00271	-5.16	4.96e-07	0.000216	-0.27	-0.3	Phosphorus levels;	chr6:135780515	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs6923513	ENSG00000231028.7	LINC00271	-5.16	4.96e-07	0.000216	-0.27	-0.3	Phosphorus levels;	chr6:135780784	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs4895457	ENSG00000231028.7	LINC00271	-5.16	4.96e-07	0.000216	-0.27	-0.3	Phosphorus levels;	chr6:135783172	chr6:135497801~135716055:+
KIRP	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	5.16	4.96e-07	0.000216	0.31	0.3	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
KIRP	cis	rs61457372	0.563	rs9916746	ENSG00000264026.1	RP11-1124B17.1	-5.16	4.96e-07	0.000216	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72359427	chr17:72342940~72355136:+
KIRP	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	5.16	4.96e-07	0.000216	0.31	0.3	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	5.16	4.96e-07	0.000216	0.35	0.3	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
KIRP	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-5.16	4.96e-07	0.000216	-0.28	-0.3	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
KIRP	cis	rs61457372	0.563	rs9302948	ENSG00000264026.1	RP11-1124B17.1	5.16	4.97e-07	0.000216	0.33	0.3	Triptolide cytotoxicity;	chr17:72360512	chr17:72342940~72355136:+
KIRP	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-5.16	4.97e-07	0.000217	-0.31	-0.3	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
KIRP	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	5.16	4.97e-07	0.000217	0.38	0.3	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
KIRP	cis	rs2976388	1	rs2920294	ENSG00000253741.1	CTD-2292P10.4	5.16	4.97e-07	0.000217	0.34	0.3	Urinary tract infection frequency;	chr8:142683908	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920293	ENSG00000253741.1	CTD-2292P10.4	5.16	4.97e-07	0.000217	0.34	0.3	Urinary tract infection frequency;	chr8:142683996	chr8:142702252~142726973:-
KIRP	cis	rs2976388	1	rs2920292	ENSG00000253741.1	CTD-2292P10.4	5.16	4.97e-07	0.000217	0.34	0.3	Urinary tract infection frequency;	chr8:142684281	chr8:142702252~142726973:-
KIRP	cis	rs1681630	1	rs1681630	ENSG00000280615.1	Y_RNA	-5.16	4.97e-07	0.000217	-0.35	-0.3	Height;	chr11:47947600	chr11:47614898~47614994:-
KIRP	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.16	4.98e-07	0.000217	0.26	0.3	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
KIRP	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-5.16	4.98e-07	0.000217	-0.43	-0.3	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-5.16	4.98e-07	0.000217	-0.43	-0.3	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-5.16	4.98e-07	0.000217	-0.43	-0.3	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-5.16	4.98e-07	0.000217	-0.43	-0.3	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
KIRP	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-5.16	4.98e-07	0.000217	-0.24	-0.3	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-5.16	4.99e-07	0.000217	-0.24	-0.3	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-5.16	4.99e-07	0.000217	-0.24	-0.3	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
KIRP	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-5.16	4.99e-07	0.000217	-0.3	-0.3	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs10002541	ENSG00000272969.1	RP11-528I4.2	-5.16	4.99e-07	0.000217	-0.3	-0.3	Personality dimensions;	chr4:55528844	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	5.16	4.99e-07	0.000217	0.3	0.3	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
KIRP	cis	rs984222	0.838	rs6428789	ENSG00000231365.4	RP11-418J17.1	-5.16	4.99e-07	0.000217	-0.28	-0.3	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119007857	chr1:119140396~119275973:+
KIRP	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-5.16	4.99e-07	0.000217	-0.24	-0.3	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
KIRP	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	5.16	4.99e-07	0.000217	0.28	0.3	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
KIRP	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-5.16	4.99e-07	0.000217	-0.25	-0.3	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
KIRP	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-5.16	4.99e-07	0.000217	-0.33	-0.3	Height;	chr3:53027361	chr3:53064283~53065091:-
KIRP	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-5.16	5e-07	0.000218	-0.25	-0.3	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-5.16	5e-07	0.000218	-0.25	-0.3	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
KIRP	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	5.16	5e-07	0.000218	0.27	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
KIRP	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-5.16	5e-07	0.000218	-0.24	-0.3	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
KIRP	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	5.16	5e-07	0.000218	0.3	0.3	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
KIRP	cis	rs4660214	0.666	rs598415	ENSG00000237624.1	OXCT2P1	5.15	5e-07	0.000218	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39514956~39516490:+
KIRP	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-5.15	5.01e-07	0.000218	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-5.15	5.01e-07	0.000218	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
KIRP	cis	rs7772486	0.875	rs2073287	ENSG00000270638.1	RP3-466P17.1	5.15	5.02e-07	0.000218	0.26	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145735570~145737218:+
KIRP	cis	rs7747960	0.706	rs7751588	ENSG00000226193.1	RP3-398G3.5	5.15	5.03e-07	0.000219	0.46	0.3	Bipolar disorder;	chr6:152476218	chr6:152402398~152404966:+
KIRP	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-5.15	5.03e-07	0.000219	-0.42	-0.3	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
KIRP	cis	rs8067545	0.72	rs6587206	ENSG00000270091.1	RP11-78O7.2	-5.15	5.04e-07	0.000219	-0.2	-0.3	Schizophrenia;	chr17:19978274	chr17:19896590~19897287:-
KIRP	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-5.15	5.05e-07	0.00022	-0.36	-0.3	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
KIRP	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-5.15	5.05e-07	0.00022	-0.26	-0.3	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-5.15	5.05e-07	0.00022	-0.25	-0.3	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-5.15	5.05e-07	0.00022	-0.25	-0.3	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
KIRP	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-5.15	5.05e-07	0.00022	-0.46	-0.3	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
KIRP	cis	rs9402743	0.641	rs6906211	ENSG00000231028.7	LINC00271	-5.15	5.05e-07	0.00022	-0.27	-0.3	Systemic lupus erythematosus;	chr6:135778283	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs6906845	ENSG00000231028.7	LINC00271	-5.15	5.05e-07	0.00022	-0.27	-0.3	Phosphorus levels;	chr6:135778363	chr6:135497801~135716055:+
KIRP	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	5.15	5.05e-07	0.00022	0.52	0.3	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
KIRP	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-5.15	5.05e-07	0.00022	-0.41	-0.3	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
KIRP	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-5.15	5.05e-07	0.00022	-0.33	-0.3	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
KIRP	cis	rs6496932	0.663	rs2062238	ENSG00000218052.5	ADAMTS7P4	-5.15	5.06e-07	0.00022	-0.42	-0.3	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85255369~85330334:-
KIRP	cis	rs4356975	0.563	rs7442453	ENSG00000248763.2	RP13-644M16.5	-5.15	5.06e-07	0.00022	-0.33	-0.3	Obesity-related traits;	chr4:69103462	chr4:69066395~69069888:+
KIRP	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-5.15	5.06e-07	0.00022	-0.26	-0.3	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-5.15	5.06e-07	0.00022	-0.26	-0.3	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-5.15	5.06e-07	0.00022	-0.26	-0.3	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
KIRP	cis	rs4934494	0.862	rs12246250	ENSG00000240996.1	RP11-80H5.7	-5.15	5.06e-07	0.00022	-0.29	-0.3	Red blood cell count;	chr10:89629540	chr10:89694295~89697928:-
KIRP	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	5.15	5.06e-07	0.00022	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
KIRP	cis	rs61457372	0.563	rs4793435	ENSG00000264026.1	RP11-1124B17.1	-5.15	5.06e-07	0.00022	-0.34	-0.3	Triptolide cytotoxicity;	chr17:72358862	chr17:72342940~72355136:+
KIRP	cis	rs6832769	1	rs1522106	ENSG00000272969.1	RP11-528I4.2	-5.15	5.08e-07	0.000221	-0.31	-0.3	Personality dimensions;	chr4:55441047	chr4:55547112~55547889:+
KIRP	cis	rs7267979	0.966	rs2257233	ENSG00000274414.1	RP5-965G21.4	5.15	5.09e-07	0.000221	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	5.15	5.09e-07	0.000221	0.25	0.3	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	5.15	5.09e-07	0.000221	0.25	0.3	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	5.15	5.09e-07	0.000221	0.25	0.3	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
KIRP	cis	rs11158026	0.603	rs68065548	ENSG00000258413.1	RP11-665C16.6	-5.15	5.1e-07	0.000222	-0.39	-0.3	Parkinson's disease;	chr14:54979835	chr14:55262767~55272075:-
KIRP	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
KIRP	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	5.15	5.1e-07	0.000222	0.5	0.3	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
KIRP	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	5.15	5.11e-07	0.000222	0.38	0.3	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
KIRP	cis	rs7169304	0.559	rs117818498	ENSG00000259531.2	RP11-295H24.3	5.15	5.11e-07	0.000222	0.43	0.3	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49436685	chr15:49365124~49366685:-
KIRP	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-5.15	5.11e-07	0.000222	-0.28	-0.3	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
KIRP	cis	rs11158026	0.603	rs56335168	ENSG00000258413.1	RP11-665C16.6	-5.15	5.11e-07	0.000222	-0.4	-0.3	Parkinson's disease;	chr14:54978414	chr14:55262767~55272075:-
KIRP	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-5.15	5.12e-07	0.000222	-0.39	-0.3	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-5.15	5.12e-07	0.000222	-0.39	-0.3	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
KIRP	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-5.15	5.12e-07	0.000222	-0.32	-0.3	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
KIRP	cis	rs2562456	0.876	rs11085467	ENSG00000268555.1	RP11-678G14.3	5.15	5.12e-07	0.000222	0.41	0.3	Pain;	chr19:21569041	chr19:21570822~21587322:-
KIRP	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-5.15	5.12e-07	0.000222	-0.29	-0.3	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
KIRP	cis	rs897984	0.806	rs12924903	ENSG00000275263.1	RP11-1072A3.4	-5.15	5.12e-07	0.000222	-0.33	-0.3	Dementia with Lewy bodies;	chr16:30917649	chr16:30956872~30957199:-
KIRP	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.15	5.12e-07	0.000222	-0.33	-0.3	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
KIRP	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-5.15	5.12e-07	0.000222	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
KIRP	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-5.15	5.12e-07	0.000222	-0.25	-0.3	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
KIRP	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	5.15	5.13e-07	0.000222	0.28	0.3	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
KIRP	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-5.15	5.13e-07	0.000222	-0.42	-0.3	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
KIRP	cis	rs12928939	0.911	rs7202840	ENSG00000260886.1	TAT-AS1	5.15	5.13e-07	0.000223	0.41	0.3	Post bronchodilator FEV1;	chr16:71790811	chr16:71565789~71578187:+
KIRP	cis	rs12928939	0.911	rs11645704	ENSG00000260886.1	TAT-AS1	5.15	5.13e-07	0.000223	0.41	0.3	Post bronchodilator FEV1;	chr16:71792708	chr16:71565789~71578187:+
KIRP	cis	rs12928939	0.911	rs11645725	ENSG00000260886.1	TAT-AS1	5.15	5.13e-07	0.000223	0.41	0.3	Post bronchodilator FEV1;	chr16:71792980	chr16:71565789~71578187:+
KIRP	cis	rs10912872	0.599	rs2143090	ENSG00000225704.2	RP4-798A17.5	5.15	5.13e-07	0.000223	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171346438	chr1:171345089~171345320:+
KIRP	cis	rs962856	1	rs11888062	ENSG00000236780.4	AC078941.1	5.15	5.13e-07	0.000223	0.37	0.3	Pancreatic cancer;	chr2:67378226	chr2:67123357~67215319:-
KIRP	cis	rs962856	0.964	rs6546303	ENSG00000236780.4	AC078941.1	5.15	5.13e-07	0.000223	0.37	0.3	Pancreatic cancer;	chr2:67385986	chr2:67123357~67215319:-
KIRP	cis	rs28386778	0.897	rs1043127	ENSG00000240280.5	TCAM1P	-5.15	5.14e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63713850	chr17:63849292~63864379:+
KIRP	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-5.15	5.14e-07	0.000223	-0.31	-0.3	Height;	chr4:55526646	chr4:55363971~55395847:-
KIRP	cis	rs28386778	0.897	rs2727320	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63787965	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2584635	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63788574	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs9915552	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63791735	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs2597633	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63795511	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2665844	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63797095	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs2597637	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63797706	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.83	rs2597636	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63798650	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2727333	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63798663	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs2597634	ENSG00000240280.5	TCAM1P	-5.15	5.15e-07	0.000223	-0.39	-0.3	Prudent dietary pattern;	chr17:63800784	chr17:63849292~63864379:+
KIRP	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-5.15	5.15e-07	0.000223	-0.33	-0.3	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
KIRP	cis	rs9287719	0.639	rs7595845	ENSG00000234818.1	AC092687.5	-5.15	5.15e-07	0.000223	-0.37	-0.3	Prostate cancer;	chr2:10692734	chr2:10589166~10604830:+
KIRP	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	5.15	5.15e-07	0.000223	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	5.15	5.15e-07	0.000223	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	5.15	5.15e-07	0.000223	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
KIRP	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-5.15	5.16e-07	0.000224	-0.26	-0.3	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-5.15	5.16e-07	0.000224	-0.26	-0.3	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
KIRP	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	5.15	5.18e-07	0.000224	0.39	0.3	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
KIRP	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-5.15	5.19e-07	0.000225	-0.37	-0.3	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
KIRP	cis	rs1858037	0.867	rs9789444	ENSG00000237979.1	AC007389.1	5.15	5.2e-07	0.000225	0.34	0.3	Rheumatoid arthritis;	chr2:65342093	chr2:65500993~65502138:-
KIRP	cis	rs1858037	0.867	rs67817304	ENSG00000237979.1	AC007389.1	5.15	5.2e-07	0.000225	0.34	0.3	Rheumatoid arthritis;	chr2:65346982	chr2:65500993~65502138:-
KIRP	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-5.15	5.2e-07	0.000225	-0.59	-0.3	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
KIRP	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	5.15	5.2e-07	0.000225	0.33	0.3	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
KIRP	cis	rs4638749	1	rs12616140	ENSG00000225328.1	AC019100.3	-5.15	5.2e-07	0.000225	-0.39	-0.3	Blood pressure;	chr2:108251272	chr2:108167748~108217841:-
KIRP	cis	rs77741769	0.507	rs11065264	ENSG00000277423.1	RP11-173P15.9	-5.15	5.2e-07	0.000225	-0.32	-0.3	Mean corpuscular volume;	chr12:120780577	chr12:120703867~120704282:+
KIRP	cis	rs6489785	0.509	rs4767937	ENSG00000277423.1	RP11-173P15.9	-5.15	5.2e-07	0.000225	-0.32	-0.3	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120785441	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs11065284	ENSG00000277423.1	RP11-173P15.9	-5.15	5.2e-07	0.000225	-0.32	-0.3	Mean corpuscular volume;	chr12:120828818	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs11611087	ENSG00000277423.1	RP11-173P15.9	-5.15	5.2e-07	0.000225	-0.32	-0.3	Mean corpuscular volume;	chr12:120829323	chr12:120703867~120704282:+
KIRP	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	5.15	5.2e-07	0.000225	0.39	0.3	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-5.15	5.2e-07	0.000225	-0.36	-0.3	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
KIRP	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	5.15	5.21e-07	0.000225	0.35	0.3	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
KIRP	cis	rs950169	0.922	rs6603022	ENSG00000275120.1	RP11-182J1.17	-5.15	5.22e-07	0.000226	-0.42	-0.3	Schizophrenia;	chr15:84161418	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs11639244	ENSG00000275120.1	RP11-182J1.17	5.15	5.22e-07	0.000226	0.42	0.3	Schizophrenia;	chr15:84163898	chr15:84599434~84606463:-
KIRP	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-5.15	5.22e-07	0.000226	-0.25	-0.3	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
KIRP	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	5.15	5.22e-07	0.000226	0.39	0.3	Depression;	chr6:28273214	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	5.15	5.22e-07	0.000226	0.39	0.3	Depression;	chr6:28273215	chr6:28943877~28944537:+
KIRP	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-5.15	5.22e-07	0.000226	-0.37	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
KIRP	cis	rs28386778	0.83	rs2854210	ENSG00000240280.5	TCAM1P	-5.15	5.23e-07	0.000226	-0.39	-0.3	Prudent dietary pattern;	chr17:63868978	chr17:63849292~63864379:+
KIRP	cis	rs9376098	0.698	rs7774081	ENSG00000232876.1	CTA-212D2.2	-5.15	5.23e-07	0.000226	-0.35	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135139861	chr6:135055033~135060550:+
KIRP	cis	rs11992162	0.56	rs13276386	ENSG00000255495.1	AC145124.2	5.15	5.24e-07	0.000227	0.29	0.3	Monocyte count;	chr8:11939912	chr8:12194467~12196280:+
KIRP	cis	rs11992162	0.621	rs13268810	ENSG00000255495.1	AC145124.2	5.15	5.24e-07	0.000227	0.29	0.3	Monocyte count;	chr8:11939921	chr8:12194467~12196280:+
KIRP	cis	rs11992162	0.636	rs13265816	ENSG00000255495.1	AC145124.2	5.15	5.24e-07	0.000227	0.29	0.3	Monocyte count;	chr8:11939976	chr8:12194467~12196280:+
KIRP	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-5.15	5.24e-07	0.000227	-0.32	-0.3	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
KIRP	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	5.15	5.25e-07	0.000227	0.28	0.3	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-5.15	5.25e-07	0.000227	-0.36	-0.3	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-5.15	5.25e-07	0.000227	-0.25	-0.3	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
KIRP	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-5.14	5.25e-07	0.000227	-0.3	-0.3	Height;	chr11:118808920	chr11:118704607~118750263:+
KIRP	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	5.14	5.25e-07	0.000227	0.29	0.3	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
KIRP	cis	rs2109514	1	rs6466579	ENSG00000237813.3	AC002066.1	5.14	5.26e-07	0.000228	0.35	0.3	Prevalent atrial fibrillation;	chr7:116511101	chr7:116238260~116499465:-
KIRP	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-5.14	5.27e-07	0.000228	-0.25	-0.3	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
KIRP	cis	rs4356203	0.875	rs7125607	ENSG00000272034.1	SNORD14A	-5.14	5.27e-07	0.000228	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17074654~17074744:-
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	5.14	5.27e-07	0.000228	0.36	0.3	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
KIRP	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	5.14	5.27e-07	0.000228	0.47	0.3	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
KIRP	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-5.14	5.27e-07	0.000228	-0.47	-0.3	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
KIRP	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	5.14	5.27e-07	0.000228	0.29	0.3	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
KIRP	cis	rs1858037	0.867	rs871974	ENSG00000281920.1	RP11-418H16.1	-5.14	5.28e-07	0.000228	-0.39	-0.3	Rheumatoid arthritis;	chr2:65330153	chr2:65623272~65628424:+
KIRP	cis	rs1005277	0.579	rs2474568	ENSG00000151963.4	RP11-775A3.1	-5.14	5.28e-07	0.000228	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:37883594~37884109:+
KIRP	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	5.14	5.29e-07	0.000228	0.42	0.3	Height;	chr6:109352852	chr6:109382795~109383666:+
KIRP	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55551447	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55551845	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55553396	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55554025	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55554380	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55554456	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	5.14	5.29e-07	0.000228	0.29	0.3	Height;	chr4:55559957	chr4:55547112~55547889:+
KIRP	cis	rs42648	0.72	rs9655741	ENSG00000225498.1	AC002064.5	5.14	5.29e-07	0.000229	0.22	0.3	Homocysteine levels;	chr7:90304560	chr7:90312496~90322592:+
KIRP	cis	rs7224610	0.801	rs4793788	ENSG00000263096.1	RP11-515O17.2	-5.14	5.29e-07	0.000229	-0.38	-0.3	Urate levels;	chr17:55304435	chr17:55271504~55273653:-
KIRP	cis	rs28386778	0.897	rs2854214	ENSG00000240280.5	TCAM1P	5.14	5.29e-07	0.000229	0.38	0.3	Prudent dietary pattern;	chr17:63868089	chr17:63849292~63864379:+
KIRP	cis	rs962856	0.897	rs7579304	ENSG00000236780.4	AC078941.1	5.14	5.29e-07	0.000229	0.36	0.3	Pancreatic cancer;	chr2:67384118	chr2:67123357~67215319:-
KIRP	cis	rs962856	0.964	rs13415002	ENSG00000236780.4	AC078941.1	5.14	5.29e-07	0.000229	0.36	0.3	Pancreatic cancer;	chr2:67384691	chr2:67123357~67215319:-
KIRP	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	5.14	5.31e-07	0.000229	0.27	0.3	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
KIRP	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-5.14	5.31e-07	0.000229	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-5.14	5.31e-07	0.000229	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
KIRP	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	5.14	5.31e-07	0.00023	0.46	0.3	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
KIRP	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-5.14	5.33e-07	0.00023	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
KIRP	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	5.14	5.33e-07	0.00023	0.37	0.3	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	5.14	5.33e-07	0.00023	0.37	0.3	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
KIRP	cis	rs1200821	0.704	rs9888115	ENSG00000151963.4	RP11-775A3.1	5.14	5.33e-07	0.00023	0.33	0.3	Hemostatic factors and hematological phenotypes;	chr10:37369423	chr10:37883594~37884109:+
KIRP	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-5.14	5.34e-07	0.00023	-0.53	-0.3	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
KIRP	cis	rs7809615	0.515	rs10257273	ENSG00000244219.5	GS1-259H13.2	-5.14	5.34e-07	0.000231	-0.35	-0.3	Blood metabolite ratios;	chr7:99590966	chr7:99598066~99610813:+
KIRP	cis	rs4660214	0.666	rs588326	ENSG00000237624.1	OXCT2P1	5.14	5.34e-07	0.000231	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39514956~39516490:+
KIRP	cis	rs11158026	0.575	rs8008150	ENSG00000258413.1	RP11-665C16.6	-5.14	5.34e-07	0.000231	-0.39	-0.3	Parkinson's disease;	chr14:54954718	chr14:55262767~55272075:-
KIRP	cis	rs950169	0.922	rs4842940	ENSG00000275120.1	RP11-182J1.17	-5.14	5.34e-07	0.000231	-0.42	-0.3	Schizophrenia;	chr15:84162473	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs4842941	ENSG00000275120.1	RP11-182J1.17	-5.14	5.34e-07	0.000231	-0.42	-0.3	Schizophrenia;	chr15:84162560	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs12911223	ENSG00000275120.1	RP11-182J1.17	-5.14	5.34e-07	0.000231	-0.42	-0.3	Schizophrenia;	chr15:84162919	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.845	rs4106951	ENSG00000275120.1	RP11-182J1.17	5.14	5.34e-07	0.000231	0.42	0.3	Schizophrenia;	chr15:84164642	chr15:84599434~84606463:-
KIRP	cis	rs11158026	0.662	rs28481699	ENSG00000258413.1	RP11-665C16.6	-5.14	5.35e-07	0.000231	-0.37	-0.3	Parkinson's disease;	chr14:54939831	chr14:55262767~55272075:-
KIRP	cis	rs7225151	0.611	rs6502851	ENSG00000234327.6	AC012146.7	5.14	5.35e-07	0.000231	0.34	0.3	Alzheimer's disease (late onset);	chr17:5247358	chr17:5111468~5115004:+
KIRP	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	5.14	5.36e-07	0.000231	0.27	0.3	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
KIRP	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	5.14	5.36e-07	0.000231	0.37	0.3	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
KIRP	cis	rs1799949	0.965	rs35521261	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.36e-07	0.000231	-0.28	-0.3	Menopause (age at onset);	chr17:43161595	chr17:43360041~43361361:-
KIRP	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-5.14	5.36e-07	0.000231	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
KIRP	cis	rs7267979	0.866	rs6138609	ENSG00000274414.1	RP5-965G21.4	-5.14	5.36e-07	0.000231	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25239007~25245229:-
KIRP	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55459921	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55461320	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55462689	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55463606	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55466010	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55467308	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55470266	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55470874	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55474259	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55475130	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55476159	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55476736	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55477545	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55479069	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55479339	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55479996	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55482317	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	5.14	5.37e-07	0.000232	0.29	0.3	Height;	chr4:55548261	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-5.14	5.37e-07	0.000232	-0.29	-0.3	Height;	chr4:55477866	chr4:55547112~55547889:+
KIRP	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-5.14	5.37e-07	0.000232	-0.29	-0.3	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
KIRP	cis	rs67311347	0.568	rs9864544	ENSG00000230274.1	PGAM1P3	5.14	5.37e-07	0.000232	0.3	0.3	Renal cell carcinoma;	chr3:40294713	chr3:40322715~40323279:-
KIRP	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	5.14	5.37e-07	0.000232	0.29	0.3	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
KIRP	cis	rs1560104	0.597	rs735819	ENSG00000274834.1	CTD-3037G24.5	-5.14	5.37e-07	0.000232	-0.34	-0.3	Obesity-related traits;	chr16:12618370	chr16:12614451~12614852:+
KIRP	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-5.14	5.38e-07	0.000232	-0.34	-0.3	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
KIRP	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-5.14	5.38e-07	0.000232	-0.26	-0.3	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
KIRP	cis	rs2625529	0.652	rs8040216	ENSG00000260037.4	CTD-2524L6.3	5.14	5.39e-07	0.000232	0.23	0.3	Red blood cell count;	chr15:71962908	chr15:71818396~71823384:+
KIRP	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	5.14	5.39e-07	0.000232	0.32	0.3	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
KIRP	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	5.14	5.39e-07	0.000233	0.29	0.3	Height;	chr4:55546378	chr4:55547112~55547889:+
KIRP	cis	rs10050311	0.932	rs55670248	ENSG00000251411.1	RP11-397E7.4	-5.14	5.39e-07	0.000233	-0.37	-0.3	Insulin-related traits;	chr4:86804830	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.891	rs3755983	ENSG00000251411.1	RP11-397E7.4	-5.14	5.39e-07	0.000233	-0.3	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87116640	chr4:86913266~86914817:-
KIRP	cis	rs9987353	0.519	rs2929465	ENSG00000253893.2	FAM85B	5.14	5.39e-07	0.000233	0.39	0.3	Recombination measurement;	chr8:9206492	chr8:8167819~8226614:-
KIRP	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	5.14	5.39e-07	0.000233	0.46	0.3	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
KIRP	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-5.14	5.4e-07	0.000233	-0.25	-0.3	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
KIRP	cis	rs7267979	0.933	rs2261109	ENSG00000274414.1	RP5-965G21.4	-5.14	5.41e-07	0.000233	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2261720	ENSG00000274414.1	RP5-965G21.4	-5.14	5.41e-07	0.000233	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2227890	ENSG00000274414.1	RP5-965G21.4	-5.14	5.41e-07	0.000233	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.934	rs2261753	ENSG00000274414.1	RP5-965G21.4	-5.14	5.41e-07	0.000233	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25239007~25245229:-
KIRP	cis	rs9925964	0.933	rs2303222	ENSG00000232748.3	RP11-196G11.6	5.14	5.41e-07	0.000233	0.35	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31056460~31062803:+
KIRP	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-5.14	5.41e-07	0.000233	-0.28	-0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
KIRP	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	5.14	5.41e-07	0.000233	0.33	0.3	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
KIRP	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	5.14	5.42e-07	0.000233	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
KIRP	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	5.14	5.42e-07	0.000234	0.23	0.3	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
KIRP	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	5.14	5.42e-07	0.000234	0.45	0.3	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
KIRP	cis	rs2273156	1	rs12050390	ENSG00000226677.3	IGBP1P1	-5.14	5.42e-07	0.000234	-0.32	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:34991873	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12050402	ENSG00000226677.3	IGBP1P1	-5.14	5.42e-07	0.000234	-0.32	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992610	chr14:34939324~34940332:+
KIRP	cis	rs2273156	1	rs12050404	ENSG00000226677.3	IGBP1P1	-5.14	5.42e-07	0.000234	-0.32	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992664	chr14:34939324~34940332:+
KIRP	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-5.14	5.43e-07	0.000234	-0.31	-0.3	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
KIRP	cis	rs77741769	0.529	rs909053	ENSG00000277423.1	RP11-173P15.9	-5.14	5.43e-07	0.000234	-0.32	-0.3	Mean corpuscular volume;	chr12:120799865	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs3861797	ENSG00000277423.1	RP11-173P15.9	-5.14	5.43e-07	0.000234	-0.32	-0.3	Mean corpuscular volume;	chr12:120817531	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs3883901	ENSG00000277423.1	RP11-173P15.9	-5.14	5.43e-07	0.000234	-0.32	-0.3	Mean corpuscular volume;	chr12:120818717	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs989987	ENSG00000277423.1	RP11-173P15.9	-5.14	5.43e-07	0.000234	-0.32	-0.3	Mean corpuscular volume;	chr12:120836259	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs989986	ENSG00000277423.1	RP11-173P15.9	-5.14	5.43e-07	0.000234	-0.32	-0.3	Mean corpuscular volume;	chr12:120836375	chr12:120703867~120704282:+
KIRP	cis	rs11673344	0.523	rs7258438	ENSG00000226686.6	LINC01535	5.14	5.43e-07	0.000234	0.36	0.3	Obesity-related traits;	chr19:37032534	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.503	rs10414520	ENSG00000226686.6	LINC01535	5.14	5.43e-07	0.000234	0.36	0.3	Obesity-related traits;	chr19:37057279	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.503	rs1829603	ENSG00000226686.6	LINC01535	5.14	5.43e-07	0.000234	0.36	0.3	Obesity-related traits;	chr19:37065396	chr19:37251912~37265535:+
KIRP	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-5.14	5.43e-07	0.000234	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-5.14	5.43e-07	0.000234	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
KIRP	cis	rs4660214	0.666	rs11205696	ENSG00000237624.1	OXCT2P1	-5.14	5.43e-07	0.000234	-0.4	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs6600290	ENSG00000237624.1	OXCT2P1	-5.14	5.43e-07	0.000234	-0.4	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39514956~39516490:+
KIRP	cis	rs7267979	0.932	rs6132848	ENSG00000274414.1	RP5-965G21.4	-5.14	5.44e-07	0.000234	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs6115215	ENSG00000274414.1	RP5-965G21.4	-5.14	5.44e-07	0.000234	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25239007~25245229:-
KIRP	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	5.14	5.44e-07	0.000234	0.32	0.3	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	5.14	5.44e-07	0.000234	0.32	0.3	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	5.14	5.44e-07	0.000234	0.32	0.3	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
KIRP	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-5.14	5.44e-07	0.000234	-0.23	-0.3	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
KIRP	cis	rs2904804	0.506	rs10751995	ENSG00000224251.5	RP11-499O7.7	5.14	5.44e-07	0.000234	0.32	0.3	Economic and political preferences (immigration/crime);	chr10:4925954	chr10:4995488~4997380:+
KIRP	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-5.14	5.44e-07	0.000235	-0.26	-0.3	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
KIRP	cis	rs2299587	0.664	rs17593192	ENSG00000254054.2	RP11-156K13.3	5.14	5.45e-07	0.000235	0.35	0.3	Economic and political preferences;	chr8:18031686	chr8:17905756~17907887:+
KIRP	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-5.14	5.45e-07	0.000235	-0.34	-0.3	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
KIRP	cis	rs2283792	0.73	rs894095	ENSG00000228050.1	TOP3BP1	5.14	5.46e-07	0.000235	0.35	0.3	Multiple sclerosis;	chr22:21928404	chr22:22223187~22224566:-
KIRP	cis	rs1200821	0.738	rs1926128	ENSG00000151963.4	RP11-775A3.1	5.14	5.46e-07	0.000235	0.33	0.3	Hemostatic factors and hematological phenotypes;	chr10:37365692	chr10:37883594~37884109:+
KIRP	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	5.14	5.47e-07	0.000235	0.27	0.3	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
KIRP	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-5.14	5.47e-07	0.000235	-0.31	-0.3	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
KIRP	cis	rs13113518	0.683	rs9761521	ENSG00000272969.1	RP11-528I4.2	5.14	5.47e-07	0.000236	0.29	0.3	Height;	chr4:55363436	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-5.14	5.47e-07	0.000236	-0.3	-0.3	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
KIRP	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-5.14	5.48e-07	0.000236	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
KIRP	cis	rs9915657	0.933	rs4793272	ENSG00000234899.8	SOX9-AS1	-5.14	5.48e-07	0.000236	-0.26	-0.3	Thyroid hormone levels;	chr17:72143116	chr17:72034107~72237203:-
KIRP	cis	rs28386778	0.863	rs6504178	ENSG00000240280.5	TCAM1P	5.14	5.48e-07	0.000236	0.38	0.3	Prudent dietary pattern;	chr17:63735373	chr17:63849292~63864379:+
KIRP	cis	rs11673344	0.504	rs2118208	ENSG00000226686.6	LINC01535	5.14	5.48e-07	0.000236	0.36	0.3	Obesity-related traits;	chr19:37135573	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs2118209	ENSG00000226686.6	LINC01535	5.14	5.48e-07	0.000236	0.36	0.3	Obesity-related traits;	chr19:37135618	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs4805204	ENSG00000226686.6	LINC01535	5.14	5.48e-07	0.000236	0.36	0.3	Obesity-related traits;	chr19:37136666	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs4805205	ENSG00000226686.6	LINC01535	5.14	5.48e-07	0.000236	0.36	0.3	Obesity-related traits;	chr19:37136693	chr19:37251912~37265535:+
KIRP	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-5.14	5.49e-07	0.000236	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-5.14	5.49e-07	0.000236	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
KIRP	cis	rs35851103	0.6	rs4841662	ENSG00000251402.3	FAM90A25P	-5.14	5.49e-07	0.000236	-0.39	-0.3	Neuroticism;	chr8:11986249	chr8:12415080~12418090:-
KIRP	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	5.14	5.49e-07	0.000236	0.29	0.3	Height;	chr4:55484534	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	5.14	5.49e-07	0.000236	0.29	0.3	Height;	chr4:55546002	chr4:55547112~55547889:+
KIRP	cis	rs1799949	1	rs33926631	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43152446	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs1960605	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43153380	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs2037076	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43153866	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs12950779	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43154506	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.929	rs12937015	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43155456	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs4340367	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43155755	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs4792981	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43156257	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.896	rs33933393	ENSG00000279602.1	CTD-3014M21.1	-5.14	5.49e-07	0.000236	-0.28	-0.3	Menopause (age at onset);	chr17:43165415	chr17:43360041~43361361:-
KIRP	cis	rs453301	0.597	rs7001187	ENSG00000253981.4	ALG1L13P	-5.14	5.5e-07	0.000237	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8935272	chr8:8236003~8244667:-
KIRP	cis	rs7267979	0.966	rs2261790	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2261794	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2145126	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2257705	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2227892	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2257712	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2257461	ENSG00000274414.1	RP5-965G21.4	-5.13	5.51e-07	0.000237	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25239007~25245229:-
KIRP	cis	rs1479119	0.681	rs10744021	ENSG00000180861.8	LINC01559	5.13	5.51e-07	0.000237	0.35	0.3	Intelligence (multi-trait analysis);	chr12:13345958	chr12:13371089~13387167:-
KIRP	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
KIRP	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	5.13	5.51e-07	0.000237	0.51	0.3	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
KIRP	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	5.13	5.53e-07	0.000238	0.23	0.3	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
KIRP	cis	rs41271473	0.526	rs942852	ENSG00000212237.1	RNA5SP18	5.13	5.54e-07	0.000238	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228543047	chr1:228647912~228648032:-
KIRP	cis	rs41271473	0.526	rs942853	ENSG00000212237.1	RNA5SP18	5.13	5.54e-07	0.000238	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228543248	chr1:228647912~228648032:-
KIRP	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-5.13	5.54e-07	0.000238	-0.32	-0.3	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-5.13	5.54e-07	0.000238	-0.32	-0.3	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
KIRP	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	5.13	5.54e-07	0.000238	0.26	0.3	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
KIRP	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	5.13	5.54e-07	0.000238	0.3	0.3	Height;	chr14:75116565	chr14:75011269~75012851:-
KIRP	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-5.13	5.54e-07	0.000238	-0.33	-0.3	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
KIRP	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-5.13	5.55e-07	0.000239	-0.26	-0.3	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
KIRP	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-5.13	5.56e-07	0.000239	-0.31	-0.3	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
KIRP	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-5.13	5.56e-07	0.000239	-0.35	-0.3	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-5.13	5.56e-07	0.000239	-0.35	-0.3	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
KIRP	cis	rs11864453	0.826	rs8062041	ENSG00000260886.1	TAT-AS1	5.13	5.57e-07	0.000239	0.38	0.3	Fibrinogen levels;	chr16:72055065	chr16:71565789~71578187:+
KIRP	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	5.13	5.57e-07	0.000239	0.37	0.3	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
KIRP	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-5.13	5.58e-07	0.00024	-0.23	-0.3	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
KIRP	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	5.13	5.58e-07	0.00024	0.35	0.3	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
KIRP	cis	rs4663866	0.908	rs2304670	ENSG00000186235.9	AC016757.3	5.13	5.58e-07	0.00024	0.57	0.3	Irritable bowel syndrome;	chr2:238256995	chr2:238224552~238231677:-
KIRP	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-5.13	5.58e-07	0.00024	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
KIRP	cis	rs453301	0.631	rs7843789	ENSG00000253981.4	ALG1L13P	-5.13	5.58e-07	0.00024	-0.25	-0.3	Joint mobility (Beighton score);	chr8:8943051	chr8:8236003~8244667:-
KIRP	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-5.13	5.59e-07	0.00024	-0.3	-0.3	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
KIRP	cis	rs6489785	0.562	rs494632	ENSG00000277423.1	RP11-173P15.9	-5.13	5.59e-07	0.00024	-0.32	-0.3	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120751313	chr12:120703867~120704282:+
KIRP	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	5.13	5.59e-07	0.00024	0.35	0.3	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
KIRP	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-5.13	5.6e-07	0.00024	-0.34	-0.3	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
KIRP	cis	rs11992162	0.636	rs4841646	ENSG00000255495.1	AC145124.2	5.13	5.6e-07	0.00024	0.29	0.3	Monocyte count;	chr8:11941198	chr8:12194467~12196280:+
KIRP	cis	rs11992162	0.613	rs6998690	ENSG00000255495.1	AC145124.2	5.13	5.6e-07	0.00024	0.29	0.3	Monocyte count;	chr8:11941287	chr8:12194467~12196280:+
KIRP	cis	rs7299940	0.967	rs9738957	ENSG00000256250.1	RP11-989F5.1	5.13	5.61e-07	0.000241	0.29	0.3	Panic disorder;	chr12:130904256	chr12:130810606~130812438:+
KIRP	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-5.13	5.61e-07	0.000241	-0.29	-0.3	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
KIRP	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	5.13	5.61e-07	0.000241	0.31	0.3	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
KIRP	cis	rs12188164	0.61	rs6555242	ENSG00000221990.4	EXOC3-AS1	5.13	5.61e-07	0.000241	0.28	0.3	Cystic fibrosis severity;	chr5:416431	chr5:441498~443160:-
KIRP	cis	rs304029	0.716	rs2307068	ENSG00000231249.1	ITPR1-AS1	5.13	5.61e-07	0.000241	0.26	0.3	Diabetic kidney disease;	chr3:4491276	chr3:4490891~4493163:-
KIRP	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	5.13	5.61e-07	0.000241	0.78	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
KIRP	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-5.13	5.62e-07	0.000241	-0.31	-0.3	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
KIRP	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-5.13	5.62e-07	0.000241	-0.39	-0.3	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
KIRP	cis	rs41271473	0.526	rs12136157	ENSG00000212237.1	RNA5SP18	5.13	5.62e-07	0.000241	0.53	0.3	Chronic lymphocytic leukemia;	chr1:228515535	chr1:228647912~228648032:-
KIRP	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	5.13	5.62e-07	0.000241	0.25	0.3	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
KIRP	cis	rs7267979	0.966	rs2261784	ENSG00000274414.1	RP5-965G21.4	-5.13	5.63e-07	0.000241	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2261785	ENSG00000274414.1	RP5-965G21.4	-5.13	5.63e-07	0.000241	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25239007~25245229:-
KIRP	cis	rs67311347	0.544	rs9864601	ENSG00000230274.1	PGAM1P3	5.13	5.63e-07	0.000241	0.31	0.3	Renal cell carcinoma;	chr3:40303827	chr3:40322715~40323279:-
KIRP	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	5.13	5.63e-07	0.000242	0.23	0.3	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
KIRP	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	5.13	5.63e-07	0.000242	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
KIRP	cis	rs61457372	0.563	rs4793434	ENSG00000264026.1	RP11-1124B17.1	-5.13	5.64e-07	0.000242	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72356396	chr17:72342940~72355136:+
KIRP	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	5.13	5.64e-07	0.000242	0.27	0.3	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
KIRP	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-5.13	5.64e-07	0.000242	-0.29	-0.3	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
KIRP	cis	rs77741769	0.571	rs3897746	ENSG00000277423.1	RP11-173P15.9	-5.13	5.64e-07	0.000242	-0.32	-0.3	Mean corpuscular volume;	chr12:120886924	chr12:120703867~120704282:+
KIRP	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-5.13	5.64e-07	0.000242	-0.35	-0.3	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
KIRP	cis	rs11264736	0.507	rs1832582	ENSG00000272030.1	RP1-178F15.4	5.13	5.65e-07	0.000242	0.31	0.3	Lentiform nucleus volume;	chr1:154053016	chr1:153631438~153634397:-
KIRP	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-5.13	5.66e-07	0.000242	-0.23	-0.3	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
KIRP	cis	rs28386778	0.897	rs2665797	ENSG00000240280.5	TCAM1P	5.13	5.66e-07	0.000243	0.39	0.3	Prudent dietary pattern;	chr17:63845125	chr17:63849292~63864379:+
KIRP	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	5.13	5.66e-07	0.000243	0.29	0.3	Height;	chr14:75028779	chr14:75011269~75012851:-
KIRP	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-5.13	5.66e-07	0.000243	-0.24	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
KIRP	cis	rs2625529	0.652	rs2930069	ENSG00000260037.4	CTD-2524L6.3	5.13	5.66e-07	0.000243	0.23	0.3	Red blood cell count;	chr15:71934636	chr15:71818396~71823384:+
KIRP	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	5.13	5.66e-07	0.000243	0.37	0.3	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
KIRP	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	5.13	5.66e-07	0.000243	0.37	0.3	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
KIRP	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	5.13	5.66e-07	0.000243	0.37	0.3	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
KIRP	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-5.13	5.66e-07	0.000243	-0.28	-0.3	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
KIRP	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5.13	5.66e-07	0.000243	0.35	0.3	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
KIRP	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	5.13	5.67e-07	0.000243	0.36	0.3	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
KIRP	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-5.13	5.67e-07	0.000243	-0.45	-0.3	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-5.13	5.67e-07	0.000243	-0.45	-0.3	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
KIRP	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	5.13	5.67e-07	0.000243	0.28	0.3	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
KIRP	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	5.13	5.67e-07	0.000243	0.22	0.3	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
KIRP	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-5.13	5.67e-07	0.000243	-0.35	-0.3	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
KIRP	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-5.13	5.67e-07	0.000243	-0.23	-0.3	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
KIRP	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-5.13	5.67e-07	0.000243	-0.23	-0.3	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
KIRP	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	5.13	5.67e-07	0.000243	0.26	0.3	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
KIRP	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-5.13	5.68e-07	0.000243	-0.36	-0.3	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
KIRP	cis	rs11773103	0.786	rs17161323	ENSG00000224046.1	AC005076.5	5.13	5.68e-07	0.000243	0.36	0.3	Bipolar disorder or major depressive disorder (combined);	chr7:87129922	chr7:87151423~87152420:-
KIRP	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-5.13	5.68e-07	0.000243	-0.32	-0.3	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
KIRP	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	5.13	5.69e-07	0.000244	0.31	0.3	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
KIRP	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	5.13	5.69e-07	0.000244	0.31	0.3	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
KIRP	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	5.13	5.69e-07	0.000244	0.46	0.3	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
KIRP	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-5.13	5.7e-07	0.000244	-0.32	-0.3	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
KIRP	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-5.13	5.7e-07	0.000244	-0.36	-0.3	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
KIRP	cis	rs7255436	0.928	rs7250870	ENSG00000269386.4	RAB11B-AS1	5.13	5.7e-07	0.000244	0.29	0.3	HDL cholesterol;	chr19:8388798	chr19:8374373~8390685:-
KIRP	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	5.13	5.7e-07	0.000244	0.31	0.3	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
KIRP	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-5.13	5.71e-07	0.000244	-0.29	-0.3	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
KIRP	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-5.13	5.71e-07	0.000244	-0.62	-0.3	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	5.13	5.71e-07	0.000244	0.62	0.3	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
KIRP	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	5.13	5.71e-07	0.000244	0.37	0.3	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
KIRP	cis	rs6801605	1	rs6801605	ENSG00000271916.1	RP11-884K10.6	5.13	5.71e-07	0.000245	0.27	0.3	Blood protein levels;	chr3:53842191	chr3:53797764~53798019:-
KIRP	cis	rs4852324	1	rs4852324	ENSG00000217702.2	RP11-287D1.4	5.13	5.71e-07	0.000245	0.45	0.3	Systemic lupus erythematosus;	chr2:73975451	chr2:74130583~74135395:+
KIRP	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-5.13	5.71e-07	0.000245	-0.25	-0.3	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
KIRP	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-5.13	5.72e-07	0.000245	-0.33	-0.3	Height;	chr3:53034139	chr3:53064283~53065091:-
KIRP	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.13	5.72e-07	0.000245	0.3	0.3	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
KIRP	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	5.13	5.72e-07	0.000245	0.32	0.3	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
KIRP	cis	rs9928842	0.941	rs8057145	ENSG00000280152.1	RP11-331F4.5	5.13	5.72e-07	0.000245	0.38	0.3	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75245994~75250077:-
KIRP	cis	rs4356975	0.509	rs4587017	ENSG00000196472.4	RP13-644M16.4	5.13	5.73e-07	0.000245	0.33	0.3	Obesity-related traits;	chr4:69081680	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.509	rs6422323	ENSG00000196472.4	RP13-644M16.4	5.13	5.73e-07	0.000245	0.33	0.3	Obesity-related traits;	chr4:69087362	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.509	rs4694169	ENSG00000196472.4	RP13-644M16.4	5.13	5.73e-07	0.000245	0.33	0.3	Obesity-related traits;	chr4:69088433	chr4:69181660~69182372:+
KIRP	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	5.13	5.74e-07	0.000245	0.32	0.3	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
KIRP	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-5.13	5.74e-07	0.000246	-0.59	-0.3	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
KIRP	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-5.13	5.74e-07	0.000246	-0.4	-0.3	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
KIRP	cis	rs7615952	0.641	rs4490307	ENSG00000241439.1	RP11-666A20.3	5.13	5.74e-07	0.000246	0.37	0.3	Blood pressure (smoking interaction);	chr3:125993833	chr3:125958556~125958817:+
KIRP	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-5.13	5.75e-07	0.000246	-0.33	-0.3	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
KIRP	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55425312	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55429416	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55430596	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55430730	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55430740	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55431595	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55434518	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55435912	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55436576	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55436985	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55439472	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55439652	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55440643	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55441110	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55441567	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55441907	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55442184	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55442875	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55444253	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55446869	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55447523	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55450812	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55452853	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55454154	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55455650	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55456620	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55457027	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55457086	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55485974	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55487368	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55489310	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55491628	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55495801	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55496737	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55496933	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55497842	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55500224	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55501629	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55501726	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55501788	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55504176	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	5.13	5.75e-07	0.000246	0.29	0.3	Height;	chr4:55504201	chr4:55547112~55547889:+
KIRP	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	5.13	5.75e-07	0.000246	0.32	0.3	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
KIRP	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-5.13	5.75e-07	0.000246	-0.29	-0.3	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
KIRP	cis	rs11783469	0.522	rs4872125	ENSG00000253390.1	CTC-756D1.2	-5.13	5.76e-07	0.000246	-0.43	-0.3	Reticulocyte count;	chr8:23410757	chr8:23458601~23484971:+
KIRP	cis	rs7267979	1	rs2424700	ENSG00000274414.1	RP5-965G21.4	-5.13	5.76e-07	0.000246	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25239007~25245229:-
KIRP	cis	rs9810089	0.814	rs696518	ENSG00000261758.1	RP11-102M11.2	5.13	5.76e-07	0.000246	0.33	0.3	Gestational age at birth (child effect);	chr3:136401458	chr3:136752630~136755780:+
KIRP	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-5.13	5.77e-07	0.000246	-0.29	-0.3	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
KIRP	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-5.13	5.77e-07	0.000246	-0.36	-0.3	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
KIRP	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-5.13	5.77e-07	0.000247	-0.33	-0.3	Height;	chr3:53009621	chr3:53064283~53065091:-
KIRP	cis	rs7267979	1	rs6050555	ENSG00000274414.1	RP5-965G21.4	5.13	5.77e-07	0.000247	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25239007~25245229:-
KIRP	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	5.13	5.78e-07	0.000247	0.42	0.3	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
KIRP	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	5.13	5.78e-07	0.000247	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
KIRP	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	5.13	5.78e-07	0.000247	0.52	0.3	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
KIRP	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-5.12	5.78e-07	0.000247	-0.37	-0.3	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
KIRP	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-5.12	5.78e-07	0.000247	-0.37	-0.3	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
KIRP	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.12	5.79e-07	0.000247	0.34	0.3	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
KIRP	cis	rs42648	0.748	rs10227385	ENSG00000225498.1	AC002064.5	5.12	5.79e-07	0.000247	0.22	0.3	Homocysteine levels;	chr7:90261054	chr7:90312496~90322592:+
KIRP	cis	rs4236601	0.72	rs6466580	ENSG00000237813.3	AC002066.1	-5.12	5.8e-07	0.000248	-0.38	-0.3	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116514672	chr7:116238260~116499465:-
KIRP	cis	rs61457372	0.563	rs9302947	ENSG00000264026.1	RP11-1124B17.1	5.12	5.8e-07	0.000248	0.33	0.3	Triptolide cytotoxicity;	chr17:72360494	chr17:72342940~72355136:+
KIRP	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	5.12	5.81e-07	0.000248	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
KIRP	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-5.12	5.81e-07	0.000248	-0.21	-0.3	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
KIRP	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-5.12	5.81e-07	0.000248	-0.23	-0.3	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
KIRP	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	5.12	5.82e-07	0.000248	0.42	0.3	Height;	chr6:109371573	chr6:109382795~109383666:+
KIRP	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-5.12	5.82e-07	0.000249	-0.28	-0.3	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
KIRP	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	5.12	5.83e-07	0.000249	0.36	0.3	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
KIRP	cis	rs79040073	0.637	rs17394420	ENSG00000259531.2	RP11-295H24.3	5.12	5.83e-07	0.000249	0.43	0.3	Lung cancer in ever smokers;	chr15:49128619	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs17473148	ENSG00000259531.2	RP11-295H24.3	5.12	5.83e-07	0.000249	0.43	0.3	Lung cancer in ever smokers;	chr15:49137213	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs74798636	ENSG00000259531.2	RP11-295H24.3	5.12	5.83e-07	0.000249	0.43	0.3	Lung cancer in ever smokers;	chr15:49143146	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs79455310	ENSG00000259531.2	RP11-295H24.3	5.12	5.83e-07	0.000249	0.43	0.3	Lung cancer in ever smokers;	chr15:49146918	chr15:49365124~49366685:-
KIRP	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-5.12	5.83e-07	0.000249	-0.28	-0.3	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
KIRP	cis	rs11992162	0.636	rs4841642	ENSG00000255495.1	AC145124.2	5.12	5.83e-07	0.000249	0.28	0.3	Monocyte count;	chr8:11940825	chr8:12194467~12196280:+
KIRP	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-5.12	5.83e-07	0.000249	-0.26	-0.3	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
KIRP	cis	rs4660214	0.666	rs11205739	ENSG00000237624.1	OXCT2P1	-5.12	5.83e-07	0.000249	-0.4	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39514956~39516490:+
KIRP	cis	rs7299940	0.967	rs7975241	ENSG00000256250.1	RP11-989F5.1	5.12	5.83e-07	0.000249	0.3	0.3	Panic disorder;	chr12:130911870	chr12:130810606~130812438:+
KIRP	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-5.12	5.83e-07	0.000249	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
KIRP	cis	rs77741769	0.571	rs11065311	ENSG00000277423.1	RP11-173P15.9	5.12	5.83e-07	0.000249	0.31	0.3	Mean corpuscular volume;	chr12:120886312	chr12:120703867~120704282:+
KIRP	cis	rs755249	0.508	rs586057	ENSG00000237624.1	OXCT2P1	5.12	5.84e-07	0.000249	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39514956~39516490:+
KIRP	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.12	5.84e-07	0.000249	0.36	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
KIRP	cis	rs6532023	0.966	rs899041	ENSG00000249973.2	CHCHD2P7	-5.12	5.85e-07	0.00025	-0.37	-0.3	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87854043	chr4:87785920~87786371:-
KIRP	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	5.12	5.85e-07	0.00025	0.36	0.3	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
KIRP	cis	rs4356203	0.905	rs11024148	ENSG00000272034.1	SNORD14A	-5.12	5.86e-07	0.00025	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17074654~17074744:-
KIRP	cis	rs4356975	0.509	rs4458521	ENSG00000196472.4	RP13-644M16.4	5.12	5.86e-07	0.00025	0.33	0.3	Obesity-related traits;	chr4:69086240	chr4:69181660~69182372:+
KIRP	cis	rs9925964	0.933	rs4889530	ENSG00000232748.3	RP11-196G11.6	5.12	5.86e-07	0.00025	0.35	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31056460~31062803:+
KIRP	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	5.12	5.86e-07	0.00025	0.33	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
KIRP	cis	rs10078	0.51	rs2278248	ENSG00000221990.4	EXOC3-AS1	5.12	5.86e-07	0.00025	0.37	0.3	Fat distribution (HIV);	chr5:469455	chr5:441498~443160:-
KIRP	cis	rs6085948	0.861	rs6085954	ENSG00000238102.1	RP11-19D2.1	-5.12	5.87e-07	0.00025	-0.43	-0.3	Interleukin-10 levels;	chr20:7257602	chr20:7256580~7258214:-
KIRP	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.12	5.87e-07	0.00025	-0.29	-0.3	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
KIRP	cis	rs4356203	0.905	rs7938820	ENSG00000272034.1	SNORD14A	5.12	5.87e-07	0.00025	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17074654~17074744:-
KIRP	cis	rs9543976	1	rs73223968	ENSG00000261105.4	LMO7-AS1	-5.12	5.87e-07	0.00025	-0.52	-0.3	Diabetic retinopathy;	chr13:75567585	chr13:75604700~75635994:-
KIRP	cis	rs9543976	1	rs2296146	ENSG00000261105.4	LMO7-AS1	-5.12	5.87e-07	0.00025	-0.52	-0.3	Diabetic retinopathy;	chr13:75569436	chr13:75604700~75635994:-
KIRP	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-5.12	5.87e-07	0.00025	-0.37	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
KIRP	cis	rs1005277	0.579	rs2474595	ENSG00000151963.4	RP11-775A3.1	5.12	5.87e-07	0.00025	0.35	0.3	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:37883594~37884109:+
KIRP	cis	rs4356203	0.87	rs10832746	ENSG00000272034.1	SNORD14A	-5.12	5.87e-07	0.00025	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17074654~17074744:-
KIRP	cis	rs11647589	0.834	rs1505100	ENSG00000262995.1	CTD-2194A8.2	5.12	5.88e-07	0.000251	0.33	0.3	Blood metabolite levels;	chr16:20470350	chr16:20440266~20447000:-
KIRP	cis	rs308403	0.568	rs1512975	ENSG00000224786.1	CETN4P	5.12	5.89e-07	0.000251	0.44	0.3	Blood protein levels;	chr4:122736187	chr4:122730548~122732193:-
KIRP	cis	rs7569084	0.663	rs6546150	ENSG00000237979.1	AC007389.1	-5.12	5.89e-07	0.000251	-0.33	-0.3	Sum eosinophil basophil counts;	chr2:65415066	chr2:65500993~65502138:-
KIRP	cis	rs2278170	1	rs12788189	ENSG00000225101.4	OR52K3P	-5.12	5.9e-07	0.000251	-0.36	-0.3	Amyotrophic lateral sclerosis;	chr11:4462401	chr11:4474813~4475755:+
KIRP	cis	rs12220777	0.818	rs7918223	ENSG00000230091.5	TMEM254-AS1	5.12	5.9e-07	0.000251	0.41	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090023	chr10:80046860~80078912:-
KIRP	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-5.12	5.9e-07	0.000251	-0.33	-0.3	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
KIRP	cis	rs2043112	1	rs35831082	ENSG00000249911.1	LINC01265	5.12	5.9e-07	0.000251	0.36	0.3	Obesity-related traits;	chr5:38963430	chr5:38710367~38720273:-
KIRP	cis	rs28386778	0.724	rs35092235	ENSG00000240280.5	TCAM1P	-5.12	5.9e-07	0.000251	-0.39	-0.3	Prudent dietary pattern;	chr17:63867261	chr17:63849292~63864379:+
KIRP	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	5.12	5.9e-07	0.000251	0.38	0.3	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
KIRP	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-5.12	5.91e-07	0.000252	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-5.12	5.91e-07	0.000252	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-5.12	5.91e-07	0.000252	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-5.12	5.91e-07	0.000252	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-5.12	5.91e-07	0.000252	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
KIRP	cis	rs6005807	0.543	rs12168849	ENSG00000226471.5	CTA-292E10.6	-5.12	5.91e-07	0.000252	-0.45	-0.3	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28806075	chr22:28800683~28848559:+
KIRP	cis	rs9660180	0.967	rs66701417	ENSG00000268575.1	RP1-283E3.8	-5.12	5.91e-07	0.000252	-0.23	-0.3	Body mass index;	chr1:1766653	chr1:1702736~1737688:-
KIRP	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-5.12	5.91e-07	0.000252	-0.26	-0.3	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
KIRP	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-5.12	5.91e-07	0.000252	-0.33	-0.3	Height;	chr3:53047596	chr3:53064283~53065091:-
KIRP	cis	rs9595908	0.785	rs9652200	ENSG00000212293.1	SNORA16	5.12	5.91e-07	0.000252	0.29	0.3	Body mass index;	chr13:32715613	chr13:32420390~32420516:-
KIRP	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	5.12	5.91e-07	0.000252	0.37	0.3	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
KIRP	cis	rs77741769	0.529	rs3213572	ENSG00000277423.1	RP11-173P15.9	5.12	5.92e-07	0.000252	0.32	0.3	Mean corpuscular volume;	chr12:120767275	chr12:120703867~120704282:+
KIRP	cis	rs8141529	0.702	rs469990	ENSG00000226471.5	CTA-292E10.6	-5.12	5.92e-07	0.000252	-0.3	-0.3	Lymphocyte counts;	chr22:28908212	chr22:28800683~28848559:+
KIRP	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	5.12	5.92e-07	0.000252	0.28	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
KIRP	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	5.12	5.92e-07	0.000252	0.52	0.3	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
KIRP	cis	rs10504130	0.569	rs11775587	ENSG00000272024.1	RP11-546K22.3	5.12	5.92e-07	0.000252	0.35	0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-5.12	5.92e-07	0.000252	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-5.12	5.92e-07	0.000252	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-5.12	5.92e-07	0.000252	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
KIRP	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	5.12	5.92e-07	0.000252	0.25	0.3	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
KIRP	cis	rs1476679	1	rs34919929	ENSG00000281827.1	AC005071.4	5.12	5.92e-07	0.000252	0.25	0.3	Alzheimer's disease (late onset);	chr7:100414711	chr7:100344375~100344475:-
KIRP	cis	rs911119	0.657	rs6114214	ENSG00000270001.1	RP11-218C14.8	-5.12	5.92e-07	0.000252	-0.38	-0.3	Chronic kidney disease;	chr20:23647287	chr20:23631826~23632316:-
KIRP	cis	rs7267979	1	rs13038834	ENSG00000274414.1	RP5-965G21.4	-5.12	5.92e-07	0.000252	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25239007~25245229:-
KIRP	cis	rs6942407	0.592	rs6964225	ENSG00000224046.1	AC005076.5	-5.12	5.93e-07	0.000252	-0.31	-0.3	Food allergy;	chr7:87145919	chr7:87151423~87152420:-
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	5.12	5.93e-07	0.000252	0.41	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
KIRP	cis	rs11079159	1	rs10445344	ENSG00000263096.1	RP11-515O17.2	5.12	5.94e-07	0.000253	0.41	0.3	QRS duration;	chr17:55290427	chr17:55271504~55273653:-
KIRP	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-5.12	5.94e-07	0.000253	-0.29	-0.3	Height;	chr4:55487920	chr4:55547112~55547889:+
KIRP	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	5.12	5.94e-07	0.000253	0.28	0.3	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
KIRP	cis	rs116095464	0.558	rs6555058	ENSG00000248925.1	CTD-2083E4.6	-5.12	5.94e-07	0.000253	-0.45	-0.3	Breast cancer;	chr5:226261	chr5:269858~271516:-
KIRP	cis	rs4660214	0.666	rs6698791	ENSG00000237624.1	OXCT2P1	-5.12	5.95e-07	0.000253	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39514956~39516490:+
KIRP	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-5.12	5.95e-07	0.000253	-0.27	-0.3	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
KIRP	cis	rs6832769	0.961	rs28445925	ENSG00000272969.1	RP11-528I4.2	-5.12	5.95e-07	0.000253	-0.3	-0.3	Personality dimensions;	chr4:55569682	chr4:55547112~55547889:+
KIRP	cis	rs4660214	0.666	rs7414381	ENSG00000237624.1	OXCT2P1	-5.12	5.95e-07	0.000253	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39514956~39516490:+
KIRP	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-5.12	5.95e-07	0.000253	-0.31	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
KIRP	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-5.12	5.95e-07	0.000253	-0.45	-0.3	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
KIRP	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-5.12	5.96e-07	0.000253	-0.35	-0.3	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
KIRP	cis	rs41271473	0.526	rs12094319	ENSG00000212237.1	RNA5SP18	5.12	5.96e-07	0.000254	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228530135	chr1:228647912~228648032:-
KIRP	cis	rs41271473	0.526	rs12143098	ENSG00000212237.1	RNA5SP18	5.12	5.96e-07	0.000254	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228533264	chr1:228647912~228648032:-
KIRP	cis	rs41271473	0.526	rs1925720	ENSG00000212237.1	RNA5SP18	5.12	5.96e-07	0.000254	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228540676	chr1:228647912~228648032:-
KIRP	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-5.12	5.96e-07	0.000254	-0.24	-0.3	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-5.12	5.96e-07	0.000254	-0.24	-0.3	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
KIRP	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-5.12	5.96e-07	0.000254	-0.24	-0.3	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-5.12	5.96e-07	0.000254	-0.24	-0.3	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-5.12	5.96e-07	0.000254	-0.24	-0.3	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
KIRP	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-5.12	5.96e-07	0.000254	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
KIRP	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-5.12	5.97e-07	0.000254	-0.32	-0.3	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
KIRP	cis	rs9925964	0.869	rs2288004	ENSG00000232748.3	RP11-196G11.6	5.12	5.97e-07	0.000254	0.35	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31056460~31062803:+
KIRP	cis	rs9925964	0.933	rs9929899	ENSG00000232748.3	RP11-196G11.6	5.12	5.97e-07	0.000254	0.35	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31056460~31062803:+
KIRP	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-5.12	5.98e-07	0.000254	-0.39	-0.3	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
KIRP	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	5.12	5.98e-07	0.000254	0.33	0.3	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
KIRP	cis	rs11671005	0.568	rs73068325	ENSG00000269600.1	AC016629.3	-5.12	5.99e-07	0.000255	-0.41	-0.3	Mean platelet volume;	chr19:58567729	chr19:58593896~58599355:-
KIRP	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	5.12	6e-07	0.000255	0.36	0.3	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	5.12	6e-07	0.000255	0.36	0.3	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
KIRP	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-5.12	6e-07	0.000255	-0.4	-0.3	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
KIRP	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.12	6.01e-07	0.000255	-0.29	-0.3	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
KIRP	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	5.12	6.01e-07	0.000255	0.33	0.3	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
KIRP	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	5.12	6.01e-07	0.000255	0.4	0.3	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
KIRP	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	5.12	6.01e-07	0.000255	0.4	0.3	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
KIRP	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-5.12	6.01e-07	0.000255	-0.23	-0.3	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
KIRP	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-5.12	6.02e-07	0.000256	-0.34	-0.3	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-5.12	6.02e-07	0.000256	-0.34	-0.3	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
KIRP	cis	rs5758659	1	rs5758660	ENSG00000205702.9	CYP2D7	5.12	6.03e-07	0.000256	0.23	0.3	Cognitive function;	chr22:42227712	chr22:42140203~42144577:-
KIRP	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-5.12	6.03e-07	0.000256	-0.32	-0.3	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
KIRP	cis	rs2273156	1	rs2273156	ENSG00000226677.3	IGBP1P1	-5.12	6.03e-07	0.000256	-0.33	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:34969593	chr14:34939324~34940332:+
KIRP	cis	rs703842	1	rs11172333	ENSG00000270039.1	RP11-571M6.17	-5.12	6.03e-07	0.000256	-0.29	-0.3	Multiple sclerosis;	chr12:57776552	chr12:57803838~57804415:+
KIRP	cis	rs962856	1	rs4671794	ENSG00000236780.4	AC078941.1	5.12	6.03e-07	0.000256	0.36	0.3	Pancreatic cancer;	chr2:67339526	chr2:67123357~67215319:-
KIRP	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-5.12	6.03e-07	0.000256	-0.23	-0.3	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-5.12	6.03e-07	0.000256	-0.23	-0.3	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-5.12	6.03e-07	0.000256	-0.23	-0.3	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
KIRP	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-5.12	6.03e-07	0.000256	-0.32	-0.3	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
KIRP	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-5.12	6.04e-07	0.000257	-0.25	-0.3	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
KIRP	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	5.12	6.04e-07	0.000257	0.26	0.3	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
KIRP	cis	rs79040073	0.637	rs11635354	ENSG00000259531.2	RP11-295H24.3	5.12	6.05e-07	0.000257	0.42	0.3	Lung cancer in ever smokers;	chr15:49419413	chr15:49365124~49366685:-
KIRP	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-5.12	6.05e-07	0.000257	-0.43	-0.3	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
KIRP	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	5.12	6.05e-07	0.000257	0.26	0.3	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-5.12	6.06e-07	0.000257	-0.36	-0.3	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
KIRP	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-5.12	6.07e-07	0.000257	-0.26	-0.3	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-5.12	6.07e-07	0.000257	-0.26	-0.3	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-5.12	6.07e-07	0.000257	-0.26	-0.3	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-5.12	6.07e-07	0.000257	-0.26	-0.3	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
KIRP	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.12	6.07e-07	0.000258	-0.58	-0.3	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
KIRP	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-5.11	6.07e-07	0.000258	-0.34	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
KIRP	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-5.11	6.07e-07	0.000258	-0.34	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
KIRP	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	5.11	6.07e-07	0.000258	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
KIRP	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-5.11	6.08e-07	0.000258	-0.32	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
KIRP	cis	rs2278170	1	rs11032345	ENSG00000225101.4	OR52K3P	-5.11	6.08e-07	0.000258	-0.37	-0.3	Amyotrophic lateral sclerosis;	chr11:4462448	chr11:4474813~4475755:+
KIRP	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-5.11	6.08e-07	0.000258	-0.29	-0.3	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
KIRP	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	5.11	6.09e-07	0.000258	0.35	0.3	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
KIRP	cis	rs9987353	0.522	rs2929466	ENSG00000253981.4	ALG1L13P	-5.11	6.09e-07	0.000258	-0.24	-0.3	Recombination measurement;	chr8:9206389	chr8:8236003~8244667:-
KIRP	cis	rs2664588	0.561	rs11086233	ENSG00000237423.1	LINC01522	-5.11	6.09e-07	0.000258	-0.35	-0.3	Cerebrospinal fluid AB1-42 levels;	chr20:47963748	chr20:47980488~47988744:-
KIRP	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	5.11	6.1e-07	0.000259	0.35	0.3	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
KIRP	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	5.11	6.1e-07	0.000259	0.62	0.3	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
KIRP	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-5.11	6.1e-07	0.000259	-0.23	-0.3	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-5.11	6.1e-07	0.000259	-0.23	-0.3	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-5.11	6.1e-07	0.000259	-0.23	-0.3	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
KIRP	cis	rs5758659	0.967	rs5758670	ENSG00000205702.9	CYP2D7	5.11	6.1e-07	0.000259	0.23	0.3	Cognitive function;	chr22:42240681	chr22:42140203~42144577:-
KIRP	cis	rs5758659	0.967	rs5751250	ENSG00000205702.9	CYP2D7	5.11	6.1e-07	0.000259	0.23	0.3	Cognitive function;	chr22:42243639	chr22:42140203~42144577:-
KIRP	cis	rs7267979	0.844	rs6050477	ENSG00000274973.1	RP13-401N8.7	5.11	6.11e-07	0.000259	0.32	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25845497~25845862:+
KIRP	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-5.11	6.13e-07	0.00026	-0.32	-0.3	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
KIRP	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	5.11	6.13e-07	0.00026	0.28	0.3	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
KIRP	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	5.11	6.14e-07	0.00026	0.25	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
KIRP	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	5.11	6.14e-07	0.00026	0.35	0.3	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
KIRP	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	5.11	6.14e-07	0.00026	0.29	0.3	Height;	chr4:55407965	chr4:55547112~55547889:+
KIRP	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	5.11	6.15e-07	0.000261	0.35	0.3	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
KIRP	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	5.11	6.15e-07	0.000261	0.47	0.3	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
KIRP	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-5.11	6.16e-07	0.000261	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
KIRP	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-5.11	6.17e-07	0.000261	-0.59	-0.3	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
KIRP	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-5.11	6.18e-07	0.000262	-0.32	-0.3	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
KIRP	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-5.11	6.18e-07	0.000262	-0.33	-0.3	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
KIRP	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-5.11	6.19e-07	0.000262	-0.38	-0.3	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
KIRP	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-5.11	6.19e-07	0.000262	-0.33	-0.3	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
KIRP	cis	rs116095464	0.867	rs7726582	ENSG00000248925.1	CTD-2083E4.6	5.11	6.2e-07	0.000262	0.45	0.3	Breast cancer;	chr5:215234	chr5:269858~271516:-
KIRP	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-5.11	6.2e-07	0.000262	-0.38	-0.3	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
KIRP	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	5.11	6.2e-07	0.000263	0.37	0.3	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
KIRP	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	5.11	6.2e-07	0.000263	0.37	0.3	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
KIRP	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	5.11	6.21e-07	0.000263	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
KIRP	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-5.11	6.21e-07	0.000263	-0.36	-0.3	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
KIRP	cis	rs12928939	0.954	rs8057568	ENSG00000260886.1	TAT-AS1	5.11	6.21e-07	0.000263	0.4	0.3	Post bronchodilator FEV1;	chr16:71778092	chr16:71565789~71578187:+
KIRP	cis	rs12928939	0.768	rs71386932	ENSG00000260886.1	TAT-AS1	5.11	6.21e-07	0.000263	0.4	0.3	Post bronchodilator FEV1;	chr16:71782288	chr16:71565789~71578187:+
KIRP	cis	rs12928939	0.911	rs8051878	ENSG00000260886.1	TAT-AS1	5.11	6.21e-07	0.000263	0.4	0.3	Post bronchodilator FEV1;	chr16:71784528	chr16:71565789~71578187:+
KIRP	cis	rs12922317	0.521	rs378372	ENSG00000260488.1	RP11-166B2.7	-5.11	6.21e-07	0.000263	-0.38	-0.3	Schizophrenia;	chr16:11985945	chr16:11976851~11977850:-
KIRP	cis	rs12922317	0.521	rs86428	ENSG00000260488.1	RP11-166B2.7	-5.11	6.21e-07	0.000263	-0.38	-0.3	Schizophrenia;	chr16:11986538	chr16:11976851~11977850:-
KIRP	cis	rs28386778	0.863	rs2251164	ENSG00000240280.5	TCAM1P	-5.11	6.22e-07	0.000263	-0.39	-0.3	Prudent dietary pattern;	chr17:63806760	chr17:63849292~63864379:+
KIRP	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-5.11	6.23e-07	0.000264	-0.33	-0.3	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
KIRP	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-5.11	6.24e-07	0.000264	-0.34	-0.3	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-5.11	6.24e-07	0.000264	-0.34	-0.3	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-5.11	6.24e-07	0.000264	-0.34	-0.3	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
KIRP	cis	rs12922317	0.964	rs16958789	ENSG00000260488.1	RP11-166B2.7	5.11	6.24e-07	0.000264	0.38	0.3	Schizophrenia;	chr16:11981791	chr16:11976851~11977850:-
KIRP	cis	rs12922317	1	rs16958792	ENSG00000260488.1	RP11-166B2.7	5.11	6.24e-07	0.000264	0.38	0.3	Schizophrenia;	chr16:11981827	chr16:11976851~11977850:-
KIRP	cis	rs7267979	1	rs1077889	ENSG00000274414.1	RP5-965G21.4	-5.11	6.24e-07	0.000264	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-5.11	6.24e-07	0.000264	-0.23	-0.3	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
KIRP	cis	rs4638749	1	rs1466213	ENSG00000225328.1	AC019100.3	-5.11	6.25e-07	0.000264	-0.38	-0.3	Blood pressure;	chr2:108240151	chr2:108167748~108217841:-
KIRP	cis	rs4660214	0.666	rs1180376	ENSG00000237624.1	OXCT2P1	5.11	6.25e-07	0.000264	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39514956~39516490:+
KIRP	cis	rs11085466	1	rs73552479	ENSG00000268555.1	RP11-678G14.3	5.11	6.26e-07	0.000264	0.4	0.3	Colorectal or endometrial cancer;	chr19:21596014	chr19:21570822~21587322:-
KIRP	cis	rs10916248	0.55	rs7544572	ENSG00000232628.4	RP11-365O16.3	-5.11	6.26e-07	0.000265	-0.33	-0.3	QT interval (drug interaction);	chr1:224077515	chr1:224208747~224213279:-
KIRP	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	5.11	6.26e-07	0.000265	0.31	0.3	Height;	chr4:55440988	chr4:55363971~55395847:-
KIRP	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-5.11	6.26e-07	0.000265	-0.47	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
KIRP	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	5.11	6.27e-07	0.000265	0.42	0.3	Height;	chr6:109454855	chr6:109382795~109383666:+
KIRP	cis	rs4356203	0.905	rs214906	ENSG00000272034.1	SNORD14A	5.11	6.27e-07	0.000265	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17074654~17074744:-
KIRP	cis	rs2483058	0.796	rs11120291	ENSG00000261000.1	RP11-534L20.5	5.11	6.27e-07	0.000265	0.33	0.3	Cholesterol and Triglycerides;	chr1:206442751	chr1:206503948~206504456:+
KIRP	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-5.11	6.27e-07	0.000265	-0.33	-0.3	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
KIRP	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	5.11	6.28e-07	0.000265	0.35	0.3	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
KIRP	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-5.11	6.28e-07	0.000265	-0.38	-0.3	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-5.11	6.28e-07	0.000265	-0.38	-0.3	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-5.11	6.28e-07	0.000265	-0.38	-0.3	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
KIRP	cis	rs72634501	0.542	rs2134472	ENSG00000237624.1	OXCT2P1	-5.11	6.28e-07	0.000265	-0.38	-0.3	HDL cholesterol;	chr1:39137542	chr1:39514956~39516490:+
KIRP	cis	rs11673344	0.504	rs12984458	ENSG00000226686.6	LINC01535	-5.11	6.28e-07	0.000265	-0.36	-0.3	Obesity-related traits;	chr19:37138189	chr19:37251912~37265535:+
KIRP	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5.11	6.28e-07	0.000265	0.35	0.3	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
KIRP	cis	rs4356975	0.83	rs10012215	ENSG00000196472.4	RP13-644M16.4	5.11	6.29e-07	0.000266	0.33	0.3	Obesity-related traits;	chr4:69048448	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs10012240	ENSG00000196472.4	RP13-644M16.4	5.11	6.29e-07	0.000266	0.33	0.3	Obesity-related traits;	chr4:69048519	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs10012607	ENSG00000196472.4	RP13-644M16.4	5.11	6.29e-07	0.000266	0.33	0.3	Obesity-related traits;	chr4:69048866	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs7435274	ENSG00000196472.4	RP13-644M16.4	5.11	6.29e-07	0.000266	0.33	0.3	Obesity-related traits;	chr4:69050281	chr4:69181660~69182372:+
KIRP	cis	rs4356975	0.83	rs7438808	ENSG00000196472.4	RP13-644M16.4	5.11	6.29e-07	0.000266	0.33	0.3	Obesity-related traits;	chr4:69050666	chr4:69181660~69182372:+
KIRP	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	5.11	6.29e-07	0.000266	0.31	0.3	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
KIRP	cis	rs3892630	0.878	rs2903759	ENSG00000267475.1	CTD-2538C1.2	-5.11	6.3e-07	0.000266	-0.42	-0.3	Red blood cell traits;	chr19:32705041	chr19:32687089~32691750:-
KIRP	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	5.11	6.3e-07	0.000266	0.32	0.3	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
KIRP	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	5.11	6.31e-07	0.000266	0.34	0.3	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
KIRP	cis	rs28386778	0.83	rs7209321	ENSG00000240280.5	TCAM1P	-5.11	6.31e-07	0.000267	-0.39	-0.3	Prudent dietary pattern;	chr17:63778308	chr17:63849292~63864379:+
KIRP	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28071237	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28071808	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28074687	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28076559	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28076704	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28078391	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28080757	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	5.11	6.31e-07	0.000267	0.35	0.3	Depression;	chr6:28080760	chr6:28073316~28074233:+
KIRP	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	5.11	6.32e-07	0.000267	0.29	0.3	Height;	chr4:55562653	chr4:55547112~55547889:+
KIRP	cis	rs1799949	1	rs2271574	ENSG00000279602.1	CTD-3014M21.1	-5.11	6.32e-07	0.000267	-0.28	-0.3	Menopause (age at onset);	chr17:43175631	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs33994002	ENSG00000279602.1	CTD-3014M21.1	-5.11	6.32e-07	0.000267	-0.28	-0.3	Menopause (age at onset);	chr17:43176801	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs33920795	ENSG00000279602.1	CTD-3014M21.1	-5.11	6.32e-07	0.000267	-0.28	-0.3	Menopause (age at onset);	chr17:43176993	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs33918839	ENSG00000279602.1	CTD-3014M21.1	-5.11	6.32e-07	0.000267	-0.28	-0.3	Menopause (age at onset);	chr17:43177155	chr17:43360041~43361361:-
KIRP	cis	rs911119	0.954	rs2254635	ENSG00000270001.1	RP11-218C14.8	-5.11	6.32e-07	0.000267	-0.32	-0.3	Chronic kidney disease;	chr20:23642121	chr20:23631826~23632316:-
KIRP	cis	rs2439831	0.867	rs935901	ENSG00000249839.1	AC011330.5	-5.11	6.33e-07	0.000267	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43359058	chr15:43663654~43684339:-
KIRP	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-5.11	6.33e-07	0.000267	-0.3	-0.3	Height;	chr4:55364952	chr4:55363971~55395847:-
KIRP	cis	rs4660214	0.666	rs10888788	ENSG00000237624.1	OXCT2P1	-5.11	6.34e-07	0.000268	-0.38	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39514956~39516490:+
KIRP	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-5.11	6.34e-07	0.000268	-0.31	-0.3	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-5.11	6.34e-07	0.000268	-0.31	-0.3	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
KIRP	cis	rs9659323	0.73	rs7512189	ENSG00000231365.4	RP11-418J17.1	-5.11	6.34e-07	0.000268	-0.27	-0.3	Body mass index;	chr1:118999909	chr1:119140396~119275973:+
KIRP	cis	rs116095464	0.558	rs10055993	ENSG00000248925.1	CTD-2083E4.6	5.11	6.35e-07	0.000268	0.53	0.3	Breast cancer;	chr5:264181	chr5:269858~271516:-
KIRP	cis	rs962856	0.964	rs12473253	ENSG00000236780.4	AC078941.1	5.11	6.35e-07	0.000268	0.35	0.3	Pancreatic cancer;	chr2:67419189	chr2:67123357~67215319:-
KIRP	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-5.11	6.36e-07	0.000268	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-5.11	6.36e-07	0.000268	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-5.11	6.36e-07	0.000268	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-5.11	6.36e-07	0.000268	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-5.11	6.36e-07	0.000268	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
KIRP	cis	rs2504916	0.668	rs316037	ENSG00000230234.1	RP1-276N6.2	-5.11	6.36e-07	0.000268	-0.33	-0.3	Response to hepatitis C treatment;	chr6:160277145	chr6:160272617~160276130:+
KIRP	cis	rs9926296	0.586	rs1800359	ENSG00000260259.1	RP11-368I7.4	-5.11	6.36e-07	0.000268	-0.25	-0.3	Vitiligo;	chr16:89738853	chr16:89682620~89686569:-
KIRP	cis	rs453301	0.605	rs7843024	ENSG00000253981.4	ALG1L13P	-5.11	6.36e-07	0.000268	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8942466	chr8:8236003~8244667:-
KIRP	cis	rs77741769	0.571	rs35905305	ENSG00000277423.1	RP11-173P15.9	-5.11	6.36e-07	0.000268	-0.32	-0.3	Mean corpuscular volume;	chr12:120890279	chr12:120703867~120704282:+
KIRP	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-5.11	6.36e-07	0.000268	-0.28	-0.3	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
KIRP	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-5.1	6.37e-07	0.000269	-0.2	-0.3	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
KIRP	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-5.1	6.37e-07	0.000269	-0.26	-0.3	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
KIRP	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	5.1	6.37e-07	0.000269	0.41	0.3	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
KIRP	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.1	6.39e-07	0.000269	-0.37	-0.3	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
KIRP	cis	rs7267979	0.934	rs2257464	ENSG00000274414.1	RP5-965G21.4	-5.1	6.39e-07	0.000269	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25239007~25245229:-
KIRP	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-5.1	6.39e-07	0.000269	-0.26	-0.3	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
KIRP	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-5.1	6.39e-07	0.000269	-0.26	-0.3	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
KIRP	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	5.1	6.39e-07	0.000269	0.23	0.3	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
KIRP	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-5.1	6.39e-07	0.000269	-0.24	-0.3	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
KIRP	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-5.1	6.39e-07	0.000269	-0.24	-0.3	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
KIRP	cis	rs7916697	0.891	rs4746748	ENSG00000233590.1	RP11-153K11.3	5.1	6.39e-07	0.00027	0.35	0.3	Optic disc area;	chr10:68249631	chr10:68233251~68242379:-
KIRP	cis	rs7916697	0.842	rs4746749	ENSG00000233590.1	RP11-153K11.3	5.1	6.39e-07	0.00027	0.35	0.3	Optic disc area;	chr10:68249632	chr10:68233251~68242379:-
KIRP	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-5.1	6.39e-07	0.00027	-0.28	-0.3	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
KIRP	cis	rs2361718	0.5	rs4889970	ENSG00000275479.1	RP11-334C17.6	-5.1	6.4e-07	0.00027	-0.25	-0.3	Yeast infection;	chr17:80122287	chr17:80149627~80149798:+
KIRP	cis	rs732716	0.504	rs9352	ENSG00000267769.1	CTB-50L17.9	-5.1	6.4e-07	0.00027	-0.29	-0.3	Mean corpuscular volume;	chr19:4442339	chr19:4454014~4455286:+
KIRP	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-5.1	6.41e-07	0.00027	-0.36	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
KIRP	cis	rs4638749	0.906	rs34974921	ENSG00000225328.1	AC019100.3	-5.1	6.42e-07	0.00027	-0.38	-0.3	Blood pressure;	chr2:108243797	chr2:108167748~108217841:-
KIRP	cis	rs4638749	1	rs10209928	ENSG00000225328.1	AC019100.3	-5.1	6.42e-07	0.00027	-0.38	-0.3	Blood pressure;	chr2:108247442	chr2:108167748~108217841:-
KIRP	cis	rs61457372	0.509	rs12453668	ENSG00000264026.1	RP11-1124B17.1	-5.1	6.42e-07	0.00027	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72355561	chr17:72342940~72355136:+
KIRP	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-5.1	6.42e-07	0.00027	-0.4	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
KIRP	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	5.1	6.42e-07	0.00027	0.33	0.3	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	5.1	6.42e-07	0.00027	0.33	0.3	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
KIRP	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	5.1	6.42e-07	0.00027	0.33	0.3	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
KIRP	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	5.1	6.42e-07	0.000271	0.25	0.3	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
KIRP	cis	rs4934494	0.768	rs12570813	ENSG00000232936.4	RP11-80H5.2	5.1	6.42e-07	0.000271	0.45	0.3	Red blood cell count;	chr10:89630974	chr10:89645282~89650667:+
KIRP	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-5.1	6.42e-07	0.000271	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
KIRP	cis	rs3820443	0.609	rs3738303	ENSG00000234020.1	CHIAP3	-5.1	6.43e-07	0.000271	-0.47	-0.3	Late-onset Alzheimer's disease;	chr1:111351558	chr1:111353275~111367409:-
KIRP	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-5.1	6.43e-07	0.000271	-0.27	-0.3	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
KIRP	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	5.1	6.43e-07	0.000271	0.32	0.3	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
KIRP	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-5.1	6.44e-07	0.000271	-0.48	-0.3	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
KIRP	cis	rs1005277	0.579	rs2505198	ENSG00000151963.4	RP11-775A3.1	-5.1	6.44e-07	0.000271	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:37883594~37884109:+
KIRP	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	5.1	6.44e-07	0.000271	0.36	0.3	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
KIRP	cis	rs7267979	0.903	rs2500400	ENSG00000274414.1	RP5-965G21.4	5.1	6.44e-07	0.000271	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25239007~25245229:-
KIRP	cis	rs28386778	0.591	rs2584619	ENSG00000240280.5	TCAM1P	-5.1	6.44e-07	0.000271	-0.38	-0.3	Prudent dietary pattern;	chr17:63835855	chr17:63849292~63864379:+
KIRP	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.1	6.45e-07	0.000271	-0.34	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
KIRP	cis	rs28386778	1	rs2955241	ENSG00000240280.5	TCAM1P	-5.1	6.45e-07	0.000272	-0.38	-0.3	Prudent dietary pattern;	chr17:63890753	chr17:63849292~63864379:+
KIRP	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-5.1	6.45e-07	0.000272	-0.32	-0.3	Temperament;	chr17:14015466	chr17:14024514~14025488:+
KIRP	cis	rs11671005	0.656	rs55652736	ENSG00000269600.1	AC016629.3	-5.1	6.45e-07	0.000272	-0.48	-0.3	Mean platelet volume;	chr19:58496199	chr19:58593896~58599355:-
KIRP	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	5.1	6.46e-07	0.000272	0.36	0.3	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
KIRP	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	5.1	6.46e-07	0.000272	0.36	0.3	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
KIRP	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	5.1	6.46e-07	0.000272	0.23	0.3	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
KIRP	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	5.1	6.48e-07	0.000273	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
KIRP	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	5.1	6.48e-07	0.000273	0.32	0.3	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
KIRP	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.1	6.48e-07	0.000273	0.32	0.3	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
KIRP	cis	rs79040073	0.637	rs76069611	ENSG00000259531.2	RP11-295H24.3	5.1	6.49e-07	0.000273	0.43	0.3	Lung cancer in ever smokers;	chr15:49281322	chr15:49365124~49366685:-
KIRP	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-5.1	6.49e-07	0.000273	-0.41	-0.3	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
KIRP	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	5.1	6.49e-07	0.000273	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
KIRP	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-5.1	6.5e-07	0.000274	-0.32	-0.3	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
KIRP	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	5.1	6.51e-07	0.000274	0.25	0.3	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	5.1	6.51e-07	0.000274	0.25	0.3	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
KIRP	cis	rs28386778	0.897	rs2036911	ENSG00000240280.5	TCAM1P	-5.1	6.51e-07	0.000274	-0.39	-0.3	Prudent dietary pattern;	chr17:63717479	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-5.1	6.51e-07	0.000274	-0.39	-0.3	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
KIRP	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-5.1	6.51e-07	0.000274	-0.22	-0.3	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
KIRP	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	5.1	6.51e-07	0.000274	0.26	0.3	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
KIRP	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	5.1	6.52e-07	0.000274	0.29	0.3	Height;	chr4:55477426	chr4:55547112~55547889:+
KIRP	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-5.1	6.52e-07	0.000274	-0.39	-0.3	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
KIRP	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-5.1	6.52e-07	0.000274	-0.47	-0.3	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
KIRP	cis	rs2765539	0.545	rs1623409	ENSG00000231365.4	RP11-418J17.1	-5.1	6.53e-07	0.000275	-0.32	-0.3	Waist-hip ratio;	chr1:118962218	chr1:119140396~119275973:+
KIRP	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	5.1	6.53e-07	0.000275	0.28	0.3	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
KIRP	cis	rs2043112	1	rs2043112	ENSG00000249911.1	LINC01265	-5.1	6.53e-07	0.000275	-0.35	-0.3	Obesity-related traits;	chr5:38955694	chr5:38710367~38720273:-
KIRP	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-5.1	6.54e-07	0.000275	-0.29	-0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
KIRP	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-5.1	6.54e-07	0.000275	-0.29	-0.3	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
KIRP	cis	rs7267979	0.932	rs1541061	ENSG00000274414.1	RP5-965G21.4	-5.1	6.55e-07	0.000275	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs6138600	ENSG00000274414.1	RP5-965G21.4	-5.1	6.55e-07	0.000275	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25239007~25245229:-
KIRP	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	5.1	6.55e-07	0.000275	0.33	0.3	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	5.1	6.55e-07	0.000275	0.33	0.3	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	5.1	6.55e-07	0.000275	0.33	0.3	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
KIRP	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-5.1	6.55e-07	0.000275	-0.24	-0.3	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
KIRP	cis	rs1005277	0.579	rs2472178	ENSG00000151963.4	RP11-775A3.1	-5.1	6.56e-07	0.000276	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474572	ENSG00000151963.4	RP11-775A3.1	-5.1	6.56e-07	0.000276	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:37883594~37884109:+
KIRP	cis	rs2976388	0.934	rs2920279	ENSG00000253741.1	CTD-2292P10.4	5.1	6.56e-07	0.000276	0.34	0.3	Urinary tract infection frequency;	chr8:142680717	chr8:142702252~142726973:-
KIRP	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-5.1	6.56e-07	0.000276	-0.28	-0.3	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
KIRP	cis	rs600231	0.706	rs4244811	ENSG00000245532.5	NEAT1	-5.1	6.56e-07	0.000276	-0.23	-0.3	Bone mineral density;	chr11:65553309	chr11:65422774~65445540:+
KIRP	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-5.1	6.56e-07	0.000276	-0.34	-0.3	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
KIRP	cis	rs9601248	0.627	rs9545151	ENSG00000227676.3	LINC01068	-5.1	6.57e-07	0.000276	-0.37	-0.3	Major depressive disorder;	chr13:79608400	chr13:79566727~79571436:+
KIRP	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	5.1	6.57e-07	0.000276	0.35	0.3	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
KIRP	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-5.1	6.57e-07	0.000276	-0.28	-0.3	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
KIRP	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	5.1	6.57e-07	0.000276	0.47	0.3	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
KIRP	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	5.1	6.57e-07	0.000276	0.47	0.3	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
KIRP	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	5.1	6.58e-07	0.000276	0.24	0.3	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	5.1	6.58e-07	0.000276	0.24	0.3	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs3735147	ENSG00000224316.1	RP11-479O9.2	5.1	6.58e-07	0.000276	0.24	0.3	Aortic root size;	chr7:66505541	chr7:65773620~65802067:+
KIRP	cis	rs7674212	0.51	rs2720468	ENSG00000230069.3	LRRC37A15P	-5.1	6.6e-07	0.000277	-0.29	-0.3	Type 2 diabetes;	chr4:103163996	chr4:102727274~102730721:-
KIRP	cis	rs7674212	0.541	rs11727498	ENSG00000230069.3	LRRC37A15P	-5.1	6.6e-07	0.000277	-0.29	-0.3	Type 2 diabetes;	chr4:103179830	chr4:102727274~102730721:-
KIRP	cis	rs4660214	0.666	rs10888682	ENSG00000237624.1	OXCT2P1	-5.1	6.6e-07	0.000277	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39514956~39516490:+
KIRP	cis	rs4660214	0.666	rs11205698	ENSG00000237624.1	OXCT2P1	-5.1	6.6e-07	0.000277	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39514956~39516490:+
KIRP	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-5.1	6.6e-07	0.000277	-0.37	-0.3	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-5.1	6.6e-07	0.000277	-0.37	-0.3	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-5.1	6.6e-07	0.000277	-0.37	-0.3	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
KIRP	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	5.1	6.6e-07	0.000277	0.28	0.3	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
KIRP	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-5.1	6.6e-07	0.000277	-0.41	-0.3	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
KIRP	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	5.1	6.61e-07	0.000277	0.41	0.3	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
KIRP	cis	rs72717009	0.825	rs11810143	ENSG00000225217.1	HSPA7	-5.1	6.61e-07	0.000278	-0.43	-0.3	Rheumatoid arthritis;	chr1:161510859	chr1:161606291~161608217:+
KIRP	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	5.1	6.61e-07	0.000278	0.33	0.3	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
KIRP	cis	rs7267979	1	rs12428	ENSG00000274414.1	RP5-965G21.4	5.1	6.62e-07	0.000278	0.28	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25239007~25245229:-
KIRP	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-5.1	6.62e-07	0.000278	-0.41	-0.3	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
KIRP	cis	rs10912872	0.634	rs1024173	ENSG00000225704.2	RP4-798A17.5	5.1	6.63e-07	0.000278	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171353659	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.634	rs4615872	ENSG00000225704.2	RP4-798A17.5	5.1	6.63e-07	0.000278	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171353889	chr1:171345089~171345320:+
KIRP	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-5.1	6.63e-07	0.000279	-0.36	-0.3	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
KIRP	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-5.1	6.65e-07	0.000279	-0.29	-0.3	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
KIRP	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-5.1	6.65e-07	0.000279	-0.25	-0.3	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
KIRP	cis	rs4356975	0.563	rs3924192	ENSG00000248763.2	RP13-644M16.5	5.1	6.65e-07	0.000279	0.34	0.3	Obesity-related traits;	chr4:69105246	chr4:69066395~69069888:+
KIRP	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	5.1	6.66e-07	0.000279	0.19	0.3	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
KIRP	cis	rs2299587	0.841	rs12550542	ENSG00000254054.2	RP11-156K13.3	5.1	6.66e-07	0.000279	0.35	0.3	Economic and political preferences;	chr8:17979781	chr8:17905756~17907887:+
KIRP	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	5.1	6.66e-07	0.00028	0.32	0.3	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	5.1	6.66e-07	0.00028	0.32	0.3	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	5.1	6.66e-07	0.00028	0.32	0.3	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	5.1	6.66e-07	0.00028	0.32	0.3	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
KIRP	cis	rs17597773	0.527	rs2484699	ENSG00000238078.1	LINC01352	-5.1	6.67e-07	0.00028	-0.34	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220829255~220832429:+
KIRP	cis	rs7267979	1	rs2257808	ENSG00000274414.1	RP5-965G21.4	-5.1	6.67e-07	0.00028	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2257809	ENSG00000274414.1	RP5-965G21.4	-5.1	6.67e-07	0.00028	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs910997	ENSG00000274414.1	RP5-965G21.4	-5.1	6.67e-07	0.00028	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25239007~25245229:-
KIRP	cis	rs6832769	0.885	rs6815516	ENSG00000272969.1	RP11-528I4.2	-5.1	6.67e-07	0.00028	-0.29	-0.3	Personality dimensions;	chr4:55533017	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs17085889	ENSG00000272969.1	RP11-528I4.2	-5.1	6.67e-07	0.00028	-0.29	-0.3	Personality dimensions;	chr4:55535948	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs10005989	ENSG00000272969.1	RP11-528I4.2	-5.1	6.67e-07	0.00028	-0.29	-0.3	Personality dimensions;	chr4:55539039	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs28582059	ENSG00000272969.1	RP11-528I4.2	-5.1	6.67e-07	0.00028	-0.29	-0.3	Personality dimensions;	chr4:55542237	chr4:55547112~55547889:+
KIRP	cis	rs9532669	0.926	rs2324747	ENSG00000239827.7	SUGT1P3	-5.1	6.67e-07	0.00028	-0.34	-0.3	Cervical cancer;	chr13:40988883	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.926	rs9525439	ENSG00000239827.7	SUGT1P3	-5.1	6.67e-07	0.00028	-0.34	-0.3	Cervical cancer;	chr13:40992645	chr13:40908159~40921774:-
KIRP	cis	rs9532669	0.89	rs1543589	ENSG00000239827.7	SUGT1P3	-5.1	6.67e-07	0.00028	-0.34	-0.3	Cervical cancer;	chr13:40999064	chr13:40908159~40921774:-
KIRP	cis	rs947583	0.517	rs4896181	ENSG00000231028.7	LINC00271	-5.1	6.68e-07	0.00028	-0.27	-0.3	Phosphorus levels;	chr6:135788742	chr6:135497801~135716055:+
KIRP	cis	rs1799949	0.965	rs7223952	ENSG00000236383.6	LINC00854	-5.09	6.68e-07	0.00028	-0.22	-0.3	Menopause (age at onset);	chr17:43042868	chr17:43216941~43305976:-
KIRP	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	5.09	6.69e-07	0.00028	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
KIRP	cis	rs7255436	0.965	rs11666003	ENSG00000269386.4	RAB11B-AS1	5.09	6.69e-07	0.00028	0.29	0.3	HDL cholesterol;	chr19:8387218	chr19:8374373~8390685:-
KIRP	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-5.09	6.69e-07	0.000281	-0.34	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-5.09	6.69e-07	0.000281	-0.34	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
KIRP	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-5.09	6.7e-07	0.000281	-0.3	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
KIRP	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	5.09	6.7e-07	0.000281	0.32	0.3	Height;	chr4:55489895	chr4:55363971~55395847:-
KIRP	cis	rs7772486	0.875	rs9403765	ENSG00000270638.1	RP3-466P17.1	-5.09	6.71e-07	0.000281	-0.26	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145735570~145737218:+
KIRP	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-5.09	6.72e-07	0.000281	-0.48	-0.3	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
KIRP	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-5.09	6.72e-07	0.000281	-0.39	-0.3	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-5.09	6.72e-07	0.000281	-0.39	-0.3	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-5.09	6.72e-07	0.000281	-0.39	-0.3	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-5.09	6.72e-07	0.000281	-0.39	-0.3	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
KIRP	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-5.09	6.72e-07	0.000281	-0.34	-0.3	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
KIRP	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	5.09	6.72e-07	0.000282	0.38	0.3	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
KIRP	cis	rs703842	1	rs3782130	ENSG00000270039.1	RP11-571M6.17	-5.09	6.72e-07	0.000282	-0.29	-0.3	Multiple sclerosis;	chr12:57768115	chr12:57803838~57804415:+
KIRP	cis	rs703842	1	rs10877012	ENSG00000270039.1	RP11-571M6.17	-5.09	6.72e-07	0.000282	-0.29	-0.3	Multiple sclerosis;	chr12:57768302	chr12:57803838~57804415:+
KIRP	cis	rs4660214	0.666	rs4617393	ENSG00000237624.1	OXCT2P1	-5.09	6.72e-07	0.000282	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39514956~39516490:+
KIRP	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	5.09	6.73e-07	0.000282	0.4	0.3	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
KIRP	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	5.09	6.73e-07	0.000282	0.24	0.3	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
KIRP	cis	rs7747960	0.803	rs7775181	ENSG00000226193.1	RP3-398G3.5	-5.09	6.73e-07	0.000282	-0.43	-0.3	Bipolar disorder;	chr6:152462919	chr6:152402398~152404966:+
KIRP	cis	rs7747960	0.803	rs7776344	ENSG00000226193.1	RP3-398G3.5	-5.09	6.73e-07	0.000282	-0.43	-0.3	Bipolar disorder;	chr6:152462940	chr6:152402398~152404966:+
KIRP	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	5.09	6.74e-07	0.000282	0.31	0.3	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
KIRP	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	5.09	6.74e-07	0.000282	0.28	0.3	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
KIRP	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	5.09	6.75e-07	0.000283	0.32	0.3	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
KIRP	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-5.09	6.75e-07	0.000283	-0.43	-0.3	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
KIRP	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	5.09	6.76e-07	0.000283	0.32	0.3	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
KIRP	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	5.09	6.76e-07	0.000283	0.39	0.3	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
KIRP	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	5.09	6.76e-07	0.000283	0.32	0.3	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
KIRP	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	5.09	6.77e-07	0.000283	0.25	0.3	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
KIRP	cis	rs712022	0.837	rs2159668	ENSG00000246225.5	RP11-17A1.3	5.09	6.77e-07	0.000283	0.33	0.3	Dialysis-related mortality;	chr11:22817914	chr11:22829380~22945393:+
KIRP	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-5.09	6.77e-07	0.000283	-0.41	-0.3	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
KIRP	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	5.09	6.77e-07	0.000283	0.25	0.3	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
KIRP	cis	rs77741769	0.571	rs3809313	ENSG00000277423.1	RP11-173P15.9	-5.09	6.77e-07	0.000283	-0.32	-0.3	Mean corpuscular volume;	chr12:120892164	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.549	rs57697145	ENSG00000277423.1	RP11-173P15.9	-5.09	6.77e-07	0.000283	-0.32	-0.3	Mean corpuscular volume;	chr12:120895749	chr12:120703867~120704282:+
KIRP	cis	rs7672749	0.63	rs1463096	ENSG00000249973.2	CHCHD2P7	-5.09	6.78e-07	0.000284	-0.46	-0.3	TB-LM or TBLH-BMD (pleiotropy);	chr4:87871563	chr4:87785920~87786371:-
KIRP	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-5.09	6.78e-07	0.000284	-0.29	-0.3	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
KIRP	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	5.09	6.79e-07	0.000284	0.47	0.3	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
KIRP	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-5.09	6.79e-07	0.000284	-0.37	-0.3	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
KIRP	cis	rs1044826	0.642	rs1580642	ENSG00000178631.7	ACTG1P1	-5.09	6.8e-07	0.000284	-0.31	-0.3	Obesity-related traits;	chr3:139413361	chr3:139493809~139494937:+
KIRP	cis	rs1799949	1	rs8074136	ENSG00000279602.1	CTD-3014M21.1	-5.09	6.8e-07	0.000284	-0.27	-0.3	Menopause (age at onset);	chr17:43190296	chr17:43360041~43361361:-
KIRP	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-5.09	6.8e-07	0.000284	-0.22	-0.3	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
KIRP	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	5.09	6.8e-07	0.000285	0.35	0.3	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
KIRP	cis	rs600231	0.706	rs11227221	ENSG00000245532.5	NEAT1	-5.09	6.81e-07	0.000285	-0.23	-0.3	Bone mineral density;	chr11:65551794	chr11:65422774~65445540:+
KIRP	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-5.09	6.81e-07	0.000285	-0.37	-0.3	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
KIRP	cis	rs6832769	1	rs6853192	ENSG00000272969.1	RP11-528I4.2	-5.09	6.82e-07	0.000285	-0.29	-0.3	Personality dimensions;	chr4:55543087	chr4:55547112~55547889:+
KIRP	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	5.09	6.82e-07	0.000285	0.47	0.3	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
KIRP	cis	rs7255436	0.965	rs11668346	ENSG00000269386.4	RAB11B-AS1	5.09	6.82e-07	0.000285	0.29	0.3	HDL cholesterol;	chr19:8385970	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.965	rs12981318	ENSG00000269386.4	RAB11B-AS1	5.09	6.82e-07	0.000285	0.29	0.3	HDL cholesterol;	chr19:8386546	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.965	rs7351098	ENSG00000269386.4	RAB11B-AS1	5.09	6.82e-07	0.000285	0.29	0.3	HDL cholesterol;	chr19:8386787	chr19:8374373~8390685:-
KIRP	cis	rs2274273	0.516	rs2149482	ENSG00000258413.1	RP11-665C16.6	-5.09	6.83e-07	0.000285	-0.37	-0.3	Protein biomarker;	chr14:54901909	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.516	rs10136972	ENSG00000258413.1	RP11-665C16.6	-5.09	6.83e-07	0.000285	-0.37	-0.3	Protein biomarker;	chr14:54903567	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.516	rs10137071	ENSG00000258413.1	RP11-665C16.6	-5.09	6.83e-07	0.000285	-0.37	-0.3	Protein biomarker;	chr14:54903622	chr14:55262767~55272075:-
KIRP	cis	rs2274273	0.516	rs3759665	ENSG00000258413.1	RP11-665C16.6	-5.09	6.83e-07	0.000285	-0.37	-0.3	Protein biomarker;	chr14:54904887	chr14:55262767~55272075:-
KIRP	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	5.09	6.83e-07	0.000285	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
KIRP	cis	rs7378815	0.685	rs442647	ENSG00000250787.1	HMGN1P17	5.09	6.83e-07	0.000285	0.29	0.3	Breast cancer;	chr5:56358031	chr5:56381781~56382075:+
KIRP	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-5.09	6.83e-07	0.000286	-0.27	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
KIRP	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-5.09	6.83e-07	0.000286	-0.32	-0.3	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
KIRP	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-5.09	6.84e-07	0.000286	-0.31	-0.3	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
KIRP	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	5.09	6.84e-07	0.000286	0.48	0.3	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
KIRP	cis	rs10050311	0.8	rs2230600	ENSG00000251411.1	RP11-397E7.4	5.09	6.85e-07	0.000286	0.36	0.3	Insulin-related traits;	chr4:86769845	chr4:86913266~86914817:-
KIRP	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	5.09	6.85e-07	0.000286	0.25	0.3	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
KIRP	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-5.09	6.86e-07	0.000286	-0.26	-0.3	Height;	chr11:118852670	chr11:118791254~118793137:+
KIRP	cis	rs2976388	1	rs2976398	ENSG00000253741.1	CTD-2292P10.4	5.09	6.86e-07	0.000287	0.34	0.3	Urinary tract infection frequency;	chr8:142683461	chr8:142702252~142726973:-
KIRP	cis	rs4660214	0.666	rs625384	ENSG00000237624.1	OXCT2P1	5.09	6.86e-07	0.000287	0.39	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39514956~39516490:+
KIRP	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	5.09	6.86e-07	0.000287	0.45	0.3	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
KIRP	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	5.09	6.87e-07	0.000287	0.35	0.3	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-5.09	6.87e-07	0.000287	-0.26	-0.3	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
KIRP	cis	rs61457372	0.545	rs12601133	ENSG00000264026.1	RP11-1124B17.1	-5.09	6.87e-07	0.000287	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72354087	chr17:72342940~72355136:+
KIRP	cis	rs61457372	0.563	rs12453481	ENSG00000264026.1	RP11-1124B17.1	-5.09	6.87e-07	0.000287	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72354517	chr17:72342940~72355136:+
KIRP	cis	rs11647589	0.834	rs9806821	ENSG00000262995.1	CTD-2194A8.2	-5.09	6.88e-07	0.000287	-0.33	-0.3	Blood metabolite levels;	chr16:20473857	chr16:20440266~20447000:-
KIRP	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	5.09	6.88e-07	0.000287	0.34	0.3	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
KIRP	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	5.09	6.88e-07	0.000287	0.33	0.3	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
KIRP	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-5.09	6.88e-07	0.000288	-0.34	-0.3	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
KIRP	cis	rs453301	0.686	rs6748	ENSG00000253981.4	ALG1L13P	-5.09	6.89e-07	0.000288	-0.23	-0.3	Joint mobility (Beighton score);	chr8:9033292	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-5.09	6.9e-07	0.000288	-0.23	-0.3	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
KIRP	cis	rs7615952	0.599	rs6438955	ENSG00000241439.1	RP11-666A20.3	5.09	6.91e-07	0.000288	0.38	0.3	Blood pressure (smoking interaction);	chr3:126011490	chr3:125958556~125958817:+
KIRP	cis	rs4356203	0.905	rs6486352	ENSG00000272034.1	SNORD14A	5.09	6.91e-07	0.000288	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17074654~17074744:-
KIRP	cis	rs2976388	0.59	rs10110970	ENSG00000253741.1	CTD-2292P10.4	5.09	6.91e-07	0.000289	0.36	0.3	Urinary tract infection frequency;	chr8:142738992	chr8:142702252~142726973:-
KIRP	cis	rs453301	0.631	rs13250781	ENSG00000253981.4	ALG1L13P	-5.09	6.92e-07	0.000289	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8935833	chr8:8236003~8244667:-
KIRP	cis	rs11673344	0.542	rs826327	ENSG00000226686.6	LINC01535	5.09	6.92e-07	0.000289	0.37	0.3	Obesity-related traits;	chr19:37004397	chr19:37251912~37265535:+
KIRP	cis	rs4660214	0.666	rs3116387	ENSG00000237624.1	OXCT2P1	-5.09	6.92e-07	0.000289	-0.39	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39514956~39516490:+
KIRP	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-5.09	6.93e-07	0.000289	-0.28	-0.3	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-5.09	6.93e-07	0.000289	-0.28	-0.3	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
KIRP	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-5.09	6.93e-07	0.000289	-0.34	-0.3	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
KIRP	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-5.09	6.94e-07	0.000289	-0.47	-0.3	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
KIRP	cis	rs7267979	1	rs2387881	ENSG00000274414.1	RP5-965G21.4	5.09	6.95e-07	0.00029	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25239007~25245229:-
KIRP	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-5.09	6.95e-07	0.00029	-0.33	-0.3	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
KIRP	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	5.09	6.95e-07	0.00029	0.28	0.3	QT interval;	chr12:29300269	chr12:29280418~29317848:-
KIRP	cis	rs77741769	0.571	rs869781	ENSG00000277423.1	RP11-173P15.9	-5.09	6.95e-07	0.00029	-0.32	-0.3	Mean corpuscular volume;	chr12:120902443	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs61946382	ENSG00000277423.1	RP11-173P15.9	-5.09	6.95e-07	0.00029	-0.32	-0.3	Mean corpuscular volume;	chr12:120906771	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs11065324	ENSG00000277423.1	RP11-173P15.9	5.09	6.95e-07	0.00029	0.32	0.3	Mean corpuscular volume;	chr12:120908992	chr12:120703867~120704282:+
KIRP	cis	rs7255436	0.965	rs11666233	ENSG00000269386.4	RAB11B-AS1	5.09	6.95e-07	0.00029	0.29	0.3	HDL cholesterol;	chr19:8387161	chr19:8374373~8390685:-
KIRP	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-5.09	6.95e-07	0.00029	-0.3	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
KIRP	cis	rs2283792	0.764	rs2298432	ENSG00000228050.1	TOP3BP1	5.09	6.96e-07	0.00029	0.36	0.3	Multiple sclerosis;	chr22:21768900	chr22:22223187~22224566:-
KIRP	cis	rs453301	0.509	rs7000323	ENSG00000253981.4	ALG1L13P	-5.09	6.97e-07	0.000291	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8934763	chr8:8236003~8244667:-
KIRP	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	5.09	6.97e-07	0.000291	0.35	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
KIRP	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-5.09	6.97e-07	0.000291	-0.48	-0.3	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
KIRP	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-5.09	6.97e-07	0.000291	-0.62	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
KIRP	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	5.09	6.98e-07	0.000291	0.25	0.3	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
KIRP	cis	rs9532669	0.926	rs4254182	ENSG00000239827.7	SUGT1P3	-5.09	6.98e-07	0.000291	-0.35	-0.3	Cervical cancer;	chr13:40879120	chr13:40908159~40921774:-
KIRP	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.09	6.98e-07	0.000291	-0.28	-0.3	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.09	6.98e-07	0.000291	-0.28	-0.3	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.09	6.98e-07	0.000291	-0.28	-0.3	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
KIRP	cis	rs1045529	0.524	rs34251783	ENSG00000253981.4	ALG1L13P	-5.09	6.98e-07	0.000291	-0.23	-0.3	Myopia (pathological);Myopia;	chr8:9033866	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.719	rs34004903	ENSG00000253981.4	ALG1L13P	-5.09	6.98e-07	0.000291	-0.23	-0.3	Joint mobility (Beighton score);	chr8:9035094	chr8:8236003~8244667:-
KIRP	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-5.09	6.98e-07	0.000291	-0.4	-0.3	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
KIRP	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-5.09	6.99e-07	0.000291	-0.24	-0.3	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
KIRP	cis	rs4356975	0.509	rs28375964	ENSG00000196472.4	RP13-644M16.4	5.09	6.99e-07	0.000291	0.33	0.3	Obesity-related traits;	chr4:69098070	chr4:69181660~69182372:+
KIRP	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	5.09	6.99e-07	0.000292	0.31	0.3	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
KIRP	cis	rs2921073	0.605	rs2976933	ENSG00000253981.4	ALG1L13P	5.09	7e-07	0.000292	0.26	0.3	Parkinson's disease;	chr8:8397365	chr8:8236003~8244667:-
KIRP	cis	rs1153858	1	rs1346266	ENSG00000259433.2	CTD-2651B20.4	-5.09	7e-07	0.000292	-0.27	-0.3	Homoarginine levels;	chr15:45402318	chr15:45330209~45332634:-
KIRP	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-5.09	7e-07	0.000292	-0.24	-0.3	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
KIRP	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-5.09	7e-07	0.000292	-0.24	-0.3	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
KIRP	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-5.09	7e-07	0.000292	-0.24	-0.3	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
KIRP	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-5.09	7e-07	0.000292	-0.24	-0.3	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
KIRP	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-5.09	7e-07	0.000292	-0.24	-0.3	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
KIRP	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	5.09	7e-07	0.000292	0.32	0.3	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	5.09	7e-07	0.000292	0.32	0.3	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
KIRP	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	5.09	7e-07	0.000292	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
KIRP	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	5.09	7.01e-07	0.000292	0.51	0.3	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
KIRP	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	5.08	7.01e-07	0.000292	0.29	0.3	Height;	chr4:55501479	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.738	rs6849883	ENSG00000272969.1	RP11-528I4.2	5.08	7.02e-07	0.000293	0.29	0.3	Height;	chr4:55387515	chr4:55547112~55547889:+
KIRP	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-5.08	7.04e-07	0.000293	-0.32	-0.3	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
KIRP	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-5.08	7.04e-07	0.000293	-0.35	-0.3	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-5.08	7.04e-07	0.000293	-0.35	-0.3	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
KIRP	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-5.08	7.04e-07	0.000293	-0.31	-0.3	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
KIRP	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-5.08	7.04e-07	0.000293	-0.32	-0.3	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
KIRP	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	5.08	7.05e-07	0.000294	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-5.08	7.05e-07	0.000294	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-5.08	7.05e-07	0.000294	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-5.08	7.05e-07	0.000294	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
KIRP	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-5.08	7.05e-07	0.000294	-0.38	-0.3	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
KIRP	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-5.08	7.05e-07	0.000294	-0.22	-0.3	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
KIRP	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-5.08	7.06e-07	0.000294	-0.29	-0.3	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
KIRP	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-5.08	7.06e-07	0.000294	-0.26	-0.3	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-5.08	7.06e-07	0.000294	-0.26	-0.3	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-5.08	7.06e-07	0.000294	-0.26	-0.3	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
KIRP	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	5.08	7.07e-07	0.000294	0.5	0.3	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
KIRP	cis	rs875971	0.545	rs13311962	ENSG00000224316.1	RP11-479O9.2	-5.08	7.07e-07	0.000294	-0.24	-0.3	Aortic root size;	chr7:66603142	chr7:65773620~65802067:+
KIRP	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-5.08	7.08e-07	0.000295	-0.31	-0.3	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
KIRP	cis	rs12449000	1	rs12449000	ENSG00000260259.1	RP11-368I7.4	-5.08	7.08e-07	0.000295	-0.21	-0.3	Schizophrenia;	chr16:89806562	chr16:89682620~89686569:-
KIRP	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	5.08	7.08e-07	0.000295	0.39	0.3	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-5.08	7.09e-07	0.000295	-0.36	-0.3	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-5.08	7.09e-07	0.000295	-0.36	-0.3	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
KIRP	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-5.08	7.09e-07	0.000295	-0.25	-0.3	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
KIRP	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	5.08	7.09e-07	0.000295	0.3	0.3	Height;	chr14:75077398	chr14:75011269~75012851:-
KIRP	cis	rs6832769	0.961	rs28713343	ENSG00000272969.1	RP11-528I4.2	-5.08	7.1e-07	0.000296	-0.29	-0.3	Personality dimensions;	chr4:55590924	chr4:55547112~55547889:+
KIRP	cis	rs7267979	0.932	rs13040655	ENSG00000274414.1	RP5-965G21.4	-5.08	7.11e-07	0.000296	-0.3	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25239007~25245229:-
KIRP	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-5.08	7.11e-07	0.000296	-0.25	-0.3	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
KIRP	cis	rs755249	0.756	rs72637908	ENSG00000237624.1	OXCT2P1	5.08	7.11e-07	0.000296	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39514956~39516490:+
KIRP	cis	rs9595908	0.869	rs9595949	ENSG00000212293.1	SNORA16	5.08	7.11e-07	0.000296	0.28	0.3	Body mass index;	chr13:32629939	chr13:32420390~32420516:-
KIRP	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	5.08	7.13e-07	0.000297	0.26	0.3	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
KIRP	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	5.08	7.13e-07	0.000297	0.25	0.3	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-5.08	7.13e-07	0.000297	-0.23	-0.3	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
KIRP	cis	rs4356975	0.509	rs5014975	ENSG00000248763.2	RP13-644M16.5	-5.08	7.14e-07	0.000297	-0.32	-0.3	Obesity-related traits;	chr4:69130244	chr4:69066395~69069888:+
KIRP	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-5.08	7.14e-07	0.000297	-0.32	-0.3	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
KIRP	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-5.08	7.14e-07	0.000297	-0.61	-0.3	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-5.08	7.14e-07	0.000297	-0.61	-0.3	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-5.08	7.14e-07	0.000297	-0.61	-0.3	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-5.08	7.14e-07	0.000297	-0.61	-0.3	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-5.08	7.14e-07	0.000297	-0.61	-0.3	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
KIRP	cis	rs72634501	0.517	rs6600289	ENSG00000237624.1	OXCT2P1	-5.08	7.14e-07	0.000297	-0.38	-0.3	HDL cholesterol;	chr1:39148140	chr1:39514956~39516490:+
KIRP	cis	rs2299587	0.932	rs6996133	ENSG00000254054.2	RP11-156K13.3	5.08	7.14e-07	0.000297	0.35	0.3	Economic and political preferences;	chr8:17970846	chr8:17905756~17907887:+
KIRP	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-5.08	7.15e-07	0.000297	-0.34	-0.3	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
KIRP	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	5.08	7.15e-07	0.000297	0.38	0.3	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
KIRP	cis	rs897984	0.806	rs8052245	ENSG00000275263.1	RP11-1072A3.4	5.08	7.15e-07	0.000297	0.32	0.3	Dementia with Lewy bodies;	chr16:30905109	chr16:30956872~30957199:-
KIRP	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-5.08	7.15e-07	0.000298	-0.28	-0.3	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
KIRP	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-5.08	7.15e-07	0.000298	-0.28	-0.3	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
KIRP	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	5.08	7.15e-07	0.000298	0.24	0.3	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
KIRP	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	5.08	7.15e-07	0.000298	0.3	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
KIRP	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-5.08	7.16e-07	0.000298	-0.38	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
KIRP	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	5.08	7.16e-07	0.000298	0.37	0.3	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
KIRP	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	5.08	7.17e-07	0.000298	0.34	0.3	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
KIRP	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-5.08	7.17e-07	0.000298	-0.31	-0.3	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
KIRP	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-5.08	7.18e-07	0.000299	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
KIRP	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-5.08	7.19e-07	0.000299	-0.24	-0.3	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-5.08	7.19e-07	0.000299	-0.24	-0.3	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
KIRP	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	5.08	7.19e-07	0.000299	0.35	0.3	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	5.08	7.19e-07	0.000299	0.35	0.3	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
KIRP	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	5.08	7.2e-07	0.000299	0.45	0.3	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	5.08	7.2e-07	0.000299	0.45	0.3	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	5.08	7.2e-07	0.000299	0.45	0.3	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
KIRP	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-5.08	7.2e-07	0.000299	-0.31	-0.3	Height;	chr3:52994045	chr3:53064283~53065091:-
KIRP	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-5.08	7.2e-07	0.000299	-0.31	-0.3	Height;	chr3:52994990	chr3:53064283~53065091:-
KIRP	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	5.08	7.2e-07	0.000299	0.38	0.3	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
KIRP	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	5.08	7.2e-07	0.000299	0.39	0.3	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	5.08	7.2e-07	0.000299	0.39	0.3	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	5.08	7.2e-07	0.000299	0.39	0.3	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-5.08	7.21e-07	0.000299	-0.36	-0.3	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-5.08	7.21e-07	0.000299	-0.36	-0.3	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-5.08	7.21e-07	0.000299	-0.36	-0.3	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
KIRP	cis	rs7255436	0.931	rs7249520	ENSG00000269386.4	RAB11B-AS1	5.08	7.21e-07	3e-04	0.29	0.3	HDL cholesterol;	chr19:8381172	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.965	rs7249624	ENSG00000269386.4	RAB11B-AS1	5.08	7.21e-07	3e-04	0.29	0.3	HDL cholesterol;	chr19:8381251	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.83	rs4350678	ENSG00000269386.4	RAB11B-AS1	5.08	7.21e-07	3e-04	0.29	0.3	HDL cholesterol;	chr19:8382482	chr19:8374373~8390685:-
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-5.08	7.21e-07	3e-04	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
KIRP	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	5.08	7.22e-07	3e-04	0.23	0.3	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
KIRP	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	5.08	7.23e-07	3e-04	0.47	0.3	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
KIRP	cis	rs1009647	1	rs1890256	ENSG00000258413.1	RP11-665C16.6	-5.08	7.23e-07	3e-04	-0.42	-0.3	Testicular germ cell tumor;	chr14:55414558	chr14:55262767~55272075:-
KIRP	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	5.08	7.23e-07	3e-04	0.19	0.3	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
KIRP	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	5.08	7.24e-07	0.000301	0.31	0.3	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
KIRP	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	5.08	7.24e-07	0.000301	0.28	0.3	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	5.08	7.24e-07	0.000301	0.28	0.3	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
KIRP	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	5.08	7.24e-07	0.000301	0.26	0.3	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
KIRP	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	5.08	7.24e-07	0.000301	0.26	0.3	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
KIRP	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	5.08	7.24e-07	0.000301	0.32	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
KIRP	cis	rs11158026	0.603	rs8022049	ENSG00000258413.1	RP11-665C16.6	5.08	7.24e-07	0.000301	0.37	0.3	Parkinson's disease;	chr14:54996151	chr14:55262767~55272075:-
KIRP	cis	rs73198271	0.74	rs10092600	ENSG00000253981.4	ALG1L13P	-5.08	7.24e-07	0.000301	-0.25	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.74	rs10105690	ENSG00000253981.4	ALG1L13P	-5.08	7.24e-07	0.000301	-0.25	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8236003~8244667:-
KIRP	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	5.08	7.25e-07	0.000301	0.35	0.3	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-5.08	7.25e-07	0.000301	-0.36	-0.3	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-5.08	7.25e-07	0.000301	-0.36	-0.3	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
KIRP	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	5.08	7.26e-07	0.000301	0.26	0.3	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	5.08	7.26e-07	0.000301	0.26	0.3	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
KIRP	cis	rs8049040	0.524	rs891125	ENSG00000260886.1	TAT-AS1	5.08	7.26e-07	0.000301	0.4	0.3	Blood protein levels;	chr16:71397718	chr16:71565789~71578187:+
KIRP	cis	rs1476679	0.962	rs34995835	ENSG00000242294.5	STAG3L5P	5.08	7.26e-07	0.000301	0.19	0.3	Alzheimer's disease (late onset);	chr7:100392741	chr7:100336079~100351900:+
KIRP	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	5.08	7.26e-07	0.000301	0.29	0.3	Height;	chr4:55558258	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	5.08	7.26e-07	0.000301	0.29	0.3	Height;	chr4:55558259	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	5.08	7.26e-07	0.000301	0.29	0.3	Height;	chr4:55558261	chr4:55547112~55547889:+
KIRP	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-5.08	7.26e-07	0.000301	-0.36	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
KIRP	cis	rs28386778	0.897	rs2665823	ENSG00000240280.5	TCAM1P	-5.08	7.26e-07	0.000301	-0.38	-0.3	Prudent dietary pattern;	chr17:63808557	chr17:63849292~63864379:+
KIRP	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-5.08	7.27e-07	0.000302	-0.35	-0.3	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
KIRP	cis	rs4356203	0.905	rs214939	ENSG00000272034.1	SNORD14A	5.08	7.27e-07	0.000302	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs214936	ENSG00000272034.1	SNORD14A	5.08	7.27e-07	0.000302	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.792	rs620241	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.875	rs667984	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs635802	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs662711	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs598946	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs545773	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.792	rs677540	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs512852	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17074654~17074744:-
KIRP	cis	rs4356203	0.905	rs511119	ENSG00000272034.1	SNORD14A	-5.08	7.27e-07	0.000302	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17074654~17074744:-
KIRP	cis	rs1964356	0.524	rs7839585	ENSG00000253981.4	ALG1L13P	-5.08	7.28e-07	0.000302	-0.24	-0.3	Mean corpuscular volume;	chr8:8996725	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-5.08	7.28e-07	0.000302	-0.36	-0.3	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
KIRP	cis	rs6569038	0.631	rs2357030	ENSG00000253194.1	RP11-351A11.1	5.08	7.28e-07	0.000302	0.37	0.3	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065138	chr6:118934785~119031541:+
KIRP	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-5.08	7.28e-07	0.000302	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
KIRP	cis	rs77741769	0.571	rs12371178	ENSG00000277423.1	RP11-173P15.9	-5.08	7.29e-07	0.000302	-0.32	-0.3	Mean corpuscular volume;	chr12:120871326	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs10849807	ENSG00000277423.1	RP11-173P15.9	-5.08	7.29e-07	0.000302	-0.32	-0.3	Mean corpuscular volume;	chr12:120876253	chr12:120703867~120704282:+
KIRP	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-5.08	7.29e-07	0.000302	-0.25	-0.3	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
KIRP	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-5.08	7.29e-07	0.000302	-0.26	-0.3	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
KIRP	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	5.08	7.3e-07	0.000302	0.32	0.3	Height;	chr4:55450662	chr4:55363971~55395847:-
KIRP	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.08	7.3e-07	0.000303	-0.24	-0.3	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-5.08	7.3e-07	0.000303	-0.24	-0.3	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
KIRP	cis	rs8030379	0.967	rs62027761	ENSG00000230373.7	GOLGA6L5P	-5.08	7.3e-07	0.000303	-0.25	-0.3	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84507885~84516814:-
KIRP	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-5.08	7.3e-07	0.000303	-0.33	-0.3	Height;	chr3:53029908	chr3:53064283~53065091:-
KIRP	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	5.08	7.3e-07	0.000303	0.39	0.3	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
KIRP	cis	rs7267979	0.738	rs2892409	ENSG00000274973.1	RP13-401N8.7	-5.08	7.3e-07	0.000303	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:25845497~25845862:+
KIRP	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	5.08	7.3e-07	0.000303	0.44	0.3	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	5.08	7.3e-07	0.000303	0.44	0.3	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
KIRP	cis	rs4356203	0.905	rs1989405	ENSG00000272034.1	SNORD14A	5.08	7.31e-07	0.000303	0.25	0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17074654~17074744:-
KIRP	cis	rs703842	1	rs8181644	ENSG00000270039.1	RP11-571M6.17	-5.08	7.31e-07	0.000303	-0.28	-0.3	Multiple sclerosis;	chr12:57779683	chr12:57803838~57804415:+
KIRP	cis	rs2976388	0.967	rs2976393	ENSG00000253741.1	CTD-2292P10.4	5.08	7.31e-07	0.000303	0.34	0.3	Urinary tract infection frequency;	chr8:142682200	chr8:142702252~142726973:-
KIRP	cis	rs6801605	0.963	rs6445607	ENSG00000271916.1	RP11-884K10.6	-5.08	7.31e-07	0.000303	-0.27	-0.3	Blood protein levels;	chr3:53843122	chr3:53797764~53798019:-
KIRP	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-5.08	7.32e-07	0.000303	-0.37	-0.3	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
KIRP	cis	rs8141529	0.764	rs5762824	ENSG00000226471.5	CTA-292E10.6	-5.08	7.32e-07	0.000303	-0.3	-0.3	Lymphocyte counts;	chr22:28826942	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.764	rs5752807	ENSG00000226471.5	CTA-292E10.6	-5.08	7.32e-07	0.000303	-0.3	-0.3	Lymphocyte counts;	chr22:28827181	chr22:28800683~28848559:+
KIRP	cis	rs4578769	0.569	rs3851822	ENSG00000265943.1	RP11-739L10.1	-5.08	7.33e-07	0.000304	-0.37	-0.3	Eosinophil percentage of white cells;	chr18:22882829	chr18:22699481~22933764:-
KIRP	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	5.08	7.34e-07	0.000304	0.45	0.3	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
KIRP	cis	rs6832769	0.696	rs7660054	ENSG00000272969.1	RP11-528I4.2	5.08	7.34e-07	0.000304	0.29	0.3	Personality dimensions;	chr4:55402340	chr4:55547112~55547889:+
KIRP	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	5.08	7.34e-07	0.000304	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
KIRP	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	5.08	7.35e-07	0.000304	0.23	0.3	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
KIRP	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-5.08	7.35e-07	0.000304	-0.26	-0.3	Height;	chr11:118859432	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-5.08	7.35e-07	0.000304	-0.26	-0.3	Height;	chr11:118860890	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-5.08	7.35e-07	0.000304	-0.26	-0.3	Height;	chr11:118861053	chr11:118791254~118793137:+
KIRP	cis	rs748404	0.578	rs2244746	ENSG00000205771.5	CATSPER2P1	-5.08	7.35e-07	0.000304	-0.34	-0.3	Lung cancer;	chr15:43402885	chr15:43726918~43747094:-
KIRP	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-5.07	7.36e-07	0.000305	-0.61	-0.3	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
KIRP	cis	rs4356203	0.905	rs651513	ENSG00000272034.1	SNORD14A	-5.07	7.36e-07	0.000305	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17074654~17074744:-
KIRP	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-5.07	7.36e-07	0.000305	-0.35	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
KIRP	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-5.07	7.36e-07	0.000305	-0.35	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
KIRP	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-5.07	7.36e-07	0.000305	-0.25	-0.3	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
KIRP	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	5.07	7.37e-07	0.000305	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	5.07	7.37e-07	0.000305	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.545	rs73142265	ENSG00000236529.1	RP13-254B10.1	5.07	7.37e-07	0.000305	0.28	0.3	Aortic root size;	chr7:66234510	chr7:65840212~65840596:+
KIRP	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-5.07	7.39e-07	0.000306	-0.41	-0.3	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
KIRP	cis	rs453301	0.686	rs1045527	ENSG00000253981.4	ALG1L13P	-5.07	7.39e-07	0.000306	-0.23	-0.3	Joint mobility (Beighton score);	chr8:9032531	chr8:8236003~8244667:-
KIRP	cis	rs77741769	0.591	rs73413868	ENSG00000277423.1	RP11-173P15.9	-5.07	7.39e-07	0.000306	-0.32	-0.3	Mean corpuscular volume;	chr12:120863929	chr12:120703867~120704282:+
KIRP	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-5.07	7.39e-07	0.000306	-0.2	-0.3	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
KIRP	cis	rs28386778	0.897	rs2665795	ENSG00000240280.5	TCAM1P	5.07	7.4e-07	0.000306	0.36	0.3	Prudent dietary pattern;	chr17:63847912	chr17:63849292~63864379:+
KIRP	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	5.07	7.41e-07	0.000306	0.38	0.3	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
KIRP	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	5.07	7.41e-07	0.000307	0.51	0.3	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
KIRP	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	5.07	7.41e-07	0.000307	0.39	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
KIRP	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	5.07	7.41e-07	0.000307	0.3	0.3	Height;	chr14:75094449	chr14:75011269~75012851:-
KIRP	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-5.07	7.42e-07	0.000307	-0.31	-0.3	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
KIRP	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-5.07	7.42e-07	0.000307	-0.25	-0.3	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-5.07	7.42e-07	0.000307	-0.25	-0.3	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
KIRP	cis	rs308403	0.568	rs13138426	ENSG00000224786.1	CETN4P	5.07	7.42e-07	0.000307	0.44	0.3	Blood protein levels;	chr4:122731425	chr4:122730548~122732193:-
KIRP	cis	rs10050311	0.698	rs4693780	ENSG00000251411.1	RP11-397E7.4	5.07	7.43e-07	0.000307	0.35	0.3	Insulin-related traits;	chr4:86720066	chr4:86913266~86914817:-
KIRP	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	5.07	7.43e-07	0.000307	0.37	0.3	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
KIRP	cis	rs5760092	0.842	rs5760103	ENSG00000250470.1	AP000351.3	5.07	7.43e-07	0.000307	0.48	0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23976904~23977585:-
KIRP	cis	rs7508	0.512	rs10112514	ENSG00000254054.2	RP11-156K13.3	5.07	7.43e-07	0.000307	0.35	0.3	Atrial fibrillation;	chr8:17972950	chr8:17905756~17907887:+
KIRP	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	5.07	7.44e-07	0.000308	0.45	0.3	Height;	chr6:109441837	chr6:109382795~109383666:+
KIRP	cis	rs6832769	0.961	rs6817663	ENSG00000272969.1	RP11-528I4.2	-5.07	7.44e-07	0.000308	-0.3	-0.3	Personality dimensions;	chr4:55581048	chr4:55547112~55547889:+
KIRP	cis	rs4356203	0.905	rs621246	ENSG00000272034.1	SNORD14A	-5.07	7.44e-07	0.000308	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17074654~17074744:-
KIRP	cis	rs7747960	1	rs7747960	ENSG00000226193.1	RP3-398G3.5	5.07	7.45e-07	0.000308	0.42	0.3	Bipolar disorder;	chr6:152470339	chr6:152402398~152404966:+
KIRP	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-5.07	7.45e-07	0.000308	-0.41	-0.3	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
KIRP	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-5.07	7.46e-07	0.000308	-0.29	-0.3	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
KIRP	cis	rs4356203	0.875	rs214935	ENSG00000272034.1	SNORD14A	-5.07	7.46e-07	0.000308	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17074654~17074744:-
KIRP	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-5.07	7.46e-07	0.000308	-0.28	-0.3	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
KIRP	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-5.07	7.47e-07	0.000309	-0.33	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
KIRP	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-5.07	7.47e-07	0.000309	-0.32	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
KIRP	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-5.07	7.47e-07	0.000309	-0.32	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-5.07	7.47e-07	0.000309	-0.32	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
KIRP	cis	rs1552244	1	rs9820598	ENSG00000180385.7	EMC3-AS1	5.07	7.48e-07	0.000309	0.28	0.3	Alzheimer's disease;	chr3:10076228	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs57631744	ENSG00000180385.7	EMC3-AS1	5.07	7.48e-07	0.000309	0.28	0.3	Alzheimer's disease;	chr3:10077278	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.935	rs6805869	ENSG00000180385.7	EMC3-AS1	5.07	7.48e-07	0.000309	0.28	0.3	Alzheimer's disease;	chr3:10078233	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs9827740	ENSG00000180385.7	EMC3-AS1	5.07	7.48e-07	0.000309	0.28	0.3	Alzheimer's disease;	chr3:10078847	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs4260416	ENSG00000180385.7	EMC3-AS1	5.07	7.48e-07	0.000309	0.28	0.3	Alzheimer's disease;	chr3:10083599	chr3:9986893~10006990:+
KIRP	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-5.07	7.5e-07	0.00031	-0.34	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
KIRP	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	5.07	7.5e-07	0.00031	0.3	0.3	Height;	chr14:75079853	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	5.07	7.5e-07	0.00031	0.3	0.3	Height;	chr14:75079880	chr14:75011269~75012851:-
KIRP	cis	rs3745672	1	rs10419620	ENSG00000219665.7	CTD-2006C1.2	-5.07	7.5e-07	0.00031	-0.68	-0.3	Multiple sclerosis;	chr19:12038132	chr19:11987617~12046275:+
KIRP	cis	rs3745672	1	rs10414248	ENSG00000219665.7	CTD-2006C1.2	-5.07	7.5e-07	0.00031	-0.68	-0.3	Multiple sclerosis;	chr19:12040811	chr19:11987617~12046275:+
KIRP	cis	rs3745672	1	rs3848588	ENSG00000219665.7	CTD-2006C1.2	-5.07	7.51e-07	0.00031	-0.68	-0.3	Multiple sclerosis;	chr19:12031470	chr19:11987617~12046275:+
KIRP	cis	rs79040073	0.637	rs11635308	ENSG00000259531.2	RP11-295H24.3	5.07	7.51e-07	0.00031	0.41	0.3	Lung cancer in ever smokers;	chr15:49426531	chr15:49365124~49366685:-
KIRP	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-5.07	7.52e-07	0.000311	-0.32	-0.3	Temperament;	chr17:14033087	chr17:14024514~14025488:+
KIRP	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-5.07	7.52e-07	0.000311	-0.62	-0.3	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
KIRP	cis	rs4660214	0.666	rs1775656	ENSG00000237624.1	OXCT2P1	5.07	7.52e-07	0.000311	0.38	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39514956~39516490:+
KIRP	cis	rs3745672	0.661	rs10404882	ENSG00000219665.7	CTD-2006C1.2	-5.07	7.52e-07	0.000311	-0.66	-0.3	Multiple sclerosis;	chr19:12012019	chr19:11987617~12046275:+
KIRP	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-5.07	7.52e-07	0.000311	-0.25	-0.3	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-5.07	7.52e-07	0.000311	-0.25	-0.3	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-5.07	7.52e-07	0.000311	-0.25	-0.3	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
KIRP	cis	rs4934494	0.813	rs12775783	ENSG00000232936.4	RP11-80H5.2	5.07	7.53e-07	0.000311	0.45	0.3	Red blood cell count;	chr10:89646494	chr10:89645282~89650667:+
KIRP	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	5.07	7.53e-07	0.000311	0.65	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
KIRP	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	5.07	7.53e-07	0.000311	0.54	0.3	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
KIRP	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	5.07	7.53e-07	0.000311	0.54	0.3	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
KIRP	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-5.07	7.54e-07	0.000311	-0.27	-0.3	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
KIRP	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.07	7.54e-07	0.000312	0.37	0.3	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
KIRP	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	5.07	7.54e-07	0.000312	0.4	0.3	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
KIRP	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	5.07	7.55e-07	0.000312	0.34	0.3	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
KIRP	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-5.07	7.55e-07	0.000312	-0.51	-0.3	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
KIRP	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	5.07	7.55e-07	0.000312	0.3	0.3	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
KIRP	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	5.07	7.55e-07	0.000312	0.45	0.3	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	5.07	7.55e-07	0.000312	0.45	0.3	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
KIRP	cis	rs2562456	0.837	rs62110205	ENSG00000268555.1	RP11-678G14.3	5.07	7.55e-07	0.000312	0.42	0.3	Pain;	chr19:21577269	chr19:21570822~21587322:-
KIRP	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	5.07	7.55e-07	0.000312	0.26	0.3	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	5.07	7.56e-07	0.000312	0.39	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
KIRP	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	5.07	7.56e-07	0.000312	0.42	0.3	Height;	chr6:109366911	chr6:109382795~109383666:+
KIRP	cis	rs11158026	0.603	rs57667631	ENSG00000258413.1	RP11-665C16.6	-5.07	7.57e-07	0.000312	-0.39	-0.3	Parkinson's disease;	chr14:54976349	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	5.07	7.57e-07	0.000312	0.25	0.3	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
KIRP	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-5.07	7.58e-07	0.000313	-0.28	-0.3	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
KIRP	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-5.07	7.58e-07	0.000313	-0.31	-0.3	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
KIRP	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	5.07	7.59e-07	0.000313	0.38	0.3	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
KIRP	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	5.07	7.59e-07	0.000313	0.27	0.3	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
KIRP	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	5.07	7.59e-07	0.000313	0.3	0.3	Height;	chr14:75097956	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	5.07	7.59e-07	0.000313	0.3	0.3	Height;	chr14:75099506	chr14:75011269~75012851:-
KIRP	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	5.07	7.59e-07	0.000313	0.26	0.3	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	5.07	7.59e-07	0.000313	0.26	0.3	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
KIRP	cis	rs9402743	0.671	rs2327650	ENSG00000234084.1	RP3-388E23.2	-5.07	7.59e-07	0.000313	-0.25	-0.3	Systemic lupus erythematosus;	chr6:135630279	chr6:135301568~135307158:+
KIRP	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-5.07	7.59e-07	0.000313	-0.5	-0.3	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
KIRP	cis	rs5758511	0.68	rs17002902	ENSG00000227370.1	RP4-669P10.19	5.07	7.6e-07	0.000313	0.36	0.3	Birth weight;	chr22:42229503	chr22:42132543~42132998:+
KIRP	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	5.07	7.6e-07	0.000313	0.36	0.3	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
KIRP	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-5.07	7.6e-07	0.000314	-0.3	-0.3	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
KIRP	cis	rs8037137	0.915	rs79548680	ENSG00000258725.1	PRC1-AS1	-5.07	7.6e-07	0.000314	-0.42	-0.3	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90962549	chr15:90966345~90988624:+
KIRP	cis	rs7267979	0.966	rs3827014	ENSG00000274414.1	RP5-965G21.4	5.07	7.6e-07	0.000314	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25239007~25245229:-
KIRP	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-5.07	7.61e-07	0.000314	-0.4	-0.3	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
KIRP	cis	rs1005277	0.579	rs932538	ENSG00000151963.4	RP11-775A3.1	-5.07	7.61e-07	0.000314	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.541	rs2472177	ENSG00000151963.4	RP11-775A3.1	-5.07	7.61e-07	0.000314	-0.35	-0.3	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:37883594~37884109:+
KIRP	cis	rs7267979	1	rs2424712	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2424714	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2424715	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050617	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.933	rs2387887	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6037121	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs1047171	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050629	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050630	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050632	ENSG00000274414.1	RP5-965G21.4	-5.07	7.61e-07	0.000314	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25239007~25245229:-
KIRP	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-5.07	7.61e-07	0.000314	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
KIRP	cis	rs4694744	0.759	rs75956093	ENSG00000250696.4	RP11-704M14.1	5.07	7.62e-07	0.000314	0.36	0.3	Bacteremia;	chr4:69471862	chr4:69182100~69216766:+
KIRP	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	5.07	7.62e-07	0.000314	0.35	0.3	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
KIRP	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	5.07	7.63e-07	0.000314	0.37	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
KIRP	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	5.07	7.63e-07	0.000315	0.26	0.3	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	5.07	7.63e-07	0.000315	0.26	0.3	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	5.07	7.63e-07	0.000315	0.26	0.3	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	5.07	7.63e-07	0.000315	0.26	0.3	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
KIRP	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	5.07	7.63e-07	0.000315	0.31	0.3	Height;	chr4:55574959	chr4:55363971~55395847:-
KIRP	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-5.07	7.64e-07	0.000315	-0.2	-0.3	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
KIRP	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	5.07	7.65e-07	0.000315	0.34	0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
KIRP	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	5.07	7.65e-07	0.000315	0.34	0.3	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
KIRP	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-5.07	7.65e-07	0.000315	-0.33	-0.3	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
KIRP	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	5.07	7.65e-07	0.000315	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
KIRP	cis	rs79040073	0.637	rs11638314	ENSG00000259531.2	RP11-295H24.3	5.07	7.66e-07	0.000315	0.42	0.3	Lung cancer in ever smokers;	chr15:49421747	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs78323502	ENSG00000259531.2	RP11-295H24.3	5.07	7.66e-07	0.000315	0.42	0.3	Lung cancer in ever smokers;	chr15:49436634	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.517	rs118069527	ENSG00000259531.2	RP11-295H24.3	5.07	7.66e-07	0.000315	0.42	0.3	Lung cancer in ever smokers;	chr15:49436684	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs79404431	ENSG00000259531.2	RP11-295H24.3	5.07	7.66e-07	0.000315	0.42	0.3	Lung cancer in ever smokers;	chr15:49436689	chr15:49365124~49366685:-
KIRP	cis	rs4646450	0.838	rs1589739	ENSG00000244219.5	GS1-259H13.2	-5.07	7.66e-07	0.000316	-0.34	-0.3	Blood metabolite levels;	chr7:99588124	chr7:99598066~99610813:+
KIRP	cis	rs7432375	0.901	rs9836231	ENSG00000261758.1	RP11-102M11.2	-5.07	7.67e-07	0.000316	-0.32	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136695479	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.804	rs6764567	ENSG00000261758.1	RP11-102M11.2	-5.07	7.67e-07	0.000316	-0.32	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136706672	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs7616204	ENSG00000261758.1	RP11-102M11.2	-5.07	7.67e-07	0.000316	-0.32	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136725747	chr3:136752630~136755780:+
KIRP	cis	rs10912872	0.634	rs2179375	ENSG00000225704.2	RP4-798A17.5	5.07	7.67e-07	0.000316	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171346507	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.634	rs6656117	ENSG00000225704.2	RP4-798A17.5	5.07	7.67e-07	0.000316	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171350346	chr1:171345089~171345320:+
KIRP	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-5.07	7.67e-07	0.000316	-0.25	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
KIRP	cis	rs7267979	1	rs2856	ENSG00000274414.1	RP5-965G21.4	-5.07	7.68e-07	0.000316	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25239007~25245229:-
KIRP	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-5.07	7.68e-07	0.000316	-0.48	-0.3	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
KIRP	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-5.07	7.69e-07	0.000316	-0.32	-0.3	Height;	chr3:53007328	chr3:53064283~53065091:-
KIRP	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	5.07	7.69e-07	0.000317	0.3	0.3	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	5.07	7.69e-07	0.000317	0.3	0.3	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
KIRP	cis	rs453301	0.631	rs11779804	ENSG00000253981.4	ALG1L13P	-5.07	7.69e-07	0.000317	-0.24	-0.3	Joint mobility (Beighton score);	chr8:8940442	chr8:8236003~8244667:-
KIRP	cis	rs17597773	0.527	rs1537806	ENSG00000238078.1	LINC01352	-5.07	7.69e-07	0.000317	-0.33	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220829255~220832429:+
KIRP	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-5.07	7.69e-07	0.000317	-0.29	-0.3	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
KIRP	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	5.06	7.72e-07	0.000318	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
KIRP	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-5.06	7.72e-07	0.000318	-0.25	-0.3	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-5.06	7.72e-07	0.000318	-0.25	-0.3	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-5.06	7.72e-07	0.000318	-0.25	-0.3	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-5.06	7.72e-07	0.000318	-0.24	-0.3	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
KIRP	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-5.06	7.72e-07	0.000318	-0.47	-0.3	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
KIRP	cis	rs7267979	1	rs6050626	ENSG00000274414.1	RP5-965G21.4	-5.06	7.73e-07	0.000318	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25239007~25245229:-
KIRP	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	5.06	7.73e-07	0.000318	0.27	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
KIRP	cis	rs1023500	1	rs3752591	ENSG00000237037.8	NDUFA6-AS1	5.06	7.73e-07	0.000318	0.33	0.3	Schizophrenia;	chr22:41943512	chr22:42090931~42137742:+
KIRP	cis	rs7829975	0.582	rs11783950	ENSG00000253981.4	ALG1L13P	-5.06	7.74e-07	0.000318	-0.23	-0.3	Mood instability;	chr8:8740321	chr8:8236003~8244667:-
KIRP	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	5.06	7.75e-07	0.000319	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	5.06	7.75e-07	0.000319	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
KIRP	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-5.06	7.76e-07	0.000319	-0.42	-0.3	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
KIRP	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	5.06	7.78e-07	0.00032	0.4	0.3	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
KIRP	cis	rs875971	0.545	rs6950988	ENSG00000224316.1	RP11-479O9.2	5.06	7.78e-07	0.00032	0.25	0.3	Aortic root size;	chr7:66511428	chr7:65773620~65802067:+
KIRP	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-5.06	7.79e-07	0.00032	-0.42	-0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
KIRP	cis	rs2043112	0.964	rs10461997	ENSG00000249911.1	LINC01265	5.06	7.79e-07	0.00032	0.35	0.3	Obesity-related traits;	chr5:38984047	chr5:38710367~38720273:-
KIRP	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	5.06	7.79e-07	0.00032	0.31	0.3	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	5.06	7.79e-07	0.00032	0.31	0.3	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
KIRP	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	5.06	7.79e-07	0.00032	0.31	0.3	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
KIRP	cis	rs1552244	1	rs56270432	ENSG00000180385.7	EMC3-AS1	5.06	7.8e-07	0.000321	0.28	0.3	Alzheimer's disease;	chr3:10045833	chr3:9986893~10006990:+
KIRP	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	5.06	7.8e-07	0.000321	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
KIRP	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	5.06	7.8e-07	0.000321	0.32	0.3	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
KIRP	cis	rs7255436	0.965	rs62117510	ENSG00000269386.4	RAB11B-AS1	5.06	7.81e-07	0.000321	0.29	0.3	HDL cholesterol;	chr19:8387729	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.965	rs28729307	ENSG00000269386.4	RAB11B-AS1	5.06	7.81e-07	0.000321	0.29	0.3	HDL cholesterol;	chr19:8387858	chr19:8374373~8390685:-
KIRP	cis	rs7255436	0.894	rs10413136	ENSG00000269386.4	RAB11B-AS1	5.06	7.81e-07	0.000321	0.29	0.3	HDL cholesterol;	chr19:8387995	chr19:8374373~8390685:-
KIRP	cis	rs10912872	0.634	rs2223477	ENSG00000225704.2	RP4-798A17.5	5.06	7.81e-07	0.000321	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171339693	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.634	rs12057885	ENSG00000225704.2	RP4-798A17.5	5.06	7.81e-07	0.000321	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171339939	chr1:171345089~171345320:+
KIRP	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-5.06	7.81e-07	0.000321	-0.51	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
KIRP	cis	rs1552244	0.808	rs17032306	ENSG00000180385.7	EMC3-AS1	5.06	7.81e-07	0.000321	0.28	0.3	Alzheimer's disease;	chr3:10049715	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.938	rs7625049	ENSG00000180385.7	EMC3-AS1	5.06	7.81e-07	0.000321	0.28	0.3	Alzheimer's disease;	chr3:10073935	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6782602	ENSG00000180385.7	EMC3-AS1	5.06	7.81e-07	0.000321	0.28	0.3	Alzheimer's disease;	chr3:10074857	chr3:9986893~10006990:+
KIRP	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-5.06	7.81e-07	0.000321	-0.25	-0.3	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
KIRP	cis	rs4934494	0.689	rs17127588	ENSG00000232936.4	RP11-80H5.2	5.06	7.82e-07	0.000321	0.43	0.3	Red blood cell count;	chr10:89815887	chr10:89645282~89650667:+
KIRP	cis	rs4604234	0.518	rs73463537	ENSG00000272129.1	RP11-250B2.6	-5.06	7.82e-07	0.000322	-0.51	-0.3	Cancer;	chr6:80275314	chr6:80355424~80356859:+
KIRP	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-5.06	7.82e-07	0.000322	-0.31	-0.3	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-5.06	7.82e-07	0.000322	-0.31	-0.3	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-5.06	7.82e-07	0.000322	-0.31	-0.3	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
KIRP	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-5.06	7.82e-07	0.000322	-0.31	-0.3	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-5.06	7.82e-07	0.000322	-0.31	-0.3	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
KIRP	cis	rs72717009	0.825	rs61802846	ENSG00000225217.1	HSPA7	-5.06	7.83e-07	0.000322	-0.42	-0.3	Rheumatoid arthritis;	chr1:161504083	chr1:161606291~161608217:+
KIRP	cis	rs72717009	0.825	rs10494360	ENSG00000225217.1	HSPA7	-5.06	7.83e-07	0.000322	-0.42	-0.3	Rheumatoid arthritis;	chr1:161505960	chr1:161606291~161608217:+
KIRP	cis	rs72717009	0.825	rs12746613	ENSG00000225217.1	HSPA7	5.06	7.83e-07	0.000322	0.42	0.3	Rheumatoid arthritis;	chr1:161497252	chr1:161606291~161608217:+
KIRP	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-5.06	7.84e-07	0.000322	-0.26	-0.3	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
KIRP	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	5.06	7.87e-07	0.000323	0.24	0.3	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
KIRP	cis	rs9595908	0.758	rs2031354	ENSG00000212293.1	SNORA16	5.06	7.87e-07	0.000323	0.28	0.3	Body mass index;	chr13:32641454	chr13:32420390~32420516:-
KIRP	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-5.06	7.88e-07	0.000323	-0.31	-0.3	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
KIRP	cis	rs4356975	0.509	rs6600884	ENSG00000250696.4	RP11-704M14.1	5.06	7.88e-07	0.000323	0.29	0.3	Obesity-related traits;	chr4:69102348	chr4:69182100~69216766:+
KIRP	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	5.06	7.88e-07	0.000324	0.44	0.3	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
KIRP	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-5.06	7.88e-07	0.000324	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-5.06	7.88e-07	0.000324	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-5.06	7.88e-07	0.000324	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
KIRP	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-5.06	7.88e-07	0.000324	-0.38	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
KIRP	cis	rs41271473	0.526	rs2182202	ENSG00000212237.1	RNA5SP18	5.06	7.89e-07	0.000324	0.52	0.3	Chronic lymphocytic leukemia;	chr1:228546258	chr1:228647912~228648032:-
KIRP	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	5.06	7.9e-07	0.000324	0.21	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
KIRP	cis	rs2109514	1	rs4727833	ENSG00000237813.3	AC002066.1	5.06	7.9e-07	0.000324	0.34	0.3	Prevalent atrial fibrillation;	chr7:116507854	chr7:116238260~116499465:-
KIRP	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-5.06	7.9e-07	0.000324	-0.26	-0.3	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
KIRP	cis	rs12571093	0.572	rs7100599	ENSG00000233590.1	RP11-153K11.3	-5.06	7.9e-07	0.000324	-0.47	-0.3	Optic nerve measurement (disc area);	chr10:68309476	chr10:68233251~68242379:-
KIRP	cis	rs6840258	0.831	rs3755980	ENSG00000251411.1	RP11-397E7.4	5.06	7.9e-07	0.000324	0.29	0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87121099	chr4:86913266~86914817:-
KIRP	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-5.06	7.9e-07	0.000324	-0.35	-0.3	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-5.06	7.9e-07	0.000324	-0.35	-0.3	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
KIRP	cis	rs7267979	0.966	rs6037097	ENSG00000274414.1	RP5-965G21.4	-5.06	7.91e-07	0.000325	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25239007~25245229:-
KIRP	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	5.06	7.91e-07	0.000325	0.42	0.3	Height;	chr6:109357908	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	5.06	7.91e-07	0.000325	0.42	0.3	Height;	chr6:109359747	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	5.06	7.91e-07	0.000325	0.42	0.3	Height;	chr6:109361318	chr6:109382795~109383666:+
KIRP	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-5.06	7.91e-07	0.000325	-0.35	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
KIRP	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.06	7.92e-07	0.000325	-0.41	-0.3	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
KIRP	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	5.06	7.92e-07	0.000325	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
KIRP	cis	rs1153858	1	rs1153849	ENSG00000259433.2	CTD-2651B20.4	-5.06	7.92e-07	0.000325	-0.27	-0.3	Homoarginine levels;	chr15:45403497	chr15:45330209~45332634:-
KIRP	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-5.06	7.92e-07	0.000325	-0.32	-0.3	Height;	chr3:52998472	chr3:53064283~53065091:-
KIRP	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	5.06	7.92e-07	0.000325	0.42	0.3	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
KIRP	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	5.06	7.92e-07	0.000325	0.42	0.3	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
KIRP	cis	rs67311347	0.544	rs9864664	ENSG00000230274.1	PGAM1P3	5.06	7.93e-07	0.000325	0.3	0.3	Renal cell carcinoma;	chr3:40294735	chr3:40322715~40323279:-
KIRP	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-5.06	7.93e-07	0.000325	-0.28	-0.3	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
KIRP	cis	rs17826219	0.561	rs4794869	ENSG00000263531.1	RP13-753N3.1	5.06	7.94e-07	0.000326	0.58	0.3	Body mass index;	chr17:30364082	chr17:30863921~30864940:-
KIRP	cis	rs308403	0.506	rs309365	ENSG00000224786.1	CETN4P	5.06	7.94e-07	0.000326	0.41	0.3	Blood protein levels;	chr4:122738188	chr4:122730548~122732193:-
KIRP	cis	rs7267979	1	rs6115153	ENSG00000274414.1	RP5-965G21.4	5.06	7.95e-07	0.000326	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs7268053	ENSG00000274414.1	RP5-965G21.4	5.06	7.95e-07	0.000326	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083809	ENSG00000274414.1	RP5-965G21.4	5.06	7.95e-07	0.000326	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25239007~25245229:-
KIRP	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.06	7.95e-07	0.000326	0.34	0.3	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
KIRP	cis	rs61457372	0.563	rs12452792	ENSG00000264026.1	RP11-1124B17.1	-5.06	7.96e-07	0.000326	-0.32	-0.3	Triptolide cytotoxicity;	chr17:72353483	chr17:72342940~72355136:+
KIRP	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-5.06	7.96e-07	0.000327	-0.27	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
KIRP	cis	rs7508	0.512	rs6984498	ENSG00000254054.2	RP11-156K13.3	5.06	7.98e-07	0.000327	0.35	0.3	Atrial fibrillation;	chr8:17974244	chr8:17905756~17907887:+
KIRP	cis	rs911119	1	rs6114208	ENSG00000270001.1	RP11-218C14.8	-5.06	7.99e-07	0.000327	-0.35	-0.3	Chronic kidney disease;	chr20:23641097	chr20:23631826~23632316:-
KIRP	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	5.06	7.99e-07	0.000327	0.35	0.3	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
KIRP	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-5.06	7.99e-07	0.000328	-0.25	-0.3	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
KIRP	cis	rs1799949	0.602	rs8176235	ENSG00000279602.1	CTD-3014M21.1	-5.06	8e-07	0.000328	-0.29	-0.3	Menopause (age at onset);	chr17:43067543	chr17:43360041~43361361:-
KIRP	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	5.06	8e-07	0.000328	0.5	0.3	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
KIRP	cis	rs875971	0.545	rs10261710	ENSG00000236529.1	RP13-254B10.1	5.06	8e-07	0.000328	0.28	0.3	Aortic root size;	chr7:66249202	chr7:65840212~65840596:+
KIRP	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-5.06	8.03e-07	0.000329	-0.36	-0.3	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
KIRP	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-5.06	8.03e-07	0.000329	-0.35	-0.3	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
KIRP	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-5.06	8.03e-07	0.000329	-0.35	-0.3	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
KIRP	cis	rs2109514	0.967	rs10271007	ENSG00000237813.3	AC002066.1	5.06	8.04e-07	0.000329	0.34	0.3	Prevalent atrial fibrillation;	chr7:116505795	chr7:116238260~116499465:-
KIRP	cis	rs2109514	0.967	rs4730743	ENSG00000237813.3	AC002066.1	5.06	8.04e-07	0.000329	0.34	0.3	Prevalent atrial fibrillation;	chr7:116505903	chr7:116238260~116499465:-
KIRP	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-5.06	8.05e-07	0.00033	-0.48	-0.3	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
KIRP	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	5.06	8.05e-07	0.00033	0.79	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
KIRP	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	5.06	8.05e-07	0.00033	0.79	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
KIRP	cis	rs9532669	0.89	rs9532627	ENSG00000239827.7	SUGT1P3	-5.06	8.06e-07	0.00033	-0.34	-0.3	Cervical cancer;	chr13:40874811	chr13:40908159~40921774:-
KIRP	cis	rs11158026	0.574	rs58055971	ENSG00000258413.1	RP11-665C16.6	-5.06	8.06e-07	0.00033	-0.39	-0.3	Parkinson's disease;	chr14:54969606	chr14:55262767~55272075:-
KIRP	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	5.06	8.06e-07	0.00033	0.24	0.3	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
KIRP	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	5.06	8.06e-07	0.00033	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
KIRP	cis	rs1044826	0.642	rs9833307	ENSG00000178631.7	ACTG1P1	5.06	8.06e-07	0.00033	0.32	0.3	Obesity-related traits;	chr3:139462528	chr3:139493809~139494937:+
KIRP	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	5.06	8.06e-07	0.00033	0.31	0.3	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
KIRP	cis	rs7945705	0.87	rs4910156	ENSG00000254860.4	TMEM9B-AS1	-5.06	8.07e-07	0.00033	-0.34	-0.3	Hemoglobin concentration;	chr11:8919650	chr11:8964675~8977527:+
KIRP	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	5.06	8.07e-07	0.000331	0.31	0.3	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
KIRP	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-5.06	8.07e-07	0.000331	-0.35	-0.3	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-5.06	8.07e-07	0.000331	-0.35	-0.3	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
KIRP	cis	rs4660214	0.666	rs587404	ENSG00000237624.1	OXCT2P1	5.06	8.07e-07	0.000331	0.38	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39514956~39516490:+
KIRP	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-5.06	8.08e-07	0.000331	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-5.06	8.08e-07	0.000331	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-5.06	8.08e-07	0.000331	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
KIRP	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-5.06	8.08e-07	0.000331	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
KIRP	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	5.06	8.08e-07	0.000331	0.41	0.3	Depression;	chr6:28430971	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	5.06	8.08e-07	0.000331	0.41	0.3	Depression;	chr6:28432562	chr6:28943877~28944537:+
KIRP	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	5.06	8.09e-07	0.000331	0.45	0.3	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	5.06	8.09e-07	0.000331	0.45	0.3	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
KIRP	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-5.05	8.09e-07	0.000331	-0.29	-0.3	Height;	chr14:75031474	chr14:75011269~75012851:-
KIRP	cis	rs72634501	0.517	rs10788925	ENSG00000237624.1	OXCT2P1	-5.05	8.1e-07	0.000332	-0.38	-0.3	HDL cholesterol;	chr1:39128430	chr1:39514956~39516490:+
KIRP	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-5.05	8.11e-07	0.000332	-0.34	-0.3	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
KIRP	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-5.05	8.11e-07	0.000332	-0.34	-0.3	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
KIRP	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-5.05	8.11e-07	0.000332	-0.28	-0.3	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
KIRP	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	5.05	8.11e-07	0.000332	0.34	0.3	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
KIRP	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-5.05	8.11e-07	0.000332	-0.26	-0.3	Height;	chr11:118855233	chr11:118791254~118793137:+
KIRP	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-5.05	8.11e-07	0.000332	-0.26	-0.3	Height;	chr11:118855938	chr11:118791254~118793137:+
KIRP	cis	rs3824867	0.738	rs1228024	ENSG00000280615.1	Y_RNA	-5.05	8.12e-07	0.000332	-0.34	-0.3	Mean corpuscular hemoglobin;	chr11:47929801	chr11:47614898~47614994:-
KIRP	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-5.05	8.12e-07	0.000332	-0.3	-0.3	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
KIRP	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	5.05	8.12e-07	0.000332	0.23	0.3	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
KIRP	cis	rs308403	0.6	rs309366	ENSG00000224786.1	CETN4P	5.05	8.12e-07	0.000332	0.39	0.3	Blood protein levels;	chr4:122740253	chr4:122730548~122732193:-
KIRP	cis	rs308403	0.6	rs309367	ENSG00000224786.1	CETN4P	5.05	8.12e-07	0.000332	0.39	0.3	Blood protein levels;	chr4:122741056	chr4:122730548~122732193:-
KIRP	cis	rs7267979	1	rs6050561	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083813	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815406	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6083817	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050564	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6083818	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815409	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815412	ENSG00000274414.1	RP5-965G21.4	-5.05	8.13e-07	0.000332	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6107031	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6115159	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4813562	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6050567	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6037099	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs4815414	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083825	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs34645895	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6115168	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6037105	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2387880	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs2387882	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2387884	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6076345	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815420	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050590	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4813566	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815421	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs3761117	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs8123949	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2184000	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050598	ENSG00000274414.1	RP5-965G21.4	-5.05	8.13e-07	0.000332	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs4815425	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050599	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050602	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6083855	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815426	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6115182	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050609	ENSG00000274414.1	RP5-965G21.4	5.05	8.13e-07	0.000332	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25239007~25245229:-
KIRP	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	5.05	8.13e-07	0.000332	0.32	0.3	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-5.05	8.13e-07	0.000332	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
KIRP	cis	rs1858037	0.867	rs1553675	ENSG00000237979.1	AC007389.1	-5.05	8.14e-07	0.000333	-0.34	-0.3	Rheumatoid arthritis;	chr2:65343173	chr2:65500993~65502138:-
KIRP	cis	rs7674212	0.541	rs2720464	ENSG00000230069.3	LRRC37A15P	-5.05	8.14e-07	0.000333	-0.29	-0.3	Type 2 diabetes;	chr4:103152044	chr4:102727274~102730721:-
KIRP	cis	rs7809615	0.515	rs6961634	ENSG00000244219.5	GS1-259H13.2	-5.05	8.14e-07	0.000333	-0.34	-0.3	Blood metabolite ratios;	chr7:99584216	chr7:99598066~99610813:+
KIRP	cis	rs8049040	0.586	rs16972663	ENSG00000260886.1	TAT-AS1	5.05	8.14e-07	0.000333	0.39	0.3	Blood protein levels;	chr16:71426661	chr16:71565789~71578187:+
KIRP	cis	rs7432375	0.901	rs900818	ENSG00000261758.1	RP11-102M11.2	-5.05	8.14e-07	0.000333	-0.32	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136752973	chr3:136752630~136755780:+
KIRP	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-5.05	8.15e-07	0.000333	-0.36	-0.3	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
KIRP	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.05	8.15e-07	0.000333	0.35	0.3	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
KIRP	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-5.05	8.15e-07	0.000333	-0.4	-0.3	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
KIRP	cis	rs9847710	1	rs12488768	ENSG00000280417.1	RP11-5O17.1	5.05	8.15e-07	0.000333	0.35	0.3	Ulcerative colitis;	chr3:53052218	chr3:53046166~53048122:+
KIRP	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-5.05	8.16e-07	0.000334	-0.35	-0.3	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
KIRP	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	5.05	8.17e-07	0.000334	0.28	0.3	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
KIRP	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-5.05	8.19e-07	0.000335	-0.31	-0.3	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
KIRP	cis	rs6832769	0.922	rs6825994	ENSG00000272969.1	RP11-528I4.2	-5.05	8.2e-07	0.000335	-0.29	-0.3	Personality dimensions;	chr4:55524244	chr4:55547112~55547889:+
KIRP	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-5.05	8.21e-07	0.000335	-0.25	-0.3	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
KIRP	cis	rs1799949	0.93	rs1554063	ENSG00000236383.6	LINC00854	-5.05	8.21e-07	0.000335	-0.23	-0.3	Menopause (age at onset);	chr17:43135128	chr17:43216941~43305976:-
KIRP	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	5.05	8.21e-07	0.000335	0.27	0.3	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
KIRP	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-5.05	8.21e-07	0.000336	-0.38	-0.3	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-5.05	8.21e-07	0.000336	-0.38	-0.3	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
KIRP	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-5.05	8.22e-07	0.000336	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
KIRP	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-5.05	8.23e-07	0.000336	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
KIRP	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	5.05	8.24e-07	0.000336	0.23	0.3	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
KIRP	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-5.05	8.24e-07	0.000337	-0.28	-0.3	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
KIRP	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-5.05	8.24e-07	0.000337	-0.24	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
KIRP	cis	rs116095464	0.558	rs7708515	ENSG00000248925.1	CTD-2083E4.6	5.05	8.25e-07	0.000337	0.44	0.3	Breast cancer;	chr5:234874	chr5:269858~271516:-
KIRP	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	5.05	8.25e-07	0.000337	0.25	0.3	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
KIRP	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	5.05	8.26e-07	0.000337	0.4	0.3	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
KIRP	cis	rs1552244	0.935	rs35586456	ENSG00000180385.7	EMC3-AS1	5.05	8.27e-07	0.000338	0.28	0.3	Alzheimer's disease;	chr3:10075254	chr3:9986893~10006990:+
KIRP	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	5.05	8.28e-07	0.000338	0.47	0.3	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
KIRP	cis	rs6540731	0.782	rs10436976	ENSG00000229983.1	RP11-15I11.2	5.05	8.28e-07	0.000338	0.35	0.3	Intelligence (childhood);	chr1:212187066	chr1:212168207~212190259:+
KIRP	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-5.05	8.29e-07	0.000338	-0.24	-0.3	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
KIRP	cis	rs1799949	0.628	rs4474733	ENSG00000279602.1	CTD-3014M21.1	-5.05	8.29e-07	0.000339	-0.29	-0.3	Menopause (age at onset);	chr17:43356292	chr17:43360041~43361361:-
KIRP	cis	rs3892630	0.818	rs80137870	ENSG00000267475.1	CTD-2538C1.2	-5.05	8.3e-07	0.000339	-0.41	-0.3	Red blood cell traits;	chr19:32691844	chr19:32687089~32691750:-
KIRP	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	5.05	8.3e-07	0.000339	0.45	0.3	Height;	chr6:109436760	chr6:109382795~109383666:+
KIRP	cis	rs7772486	0.875	rs2748485	ENSG00000270638.1	RP3-466P17.1	5.05	8.3e-07	0.000339	0.26	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs2207785	ENSG00000270638.1	RP3-466P17.1	5.05	8.3e-07	0.000339	0.26	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.748	rs2748484	ENSG00000270638.1	RP3-466P17.1	5.05	8.3e-07	0.000339	0.26	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145735570~145737218:+
KIRP	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-5.05	8.3e-07	0.000339	-0.31	-0.3	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
KIRP	cis	rs4660214	0.639	rs6699928	ENSG00000237624.1	OXCT2P1	-5.05	8.31e-07	0.000339	-0.38	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39514956~39516490:+
KIRP	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	5.05	8.32e-07	0.000339	0.45	0.3	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
KIRP	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	5.05	8.32e-07	0.000339	0.25	0.3	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
KIRP	cis	rs42648	0.567	rs12669304	ENSG00000225498.1	AC002064.5	5.05	8.32e-07	0.00034	0.21	0.3	Homocysteine levels;	chr7:90261726	chr7:90312496~90322592:+
KIRP	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-5.05	8.33e-07	0.00034	-0.33	-0.3	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
KIRP	cis	rs755249	0.501	rs2484133	ENSG00000237624.1	OXCT2P1	5.05	8.33e-07	0.00034	0.41	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39514956~39516490:+
KIRP	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-5.05	8.33e-07	0.00034	-0.32	-0.3	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
KIRP	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	5.05	8.33e-07	0.00034	0.44	0.3	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	5.05	8.33e-07	0.00034	0.44	0.3	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	5.05	8.33e-07	0.00034	0.44	0.3	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
KIRP	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55506498	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55507248	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55507729	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55508587	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55509367	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55510352	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	5.05	8.33e-07	0.00034	0.29	0.3	Height;	chr4:55511198	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	5.05	8.34e-07	0.00034	0.29	0.3	Height;	chr4:55451955	chr4:55547112~55547889:+
KIRP	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-5.05	8.34e-07	0.00034	-0.33	-0.3	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
KIRP	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-5.05	8.34e-07	0.00034	-0.33	-0.3	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
KIRP	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-5.05	8.34e-07	0.00034	-0.23	-0.3	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
KIRP	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-5.05	8.34e-07	0.00034	-0.25	-0.3	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
KIRP	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-5.05	8.36e-07	0.000341	-0.4	-0.3	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-5.05	8.36e-07	0.000341	-0.4	-0.3	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
KIRP	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-5.05	8.36e-07	0.000341	-0.4	-0.3	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
KIRP	cis	rs72717009	0.756	rs10494359	ENSG00000225217.1	HSPA7	-5.05	8.36e-07	0.000341	-0.42	-0.3	Rheumatoid arthritis;	chr1:161494086	chr1:161606291~161608217:+
KIRP	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-5.05	8.37e-07	0.000341	-0.39	-0.3	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-5.05	8.37e-07	0.000341	-0.39	-0.3	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
KIRP	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	5.05	8.37e-07	0.000341	0.25	0.3	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
KIRP	cis	rs42648	0.748	rs6972119	ENSG00000225498.1	AC002064.5	5.05	8.37e-07	0.000341	0.21	0.3	Homocysteine levels;	chr7:90264694	chr7:90312496~90322592:+
KIRP	cis	rs962856	0.964	rs2171175	ENSG00000236780.4	AC078941.1	5.05	8.37e-07	0.000341	0.35	0.3	Pancreatic cancer;	chr2:67413595	chr2:67123357~67215319:-
KIRP	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-5.05	8.37e-07	0.000341	-0.41	-0.3	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-5.05	8.37e-07	0.000341	-0.41	-0.3	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
KIRP	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-5.05	8.37e-07	0.000341	-0.41	-0.3	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
KIRP	cis	rs7615952	0.599	rs6766327	ENSG00000241439.1	RP11-666A20.3	5.05	8.37e-07	0.000341	0.42	0.3	Blood pressure (smoking interaction);	chr3:126004834	chr3:125958556~125958817:+
KIRP	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	5.05	8.38e-07	0.000342	0.24	0.3	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
KIRP	cis	rs28386778	0.734	rs7210724	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63721838	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs1470697	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63722480	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs57108948	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63725018	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs7501614	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63725252	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.897	rs10221279	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63728778	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.687	rs59596917	ENSG00000240280.5	TCAM1P	-5.05	8.39e-07	0.000342	-0.38	-0.3	Prudent dietary pattern;	chr17:63728904	chr17:63849292~63864379:+
KIRP	cis	rs6832769	0.961	rs1011095	ENSG00000272969.1	RP11-528I4.2	5.05	8.39e-07	0.000342	0.28	0.3	Personality dimensions;	chr4:55398774	chr4:55547112~55547889:+
KIRP	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-5.05	8.4e-07	0.000342	-0.4	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
KIRP	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-5.05	8.4e-07	0.000342	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-5.05	8.4e-07	0.000342	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
KIRP	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	5.05	8.4e-07	0.000342	0.51	0.3	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
KIRP	cis	rs1560104	0.597	rs17227296	ENSG00000274834.1	CTD-3037G24.5	5.05	8.42e-07	0.000343	0.33	0.3	Obesity-related traits;	chr16:12618342	chr16:12614451~12614852:+
KIRP	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-5.05	8.42e-07	0.000343	-0.32	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
KIRP	cis	rs11158026	0.603	rs66820631	ENSG00000258413.1	RP11-665C16.6	-5.05	8.42e-07	0.000343	-0.39	-0.3	Parkinson's disease;	chr14:54998835	chr14:55262767~55272075:-
KIRP	cis	rs11158026	0.603	rs4335711	ENSG00000258413.1	RP11-665C16.6	-5.05	8.42e-07	0.000343	-0.39	-0.3	Parkinson's disease;	chr14:55004145	chr14:55262767~55272075:-
KIRP	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	5.05	8.42e-07	0.000343	0.32	0.3	Height;	chr4:55570843	chr4:55363971~55395847:-
KIRP	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-5.05	8.42e-07	0.000343	-0.33	-0.3	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
KIRP	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-5.05	8.42e-07	0.000343	-0.33	-0.3	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
KIRP	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-5.05	8.43e-07	0.000343	-0.28	-0.3	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-5.05	8.43e-07	0.000343	-0.28	-0.3	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-5.05	8.43e-07	0.000343	-0.28	-0.3	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-5.05	8.43e-07	0.000343	-0.28	-0.3	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
KIRP	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	5.05	8.43e-07	0.000343	0.3	0.3	Height;	chr14:75058746	chr14:75011269~75012851:-
KIRP	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-5.05	8.43e-07	0.000343	-0.25	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
KIRP	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-5.05	8.43e-07	0.000343	-0.25	-0.3	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
KIRP	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-5.05	8.43e-07	0.000344	-0.32	-0.3	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
KIRP	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5.05	8.45e-07	0.000344	-0.28	-0.3	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	5.05	8.45e-07	0.000344	0.31	0.3	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
KIRP	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-5.05	8.45e-07	0.000344	-0.35	-0.3	Depression;	chr6:28422360	chr6:28176188~28176674:+
KIRP	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	5.05	8.45e-07	0.000344	0.32	0.3	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
KIRP	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	5.05	8.45e-07	0.000344	0.38	0.3	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
KIRP	cis	rs1065656	0.619	rs2492883	ENSG00000280231.1	LA16c-380F5.3	-5.05	8.45e-07	0.000344	-0.39	-0.3	Insulin-like growth factors;	chr16:1852104	chr16:1553655~1554130:-
KIRP	cis	rs9595908	0.709	rs7318563	ENSG00000212293.1	SNORA16	5.05	8.46e-07	0.000344	0.28	0.3	Body mass index;	chr13:32749348	chr13:32420390~32420516:-
KIRP	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	5.05	8.46e-07	0.000345	0.25	0.3	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
KIRP	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	5.05	8.46e-07	0.000345	0.25	0.3	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
KIRP	cis	rs77741769	0.571	rs7969140	ENSG00000277423.1	RP11-173P15.9	-5.05	8.46e-07	0.000345	-0.32	-0.3	Mean corpuscular volume;	chr12:120865823	chr12:120703867~120704282:+
KIRP	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	5.05	8.47e-07	0.000345	0.28	0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
KIRP	cis	rs964611	0.882	rs3784621	ENSG00000259488.2	RP11-154J22.1	5.05	8.47e-07	0.000345	0.28	0.3	Metabolite levels (Pyroglutamine);	chr15:48340895	chr15:48312353~48331856:-
KIRP	cis	rs2281558	0.793	rs6115227	ENSG00000274414.1	RP5-965G21.4	-5.05	8.47e-07	0.000345	-0.34	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:25239007~25245229:-
KIRP	cis	rs10912872	0.634	rs6425167	ENSG00000225704.2	RP4-798A17.5	5.05	8.47e-07	0.000345	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171347751	chr1:171345089~171345320:+
KIRP	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	5.05	8.47e-07	0.000345	0.27	0.3	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	5.05	8.47e-07	0.000345	0.27	0.3	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
KIRP	cis	rs9532669	0.926	rs4942007	ENSG00000239827.7	SUGT1P3	-5.04	8.49e-07	0.000346	-0.33	-0.3	Cervical cancer;	chr13:40871887	chr13:40908159~40921774:-
KIRP	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-5.04	8.49e-07	0.000346	-0.28	-0.3	Height;	chr14:75013191	chr14:75011269~75012851:-
KIRP	cis	rs6532023	0.966	rs899040	ENSG00000249973.2	CHCHD2P7	-5.04	8.49e-07	0.000346	-0.36	-0.3	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87854008	chr4:87785920~87786371:-
KIRP	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	5.04	8.49e-07	0.000346	0.35	0.3	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
KIRP	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	5.04	8.49e-07	0.000346	0.24	0.3	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
KIRP	cis	rs61457372	0.527	rs4793284	ENSG00000264026.1	RP11-1124B17.1	-5.04	8.5e-07	0.000346	-0.33	-0.3	Triptolide cytotoxicity;	chr17:72347218	chr17:72342940~72355136:+
KIRP	cis	rs9847710	1	rs13088455	ENSG00000280417.1	RP11-5O17.1	5.04	8.51e-07	0.000346	0.35	0.3	Ulcerative colitis;	chr3:53053466	chr3:53046166~53048122:+
KIRP	cis	rs9847710	1	rs4687697	ENSG00000280417.1	RP11-5O17.1	5.04	8.51e-07	0.000346	0.35	0.3	Ulcerative colitis;	chr3:53056474	chr3:53046166~53048122:+
KIRP	cis	rs4236601	0.72	rs17516287	ENSG00000237813.3	AC002066.1	-5.04	8.51e-07	0.000346	-0.37	-0.3	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116514132	chr7:116238260~116499465:-
KIRP	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-5.04	8.51e-07	0.000346	-0.35	-0.3	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
KIRP	cis	rs116095464	0.614	rs28736753	ENSG00000248925.1	CTD-2083E4.6	5.04	8.52e-07	0.000346	0.45	0.3	Breast cancer;	chr5:273966	chr5:269858~271516:-
KIRP	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-5.04	8.52e-07	0.000347	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-5.04	8.52e-07	0.000347	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
KIRP	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-5.04	8.53e-07	0.000347	-0.45	-0.3	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
KIRP	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-5.04	8.53e-07	0.000347	-0.3	-0.3	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
KIRP	cis	rs9959145	1	rs9946557	ENSG00000267108.1	RP11-861E21.1	5.04	8.53e-07	0.000347	0.48	0.3	Immune response to smallpox vaccine (IL-6);	chr18:12563862	chr18:12432897~12437635:+
KIRP	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	5.04	8.54e-07	0.000347	0.25	0.3	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
KIRP	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	5.04	8.54e-07	0.000347	0.39	0.3	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
KIRP	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-5.04	8.54e-07	0.000347	-0.23	-0.3	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-5.04	8.54e-07	0.000347	-0.23	-0.3	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
KIRP	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-5.04	8.54e-07	0.000347	-0.23	-0.3	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
KIRP	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-5.04	8.54e-07	0.000347	-0.41	-0.3	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
KIRP	cis	rs7267979	1	rs2424704	ENSG00000274414.1	RP5-965G21.4	-5.04	8.55e-07	0.000348	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25239007~25245229:-
KIRP	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-5.04	8.56e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
KIRP	cis	rs5760092	0.842	rs5760103	ENSG00000228039.3	KB-1125A3.10	5.04	8.57e-07	0.000348	0.47	0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23963780~23964374:+
KIRP	cis	rs11671005	0.568	rs73068329	ENSG00000269600.1	AC016629.3	-5.04	8.57e-07	0.000348	-0.41	-0.3	Mean platelet volume;	chr19:58568958	chr19:58593896~58599355:-
KIRP	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-5.04	8.57e-07	0.000348	-0.28	-0.3	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
KIRP	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-5.04	8.57e-07	0.000348	-0.25	-0.3	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
KIRP	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-5.04	8.57e-07	0.000348	-0.2	-0.3	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
KIRP	cis	rs453301	0.624	rs330056	ENSG00000253981.4	ALG1L13P	-5.04	8.57e-07	0.000348	-0.24	-0.3	Joint mobility (Beighton score);	chr8:9232185	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.624	rs330058	ENSG00000253981.4	ALG1L13P	-5.04	8.57e-07	0.000348	-0.24	-0.3	Joint mobility (Beighton score);	chr8:9232299	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.624	rs330060	ENSG00000253981.4	ALG1L13P	-5.04	8.57e-07	0.000348	-0.24	-0.3	Joint mobility (Beighton score);	chr8:9233392	chr8:8236003~8244667:-
KIRP	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-5.04	8.59e-07	0.000349	-0.25	-0.3	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
KIRP	cis	rs1552244	1	rs6789156	ENSG00000180385.7	EMC3-AS1	5.04	8.59e-07	0.000349	0.28	0.3	Alzheimer's disease;	chr3:10082436	chr3:9986893~10006990:+
KIRP	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	5.04	8.59e-07	0.000349	0.38	0.3	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
KIRP	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-5.04	8.59e-07	0.000349	-0.2	-0.3	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
KIRP	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-5.04	8.6e-07	0.000349	-0.39	-0.3	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
KIRP	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-5.04	8.6e-07	0.000349	-0.32	-0.3	Height;	chr3:53015087	chr3:53064283~53065091:-
KIRP	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-5.04	8.6e-07	0.000349	-0.26	-0.3	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
KIRP	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-5.04	8.6e-07	0.000349	-0.32	-0.3	Height;	chr3:52972039	chr3:53064283~53065091:-
KIRP	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-5.04	8.61e-07	0.00035	-0.24	-0.3	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
KIRP	cis	rs9388451	0.513	rs1268069	ENSG00000237742.5	RP11-624M8.1	-5.04	8.61e-07	0.00035	-0.32	-0.3	Brugada syndrome;	chr6:125718848	chr6:125578558~125749190:-
KIRP	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	5.04	8.61e-07	0.00035	0.3	0.3	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
KIRP	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	5.04	8.61e-07	0.00035	0.3	0.3	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
KIRP	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	5.04	8.62e-07	0.00035	0.34	0.3	Depression;	chr6:28430971	chr6:28176188~28176674:+
KIRP	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	5.04	8.62e-07	0.00035	0.34	0.3	Depression;	chr6:28432562	chr6:28176188~28176674:+
KIRP	cis	rs2386661	0.956	rs10905489	ENSG00000228951.1	RP11-336A10.4	-5.04	8.62e-07	0.00035	-0.36	-0.3	Breast cancer;	chr10:5628578	chr10:5616862~5618161:-
KIRP	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	5.04	8.63e-07	0.00035	0.31	0.3	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
KIRP	cis	rs1005277	0.579	rs2505237	ENSG00000151963.4	RP11-775A3.1	-5.04	8.64e-07	0.000351	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474599	ENSG00000151963.4	RP11-775A3.1	-5.04	8.64e-07	0.000351	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474608	ENSG00000151963.4	RP11-775A3.1	-5.04	8.64e-07	0.000351	-0.34	-0.3	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:37883594~37884109:+
KIRP	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	5.04	8.65e-07	0.000351	0.29	0.3	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
KIRP	cis	rs2504916	0.784	rs2457561	ENSG00000230234.1	RP1-276N6.2	-5.04	8.66e-07	0.000351	-0.3	-0.3	Response to hepatitis C treatment;	chr6:160334778	chr6:160272617~160276130:+
KIRP	cis	rs1479119	0.681	rs7961936	ENSG00000180861.8	LINC01559	5.04	8.66e-07	0.000351	0.35	0.3	Intelligence (multi-trait analysis);	chr12:13347907	chr12:13371089~13387167:-
KIRP	cis	rs4660456	0.572	rs10789191	ENSG00000237899.1	RP4-739H11.3	5.04	8.66e-07	0.000351	0.37	0.3	Platelet count;	chr1:40690819	chr1:40669089~40687588:-
KIRP	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-5.04	8.69e-07	0.000353	-0.33	-0.3	Height;	chr3:53027969	chr3:53064283~53065091:-
KIRP	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-5.04	8.7e-07	0.000353	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
KIRP	cis	rs1044826	0.642	rs6784684	ENSG00000178631.7	ACTG1P1	5.04	8.7e-07	0.000353	0.31	0.3	Obesity-related traits;	chr3:139458792	chr3:139493809~139494937:+
KIRP	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	5.04	8.7e-07	0.000353	0.31	0.3	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
KIRP	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.04	8.7e-07	0.000353	0.25	0.3	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
KIRP	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	5.04	8.72e-07	0.000354	0.27	0.3	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	5.04	8.72e-07	0.000354	0.27	0.3	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	5.04	8.72e-07	0.000354	0.27	0.3	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
KIRP	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	5.04	8.72e-07	0.000354	0.3	0.3	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-5.04	8.72e-07	0.000354	-0.3	-0.3	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-5.04	8.72e-07	0.000354	-0.3	-0.3	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
KIRP	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	5.04	8.72e-07	0.000354	0.25	0.3	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
KIRP	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	5.04	8.74e-07	0.000354	0.39	0.3	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
KIRP	cis	rs1552244	0.572	rs3843008	ENSG00000180385.7	EMC3-AS1	5.04	8.75e-07	0.000355	0.38	0.3	Alzheimer's disease;	chr3:10132058	chr3:9986893~10006990:+
KIRP	cis	rs7849973	0.581	rs62574662	ENSG00000224549.1	RP11-370B11.3	-5.04	8.76e-07	0.000355	-0.33	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22812202	chr9:22767175~22768316:+
KIRP	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	5.04	8.76e-07	0.000355	0.31	0.3	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
KIRP	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	5.04	8.77e-07	0.000355	0.37	0.3	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
KIRP	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-5.04	8.77e-07	0.000355	-0.38	-0.3	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
KIRP	cis	rs7267979	0.932	rs424487	ENSG00000274414.1	RP5-965G21.4	-5.04	8.77e-07	0.000355	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25239007~25245229:-
KIRP	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-5.04	8.78e-07	0.000356	-0.3	-0.3	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
KIRP	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	5.04	8.78e-07	0.000356	0.61	0.3	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	5.04	8.78e-07	0.000356	0.61	0.3	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	5.04	8.78e-07	0.000356	0.61	0.3	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	5.04	8.78e-07	0.000356	0.61	0.3	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
KIRP	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	5.04	8.79e-07	0.000356	0.3	0.3	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
KIRP	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-5.04	8.79e-07	0.000356	-0.25	-0.3	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
KIRP	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	5.04	8.79e-07	0.000356	0.3	0.3	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
KIRP	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	5.04	8.79e-07	0.000356	0.24	0.3	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
KIRP	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-5.04	8.79e-07	0.000356	-0.31	-0.3	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
KIRP	cis	rs6832769	0.767	rs6850524	ENSG00000272969.1	RP11-528I4.2	5.04	8.8e-07	0.000357	0.28	0.3	Personality dimensions;	chr4:55515830	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.767	rs11133394	ENSG00000272969.1	RP11-528I4.2	5.04	8.8e-07	0.000357	0.28	0.3	Personality dimensions;	chr4:55517071	chr4:55547112~55547889:+
KIRP	cis	rs7225151	0.901	rs61481506	ENSG00000234327.6	AC012146.7	-5.04	8.8e-07	0.000357	-0.45	-0.3	Alzheimer's disease (late onset);	chr17:5255419	chr17:5111468~5115004:+
KIRP	cis	rs11673344	0.504	rs2385374	ENSG00000226686.6	LINC01535	5.04	8.81e-07	0.000357	0.36	0.3	Obesity-related traits;	chr19:37092115	chr19:37251912~37265535:+
KIRP	cis	rs7267979	0.753	rs404148	ENSG00000274973.1	RP13-401N8.7	-5.04	8.82e-07	0.000357	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:25845497~25845862:+
KIRP	cis	rs234043	1	rs234051	ENSG00000224426.1	SLC31A1P1	-5.04	8.83e-07	0.000357	-0.26	-0.3	Renal cell carcinoma;	chr3:172593922	chr3:172603440~172604006:-
KIRP	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	5.04	8.83e-07	0.000357	0.37	0.3	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
KIRP	cis	rs79349575	0.715	rs1058018	ENSG00000248278.1	SUMO2P17	5.04	8.83e-07	0.000357	0.31	0.3	Type 2 diabetes;	chr17:48922889	chr17:48874860~48908983:-
KIRP	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-5.04	8.85e-07	0.000358	-0.25	-0.3	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-5.04	8.85e-07	0.000358	-0.25	-0.3	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-5.04	8.85e-07	0.000358	-0.25	-0.3	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
KIRP	cis	rs58722170	0.61	rs55884510	ENSG00000232273.1	FTH1P1	5.04	8.85e-07	0.000358	0.4	0.3	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37603342	chr1:37544763~37545294:+
KIRP	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-5.04	8.85e-07	0.000358	-0.31	-0.3	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
KIRP	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-5.04	8.86e-07	0.000359	-0.25	-0.3	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
KIRP	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-5.04	8.86e-07	0.000359	-0.27	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
KIRP	cis	rs10912872	0.599	rs6425192	ENSG00000225704.2	RP4-798A17.5	5.04	8.86e-07	0.000359	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171358489	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.598	rs6425194	ENSG00000225704.2	RP4-798A17.5	5.04	8.86e-07	0.000359	0.28	0.3	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171358944	chr1:171345089~171345320:+
KIRP	cis	rs1552244	0.872	rs6792951	ENSG00000180385.7	EMC3-AS1	5.04	8.87e-07	0.000359	0.28	0.3	Alzheimer's disease;	chr3:10077919	chr3:9986893~10006990:+
KIRP	cis	rs2562456	0.833	rs2650801	ENSG00000268081.1	RP11-678G14.2	5.04	8.87e-07	0.000359	0.4	0.3	Pain;	chr19:21452553	chr19:21554640~21569237:-
KIRP	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-5.04	8.87e-07	0.000359	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
KIRP	cis	rs7432375	0.901	rs35874192	ENSG00000261758.1	RP11-102M11.2	-5.04	8.87e-07	0.000359	-0.32	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136751162	chr3:136752630~136755780:+
KIRP	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-5.04	8.88e-07	0.000359	-0.25	-0.3	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
KIRP	cis	rs711830	1	rs2857540	ENSG00000226363.3	HAGLROS	-5.04	8.88e-07	0.00036	-0.48	-0.3	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176161970	chr2:176177717~176179008:+
KIRP	cis	rs6540731	0.754	rs6679064	ENSG00000229983.1	RP11-15I11.2	5.04	8.89e-07	0.00036	0.33	0.3	Intelligence (childhood);	chr1:212186366	chr1:212168207~212190259:+
KIRP	cis	rs2278170	1	rs2278171	ENSG00000225101.4	OR52K3P	-5.04	8.89e-07	0.00036	-0.36	-0.3	Amyotrophic lateral sclerosis;	chr11:4475686	chr11:4474813~4475755:+
KIRP	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-5.04	8.89e-07	0.00036	-0.28	-0.3	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
KIRP	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	5.03	8.92e-07	0.000361	0.25	0.3	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
KIRP	cis	rs9595908	0.746	rs2031355	ENSG00000212293.1	SNORA16	5.03	8.93e-07	0.000361	0.3	0.3	Body mass index;	chr13:32641495	chr13:32420390~32420516:-
KIRP	cis	rs9959145	1	rs9989546	ENSG00000267108.1	RP11-861E21.1	5.03	8.93e-07	0.000361	0.48	0.3	Immune response to smallpox vaccine (IL-6);	chr18:12562538	chr18:12432897~12437635:+
KIRP	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-5.03	8.94e-07	0.000361	-0.25	-0.3	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
KIRP	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	5.03	8.94e-07	0.000362	0.24	0.3	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
KIRP	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	5.03	8.94e-07	0.000362	0.31	0.3	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
KIRP	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	5.03	8.94e-07	0.000362	0.28	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
KIRP	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	5.03	8.95e-07	0.000362	0.55	0.3	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
KIRP	cis	rs3820443	0.563	rs3738304	ENSG00000234020.1	CHIAP3	-5.03	8.95e-07	0.000362	-0.46	-0.3	Late-onset Alzheimer's disease;	chr1:111348319	chr1:111353275~111367409:-
KIRP	cis	rs1479119	0.681	rs10772656	ENSG00000180861.8	LINC01559	5.03	8.96e-07	0.000362	0.35	0.3	Intelligence (multi-trait analysis);	chr12:13348720	chr12:13371089~13387167:-
KIRP	cis	rs9959145	1	rs28821540	ENSG00000267108.1	RP11-861E21.1	5.03	8.96e-07	0.000362	0.48	0.3	Immune response to smallpox vaccine (IL-6);	chr18:12558309	chr18:12432897~12437635:+
KIRP	cis	rs9595908	0.746	rs2301391	ENSG00000212293.1	SNORA16	5.03	8.96e-07	0.000362	0.3	0.3	Body mass index;	chr13:32668398	chr13:32420390~32420516:-
KIRP	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.03	8.99e-07	0.000363	0.26	0.3	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
KIRP	cis	rs947583	0.517	rs9376148	ENSG00000231028.7	LINC00271	-5.03	8.99e-07	0.000363	-0.26	-0.3	Phosphorus levels;	chr6:135777362	chr6:135497801~135716055:+
KIRP	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-5.03	8.99e-07	0.000364	-0.6	-0.3	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
KIRP	cis	rs6496932	0.635	rs2200214	ENSG00000218052.5	ADAMTS7P4	-5.03	9e-07	0.000364	-0.41	-0.3	Central corneal thickness;Corneal structure;	chr15:85383745	chr15:85255369~85330334:-
KIRP	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	5.03	9.01e-07	0.000364	0.5	0.3	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
KIRP	cis	rs1799949	0.757	rs9915489	ENSG00000236383.6	LINC00854	-5.03	9.01e-07	0.000364	-0.22	-0.3	Menopause (age at onset);	chr17:43021209	chr17:43216941~43305976:-
KIRP	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	5.03	9.03e-07	0.000365	0.31	0.3	Height;	chr4:55570311	chr4:55363971~55395847:-
KIRP	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-5.03	9.03e-07	0.000365	-0.25	-0.3	Height;	chr2:46629946	chr2:46668870~46670778:+
KIRP	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-5.03	9.03e-07	0.000365	-0.29	-0.3	Height;	chr14:75119585	chr14:75011269~75012851:-
KIRP	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-5.03	9.03e-07	0.000365	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-5.03	9.03e-07	0.000365	-0.33	-0.3	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
KIRP	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-5.03	9.05e-07	0.000366	-0.31	-0.3	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-5.03	9.05e-07	0.000366	-0.31	-0.3	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-5.03	9.05e-07	0.000366	-0.31	-0.3	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
KIRP	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-5.03	9.06e-07	0.000366	-0.33	-0.3	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
KIRP	cis	rs9595908	0.746	rs12427832	ENSG00000212293.1	SNORA16	-5.03	9.07e-07	0.000366	-0.29	-0.3	Body mass index;	chr13:32644896	chr13:32420390~32420516:-
KIRP	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	5.03	9.07e-07	0.000366	0.23	0.3	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
KIRP	cis	rs4356975	0.563	rs7657423	ENSG00000248763.2	RP13-644M16.5	5.03	9.07e-07	0.000366	0.32	0.3	Obesity-related traits;	chr4:69090196	chr4:69066395~69069888:+
KIRP	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-5.03	9.08e-07	0.000367	-0.37	-0.3	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
KIRP	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	5.03	9.08e-07	0.000367	0.37	0.3	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
KIRP	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-5.03	9.08e-07	0.000367	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
KIRP	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-5.03	9.08e-07	0.000367	-0.26	-0.3	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
KIRP	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-5.03	9.09e-07	0.000367	-0.3	-0.3	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-5.03	9.09e-07	0.000367	-0.3	-0.3	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
KIRP	cis	rs5758659	0.819	rs134871	ENSG00000205702.9	CYP2D7	5.03	9.09e-07	0.000367	0.23	0.3	Cognitive function;	chr22:42256710	chr22:42140203~42144577:-
KIRP	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66679692	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66692349	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66693028	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66693433	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66694214	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66701371	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66702658	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66706390	chr7:66654538~66669855:+
KIRP	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66710076	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66715944	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66721259	chr7:66654538~66669855:+
KIRP	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-5.03	9.09e-07	0.000367	-0.6	-0.3	Gout;	chr7:66732812	chr7:66654538~66669855:+
KIRP	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	5.03	9.09e-07	0.000367	0.6	0.3	Gout;	chr7:66682070	chr7:66654538~66669855:+
KIRP	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	5.03	9.09e-07	0.000367	0.6	0.3	Gout;	chr7:66682162	chr7:66654538~66669855:+
KIRP	cis	rs12922317	0.964	rs8043644	ENSG00000260488.1	RP11-166B2.7	5.03	9.09e-07	0.000367	0.37	0.3	Schizophrenia;	chr16:11983267	chr16:11976851~11977850:-
KIRP	cis	rs12922317	1	rs12922317	ENSG00000260488.1	RP11-166B2.7	5.03	9.09e-07	0.000367	0.37	0.3	Schizophrenia;	chr16:11983775	chr16:11976851~11977850:-
KIRP	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-5.03	9.09e-07	0.000367	-0.28	-0.3	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
KIRP	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-5.03	9.1e-07	0.000367	-0.31	-0.3	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
KIRP	cis	rs10504130	0.569	rs35032384	ENSG00000272024.1	RP11-546K22.3	-5.03	9.11e-07	0.000368	-0.34	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51950284~51950690:+
KIRP	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	5.03	9.11e-07	0.000368	0.24	0.3	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
KIRP	cis	rs7615952	0.599	rs66532274	ENSG00000241439.1	RP11-666A20.3	5.03	9.12e-07	0.000368	0.38	0.3	Blood pressure (smoking interaction);	chr3:126013002	chr3:125958556~125958817:+
KIRP	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-5.03	9.12e-07	0.000368	-0.35	-0.3	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
KIRP	cis	rs4578769	0.569	rs12955131	ENSG00000265943.1	RP11-739L10.1	-5.03	9.12e-07	0.000368	-0.37	-0.3	Eosinophil percentage of white cells;	chr18:22900424	chr18:22699481~22933764:-
KIRP	cis	rs911119	1	rs1064039	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23637790	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs73318135	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23637934	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs5030707	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23638019	chr20:23631826~23632316:-
KIRP	cis	rs911119	0.909	rs111360484	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23638347	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs67567111	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23638438	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs3827143	ENSG00000270001.1	RP11-218C14.8	-5.03	9.13e-07	0.000368	-0.35	-0.3	Chronic kidney disease;	chr20:23638980	chr20:23631826~23632316:-
KIRP	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	5.03	9.13e-07	0.000368	0.31	0.3	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-5.03	9.14e-07	0.000369	-0.24	-0.3	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-5.03	9.14e-07	0.000369	-0.31	-0.3	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.597	rs11763224	ENSG00000224316.1	RP11-479O9.2	5.03	9.15e-07	0.000369	0.25	0.3	Aortic root size;	chr7:66518628	chr7:65773620~65802067:+
KIRP	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	5.03	9.16e-07	0.000369	0.31	0.3	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
KIRP	cis	rs7267979	0.873	rs7453	ENSG00000277938.1	RP5-965G21.3	5.03	9.16e-07	0.000369	0.28	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25229150~25231933:+
KIRP	cis	rs1552244	0.572	rs67227131	ENSG00000180385.7	EMC3-AS1	5.03	9.16e-07	0.00037	0.38	0.3	Alzheimer's disease;	chr3:10131060	chr3:9986893~10006990:+
KIRP	cis	rs453301	0.686	rs11785634	ENSG00000253981.4	ALG1L13P	-5.03	9.16e-07	0.00037	-0.23	-0.3	Joint mobility (Beighton score);	chr8:9035087	chr8:8236003~8244667:-
KIRP	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-5.03	9.17e-07	0.00037	-0.25	-0.3	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
KIRP	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-5.03	9.19e-07	0.00037	-0.39	-0.3	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
KIRP	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-5.03	9.19e-07	0.00037	-0.39	-0.3	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
KIRP	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-5.03	9.19e-07	0.00037	-0.39	-0.3	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
KIRP	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	5.03	9.19e-07	0.00037	0.26	0.3	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
KIRP	cis	rs61457372	0.563	rs56008432	ENSG00000264026.1	RP11-1124B17.1	-5.03	9.2e-07	0.000371	-0.32	-0.3	Triptolide cytotoxicity;	chr17:72352881	chr17:72342940~72355136:+
KIRP	cis	rs11723261	0.527	rs11731581	ENSG00000211553.1	AC253576.2	-5.03	9.2e-07	0.000371	-0.4	-0.3	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:136461~136568:+
KIRP	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-5.03	9.2e-07	0.000371	-0.25	-0.3	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
KIRP	cis	rs17228178	0.961	rs9920109	ENSG00000215302.7	CTD-3092A11.1	-5.03	9.2e-07	0.000371	-0.38	-0.3	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177120	chr15:30470779~30507623:+
KIRP	cis	rs9928842	0.823	rs8061356	ENSG00000280152.1	RP11-331F4.5	5.03	9.21e-07	0.000371	0.36	0.3	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75245994~75250077:-
KIRP	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	5.03	9.22e-07	0.000371	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
KIRP	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-5.03	9.22e-07	0.000372	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
KIRP	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.03	9.22e-07	0.000372	0.34	0.3	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
KIRP	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-5.03	9.24e-07	0.000372	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-5.03	9.24e-07	0.000372	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
KIRP	cis	rs1799949	0.931	rs34410138	ENSG00000279602.1	CTD-3014M21.1	-5.03	9.24e-07	0.000372	-0.27	-0.3	Menopause (age at onset);	chr17:43127753	chr17:43360041~43361361:-
KIRP	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	5.03	9.24e-07	0.000372	0.79	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
KIRP	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-5.03	9.24e-07	0.000372	-0.4	-0.3	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
KIRP	cis	rs1799949	0.965	rs799917	ENSG00000236383.6	LINC00854	-5.03	9.25e-07	0.000372	-0.22	-0.3	Menopause (age at onset);	chr17:43092919	chr17:43216941~43305976:-
KIRP	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	5.03	9.26e-07	0.000373	0.33	0.3	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
KIRP	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-5.03	9.27e-07	0.000373	-0.3	-0.3	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
KIRP	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	5.03	9.27e-07	0.000373	0.3	0.3	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
KIRP	cis	rs2976388	0.566	rs4736373	ENSG00000253741.1	CTD-2292P10.4	5.03	9.28e-07	0.000374	0.38	0.3	Urinary tract infection frequency;	chr8:142710939	chr8:142702252~142726973:-
KIRP	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-5.03	9.3e-07	0.000374	-0.27	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
KIRP	cis	rs3892630	0.757	rs8109823	ENSG00000267475.1	CTD-2538C1.2	-5.03	9.3e-07	0.000374	-0.41	-0.3	Red blood cell traits;	chr19:32692410	chr19:32687089~32691750:-
KIRP	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-5.03	9.3e-07	0.000374	-0.25	-0.3	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
KIRP	cis	rs4638749	0.953	rs12475415	ENSG00000225328.1	AC019100.3	-5.03	9.3e-07	0.000374	-0.38	-0.3	Blood pressure;	chr2:108244021	chr2:108167748~108217841:-
KIRP	cis	rs2361718	0.521	rs2361724	ENSG00000275479.1	RP11-334C17.6	5.03	9.3e-07	0.000374	0.23	0.3	Yeast infection;	chr17:80125315	chr17:80149627~80149798:+
KIRP	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	5.03	9.3e-07	0.000374	0.4	0.3	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
KIRP	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	5.03	9.31e-07	0.000374	0.24	0.3	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
KIRP	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	5.03	9.31e-07	0.000375	0.18	0.3	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
KIRP	cis	rs295490	1	rs397940	ENSG00000272656.1	RP11-219D15.3	-5.03	9.31e-07	0.000375	-0.35	-0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520429	chr3:139349024~139349371:-
KIRP	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	5.03	9.31e-07	0.000375	0.29	0.3	Height;	chr4:55450662	chr4:55547112~55547889:+
KIRP	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	5.03	9.31e-07	0.000375	0.37	0.3	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
KIRP	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-5.03	9.32e-07	0.000375	-0.58	-0.3	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-5.03	9.32e-07	0.000375	-0.58	-0.3	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-5.03	9.32e-07	0.000375	-0.58	-0.3	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-5.03	9.32e-07	0.000375	-0.58	-0.3	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
KIRP	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-5.03	9.32e-07	0.000375	-0.32	-0.3	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
KIRP	cis	rs4934494	0.768	rs34663515	ENSG00000232936.4	RP11-80H5.2	5.03	9.32e-07	0.000375	0.45	0.3	Red blood cell count;	chr10:89632786	chr10:89645282~89650667:+
KIRP	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	5.02	9.35e-07	0.000376	0.37	0.3	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
KIRP	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	5.02	9.35e-07	0.000376	0.37	0.3	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
KIRP	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-5.02	9.35e-07	0.000376	-0.3	-0.3	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
KIRP	cis	rs1552244	0.81	rs4019706	ENSG00000180385.7	EMC3-AS1	5.02	9.35e-07	0.000376	0.28	0.3	Alzheimer's disease;	chr3:10071178	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.872	rs6771931	ENSG00000180385.7	EMC3-AS1	5.02	9.35e-07	0.000376	0.28	0.3	Alzheimer's disease;	chr3:10071724	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs9824585	ENSG00000180385.7	EMC3-AS1	5.02	9.35e-07	0.000376	0.28	0.3	Alzheimer's disease;	chr3:10073118	chr3:9986893~10006990:+
KIRP	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	5.02	9.35e-07	0.000376	0.3	0.3	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	5.02	9.35e-07	0.000376	0.3	0.3	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	5.02	9.35e-07	0.000376	0.3	0.3	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	5.02	9.35e-07	0.000376	0.3	0.3	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	5.02	9.35e-07	0.000376	0.3	0.3	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
KIRP	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-5.02	9.35e-07	0.000376	-0.39	-0.3	Depression;	chr6:28192182	chr6:28115628~28116551:+
KIRP	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	5.02	9.36e-07	0.000376	0.34	0.3	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
KIRP	cis	rs7432375	0.901	rs6802702	ENSG00000261758.1	RP11-102M11.2	-5.02	9.37e-07	0.000377	-0.31	-0.3	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136770721	chr3:136752630~136755780:+
KIRP	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-5.02	9.39e-07	0.000377	-0.42	-0.3	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
KIRP	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-5.02	9.39e-07	0.000377	-0.58	-0.3	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-5.02	9.39e-07	0.000377	-0.58	-0.3	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-5.02	9.39e-07	0.000377	-0.58	-0.3	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-5.02	9.39e-07	0.000377	-0.58	-0.3	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
KIRP	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-5.02	9.4e-07	0.000377	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
KIRP	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-5.02	9.4e-07	0.000377	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
KIRP	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	5.02	9.4e-07	0.000378	0.65	0.3	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
KIRP	cis	rs11673344	0.504	rs4254428	ENSG00000226686.6	LINC01535	5.02	9.41e-07	0.000378	0.35	0.3	Obesity-related traits;	chr19:37093748	chr19:37251912~37265535:+
KIRP	cis	rs7008867	0.649	rs4871878	ENSG00000253390.1	CTC-756D1.2	-5.02	9.42e-07	0.000378	-0.42	-0.3	Hip circumference adjusted for BMI;	chr8:23523258	chr8:23458601~23484971:+
KIRP	cis	rs8037137	0.915	rs8028409	ENSG00000258725.1	PRC1-AS1	-5.02	9.42e-07	0.000378	-0.42	-0.3	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90963192	chr15:90966345~90988624:+
KIRP	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	5.02	9.42e-07	0.000378	0.31	0.3	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
KIRP	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-5.02	9.43e-07	0.000379	-0.43	-0.3	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
KIRP	cis	rs7267979	0.932	rs1985737	ENSG00000274414.1	RP5-965G21.4	-5.02	9.45e-07	0.00038	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25239007~25245229:-
KIRP	cis	rs4663866	1	rs4663866	ENSG00000186235.9	AC016757.3	5.02	9.47e-07	0.00038	0.56	0.3	Irritable bowel syndrome;	chr2:238242174	chr2:238224552~238231677:-
KIRP	cis	rs4663866	0.908	rs35093813	ENSG00000186235.9	AC016757.3	5.02	9.47e-07	0.00038	0.56	0.3	Irritable bowel syndrome;	chr2:238245124	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs4663867	ENSG00000186235.9	AC016757.3	5.02	9.47e-07	0.00038	0.56	0.3	Irritable bowel syndrome;	chr2:238251323	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs4663868	ENSG00000186235.9	AC016757.3	5.02	9.47e-07	0.00038	0.56	0.3	Irritable bowel syndrome;	chr2:238252450	chr2:238224552~238231677:-
KIRP	cis	rs4663866	0.803	rs71426511	ENSG00000186235.9	AC016757.3	5.02	9.47e-07	0.00038	0.56	0.3	Irritable bowel syndrome;	chr2:238271559	chr2:238224552~238231677:-
KIRP	cis	rs1799949	0.896	rs35908185	ENSG00000279602.1	CTD-3014M21.1	-5.02	9.47e-07	0.00038	-0.27	-0.3	Menopause (age at onset);	chr17:43103094	chr17:43360041~43361361:-
KIRP	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	5.02	9.47e-07	0.00038	0.26	0.3	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	5.02	9.47e-07	0.00038	0.26	0.3	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
KIRP	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-5.02	9.48e-07	0.00038	-0.26	-0.3	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
KIRP	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-5.02	9.48e-07	0.000381	-0.36	-0.3	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
KIRP	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	5.02	9.49e-07	0.000381	0.27	0.3	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	5.02	9.49e-07	0.000381	0.27	0.3	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
KIRP	cis	rs12530	0.715	rs5998475	ENSG00000241954.1	RP1-149A16.17	-5.02	9.49e-07	0.000381	-0.34	-0.3	IgG glycosylation;	chr22:32405345	chr22:32383786~32385631:+
KIRP	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	5.02	9.5e-07	0.000381	0.26	0.3	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
KIRP	cis	rs9543976	1	rs73223984	ENSG00000261105.4	LMO7-AS1	-5.02	9.51e-07	0.000381	-0.54	-0.3	Diabetic retinopathy;	chr13:75607005	chr13:75604700~75635994:-
KIRP	cis	rs6832769	0.961	rs7660808	ENSG00000272969.1	RP11-528I4.2	-5.02	9.51e-07	0.000381	-0.29	-0.3	Personality dimensions;	chr4:55590505	chr4:55547112~55547889:+
KIRP	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	5.02	9.52e-07	0.000382	0.31	0.3	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	5.02	9.52e-07	0.000382	0.31	0.3	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	5.02	9.52e-07	0.000382	0.31	0.3	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
KIRP	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-5.02	9.52e-07	0.000382	-0.24	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
KIRP	cis	rs962856	0.964	rs1486133	ENSG00000236780.4	AC078941.1	-5.02	9.54e-07	0.000382	-0.34	-0.3	Pancreatic cancer;	chr2:67414889	chr2:67123357~67215319:-
KIRP	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	5.02	9.54e-07	0.000382	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
KIRP	cis	rs73198271	0.74	rs10092720	ENSG00000253981.4	ALG1L13P	-5.02	9.55e-07	0.000383	-0.25	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8236003~8244667:-
KIRP	cis	rs2395128	0.765	rs11001179	ENSG00000272692.1	RP11-399K21.14	5.02	9.55e-07	0.000383	0.31	0.3	Ulcerative colitis;Inflammatory bowel disease;	chr10:74843724	chr10:75409157~75411842:+
KIRP	cis	rs7267979	1	rs6050547	ENSG00000274414.1	RP5-965G21.4	5.02	9.55e-07	0.000383	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25239007~25245229:-
KIRP	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-5.02	9.55e-07	0.000383	-0.25	-0.3	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
KIRP	cis	rs1552244	0.81	rs7612908	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10047464	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.935	rs7649243	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10047786	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs7615646	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10048089	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.81	rs6809572	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10058461	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs112847840	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10059968	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs722509	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10060693	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6793396	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10069243	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6772315	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10071960	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.935	rs7621551	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10072521	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6786638	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10076391	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6442150	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10080891	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs6764168	ENSG00000180385.7	EMC3-AS1	5.02	9.55e-07	0.000383	0.3	0.3	Alzheimer's disease;	chr3:10082121	chr3:9986893~10006990:+
KIRP	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-5.02	9.56e-07	0.000383	-0.58	-0.3	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
KIRP	cis	rs77741769	0.529	rs12579868	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Mean corpuscular volume;	chr12:120769344	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.529	rs1467283	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Mean corpuscular volume;	chr12:120772417	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.529	rs7137504	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Mean corpuscular volume;	chr12:120783825	chr12:120703867~120704282:+
KIRP	cis	rs6489785	0.509	rs3213570	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120784608	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.529	rs3901854	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Mean corpuscular volume;	chr12:120787723	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs11065282	ENSG00000277423.1	RP11-173P15.9	-5.02	9.56e-07	0.000383	-0.31	-0.3	Mean corpuscular volume;	chr12:120826612	chr12:120703867~120704282:+
KIRP	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-5.02	9.58e-07	0.000384	-0.35	-0.3	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
KIRP	cis	rs1552244	0.752	rs9867091	ENSG00000180385.7	EMC3-AS1	5.02	9.58e-07	0.000384	0.26	0.3	Alzheimer's disease;	chr3:10001745	chr3:9986893~10006990:+
KIRP	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-5.02	9.59e-07	0.000384	-0.32	-0.3	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
KIRP	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-5.02	9.59e-07	0.000384	-0.29	-0.3	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
KIRP	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-5.02	9.61e-07	0.000385	-0.3	-0.3	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
KIRP	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	5.02	9.61e-07	0.000385	0.24	0.3	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
KIRP	cis	rs7267979	1	rs3002702	ENSG00000274414.1	RP5-965G21.4	-5.02	9.62e-07	0.000385	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25239007~25245229:-
KIRP	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-5.02	9.62e-07	0.000385	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-5.02	9.62e-07	0.000385	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-5.02	9.62e-07	0.000385	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
KIRP	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	5.02	9.62e-07	0.000385	0.46	0.3	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
KIRP	cis	rs728616	0.867	rs28365998	ENSG00000234382.2	RP11-40F6.1	-5.02	9.63e-07	0.000385	-0.46	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:80233664~80245367:+
KIRP	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-5.02	9.63e-07	0.000385	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
KIRP	cis	rs12922317	0.535	rs8051349	ENSG00000260488.1	RP11-166B2.7	-5.02	9.63e-07	0.000386	-0.35	-0.3	Schizophrenia;	chr16:12011666	chr16:11976851~11977850:-
KIRP	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-5.02	9.63e-07	0.000386	-0.24	-0.3	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
KIRP	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-5.02	9.64e-07	0.000386	-0.34	-0.3	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
KIRP	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-5.02	9.64e-07	0.000386	-0.3	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
KIRP	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-5.02	9.64e-07	0.000386	-0.3	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
KIRP	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-5.02	9.64e-07	0.000386	-0.3	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
KIRP	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-5.02	9.64e-07	0.000386	-0.3	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
KIRP	cis	rs11673344	0.504	rs4806409	ENSG00000226686.6	LINC01535	5.02	9.64e-07	0.000386	0.35	0.3	Obesity-related traits;	chr19:37097923	chr19:37251912~37265535:+
KIRP	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-5.02	9.64e-07	0.000386	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
KIRP	cis	rs2976388	0.566	rs13250661	ENSG00000253741.1	CTD-2292P10.4	5.02	9.64e-07	0.000386	0.37	0.3	Urinary tract infection frequency;	chr8:142722716	chr8:142702252~142726973:-
KIRP	cis	rs7267979	1	rs2257982	ENSG00000274414.1	RP5-965G21.4	-5.02	9.64e-07	0.000386	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2257985	ENSG00000274414.1	RP5-965G21.4	-5.02	9.64e-07	0.000386	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2257988	ENSG00000274414.1	RP5-965G21.4	-5.02	9.64e-07	0.000386	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25239007~25245229:-
KIRP	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.02	9.65e-07	0.000386	0.34	0.3	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
KIRP	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	5.02	9.65e-07	0.000386	0.44	0.3	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
KIRP	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	5.02	9.66e-07	0.000386	0.34	0.3	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
KIRP	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	5.02	9.67e-07	0.000387	0.24	0.3	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
KIRP	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-5.02	9.67e-07	0.000387	-0.24	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
KIRP	cis	rs497273	0.534	rs608394	ENSG00000277423.1	RP11-173P15.9	-5.02	9.67e-07	0.000387	-0.31	-0.3	Systemic lupus erythematosus;	chr12:120756250	chr12:120703867~120704282:+
KIRP	cis	rs2278170	1	rs2278170	ENSG00000225101.4	OR52K3P	-5.02	9.68e-07	0.000387	-0.36	-0.3	Amyotrophic lateral sclerosis;	chr11:4475616	chr11:4474813~4475755:+
KIRP	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	5.02	9.69e-07	0.000387	0.25	0.3	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
KIRP	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-5.02	9.7e-07	0.000388	-0.36	-0.3	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
KIRP	cis	rs4638749	0.677	rs2219082	ENSG00000231221.1	AC023672.2	-5.02	9.7e-07	0.000388	-0.35	-0.3	Blood pressure;	chr2:108237726	chr2:108049200~108052755:-
KIRP	cis	rs11671005	0.568	rs55987239	ENSG00000269600.1	AC016629.3	-5.02	9.7e-07	0.000388	-0.4	-0.3	Mean platelet volume;	chr19:58573678	chr19:58593896~58599355:-
KIRP	cis	rs11671005	0.569	rs73068335	ENSG00000269600.1	AC016629.3	-5.02	9.7e-07	0.000388	-0.4	-0.3	Mean platelet volume;	chr19:58577941	chr19:58593896~58599355:-
KIRP	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-5.02	9.7e-07	0.000388	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
KIRP	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-5.02	9.7e-07	0.000388	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
KIRP	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-5.02	9.7e-07	0.000388	-0.44	-0.3	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
KIRP	cis	rs755249	0.529	rs604316	ENSG00000237624.1	OXCT2P1	5.02	9.7e-07	0.000388	0.38	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39514956~39516490:+
KIRP	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-5.02	9.71e-07	0.000388	-0.21	-0.3	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
KIRP	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-5.02	9.72e-07	0.000389	-0.34	-0.3	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
KIRP	cis	rs11079159	0.959	rs3794752	ENSG00000263096.1	RP11-515O17.2	5.02	9.73e-07	0.000389	0.41	0.3	QRS duration;	chr17:55305468	chr17:55271504~55273653:-
KIRP	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	5.02	9.74e-07	0.000389	0.32	0.3	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
KIRP	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	5.02	9.75e-07	0.00039	0.26	0.3	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
KIRP	cis	rs79040073	0.607	rs73400205	ENSG00000259531.2	RP11-295H24.3	5.02	9.75e-07	0.00039	0.39	0.3	Lung cancer in ever smokers;	chr15:49442346	chr15:49365124~49366685:-
KIRP	cis	rs7474896	0.537	rs1208683	ENSG00000151963.4	RP11-775A3.1	5.02	9.75e-07	0.00039	0.4	0.3	Obesity (extreme);	chr10:37804795	chr10:37883594~37884109:+
KIRP	cis	rs12922317	0.964	rs8061496	ENSG00000260488.1	RP11-166B2.7	5.02	9.76e-07	0.00039	0.37	0.3	Schizophrenia;	chr16:11982895	chr16:11976851~11977850:-
KIRP	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	5.02	9.76e-07	0.00039	0.25	0.3	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	5.02	9.76e-07	0.00039	0.25	0.3	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
KIRP	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-5.02	9.76e-07	0.00039	-0.25	-0.3	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
KIRP	cis	rs712039	0.652	rs829163	ENSG00000276054.1	RP11-378E13.3	5.02	9.76e-07	0.00039	0.43	0.3	Tuberculosis;	chr17:37405936	chr17:37386886~37387926:+
KIRP	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	5.02	9.76e-07	0.00039	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	5.02	9.76e-07	0.00039	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	5.02	9.76e-07	0.00039	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
KIRP	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-5.02	9.76e-07	0.00039	-0.37	-0.3	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
KIRP	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	5.02	9.77e-07	0.00039	0.27	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
KIRP	cis	rs964611	0.816	rs1426722	ENSG00000259488.2	RP11-154J22.1	-5.02	9.77e-07	0.00039	-0.27	-0.3	Metabolite levels (Pyroglutamine);	chr15:48277212	chr15:48312353~48331856:-
KIRP	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-5.02	9.77e-07	0.00039	-0.26	-0.3	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-5.02	9.77e-07	0.00039	-0.26	-0.3	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
KIRP	cis	rs7267979	1	rs4815418	ENSG00000274414.1	RP5-965G21.4	5.02	9.79e-07	0.000391	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25239007~25245229:-
KIRP	cis	rs4356203	0.905	rs594034	ENSG00000272034.1	SNORD14A	-5.01	9.79e-07	0.000391	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17074654~17074744:-
KIRP	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	5.01	9.79e-07	0.000391	0.27	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
KIRP	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	5.01	9.79e-07	0.000391	0.32	0.3	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
KIRP	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-5.01	9.79e-07	0.000391	-0.32	-0.3	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
KIRP	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-5.01	9.79e-07	0.000391	-0.32	-0.3	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
KIRP	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-5.01	9.81e-07	0.000392	-0.25	-0.3	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
KIRP	cis	rs11671005	0.656	rs55928441	ENSG00000269600.1	AC016629.3	-5.01	9.81e-07	0.000392	-0.47	-0.3	Mean platelet volume;	chr19:58498307	chr19:58593896~58599355:-
KIRP	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	5.01	9.82e-07	0.000392	0.37	0.3	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
KIRP	cis	rs1479119	0.78	rs7971776	ENSG00000180861.8	LINC01559	5.01	9.83e-07	0.000392	0.36	0.3	Intelligence (multi-trait analysis);	chr12:13347962	chr12:13371089~13387167:-
KIRP	cis	rs950169	0.922	rs8037078	ENSG00000275120.1	RP11-182J1.17	-5.01	9.83e-07	0.000392	-0.41	-0.3	Schizophrenia;	chr15:84150119	chr15:84599434~84606463:-
KIRP	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-5.01	9.83e-07	0.000392	-0.25	-0.3	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-5.01	9.83e-07	0.000392	-0.25	-0.3	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
KIRP	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	5.01	9.83e-07	0.000392	0.26	0.3	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
KIRP	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-5.01	9.83e-07	0.000392	-0.25	-0.3	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
KIRP	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-5.01	9.84e-07	0.000393	-0.25	-0.3	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
KIRP	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	5.01	9.84e-07	0.000393	0.26	0.3	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	5.01	9.84e-07	0.000393	0.26	0.3	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
KIRP	cis	rs2976388	0.566	rs2585141	ENSG00000253741.1	CTD-2292P10.4	5.01	9.85e-07	0.000393	0.37	0.3	Urinary tract infection frequency;	chr8:142724925	chr8:142702252~142726973:-
KIRP	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	5.01	9.85e-07	0.000393	0.31	0.3	Height;	chr4:55558258	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	5.01	9.85e-07	0.000393	0.31	0.3	Height;	chr4:55558259	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	5.01	9.85e-07	0.000393	0.31	0.3	Height;	chr4:55558261	chr4:55363971~55395847:-
KIRP	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	5.01	9.86e-07	0.000393	0.31	0.3	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
KIRP	cis	rs4356203	0.87	rs1979603	ENSG00000272034.1	SNORD14A	-5.01	9.87e-07	0.000393	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17074654~17074744:-
KIRP	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-5.01	9.87e-07	0.000394	-0.3	-0.3	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-5.01	9.87e-07	0.000394	-0.3	-0.3	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
KIRP	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-5.01	9.87e-07	0.000394	-0.25	-0.3	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-5.01	9.87e-07	0.000394	-0.25	-0.3	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-5.01	9.87e-07	0.000394	-0.25	-0.3	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
KIRP	cis	rs2395128	0.705	rs4745760	ENSG00000272692.1	RP11-399K21.14	-5.01	9.9e-07	0.000395	-0.32	-0.3	Ulcerative colitis;Inflammatory bowel disease;	chr10:74898572	chr10:75409157~75411842:+
KIRP	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-5.01	9.9e-07	0.000395	-0.25	-0.3	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
KIRP	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	5.01	9.91e-07	0.000395	0.51	0.3	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
KIRP	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-5.01	9.92e-07	0.000395	-0.32	-0.3	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
KIRP	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-5.01	9.92e-07	0.000395	-0.47	-0.3	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-5.01	9.92e-07	0.000395	-0.47	-0.3	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-5.01	9.92e-07	0.000395	-0.47	-0.3	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
KIRP	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-5.01	9.92e-07	0.000395	-0.47	-0.3	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
KIRP	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-5.01	9.92e-07	0.000395	-0.33	-0.3	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
KIRP	cis	rs12928939	0.911	rs12917983	ENSG00000260886.1	TAT-AS1	5.01	9.92e-07	0.000395	0.4	0.3	Post bronchodilator FEV1;	chr16:71801340	chr16:71565789~71578187:+
KIRP	cis	rs7267979	0.966	rs6037083	ENSG00000274414.1	RP5-965G21.4	5.01	9.93e-07	0.000396	0.28	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25239007~25245229:-
KIRP	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-5.01	9.93e-07	0.000396	-0.2	-0.3	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
KIRP	cis	rs6840258	0.891	rs10032710	ENSG00000251411.1	RP11-397E7.4	-5.01	9.93e-07	0.000396	-0.3	-0.3	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87145107	chr4:86913266~86914817:-
KIRP	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-5.01	9.94e-07	0.000396	-0.23	-0.3	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
KIRP	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-5.01	9.94e-07	0.000396	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
KIRP	cis	rs12530	0.715	rs5749428	ENSG00000241954.1	RP1-149A16.17	-5.01	9.96e-07	0.000397	-0.34	-0.3	IgG glycosylation;	chr22:32403709	chr22:32383786~32385631:+
KIRP	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
KIRP	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-5.01	9.96e-07	0.000397	-0.3	-0.3	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
KIRP	cis	rs4663866	1	rs71426509	ENSG00000186235.9	AC016757.3	5.01	9.96e-07	0.000397	0.56	0.3	Irritable bowel syndrome;	chr2:238266693	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs13026475	ENSG00000186235.9	AC016757.3	5.01	9.96e-07	0.000397	0.56	0.3	Irritable bowel syndrome;	chr2:238269814	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs71426510	ENSG00000186235.9	AC016757.3	5.01	9.96e-07	0.000397	0.56	0.3	Irritable bowel syndrome;	chr2:238270268	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs6741269	ENSG00000186235.9	AC016757.3	5.01	9.96e-07	0.000397	0.56	0.3	Irritable bowel syndrome;	chr2:238270777	chr2:238224552~238231677:-
KIRP	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.01	9.98e-07	0.000398	0.3	0.3	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
KIRP	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	5.01	9.98e-07	0.000398	0.3	0.3	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
KIRP	cis	rs4601821	0.635	rs11214579	ENSG00000270179.1	RP11-159N11.4	5.01	9.99e-07	0.000398	0.27	0.3	Alcoholic chronic pancreatitis;	chr11:113337464	chr11:113368478~113369117:+
KIRP	cis	rs77741769	0.529	rs10849791	ENSG00000277423.1	RP11-173P15.9	-5.01	1e-06	0.000398	-0.31	-0.3	Mean corpuscular volume;	chr12:120797477	chr12:120703867~120704282:+
KIRP	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	5.01	1e-06	0.000398	0.36	0.3	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	5.01	1e-06	0.000398	0.36	0.3	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
KIRP	cis	rs911119	0.909	rs3761279	ENSG00000270001.1	RP11-218C14.8	-5.01	1e-06	0.000398	-0.35	-0.3	Chronic kidney disease;	chr20:23639438	chr20:23631826~23632316:-
KIRP	cis	rs911119	0.779	rs3761280	ENSG00000270001.1	RP11-218C14.8	-5.01	1e-06	0.000398	-0.35	-0.3	Chronic kidney disease;	chr20:23639439	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs34897231	ENSG00000270001.1	RP11-218C14.8	-5.01	1e-06	0.000398	-0.35	-0.3	Chronic kidney disease;	chr20:23639631	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs35488434	ENSG00000270001.1	RP11-218C14.8	-5.01	1e-06	0.000398	-0.35	-0.3	Chronic kidney disease;	chr20:23639764	chr20:23631826~23632316:-
KIRP	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55506498	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55507248	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55507729	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55508587	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55509367	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55510352	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	5.01	1e-06	0.000398	0.31	0.3	Height;	chr4:55511198	chr4:55363971~55395847:-
KIRP	cis	rs2274273	0.622	rs11846809	ENSG00000258413.1	RP11-665C16.6	-5.01	1e-06	0.000399	-0.36	-0.3	Protein biomarker;	chr14:54935064	chr14:55262767~55272075:-
KIRP	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	5.01	1e-06	0.000399	0.26	0.3	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
KIRP	cis	rs9595908	0.746	rs9591229	ENSG00000212293.1	SNORA16	5.01	1e-06	0.000399	0.29	0.3	Body mass index;	chr13:32658870	chr13:32420390~32420516:-
KIRP	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	5.01	1e-06	4e-04	0.31	0.3	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
KIRP	cis	rs2976388	1	rs2920295	ENSG00000253741.1	CTD-2292P10.4	5.01	1e-06	4e-04	0.34	0.3	Urinary tract infection frequency;	chr8:142683519	chr8:142702252~142726973:-
KIRP	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	5.01	1e-06	4e-04	0.26	0.3	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
KIRP	cis	rs72717009	0.825	rs12722986	ENSG00000225217.1	HSPA7	-5.01	1.01e-06	4e-04	-0.44	-0.3	Rheumatoid arthritis;	chr1:161495630	chr1:161606291~161608217:+
KIRP	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-5.01	1.01e-06	0.000401	-0.32	-0.3	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
KIRP	cis	rs7267979	0.966	rs454723	ENSG00000274414.1	RP5-965G21.4	-5.01	1.01e-06	0.000401	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25239007~25245229:-
KIRP	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-5.01	1.01e-06	0.000401	-0.33	-0.3	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
KIRP	cis	rs9595908	0.709	rs7331632	ENSG00000212293.1	SNORA16	5.01	1.01e-06	0.000401	0.28	0.3	Body mass index;	chr13:32753864	chr13:32420390~32420516:-
KIRP	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	5.01	1.01e-06	0.000401	0.35	0.3	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	5.01	1.01e-06	0.000401	0.35	0.3	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
KIRP	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-5.01	1.01e-06	0.000402	-0.3	-0.3	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
KIRP	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-5.01	1.01e-06	0.000402	-0.25	-0.3	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
KIRP	cis	rs4356203	0.87	rs214925	ENSG00000272034.1	SNORD14A	-5.01	1.01e-06	0.000402	-0.25	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17074654~17074744:-
KIRP	cis	rs875971	0.545	rs4441996	ENSG00000236529.1	RP13-254B10.1	-5.01	1.01e-06	0.000402	-0.27	-0.3	Aortic root size;	chr7:66123233	chr7:65840212~65840596:+
KIRP	cis	rs10078	0.571	rs2721014	ENSG00000221990.4	EXOC3-AS1	5.01	1.01e-06	0.000402	0.39	0.3	Fat distribution (HIV);	chr5:463424	chr5:441498~443160:-
KIRP	cis	rs10078	0.528	rs2434697	ENSG00000221990.4	EXOC3-AS1	5.01	1.01e-06	0.000402	0.39	0.3	Fat distribution (HIV);	chr5:466696	chr5:441498~443160:-
KIRP	cis	rs10078	0.515	rs1053299	ENSG00000221990.4	EXOC3-AS1	5.01	1.01e-06	0.000402	0.39	0.3	Fat distribution (HIV);	chr5:470645	chr5:441498~443160:-
KIRP	cis	rs10078	0.571	rs890973	ENSG00000221990.4	EXOC3-AS1	5.01	1.01e-06	0.000402	0.39	0.3	Fat distribution (HIV);	chr5:471379	chr5:441498~443160:-
KIRP	cis	rs12571093	0.541	rs7893837	ENSG00000233590.1	RP11-153K11.3	-5.01	1.01e-06	0.000402	-0.49	-0.3	Optic nerve measurement (disc area);	chr10:68295578	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.522	rs11816028	ENSG00000233590.1	RP11-153K11.3	-5.01	1.01e-06	0.000402	-0.49	-0.3	Optic nerve measurement (disc area);	chr10:68296566	chr10:68233251~68242379:-
KIRP	cis	rs7702057	0.53	rs17138841	ENSG00000271918.1	CTD-2287O16.5	5.01	1.01e-06	0.000403	0.26	0.3	Amyotrophic lateral sclerosis;	chr5:116077109	chr5:116083807~116085416:-
KIRP	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	5.01	1.01e-06	0.000403	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
KIRP	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-5.01	1.01e-06	0.000403	-0.36	-0.3	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
KIRP	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	5.01	1.01e-06	0.000403	0.3	0.3	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	5.01	1.01e-06	0.000403	0.3	0.3	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
KIRP	cis	rs9595908	0.746	rs9591222	ENSG00000212293.1	SNORA16	5.01	1.01e-06	0.000403	0.29	0.3	Body mass index;	chr13:32653261	chr13:32420390~32420516:-
KIRP	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	5.01	1.02e-06	0.000403	0.41	0.3	Height;	chr6:109347085	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	5.01	1.02e-06	0.000403	0.41	0.3	Height;	chr6:109347277	chr6:109382795~109383666:+
KIRP	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	5.01	1.02e-06	0.000403	0.44	0.3	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
KIRP	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	5.01	1.02e-06	0.000404	0.31	0.3	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
KIRP	cis	rs11673344	0.504	rs8109501	ENSG00000226686.6	LINC01535	5.01	1.02e-06	0.000404	0.35	0.3	Obesity-related traits;	chr19:37102194	chr19:37251912~37265535:+
KIRP	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-5.01	1.02e-06	0.000404	-0.58	-0.3	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
KIRP	cis	rs728616	0.867	rs55666905	ENSG00000234382.2	RP11-40F6.1	-5.01	1.02e-06	0.000404	-0.44	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:80233664~80245367:+
KIRP	cis	rs950169	0.922	rs62021167	ENSG00000275120.1	RP11-182J1.17	5.01	1.02e-06	0.000404	0.39	0.3	Schizophrenia;	chr15:84574820	chr15:84599434~84606463:-
KIRP	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-5.01	1.02e-06	0.000404	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
KIRP	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-5.01	1.02e-06	0.000404	-0.3	-0.3	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
KIRP	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-5.01	1.02e-06	0.000404	-0.31	-0.3	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
KIRP	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-5.01	1.02e-06	0.000404	-0.28	-0.3	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
KIRP	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-5.01	1.02e-06	0.000405	-0.42	-0.3	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
KIRP	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-5.01	1.02e-06	0.000405	-0.4	-0.3	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
KIRP	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-5.01	1.02e-06	0.000405	-0.23	-0.3	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-5.01	1.02e-06	0.000405	-0.23	-0.3	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
KIRP	cis	rs7829975	0.846	rs1879957	ENSG00000253981.4	ALG1L13P	-5.01	1.02e-06	0.000405	-0.23	-0.3	Mood instability;	chr8:8687298	chr8:8236003~8244667:-
KIRP	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	5.01	1.02e-06	0.000405	0.26	0.3	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
KIRP	cis	rs7267979	0.718	rs2983489	ENSG00000274414.1	RP5-965G21.4	-5.01	1.02e-06	0.000405	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.727	rs2474765	ENSG00000274414.1	RP5-965G21.4	-5.01	1.02e-06	0.000405	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.764	rs2474767	ENSG00000274414.1	RP5-965G21.4	-5.01	1.02e-06	0.000405	-0.28	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25239007~25245229:-
KIRP	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	5.01	1.02e-06	0.000406	0.23	0.3	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	5.01	1.02e-06	0.000406	0.23	0.3	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
KIRP	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-5.01	1.02e-06	0.000406	-0.31	-0.3	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
KIRP	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-5.01	1.02e-06	0.000406	-0.25	-0.3	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
KIRP	cis	rs6453278	0.732	rs4703727	ENSG00000250802.5	ZBED3-AS1	-5.01	1.02e-06	0.000407	-0.36	-0.3	Autism;	chr5:77111752	chr5:77086740~77166909:+
KIRP	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-5.01	1.03e-06	0.000407	-0.34	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
KIRP	cis	rs1552244	0.935	rs35148833	ENSG00000180385.7	EMC3-AS1	5.01	1.03e-06	0.000407	0.3	0.3	Alzheimer's disease;	chr3:10075253	chr3:9986893~10006990:+
KIRP	cis	rs1075265	0.868	rs1877906	ENSG00000233266.1	HMGB1P31	5	1.03e-06	0.000407	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54136700	chr2:54051334~54051760:+
KIRP	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	5	1.03e-06	0.000408	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	5	1.03e-06	0.000408	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	5	1.03e-06	0.000408	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
KIRP	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-5	1.03e-06	0.000408	-0.23	-0.3	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
KIRP	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	5	1.03e-06	0.000408	0.36	0.3	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
KIRP	cis	rs1153858	0.832	rs1145078	ENSG00000259433.2	CTD-2651B20.4	-5	1.03e-06	0.000408	-0.26	-0.3	Homoarginine levels;	chr15:45390079	chr15:45330209~45332634:-
KIRP	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5	1.03e-06	0.000408	0.33	0.3	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
KIRP	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-5	1.03e-06	0.000408	-0.29	-0.3	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-5	1.03e-06	0.000408	-0.29	-0.3	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
KIRP	cis	rs12922317	0.823	rs350222	ENSG00000260488.1	RP11-166B2.7	-5	1.03e-06	0.000409	-0.37	-0.3	Schizophrenia;	chr16:12027722	chr16:11976851~11977850:-
KIRP	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-5	1.03e-06	0.000409	-0.35	-0.3	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
KIRP	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-5	1.03e-06	0.00041	-0.33	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
KIRP	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-5	1.03e-06	0.00041	-0.27	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-5	1.03e-06	0.00041	-0.27	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
KIRP	cis	rs308403	0.568	rs309358	ENSG00000224786.1	CETN4P	5	1.03e-06	0.00041	0.4	0.3	Blood protein levels;	chr4:122732771	chr4:122730548~122732193:-
KIRP	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	5	1.03e-06	0.00041	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
KIRP	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-5	1.03e-06	0.00041	-0.29	-0.3	Height;	chr14:75002247	chr14:75011269~75012851:-
KIRP	cis	rs42648	0.869	rs2027965	ENSG00000225498.1	AC002064.5	5	1.03e-06	0.00041	0.21	0.3	Homocysteine levels;	chr7:90283199	chr7:90312496~90322592:+
KIRP	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-5	1.04e-06	0.00041	-0.43	-0.3	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
KIRP	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-5	1.04e-06	0.00041	-0.33	-0.3	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-5	1.04e-06	0.00041	-0.33	-0.3	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
KIRP	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-5	1.04e-06	0.00041	-0.2	-0.3	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
KIRP	cis	rs9595908	0.746	rs4942792	ENSG00000212293.1	SNORA16	5	1.04e-06	0.00041	0.29	0.3	Body mass index;	chr13:32663326	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.746	rs9596048	ENSG00000212293.1	SNORA16	5	1.04e-06	0.00041	0.29	0.3	Body mass index;	chr13:32664595	chr13:32420390~32420516:-
KIRP	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-5	1.04e-06	0.000411	-0.23	-0.3	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
KIRP	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	5	1.04e-06	0.000411	0.37	0.3	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
KIRP	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-5	1.04e-06	0.000411	-0.32	-0.3	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
KIRP	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-5	1.04e-06	0.000411	-0.31	-0.3	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
KIRP	cis	rs12935418	0.733	rs12448615	ENSG00000261061.1	RP11-303E16.2	-5	1.04e-06	0.000411	-0.42	-0.3	Mean corpuscular volume;	chr16:80947132	chr16:81030770~81031485:+
KIRP	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	5	1.04e-06	0.000412	0.25	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
KIRP	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	5	1.04e-06	0.000413	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
KIRP	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	5	1.04e-06	0.000413	0.54	0.3	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
KIRP	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-5	1.04e-06	0.000414	-0.31	-0.3	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
KIRP	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-5	1.05e-06	0.000414	-0.29	-0.3	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
KIRP	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-5	1.05e-06	0.000414	-0.26	-0.3	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
KIRP	cis	rs7672749	0.73	rs17013280	ENSG00000249973.2	CHCHD2P7	-5	1.05e-06	0.000414	-0.53	-0.3	TB-LM or TBLH-BMD (pleiotropy);	chr4:87841144	chr4:87785920~87786371:-
KIRP	cis	rs1560104	1	rs1560104	ENSG00000274834.1	CTD-3037G24.5	-5	1.05e-06	0.000414	-0.34	-0.3	Obesity-related traits;	chr16:12614351	chr16:12614451~12614852:+
KIRP	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-5	1.05e-06	0.000415	-0.28	-0.3	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
KIRP	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	5	1.05e-06	0.000415	0.61	0.3	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	5	1.05e-06	0.000415	0.61	0.3	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
KIRP	cis	rs1552244	1	rs6768102	ENSG00000180385.7	EMC3-AS1	5	1.05e-06	0.000415	0.3	0.3	Alzheimer's disease;	chr3:10107696	chr3:9986893~10006990:+
KIRP	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-5	1.05e-06	0.000415	-0.24	-0.3	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-5	1.05e-06	0.000415	-0.24	-0.3	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-5	1.05e-06	0.000415	-0.25	-0.3	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
KIRP	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-5	1.05e-06	0.000415	-0.42	-0.3	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
KIRP	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	5	1.05e-06	0.000415	0.42	0.3	Height;	chr6:109465229	chr6:109382795~109383666:+
KIRP	cis	rs7976059	0.824	rs12230839	ENSG00000261586.2	RP11-923I11.6	-5	1.05e-06	0.000415	-0.29	-0.3	Urate levels;	chr12:51855621	chr12:51817899~51820150:+
KIRP	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	5	1.05e-06	0.000415	0.23	0.3	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
KIRP	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000415	0.27	0.3	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
KIRP	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-5	1.05e-06	0.000416	-0.26	-0.3	Height;	chr11:118854014	chr11:118791254~118793137:+
KIRP	cis	rs11673344	0.504	rs6510593	ENSG00000226686.6	LINC01535	5	1.05e-06	0.000416	0.36	0.3	Obesity-related traits;	chr19:37143153	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs7259332	ENSG00000226686.6	LINC01535	5	1.05e-06	0.000416	0.36	0.3	Obesity-related traits;	chr19:37143389	chr19:37251912~37265535:+
KIRP	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	5	1.05e-06	0.000416	0.29	0.3	Height;	chr4:55570843	chr4:55547112~55547889:+
KIRP	cis	rs17826219	0.568	rs11658027	ENSG00000264538.5	SUZ12P1	5	1.05e-06	0.000416	0.26	0.3	Body mass index;	chr17:30767864	chr17:30709299~30790908:+
KIRP	cis	rs4356203	0.87	rs7937176	ENSG00000272034.1	SNORD14A	-5	1.05e-06	0.000417	-0.24	-0.3	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17074654~17074744:-
KIRP	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-5	1.05e-06	0.000417	-0.3	-0.3	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
KIRP	cis	rs116095464	0.619	rs2303741	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:218241	chr5:269858~271516:-
KIRP	cis	rs116095464	0.614	rs10067482	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:219213	chr5:269858~271516:-
KIRP	cis	rs116095464	0.614	rs56299325	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:220479	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs62346526	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:220499	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs56043030	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:220802	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10067021	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:221375	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs9312977	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:221801	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6881920	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:222296	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6878061	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:222957	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6882584	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:223296	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs3213838	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:223775	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6555052	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:224153	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs61689490	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:224789	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs61492827	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:225659	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs56342538	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:225681	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6555055	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:226045	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6555056	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:226107	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10043002	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:226638	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs2162870	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:228014	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs28729548	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:228910	chr5:269858~271516:-
KIRP	cis	rs116095464	0.681	rs9687745	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:229194	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs9688136	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:229233	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs62347683	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:230216	chr5:269858~271516:-
KIRP	cis	rs116095464	0.51	rs55750776	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:230352	chr5:269858~271516:-
KIRP	cis	rs116095464	0.764	rs10069197	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:230707	chr5:269858~271516:-
KIRP	cis	rs116095464	0.867	rs10074958	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:230713	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs2288459	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231028	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs2288458	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231145	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs2288457	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231155	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7736600	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231222	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10052012	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231793	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10077076	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:231825	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10080225	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:232060	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10475136	ENSG00000248925.1	CTD-2083E4.6	5	1.05e-06	0.000417	0.44	0.3	Breast cancer;	chr5:232681	chr5:269858~271516:-
KIRP	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	5	1.05e-06	0.000417	0.26	0.3	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
KIRP	cis	rs1044826	0.597	rs6772199	ENSG00000178631.7	ACTG1P1	5	1.06e-06	0.000417	0.31	0.3	Obesity-related traits;	chr3:139459291	chr3:139493809~139494937:+
KIRP	cis	rs2043112	1	rs7318	ENSG00000249911.1	LINC01265	5	1.06e-06	0.000418	0.34	0.3	Obesity-related traits;	chr5:38935580	chr5:38710367~38720273:-
KIRP	cis	rs3745672	0.744	rs10403392	ENSG00000219665.7	CTD-2006C1.2	-5	1.06e-06	0.000418	-0.67	-0.3	Multiple sclerosis;	chr19:12042774	chr19:11987617~12046275:+
KIRP	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-5	1.06e-06	0.000418	-0.25	-0.3	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
KIRP	cis	rs7404843	0.733	rs153003	ENSG00000263335.1	AF001548.5	5	1.06e-06	0.000418	0.37	0.3	Testicular germ cell tumor;	chr16:15397543	chr16:15726674~15732993:+
KIRP	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-5	1.06e-06	0.000418	-0.45	-0.3	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
KIRP	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-5	1.06e-06	0.000418	-0.26	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
KIRP	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-5	1.06e-06	0.000418	-0.27	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
KIRP	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	5	1.06e-06	0.000418	0.38	0.3	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	5	1.06e-06	0.000418	0.38	0.3	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
KIRP	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	5	1.06e-06	0.000418	0.3	0.3	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
KIRP	cis	rs1552244	1	rs35741213	ENSG00000180385.7	EMC3-AS1	5	1.06e-06	0.000419	0.3	0.3	Alzheimer's disease;	chr3:10045977	chr3:9986893~10006990:+
KIRP	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-5	1.06e-06	0.000419	-0.24	-0.3	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
KIRP	cis	rs1799949	0.93	rs34210004	ENSG00000279602.1	CTD-3014M21.1	-5	1.06e-06	0.000419	-0.26	-0.3	Menopause (age at onset);	chr17:43218318	chr17:43360041~43361361:-
KIRP	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-5	1.06e-06	0.000419	-0.25	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
KIRP	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-5	1.06e-06	0.000419	-0.25	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
KIRP	cis	rs454217	0.791	rs337650	ENSG00000277851.1	RP11-756G20.1	5	1.06e-06	0.00042	0.37	0.3	Smoking quantity;	chr12:92309130	chr12:92247756~92363832:-
KIRP	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-5	1.06e-06	0.00042	-0.28	-0.3	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
KIRP	cis	rs1200821	0.671	rs2226276	ENSG00000151963.4	RP11-775A3.1	5	1.06e-06	0.00042	0.32	0.29	Hemostatic factors and hematological phenotypes;	chr10:37384124	chr10:37883594~37884109:+
KIRP	cis	rs2043112	0.965	rs6865364	ENSG00000249911.1	LINC01265	5	1.06e-06	0.00042	0.34	0.29	Obesity-related traits;	chr5:39063788	chr5:38710367~38720273:-
KIRP	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-5	1.06e-06	0.000421	-0.33	-0.29	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
KIRP	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-5	1.06e-06	0.000421	-0.26	-0.29	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
KIRP	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	5	1.07e-06	0.000421	0.38	0.29	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
KIRP	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	5	1.07e-06	0.000421	0.31	0.29	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
KIRP	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-5	1.07e-06	0.000421	-0.35	-0.29	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
KIRP	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-5	1.07e-06	0.000421	-0.24	-0.29	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
KIRP	cis	rs9595908	0.785	rs9596058	ENSG00000212293.1	SNORA16	5	1.07e-06	0.000421	0.29	0.29	Body mass index;	chr13:32669938	chr13:32420390~32420516:-
KIRP	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-5	1.07e-06	0.000421	-0.24	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
KIRP	cis	rs9925964	0.9	rs56813533	ENSG00000232748.3	RP11-196G11.6	5	1.07e-06	0.000421	0.36	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:31056460~31062803:+
KIRP	cis	rs1153858	1	rs1613559	ENSG00000259433.2	CTD-2651B20.4	-5	1.07e-06	0.000421	-0.26	-0.29	Homoarginine levels;	chr15:45329918	chr15:45330209~45332634:-
KIRP	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	5	1.07e-06	0.000422	0.27	0.29	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	5	1.07e-06	0.000422	0.27	0.29	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	5	1.07e-06	0.000422	0.27	0.29	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	5	1.07e-06	0.000422	0.27	0.29	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	5	1.07e-06	0.000422	0.27	0.29	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
KIRP	cis	rs77741769	0.571	rs34009825	ENSG00000277423.1	RP11-173P15.9	-5	1.07e-06	0.000422	-0.31	-0.29	Mean corpuscular volume;	chr12:120888380	chr12:120703867~120704282:+
KIRP	cis	rs2043112	1	rs13168867	ENSG00000249911.1	LINC01265	5	1.07e-06	0.000422	0.34	0.29	Obesity-related traits;	chr5:38975356	chr5:38710367~38720273:-
KIRP	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	5	1.07e-06	0.000422	0.21	0.29	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
KIRP	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-5	1.07e-06	0.000423	-0.35	-0.29	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
KIRP	cis	rs7267979	1	rs6083844	ENSG00000274414.1	RP5-965G21.4	5	1.07e-06	0.000423	0.29	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25239007~25245229:-
KIRP	cis	rs8049040	0.524	rs34538886	ENSG00000260886.1	TAT-AS1	5	1.07e-06	0.000424	0.39	0.29	Blood protein levels;	chr16:71389584	chr16:71565789~71578187:+
KIRP	cis	rs8049040	0.524	rs35326792	ENSG00000260886.1	TAT-AS1	5	1.07e-06	0.000424	0.39	0.29	Blood protein levels;	chr16:71393158	chr16:71565789~71578187:+
KIRP	cis	rs8049040	0.524	rs35331976	ENSG00000260886.1	TAT-AS1	5	1.07e-06	0.000424	0.39	0.29	Blood protein levels;	chr16:71393203	chr16:71565789~71578187:+
KIRP	cis	rs6532023	1	rs7683315	ENSG00000249973.2	CHCHD2P7	5	1.07e-06	0.000424	0.36	0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851943	chr4:87785920~87786371:-
KIRP	cis	rs295490	0.748	rs2291555	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139355352	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs17335312	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356544	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs58060926	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356577	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs78116750	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356886	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs74365525	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357107	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.667	rs80049554	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357161	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs2307031	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357978	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.915	rs79695313	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139358335	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs78490940	ENSG00000272656.1	RP11-219D15.3	5	1.07e-06	0.000424	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139370333	chr3:139349024~139349371:-
KIRP	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-5	1.07e-06	0.000424	-0.24	-0.29	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
KIRP	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	5	1.08e-06	0.000424	0.39	0.29	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
KIRP	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-5	1.08e-06	0.000424	-0.28	-0.29	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-4.99	1.08e-06	0.000425	-0.23	-0.29	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
KIRP	cis	rs6832769	0.925	rs2412663	ENSG00000272969.1	RP11-528I4.2	-4.99	1.08e-06	0.000426	-0.29	-0.29	Personality dimensions;	chr4:55589649	chr4:55547112~55547889:+
KIRP	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	4.99	1.08e-06	0.000426	0.32	0.29	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
KIRP	cis	rs8141529	0.719	rs5762825	ENSG00000226471.5	CTA-292E10.6	-4.99	1.08e-06	0.000426	-0.29	-0.29	Lymphocyte counts;	chr22:28827654	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.764	rs5752809	ENSG00000226471.5	CTA-292E10.6	-4.99	1.08e-06	0.000426	-0.29	-0.29	Lymphocyte counts;	chr22:28829512	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.764	rs5752812	ENSG00000226471.5	CTA-292E10.6	-4.99	1.08e-06	0.000426	-0.29	-0.29	Lymphocyte counts;	chr22:28829615	chr22:28800683~28848559:+
KIRP	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-4.99	1.08e-06	0.000426	-0.29	-0.29	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
KIRP	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	4.99	1.08e-06	0.000426	0.27	0.29	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
KIRP	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-4.99	1.08e-06	0.000426	-0.32	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
KIRP	cis	rs1552244	0.872	rs7646073	ENSG00000180385.7	EMC3-AS1	4.99	1.08e-06	0.000427	0.28	0.29	Alzheimer's disease;	chr3:10055721	chr3:9986893~10006990:+
KIRP	cis	rs35146811	0.624	rs1727134	ENSG00000281827.1	AC005071.4	4.99	1.08e-06	0.000427	0.24	0.29	Coronary artery disease;	chr7:100216049	chr7:100344375~100344475:-
KIRP	cis	rs35146811	0.735	rs1636978	ENSG00000281827.1	AC005071.4	4.99	1.08e-06	0.000427	0.24	0.29	Coronary artery disease;	chr7:100216289	chr7:100344375~100344475:-
KIRP	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-4.99	1.08e-06	0.000427	-0.35	-0.29	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
KIRP	cis	rs61457372	0.563	rs1861683	ENSG00000264026.1	RP11-1124B17.1	4.99	1.08e-06	0.000427	0.32	0.29	Triptolide cytotoxicity;	chr17:72359100	chr17:72342940~72355136:+
KIRP	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	4.99	1.08e-06	0.000427	0.31	0.29	Height;	chr4:55501479	chr4:55363971~55395847:-
KIRP	cis	rs6832769	0.925	rs2899037	ENSG00000272969.1	RP11-528I4.2	-4.99	1.08e-06	0.000427	-0.29	-0.29	Personality dimensions;	chr4:55591180	chr4:55547112~55547889:+
KIRP	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	4.99	1.08e-06	0.000427	0.38	0.29	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
KIRP	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-4.99	1.08e-06	0.000427	-0.27	-0.29	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
KIRP	cis	rs3892630	0.878	rs6510277	ENSG00000267475.1	CTD-2538C1.2	-4.99	1.08e-06	0.000427	-0.41	-0.29	Red blood cell traits;	chr19:32692763	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.817	rs12609866	ENSG00000267475.1	CTD-2538C1.2	-4.99	1.08e-06	0.000427	-0.41	-0.29	Red blood cell traits;	chr19:32693506	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.817	rs35408716	ENSG00000267475.1	CTD-2538C1.2	-4.99	1.08e-06	0.000427	-0.41	-0.29	Red blood cell traits;	chr19:32697055	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.878	rs66788054	ENSG00000267475.1	CTD-2538C1.2	-4.99	1.08e-06	0.000427	-0.41	-0.29	Red blood cell traits;	chr19:32699240	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.878	rs8112955	ENSG00000267475.1	CTD-2538C1.2	-4.99	1.08e-06	0.000427	-0.41	-0.29	Red blood cell traits;	chr19:32700286	chr19:32687089~32691750:-
KIRP	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	4.99	1.08e-06	0.000428	0.32	0.29	Height;	chr4:55611014	chr4:55363971~55395847:-
KIRP	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	4.99	1.09e-06	0.000428	0.44	0.29	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
KIRP	cis	rs964611	0.882	rs11854679	ENSG00000259488.2	RP11-154J22.1	-4.99	1.09e-06	0.000428	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48265376	chr15:48312353~48331856:-
KIRP	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	4.99	1.09e-06	0.000429	0.26	0.29	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
KIRP	cis	rs2617170	0.922	rs2617160	ENSG00000245648.1	RP11-277P12.20	4.99	1.09e-06	0.000429	0.33	0.29	Behcet's disease;	chr12:10392998	chr12:10363769~10398506:+
KIRP	cis	rs1799949	0.965	rs799910	ENSG00000279602.1	CTD-3014M21.1	-4.99	1.09e-06	0.000429	-0.25	-0.29	Menopause (age at onset);	chr17:43127544	chr17:43360041~43361361:-
KIRP	cis	rs7976059	0.895	rs73109568	ENSG00000261586.2	RP11-923I11.6	-4.99	1.09e-06	0.000429	-0.29	-0.29	Urate levels;	chr12:51855219	chr12:51817899~51820150:+
KIRP	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-4.99	1.09e-06	0.000429	-0.33	-0.29	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-4.99	1.09e-06	0.000429	-0.33	-0.29	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-4.99	1.09e-06	0.000429	-0.33	-0.29	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-4.99	1.09e-06	0.000429	-0.33	-0.29	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
KIRP	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-4.99	1.09e-06	0.000429	-0.29	-0.29	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
KIRP	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-4.99	1.09e-06	0.00043	-0.27	-0.29	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
KIRP	cis	rs911119	0.657	rs2145231	ENSG00000270001.1	RP11-218C14.8	4.99	1.09e-06	0.00043	0.38	0.29	Chronic kidney disease;	chr20:23644910	chr20:23631826~23632316:-
KIRP	cis	rs11673344	0.523	rs2562599	ENSG00000226686.6	LINC01535	-4.99	1.09e-06	0.00043	-0.36	-0.29	Obesity-related traits;	chr19:37025472	chr19:37251912~37265535:+
KIRP	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	4.99	1.09e-06	0.000431	0.29	0.29	Height;	chr14:75075251	chr14:75011269~75012851:-
KIRP	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	4.99	1.09e-06	0.000431	0.45	0.29	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
KIRP	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-4.99	1.09e-06	0.000431	-0.31	-0.29	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
KIRP	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-4.99	1.09e-06	0.000431	-0.31	-0.29	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
KIRP	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-4.99	1.1e-06	0.000431	-0.25	-0.29	Height;	chr2:46630262	chr2:46668870~46670778:+
KIRP	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	4.99	1.1e-06	0.000432	0.44	0.29	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
KIRP	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-4.99	1.1e-06	0.000432	-0.25	-0.29	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
KIRP	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	4.99	1.1e-06	0.000432	0.28	0.29	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
KIRP	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-4.99	1.1e-06	0.000432	-0.25	-0.29	Height;	chr2:46627225	chr2:46668870~46670778:+
KIRP	cis	rs35146811	0.731	rs2257213	ENSG00000281827.1	AC005071.4	4.99	1.1e-06	0.000433	0.24	0.29	Coronary artery disease;	chr7:100212490	chr7:100344375~100344475:-
KIRP	cis	rs10078	0.559	rs2671891	ENSG00000221990.4	EXOC3-AS1	4.99	1.1e-06	0.000433	0.39	0.29	Fat distribution (HIV);	chr5:456271	chr5:441498~443160:-
KIRP	cis	rs10078	0.571	rs2671890	ENSG00000221990.4	EXOC3-AS1	4.99	1.1e-06	0.000433	0.39	0.29	Fat distribution (HIV);	chr5:456342	chr5:441498~443160:-
KIRP	cis	rs10078	0.571	rs2561664	ENSG00000221990.4	EXOC3-AS1	4.99	1.1e-06	0.000433	0.39	0.29	Fat distribution (HIV);	chr5:459678	chr5:441498~443160:-
KIRP	cis	rs2269497	0.59	rs2471343	ENSG00000199335.1	RNU6-204P	4.99	1.1e-06	0.000433	0.71	0.29	Tuberculosis;	chr4:3041175	chr4:3044101~3044207:+
KIRP	cis	rs7674212	0.541	rs4699050	ENSG00000230069.3	LRRC37A15P	-4.99	1.1e-06	0.000434	-0.28	-0.29	Type 2 diabetes;	chr4:103193140	chr4:102727274~102730721:-
KIRP	cis	rs7674212	0.541	rs17217473	ENSG00000230069.3	LRRC37A15P	-4.99	1.1e-06	0.000434	-0.28	-0.29	Type 2 diabetes;	chr4:103193585	chr4:102727274~102730721:-
KIRP	cis	rs1799949	0.965	rs8067269	ENSG00000279602.1	CTD-3014M21.1	-4.99	1.1e-06	0.000434	-0.25	-0.29	Menopause (age at onset);	chr17:43083782	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs8176145	ENSG00000279602.1	CTD-3014M21.1	-4.99	1.1e-06	0.000434	-0.27	-0.29	Menopause (age at onset);	chr17:43097077	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.965	rs8176140	ENSG00000279602.1	CTD-3014M21.1	-4.99	1.1e-06	0.000434	-0.27	-0.29	Menopause (age at onset);	chr17:43099629	chr17:43360041~43361361:-
KIRP	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	4.99	1.1e-06	0.000434	0.29	0.29	Height;	chr14:75082667	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	4.99	1.1e-06	0.000434	0.29	0.29	Height;	chr14:75088933	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	4.99	1.1e-06	0.000434	0.29	0.29	Height;	chr14:75100475	chr14:75011269~75012851:-
KIRP	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	4.99	1.1e-06	0.000434	0.29	0.29	Height;	chr4:55548666	chr4:55547112~55547889:+
KIRP	cis	rs231513	0.954	rs11654245	ENSG00000198496.9	NBR2	-4.99	1.11e-06	0.000435	-0.47	-0.29	Cognitive function;	chr17:43915282	chr17:43125610~43153671:+
KIRP	cis	rs9959145	0.925	rs78425322	ENSG00000267108.1	RP11-861E21.1	4.99	1.11e-06	0.000435	0.47	0.29	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12432897~12437635:+
KIRP	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	4.99	1.11e-06	0.000435	0.36	0.29	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
KIRP	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	4.99	1.11e-06	0.000435	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
KIRP	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	4.99	1.11e-06	0.000435	0.32	0.29	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
KIRP	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-4.99	1.11e-06	0.000435	-0.31	-0.29	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-4.99	1.11e-06	0.000435	-0.31	-0.29	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
KIRP	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	4.99	1.11e-06	0.000435	0.26	0.29	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
KIRP	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	4.99	1.11e-06	0.000436	0.37	0.29	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	4.99	1.11e-06	0.000436	0.37	0.29	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	4.99	1.11e-06	0.000436	0.37	0.29	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	4.99	1.11e-06	0.000436	0.37	0.29	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	4.99	1.11e-06	0.000436	0.37	0.29	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
KIRP	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	4.99	1.11e-06	0.000436	0.25	0.29	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
KIRP	cis	rs9595908	0.785	rs17515873	ENSG00000212293.1	SNORA16	4.99	1.11e-06	0.000436	0.28	0.29	Body mass index;	chr13:32647711	chr13:32420390~32420516:-
KIRP	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-4.99	1.11e-06	0.000436	-0.28	-0.29	Height;	chr4:55547636	chr4:55547112~55547889:+
KIRP	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	4.99	1.11e-06	0.000436	0.5	0.29	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
KIRP	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	4.99	1.11e-06	0.000436	0.29	0.29	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
KIRP	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-4.99	1.11e-06	0.000437	-0.25	-0.29	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
KIRP	cis	rs6005807	0.543	rs2235432	ENSG00000226471.5	CTA-292E10.6	-4.99	1.11e-06	0.000437	-0.42	-0.29	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28773432	chr22:28800683~28848559:+
KIRP	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	4.99	1.11e-06	0.000437	0.36	0.29	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
KIRP	cis	rs11992162	0.56	rs7846248	ENSG00000255495.1	AC145124.2	4.99	1.11e-06	0.000437	0.28	0.29	Monocyte count;	chr8:11936540	chr8:12194467~12196280:+
KIRP	cis	rs2299587	0.932	rs10088513	ENSG00000254054.2	RP11-156K13.3	4.99	1.11e-06	0.000437	0.35	0.29	Economic and political preferences;	chr8:17987361	chr8:17905756~17907887:+
KIRP	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	4.99	1.11e-06	0.000437	0.36	0.29	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
KIRP	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	4.99	1.11e-06	0.000437	0.32	0.29	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	4.99	1.11e-06	0.000437	0.32	0.29	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-4.99	1.11e-06	0.000438	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-4.99	1.11e-06	0.000438	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-4.99	1.11e-06	0.000438	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
KIRP	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	4.99	1.11e-06	0.000438	0.34	0.29	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
KIRP	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-4.99	1.11e-06	0.000438	-0.31	-0.29	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
KIRP	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-4.99	1.11e-06	0.000438	-0.31	-0.29	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
KIRP	cis	rs295490	0.748	rs79654016	ENSG00000272656.1	RP11-219D15.3	4.99	1.11e-06	0.000438	0.5	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139374644	chr3:139349024~139349371:-
KIRP	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-4.99	1.11e-06	0.000438	-0.3	-0.29	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
KIRP	cis	rs1799949	1	rs35668327	ENSG00000279602.1	CTD-3014M21.1	-4.99	1.11e-06	0.000438	-0.27	-0.29	Menopause (age at onset);	chr17:43121078	chr17:43360041~43361361:-
KIRP	cis	rs1044826	0.667	rs295471	ENSG00000178631.7	ACTG1P1	4.99	1.12e-06	0.000438	0.31	0.29	Obesity-related traits;	chr3:139495080	chr3:139493809~139494937:+
KIRP	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-4.99	1.12e-06	0.000438	-0.47	-0.29	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
KIRP	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	4.99	1.12e-06	0.000439	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
KIRP	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	4.99	1.12e-06	0.000439	0.27	0.29	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
KIRP	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	4.99	1.12e-06	0.000439	0.35	0.29	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
KIRP	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	4.99	1.12e-06	0.00044	0.29	0.29	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
KIRP	cis	rs77741769	0.571	rs12822123	ENSG00000277423.1	RP11-173P15.9	-4.99	1.12e-06	0.00044	-0.31	-0.29	Mean corpuscular volume;	chr12:120860841	chr12:120703867~120704282:+
KIRP	cis	rs35146811	0.7	rs2950520	ENSG00000281827.1	AC005071.4	4.99	1.12e-06	0.00044	0.25	0.29	Coronary artery disease;	chr7:100229525	chr7:100344375~100344475:-
KIRP	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-4.99	1.12e-06	0.00044	-0.3	-0.29	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
KIRP	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-4.99	1.12e-06	0.00044	-0.3	-0.29	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
KIRP	cis	rs4934494	0.727	rs12764076	ENSG00000232936.4	RP11-80H5.2	4.99	1.12e-06	0.00044	0.44	0.29	Red blood cell count;	chr10:89630443	chr10:89645282~89650667:+
KIRP	cis	rs4934494	0.634	rs12762448	ENSG00000232936.4	RP11-80H5.2	4.99	1.12e-06	0.00044	0.44	0.29	Red blood cell count;	chr10:89630483	chr10:89645282~89650667:+
KIRP	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-4.99	1.12e-06	0.00044	-0.33	-0.29	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
KIRP	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-4.99	1.12e-06	0.00044	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
KIRP	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-4.99	1.12e-06	0.000441	-0.4	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
KIRP	cis	rs6480314	0.522	rs80326649	ENSG00000233590.1	RP11-153K11.3	-4.99	1.12e-06	0.000441	-0.47	-0.29	Optic nerve measurement (disc area);	chr10:68285667	chr10:68233251~68242379:-
KIRP	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-4.99	1.12e-06	0.000441	-0.22	-0.29	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
KIRP	cis	rs12530	0.715	rs2294311	ENSG00000241954.1	RP1-149A16.17	-4.99	1.12e-06	0.000441	-0.34	-0.29	IgG glycosylation;	chr22:32397282	chr22:32383786~32385631:+
KIRP	cis	rs12530	0.715	rs2294313	ENSG00000241954.1	RP1-149A16.17	-4.99	1.12e-06	0.000441	-0.34	-0.29	IgG glycosylation;	chr22:32398452	chr22:32383786~32385631:+
KIRP	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.99	1.12e-06	0.000441	0.24	0.29	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
KIRP	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.99	1.12e-06	0.000441	0.24	0.29	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
KIRP	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.99	1.12e-06	0.000441	0.24	0.29	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
KIRP	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-4.99	1.12e-06	0.000441	-0.3	-0.29	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
KIRP	cis	rs67311347	0.544	rs12633295	ENSG00000230274.1	PGAM1P3	-4.99	1.12e-06	0.000441	-0.29	-0.29	Renal cell carcinoma;	chr3:40293801	chr3:40322715~40323279:-
KIRP	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-4.99	1.12e-06	0.000442	-0.3	-0.29	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
KIRP	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-4.99	1.13e-06	0.000442	-0.21	-0.29	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
KIRP	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-4.99	1.13e-06	0.000442	-0.21	-0.29	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
KIRP	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	4.99	1.13e-06	0.000442	0.37	0.29	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
KIRP	cis	rs4660456	0.556	rs823674	ENSG00000237899.1	RP4-739H11.3	-4.99	1.13e-06	0.000442	-0.34	-0.29	Platelet count;	chr1:40774799	chr1:40669089~40687588:-
KIRP	cis	rs4927850	0.829	rs6768483	ENSG00000207650.1	MIR570	4.99	1.13e-06	0.000443	0.31	0.29	Pancreatic cancer;	chr3:196019092	chr3:195699401~195699497:+
KIRP	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	4.98	1.13e-06	0.000443	0.31	0.29	Height;	chr4:55578787	chr4:55363971~55395847:-
KIRP	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-4.98	1.13e-06	0.000443	-0.3	-0.29	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
KIRP	cis	rs4356203	0.87	rs10832751	ENSG00000272034.1	SNORD14A	-4.98	1.13e-06	0.000443	-0.24	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17074654~17074744:-
KIRP	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-4.98	1.13e-06	0.000443	-0.39	-0.29	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-4.98	1.13e-06	0.000443	-0.39	-0.29	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
KIRP	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	4.98	1.13e-06	0.000443	0.29	0.29	Height;	chr14:75125780	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	4.98	1.13e-06	0.000443	0.29	0.29	Height;	chr14:75128451	chr14:75011269~75012851:-
KIRP	cis	rs1858037	0.867	rs67453645	ENSG00000237979.1	AC007389.1	4.98	1.13e-06	0.000443	0.33	0.29	Rheumatoid arthritis;	chr2:65358908	chr2:65500993~65502138:-
KIRP	cis	rs1858037	0.867	rs57913336	ENSG00000237979.1	AC007389.1	4.98	1.13e-06	0.000443	0.33	0.29	Rheumatoid arthritis;	chr2:65360485	chr2:65500993~65502138:-
KIRP	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	4.98	1.13e-06	0.000444	0.29	0.29	Height;	chr4:55460485	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	4.98	1.13e-06	0.000444	0.29	0.29	Height;	chr4:55465165	chr4:55547112~55547889:+
KIRP	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-4.98	1.13e-06	0.000445	-0.36	-0.29	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
KIRP	cis	rs950169	0.84	rs62019457	ENSG00000275120.1	RP11-182J1.17	4.98	1.13e-06	0.000445	0.38	0.29	Schizophrenia;	chr15:84558911	chr15:84599434~84606463:-
KIRP	cis	rs697003	0.705	rs701926	ENSG00000231057.3	RP11-122M14.1	-4.98	1.13e-06	0.000445	-0.27	-0.29	Red cell distribution width;	chr1:211678277	chr1:211675762~211690103:+
KIRP	cis	rs17684571	0.751	rs1903332	ENSG00000231441.1	RP11-472M19.2	-4.98	1.14e-06	0.000445	-0.43	-0.29	Schizophrenia;	chr6:56857437	chr6:56844002~56864078:+
KIRP	cis	rs4356203	0.87	rs7935219	ENSG00000272034.1	SNORD14A	4.98	1.14e-06	0.000446	0.25	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17074654~17074744:-
KIRP	cis	rs9595908	0.785	rs7332884	ENSG00000212293.1	SNORA16	4.98	1.14e-06	0.000446	0.28	0.29	Body mass index;	chr13:32642412	chr13:32420390~32420516:-
KIRP	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-4.98	1.14e-06	0.000446	-0.33	-0.29	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
KIRP	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55425312	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55429416	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55430596	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55430730	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55430740	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55431595	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55434518	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55435912	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55436576	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55436985	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55439472	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55439652	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55440643	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55441110	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55441567	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55441907	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55442184	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55442875	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55444253	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55446869	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55447523	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55450812	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55452853	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55454154	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55455650	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55456620	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55457027	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55457086	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55485974	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55487368	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55489310	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55491628	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55495801	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55496737	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55496933	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55497842	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55500224	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55501629	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55501726	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55501788	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55504176	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	4.98	1.14e-06	0.000446	0.31	0.29	Height;	chr4:55504201	chr4:55363971~55395847:-
KIRP	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-4.98	1.14e-06	0.000446	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
KIRP	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-4.98	1.14e-06	0.000446	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
KIRP	cis	rs17213965	0.925	rs62030569	ENSG00000263335.1	AF001548.5	-4.98	1.14e-06	0.000447	-0.41	-0.29	Waist-hip ratio;	chr16:15786892	chr16:15726674~15732993:+
KIRP	cis	rs4218	0.681	rs12913177	ENSG00000277144.1	RP11-59H7.4	4.98	1.14e-06	0.000447	0.3	0.29	Social communication problems;	chr15:59066273	chr15:59115547~59116089:-
KIRP	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	4.98	1.14e-06	0.000447	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
KIRP	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-4.98	1.14e-06	0.000447	-0.28	-0.29	Height;	chr14:75022243	chr14:75011269~75012851:-
KIRP	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	4.98	1.14e-06	0.000448	0.33	0.29	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	4.98	1.14e-06	0.000448	0.33	0.29	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	4.98	1.14e-06	0.000448	0.33	0.29	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
KIRP	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	4.98	1.14e-06	0.000448	0.26	0.29	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
KIRP	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	4.98	1.14e-06	0.000448	0.4	0.29	Depression;	chr6:28428413	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	4.98	1.14e-06	0.000448	0.4	0.29	Depression;	chr6:28431469	chr6:28943877~28944537:+
KIRP	cis	rs58722170	0.659	rs72659423	ENSG00000232273.1	FTH1P1	4.98	1.14e-06	0.000448	0.39	0.29	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;	chr1:37617800	chr1:37544763~37545294:+
KIRP	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-4.98	1.14e-06	0.000448	-0.3	-0.29	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
KIRP	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	4.98	1.15e-06	0.000448	0.47	0.29	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
KIRP	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-4.98	1.15e-06	0.000448	-0.42	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
KIRP	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.98	1.15e-06	0.000449	0.38	0.29	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
KIRP	cis	rs9926296	0.618	rs8058179	ENSG00000260259.1	RP11-368I7.4	4.98	1.15e-06	0.000449	0.23	0.29	Vitiligo;	chr16:89780579	chr16:89682620~89686569:-
KIRP	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	4.98	1.15e-06	0.000449	0.24	0.29	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
KIRP	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-4.98	1.15e-06	0.000449	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
KIRP	cis	rs7225151	0.808	rs77493189	ENSG00000234327.6	AC012146.7	-4.98	1.15e-06	0.000449	-0.43	-0.29	Alzheimer's disease (late onset);	chr17:5215656	chr17:5111468~5115004:+
KIRP	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	4.98	1.15e-06	0.000449	0.29	0.29	Height;	chr14:75132944	chr14:75011269~75012851:-
KIRP	cis	rs10771431	0.597	rs10843144	ENSG00000111788.10	RP11-22B23.1	4.98	1.15e-06	0.00045	0.32	0.29	Breast size;	chr12:9204981	chr12:9277235~9313241:+
KIRP	cis	rs8141529	0.778	rs7287806	ENSG00000226471.5	CTA-292E10.6	-4.98	1.15e-06	0.000451	-0.3	-0.29	Lymphocyte counts;	chr22:28817023	chr22:28800683~28848559:+
KIRP	cis	rs713477	0.935	rs4901567	ENSG00000258413.1	RP11-665C16.6	4.98	1.15e-06	0.000451	0.36	0.29	Pediatric bone mineral content (femoral neck);	chr14:55445980	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-4.98	1.15e-06	0.000451	-0.24	-0.29	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
KIRP	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-4.98	1.16e-06	0.000452	-0.2	-0.29	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
KIRP	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-4.98	1.16e-06	0.000452	-0.2	-0.29	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
KIRP	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-4.98	1.16e-06	0.000452	-0.38	-0.29	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
KIRP	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-4.98	1.16e-06	0.000452	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
KIRP	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-4.98	1.16e-06	0.000453	-0.34	-0.29	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
KIRP	cis	rs11671005	0.656	rs11671092	ENSG00000269600.1	AC016629.3	-4.98	1.16e-06	0.000453	-0.46	-0.29	Mean platelet volume;	chr19:58497742	chr19:58593896~58599355:-
KIRP	cis	rs34286592	1	rs4788187	ENSG00000214725.6	CDIPT-AS1	4.98	1.16e-06	0.000453	0.36	0.29	Multiple sclerosis;	chr16:29834364	chr16:29863593~29868053:+
KIRP	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-4.98	1.16e-06	0.000453	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
KIRP	cis	rs8037137	0.915	rs3826033	ENSG00000258725.1	PRC1-AS1	-4.98	1.16e-06	0.000453	-0.43	-0.29	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91005371	chr15:90966345~90988624:+
KIRP	cis	rs755249	0.501	rs2484749	ENSG00000237624.1	OXCT2P1	-4.98	1.16e-06	0.000453	-0.4	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39514956~39516490:+
KIRP	cis	rs8141529	0.764	rs8137969	ENSG00000226471.5	CTA-292E10.6	-4.98	1.16e-06	0.000453	-0.29	-0.29	Lymphocyte counts;	chr22:28832496	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.719	rs6005916	ENSG00000226471.5	CTA-292E10.6	-4.98	1.16e-06	0.000453	-0.29	-0.29	Lymphocyte counts;	chr22:28837354	chr22:28800683~28848559:+
KIRP	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	4.98	1.16e-06	0.000454	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
KIRP	cis	rs7267979	1	rs10966	ENSG00000274414.1	RP5-965G21.4	-4.98	1.16e-06	0.000454	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25239007~25245229:-
KIRP	cis	rs12922317	0.556	rs8062691	ENSG00000260488.1	RP11-166B2.7	-4.98	1.16e-06	0.000454	-0.36	-0.29	Schizophrenia;	chr16:11997972	chr16:11976851~11977850:-
KIRP	cis	rs7849973	0.579	rs13285009	ENSG00000224549.1	RP11-370B11.3	-4.98	1.16e-06	0.000455	-0.32	-0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763642	chr9:22767175~22768316:+
KIRP	cis	rs6671200	0.667	rs76833598	ENSG00000235501.4	RP4-639F20.1	-4.98	1.16e-06	0.000455	-0.62	-0.29	Stearic acid (18:0) levels;	chr1:94928425	chr1:94927566~94963270:+
KIRP	cis	rs6671200	0.667	rs113926595	ENSG00000235501.4	RP4-639F20.1	-4.98	1.16e-06	0.000455	-0.62	-0.29	Stearic acid (18:0) levels;	chr1:94930060	chr1:94927566~94963270:+
KIRP	cis	rs6671200	0.667	rs76468062	ENSG00000235501.4	RP4-639F20.1	-4.98	1.16e-06	0.000455	-0.62	-0.29	Stearic acid (18:0) levels;	chr1:94932483	chr1:94927566~94963270:+
KIRP	cis	rs1799949	0.965	rs8176130	ENSG00000279602.1	CTD-3014M21.1	-4.98	1.16e-06	0.000455	-0.27	-0.29	Menopause (age at onset);	chr17:43106026	chr17:43360041~43361361:-
KIRP	cis	rs77741769	0.571	rs4766979	ENSG00000277423.1	RP11-173P15.9	-4.98	1.17e-06	0.000455	-0.31	-0.29	Mean corpuscular volume;	chr12:120843945	chr12:120703867~120704282:+
KIRP	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-4.98	1.17e-06	0.000455	-0.33	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
KIRP	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.98	1.17e-06	0.000455	-0.34	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
KIRP	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-4.98	1.17e-06	0.000455	-0.34	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
KIRP	cis	rs11079159	0.637	rs7218159	ENSG00000263096.1	RP11-515O17.2	-4.98	1.17e-06	0.000455	-0.48	-0.29	QRS duration;	chr17:55277434	chr17:55271504~55273653:-
KIRP	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	4.98	1.17e-06	0.000456	0.29	0.29	Height;	chr4:55483718	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	4.98	1.17e-06	0.000456	0.29	0.29	Height;	chr4:55544621	chr4:55547112~55547889:+
KIRP	cis	rs4820539	0.966	rs2267001	ENSG00000275635.1	U7	4.98	1.17e-06	0.000456	0.31	0.29	Bone mineral density;	chr22:23114509	chr22:23137805~23137864:-
KIRP	cis	rs4820539	1	rs2267003	ENSG00000275635.1	U7	4.98	1.17e-06	0.000456	0.31	0.29	Bone mineral density;	chr22:23114911	chr22:23137805~23137864:-
KIRP	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	4.98	1.17e-06	0.000456	0.5	0.29	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
KIRP	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	4.98	1.17e-06	0.000457	0.31	0.29	Height;	chr4:55484534	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	4.98	1.17e-06	0.000457	0.31	0.29	Height;	chr4:55546002	chr4:55363971~55395847:-
KIRP	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	4.98	1.17e-06	0.000457	0.4	0.29	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
KIRP	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	4.98	1.17e-06	0.000457	0.27	0.29	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
KIRP	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	4.98	1.17e-06	0.000457	0.26	0.29	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
KIRP	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	4.98	1.17e-06	0.000458	0.33	0.29	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
KIRP	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	4.98	1.17e-06	0.000458	0.29	0.29	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	4.98	1.17e-06	0.000458	0.29	0.29	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
KIRP	cis	rs1560104	0.597	rs735820	ENSG00000274834.1	CTD-3037G24.5	4.98	1.17e-06	0.000458	0.33	0.29	Obesity-related traits;	chr16:12618269	chr16:12614451~12614852:+
KIRP	cis	rs4660214	0.724	rs3931300	ENSG00000237624.1	OXCT2P1	-4.98	1.17e-06	0.000458	-0.39	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39514956~39516490:+
KIRP	cis	rs964611	0.938	rs8039653	ENSG00000259488.2	RP11-154J22.1	-4.98	1.17e-06	0.000458	-0.28	-0.29	Metabolite levels (Pyroglutamine);	chr15:48280438	chr15:48312353~48331856:-
KIRP	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	4.98	1.17e-06	0.000458	0.43	0.29	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
KIRP	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-4.98	1.17e-06	0.000459	-0.37	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
KIRP	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	4.98	1.18e-06	0.000459	0.36	0.29	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	4.98	1.18e-06	0.000459	0.36	0.29	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
KIRP	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	4.98	1.18e-06	0.000459	0.26	0.29	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
KIRP	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.98	1.18e-06	0.000459	-0.32	-0.29	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
KIRP	cis	rs72634501	0.517	rs7522362	ENSG00000237624.1	OXCT2P1	-4.98	1.18e-06	0.000459	-0.38	-0.29	HDL cholesterol;	chr1:39139419	chr1:39514956~39516490:+
KIRP	cis	rs9595908	0.709	rs9285093	ENSG00000212293.1	SNORA16	4.98	1.18e-06	0.000459	0.28	0.29	Body mass index;	chr13:32745500	chr13:32420390~32420516:-
KIRP	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-4.98	1.18e-06	0.00046	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-4.98	1.18e-06	0.00046	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-4.98	1.18e-06	0.00046	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
KIRP	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-4.98	1.18e-06	0.00046	-0.3	-0.29	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
KIRP	cis	rs75920871	0.544	rs76868258	ENSG00000254851.1	RP11-109L13.1	-4.98	1.18e-06	0.00046	-0.59	-0.29	Subjective well-being;	chr11:117122576	chr11:117135528~117138582:+
KIRP	cis	rs7432375	0.901	rs1729951	ENSG00000261758.1	RP11-102M11.2	-4.98	1.18e-06	0.00046	-0.32	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136781891	chr3:136752630~136755780:+
KIRP	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	4.98	1.18e-06	0.00046	0.27	0.29	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
KIRP	cis	rs2299587	0.901	rs36049816	ENSG00000254054.2	RP11-156K13.3	4.98	1.18e-06	0.000461	0.35	0.29	Economic and political preferences;	chr8:17984991	chr8:17905756~17907887:+
KIRP	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	4.98	1.18e-06	0.000461	0.34	0.29	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
KIRP	cis	rs308403	0.568	rs13102440	ENSG00000224786.1	CETN4P	4.98	1.18e-06	0.000461	0.43	0.29	Blood protein levels;	chr4:122743764	chr4:122730548~122732193:-
KIRP	cis	rs4128705	0.837	rs12511436	ENSG00000249049.1	RP11-763F8.1	4.98	1.18e-06	0.000461	0.27	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91359741	chr4:91319034~91325306:-
KIRP	cis	rs7747960	0.706	rs9371253	ENSG00000226193.1	RP3-398G3.5	-4.98	1.18e-06	0.000461	-0.46	-0.29	Bipolar disorder;	chr6:152482384	chr6:152402398~152404966:+
KIRP	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	4.97	1.18e-06	0.000461	0.38	0.29	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
KIRP	cis	rs77741769	0.571	rs12831094	ENSG00000277423.1	RP11-173P15.9	-4.97	1.18e-06	0.000462	-0.31	-0.29	Mean corpuscular volume;	chr12:120854901	chr12:120703867~120704282:+
KIRP	cis	rs9595908	0.758	rs9591219	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32653020	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.758	rs9591220	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32653059	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs12428283	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32653775	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596035	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32654803	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9591226	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32655322	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs7335546	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32658197	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9591228	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32658632	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9591230	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32663944	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs2874282	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32665876	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596051	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32666528	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596057	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32669831	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596059	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32670145	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596060	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32670467	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs7317147	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32670838	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs6561499	ENSG00000212293.1	SNORA16	4.97	1.18e-06	0.000462	0.28	0.29	Body mass index;	chr13:32681075	chr13:32420390~32420516:-
KIRP	cis	rs4660214	0.666	rs1537818	ENSG00000237624.1	OXCT2P1	-4.97	1.18e-06	0.000462	-0.39	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39514956~39516490:+
KIRP	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-4.97	1.18e-06	0.000462	-0.28	-0.29	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
KIRP	cis	rs2043112	1	rs13177882	ENSG00000249911.1	LINC01265	4.97	1.18e-06	0.000462	0.34	0.29	Obesity-related traits;	chr5:39021391	chr5:38710367~38720273:-
KIRP	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	4.97	1.19e-06	0.000462	0.27	0.29	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
KIRP	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-4.97	1.19e-06	0.000462	-0.22	-0.29	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
KIRP	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-4.97	1.19e-06	0.000463	-0.37	-0.29	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
KIRP	cis	rs6832769	1	rs6811520	ENSG00000272969.1	RP11-528I4.2	4.97	1.19e-06	0.000463	0.3	0.29	Personality dimensions;	chr4:55449011	chr4:55547112~55547889:+
KIRP	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-4.97	1.19e-06	0.000463	-0.25	-0.29	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
KIRP	cis	rs6832769	0.961	rs7684810	ENSG00000272969.1	RP11-528I4.2	4.97	1.19e-06	0.000463	0.3	0.29	Personality dimensions;	chr4:55486627	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs13138697	ENSG00000272969.1	RP11-528I4.2	4.97	1.19e-06	0.000463	0.3	0.29	Personality dimensions;	chr4:55497142	chr4:55547112~55547889:+
KIRP	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	4.97	1.19e-06	0.000463	0.26	0.29	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
KIRP	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	4.97	1.19e-06	0.000463	0.33	0.29	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-4.97	1.19e-06	0.000463	-0.33	-0.29	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
KIRP	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	4.97	1.19e-06	0.000464	0.27	0.29	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	4.97	1.19e-06	0.000464	0.27	0.29	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	4.97	1.19e-06	0.000464	0.27	0.29	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
KIRP	cis	rs2281558	0.754	rs73597824	ENSG00000274414.1	RP5-965G21.4	-4.97	1.19e-06	0.000464	-0.34	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:25239007~25245229:-
KIRP	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-4.97	1.19e-06	0.000464	-0.23	-0.29	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
KIRP	cis	rs11673344	0.504	rs1667378	ENSG00000226686.6	LINC01535	4.97	1.19e-06	0.000464	0.36	0.29	Obesity-related traits;	chr19:37001171	chr19:37251912~37265535:+
KIRP	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-4.97	1.19e-06	0.000464	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
KIRP	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	4.97	1.19e-06	0.000464	0.21	0.29	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
KIRP	cis	rs9595908	0.758	rs2301389	ENSG00000212293.1	SNORA16	4.97	1.19e-06	0.000464	0.28	0.29	Body mass index;	chr13:32648694	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs2301390	ENSG00000212293.1	SNORA16	4.97	1.19e-06	0.000464	0.28	0.29	Body mass index;	chr13:32649307	chr13:32420390~32420516:-
KIRP	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-4.97	1.19e-06	0.000464	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
KIRP	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	4.97	1.19e-06	0.000465	0.31	0.29	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
KIRP	cis	rs11009175	0.556	rs1418540	ENSG00000273038.2	RP11-479G22.8	-4.97	1.19e-06	0.000465	-0.29	-0.29	Depression (quantitative trait);	chr10:33008739	chr10:32887255~32889311:-
KIRP	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-4.97	1.19e-06	0.000465	-0.26	-0.29	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
KIRP	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-4.97	1.19e-06	0.000465	-0.28	-0.29	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
KIRP	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-4.97	1.19e-06	0.000465	-0.33	-0.29	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
KIRP	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-4.97	1.19e-06	0.000465	-0.37	-0.29	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
KIRP	cis	rs2299587	1	rs17514360	ENSG00000254054.2	RP11-156K13.3	4.97	1.2e-06	0.000466	0.35	0.29	Economic and political preferences;	chr8:17955068	chr8:17905756~17907887:+
KIRP	cis	rs308403	0.568	rs13120869	ENSG00000224786.1	CETN4P	4.97	1.2e-06	0.000466	0.44	0.29	Blood protein levels;	chr4:122724997	chr4:122730548~122732193:-
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	4.97	1.2e-06	0.000466	0.3	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
KIRP	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-4.97	1.2e-06	0.000466	-0.24	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
KIRP	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	4.97	1.2e-06	0.000466	0.41	0.29	Height;	chr6:109479396	chr6:109382795~109383666:+
KIRP	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	4.97	1.2e-06	0.000466	0.37	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
KIRP	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-4.97	1.2e-06	0.000467	-0.31	-0.29	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
KIRP	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-4.97	1.2e-06	0.000467	-0.28	-0.29	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
KIRP	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	4.97	1.2e-06	0.000467	0.25	0.29	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
KIRP	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	4.97	1.2e-06	0.000467	0.29	0.29	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
KIRP	cis	rs9595908	0.785	rs4942791	ENSG00000212293.1	SNORA16	4.97	1.2e-06	0.000467	0.28	0.29	Body mass index;	chr13:32663085	chr13:32420390~32420516:-
KIRP	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-4.97	1.2e-06	0.000467	-0.36	-0.29	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
KIRP	cis	rs5758511	0.68	rs5758652	ENSG00000227370.1	RP4-669P10.19	4.97	1.2e-06	0.000467	0.35	0.29	Birth weight;	chr22:42216402	chr22:42132543~42132998:+
KIRP	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	4.97	1.2e-06	0.000468	0.26	0.29	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
KIRP	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-4.97	1.2e-06	0.000468	-0.3	-0.29	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
KIRP	cis	rs2562456	0.917	rs2562466	ENSG00000268555.1	RP11-678G14.3	-4.97	1.2e-06	0.000468	-0.4	-0.29	Pain;	chr19:21531402	chr19:21570822~21587322:-
KIRP	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-4.97	1.2e-06	0.000468	-0.24	-0.29	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-4.97	1.2e-06	0.000468	-0.24	-0.29	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
KIRP	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	4.97	1.2e-06	0.000468	0.25	0.29	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
KIRP	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	4.97	1.2e-06	0.000468	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
KIRP	cis	rs763121	0.853	rs6001175	ENSG00000273076.1	RP3-508I15.22	4.97	1.2e-06	0.000468	0.27	0.29	Menopause (age at onset);	chr22:38622329	chr22:38743495~38743910:+
KIRP	cis	rs4578769	0.55	rs9956087	ENSG00000265943.1	RP11-739L10.1	4.97	1.2e-06	0.000468	0.39	0.29	Eosinophil percentage of white cells;	chr18:23030538	chr18:22699481~22933764:-
KIRP	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	4.97	1.2e-06	0.000468	0.36	0.29	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	4.97	1.2e-06	0.000468	0.36	0.29	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
KIRP	cis	rs1005277	0.579	rs2472181	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474574	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2504140	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474575	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2472182	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.541	rs2263163	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2472183	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2505197	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2505196	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.541	rs2505193	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474580	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2504148	ENSG00000151963.4	RP11-775A3.1	-4.97	1.2e-06	0.000468	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:37883594~37884109:+
KIRP	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	4.97	1.2e-06	0.000468	0.29	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
KIRP	cis	rs4578769	0.55	rs11082258	ENSG00000265943.1	RP11-739L10.1	4.97	1.2e-06	0.000469	0.39	0.29	Eosinophil percentage of white cells;	chr18:23037401	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.55	rs4280358	ENSG00000265943.1	RP11-739L10.1	4.97	1.2e-06	0.000469	0.39	0.29	Eosinophil percentage of white cells;	chr18:23037844	chr18:22699481~22933764:-
KIRP	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	4.97	1.21e-06	0.000469	0.46	0.29	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	4.97	1.21e-06	0.000469	0.46	0.29	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
KIRP	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	4.97	1.21e-06	0.000469	0.46	0.29	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
KIRP	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	4.97	1.21e-06	0.000469	0.24	0.29	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
KIRP	cis	rs703842	0.963	rs2291617	ENSG00000270039.1	RP11-571M6.17	-4.97	1.21e-06	0.000469	-0.27	-0.29	Multiple sclerosis;	chr12:57772620	chr12:57803838~57804415:+
KIRP	cis	rs4356975	0.509	rs6600884	ENSG00000248763.2	RP13-644M16.5	-4.97	1.21e-06	0.000469	-0.32	-0.29	Obesity-related traits;	chr4:69102348	chr4:69066395~69069888:+
KIRP	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	4.97	1.21e-06	0.00047	0.24	0.29	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
KIRP	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	4.97	1.21e-06	0.000471	0.42	0.29	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
KIRP	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-4.97	1.21e-06	0.000471	-0.32	-0.29	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-4.97	1.21e-06	0.000471	-0.32	-0.29	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
KIRP	cis	rs1044826	0.642	rs295473	ENSG00000178631.7	ACTG1P1	4.97	1.21e-06	0.000471	0.31	0.29	Obesity-related traits;	chr3:139496743	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs7624321	ENSG00000178631.7	ACTG1P1	4.97	1.21e-06	0.000471	0.31	0.29	Obesity-related traits;	chr3:139501317	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs295478	ENSG00000178631.7	ACTG1P1	4.97	1.21e-06	0.000471	0.31	0.29	Obesity-related traits;	chr3:139504293	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs295479	ENSG00000178631.7	ACTG1P1	4.97	1.21e-06	0.000471	0.31	0.29	Obesity-related traits;	chr3:139505023	chr3:139493809~139494937:+
KIRP	cis	rs9402743	0.667	rs4896179	ENSG00000231028.7	LINC00271	-4.97	1.21e-06	0.000471	-0.26	-0.29	Systemic lupus erythematosus;	chr6:135788352	chr6:135497801~135716055:+
KIRP	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-4.97	1.21e-06	0.000471	-0.22	-0.29	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
KIRP	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-4.97	1.21e-06	0.000471	-0.24	-0.29	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
KIRP	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	4.97	1.21e-06	0.000471	0.58	0.29	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	4.97	1.21e-06	0.000471	0.58	0.29	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-4.97	1.21e-06	0.000471	-0.58	-0.29	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
KIRP	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-4.97	1.21e-06	0.000471	-0.26	-0.29	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
KIRP	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	4.97	1.21e-06	0.000471	0.28	0.29	Height;	chr4:55533481	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55551447	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55551845	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55553396	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55554025	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55554380	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55554456	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	4.97	1.21e-06	0.000471	0.31	0.29	Height;	chr4:55559957	chr4:55363971~55395847:-
KIRP	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	4.97	1.21e-06	0.000472	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
KIRP	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	4.97	1.21e-06	0.000472	0.41	0.29	Height;	chr6:109480428	chr6:109382795~109383666:+
KIRP	cis	rs711830	1	rs2113559	ENSG00000226363.3	HAGLROS	-4.97	1.21e-06	0.000472	-0.47	-0.29	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166371	chr2:176177717~176179008:+
KIRP	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-4.97	1.21e-06	0.000472	-0.2	-0.29	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
KIRP	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	4.97	1.22e-06	0.000472	0.59	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
KIRP	cis	rs9925964	0.933	rs11150604	ENSG00000232748.3	RP11-196G11.6	4.97	1.22e-06	0.000472	0.36	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:31056460~31062803:+
KIRP	cis	rs1858037	0.867	rs4671658	ENSG00000237979.1	AC007389.1	-4.97	1.22e-06	0.000472	-0.33	-0.29	Rheumatoid arthritis;	chr2:65334258	chr2:65500993~65502138:-
KIRP	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-4.97	1.22e-06	0.000473	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
KIRP	cis	rs6532023	1	rs9998898	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851037	chr4:87785920~87786371:-
KIRP	cis	rs6532023	1	rs9998975	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851081	chr4:87785920~87786371:-
KIRP	cis	rs6532023	1	rs9990702	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851164	chr4:87785920~87786371:-
KIRP	cis	rs6532023	0.865	rs10001601	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851620	chr4:87785920~87786371:-
KIRP	cis	rs6532023	0.901	rs9991133	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851633	chr4:87785920~87786371:-
KIRP	cis	rs6532023	1	rs6532022	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87852582	chr4:87785920~87786371:-
KIRP	cis	rs6532023	1	rs6532023	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87852697	chr4:87785920~87786371:-
KIRP	cis	rs6532023	1	rs1471399	ENSG00000249973.2	CHCHD2P7	-4.97	1.22e-06	0.000473	-0.36	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87852921	chr4:87785920~87786371:-
KIRP	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-4.97	1.22e-06	0.000473	-0.28	-0.29	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
KIRP	cis	rs35146811	0.735	rs1138417	ENSG00000281827.1	AC005071.4	4.97	1.22e-06	0.000473	0.23	0.29	Coronary artery disease;	chr7:100209523	chr7:100344375~100344475:-
KIRP	cis	rs2154427	0.752	rs79114597	ENSG00000238197.4	PAXBP1-AS1	4.97	1.22e-06	0.000474	0.38	0.29	Bilirubin levels;	chr21:32828420	chr21:32728115~32743122:+
KIRP	cis	rs2154427	0.938	rs114440021	ENSG00000238197.4	PAXBP1-AS1	4.97	1.22e-06	0.000474	0.38	0.29	Bilirubin levels;	chr21:32830362	chr21:32728115~32743122:+
KIRP	cis	rs2154427	0.938	rs113791275	ENSG00000238197.4	PAXBP1-AS1	4.97	1.22e-06	0.000474	0.38	0.29	Bilirubin levels;	chr21:32830496	chr21:32728115~32743122:+
KIRP	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	4.97	1.22e-06	0.000474	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
KIRP	cis	rs2739330	0.796	rs5760097	ENSG00000206090.4	AP000350.7	4.97	1.22e-06	0.000474	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23939998~23942798:+
KIRP	cis	rs2739330	0.828	rs4822451	ENSG00000206090.4	AP000350.7	4.97	1.22e-06	0.000474	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23939998~23942798:+
KIRP	cis	rs2739330	0.828	rs5760099	ENSG00000206090.4	AP000350.7	4.97	1.22e-06	0.000474	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23939998~23942798:+
KIRP	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	4.97	1.22e-06	0.000474	0.35	0.29	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
KIRP	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-4.97	1.22e-06	0.000474	-0.3	-0.29	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
KIRP	cis	rs1799949	0.683	rs55737636	ENSG00000236383.6	LINC00854	-4.97	1.22e-06	0.000474	-0.22	-0.29	Menopause (age at onset);	chr17:43112722	chr17:43216941~43305976:-
KIRP	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	4.97	1.22e-06	0.000474	0.27	0.29	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
KIRP	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-4.97	1.22e-06	0.000475	-0.31	-0.29	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
KIRP	cis	rs7976059	0.895	rs12367434	ENSG00000261586.2	RP11-923I11.6	-4.97	1.22e-06	0.000475	-0.29	-0.29	Urate levels;	chr12:51854131	chr12:51817899~51820150:+
KIRP	cis	rs4927850	0.794	rs13070153	ENSG00000207650.1	MIR570	4.97	1.22e-06	0.000475	0.31	0.29	Pancreatic cancer;	chr3:196014314	chr3:195699401~195699497:+
KIRP	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-4.97	1.22e-06	0.000475	-0.25	-0.29	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
KIRP	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	4.97	1.23e-06	0.000476	0.38	0.29	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
KIRP	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-4.97	1.23e-06	0.000476	-0.27	-0.29	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
KIRP	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-4.97	1.23e-06	0.000476	-0.25	-0.29	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-4.97	1.23e-06	0.000476	-0.25	-0.29	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-4.97	1.23e-06	0.000476	-0.25	-0.29	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-4.97	1.23e-06	0.000476	-0.25	-0.29	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-4.97	1.23e-06	0.000476	-0.25	-0.29	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
KIRP	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000476	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	4.97	1.23e-06	0.000476	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	4.97	1.23e-06	0.000476	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
KIRP	cis	rs1005277	0.579	rs11011461	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs1985707	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.557	rs1854563	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2505240	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2505241	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.54	rs2224248	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000476	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474571	ENSG00000151963.4	RP11-775A3.1	-4.97	1.23e-06	0.000477	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:37883594~37884109:+
KIRP	cis	rs2278170	1	rs331529	ENSG00000225101.4	OR52K3P	-4.97	1.23e-06	0.000477	-0.32	-0.29	Amyotrophic lateral sclerosis;	chr11:4457161	chr11:4474813~4475755:+
KIRP	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-4.97	1.23e-06	0.000477	-0.29	-0.29	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
KIRP	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-4.97	1.23e-06	0.000477	-0.29	-0.29	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
KIRP	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	4.97	1.23e-06	0.000478	0.32	0.29	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
KIRP	cis	rs4218	0.531	rs10431791	ENSG00000277144.1	RP11-59H7.4	-4.97	1.23e-06	0.000478	-0.29	-0.29	Social communication problems;	chr15:59055159	chr15:59115547~59116089:-
KIRP	cis	rs1165668	0.785	rs1165681	ENSG00000257327.1	RP11-650K20.3	-4.97	1.23e-06	0.000479	-0.32	-0.29	Coronary heart disease (SNP X SNP interaction);	chr12:103931333	chr12:103841451~103844664:+
KIRP	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-4.97	1.24e-06	0.000479	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
KIRP	cis	rs4356203	0.87	rs214926	ENSG00000272034.1	SNORD14A	-4.97	1.24e-06	0.000479	-0.24	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17074654~17074744:-
KIRP	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55436423	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55437438	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55452295	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55454900	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55454938	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55455102	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55486718	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55493557	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55495262	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	4.97	1.24e-06	0.00048	0.29	0.29	Height;	chr4:55502504	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-4.97	1.24e-06	0.00048	-0.28	-0.29	Height;	chr4:55542948	chr4:55547112~55547889:+
KIRP	cis	rs875971	0.545	rs73142233	ENSG00000236529.1	RP13-254B10.1	4.96	1.24e-06	0.000481	0.27	0.29	Aortic root size;	chr7:66221293	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-4.96	1.24e-06	0.000481	-0.25	-0.29	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
KIRP	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-4.96	1.24e-06	0.000481	-0.61	-0.29	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
KIRP	cis	rs867371	0.929	rs1501371	ENSG00000255769.6	GOLGA2P10	-4.96	1.24e-06	0.000481	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472993~82513950:-
KIRP	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-4.96	1.24e-06	0.000481	-0.33	-0.29	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
KIRP	cis	rs1799949	1	rs3950989	ENSG00000279602.1	CTD-3014M21.1	-4.96	1.24e-06	0.000481	-0.27	-0.29	Menopause (age at onset);	chr17:43085936	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs2070834	ENSG00000279602.1	CTD-3014M21.1	-4.96	1.24e-06	0.000481	-0.27	-0.29	Menopause (age at onset);	chr17:43090268	chr17:43360041~43361361:-
KIRP	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-4.96	1.24e-06	0.000482	-0.33	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
KIRP	cis	rs712022	0.534	rs4281481	ENSG00000246225.5	RP11-17A1.3	-4.96	1.25e-06	0.000482	-0.34	-0.29	Dialysis-related mortality;	chr11:22859013	chr11:22829380~22945393:+
KIRP	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	4.96	1.25e-06	0.000482	0.31	0.29	Height;	chr4:55451955	chr4:55363971~55395847:-
KIRP	cis	rs2278170	1	rs331502	ENSG00000225101.4	OR52K3P	-4.96	1.25e-06	0.000483	-0.35	-0.29	Amyotrophic lateral sclerosis;	chr11:4470602	chr11:4474813~4475755:+
KIRP	cis	rs77741769	0.534	rs58918988	ENSG00000277423.1	RP11-173P15.9	-4.96	1.25e-06	0.000483	-0.31	-0.29	Mean corpuscular volume;	chr12:120895150	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs1542859	ENSG00000277423.1	RP11-173P15.9	-4.96	1.25e-06	0.000483	-0.31	-0.29	Mean corpuscular volume;	chr12:120898963	chr12:120703867~120704282:+
KIRP	cis	rs453301	0.631	rs17700611	ENSG00000253981.4	ALG1L13P	-4.96	1.25e-06	0.000483	-0.24	-0.29	Joint mobility (Beighton score);	chr8:8936144	chr8:8236003~8244667:-
KIRP	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-4.96	1.25e-06	0.000483	-0.31	-0.29	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
KIRP	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	4.96	1.25e-06	0.000483	0.21	0.29	Height;	chr20:35064164	chr20:35201747~35203288:-
KIRP	cis	rs897984	0.806	rs1046276	ENSG00000275263.1	RP11-1072A3.4	4.96	1.25e-06	0.000483	0.31	0.29	Dementia with Lewy bodies;	chr16:30903305	chr16:30956872~30957199:-
KIRP	cis	rs1044826	0.619	rs7375091	ENSG00000178631.7	ACTG1P1	-4.96	1.25e-06	0.000484	-0.31	-0.29	Obesity-related traits;	chr3:139371547	chr3:139493809~139494937:+
KIRP	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-4.96	1.25e-06	0.000485	-0.25	-0.29	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
KIRP	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	4.96	1.25e-06	0.000485	0.34	0.29	Depression;	chr6:28079011	chr6:28073316~28074233:+
KIRP	cis	rs2439831	0.681	rs2242067	ENSG00000205771.5	CATSPER2P1	-4.96	1.25e-06	0.000486	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43407105	chr15:43726918~43747094:-
KIRP	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.96	1.26e-06	0.000486	-0.24	-0.29	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
KIRP	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.96	1.26e-06	0.000486	-0.24	-0.29	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
KIRP	cis	rs1153858	1	rs1618874	ENSG00000259433.2	CTD-2651B20.4	-4.96	1.26e-06	0.000486	-0.25	-0.29	Homoarginine levels;	chr15:45330588	chr15:45330209~45332634:-
KIRP	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-4.96	1.26e-06	0.000487	-0.38	-0.29	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
KIRP	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-4.96	1.26e-06	0.000488	-0.27	-0.29	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
KIRP	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-4.96	1.26e-06	0.000488	-0.24	-0.29	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
KIRP	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-4.96	1.26e-06	0.000488	-0.38	-0.29	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
KIRP	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-4.96	1.26e-06	0.000488	-0.3	-0.29	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
KIRP	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	4.96	1.26e-06	0.000489	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
KIRP	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-4.96	1.26e-06	0.000489	-0.29	-0.29	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
KIRP	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-4.96	1.26e-06	0.000489	-0.29	-0.29	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
KIRP	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	4.96	1.27e-06	0.000489	0.29	0.29	Height;	chr14:75101435	chr14:75011269~75012851:-
KIRP	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-4.96	1.27e-06	0.00049	-0.36	-0.29	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
KIRP	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-4.96	1.27e-06	0.000491	-0.2	-0.29	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
KIRP	cis	rs6832769	0.925	rs4371676	ENSG00000272969.1	RP11-528I4.2	4.96	1.27e-06	0.000491	0.3	0.29	Personality dimensions;	chr4:55462841	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs4864998	ENSG00000272969.1	RP11-528I4.2	4.96	1.27e-06	0.000491	0.3	0.29	Personality dimensions;	chr4:55466439	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs2140077	ENSG00000272969.1	RP11-528I4.2	4.96	1.27e-06	0.000491	0.3	0.29	Personality dimensions;	chr4:55472786	chr4:55547112~55547889:+
KIRP	cis	rs1799949	0.965	rs7212284	ENSG00000236383.6	LINC00854	-4.96	1.27e-06	0.000491	-0.21	-0.29	Menopause (age at onset);	chr17:43053924	chr17:43216941~43305976:-
KIRP	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	4.96	1.27e-06	0.000491	0.29	0.29	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
KIRP	cis	rs34286592	1	rs9938630	ENSG00000214725.6	CDIPT-AS1	-4.96	1.27e-06	0.000491	-0.38	-0.29	Multiple sclerosis;	chr16:29825787	chr16:29863593~29868053:+
KIRP	cis	rs11158026	0.603	rs34988865	ENSG00000258413.1	RP11-665C16.6	-4.96	1.27e-06	0.000491	-0.37	-0.29	Parkinson's disease;	chr14:55008131	chr14:55262767~55272075:-
KIRP	cis	rs2839627	0.638	rs7281701	ENSG00000225218.1	AP001628.6	4.96	1.27e-06	0.000491	0.29	0.29	Information processing speed;	chr21:42857186	chr21:42831040~42836477:-
KIRP	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	4.96	1.27e-06	0.000491	0.33	0.29	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
KIRP	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4.96	1.27e-06	0.000491	-0.26	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
KIRP	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-4.96	1.27e-06	0.000491	-0.26	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
KIRP	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-4.96	1.27e-06	0.000491	-0.26	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
KIRP	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	4.96	1.27e-06	0.000491	0.39	0.29	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
KIRP	cis	rs9595908	0.709	rs4942880	ENSG00000212293.1	SNORA16	4.96	1.27e-06	0.000492	0.27	0.29	Body mass index;	chr13:32751641	chr13:32420390~32420516:-
KIRP	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	4.96	1.27e-06	0.000492	0.21	0.29	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
KIRP	cis	rs2273156	1	rs2273158	ENSG00000226677.3	IGBP1P1	4.96	1.28e-06	0.000493	0.32	0.29	Immunoglobulin light chain (AL) amyloidosis;	chr14:34996578	chr14:34939324~34940332:+
KIRP	cis	rs600231	0.706	rs3782091	ENSG00000245532.5	NEAT1	-4.96	1.28e-06	0.000493	-0.22	-0.29	Bone mineral density;	chr11:65569012	chr11:65422774~65445540:+
KIRP	cis	rs712039	0.652	rs866465	ENSG00000276054.1	RP11-378E13.3	4.96	1.28e-06	0.000493	0.41	0.29	Tuberculosis;	chr17:37499298	chr17:37386886~37387926:+
KIRP	cis	rs2299587	0.932	rs3780103	ENSG00000254054.2	RP11-156K13.3	4.96	1.28e-06	0.000494	0.34	0.29	Economic and political preferences;	chr8:17962063	chr8:17905756~17907887:+
KIRP	cis	rs1681630	0.848	rs1631174	ENSG00000280615.1	Y_RNA	-4.96	1.28e-06	0.000494	-0.33	-0.29	Height;	chr11:47952821	chr11:47614898~47614994:-
KIRP	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-4.96	1.28e-06	0.000494	-0.72	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
KIRP	cis	rs5758511	0.68	rs5758651	ENSG00000227370.1	RP4-669P10.19	4.96	1.28e-06	0.000494	0.35	0.29	Birth weight;	chr22:42213142	chr22:42132543~42132998:+
KIRP	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-4.96	1.28e-06	0.000494	-0.32	-0.29	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-4.96	1.28e-06	0.000494	-0.32	-0.29	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-4.96	1.28e-06	0.000494	-0.32	-0.29	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
KIRP	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	4.96	1.28e-06	0.000494	0.25	0.29	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	4.96	1.28e-06	0.000494	0.25	0.29	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
KIRP	cis	rs947583	0.588	rs6925090	ENSG00000231028.7	LINC00271	-4.96	1.28e-06	0.000494	-0.25	-0.29	Phosphorus levels;	chr6:135795339	chr6:135497801~135716055:+
KIRP	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-4.96	1.28e-06	0.000494	-0.36	-0.29	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
KIRP	cis	rs7772486	0.846	rs2748496	ENSG00000270638.1	RP3-466P17.1	4.96	1.28e-06	0.000495	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145735570~145737218:+
KIRP	cis	rs7267979	1	rs2257432	ENSG00000274414.1	RP5-965G21.4	-4.96	1.28e-06	0.000495	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258066	ENSG00000274414.1	RP5-965G21.4	-4.96	1.28e-06	0.000495	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258135	ENSG00000274414.1	RP5-965G21.4	-4.96	1.28e-06	0.000495	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25239007~25245229:-
KIRP	cis	rs77741769	0.571	rs4454799	ENSG00000277423.1	RP11-173P15.9	4.96	1.28e-06	0.000495	0.31	0.29	Mean corpuscular volume;	chr12:120879272	chr12:120703867~120704282:+
KIRP	cis	rs77741769	0.571	rs73415720	ENSG00000277423.1	RP11-173P15.9	-4.96	1.28e-06	0.000495	-0.31	-0.29	Mean corpuscular volume;	chr12:120906712	chr12:120703867~120704282:+
KIRP	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-4.96	1.28e-06	0.000496	-0.34	-0.29	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
KIRP	cis	rs703842	1	rs10877019	ENSG00000270039.1	RP11-571M6.17	4.96	1.28e-06	0.000496	0.28	0.29	Multiple sclerosis;	chr12:57779146	chr12:57803838~57804415:+
KIRP	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	4.96	1.28e-06	0.000496	0.34	0.29	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
KIRP	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-4.96	1.28e-06	0.000496	-0.33	-0.29	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-4.96	1.28e-06	0.000496	-0.33	-0.29	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
KIRP	cis	rs962856	1	rs6710832	ENSG00000236780.4	AC078941.1	4.96	1.28e-06	0.000496	0.36	0.29	Pancreatic cancer;	chr2:67374810	chr2:67123357~67215319:-
KIRP	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-4.96	1.29e-06	0.000496	-0.33	-0.29	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-4.96	1.29e-06	0.000496	-0.33	-0.29	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
KIRP	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-4.96	1.29e-06	0.000496	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
KIRP	cis	rs4820539	1	rs4822361	ENSG00000275635.1	U7	-4.96	1.29e-06	0.000496	-0.31	-0.29	Bone mineral density;	chr22:23140531	chr22:23137805~23137864:-
KIRP	cis	rs3745672	1	rs3745672	ENSG00000219665.7	CTD-2006C1.2	-4.96	1.29e-06	0.000496	-0.68	-0.29	Multiple sclerosis;	chr19:12035555	chr19:11987617~12046275:+
KIRP	cis	rs2625529	0.823	rs11072332	ENSG00000260037.4	CTD-2524L6.3	-4.96	1.29e-06	0.000496	-0.24	-0.29	Red blood cell count;	chr15:71815966	chr15:71818396~71823384:+
KIRP	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-4.96	1.29e-06	0.000497	-0.34	-0.29	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
KIRP	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	4.96	1.29e-06	0.000497	0.44	0.29	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
KIRP	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-4.96	1.29e-06	0.000497	-0.31	-0.29	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
KIRP	cis	rs755249	0.501	rs661316	ENSG00000237624.1	OXCT2P1	4.96	1.29e-06	0.000497	0.4	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39514956~39516490:+
KIRP	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-4.96	1.29e-06	0.000497	-0.39	-0.29	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
KIRP	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-4.96	1.29e-06	0.000497	-0.31	-0.29	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
KIRP	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	4.96	1.29e-06	0.000497	0.24	0.29	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	4.96	1.29e-06	0.000497	0.24	0.29	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
KIRP	cis	rs61457372	0.563	rs11077601	ENSG00000264026.1	RP11-1124B17.1	-4.96	1.29e-06	0.000497	-0.32	-0.29	Triptolide cytotoxicity;	chr17:72353999	chr17:72342940~72355136:+
KIRP	cis	rs1400745	0.756	rs799683	ENSG00000258738.1	RP11-73E17.2	4.96	1.29e-06	0.000497	0.27	0.29	Monocyte count;	chr14:34880030	chr14:34874343~34876459:+
KIRP	cis	rs1400745	0.756	rs799682	ENSG00000258738.1	RP11-73E17.2	4.96	1.29e-06	0.000497	0.27	0.29	Monocyte count;	chr14:34880778	chr14:34874343~34876459:+
KIRP	cis	rs11864453	0.616	rs9938025	ENSG00000260886.1	TAT-AS1	-4.96	1.29e-06	0.000498	-0.37	-0.29	Fibrinogen levels;	chr16:71988142	chr16:71565789~71578187:+
KIRP	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-4.96	1.29e-06	0.000498	-0.43	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
KIRP	cis	rs7267979	1	rs2257420	ENSG00000274414.1	RP5-965G21.4	-4.96	1.29e-06	0.000498	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25239007~25245229:-
KIRP	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.96	1.29e-06	0.000498	-0.61	-0.29	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.545	rs11767262	ENSG00000236529.1	RP13-254B10.1	4.96	1.29e-06	0.000498	0.26	0.29	Aortic root size;	chr7:66302237	chr7:65840212~65840596:+
KIRP	cis	rs2299587	0.932	rs11784021	ENSG00000254054.2	RP11-156K13.3	4.96	1.29e-06	0.000498	0.34	0.29	Economic and political preferences;	chr8:17951768	chr8:17905756~17907887:+
KIRP	cis	rs11992162	0.636	rs4841645	ENSG00000255495.1	AC145124.2	-4.96	1.29e-06	0.000498	-0.28	-0.29	Monocyte count;	chr8:11941175	chr8:12194467~12196280:+
KIRP	cis	rs2904804	0.506	rs4427477	ENSG00000224251.5	RP11-499O7.7	4.96	1.29e-06	0.000498	0.31	0.29	Economic and political preferences (immigration/crime);	chr10:4926905	chr10:4995488~4997380:+
KIRP	cis	rs4356203	0.87	rs7936310	ENSG00000272034.1	SNORD14A	4.96	1.29e-06	0.000499	0.24	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17074654~17074744:-
KIRP	cis	rs875971	0.545	rs73142245	ENSG00000236529.1	RP13-254B10.1	4.96	1.29e-06	0.000499	0.27	0.29	Aortic root size;	chr7:66226662	chr7:65840212~65840596:+
KIRP	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	4.96	1.29e-06	0.000499	0.28	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
KIRP	cis	rs7569084	0.687	rs963539	ENSG00000237979.1	AC007389.1	-4.96	1.29e-06	0.000499	-0.32	-0.29	Sum eosinophil basophil counts;	chr2:65421413	chr2:65500993~65502138:-
KIRP	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	4.96	1.3e-06	5e-04	0.57	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
KIRP	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.96	1.3e-06	5e-04	0.3	0.29	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
KIRP	cis	rs9810089	0.814	rs866758	ENSG00000261758.1	RP11-102M11.2	4.96	1.3e-06	5e-04	0.32	0.29	Gestational age at birth (child effect);	chr3:136399028	chr3:136752630~136755780:+
KIRP	cis	rs116095464	0.558	rs7725227	ENSG00000248925.1	CTD-2083E4.6	4.96	1.3e-06	5e-04	0.44	0.29	Breast cancer;	chr5:233402	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7710005	ENSG00000248925.1	CTD-2083E4.6	4.96	1.3e-06	5e-04	0.44	0.29	Breast cancer;	chr5:233457	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs57335027	ENSG00000248925.1	CTD-2083E4.6	4.96	1.3e-06	5e-04	0.44	0.29	Breast cancer;	chr5:262792	chr5:269858~271516:-
KIRP	cis	rs9450351	0.744	rs6900270	ENSG00000203875.9	SNHG5	-4.96	1.3e-06	0.000501	-0.51	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85504789	chr6:85660950~85678736:-
KIRP	cis	rs1799949	1	rs8176120	ENSG00000279602.1	CTD-3014M21.1	-4.96	1.3e-06	0.000501	-0.27	-0.29	Menopause (age at onset);	chr17:43109216	chr17:43360041~43361361:-
KIRP	cis	rs1858037	0.765	rs67404371	ENSG00000237979.1	AC007389.1	4.96	1.3e-06	0.000501	0.33	0.29	Rheumatoid arthritis;	chr2:65370137	chr2:65500993~65502138:-
KIRP	cis	rs9595908	0.785	rs9315174	ENSG00000212293.1	SNORA16	4.95	1.3e-06	0.000501	0.27	0.29	Body mass index;	chr13:32645750	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.758	rs7329120	ENSG00000212293.1	SNORA16	4.95	1.3e-06	0.000501	0.27	0.29	Body mass index;	chr13:32646605	chr13:32420390~32420516:-
KIRP	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-4.95	1.3e-06	0.000501	-0.33	-0.29	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
KIRP	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-4.95	1.3e-06	0.000501	-0.35	-0.29	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
KIRP	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-4.95	1.3e-06	0.000502	-0.34	-0.29	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
KIRP	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	4.95	1.3e-06	0.000502	0.31	0.29	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
KIRP	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-4.95	1.3e-06	0.000502	-0.3	-0.29	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
KIRP	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	4.95	1.3e-06	0.000502	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	4.95	1.3e-06	0.000502	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	4.95	1.3e-06	0.000502	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-4.95	1.3e-06	0.000502	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-4.95	1.3e-06	0.000502	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
KIRP	cis	rs1150668	0.699	rs13408	ENSG00000220721.1	OR1F12	4.95	1.3e-06	0.000502	0.31	0.29	Pubertal anthropometrics;	chr6:28244970	chr6:28073316~28074233:+
KIRP	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-4.95	1.3e-06	0.000502	-0.34	-0.29	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
KIRP	cis	rs10504130	0.502	rs71513552	ENSG00000272024.1	RP11-546K22.3	-4.95	1.3e-06	0.000502	-0.34	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs34073804	ENSG00000272024.1	RP11-546K22.3	-4.95	1.3e-06	0.000502	-0.34	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs34319820	ENSG00000272024.1	RP11-546K22.3	-4.95	1.3e-06	0.000502	-0.34	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-4.95	1.3e-06	0.000502	-0.34	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
KIRP	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	4.95	1.3e-06	0.000502	0.32	0.29	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
KIRP	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55459921	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55461320	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55462689	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55463606	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55466010	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55467308	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55470266	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55470874	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55474259	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55475130	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55476159	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55476736	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55477545	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55479069	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55479339	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55479996	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55482317	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	4.95	1.3e-06	0.000503	0.31	0.29	Height;	chr4:55548261	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-4.95	1.3e-06	0.000503	-0.31	-0.29	Height;	chr4:55477866	chr4:55363971~55395847:-
KIRP	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-4.95	1.31e-06	0.000503	-0.31	-0.29	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
KIRP	cis	rs308403	0.568	rs13135778	ENSG00000224786.1	CETN4P	4.95	1.31e-06	0.000503	0.43	0.29	Blood protein levels;	chr4:122743291	chr4:122730548~122732193:-
KIRP	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-4.95	1.31e-06	0.000503	-0.26	-0.29	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
KIRP	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.95	1.31e-06	0.000503	-0.38	-0.29	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
KIRP	cis	rs2562456	0.652	rs4809145	ENSG00000268555.1	RP11-678G14.3	4.95	1.31e-06	0.000503	0.45	0.29	Pain;	chr19:21597907	chr19:21570822~21587322:-
KIRP	cis	rs875971	0.545	rs4718325	ENSG00000236529.1	RP13-254B10.1	4.95	1.31e-06	0.000504	0.27	0.29	Aortic root size;	chr7:66215323	chr7:65840212~65840596:+
KIRP	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-4.95	1.31e-06	0.000504	-0.34	-0.29	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
KIRP	cis	rs9595908	0.9	rs61947058	ENSG00000212293.1	SNORA16	4.95	1.31e-06	0.000504	0.27	0.29	Body mass index;	chr13:32617419	chr13:32420390~32420516:-
KIRP	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-4.95	1.31e-06	0.000504	-0.24	-0.29	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
KIRP	cis	rs9595908	0.84	rs2301388	ENSG00000212293.1	SNORA16	4.95	1.31e-06	0.000504	0.28	0.29	Body mass index;	chr13:32648478	chr13:32420390~32420516:-
KIRP	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-4.95	1.31e-06	0.000505	-0.26	-0.29	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-4.95	1.31e-06	0.000505	-0.35	-0.29	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
KIRP	cis	rs8030379	1	rs117031571	ENSG00000230373.7	GOLGA6L5P	-4.95	1.31e-06	0.000505	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84507885~84516814:-
KIRP	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-4.95	1.31e-06	0.000505	-0.25	-0.29	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
KIRP	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	4.95	1.31e-06	0.000505	0.31	0.29	Height;	chr4:55409063	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	4.95	1.31e-06	0.000505	0.28	0.29	Height;	chr4:55570311	chr4:55547112~55547889:+
KIRP	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-4.95	1.31e-06	0.000505	-0.33	-0.29	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-4.95	1.31e-06	0.000505	-0.33	-0.29	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
KIRP	cis	rs9595908	0.785	rs9596032	ENSG00000212293.1	SNORA16	4.95	1.31e-06	0.000505	0.28	0.29	Body mass index;	chr13:32654708	chr13:32420390~32420516:-
KIRP	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-4.95	1.31e-06	0.000505	-0.29	-0.29	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
KIRP	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-4.95	1.31e-06	0.000506	-0.35	-0.29	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
KIRP	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	4.95	1.31e-06	0.000506	0.36	0.29	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	4.95	1.31e-06	0.000506	0.36	0.29	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
KIRP	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	4.95	1.32e-06	0.000506	0.28	0.29	Height;	chr4:55409063	chr4:55547112~55547889:+
KIRP	cis	rs1005277	0.579	rs2505257	ENSG00000151963.4	RP11-775A3.1	-4.95	1.32e-06	0.000506	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:37883594~37884109:+
KIRP	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	4.95	1.32e-06	0.000507	0.28	0.29	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
KIRP	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	4.95	1.32e-06	0.000507	0.28	0.29	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
KIRP	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-4.95	1.32e-06	0.000507	-0.54	-0.29	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
KIRP	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-4.95	1.32e-06	0.000507	-0.32	-0.29	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
KIRP	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	4.95	1.32e-06	0.000507	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
KIRP	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-4.95	1.32e-06	0.000507	-0.2	-0.29	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
KIRP	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-4.95	1.32e-06	0.000507	-0.2	-0.29	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
KIRP	cis	rs17228178	0.961	rs10152953	ENSG00000215302.7	CTD-3092A11.1	-4.95	1.32e-06	0.000508	-0.37	-0.29	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175740	chr15:30470779~30507623:+
KIRP	cis	rs2562456	0.917	rs11085463	ENSG00000268555.1	RP11-678G14.3	4.95	1.32e-06	0.000508	0.38	0.29	Pain;	chr19:21568500	chr19:21570822~21587322:-
KIRP	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-4.95	1.32e-06	0.000508	-0.34	-0.29	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
KIRP	cis	rs4638749	1	rs1466211	ENSG00000225328.1	AC019100.3	-4.95	1.32e-06	0.000508	-0.38	-0.29	Blood pressure;	chr2:108239956	chr2:108167748~108217841:-
KIRP	cis	rs4638749	1	rs1466212	ENSG00000225328.1	AC019100.3	-4.95	1.32e-06	0.000508	-0.38	-0.29	Blood pressure;	chr2:108240076	chr2:108167748~108217841:-
KIRP	cis	rs9915657	0.87	rs12941066	ENSG00000234899.8	SOX9-AS1	-4.95	1.32e-06	0.000508	-0.27	-0.29	Thyroid hormone levels;	chr17:72145085	chr17:72034107~72237203:-
KIRP	cis	rs1799949	0.965	rs6503727	ENSG00000279602.1	CTD-3014M21.1	-4.95	1.32e-06	0.000508	-0.25	-0.29	Menopause (age at onset);	chr17:43160842	chr17:43360041~43361361:-
KIRP	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.95	1.32e-06	0.000508	0.25	0.29	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
KIRP	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	4.95	1.32e-06	0.000508	0.27	0.29	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
KIRP	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.95	1.32e-06	0.000508	0.23	0.29	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
KIRP	cis	rs2278170	1	rs10768026	ENSG00000225101.4	OR52K3P	-4.95	1.32e-06	0.000509	-0.36	-0.29	Amyotrophic lateral sclerosis;	chr11:4468880	chr11:4474813~4475755:+
KIRP	cis	rs8030379	0.967	rs8036748	ENSG00000230373.7	GOLGA6L5P	-4.95	1.32e-06	0.000509	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903084	chr15:84507885~84516814:-
KIRP	cis	rs4578769	0.569	rs12605341	ENSG00000265943.1	RP11-739L10.1	-4.95	1.32e-06	0.000509	-0.37	-0.29	Eosinophil percentage of white cells;	chr18:22803011	chr18:22699481~22933764:-
KIRP	cis	rs8141529	0.719	rs2097461	ENSG00000226471.5	CTA-292E10.6	-4.95	1.33e-06	0.00051	-0.29	-0.29	Lymphocyte counts;	chr22:28795891	chr22:28800683~28848559:+
KIRP	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	4.95	1.33e-06	0.00051	0.37	0.29	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
KIRP	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-4.95	1.33e-06	0.000511	-0.38	-0.29	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
KIRP	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	4.95	1.33e-06	0.000511	0.35	0.29	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	4.95	1.33e-06	0.000511	0.35	0.29	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	4.95	1.33e-06	0.000511	0.35	0.29	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
KIRP	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-4.95	1.33e-06	0.000511	-0.36	-0.29	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
KIRP	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	4.95	1.33e-06	0.000512	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
KIRP	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	4.95	1.33e-06	0.000512	0.39	0.29	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
KIRP	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	4.95	1.33e-06	0.000512	0.39	0.29	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
KIRP	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	4.95	1.33e-06	0.000512	0.39	0.29	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
KIRP	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	4.95	1.33e-06	0.000512	0.39	0.29	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
KIRP	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	4.95	1.33e-06	0.000512	0.39	0.29	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
KIRP	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	4.95	1.33e-06	0.000512	0.28	0.29	Height;	chr14:75189542	chr14:75011269~75012851:-
KIRP	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	4.95	1.33e-06	0.000512	0.33	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
KIRP	cis	rs4639966	0.836	rs73001486	ENSG00000255239.1	AP002954.6	-4.95	1.33e-06	0.000512	-0.38	-0.29	Systemic lupus erythematosus;	chr11:118758655	chr11:118688039~118690600:-
KIRP	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	4.95	1.33e-06	0.000512	0.3	0.29	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
KIRP	cis	rs42648	0.748	rs10226014	ENSG00000225498.1	AC002064.5	-4.95	1.34e-06	0.000513	-0.21	-0.29	Homocysteine levels;	chr7:90273219	chr7:90312496~90322592:+
KIRP	cis	rs1005277	0.579	rs2504143	ENSG00000151963.4	RP11-775A3.1	-4.95	1.34e-06	0.000513	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:37883594~37884109:+
KIRP	cis	rs11148252	0.904	rs9568732	ENSG00000235660.1	LINC00345	4.95	1.34e-06	0.000513	0.31	0.29	Lewy body disease;	chr13:52419277	chr13:52484161~52484680:-
KIRP	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	4.95	1.34e-06	0.000513	0.31	0.29	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
KIRP	cis	rs11009175	0.556	rs7072034	ENSG00000273038.2	RP11-479G22.8	-4.95	1.34e-06	0.000514	-0.29	-0.29	Depression (quantitative trait);	chr10:33009689	chr10:32887255~32889311:-
KIRP	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-4.95	1.34e-06	0.000515	-0.27	-0.29	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
KIRP	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.95	1.34e-06	0.000515	-0.26	-0.29	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
KIRP	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-4.95	1.34e-06	0.000516	-0.3	-0.29	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
KIRP	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	4.95	1.34e-06	0.000516	0.28	0.29	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
KIRP	cis	rs2976388	0.647	rs2920288	ENSG00000253741.1	CTD-2292P10.4	-4.95	1.34e-06	0.000516	-0.33	-0.29	Urinary tract infection frequency;	chr8:142671871	chr8:142702252~142726973:-
KIRP	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	4.95	1.34e-06	0.000516	0.41	0.29	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
KIRP	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	4.95	1.34e-06	0.000516	0.41	0.29	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
KIRP	cis	rs116095464	0.558	rs7703803	ENSG00000248925.1	CTD-2083E4.6	4.95	1.35e-06	0.000516	0.44	0.29	Breast cancer;	chr5:292196	chr5:269858~271516:-
KIRP	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-4.95	1.35e-06	0.000517	-0.4	-0.29	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
KIRP	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-4.95	1.35e-06	0.000517	-0.25	-0.29	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
KIRP	cis	rs77741769	0.569	rs10774572	ENSG00000277423.1	RP11-173P15.9	-4.95	1.35e-06	0.000517	-0.31	-0.29	Mean corpuscular volume;	chr12:120871758	chr12:120703867~120704282:+
KIRP	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	4.95	1.35e-06	0.000518	0.48	0.29	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
KIRP	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-4.95	1.35e-06	0.000518	-0.31	-0.29	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
KIRP	cis	rs12922317	0.538	rs442234	ENSG00000260488.1	RP11-166B2.7	4.95	1.35e-06	0.000518	0.35	0.29	Schizophrenia;	chr16:11978304	chr16:11976851~11977850:-
KIRP	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	4.95	1.35e-06	0.000518	0.31	0.29	Height;	chr4:55546378	chr4:55363971~55395847:-
KIRP	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-4.95	1.35e-06	0.000518	-0.38	-0.29	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
KIRP	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	4.95	1.35e-06	0.000518	0.31	0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
KIRP	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	4.95	1.35e-06	0.000519	0.51	0.29	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
KIRP	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	4.95	1.35e-06	0.000519	0.44	0.29	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
KIRP	cis	rs10208649	0.656	rs74693460	ENSG00000272156.1	RP11-477N3.1	4.95	1.35e-06	0.000519	0.57	0.29	Body mass index;	chr2:54071471	chr2:54082554~54085066:+
KIRP	cis	rs4638749	1	rs12477202	ENSG00000225328.1	AC019100.3	-4.95	1.35e-06	0.000519	-0.38	-0.29	Blood pressure;	chr2:108250656	chr2:108167748~108217841:-
KIRP	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.95	1.35e-06	0.000519	-0.24	-0.29	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
KIRP	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-4.95	1.35e-06	0.000519	-0.42	-0.29	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
KIRP	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-4.95	1.35e-06	0.000519	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
KIRP	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-4.95	1.35e-06	0.00052	-0.32	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
KIRP	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-4.95	1.35e-06	0.00052	-0.32	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
KIRP	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	4.95	1.36e-06	0.00052	0.21	0.29	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
KIRP	cis	rs2043112	0.965	rs12233987	ENSG00000249911.1	LINC01265	4.95	1.36e-06	0.00052	0.34	0.29	Obesity-related traits;	chr5:39053445	chr5:38710367~38720273:-
KIRP	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-4.95	1.36e-06	0.000521	-0.3	-0.29	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
KIRP	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-4.95	1.36e-06	0.000521	-0.47	-0.29	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
KIRP	cis	rs950169	0.686	rs12906474	ENSG00000275120.1	RP11-182J1.17	4.95	1.36e-06	0.000521	0.38	0.29	Schizophrenia;	chr15:84566006	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.81	rs2879976	ENSG00000275120.1	RP11-182J1.17	4.95	1.36e-06	0.000521	0.38	0.29	Schizophrenia;	chr15:84566347	chr15:84599434~84606463:-
KIRP	cis	rs2299587	0.932	rs11776688	ENSG00000254054.2	RP11-156K13.3	4.95	1.36e-06	0.000521	0.34	0.29	Economic and political preferences;	chr8:17986417	chr8:17905756~17907887:+
KIRP	cis	rs308403	0.6	rs309361	ENSG00000224786.1	CETN4P	4.95	1.36e-06	0.000521	0.37	0.29	Blood protein levels;	chr4:122736823	chr4:122730548~122732193:-
KIRP	cis	rs2278170	1	rs331532	ENSG00000225101.4	OR52K3P	-4.95	1.36e-06	0.000521	-0.32	-0.29	Amyotrophic lateral sclerosis;	chr11:4456865	chr11:4474813~4475755:+
KIRP	cis	rs2278170	1	rs2081575	ENSG00000225101.4	OR52K3P	-4.95	1.36e-06	0.000521	-0.32	-0.29	Amyotrophic lateral sclerosis;	chr11:4457238	chr11:4474813~4475755:+
KIRP	cis	rs2278170	1	rs331527	ENSG00000225101.4	OR52K3P	-4.95	1.36e-06	0.000521	-0.32	-0.29	Amyotrophic lateral sclerosis;	chr11:4457736	chr11:4474813~4475755:+
KIRP	cis	rs2278170	0.962	rs1864499	ENSG00000225101.4	OR52K3P	-4.95	1.36e-06	0.000521	-0.32	-0.29	Amyotrophic lateral sclerosis;	chr11:4458002	chr11:4474813~4475755:+
KIRP	cis	rs4663866	0.901	rs71426512	ENSG00000186235.9	AC016757.3	4.95	1.36e-06	0.000521	0.56	0.29	Irritable bowel syndrome;	chr2:238278487	chr2:238224552~238231677:-
KIRP	cis	rs4663866	0.901	rs76312449	ENSG00000186235.9	AC016757.3	4.95	1.36e-06	0.000521	0.56	0.29	Irritable bowel syndrome;	chr2:238282265	chr2:238224552~238231677:-
KIRP	cis	rs11673344	0.504	rs11084874	ENSG00000226686.6	LINC01535	4.95	1.36e-06	0.000521	0.35	0.29	Obesity-related traits;	chr19:37096667	chr19:37251912~37265535:+
KIRP	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-4.95	1.36e-06	0.000522	-0.29	-0.29	Height;	chr14:74996984	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-4.95	1.36e-06	0.000522	-0.29	-0.29	Height;	chr14:75004130	chr14:75011269~75012851:-
KIRP	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	4.95	1.36e-06	0.000522	0.51	0.29	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
KIRP	cis	rs13113518	0.812	rs12500456	ENSG00000272969.1	RP11-528I4.2	4.95	1.36e-06	0.000522	0.28	0.29	Height;	chr4:55561053	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.783	rs2171618	ENSG00000272969.1	RP11-528I4.2	4.95	1.36e-06	0.000522	0.28	0.29	Height;	chr4:55564241	chr4:55547112~55547889:+
KIRP	cis	rs7615952	0.534	rs1503072	ENSG00000241439.1	RP11-666A20.3	4.95	1.36e-06	0.000522	0.42	0.29	Blood pressure (smoking interaction);	chr3:126035848	chr3:125958556~125958817:+
KIRP	cis	rs7615952	0.599	rs7631268	ENSG00000241439.1	RP11-666A20.3	4.95	1.36e-06	0.000522	0.42	0.29	Blood pressure (smoking interaction);	chr3:126036821	chr3:125958556~125958817:+
KIRP	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	4.94	1.36e-06	0.000522	0.3	0.29	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
KIRP	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-4.94	1.37e-06	0.000524	-0.24	-0.29	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
KIRP	cis	rs11158026	0.79	rs1107960	ENSG00000258413.1	RP11-665C16.6	-4.94	1.37e-06	0.000524	-0.36	-0.29	Parkinson's disease;	chr14:54917622	chr14:55262767~55272075:-
KIRP	cis	rs4820539	1	rs2267002	ENSG00000275635.1	U7	4.94	1.37e-06	0.000525	0.31	0.29	Bone mineral density;	chr22:23114515	chr22:23137805~23137864:-
KIRP	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	4.94	1.37e-06	0.000525	0.32	0.29	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
KIRP	cis	rs7267979	1	rs6115146	ENSG00000274414.1	RP5-965G21.4	4.94	1.37e-06	0.000526	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.934	rs6037085	ENSG00000274414.1	RP5-965G21.4	4.94	1.37e-06	0.000526	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25239007~25245229:-
KIRP	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-4.94	1.38e-06	0.000527	-0.25	-0.29	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
KIRP	cis	rs7267979	1	rs2297496	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs7343481	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs6050532	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6083804	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs4815405	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6050542	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs6076336	ENSG00000274414.1	RP5-965G21.4	4.94	1.38e-06	0.000527	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258201	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258617	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258769	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258879	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2257496	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2258884	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2259837	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2259873	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs11100	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs1046073	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2259926	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2259928	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs2259956	ENSG00000274414.1	RP5-965G21.4	-4.94	1.38e-06	0.000527	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25239007~25245229:-
KIRP	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	4.94	1.38e-06	0.000527	0.33	0.29	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
KIRP	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	4.94	1.38e-06	0.000527	0.28	0.29	Height;	chr4:55545574	chr4:55547112~55547889:+
KIRP	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-4.94	1.38e-06	0.000528	-0.3	-0.29	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
KIRP	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-4.94	1.38e-06	0.000528	-0.41	-0.29	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
KIRP	cis	rs9595908	0.686	rs1015364	ENSG00000212293.1	SNORA16	4.94	1.38e-06	0.000528	0.28	0.29	Body mass index;	chr13:32784455	chr13:32420390~32420516:-
KIRP	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-4.94	1.38e-06	0.000528	-0.24	-0.29	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
KIRP	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-4.94	1.38e-06	0.000528	-0.29	-0.29	Height;	chr14:75095168	chr14:75011269~75012851:-
KIRP	cis	rs7829975	0.66	rs10093926	ENSG00000253981.4	ALG1L13P	-4.94	1.38e-06	0.000528	-0.22	-0.29	Mood instability;	chr8:8691510	chr8:8236003~8244667:-
KIRP	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-4.94	1.38e-06	0.000528	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
KIRP	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	4.94	1.38e-06	0.000528	0.3	0.29	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
KIRP	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	4.94	1.38e-06	0.000528	0.31	0.29	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
KIRP	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	4.94	1.38e-06	0.000529	0.38	0.29	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	4.94	1.38e-06	0.000529	0.38	0.29	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	4.94	1.38e-06	0.00053	0.38	0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
KIRP	cis	rs6480314	0.522	rs17231602	ENSG00000233590.1	RP11-153K11.3	-4.94	1.38e-06	0.00053	-0.48	-0.29	Optic nerve measurement (disc area);	chr10:68252532	chr10:68233251~68242379:-
KIRP	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	4.94	1.38e-06	0.00053	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
KIRP	cis	rs11079159	0.917	rs12452367	ENSG00000263096.1	RP11-515O17.2	4.94	1.38e-06	0.00053	0.4	0.29	QRS duration;	chr17:55297249	chr17:55271504~55273653:-
KIRP	cis	rs728616	0.867	rs723191	ENSG00000234382.2	RP11-40F6.1	-4.94	1.39e-06	0.00053	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs723193	ENSG00000234382.2	RP11-40F6.1	-4.94	1.39e-06	0.00053	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:80233664~80245367:+
KIRP	cis	rs1914816	0.941	rs2938691	ENSG00000196274.5	Metazoa_SRP	4.94	1.39e-06	0.000531	0.31	0.29	Response to tocilizumab in rheumatoid arthritis;	chr15:76214865	chr15:76230048~76230390:-
KIRP	cis	rs193541	0.632	rs246279	ENSG00000263432.2	RN7SL689P	-4.94	1.39e-06	0.000531	-0.4	-0.29	Glucose homeostasis traits;	chr5:122905568	chr5:123022487~123022783:-
KIRP	cis	rs11158026	0.757	rs8013521	ENSG00000258413.1	RP11-665C16.6	-4.94	1.39e-06	0.000531	-0.36	-0.29	Parkinson's disease;	chr14:54947007	chr14:55262767~55272075:-
KIRP	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	4.94	1.39e-06	0.000531	0.23	0.29	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
KIRP	cis	rs8114671	0.967	rs6088747	ENSG00000269202.1	RP4-614O4.12	-4.94	1.39e-06	0.000531	-0.22	-0.29	Height;	chr20:35166801	chr20:35201747~35203288:-
KIRP	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	4.94	1.39e-06	0.000531	0.36	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
KIRP	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-4.94	1.39e-06	0.000532	-0.27	-0.29	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
KIRP	cis	rs728616	0.867	rs61859763	ENSG00000234382.2	RP11-40F6.1	-4.94	1.39e-06	0.000532	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:80233664~80245367:+
KIRP	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-4.94	1.39e-06	0.000532	-0.24	-0.29	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-4.94	1.39e-06	0.000532	-0.24	-0.29	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
KIRP	cis	rs1799949	1	rs8176126	ENSG00000279602.1	CTD-3014M21.1	4.94	1.39e-06	0.000532	0.27	0.29	Menopause (age at onset);	chr17:43107032	chr17:43360041~43361361:-
KIRP	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	4.94	1.39e-06	0.000532	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
KIRP	cis	rs17228178	1	rs17228178	ENSG00000215302.7	CTD-3092A11.1	-4.94	1.39e-06	0.000532	-0.37	-0.29	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177725	chr15:30470779~30507623:+
KIRP	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-4.94	1.39e-06	0.000533	-0.3	-0.29	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
KIRP	cis	rs12039431	0.788	rs58284750	ENSG00000232273.1	FTH1P1	4.94	1.4e-06	0.000534	0.39	0.29	Epithelial ovarian cancer;	chr1:37577325	chr1:37544763~37545294:+
KIRP	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	4.94	1.4e-06	0.000534	0.35	0.29	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
KIRP	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.94	1.4e-06	0.000534	0.47	0.29	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
KIRP	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-4.94	1.4e-06	0.000534	-0.33	-0.29	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
KIRP	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-4.94	1.4e-06	0.000534	-0.33	-0.29	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
KIRP	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-4.94	1.4e-06	0.000534	-0.33	-0.29	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
KIRP	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-4.94	1.4e-06	0.000534	-0.33	-0.29	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
KIRP	cis	rs2043112	1	rs13171123	ENSG00000249911.1	LINC01265	4.94	1.4e-06	0.000535	0.34	0.29	Obesity-related traits;	chr5:39060541	chr5:38710367~38720273:-
KIRP	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	4.94	1.4e-06	0.000535	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
KIRP	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	4.94	1.4e-06	0.000535	0.37	0.29	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	4.94	1.4e-06	0.000535	0.37	0.29	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
KIRP	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	4.94	1.4e-06	0.000535	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
KIRP	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-4.94	1.4e-06	0.000535	-0.23	-0.29	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
KIRP	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-4.94	1.4e-06	0.000535	-0.37	-0.29	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
KIRP	cis	rs2980439	0.517	rs17594093	ENSG00000253981.4	ALG1L13P	-4.94	1.4e-06	0.000535	-0.26	-0.29	Neuroticism;	chr8:8248884	chr8:8236003~8244667:-
KIRP	cis	rs4820539	1	rs885963	ENSG00000275635.1	U7	4.94	1.4e-06	0.000535	0.32	0.29	Bone mineral density;	chr22:23118752	chr22:23137805~23137864:-
KIRP	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	4.94	1.4e-06	0.000535	0.31	0.29	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
KIRP	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	4.94	1.4e-06	0.000536	0.39	0.29	Depression;	chr6:28402301	chr6:28943877~28944537:+
KIRP	cis	rs10760158	0.587	rs10985212	ENSG00000226752.6	PSMD5-AS1	-4.94	1.4e-06	0.000536	-0.34	-0.29	Pulse pressure;	chr9:121338550	chr9:120824828~120854385:+
KIRP	cis	rs6480314	0.522	rs61857273	ENSG00000233590.1	RP11-153K11.3	-4.94	1.4e-06	0.000536	-0.48	-0.29	Optic nerve measurement (disc area);	chr10:68307530	chr10:68233251~68242379:-
KIRP	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	4.94	1.4e-06	0.000536	0.28	0.29	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
KIRP	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	4.94	1.4e-06	0.000536	0.28	0.29	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	4.94	1.4e-06	0.000536	0.28	0.29	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
KIRP	cis	rs5751901	0.929	rs2330805	ENSG00000225098.1	BCRP1	4.94	1.41e-06	0.000537	0.32	0.29	Protein quantitative trait loci;	chr22:24602652	chr22:24259929~24263764:-
KIRP	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-4.94	1.41e-06	0.000538	-0.26	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
KIRP	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	4.94	1.41e-06	0.000538	0.3	0.29	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	4.94	1.41e-06	0.000538	0.3	0.29	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	4.94	1.41e-06	0.000538	0.3	0.29	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
KIRP	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	4.94	1.41e-06	0.000538	0.3	0.29	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
KIRP	cis	rs1005277	0.579	rs2472173	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2472174	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs9418322	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs9299760	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2023351	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.565	rs2474565	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474567	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2472175	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2472176	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2983343	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.602	rs2504142	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474594	ENSG00000151963.4	RP11-775A3.1	-4.94	1.41e-06	0.000538	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:37883594~37884109:+
KIRP	cis	rs7267979	0.932	rs367666	ENSG00000274414.1	RP5-965G21.4	-4.94	1.41e-06	0.000538	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25239007~25245229:-
KIRP	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-4.94	1.41e-06	0.000538	-0.25	-0.29	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
KIRP	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	4.94	1.41e-06	0.000538	0.23	0.29	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
KIRP	cis	rs7267979	1	rs2258563	ENSG00000274414.1	RP5-965G21.4	-4.94	1.41e-06	0.000539	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25239007~25245229:-
KIRP	cis	rs9350100	0.512	rs1322526	ENSG00000228412.5	RP4-625H18.2	-4.94	1.41e-06	0.000539	-0.28	-0.29	Age at voice drop;	chr6:19092814	chr6:19802164~19804752:-
KIRP	cis	rs8081395	0.899	rs2645477	ENSG00000266992.1	DHX40P1	-4.94	1.42e-06	0.00054	-0.33	-0.29	White blood cell count;	chr17:59768263	chr17:59976009~60002384:-
KIRP	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-4.94	1.42e-06	0.000541	-0.36	-0.29	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-4.94	1.42e-06	0.000541	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
KIRP	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	4.94	1.42e-06	0.000542	0.33	0.29	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
KIRP	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	4.94	1.42e-06	0.000542	0.25	0.29	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	4.94	1.42e-06	0.000542	0.25	0.29	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
KIRP	cis	rs728616	0.867	rs61860034	ENSG00000234382.2	RP11-40F6.1	-4.94	1.42e-06	0.000542	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs56008106	ENSG00000234382.2	RP11-40F6.1	-4.94	1.42e-06	0.000542	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:80233664~80245367:+
KIRP	cis	rs1552244	1	rs76041173	ENSG00000180385.7	EMC3-AS1	4.94	1.42e-06	0.000542	0.29	0.29	Alzheimer's disease;	chr3:10037011	chr3:9986893~10006990:+
KIRP	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-4.94	1.42e-06	0.000542	-0.32	-0.29	Height;	chr4:55593918	chr4:55363971~55395847:-
KIRP	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	4.94	1.42e-06	0.000543	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
KIRP	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	4.94	1.42e-06	0.000543	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
KIRP	cis	rs713477	1	rs12893964	ENSG00000258413.1	RP11-665C16.6	4.94	1.42e-06	0.000543	0.36	0.29	Pediatric bone mineral content (femoral neck);	chr14:55445550	chr14:55262767~55272075:-
KIRP	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-4.94	1.42e-06	0.000543	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	4.94	1.42e-06	0.000543	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
KIRP	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-4.94	1.42e-06	0.000543	-0.33	-0.29	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
KIRP	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-4.94	1.42e-06	0.000543	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
KIRP	cis	rs10078	0.515	rs890984	ENSG00000221990.4	EXOC3-AS1	4.94	1.42e-06	0.000543	0.39	0.29	Fat distribution (HIV);	chr5:479425	chr5:441498~443160:-
KIRP	cis	rs962856	0.822	rs6546307	ENSG00000236780.4	AC078941.1	4.94	1.42e-06	0.000543	0.34	0.29	Pancreatic cancer;	chr2:67416921	chr2:67123357~67215319:-
KIRP	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-4.94	1.42e-06	0.000543	-0.28	-0.29	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
KIRP	cis	rs4218	0.635	rs10431792	ENSG00000277144.1	RP11-59H7.4	-4.94	1.42e-06	0.000544	-0.29	-0.29	Social communication problems;	chr15:59066181	chr15:59115547~59116089:-
KIRP	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	4.94	1.42e-06	0.000544	0.3	0.29	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
KIRP	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-4.94	1.43e-06	0.000544	-0.31	-0.29	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
KIRP	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	4.94	1.43e-06	0.000544	0.28	0.29	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
KIRP	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	4.94	1.43e-06	0.000544	0.28	0.29	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
KIRP	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-4.94	1.43e-06	0.000544	-0.33	-0.29	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
KIRP	cis	rs9959145	0.866	rs78596711	ENSG00000267108.1	RP11-861E21.1	4.94	1.43e-06	0.000544	0.48	0.29	Immune response to smallpox vaccine (IL-6);	chr18:12732779	chr18:12432897~12437635:+
KIRP	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-4.93	1.43e-06	0.000545	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
KIRP	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-4.93	1.43e-06	0.000545	-0.28	-0.29	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
KIRP	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	4.93	1.43e-06	0.000545	0.3	0.29	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	4.93	1.43e-06	0.000545	0.3	0.29	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	4.93	1.43e-06	0.000545	0.3	0.29	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
KIRP	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
KIRP	cis	rs42648	0.869	rs42609	ENSG00000225498.1	AC002064.5	4.93	1.43e-06	0.000545	0.21	0.29	Homocysteine levels;	chr7:90320541	chr7:90312496~90322592:+
KIRP	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-4.93	1.43e-06	0.000545	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
KIRP	cis	rs116095464	0.558	rs28635197	ENSG00000248925.1	CTD-2083E4.6	4.93	1.43e-06	0.000545	0.44	0.29	Breast cancer;	chr5:278956	chr5:269858~271516:-
KIRP	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	4.93	1.43e-06	0.000545	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
KIRP	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-4.93	1.43e-06	0.000545	-0.31	-0.29	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
KIRP	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	4.93	1.43e-06	0.000545	0.39	0.29	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
KIRP	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	4.93	1.43e-06	0.000545	0.39	0.29	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
KIRP	cis	rs308403	0.568	rs13146929	ENSG00000224786.1	CETN4P	4.93	1.43e-06	0.000546	0.43	0.29	Blood protein levels;	chr4:122749996	chr4:122730548~122732193:-
KIRP	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	4.93	1.43e-06	0.000546	0.28	0.29	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
KIRP	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	4.93	1.43e-06	0.000546	0.28	0.29	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
KIRP	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-4.93	1.43e-06	0.000546	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
KIRP	cis	rs2287641	0.677	rs58015041	ENSG00000272156.1	RP11-477N3.1	4.93	1.43e-06	0.000547	0.63	0.29	Cannabis dependence symptom count;	chr2:54037239	chr2:54082554~54085066:+
KIRP	cis	rs10050311	0.746	rs969734	ENSG00000251411.1	RP11-397E7.4	-4.93	1.43e-06	0.000547	-0.33	-0.29	Insulin-related traits;	chr4:86744231	chr4:86913266~86914817:-
KIRP	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-4.93	1.44e-06	0.000547	-0.45	-0.29	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
KIRP	cis	rs2109514	1	rs2270188	ENSG00000237813.3	AC002066.1	4.93	1.44e-06	0.000548	0.33	0.29	Prevalent atrial fibrillation;	chr7:116500470	chr7:116238260~116499465:-
KIRP	cis	rs2109514	1	rs2270189	ENSG00000237813.3	AC002066.1	4.93	1.44e-06	0.000548	0.33	0.29	Prevalent atrial fibrillation;	chr7:116500562	chr7:116238260~116499465:-
KIRP	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	4.93	1.44e-06	0.000548	0.44	0.29	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
KIRP	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	4.93	1.44e-06	0.000548	0.44	0.29	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
KIRP	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-4.93	1.44e-06	0.000548	-0.24	-0.29	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
KIRP	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	4.93	1.44e-06	0.000548	0.26	0.29	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
KIRP	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-4.93	1.44e-06	0.000549	-0.35	-0.29	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
KIRP	cis	rs962856	0.866	rs13387185	ENSG00000236780.4	AC078941.1	4.93	1.44e-06	0.000549	0.34	0.29	Pancreatic cancer;	chr2:67401517	chr2:67123357~67215319:-
KIRP	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-4.93	1.44e-06	0.000549	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
KIRP	cis	rs9810089	0.843	rs834304	ENSG00000261758.1	RP11-102M11.2	4.93	1.44e-06	0.000549	0.32	0.29	Gestational age at birth (child effect);	chr3:136392816	chr3:136752630~136755780:+
KIRP	cis	rs12936587	0.69	rs7213809	ENSG00000223979.2	SMCR2	4.93	1.44e-06	0.000549	0.28	0.29	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17630436	chr17:17674026~17677688:-
KIRP	cis	rs9813712	0.595	rs1453240	ENSG00000249846.5	RP11-77P16.4	-4.93	1.44e-06	0.000549	-0.29	-0.29	Response to amphetamines;	chr3:130282849	chr3:130112550~130120579:+
KIRP	cis	rs28386778	0.897	rs8079818	ENSG00000240280.5	TCAM1P	-4.93	1.44e-06	0.00055	-0.38	-0.29	Prudent dietary pattern;	chr17:63747307	chr17:63849292~63864379:+
KIRP	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-4.93	1.44e-06	0.00055	-0.23	-0.29	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
KIRP	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	4.93	1.44e-06	0.00055	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
KIRP	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-4.93	1.44e-06	0.00055	-0.29	-0.29	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
KIRP	cis	rs7747960	0.61	rs62427696	ENSG00000226193.1	RP3-398G3.5	-4.93	1.45e-06	0.000551	-0.49	-0.29	Bipolar disorder;	chr6:152491007	chr6:152402398~152404966:+
KIRP	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-4.93	1.45e-06	0.000552	-0.29	-0.29	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
KIRP	cis	rs12935418	0.733	rs35115578	ENSG00000261061.1	RP11-303E16.2	-4.93	1.45e-06	0.000552	-0.37	-0.29	Mean corpuscular volume;	chr16:80946392	chr16:81030770~81031485:+
KIRP	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	4.93	1.45e-06	0.000552	0.29	0.29	Height;	chr4:55452921	chr4:55547112~55547889:+
KIRP	cis	rs4820539	1	rs885964	ENSG00000275635.1	U7	4.93	1.45e-06	0.000553	0.32	0.29	Bone mineral density;	chr22:23118816	chr22:23137805~23137864:-
KIRP	cis	rs4927850	1	rs4927704	ENSG00000207650.1	MIR570	4.93	1.45e-06	0.000553	0.3	0.29	Pancreatic cancer;	chr3:196011357	chr3:195699401~195699497:+
KIRP	cis	rs4927850	1	rs4927848	ENSG00000207650.1	MIR570	4.93	1.45e-06	0.000553	0.3	0.29	Pancreatic cancer;	chr3:196011535	chr3:195699401~195699497:+
KIRP	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-4.93	1.45e-06	0.000553	-0.32	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
KIRP	cis	rs9595908	0.709	rs9285092	ENSG00000212293.1	SNORA16	4.93	1.45e-06	0.000553	0.28	0.29	Body mass index;	chr13:32745496	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs4942867	ENSG00000212293.1	SNORA16	4.93	1.45e-06	0.000553	0.28	0.29	Body mass index;	chr13:32745916	chr13:32420390~32420516:-
KIRP	cis	rs17767294	1	rs17767294	ENSG00000219392.1	RP1-265C24.5	-4.93	1.45e-06	0.000553	-0.55	-0.29	Parkinson's disease;	chr6:28086420	chr6:28115628~28116551:+
KIRP	cis	rs1552244	1	rs6807846	ENSG00000180385.7	EMC3-AS1	4.93	1.45e-06	0.000553	0.28	0.29	Alzheimer's disease;	chr3:10092807	chr3:9986893~10006990:+
KIRP	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	4.93	1.45e-06	0.000554	0.34	0.29	Depression;	chr6:28070115	chr6:28073316~28074233:+
KIRP	cis	rs7615952	0.599	rs1875683	ENSG00000241439.1	RP11-666A20.3	4.93	1.45e-06	0.000554	0.42	0.29	Blood pressure (smoking interaction);	chr3:126013638	chr3:125958556~125958817:+
KIRP	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.93	1.46e-06	0.000554	-0.22	-0.29	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
KIRP	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.93	1.46e-06	0.000554	-0.24	-0.29	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
KIRP	cis	rs1005277	0.579	rs2021649	ENSG00000151963.4	RP11-775A3.1	-4.93	1.46e-06	0.000555	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:37883594~37884109:+
KIRP	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-4.93	1.46e-06	0.000555	-0.28	-0.29	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
KIRP	cis	rs7432375	0.901	rs1681817	ENSG00000261758.1	RP11-102M11.2	-4.93	1.46e-06	0.000555	-0.3	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136754886	chr3:136752630~136755780:+
KIRP	cis	rs9595908	0.708	rs12429740	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000555	0.29	0.29	Body mass index;	chr13:32684928	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.746	rs2301393	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000557	0.28	0.29	Body mass index;	chr13:32658298	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs7985656	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000557	0.28	0.29	Body mass index;	chr13:32664414	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596056	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000557	0.28	0.29	Body mass index;	chr13:32669402	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs3783267	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000557	0.28	0.29	Body mass index;	chr13:32670719	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs60088097	ENSG00000212293.1	SNORA16	4.93	1.46e-06	0.000557	0.28	0.29	Body mass index;	chr13:32678043	chr13:32420390~32420516:-
KIRP	cis	rs1005277	0.579	rs176886	ENSG00000151963.4	RP11-775A3.1	-4.93	1.46e-06	0.000557	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.557	rs176887	ENSG00000151963.4	RP11-775A3.1	-4.93	1.46e-06	0.000557	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:37883594~37884109:+
KIRP	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-4.93	1.47e-06	0.000558	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
KIRP	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-4.93	1.47e-06	0.000558	-0.31	-0.29	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-4.93	1.47e-06	0.000558	-0.31	-0.29	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
KIRP	cis	rs7586673	0.578	rs6723840	ENSG00000235724.7	AC009299.2	-4.93	1.47e-06	0.000558	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161023104	chr2:161222785~161308303:-
KIRP	cis	rs7586673	0.578	rs6723841	ENSG00000235724.7	AC009299.2	-4.93	1.47e-06	0.000558	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161023105	chr2:161222785~161308303:-
KIRP	cis	rs728616	0.867	rs61860044	ENSG00000234382.2	RP11-40F6.1	-4.93	1.47e-06	0.000559	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:80233664~80245367:+
KIRP	cis	rs308403	0.608	rs309368	ENSG00000224786.1	CETN4P	4.93	1.47e-06	0.000559	0.4	0.29	Blood protein levels;	chr4:122741842	chr4:122730548~122732193:-
KIRP	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-4.93	1.47e-06	0.000559	-0.22	-0.29	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
KIRP	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-4.93	1.47e-06	0.000559	-0.22	-0.29	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
KIRP	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-4.93	1.47e-06	0.000559	-0.22	-0.29	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
KIRP	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-4.93	1.47e-06	0.000559	-0.22	-0.29	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
KIRP	cis	rs1153858	0.723	rs11855527	ENSG00000259433.2	CTD-2651B20.4	4.93	1.47e-06	0.00056	0.27	0.29	Homoarginine levels;	chr15:45314487	chr15:45330209~45332634:-
KIRP	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-4.93	1.47e-06	0.00056	-0.29	-0.29	Height;	chr14:75135159	chr14:75011269~75012851:-
KIRP	cis	rs875971	0.545	rs4718348	ENSG00000224316.1	RP11-479O9.2	4.93	1.47e-06	0.00056	0.24	0.29	Aortic root size;	chr7:66441589	chr7:65773620~65802067:+
KIRP	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-4.93	1.47e-06	0.000561	-0.33	-0.29	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
KIRP	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-4.93	1.48e-06	0.000561	-0.28	-0.29	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
KIRP	cis	rs2976388	0.524	rs7012804	ENSG00000253741.1	CTD-2292P10.4	-4.93	1.48e-06	0.000561	-0.34	-0.29	Urinary tract infection frequency;	chr8:142763232	chr8:142702252~142726973:-
KIRP	cis	rs12922317	0.681	rs2869492	ENSG00000260488.1	RP11-166B2.7	4.93	1.48e-06	0.000561	0.34	0.29	Schizophrenia;	chr16:11977484	chr16:11976851~11977850:-
KIRP	cis	rs308447	0.522	rs309363	ENSG00000224786.1	CETN4P	4.93	1.48e-06	0.000561	0.37	0.29	Perceived unattractiveness to mosquitoes;	chr4:122737014	chr4:122730548~122732193:-
KIRP	cis	rs964611	0.882	rs11629725	ENSG00000259488.2	RP11-154J22.1	4.93	1.48e-06	0.000561	0.27	0.29	Metabolite levels (Pyroglutamine);	chr15:48347986	chr15:48312353~48331856:-
KIRP	cis	rs9915657	0.933	rs17246133	ENSG00000234899.8	SOX9-AS1	-4.93	1.48e-06	0.000562	-0.24	-0.29	Thyroid hormone levels;	chr17:72144344	chr17:72034107~72237203:-
KIRP	cis	rs10771431	0.597	rs3759275	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000562	0.32	0.29	Breast size;	chr12:9201232	chr12:9277235~9313241:+
KIRP	cis	rs10771431	0.597	rs3759274	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000562	0.32	0.29	Breast size;	chr12:9201279	chr12:9277235~9313241:+
KIRP	cis	rs10771431	0.597	rs10771412	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000562	0.32	0.29	Breast size;	chr12:9201757	chr12:9277235~9313241:+
KIRP	cis	rs10771431	0.597	rs10771413	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000562	0.32	0.29	Breast size;	chr12:9201817	chr12:9277235~9313241:+
KIRP	cis	rs10771431	0.597	rs10843142	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000562	0.32	0.29	Breast size;	chr12:9204906	chr12:9277235~9313241:+
KIRP	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.93	1.48e-06	0.000562	0.25	0.29	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
KIRP	cis	rs9847710	0.791	rs6808387	ENSG00000280417.1	RP11-5O17.1	4.93	1.48e-06	0.000562	0.34	0.29	Ulcerative colitis;	chr3:53045716	chr3:53046166~53048122:+
KIRP	cis	rs9402743	0.666	rs9385737	ENSG00000231028.7	LINC00271	-4.93	1.48e-06	0.000562	-0.26	-0.29	Systemic lupus erythematosus;	chr6:135759379	chr6:135497801~135716055:+
KIRP	cis	rs4273100	1	rs12602286	ENSG00000228157.4	AC007952.5	-4.93	1.48e-06	0.000562	-0.48	-0.29	Schizophrenia;	chr17:19333641	chr17:19092974~19096837:+
KIRP	cis	rs1799949	0.965	rs9646418	ENSG00000279602.1	CTD-3014M21.1	-4.93	1.48e-06	0.000562	-0.25	-0.29	Menopause (age at onset);	chr17:43348533	chr17:43360041~43361361:-
KIRP	cis	rs4639966	0.836	rs7110526	ENSG00000255239.1	AP002954.6	-4.93	1.48e-06	0.000563	-0.38	-0.29	Systemic lupus erythematosus;	chr11:118762824	chr11:118688039~118690600:-
KIRP	cis	rs4639966	0.836	rs11217018	ENSG00000255239.1	AP002954.6	-4.93	1.48e-06	0.000563	-0.38	-0.29	Systemic lupus erythematosus;	chr11:118764656	chr11:118688039~118690600:-
KIRP	cis	rs4639966	0.797	rs11217021	ENSG00000255239.1	AP002954.6	-4.93	1.48e-06	0.000563	-0.38	-0.29	Systemic lupus erythematosus;	chr11:118770119	chr11:118688039~118690600:-
KIRP	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	4.93	1.48e-06	0.000563	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
KIRP	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	4.93	1.48e-06	0.000563	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
KIRP	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	4.93	1.48e-06	0.000563	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
KIRP	cis	rs10771431	0.597	rs7976807	ENSG00000111788.10	RP11-22B23.1	4.93	1.48e-06	0.000563	0.32	0.29	Breast size;	chr12:9199863	chr12:9277235~9313241:+
KIRP	cis	rs1799949	1	rs16942	ENSG00000279602.1	CTD-3014M21.1	-4.93	1.48e-06	0.000563	-0.27	-0.29	Menopause (age at onset);	chr17:43091983	chr17:43360041~43361361:-
KIRP	cis	rs7267979	0.933	rs2258728	ENSG00000274414.1	RP5-965G21.4	-4.93	1.48e-06	0.000563	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25239007~25245229:-
KIRP	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	4.93	1.48e-06	0.000563	0.31	0.29	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
KIRP	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	4.93	1.48e-06	0.000563	0.3	0.29	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
KIRP	cis	rs116095464	0.51	rs7714944	ENSG00000248925.1	CTD-2083E4.6	4.93	1.48e-06	0.000564	0.44	0.29	Breast cancer;	chr5:231650	chr5:269858~271516:-
KIRP	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-4.93	1.48e-06	0.000564	-0.28	-0.29	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
KIRP	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-4.93	1.48e-06	0.000564	-0.28	-0.29	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
KIRP	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	4.93	1.48e-06	0.000564	0.28	0.29	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
KIRP	cis	rs964611	0.808	rs35405890	ENSG00000259488.2	RP11-154J22.1	-4.93	1.48e-06	0.000564	-0.28	-0.29	Metabolite levels (Pyroglutamine);	chr15:48299070	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs16960737	ENSG00000259488.2	RP11-154J22.1	-4.93	1.48e-06	0.000564	-0.28	-0.29	Metabolite levels (Pyroglutamine);	chr15:48299863	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs66823218	ENSG00000259488.2	RP11-154J22.1	-4.93	1.48e-06	0.000564	-0.28	-0.29	Metabolite levels (Pyroglutamine);	chr15:48299886	chr15:48312353~48331856:-
KIRP	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000564	0.28	0.29	Height;	chr4:55490176	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000564	0.28	0.29	Height;	chr4:55490228	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000564	0.28	0.29	Height;	chr4:55491150	chr4:55547112~55547889:+
KIRP	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-4.93	1.49e-06	0.000564	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-4.93	1.49e-06	0.000564	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-4.93	1.49e-06	0.000564	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
KIRP	cis	rs911119	1	rs71334202	ENSG00000270001.1	RP11-218C14.8	-4.93	1.49e-06	0.000565	-0.33	-0.29	Chronic kidney disease;	chr20:23638015	chr20:23631826~23632316:-
KIRP	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-4.93	1.49e-06	0.000565	-0.33	-0.29	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-4.93	1.49e-06	0.000565	-0.33	-0.29	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
KIRP	cis	rs42648	0.869	rs1015403	ENSG00000225498.1	AC002064.5	4.93	1.49e-06	0.000565	0.21	0.29	Homocysteine levels;	chr7:90284388	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.869	rs1015404	ENSG00000225498.1	AC002064.5	4.93	1.49e-06	0.000565	0.21	0.29	Homocysteine levels;	chr7:90284632	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.869	rs12704518	ENSG00000225498.1	AC002064.5	4.93	1.49e-06	0.000565	0.21	0.29	Homocysteine levels;	chr7:90285074	chr7:90312496~90322592:+
KIRP	cis	rs1044826	0.642	rs167187	ENSG00000178631.7	ACTG1P1	-4.93	1.49e-06	0.000566	-0.3	-0.29	Obesity-related traits;	chr3:139518166	chr3:139493809~139494937:+
KIRP	cis	rs4578769	0.531	rs9957103	ENSG00000265943.1	RP11-739L10.1	4.93	1.49e-06	0.000566	0.37	0.29	Eosinophil percentage of white cells;	chr18:22870172	chr18:22699481~22933764:-
KIRP	cis	rs2745572	0.515	rs2250686	ENSG00000272279.1	RP11-157J24.2	-4.93	1.49e-06	0.000566	-0.36	-0.29	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548909	chr6:1528364~1528911:-
KIRP	cis	rs2745572	0.557	rs2745574	ENSG00000272279.1	RP11-157J24.2	-4.93	1.49e-06	0.000566	-0.36	-0.29	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548990	chr6:1528364~1528911:-
KIRP	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000566	0.29	0.29	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000566	0.29	0.29	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	4.93	1.49e-06	0.000566	0.29	0.29	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
KIRP	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	4.93	1.49e-06	0.000567	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
KIRP	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	4.93	1.49e-06	0.000567	0.25	0.29	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
KIRP	cis	rs7849973	0.579	rs10965453	ENSG00000224549.1	RP11-370B11.3	4.93	1.49e-06	0.000567	0.3	0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22778493	chr9:22767175~22768316:+
KIRP	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	4.93	1.49e-06	0.000567	0.32	0.29	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	4.93	1.49e-06	0.000567	0.32	0.29	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
KIRP	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	4.92	1.5e-06	0.000568	0.29	0.29	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
KIRP	cis	rs4356203	0.87	rs7342262	ENSG00000272034.1	SNORD14A	-4.92	1.5e-06	0.000568	-0.24	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17074654~17074744:-
KIRP	cis	rs1487614	0.777	rs7694153	ENSG00000250781.1	RP11-63A11.1	4.92	1.5e-06	0.000568	0.37	0.29	Longevity;	chr4:42268143	chr4:42281830~42391268:-
KIRP	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-4.92	1.5e-06	0.000569	-0.3	-0.29	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
KIRP	cis	rs2278170	1	rs2278173	ENSG00000225101.4	OR52K3P	-4.92	1.5e-06	0.000569	-0.35	-0.29	Amyotrophic lateral sclerosis;	chr11:4475867	chr11:4474813~4475755:+
KIRP	cis	rs6532023	1	rs10023907	ENSG00000249973.2	CHCHD2P7	-4.92	1.5e-06	0.000569	-0.35	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851383	chr4:87785920~87786371:-
KIRP	cis	rs11838725	1	rs11838725	ENSG00000239827.7	SUGT1P3	-4.92	1.5e-06	0.000569	-0.34	-0.29	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40908159~40921774:-
KIRP	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	4.92	1.5e-06	0.00057	0.33	0.29	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
KIRP	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-4.92	1.5e-06	0.00057	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-4.92	1.5e-06	0.00057	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
KIRP	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-4.92	1.5e-06	0.00057	-0.25	-0.29	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
KIRP	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	4.92	1.5e-06	0.00057	0.24	0.29	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
KIRP	cis	rs950169	0.922	rs62028133	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84250623	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.723	rs17589320	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84251244	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.845	rs4502182	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84254768	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.8	rs4842847	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84262447	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.881	rs4842852	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84387263	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.84	rs4842853	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84387606	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.922	rs4842946	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84387633	chr15:84599434~84606463:-
KIRP	cis	rs950169	0.84	rs4842854	ENSG00000275120.1	RP11-182J1.17	4.92	1.5e-06	0.00057	0.41	0.29	Schizophrenia;	chr15:84387641	chr15:84599434~84606463:-
KIRP	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	4.92	1.5e-06	0.00057	0.8	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
KIRP	cis	rs712022	0.507	rs11026815	ENSG00000246225.5	RP11-17A1.3	-4.92	1.5e-06	0.00057	-0.34	-0.29	Dialysis-related mortality;	chr11:22854432	chr11:22829380~22945393:+
KIRP	cis	rs28386778	0.701	rs2727337	ENSG00000240280.5	TCAM1P	4.92	1.5e-06	0.000571	0.36	0.29	Prudent dietary pattern;	chr17:63914606	chr17:63849292~63864379:+
KIRP	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	4.92	1.51e-06	0.000571	0.46	0.29	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
KIRP	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-4.92	1.51e-06	0.000571	-0.35	-0.29	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
KIRP	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-4.92	1.51e-06	0.000572	-0.31	-0.29	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
KIRP	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-4.92	1.51e-06	0.000573	-0.37	-0.29	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
KIRP	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	4.92	1.51e-06	0.000573	0.3	0.29	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	4.92	1.51e-06	0.000573	0.3	0.29	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	4.92	1.51e-06	0.000573	0.3	0.29	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
KIRP	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	4.92	1.51e-06	0.000573	0.29	0.29	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
KIRP	cis	rs950169	0.922	rs4338765	ENSG00000275120.1	RP11-182J1.17	4.92	1.51e-06	0.000573	0.41	0.29	Schizophrenia;	chr15:84248084	chr15:84599434~84606463:-
KIRP	cis	rs964611	0.872	rs72623972	ENSG00000259488.2	RP11-154J22.1	-4.92	1.51e-06	0.000574	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48294797	chr15:48312353~48331856:-
KIRP	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-4.92	1.52e-06	0.000574	-0.34	-0.29	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
KIRP	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-4.92	1.52e-06	0.000574	-0.37	-0.29	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
KIRP	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	4.92	1.52e-06	0.000575	0.43	0.29	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
KIRP	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-4.92	1.52e-06	0.000575	-0.46	-0.29	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
KIRP	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	4.92	1.52e-06	0.000575	0.36	0.29	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
KIRP	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	4.92	1.52e-06	0.000575	0.3	0.29	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	4.92	1.52e-06	0.000575	0.3	0.29	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	4.92	1.52e-06	0.000575	0.3	0.29	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	4.92	1.52e-06	0.000575	0.3	0.29	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	4.92	1.52e-06	0.000575	0.3	0.29	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
KIRP	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.92	1.52e-06	0.000575	-0.26	-0.29	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
KIRP	cis	rs79349575	0.594	rs62078375	ENSG00000270781.1	RP11-501C14.9	-4.92	1.52e-06	0.000575	-0.31	-0.29	Type 2 diabetes;	chr17:48957612	chr17:48899131~48899748:+
KIRP	cis	rs1005277	0.579	rs1548255	ENSG00000151963.4	RP11-775A3.1	-4.92	1.52e-06	0.000576	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:37883594~37884109:+
KIRP	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-4.92	1.52e-06	0.000576	-0.41	-0.29	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-4.92	1.52e-06	0.000576	-0.41	-0.29	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
KIRP	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-4.92	1.52e-06	0.000576	-0.47	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
KIRP	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	4.92	1.52e-06	0.000576	0.21	0.29	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
KIRP	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-4.92	1.52e-06	0.000576	-0.28	-0.29	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
KIRP	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-4.92	1.52e-06	0.000576	-0.33	-0.29	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
KIRP	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	4.92	1.52e-06	0.000576	0.36	0.29	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
KIRP	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	4.92	1.52e-06	0.000576	0.23	0.29	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
KIRP	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	4.92	1.52e-06	0.000576	0.23	0.29	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	4.92	1.52e-06	0.000576	0.23	0.29	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	4.92	1.52e-06	0.000576	0.23	0.29	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
KIRP	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	4.92	1.52e-06	0.000576	0.23	0.29	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
KIRP	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	4.92	1.52e-06	0.000577	0.27	0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
KIRP	cis	rs703842	1	rs10877015	ENSG00000270039.1	RP11-571M6.17	-4.92	1.52e-06	0.000577	-0.28	-0.29	Multiple sclerosis;	chr12:57774005	chr12:57803838~57804415:+
KIRP	cis	rs2235642	0.826	rs8048410	ENSG00000280231.1	LA16c-380F5.3	-4.92	1.53e-06	0.000578	-0.38	-0.29	Coronary artery disease;	chr16:1564096	chr16:1553655~1554130:-
KIRP	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-4.92	1.53e-06	0.000578	-0.22	-0.29	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
KIRP	cis	rs12530	0.651	rs2072816	ENSG00000241954.1	RP1-149A16.17	-4.92	1.53e-06	0.000578	-0.33	-0.29	IgG glycosylation;	chr22:32394411	chr22:32383786~32385631:+
KIRP	cis	rs79040073	0.607	rs17479205	ENSG00000259531.2	RP11-295H24.3	4.92	1.53e-06	0.000578	0.38	0.29	Lung cancer in ever smokers;	chr15:49456065	chr15:49365124~49366685:-
KIRP	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	4.92	1.53e-06	0.000579	0.29	0.29	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
KIRP	cis	rs41271473	0.706	rs72763990	ENSG00000212237.1	RNA5SP18	4.92	1.53e-06	0.000579	0.53	0.29	Chronic lymphocytic leukemia;	chr1:228531370	chr1:228647912~228648032:-
KIRP	cis	rs950169	0.763	rs35372971	ENSG00000275120.1	RP11-182J1.17	4.92	1.53e-06	0.00058	0.41	0.29	Schizophrenia;	chr15:84387097	chr15:84599434~84606463:-
KIRP	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-4.92	1.53e-06	0.00058	-0.32	-0.29	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
KIRP	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-4.92	1.53e-06	0.000581	-0.25	-0.29	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
KIRP	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4.92	1.53e-06	0.000581	-0.26	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
KIRP	cis	rs9532669	0.889	rs1989252	ENSG00000239827.7	SUGT1P3	4.92	1.53e-06	0.000581	0.34	0.29	Cervical cancer;	chr13:40911532	chr13:40908159~40921774:-
KIRP	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	4.92	1.54e-06	0.000581	0.25	0.29	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	4.92	1.54e-06	0.000581	0.25	0.29	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
KIRP	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-4.92	1.54e-06	0.000582	-0.24	-0.29	Height;	chr2:46636733	chr2:46668870~46670778:+
KIRP	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-4.92	1.54e-06	0.000582	-0.28	-0.29	Height;	chr14:75189865	chr14:75011269~75012851:-
KIRP	cis	rs11158026	0.603	rs67571433	ENSG00000258413.1	RP11-665C16.6	-4.92	1.54e-06	0.000582	-0.37	-0.29	Parkinson's disease;	chr14:54981264	chr14:55262767~55272075:-
KIRP	cis	rs728616	0.85	rs3889823	ENSG00000234382.2	RP11-40F6.1	-4.92	1.54e-06	0.000582	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:80233664~80245367:+
KIRP	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-4.92	1.54e-06	0.000583	-0.38	-0.29	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
KIRP	cis	rs964611	0.882	rs12148383	ENSG00000259488.2	RP11-154J22.1	4.92	1.54e-06	0.000583	0.27	0.29	Metabolite levels (Pyroglutamine);	chr15:48368235	chr15:48312353~48331856:-
KIRP	cis	rs7590983	1	rs73971771	ENSG00000271151.1	RP11-394I13.2	4.92	1.54e-06	0.000583	0.36	0.29	Anthropometric traits;	chr2:173497375	chr2:173968351~173969418:+
KIRP	cis	rs7590983	1	rs73971772	ENSG00000271151.1	RP11-394I13.2	4.92	1.54e-06	0.000583	0.36	0.29	Anthropometric traits;	chr2:173497393	chr2:173968351~173969418:+
KIRP	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-4.92	1.54e-06	0.000584	-0.24	-0.29	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-4.92	1.54e-06	0.000584	-0.24	-0.29	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
KIRP	cis	rs2109514	1	rs7795510	ENSG00000237813.3	AC002066.1	4.92	1.54e-06	0.000584	0.33	0.29	Prevalent atrial fibrillation;	chr7:116516907	chr7:116238260~116499465:-
KIRP	cis	rs2109514	1	rs2109514	ENSG00000237813.3	AC002066.1	4.92	1.54e-06	0.000584	0.33	0.29	Prevalent atrial fibrillation;	chr7:116519907	chr7:116238260~116499465:-
KIRP	cis	rs2109514	0.967	rs55883210	ENSG00000237813.3	AC002066.1	4.92	1.54e-06	0.000584	0.33	0.29	Prevalent atrial fibrillation;	chr7:116520470	chr7:116238260~116499465:-
KIRP	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-4.92	1.54e-06	0.000584	-0.27	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
KIRP	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-4.92	1.54e-06	0.000584	-0.31	-0.29	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
KIRP	cis	rs728616	0.867	rs4633405	ENSG00000234382.2	RP11-40F6.1	-4.92	1.54e-06	0.000584	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61860039	ENSG00000234382.2	RP11-40F6.1	-4.92	1.54e-06	0.000584	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:80233664~80245367:+
KIRP	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	4.92	1.54e-06	0.000584	0.22	0.29	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
KIRP	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	4.92	1.54e-06	0.000584	0.39	0.29	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
KIRP	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	4.92	1.55e-06	0.000584	0.32	0.29	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	4.92	1.55e-06	0.000584	0.32	0.29	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
KIRP	cis	rs1015213	0.609	rs117452492	ENSG00000272024.1	RP11-546K22.3	-4.92	1.55e-06	0.000584	-0.59	-0.29	Glaucoma (primary angle closure);	chr8:51905091	chr8:51950284~51950690:+
KIRP	cis	rs1015213	0.609	rs117144627	ENSG00000272024.1	RP11-546K22.3	-4.92	1.55e-06	0.000584	-0.59	-0.29	Glaucoma (primary angle closure);	chr8:51910597	chr8:51950284~51950690:+
KIRP	cis	rs9305354	0.818	rs12482111	ENSG00000232079.5	AL035610.1	4.92	1.55e-06	0.000585	0.4	0.29	Urinary albumin excretion;	chr21:28106127	chr21:28048404~28137611:+
KIRP	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	4.92	1.55e-06	0.000585	0.37	0.29	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
KIRP	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	4.92	1.55e-06	0.000585	0.37	0.29	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
KIRP	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.92	1.55e-06	0.000585	-0.38	-0.29	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
KIRP	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	4.92	1.55e-06	0.000585	0.29	0.29	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
KIRP	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	4.92	1.55e-06	0.000585	0.29	0.29	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
KIRP	cis	rs7586673	0.725	rs6757645	ENSG00000227403.1	AC009299.3	-4.92	1.55e-06	0.000586	-0.39	-0.29	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161244739~161249050:+
KIRP	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-4.92	1.55e-06	0.000587	-0.38	-0.29	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
KIRP	cis	rs7267979	0.789	rs6083810	ENSG00000274973.1	RP13-401N8.7	4.92	1.55e-06	0.000587	0.31	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25845497~25845862:+
KIRP	cis	rs7267979	0.789	rs6083841	ENSG00000274973.1	RP13-401N8.7	4.92	1.55e-06	0.000587	0.31	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25845497~25845862:+
KIRP	cis	rs2299587	0.932	rs7837060	ENSG00000254054.2	RP11-156K13.3	4.92	1.55e-06	0.000587	0.34	0.29	Economic and political preferences;	chr8:17952632	chr8:17905756~17907887:+
KIRP	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	4.92	1.55e-06	0.000588	0.25	0.29	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
KIRP	cis	rs7508	0.553	rs7828234	ENSG00000254054.2	RP11-156K13.3	4.92	1.55e-06	0.000588	0.33	0.29	Atrial fibrillation;	chr8:18025891	chr8:17905756~17907887:+
KIRP	cis	rs2299587	0.841	rs3213605	ENSG00000254054.2	RP11-156K13.3	4.92	1.55e-06	0.000588	0.33	0.29	Economic and political preferences;	chr8:18027582	chr8:17905756~17907887:+
KIRP	cis	rs792448	0.501	rs11119880	ENSG00000229983.1	RP11-15I11.2	4.92	1.56e-06	0.000588	0.33	0.29	White blood cell count (basophil);	chr1:212205143	chr1:212168207~212190259:+
KIRP	cis	rs728616	0.867	rs34870056	ENSG00000234382.2	RP11-40F6.1	-4.92	1.56e-06	0.000589	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:80233664~80245367:+
KIRP	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.92	1.56e-06	0.000589	-0.25	-0.29	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
KIRP	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	4.92	1.56e-06	0.000589	0.38	0.29	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	4.92	1.56e-06	0.000589	0.38	0.29	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
KIRP	cis	rs5758659	0.845	rs5758645	ENSG00000205702.9	CYP2D7	4.92	1.56e-06	0.00059	0.23	0.29	Cognitive function;	chr22:42202945	chr22:42140203~42144577:-
KIRP	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	4.92	1.56e-06	0.00059	0.23	0.29	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
KIRP	cis	rs7432375	0.901	rs11919030	ENSG00000261758.1	RP11-102M11.2	4.92	1.56e-06	0.00059	0.31	0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136629757	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs1017882	ENSG00000261758.1	RP11-102M11.2	4.92	1.56e-06	0.00059	0.31	0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136638863	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs4521165	ENSG00000261758.1	RP11-102M11.2	-4.92	1.56e-06	0.00059	-0.31	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136650868	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs7618518	ENSG00000261758.1	RP11-102M11.2	-4.92	1.56e-06	0.00059	-0.31	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136651250	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs4038587	ENSG00000261758.1	RP11-102M11.2	-4.92	1.56e-06	0.00059	-0.31	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136662526	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.901	rs4408829	ENSG00000261758.1	RP11-102M11.2	-4.92	1.56e-06	0.00059	-0.31	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136685841	chr3:136752630~136755780:+
KIRP	cis	rs1799949	0.965	rs6503726	ENSG00000279602.1	CTD-3014M21.1	-4.92	1.56e-06	0.00059	-0.26	-0.29	Menopause (age at onset);	chr17:43132725	chr17:43360041~43361361:-
KIRP	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-4.92	1.56e-06	0.000591	-0.31	-0.29	Height;	chr3:52991821	chr3:53064283~53065091:-
KIRP	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-4.92	1.56e-06	0.000591	-0.31	-0.29	Height;	chr3:52992698	chr3:53064283~53065091:-
KIRP	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-4.92	1.56e-06	0.000591	-0.24	-0.29	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
KIRP	cis	rs1005277	0.579	rs2474569	ENSG00000151963.4	RP11-775A3.1	-4.92	1.57e-06	0.000591	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:37883594~37884109:+
KIRP	cis	rs6532023	1	rs1471403	ENSG00000249973.2	CHCHD2P7	4.92	1.57e-06	0.000591	0.35	0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87854091	chr4:87785920~87786371:-
KIRP	cis	rs4660214	0.568	rs967530	ENSG00000237624.1	OXCT2P1	-4.92	1.57e-06	0.000591	-0.37	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39514956~39516490:+
KIRP	cis	rs7267979	0.789	rs6083820	ENSG00000274973.1	RP13-401N8.7	4.91	1.57e-06	0.000592	0.31	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25845497~25845862:+
KIRP	cis	rs9847710	1	rs2564956	ENSG00000280417.1	RP11-5O17.1	-4.91	1.57e-06	0.000592	-0.34	-0.29	Ulcerative colitis;	chr3:53036446	chr3:53046166~53048122:+
KIRP	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-4.91	1.57e-06	0.000592	-0.21	-0.29	Height;	chr20:35142661	chr20:35201747~35203288:-
KIRP	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	4.91	1.57e-06	0.000592	0.28	0.29	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
KIRP	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-4.91	1.57e-06	0.000592	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
KIRP	cis	rs4356203	0.905	rs7946010	ENSG00000272034.1	SNORD14A	4.91	1.57e-06	0.000593	0.24	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17074654~17074744:-
KIRP	cis	rs4663866	0.901	rs35390666	ENSG00000186235.9	AC016757.3	4.91	1.57e-06	0.000593	0.56	0.29	Irritable bowel syndrome;	chr2:238284937	chr2:238224552~238231677:-
KIRP	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-4.91	1.57e-06	0.000593	-0.33	-0.29	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
KIRP	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-4.91	1.57e-06	0.000593	-0.25	-0.29	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-4.91	1.57e-06	0.000593	-0.25	-0.29	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
KIRP	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	4.91	1.57e-06	0.000593	0.27	0.29	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
KIRP	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-4.91	1.57e-06	0.000593	-0.2	-0.29	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
KIRP	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	4.91	1.57e-06	0.000593	0.22	0.29	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
KIRP	cis	rs8030379	0.967	rs7182563	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83879994	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs11629657	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880228	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs7181926	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880676	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs6603000	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883142	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs12916223	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883742	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.875	rs28801104	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884091	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs12900412	ENSG00000230373.7	GOLGA6L5P	-4.91	1.57e-06	0.000593	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884314	chr15:84507885~84516814:-
KIRP	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-4.91	1.57e-06	0.000594	-0.45	-0.29	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
KIRP	cis	rs875971	0.545	rs1638724	ENSG00000236529.1	RP13-254B10.1	-4.91	1.57e-06	0.000594	-0.26	-0.29	Aortic root size;	chr7:66575494	chr7:65840212~65840596:+
KIRP	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	4.91	1.58e-06	0.000594	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	4.91	1.58e-06	0.000594	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
KIRP	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-4.91	1.58e-06	0.000595	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
KIRP	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	4.91	1.58e-06	0.000595	0.27	0.29	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
KIRP	cis	rs11098499	0.644	rs2389880	ENSG00000250412.1	KLHL2P1	4.91	1.58e-06	0.000595	0.36	0.29	Corneal astigmatism;	chr4:119638715	chr4:119334329~119378233:+
KIRP	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-4.91	1.58e-06	0.000595	-0.33	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
KIRP	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	4.91	1.58e-06	0.000596	0.23	0.29	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
KIRP	cis	rs7267979	1	rs2297497	ENSG00000274414.1	RP5-965G21.4	4.91	1.58e-06	0.000596	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25239007~25245229:-
KIRP	cis	rs728616	0.867	rs61860043	ENSG00000234382.2	RP11-40F6.1	-4.91	1.58e-06	0.000596	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs12414521	ENSG00000234382.2	RP11-40F6.1	-4.91	1.58e-06	0.000596	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:80233664~80245367:+
KIRP	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-4.91	1.58e-06	0.000596	-0.3	-0.29	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
KIRP	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	4.91	1.58e-06	0.000596	0.37	0.29	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
KIRP	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	4.91	1.58e-06	0.000597	0.38	0.29	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
KIRP	cis	rs308447	0.546	rs309355	ENSG00000224786.1	CETN4P	4.91	1.58e-06	0.000597	0.36	0.29	Perceived unattractiveness to mosquitoes;	chr4:122730874	chr4:122730548~122732193:-
KIRP	cis	rs8141529	0.732	rs2269577	ENSG00000226471.5	CTA-292E10.6	-4.91	1.58e-06	0.000597	-0.29	-0.29	Lymphocyte counts;	chr22:28800769	chr22:28800683~28848559:+
KIRP	cis	rs950169	0.8	rs34302901	ENSG00000254414.1	RP11-182J1.1	4.91	1.58e-06	0.000597	0.35	0.29	Schizophrenia;	chr15:84567712	chr15:84631898~84633987:-
KIRP	cis	rs3892630	0.588	rs2287881	ENSG00000267475.1	CTD-2538C1.2	4.91	1.59e-06	0.000598	0.36	0.29	Red blood cell traits;	chr19:32842249	chr19:32687089~32691750:-
KIRP	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-4.91	1.59e-06	0.000598	-0.22	-0.29	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
KIRP	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-4.91	1.59e-06	0.000598	-0.37	-0.29	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
KIRP	cis	rs728616	0.867	rs1983775	ENSG00000234382.2	RP11-40F6.1	-4.91	1.59e-06	0.000599	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs1983776	ENSG00000234382.2	RP11-40F6.1	-4.91	1.59e-06	0.000599	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:80233664~80245367:+
KIRP	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-4.91	1.59e-06	0.000599	-0.24	-0.29	Height;	chr2:46631182	chr2:46668870~46670778:+
KIRP	cis	rs712022	0.534	rs7395098	ENSG00000246225.5	RP11-17A1.3	-4.91	1.59e-06	6e-04	-0.34	-0.29	Dialysis-related mortality;	chr11:22856901	chr11:22829380~22945393:+
KIRP	cis	rs728616	0.867	rs55690691	ENSG00000234382.2	RP11-40F6.1	-4.91	1.59e-06	6e-04	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:80233664~80245367:+
KIRP	cis	rs79349575	0.756	rs4793605	ENSG00000270781.1	RP11-501C14.9	-4.91	1.59e-06	6e-04	-0.31	-0.29	Type 2 diabetes;	chr17:48958507	chr17:48899131~48899748:+
KIRP	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-4.91	1.59e-06	6e-04	-0.32	-0.29	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
KIRP	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-4.91	1.59e-06	6e-04	-0.36	-0.29	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
KIRP	cis	rs1400745	0.718	rs799681	ENSG00000258738.1	RP11-73E17.2	4.91	1.59e-06	0.000601	0.27	0.29	Monocyte count;	chr14:34881373	chr14:34874343~34876459:+
KIRP	cis	rs728616	0.867	rs61860041	ENSG00000234382.2	RP11-40F6.1	-4.91	1.6e-06	0.000601	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61860042	ENSG00000234382.2	RP11-40F6.1	-4.91	1.6e-06	0.000601	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs12415870	ENSG00000234382.2	RP11-40F6.1	-4.91	1.6e-06	0.000601	-0.43	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:80233664~80245367:+
KIRP	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	4.91	1.6e-06	0.000602	0.46	0.29	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
KIRP	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-4.91	1.6e-06	0.000602	-0.33	-0.29	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
KIRP	cis	rs6832769	1	rs1522111	ENSG00000272969.1	RP11-528I4.2	4.91	1.6e-06	0.000602	0.29	0.29	Personality dimensions;	chr4:55463396	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	4.91	1.6e-06	0.000602	0.29	0.29	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
KIRP	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	4.91	1.6e-06	0.000602	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
KIRP	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	4.91	1.6e-06	0.000602	0.29	0.29	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
KIRP	cis	rs964611	0.938	rs8026751	ENSG00000259488.2	RP11-154J22.1	-4.91	1.6e-06	0.000603	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48290648	chr15:48312353~48331856:-
KIRP	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-4.91	1.6e-06	0.000604	-0.39	-0.29	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
KIRP	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
KIRP	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	4.91	1.6e-06	0.000604	0.24	0.29	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
KIRP	cis	rs2904804	0.522	rs10904378	ENSG00000224251.5	RP11-499O7.7	4.91	1.61e-06	0.000604	0.3	0.29	Economic and political preferences (immigration/crime);	chr10:4945047	chr10:4995488~4997380:+
KIRP	cis	rs8037137	0.915	rs112770790	ENSG00000258725.1	PRC1-AS1	-4.91	1.61e-06	0.000605	-0.4	-0.29	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90964265	chr15:90966345~90988624:+
KIRP	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	4.91	1.61e-06	0.000605	0.28	0.29	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
KIRP	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-4.91	1.61e-06	0.000605	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
KIRP	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-4.91	1.61e-06	0.000605	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
KIRP	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-4.91	1.61e-06	0.000605	-0.3	-0.29	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
KIRP	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-4.91	1.61e-06	0.000605	-0.3	-0.29	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
KIRP	cis	rs11673344	0.542	rs826324	ENSG00000226686.6	LINC01535	4.91	1.61e-06	0.000606	0.36	0.29	Obesity-related traits;	chr19:37014343	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.542	rs2562585	ENSG00000226686.6	LINC01535	4.91	1.61e-06	0.000606	0.36	0.29	Obesity-related traits;	chr19:37018321	chr19:37251912~37265535:+
KIRP	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-4.91	1.61e-06	0.000606	-0.32	-0.29	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
KIRP	cis	rs2439831	1	rs689754	ENSG00000205771.5	CATSPER2P1	-4.91	1.61e-06	0.000606	-0.42	-0.29	Lung cancer in ever smokers;	chr15:43483697	chr15:43726918~43747094:-
KIRP	cis	rs8141529	0.732	rs11556025	ENSG00000226471.5	CTA-292E10.6	-4.91	1.61e-06	0.000606	-0.29	-0.29	Lymphocyte counts;	chr22:28772767	chr22:28800683~28848559:+
KIRP	cis	rs7672749	0.63	rs1463092	ENSG00000249973.2	CHCHD2P7	-4.91	1.61e-06	0.000607	-0.45	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87870466	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs8180317	ENSG00000249973.2	CHCHD2P7	-4.91	1.61e-06	0.000607	-0.45	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87870588	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.524	rs8180318	ENSG00000249973.2	CHCHD2P7	-4.91	1.61e-06	0.000607	-0.45	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87870614	chr4:87785920~87786371:-
KIRP	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	4.91	1.61e-06	0.000607	0.3	0.29	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
KIRP	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	4.91	1.61e-06	0.000607	0.3	0.29	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
KIRP	cis	rs755249	0.501	rs2455648	ENSG00000237624.1	OXCT2P1	4.91	1.61e-06	0.000607	0.41	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39514956~39516490:+
KIRP	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	4.91	1.61e-06	0.000607	0.36	0.29	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
KIRP	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	4.91	1.62e-06	0.000607	0.28	0.29	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	4.91	1.62e-06	0.000607	0.28	0.29	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	4.91	1.62e-06	0.000607	0.28	0.29	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
KIRP	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	4.91	1.62e-06	0.000607	0.24	0.29	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
KIRP	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-4.91	1.62e-06	0.000608	-0.29	-0.29	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
KIRP	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.91	1.62e-06	0.000608	0.44	0.29	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
KIRP	cis	rs1552244	0.81	rs35711405	ENSG00000180385.7	EMC3-AS1	4.91	1.62e-06	0.000608	0.29	0.29	Alzheimer's disease;	chr3:10075255	chr3:9986893~10006990:+
KIRP	cis	rs712039	0.687	rs11656455	ENSG00000276054.1	RP11-378E13.3	4.91	1.62e-06	0.000608	0.41	0.29	Tuberculosis;	chr17:37411798	chr17:37386886~37387926:+
KIRP	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-4.91	1.62e-06	0.000608	-0.33	-0.29	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
KIRP	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	4.91	1.62e-06	0.000608	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
KIRP	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	4.91	1.62e-06	0.000608	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
KIRP	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-4.91	1.62e-06	0.000609	-0.58	-0.29	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
KIRP	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-4.91	1.62e-06	0.000609	-0.37	-0.29	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
KIRP	cis	rs2043112	1	rs12515328	ENSG00000249911.1	LINC01265	4.91	1.62e-06	0.000609	0.34	0.29	Obesity-related traits;	chr5:39019448	chr5:38710367~38720273:-
KIRP	cis	rs728616	0.867	rs118134654	ENSG00000234382.2	RP11-40F6.1	-4.91	1.62e-06	0.000609	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:80233664~80245367:+
KIRP	cis	rs1185460	0.967	rs1784461	ENSG00000272186.1	RP11-110I1.13	-4.91	1.62e-06	0.00061	-0.29	-0.29	Coronary artery disease;	chr11:119067274	chr11:119067374~119067698:-
KIRP	cis	rs1185460	0.967	rs1784459	ENSG00000272186.1	RP11-110I1.13	-4.91	1.62e-06	0.00061	-0.29	-0.29	Coronary artery disease;	chr11:119067677	chr11:119067374~119067698:-
KIRP	cis	rs1185460	0.967	rs1786684	ENSG00000272186.1	RP11-110I1.13	-4.91	1.62e-06	0.00061	-0.29	-0.29	Coronary artery disease;	chr11:119067724	chr11:119067374~119067698:-
KIRP	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-4.91	1.62e-06	0.00061	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
KIRP	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-4.91	1.62e-06	0.00061	-0.32	-0.29	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
KIRP	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	4.91	1.62e-06	0.00061	0.43	0.29	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
KIRP	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	4.91	1.62e-06	0.00061	0.29	0.29	Height;	chr14:75044372	chr14:75011269~75012851:-
KIRP	cis	rs7267979	1	rs6132835	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.933	rs11699203	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.933	rs6138571	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.966	rs416745	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs448396	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs447722	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs422424	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs422844	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs401166	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25239007~25245229:-
KIRP	cis	rs7267979	1	rs404394	ENSG00000274414.1	RP5-965G21.4	-4.91	1.62e-06	0.00061	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25239007~25245229:-
KIRP	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.91	1.62e-06	0.00061	-0.27	-0.29	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
KIRP	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-4.91	1.63e-06	0.00061	-0.44	-0.29	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
KIRP	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-4.91	1.63e-06	0.00061	-0.37	-0.29	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
KIRP	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	4.91	1.63e-06	0.00061	0.27	0.29	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
KIRP	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	4.91	1.63e-06	0.00061	0.24	0.29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
KIRP	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	4.91	1.63e-06	0.000611	0.3	0.29	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-4.91	1.63e-06	0.000611	-0.3	-0.29	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
KIRP	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	4.91	1.63e-06	0.000611	0.29	0.29	Height;	chr14:75122492	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	4.91	1.63e-06	0.000611	0.29	0.29	Height;	chr14:75127136	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	4.91	1.63e-06	0.000611	0.29	0.29	Height;	chr14:75128243	chr14:75011269~75012851:-
KIRP	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-4.91	1.63e-06	0.000612	-0.3	-0.29	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-4.91	1.63e-06	0.000612	-0.3	-0.29	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
KIRP	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-4.91	1.63e-06	0.000612	-0.29	-0.29	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
KIRP	cis	rs4820539	0.902	rs737846	ENSG00000275635.1	U7	4.91	1.63e-06	0.000612	0.32	0.29	Bone mineral density;	chr22:23118482	chr22:23137805~23137864:-
KIRP	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-4.91	1.63e-06	0.000612	-0.22	-0.29	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
KIRP	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.91	1.63e-06	0.000613	0.27	0.29	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
KIRP	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	4.91	1.63e-06	0.000614	0.29	0.29	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
KIRP	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-4.91	1.64e-06	0.000614	-0.37	-0.29	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
KIRP	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	4.91	1.64e-06	0.000614	0.25	0.29	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
KIRP	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-4.91	1.64e-06	0.000614	-0.3	-0.29	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
KIRP	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-4.91	1.64e-06	0.000614	-0.54	-0.29	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
KIRP	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-4.91	1.64e-06	0.000614	-0.38	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
KIRP	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-4.91	1.64e-06	0.000614	-0.38	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
KIRP	cis	rs1005277	0.579	rs2474563	ENSG00000151963.4	RP11-775A3.1	-4.91	1.64e-06	0.000614	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:37883594~37884109:+
KIRP	cis	rs713477	0.967	rs6573029	ENSG00000258413.1	RP11-665C16.6	4.91	1.64e-06	0.000615	0.36	0.29	Pediatric bone mineral content (femoral neck);	chr14:55446832	chr14:55262767~55272075:-
KIRP	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-4.91	1.64e-06	0.000615	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
KIRP	cis	rs234043	1	rs234043	ENSG00000224426.1	SLC31A1P1	4.91	1.64e-06	0.000615	0.25	0.29	Renal cell carcinoma;	chr3:172595577	chr3:172603440~172604006:-
KIRP	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	4.91	1.64e-06	0.000616	0.23	0.29	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
KIRP	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	4.91	1.64e-06	0.000616	0.41	0.29	Height;	chr6:109581800	chr6:109382795~109383666:+
KIRP	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-4.9	1.64e-06	0.000616	-0.26	-0.29	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
KIRP	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-4.9	1.64e-06	0.000616	-0.3	-0.29	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-4.9	1.64e-06	0.000616	-0.3	-0.29	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
KIRP	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-4.9	1.64e-06	0.000616	-0.3	-0.29	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	4.9	1.65e-06	0.000617	0.3	0.29	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	4.9	1.65e-06	0.000617	0.3	0.29	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
KIRP	cis	rs1044826	0.642	rs9859864	ENSG00000178631.7	ACTG1P1	-4.9	1.65e-06	0.000617	-0.31	-0.29	Obesity-related traits;	chr3:139372377	chr3:139493809~139494937:+
KIRP	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	4.9	1.65e-06	0.000618	0.36	0.29	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
KIRP	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	4.9	1.65e-06	0.000618	0.3	0.29	Height;	chr4:55477426	chr4:55363971~55395847:-
KIRP	cis	rs2299587	0.901	rs7836639	ENSG00000254054.2	RP11-156K13.3	4.9	1.65e-06	0.000618	0.34	0.29	Economic and political preferences;	chr8:17952301	chr8:17905756~17907887:+
KIRP	cis	rs11158026	0.603	rs66769866	ENSG00000258413.1	RP11-665C16.6	-4.9	1.65e-06	0.000618	-0.37	-0.29	Parkinson's disease;	chr14:54979435	chr14:55262767~55272075:-
KIRP	cis	rs11158026	0.603	rs7151670	ENSG00000258413.1	RP11-665C16.6	-4.9	1.65e-06	0.000618	-0.37	-0.29	Parkinson's disease;	chr14:54986041	chr14:55262767~55272075:-
KIRP	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	4.9	1.65e-06	0.000618	0.3	0.29	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
KIRP	cis	rs7747960	0.706	rs9397510	ENSG00000226193.1	RP3-398G3.5	-4.9	1.65e-06	0.000618	-0.42	-0.29	Bipolar disorder;	chr6:152475930	chr6:152402398~152404966:+
KIRP	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	4.9	1.65e-06	0.000619	0.32	0.29	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
KIRP	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-4.9	1.65e-06	0.000619	-0.37	-0.29	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
KIRP	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	4.9	1.65e-06	0.000619	0.3	0.29	Height;	chr4:55533481	chr4:55363971~55395847:-
KIRP	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-4.9	1.65e-06	0.00062	-0.24	-0.29	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-4.9	1.65e-06	0.00062	-0.24	-0.29	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
KIRP	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	4.9	1.65e-06	0.00062	0.26	0.29	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
KIRP	cis	rs8005677	0.828	rs2295680	ENSG00000257285.4	RP11-298I3.1	-4.9	1.65e-06	0.00062	-0.27	-0.29	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:22929609~22955562:+
KIRP	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	4.9	1.65e-06	0.00062	0.25	0.29	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
KIRP	cis	rs6832769	1	rs6819660	ENSG00000272969.1	RP11-528I4.2	4.9	1.65e-06	0.00062	0.28	0.29	Personality dimensions;	chr4:55508410	chr4:55547112~55547889:+
KIRP	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-4.9	1.65e-06	0.00062	-0.38	-0.29	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
KIRP	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	4.9	1.65e-06	0.00062	0.32	0.29	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
KIRP	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	4.9	1.66e-06	0.000621	0.23	0.29	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	4.9	1.66e-06	0.000621	0.23	0.29	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
KIRP	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.9	1.66e-06	0.000621	-0.23	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
KIRP	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.9	1.66e-06	0.000621	-0.23	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
KIRP	cis	rs4356203	0.87	rs7925692	ENSG00000272034.1	SNORD14A	4.9	1.66e-06	0.000621	0.24	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17074654~17074744:-
KIRP	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-4.9	1.66e-06	0.000621	-0.37	-0.29	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
KIRP	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-4.9	1.66e-06	0.000621	-0.24	-0.29	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
KIRP	cis	rs2739330	0.828	rs5760102	ENSG00000206090.4	AP000350.7	4.9	1.66e-06	0.000621	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23939998~23942798:+
KIRP	cis	rs1552244	1	rs3895942	ENSG00000180385.7	EMC3-AS1	4.9	1.66e-06	0.000621	0.27	0.29	Alzheimer's disease;	chr3:10067061	chr3:9986893~10006990:+
KIRP	cis	rs728616	0.717	rs12412999	ENSG00000234382.2	RP11-40F6.1	-4.9	1.66e-06	0.000622	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:80233664~80245367:+
KIRP	cis	rs7747960	0.61	rs12194509	ENSG00000226193.1	RP3-398G3.5	-4.9	1.66e-06	0.000622	-0.48	-0.29	Bipolar disorder;	chr6:152505927	chr6:152402398~152404966:+
KIRP	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-4.9	1.66e-06	0.000622	-0.32	-0.29	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
KIRP	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.66e-06	0.000622	-0.33	-0.29	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.66e-06	0.000622	-0.33	-0.29	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.66e-06	0.000622	-0.33	-0.29	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.66e-06	0.000622	-0.33	-0.29	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-4.9	1.66e-06	0.000622	-0.33	-0.29	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
KIRP	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-4.9	1.66e-06	0.000623	-0.31	-0.29	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
KIRP	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-4.9	1.66e-06	0.000623	-0.26	-0.29	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
KIRP	cis	rs2904804	0.555	rs7067963	ENSG00000224251.5	RP11-499O7.7	4.9	1.66e-06	0.000623	0.29	0.29	Economic and political preferences (immigration/crime);	chr10:4947800	chr10:4995488~4997380:+
KIRP	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-4.9	1.66e-06	0.000623	-0.22	-0.29	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
KIRP	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-4.9	1.67e-06	0.000624	-0.25	-0.29	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
KIRP	cis	rs116095464	0.558	rs9654452	ENSG00000248925.1	CTD-2083E4.6	4.9	1.67e-06	0.000625	0.44	0.29	Breast cancer;	chr5:299446	chr5:269858~271516:-
KIRP	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-4.9	1.67e-06	0.000626	-0.31	-0.29	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
KIRP	cis	rs2075371	0.501	rs1646654	ENSG00000272941.1	RP11-134L10.1	4.9	1.67e-06	0.000626	0.3	0.29	Mean platelet volume;	chr7:134342795	chr7:135168403~135169547:+
KIRP	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	4.9	1.67e-06	0.000626	0.3	0.29	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	4.9	1.67e-06	0.000626	0.3	0.29	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
KIRP	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-4.9	1.67e-06	0.000627	-0.58	-0.29	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
KIRP	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-4.9	1.67e-06	0.000627	-0.58	-0.29	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
KIRP	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	4.9	1.68e-06	0.000628	0.39	0.29	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
KIRP	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-4.9	1.68e-06	0.000629	-0.38	-0.29	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-4.9	1.68e-06	0.000629	-0.38	-0.29	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
KIRP	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-4.9	1.68e-06	0.000629	-0.27	-0.29	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
KIRP	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.9	1.68e-06	0.000629	0.25	0.29	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
KIRP	cis	rs9595908	0.709	rs4942892	ENSG00000212293.1	SNORA16	-4.9	1.68e-06	0.000629	-0.27	-0.29	Body mass index;	chr13:32754269	chr13:32420390~32420516:-
KIRP	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
KIRP	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-4.9	1.68e-06	0.000629	-0.28	-0.29	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
KIRP	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-4.9	1.68e-06	0.000629	-0.31	-0.29	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
KIRP	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	4.9	1.68e-06	0.00063	0.29	0.29	Height;	chr14:75139089	chr14:75011269~75012851:-
KIRP	cis	rs6540731	0.782	rs10436962	ENSG00000229983.1	RP11-15I11.2	4.9	1.68e-06	0.00063	0.33	0.29	Intelligence (childhood);	chr1:212188280	chr1:212168207~212190259:+
KIRP	cis	rs1200821	0.641	rs11011162	ENSG00000151963.4	RP11-775A3.1	4.9	1.69e-06	0.000631	0.32	0.29	Hemostatic factors and hematological phenotypes;	chr10:37385555	chr10:37883594~37884109:+
KIRP	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	4.9	1.69e-06	0.000631	0.37	0.29	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
KIRP	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-4.9	1.69e-06	0.000631	-0.23	-0.29	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
KIRP	cis	rs9402743	0.632	rs6570028	ENSG00000231028.7	LINC00271	-4.9	1.69e-06	0.000631	-0.26	-0.29	Systemic lupus erythematosus;	chr6:135754784	chr6:135497801~135716055:+
KIRP	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000631	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000631	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000631	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000631	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
KIRP	cis	rs2299587	0.582	rs10112000	ENSG00000254054.2	RP11-156K13.3	4.9	1.69e-06	0.000631	0.34	0.29	Economic and political preferences;	chr8:18053160	chr8:17905756~17907887:+
KIRP	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-4.9	1.69e-06	0.000631	-0.42	-0.29	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
KIRP	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-4.9	1.69e-06	0.000632	-0.35	-0.29	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
KIRP	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000632	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-4.9	1.69e-06	0.000632	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
KIRP	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-4.9	1.69e-06	0.000632	-0.31	-0.29	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
KIRP	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-4.9	1.69e-06	0.000633	-0.37	-0.29	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
KIRP	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.9	1.69e-06	0.000633	0.28	0.29	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
KIRP	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	4.9	1.69e-06	0.000634	0.26	0.29	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
KIRP	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-4.9	1.69e-06	0.000634	-0.37	-0.29	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
KIRP	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	4.9	1.69e-06	0.000634	0.29	0.29	Height;	chr14:75077276	chr14:75011269~75012851:-
KIRP	cis	rs9532669	0.926	rs4942014	ENSG00000239827.7	SUGT1P3	-4.9	1.7e-06	0.000634	-0.33	-0.29	Cervical cancer;	chr13:40966366	chr13:40908159~40921774:-
KIRP	cis	rs703842	1	rs10747783	ENSG00000270039.1	RP11-571M6.17	-4.9	1.7e-06	0.000635	-0.27	-0.29	Multiple sclerosis;	chr12:57782831	chr12:57803838~57804415:+
KIRP	cis	rs703842	0.964	rs10431552	ENSG00000270039.1	RP11-571M6.17	-4.9	1.7e-06	0.000635	-0.27	-0.29	Multiple sclerosis;	chr12:57784365	chr12:57803838~57804415:+
KIRP	cis	rs7432375	0.966	rs7618871	ENSG00000261758.1	RP11-102M11.2	-4.9	1.7e-06	0.000635	-0.31	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136681578	chr3:136752630~136755780:+
KIRP	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	4.9	1.7e-06	0.000635	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
KIRP	cis	rs9925964	0.933	rs10871454	ENSG00000232748.3	RP11-196G11.6	4.9	1.7e-06	0.000635	0.35	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:31056460~31062803:+
KIRP	cis	rs9925964	0.933	rs12448321	ENSG00000232748.3	RP11-196G11.6	4.9	1.7e-06	0.000635	0.35	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:31056460~31062803:+
KIRP	cis	rs1799949	0.965	rs11080034	ENSG00000236383.6	LINC00854	-4.9	1.7e-06	0.000635	-0.22	-0.29	Menopause (age at onset);	chr17:43365646	chr17:43216941~43305976:-
KIRP	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-4.9	1.7e-06	0.000635	-0.33	-0.29	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
KIRP	cis	rs875971	0.545	rs1796219	ENSG00000236529.1	RP13-254B10.1	-4.9	1.7e-06	0.000636	-0.27	-0.29	Aortic root size;	chr7:66645977	chr7:65840212~65840596:+
KIRP	cis	rs6540731	0.782	rs12038888	ENSG00000229983.1	RP11-15I11.2	4.9	1.7e-06	0.000636	0.34	0.29	Intelligence (childhood);	chr1:212192711	chr1:212168207~212190259:+
KIRP	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	4.9	1.7e-06	0.000636	0.33	0.29	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
KIRP	cis	rs9959145	0.866	rs113413902	ENSG00000267108.1	RP11-861E21.1	4.9	1.71e-06	0.000637	0.47	0.29	Immune response to smallpox vaccine (IL-6);	chr18:12731558	chr18:12432897~12437635:+
KIRP	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-4.9	1.71e-06	0.000638	-0.27	-0.29	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
KIRP	cis	rs4639966	0.723	rs11217022	ENSG00000255239.1	AP002954.6	-4.9	1.71e-06	0.000638	-0.38	-0.29	Systemic lupus erythematosus;	chr11:118770897	chr11:118688039~118690600:-
KIRP	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-4.9	1.71e-06	0.000638	-0.25	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
KIRP	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-4.9	1.71e-06	0.000639	-0.31	-0.29	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
KIRP	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-4.9	1.71e-06	0.000639	-0.31	-0.29	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
KIRP	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-4.9	1.71e-06	0.000639	-0.31	-0.29	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
KIRP	cis	rs9595908	0.671	rs12428598	ENSG00000212293.1	SNORA16	4.9	1.71e-06	0.000639	0.27	0.29	Body mass index;	chr13:32684839	chr13:32420390~32420516:-
KIRP	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	4.9	1.71e-06	0.000639	0.34	0.29	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
KIRP	cis	rs9928842	1	rs9928842	ENSG00000280152.1	RP11-331F4.5	4.9	1.71e-06	0.000639	0.37	0.29	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75245994~75250077:-
KIRP	cis	rs73198271	0.74	rs67766414	ENSG00000253981.4	ALG1L13P	-4.9	1.71e-06	0.00064	-0.24	-0.29	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8236003~8244667:-
KIRP	cis	rs4639966	0.836	rs7943039	ENSG00000255239.1	AP002954.6	-4.9	1.71e-06	0.00064	-0.37	-0.29	Systemic lupus erythematosus;	chr11:118732321	chr11:118688039~118690600:-
KIRP	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-4.9	1.71e-06	0.00064	-0.25	-0.29	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
KIRP	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	4.9	1.71e-06	0.00064	0.19	0.29	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
KIRP	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-4.9	1.71e-06	0.00064	-0.37	-0.29	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
KIRP	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-4.9	1.72e-06	0.000641	-0.24	-0.29	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
KIRP	cis	rs1005277	0.579	rs2474584	ENSG00000151963.4	RP11-775A3.1	-4.9	1.72e-06	0.000641	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474586	ENSG00000151963.4	RP11-775A3.1	-4.9	1.72e-06	0.000641	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:37883594~37884109:+
KIRP	cis	rs9494145	0.652	rs9399137	ENSG00000232876.1	CTA-212D2.2	-4.9	1.72e-06	0.000641	-0.39	-0.29	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135097880	chr6:135055033~135060550:+
KIRP	cis	rs9494145	0.567	rs35786788	ENSG00000232876.1	CTA-212D2.2	-4.9	1.72e-06	0.000641	-0.39	-0.29	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135097904	chr6:135055033~135060550:+
KIRP	cis	rs9595908	0.746	rs9596076	ENSG00000212293.1	SNORA16	4.9	1.72e-06	0.000641	0.29	0.29	Body mass index;	chr13:32693515	chr13:32420390~32420516:-
KIRP	cis	rs12188164	0.515	rs11742006	ENSG00000221990.4	EXOC3-AS1	4.9	1.72e-06	0.000641	0.29	0.29	Cystic fibrosis severity;	chr5:408414	chr5:441498~443160:-
KIRP	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	4.9	1.72e-06	0.000641	0.28	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
KIRP	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	4.9	1.72e-06	0.000641	0.28	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
KIRP	cis	rs763121	0.853	rs2179142	ENSG00000273076.1	RP3-508I15.22	4.9	1.72e-06	0.000641	0.27	0.29	Menopause (age at onset);	chr22:38641949	chr22:38743495~38743910:+
KIRP	cis	rs4128705	1	rs12507399	ENSG00000249049.1	RP11-763F8.1	4.9	1.72e-06	0.000642	0.26	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91359698	chr4:91319034~91325306:-
KIRP	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-4.9	1.72e-06	0.000642	-0.3	-0.29	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
KIRP	cis	rs9987353	0.544	rs2929469	ENSG00000253893.2	FAM85B	-4.9	1.72e-06	0.000642	-0.38	-0.29	Recombination measurement;	chr8:9205146	chr8:8167819~8226614:-
KIRP	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	4.9	1.72e-06	0.000642	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
KIRP	cis	rs7176527	0.796	rs72630460	ENSG00000188388.10	GOLGA6L3	4.89	1.72e-06	0.000642	0.41	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84615425	chr15:85240472~85247170:+
KIRP	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.89	1.72e-06	0.000643	0.36	0.29	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
KIRP	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	4.89	1.72e-06	0.000643	0.32	0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
KIRP	cis	rs2625529	0.761	rs972029	ENSG00000260037.4	CTD-2524L6.3	-4.89	1.72e-06	0.000643	-0.25	-0.29	Red blood cell count;	chr15:71880645	chr15:71818396~71823384:+
KIRP	cis	rs950169	0.84	rs12905223	ENSG00000254414.1	RP11-182J1.1	4.89	1.72e-06	0.000643	0.35	0.29	Schizophrenia;	chr15:84571037	chr15:84631898~84633987:-
KIRP	cis	rs2273156	1	rs17102967	ENSG00000226677.3	IGBP1P1	-4.89	1.72e-06	0.000644	-0.32	-0.29	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011182	chr14:34939324~34940332:+
KIRP	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.89	1.72e-06	0.000644	0.46	0.29	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
KIRP	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	4.89	1.73e-06	0.000645	0.29	0.29	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
KIRP	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000645	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
KIRP	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	4.89	1.73e-06	0.000645	0.31	0.29	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
KIRP	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-4.89	1.73e-06	0.000645	-0.24	-0.29	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
KIRP	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.89	1.73e-06	0.000645	0.25	0.29	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
KIRP	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	4.89	1.73e-06	0.000646	0.6	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
KIRP	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-4.89	1.73e-06	0.000646	-0.37	-0.29	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
KIRP	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-4.89	1.73e-06	0.000646	-0.37	-0.29	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
KIRP	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-4.89	1.73e-06	0.000646	-0.37	-0.29	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
KIRP	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-4.89	1.73e-06	0.000646	-0.37	-0.29	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
KIRP	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-4.89	1.73e-06	0.000646	-0.54	-0.29	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
KIRP	cis	rs1858037	0.867	rs61226353	ENSG00000237979.1	AC007389.1	4.89	1.73e-06	0.000647	0.32	0.29	Rheumatoid arthritis;	chr2:65363637	chr2:65500993~65502138:-
KIRP	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	4.89	1.73e-06	0.000647	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
KIRP	cis	rs4631830	0.863	rs2611508	ENSG00000229927.2	RHEBP1	4.89	1.73e-06	0.000647	0.36	0.29	Prostate-specific antigen levels;	chr10:46077775	chr10:46634911~46635466:-
KIRP	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-4.89	1.73e-06	0.000647	-0.32	-0.29	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-4.89	1.73e-06	0.000647	-0.32	-0.29	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-4.89	1.73e-06	0.000647	-0.32	-0.29	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-4.89	1.73e-06	0.000647	-0.32	-0.29	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-4.89	1.73e-06	0.000647	-0.32	-0.29	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
KIRP	cis	rs1552244	0.938	rs66915020	ENSG00000180385.7	EMC3-AS1	4.89	1.74e-06	0.000647	0.27	0.29	Alzheimer's disease;	chr3:10068490	chr3:9986893~10006990:+
KIRP	cis	rs6834314	0.7	rs11929874	ENSG00000251411.1	RP11-397E7.4	-4.89	1.74e-06	0.000647	-0.24	-0.29	Liver enzyme levels (alanine transaminase);	chr4:87240948	chr4:86913266~86914817:-
KIRP	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	4.89	1.74e-06	0.000648	0.36	0.29	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
KIRP	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.89	1.74e-06	0.000648	0.25	0.29	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
KIRP	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	4.89	1.74e-06	0.000648	0.36	0.29	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
KIRP	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	4.89	1.74e-06	0.000649	0.34	0.29	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
KIRP	cis	rs2043112	0.728	rs11750346	ENSG00000249911.1	LINC01265	4.89	1.74e-06	0.000649	0.35	0.29	Obesity-related traits;	chr5:38968482	chr5:38710367~38720273:-
KIRP	cis	rs8081395	0.834	rs2665397	ENSG00000266992.1	DHX40P1	-4.89	1.74e-06	0.00065	-0.33	-0.29	White blood cell count;	chr17:59749370	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.804	rs2777884	ENSG00000266992.1	DHX40P1	-4.89	1.74e-06	0.00065	-0.33	-0.29	White blood cell count;	chr17:59753065	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.932	rs2777885	ENSG00000266992.1	DHX40P1	-4.89	1.74e-06	0.00065	-0.33	-0.29	White blood cell count;	chr17:59753112	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.866	rs2777899	ENSG00000266992.1	DHX40P1	-4.89	1.74e-06	0.00065	-0.33	-0.29	White blood cell count;	chr17:59755030	chr17:59976009~60002384:-
KIRP	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	4.89	1.74e-06	0.00065	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	4.89	1.74e-06	0.00065	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
KIRP	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-4.89	1.74e-06	0.00065	-0.54	-0.29	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
KIRP	cis	rs1665050	0.598	rs8041221	ENSG00000277144.1	RP11-59H7.4	-4.89	1.74e-06	0.00065	-0.29	-0.29	Atopic dermatitis;	chr15:59042609	chr15:59115547~59116089:-
KIRP	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-4.89	1.74e-06	0.00065	-0.37	-0.29	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
KIRP	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	4.89	1.74e-06	0.00065	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	4.89	1.74e-06	0.00065	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
KIRP	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	4.89	1.74e-06	0.00065	0.25	0.29	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
KIRP	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	4.89	1.74e-06	0.00065	0.27	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
KIRP	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-4.89	1.75e-06	0.000651	-0.27	-0.29	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-4.89	1.75e-06	0.000651	-0.27	-0.29	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
KIRP	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.89	1.75e-06	0.000651	-0.31	-0.29	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
KIRP	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	4.89	1.75e-06	0.000652	0.32	0.29	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	4.89	1.75e-06	0.000652	0.32	0.29	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
KIRP	cis	rs6832769	1	rs6851838	ENSG00000272969.1	RP11-528I4.2	-4.89	1.75e-06	0.000652	-0.28	-0.29	Personality dimensions;	chr4:55554580	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs10034433	ENSG00000272969.1	RP11-528I4.2	-4.89	1.75e-06	0.000652	-0.28	-0.29	Personality dimensions;	chr4:55555009	chr4:55547112~55547889:+
KIRP	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	4.89	1.75e-06	0.000652	0.33	0.29	Depression;	chr6:28428413	chr6:28176188~28176674:+
KIRP	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	4.89	1.75e-06	0.000652	0.33	0.29	Depression;	chr6:28431469	chr6:28176188~28176674:+
KIRP	cis	rs8141529	0.732	rs3788409	ENSG00000226471.5	CTA-292E10.6	-4.89	1.75e-06	0.000652	-0.29	-0.29	Lymphocyte counts;	chr22:28802163	chr22:28800683~28848559:+
KIRP	cis	rs7615952	0.599	rs12486459	ENSG00000241439.1	RP11-666A20.3	4.89	1.75e-06	0.000652	0.41	0.29	Blood pressure (smoking interaction);	chr3:126022622	chr3:125958556~125958817:+
KIRP	cis	rs7615952	0.599	rs67575510	ENSG00000241439.1	RP11-666A20.3	4.89	1.75e-06	0.000652	0.41	0.29	Blood pressure (smoking interaction);	chr3:126023512	chr3:125958556~125958817:+
KIRP	cis	rs7615952	0.599	rs60847438	ENSG00000241439.1	RP11-666A20.3	4.89	1.75e-06	0.000652	0.41	0.29	Blood pressure (smoking interaction);	chr3:126027162	chr3:125958556~125958817:+
KIRP	cis	rs42648	0.869	rs1015402	ENSG00000225498.1	AC002064.5	4.89	1.75e-06	0.000652	0.21	0.29	Homocysteine levels;	chr7:90283955	chr7:90312496~90322592:+
KIRP	cis	rs7267979	0.966	rs2261698	ENSG00000274414.1	RP5-965G21.4	-4.89	1.75e-06	0.000652	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25239007~25245229:-
KIRP	cis	rs964611	0.786	rs5020564	ENSG00000259488.2	RP11-154J22.1	-4.89	1.75e-06	0.000652	-0.31	-0.29	Metabolite levels (Pyroglutamine);	chr15:48372356	chr15:48312353~48331856:-
KIRP	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	4.89	1.75e-06	0.000652	0.37	0.29	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
KIRP	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	4.89	1.75e-06	0.000652	0.24	0.29	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
KIRP	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-4.89	1.75e-06	0.000653	-0.23	-0.29	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
KIRP	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-4.89	1.75e-06	0.000653	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.89	1.75e-06	0.000653	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
KIRP	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.89	1.75e-06	0.000653	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
KIRP	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-4.89	1.76e-06	0.000653	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
KIRP	cis	rs7569084	0.663	rs10190233	ENSG00000237979.1	AC007389.1	-4.89	1.76e-06	0.000653	-0.31	-0.29	Sum eosinophil basophil counts;	chr2:65413095	chr2:65500993~65502138:-
KIRP	cis	rs116095464	0.558	rs7708182	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:234673	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10058428	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:235493	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10036253	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:238404	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10076655	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:239349	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10057492	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:239388	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs28418643	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:240744	chr5:269858~271516:-
KIRP	cis	rs116095464	0.681	rs10060016	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:240985	chr5:269858~271516:-
KIRP	cis	rs116095464	0.614	rs62344339	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:252880	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs9687898	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:253837	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs9688045	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:253920	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs112343653	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:257059	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs73024831	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:257077	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6869925	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:263921	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6875291	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:264077	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6866776	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:264380	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs6874745	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:264412	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7715108	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:264546	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7730700	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:264598	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10057674	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:266698	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs1812843	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:267543	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs1971229	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:268072	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs12173244	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:269409	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs56127718	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:270158	chr5:269858~271516:-
KIRP	cis	rs116095464	0.614	rs10061564	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:271214	chr5:269858~271516:-
KIRP	cis	rs116095464	0.542	rs28650039	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:273839	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs59113266	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:279850	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs11959126	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:283765	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7356696	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:284136	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7356561	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:284266	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs59284383	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:284410	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs7731089	ENSG00000248925.1	CTD-2083E4.6	4.89	1.76e-06	0.000653	0.44	0.29	Breast cancer;	chr5:290307	chr5:269858~271516:-
KIRP	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	4.89	1.76e-06	0.000653	0.32	0.29	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
KIRP	cis	rs911119	0.913	rs2405392	ENSG00000270001.1	RP11-218C14.8	-4.89	1.76e-06	0.000653	-0.33	-0.29	Chronic kidney disease;	chr20:23588549	chr20:23631826~23632316:-
KIRP	cis	rs42648	0.869	rs42617	ENSG00000225498.1	AC002064.5	4.89	1.76e-06	0.000654	0.21	0.29	Homocysteine levels;	chr7:90322732	chr7:90312496~90322592:+
KIRP	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	4.89	1.76e-06	0.000654	0.37	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
KIRP	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28082231	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28082261	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28082984	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28083994	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28084025	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	4.89	1.76e-06	0.000654	0.34	0.29	Depression;	chr6:28085319	chr6:28073316~28074233:+
KIRP	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	4.89	1.76e-06	0.000656	0.28	0.29	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
KIRP	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	4.89	1.76e-06	0.000656	0.28	0.29	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
KIRP	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	4.89	1.77e-06	0.000656	0.23	0.29	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
KIRP	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	4.89	1.77e-06	0.000656	0.3	0.29	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
KIRP	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	4.89	1.77e-06	0.000657	0.33	0.29	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
KIRP	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-4.89	1.77e-06	0.000657	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-4.89	1.77e-06	0.000657	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-4.89	1.77e-06	0.000657	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-4.89	1.77e-06	0.000657	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
KIRP	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-4.89	1.77e-06	0.000657	-0.24	-0.29	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
KIRP	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	4.89	1.77e-06	0.000658	0.23	0.29	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	4.89	1.77e-06	0.000658	0.23	0.29	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
KIRP	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	4.89	1.77e-06	0.000658	0.29	0.29	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
KIRP	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	4.89	1.77e-06	0.000658	0.23	0.29	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
KIRP	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	4.89	1.77e-06	0.000658	0.21	0.29	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
KIRP	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-4.89	1.77e-06	0.000658	-0.37	-0.29	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
KIRP	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-4.89	1.77e-06	0.000658	-0.37	-0.29	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
KIRP	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-4.89	1.77e-06	0.000658	-0.37	-0.29	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
KIRP	cis	rs962856	0.891	rs638190	ENSG00000236780.4	AC078941.1	4.89	1.77e-06	0.000658	0.35	0.29	Pancreatic cancer;	chr2:67434958	chr2:67123357~67215319:-
KIRP	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	4.89	1.77e-06	0.000659	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
KIRP	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-4.89	1.77e-06	0.000659	-0.32	-0.29	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
KIRP	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.89	1.77e-06	0.000659	0.26	0.29	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
KIRP	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-4.89	1.78e-06	0.00066	-0.35	-0.29	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
KIRP	cis	rs7772486	0.875	rs2814866	ENSG00000270638.1	RP3-466P17.1	4.89	1.78e-06	0.000661	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs2328712	ENSG00000270638.1	RP3-466P17.1	4.89	1.78e-06	0.000661	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145735570~145737218:+
KIRP	cis	rs7267979	0.789	rs62213729	ENSG00000274973.1	RP13-401N8.7	4.89	1.78e-06	0.000661	0.31	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25845497~25845862:+
KIRP	cis	rs8049040	0.524	rs12445377	ENSG00000260886.1	TAT-AS1	4.89	1.78e-06	0.000661	0.38	0.29	Blood protein levels;	chr16:71394698	chr16:71565789~71578187:+
KIRP	cis	rs8049040	0.524	rs12445403	ENSG00000260886.1	TAT-AS1	4.89	1.78e-06	0.000661	0.38	0.29	Blood protein levels;	chr16:71394767	chr16:71565789~71578187:+
KIRP	cis	rs1044826	0.619	rs57357132	ENSG00000178631.7	ACTG1P1	-4.89	1.78e-06	0.000661	-0.31	-0.29	Obesity-related traits;	chr3:139399516	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs4607068	ENSG00000178631.7	ACTG1P1	4.89	1.78e-06	0.000661	0.31	0.29	Obesity-related traits;	chr3:139444152	chr3:139493809~139494937:+
KIRP	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	4.89	1.78e-06	0.000661	0.24	0.29	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
KIRP	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	4.89	1.78e-06	0.000662	0.38	0.29	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
KIRP	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-4.89	1.78e-06	0.000662	-0.24	-0.29	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
KIRP	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-4.89	1.78e-06	0.000662	-0.28	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
KIRP	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	4.89	1.78e-06	0.000663	0.29	0.29	Height;	chr14:74990535	chr14:75011269~75012851:-
KIRP	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-4.89	1.79e-06	0.000663	-0.26	-0.29	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
KIRP	cis	rs11673344	0.523	rs2385415	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37035291	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.562	rs6510580	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37038452	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs2082009	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37039834	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs7246739	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37040829	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs7260488	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37058883	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs8110158	ENSG00000226686.6	LINC01535	4.89	1.79e-06	0.000663	0.35	0.29	Obesity-related traits;	chr19:37063491	chr19:37251912~37265535:+
KIRP	cis	rs2562456	0.917	rs2562468	ENSG00000268555.1	RP11-678G14.3	-4.89	1.79e-06	0.000663	-0.39	-0.29	Pain;	chr19:21532048	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.917	rs2562471	ENSG00000268555.1	RP11-678G14.3	-4.89	1.79e-06	0.000663	-0.39	-0.29	Pain;	chr19:21533017	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.917	rs2681377	ENSG00000268555.1	RP11-678G14.3	-4.89	1.79e-06	0.000663	-0.39	-0.29	Pain;	chr19:21533718	chr19:21570822~21587322:-
KIRP	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	4.89	1.79e-06	0.000663	0.51	0.29	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
KIRP	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-4.89	1.79e-06	0.000663	-0.42	-0.29	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
KIRP	cis	rs2617170	0.713	rs11053803	ENSG00000245648.1	RP11-277P12.20	-4.89	1.79e-06	0.000663	-0.33	-0.29	Behcet's disease;	chr12:10447063	chr12:10363769~10398506:+
KIRP	cis	rs664154	0.522	rs2743000	ENSG00000228412.5	RP4-625H18.2	-4.89	1.79e-06	0.000663	-0.28	-0.29	Information processing speed;	chr6:19094211	chr6:19802164~19804752:-
KIRP	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	4.89	1.79e-06	0.000664	0.21	0.29	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
KIRP	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	4.89	1.79e-06	0.000664	0.36	0.29	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
KIRP	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	4.89	1.79e-06	0.000664	0.42	0.29	Height;	chr6:109339681	chr6:109382795~109383666:+
KIRP	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-4.89	1.79e-06	0.000664	-0.48	-0.29	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
KIRP	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.89	1.79e-06	0.000664	-0.37	-0.29	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
KIRP	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	4.89	1.79e-06	0.000664	0.37	0.29	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
KIRP	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-4.89	1.79e-06	0.000664	-0.42	-0.29	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
KIRP	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-4.89	1.79e-06	0.000664	-0.42	-0.29	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
KIRP	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	4.89	1.79e-06	0.000665	0.3	0.29	Height;	chr4:55562653	chr4:55363971~55395847:-
KIRP	cis	rs875971	0.545	rs73146609	ENSG00000236529.1	RP13-254B10.1	4.89	1.79e-06	0.000665	0.27	0.29	Aortic root size;	chr7:66302477	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs2173571	ENSG00000236529.1	RP13-254B10.1	4.89	1.79e-06	0.000665	0.27	0.29	Aortic root size;	chr7:66305392	chr7:65840212~65840596:+
KIRP	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	4.89	1.79e-06	0.000666	0.32	0.29	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
KIRP	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-4.89	1.79e-06	0.000666	-0.29	-0.29	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
KIRP	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-4.89	1.8e-06	0.000666	-0.37	-0.29	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
KIRP	cis	rs8081395	0.899	rs2777898	ENSG00000266992.1	DHX40P1	-4.89	1.8e-06	0.000666	-0.33	-0.29	White blood cell count;	chr17:59738247	chr17:59976009~60002384:-
KIRP	cis	rs8081395	0.899	rs8070345	ENSG00000266992.1	DHX40P1	-4.89	1.8e-06	0.000666	-0.33	-0.29	White blood cell count;	chr17:59739396	chr17:59976009~60002384:-
KIRP	cis	rs17597773	0.527	rs2484698	ENSG00000238078.1	LINC01352	4.89	1.8e-06	0.000666	0.33	0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220829255~220832429:+
KIRP	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	4.89	1.8e-06	0.000667	0.23	0.29	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
KIRP	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	4.89	1.8e-06	0.000667	0.32	0.29	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	4.89	1.8e-06	0.000667	0.32	0.29	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
KIRP	cis	rs964611	0.882	rs4775747	ENSG00000259488.2	RP11-154J22.1	-4.89	1.8e-06	0.000667	-0.26	-0.29	Metabolite levels (Pyroglutamine);	chr15:48346146	chr15:48312353~48331856:-
KIRP	cis	rs2504916	0.712	rs2450977	ENSG00000230234.1	RP1-276N6.2	-4.89	1.8e-06	0.000667	-0.31	-0.29	Response to hepatitis C treatment;	chr6:160292816	chr6:160272617~160276130:+
KIRP	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	4.89	1.8e-06	0.000667	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
KIRP	cis	rs2562456	0.755	rs2562421	ENSG00000268555.1	RP11-678G14.3	-4.89	1.8e-06	0.000668	-0.39	-0.29	Pain;	chr19:21448502	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.793	rs2562420	ENSG00000268555.1	RP11-678G14.3	-4.89	1.8e-06	0.000668	-0.39	-0.29	Pain;	chr19:21448503	chr19:21570822~21587322:-
KIRP	cis	rs9595908	0.709	rs7318510	ENSG00000212293.1	SNORA16	4.89	1.8e-06	0.000668	0.27	0.29	Body mass index;	chr13:32752122	chr13:32420390~32420516:-
KIRP	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-4.88	1.8e-06	0.000669	-0.37	-0.29	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
KIRP	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-4.88	1.8e-06	0.000669	-0.4	-0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
KIRP	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-4.88	1.81e-06	0.000669	-0.36	-0.29	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
KIRP	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	4.88	1.81e-06	0.000669	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
KIRP	cis	rs1044826	0.619	rs6439856	ENSG00000178631.7	ACTG1P1	-4.88	1.81e-06	0.00067	-0.31	-0.29	Obesity-related traits;	chr3:139416026	chr3:139493809~139494937:+
KIRP	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-4.88	1.81e-06	0.00067	-0.29	-0.29	Height;	chr14:74990372	chr14:75011269~75012851:-
KIRP	cis	rs886774	0.932	rs2007425	ENSG00000273055.1	CTB-13F3.1	-4.88	1.81e-06	0.00067	-0.18	-0.29	Ulcerative colitis;	chr7:107859685	chr7:107942116~107942740:+
KIRP	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	4.88	1.81e-06	0.000671	0.43	0.29	Height;	chr6:109427303	chr6:109382795~109383666:+
KIRP	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-4.88	1.81e-06	0.000671	-0.29	-0.29	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
KIRP	cis	rs72634501	0.568	rs6679564	ENSG00000237624.1	OXCT2P1	-4.88	1.81e-06	0.000671	-0.37	-0.29	HDL cholesterol;	chr1:39151408	chr1:39514956~39516490:+
KIRP	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-4.88	1.81e-06	0.000672	-0.29	-0.29	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
KIRP	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	4.88	1.81e-06	0.000672	0.28	0.29	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
KIRP	cis	rs116095464	0.558	rs7713524	ENSG00000248925.1	CTD-2083E4.6	-4.88	1.82e-06	0.000673	-0.44	-0.29	Breast cancer;	chr5:276085	chr5:269858~271516:-
KIRP	cis	rs9926296	0.585	rs8058009	ENSG00000260259.1	RP11-368I7.4	-4.88	1.82e-06	0.000673	-0.22	-0.29	Vitiligo;	chr16:89790031	chr16:89682620~89686569:-
KIRP	cis	rs11700536	1	rs4919965	ENSG00000236663.1	AP001631.9	-4.88	1.82e-06	0.000673	-0.3	-0.29	Interleukin-18 levels;	chr21:43137961	chr21:43140523~43141092:-
KIRP	cis	rs2075371	0.501	rs1646653	ENSG00000272941.1	RP11-134L10.1	4.88	1.82e-06	0.000673	0.3	0.29	Mean platelet volume;	chr7:134339934	chr7:135168403~135169547:+
KIRP	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	4.88	1.82e-06	0.000673	0.29	0.29	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
KIRP	cis	rs77741769	0.571	rs11065292	ENSG00000277423.1	RP11-173P15.9	-4.88	1.82e-06	0.000673	-0.31	-0.29	Mean corpuscular volume;	chr12:120851352	chr12:120703867~120704282:+
KIRP	cis	rs2043112	0.965	rs7724222	ENSG00000249911.1	LINC01265	4.88	1.82e-06	0.000674	0.33	0.29	Obesity-related traits;	chr5:38931211	chr5:38710367~38720273:-
KIRP	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	4.88	1.82e-06	0.000674	0.44	0.29	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
KIRP	cis	rs962856	0.964	rs600388	ENSG00000236780.4	AC078941.1	4.88	1.82e-06	0.000674	0.35	0.29	Pancreatic cancer;	chr2:67429677	chr2:67123357~67215319:-
KIRP	cis	rs9595908	0.693	rs4942911	ENSG00000212293.1	SNORA16	4.88	1.82e-06	0.000675	0.29	0.29	Body mass index;	chr13:32793038	chr13:32420390~32420516:-
KIRP	cis	rs7829975	0.846	rs11779061	ENSG00000253981.4	ALG1L13P	-4.88	1.82e-06	0.000675	-0.22	-0.29	Mood instability;	chr8:8691922	chr8:8236003~8244667:-
KIRP	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-4.88	1.82e-06	0.000675	-0.36	-0.29	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
KIRP	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-4.88	1.82e-06	0.000675	-0.54	-0.29	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
KIRP	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	4.88	1.82e-06	0.000676	0.33	0.29	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
KIRP	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	4.88	1.82e-06	0.000676	0.3	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
KIRP	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	4.88	1.83e-06	0.000676	0.29	0.29	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
KIRP	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	4.88	1.83e-06	0.000676	0.37	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
KIRP	cis	rs42648	0.693	rs3747800	ENSG00000225498.1	AC002064.5	4.88	1.83e-06	0.000676	0.2	0.29	Homocysteine levels;	chr7:90270174	chr7:90312496~90322592:+
KIRP	cis	rs8030379	0.967	rs2401171	ENSG00000230373.7	GOLGA6L5P	-4.88	1.83e-06	0.000677	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83888924	chr15:84507885~84516814:-
KIRP	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-4.88	1.83e-06	0.000677	-0.38	-0.29	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
KIRP	cis	rs1552244	0.938	rs34750074	ENSG00000180385.7	EMC3-AS1	4.88	1.83e-06	0.000677	0.29	0.29	Alzheimer's disease;	chr3:10050056	chr3:9986893~10006990:+
KIRP	cis	rs116095464	0.558	rs62344345	ENSG00000248925.1	CTD-2083E4.6	4.88	1.83e-06	0.000677	0.44	0.29	Breast cancer;	chr5:257305	chr5:269858~271516:-
KIRP	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-4.88	1.83e-06	0.000677	-0.22	-0.29	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
KIRP	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	4.88	1.83e-06	0.000678	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
KIRP	cis	rs2562456	0.876	rs11085468	ENSG00000268555.1	RP11-678G14.3	4.88	1.83e-06	0.000678	0.4	0.29	Pain;	chr19:21569087	chr19:21570822~21587322:-
KIRP	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	4.88	1.83e-06	0.000678	0.25	0.29	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
KIRP	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	4.88	1.83e-06	0.000678	0.23	0.29	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
KIRP	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	4.88	1.83e-06	0.000678	0.25	0.29	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
KIRP	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	4.88	1.83e-06	0.000678	0.44	0.29	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
KIRP	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	4.88	1.83e-06	0.000678	0.44	0.29	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
KIRP	cis	rs9388451	0.807	rs1269175	ENSG00000237742.5	RP11-624M8.1	4.88	1.83e-06	0.000679	0.31	0.29	Brugada syndrome;	chr6:125719289	chr6:125578558~125749190:-
KIRP	cis	rs1858037	0.836	rs1396209	ENSG00000237979.1	AC007389.1	4.88	1.84e-06	0.00068	0.33	0.29	Rheumatoid arthritis;	chr2:65374100	chr2:65500993~65502138:-
KIRP	cis	rs1858037	0.867	rs2118305	ENSG00000237979.1	AC007389.1	4.88	1.84e-06	0.00068	0.33	0.29	Rheumatoid arthritis;	chr2:65378086	chr2:65500993~65502138:-
KIRP	cis	rs1858037	0.836	rs17475335	ENSG00000237979.1	AC007389.1	4.88	1.84e-06	0.00068	0.33	0.29	Rheumatoid arthritis;	chr2:65378646	chr2:65500993~65502138:-
KIRP	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.88	1.84e-06	0.00068	-0.33	-0.29	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
KIRP	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.88	1.84e-06	0.00068	-0.33	-0.29	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
KIRP	cis	rs7747960	0.706	rs9478332	ENSG00000226193.1	RP3-398G3.5	-4.88	1.84e-06	0.00068	-0.41	-0.29	Bipolar disorder;	chr6:152475105	chr6:152402398~152404966:+
KIRP	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-4.88	1.84e-06	0.00068	-0.3	-0.29	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
KIRP	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-4.88	1.84e-06	0.00068	-0.31	-0.29	Height;	chr3:52936861	chr3:53064283~53065091:-
KIRP	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-4.88	1.84e-06	0.00068	-0.31	-0.29	Height;	chr3:52938846	chr3:53064283~53065091:-
KIRP	cis	rs1005277	0.579	rs176880	ENSG00000151963.4	RP11-775A3.1	4.88	1.84e-06	0.00068	0.34	0.29	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:37883594~37884109:+
KIRP	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-4.88	1.84e-06	0.00068	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
KIRP	cis	rs7508	0.512	rs2283109	ENSG00000254054.2	RP11-156K13.3	4.88	1.84e-06	0.000681	0.33	0.29	Atrial fibrillation;	chr8:18021063	chr8:17905756~17907887:+
KIRP	cis	rs7508	0.512	rs2283114	ENSG00000254054.2	RP11-156K13.3	4.88	1.84e-06	0.000681	0.33	0.29	Atrial fibrillation;	chr8:18022751	chr8:17905756~17907887:+
KIRP	cis	rs7508	0.512	rs3886398	ENSG00000254054.2	RP11-156K13.3	4.88	1.84e-06	0.000681	0.33	0.29	Atrial fibrillation;	chr8:18023107	chr8:17905756~17907887:+
KIRP	cis	rs2299587	0.841	rs17514812	ENSG00000254054.2	RP11-156K13.3	4.88	1.84e-06	0.000681	0.33	0.29	Economic and political preferences;	chr8:18023360	chr8:17905756~17907887:+
KIRP	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	4.88	1.84e-06	0.000681	0.23	0.29	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	4.88	1.84e-06	0.000681	0.23	0.29	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	4.88	1.84e-06	0.000681	0.23	0.29	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	4.88	1.84e-06	0.000681	0.23	0.29	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
KIRP	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-4.88	1.84e-06	0.000681	-0.21	-0.29	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
KIRP	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.88	1.84e-06	0.000681	0.23	0.29	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
KIRP	cis	rs1185460	0.967	rs1786685	ENSG00000272186.1	RP11-110I1.13	-4.88	1.84e-06	0.000681	-0.29	-0.29	Coronary artery disease;	chr11:119068246	chr11:119067374~119067698:-
KIRP	cis	rs1185460	0.967	rs1784302	ENSG00000272186.1	RP11-110I1.13	-4.88	1.84e-06	0.000681	-0.29	-0.29	Coronary artery disease;	chr11:119070247	chr11:119067374~119067698:-
KIRP	cis	rs11673344	0.543	rs1818748	ENSG00000226686.6	LINC01535	4.88	1.84e-06	0.000682	0.35	0.29	Obesity-related traits;	chr19:37065416	chr19:37251912~37265535:+
KIRP	cis	rs964611	0.938	rs7174204	ENSG00000259488.2	RP11-154J22.1	-4.88	1.84e-06	0.000682	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48286949	chr15:48312353~48331856:-
KIRP	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	4.88	1.84e-06	0.000682	0.38	0.29	Height;	chr6:109415411	chr6:109382795~109383666:+
KIRP	cis	rs4128705	1	rs12507382	ENSG00000249049.1	RP11-763F8.1	4.88	1.84e-06	0.000682	0.26	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91359782	chr4:91319034~91325306:-
KIRP	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	4.88	1.85e-06	0.000682	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-4.88	1.85e-06	0.000683	-0.34	-0.29	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
KIRP	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-4.88	1.85e-06	0.000683	-0.29	-0.29	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
KIRP	cis	rs9305354	1	rs10446078	ENSG00000232079.5	AL035610.1	4.88	1.85e-06	0.000683	0.39	0.29	Urinary albumin excretion;	chr21:28104850	chr21:28048404~28137611:+
KIRP	cis	rs10760158	0.62	rs10739596	ENSG00000226752.6	PSMD5-AS1	-4.88	1.85e-06	0.000683	-0.34	-0.29	Pulse pressure;	chr9:121327845	chr9:120824828~120854385:+
KIRP	cis	rs79040073	0.607	rs10519227	ENSG00000259531.2	RP11-295H24.3	4.88	1.85e-06	0.000683	0.37	0.29	Lung cancer in ever smokers;	chr15:49454167	chr15:49365124~49366685:-
KIRP	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-4.88	1.85e-06	0.000683	-0.29	-0.29	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
KIRP	cis	rs6832769	1	rs11726609	ENSG00000272969.1	RP11-528I4.2	4.88	1.85e-06	0.000684	0.3	0.29	Personality dimensions;	chr4:55534702	chr4:55547112~55547889:+
KIRP	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	4.88	1.85e-06	0.000684	0.36	0.29	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	4.88	1.85e-06	0.000684	0.36	0.29	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	4.88	1.85e-06	0.000684	0.36	0.29	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
KIRP	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	4.88	1.85e-06	0.000684	0.23	0.29	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
KIRP	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-4.88	1.85e-06	0.000684	-0.29	-0.29	Height;	chr14:75056679	chr14:75011269~75012851:-
KIRP	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	4.88	1.85e-06	0.000684	0.27	0.29	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	4.88	1.85e-06	0.000684	0.28	0.29	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	4.88	1.85e-06	0.000684	0.28	0.29	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
KIRP	cis	rs308403	0.64	rs13110096	ENSG00000224786.1	CETN4P	4.88	1.85e-06	0.000684	0.43	0.29	Blood protein levels;	chr4:122712777	chr4:122730548~122732193:-
KIRP	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-4.88	1.85e-06	0.000685	-0.37	-0.29	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
KIRP	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-4.88	1.85e-06	0.000685	-0.37	-0.29	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
KIRP	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-4.88	1.85e-06	0.000685	-0.37	-0.29	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
KIRP	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-4.88	1.85e-06	0.000685	-0.37	-0.29	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
KIRP	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-4.88	1.85e-06	0.000685	-0.37	-0.29	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
KIRP	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	4.88	1.85e-06	0.000685	0.31	0.29	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
KIRP	cis	rs6005807	0.543	rs2294431	ENSG00000226471.5	CTA-292E10.6	-4.88	1.85e-06	0.000685	-0.44	-0.29	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28781212	chr22:28800683~28848559:+
KIRP	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	4.88	1.86e-06	0.000685	0.28	0.29	Height;	chr4:55508982	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	4.88	1.86e-06	0.000685	0.28	0.29	Height;	chr4:55509442	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	4.88	1.86e-06	0.000685	0.28	0.29	Height;	chr4:55510177	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	4.88	1.86e-06	0.000685	0.28	0.29	Height;	chr4:55542243	chr4:55547112~55547889:+
KIRP	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	4.88	1.86e-06	0.000685	0.43	0.29	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	4.88	1.86e-06	0.000685	0.43	0.29	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	4.88	1.86e-06	0.000685	0.43	0.29	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
KIRP	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-4.88	1.86e-06	0.000686	-0.25	-0.29	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-4.88	1.86e-06	0.000686	-0.25	-0.29	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-4.88	1.86e-06	0.000686	-0.25	-0.29	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
KIRP	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	4.88	1.86e-06	0.000687	0.23	0.29	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
KIRP	cis	rs728616	0.614	rs61860413	ENSG00000234382.2	RP11-40F6.1	-4.88	1.86e-06	0.000687	-0.33	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs61860414	ENSG00000234382.2	RP11-40F6.1	-4.88	1.86e-06	0.000687	-0.33	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:80233664~80245367:+
KIRP	cis	rs6480314	0.522	rs61854800	ENSG00000233590.1	RP11-153K11.3	-4.88	1.86e-06	0.000687	-0.48	-0.29	Optic nerve measurement (disc area);	chr10:68248271	chr10:68233251~68242379:-
KIRP	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	4.88	1.86e-06	0.000688	0.34	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
KIRP	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	4.88	1.86e-06	0.000688	0.43	0.29	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
KIRP	cis	rs7674212	0.541	rs2045746	ENSG00000230069.3	LRRC37A15P	4.88	1.86e-06	0.000688	0.27	0.29	Type 2 diabetes;	chr4:103162421	chr4:102727274~102730721:-
KIRP	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	4.88	1.87e-06	0.000689	0.3	0.29	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
KIRP	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-4.88	1.87e-06	0.000689	-0.44	-0.29	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
KIRP	cis	rs8027181	0.583	rs11072384	ENSG00000260037.4	CTD-2524L6.3	4.88	1.87e-06	0.000689	0.24	0.29	Triglyceride levels;	chr15:72708973	chr15:71818396~71823384:+
KIRP	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	4.88	1.87e-06	0.00069	0.25	0.29	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	4.88	1.87e-06	0.00069	0.25	0.29	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
KIRP	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	4.88	1.87e-06	0.000691	0.35	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
KIRP	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	4.88	1.87e-06	0.000691	0.36	0.29	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
KIRP	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	4.88	1.87e-06	0.000691	0.23	0.29	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
KIRP	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	4.88	1.87e-06	0.000691	0.23	0.29	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
KIRP	cis	rs9595908	0.746	rs17516171	ENSG00000212293.1	SNORA16	4.88	1.87e-06	0.000691	0.29	0.29	Body mass index;	chr13:32694914	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.746	rs3848087	ENSG00000212293.1	SNORA16	4.88	1.87e-06	0.000691	0.29	0.29	Body mass index;	chr13:32697637	chr13:32420390~32420516:-
KIRP	cis	rs66486766	1	rs66486766	ENSG00000275120.1	RP11-182J1.17	4.88	1.87e-06	0.000691	0.41	0.29	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84599434~84606463:-
KIRP	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.88	1.87e-06	0.000691	0.47	0.29	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
KIRP	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	4.88	1.87e-06	0.000691	0.47	0.29	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
KIRP	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-4.88	1.87e-06	0.000691	-0.31	-0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	4.88	1.87e-06	0.000691	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	4.88	1.87e-06	0.000691	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	4.88	1.87e-06	0.000691	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	4.88	1.87e-06	0.000691	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
KIRP	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.88	1.88e-06	0.000692	0.34	0.29	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
KIRP	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	4.88	1.88e-06	0.000693	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
KIRP	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-4.88	1.88e-06	0.000693	-0.35	-0.29	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
KIRP	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-4.88	1.88e-06	0.000694	-0.33	-0.29	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
KIRP	cis	rs947583	0.517	rs6570039	ENSG00000231028.7	LINC00271	-4.88	1.88e-06	0.000694	-0.25	-0.29	Phosphorus levels;	chr6:135775602	chr6:135497801~135716055:+
KIRP	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-4.88	1.88e-06	0.000694	-0.19	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
KIRP	cis	rs12449964	0.515	rs7225141	ENSG00000223979.2	SMCR2	4.88	1.88e-06	0.000694	0.28	0.29	Coronary artery disease or ischemic stroke;	chr17:17667513	chr17:17674026~17677688:-
KIRP	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-4.88	1.88e-06	0.000694	-0.3	-0.29	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
KIRP	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	4.88	1.88e-06	0.000694	0.58	0.29	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	4.88	1.88e-06	0.000694	0.58	0.29	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
KIRP	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	4.88	1.88e-06	0.000695	0.36	0.29	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
KIRP	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	4.88	1.88e-06	0.000695	0.36	0.29	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	4.88	1.88e-06	0.000695	0.36	0.29	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	4.88	1.88e-06	0.000695	0.36	0.29	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
KIRP	cis	rs8037137	0.915	rs79253100	ENSG00000258725.1	PRC1-AS1	-4.88	1.88e-06	0.000695	-0.4	-0.29	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91008646	chr15:90966345~90988624:+
KIRP	cis	rs42648	0.869	rs42611	ENSG00000225498.1	AC002064.5	4.88	1.88e-06	0.000695	0.21	0.29	Homocysteine levels;	chr7:90320746	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.869	rs42613	ENSG00000225498.1	AC002064.5	4.88	1.89e-06	0.000695	0.21	0.29	Homocysteine levels;	chr7:90320989	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.837	rs42615	ENSG00000225498.1	AC002064.5	4.88	1.89e-06	0.000695	0.21	0.29	Homocysteine levels;	chr7:90321187	chr7:90312496~90322592:+
KIRP	cis	rs308403	0.568	rs309344	ENSG00000224786.1	CETN4P	4.88	1.89e-06	0.000695	0.4	0.29	Blood protein levels;	chr4:122723657	chr4:122730548~122732193:-
KIRP	cis	rs1185460	0.967	rs1786141	ENSG00000272186.1	RP11-110I1.13	-4.88	1.89e-06	0.000696	-0.28	-0.29	Coronary artery disease;	chr11:119067604	chr11:119067374~119067698:-
KIRP	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-4.87	1.89e-06	0.000696	-0.37	-0.29	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
KIRP	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	4.87	1.89e-06	0.000696	0.44	0.29	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
KIRP	cis	rs8049040	0.547	rs891131	ENSG00000260886.1	TAT-AS1	4.87	1.89e-06	0.000696	0.37	0.29	Blood protein levels;	chr16:71398514	chr16:71565789~71578187:+
KIRP	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	4.87	1.89e-06	0.000697	0.36	0.29	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	4.87	1.89e-06	0.000697	0.36	0.29	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
KIRP	cis	rs1552244	0.935	rs11926481	ENSG00000180385.7	EMC3-AS1	4.87	1.89e-06	0.000698	0.27	0.29	Alzheimer's disease;	chr3:10100418	chr3:9986893~10006990:+
KIRP	cis	rs728616	0.867	rs76239460	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61860412	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs12412257	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs12412226	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs4387301	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.764	rs117833443	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs116994688	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61860420	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs75447386	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs4520539	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61860421	ENSG00000234382.2	RP11-40F6.1	-4.87	1.89e-06	0.000698	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:80233664~80245367:+
KIRP	cis	rs9595908	0.709	rs7983889	ENSG00000212293.1	SNORA16	4.87	1.89e-06	0.000698	0.27	0.29	Body mass index;	chr13:32785441	chr13:32420390~32420516:-
KIRP	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	4.87	1.89e-06	0.000698	0.37	0.29	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
KIRP	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-4.87	1.89e-06	0.000698	-0.29	-0.29	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
KIRP	cis	rs9595908	0.869	rs9595946	ENSG00000212293.1	SNORA16	4.87	1.89e-06	0.000698	0.27	0.29	Body mass index;	chr13:32628998	chr13:32420390~32420516:-
KIRP	cis	rs703842	1	rs11172342	ENSG00000270039.1	RP11-571M6.17	-4.87	1.9e-06	0.000698	-0.28	-0.29	Multiple sclerosis;	chr12:57793975	chr12:57803838~57804415:+
KIRP	cis	rs703842	1	rs11172343	ENSG00000270039.1	RP11-571M6.17	-4.87	1.9e-06	0.000698	-0.28	-0.29	Multiple sclerosis;	chr12:57794374	chr12:57803838~57804415:+
KIRP	cis	rs703842	1	rs1875124	ENSG00000270039.1	RP11-571M6.17	-4.87	1.9e-06	0.000698	-0.28	-0.29	Multiple sclerosis;	chr12:57803019	chr12:57803838~57804415:+
KIRP	cis	rs712022	0.534	rs10833839	ENSG00000246225.5	RP11-17A1.3	-4.87	1.9e-06	0.000698	-0.34	-0.29	Dialysis-related mortality;	chr11:22846282	chr11:22829380~22945393:+
KIRP	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	4.87	1.9e-06	0.000699	0.51	0.29	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
KIRP	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-4.87	1.9e-06	0.000699	-0.58	-0.29	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
KIRP	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-4.87	1.9e-06	0.000699	-0.31	-0.29	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
KIRP	cis	rs11673344	0.504	rs6510588	ENSG00000226686.6	LINC01535	-4.87	1.9e-06	7e-04	-0.34	-0.29	Obesity-related traits;	chr19:37106493	chr19:37251912~37265535:+
KIRP	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-4.87	1.9e-06	7e-04	-0.3	-0.29	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-4.87	1.9e-06	7e-04	-0.3	-0.29	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
KIRP	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	4.87	1.9e-06	7e-04	0.24	0.29	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	4.87	1.9e-06	7e-04	0.24	0.29	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	4.87	1.9e-06	7e-04	0.24	0.29	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
KIRP	cis	rs2904967	0.598	rs2904978	ENSG00000254614.2	AP003068.23	4.87	1.9e-06	0.000701	0.39	0.29	Mean corpuscular volume;	chr11:65233007	chr11:65177606~65181834:-
KIRP	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-4.87	1.9e-06	0.000701	-0.31	-0.29	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
KIRP	cis	rs79349575	0.756	rs62078385	ENSG00000270781.1	RP11-501C14.9	-4.87	1.9e-06	0.000701	-0.31	-0.29	Type 2 diabetes;	chr17:48967647	chr17:48899131~48899748:+
KIRP	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-4.87	1.9e-06	0.000701	-0.27	-0.29	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
KIRP	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	4.87	1.9e-06	0.000702	0.34	0.29	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
KIRP	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	4.87	1.9e-06	0.000702	0.25	0.29	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
KIRP	cis	rs8114671	0.836	rs6141526	ENSG00000269202.1	RP4-614O4.12	4.87	1.91e-06	0.000702	0.21	0.29	Height;	chr20:35027452	chr20:35201747~35203288:-
KIRP	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-4.87	1.91e-06	0.000702	-0.3	-0.29	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
KIRP	cis	rs11673344	0.503	rs1667370	ENSG00000226686.6	LINC01535	4.87	1.91e-06	0.000703	0.34	0.29	Obesity-related traits;	chr19:36999318	chr19:37251912~37265535:+
KIRP	cis	rs910316	0.763	rs175435	ENSG00000279594.1	RP11-950C14.10	4.87	1.91e-06	0.000703	0.28	0.29	Height;	chr14:75145322	chr14:75011269~75012851:-
KIRP	cis	rs2562456	0.874	rs2562408	ENSG00000268555.1	RP11-678G14.3	-4.87	1.91e-06	0.000703	-0.39	-0.29	Pain;	chr19:21527079	chr19:21570822~21587322:-
KIRP	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.87	1.91e-06	0.000703	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
KIRP	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-4.87	1.91e-06	0.000704	-0.28	-0.29	Height;	chr14:75036124	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-4.87	1.91e-06	0.000704	-0.28	-0.29	Height;	chr14:75037751	chr14:75011269~75012851:-
KIRP	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	4.87	1.91e-06	0.000704	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
KIRP	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	4.87	1.91e-06	0.000704	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
KIRP	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	4.87	1.91e-06	0.000704	0.31	0.29	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
KIRP	cis	rs7672749	0.63	rs1463098	ENSG00000249973.2	CHCHD2P7	-4.87	1.91e-06	0.000705	-0.44	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87871802	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs1463100	ENSG00000249973.2	CHCHD2P7	-4.87	1.91e-06	0.000705	-0.44	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87872447	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs1463101	ENSG00000249973.2	CHCHD2P7	-4.87	1.91e-06	0.000705	-0.44	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87872502	chr4:87785920~87786371:-
KIRP	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	4.87	1.92e-06	0.000705	0.37	0.29	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
KIRP	cis	rs526231	0.926	rs35805	ENSG00000175749.11	EIF3KP1	4.87	1.92e-06	0.000706	0.34	0.29	Primary biliary cholangitis;	chr5:103337432	chr5:103032376~103033031:+
KIRP	cis	rs3121446	1	rs3121446	ENSG00000229654.1	RP1-60O19.2	4.87	1.92e-06	0.000706	0.3	0.29	Daytime sleep phenotypes;	chr6:106692991	chr6:106695535~106699994:+
KIRP	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	4.87	1.92e-06	0.000706	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
KIRP	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	4.87	1.92e-06	0.000706	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
KIRP	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	4.87	1.92e-06	0.000707	0.3	0.29	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
KIRP	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-4.87	1.92e-06	0.000707	-0.27	-0.29	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
KIRP	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-4.87	1.92e-06	0.000707	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
KIRP	cis	rs9810089	0.843	rs11717954	ENSG00000261758.1	RP11-102M11.2	4.87	1.92e-06	0.000708	0.31	0.29	Gestational age at birth (child effect);	chr3:136393267	chr3:136752630~136755780:+
KIRP	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	4.87	1.92e-06	0.000708	0.23	0.29	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
KIRP	cis	rs79349575	0.783	rs12603969	ENSG00000270781.1	RP11-501C14.9	-4.87	1.92e-06	0.000708	-0.31	-0.29	Type 2 diabetes;	chr17:48957057	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs12601955	ENSG00000270781.1	RP11-501C14.9	-4.87	1.92e-06	0.000708	-0.31	-0.29	Type 2 diabetes;	chr17:48957058	chr17:48899131~48899748:+
KIRP	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-4.87	1.93e-06	0.000709	-0.21	-0.29	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
KIRP	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	4.87	1.93e-06	0.000709	0.38	0.29	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
KIRP	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-4.87	1.93e-06	0.000709	-0.35	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
KIRP	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	4.87	1.93e-06	0.00071	0.46	0.29	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
KIRP	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-4.87	1.93e-06	0.00071	-0.21	-0.29	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
KIRP	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	4.87	1.93e-06	0.000711	0.26	0.29	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
KIRP	cis	rs703842	0.642	rs10876994	ENSG00000270039.1	RP11-571M6.17	-4.87	1.93e-06	0.000711	-0.31	-0.29	Multiple sclerosis;	chr12:57670954	chr12:57803838~57804415:+
KIRP	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	4.87	1.93e-06	0.000711	0.3	0.29	Height;	chr4:55589624	chr4:55363971~55395847:-
KIRP	cis	rs9402743	0.598	rs2327654	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Systemic lupus erythematosus;	chr6:135758303	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.703	rs6933668	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Systemic lupus erythematosus;	chr6:135760013	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.703	rs7756751	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Systemic lupus erythematosus;	chr6:135761314	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.703	rs6570030	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Systemic lupus erythematosus;	chr6:135761688	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs6909996	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Phosphorus levels;	chr6:135763365	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs9399164	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Phosphorus levels;	chr6:135765408	chr6:135497801~135716055:+
KIRP	cis	rs947583	0.517	rs4385331	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Phosphorus levels;	chr6:135772025	chr6:135497801~135716055:+
KIRP	cis	rs9402743	0.641	rs9402752	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Systemic lupus erythematosus;	chr6:135772549	chr6:135497801~135716055:+
KIRP	cis	rs6671200	0.518	rs77369148	ENSG00000235501.4	RP4-639F20.1	-4.87	1.93e-06	0.000711	-0.6	-0.29	Stearic acid (18:0) levels;	chr1:94912122	chr1:94927566~94963270:+
KIRP	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	4.87	1.93e-06	0.000711	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	4.87	1.93e-06	0.000711	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	4.87	1.93e-06	0.000711	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
KIRP	cis	rs947583	0.517	rs9376147	ENSG00000231028.7	LINC00271	-4.87	1.93e-06	0.000711	-0.25	-0.29	Phosphorus levels;	chr6:135774774	chr6:135497801~135716055:+
KIRP	cis	rs7267979	0.932	rs446649	ENSG00000274414.1	RP5-965G21.4	-4.87	1.93e-06	0.000711	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25239007~25245229:-
KIRP	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	4.87	1.94e-06	0.000712	0.4	0.29	Height;	chr6:109333018	chr6:109382795~109383666:+
KIRP	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-4.87	1.94e-06	0.000712	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
KIRP	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-4.87	1.94e-06	0.000713	-0.33	-0.29	Depression;	chr6:28086929	chr6:28073316~28074233:+
KIRP	cis	rs2481044	0.592	rs2634656	ENSG00000230234.1	RP1-276N6.2	-4.87	1.94e-06	0.000713	-0.33	-0.29	Body mass index;	chr6:160263992	chr6:160272617~160276130:+
KIRP	cis	rs2481044	0.592	rs2619272	ENSG00000230234.1	RP1-276N6.2	-4.87	1.94e-06	0.000713	-0.33	-0.29	Body mass index;	chr6:160263997	chr6:160272617~160276130:+
KIRP	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-4.87	1.94e-06	0.000713	-0.31	-0.29	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
KIRP	cis	rs11148252	0.74	rs9536052	ENSG00000235660.1	LINC00345	4.87	1.94e-06	0.000714	0.31	0.29	Lewy body disease;	chr13:52386574	chr13:52484161~52484680:-
KIRP	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	4.87	1.94e-06	0.000714	0.3	0.29	Height;	chr4:55531811	chr4:55363971~55395847:-
KIRP	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	4.87	1.95e-06	0.000715	0.29	0.29	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
KIRP	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	4.87	1.95e-06	0.000715	0.29	0.29	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
KIRP	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-4.87	1.95e-06	0.000715	-0.38	-0.29	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
KIRP	cis	rs7615952	0.599	rs6779141	ENSG00000241439.1	RP11-666A20.3	4.87	1.95e-06	0.000715	0.4	0.29	Blood pressure (smoking interaction);	chr3:125991152	chr3:125958556~125958817:+
KIRP	cis	rs964611	0.786	rs10519169	ENSG00000259488.2	RP11-154J22.1	-4.87	1.95e-06	0.000716	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48372829	chr15:48312353~48331856:-
KIRP	cis	rs72634501	0.568	rs590214	ENSG00000237624.1	OXCT2P1	4.87	1.95e-06	0.000717	0.39	0.29	HDL cholesterol;	chr1:39146821	chr1:39514956~39516490:+
KIRP	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-4.87	1.95e-06	0.000718	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
KIRP	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	4.87	1.95e-06	0.000718	0.68	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
KIRP	cis	rs2562456	0.917	rs2681376	ENSG00000268555.1	RP11-678G14.3	-4.87	1.95e-06	0.000718	-0.39	-0.29	Pain;	chr19:21532723	chr19:21570822~21587322:-
KIRP	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	4.87	1.95e-06	0.000718	0.24	0.29	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
KIRP	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-4.87	1.96e-06	0.000718	-0.39	-0.29	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
KIRP	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-4.87	1.96e-06	0.000718	-0.22	-0.29	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
KIRP	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-4.87	1.96e-06	0.000718	-0.22	-0.29	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
KIRP	cis	rs4820539	0.966	rs2283803	ENSG00000275635.1	U7	4.87	1.96e-06	0.000719	0.31	0.29	Bone mineral density;	chr22:23112694	chr22:23137805~23137864:-
KIRP	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-4.87	1.96e-06	0.000719	-0.35	-0.29	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
KIRP	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-4.87	1.96e-06	0.000719	-0.3	-0.29	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-4.87	1.96e-06	0.000719	-0.3	-0.29	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-4.87	1.96e-06	0.000719	-0.3	-0.29	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
KIRP	cis	rs2625529	0.53	rs2959930	ENSG00000260037.4	CTD-2524L6.3	-4.87	1.96e-06	0.000719	-0.22	-0.29	Red blood cell count;	chr15:72306273	chr15:71818396~71823384:+
KIRP	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-4.87	1.96e-06	0.000719	-0.37	-0.29	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
KIRP	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-4.87	1.96e-06	0.000719	-0.31	-0.29	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
KIRP	cis	rs1799949	0.965	rs799912	ENSG00000279602.1	CTD-3014M21.1	-4.87	1.96e-06	0.000719	-0.25	-0.29	Menopause (age at onset);	chr17:43105117	chr17:43360041~43361361:-
KIRP	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4.87	1.96e-06	0.00072	-0.37	-0.29	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
KIRP	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	4.87	1.96e-06	0.00072	0.37	0.29	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
KIRP	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-4.87	1.96e-06	0.00072	-0.49	-0.29	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
KIRP	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	4.87	1.96e-06	0.000721	0.37	0.29	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
KIRP	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	4.87	1.96e-06	0.000721	0.39	0.29	Depression;	chr6:28399846	chr6:28943877~28944537:+
KIRP	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-4.87	1.97e-06	0.000721	-0.37	-0.29	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
KIRP	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-4.87	1.97e-06	0.000722	-0.29	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
KIRP	cis	rs116095464	0.558	rs9654453	ENSG00000248925.1	CTD-2083E4.6	4.87	1.97e-06	0.000722	0.52	0.29	Breast cancer;	chr5:299506	chr5:269858~271516:-
KIRP	cis	rs12682352	0.602	rs635594	ENSG00000253981.4	ALG1L13P	-4.87	1.97e-06	0.000723	-0.24	-0.29	Neuroticism;	chr8:8755877	chr8:8236003~8244667:-
KIRP	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-4.87	1.97e-06	0.000723	-0.26	-0.29	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
KIRP	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-4.87	1.97e-06	0.000723	-0.26	-0.29	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
KIRP	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-4.87	1.97e-06	0.000723	-0.31	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
KIRP	cis	rs4663866	1	rs13033501	ENSG00000186235.9	AC016757.3	4.87	1.97e-06	0.000723	0.54	0.29	Irritable bowel syndrome;	chr2:238273219	chr2:238224552~238231677:-
KIRP	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-4.87	1.97e-06	0.000723	-0.37	-0.29	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-4.87	1.97e-06	0.000723	-0.37	-0.29	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
KIRP	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-4.87	1.97e-06	0.000724	-0.22	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
KIRP	cis	rs11673344	0.523	rs8101392	ENSG00000226686.6	LINC01535	4.87	1.97e-06	0.000724	0.36	0.29	Obesity-related traits;	chr19:37024416	chr19:37251912~37265535:+
KIRP	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-4.87	1.97e-06	0.000724	-0.34	-0.29	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-4.87	1.97e-06	0.000724	-0.34	-0.29	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-4.87	1.97e-06	0.000724	-0.34	-0.29	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
KIRP	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-4.87	1.97e-06	0.000724	-0.25	-0.29	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-4.87	1.97e-06	0.000724	-0.25	-0.29	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-4.87	1.97e-06	0.000724	-0.25	-0.29	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
KIRP	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	4.87	1.97e-06	0.000724	0.29	0.29	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
KIRP	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	4.87	1.98e-06	0.000725	0.5	0.29	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	4.87	1.98e-06	0.000725	0.5	0.29	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
KIRP	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-4.87	1.98e-06	0.000725	-0.54	-0.29	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-4.87	1.98e-06	0.000725	-0.54	-0.29	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-4.87	1.98e-06	0.000725	-0.54	-0.29	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-4.87	1.98e-06	0.000725	-0.54	-0.29	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
KIRP	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-4.87	1.98e-06	0.000725	-0.26	-0.29	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
KIRP	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-4.87	1.98e-06	0.000725	-0.36	-0.29	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
KIRP	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	4.86	1.98e-06	0.000725	0.24	0.29	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
KIRP	cis	rs395157	0.591	rs357286	ENSG00000249911.1	LINC01265	4.86	1.98e-06	0.000725	0.32	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38837759	chr5:38710367~38720273:-
KIRP	cis	rs35934224	0.504	rs35169076	ENSG00000232926.1	AC000078.5	4.86	1.98e-06	0.000725	0.29	0.29	Glaucoma (primary open-angle);	chr22:19853978	chr22:19887289~19887970:+
KIRP	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-4.86	1.98e-06	0.000725	-0.39	-0.29	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
KIRP	cis	rs4356203	0.84	rs7942094	ENSG00000272034.1	SNORD14A	-4.86	1.98e-06	0.000726	-0.24	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17237862	chr11:17074654~17074744:-
KIRP	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-4.86	1.98e-06	0.000726	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
KIRP	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	4.86	1.98e-06	0.000726	0.28	0.29	Height;	chr4:55578154	chr4:55547112~55547889:+
KIRP	cis	rs9595908	0.669	rs2032508	ENSG00000212293.1	SNORA16	4.86	1.98e-06	0.000726	0.28	0.29	Body mass index;	chr13:32779332	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.746	rs7985640	ENSG00000212293.1	SNORA16	4.86	1.98e-06	0.000726	0.27	0.29	Body mass index;	chr13:32698228	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9591252	ENSG00000212293.1	SNORA16	4.86	1.98e-06	0.000726	0.27	0.29	Body mass index;	chr13:32698297	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596083	ENSG00000212293.1	SNORA16	4.86	1.98e-06	0.000726	0.27	0.29	Body mass index;	chr13:32700494	chr13:32420390~32420516:-
KIRP	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-4.86	1.98e-06	0.000727	-0.32	-0.29	Temperament;	chr17:14019308	chr17:14024514~14025488:+
KIRP	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-4.86	1.98e-06	0.000727	-0.29	-0.29	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
KIRP	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	4.86	1.98e-06	0.000727	0.24	0.29	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
KIRP	cis	rs7432375	0.933	rs6791142	ENSG00000261758.1	RP11-102M11.2	4.86	1.98e-06	0.000727	0.31	0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136658535	chr3:136752630~136755780:+
KIRP	cis	rs1552244	1	rs35198334	ENSG00000180385.7	EMC3-AS1	4.86	1.99e-06	0.000728	0.29	0.29	Alzheimer's disease;	chr3:10062869	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.935	rs7652190	ENSG00000180385.7	EMC3-AS1	4.86	1.99e-06	0.000728	0.29	0.29	Alzheimer's disease;	chr3:10063466	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs7619340	ENSG00000180385.7	EMC3-AS1	4.86	1.99e-06	0.000728	0.29	0.29	Alzheimer's disease;	chr3:10066494	chr3:9986893~10006990:+
KIRP	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	4.86	1.99e-06	0.000729	0.3	0.29	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	4.86	1.99e-06	0.000729	0.3	0.29	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
KIRP	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	4.86	1.99e-06	0.000729	0.35	0.29	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
KIRP	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	4.86	1.99e-06	0.000729	0.29	0.29	Height;	chr14:75082053	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	4.86	1.99e-06	0.000729	0.29	0.29	Height;	chr14:75088921	chr14:75011269~75012851:-
KIRP	cis	rs875971	0.502	rs2465121	ENSG00000224316.1	RP11-479O9.2	-4.86	1.99e-06	0.00073	-0.25	-0.29	Aortic root size;	chr7:66156017	chr7:65773620~65802067:+
KIRP	cis	rs4934494	0.723	rs17127001	ENSG00000232936.4	RP11-80H5.2	4.86	1.99e-06	0.00073	0.44	0.29	Red blood cell count;	chr10:89762932	chr10:89645282~89650667:+
KIRP	cis	rs914615	0.508	rs7535292	ENSG00000160766.13	GBAP1	-4.86	1.99e-06	0.00073	-0.26	-0.29	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155213821~155227422:-
KIRP	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-4.86	1.99e-06	0.00073	-0.3	-0.29	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
KIRP	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	4.86	1.99e-06	0.00073	0.29	0.29	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
KIRP	cis	rs7005380	0.58	rs1467044	ENSG00000245330.4	KB-1471A8.1	4.86	1.99e-06	0.00073	0.35	0.29	Interstitial lung disease;	chr8:119874801	chr8:119867419~119874488:-
KIRP	cis	rs497273	0.553	rs508595	ENSG00000277423.1	RP11-173P15.9	-4.86	1.99e-06	0.00073	-0.3	-0.29	Systemic lupus erythematosus;	chr12:120761088	chr12:120703867~120704282:+
KIRP	cis	rs497273	0.517	rs580240	ENSG00000277423.1	RP11-173P15.9	-4.86	1.99e-06	0.00073	-0.3	-0.29	Systemic lupus erythematosus;	chr12:120762100	chr12:120703867~120704282:+
KIRP	cis	rs497273	0.534	rs13746	ENSG00000277423.1	RP11-173P15.9	-4.86	1.99e-06	0.00073	-0.3	-0.29	Systemic lupus erythematosus;	chr12:120763364	chr12:120703867~120704282:+
KIRP	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	4.86	1.99e-06	0.00073	0.34	0.29	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	4.86	1.99e-06	0.00073	0.34	0.29	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
KIRP	cis	rs2562456	0.516	rs56072098	ENSG00000268555.1	RP11-678G14.3	-4.86	2e-06	0.000731	-0.38	-0.29	Pain;	chr19:21469158	chr19:21570822~21587322:-
KIRP	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-4.86	2e-06	0.000731	-0.37	-0.29	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
KIRP	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-4.86	2e-06	0.000731	-0.31	-0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
KIRP	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	4.86	2e-06	0.000732	0.42	0.29	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
KIRP	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	4.86	2e-06	0.000732	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
KIRP	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	4.86	2e-06	0.000732	0.31	0.29	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
KIRP	cis	rs9925964	0.933	rs9939417	ENSG00000232748.3	RP11-196G11.6	4.86	2e-06	0.000733	0.35	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:31056460~31062803:+
KIRP	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	4.86	2e-06	0.000733	0.43	0.29	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
KIRP	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-4.86	2e-06	0.000733	-0.37	-0.29	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
KIRP	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	4.86	2e-06	0.000733	0.28	0.29	Height;	chr4:55489895	chr4:55547112~55547889:+
KIRP	cis	rs6532023	1	rs1471401	ENSG00000249973.2	CHCHD2P7	-4.86	2e-06	0.000734	-0.35	-0.29	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87853188	chr4:87785920~87786371:-
KIRP	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-4.86	2e-06	0.000734	-0.25	-0.29	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
KIRP	cis	rs7747960	0.706	rs7740022	ENSG00000226193.1	RP3-398G3.5	-4.86	2e-06	0.000734	-0.45	-0.29	Bipolar disorder;	chr6:152481074	chr6:152402398~152404966:+
KIRP	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-4.86	2e-06	0.000734	-0.3	-0.29	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
KIRP	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	4.86	2.01e-06	0.000734	0.28	0.29	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
KIRP	cis	rs7747960	0.572	rs9397513	ENSG00000226193.1	RP3-398G3.5	-4.86	2.01e-06	0.000734	-0.38	-0.29	Bipolar disorder;	chr6:152485428	chr6:152402398~152404966:+
KIRP	cis	rs9847710	1	rs2581817	ENSG00000280417.1	RP11-5O17.1	-4.86	2.01e-06	0.000734	-0.34	-0.29	Ulcerative colitis;	chr3:53037781	chr3:53046166~53048122:+
KIRP	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	4.86	2.01e-06	0.000735	0.38	0.29	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
KIRP	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	4.86	2.01e-06	0.000735	0.31	0.29	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
KIRP	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-4.86	2.01e-06	0.000735	-0.29	-0.29	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
KIRP	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-4.86	2.01e-06	0.000735	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
KIRP	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	4.86	2.01e-06	0.000736	0.33	0.29	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
KIRP	cis	rs9595908	0.785	rs7326809	ENSG00000212293.1	SNORA16	4.86	2.01e-06	0.000736	0.27	0.29	Body mass index;	chr13:32662135	chr13:32420390~32420516:-
KIRP	cis	rs12039431	0.706	rs61605574	ENSG00000232273.1	FTH1P1	4.86	2.01e-06	0.000736	0.39	0.29	Epithelial ovarian cancer;	chr1:37508342	chr1:37544763~37545294:+
KIRP	cis	rs12039431	0.706	rs61779866	ENSG00000232273.1	FTH1P1	4.86	2.01e-06	0.000736	0.39	0.29	Epithelial ovarian cancer;	chr1:37513296	chr1:37544763~37545294:+
KIRP	cis	rs12039431	0.706	rs59482985	ENSG00000232273.1	FTH1P1	4.86	2.01e-06	0.000736	0.39	0.29	Epithelial ovarian cancer;	chr1:37516307	chr1:37544763~37545294:+
KIRP	cis	rs12039431	0.706	rs61776179	ENSG00000232273.1	FTH1P1	4.86	2.01e-06	0.000736	0.39	0.29	Epithelial ovarian cancer;	chr1:37521203	chr1:37544763~37545294:+
KIRP	cis	rs2946505	1	rs2946505	ENSG00000251468.2	RP11-369K16.1	4.86	2.01e-06	0.000736	0.37	0.29	Migraine;	chr8:12953643	chr8:12958387~12962200:+
KIRP	cis	rs1005277	0.579	rs2505194	ENSG00000151963.4	RP11-775A3.1	-4.86	2.01e-06	0.000736	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:37883594~37884109:+
KIRP	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	4.86	2.01e-06	0.000736	0.58	0.29	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	4.86	2.01e-06	0.000736	0.58	0.29	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	4.86	2.01e-06	0.000736	0.58	0.29	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
KIRP	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-4.86	2.02e-06	0.000737	-0.4	-0.29	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
KIRP	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-4.86	2.02e-06	0.000737	-0.24	-0.29	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
KIRP	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-4.86	2.02e-06	0.000738	-0.25	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
KIRP	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-4.86	2.02e-06	0.000738	-0.42	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
KIRP	cis	rs6832769	0.961	rs11133379	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55439944	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs3736545	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55444176	chr4:55547112~55547889:+
KIRP	cis	rs12936587	0.69	rs8074794	ENSG00000223979.2	SMCR2	4.86	2.02e-06	0.000739	0.28	0.29	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17631415	chr17:17674026~17677688:-
KIRP	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55531150	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55531218	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55534166	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55534180	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55534788	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55535489	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55536421	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55537080	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	4.86	2.02e-06	0.000739	0.3	0.29	Height;	chr4:55541259	chr4:55363971~55395847:-
KIRP	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-4.86	2.02e-06	0.000739	-0.24	-0.29	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
KIRP	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-4.86	2.02e-06	0.000739	-0.32	-0.29	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-4.86	2.02e-06	0.000739	-0.32	-0.29	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-4.86	2.02e-06	0.000739	-0.32	-0.29	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
KIRP	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-4.86	2.02e-06	0.000739	-0.32	-0.29	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
KIRP	cis	rs6832769	1	rs7677526	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55483741	chr4:55547112~55547889:+
KIRP	cis	rs11158026	0.757	rs56164809	ENSG00000258413.1	RP11-665C16.6	-4.86	2.02e-06	0.000739	-0.35	-0.29	Parkinson's disease;	chr14:54933494	chr14:55262767~55272075:-
KIRP	cis	rs6832769	1	rs12643926	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55444454	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs12647034	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55444455	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs2412646	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55452605	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs11733864	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55455363	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.925	rs1965467	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55456573	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs11939815	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55492116	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.826	rs58894703	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55492371	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs3805157	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55497936	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs2177129	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55499247	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.89	rs1980273	ENSG00000272969.1	RP11-528I4.2	4.86	2.02e-06	0.000739	0.28	0.29	Personality dimensions;	chr4:55501234	chr4:55547112~55547889:+
KIRP	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	4.86	2.02e-06	0.000739	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
KIRP	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	4.86	2.02e-06	0.000739	0.28	0.29	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
KIRP	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	4.86	2.02e-06	0.000739	0.28	0.29	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
KIRP	cis	rs7829975	0.56	rs4841013	ENSG00000253981.4	ALG1L13P	-4.86	2.02e-06	0.00074	-0.23	-0.29	Mood instability;	chr8:8694503	chr8:8236003~8244667:-
KIRP	cis	rs11098499	0.644	rs10012252	ENSG00000250412.1	KLHL2P1	4.86	2.03e-06	0.00074	0.36	0.29	Corneal astigmatism;	chr4:119637984	chr4:119334329~119378233:+
KIRP	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-4.86	2.03e-06	0.000741	-0.37	-0.29	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
KIRP	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-4.86	2.03e-06	0.000741	-0.37	-0.29	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
KIRP	cis	rs79349575	0.655	rs62078384	ENSG00000270781.1	RP11-501C14.9	-4.86	2.03e-06	0.000741	-0.31	-0.29	Type 2 diabetes;	chr17:48967101	chr17:48899131~48899748:+
KIRP	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	4.86	2.03e-06	0.000741	0.26	0.29	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	4.86	2.03e-06	0.000741	0.26	0.29	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
KIRP	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	4.86	2.03e-06	0.000741	0.26	0.29	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
KIRP	cis	rs116095464	0.558	rs55776650	ENSG00000248925.1	CTD-2083E4.6	4.86	2.03e-06	0.000742	0.43	0.29	Breast cancer;	chr5:273711	chr5:269858~271516:-
KIRP	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-4.86	2.03e-06	0.000742	-0.35	-0.29	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-4.86	2.03e-06	0.000742	-0.35	-0.29	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-4.86	2.03e-06	0.000742	-0.35	-0.29	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
KIRP	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-4.86	2.03e-06	0.000743	-0.39	-0.29	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
KIRP	cis	rs4820539	0.966	rs3788350	ENSG00000275635.1	U7	4.86	2.03e-06	0.000743	0.31	0.29	Bone mineral density;	chr22:23126281	chr22:23137805~23137864:-
KIRP	cis	rs728616	0.867	rs1054054	ENSG00000234382.2	RP11-40F6.1	-4.86	2.03e-06	0.000743	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs61859766	ENSG00000234382.2	RP11-40F6.1	-4.86	2.03e-06	0.000743	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs56198874	ENSG00000234382.2	RP11-40F6.1	-4.86	2.03e-06	0.000743	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:80233664~80245367:+
KIRP	cis	rs2283792	0.73	rs738858	ENSG00000228050.1	TOP3BP1	4.86	2.03e-06	0.000743	0.32	0.29	Multiple sclerosis;	chr22:21926544	chr22:22223187~22224566:-
KIRP	cis	rs67311347	0.544	rs60329764	ENSG00000230274.1	PGAM1P3	-4.86	2.04e-06	0.000744	-0.28	-0.29	Renal cell carcinoma;	chr3:40293130	chr3:40322715~40323279:-
KIRP	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	4.86	2.04e-06	0.000744	0.32	0.29	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	4.86	2.04e-06	0.000744	0.32	0.29	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
KIRP	cis	rs728616	0.867	rs17886286	ENSG00000234382.2	RP11-40F6.1	-4.86	2.04e-06	0.000744	-0.46	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:80233664~80245367:+
KIRP	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	4.86	2.04e-06	0.000744	0.39	0.29	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
KIRP	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-4.86	2.04e-06	0.000745	-0.32	-0.29	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-4.86	2.04e-06	0.000745	-0.32	-0.29	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
KIRP	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	4.86	2.04e-06	0.000745	0.38	0.29	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
KIRP	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-4.86	2.04e-06	0.000745	-0.32	-0.29	Height;	chr3:53029854	chr3:53064283~53065091:-
KIRP	cis	rs453301	0.658	rs6983877	ENSG00000173295.6	FAM86B3P	-4.86	2.04e-06	0.000746	-0.22	-0.29	Joint mobility (Beighton score);	chr8:9047129	chr8:8228595~8244865:+
KIRP	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-4.86	2.04e-06	0.000746	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-4.86	2.04e-06	0.000746	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
KIRP	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-4.86	2.04e-06	0.000746	-0.44	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
KIRP	cis	rs8141529	0.732	rs5997408	ENSG00000226471.5	CTA-292E10.6	-4.86	2.05e-06	0.000747	-0.29	-0.29	Lymphocyte counts;	chr22:28811927	chr22:28800683~28848559:+
KIRP	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	4.86	2.05e-06	0.000747	0.62	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
KIRP	cis	rs453301	0.631	rs11779804	ENSG00000173295.6	FAM86B3P	-4.86	2.05e-06	0.000747	-0.23	-0.29	Joint mobility (Beighton score);	chr8:8940442	chr8:8228595~8244865:+
KIRP	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-4.86	2.05e-06	0.000747	-0.24	-0.29	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-4.86	2.05e-06	0.000747	-0.24	-0.29	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-4.86	2.05e-06	0.000747	-0.24	-0.29	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-4.86	2.05e-06	0.000747	-0.24	-0.29	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
KIRP	cis	rs77741769	0.571	rs11065300	ENSG00000277423.1	RP11-173P15.9	-4.86	2.05e-06	0.000748	-0.31	-0.29	Mean corpuscular volume;	chr12:120860709	chr12:120703867~120704282:+
KIRP	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	4.86	2.05e-06	0.000748	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
KIRP	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	4.86	2.05e-06	0.000748	0.36	0.29	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
KIRP	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	4.86	2.05e-06	0.000749	0.28	0.29	Height;	chr14:75133994	chr14:75011269~75012851:-
KIRP	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	4.86	2.05e-06	0.000749	0.28	0.29	Height;	chr14:75136131	chr14:75011269~75012851:-
KIRP	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	4.86	2.05e-06	0.000749	0.36	0.29	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
KIRP	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-4.86	2.05e-06	0.000749	-0.22	-0.29	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
KIRP	cis	rs7267979	1	rs6050565	ENSG00000274414.1	RP5-965G21.4	4.86	2.05e-06	0.000749	0.27	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25239007~25245229:-
KIRP	cis	rs1799949	0.965	rs4239149	ENSG00000279602.1	CTD-3014M21.1	4.86	2.05e-06	0.000749	0.25	0.29	Menopause (age at onset);	chr17:43176078	chr17:43360041~43361361:-
KIRP	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-4.86	2.05e-06	0.000749	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
KIRP	cis	rs453301	0.658	rs12114954	ENSG00000173295.6	FAM86B3P	-4.86	2.06e-06	0.000752	-0.22	-0.29	Joint mobility (Beighton score);	chr8:9047352	chr8:8228595~8244865:+
KIRP	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	4.86	2.06e-06	0.000752	0.27	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
KIRP	cis	rs875971	0.545	rs1796219	ENSG00000224316.1	RP11-479O9.2	-4.86	2.06e-06	0.000752	-0.25	-0.29	Aortic root size;	chr7:66645977	chr7:65773620~65802067:+
KIRP	cis	rs11673344	0.523	rs2562609	ENSG00000226686.6	LINC01535	4.86	2.06e-06	0.000752	0.35	0.29	Obesity-related traits;	chr19:37036255	chr19:37251912~37265535:+
KIRP	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	4.86	2.07e-06	0.000753	0.36	0.29	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
KIRP	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-4.86	2.07e-06	0.000753	-0.23	-0.29	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-4.86	2.07e-06	0.000753	-0.23	-0.29	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
KIRP	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	4.86	2.07e-06	0.000754	0.25	0.29	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
KIRP	cis	rs4638749	1	rs2123694	ENSG00000225328.1	AC019100.3	-4.86	2.07e-06	0.000754	-0.37	-0.29	Blood pressure;	chr2:108241049	chr2:108167748~108217841:-
KIRP	cis	rs6832769	0.961	rs13128582	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55462777	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.925	rs6817267	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55472374	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs11931061	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55472626	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs7668147	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55473217	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs11947476	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55473584	chr4:55547112~55547889:+
KIRP	cis	rs6832769	1	rs13102385	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55479088	chr4:55547112~55547889:+
KIRP	cis	rs6832769	0.961	rs11947623	ENSG00000272969.1	RP11-528I4.2	4.86	2.07e-06	0.000754	0.28	0.29	Personality dimensions;	chr4:55483023	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-4.86	2.07e-06	0.000754	-0.3	-0.29	Height;	chr4:55547636	chr4:55363971~55395847:-
KIRP	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	4.86	2.07e-06	0.000755	0.27	0.29	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
KIRP	cis	rs116095464	0.558	rs1541822	ENSG00000248925.1	CTD-2083E4.6	-4.86	2.07e-06	0.000755	-0.44	-0.29	Breast cancer;	chr5:269119	chr5:269858~271516:-
KIRP	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	4.85	2.07e-06	0.000755	0.29	0.29	Height;	chr14:75083881	chr14:75011269~75012851:-
KIRP	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	4.85	2.07e-06	0.000756	0.3	0.29	Height;	chr4:55582068	chr4:55363971~55395847:-
KIRP	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	4.85	2.08e-06	0.000756	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
KIRP	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	4.85	2.08e-06	0.000756	0.28	0.29	Height;	chr4:55561218	chr4:55547112~55547889:+
KIRP	cis	rs4639966	0.836	rs10892282	ENSG00000255239.1	AP002954.6	4.85	2.08e-06	0.000756	0.38	0.29	Systemic lupus erythematosus;	chr11:118757069	chr11:118688039~118690600:-
KIRP	cis	rs2562456	0.917	rs6511253	ENSG00000268555.1	RP11-678G14.3	-4.85	2.08e-06	0.000757	-0.37	-0.29	Pain;	chr19:21495996	chr19:21570822~21587322:-
KIRP	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	4.85	2.08e-06	0.000757	0.44	0.29	Height;	chr6:109732047	chr6:109382795~109383666:+
KIRP	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	4.85	2.08e-06	0.000757	0.28	0.29	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
KIRP	cis	rs2361718	0.522	rs11867921	ENSG00000275479.1	RP11-334C17.6	4.85	2.08e-06	0.000758	0.26	0.29	Yeast infection;	chr17:80147371	chr17:80149627~80149798:+
KIRP	cis	rs8141529	0.644	rs5752795	ENSG00000226471.5	CTA-292E10.6	-4.85	2.08e-06	0.000758	-0.29	-0.29	Lymphocyte counts;	chr22:28782832	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.732	rs2347447	ENSG00000226471.5	CTA-292E10.6	-4.85	2.08e-06	0.000758	-0.29	-0.29	Lymphocyte counts;	chr22:28783751	chr22:28800683~28848559:+
KIRP	cis	rs8141529	0.732	rs5752798	ENSG00000226471.5	CTA-292E10.6	-4.85	2.08e-06	0.000758	-0.29	-0.29	Lymphocyte counts;	chr22:28785880	chr22:28800683~28848559:+
KIRP	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	4.85	2.08e-06	0.000758	0.36	0.29	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
KIRP	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	4.85	2.08e-06	0.000758	0.32	0.29	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
KIRP	cis	rs2732480	1	rs2732480	ENSG00000269514.1	RP11-370I10.12	-4.85	2.08e-06	0.000759	-0.24	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48198387~48202031:+
KIRP	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.85	2.08e-06	0.000759	0.34	0.29	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
KIRP	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	4.85	2.08e-06	0.000759	0.38	0.29	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
KIRP	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	4.85	2.08e-06	0.000759	0.38	0.29	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
KIRP	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	4.85	2.08e-06	0.000759	0.38	0.29	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
KIRP	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	4.85	2.08e-06	0.000759	0.27	0.29	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
KIRP	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-4.85	2.09e-06	0.000759	-0.3	-0.29	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
KIRP	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-4.85	2.09e-06	0.00076	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
KIRP	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	4.85	2.09e-06	0.00076	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
KIRP	cis	rs4805272	0.962	rs4805277	ENSG00000267799.1	MAN1A2P1	4.85	2.09e-06	0.00076	0.35	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840036	chr19:28790812~28792871:-
KIRP	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-4.85	2.09e-06	0.000761	-0.37	-0.29	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
KIRP	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000761	0.32	0.29	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
KIRP	cis	rs7299940	0.694	rs12296337	ENSG00000256250.1	RP11-989F5.1	4.85	2.09e-06	0.000761	0.29	0.29	Panic disorder;	chr12:130891406	chr12:130810606~130812438:+
KIRP	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	4.85	2.09e-06	0.000762	0.32	0.29	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
KIRP	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-4.85	2.09e-06	0.000762	-0.31	-0.29	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
KIRP	cis	rs9494145	0.59	rs9376090	ENSG00000232876.1	CTA-212D2.2	-4.85	2.09e-06	0.000762	-0.4	-0.29	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135090090	chr6:135055033~135060550:+
KIRP	cis	rs962856	0.729	rs1483350	ENSG00000236780.4	AC078941.1	4.85	2.1e-06	0.000763	0.35	0.29	Pancreatic cancer;	chr2:67292771	chr2:67123357~67215319:-
KIRP	cis	rs1044826	0.642	rs407958	ENSG00000178631.7	ACTG1P1	4.85	2.1e-06	0.000763	0.3	0.29	Obesity-related traits;	chr3:139494790	chr3:139493809~139494937:+
KIRP	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	4.85	2.1e-06	0.000763	0.3	0.29	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
KIRP	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	4.85	2.1e-06	0.000763	0.3	0.29	Height;	chr4:55540912	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	4.85	2.1e-06	0.000763	0.3	0.29	Height;	chr4:55540972	chr4:55363971~55395847:-
KIRP	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-4.85	2.1e-06	0.000763	-0.19	-0.29	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
KIRP	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	4.85	2.1e-06	0.000764	0.31	0.29	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	4.85	2.1e-06	0.000764	0.31	0.29	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
KIRP	cis	rs2154427	0.752	rs78511491	ENSG00000238197.4	PAXBP1-AS1	4.85	2.1e-06	0.000764	0.42	0.29	Bilirubin levels;	chr21:32751938	chr21:32728115~32743122:+
KIRP	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-4.85	2.1e-06	0.000764	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
KIRP	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-4.85	2.1e-06	0.000764	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
KIRP	cis	rs2562456	0.874	rs2562417	ENSG00000268555.1	RP11-678G14.3	-4.85	2.1e-06	0.000764	-0.39	-0.29	Pain;	chr19:21528400	chr19:21570822~21587322:-
KIRP	cis	rs9595908	0.785	rs7328827	ENSG00000212293.1	SNORA16	4.85	2.1e-06	0.000764	0.27	0.29	Body mass index;	chr13:32686650	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs3858846	ENSG00000212293.1	SNORA16	4.85	2.1e-06	0.000764	0.27	0.29	Body mass index;	chr13:32687408	chr13:32420390~32420516:-
KIRP	cis	rs964611	0.882	rs12148465	ENSG00000259488.2	RP11-154J22.1	4.85	2.1e-06	0.000764	0.26	0.29	Metabolite levels (Pyroglutamine);	chr15:48368261	chr15:48312353~48331856:-
KIRP	cis	rs7672749	0.63	rs2904178	ENSG00000249973.2	CHCHD2P7	-4.85	2.1e-06	0.000765	-0.44	-0.29	TB-LM or TBLH-BMD (pleiotropy);	chr4:87872856	chr4:87785920~87786371:-
KIRP	cis	rs4236601	0.72	rs1052990	ENSG00000237813.3	AC002066.1	-4.85	2.11e-06	0.000766	-0.36	-0.29	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116508316	chr7:116238260~116499465:-
KIRP	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	4.85	2.11e-06	0.000767	0.44	0.29	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
KIRP	cis	rs9302635	0.513	rs12928732	ENSG00000260886.1	TAT-AS1	4.85	2.11e-06	0.000767	0.4	0.29	Blood protein levels;	chr16:72154784	chr16:71565789~71578187:+
KIRP	cis	rs9302635	0.513	rs13334151	ENSG00000260886.1	TAT-AS1	4.85	2.11e-06	0.000767	0.4	0.29	Blood protein levels;	chr16:72155828	chr16:71565789~71578187:+
KIRP	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	4.85	2.11e-06	0.000767	0.24	0.29	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
KIRP	cis	rs964611	0.706	rs11070638	ENSG00000259488.2	RP11-154J22.1	4.85	2.11e-06	0.000767	0.27	0.29	Metabolite levels (Pyroglutamine);	chr15:48371906	chr15:48312353~48331856:-
KIRP	cis	rs2625529	1	rs2625529	ENSG00000260037.4	CTD-2524L6.3	4.85	2.11e-06	0.000767	0.25	0.29	Red blood cell count;	chr15:71826436	chr15:71818396~71823384:+
KIRP	cis	rs8030379	1	rs10152139	ENSG00000230373.7	GOLGA6L5P	-4.85	2.11e-06	0.000767	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901510	chr15:84507885~84516814:-
KIRP	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-4.85	2.11e-06	0.000767	-0.24	-0.29	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-4.85	2.11e-06	0.000767	-0.24	-0.29	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
KIRP	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-4.85	2.11e-06	0.000768	-0.25	-0.29	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
KIRP	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	4.85	2.11e-06	0.000768	0.33	0.29	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
KIRP	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-4.85	2.12e-06	0.000769	-0.38	-0.29	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
KIRP	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-4.85	2.12e-06	0.000769	-0.21	-0.29	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
KIRP	cis	rs9595908	0.709	rs9596222	ENSG00000212293.1	SNORA16	4.85	2.12e-06	0.000769	0.27	0.29	Body mass index;	chr13:32767679	chr13:32420390~32420516:-
KIRP	cis	rs308403	0.6	rs376131	ENSG00000224786.1	CETN4P	4.85	2.12e-06	0.000769	0.39	0.29	Blood protein levels;	chr4:122708070	chr4:122730548~122732193:-
KIRP	cis	rs1799949	1	rs11649954	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.12e-06	0.000769	-0.26	-0.29	Menopause (age at onset);	chr17:43342667	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs1824889	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.12e-06	0.000769	-0.26	-0.29	Menopause (age at onset);	chr17:43344508	chr17:43360041~43361361:-
KIRP	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	4.85	2.12e-06	0.000769	0.26	0.29	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
KIRP	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	4.85	2.12e-06	0.00077	0.23	0.29	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
KIRP	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	4.85	2.12e-06	0.000771	0.28	0.29	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
KIRP	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	4.85	2.12e-06	0.000771	0.28	0.29	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
KIRP	cis	rs11671005	0.656	rs11672609	ENSG00000269600.1	AC016629.3	-4.85	2.13e-06	0.000772	-0.45	-0.29	Mean platelet volume;	chr19:58495557	chr19:58593896~58599355:-
KIRP	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	4.85	2.13e-06	0.000772	0.28	0.29	Height;	chr14:75017109	chr14:75011269~75012851:-
KIRP	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	4.85	2.13e-06	0.000772	0.35	0.29	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
KIRP	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-4.85	2.13e-06	0.000773	-0.3	-0.29	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
KIRP	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	4.85	2.13e-06	0.000773	0.36	0.29	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	4.85	2.13e-06	0.000773	0.36	0.29	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
KIRP	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-4.85	2.13e-06	0.000773	-0.29	-0.29	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
KIRP	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-4.85	2.13e-06	0.000773	-0.23	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
KIRP	cis	rs4820539	1	rs2157710	ENSG00000275635.1	U7	4.85	2.13e-06	0.000774	0.31	0.29	Bone mineral density;	chr22:23115299	chr22:23137805~23137864:-
KIRP	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	4.85	2.13e-06	0.000774	0.32	0.29	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	4.85	2.13e-06	0.000774	0.32	0.29	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	4.85	2.13e-06	0.000774	0.32	0.29	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
KIRP	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-4.85	2.13e-06	0.000774	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
KIRP	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.85	2.13e-06	0.000775	0.27	0.29	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
KIRP	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.85	2.13e-06	0.000775	0.27	0.29	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
KIRP	cis	rs1552244	1	rs7628448	ENSG00000180385.7	EMC3-AS1	4.85	2.13e-06	0.000775	0.31	0.29	Alzheimer's disease;	chr3:10105144	chr3:9986893~10006990:+
KIRP	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	4.85	2.14e-06	0.000775	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
KIRP	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	4.85	2.14e-06	0.000775	0.35	0.29	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
KIRP	cis	rs7829975	0.56	rs56094035	ENSG00000253981.4	ALG1L13P	-4.85	2.14e-06	0.000776	-0.23	-0.29	Mood instability;	chr8:8694112	chr8:8236003~8244667:-
KIRP	cis	rs7829975	0.539	rs4841012	ENSG00000253981.4	ALG1L13P	-4.85	2.14e-06	0.000776	-0.23	-0.29	Mood instability;	chr8:8694200	chr8:8236003~8244667:-
KIRP	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-4.85	2.14e-06	0.000776	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
KIRP	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	4.85	2.14e-06	0.000776	0.28	0.29	Height;	chr4:55578787	chr4:55547112~55547889:+
KIRP	cis	rs9305354	1	rs2831494	ENSG00000232079.5	AL035610.1	4.85	2.14e-06	0.000777	0.39	0.29	Urinary albumin excretion;	chr21:28105418	chr21:28048404~28137611:+
KIRP	cis	rs507080	0.769	rs12290522	ENSG00000278376.1	RP11-158I9.8	-4.85	2.14e-06	0.000777	-0.28	-0.29	Serum metabolite levels;	chr11:118615610	chr11:118791254~118793137:+
KIRP	cis	rs8141529	0.753	rs5752813	ENSG00000226471.5	CTA-292E10.6	-4.85	2.14e-06	0.000778	-0.29	-0.29	Lymphocyte counts;	chr22:28830582	chr22:28800683~28848559:+
KIRP	cis	rs1799949	0.501	rs2343819	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.14e-06	0.000778	-0.27	-0.29	Menopause (age at onset);	chr17:43332285	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.501	rs35399157	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.14e-06	0.000778	-0.27	-0.29	Menopause (age at onset);	chr17:43334234	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.602	rs4600503	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.14e-06	0.000778	-0.27	-0.29	Menopause (age at onset);	chr17:43336956	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.501	rs9675035	ENSG00000279602.1	CTD-3014M21.1	-4.85	2.14e-06	0.000778	-0.27	-0.29	Menopause (age at onset);	chr17:43337648	chr17:43360041~43361361:-
KIRP	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-4.85	2.14e-06	0.000778	-0.22	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
KIRP	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-4.85	2.14e-06	0.000778	-0.22	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
KIRP	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	4.85	2.15e-06	0.000778	0.35	0.29	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
KIRP	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	4.85	2.15e-06	0.000779	0.27	0.29	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
KIRP	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	4.85	2.15e-06	0.000779	0.43	0.29	Height;	chr6:109403951	chr6:109382795~109383666:+
KIRP	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-4.85	2.15e-06	0.000779	-0.3	-0.29	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
KIRP	cis	rs7176527	0.848	rs16974951	ENSG00000188388.10	GOLGA6L3	4.85	2.15e-06	0.000779	0.41	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84618041	chr15:85240472~85247170:+
KIRP	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-4.85	2.15e-06	0.00078	-0.39	-0.29	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
KIRP	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	4.85	2.15e-06	0.000781	0.28	0.29	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
KIRP	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-4.85	2.15e-06	0.000781	-0.31	-0.29	Height;	chr3:52989412	chr3:53064283~53065091:-
KIRP	cis	rs7976059	0.895	rs73109505	ENSG00000261586.2	RP11-923I11.6	-4.85	2.16e-06	0.000781	-0.29	-0.29	Urate levels;	chr12:51851137	chr12:51817899~51820150:+
KIRP	cis	rs638893	0.673	rs538645	ENSG00000255239.1	AP002954.6	-4.85	2.16e-06	0.000782	-0.39	-0.29	Vitiligo;	chr11:118840360	chr11:118688039~118690600:-
KIRP	cis	rs4984778	0.717	rs2738892	ENSG00000260182.1	RP11-616M22.5	4.85	2.16e-06	0.000782	0.29	0.29	Blood protein levels;	chr16:1218758	chr16:1257339~1258074:+
KIRP	cis	rs7615952	0.599	rs12485717	ENSG00000241439.1	RP11-666A20.3	-4.85	2.16e-06	0.000782	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:125988232	chr3:125958556~125958817:+
KIRP	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-4.85	2.16e-06	0.000783	-0.24	-0.29	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
KIRP	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-4.85	2.16e-06	0.000783	-0.3	-0.29	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-4.85	2.16e-06	0.000783	-0.3	-0.29	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
KIRP	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-4.85	2.16e-06	0.000783	-0.3	-0.29	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
KIRP	cis	rs75920871	0.764	rs74428560	ENSG00000254851.1	RP11-109L13.1	-4.85	2.16e-06	0.000783	-0.58	-0.29	Subjective well-being;	chr11:117119266	chr11:117135528~117138582:+
KIRP	cis	rs7824557	0.51	rs1435274	ENSG00000254527.1	ENPP7P12	-4.85	2.16e-06	0.000784	-0.31	-0.29	Retinal vascular caliber;	chr8:11378401	chr8:12205759~12206389:-
KIRP	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-4.85	2.16e-06	0.000784	-0.36	-0.29	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
KIRP	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.85	2.17e-06	0.000785	0.32	0.29	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
KIRP	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	4.85	2.17e-06	0.000785	0.36	0.29	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
KIRP	cis	rs875971	0.545	rs11770063	ENSG00000224316.1	RP11-479O9.2	4.85	2.17e-06	0.000786	0.24	0.29	Aortic root size;	chr7:66318029	chr7:65773620~65802067:+
KIRP	cis	rs875971	0.545	rs4718335	ENSG00000224316.1	RP11-479O9.2	4.85	2.17e-06	0.000786	0.24	0.29	Aortic root size;	chr7:66339619	chr7:65773620~65802067:+
KIRP	cis	rs1005277	0.579	rs2474587	ENSG00000151963.4	RP11-775A3.1	-4.85	2.17e-06	0.000786	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:37883594~37884109:+
KIRP	cis	rs1005277	0.579	rs2474588	ENSG00000151963.4	RP11-775A3.1	-4.85	2.17e-06	0.000786	-0.34	-0.29	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:37883594~37884109:+
KIRP	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-4.85	2.17e-06	0.000786	-0.36	-0.29	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
KIRP	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-4.84	2.17e-06	0.000786	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
KIRP	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-4.84	2.17e-06	0.000786	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
KIRP	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-4.84	2.17e-06	0.000786	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
KIRP	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	4.84	2.17e-06	0.000786	0.36	0.29	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
KIRP	cis	rs6834314	0.7	rs13151329	ENSG00000251411.1	RP11-397E7.4	-4.84	2.17e-06	0.000786	-0.24	-0.29	Liver enzyme levels (alanine transaminase);	chr4:87245889	chr4:86913266~86914817:-
KIRP	cis	rs6834314	0.7	rs67927896	ENSG00000251411.1	RP11-397E7.4	-4.84	2.17e-06	0.000786	-0.24	-0.29	Liver enzyme levels (alanine transaminase);	chr4:87248082	chr4:86913266~86914817:-
KIRP	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	4.84	2.17e-06	0.000787	0.31	0.29	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
KIRP	cis	rs4578769	0.569	rs4800438	ENSG00000265943.1	RP11-739L10.1	4.84	2.17e-06	0.000787	0.37	0.29	Eosinophil percentage of white cells;	chr18:22920482	chr18:22699481~22933764:-
KIRP	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	4.84	2.17e-06	0.000787	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	4.84	2.17e-06	0.000787	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	4.84	2.17e-06	0.000787	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
KIRP	cis	rs77741769	0.571	rs12580949	ENSG00000277423.1	RP11-173P15.9	-4.84	2.17e-06	0.000787	-0.31	-0.29	Mean corpuscular volume;	chr12:120860361	chr12:120703867~120704282:+
KIRP	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	4.84	2.17e-06	0.000787	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
KIRP	cis	rs964611	0.882	rs6493316	ENSG00000259488.2	RP11-154J22.1	-4.84	2.17e-06	0.000787	-0.27	-0.29	Metabolite levels (Pyroglutamine);	chr15:48275280	chr15:48312353~48331856:-
KIRP	cis	rs4663866	0.901	rs34040298	ENSG00000186235.9	AC016757.3	4.84	2.17e-06	0.000787	0.55	0.29	Irritable bowel syndrome;	chr2:238282966	chr2:238224552~238231677:-
KIRP	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	4.84	2.18e-06	0.000788	0.59	0.29	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
KIRP	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-4.84	2.18e-06	0.000789	-0.27	-0.29	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
KIRP	cis	rs728616	0.867	rs1923534	ENSG00000234382.2	RP11-40F6.1	-4.84	2.18e-06	0.00079	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.557	rs17107449	ENSG00000234382.2	RP11-40F6.1	-4.84	2.18e-06	0.00079	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:80233664~80245367:+
KIRP	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-4.84	2.18e-06	0.000791	-0.34	-0.29	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
KIRP	cis	rs6832769	1	rs28514423	ENSG00000272969.1	RP11-528I4.2	-4.84	2.18e-06	0.000791	-0.28	-0.29	Personality dimensions;	chr4:55563072	chr4:55547112~55547889:+
KIRP	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-4.84	2.19e-06	0.000791	-0.42	-0.29	Height;	chr6:109485060	chr6:109382795~109383666:+
KIRP	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-4.84	2.19e-06	0.000791	-0.4	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
KIRP	cis	rs910316	0.737	rs175510	ENSG00000279594.1	RP11-950C14.10	-4.84	2.19e-06	0.000791	-0.29	-0.29	Height;	chr14:75058136	chr14:75011269~75012851:-
KIRP	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	4.84	2.19e-06	0.000791	0.28	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
KIRP	cis	rs1799949	1	rs35956818	ENSG00000279602.1	CTD-3014M21.1	-4.84	2.19e-06	0.000791	-0.26	-0.29	Menopause (age at onset);	chr17:43345617	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.93	rs4584865	ENSG00000279602.1	CTD-3014M21.1	-4.84	2.19e-06	0.000791	-0.26	-0.29	Menopause (age at onset);	chr17:43347551	chr17:43360041~43361361:-
KIRP	cis	rs1908814	0.516	rs4841641	ENSG00000255495.1	AC145124.2	4.84	2.19e-06	0.000791	0.27	0.29	Neuroticism;	chr8:11940718	chr8:12194467~12196280:+
KIRP	cis	rs7912580	0.929	rs61850826	ENSG00000233643.2	RP11-491H19.1	4.84	2.19e-06	0.000792	0.61	0.29	Response to haloperidol in psychosis;	chr10:62195938	chr10:61781745~61821246:-
KIRP	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	4.84	2.19e-06	0.000792	0.33	0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
KIRP	cis	rs875971	0.545	rs1796226	ENSG00000224316.1	RP11-479O9.2	4.84	2.19e-06	0.000792	0.23	0.29	Aortic root size;	chr7:66622723	chr7:65773620~65802067:+
KIRP	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-4.84	2.19e-06	0.000792	-0.21	-0.29	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
KIRP	cis	rs13113518	0.678	rs7663650	ENSG00000272969.1	RP11-528I4.2	-4.84	2.19e-06	0.000792	-0.26	-0.29	Height;	chr4:55364952	chr4:55547112~55547889:+
KIRP	cis	rs5760092	0.842	rs5751763	ENSG00000250470.1	AP000351.3	4.84	2.19e-06	0.000793	0.44	0.29	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23976904~23977585:-
KIRP	cis	rs2562456	0.876	rs62110202	ENSG00000268555.1	RP11-678G14.3	4.84	2.19e-06	0.000793	0.38	0.29	Pain;	chr19:21571799	chr19:21570822~21587322:-
KIRP	cis	rs6834314	0.743	rs13137873	ENSG00000251411.1	RP11-397E7.4	-4.84	2.19e-06	0.000793	-0.27	-0.29	Liver enzyme levels (alanine transaminase);	chr4:87238277	chr4:86913266~86914817:-
KIRP	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-4.84	2.19e-06	0.000793	-0.25	-0.29	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
KIRP	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	4.84	2.19e-06	0.000794	0.24	0.29	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
KIRP	cis	rs7267979	0.932	rs449370	ENSG00000274414.1	RP5-965G21.4	4.84	2.19e-06	0.000794	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25239007~25245229:-
KIRP	cis	rs600231	0.706	rs10896016	ENSG00000245532.5	NEAT1	-4.84	2.19e-06	0.000794	-0.22	-0.29	Bone mineral density;	chr11:65568234	chr11:65422774~65445540:+
KIRP	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	4.84	2.19e-06	0.000794	0.21	0.29	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
KIRP	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-4.84	2.19e-06	0.000794	-0.22	-0.29	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
KIRP	cis	rs712022	0.505	rs11026816	ENSG00000246225.5	RP11-17A1.3	-4.84	2.19e-06	0.000794	-0.34	-0.29	Dialysis-related mortality;	chr11:22855277	chr11:22829380~22945393:+
KIRP	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	4.84	2.19e-06	0.000794	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
KIRP	cis	rs9926296	0.706	rs2159115	ENSG00000260259.1	RP11-368I7.4	-4.84	2.2e-06	0.000794	-0.23	-0.29	Vitiligo;	chr16:89765411	chr16:89682620~89686569:-
KIRP	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-4.84	2.2e-06	0.000795	-0.24	-0.29	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
KIRP	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-4.84	2.2e-06	0.000795	-0.24	-0.29	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
KIRP	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-4.84	2.2e-06	0.000795	-0.24	-0.29	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
KIRP	cis	rs2562456	0.833	rs8106025	ENSG00000268555.1	RP11-678G14.3	-4.84	2.2e-06	0.000795	-0.38	-0.29	Pain;	chr19:21451922	chr19:21570822~21587322:-
KIRP	cis	rs395157	0.591	rs395967	ENSG00000249911.1	LINC01265	4.84	2.2e-06	0.000796	0.32	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38842857	chr5:38710367~38720273:-
KIRP	cis	rs10760158	0.62	rs767769	ENSG00000226752.6	PSMD5-AS1	4.84	2.2e-06	0.000796	0.33	0.29	Pulse pressure;	chr9:121336058	chr9:120824828~120854385:+
KIRP	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-4.84	2.2e-06	0.000796	-0.21	-0.29	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
KIRP	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-4.84	2.2e-06	0.000796	-0.31	-0.29	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
KIRP	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	4.84	2.2e-06	0.000796	0.41	0.29	Height;	chr6:109482392	chr6:109382795~109383666:+
KIRP	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	4.84	2.2e-06	0.000797	0.22	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
KIRP	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-4.84	2.2e-06	0.000797	-0.29	-0.29	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
KIRP	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	4.84	2.2e-06	0.000797	0.46	0.29	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
KIRP	cis	rs2745572	0.557	rs2745576	ENSG00000272279.1	RP11-157J24.2	-4.84	2.2e-06	0.000797	-0.36	-0.29	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1549211	chr6:1528364~1528911:-
KIRP	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-4.84	2.21e-06	0.000797	-0.22	-0.29	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
KIRP	cis	rs4128705	1	rs17018388	ENSG00000249049.1	RP11-763F8.1	4.84	2.21e-06	0.000798	0.26	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91360683	chr4:91319034~91325306:-
KIRP	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-4.84	2.21e-06	0.000798	-0.29	-0.29	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
KIRP	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-4.84	2.21e-06	0.000798	-0.3	-0.29	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
KIRP	cis	rs7176527	0.848	rs1374463	ENSG00000188388.10	GOLGA6L3	4.84	2.21e-06	0.000798	0.42	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:85240472~85247170:+
KIRP	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	4.84	2.21e-06	0.000798	0.32	0.29	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
KIRP	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-4.84	2.21e-06	0.000799	-0.23	-0.29	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
KIRP	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	4.84	2.21e-06	0.000799	0.3	0.29	Height;	chr4:55538228	chr4:55363971~55395847:-
KIRP	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	4.84	2.21e-06	8e-04	0.5	0.29	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
KIRP	cis	rs9532669	0.926	rs11147831	ENSG00000176268.5	CYCSP34	4.84	2.22e-06	0.000801	0.29	0.29	Cervical cancer;	chr13:40978593	chr13:40863599~40863902:-
KIRP	cis	rs11864453	0.826	rs9941087	ENSG00000260886.1	TAT-AS1	4.84	2.22e-06	0.000802	0.36	0.29	Fibrinogen levels;	chr16:72084425	chr16:71565789~71578187:+
KIRP	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-4.84	2.22e-06	0.000802	-0.32	-0.29	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
KIRP	cis	rs9925964	0.744	rs12716979	ENSG00000232748.3	RP11-196G11.6	4.84	2.22e-06	0.000802	0.34	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:31056460~31062803:+
KIRP	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-4.84	2.22e-06	0.000802	-0.24	-0.29	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
KIRP	cis	rs11647589	0.553	rs7195201	ENSG00000262995.1	CTD-2194A8.2	-4.84	2.22e-06	0.000803	-0.32	-0.29	Blood metabolite levels;	chr16:20467280	chr16:20440266~20447000:-
KIRP	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-4.84	2.22e-06	0.000803	-0.33	-0.29	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
KIRP	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-4.84	2.22e-06	0.000803	-0.28	-0.29	Height;	chr14:75193177	chr14:75011269~75012851:-
KIRP	cis	rs875971	0.545	rs73378304	ENSG00000236529.1	RP13-254B10.1	4.84	2.22e-06	0.000804	0.26	0.29	Aortic root size;	chr7:66175760	chr7:65840212~65840596:+
KIRP	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-4.84	2.22e-06	0.000804	-0.36	-0.29	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
KIRP	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-4.84	2.23e-06	0.000804	-0.29	-0.29	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
KIRP	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-4.84	2.23e-06	0.000804	-0.29	-0.29	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
KIRP	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-4.84	2.23e-06	0.000804	-0.25	-0.29	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
KIRP	cis	rs6840258	0.891	rs3775209	ENSG00000251411.1	RP11-397E7.4	-4.84	2.23e-06	0.000804	-0.27	-0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87125794	chr4:86913266~86914817:-
KIRP	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-4.84	2.23e-06	0.000805	-0.38	-0.29	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
KIRP	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.84	2.23e-06	0.000806	0.24	0.29	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
KIRP	cis	rs11673344	0.542	rs2562598	ENSG00000226686.6	LINC01535	4.84	2.23e-06	0.000806	0.35	0.29	Obesity-related traits;	chr19:37025318	chr19:37251912~37265535:+
KIRP	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	4.84	2.23e-06	0.000807	0.31	0.29	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
KIRP	cis	rs9302635	0.678	rs8054585	ENSG00000260886.1	TAT-AS1	4.84	2.23e-06	0.000807	0.38	0.29	Blood protein levels;	chr16:72191415	chr16:71565789~71578187:+
KIRP	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	4.84	2.23e-06	0.000807	0.21	0.29	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
KIRP	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.84	2.23e-06	0.000807	-0.36	-0.29	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
KIRP	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	4.84	2.24e-06	0.000807	0.5	0.29	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
KIRP	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-4.84	2.24e-06	0.000808	-0.34	-0.29	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
KIRP	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	4.84	2.24e-06	0.000808	0.41	0.29	Height;	chr6:109613205	chr6:109382795~109383666:+
KIRP	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	4.84	2.24e-06	0.000808	0.25	0.29	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
KIRP	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-4.84	2.24e-06	0.000808	-0.39	-0.29	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
KIRP	cis	rs12039431	0.666	rs61778058	ENSG00000232273.1	FTH1P1	4.84	2.24e-06	0.000808	0.39	0.29	Epithelial ovarian cancer;	chr1:37503391	chr1:37544763~37545294:+
KIRP	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	4.84	2.24e-06	0.000808	0.25	0.29	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
KIRP	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	4.84	2.24e-06	0.000808	0.28	0.29	Height;	chr4:55575856	chr4:55547112~55547889:+
KIRP	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	4.84	2.24e-06	0.000808	0.28	0.29	Height;	chr4:55577294	chr4:55547112~55547889:+
KIRP	cis	rs9925964	0.687	rs12917722	ENSG00000232748.3	RP11-196G11.6	4.84	2.24e-06	0.000808	0.35	0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:31056460~31062803:+
KIRP	cis	rs703842	1	rs6581155	ENSG00000270039.1	RP11-571M6.17	-4.84	2.24e-06	0.000809	-0.26	-0.29	Multiple sclerosis;	chr12:57784379	chr12:57803838~57804415:+
KIRP	cis	rs11673344	0.523	rs8108509	ENSG00000226686.6	LINC01535	4.84	2.24e-06	0.000809	0.35	0.29	Obesity-related traits;	chr19:37060370	chr19:37251912~37265535:+
KIRP	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	4.84	2.24e-06	0.000809	0.36	0.29	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
KIRP	cis	rs911119	1	rs13041070	ENSG00000270001.1	RP11-218C14.8	-4.84	2.24e-06	0.000809	-0.36	-0.29	Chronic kidney disease;	chr20:23633624	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs3787498	ENSG00000270001.1	RP11-218C14.8	-4.84	2.24e-06	0.000809	-0.36	-0.29	Chronic kidney disease;	chr20:23636144	chr20:23631826~23632316:-
KIRP	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	4.84	2.25e-06	0.000811	0.33	0.29	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
KIRP	cis	rs324126	0.78	rs11084155	ENSG00000269834.4	ZNF528-AS1	4.84	2.25e-06	0.000811	0.29	0.29	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.752	rs11084156	ENSG00000269834.4	ZNF528-AS1	4.84	2.25e-06	0.000811	0.29	0.29	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52388842~52397766:-
KIRP	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	4.84	2.25e-06	0.000811	0.32	0.29	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	4.84	2.25e-06	0.000811	0.32	0.29	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
KIRP	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55515292	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55518776	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55518922	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55520278	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55523835	chr4:55363971~55395847:-
KIRP	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55524246	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55525589	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55525781	chr4:55363971~55395847:-
KIRP	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	4.84	2.25e-06	0.000811	0.3	0.29	Height;	chr4:55526514	chr4:55363971~55395847:-
KIRP	cis	rs664154	0.522	rs2842391	ENSG00000228412.5	RP4-625H18.2	-4.84	2.25e-06	0.000811	-0.28	-0.29	Information processing speed;	chr6:19094754	chr6:19802164~19804752:-
KIRP	cis	rs6005807	0.543	rs6005868	ENSG00000226471.5	CTA-292E10.6	-4.84	2.25e-06	0.000811	-0.44	-0.29	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28769778	chr22:28800683~28848559:+
KIRP	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	4.84	2.25e-06	0.000812	0.58	0.29	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
KIRP	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	4.84	2.25e-06	0.000812	0.24	0.29	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
KIRP	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	4.84	2.25e-06	0.000812	0.33	0.29	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
KIRP	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	4.84	2.25e-06	0.000812	0.31	0.29	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
KIRP	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-4.84	2.25e-06	0.000813	-0.28	-0.29	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
KIRP	cis	rs9926296	0.656	rs2376881	ENSG00000260259.1	RP11-368I7.4	-4.84	2.25e-06	0.000813	-0.23	-0.29	Vitiligo;	chr16:89760603	chr16:89682620~89686569:-
KIRP	cis	rs2361701	0.636	rs1982244	ENSG00000279259.1	RP11-334C17.3	4.84	2.25e-06	0.000813	0.28	0.29	IgG glycosylation;	chr17:80095149	chr17:80147250~80148596:+
KIRP	cis	rs35934224	0.504	rs11704009	ENSG00000232926.1	AC000078.5	4.84	2.25e-06	0.000813	0.29	0.29	Glaucoma (primary open-angle);	chr22:19852600	chr22:19887289~19887970:+
KIRP	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	4.84	2.26e-06	0.000815	0.24	0.29	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
KIRP	cis	rs728616	0.541	rs61860401	ENSG00000234382.2	RP11-40F6.1	-4.84	2.26e-06	0.000815	-0.33	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs58606426	ENSG00000234382.2	RP11-40F6.1	-4.84	2.26e-06	0.000815	-0.33	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs57966752	ENSG00000234382.2	RP11-40F6.1	-4.84	2.26e-06	0.000815	-0.33	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:80233664~80245367:+
KIRP	cis	rs7189233	0.955	rs7189726	ENSG00000279344.1	RP11-44F14.7	4.84	2.26e-06	0.000816	0.23	0.29	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53478957~53481550:-
KIRP	cis	rs4128705	1	rs78928013	ENSG00000249049.1	RP11-763F8.1	4.84	2.26e-06	0.000816	0.26	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91360654	chr4:91319034~91325306:-
KIRP	cis	rs4128705	1	rs76873040	ENSG00000249049.1	RP11-763F8.1	4.84	2.26e-06	0.000816	0.26	0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91360655	chr4:91319034~91325306:-
KIRP	cis	rs7674212	0.541	rs2720460	ENSG00000230069.3	LRRC37A15P	4.84	2.26e-06	0.000816	0.27	0.29	Type 2 diabetes;	chr4:103133529	chr4:102727274~102730721:-
KIRP	cis	rs1476679	1	rs34919929	ENSG00000242294.5	STAG3L5P	4.84	2.26e-06	0.000816	0.18	0.29	Alzheimer's disease (late onset);	chr7:100414711	chr7:100336079~100351900:+
KIRP	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	4.84	2.27e-06	0.000817	0.21	0.29	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
KIRP	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	4.84	2.27e-06	0.000818	0.4	0.29	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
KIRP	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	4.84	2.27e-06	0.000819	0.33	0.29	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
KIRP	cis	rs9595908	0.669	rs4941669	ENSG00000212293.1	SNORA16	4.84	2.27e-06	0.000819	0.28	0.29	Body mass index;	chr13:32793045	chr13:32420390~32420516:-
KIRP	cis	rs1075265	0.547	rs6741891	ENSG00000272156.1	RP11-477N3.1	4.84	2.27e-06	0.000819	0.3	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54082554~54085066:+
KIRP	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-4.84	2.27e-06	0.000819	-0.28	-0.29	Height;	chr14:75185155	chr14:75011269~75012851:-
KIRP	cis	rs42648	0.693	rs194533	ENSG00000225498.1	AC002064.5	4.83	2.27e-06	0.000819	0.2	0.29	Homocysteine levels;	chr7:90241463	chr7:90312496~90322592:+
KIRP	cis	rs12188164	0.515	rs11745246	ENSG00000221990.4	EXOC3-AS1	4.83	2.27e-06	0.000819	0.28	0.29	Cystic fibrosis severity;	chr5:410828	chr5:441498~443160:-
KIRP	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-4.83	2.27e-06	0.00082	-0.32	-0.29	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
KIRP	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	4.83	2.28e-06	0.00082	0.4	0.29	Height;	chr6:109530435	chr6:109382795~109383666:+
KIRP	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	4.83	2.28e-06	0.00082	0.36	0.29	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
KIRP	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	4.83	2.28e-06	0.000821	0.26	0.29	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
KIRP	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	4.83	2.28e-06	0.000821	0.29	0.29	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
KIRP	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	4.83	2.28e-06	0.000821	0.29	0.29	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
KIRP	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	4.83	2.28e-06	0.000821	0.44	0.29	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
KIRP	cis	rs9595908	0.733	rs9315175	ENSG00000212293.1	SNORA16	4.83	2.28e-06	0.000821	0.27	0.29	Body mass index;	chr13:32649581	chr13:32420390~32420516:-
KIRP	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	4.83	2.28e-06	0.000822	0.31	0.29	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
KIRP	cis	rs73198271	0.813	rs17697237	ENSG00000253981.4	ALG1L13P	4.83	2.28e-06	0.000823	0.24	0.29	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8236003~8244667:-
KIRP	cis	rs1552244	1	rs4269070	ENSG00000180385.7	EMC3-AS1	4.83	2.28e-06	0.000823	0.27	0.29	Alzheimer's disease;	chr3:10084399	chr3:9986893~10006990:+
KIRP	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-4.83	2.28e-06	0.000823	-0.29	-0.29	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
KIRP	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-4.83	2.28e-06	0.000823	-0.29	-0.29	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
KIRP	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-4.83	2.28e-06	0.000823	-0.34	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
KIRP	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	4.83	2.29e-06	0.000823	0.34	0.29	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	4.83	2.29e-06	0.000823	0.34	0.29	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	4.83	2.29e-06	0.000823	0.34	0.29	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
KIRP	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-4.83	2.29e-06	0.000824	-0.38	-0.29	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
KIRP	cis	rs9595908	0.709	rs7322668	ENSG00000212293.1	SNORA16	4.83	2.29e-06	0.000824	0.27	0.29	Body mass index;	chr13:32780298	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs7318610	ENSG00000212293.1	SNORA16	4.83	2.29e-06	0.000824	0.27	0.29	Body mass index;	chr13:32781912	chr13:32420390~32420516:-
KIRP	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-4.83	2.29e-06	0.000824	-0.36	-0.29	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
KIRP	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	4.83	2.29e-06	0.000825	0.41	0.29	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
KIRP	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-4.83	2.29e-06	0.000825	-0.35	-0.29	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
KIRP	cis	rs11158026	1	rs11158026	ENSG00000258413.1	RP11-665C16.6	-4.83	2.29e-06	0.000825	-0.35	-0.29	Parkinson's disease;	chr14:54882151	chr14:55262767~55272075:-
KIRP	cis	rs12936587	0.714	rs9890064	ENSG00000223979.2	SMCR2	4.83	2.29e-06	0.000826	0.28	0.29	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17634694	chr17:17674026~17677688:-
KIRP	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	4.83	2.29e-06	0.000826	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	4.83	2.29e-06	0.000826	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
KIRP	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	4.83	2.3e-06	0.000826	0.36	0.29	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
KIRP	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-4.83	2.3e-06	0.000826	-0.37	-0.29	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-4.83	2.3e-06	0.000826	-0.37	-0.29	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
KIRP	cis	rs453301	0.597	rs7001187	ENSG00000173295.6	FAM86B3P	-4.83	2.3e-06	0.000827	-0.23	-0.29	Joint mobility (Beighton score);	chr8:8935272	chr8:8228595~8244865:+
KIRP	cis	rs11673344	0.503	rs7246720	ENSG00000226686.6	LINC01535	4.83	2.3e-06	0.000827	0.35	0.29	Obesity-related traits;	chr19:37073726	chr19:37251912~37265535:+
KIRP	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-4.83	2.3e-06	0.000828	-0.26	-0.29	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-4.83	2.3e-06	0.000828	-0.26	-0.29	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
KIRP	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	4.83	2.3e-06	0.000828	0.31	0.29	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
KIRP	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.83	2.3e-06	0.000828	0.53	0.29	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
KIRP	cis	rs2880765	0.566	rs55899824	ENSG00000259630.2	CTD-2262B20.1	-4.83	2.3e-06	0.000829	-0.28	-0.29	Coronary artery disease;	chr15:85460860	chr15:85415228~85415633:+
KIRP	cis	rs2880765	0.631	rs55767890	ENSG00000259630.2	CTD-2262B20.1	-4.83	2.3e-06	0.000829	-0.28	-0.29	Coronary artery disease;	chr15:85460911	chr15:85415228~85415633:+
KIRP	cis	rs6502050	0.871	rs6502051	ENSG00000266654.1	RP11-1376P16.1	4.83	2.3e-06	0.000829	0.26	0.29	Life satisfaction;	chr17:82101456	chr17:82160056~82160452:+
KIRP	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	4.83	2.31e-06	0.00083	0.27	0.29	QT interval;	chr12:29272168	chr12:29280418~29317848:-
KIRP	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	4.83	2.31e-06	0.00083	0.32	0.29	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
KIRP	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	4.83	2.31e-06	0.00083	0.37	0.29	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
KIRP	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	4.83	2.31e-06	0.00083	0.32	0.29	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	4.83	2.31e-06	0.00083	0.32	0.29	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	4.83	2.31e-06	0.00083	0.32	0.29	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	4.83	2.31e-06	0.00083	0.32	0.29	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
KIRP	cis	rs703842	1	rs11172335	ENSG00000270039.1	RP11-571M6.17	-4.83	2.31e-06	0.000831	-0.27	-0.29	Multiple sclerosis;	chr12:57781418	chr12:57803838~57804415:+
KIRP	cis	rs703842	0.964	rs2014886	ENSG00000270039.1	RP11-571M6.17	-4.83	2.31e-06	0.000831	-0.27	-0.29	Multiple sclerosis;	chr12:57783654	chr12:57803838~57804415:+
KIRP	cis	rs703842	1	rs1599932	ENSG00000270039.1	RP11-571M6.17	-4.83	2.31e-06	0.000831	-0.27	-0.29	Multiple sclerosis;	chr12:57784160	chr12:57803838~57804415:+
KIRP	cis	rs875971	0.545	rs3936065	ENSG00000236529.1	RP13-254B10.1	4.83	2.31e-06	0.000831	0.26	0.29	Aortic root size;	chr7:66325577	chr7:65840212~65840596:+
KIRP	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	4.83	2.31e-06	0.000831	0.25	0.29	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
KIRP	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-4.83	2.31e-06	0.000831	-0.36	-0.29	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
KIRP	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-4.83	2.31e-06	0.000831	-0.42	-0.29	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
KIRP	cis	rs7404843	1	rs7404843	ENSG00000263335.1	AF001548.5	-4.83	2.31e-06	0.000832	-0.42	-0.29	Testicular germ cell tumor;	chr16:15436851	chr16:15726674~15732993:+
KIRP	cis	rs11673344	0.562	rs7257320	ENSG00000226686.6	LINC01535	4.83	2.31e-06	0.000832	0.35	0.29	Obesity-related traits;	chr19:37080933	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs35162188	ENSG00000226686.6	LINC01535	4.83	2.31e-06	0.000832	0.35	0.29	Obesity-related traits;	chr19:37088908	chr19:37251912~37265535:+
KIRP	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	4.83	2.31e-06	0.000832	0.24	0.29	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
KIRP	cis	rs1044826	0.642	rs9826544	ENSG00000178631.7	ACTG1P1	4.83	2.32e-06	0.000832	0.3	0.29	Obesity-related traits;	chr3:139443989	chr3:139493809~139494937:+
KIRP	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.83	2.32e-06	0.000832	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
KIRP	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	4.83	2.32e-06	0.000833	0.35	0.29	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
KIRP	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	4.83	2.32e-06	0.000834	0.36	0.29	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
KIRP	cis	rs2946505	1	rs2977086	ENSG00000251468.2	RP11-369K16.1	4.83	2.32e-06	0.000834	0.37	0.29	Migraine;	chr8:12953436	chr8:12958387~12962200:+
KIRP	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	4.83	2.32e-06	0.000835	0.36	0.29	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
KIRP	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	4.83	2.32e-06	0.000835	0.36	0.29	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
KIRP	cis	rs1858037	0.806	rs12612780	ENSG00000237979.1	AC007389.1	4.83	2.32e-06	0.000835	0.32	0.29	Rheumatoid arthritis;	chr2:65355967	chr2:65500993~65502138:-
KIRP	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	4.83	2.32e-06	0.000835	0.28	0.29	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
KIRP	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	4.83	2.33e-06	0.000836	0.33	0.29	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
KIRP	cis	rs9595908	0.785	rs7981925	ENSG00000212293.1	SNORA16	4.83	2.33e-06	0.000836	0.27	0.29	Body mass index;	chr13:32693706	chr13:32420390~32420516:-
KIRP	cis	rs950169	0.96	rs35159785	ENSG00000275120.1	RP11-182J1.17	4.83	2.33e-06	0.000836	0.4	0.29	Schizophrenia;	chr15:84135262	chr15:84599434~84606463:-
KIRP	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	4.83	2.33e-06	0.000836	0.33	0.29	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
KIRP	cis	rs9595908	0.669	rs9596218	ENSG00000212293.1	SNORA16	4.83	2.33e-06	0.000836	0.28	0.29	Body mass index;	chr13:32764222	chr13:32420390~32420516:-
KIRP	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	4.83	2.33e-06	0.000837	0.23	0.29	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
KIRP	cis	rs7189233	0.955	rs72801821	ENSG00000279344.1	RP11-44F14.7	4.83	2.33e-06	0.000837	0.23	0.29	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53478957~53481550:-
KIRP	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.83	2.33e-06	0.000838	0.35	0.29	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
KIRP	cis	rs7772486	0.875	rs7739418	ENSG00000270638.1	RP3-466P17.1	4.83	2.34e-06	0.000838	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs9390371	ENSG00000270638.1	RP3-466P17.1	4.83	2.34e-06	0.000838	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs6909827	ENSG00000270638.1	RP3-466P17.1	4.83	2.34e-06	0.000838	0.25	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145735570~145737218:+
KIRP	cis	rs12928939	0.911	rs77823468	ENSG00000260886.1	TAT-AS1	4.83	2.34e-06	0.000839	0.39	0.29	Post bronchodilator FEV1;	chr16:71794713	chr16:71565789~71578187:+
KIRP	cis	rs12928939	0.954	rs34998650	ENSG00000260886.1	TAT-AS1	4.83	2.34e-06	0.000839	0.39	0.29	Post bronchodilator FEV1;	chr16:71795426	chr16:71565789~71578187:+
KIRP	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-4.83	2.34e-06	0.000839	-0.28	-0.29	Height;	chr14:75157285	chr14:75011269~75012851:-
KIRP	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	4.83	2.34e-06	0.000839	0.28	0.29	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
KIRP	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-4.83	2.34e-06	0.000839	-0.29	-0.29	Height;	chr14:75173651	chr14:75011269~75012851:-
KIRP	cis	rs11673344	0.523	rs6510584	ENSG00000226686.6	LINC01535	4.83	2.34e-06	0.000839	0.35	0.29	Obesity-related traits;	chr19:37058699	chr19:37251912~37265535:+
KIRP	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	4.83	2.34e-06	0.00084	0.28	0.29	Height;	chr14:75118164	chr14:75011269~75012851:-
KIRP	cis	rs7432375	1	rs10935186	ENSG00000261758.1	RP11-102M11.2	4.83	2.34e-06	0.00084	0.3	0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136627364	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.933	rs55970317	ENSG00000261758.1	RP11-102M11.2	4.83	2.34e-06	0.00084	0.3	0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136634351	chr3:136752630~136755780:+
KIRP	cis	rs7432375	0.966	rs6808312	ENSG00000261758.1	RP11-102M11.2	-4.83	2.34e-06	0.00084	-0.3	-0.29	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652662	chr3:136752630~136755780:+
KIRP	cis	rs7634476	1	rs7634476	ENSG00000261758.1	RP11-102M11.2	-4.83	2.34e-06	0.00084	-0.3	-0.29	Neuroticism;	chr3:136679545	chr3:136752630~136755780:+
KIRP	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	4.83	2.34e-06	0.00084	0.26	0.29	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
KIRP	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	4.83	2.34e-06	0.000841	0.28	0.29	Height;	chr4:55451489	chr4:55547112~55547889:+
KIRP	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28089816	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28090857	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28091439	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28091659	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28093966	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28094014	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28096077	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	4.83	2.34e-06	0.000841	0.33	0.29	Depression;	chr6:28096855	chr6:28073316~28074233:+
KIRP	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-4.83	2.35e-06	0.000842	-0.37	-0.29	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
KIRP	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-4.83	2.35e-06	0.000843	-0.22	-0.29	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
KIRP	cis	rs6840258	0.582	rs28670747	ENSG00000251411.1	RP11-397E7.4	-4.83	2.35e-06	0.000843	-0.26	-0.29	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87157327	chr4:86913266~86914817:-
KIRP	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	4.83	2.35e-06	0.000844	0.31	0.29	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
KIRP	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	4.83	2.35e-06	0.000844	0.28	0.29	Height;	chr4:55574959	chr4:55547112~55547889:+
KIRP	cis	rs9595908	0.694	rs2224883	ENSG00000212293.1	SNORA16	4.83	2.35e-06	0.000844	0.27	0.29	Body mass index;	chr13:32763753	chr13:32420390~32420516:-
KIRP	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	4.83	2.35e-06	0.000844	0.33	0.29	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
KIRP	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	4.83	2.35e-06	0.000844	0.32	0.29	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
KIRP	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	4.83	2.35e-06	0.000845	0.36	0.29	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
KIRP	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	4.83	2.36e-06	0.000845	0.36	0.29	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
KIRP	cis	rs7615952	0.599	rs2279821	ENSG00000241439.1	RP11-666A20.3	4.83	2.36e-06	0.000845	0.41	0.29	Blood pressure (smoking interaction);	chr3:126015465	chr3:125958556~125958817:+
KIRP	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-4.83	2.36e-06	0.000845	-0.35	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
KIRP	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-4.83	2.36e-06	0.000845	-0.27	-0.29	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
KIRP	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-4.83	2.36e-06	0.000846	-0.22	-0.29	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
KIRP	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	4.83	2.36e-06	0.000846	0.41	0.29	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
KIRP	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-4.83	2.36e-06	0.000847	-0.34	-0.29	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
KIRP	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.83	2.36e-06	0.000847	0.24	0.29	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
KIRP	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	4.83	2.36e-06	0.000847	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
KIRP	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	4.83	2.36e-06	0.000847	0.28	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
KIRP	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	4.83	2.36e-06	0.000847	0.33	0.29	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	4.83	2.36e-06	0.000847	0.33	0.29	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
KIRP	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	4.83	2.36e-06	0.000847	0.28	0.29	Height;	chr4:55587104	chr4:55547112~55547889:+
KIRP	cis	rs911119	0.954	rs2405367	ENSG00000270001.1	RP11-218C14.8	4.83	2.37e-06	0.000848	0.31	0.29	Chronic kidney disease;	chr20:23642243	chr20:23631826~23632316:-
KIRP	cis	rs7772486	0.79	rs9485024	ENSG00000270638.1	RP3-466P17.1	-4.83	2.37e-06	0.000849	-0.26	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145735570~145737218:+
KIRP	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	4.83	2.37e-06	0.000849	0.25	0.29	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
KIRP	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-4.83	2.37e-06	0.00085	-0.39	-0.29	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
KIRP	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	4.83	2.37e-06	0.00085	0.26	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
KIRP	cis	rs984222	0.838	rs7553422	ENSG00000231365.4	RP11-418J17.1	-4.83	2.37e-06	0.000851	-0.27	-0.29	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998096	chr1:119140396~119275973:+
KIRP	cis	rs6832769	1	rs9997288	ENSG00000272969.1	RP11-528I4.2	4.83	2.37e-06	0.000851	0.3	0.29	Personality dimensions;	chr4:55481060	chr4:55547112~55547889:+
KIRP	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	4.83	2.38e-06	0.000851	0.25	0.29	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
KIRP	cis	rs947583	0.517	rs9494390	ENSG00000231028.7	LINC00271	-4.83	2.38e-06	0.000851	-0.25	-0.29	Phosphorus levels;	chr6:135794875	chr6:135497801~135716055:+
KIRP	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-4.83	2.38e-06	0.000852	-0.22	-0.29	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
KIRP	cis	rs1799949	0.93	rs35292991	ENSG00000279602.1	CTD-3014M21.1	-4.83	2.38e-06	0.000852	-0.26	-0.29	Menopause (age at onset);	chr17:43181999	chr17:43360041~43361361:-
KIRP	cis	rs8067287	1	rs62065413	ENSG00000205312.7	KRT17P4	4.83	2.38e-06	0.000852	0.44	0.29	Diabetic kidney disease;	chr17:16910664	chr17:16847635~16852777:-
KIRP	cis	rs4578769	0.959	rs9945114	ENSG00000266850.1	RP11-370A5.1	4.83	2.38e-06	0.000852	0.37	0.29	Eosinophil percentage of white cells;	chr18:22884044	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.918	rs8089471	ENSG00000266850.1	RP11-370A5.1	4.83	2.38e-06	0.000852	0.37	0.29	Eosinophil percentage of white cells;	chr18:22892994	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.959	rs3863525	ENSG00000266850.1	RP11-370A5.1	4.83	2.38e-06	0.000852	0.37	0.29	Eosinophil percentage of white cells;	chr18:22898714	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.959	rs4800137	ENSG00000266850.1	RP11-370A5.1	4.83	2.38e-06	0.000852	0.37	0.29	Eosinophil percentage of white cells;	chr18:22899721	chr18:22723491~22907721:-
KIRP	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	4.83	2.38e-06	0.000852	0.51	0.29	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
KIRP	cis	rs875971	0.502	rs6460311	ENSG00000224316.1	RP11-479O9.2	-4.82	2.38e-06	0.000853	-0.24	-0.29	Aortic root size;	chr7:66646886	chr7:65773620~65802067:+
KIRP	cis	rs2904967	0.636	rs239253	ENSG00000254614.2	AP003068.23	-4.82	2.38e-06	0.000853	-0.38	-0.29	Mean corpuscular volume;	chr11:65217272	chr11:65177606~65181834:-
KIRP	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	4.82	2.38e-06	0.000853	0.24	0.29	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
KIRP	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	4.82	2.38e-06	0.000853	0.37	0.29	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	4.82	2.38e-06	0.000853	0.37	0.29	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	4.82	2.38e-06	0.000853	0.37	0.29	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	4.82	2.38e-06	0.000853	0.37	0.29	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
KIRP	cis	rs9595908	0.709	rs4942897	ENSG00000212293.1	SNORA16	4.82	2.38e-06	0.000854	0.27	0.29	Body mass index;	chr13:32757615	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.694	rs3752474	ENSG00000212293.1	SNORA16	4.82	2.38e-06	0.000854	0.27	0.29	Body mass index;	chr13:32758510	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs7988089	ENSG00000212293.1	SNORA16	4.82	2.38e-06	0.000854	0.27	0.29	Body mass index;	chr13:32759738	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs9285094	ENSG00000212293.1	SNORA16	4.82	2.38e-06	0.000854	0.27	0.29	Body mass index;	chr13:32761453	chr13:32420390~32420516:-
KIRP	cis	rs42648	0.869	rs10266179	ENSG00000225498.1	AC002064.5	4.82	2.38e-06	0.000854	0.2	0.29	Homocysteine levels;	chr7:90280668	chr7:90312496~90322592:+
KIRP	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	4.82	2.38e-06	0.000854	0.26	0.29	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
KIRP	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-4.82	2.39e-06	0.000854	-0.31	-0.29	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-4.82	2.39e-06	0.000854	-0.31	-0.29	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-4.82	2.39e-06	0.000854	-0.31	-0.29	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
KIRP	cis	rs1044826	0.642	rs6771831	ENSG00000178631.7	ACTG1P1	4.82	2.39e-06	0.000855	0.3	0.29	Obesity-related traits;	chr3:139458743	chr3:139493809~139494937:+
KIRP	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-4.82	2.39e-06	0.000856	-0.3	-0.29	Height;	chr4:55487920	chr4:55363971~55395847:-
KIRP	cis	rs9810089	0.814	rs2688600	ENSG00000261758.1	RP11-102M11.2	4.82	2.39e-06	0.000856	0.31	0.29	Gestational age at birth (child effect);	chr3:136533754	chr3:136752630~136755780:+
KIRP	cis	rs9810089	0.777	rs2688601	ENSG00000261758.1	RP11-102M11.2	4.82	2.39e-06	0.000856	0.31	0.29	Gestational age at birth (child effect);	chr3:136533759	chr3:136752630~136755780:+
KIRP	cis	rs6834314	0.699	rs28636836	ENSG00000251411.1	RP11-397E7.4	-4.82	2.39e-06	0.000857	-0.27	-0.29	Liver enzyme levels (alanine transaminase);	chr4:87310713	chr4:86913266~86914817:-
KIRP	cis	rs7615952	0.599	rs12496921	ENSG00000241439.1	RP11-666A20.3	4.82	2.39e-06	0.000857	0.39	0.29	Blood pressure (smoking interaction);	chr3:125983105	chr3:125958556~125958817:+
KIRP	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-4.82	2.4e-06	0.000858	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
KIRP	cis	rs4841097	0.876	rs6601288	ENSG00000253981.4	ALG1L13P	4.82	2.4e-06	0.000859	0.24	0.29	Platelet distribution width;	chr8:9085920	chr8:8236003~8244667:-
KIRP	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-4.82	2.4e-06	0.000859	-0.27	-0.29	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
KIRP	cis	rs10872587	0.657	rs11155459	ENSG00000235652.6	RP11-545I5.3	-4.82	2.4e-06	0.000859	-0.31	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146257615	chr6:145799409~145886585:+
KIRP	cis	rs7225151	0.731	rs77972827	ENSG00000234327.6	AC012146.7	-4.82	2.4e-06	0.000859	-0.41	-0.29	Alzheimer's disease (late onset);	chr17:5213084	chr17:5111468~5115004:+
KIRP	cis	rs4601821	0.635	rs12282356	ENSG00000270179.1	RP11-159N11.4	-4.82	2.4e-06	0.00086	-0.25	-0.29	Alcoholic chronic pancreatitis;	chr11:113337660	chr11:113368478~113369117:+
KIRP	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	4.82	2.4e-06	0.00086	0.29	0.29	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
KIRP	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-4.82	2.4e-06	0.00086	-0.29	-0.29	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-4.82	2.4e-06	0.00086	-0.29	-0.29	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
KIRP	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-4.82	2.4e-06	0.00086	-0.29	-0.29	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
KIRP	cis	rs1150668	0.699	rs1736895	ENSG00000220721.1	OR1F12	4.82	2.4e-06	0.00086	0.3	0.29	Pubertal anthropometrics;	chr6:28252048	chr6:28073316~28074233:+
KIRP	cis	rs1075265	0.901	rs2112124	ENSG00000233266.1	HMGB1P31	4.82	2.41e-06	0.000861	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54137385	chr2:54051334~54051760:+
KIRP	cis	rs964611	0.882	rs873661	ENSG00000259488.2	RP11-154J22.1	4.82	2.41e-06	0.000861	0.26	0.29	Metabolite levels (Pyroglutamine);	chr15:48368914	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs4775753	ENSG00000259488.2	RP11-154J22.1	4.82	2.41e-06	0.000861	0.26	0.29	Metabolite levels (Pyroglutamine);	chr15:48369022	chr15:48312353~48331856:-
KIRP	cis	rs984222	0.838	rs10923724	ENSG00000231365.4	RP11-418J17.1	-4.82	2.41e-06	0.000862	-0.26	-0.29	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119140396~119275973:+
KIRP	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	4.82	2.41e-06	0.000862	0.36	0.29	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
KIRP	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-4.82	2.41e-06	0.000863	-0.31	-0.29	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
KIRP	cis	rs728616	0.717	rs61860016	ENSG00000234382.2	RP11-40F6.1	-4.82	2.41e-06	0.000863	-0.44	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:80233664~80245367:+
KIRP	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	4.82	2.41e-06	0.000863	0.34	0.29	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
KIRP	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-4.82	2.42e-06	0.000864	-0.22	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
KIRP	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	4.82	2.42e-06	0.000864	0.24	0.29	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
KIRP	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-4.82	2.42e-06	0.000866	-0.38	-0.29	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
KIRP	cis	rs11673344	0.504	rs4806408	ENSG00000226686.6	LINC01535	4.82	2.42e-06	0.000866	0.35	0.29	Obesity-related traits;	chr19:37097875	chr19:37251912~37265535:+
KIRP	cis	rs35146811	0.695	rs1623264	ENSG00000078319.8	PMS2P1	4.82	2.42e-06	0.000866	0.36	0.29	Coronary artery disease;	chr7:100213581	chr7:100320992~100341908:-
KIRP	cis	rs875971	0.545	rs73152714	ENSG00000236529.1	RP13-254B10.1	4.82	2.42e-06	0.000866	0.25	0.29	Aortic root size;	chr7:66534641	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs4718364	ENSG00000236529.1	RP13-254B10.1	4.82	2.42e-06	0.000866	0.25	0.29	Aortic root size;	chr7:66536353	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs6961853	ENSG00000236529.1	RP13-254B10.1	4.82	2.42e-06	0.000866	0.25	0.29	Aortic root size;	chr7:66537035	chr7:65840212~65840596:+
KIRP	cis	rs7615952	0.641	rs12491577	ENSG00000241439.1	RP11-666A20.3	4.82	2.42e-06	0.000866	0.41	0.29	Blood pressure (smoking interaction);	chr3:126012288	chr3:125958556~125958817:+
KIRP	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	4.82	2.43e-06	0.000867	0.26	0.29	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
KIRP	cis	rs198426	0.506	rs198465	ENSG00000124915.9	DKFZP434K028	4.82	2.43e-06	0.000868	0.34	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61753846	chr11:61746493~61757655:-
KIRP	cis	rs9810089	0.814	rs834305	ENSG00000261758.1	RP11-102M11.2	4.82	2.43e-06	0.000868	0.31	0.29	Gestational age at birth (child effect);	chr3:136400512	chr3:136752630~136755780:+
KIRP	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.82	2.43e-06	0.000868	-0.38	-0.29	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
KIRP	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	4.82	2.43e-06	0.000869	0.3	0.29	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
KIRP	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	4.82	2.43e-06	0.000869	0.3	0.29	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
KIRP	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-4.82	2.43e-06	0.000869	-0.23	-0.29	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
KIRP	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	4.82	2.43e-06	0.00087	0.22	0.29	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
KIRP	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	4.82	2.43e-06	0.00087	0.22	0.29	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
KIRP	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	4.82	2.43e-06	0.00087	0.34	0.29	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
KIRP	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	4.82	2.43e-06	0.00087	0.27	0.29	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
KIRP	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	4.82	2.44e-06	0.00087	0.24	0.29	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
KIRP	cis	rs6480314	0.636	rs34888891	ENSG00000233590.1	RP11-153K11.3	-4.82	2.44e-06	0.00087	-0.43	-0.29	Optic nerve measurement (disc area);	chr10:68242351	chr10:68233251~68242379:-
KIRP	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	4.82	2.44e-06	0.000872	0.23	0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
KIRP	cis	rs4631830	0.828	rs10763567	ENSG00000229927.2	RHEBP1	-4.82	2.44e-06	0.000873	-0.37	-0.29	Prostate-specific antigen levels;	chr10:46057653	chr10:46634911~46635466:-
KIRP	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-4.82	2.44e-06	0.000873	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
KIRP	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	4.82	2.45e-06	0.000873	0.32	0.29	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
KIRP	cis	rs763512	0.504	rs853216	ENSG00000276054.1	RP11-378E13.3	4.82	2.45e-06	0.000873	0.4	0.29	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37502902	chr17:37386886~37387926:+
KIRP	cis	rs6832769	1	rs1522108	ENSG00000272969.1	RP11-528I4.2	4.82	2.45e-06	0.000874	0.3	0.29	Personality dimensions;	chr4:55514566	chr4:55547112~55547889:+
KIRP	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	4.82	2.45e-06	0.000874	0.3	0.29	Height;	chr4:55545574	chr4:55363971~55395847:-
KIRP	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-4.82	2.45e-06	0.000875	-0.44	-0.29	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
KIRP	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	4.82	2.45e-06	0.000875	0.26	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
KIRP	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-4.82	2.45e-06	0.000875	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-4.82	2.45e-06	0.000875	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-4.82	2.45e-06	0.000875	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
KIRP	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-4.82	2.45e-06	0.000875	-0.3	-0.29	Height;	chr3:52949886	chr3:53064283~53065091:-
KIRP	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	4.82	2.45e-06	0.000876	0.23	0.29	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	4.82	2.45e-06	0.000876	0.23	0.29	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	4.82	2.45e-06	0.000876	0.23	0.29	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	4.82	2.45e-06	0.000876	0.23	0.29	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	4.82	2.45e-06	0.000876	0.23	0.29	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
KIRP	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	4.82	2.45e-06	0.000876	0.33	0.29	Depression;	chr6:28092227	chr6:28073316~28074233:+
KIRP	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	4.82	2.45e-06	0.000876	0.49	0.29	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
KIRP	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-4.82	2.46e-06	0.000877	-0.38	-0.29	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
KIRP	cis	rs9595908	0.537	rs7993153	ENSG00000212293.1	SNORA16	4.82	2.46e-06	0.000878	0.27	0.29	Body mass index;	chr13:32804647	chr13:32420390~32420516:-
KIRP	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-4.82	2.46e-06	0.000878	-0.31	-0.29	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
KIRP	cis	rs9595908	0.785	rs9315177	ENSG00000212293.1	SNORA16	4.82	2.46e-06	0.000878	0.27	0.29	Body mass index;	chr13:32696214	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.785	rs9596081	ENSG00000212293.1	SNORA16	4.82	2.46e-06	0.000878	0.27	0.29	Body mass index;	chr13:32698405	chr13:32420390~32420516:-
KIRP	cis	rs11085466	1	rs11085466	ENSG00000268555.1	RP11-678G14.3	4.82	2.46e-06	0.000878	0.38	0.29	Colorectal or endometrial cancer;	chr19:21569009	chr19:21570822~21587322:-
KIRP	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	4.82	2.46e-06	0.000878	0.22	0.29	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
KIRP	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	4.82	2.46e-06	0.000879	0.33	0.29	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
KIRP	cis	rs12962334	0.568	rs2034932	ENSG00000265943.1	RP11-739L10.1	4.82	2.46e-06	0.00088	0.37	0.29	Breast cancer;	chr18:22918727	chr18:22699481~22933764:-
KIRP	cis	rs2361701	0.636	rs1982244	ENSG00000275479.1	RP11-334C17.6	4.82	2.47e-06	0.00088	0.23	0.29	IgG glycosylation;	chr17:80095149	chr17:80149627~80149798:+
KIRP	cis	rs664154	0.522	rs2205743	ENSG00000228412.5	RP4-625H18.2	-4.82	2.47e-06	0.00088	-0.28	-0.29	Information processing speed;	chr6:19123327	chr6:19802164~19804752:-
KIRP	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-4.82	2.47e-06	0.00088	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
KIRP	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-4.82	2.47e-06	0.00088	-0.26	-0.29	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
KIRP	cis	rs9353324	1	rs58334368	ENSG00000203875.9	SNHG5	-4.82	2.47e-06	0.000881	-0.49	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85660950~85678736:-
KIRP	cis	rs886774	0.932	rs722691	ENSG00000273055.1	CTB-13F3.1	-4.82	2.47e-06	0.000882	-0.18	-0.29	Ulcerative colitis;	chr7:107859739	chr7:107942116~107942740:+
KIRP	cis	rs886774	0.899	rs4404839	ENSG00000273055.1	CTB-13F3.1	-4.82	2.47e-06	0.000882	-0.18	-0.29	Ulcerative colitis;	chr7:107860052	chr7:107942116~107942740:+
KIRP	cis	rs875971	0.502	rs1796227	ENSG00000224316.1	RP11-479O9.2	-4.82	2.47e-06	0.000882	-0.24	-0.29	Aortic root size;	chr7:66622032	chr7:65773620~65802067:+
KIRP	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-4.82	2.47e-06	0.000882	-0.38	-0.29	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
KIRP	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-4.82	2.48e-06	0.000883	-0.38	-0.29	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
KIRP	cis	rs792448	0.743	rs351373	ENSG00000226251.4	RP11-15I11.3	-4.82	2.48e-06	0.000883	-0.29	-0.29	White blood cell count (basophil);	chr1:212253289	chr1:212225278~212238977:-
KIRP	cis	rs35146811	0.7	rs866500	ENSG00000281827.1	AC005071.4	4.82	2.48e-06	0.000883	0.26	0.29	Coronary artery disease;	chr7:100242838	chr7:100344375~100344475:-
KIRP	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	4.82	2.48e-06	0.000883	0.35	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
KIRP	cis	rs2976388	1	rs2976396	ENSG00000253741.1	CTD-2292P10.4	-4.82	2.48e-06	0.000883	-0.33	-0.29	Urinary tract infection frequency;	chr8:142682583	chr8:142702252~142726973:-
KIRP	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	4.82	2.48e-06	0.000883	0.32	0.29	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	4.82	2.48e-06	0.000883	0.32	0.29	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
KIRP	cis	rs9595908	0.709	rs9315179	ENSG00000212293.1	SNORA16	4.82	2.48e-06	0.000883	0.27	0.29	Body mass index;	chr13:32773889	chr13:32420390~32420516:-
KIRP	cis	rs1065852	0.51	rs5751247	ENSG00000227370.1	RP4-669P10.19	4.82	2.48e-06	0.000884	0.29	0.29	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42132543~42132998:+
KIRP	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-4.82	2.48e-06	0.000884	-0.23	-0.29	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
KIRP	cis	rs324126	0.78	rs62108319	ENSG00000269834.4	ZNF528-AS1	4.82	2.48e-06	0.000884	0.29	0.29	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs62108320	ENSG00000269834.4	ZNF528-AS1	4.82	2.48e-06	0.000884	0.29	0.29	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.752	rs62108321	ENSG00000269834.4	ZNF528-AS1	4.82	2.48e-06	0.000884	0.29	0.29	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52388842~52397766:-
KIRP	cis	rs7170668	0.965	rs9920389	ENSG00000258489.3	RP11-398J10.2	-4.82	2.48e-06	0.000884	-0.33	-0.29	Motion sickness;	chr15:95488331	chr15:95463592~95493770:-
KIRP	cis	rs77204473	1	rs17120099	ENSG00000254851.1	RP11-109L13.1	4.82	2.48e-06	0.000885	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116864744	chr11:117135528~117138582:+
KIRP	cis	rs10200159	0.744	rs12616502	ENSG00000272606.1	RP11-554J4.1	4.82	2.48e-06	0.000885	0.41	0.29	Vitiligo;	chr2:55581879	chr2:55617909~55618373:+
KIRP	cis	rs1185460	0.967	rs1177563	ENSG00000272186.1	RP11-110I1.13	-4.82	2.48e-06	0.000885	-0.29	-0.29	Coronary artery disease;	chr11:119078373	chr11:119067374~119067698:-
KIRP	cis	rs2386661	0.826	rs4427479	ENSG00000228951.1	RP11-336A10.4	-4.82	2.48e-06	0.000885	-0.35	-0.29	Breast cancer;	chr10:5640892	chr10:5616862~5618161:-
KIRP	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	4.82	2.48e-06	0.000886	0.27	0.29	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
KIRP	cis	rs12922317	0.964	rs12930612	ENSG00000260488.1	RP11-166B2.7	4.82	2.48e-06	0.000886	0.35	0.29	Schizophrenia;	chr16:11978346	chr16:11976851~11977850:-
KIRP	cis	rs12922317	0.927	rs12923439	ENSG00000260488.1	RP11-166B2.7	4.82	2.48e-06	0.000886	0.35	0.29	Schizophrenia;	chr16:11980101	chr16:11976851~11977850:-
KIRP	cis	rs875971	0.545	rs11770063	ENSG00000236529.1	RP13-254B10.1	4.82	2.48e-06	0.000886	0.26	0.29	Aortic root size;	chr7:66318029	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs4718335	ENSG00000236529.1	RP13-254B10.1	4.82	2.48e-06	0.000886	0.26	0.29	Aortic root size;	chr7:66339619	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	4.82	2.48e-06	0.000886	0.29	0.29	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
KIRP	cis	rs42648	0.869	rs3810890	ENSG00000225498.1	AC002064.5	4.82	2.48e-06	0.000886	0.2	0.29	Homocysteine levels;	chr7:90279519	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.837	rs10262603	ENSG00000225498.1	AC002064.5	4.82	2.48e-06	0.000886	0.2	0.29	Homocysteine levels;	chr7:90280128	chr7:90312496~90322592:+
KIRP	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	4.82	2.49e-06	0.000886	0.28	0.29	Height;	chr4:55573424	chr4:55547112~55547889:+
KIRP	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-4.82	2.49e-06	0.000886	-0.25	-0.29	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
KIRP	cis	rs9595908	0.746	rs1029306	ENSG00000212293.1	SNORA16	4.82	2.49e-06	0.000886	0.28	0.29	Body mass index;	chr13:32707695	chr13:32420390~32420516:-
KIRP	cis	rs453301	0.658	rs9329175	ENSG00000253981.4	ALG1L13P	-4.82	2.49e-06	0.000886	-0.22	-0.29	Joint mobility (Beighton score);	chr8:9009151	chr8:8236003~8244667:-
KIRP	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-4.82	2.49e-06	0.000887	-0.25	-0.29	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
KIRP	cis	rs886774	0.899	rs6947045	ENSG00000273055.1	CTB-13F3.1	-4.82	2.49e-06	0.000887	-0.18	-0.29	Ulcerative colitis;	chr7:107859502	chr7:107942116~107942740:+
KIRP	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	4.82	2.49e-06	0.000887	0.3	0.29	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
KIRP	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	4.82	2.49e-06	0.000887	0.29	0.29	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	4.82	2.49e-06	0.000887	0.29	0.29	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
KIRP	cis	rs1044826	0.642	rs176983	ENSG00000178631.7	ACTG1P1	4.82	2.49e-06	0.000887	0.3	0.29	Obesity-related traits;	chr3:139494913	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs295470	ENSG00000178631.7	ACTG1P1	4.82	2.49e-06	0.000887	0.3	0.29	Obesity-related traits;	chr3:139495061	chr3:139493809~139494937:+
KIRP	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-4.82	2.49e-06	0.000887	-0.31	-0.29	Height;	chr3:52971094	chr3:53064283~53065091:-
KIRP	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	4.82	2.49e-06	0.000887	0.37	0.29	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
KIRP	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	4.81	2.49e-06	0.000888	0.31	0.29	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
KIRP	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-4.81	2.49e-06	0.000888	-0.23	-0.29	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
KIRP	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-4.81	2.49e-06	0.000888	-0.23	-0.29	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
KIRP	cis	rs79349575	0.721	rs2291725	ENSG00000270781.1	RP11-501C14.9	-4.81	2.49e-06	0.000888	-0.31	-0.29	Type 2 diabetes;	chr17:48961770	chr17:48899131~48899748:+
KIRP	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	4.81	2.49e-06	0.000888	0.26	0.29	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs75577046	ENSG00000236529.1	RP13-254B10.1	4.81	2.49e-06	0.000888	0.26	0.29	Aortic root size;	chr7:66493729	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs3735147	ENSG00000236529.1	RP13-254B10.1	4.81	2.49e-06	0.000888	0.26	0.29	Aortic root size;	chr7:66505541	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	4.81	2.5e-06	0.000889	0.29	0.29	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
KIRP	cis	rs1150668	0.699	rs12214383	ENSG00000220721.1	OR1F12	-4.81	2.5e-06	0.000889	-0.3	-0.29	Pubertal anthropometrics;	chr6:28255953	chr6:28073316~28074233:+
KIRP	cis	rs308403	0.568	rs67050821	ENSG00000224786.1	CETN4P	4.81	2.5e-06	0.000889	0.42	0.29	Blood protein levels;	chr4:122753228	chr4:122730548~122732193:-
KIRP	cis	rs308403	0.568	rs13138520	ENSG00000224786.1	CETN4P	4.81	2.5e-06	0.000889	0.42	0.29	Blood protein levels;	chr4:122754328	chr4:122730548~122732193:-
KIRP	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-4.81	2.5e-06	0.00089	-0.35	-0.29	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
KIRP	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	4.81	2.5e-06	0.00089	0.29	0.29	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
KIRP	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	4.81	2.5e-06	0.00089	0.45	0.29	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
KIRP	cis	rs4820539	0.966	rs2157709	ENSG00000275635.1	U7	4.81	2.5e-06	0.00089	0.31	0.29	Bone mineral density;	chr22:23115233	chr22:23137805~23137864:-
KIRP	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	4.81	2.5e-06	0.00089	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
KIRP	cis	rs41271473	0.526	rs10916339	ENSG00000212237.1	RNA5SP18	4.81	2.5e-06	0.000891	0.47	0.29	Chronic lymphocytic leukemia;	chr1:228529193	chr1:228647912~228648032:-
KIRP	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-4.81	2.5e-06	0.000891	-0.28	-0.29	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
KIRP	cis	rs11673344	0.562	rs7250507	ENSG00000226686.6	LINC01535	4.81	2.5e-06	0.000891	0.35	0.29	Obesity-related traits;	chr19:37095772	chr19:37251912~37265535:+
KIRP	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-4.81	2.5e-06	0.000892	-0.36	-0.29	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
KIRP	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-4.81	2.5e-06	0.000892	-0.36	-0.29	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
KIRP	cis	rs875971	0.545	rs2707851	ENSG00000236529.1	RP13-254B10.1	-4.81	2.5e-06	0.000892	-0.25	-0.29	Aortic root size;	chr7:66624178	chr7:65840212~65840596:+
KIRP	cis	rs11512640	1	rs118093992	ENSG00000254671.2	STT3A-AS1	4.81	2.5e-06	0.000892	0.63	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125515784	chr11:125570284~125592568:-
KIRP	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	4.81	2.51e-06	0.000892	0.32	0.29	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
KIRP	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	4.81	2.51e-06	0.000893	0.38	0.29	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
KIRP	cis	rs308403	0.6	rs309364	ENSG00000224786.1	CETN4P	-4.81	2.51e-06	0.000893	-0.37	-0.29	Blood protein levels;	chr4:122737704	chr4:122730548~122732193:-
KIRP	cis	rs10200159	1	rs10195281	ENSG00000272606.1	RP11-554J4.1	4.81	2.51e-06	0.000894	0.41	0.29	Vitiligo;	chr2:55620886	chr2:55617909~55618373:+
KIRP	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	4.81	2.51e-06	0.000895	0.33	0.29	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	4.81	2.51e-06	0.000895	0.33	0.29	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	4.81	2.51e-06	0.000895	0.33	0.29	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	4.81	2.51e-06	0.000895	0.33	0.29	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	4.81	2.51e-06	0.000895	0.33	0.29	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
KIRP	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	4.81	2.52e-06	0.000895	0.39	0.29	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
KIRP	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	4.81	2.52e-06	0.000895	0.21	0.29	Height;	chr20:35002555	chr20:35201747~35203288:-
KIRP	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	4.81	2.52e-06	0.000896	0.31	0.29	Depression;	chr6:28402301	chr6:28176188~28176674:+
KIRP	cis	rs8030379	0.967	rs6603001	ENSG00000230373.7	GOLGA6L5P	-4.81	2.52e-06	0.000896	-0.24	-0.29	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84507885~84516814:-
KIRP	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-4.81	2.52e-06	0.000896	-0.58	-0.29	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-4.81	2.52e-06	0.000896	-0.58	-0.29	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
KIRP	cis	rs9595908	0.63	rs79837633	ENSG00000212293.1	SNORA16	4.81	2.52e-06	0.000897	0.27	0.28	Body mass index;	chr13:32754590	chr13:32420390~32420516:-
KIRP	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	4.81	2.52e-06	0.000897	0.22	0.28	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
KIRP	cis	rs11673344	0.523	rs10406110	ENSG00000226686.6	LINC01535	4.81	2.52e-06	0.000897	0.35	0.28	Obesity-related traits;	chr19:37160027	chr19:37251912~37265535:+
KIRP	cis	rs4236601	0.679	rs12668473	ENSG00000237813.3	AC002066.1	-4.81	2.52e-06	0.000898	-0.36	-0.28	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116505585	chr7:116238260~116499465:-
KIRP	cis	rs4236601	0.72	rs28587043	ENSG00000237813.3	AC002066.1	-4.81	2.52e-06	0.000898	-0.36	-0.28	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116505642	chr7:116238260~116499465:-
KIRP	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	4.81	2.53e-06	0.000899	0.25	0.28	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
KIRP	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-4.81	2.53e-06	0.000899	-0.25	-0.28	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
KIRP	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-4.81	2.53e-06	0.000899	-0.36	-0.28	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
KIRP	cis	rs453301	0.686	rs4840389	ENSG00000253981.4	ALG1L13P	-4.81	2.53e-06	0.000899	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9026993	chr8:8236003~8244667:-
KIRP	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	4.81	2.53e-06	9e-04	0.35	0.28	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
KIRP	cis	rs964611	0.882	rs4775750	ENSG00000259488.2	RP11-154J22.1	4.81	2.53e-06	9e-04	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48360567	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs4775751	ENSG00000259488.2	RP11-154J22.1	4.81	2.53e-06	9e-04	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48360910	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs11631831	ENSG00000259488.2	RP11-154J22.1	4.81	2.53e-06	9e-04	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48361563	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs11629805	ENSG00000259488.2	RP11-154J22.1	4.81	2.53e-06	9e-04	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48363267	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs12439526	ENSG00000259488.2	RP11-154J22.1	4.81	2.53e-06	9e-04	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48366050	chr15:48312353~48331856:-
KIRP	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	4.81	2.53e-06	9e-04	0.36	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
KIRP	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	4.81	2.53e-06	9e-04	0.36	0.28	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
KIRP	cis	rs172166	0.516	rs2622322	ENSG00000220721.1	OR1F12	4.81	2.53e-06	9e-04	0.29	0.28	Cardiac Troponin-T levels;	chr6:28149665	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.516	rs1150670	ENSG00000220721.1	OR1F12	4.81	2.53e-06	9e-04	0.29	0.28	Cardiac Troponin-T levels;	chr6:28162781	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.516	rs2021826	ENSG00000220721.1	OR1F12	4.81	2.53e-06	9e-04	0.29	0.28	Cardiac Troponin-T levels;	chr6:28164978	chr6:28073316~28074233:+
KIRP	cis	rs1150668	0.835	rs1233696	ENSG00000220721.1	OR1F12	4.81	2.53e-06	9e-04	0.29	0.28	Pubertal anthropometrics;	chr6:28175232	chr6:28073316~28074233:+
KIRP	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-4.81	2.53e-06	0.000901	-0.37	-0.28	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
KIRP	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	4.81	2.53e-06	0.000901	0.27	0.28	Height;	chr4:55582068	chr4:55547112~55547889:+
KIRP	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-4.81	2.53e-06	0.000901	-0.26	-0.28	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
KIRP	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	4.81	2.54e-06	0.000902	0.3	0.28	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
KIRP	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	4.81	2.54e-06	0.000902	0.46	0.28	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
KIRP	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	4.81	2.54e-06	0.000902	0.44	0.28	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
KIRP	cis	rs13129231	0.806	rs17676882	ENSG00000206820.1	RNU1-138P	-4.81	2.54e-06	0.000902	-0.37	-0.28	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113451912	chr4:113420323~113420486:+
KIRP	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	4.81	2.54e-06	0.000902	0.29	0.28	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
KIRP	cis	rs42648	0.869	rs3810891	ENSG00000225498.1	AC002064.5	4.81	2.54e-06	0.000904	0.2	0.28	Homocysteine levels;	chr7:90279537	chr7:90312496~90322592:+
KIRP	cis	rs2732480	0.967	rs2732469	ENSG00000269514.1	RP11-370I10.12	4.81	2.54e-06	0.000904	0.24	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48198387~48202031:+
KIRP	cis	rs9595908	0.669	rs17594908	ENSG00000212293.1	SNORA16	4.81	2.54e-06	0.000904	0.28	0.28	Body mass index;	chr13:32789427	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs2025474	ENSG00000212293.1	SNORA16	4.81	2.54e-06	0.000904	0.28	0.28	Body mass index;	chr13:32792319	chr13:32420390~32420516:-
KIRP	cis	rs6840258	0.64	rs17012517	ENSG00000251411.1	RP11-397E7.4	-4.81	2.55e-06	0.000905	-0.26	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87149332	chr4:86913266~86914817:-
KIRP	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	4.81	2.55e-06	0.000906	0.25	0.28	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	4.81	2.55e-06	0.000906	0.25	0.28	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	4.81	2.55e-06	0.000906	0.25	0.28	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	4.81	2.55e-06	0.000906	0.25	0.28	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	4.81	2.55e-06	0.000906	0.25	0.28	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
KIRP	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-4.81	2.55e-06	0.000906	-0.26	-0.28	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
KIRP	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	4.81	2.55e-06	0.000906	0.25	0.28	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
KIRP	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	4.81	2.55e-06	0.000906	0.26	0.28	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
KIRP	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	4.81	2.55e-06	0.000907	0.27	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
KIRP	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	4.81	2.55e-06	0.000907	0.27	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
KIRP	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	4.81	2.55e-06	0.000907	0.27	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
KIRP	cis	rs7267979	0.866	rs437635	ENSG00000274414.1	RP5-965G21.4	-4.81	2.55e-06	0.000907	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.899	rs442834	ENSG00000274414.1	RP5-965G21.4	-4.81	2.55e-06	0.000907	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs417110	ENSG00000274414.1	RP5-965G21.4	-4.81	2.55e-06	0.000907	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs449703	ENSG00000274414.1	RP5-965G21.4	-4.81	2.55e-06	0.000907	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25239007~25245229:-
KIRP	cis	rs7267979	0.932	rs431579	ENSG00000274414.1	RP5-965G21.4	-4.81	2.55e-06	0.000907	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25239007~25245229:-
KIRP	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.81	2.55e-06	0.000908	-0.37	-0.28	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
KIRP	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-4.81	2.55e-06	0.000908	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
KIRP	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	4.81	2.56e-06	0.000908	0.31	0.28	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	4.81	2.56e-06	0.000908	0.31	0.28	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	4.81	2.56e-06	0.000908	0.31	0.28	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
KIRP	cis	rs875971	0.528	rs801213	ENSG00000236529.1	RP13-254B10.1	-4.81	2.56e-06	0.000909	-0.26	-0.28	Aortic root size;	chr7:66549931	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs801212	ENSG00000236529.1	RP13-254B10.1	-4.81	2.56e-06	0.000909	-0.26	-0.28	Aortic root size;	chr7:66550643	chr7:65840212~65840596:+
KIRP	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-4.81	2.56e-06	0.000909	-0.26	-0.28	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
KIRP	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-4.81	2.56e-06	0.000909	-0.37	-0.28	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
KIRP	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-4.81	2.56e-06	0.000909	-0.29	-0.28	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
KIRP	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-4.81	2.56e-06	0.000909	-0.24	-0.28	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
KIRP	cis	rs9595908	0.629	rs962454	ENSG00000212293.1	SNORA16	4.81	2.56e-06	0.000909	0.27	0.28	Body mass index;	chr13:32719131	chr13:32420390~32420516:-
KIRP	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-4.81	2.56e-06	0.000909	-0.36	-0.28	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-4.81	2.56e-06	0.000909	-0.36	-0.28	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
KIRP	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-4.81	2.56e-06	0.00091	-0.28	-0.28	Height;	chr14:75002852	chr14:75011269~75012851:-
KIRP	cis	rs7432375	0.901	rs7648531	ENSG00000261758.1	RP11-102M11.2	-4.81	2.56e-06	0.000911	-0.3	-0.28	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136743381	chr3:136752630~136755780:+
KIRP	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	4.81	2.56e-06	0.000911	0.29	0.28	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
KIRP	cis	rs3892630	0.588	rs7248798	ENSG00000267475.1	CTD-2538C1.2	-4.81	2.57e-06	0.000912	-0.36	-0.28	Red blood cell traits;	chr19:32812778	chr19:32687089~32691750:-
KIRP	cis	rs2976388	1	rs1045574	ENSG00000253741.1	CTD-2292P10.4	4.81	2.57e-06	0.000912	0.32	0.28	Urinary tract infection frequency;	chr8:142682540	chr8:142702252~142726973:-
KIRP	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.57e-06	0.000912	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.57e-06	0.000912	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.57e-06	0.000912	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.57e-06	0.000912	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
KIRP	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-4.81	2.57e-06	0.000912	-0.32	-0.28	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
KIRP	cis	rs113835537	0.808	rs10896128	ENSG00000255517.5	CTD-3074O7.5	-4.81	2.57e-06	0.000913	-0.37	-0.28	Airway imaging phenotypes;	chr11:66557058	chr11:66473490~66480233:-
KIRP	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	4.81	2.57e-06	0.000913	0.32	0.28	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
KIRP	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-4.81	2.57e-06	0.000913	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
KIRP	cis	rs79349575	0.783	rs62075838	ENSG00000270781.1	RP11-501C14.9	-4.81	2.58e-06	0.000914	-0.3	-0.28	Type 2 diabetes;	chr17:48919070	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs62075839	ENSG00000270781.1	RP11-501C14.9	-4.81	2.58e-06	0.000914	-0.3	-0.28	Type 2 diabetes;	chr17:48919072	chr17:48899131~48899748:+
KIRP	cis	rs7267979	1	rs4815417	ENSG00000274414.1	RP5-965G21.4	4.81	2.58e-06	0.000914	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25239007~25245229:-
KIRP	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-4.81	2.58e-06	0.000915	-0.37	-0.28	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
KIRP	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	4.81	2.58e-06	0.000915	0.57	0.28	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	4.81	2.58e-06	0.000915	0.57	0.28	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	4.81	2.58e-06	0.000915	0.57	0.28	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	4.81	2.58e-06	0.000915	0.57	0.28	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	4.81	2.58e-06	0.000915	0.57	0.28	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
KIRP	cis	rs911119	1	rs2016161	ENSG00000270001.1	RP11-218C14.8	4.81	2.58e-06	0.000916	0.31	0.28	Chronic kidney disease;	chr20:23640537	chr20:23631826~23632316:-
KIRP	cis	rs738322	1	rs738320	ENSG00000233360.4	Z83844.1	4.81	2.58e-06	0.000916	0.29	0.28	Cutaneous nevi;	chr22:38172708	chr22:37641832~37658377:-
KIRP	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	4.81	2.58e-06	0.000916	0.31	0.28	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	4.81	2.58e-06	0.000916	0.31	0.28	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
KIRP	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	4.81	2.58e-06	0.000916	0.27	0.28	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
KIRP	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	4.81	2.58e-06	0.000917	0.29	0.28	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
KIRP	cis	rs6834314	0.659	rs13118664	ENSG00000251411.1	RP11-397E7.4	-4.81	2.58e-06	0.000917	-0.26	-0.28	Liver enzyme levels (alanine transaminase);	chr4:87318457	chr4:86913266~86914817:-
KIRP	cis	rs324126	0.78	rs11084153	ENSG00000269834.4	ZNF528-AS1	4.81	2.59e-06	0.000918	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs11084154	ENSG00000269834.4	ZNF528-AS1	4.81	2.59e-06	0.000918	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52388842~52397766:-
KIRP	cis	rs1799949	1	rs4793229	ENSG00000279602.1	CTD-3014M21.1	4.81	2.59e-06	0.000918	0.26	0.28	Menopause (age at onset);	chr17:43340966	chr17:43360041~43361361:-
KIRP	cis	rs7289126	1	rs5995558	ENSG00000233360.4	Z83844.1	4.81	2.59e-06	0.000918	0.29	0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38251633	chr22:37641832~37658377:-
KIRP	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-4.81	2.59e-06	0.000919	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
KIRP	cis	rs42648	0.617	rs11563435	ENSG00000225498.1	AC002064.5	4.81	2.59e-06	0.000919	0.2	0.28	Homocysteine levels;	chr7:90270893	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.642	rs11771963	ENSG00000225498.1	AC002064.5	4.81	2.59e-06	0.000919	0.2	0.28	Homocysteine levels;	chr7:90258273	chr7:90312496~90322592:+
KIRP	cis	rs453301	0.631	rs28572014	ENSG00000173295.6	FAM86B3P	-4.81	2.59e-06	0.00092	-0.22	-0.28	Joint mobility (Beighton score);	chr8:8936097	chr8:8228595~8244865:+
KIRP	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-4.81	2.6e-06	0.000921	-0.28	-0.28	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
KIRP	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-4.81	2.6e-06	0.000921	-0.32	-0.28	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
KIRP	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-4.81	2.6e-06	0.000921	-0.22	-0.28	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
KIRP	cis	rs1799949	0.965	rs8176193	ENSG00000279602.1	CTD-3014M21.1	-4.81	2.6e-06	0.000922	-0.26	-0.28	Menopause (age at onset);	chr17:43079499	chr17:43360041~43361361:-
KIRP	cis	rs13113518	0.678	rs13149568	ENSG00000272969.1	RP11-528I4.2	4.81	2.6e-06	0.000923	0.27	0.28	Height;	chr4:55370412	chr4:55547112~55547889:+
KIRP	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.81	2.61e-06	0.000924	0.62	0.28	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
KIRP	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.81	2.61e-06	0.000924	0.25	0.28	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
KIRP	cis	rs324126	0.78	rs1993531	ENSG00000269834.4	ZNF528-AS1	4.81	2.61e-06	0.000924	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs11084157	ENSG00000269834.4	ZNF528-AS1	4.81	2.61e-06	0.000924	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs8104808	ENSG00000269834.4	ZNF528-AS1	4.81	2.61e-06	0.000924	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs8104812	ENSG00000269834.4	ZNF528-AS1	4.81	2.61e-06	0.000924	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs11084150	ENSG00000269834.4	ZNF528-AS1	-4.81	2.61e-06	0.000924	-0.29	-0.28	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52388842~52397766:-
KIRP	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-4.81	2.61e-06	0.000924	-0.29	-0.28	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
KIRP	cis	rs11158026	0.894	rs10133650	ENSG00000258413.1	RP11-665C16.6	-4.81	2.61e-06	0.000925	-0.35	-0.28	Parkinson's disease;	chr14:54879555	chr14:55262767~55272075:-
KIRP	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-4.8	2.61e-06	0.000926	-0.23	-0.28	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
KIRP	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	4.8	2.61e-06	0.000926	0.32	0.28	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
KIRP	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-4.8	2.61e-06	0.000926	-0.27	-0.28	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
KIRP	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	4.8	2.61e-06	0.000927	0.27	0.28	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
KIRP	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	4.8	2.61e-06	0.000927	0.27	0.28	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
KIRP	cis	rs7674212	0.865	rs1481279	ENSG00000230069.3	LRRC37A15P	4.8	2.61e-06	0.000927	0.27	0.28	Type 2 diabetes;	chr4:103056781	chr4:102727274~102730721:-
KIRP	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	4.8	2.62e-06	0.000927	0.24	0.28	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
KIRP	cis	rs1005277	0.603	rs1998062	ENSG00000151963.4	RP11-775A3.1	-4.8	2.62e-06	0.000927	-0.33	-0.28	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:37883594~37884109:+
KIRP	cis	rs712022	0.534	rs3213706	ENSG00000246225.5	RP11-17A1.3	-4.8	2.62e-06	0.000928	-0.34	-0.28	Dialysis-related mortality;	chr11:22859456	chr11:22829380~22945393:+
KIRP	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.8	2.62e-06	0.000928	0.23	0.28	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
KIRP	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	4.8	2.62e-06	0.000928	0.27	0.28	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
KIRP	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	4.8	2.62e-06	0.000928	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	4.8	2.62e-06	0.000928	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	4.8	2.62e-06	0.000928	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
KIRP	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-4.8	2.62e-06	0.000929	-0.45	-0.28	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
KIRP	cis	rs8030379	1	rs2030839	ENSG00000230373.7	GOLGA6L5P	-4.8	2.62e-06	0.000929	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915207	chr15:84507885~84516814:-
KIRP	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-4.8	2.62e-06	0.000929	-0.25	-0.28	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
KIRP	cis	rs79040073	0.637	rs1023683	ENSG00000259531.2	RP11-295H24.3	4.8	2.62e-06	0.000929	0.36	0.28	Lung cancer in ever smokers;	chr15:49415250	chr15:49365124~49366685:-
KIRP	cis	rs79040073	0.637	rs11639423	ENSG00000259531.2	RP11-295H24.3	4.8	2.62e-06	0.000929	0.36	0.28	Lung cancer in ever smokers;	chr15:49415448	chr15:49365124~49366685:-
KIRP	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	4.8	2.62e-06	0.00093	0.23	0.28	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
KIRP	cis	rs295490	0.667	rs59960641	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139346587	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs80248005	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139347834	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs17394620	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348541	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs17316181	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139350851	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs61613889	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352279	chr3:139349024~139349371:-
KIRP	cis	rs295490	0.748	rs59958973	ENSG00000272656.1	RP11-219D15.3	4.8	2.62e-06	0.00093	0.48	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352385	chr3:139349024~139349371:-
KIRP	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	4.8	2.62e-06	0.00093	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
KIRP	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	4.8	2.63e-06	0.00093	0.31	0.28	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	4.8	2.63e-06	0.00093	0.31	0.28	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
KIRP	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	4.8	2.63e-06	0.00093	0.28	0.28	Height;	chr4:55589624	chr4:55547112~55547889:+
KIRP	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	4.8	2.63e-06	0.00093	0.66	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
KIRP	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-4.8	2.63e-06	0.000931	-0.34	-0.28	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
KIRP	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-4.8	2.63e-06	0.000932	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-4.8	2.63e-06	0.000932	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
KIRP	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.8	2.63e-06	0.000932	0.29	0.28	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
KIRP	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	4.8	2.63e-06	0.000932	0.23	0.28	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
KIRP	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	4.8	2.63e-06	0.000932	0.21	0.28	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
KIRP	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-4.8	2.63e-06	0.000932	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
KIRP	cis	rs9450351	0.744	rs7772723	ENSG00000203875.9	SNHG5	-4.8	2.63e-06	0.000932	-0.5	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85913980	chr6:85660950~85678736:-
KIRP	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	4.8	2.63e-06	0.000933	0.37	0.28	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
KIRP	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	4.8	2.63e-06	0.000933	0.37	0.28	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
KIRP	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	4.8	2.64e-06	0.000933	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	4.8	2.64e-06	0.000933	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
KIRP	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	4.8	2.64e-06	0.000934	0.46	0.28	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
KIRP	cis	rs8030379	1	rs1564473	ENSG00000230373.7	GOLGA6L5P	-4.8	2.64e-06	0.000934	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84507885~84516814:-
KIRP	cis	rs2278170	1	rs331531	ENSG00000225101.4	OR52K3P	-4.8	2.64e-06	0.000934	-0.32	-0.28	Amyotrophic lateral sclerosis;	chr11:4457006	chr11:4474813~4475755:+
KIRP	cis	rs2278170	1	rs331530	ENSG00000225101.4	OR52K3P	-4.8	2.64e-06	0.000934	-0.32	-0.28	Amyotrophic lateral sclerosis;	chr11:4457054	chr11:4474813~4475755:+
KIRP	cis	rs4639966	0.836	rs3825057	ENSG00000255239.1	AP002954.6	-4.8	2.64e-06	0.000934	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118752276	chr11:118688039~118690600:-
KIRP	cis	rs4639966	0.758	rs11217013	ENSG00000255239.1	AP002954.6	-4.8	2.64e-06	0.000934	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118754210	chr11:118688039~118690600:-
KIRP	cis	rs4639966	0.836	rs11217014	ENSG00000255239.1	AP002954.6	-4.8	2.64e-06	0.000934	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118755577	chr11:118688039~118690600:-
KIRP	cis	rs4639966	0.836	rs11217016	ENSG00000255239.1	AP002954.6	-4.8	2.64e-06	0.000934	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118756440	chr11:118688039~118690600:-
KIRP	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-4.8	2.64e-06	0.000934	-0.28	-0.28	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
KIRP	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	4.8	2.64e-06	0.000935	0.3	0.28	Height;	chr4:55515118	chr4:55363971~55395847:-
KIRP	cis	rs4631830	0.9	rs11006274	ENSG00000229927.2	RHEBP1	-4.8	2.64e-06	0.000935	-0.35	-0.28	Prostate-specific antigen levels;	chr10:46055531	chr10:46634911~46635466:-
KIRP	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	4.8	2.64e-06	0.000935	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
KIRP	cis	rs1799949	1	rs2298862	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43024671	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.93	rs2298861	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43024814	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs12944458	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43028755	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs36036395	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43029280	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs72829113	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43029818	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11653253	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43030645	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs12951869	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43035550	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11654452	ENSG00000279602.1	CTD-3014M21.1	-4.8	2.64e-06	0.000935	-0.25	-0.28	Menopause (age at onset);	chr17:43037366	chr17:43360041~43361361:-
KIRP	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.8	2.64e-06	0.000935	-0.36	-0.28	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
KIRP	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	4.8	2.65e-06	0.000936	0.37	0.28	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
KIRP	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-4.8	2.65e-06	0.000937	-0.24	-0.28	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-4.8	2.65e-06	0.000937	-0.24	-0.28	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
KIRP	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	4.8	2.65e-06	0.000937	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
KIRP	cis	rs2120243	0.533	rs1392798	ENSG00000244515.1	KRT18P34	4.8	2.65e-06	0.000938	0.33	0.28	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157162663~157163932:-
KIRP	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-4.8	2.65e-06	0.000938	-0.3	-0.28	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
KIRP	cis	rs7849973	0.579	rs12335498	ENSG00000224549.1	RP11-370B11.3	-4.8	2.65e-06	0.000938	-0.31	-0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22763089	chr9:22767175~22768316:+
KIRP	cis	rs2274273	0.564	rs10140164	ENSG00000258413.1	RP11-665C16.6	-4.8	2.65e-06	0.000938	-0.34	-0.28	Protein biomarker;	chr14:54939405	chr14:55262767~55272075:-
KIRP	cis	rs7289126	0.966	rs4820329	ENSG00000233360.4	Z83844.1	4.8	2.65e-06	0.000939	0.29	0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38250057	chr22:37641832~37658377:-
KIRP	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	4.8	2.65e-06	0.000939	0.37	0.28	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
KIRP	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	4.8	2.65e-06	0.000939	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
KIRP	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	4.8	2.65e-06	0.000939	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
KIRP	cis	rs728616	0.614	rs59169164	ENSG00000234382.2	RP11-40F6.1	-4.8	2.66e-06	0.000939	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:80233664~80245367:+
KIRP	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	4.8	2.66e-06	0.000939	0.36	0.28	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
KIRP	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-4.8	2.66e-06	0.00094	-0.3	-0.28	Height;	chr3:52967831	chr3:53064283~53065091:-
KIRP	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	4.8	2.66e-06	0.00094	0.26	0.28	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
KIRP	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	4.8	2.66e-06	0.00094	0.31	0.28	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
KIRP	cis	rs4820539	1	rs756631	ENSG00000275635.1	U7	4.8	2.66e-06	0.000941	0.31	0.28	Bone mineral density;	chr22:23120996	chr22:23137805~23137864:-
KIRP	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	4.8	2.66e-06	0.000941	0.26	0.28	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
KIRP	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-4.8	2.66e-06	0.000941	-0.28	-0.28	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
KIRP	cis	rs1400745	0.812	rs72678789	ENSG00000258738.1	RP11-73E17.2	-4.8	2.66e-06	0.000942	-0.26	-0.28	Monocyte count;	chr14:34878995	chr14:34874343~34876459:+
KIRP	cis	rs2911132	0.564	rs28580505	ENSG00000248734.2	CTD-2260A17.1	4.8	2.66e-06	0.000942	0.27	0.28	Urate levels (BMI interaction);	chr5:96765516	chr5:96784777~96785999:+
KIRP	cis	rs2911132	0.621	rs28432918	ENSG00000248734.2	CTD-2260A17.1	4.8	2.66e-06	0.000942	0.27	0.28	Urate levels (BMI interaction);	chr5:96765522	chr5:96784777~96785999:+
KIRP	cis	rs8141529	0.732	rs2239815	ENSG00000226471.5	CTA-292E10.6	4.8	2.67e-06	0.000942	0.3	0.28	Lymphocyte counts;	chr22:28796682	chr22:28800683~28848559:+
KIRP	cis	rs962856	1	rs6722203	ENSG00000236605.1	AC023115.4	4.8	2.67e-06	0.000943	0.36	0.28	Pancreatic cancer;	chr2:67342061	chr2:67324627~67325304:+
KIRP	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	4.8	2.67e-06	0.000943	0.29	0.28	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
KIRP	cis	rs324126	0.78	rs10445583	ENSG00000269834.4	ZNF528-AS1	4.8	2.67e-06	0.000943	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.752	rs10445584	ENSG00000269834.4	ZNF528-AS1	4.8	2.67e-06	0.000943	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs10445585	ENSG00000269834.4	ZNF528-AS1	4.8	2.67e-06	0.000943	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs10445586	ENSG00000269834.4	ZNF528-AS1	4.8	2.67e-06	0.000943	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52388842~52397766:-
KIRP	cis	rs324126	0.78	rs62108317	ENSG00000269834.4	ZNF528-AS1	4.8	2.67e-06	0.000943	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52388842~52397766:-
KIRP	cis	rs1023500	0.505	rs134891	ENSG00000226450.2	CYP2D8P	4.8	2.67e-06	0.000943	0.22	0.28	Schizophrenia;	chr22:42279876	chr22:42149886~42155001:-
KIRP	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	4.8	2.67e-06	0.000944	0.37	0.28	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
KIRP	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-4.8	2.67e-06	0.000944	-0.24	-0.28	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
KIRP	cis	rs962856	1	rs1032157	ENSG00000236605.1	AC023115.4	4.8	2.67e-06	0.000945	0.36	0.28	Pancreatic cancer;	chr2:67374684	chr2:67324627~67325304:+
KIRP	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.8	2.67e-06	0.000945	0.39	0.28	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
KIRP	cis	rs962856	0.964	rs11890812	ENSG00000236605.1	AC023115.4	4.8	2.67e-06	0.000945	0.35	0.28	Pancreatic cancer;	chr2:67392883	chr2:67324627~67325304:+
KIRP	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-4.8	2.68e-06	0.000946	-0.31	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
KIRP	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-4.8	2.68e-06	0.000946	-0.35	-0.28	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
KIRP	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	4.8	2.68e-06	0.000946	0.25	0.28	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	4.8	2.68e-06	0.000946	0.25	0.28	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
KIRP	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	4.8	2.68e-06	0.000946	0.25	0.28	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
KIRP	cis	rs9305354	1	rs12482043	ENSG00000232079.5	AL035610.1	4.8	2.68e-06	0.000947	0.39	0.28	Urinary albumin excretion;	chr21:28106336	chr21:28048404~28137611:+
KIRP	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	4.8	2.68e-06	0.000947	0.29	0.28	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	4.8	2.68e-06	0.000947	0.29	0.28	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
KIRP	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	4.8	2.68e-06	0.000947	0.29	0.28	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
KIRP	cis	rs3781264	0.677	rs7100870	ENSG00000273450.1	RP11-76P2.4	4.8	2.68e-06	0.000947	0.35	0.28	Esophageal cancer and gastric cancer;	chr10:94363069	chr10:94314907~94315327:-
KIRP	cis	rs1914816	1	rs1914816	ENSG00000196274.5	Metazoa_SRP	4.8	2.68e-06	0.000947	0.3	0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76254592	chr15:76230048~76230390:-
KIRP	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	4.8	2.68e-06	0.000948	0.25	0.28	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
KIRP	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-4.8	2.68e-06	0.000948	-0.55	-0.28	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
KIRP	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	4.8	2.68e-06	0.000948	0.33	0.28	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
KIRP	cis	rs9305354	1	rs2831491	ENSG00000232079.5	AL035610.1	4.8	2.69e-06	0.000949	0.38	0.28	Urinary albumin excretion;	chr21:28104423	chr21:28048404~28137611:+
KIRP	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	4.8	2.69e-06	0.000949	0.24	0.28	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
KIRP	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	4.8	2.69e-06	0.000949	0.24	0.28	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
KIRP	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	4.8	2.69e-06	0.000949	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
KIRP	cis	rs9595908	0.785	rs4942829	ENSG00000212293.1	SNORA16	4.8	2.69e-06	0.00095	0.27	0.28	Body mass index;	chr13:32708994	chr13:32420390~32420516:-
KIRP	cis	rs950169	0.84	rs12905223	ENSG00000275120.1	RP11-182J1.17	4.8	2.69e-06	0.00095	0.36	0.28	Schizophrenia;	chr15:84571037	chr15:84599434~84606463:-
KIRP	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.8	2.69e-06	0.00095	0.31	0.28	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
KIRP	cis	rs7772486	0.846	rs1854901	ENSG00000270638.1	RP3-466P17.1	4.8	2.69e-06	0.00095	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs1960885	ENSG00000270638.1	RP3-466P17.1	4.8	2.69e-06	0.00095	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.817	rs2748491	ENSG00000270638.1	RP3-466P17.1	4.8	2.69e-06	0.00095	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.875	rs2777483	ENSG00000270638.1	RP3-466P17.1	4.8	2.69e-06	0.00095	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145735570~145737218:+
KIRP	cis	rs2299587	0.932	rs13279395	ENSG00000254054.2	RP11-156K13.3	4.8	2.69e-06	0.00095	0.34	0.28	Economic and political preferences;	chr8:17994527	chr8:17905756~17907887:+
KIRP	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	4.8	2.69e-06	0.000951	0.4	0.28	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	4.8	2.69e-06	0.000951	0.4	0.28	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	4.8	2.69e-06	0.000951	0.4	0.28	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	4.8	2.69e-06	0.000951	0.4	0.28	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	4.8	2.69e-06	0.000951	0.4	0.28	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
KIRP	cis	rs8049040	0.547	rs12929335	ENSG00000260886.1	TAT-AS1	4.8	2.69e-06	0.000951	0.37	0.28	Blood protein levels;	chr16:71401849	chr16:71565789~71578187:+
KIRP	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	4.8	2.7e-06	0.000952	0.38	0.28	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
KIRP	cis	rs1185460	0.967	rs4454730	ENSG00000272186.1	RP11-110I1.13	-4.8	2.7e-06	0.000952	-0.28	-0.28	Coronary artery disease;	chr11:119066733	chr11:119067374~119067698:-
KIRP	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-4.8	2.7e-06	0.000953	-0.3	-0.28	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
KIRP	cis	rs964611	0.882	rs11070636	ENSG00000259488.2	RP11-154J22.1	4.8	2.7e-06	0.000953	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48364720	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.882	rs11070637	ENSG00000259488.2	RP11-154J22.1	4.8	2.7e-06	0.000953	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48364881	chr15:48312353~48331856:-
KIRP	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-4.8	2.7e-06	0.000953	-0.36	-0.28	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
KIRP	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	4.8	2.7e-06	0.000953	0.27	0.28	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
KIRP	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.8	2.7e-06	0.000954	-0.39	-0.28	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
KIRP	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-4.8	2.7e-06	0.000954	-0.52	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
KIRP	cis	rs7590983	1	rs55716747	ENSG00000271151.1	RP11-394I13.2	4.8	2.7e-06	0.000954	0.35	0.28	Anthropometric traits;	chr2:173498702	chr2:173968351~173969418:+
KIRP	cis	rs703842	0.928	rs724834	ENSG00000270039.1	RP11-571M6.17	-4.8	2.71e-06	0.000955	-0.27	-0.28	Multiple sclerosis;	chr12:57786633	chr12:57803838~57804415:+
KIRP	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	4.8	2.71e-06	0.000956	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
KIRP	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-4.8	2.71e-06	0.000956	-0.29	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
KIRP	cis	rs1185460	0.967	rs4545564	ENSG00000272186.1	RP11-110I1.13	-4.8	2.71e-06	0.000956	-0.28	-0.28	Coronary artery disease;	chr11:119066807	chr11:119067374~119067698:-
KIRP	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.8	2.71e-06	0.000956	0.28	0.28	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
KIRP	cis	rs2581828	0.656	rs2336723	ENSG00000271976.1	RP11-884K10.7	4.8	2.71e-06	0.000956	0.18	0.28	Crohn's disease;	chr3:53072031	chr3:53858994~53861576:-
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	4.8	2.71e-06	0.000957	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
KIRP	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	4.8	2.71e-06	0.000957	0.33	0.28	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
KIRP	cis	rs1552244	1	rs68067759	ENSG00000180385.7	EMC3-AS1	4.8	2.71e-06	0.000957	0.29	0.28	Alzheimer's disease;	chr3:10108851	chr3:9986893~10006990:+
KIRP	cis	rs2504916	0.68	rs1118328	ENSG00000230234.1	RP1-276N6.2	-4.8	2.71e-06	0.000957	-0.28	-0.28	Response to hepatitis C treatment;	chr6:160285686	chr6:160272617~160276130:+
KIRP	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-4.8	2.71e-06	0.000958	-0.35	-0.28	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-4.8	2.71e-06	0.000958	-0.35	-0.28	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-4.8	2.71e-06	0.000958	-0.35	-0.28	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-4.8	2.71e-06	0.000958	-0.35	-0.28	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-4.8	2.71e-06	0.000958	-0.35	-0.28	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
KIRP	cis	rs8030379	1	rs2061999	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs3934135	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2030838	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2030840	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1880730	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs7496814	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs8024418	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs8042970	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259937	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11637866	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2135880	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1526080	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921168	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1852264	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921188	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1526081	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921314	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs8030379	ENSG00000230373.7	GOLGA6L5P	-4.8	2.72e-06	0.000958	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922158	chr15:84507885~84516814:-
KIRP	cis	rs4578769	1	rs4578769	ENSG00000266850.1	RP11-370A5.1	4.8	2.72e-06	0.000958	0.37	0.28	Eosinophil percentage of white cells;	chr18:22815141	chr18:22723491~22907721:-
KIRP	cis	rs1044826	0.597	rs1017468	ENSG00000178631.7	ACTG1P1	4.8	2.72e-06	0.000959	0.3	0.28	Obesity-related traits;	chr3:139426936	chr3:139493809~139494937:+
KIRP	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-4.8	2.72e-06	0.000959	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
KIRP	cis	rs8114671	0.836	rs6142294	ENSG00000269202.1	RP4-614O4.12	4.8	2.72e-06	0.000959	0.21	0.28	Height;	chr20:35083694	chr20:35201747~35203288:-
KIRP	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	4.8	2.72e-06	0.00096	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
KIRP	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	4.8	2.72e-06	0.00096	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
KIRP	cis	rs7615952	0.599	rs6803160	ENSG00000241439.1	RP11-666A20.3	4.8	2.72e-06	0.00096	0.38	0.28	Blood pressure (smoking interaction);	chr3:125990711	chr3:125958556~125958817:+
KIRP	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	4.8	2.72e-06	0.00096	0.29	0.28	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
KIRP	cis	rs8141529	0.748	rs132533	ENSG00000226471.5	CTA-292E10.6	4.8	2.72e-06	0.00096	0.29	0.28	Lymphocyte counts;	chr22:28903583	chr22:28800683~28848559:+
KIRP	cis	rs5758511	0.68	rs1033459	ENSG00000227370.1	RP4-669P10.19	4.8	2.72e-06	0.000961	0.34	0.28	Birth weight;	chr22:42223061	chr22:42132543~42132998:+
KIRP	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	4.8	2.73e-06	0.000961	0.23	0.28	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
KIRP	cis	rs198426	0.506	rs198464	ENSG00000124915.9	DKFZP434K028	4.8	2.73e-06	0.000962	0.34	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61754149	chr11:61746493~61757655:-
KIRP	cis	rs1159787	0.517	rs7045301	ENSG00000233569.1	RP11-500B12.1	-4.8	2.73e-06	0.000962	-0.5	-0.28	Blood protein levels;	chr9:117640955	chr9:117648606~117657027:+
KIRP	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.79	2.73e-06	0.000963	-0.22	-0.28	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
KIRP	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	4.79	2.73e-06	0.000964	0.42	0.28	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
KIRP	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.79	2.73e-06	0.000964	-0.24	-0.28	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
KIRP	cis	rs7299940	0.694	rs12296337	ENSG00000256299.1	RP11-989F5.3	4.79	2.74e-06	0.000964	0.28	0.28	Panic disorder;	chr12:130891406	chr12:130810821~130812622:-
KIRP	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	4.79	2.74e-06	0.000965	0.4	0.28	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
KIRP	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	4.79	2.74e-06	0.000965	0.4	0.28	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	4.79	2.74e-06	0.000965	0.4	0.28	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
KIRP	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	4.79	2.74e-06	0.000965	0.29	0.28	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
KIRP	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	4.79	2.74e-06	0.000965	0.29	0.28	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
KIRP	cis	rs4694744	0.508	rs13138057	ENSG00000250696.4	RP11-704M14.1	4.79	2.74e-06	0.000966	0.38	0.28	Bacteremia;	chr4:69442954	chr4:69182100~69216766:+
KIRP	cis	rs11148252	0.774	rs7993748	ENSG00000235660.1	LINC00345	-4.79	2.74e-06	0.000966	-0.3	-0.28	Lewy body disease;	chr13:52367496	chr13:52484161~52484680:-
KIRP	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	4.79	2.74e-06	0.000966	0.31	0.28	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	4.79	2.74e-06	0.000966	0.31	0.28	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
KIRP	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	4.79	2.74e-06	0.000966	0.31	0.28	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
KIRP	cis	rs8141529	0.956	rs132539	ENSG00000226471.5	CTA-292E10.6	-4.79	2.74e-06	0.000966	-0.31	-0.28	Lymphocyte counts;	chr22:28908265	chr22:28800683~28848559:+
KIRP	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	4.79	2.74e-06	0.000967	0.28	0.28	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
KIRP	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-4.79	2.74e-06	0.000967	-0.31	-0.28	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
KIRP	cis	rs9595908	0.669	rs28637641	ENSG00000212293.1	SNORA16	4.79	2.74e-06	0.000967	0.28	0.28	Body mass index;	chr13:32726997	chr13:32420390~32420516:-
KIRP	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	4.79	2.75e-06	0.000967	0.36	0.28	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	4.79	2.75e-06	0.000967	0.36	0.28	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
KIRP	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	4.79	2.75e-06	0.000967	0.36	0.28	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
KIRP	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-4.79	2.75e-06	0.000968	-0.24	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
KIRP	cis	rs1560104	0.833	rs4381588	ENSG00000274834.1	CTD-3037G24.5	-4.79	2.75e-06	0.000968	-0.33	-0.28	Obesity-related traits;	chr16:12623414	chr16:12614451~12614852:+
KIRP	cis	rs1560104	0.879	rs2865578	ENSG00000274834.1	CTD-3037G24.5	-4.79	2.75e-06	0.000968	-0.33	-0.28	Obesity-related traits;	chr16:12623457	chr16:12614451~12614852:+
KIRP	cis	rs1487614	0.769	rs62302161	ENSG00000250781.1	RP11-63A11.1	-4.79	2.75e-06	0.000968	-0.36	-0.28	Longevity;	chr4:42257122	chr4:42281830~42391268:-
KIRP	cis	rs9926296	0.643	rs2159114	ENSG00000260259.1	RP11-368I7.4	-4.79	2.75e-06	0.000969	-0.23	-0.28	Vitiligo;	chr16:89765433	chr16:89682620~89686569:-
KIRP	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-4.79	2.75e-06	0.000969	-0.3	-0.28	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-4.79	2.75e-06	0.000969	-0.3	-0.28	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
KIRP	cis	rs17684571	0.751	rs6910414	ENSG00000231441.1	RP11-472M19.2	4.79	2.75e-06	0.00097	0.43	0.28	Schizophrenia;	chr6:56861939	chr6:56844002~56864078:+
KIRP	cis	rs950169	0.922	rs4586394	ENSG00000275120.1	RP11-182J1.17	-4.79	2.75e-06	0.00097	-0.4	-0.28	Schizophrenia;	chr15:84153633	chr15:84599434~84606463:-
KIRP	cis	rs964611	0.882	rs7175172	ENSG00000259488.2	RP11-154J22.1	-4.79	2.75e-06	0.00097	-0.27	-0.28	Metabolite levels (Pyroglutamine);	chr15:48280021	chr15:48312353~48331856:-
KIRP	cis	rs42648	0.792	rs4236517	ENSG00000225498.1	AC002064.5	4.79	2.76e-06	0.00097	0.21	0.28	Homocysteine levels;	chr7:90334151	chr7:90312496~90322592:+
KIRP	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-4.79	2.76e-06	0.000971	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
KIRP	cis	rs9915657	0.87	rs720244	ENSG00000234899.8	SOX9-AS1	-4.79	2.76e-06	0.000972	-0.26	-0.28	Thyroid hormone levels;	chr17:72135502	chr17:72034107~72237203:-
KIRP	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	4.79	2.76e-06	0.000973	0.29	0.28	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
KIRP	cis	rs73198271	0.74	rs11781430	ENSG00000253981.4	ALG1L13P	-4.79	2.77e-06	0.000973	-0.24	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8236003~8244667:-
KIRP	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-4.79	2.77e-06	0.000973	-0.39	-0.28	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
KIRP	cis	rs6840258	0.891	rs75921854	ENSG00000251411.1	RP11-397E7.4	-4.79	2.77e-06	0.000974	-0.27	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87110944	chr4:86913266~86914817:-
KIRP	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-4.79	2.77e-06	0.000974	-0.36	-0.28	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
KIRP	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	4.79	2.77e-06	0.000975	0.32	0.28	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
KIRP	cis	rs75920871	0.589	rs7941150	ENSG00000254851.1	RP11-109L13.1	-4.79	2.77e-06	0.000975	-0.48	-0.28	Subjective well-being;	chr11:117221105	chr11:117135528~117138582:+
KIRP	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	4.79	2.77e-06	0.000976	0.29	0.28	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
KIRP	cis	rs1552244	1	rs61052895	ENSG00000180385.7	EMC3-AS1	4.79	2.77e-06	0.000976	0.29	0.28	Alzheimer's disease;	chr3:10105832	chr3:9986893~10006990:+
KIRP	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.79	2.77e-06	0.000976	-0.3	-0.28	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
KIRP	cis	rs5751901	0.614	rs4820599	ENSG00000225098.1	BCRP1	4.79	2.77e-06	0.000976	0.3	0.28	Protein quantitative trait loci;	chr22:24594246	chr22:24259929~24263764:-
KIRP	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	4.79	2.77e-06	0.000976	0.25	0.28	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
KIRP	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	4.79	2.77e-06	0.000976	0.42	0.28	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
KIRP	cis	rs10078	0.571	rs2241597	ENSG00000221990.4	EXOC3-AS1	4.79	2.77e-06	0.000976	0.37	0.28	Fat distribution (HIV);	chr5:480394	chr5:441498~443160:-
KIRP	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-4.79	2.78e-06	0.000976	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	4.79	2.78e-06	0.000976	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	4.79	2.78e-06	0.000976	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
KIRP	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	4.79	2.78e-06	0.000976	0.24	0.28	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
KIRP	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-4.79	2.78e-06	0.000977	-0.37	-0.28	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
KIRP	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	4.79	2.78e-06	0.000977	0.18	0.28	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
KIRP	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-4.79	2.78e-06	0.000977	-0.3	-0.28	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
KIRP	cis	rs7432375	1	rs940174	ENSG00000261758.1	RP11-102M11.2	4.79	2.78e-06	0.000978	0.3	0.28	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136590868	chr3:136752630~136755780:+
KIRP	cis	rs172166	0.56	rs203878	ENSG00000220721.1	OR1F12	4.79	2.78e-06	0.000979	0.29	0.28	Cardiac Troponin-T levels;	chr6:28081218	chr6:28073316~28074233:+
KIRP	cis	rs11158026	1	rs2183081	ENSG00000258413.1	RP11-665C16.6	-4.79	2.78e-06	0.000979	-0.35	-0.28	Parkinson's disease;	chr14:54870033	chr14:55262767~55272075:-
KIRP	cis	rs1476679	0.927	rs2405442	ENSG00000242294.5	STAG3L5P	4.79	2.78e-06	0.000979	0.18	0.28	Alzheimer's disease (late onset);	chr7:100373690	chr7:100336079~100351900:+
KIRP	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	4.79	2.79e-06	0.000979	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
KIRP	cis	rs8037137	1	rs8037137	ENSG00000258725.1	PRC1-AS1	-4.79	2.79e-06	0.000981	-0.38	-0.28	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90963407	chr15:90966345~90988624:+
KIRP	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-4.79	2.79e-06	0.000981	-0.35	-0.28	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
KIRP	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	4.79	2.79e-06	0.000981	0.51	0.28	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
KIRP	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-4.79	2.79e-06	0.000982	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
KIRP	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	4.79	2.79e-06	0.000982	0.28	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
KIRP	cis	rs9595908	0.709	rs3492	ENSG00000212293.1	SNORA16	4.79	2.8e-06	0.000983	0.27	0.28	Body mass index;	chr13:32775203	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs7326102	ENSG00000212293.1	SNORA16	4.79	2.8e-06	0.000983	0.27	0.28	Body mass index;	chr13:32777857	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs17516561	ENSG00000212293.1	SNORA16	4.79	2.8e-06	0.000983	0.27	0.28	Body mass index;	chr13:32782063	chr13:32420390~32420516:-
KIRP	cis	rs79040073	0.607	rs7168316	ENSG00000259531.2	RP11-295H24.3	4.79	2.8e-06	0.000983	0.37	0.28	Lung cancer in ever smokers;	chr15:49441549	chr15:49365124~49366685:-
KIRP	cis	rs7829975	0.56	rs6994131	ENSG00000253981.4	ALG1L13P	-4.79	2.8e-06	0.000984	-0.22	-0.28	Mood instability;	chr8:8693448	chr8:8236003~8244667:-
KIRP	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	4.79	2.8e-06	0.000984	0.27	0.28	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	4.79	2.8e-06	0.000984	0.27	0.28	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
KIRP	cis	rs4578769	0.959	rs12964817	ENSG00000266850.1	RP11-370A5.1	4.79	2.8e-06	0.000984	0.37	0.28	Eosinophil percentage of white cells;	chr18:22876657	chr18:22723491~22907721:-
KIRP	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-4.79	2.8e-06	0.000985	-0.22	-0.28	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
KIRP	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-4.79	2.8e-06	0.000985	-0.22	-0.28	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
KIRP	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-4.79	2.8e-06	0.000985	-0.22	-0.28	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
KIRP	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	4.79	2.8e-06	0.000985	0.31	0.28	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	4.79	2.8e-06	0.000985	0.31	0.28	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	4.79	2.8e-06	0.000985	0.31	0.28	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
KIRP	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	4.79	2.8e-06	0.000985	0.36	0.28	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
KIRP	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	4.79	2.8e-06	0.000985	0.31	0.28	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
KIRP	cis	rs4218	0.531	rs6494065	ENSG00000277144.1	RP11-59H7.4	4.79	2.8e-06	0.000985	0.28	0.28	Social communication problems;	chr15:59053249	chr15:59115547~59116089:-
KIRP	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	4.79	2.81e-06	0.000985	0.29	0.28	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
KIRP	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	4.79	2.81e-06	0.000986	0.49	0.28	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
KIRP	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	4.79	2.81e-06	0.000986	0.33	0.28	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	4.79	2.81e-06	0.000986	0.33	0.28	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	4.79	2.81e-06	0.000986	0.33	0.28	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	4.79	2.81e-06	0.000986	0.33	0.28	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	4.79	2.81e-06	0.000986	0.33	0.28	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
KIRP	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	4.79	2.81e-06	0.000986	0.38	0.28	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
KIRP	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	4.79	2.81e-06	0.000986	0.24	0.28	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
KIRP	cis	rs8141529	0.732	rs6005872	ENSG00000226471.5	CTA-292E10.6	-4.79	2.81e-06	0.000986	-0.29	-0.28	Lymphocyte counts;	chr22:28776910	chr22:28800683~28848559:+
KIRP	cis	rs5769707	0.681	rs739236	ENSG00000235111.1	RP1-29C18.8	-4.79	2.81e-06	0.000986	-0.31	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49612657~49615716:-
KIRP	cis	rs5769707	0.681	rs1107514	ENSG00000235111.1	RP1-29C18.8	-4.79	2.81e-06	0.000986	-0.31	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49612657~49615716:-
KIRP	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-4.79	2.81e-06	0.000986	-0.35	-0.28	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
KIRP	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-4.79	2.81e-06	0.000986	-0.35	-0.28	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
KIRP	cis	rs962856	1	rs962856	ENSG00000236605.1	AC023115.4	4.79	2.81e-06	0.000986	0.36	0.28	Pancreatic cancer;	chr2:67366671	chr2:67324627~67325304:+
KIRP	cis	rs4356975	0.509	rs4309908	ENSG00000196472.4	RP13-644M16.4	4.79	2.81e-06	0.000987	0.3	0.28	Obesity-related traits;	chr4:69086022	chr4:69181660~69182372:+
KIRP	cis	rs295490	0.748	rs77869711	ENSG00000272656.1	RP11-219D15.3	4.79	2.81e-06	0.000987	0.49	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348416	chr3:139349024~139349371:-
KIRP	cis	rs2562456	0.682	rs11085464	ENSG00000268555.1	RP11-678G14.3	4.79	2.81e-06	0.000987	0.38	0.28	Pain;	chr19:21568976	chr19:21570822~21587322:-
KIRP	cis	rs1799949	1	rs3092994	ENSG00000279602.1	CTD-3014M21.1	-4.79	2.81e-06	0.000988	-0.26	-0.28	Menopause (age at onset);	chr17:43063808	chr17:43360041~43361361:-
KIRP	cis	rs295490	0.748	rs41399544	ENSG00000272656.1	RP11-219D15.3	4.79	2.81e-06	0.000988	0.47	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139349024~139349371:-
KIRP	cis	rs116095464	0.51	rs73016876	ENSG00000248925.1	CTD-2083E4.6	4.79	2.82e-06	0.000988	0.43	0.28	Breast cancer;	chr5:244360	chr5:269858~271516:-
KIRP	cis	rs6840258	0.891	rs3733377	ENSG00000251411.1	RP11-397E7.4	4.79	2.82e-06	0.000989	0.27	0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87108330	chr4:86913266~86914817:-
KIRP	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	4.79	2.82e-06	0.00099	0.32	0.28	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
KIRP	cis	rs12936587	0.69	rs12453926	ENSG00000223979.2	SMCR2	4.79	2.82e-06	0.00099	0.28	0.28	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17630893	chr17:17674026~17677688:-
KIRP	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	4.79	2.82e-06	0.00099	0.25	0.28	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	4.79	2.82e-06	0.00099	0.25	0.28	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	4.79	2.82e-06	0.00099	0.25	0.28	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
KIRP	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	4.79	2.82e-06	0.000991	0.39	0.28	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
KIRP	cis	rs7590983	1	rs73971773	ENSG00000271151.1	RP11-394I13.2	4.79	2.82e-06	0.000991	0.35	0.28	Anthropometric traits;	chr2:173500687	chr2:173968351~173969418:+
KIRP	cis	rs1799949	1	rs35330014	ENSG00000279602.1	CTD-3014M21.1	-4.79	2.83e-06	0.000991	-0.26	-0.28	Menopause (age at onset);	chr17:43060530	chr17:43360041~43361361:-
KIRP	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-4.79	2.83e-06	0.000992	-0.3	-0.28	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
KIRP	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-4.79	2.83e-06	0.000992	-0.36	-0.28	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-4.79	2.83e-06	0.000992	-0.36	-0.28	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
KIRP	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-4.79	2.83e-06	0.000992	-0.36	-0.28	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
KIRP	cis	rs9450351	0.744	rs9344559	ENSG00000203875.9	SNHG5	-4.79	2.83e-06	0.000993	-0.49	-0.28	Interferon gamma-induced protein 10 levels;	chr6:86012192	chr6:85660950~85678736:-
KIRP	cis	rs9915657	0.87	rs918081	ENSG00000234899.8	SOX9-AS1	-4.79	2.83e-06	0.000993	-0.26	-0.28	Thyroid hormone levels;	chr17:72131667	chr17:72034107~72237203:-
KIRP	cis	rs2504916	0.635	rs2634657	ENSG00000230234.1	RP1-276N6.2	-4.79	2.83e-06	0.000993	-0.28	-0.28	Response to hepatitis C treatment;	chr6:160278891	chr6:160272617~160276130:+
KIRP	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	4.79	2.83e-06	0.000993	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
KIRP	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	4.79	2.84e-06	0.000995	0.36	0.28	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
KIRP	cis	rs7672749	0.524	rs1463102	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87873380	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs1463103	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87873726	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs2045832	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87874048	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs6815121	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87874837	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.591	rs1381956	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87875440	chr4:87785920~87786371:-
KIRP	cis	rs7672749	0.63	rs1381957	ENSG00000249973.2	CHCHD2P7	-4.79	2.84e-06	0.000995	-0.43	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87875547	chr4:87785920~87786371:-
KIRP	cis	rs1044826	0.597	rs6803593	ENSG00000178631.7	ACTG1P1	4.79	2.84e-06	0.000995	0.3	0.28	Obesity-related traits;	chr3:139475145	chr3:139493809~139494937:+
KIRP	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	4.79	2.84e-06	0.000996	0.32	0.28	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
KIRP	cis	rs7432375	1	rs6439649	ENSG00000261758.1	RP11-102M11.2	-4.79	2.84e-06	0.000996	-0.3	-0.28	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652849	chr3:136752630~136755780:+
KIRP	cis	rs875971	0.545	rs12670811	ENSG00000224316.1	RP11-479O9.2	4.79	2.84e-06	0.000996	0.24	0.28	Aortic root size;	chr7:66358032	chr7:65773620~65802067:+
KIRP	cis	rs72717009	0.825	rs7515174	ENSG00000225217.1	HSPA7	-4.79	2.84e-06	0.000997	-0.39	-0.28	Rheumatoid arthritis;	chr1:161507159	chr1:161606291~161608217:+
KIRP	cis	rs72717009	0.825	rs7539468	ENSG00000225217.1	HSPA7	-4.79	2.84e-06	0.000997	-0.39	-0.28	Rheumatoid arthritis;	chr1:161507276	chr1:161606291~161608217:+
KIRP	cis	rs72717009	0.778	rs9427400	ENSG00000225217.1	HSPA7	-4.79	2.84e-06	0.000997	-0.39	-0.28	Rheumatoid arthritis;	chr1:161507414	chr1:161606291~161608217:+
KIRP	cis	rs72717009	0.825	rs6671753	ENSG00000225217.1	HSPA7	-4.79	2.84e-06	0.000997	-0.39	-0.28	Rheumatoid arthritis;	chr1:161508918	chr1:161606291~161608217:+
KIRP	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-4.79	2.84e-06	0.000997	-0.36	-0.28	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-4.79	2.84e-06	0.000997	-0.36	-0.28	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-4.79	2.84e-06	0.000997	-0.36	-0.28	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-4.79	2.84e-06	0.000997	-0.36	-0.28	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-4.79	2.84e-06	0.000997	-0.36	-0.28	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
KIRP	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-4.79	2.84e-06	0.000997	-0.28	-0.28	Height;	chr14:75124143	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-4.79	2.84e-06	0.000997	-0.28	-0.28	Height;	chr14:75124368	chr14:75011269~75012851:-
KIRP	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	4.79	2.85e-06	0.000998	0.42	0.28	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
KIRP	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.79	2.85e-06	0.000998	0.24	0.28	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
KIRP	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.79	2.85e-06	0.000998	0.24	0.28	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
KIRP	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-4.79	2.85e-06	0.000998	-0.27	-0.28	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
KIRP	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	4.79	2.85e-06	0.000998	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
KIRP	cis	rs4578769	0.55	rs9961760	ENSG00000265943.1	RP11-739L10.1	4.79	2.85e-06	0.000999	0.37	0.28	Eosinophil percentage of white cells;	chr18:23021545	chr18:22699481~22933764:-
KIRP	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-4.79	2.85e-06	0.000999	-0.26	-0.28	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
KIRP	cis	rs728616	0.614	rs10887218	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs1885552	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs1885551	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs12253608	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.764	rs1885549	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs12245076	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10788319	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs11200859	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887229	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10788321	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs61858839	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs61858841	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs61858842	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887233	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887234	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887235	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs2146192	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs2146191	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887243	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.614	rs10887244	ENSG00000234382.2	RP11-40F6.1	-4.79	2.86e-06	0.001	-0.33	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:80233664~80245367:+
KIRP	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-4.79	2.86e-06	0.001	-0.37	-0.28	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
KIRP	cis	rs1552244	1	rs7610821	ENSG00000180385.7	EMC3-AS1	4.79	2.86e-06	0.001	0.26	0.28	Alzheimer's disease;	chr3:10094466	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs2272125	ENSG00000180385.7	EMC3-AS1	4.79	2.86e-06	0.001	0.26	0.28	Alzheimer's disease;	chr3:10096385	chr3:9986893~10006990:+
KIRP	cis	rs1552244	0.935	rs2272124	ENSG00000180385.7	EMC3-AS1	4.79	2.86e-06	0.001	0.26	0.28	Alzheimer's disease;	chr3:10096505	chr3:9986893~10006990:+
KIRP	cis	rs7590983	1	rs16861829	ENSG00000271151.1	RP11-394I13.2	-4.79	2.86e-06	0.001	-0.35	-0.28	Anthropometric traits;	chr2:173504012	chr2:173968351~173969418:+
KIRP	cis	rs1799949	0.965	rs4239149	ENSG00000236383.6	LINC00854	4.78	2.86e-06	0.001	0.21	0.28	Menopause (age at onset);	chr17:43176078	chr17:43216941~43305976:-
KIRP	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	4.78	2.86e-06	0.001	0.31	0.28	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
KIRP	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	4.78	2.86e-06	0.001	0.31	0.28	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
KIRP	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	4.78	2.86e-06	0.001	0.28	0.28	Height;	chr14:75127199	chr14:75011269~75012851:-
KIRP	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.78	2.86e-06	0.001	-0.3	-0.28	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
KIRP	cis	rs964611	0.882	rs8040405	ENSG00000259488.2	RP11-154J22.1	-4.78	2.86e-06	0.001	-0.27	-0.28	Metabolite levels (Pyroglutamine);	chr15:48280640	chr15:48312353~48331856:-
KIRP	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.78	2.87e-06	0.001	0.24	0.28	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
KIRP	cis	rs712039	0.652	rs2946340	ENSG00000276054.1	RP11-378E13.3	4.78	2.87e-06	0.001	0.4	0.28	Tuberculosis;	chr17:37392762	chr17:37386886~37387926:+
KIRP	cis	rs7224610	0.57	rs963955	ENSG00000263096.1	RP11-515O17.2	-4.78	2.87e-06	0.00101	-0.36	-0.28	Urate levels;	chr17:55309465	chr17:55271504~55273653:-
KIRP	cis	rs1061377	0.862	rs12508577	ENSG00000249685.1	RP11-360F5.3	4.78	2.87e-06	0.00101	0.32	0.28	Uric acid levels;	chr4:39107779	chr4:39133913~39135608:+
KIRP	cis	rs897984	0.683	rs72799316	ENSG00000275263.1	RP11-1072A3.4	-4.78	2.88e-06	0.00101	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30815884	chr16:30956872~30957199:-
KIRP	cis	rs4934494	0.588	rs2026554	ENSG00000232936.4	RP11-80H5.2	4.78	2.88e-06	0.00101	0.42	0.28	Red blood cell count;	chr10:89829699	chr10:89645282~89650667:+
KIRP	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	4.78	2.88e-06	0.00101	0.48	0.28	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
KIRP	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	4.78	2.88e-06	0.00101	0.33	0.28	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
KIRP	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	4.78	2.88e-06	0.00101	0.32	0.28	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
KIRP	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-4.78	2.89e-06	0.00101	-0.29	-0.28	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
KIRP	cis	rs9913711	0.689	rs8076087	ENSG00000234899.8	SOX9-AS1	4.78	2.89e-06	0.00101	0.24	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr17:72139914	chr17:72034107~72237203:-
KIRP	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-4.78	2.89e-06	0.00101	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-4.78	2.89e-06	0.00101	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
KIRP	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-4.78	2.89e-06	0.00101	-0.36	-0.28	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
KIRP	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-4.78	2.89e-06	0.00101	-0.36	-0.28	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
KIRP	cis	rs964611	0.882	rs11857977	ENSG00000259488.2	RP11-154J22.1	4.78	2.89e-06	0.00101	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48353478	chr15:48312353~48331856:-
KIRP	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-4.78	2.89e-06	0.00101	-0.24	-0.28	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
KIRP	cis	rs11673344	0.523	rs2562605	ENSG00000226686.6	LINC01535	4.78	2.9e-06	0.00101	0.35	0.28	Obesity-related traits;	chr19:37029302	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.523	rs2562607	ENSG00000226686.6	LINC01535	4.78	2.9e-06	0.00101	0.35	0.28	Obesity-related traits;	chr19:37031358	chr19:37251912~37265535:+
KIRP	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	4.78	2.9e-06	0.00101	0.22	0.28	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
KIRP	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-4.78	2.9e-06	0.00101	-0.29	-0.28	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
KIRP	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	4.78	2.9e-06	0.00101	0.31	0.28	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
KIRP	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	4.78	2.9e-06	0.00101	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
KIRP	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.78	2.9e-06	0.00101	-0.25	-0.28	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
KIRP	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-4.78	2.9e-06	0.00101	-0.28	-0.28	Height;	chr14:75132452	chr14:75011269~75012851:-
KIRP	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	4.78	2.9e-06	0.00101	0.31	0.28	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
KIRP	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-4.78	2.9e-06	0.00101	-0.36	-0.28	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
KIRP	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-4.78	2.9e-06	0.00101	-0.34	-0.28	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
KIRP	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	4.78	2.9e-06	0.00101	0.24	0.28	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
KIRP	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	4.78	2.9e-06	0.00101	0.27	0.28	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
KIRP	cis	rs9467773	0.596	rs3001369	ENSG00000241549.7	GUSBP2	4.78	2.9e-06	0.00102	0.23	0.28	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26871484~26956554:-
KIRP	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-4.78	2.91e-06	0.00102	-0.4	-0.28	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
KIRP	cis	rs763121	0.853	rs11704021	ENSG00000273076.1	RP3-508I15.22	4.78	2.91e-06	0.00102	0.28	0.28	Menopause (age at onset);	chr22:38678711	chr22:38743495~38743910:+
KIRP	cis	rs35146811	0.625	rs858514	ENSG00000281827.1	AC005071.4	4.78	2.91e-06	0.00102	0.24	0.28	Coronary artery disease;	chr7:100228125	chr7:100344375~100344475:-
KIRP	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	4.78	2.91e-06	0.00102	0.36	0.28	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
KIRP	cis	rs897984	0.683	rs13337900	ENSG00000275263.1	RP11-1072A3.4	-4.78	2.91e-06	0.00102	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30811088	chr16:30956872~30957199:-
KIRP	cis	rs763121	0.819	rs5757237	ENSG00000273076.1	RP3-508I15.22	4.78	2.91e-06	0.00102	0.28	0.28	Menopause (age at onset);	chr22:38677830	chr22:38743495~38743910:+
KIRP	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	4.78	2.91e-06	0.00102	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	4.78	2.91e-06	0.00102	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
KIRP	cis	rs7289126	1	rs7289126	ENSG00000233360.4	Z83844.1	-4.78	2.92e-06	0.00102	-0.28	-0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38232300	chr22:37641832~37658377:-
KIRP	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	4.78	2.92e-06	0.00102	0.35	0.28	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
KIRP	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	4.78	2.92e-06	0.00102	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
KIRP	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	4.78	2.92e-06	0.00102	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
KIRP	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	4.78	2.92e-06	0.00102	0.38	0.28	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
KIRP	cis	rs11673344	0.523	rs7255724	ENSG00000226686.6	LINC01535	4.78	2.92e-06	0.00102	0.35	0.28	Obesity-related traits;	chr19:37158675	chr19:37251912~37265535:+
KIRP	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	4.78	2.92e-06	0.00102	0.5	0.28	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
KIRP	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	4.78	2.92e-06	0.00102	0.31	0.28	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
KIRP	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	4.78	2.92e-06	0.00102	0.28	0.28	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
KIRP	cis	rs35851103	0.627	rs58602899	ENSG00000251402.3	FAM90A25P	4.78	2.92e-06	0.00102	0.36	0.28	Neuroticism;	chr8:11991324	chr8:12415080~12418090:-
KIRP	cis	rs875971	0.502	rs6460311	ENSG00000236529.1	RP13-254B10.1	-4.78	2.92e-06	0.00102	-0.26	-0.28	Aortic root size;	chr7:66646886	chr7:65840212~65840596:+
KIRP	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-4.78	2.92e-06	0.00102	-0.26	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
KIRP	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	4.78	2.92e-06	0.00102	0.33	0.28	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
KIRP	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	4.78	2.93e-06	0.00102	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
KIRP	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	4.78	2.93e-06	0.00102	0.29	0.28	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
KIRP	cis	rs42648	0.869	rs1134956	ENSG00000225498.1	AC002064.5	4.78	2.93e-06	0.00102	0.2	0.28	Homocysteine levels;	chr7:90309366	chr7:90312496~90322592:+
KIRP	cis	rs2911132	0.564	rs13181579	ENSG00000248734.2	CTD-2260A17.1	4.78	2.93e-06	0.00102	0.27	0.28	Urate levels (BMI interaction);	chr5:96755234	chr5:96784777~96785999:+
KIRP	cis	rs9595908	0.709	rs7322505	ENSG00000212293.1	SNORA16	4.78	2.93e-06	0.00102	0.27	0.28	Body mass index;	chr13:32756282	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs9591311	ENSG00000212293.1	SNORA16	4.78	2.93e-06	0.00102	0.27	0.28	Body mass index;	chr13:32757339	chr13:32420390~32420516:-
KIRP	cis	rs7508	0.512	rs2237851	ENSG00000254054.2	RP11-156K13.3	4.78	2.93e-06	0.00102	0.33	0.28	Atrial fibrillation;	chr8:18020240	chr8:17905756~17907887:+
KIRP	cis	rs13129231	0.882	rs6835088	ENSG00000206820.1	RNU1-138P	-4.78	2.93e-06	0.00102	-0.36	-0.28	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113436700	chr4:113420323~113420486:+
KIRP	cis	rs35146811	0.696	rs1727124	ENSG00000078319.8	PMS2P1	4.78	2.93e-06	0.00102	0.37	0.28	Coronary artery disease;	chr7:100206481	chr7:100320992~100341908:-
KIRP	cis	rs6502050	0.871	rs8080366	ENSG00000266654.1	RP11-1376P16.1	4.78	2.93e-06	0.00102	0.27	0.28	Life satisfaction;	chr17:82109422	chr17:82160056~82160452:+
KIRP	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	4.78	2.94e-06	0.00102	0.29	0.28	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
KIRP	cis	rs8177876	0.731	rs74878296	ENSG00000261838.4	RP11-303E16.6	4.78	2.94e-06	0.00102	0.54	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81069854~81076598:+
KIRP	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	4.78	2.94e-06	0.00103	0.34	0.28	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
KIRP	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	4.78	2.94e-06	0.00103	0.27	0.28	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
KIRP	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	4.78	2.94e-06	0.00103	0.23	0.28	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
KIRP	cis	rs4578769	0.569	rs11659166	ENSG00000265943.1	RP11-739L10.1	4.78	2.94e-06	0.00103	0.37	0.28	Eosinophil percentage of white cells;	chr18:22926143	chr18:22699481~22933764:-
KIRP	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.78	2.94e-06	0.00103	-0.32	-0.28	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
KIRP	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.78	2.94e-06	0.00103	-0.32	-0.28	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
KIRP	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.32	-0.28	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.32	-0.28	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.32	-0.28	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.32	-0.28	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.32	-0.28	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
KIRP	cis	rs728616	0.867	rs41298231	ENSG00000234382.2	RP11-40F6.1	-4.78	2.95e-06	0.00103	-0.43	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:80233664~80245367:+
KIRP	cis	rs10504130	0.569	rs34213209	ENSG00000272024.1	RP11-546K22.3	-4.78	2.95e-06	0.00103	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51950284~51950690:+
KIRP	cis	rs728616	0.702	rs78734698	ENSG00000234382.2	RP11-40F6.1	-4.78	2.95e-06	0.00103	-0.44	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:80233664~80245367:+
KIRP	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.31	-0.28	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-4.78	2.95e-06	0.00103	-0.31	-0.28	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
KIRP	cis	rs964611	0.882	rs3784616	ENSG00000259488.2	RP11-154J22.1	-4.78	2.96e-06	0.00103	-0.27	-0.28	Metabolite levels (Pyroglutamine);	chr15:48278381	chr15:48312353~48331856:-
KIRP	cis	rs2562456	0.561	rs12610883	ENSG00000268555.1	RP11-678G14.3	4.78	2.96e-06	0.00103	0.38	0.28	Pain;	chr19:21567257	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.837	rs11085462	ENSG00000268555.1	RP11-678G14.3	4.78	2.96e-06	0.00103	0.38	0.28	Pain;	chr19:21567449	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.793	rs7259708	ENSG00000268555.1	RP11-678G14.3	4.78	2.96e-06	0.00103	0.38	0.28	Pain;	chr19:21567846	chr19:21570822~21587322:-
KIRP	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-4.78	2.96e-06	0.00103	-0.34	-0.28	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
KIRP	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	4.78	2.96e-06	0.00103	0.39	0.28	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
KIRP	cis	rs10050311	0.698	rs3775238	ENSG00000251411.1	RP11-397E7.4	-4.78	2.96e-06	0.00103	-0.34	-0.28	Insulin-related traits;	chr4:86712231	chr4:86913266~86914817:-
KIRP	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-4.78	2.96e-06	0.00103	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
KIRP	cis	rs8141529	0.732	rs5762784	ENSG00000226471.5	CTA-292E10.6	-4.78	2.96e-06	0.00103	-0.29	-0.28	Lymphocyte counts;	chr22:28775310	chr22:28800683~28848559:+
KIRP	cis	rs7170668	0.965	rs9920453	ENSG00000258489.3	RP11-398J10.2	-4.78	2.97e-06	0.00103	-0.32	-0.28	Motion sickness;	chr15:95488515	chr15:95463592~95493770:-
KIRP	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.78	2.97e-06	0.00104	-0.3	-0.28	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.78	2.97e-06	0.00104	-0.3	-0.28	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.78	2.97e-06	0.00104	-0.3	-0.28	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
KIRP	cis	rs35146811	0.695	rs858508	ENSG00000281827.1	AC005071.4	4.78	2.97e-06	0.00104	0.23	0.28	Coronary artery disease;	chr7:100223758	chr7:100344375~100344475:-
KIRP	cis	rs35146811	0.659	rs863450	ENSG00000281827.1	AC005071.4	4.78	2.97e-06	0.00104	0.23	0.28	Coronary artery disease;	chr7:100224062	chr7:100344375~100344475:-
KIRP	cis	rs35146811	0.735	rs858512	ENSG00000281827.1	AC005071.4	4.78	2.97e-06	0.00104	0.23	0.28	Coronary artery disease;	chr7:100226830	chr7:100344375~100344475:-
KIRP	cis	rs35146811	0.7	rs858513	ENSG00000281827.1	AC005071.4	4.78	2.97e-06	0.00104	0.23	0.28	Coronary artery disease;	chr7:100227935	chr7:100344375~100344475:-
KIRP	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-4.78	2.98e-06	0.00104	-0.24	-0.28	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-4.78	2.98e-06	0.00104	-0.24	-0.28	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-4.78	2.98e-06	0.00104	-0.24	-0.28	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
KIRP	cis	rs897984	0.644	rs73524556	ENSG00000275263.1	RP11-1072A3.4	-4.78	2.98e-06	0.00104	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30811841	chr16:30956872~30957199:-
KIRP	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-4.78	2.98e-06	0.00104	-0.27	-0.28	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
KIRP	cis	rs4689592	0.523	rs4256224	ENSG00000245468.3	RP11-367J11.3	4.78	2.98e-06	0.00104	0.31	0.28	Monocyte percentage of white cells;	chr4:7072856	chr4:7094571~7103385:-
KIRP	cis	rs116095464	0.558	rs62347677	ENSG00000248925.1	CTD-2083E4.6	4.78	2.98e-06	0.00104	0.43	0.28	Breast cancer;	chr5:227338	chr5:269858~271516:-
KIRP	cis	rs453301	0.686	rs7814328	ENSG00000253981.4	ALG1L13P	-4.78	2.98e-06	0.00104	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9018719	chr8:8236003~8244667:-
KIRP	cis	rs9467773	0.596	rs62396201	ENSG00000241549.7	GUSBP2	4.78	2.98e-06	0.00104	0.23	0.28	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26871484~26956554:-
KIRP	cis	rs964611	0.882	rs4630496	ENSG00000259488.2	RP11-154J22.1	-4.78	2.99e-06	0.00104	-0.31	-0.28	Metabolite levels (Pyroglutamine);	chr15:48366466	chr15:48312353~48331856:-
KIRP	cis	rs964611	0.938	rs7163887	ENSG00000259488.2	RP11-154J22.1	4.78	2.99e-06	0.00104	0.31	0.28	Metabolite levels (Pyroglutamine);	chr15:48367357	chr15:48312353~48331856:-
KIRP	cis	rs453301	0.631	rs13250781	ENSG00000173295.6	FAM86B3P	-4.78	2.99e-06	0.00104	-0.22	-0.28	Joint mobility (Beighton score);	chr8:8935833	chr8:8228595~8244865:+
KIRP	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	4.78	2.99e-06	0.00104	0.4	0.28	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
KIRP	cis	rs1044826	0.553	rs295469	ENSG00000178631.7	ACTG1P1	4.78	2.99e-06	0.00104	0.3	0.28	Obesity-related traits;	chr3:139494058	chr3:139493809~139494937:+
KIRP	cis	rs2386661	0.547	rs4747358	ENSG00000228951.1	RP11-336A10.4	-4.78	2.99e-06	0.00104	-0.36	-0.28	Breast cancer;	chr10:5608230	chr10:5616862~5618161:-
KIRP	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	4.78	2.99e-06	0.00104	0.33	0.28	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
KIRP	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	4.77	2.99e-06	0.00104	0.18	0.28	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
KIRP	cis	rs6832769	1	rs13121235	ENSG00000272969.1	RP11-528I4.2	4.77	3e-06	0.00104	0.28	0.28	Personality dimensions;	chr4:55445780	chr4:55547112~55547889:+
KIRP	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	4.77	3e-06	0.00104	0.24	0.28	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
KIRP	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.77	3e-06	0.00104	-0.59	-0.28	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
KIRP	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	4.77	3e-06	0.00105	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	4.77	3e-06	0.00105	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
KIRP	cis	rs703842	0.963	rs2069506	ENSG00000270039.1	RP11-571M6.17	-4.77	3e-06	0.00105	-0.27	-0.28	Multiple sclerosis;	chr12:57749071	chr12:57803838~57804415:+
KIRP	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-4.77	3e-06	0.00105	-0.28	-0.28	Height;	chr14:75123026	chr14:75011269~75012851:-
KIRP	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	4.77	3.01e-06	0.00105	0.4	0.28	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
KIRP	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	4.77	3.01e-06	0.00105	0.4	0.28	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
KIRP	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	4.77	3.01e-06	0.00105	0.36	0.28	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
KIRP	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	4.77	3.01e-06	0.00105	0.39	0.28	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
KIRP	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	4.77	3.01e-06	0.00105	0.32	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
KIRP	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	4.77	3.01e-06	0.00105	0.33	0.28	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
KIRP	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.77	3.02e-06	0.00105	-0.36	-0.28	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.77	3.02e-06	0.00105	-0.36	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
KIRP	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	4.77	3.02e-06	0.00105	0.27	0.28	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
KIRP	cis	rs1400745	0.729	rs1741196	ENSG00000258738.1	RP11-73E17.2	4.77	3.02e-06	0.00105	0.26	0.28	Monocyte count;	chr14:34877814	chr14:34874343~34876459:+
KIRP	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-4.77	3.02e-06	0.00105	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
KIRP	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-4.77	3.02e-06	0.00105	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
KIRP	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-4.77	3.02e-06	0.00105	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
KIRP	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-4.77	3.02e-06	0.00105	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
KIRP	cis	rs7299940	0.967	rs10848243	ENSG00000256250.1	RP11-989F5.1	-4.77	3.02e-06	0.00105	-0.27	-0.28	Panic disorder;	chr12:130894769	chr12:130810606~130812438:+
KIRP	cis	rs3892630	0.878	rs7246451	ENSG00000267475.1	CTD-2538C1.2	-4.77	3.02e-06	0.00105	-0.4	-0.28	Red blood cell traits;	chr19:32718708	chr19:32687089~32691750:-
KIRP	cis	rs3892630	0.878	rs1559177	ENSG00000267475.1	CTD-2538C1.2	-4.77	3.02e-06	0.00105	-0.4	-0.28	Red blood cell traits;	chr19:32719740	chr19:32687089~32691750:-
KIRP	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	4.77	3.03e-06	0.00105	0.32	0.28	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
KIRP	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	4.77	3.03e-06	0.00105	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	4.77	3.03e-06	0.00105	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	4.77	3.03e-06	0.00105	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
KIRP	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	4.77	3.03e-06	0.00105	0.35	0.28	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
KIRP	cis	rs113835537	0.877	rs2229456	ENSG00000255517.5	CTD-3074O7.5	-4.77	3.03e-06	0.00105	-0.35	-0.28	Airway imaging phenotypes;	chr11:66561270	chr11:66473490~66480233:-
KIRP	cis	rs11098499	0.82	rs11737395	ENSG00000250412.1	KLHL2P1	4.77	3.03e-06	0.00105	0.37	0.28	Corneal astigmatism;	chr4:119599549	chr4:119334329~119378233:+
KIRP	cis	rs4639966	0.836	rs4499035	ENSG00000255239.1	AP002954.6	-4.77	3.03e-06	0.00105	-0.36	-0.28	Systemic lupus erythematosus;	chr11:118739754	chr11:118688039~118690600:-
KIRP	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	4.77	3.03e-06	0.00106	0.4	0.28	Height;	chr6:109582583	chr6:109382795~109383666:+
KIRP	cis	rs910316	0.726	rs61979167	ENSG00000279594.1	RP11-950C14.10	-4.77	3.03e-06	0.00106	-0.28	-0.28	Height;	chr14:75196907	chr14:75011269~75012851:-
KIRP	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-4.77	3.03e-06	0.00106	-0.31	-0.28	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
KIRP	cis	rs31872	0.597	rs31874	ENSG00000272070.1	AC005618.6	4.77	3.04e-06	0.00106	0.44	0.28	Visceral adipose tissue adjusted for BMI;	chr5:140989733	chr5:141326210~141329357:+
KIRP	cis	rs962856	0.964	rs1552359	ENSG00000236605.1	AC023115.4	4.77	3.04e-06	0.00106	0.35	0.28	Pancreatic cancer;	chr2:67388297	chr2:67324627~67325304:+
KIRP	cis	rs962856	0.964	rs5022017	ENSG00000236605.1	AC023115.4	4.77	3.04e-06	0.00106	0.35	0.28	Pancreatic cancer;	chr2:67392045	chr2:67324627~67325304:+
KIRP	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	4.77	3.04e-06	0.00106	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
KIRP	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	4.77	3.04e-06	0.00106	0.23	0.28	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	4.77	3.04e-06	0.00106	0.23	0.28	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
KIRP	cis	rs875971	0.502	rs11769702	ENSG00000236529.1	RP13-254B10.1	4.77	3.04e-06	0.00106	0.26	0.28	Aortic root size;	chr7:66255529	chr7:65840212~65840596:+
KIRP	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	4.77	3.04e-06	0.00106	0.28	0.28	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
KIRP	cis	rs4578769	0.55	rs721578	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22922719	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs7229422	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22923157	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.589	rs9964726	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22925516	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs9958831	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22926050	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs12957183	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22927124	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs9948922	ENSG00000265943.1	RP11-739L10.1	4.77	3.04e-06	0.00106	0.37	0.28	Eosinophil percentage of white cells;	chr18:22930198	chr18:22699481~22933764:-
KIRP	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-4.77	3.04e-06	0.00106	-0.25	-0.28	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
KIRP	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	4.77	3.04e-06	0.00106	0.23	0.28	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
KIRP	cis	rs7615952	0.673	rs3811677	ENSG00000250012.1	RP11-124N2.1	-4.77	3.04e-06	0.00106	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125929237	chr3:126084220~126095349:+
KIRP	cis	rs7615952	0.932	rs3811679	ENSG00000250012.1	RP11-124N2.1	-4.77	3.04e-06	0.00106	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125929440	chr3:126084220~126095349:+
KIRP	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.77	3.04e-06	0.00106	-0.6	-0.28	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
KIRP	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	4.77	3.04e-06	0.00106	0.25	0.28	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
KIRP	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-4.77	3.04e-06	0.00106	-0.24	-0.28	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-4.77	3.04e-06	0.00106	-0.24	-0.28	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-4.77	3.04e-06	0.00106	-0.24	-0.28	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
KIRP	cis	rs4578769	0.569	rs8094359	ENSG00000265943.1	RP11-739L10.1	4.77	3.05e-06	0.00106	0.36	0.28	Eosinophil percentage of white cells;	chr18:22907743	chr18:22699481~22933764:-
KIRP	cis	rs10916248	0.569	rs7528528	ENSG00000232628.4	RP11-365O16.3	-4.77	3.05e-06	0.00106	-0.31	-0.28	QT interval (drug interaction);	chr1:224077615	chr1:224208747~224213279:-
KIRP	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	4.77	3.05e-06	0.00106	0.33	0.28	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
KIRP	cis	rs9595908	0.709	rs3213532	ENSG00000212293.1	SNORA16	4.77	3.05e-06	0.00106	0.27	0.28	Body mass index;	chr13:32773550	chr13:32420390~32420516:-
KIRP	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-4.77	3.05e-06	0.00106	-0.34	-0.28	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
KIRP	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	4.77	3.05e-06	0.00106	0.4	0.28	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
KIRP	cis	rs1552244	1	rs13319597	ENSG00000180385.7	EMC3-AS1	-4.77	3.05e-06	0.00106	-0.27	-0.28	Alzheimer's disease;	chr3:10084628	chr3:9986893~10006990:+
KIRP	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-4.77	3.06e-06	0.00106	-0.24	-0.28	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
KIRP	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-4.77	3.06e-06	0.00106	-0.32	-0.28	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
KIRP	cis	rs947583	0.517	rs9376144	ENSG00000231028.7	LINC00271	-4.77	3.06e-06	0.00106	-0.25	-0.28	Phosphorus levels;	chr6:135756247	chr6:135497801~135716055:+
KIRP	cis	rs7580658	0.521	rs7605733	ENSG00000236682.1	AC068282.3	-4.77	3.06e-06	0.00106	-0.31	-0.28	Protein C levels;	chr2:127174211	chr2:127389130~127400580:+
KIRP	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-4.77	3.06e-06	0.00106	-0.45	-0.28	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
KIRP	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-4.77	3.06e-06	0.00106	-0.4	-0.28	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
KIRP	cis	rs42648	0.748	rs10225744	ENSG00000225498.1	AC002064.5	4.77	3.06e-06	0.00106	0.2	0.28	Homocysteine levels;	chr7:90316689	chr7:90312496~90322592:+
KIRP	cis	rs4578769	0.569	rs12960915	ENSG00000265943.1	RP11-739L10.1	4.77	3.06e-06	0.00106	0.36	0.28	Eosinophil percentage of white cells;	chr18:22924013	chr18:22699481~22933764:-
KIRP	cis	rs728616	0.571	rs113030473	ENSG00000234382.2	RP11-40F6.1	-4.77	3.06e-06	0.00106	-0.43	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:80233664~80245367:+
KIRP	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	4.77	3.06e-06	0.00106	0.29	0.28	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
KIRP	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-4.77	3.07e-06	0.00106	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-4.77	3.07e-06	0.00106	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-4.77	3.07e-06	0.00106	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-4.77	3.07e-06	0.00106	-0.36	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
KIRP	cis	rs7267979	0.727	rs4815431	ENSG00000274414.1	RP5-965G21.4	4.77	3.07e-06	0.00106	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25239007~25245229:-
KIRP	cis	rs7849973	0.517	rs12345463	ENSG00000224549.1	RP11-370B11.3	-4.77	3.07e-06	0.00107	-0.31	-0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr9:22776096	chr9:22767175~22768316:+
KIRP	cis	rs1799949	0.965	rs8176161	ENSG00000279602.1	CTD-3014M21.1	-4.77	3.07e-06	0.00107	-0.26	-0.28	Menopause (age at onset);	chr17:43089373	chr17:43360041~43361361:-
KIRP	cis	rs1799949	0.894	rs8176160	ENSG00000279602.1	CTD-3014M21.1	-4.77	3.07e-06	0.00107	-0.26	-0.28	Menopause (age at onset);	chr17:43089486	chr17:43360041~43361361:-
KIRP	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-4.77	3.07e-06	0.00107	-0.57	-0.28	Gout;	chr7:66671562	chr7:66654538~66669855:+
KIRP	cis	rs8030379	1	rs4842923	ENSG00000230373.7	GOLGA6L5P	-4.77	3.07e-06	0.00107	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913152	chr15:84507885~84516814:-
KIRP	cis	rs116095464	0.558	rs10057299	ENSG00000248925.1	CTD-2083E4.6	4.77	3.07e-06	0.00107	0.42	0.28	Breast cancer;	chr5:242020	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs13356367	ENSG00000248925.1	CTD-2083E4.6	4.77	3.07e-06	0.00107	0.42	0.28	Breast cancer;	chr5:242280	chr5:269858~271516:-
KIRP	cis	rs116095464	0.85	rs10055295	ENSG00000248925.1	CTD-2083E4.6	4.77	3.07e-06	0.00107	0.42	0.28	Breast cancer;	chr5:243634	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs10055354	ENSG00000248925.1	CTD-2083E4.6	4.77	3.07e-06	0.00107	0.42	0.28	Breast cancer;	chr5:243679	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs60251075	ENSG00000248925.1	CTD-2083E4.6	4.77	3.07e-06	0.00107	0.42	0.28	Breast cancer;	chr5:245177	chr5:269858~271516:-
KIRP	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	4.77	3.07e-06	0.00107	0.24	0.28	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
KIRP	cis	rs324126	0.743	rs34221182	ENSG00000269834.4	ZNF528-AS1	4.77	3.07e-06	0.00107	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52388842~52397766:-
KIRP	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-4.77	3.07e-06	0.00107	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
KIRP	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-4.77	3.07e-06	0.00107	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
KIRP	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-4.77	3.07e-06	0.00107	-0.23	-0.28	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
KIRP	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-4.77	3.08e-06	0.00107	-0.32	-0.28	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
KIRP	cis	rs8177876	0.731	rs79546329	ENSG00000261838.4	RP11-303E16.6	4.77	3.08e-06	0.00107	0.57	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103636	chr16:81069854~81076598:+
KIRP	cis	rs8177876	0.731	rs12448806	ENSG00000261838.4	RP11-303E16.6	4.77	3.08e-06	0.00107	0.57	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104597	chr16:81069854~81076598:+
KIRP	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	4.77	3.08e-06	0.00107	0.35	0.28	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
KIRP	cis	rs7590983	1	rs75263303	ENSG00000271151.1	RP11-394I13.2	4.77	3.08e-06	0.00107	0.35	0.28	Anthropometric traits;	chr2:173499598	chr2:173968351~173969418:+
KIRP	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-4.77	3.08e-06	0.00107	-0.31	-0.28	Height;	chr3:52975027	chr3:53064283~53065091:-
KIRP	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-4.77	3.09e-06	0.00107	-0.31	-0.28	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
KIRP	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	4.77	3.09e-06	0.00107	0.36	0.28	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
KIRP	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-4.77	3.09e-06	0.00107	-0.37	-0.28	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
KIRP	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.77	3.09e-06	0.00107	-0.54	-0.28	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-4.77	3.09e-06	0.00107	-0.32	-0.28	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
KIRP	cis	rs4934494	0.689	rs17127596	ENSG00000232936.4	RP11-80H5.2	-4.77	3.09e-06	0.00107	-0.4	-0.28	Red blood cell count;	chr10:89816128	chr10:89645282~89650667:+
KIRP	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-4.77	3.1e-06	0.00107	-0.3	-0.28	Height;	chr3:52941053	chr3:53064283~53065091:-
KIRP	cis	rs72634501	0.531	rs67758468	ENSG00000237624.1	OXCT2P1	4.77	3.1e-06	0.00107	0.43	0.28	HDL cholesterol;	chr1:39156916	chr1:39514956~39516490:+
KIRP	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-4.77	3.1e-06	0.00107	-0.23	-0.28	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
KIRP	cis	rs9595908	0.669	rs56291634	ENSG00000212293.1	SNORA16	4.77	3.1e-06	0.00107	0.28	0.28	Body mass index;	chr13:32720404	chr13:32420390~32420516:-
KIRP	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-4.77	3.1e-06	0.00108	-0.19	-0.28	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
KIRP	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	4.77	3.1e-06	0.00108	0.37	0.28	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
KIRP	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	4.77	3.1e-06	0.00108	0.23	0.28	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
KIRP	cis	rs8141529	0.687	rs6005867	ENSG00000226471.5	CTA-292E10.6	-4.77	3.1e-06	0.00108	-0.29	-0.28	Lymphocyte counts;	chr22:28769132	chr22:28800683~28848559:+
KIRP	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	4.77	3.1e-06	0.00108	0.36	0.28	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
KIRP	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	4.77	3.1e-06	0.00108	0.44	0.28	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
KIRP	cis	rs1005277	0.54	rs2474598	ENSG00000151963.4	RP11-775A3.1	4.77	3.1e-06	0.00108	0.33	0.28	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:37883594~37884109:+
KIRP	cis	rs497273	0.534	rs9431	ENSG00000277423.1	RP11-173P15.9	-4.77	3.1e-06	0.00108	-0.3	-0.28	Systemic lupus erythematosus;	chr12:120764861	chr12:120703867~120704282:+
KIRP	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	4.77	3.1e-06	0.00108	0.3	0.28	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
KIRP	cis	rs962856	0.964	rs1486135	ENSG00000236605.1	AC023115.4	4.77	3.11e-06	0.00108	0.36	0.28	Pancreatic cancer;	chr2:67369133	chr2:67324627~67325304:+
KIRP	cis	rs962856	0.633	rs6755775	ENSG00000236605.1	AC023115.4	4.77	3.11e-06	0.00108	0.36	0.28	Pancreatic cancer;	chr2:67371451	chr2:67324627~67325304:+
KIRP	cis	rs962856	1	rs6755797	ENSG00000236605.1	AC023115.4	4.77	3.11e-06	0.00108	0.36	0.28	Pancreatic cancer;	chr2:67371501	chr2:67324627~67325304:+
KIRP	cis	rs962856	1	rs6739392	ENSG00000236605.1	AC023115.4	4.77	3.11e-06	0.00108	0.36	0.28	Pancreatic cancer;	chr2:67374839	chr2:67324627~67325304:+
KIRP	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	4.77	3.11e-06	0.00108	0.42	0.28	Height;	chr6:109373851	chr6:109382795~109383666:+
KIRP	cis	rs911119	0.955	rs35610040	ENSG00000270001.1	RP11-218C14.8	-4.77	3.11e-06	0.00108	-0.35	-0.28	Chronic kidney disease;	chr20:23635832	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs3787499	ENSG00000270001.1	RP11-218C14.8	-4.77	3.11e-06	0.00108	-0.35	-0.28	Chronic kidney disease;	chr20:23636170	chr20:23631826~23632316:-
KIRP	cis	rs911119	1	rs3827142	ENSG00000270001.1	RP11-218C14.8	-4.77	3.11e-06	0.00108	-0.35	-0.28	Chronic kidney disease;	chr20:23636370	chr20:23631826~23632316:-
KIRP	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	4.77	3.11e-06	0.00108	0.32	0.28	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	4.77	3.11e-06	0.00108	0.32	0.28	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	4.77	3.11e-06	0.00108	0.32	0.28	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
KIRP	cis	rs4663866	1	rs4663300	ENSG00000186235.9	AC016757.3	4.77	3.11e-06	0.00108	0.53	0.28	Irritable bowel syndrome;	chr2:238272850	chr2:238224552~238231677:-
KIRP	cis	rs4663866	1	rs34897410	ENSG00000186235.9	AC016757.3	4.77	3.11e-06	0.00108	0.53	0.28	Irritable bowel syndrome;	chr2:238273482	chr2:238224552~238231677:-
KIRP	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-4.77	3.11e-06	0.00108	-0.33	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
KIRP	cis	rs728616	0.614	rs726014	ENSG00000234382.2	RP11-40F6.1	-4.77	3.11e-06	0.00108	-0.31	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:80233664~80245367:+
KIRP	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	4.77	3.11e-06	0.00108	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
KIRP	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	4.77	3.11e-06	0.00108	0.4	0.28	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
KIRP	cis	rs61457372	0.563	rs9911577	ENSG00000264026.1	RP11-1124B17.1	-4.77	3.11e-06	0.00108	-0.3	-0.28	Triptolide cytotoxicity;	chr17:72355133	chr17:72342940~72355136:+
KIRP	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-4.77	3.11e-06	0.00108	-0.24	-0.28	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
KIRP	cis	rs910316	0.737	rs398896	ENSG00000279594.1	RP11-950C14.10	-4.77	3.11e-06	0.00108	-0.28	-0.28	Height;	chr14:75016124	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.737	rs424120	ENSG00000279594.1	RP11-950C14.10	-4.77	3.11e-06	0.00108	-0.28	-0.28	Height;	chr14:75016125	chr14:75011269~75012851:-
KIRP	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	4.77	3.12e-06	0.00108	0.36	0.28	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
KIRP	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-4.77	3.12e-06	0.00108	-0.36	-0.28	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
KIRP	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-4.77	3.12e-06	0.00108	-0.21	-0.28	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
KIRP	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	4.77	3.12e-06	0.00108	0.28	0.28	Height;	chr14:75145380	chr14:75011269~75012851:-
KIRP	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	4.77	3.12e-06	0.00108	0.4	0.28	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
KIRP	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	4.77	3.12e-06	0.00108	0.24	0.28	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
KIRP	cis	rs8030379	1	rs11259928	ENSG00000230373.7	GOLGA6L5P	-4.77	3.12e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899343	chr15:84507885~84516814:-
KIRP	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-4.77	3.12e-06	0.00108	-0.27	-0.28	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
KIRP	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-4.77	3.12e-06	0.00108	-0.27	-0.28	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
KIRP	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.77	3.12e-06	0.00108	-0.36	-0.28	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.77	3.12e-06	0.00108	-0.36	-0.28	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
KIRP	cis	rs703842	0.642	rs73123375	ENSG00000270039.1	RP11-571M6.17	-4.77	3.13e-06	0.00108	-0.31	-0.28	Multiple sclerosis;	chr12:57669881	chr12:57803838~57804415:+
KIRP	cis	rs7590983	1	rs73971774	ENSG00000271151.1	RP11-394I13.2	4.77	3.13e-06	0.00108	0.35	0.28	Anthropometric traits;	chr2:173504182	chr2:173968351~173969418:+
KIRP	cis	rs1799949	0.965	rs11658499	ENSG00000279602.1	CTD-3014M21.1	-4.77	3.13e-06	0.00108	-0.26	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43360041~43361361:-
KIRP	cis	rs4460629	0.905	rs4971077	ENSG00000160766.13	GBAP1	-4.77	3.13e-06	0.00108	-0.26	-0.28	Serum magnesium levels;	chr1:155156241	chr1:155213821~155227422:-
KIRP	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	4.77	3.13e-06	0.00108	0.24	0.28	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
KIRP	cis	rs8030379	0.967	rs11857009	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83898661	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2046120	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899010	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs10906983	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs922664	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1564474	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs10152119	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1471552	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1471553	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1564475	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs7183263	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs7178962	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs899926	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs8029387	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.967	rs8028359	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs940934	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84507885~84516814:-
KIRP	cis	rs8030379	0.935	rs1815172	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1810049	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11853052	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401172	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401174	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259929	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259930	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs1480827	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401176	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401179	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401180	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259932	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259934	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs11259935	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs12914857	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2055712	ENSG00000230373.7	GOLGA6L5P	-4.77	3.13e-06	0.00108	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84507885~84516814:-
KIRP	cis	rs2562456	0.917	rs9304987	ENSG00000268555.1	RP11-678G14.3	-4.77	3.13e-06	0.00108	-0.37	-0.28	Pain;	chr19:21499472	chr19:21570822~21587322:-
KIRP	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-4.76	3.13e-06	0.00109	-0.33	-0.28	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
KIRP	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	4.76	3.13e-06	0.00109	0.23	0.28	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
KIRP	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	4.76	3.13e-06	0.00109	0.23	0.28	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
KIRP	cis	rs2299587	1	rs2299587	ENSG00000254054.2	RP11-156K13.3	4.76	3.14e-06	0.00109	0.34	0.28	Economic and political preferences;	chr8:17943260	chr8:17905756~17907887:+
KIRP	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	4.76	3.14e-06	0.00109	0.35	0.28	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
KIRP	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	4.76	3.14e-06	0.00109	0.26	0.28	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
KIRP	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	4.76	3.14e-06	0.00109	0.49	0.28	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
KIRP	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-4.76	3.14e-06	0.00109	-0.39	-0.28	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
KIRP	cis	rs116095464	0.614	rs62344292	ENSG00000248925.1	CTD-2083E4.6	4.76	3.14e-06	0.00109	0.43	0.28	Breast cancer;	chr5:244515	chr5:269858~271516:-
KIRP	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-4.76	3.14e-06	0.00109	-0.25	-0.28	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
KIRP	cis	rs763121	0.853	rs4821798	ENSG00000273076.1	RP3-508I15.22	4.76	3.14e-06	0.00109	0.26	0.28	Menopause (age at onset);	chr22:38625160	chr22:38743495~38743910:+
KIRP	cis	rs9926296	0.643	rs12596429	ENSG00000260259.1	RP11-368I7.4	-4.76	3.14e-06	0.00109	-0.22	-0.28	Vitiligo;	chr16:89774966	chr16:89682620~89686569:-
KIRP	cis	rs9595908	0.785	rs9591261	ENSG00000212293.1	SNORA16	4.76	3.15e-06	0.00109	0.27	0.28	Body mass index;	chr13:32710989	chr13:32420390~32420516:-
KIRP	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	4.76	3.15e-06	0.00109	0.29	0.28	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
KIRP	cis	rs1487614	0.739	rs28605572	ENSG00000250781.1	RP11-63A11.1	-4.76	3.15e-06	0.00109	-0.36	-0.28	Longevity;	chr4:42257635	chr4:42281830~42391268:-
KIRP	cis	rs7615952	0.641	rs6438951	ENSG00000241439.1	RP11-666A20.3	4.76	3.15e-06	0.00109	0.37	0.28	Blood pressure (smoking interaction);	chr3:125978156	chr3:125958556~125958817:+
KIRP	cis	rs28386778	0.734	rs12946669	ENSG00000240280.5	TCAM1P	-4.76	3.15e-06	0.00109	-0.34	-0.28	Prudent dietary pattern;	chr17:63928647	chr17:63849292~63864379:+
KIRP	cis	rs4694744	1	rs4694745	ENSG00000251284.2	RP13-644M16.1	-4.76	3.16e-06	0.00109	-0.29	-0.28	Bacteremia;	chr4:69469058	chr4:69125274~69126451:+
KIRP	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-4.76	3.16e-06	0.00109	-0.34	-0.28	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
KIRP	cis	rs8177876	1	rs8177876	ENSG00000261838.4	RP11-303E16.6	4.76	3.16e-06	0.00109	0.56	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81069854~81076598:+
KIRP	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-4.76	3.17e-06	0.00109	-0.44	-0.28	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
KIRP	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	4.76	3.17e-06	0.00109	0.36	0.28	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
KIRP	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-4.76	3.17e-06	0.0011	-0.27	-0.28	Height;	chr14:75188649	chr14:75011269~75012851:-
KIRP	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-4.76	3.17e-06	0.0011	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
KIRP	cis	rs17213965	1	rs17213965	ENSG00000263335.1	AF001548.5	-4.76	3.17e-06	0.0011	-0.39	-0.28	Waist-hip ratio;	chr16:15788110	chr16:15726674~15732993:+
KIRP	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	4.76	3.17e-06	0.0011	0.33	0.28	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
KIRP	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	4.76	3.17e-06	0.0011	0.33	0.28	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
KIRP	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-4.76	3.17e-06	0.0011	-0.3	-0.28	Height;	chr4:55514317	chr4:55363971~55395847:-
KIRP	cis	rs4578769	0.55	rs8092358	ENSG00000265943.1	RP11-739L10.1	4.76	3.17e-06	0.0011	0.36	0.28	Eosinophil percentage of white cells;	chr18:22911835	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs1379805	ENSG00000265943.1	RP11-739L10.1	4.76	3.17e-06	0.0011	0.36	0.28	Eosinophil percentage of white cells;	chr18:22914589	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs1031652	ENSG00000265943.1	RP11-739L10.1	4.76	3.17e-06	0.0011	0.36	0.28	Eosinophil percentage of white cells;	chr18:22916035	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs9967326	ENSG00000265943.1	RP11-739L10.1	4.76	3.17e-06	0.0011	0.36	0.28	Eosinophil percentage of white cells;	chr18:22916787	chr18:22699481~22933764:-
KIRP	cis	rs4578769	0.569	rs9946660	ENSG00000265943.1	RP11-739L10.1	4.76	3.17e-06	0.0011	0.36	0.28	Eosinophil percentage of white cells;	chr18:22917007	chr18:22699481~22933764:-
KIRP	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-4.76	3.17e-06	0.0011	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
KIRP	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	4.76	3.18e-06	0.0011	0.5	0.28	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	4.76	3.18e-06	0.0011	0.5	0.28	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
KIRP	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-4.76	3.18e-06	0.0011	-0.36	-0.28	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
KIRP	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-4.76	3.18e-06	0.0011	-0.3	-0.28	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-4.76	3.18e-06	0.0011	-0.3	-0.28	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
KIRP	cis	rs7289126	1	rs7290372	ENSG00000233360.4	Z83844.1	4.76	3.18e-06	0.0011	0.28	0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38232382	chr22:37641832~37658377:-
KIRP	cis	rs40363	0.645	rs37774	ENSG00000240311.1	LA16c-306E5.1	-4.76	3.18e-06	0.0011	-0.37	-0.28	Tuberculosis;	chr16:3462695	chr16:3496201~3496768:+
KIRP	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-4.76	3.18e-06	0.0011	-0.22	-0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
KIRP	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	4.76	3.18e-06	0.0011	0.3	0.28	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
KIRP	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-4.76	3.18e-06	0.0011	-0.3	-0.28	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
KIRP	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-4.76	3.18e-06	0.0011	-0.35	-0.28	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
KIRP	cis	rs295490	1	rs295490	ENSG00000272656.1	RP11-219D15.3	-4.76	3.19e-06	0.0011	-0.33	-0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522529	chr3:139349024~139349371:-
KIRP	cis	rs72717009	0.825	rs9427399	ENSG00000225217.1	HSPA7	-4.76	3.19e-06	0.0011	-0.39	-0.28	Rheumatoid arthritis;	chr1:161506743	chr1:161606291~161608217:+
KIRP	cis	rs1799949	0.965	rs4793230	ENSG00000236383.6	LINC00854	-4.76	3.19e-06	0.0011	-0.21	-0.28	Menopause (age at onset);	chr17:43350035	chr17:43216941~43305976:-
KIRP	cis	rs7829975	0.545	rs13261926	ENSG00000253981.4	ALG1L13P	-4.76	3.19e-06	0.0011	-0.23	-0.28	Mood instability;	chr8:8694100	chr8:8236003~8244667:-
KIRP	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-4.76	3.19e-06	0.0011	-0.36	-0.28	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-4.76	3.19e-06	0.0011	-0.36	-0.28	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
KIRP	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-4.76	3.2e-06	0.0011	-0.32	-0.28	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
KIRP	cis	rs5758511	0.68	rs1033460	ENSG00000227370.1	RP4-669P10.19	4.76	3.2e-06	0.00111	0.34	0.28	Birth weight;	chr22:42223302	chr22:42132543~42132998:+
KIRP	cis	rs5758511	0.679	rs55867855	ENSG00000227370.1	RP4-669P10.19	4.76	3.2e-06	0.00111	0.34	0.28	Birth weight;	chr22:42227252	chr22:42132543~42132998:+
KIRP	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	4.76	3.2e-06	0.00111	0.34	0.28	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
KIRP	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	4.76	3.2e-06	0.00111	0.34	0.28	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
KIRP	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-4.76	3.2e-06	0.00111	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-4.76	3.2e-06	0.00111	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-4.76	3.2e-06	0.00111	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
KIRP	cis	rs1552244	1	rs7622963	ENSG00000180385.7	EMC3-AS1	4.76	3.2e-06	0.00111	0.26	0.28	Alzheimer's disease;	chr3:10098141	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs7622966	ENSG00000180385.7	EMC3-AS1	4.76	3.2e-06	0.00111	0.26	0.28	Alzheimer's disease;	chr3:10098149	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs34179822	ENSG00000180385.7	EMC3-AS1	4.76	3.2e-06	0.00111	0.26	0.28	Alzheimer's disease;	chr3:10098333	chr3:9986893~10006990:+
KIRP	cis	rs11673344	0.504	rs7245882	ENSG00000226686.6	LINC01535	-4.76	3.2e-06	0.00111	-0.34	-0.28	Obesity-related traits;	chr19:37089513	chr19:37251912~37265535:+
KIRP	cis	rs2455601	0.608	rs11042097	ENSG00000254860.4	TMEM9B-AS1	4.76	3.2e-06	0.00111	0.31	0.28	Schizophrenia;	chr11:8841297	chr11:8964675~8977527:+
KIRP	cis	rs2455601	0.58	rs11042098	ENSG00000254860.4	TMEM9B-AS1	4.76	3.2e-06	0.00111	0.31	0.28	Schizophrenia;	chr11:8843632	chr11:8964675~8977527:+
KIRP	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	4.76	3.2e-06	0.00111	0.31	0.28	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	4.76	3.2e-06	0.00111	0.31	0.28	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	4.76	3.2e-06	0.00111	0.31	0.28	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	4.76	3.2e-06	0.00111	0.31	0.28	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
KIRP	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-4.76	3.2e-06	0.00111	-0.23	-0.28	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
KIRP	cis	rs2278170	1	rs2554944	ENSG00000225101.4	OR52K3P	-4.76	3.2e-06	0.00111	-0.31	-0.28	Amyotrophic lateral sclerosis;	chr11:4458671	chr11:4474813~4475755:+
KIRP	cis	rs6908034	0.654	rs6456272	ENSG00000228412.5	RP4-625H18.2	-4.76	3.21e-06	0.00111	-0.35	-0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804805	chr6:19802164~19804752:-
KIRP	cis	rs79040073	0.637	rs73398264	ENSG00000259531.2	RP11-295H24.3	4.76	3.21e-06	0.00111	0.35	0.28	Lung cancer in ever smokers;	chr15:49414220	chr15:49365124~49366685:-
KIRP	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.76	3.21e-06	0.00111	-0.3	-0.28	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
KIRP	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-4.76	3.21e-06	0.00111	-0.24	-0.28	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
KIRP	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.76	3.22e-06	0.00111	0.23	0.28	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
KIRP	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	4.76	3.22e-06	0.00111	0.42	0.28	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
KIRP	cis	rs9595908	0.785	rs2183873	ENSG00000212293.1	SNORA16	4.76	3.22e-06	0.00111	0.27	0.28	Body mass index;	chr13:32710508	chr13:32420390~32420516:-
KIRP	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-4.76	3.22e-06	0.00111	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
KIRP	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-4.76	3.22e-06	0.00111	-0.3	-0.28	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
KIRP	cis	rs4578769	0.959	rs9955664	ENSG00000266850.1	RP11-370A5.1	4.76	3.22e-06	0.00111	0.36	0.28	Eosinophil percentage of white cells;	chr18:22901330	chr18:22723491~22907721:-
KIRP	cis	rs6908034	0.607	rs73378506	ENSG00000228412.5	RP4-625H18.2	4.76	3.22e-06	0.00111	0.41	0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19802164~19804752:-
KIRP	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	4.76	3.23e-06	0.00111	0.27	0.28	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
KIRP	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	4.76	3.23e-06	0.00111	0.26	0.28	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
KIRP	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	4.76	3.23e-06	0.00111	0.26	0.28	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
KIRP	cis	rs2043112	0.691	rs10064513	ENSG00000249911.1	LINC01265	4.76	3.23e-06	0.00111	0.33	0.28	Obesity-related traits;	chr5:39081373	chr5:38710367~38720273:-
KIRP	cis	rs11992162	0.636	rs4841644	ENSG00000255495.1	AC145124.2	4.76	3.23e-06	0.00111	0.27	0.28	Monocyte count;	chr8:11940924	chr8:12194467~12196280:+
KIRP	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-4.76	3.24e-06	0.00112	-0.31	-0.28	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
KIRP	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	4.76	3.24e-06	0.00112	0.38	0.28	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
KIRP	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	4.76	3.24e-06	0.00112	0.41	0.28	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
KIRP	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	4.76	3.24e-06	0.00112	0.41	0.28	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
KIRP	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-4.76	3.24e-06	0.00112	-0.31	-0.28	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
KIRP	cis	rs75920871	0.841	rs78442878	ENSG00000254851.1	RP11-109L13.1	-4.76	3.25e-06	0.00112	-0.46	-0.28	Subjective well-being;	chr11:117052138	chr11:117135528~117138582:+
KIRP	cis	rs897984	0.683	rs8046001	ENSG00000275263.1	RP11-1072A3.4	-4.76	3.25e-06	0.00112	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30822000	chr16:30956872~30957199:-
KIRP	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-4.76	3.25e-06	0.00112	-0.35	-0.28	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
KIRP	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	4.76	3.25e-06	0.00112	0.26	0.28	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
KIRP	cis	rs9915657	0.87	rs759499	ENSG00000234899.8	SOX9-AS1	-4.76	3.25e-06	0.00112	-0.25	-0.28	Thyroid hormone levels;	chr17:72137036	chr17:72034107~72237203:-
KIRP	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-4.76	3.25e-06	0.00112	-0.29	-0.28	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
KIRP	cis	rs1799949	1	rs4793194	ENSG00000279602.1	CTD-3014M21.1	-4.76	3.25e-06	0.00112	-0.26	-0.28	Menopause (age at onset);	chr17:43066316	chr17:43360041~43361361:-
KIRP	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-4.76	3.25e-06	0.00112	-0.33	-0.28	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
KIRP	cis	rs8030379	0.667	rs4842921	ENSG00000230373.7	GOLGA6L5P	-4.76	3.25e-06	0.00112	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84507885~84516814:-
KIRP	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-4.76	3.25e-06	0.00112	-0.35	-0.28	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
KIRP	cis	rs7189233	0.955	rs72801853	ENSG00000279344.1	RP11-44F14.7	4.76	3.25e-06	0.00112	0.22	0.28	Intelligence (multi-trait analysis);	chr16:53482912	chr16:53478957~53481550:-
KIRP	cis	rs962856	0.897	rs7579304	ENSG00000236605.1	AC023115.4	4.76	3.26e-06	0.00112	0.35	0.28	Pancreatic cancer;	chr2:67384118	chr2:67324627~67325304:+
KIRP	cis	rs962856	0.964	rs13415002	ENSG00000236605.1	AC023115.4	4.76	3.26e-06	0.00112	0.35	0.28	Pancreatic cancer;	chr2:67384691	chr2:67324627~67325304:+
KIRP	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.733	rs9591282	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32725844	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	4.76	3.26e-06	0.00112	0.27	0.28	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
KIRP	cis	rs11647589	0.678	rs6497489	ENSG00000262995.1	CTD-2194A8.2	-4.76	3.26e-06	0.00112	-0.32	-0.28	Blood metabolite levels;	chr16:20460042	chr16:20440266~20447000:-
KIRP	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	4.76	3.26e-06	0.00112	0.27	0.28	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
KIRP	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.76	3.26e-06	0.00112	-0.36	-0.28	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-4.76	3.26e-06	0.00112	-0.36	-0.28	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
KIRP	cis	rs9402743	0.702	rs9399150	ENSG00000234084.1	RP3-388E23.2	-4.76	3.26e-06	0.00112	-0.23	-0.28	Systemic lupus erythematosus;	chr6:135599752	chr6:135301568~135307158:+
KIRP	cis	rs964611	0.882	rs7162774	ENSG00000259488.2	RP11-154J22.1	4.76	3.26e-06	0.00112	0.31	0.28	Metabolite levels (Pyroglutamine);	chr15:48367336	chr15:48312353~48331856:-
KIRP	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-4.76	3.26e-06	0.00113	-0.24	-0.28	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
KIRP	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	4.76	3.27e-06	0.00113	0.23	0.28	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
KIRP	cis	rs2299587	0.932	rs34134751	ENSG00000254054.2	RP11-156K13.3	4.76	3.27e-06	0.00113	0.34	0.28	Economic and political preferences;	chr8:17990530	chr8:17905756~17907887:+
KIRP	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-4.76	3.27e-06	0.00113	-0.37	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
KIRP	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	4.76	3.27e-06	0.00113	0.26	0.28	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
KIRP	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-4.76	3.27e-06	0.00113	-0.39	-0.28	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
KIRP	cis	rs4453827	0.625	rs3774573	ENSG00000271916.1	RP11-884K10.6	4.76	3.27e-06	0.00113	0.28	0.28	Blood protein levels;	chr3:53765933	chr3:53797764~53798019:-
KIRP	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	4.76	3.27e-06	0.00113	0.51	0.28	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
KIRP	cis	rs7508	0.512	rs1057016	ENSG00000254054.2	RP11-156K13.3	4.76	3.27e-06	0.00113	0.32	0.28	Atrial fibrillation;	chr8:18029574	chr8:17905756~17907887:+
KIRP	cis	rs950169	0.922	rs11633534	ENSG00000254414.1	RP11-182J1.1	4.76	3.28e-06	0.00113	0.35	0.28	Schizophrenia;	chr15:84581411	chr15:84631898~84633987:-
KIRP	cis	rs950169	0.65	rs12902052	ENSG00000254414.1	RP11-182J1.1	4.76	3.28e-06	0.00113	0.35	0.28	Schizophrenia;	chr15:84582607	chr15:84631898~84633987:-
KIRP	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-4.76	3.28e-06	0.00113	-0.24	-0.28	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
KIRP	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-4.76	3.28e-06	0.00113	-0.24	-0.28	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
KIRP	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	4.76	3.28e-06	0.00113	0.28	0.28	Height;	chr14:75040822	chr14:75011269~75012851:-
KIRP	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-4.75	3.28e-06	0.00113	-0.56	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
KIRP	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	4.75	3.28e-06	0.00113	0.23	0.28	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
KIRP	cis	rs7772486	0.875	rs10872582	ENSG00000270638.1	RP3-466P17.1	4.75	3.28e-06	0.00113	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.846	rs2892453	ENSG00000270638.1	RP3-466P17.1	4.75	3.28e-06	0.00113	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145735570~145737218:+
KIRP	cis	rs9625935	0.752	rs140108	ENSG00000250318.1	CTA-963H5.5	-4.75	3.29e-06	0.00113	-0.18	-0.28	Tonsillectomy;	chr22:29734787	chr22:30653877~30654814:-
KIRP	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.29e-06	0.00113	-0.28	-0.28	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.29e-06	0.00113	-0.28	-0.28	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.29e-06	0.00113	-0.28	-0.28	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.29e-06	0.00113	-0.28	-0.28	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
KIRP	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	4.75	3.29e-06	0.00113	0.28	0.28	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
KIRP	cis	rs1577917	0.655	rs1059307	ENSG00000220563.1	PKMP3	4.75	3.29e-06	0.00113	0.22	0.28	Response to antipsychotic treatment;	chr6:85678170	chr6:85659892~85660606:-
KIRP	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	4.75	3.29e-06	0.00113	0.23	0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
KIRP	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	4.75	3.29e-06	0.00113	0.22	0.28	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
KIRP	cis	rs1487614	0.582	rs6850438	ENSG00000250781.1	RP11-63A11.1	-4.75	3.29e-06	0.00113	-0.36	-0.28	Longevity;	chr4:42260026	chr4:42281830~42391268:-
KIRP	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	4.75	3.29e-06	0.00113	0.28	0.28	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
KIRP	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-4.75	3.29e-06	0.00113	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
KIRP	cis	rs11148252	0.904	rs3892337	ENSG00000235660.1	LINC00345	-4.75	3.3e-06	0.00113	-0.3	-0.28	Lewy body disease;	chr13:52455350	chr13:52484161~52484680:-
KIRP	cis	rs453301	0.658	rs13271797	ENSG00000253981.4	ALG1L13P	-4.75	3.3e-06	0.00113	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9028444	chr8:8236003~8244667:-
KIRP	cis	rs897984	0.683	rs9932572	ENSG00000275263.1	RP11-1072A3.4	-4.75	3.3e-06	0.00113	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30830321	chr16:30956872~30957199:-
KIRP	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-4.75	3.3e-06	0.00114	-0.32	-0.28	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
KIRP	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-4.75	3.3e-06	0.00114	-0.35	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
KIRP	cis	rs6832769	0.922	rs819271	ENSG00000272969.1	RP11-528I4.2	4.75	3.3e-06	0.00114	0.29	0.28	Personality dimensions;	chr4:55372680	chr4:55547112~55547889:+
KIRP	cis	rs984222	0.741	rs1886914	ENSG00000231365.4	RP11-418J17.1	-4.75	3.3e-06	0.00114	-0.27	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998829	chr1:119140396~119275973:+
KIRP	cis	rs4927850	0.529	rs6800500	ENSG00000231464.1	AC024937.4	4.75	3.3e-06	0.00114	0.31	0.28	Pancreatic cancer;	chr3:196106636	chr3:195996738~195998233:+
KIRP	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	4.75	3.31e-06	0.00114	0.43	0.28	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
KIRP	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.75	3.31e-06	0.00114	0.24	0.28	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
KIRP	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.75	3.31e-06	0.00114	0.4	0.28	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
KIRP	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-4.75	3.31e-06	0.00114	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
KIRP	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-4.75	3.31e-06	0.00114	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
KIRP	cis	rs2299587	0.865	rs10108545	ENSG00000254054.2	RP11-156K13.3	4.75	3.31e-06	0.00114	0.33	0.28	Economic and political preferences;	chr8:17941732	chr8:17905756~17907887:+
KIRP	cis	rs9595908	0.785	rs7326314	ENSG00000212293.1	SNORA16	4.75	3.31e-06	0.00114	0.27	0.28	Body mass index;	chr13:32706422	chr13:32420390~32420516:-
KIRP	cis	rs35146811	0.735	rs2272345	ENSG00000078319.8	PMS2P1	-4.75	3.31e-06	0.00114	-0.36	-0.28	Coronary artery disease;	chr7:100199408	chr7:100320992~100341908:-
KIRP	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	4.75	3.31e-06	0.00114	0.27	0.28	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
KIRP	cis	rs910316	0.789	rs4899552	ENSG00000279594.1	RP11-950C14.10	-4.75	3.31e-06	0.00114	-0.28	-0.28	Height;	chr14:75201218	chr14:75011269~75012851:-
KIRP	cis	rs875971	0.545	rs1796217	ENSG00000224316.1	RP11-479O9.2	-4.75	3.31e-06	0.00114	-0.23	-0.28	Aortic root size;	chr7:66620931	chr7:65773620~65802067:+
KIRP	cis	rs8030379	1	rs11259933	ENSG00000230373.7	GOLGA6L5P	-4.75	3.32e-06	0.00114	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911404	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs6603004	ENSG00000230373.7	GOLGA6L5P	4.75	3.32e-06	0.00114	0.23	0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899752	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs2401175	ENSG00000230373.7	GOLGA6L5P	4.75	3.32e-06	0.00114	0.23	0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909465	chr15:84507885~84516814:-
KIRP	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	4.75	3.32e-06	0.00114	0.47	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
KIRP	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-4.75	3.32e-06	0.00114	-0.3	-0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
KIRP	cis	rs2115630	0.645	rs4842978	ENSG00000254414.1	RP11-182J1.1	-4.75	3.32e-06	0.00114	-0.3	-0.28	P wave terminal force;	chr15:84654022	chr15:84631898~84633987:-
KIRP	cis	rs712022	0.868	rs10833819	ENSG00000246225.5	RP11-17A1.3	-4.75	3.32e-06	0.00114	-0.32	-0.28	Dialysis-related mortality;	chr11:22801736	chr11:22829380~22945393:+
KIRP	cis	rs9494145	0.667	rs1331309	ENSG00000232876.1	CTA-212D2.2	-4.75	3.32e-06	0.00114	-0.39	-0.28	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135085040	chr6:135055033~135060550:+
KIRP	cis	rs6834314	0.743	rs10001545	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.26	-0.28	Liver enzyme levels (alanine transaminase);	chr4:87254878	chr4:86913266~86914817:-
KIRP	cis	rs6834314	0.743	rs28439498	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.26	-0.28	Liver enzyme levels (alanine transaminase);	chr4:87255191	chr4:86913266~86914817:-
KIRP	cis	rs6834314	0.743	rs28418877	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.26	-0.28	Liver enzyme levels (alanine transaminase);	chr4:87257382	chr4:86913266~86914817:-
KIRP	cis	rs6834314	0.703	rs9997582	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.26	-0.28	Liver enzyme levels (alanine transaminase);	chr4:87260377	chr4:86913266~86914817:-
KIRP	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	4.75	3.33e-06	0.00114	0.28	0.28	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
KIRP	cis	rs6840258	0.64	rs28882732	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87154824	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.582	rs7437661	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87156860	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.582	rs1021104	ENSG00000251411.1	RP11-397E7.4	-4.75	3.33e-06	0.00114	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87157017	chr4:86913266~86914817:-
KIRP	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-4.75	3.33e-06	0.00114	-0.36	-0.28	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
KIRP	cis	rs2299587	0.729	rs7825899	ENSG00000254054.2	RP11-156K13.3	4.75	3.33e-06	0.00114	0.33	0.28	Economic and political preferences;	chr8:18000371	chr8:17905756~17907887:+
KIRP	cis	rs7615952	1	rs7616044	ENSG00000250012.1	RP11-124N2.1	-4.75	3.33e-06	0.00114	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125930511	chr3:126084220~126095349:+
KIRP	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-4.75	3.33e-06	0.00114	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
KIRP	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-4.75	3.33e-06	0.00114	-0.31	-0.28	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
KIRP	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	4.75	3.33e-06	0.00115	0.42	0.28	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
KIRP	cis	rs28386778	0.966	rs2854161	ENSG00000240280.5	TCAM1P	4.75	3.33e-06	0.00115	0.34	0.28	Prudent dietary pattern;	chr17:63898733	chr17:63849292~63864379:+
KIRP	cis	rs11148252	0.904	rs7990581	ENSG00000235660.1	LINC00345	-4.75	3.33e-06	0.00115	-0.3	-0.28	Lewy body disease;	chr13:52445298	chr13:52484161~52484680:-
KIRP	cis	rs2386661	0.547	rs11259742	ENSG00000228951.1	RP11-336A10.4	4.75	3.33e-06	0.00115	0.35	0.28	Breast cancer;	chr10:5605115	chr10:5616862~5618161:-
KIRP	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-4.75	3.34e-06	0.00115	-0.32	-0.28	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
KIRP	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	4.75	3.34e-06	0.00115	0.25	0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
KIRP	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-4.75	3.34e-06	0.00115	-0.21	-0.28	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
KIRP	cis	rs61457372	0.545	rs9302946	ENSG00000264026.1	RP11-1124B17.1	-4.75	3.34e-06	0.00115	-0.29	-0.28	Triptolide cytotoxicity;	chr17:72350557	chr17:72342940~72355136:+
KIRP	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-4.75	3.34e-06	0.00115	-0.23	-0.28	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
KIRP	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
KIRP	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
KIRP	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	4.75	3.34e-06	0.00115	0.31	0.28	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
KIRP	cis	rs8030379	1	rs7162129	ENSG00000230373.7	GOLGA6L5P	-4.75	3.34e-06	0.00115	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84507885~84516814:-
KIRP	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-4.75	3.34e-06	0.00115	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
KIRP	cis	rs9859260	0.701	rs9872347	ENSG00000231464.1	AC024937.4	4.75	3.35e-06	0.00115	0.31	0.28	Mean corpuscular volume;	chr3:196104366	chr3:195996738~195998233:+
KIRP	cis	rs9859260	0.555	rs9877493	ENSG00000231464.1	AC024937.4	4.75	3.35e-06	0.00115	0.31	0.28	Mean corpuscular volume;	chr3:196105276	chr3:195996738~195998233:+
KIRP	cis	rs7674212	0.541	rs2720458	ENSG00000230069.3	LRRC37A15P	-4.75	3.35e-06	0.00115	-0.27	-0.28	Type 2 diabetes;	chr4:103131806	chr4:102727274~102730721:-
KIRP	cis	rs9625935	0.788	rs140125	ENSG00000250318.1	CTA-963H5.5	-4.75	3.35e-06	0.00115	-0.19	-0.28	Tonsillectomy;	chr22:29750518	chr22:30653877~30654814:-
KIRP	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	4.75	3.35e-06	0.00115	0.38	0.28	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
KIRP	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	4.75	3.35e-06	0.00115	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
KIRP	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	4.75	3.35e-06	0.00115	0.36	0.28	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
KIRP	cis	rs2439831	0.541	rs12440854	ENSG00000249839.1	AC011330.5	-4.75	3.35e-06	0.00115	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43318474	chr15:43663654~43684339:-
KIRP	cis	rs11673344	0.523	rs2562594	ENSG00000226686.6	LINC01535	4.75	3.35e-06	0.00115	0.35	0.28	Obesity-related traits;	chr19:37023783	chr19:37251912~37265535:+
KIRP	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-4.75	3.35e-06	0.00115	-0.24	-0.28	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-4.75	3.35e-06	0.00115	-0.24	-0.28	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-4.75	3.35e-06	0.00115	-0.24	-0.28	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-4.75	3.35e-06	0.00115	-0.24	-0.28	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
KIRP	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	4.75	3.35e-06	0.00115	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	4.75	3.35e-06	0.00115	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	4.75	3.35e-06	0.00115	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	4.75	3.35e-06	0.00115	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
KIRP	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-4.75	3.36e-06	0.00115	-0.35	-0.28	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
KIRP	cis	rs2299587	0.786	rs3886397	ENSG00000254054.2	RP11-156K13.3	4.75	3.36e-06	0.00115	0.33	0.28	Economic and political preferences;	chr8:18023116	chr8:17905756~17907887:+
KIRP	cis	rs308447	0.516	rs6815982	ENSG00000224786.1	CETN4P	-4.75	3.36e-06	0.00115	-0.38	-0.28	Perceived unattractiveness to mosquitoes;	chr4:122756317	chr4:122730548~122732193:-
KIRP	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-4.75	3.36e-06	0.00115	-0.3	-0.28	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
KIRP	cis	rs116095464	0.558	rs6878087	ENSG00000248925.1	CTD-2083E4.6	-4.75	3.36e-06	0.00115	-0.42	-0.28	Breast cancer;	chr5:223002	chr5:269858~271516:-
KIRP	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-4.75	3.36e-06	0.00115	-0.23	-0.28	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
KIRP	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	4.75	3.36e-06	0.00115	0.53	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
KIRP	cis	rs11148252	0.904	rs9536079	ENSG00000235660.1	LINC00345	-4.75	3.36e-06	0.00115	-0.3	-0.28	Lewy body disease;	chr13:52456430	chr13:52484161~52484680:-
KIRP	cis	rs131777	0.545	rs140514	ENSG00000272940.1	CTA-384D8.33	4.75	3.36e-06	0.00115	0.31	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50597152~50597599:+
KIRP	cis	rs73411413	0.608	rs7126170	ENSG00000233930.3	KRTAP5-AS1	-4.75	3.36e-06	0.00115	-0.37	-0.28	Myringotomy;	chr11:1518157	chr11:1571353~1599184:+
KIRP	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	4.75	3.36e-06	0.00115	0.32	0.28	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
KIRP	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	4.75	3.37e-06	0.00116	0.3	0.28	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
KIRP	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	4.75	3.37e-06	0.00116	0.42	0.28	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
KIRP	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-4.75	3.37e-06	0.00116	-0.28	-0.28	Height;	chr14:75071514	chr14:75011269~75012851:-
KIRP	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	4.75	3.37e-06	0.00116	0.32	0.28	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
KIRP	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.75	3.37e-06	0.00116	0.44	0.28	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
KIRP	cis	rs11158026	0.603	rs12147796	ENSG00000258413.1	RP11-665C16.6	-4.75	3.37e-06	0.00116	-0.36	-0.28	Parkinson's disease;	chr14:54941978	chr14:55262767~55272075:-
KIRP	cis	rs7615952	0.599	rs2270986	ENSG00000241439.1	RP11-666A20.3	4.75	3.38e-06	0.00116	0.39	0.28	Blood pressure (smoking interaction);	chr3:125982256	chr3:125958556~125958817:+
KIRP	cis	rs7586673	0.725	rs6757645	ENSG00000235724.7	AC009299.2	-4.75	3.38e-06	0.00116	-0.33	-0.28	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161222785~161308303:-
KIRP	cis	rs4820539	1	rs4822362	ENSG00000275635.1	U7	4.75	3.38e-06	0.00116	0.3	0.28	Bone mineral density;	chr22:23140557	chr22:23137805~23137864:-
KIRP	cis	rs2562456	0.917	rs2650805	ENSG00000268555.1	RP11-678G14.3	-4.75	3.38e-06	0.00116	-0.38	-0.28	Pain;	chr19:21505137	chr19:21570822~21587322:-
KIRP	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-4.75	3.38e-06	0.00116	-0.35	-0.28	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
KIRP	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-4.75	3.38e-06	0.00116	-0.35	-0.28	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
KIRP	cis	rs10266483	0.96	rs13221291	ENSG00000227986.1	TRIM60P18	-4.75	3.38e-06	0.00116	-0.2	-0.28	Response to statin therapy;	chr7:64279114	chr7:64355078~64356199:+
KIRP	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-4.75	3.38e-06	0.00116	-0.27	-0.28	Height;	chr14:75028280	chr14:75011269~75012851:-
KIRP	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.38e-06	0.00116	-0.26	-0.28	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
KIRP	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-4.75	3.38e-06	0.00116	-0.24	-0.28	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
KIRP	cis	rs1044826	0.692	rs188421	ENSG00000178631.7	ACTG1P1	-4.75	3.39e-06	0.00116	-0.3	-0.28	Obesity-related traits;	chr3:139515224	chr3:139493809~139494937:+
KIRP	cis	rs1046896	0.961	rs7208565	ENSG00000262410.1	RP11-388C12.8	-4.75	3.39e-06	0.00116	-0.24	-0.28	Glycated hemoglobin levels;	chr17:82738816	chr17:82745068~82745709:+
KIRP	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.75	3.39e-06	0.00116	-0.59	-0.28	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
KIRP	cis	rs4852324	1	rs6707395	ENSG00000217702.2	RP11-287D1.4	4.75	3.4e-06	0.00116	0.44	0.28	Systemic lupus erythematosus;	chr2:73976670	chr2:74130583~74135395:+
KIRP	cis	rs2562456	0.793	rs2650819	ENSG00000268555.1	RP11-678G14.3	-4.75	3.4e-06	0.00116	-0.38	-0.28	Pain;	chr19:21456071	chr19:21570822~21587322:-
KIRP	cis	rs308403	0.6	rs13129352	ENSG00000224786.1	CETN4P	4.75	3.4e-06	0.00117	0.42	0.28	Blood protein levels;	chr4:122712581	chr4:122730548~122732193:-
KIRP	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	4.75	3.4e-06	0.00117	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
KIRP	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-4.75	3.4e-06	0.00117	-0.29	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
KIRP	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	4.75	3.4e-06	0.00117	0.23	0.28	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
KIRP	cis	rs4356203	0.87	rs214901	ENSG00000272034.1	SNORD14A	4.75	3.4e-06	0.00117	0.24	0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17074654~17074744:-
KIRP	cis	rs2278170	1	rs11032351	ENSG00000225101.4	OR52K3P	-4.75	3.4e-06	0.00117	-0.34	-0.28	Amyotrophic lateral sclerosis;	chr11:4465471	chr11:4474813~4475755:+
KIRP	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	4.75	3.4e-06	0.00117	0.28	0.28	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
KIRP	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	4.75	3.4e-06	0.00117	0.43	0.28	Height;	chr6:109773423	chr6:109382795~109383666:+
KIRP	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-4.75	3.4e-06	0.00117	-0.35	-0.28	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
KIRP	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	4.75	3.4e-06	0.00117	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
KIRP	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-4.75	3.41e-06	0.00117	-0.33	-0.28	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
KIRP	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	4.75	3.41e-06	0.00117	0.47	0.28	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
KIRP	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-4.75	3.41e-06	0.00117	-0.3	-0.28	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
KIRP	cis	rs1185460	0.967	rs1168568	ENSG00000272186.1	RP11-110I1.13	-4.75	3.41e-06	0.00117	-0.28	-0.28	Coronary artery disease;	chr11:119079089	chr11:119067374~119067698:-
KIRP	cis	rs1185460	0.967	rs1307145	ENSG00000272186.1	RP11-110I1.13	-4.75	3.41e-06	0.00117	-0.28	-0.28	Coronary artery disease;	chr11:119079507	chr11:119067374~119067698:-
KIRP	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-4.75	3.41e-06	0.00117	-0.28	-0.28	Height;	chr14:74997592	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-4.75	3.41e-06	0.00117	-0.28	-0.28	Height;	chr14:74998335	chr14:75011269~75012851:-
KIRP	cis	rs6671200	0.667	rs79658099	ENSG00000235501.4	RP4-639F20.1	-4.75	3.42e-06	0.00117	-0.57	-0.28	Stearic acid (18:0) levels;	chr1:94951833	chr1:94927566~94963270:+
KIRP	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	4.75	3.42e-06	0.00117	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
KIRP	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	4.75	3.42e-06	0.00117	0.38	0.28	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
KIRP	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	4.75	3.42e-06	0.00117	0.44	0.28	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
KIRP	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-4.75	3.42e-06	0.00117	-0.3	-0.28	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
KIRP	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	4.75	3.42e-06	0.00117	0.44	0.28	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
KIRP	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-4.75	3.42e-06	0.00117	-0.28	-0.28	Height;	chr14:75141980	chr14:75011269~75012851:-
KIRP	cis	rs35146811	0.735	rs2528900	ENSG00000078319.8	PMS2P1	4.75	3.42e-06	0.00117	0.36	0.28	Coronary artery disease;	chr7:100207696	chr7:100320992~100341908:-
KIRP	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	4.75	3.43e-06	0.00117	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
KIRP	cis	rs962856	0.964	rs6546303	ENSG00000236605.1	AC023115.4	4.75	3.43e-06	0.00117	0.35	0.28	Pancreatic cancer;	chr2:67385986	chr2:67324627~67325304:+
KIRP	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	4.74	3.43e-06	0.00118	0.28	0.28	Height;	chr14:75045806	chr14:75011269~75012851:-
KIRP	cis	rs7615952	0.551	rs6438945	ENSG00000250012.1	RP11-124N2.1	-4.74	3.44e-06	0.00118	-0.41	-0.28	Blood pressure (smoking interaction);	chr3:125915630	chr3:126084220~126095349:+
KIRP	cis	rs7615952	0.673	rs7632557	ENSG00000250012.1	RP11-124N2.1	-4.74	3.44e-06	0.00118	-0.41	-0.28	Blood pressure (smoking interaction);	chr3:125916038	chr3:126084220~126095349:+
KIRP	cis	rs7615952	0.932	rs9841157	ENSG00000250012.1	RP11-124N2.1	-4.74	3.44e-06	0.00118	-0.41	-0.28	Blood pressure (smoking interaction);	chr3:125916812	chr3:126084220~126095349:+
KIRP	cis	rs7615952	0.551	rs12695470	ENSG00000250012.1	RP11-124N2.1	-4.74	3.44e-06	0.00118	-0.41	-0.28	Blood pressure (smoking interaction);	chr3:125916875	chr3:126084220~126095349:+
KIRP	cis	rs7615952	0.932	rs13325495	ENSG00000250012.1	RP11-124N2.1	-4.74	3.44e-06	0.00118	-0.41	-0.28	Blood pressure (smoking interaction);	chr3:125918573	chr3:126084220~126095349:+
KIRP	cis	rs964611	0.882	rs10152424	ENSG00000259488.2	RP11-154J22.1	-4.74	3.44e-06	0.00118	-0.26	-0.28	Metabolite levels (Pyroglutamine);	chr15:48299790	chr15:48312353~48331856:-
KIRP	cis	rs897984	0.683	rs8050330	ENSG00000275263.1	RP11-1072A3.4	-4.74	3.44e-06	0.00118	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30813649	chr16:30956872~30957199:-
KIRP	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	4.74	3.44e-06	0.00118	0.49	0.28	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
KIRP	cis	rs9810089	0.903	rs711975	ENSG00000261758.1	RP11-102M11.2	4.74	3.44e-06	0.00118	0.3	0.28	Gestational age at birth (child effect);	chr3:136517066	chr3:136752630~136755780:+
KIRP	cis	rs1153858	1	rs1719247	ENSG00000259433.2	CTD-2651B20.4	-4.74	3.44e-06	0.00118	-0.24	-0.28	Homoarginine levels;	chr15:45328787	chr15:45330209~45332634:-
KIRP	cis	rs453301	0.686	rs28482034	ENSG00000253981.4	ALG1L13P	-4.74	3.44e-06	0.00118	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9012154	chr8:8236003~8244667:-
KIRP	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	4.74	3.44e-06	0.00118	0.39	0.28	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
KIRP	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	4.74	3.44e-06	0.00118	0.26	0.28	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
KIRP	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	4.74	3.45e-06	0.00118	0.42	0.28	Height;	chr6:109372084	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	4.74	3.45e-06	0.00118	0.42	0.28	Height;	chr6:109375848	chr6:109382795~109383666:+
KIRP	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-4.74	3.45e-06	0.00118	-0.34	-0.28	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
KIRP	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
KIRP	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	4.74	3.45e-06	0.00118	0.31	0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
KIRP	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	4.74	3.45e-06	0.00118	0.25	0.28	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
KIRP	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-4.74	3.45e-06	0.00118	-0.34	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
KIRP	cis	rs9302635	0.513	rs7198572	ENSG00000260886.1	TAT-AS1	4.74	3.45e-06	0.00118	0.4	0.28	Blood protein levels;	chr16:72149321	chr16:71565789~71578187:+
KIRP	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-4.74	3.45e-06	0.00118	-0.3	-0.28	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
KIRP	cis	rs11098499	0.644	rs3806808	ENSG00000250412.1	KLHL2P1	4.74	3.45e-06	0.00118	0.35	0.28	Corneal astigmatism;	chr4:119629930	chr4:119334329~119378233:+
KIRP	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	4.74	3.45e-06	0.00118	0.28	0.28	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
KIRP	cis	rs9810089	0.903	rs7427564	ENSG00000261758.1	RP11-102M11.2	4.74	3.45e-06	0.00118	0.3	0.28	Gestational age at birth (child effect);	chr3:136555593	chr3:136752630~136755780:+
KIRP	cis	rs9810089	0.903	rs7432375	ENSG00000261758.1	RP11-102M11.2	4.74	3.45e-06	0.00118	0.3	0.28	Gestational age at birth (child effect);	chr3:136569563	chr3:136752630~136755780:+
KIRP	cis	rs9810089	0.903	rs10935185	ENSG00000261758.1	RP11-102M11.2	4.74	3.45e-06	0.00118	0.3	0.28	Gestational age at birth (child effect);	chr3:136571687	chr3:136752630~136755780:+
KIRP	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-4.74	3.45e-06	0.00118	-0.36	-0.28	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
KIRP	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-4.74	3.46e-06	0.00118	-0.35	-0.28	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
KIRP	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-4.74	3.46e-06	0.00118	-0.23	-0.28	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-4.74	3.46e-06	0.00118	-0.23	-0.28	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-4.74	3.46e-06	0.00118	-0.23	-0.28	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-4.74	3.46e-06	0.00118	-0.23	-0.28	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-4.74	3.46e-06	0.00118	-0.23	-0.28	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
KIRP	cis	rs73252553	0.615	rs1973604	ENSG00000281501.1	SEPSECS-AS1	-4.74	3.46e-06	0.00118	-0.38	-0.28	Cannabis dependence symptom count;	chr4:25252741	chr4:25160641~25201440:+
KIRP	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-4.74	3.46e-06	0.00118	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
KIRP	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-4.74	3.46e-06	0.00118	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
KIRP	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-4.74	3.46e-06	0.00118	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
KIRP	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-4.74	3.46e-06	0.00118	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
KIRP	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-4.74	3.46e-06	0.00118	-0.48	-0.28	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
KIRP	cis	rs6480314	0.636	rs61854790	ENSG00000233590.1	RP11-153K11.3	-4.74	3.46e-06	0.00118	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68242491	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.636	rs61854792	ENSG00000233590.1	RP11-153K11.3	-4.74	3.46e-06	0.00118	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68243902	chr10:68233251~68242379:-
KIRP	cis	rs6480314	0.636	rs77760458	ENSG00000233590.1	RP11-153K11.3	-4.74	3.46e-06	0.00118	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68244248	chr10:68233251~68242379:-
KIRP	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	4.74	3.46e-06	0.00118	0.27	0.28	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	4.74	3.46e-06	0.00118	0.27	0.28	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
KIRP	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-4.74	3.46e-06	0.00118	-0.33	-0.28	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
KIRP	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	4.74	3.47e-06	0.00119	0.39	0.28	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
KIRP	cis	rs2562456	0.755	rs1879234	ENSG00000268555.1	RP11-678G14.3	-4.74	3.47e-06	0.00119	-0.38	-0.28	Pain;	chr19:21521677	chr19:21570822~21587322:-
KIRP	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	4.74	3.47e-06	0.00119	0.24	0.28	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
KIRP	cis	rs8030379	1	rs8041056	ENSG00000230373.7	GOLGA6L5P	-4.74	3.47e-06	0.00119	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84507885~84516814:-
KIRP	cis	rs8030379	1	rs6603003	ENSG00000230373.7	GOLGA6L5P	-4.74	3.47e-06	0.00119	-0.23	-0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84507885~84516814:-
KIRP	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	4.74	3.47e-06	0.00119	0.32	0.28	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
KIRP	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
KIRP	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	4.74	3.47e-06	0.00119	0.24	0.28	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
KIRP	cis	rs4128705	1	rs12507411	ENSG00000249049.1	RP11-763F8.1	4.74	3.47e-06	0.00119	0.26	0.28	Amyotrophic lateral sclerosis (sporadic);	chr4:91359906	chr4:91319034~91325306:-
KIRP	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.74	3.47e-06	0.00119	0.33	0.28	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
KIRP	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-4.74	3.47e-06	0.00119	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
KIRP	cis	rs2562456	0.833	rs2928211	ENSG00000268555.1	RP11-678G14.3	-4.74	3.47e-06	0.00119	-0.39	-0.28	Pain;	chr19:21358495	chr19:21570822~21587322:-
KIRP	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-4.74	3.47e-06	0.00119	-0.37	-0.28	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
KIRP	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-4.74	3.47e-06	0.00119	-0.37	-0.28	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
KIRP	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	4.74	3.47e-06	0.00119	0.34	0.28	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
KIRP	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-4.74	3.48e-06	0.00119	-0.29	-0.28	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
KIRP	cis	rs9543976	1	rs9573592	ENSG00000261105.4	LMO7-AS1	-4.74	3.48e-06	0.00119	-0.49	-0.28	Diabetic retinopathy;	chr13:75623707	chr13:75604700~75635994:-
KIRP	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-4.74	3.48e-06	0.00119	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
KIRP	cis	rs10504130	0.569	rs4534123	ENSG00000272024.1	RP11-546K22.3	4.74	3.48e-06	0.00119	0.33	0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51950284~51950690:+
KIRP	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-4.74	3.48e-06	0.00119	-0.3	-0.28	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-4.74	3.48e-06	0.00119	-0.3	-0.28	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
KIRP	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	4.74	3.48e-06	0.00119	0.42	0.28	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	4.74	3.48e-06	0.00119	0.42	0.28	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	4.74	3.48e-06	0.00119	0.42	0.28	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
KIRP	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	4.74	3.48e-06	0.00119	0.23	0.28	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
KIRP	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	4.74	3.48e-06	0.00119	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	4.74	3.48e-06	0.00119	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
KIRP	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-4.74	3.49e-06	0.00119	-0.36	-0.28	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
KIRP	cis	rs2299587	0.901	rs12546695	ENSG00000254054.2	RP11-156K13.3	4.74	3.49e-06	0.00119	0.33	0.28	Economic and political preferences;	chr8:17939252	chr8:17905756~17907887:+
KIRP	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	4.74	3.5e-06	0.00119	0.26	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
KIRP	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	4.74	3.5e-06	0.00119	0.28	0.28	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
KIRP	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	4.74	3.5e-06	0.00119	0.28	0.28	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
KIRP	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-4.74	3.5e-06	0.00119	-0.34	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
KIRP	cis	rs7747960	0.61	rs12215935	ENSG00000226193.1	RP3-398G3.5	-4.74	3.5e-06	0.00119	-0.43	-0.28	Bipolar disorder;	chr6:152497370	chr6:152402398~152404966:+
KIRP	cis	rs2911132	0.506	rs7705827	ENSG00000248734.2	CTD-2260A17.1	4.74	3.5e-06	0.0012	0.27	0.28	Urate levels (BMI interaction);	chr5:96746729	chr5:96784777~96785999:+
KIRP	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-4.74	3.5e-06	0.0012	-0.36	-0.28	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-4.74	3.5e-06	0.0012	-0.36	-0.28	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
KIRP	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-4.74	3.5e-06	0.0012	-0.36	-0.28	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
KIRP	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-4.74	3.5e-06	0.0012	-0.28	-0.28	Height;	chr14:74992930	chr14:75011269~75012851:-
KIRP	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.74	3.5e-06	0.0012	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
KIRP	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-4.74	3.51e-06	0.0012	-0.35	-0.28	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
KIRP	cis	rs42648	0.755	rs1557650	ENSG00000225498.1	AC002064.5	4.74	3.51e-06	0.0012	0.21	0.28	Homocysteine levels;	chr7:90342242	chr7:90312496~90322592:+
KIRP	cis	rs2299587	0.965	rs7843298	ENSG00000254054.2	RP11-156K13.3	4.74	3.51e-06	0.0012	0.34	0.28	Economic and political preferences;	chr8:17948647	chr8:17905756~17907887:+
KIRP	cis	rs897984	0.537	rs8045637	ENSG00000275263.1	RP11-1072A3.4	-4.74	3.51e-06	0.0012	-0.29	-0.28	Dementia with Lewy bodies;	chr16:30807341	chr16:30956872~30957199:-
KIRP	cis	rs7508	0.512	rs6981130	ENSG00000254054.2	RP11-156K13.3	4.74	3.51e-06	0.0012	0.32	0.28	Atrial fibrillation;	chr8:18035009	chr8:17905756~17907887:+
KIRP	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-4.74	3.51e-06	0.0012	-0.35	-0.28	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
KIRP	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-4.74	3.51e-06	0.0012	-0.35	-0.28	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
KIRP	cis	rs7299940	1	rs6486613	ENSG00000256299.1	RP11-989F5.3	4.74	3.51e-06	0.0012	0.27	0.28	Panic disorder;	chr12:130909133	chr12:130810821~130812622:-
KIRP	cis	rs713477	0.967	rs10150617	ENSG00000258413.1	RP11-665C16.6	-4.74	3.51e-06	0.0012	-0.34	-0.28	Pediatric bone mineral content (femoral neck);	chr14:55449507	chr14:55262767~55272075:-
KIRP	cis	rs2562456	0.917	rs2681392	ENSG00000268555.1	RP11-678G14.3	-4.74	3.51e-06	0.0012	-0.38	-0.28	Pain;	chr19:21513185	chr19:21570822~21587322:-
KIRP	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-4.74	3.52e-06	0.0012	-0.26	-0.28	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
KIRP	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	4.74	3.52e-06	0.0012	0.2	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
KIRP	cis	rs738322	1	rs4379	ENSG00000233360.4	Z83844.1	4.74	3.52e-06	0.0012	0.28	0.28	Cutaneous nevi;	chr22:38173164	chr22:37641832~37658377:-
KIRP	cis	rs12039431	0.788	rs61776188	ENSG00000232273.1	FTH1P1	4.74	3.52e-06	0.0012	0.37	0.28	Epithelial ovarian cancer;	chr1:37555725	chr1:37544763~37545294:+
KIRP	cis	rs5758511	0.68	rs5758657	ENSG00000227370.1	RP4-669P10.19	4.74	3.52e-06	0.0012	0.34	0.28	Birth weight;	chr22:42222663	chr22:42132543~42132998:+
KIRP	cis	rs2242194	0.816	rs6671688	ENSG00000232093.1	RP11-307C12.11	-4.74	3.52e-06	0.0012	-0.25	-0.28	Schizophrenia;	chr1:155021789	chr1:155045191~155046118:-
KIRP	cis	rs2242194	0.816	rs11264296	ENSG00000232093.1	RP11-307C12.11	-4.74	3.52e-06	0.0012	-0.25	-0.28	Schizophrenia;	chr1:155022274	chr1:155045191~155046118:-
KIRP	cis	rs7772486	0.754	rs9497419	ENSG00000270638.1	RP3-466P17.1	4.74	3.52e-06	0.0012	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.754	rs6921073	ENSG00000270638.1	RP3-466P17.1	4.74	3.52e-06	0.0012	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145735570~145737218:+
KIRP	cis	rs7772486	0.727	rs12190966	ENSG00000270638.1	RP3-466P17.1	4.74	3.52e-06	0.0012	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145735570~145737218:+
KIRP	cis	rs4639966	0.836	rs1893029	ENSG00000255239.1	AP002954.6	-4.74	3.52e-06	0.0012	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118740117	chr11:118688039~118690600:-
KIRP	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	4.74	3.52e-06	0.0012	0.47	0.28	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
KIRP	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	4.74	3.53e-06	0.0012	0.25	0.28	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
KIRP	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	4.74	3.53e-06	0.0012	0.29	0.28	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
KIRP	cis	rs9305354	1	rs7279150	ENSG00000232079.5	AL035610.1	4.74	3.53e-06	0.0012	0.38	0.28	Urinary albumin excretion;	chr21:28104169	chr21:28048404~28137611:+
KIRP	cis	rs9305354	1	rs7279291	ENSG00000232079.5	AL035610.1	4.74	3.53e-06	0.0012	0.38	0.28	Urinary albumin excretion;	chr21:28104213	chr21:28048404~28137611:+
KIRP	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	4.74	3.53e-06	0.0012	0.32	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
KIRP	cis	rs728616	0.614	rs958865	ENSG00000234382.2	RP11-40F6.1	-4.74	3.53e-06	0.0012	-0.31	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:80233664~80245367:+
KIRP	cis	rs116095464	0.558	rs62346508	ENSG00000248925.1	CTD-2083E4.6	4.74	3.53e-06	0.0012	0.46	0.28	Breast cancer;	chr5:203553	chr5:269858~271516:-
KIRP	cis	rs9810089	0.706	rs521746	ENSG00000261758.1	RP11-102M11.2	-4.74	3.53e-06	0.0012	-0.29	-0.28	Gestational age at birth (child effect);	chr3:136385078	chr3:136752630~136755780:+
KIRP	cis	rs2018683	0.6	rs6948880	ENSG00000272568.4	CTB-113D17.1	4.74	3.53e-06	0.00121	0.25	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28979967~29013367:+
KIRP	cis	rs2018683	0.624	rs6462119	ENSG00000272568.4	CTB-113D17.1	4.74	3.53e-06	0.00121	0.25	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28979967~29013367:+
KIRP	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	4.74	3.54e-06	0.00121	0.36	0.28	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
KIRP	cis	rs6502050	0.835	rs7209474	ENSG00000266654.1	RP11-1376P16.1	-4.74	3.54e-06	0.00121	-0.27	-0.28	Life satisfaction;	chr17:82178542	chr17:82160056~82160452:+
KIRP	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	4.74	3.54e-06	0.00121	0.26	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
KIRP	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	4.74	3.54e-06	0.00121	0.26	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
KIRP	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.74	3.54e-06	0.00121	-0.36	-0.28	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
KIRP	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.74	3.54e-06	0.00121	-0.36	-0.28	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
KIRP	cis	rs9810089	0.758	rs12492510	ENSG00000261758.1	RP11-102M11.2	4.74	3.54e-06	0.00121	0.3	0.28	Gestational age at birth (child effect);	chr3:136432789	chr3:136752630~136755780:+
KIRP	cis	rs875971	0.545	rs316328	ENSG00000236529.1	RP13-254B10.1	-4.74	3.55e-06	0.00121	-0.25	-0.28	Aortic root size;	chr7:66143851	chr7:65840212~65840596:+
KIRP	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-4.74	3.55e-06	0.00121	-0.24	-0.28	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
KIRP	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-4.74	3.55e-06	0.00121	-0.33	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
KIRP	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-4.74	3.55e-06	0.00121	-0.29	-0.28	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
KIRP	cis	rs795484	0.507	rs795482	ENSG00000275759.1	RP11-131L12.3	4.74	3.55e-06	0.00121	0.24	0.28	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118153011	chr12:118428281~118428870:+
KIRP	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-4.74	3.55e-06	0.00121	-0.3	-0.28	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
KIRP	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	4.74	3.55e-06	0.00121	0.25	0.28	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
KIRP	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-4.74	3.56e-06	0.00121	-0.21	-0.28	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
KIRP	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	4.74	3.56e-06	0.00121	0.34	0.28	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
KIRP	cis	rs35146811	0.735	rs1061230	ENSG00000078319.8	PMS2P1	4.74	3.56e-06	0.00121	0.36	0.28	Coronary artery disease;	chr7:100209642	chr7:100320992~100341908:-
KIRP	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	4.74	3.56e-06	0.00121	0.33	0.28	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
KIRP	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-4.74	3.57e-06	0.00122	-0.35	-0.28	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
KIRP	cis	rs9305354	1	rs10446069	ENSG00000232079.5	AL035610.1	4.74	3.57e-06	0.00122	0.38	0.28	Urinary albumin excretion;	chr21:28104952	chr21:28048404~28137611:+
KIRP	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-4.74	3.57e-06	0.00122	-0.32	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
KIRP	cis	rs4639966	0.684	rs487177	ENSG00000255239.1	AP002954.6	-4.74	3.57e-06	0.00122	-0.37	-0.28	Systemic lupus erythematosus;	chr11:118786588	chr11:118688039~118690600:-
KIRP	cis	rs4578769	0.959	rs3911557	ENSG00000266850.1	RP11-370A5.1	-4.74	3.57e-06	0.00122	-0.36	-0.28	Eosinophil percentage of white cells;	chr18:22892600	chr18:22723491~22907721:-
KIRP	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-4.74	3.57e-06	0.00122	-0.3	-0.28	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
KIRP	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	4.74	3.57e-06	0.00122	0.26	0.28	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
KIRP	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	4.74	3.57e-06	0.00122	0.27	0.28	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
KIRP	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.74	3.58e-06	0.00122	0.51	0.28	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
KIRP	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-4.74	3.58e-06	0.00122	-0.3	-0.28	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
KIRP	cis	rs795484	0.507	rs2249624	ENSG00000275759.1	RP11-131L12.3	4.74	3.58e-06	0.00122	0.24	0.28	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118151264	chr12:118428281~118428870:+
KIRP	cis	rs2562456	0.917	rs10420016	ENSG00000268555.1	RP11-678G14.3	-4.74	3.58e-06	0.00122	-0.38	-0.28	Pain;	chr19:21505800	chr19:21570822~21587322:-
KIRP	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	4.74	3.58e-06	0.00122	0.3	0.28	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
KIRP	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-4.74	3.59e-06	0.00122	-0.34	-0.28	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
KIRP	cis	rs7289126	0.966	rs5995554	ENSG00000233360.4	Z83844.1	4.74	3.59e-06	0.00122	0.28	0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38234266	chr22:37641832~37658377:-
KIRP	cis	rs7289126	0.966	rs2267380	ENSG00000233360.4	Z83844.1	4.74	3.59e-06	0.00122	0.28	0.28	Mammographic density (dense area);Percent mammographic density;	chr22:38235762	chr22:37641832~37658377:-
KIRP	cis	rs962856	1	rs1601531	ENSG00000236605.1	AC023115.4	4.74	3.59e-06	0.00122	0.36	0.28	Pancreatic cancer;	chr2:67370972	chr2:67324627~67325304:+
KIRP	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
KIRP	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	4.74	3.59e-06	0.00122	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
KIRP	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	4.73	3.59e-06	0.00122	0.33	0.28	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
KIRP	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.73	3.6e-06	0.00122	-0.4	-0.28	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
KIRP	cis	rs9305354	1	rs2831493	ENSG00000232079.5	AL035610.1	4.73	3.6e-06	0.00122	0.38	0.28	Urinary albumin excretion;	chr21:28105365	chr21:28048404~28137611:+
KIRP	cis	rs7674212	0.512	rs2720462	ENSG00000230069.3	LRRC37A15P	-4.73	3.6e-06	0.00122	-0.27	-0.28	Type 2 diabetes;	chr4:103135053	chr4:102727274~102730721:-
KIRP	cis	rs9595908	0.63	rs4057297	ENSG00000212293.1	SNORA16	4.73	3.6e-06	0.00122	0.27	0.28	Body mass index;	chr13:32731612	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.63	rs1929939	ENSG00000212293.1	SNORA16	4.73	3.6e-06	0.00122	0.27	0.28	Body mass index;	chr13:32733547	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.669	rs7983309	ENSG00000212293.1	SNORA16	4.73	3.6e-06	0.00122	0.27	0.28	Body mass index;	chr13:32740254	chr13:32420390~32420516:-
KIRP	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-4.73	3.6e-06	0.00123	-0.24	-0.28	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
KIRP	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-4.73	3.6e-06	0.00123	-0.24	-0.28	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-4.73	3.61e-06	0.00123	-0.29	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
KIRP	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
KIRP	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-4.73	3.61e-06	0.00123	-0.32	-0.28	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
KIRP	cis	rs79040073	0.681	rs4775800	ENSG00000259531.2	RP11-295H24.3	4.73	3.61e-06	0.00123	0.41	0.28	Lung cancer in ever smokers;	chr15:49117270	chr15:49365124~49366685:-
KIRP	cis	rs1799949	1	rs8176083	ENSG00000279602.1	CTD-3014M21.1	-4.73	3.61e-06	0.00123	-0.26	-0.28	Menopause (age at onset);	chr17:43123134	chr17:43360041~43361361:-
KIRP	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-4.73	3.61e-06	0.00123	-0.3	-0.28	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
KIRP	cis	rs4694744	0.927	rs13108764	ENSG00000251284.2	RP13-644M16.1	-4.73	3.61e-06	0.00123	-0.29	-0.28	Bacteremia;	chr4:69469703	chr4:69125274~69126451:+
KIRP	cis	rs756699	0.822	rs244656	ENSG00000279469.1	RP11-215P8.2	-4.73	3.62e-06	0.00123	-0.39	-0.28	Multiple sclerosis;	chr5:134114136	chr5:134394360~134395008:-
KIRP	cis	rs964611	0.882	rs12442530	ENSG00000259488.2	RP11-154J22.1	-4.73	3.62e-06	0.00123	-0.27	-0.28	Metabolite levels (Pyroglutamine);	chr15:48288376	chr15:48312353~48331856:-
KIRP	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-4.73	3.62e-06	0.00123	-0.23	-0.28	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
KIRP	cis	rs4218	0.701	rs7174277	ENSG00000259732.1	RP11-59H7.3	-4.73	3.62e-06	0.00123	-0.28	-0.28	Social communication problems;	chr15:59150390	chr15:59121034~59133250:+
KIRP	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-4.73	3.62e-06	0.00123	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
KIRP	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	4.73	3.62e-06	0.00123	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	4.73	3.62e-06	0.00123	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
KIRP	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	4.73	3.62e-06	0.00123	0.5	0.28	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
KIRP	cis	rs2043112	0.929	rs13160161	ENSG00000249911.1	LINC01265	-4.73	3.62e-06	0.00123	-0.33	-0.28	Obesity-related traits;	chr5:39058254	chr5:38710367~38720273:-
KIRP	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	4.73	3.63e-06	0.00123	0.23	0.28	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
KIRP	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	4.73	3.63e-06	0.00123	0.56	0.28	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
KIRP	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-4.73	3.63e-06	0.00123	-0.35	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
KIRP	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	4.73	3.64e-06	0.00124	0.23	0.28	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
KIRP	cis	rs1799949	0.965	rs8176310	ENSG00000236383.6	LINC00854	-4.73	3.64e-06	0.00124	-0.21	-0.28	Menopause (age at onset);	chr17:43047896	chr17:43216941~43305976:-
KIRP	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	4.73	3.64e-06	0.00124	0.49	0.28	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
KIRP	cis	rs1552244	0.938	rs7647987	ENSG00000180385.7	EMC3-AS1	4.73	3.64e-06	0.00124	0.26	0.28	Alzheimer's disease;	chr3:10099012	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs3826	ENSG00000180385.7	EMC3-AS1	4.73	3.64e-06	0.00124	0.26	0.28	Alzheimer's disease;	chr3:10099381	chr3:9986893~10006990:+
KIRP	cis	rs9595908	0.669	rs4057298	ENSG00000212293.1	SNORA16	4.73	3.65e-06	0.00124	0.28	0.28	Body mass index;	chr13:32734227	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.655	rs2213377	ENSG00000212293.1	SNORA16	4.73	3.65e-06	0.00124	0.28	0.28	Body mass index;	chr13:32743076	chr13:32420390~32420516:-
KIRP	cis	rs728616	0.867	rs61860400	ENSG00000234382.2	RP11-40F6.1	-4.73	3.65e-06	0.00124	-0.45	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:80233664~80245367:+
KIRP	cis	rs728616	0.867	rs117139504	ENSG00000234382.2	RP11-40F6.1	-4.73	3.65e-06	0.00124	-0.45	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:80233664~80245367:+
KIRP	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	4.73	3.65e-06	0.00124	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
KIRP	cis	rs2109514	1	rs3919515	ENSG00000237813.3	AC002066.1	-4.73	3.65e-06	0.00124	-0.32	-0.28	Prevalent atrial fibrillation;	chr7:116511730	chr7:116238260~116499465:-
KIRP	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	4.73	3.65e-06	0.00124	0.26	0.28	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
KIRP	cis	rs962856	0.964	rs4671183	ENSG00000236605.1	AC023115.4	4.73	3.65e-06	0.00124	0.35	0.28	Pancreatic cancer;	chr2:67416545	chr2:67324627~67325304:+
KIRP	cis	rs4236601	0.72	rs7811851	ENSG00000237813.3	AC002066.1	-4.73	3.65e-06	0.00124	-0.35	-0.28	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116516677	chr7:116238260~116499465:-
KIRP	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	4.73	3.65e-06	0.00124	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
KIRP	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	4.73	3.65e-06	0.00124	0.43	0.28	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
KIRP	cis	rs35146811	0.695	rs858509	ENSG00000281827.1	AC005071.4	4.73	3.65e-06	0.00124	0.23	0.28	Coronary artery disease;	chr7:100223847	chr7:100344375~100344475:-
KIRP	cis	rs9659323	1	rs6680737	ENSG00000231365.4	RP11-418J17.1	-4.73	3.65e-06	0.00124	-0.25	-0.28	Body mass index;	chr1:118979008	chr1:119140396~119275973:+
KIRP	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-4.73	3.66e-06	0.00124	-0.36	-0.28	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
KIRP	cis	rs7267979	0.873	rs6037062	ENSG00000277938.1	RP5-965G21.3	4.73	3.66e-06	0.00124	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25229150~25231933:+
KIRP	cis	rs7674212	0.772	rs13113099	ENSG00000230069.3	LRRC37A15P	-4.73	3.66e-06	0.00124	-0.27	-0.28	Type 2 diabetes;	chr4:103052965	chr4:102727274~102730721:-
KIRP	cis	rs11148252	0.774	rs9536066	ENSG00000235660.1	LINC00345	-4.73	3.66e-06	0.00124	-0.29	-0.28	Lewy body disease;	chr13:52409846	chr13:52484161~52484680:-
KIRP	cis	rs308403	0.53	rs13135766	ENSG00000224786.1	CETN4P	-4.73	3.67e-06	0.00124	-0.39	-0.28	Blood protein levels;	chr4:122743272	chr4:122730548~122732193:-
KIRP	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	4.73	3.67e-06	0.00124	0.28	0.28	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
KIRP	cis	rs962856	0.897	rs644055	ENSG00000236780.4	AC078941.1	4.73	3.67e-06	0.00124	0.33	0.28	Pancreatic cancer;	chr2:67432539	chr2:67123357~67215319:-
KIRP	cis	rs950169	0.922	rs11635505	ENSG00000254414.1	RP11-182J1.1	-4.73	3.67e-06	0.00125	-0.35	-0.28	Schizophrenia;	chr15:84553803	chr15:84631898~84633987:-
KIRP	cis	rs6728642	1	rs7593754	ENSG00000230606.9	AC159540.1	4.73	3.67e-06	0.00125	0.3	0.28	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941807	chr2:97416165~97433527:-
KIRP	cis	rs889398	0.9	rs4783722	ENSG00000226232.7	RP11-419C5.2	4.73	3.67e-06	0.00125	0.2	0.28	Body mass index;	chr16:69548009	chr16:69976388~69996188:-
KIRP	cis	rs79040073	0.607	rs17400706	ENSG00000259531.2	RP11-295H24.3	4.73	3.68e-06	0.00125	0.39	0.28	Lung cancer in ever smokers;	chr15:49455148	chr15:49365124~49366685:-
KIRP	cis	rs886774	0.866	rs2395933	ENSG00000273055.1	CTB-13F3.1	-4.73	3.68e-06	0.00125	-0.17	-0.28	Ulcerative colitis;	chr7:107869207	chr7:107942116~107942740:+
KIRP	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-4.73	3.68e-06	0.00125	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
KIRP	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	4.73	3.68e-06	0.00125	0.41	0.28	Height;	chr6:109351533	chr6:109382795~109383666:+
KIRP	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	4.73	3.68e-06	0.00125	0.3	0.28	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
KIRP	cis	rs1044826	0.667	rs2083336	ENSG00000178631.7	ACTG1P1	4.73	3.68e-06	0.00125	0.3	0.28	Obesity-related traits;	chr3:139482430	chr3:139493809~139494937:+
KIRP	cis	rs1044826	0.642	rs1080371	ENSG00000178631.7	ACTG1P1	4.73	3.68e-06	0.00125	0.3	0.28	Obesity-related traits;	chr3:139492052	chr3:139493809~139494937:+
KIRP	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	4.73	3.68e-06	0.00125	0.37	0.28	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	4.73	3.68e-06	0.00125	0.37	0.28	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	4.73	3.68e-06	0.00125	0.37	0.28	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
KIRP	cis	rs1552244	1	rs12152512	ENSG00000180385.7	EMC3-AS1	4.73	3.68e-06	0.00125	0.26	0.28	Alzheimer's disease;	chr3:10102086	chr3:9986893~10006990:+
KIRP	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-4.73	3.68e-06	0.00125	-0.35	-0.28	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
KIRP	cis	rs35146811	0.735	rs1637001	ENSG00000078319.8	PMS2P1	4.73	3.68e-06	0.00125	0.36	0.28	Coronary artery disease;	chr7:100210528	chr7:100320992~100341908:-
KIRP	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	4.73	3.69e-06	0.00125	0.37	0.28	Height;	chr6:109403287	chr6:109382795~109383666:+
KIRP	cis	rs703842	1	rs3825079	ENSG00000270039.1	RP11-571M6.17	-4.73	3.69e-06	0.00125	-0.27	-0.28	Multiple sclerosis;	chr12:57809571	chr12:57803838~57804415:+
KIRP	cis	rs295490	0.748	rs56993164	ENSG00000272656.1	RP11-219D15.3	4.73	3.69e-06	0.00125	0.47	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139388391	chr3:139349024~139349371:-
KIRP	cis	rs6832769	0.922	rs28665088	ENSG00000272969.1	RP11-528I4.2	4.73	3.69e-06	0.00125	0.28	0.28	Personality dimensions;	chr4:55384913	chr4:55547112~55547889:+
KIRP	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	4.73	3.69e-06	0.00125	0.36	0.28	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
KIRP	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	4.73	3.69e-06	0.00125	0.36	0.28	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
KIRP	cis	rs11673344	0.504	rs10403975	ENSG00000226686.6	LINC01535	4.73	3.69e-06	0.00125	0.34	0.28	Obesity-related traits;	chr19:37082172	chr19:37251912~37265535:+
KIRP	cis	rs11673344	0.504	rs2385375	ENSG00000226686.6	LINC01535	4.73	3.69e-06	0.00125	0.34	0.28	Obesity-related traits;	chr19:37087620	chr19:37251912~37265535:+
KIRP	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-4.73	3.7e-06	0.00125	-0.28	-0.28	Height;	chr14:75122121	chr14:75011269~75012851:-
KIRP	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-4.73	3.7e-06	0.00125	-0.24	-0.28	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-4.73	3.7e-06	0.00125	-0.24	-0.28	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
KIRP	cis	rs5006884	0.526	rs12808394	ENSG00000167355.6	AC104389.28	-4.73	3.7e-06	0.00125	-0.34	-0.28	Fetal hemoglobin levels;	chr11:5361551	chr11:5304976~5505652:-
KIRP	cis	rs5006884	0.526	rs12802814	ENSG00000167355.6	AC104389.28	-4.73	3.7e-06	0.00125	-0.34	-0.28	Fetal hemoglobin levels;	chr11:5361574	chr11:5304976~5505652:-
KIRP	cis	rs116095464	0.558	rs62344300	ENSG00000248925.1	CTD-2083E4.6	4.73	3.7e-06	0.00125	0.42	0.28	Breast cancer;	chr5:246221	chr5:269858~271516:-
KIRP	cis	rs35146811	0.735	rs858505	ENSG00000281827.1	AC005071.4	4.73	3.7e-06	0.00126	0.23	0.28	Coronary artery disease;	chr7:100221954	chr7:100344375~100344475:-
KIRP	cis	rs783540	0.5	rs1313494	ENSG00000278603.1	RP13-608F4.5	-4.73	3.71e-06	0.00126	-0.38	-0.28	Schizophrenia;	chr15:82605530	chr15:82472203~82472426:+
KIRP	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-4.73	3.71e-06	0.00126	-0.24	-0.28	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
KIRP	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-4.73	3.71e-06	0.00126	-0.24	-0.28	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
KIRP	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-4.73	3.72e-06	0.00126	-0.24	-0.28	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
KIRP	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	4.73	3.72e-06	0.00126	0.39	0.28	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
KIRP	cis	rs79349575	0.783	rs11079844	ENSG00000270781.1	RP11-501C14.9	-4.73	3.72e-06	0.00126	-0.3	-0.28	Type 2 diabetes;	chr17:48950972	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs62078372	ENSG00000270781.1	RP11-501C14.9	-4.73	3.72e-06	0.00126	-0.3	-0.28	Type 2 diabetes;	chr17:48951627	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs12602933	ENSG00000270781.1	RP11-501C14.9	-4.73	3.72e-06	0.00126	-0.3	-0.28	Type 2 diabetes;	chr17:48951918	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs4794003	ENSG00000270781.1	RP11-501C14.9	-4.73	3.72e-06	0.00126	-0.3	-0.28	Type 2 diabetes;	chr17:48952542	chr17:48899131~48899748:+
KIRP	cis	rs79349575	0.783	rs12602746	ENSG00000270781.1	RP11-501C14.9	-4.73	3.72e-06	0.00126	-0.3	-0.28	Type 2 diabetes;	chr17:48954379	chr17:48899131~48899748:+
KIRP	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-4.73	3.72e-06	0.00126	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
KIRP	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	4.73	3.72e-06	0.00126	0.35	0.28	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
KIRP	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	4.73	3.72e-06	0.00126	0.4	0.28	Height;	chr6:109694120	chr6:109382795~109383666:+
KIRP	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-4.73	3.72e-06	0.00126	-0.33	-0.28	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
KIRP	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	4.73	3.72e-06	0.00126	0.27	0.28	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
KIRP	cis	rs4236601	0.72	rs17588172	ENSG00000237813.3	AC002066.1	4.73	3.73e-06	0.00126	0.35	0.28	Glaucoma (primary open-angle);Intraocular pressure;	chr7:116513961	chr7:116238260~116499465:-
KIRP	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	4.73	3.73e-06	0.00126	0.33	0.28	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
KIRP	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	4.73	3.73e-06	0.00126	0.33	0.28	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
KIRP	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-4.73	3.73e-06	0.00126	-0.36	-0.28	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
KIRP	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-4.73	3.73e-06	0.00126	-0.36	-0.28	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
KIRP	cis	rs35146811	0.625	rs2906645	ENSG00000281827.1	AC005071.4	4.73	3.74e-06	0.00127	0.23	0.28	Coronary artery disease;	chr7:100220236	chr7:100344375~100344475:-
KIRP	cis	rs35146811	0.735	rs858506	ENSG00000281827.1	AC005071.4	4.73	3.74e-06	0.00127	0.23	0.28	Coronary artery disease;	chr7:100222427	chr7:100344375~100344475:-
KIRP	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	4.73	3.74e-06	0.00127	0.26	0.28	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
KIRP	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	4.73	3.75e-06	0.00127	0.27	0.28	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
KIRP	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-4.73	3.75e-06	0.00127	-0.41	-0.28	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
KIRP	cis	rs2278170	0.962	rs189118	ENSG00000225101.4	OR52K3P	-4.73	3.75e-06	0.00127	-0.34	-0.28	Amyotrophic lateral sclerosis;	chr11:4455167	chr11:4474813~4475755:+
KIRP	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-4.73	3.75e-06	0.00127	-0.54	-0.28	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
KIRP	cis	rs875971	0.502	rs1796227	ENSG00000236529.1	RP13-254B10.1	-4.73	3.75e-06	0.00127	-0.26	-0.28	Aortic root size;	chr7:66622032	chr7:65840212~65840596:+
KIRP	cis	rs8049040	0.547	rs12934168	ENSG00000260886.1	TAT-AS1	4.73	3.75e-06	0.00127	0.36	0.28	Blood protein levels;	chr16:71402875	chr16:71565789~71578187:+
KIRP	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	4.73	3.75e-06	0.00127	0.38	0.28	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
KIRP	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	4.73	3.75e-06	0.00127	0.38	0.28	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
KIRP	cis	rs4689592	0.523	rs6446565	ENSG00000245468.3	RP11-367J11.3	4.73	3.75e-06	0.00127	0.3	0.28	Monocyte percentage of white cells;	chr4:7072300	chr4:7094571~7103385:-
KIRP	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-4.73	3.75e-06	0.00127	-0.3	-0.28	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
KIRP	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-4.73	3.76e-06	0.00127	-0.42	-0.28	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
KIRP	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	4.72	3.76e-06	0.00127	0.37	0.28	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
KIRP	cis	rs4072705	1	rs7874367	ENSG00000224020.1	MIR181A2HG	4.72	3.76e-06	0.00127	0.28	0.28	Menarche (age at onset);	chr9:124615501	chr9:124658467~124698631:+
KIRP	cis	rs2235642	1	rs2076438	ENSG00000280231.1	LA16c-380F5.3	-4.72	3.76e-06	0.00127	-0.35	-0.28	Coronary artery disease;	chr16:1534617	chr16:1553655~1554130:-
KIRP	cis	rs6005807	0.543	rs6005866	ENSG00000226471.5	CTA-292E10.6	-4.72	3.77e-06	0.00127	-0.44	-0.28	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28766952	chr22:28800683~28848559:+
KIRP	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	4.72	3.77e-06	0.00127	0.34	0.28	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
KIRP	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	4.72	3.77e-06	0.00127	0.27	0.28	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
KIRP	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.72	3.77e-06	0.00128	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
KIRP	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.72	3.77e-06	0.00128	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
KIRP	cis	rs1858037	0.867	rs871974	ENSG00000237979.1	AC007389.1	-4.72	3.77e-06	0.00128	-0.31	-0.28	Rheumatoid arthritis;	chr2:65330153	chr2:65500993~65502138:-
KIRP	cis	rs12039431	0.748	rs6692773	ENSG00000232273.1	FTH1P1	4.72	3.77e-06	0.00128	0.37	0.28	Epithelial ovarian cancer;	chr1:37559806	chr1:37544763~37545294:+
KIRP	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-4.72	3.77e-06	0.00128	-0.32	-0.28	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-4.72	3.77e-06	0.00128	-0.32	-0.28	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
KIRP	cis	rs11148252	0.74	rs9596648	ENSG00000235660.1	LINC00345	4.72	3.78e-06	0.00128	0.3	0.28	Lewy body disease;	chr13:52360434	chr13:52484161~52484680:-
KIRP	cis	rs911119	1	rs6515375	ENSG00000270001.1	RP11-218C14.8	-4.72	3.78e-06	0.00128	-0.34	-0.28	Chronic kidney disease;	chr20:23630204	chr20:23631826~23632316:-
KIRP	cis	rs1577917	0.56	rs12193777	ENSG00000220563.1	PKMP3	4.72	3.78e-06	0.00128	0.21	0.28	Response to antipsychotic treatment;	chr6:85536991	chr6:85659892~85660606:-
KIRP	cis	rs1577917	0.655	rs9444351	ENSG00000220563.1	PKMP3	4.72	3.78e-06	0.00128	0.21	0.28	Response to antipsychotic treatment;	chr6:85538081	chr6:85659892~85660606:-
KIRP	cis	rs1799949	0.965	rs33961729	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43135907	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs11657835	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43139936	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs1135214	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43140306	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs4793212	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43150733	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs34534709	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43150923	chr17:43360041~43361361:-
KIRP	cis	rs1799949	1	rs34059614	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.78e-06	0.00128	-0.26	-0.28	Menopause (age at onset);	chr17:43151054	chr17:43360041~43361361:-
KIRP	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-4.72	3.78e-06	0.00128	-0.4	-0.28	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
KIRP	cis	rs6840258	0.64	rs4577539	ENSG00000251411.1	RP11-397E7.4	-4.72	3.78e-06	0.00128	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87202806	chr4:86913266~86914817:-
KIRP	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	4.72	3.79e-06	0.00128	0.25	0.28	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	4.72	3.79e-06	0.00128	0.25	0.28	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
KIRP	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	4.72	3.79e-06	0.00128	0.25	0.28	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
KIRP	cis	rs7225151	1	rs4456560	ENSG00000234327.6	AC012146.7	-4.72	3.79e-06	0.00128	-0.37	-0.28	Alzheimer's disease (late onset);	chr17:5237104	chr17:5111468~5115004:+
KIRP	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-4.72	3.79e-06	0.00128	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
KIRP	cis	rs6840258	0.64	rs28505236	ENSG00000251411.1	RP11-397E7.4	-4.72	3.79e-06	0.00128	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87172309	chr4:86913266~86914817:-
KIRP	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.72	3.8e-06	0.00128	-0.29	-0.28	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
KIRP	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	4.72	3.8e-06	0.00128	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
KIRP	cis	rs2043112	0.965	rs6864478	ENSG00000249911.1	LINC01265	4.72	3.8e-06	0.00128	0.32	0.28	Obesity-related traits;	chr5:38922724	chr5:38710367~38720273:-
KIRP	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-4.72	3.8e-06	0.00128	-0.23	-0.28	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
KIRP	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	4.72	3.8e-06	0.00128	0.3	0.28	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
KIRP	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	4.72	3.8e-06	0.00128	0.36	0.28	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
KIRP	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-4.72	3.8e-06	0.00128	-0.31	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
KIRP	cis	rs10266483	0.774	rs1404679	ENSG00000227986.1	TRIM60P18	4.72	3.8e-06	0.00128	0.22	0.28	Response to statin therapy;	chr7:64358254	chr7:64355078~64356199:+
KIRP	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	4.72	3.8e-06	0.00129	0.23	0.28	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
KIRP	cis	rs68170813	0.641	rs34084719	ENSG00000241764.3	AC002467.7	4.72	3.81e-06	0.00129	0.33	0.28	Coronary artery disease;	chr7:107454782	chr7:107742817~107744581:-
KIRP	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	4.72	3.81e-06	0.00129	0.59	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
KIRP	cis	rs1106529	0.51	rs7526102	ENSG00000231365.4	RP11-418J17.1	-4.72	3.81e-06	0.00129	-0.3	-0.28	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119140396~119275973:+
KIRP	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	4.72	3.81e-06	0.00129	0.24	0.28	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
KIRP	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-4.72	3.81e-06	0.00129	-0.29	-0.28	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
KIRP	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-4.72	3.81e-06	0.00129	-0.29	-0.28	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
KIRP	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	4.72	3.82e-06	0.00129	0.18	0.28	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
KIRP	cis	rs10912872	0.659	rs7518648	ENSG00000225704.2	RP4-798A17.5	4.72	3.82e-06	0.00129	0.26	0.28	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171344602	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.634	rs2235508	ENSG00000225704.2	RP4-798A17.5	4.72	3.82e-06	0.00129	0.26	0.28	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171344796	chr1:171345089~171345320:+
KIRP	cis	rs10912872	0.634	rs2235510	ENSG00000225704.2	RP4-798A17.5	4.72	3.82e-06	0.00129	0.26	0.28	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171345003	chr1:171345089~171345320:+
KIRP	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-4.72	3.82e-06	0.00129	-0.36	-0.28	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
KIRP	cis	rs2504916	0.668	rs2484240	ENSG00000230234.1	RP1-276N6.2	-4.72	3.82e-06	0.00129	-0.3	-0.28	Response to hepatitis C treatment;	chr6:160312807	chr6:160272617~160276130:+
KIRP	cis	rs1185460	0.967	rs1784460	ENSG00000272186.1	RP11-110I1.13	4.72	3.82e-06	0.00129	0.28	0.28	Coronary artery disease;	chr11:119067660	chr11:119067374~119067698:-
KIRP	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-4.72	3.83e-06	0.00129	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
KIRP	cis	rs2235642	1	rs2235642	ENSG00000280231.1	LA16c-380F5.3	-4.72	3.83e-06	0.00129	-0.35	-0.28	Coronary artery disease;	chr16:1534865	chr16:1553655~1554130:-
KIRP	cis	rs4694744	0.54	rs7684949	ENSG00000250696.4	RP11-704M14.1	4.72	3.83e-06	0.00129	0.38	0.28	Bacteremia;	chr4:69445938	chr4:69182100~69216766:+
KIRP	cis	rs453301	0.658	rs9650616	ENSG00000253981.4	ALG1L13P	-4.72	3.83e-06	0.00129	-0.21	-0.28	Joint mobility (Beighton score);	chr8:9011689	chr8:8236003~8244667:-
KIRP	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-4.72	3.83e-06	0.00129	-0.3	-0.28	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
KIRP	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	4.72	3.83e-06	0.00129	0.31	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
KIRP	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	4.72	3.83e-06	0.00129	0.28	0.28	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
KIRP	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-4.72	3.84e-06	0.0013	-0.23	-0.28	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
KIRP	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-4.72	3.84e-06	0.0013	-0.35	-0.28	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
KIRP	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	4.72	3.84e-06	0.0013	0.28	0.28	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
KIRP	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	4.72	3.84e-06	0.0013	0.28	0.28	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
KIRP	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	4.72	3.84e-06	0.0013	0.28	0.28	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
KIRP	cis	rs9915657	0.715	rs34624256	ENSG00000234899.8	SOX9-AS1	-4.72	3.84e-06	0.0013	-0.26	-0.28	Thyroid hormone levels;	chr17:72109707	chr17:72034107~72237203:-
KIRP	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	4.72	3.84e-06	0.0013	0.34	0.28	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
KIRP	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	4.72	3.84e-06	0.0013	0.34	0.28	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
KIRP	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	4.72	3.84e-06	0.0013	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
KIRP	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-4.72	3.84e-06	0.0013	-0.3	-0.28	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
KIRP	cis	rs1183201	0.505	rs1165201	ENSG00000242387.1	HIST1H2APS2	4.72	3.85e-06	0.0013	0.34	0.28	Uric acid levels;	chr6:25874595	chr6:25882026~25882395:-
KIRP	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	4.72	3.85e-06	0.0013	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
KIRP	cis	rs6942407	0.64	rs4728690	ENSG00000224046.1	AC005076.5	-4.72	3.85e-06	0.0013	-0.27	-0.28	Food allergy;	chr7:87224688	chr7:87151423~87152420:-
KIRP	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	4.72	3.85e-06	0.0013	0.3	0.28	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
KIRP	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	4.72	3.85e-06	0.0013	0.25	0.28	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
KIRP	cis	rs11673344	0.504	rs10403728	ENSG00000226686.6	LINC01535	4.72	3.85e-06	0.0013	0.34	0.28	Obesity-related traits;	chr19:37091569	chr19:37251912~37265535:+
KIRP	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-4.72	3.85e-06	0.0013	-0.53	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
KIRP	cis	rs28386778	0.965	rs2854154	ENSG00000240280.5	TCAM1P	4.72	3.85e-06	0.0013	0.35	0.28	Prudent dietary pattern;	chr17:63904336	chr17:63849292~63864379:+
KIRP	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	4.72	3.85e-06	0.0013	0.18	0.28	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
KIRP	cis	rs1075265	0.584	rs7590846	ENSG00000272156.1	RP11-477N3.1	4.72	3.85e-06	0.0013	0.3	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54082554~54085066:+
KIRP	cis	rs763121	0.853	rs5757231	ENSG00000273076.1	RP3-508I15.22	-4.72	3.86e-06	0.0013	-0.28	-0.28	Menopause (age at onset);	chr22:38675653	chr22:38743495~38743910:+
KIRP	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-4.72	3.86e-06	0.0013	-0.23	-0.28	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
KIRP	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-4.72	3.86e-06	0.0013	-0.23	-0.28	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
KIRP	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-4.72	3.86e-06	0.0013	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
KIRP	cis	rs886774	0.932	rs6964972	ENSG00000273055.1	CTB-13F3.1	-4.72	3.86e-06	0.0013	-0.17	-0.28	Ulcerative colitis;	chr7:107859551	chr7:107942116~107942740:+
KIRP	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.72	3.86e-06	0.0013	0.26	0.28	Height;	chr4:55537960	chr4:55547112~55547889:+
KIRP	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-4.72	3.87e-06	0.0013	-0.38	-0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
KIRP	cis	rs7674212	0.541	rs2720448	ENSG00000230069.3	LRRC37A15P	-4.72	3.87e-06	0.0013	-0.26	-0.28	Type 2 diabetes;	chr4:103109432	chr4:102727274~102730721:-
KIRP	cis	rs7674212	0.541	rs2623064	ENSG00000230069.3	LRRC37A15P	-4.72	3.87e-06	0.0013	-0.26	-0.28	Type 2 diabetes;	chr4:103109635	chr4:102727274~102730721:-
KIRP	cis	rs2839627	0.564	rs2839595	ENSG00000225218.1	AP001628.6	4.72	3.87e-06	0.0013	0.27	0.28	Information processing speed;	chr21:42878856	chr21:42831040~42836477:-
KIRP	cis	rs2839627	0.513	rs67571721	ENSG00000225218.1	AP001628.6	4.72	3.87e-06	0.0013	0.27	0.28	Information processing speed;	chr21:42886336	chr21:42831040~42836477:-
KIRP	cis	rs2839627	0.638	rs60342559	ENSG00000225218.1	AP001628.6	4.72	3.87e-06	0.0013	0.27	0.28	Information processing speed;	chr21:42889941	chr21:42831040~42836477:-
KIRP	cis	rs2839627	0.683	rs6586259	ENSG00000225218.1	AP001628.6	4.72	3.87e-06	0.0013	0.27	0.28	Information processing speed;	chr21:42895156	chr21:42831040~42836477:-
KIRP	cis	rs2839627	0.638	rs9974287	ENSG00000225218.1	AP001628.6	4.72	3.87e-06	0.0013	0.27	0.28	Information processing speed;	chr21:42896893	chr21:42831040~42836477:-
KIRP	cis	rs875971	0.545	rs1909508	ENSG00000236529.1	RP13-254B10.1	4.72	3.87e-06	0.0013	0.25	0.28	Aortic root size;	chr7:66301366	chr7:65840212~65840596:+
KIRP	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	4.72	3.87e-06	0.00131	0.37	0.28	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
KIRP	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-4.72	3.87e-06	0.00131	-0.34	-0.28	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
KIRP	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-4.72	3.87e-06	0.00131	-0.34	-0.28	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
KIRP	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	4.72	3.87e-06	0.00131	0.22	0.28	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
KIRP	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	4.72	3.87e-06	0.00131	0.22	0.28	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
KIRP	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-4.72	3.88e-06	0.00131	-0.35	-0.28	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
KIRP	cis	rs911119	1	rs6114209	ENSG00000270001.1	RP11-218C14.8	-4.72	3.88e-06	0.00131	-0.34	-0.28	Chronic kidney disease;	chr20:23641629	chr20:23631826~23632316:-
KIRP	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	4.72	3.88e-06	0.00131	0.3	0.28	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
KIRP	cis	rs1799949	1	rs11652332	ENSG00000279602.1	CTD-3014M21.1	-4.72	3.88e-06	0.00131	-0.26	-0.28	Menopause (age at onset);	chr17:43143472	chr17:43360041~43361361:-
KIRP	cis	rs1577917	0.655	rs7766485	ENSG00000220563.1	PKMP3	4.72	3.88e-06	0.00131	0.21	0.28	Response to antipsychotic treatment;	chr6:85553837	chr6:85659892~85660606:-
KIRP	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-4.72	3.88e-06	0.00131	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
KIRP	cis	rs35146811	0.735	rs7811662	ENSG00000078319.8	PMS2P1	-4.72	3.88e-06	0.00131	-0.36	-0.28	Coronary artery disease;	chr7:100194985	chr7:100320992~100341908:-
KIRP	cis	rs962856	1	rs4671794	ENSG00000236605.1	AC023115.4	4.72	3.89e-06	0.00131	0.35	0.28	Pancreatic cancer;	chr2:67339526	chr2:67324627~67325304:+
KIRP	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-4.72	3.89e-06	0.00131	-0.29	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
KIRP	cis	rs9543976	1	rs2031236	ENSG00000261105.4	LMO7-AS1	-4.72	3.89e-06	0.00131	-0.48	-0.28	Diabetic retinopathy;	chr13:75595641	chr13:75604700~75635994:-
KIRP	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	4.72	3.89e-06	0.00131	0.25	0.28	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
KIRP	cis	rs17301013	0.794	rs1793293	ENSG00000227373.4	RP11-160H22.5	-4.72	3.9e-06	0.00131	-0.39	-0.28	Systemic lupus erythematosus;	chr1:174774451	chr1:174115300~174160004:-
KIRP	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-4.72	3.9e-06	0.00131	-0.34	-0.28	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
KIRP	cis	rs42648	0.819	rs2285399	ENSG00000225498.1	AC002064.5	4.72	3.91e-06	0.00132	0.21	0.28	Homocysteine levels;	chr7:90340564	chr7:90312496~90322592:+
KIRP	cis	rs1564271	0.704	rs1780191	ENSG00000279212.1	RP13-16H11.8	4.72	3.91e-06	0.00132	0.32	0.28	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr10:26705483	chr10:26695091~26697625:-
KIRP	cis	rs6502050	0.835	rs7502078	ENSG00000266654.1	RP11-1376P16.1	-4.72	3.91e-06	0.00132	-0.27	-0.28	Life satisfaction;	chr17:82174003	chr17:82160056~82160452:+
KIRP	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	4.72	3.91e-06	0.00132	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
KIRP	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	4.72	3.91e-06	0.00132	0.57	0.28	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	4.72	3.91e-06	0.00132	0.57	0.28	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	4.72	3.91e-06	0.00132	0.57	0.28	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	4.72	3.91e-06	0.00132	0.57	0.28	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
KIRP	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-4.72	3.92e-06	0.00132	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
KIRP	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	4.72	3.92e-06	0.00132	0.32	0.28	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
KIRP	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	4.72	3.92e-06	0.00132	0.32	0.28	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
KIRP	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	4.72	3.92e-06	0.00132	0.32	0.28	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
KIRP	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	4.72	3.92e-06	0.00132	0.32	0.28	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
KIRP	cis	rs10050311	0.698	rs78818211	ENSG00000251411.1	RP11-397E7.4	-4.72	3.92e-06	0.00132	-0.33	-0.28	Insulin-related traits;	chr4:86715235	chr4:86913266~86914817:-
KIRP	cis	rs453301	0.658	rs6986044	ENSG00000253981.4	ALG1L13P	-4.72	3.92e-06	0.00132	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9017276	chr8:8236003~8244667:-
KIRP	cis	rs9450351	0.744	rs6906618	ENSG00000203875.9	SNHG5	-4.72	3.93e-06	0.00132	-0.49	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85660950~85678736:-
KIRP	cis	rs9595908	0.686	rs7988353	ENSG00000212293.1	SNORA16	4.72	3.93e-06	0.00132	0.26	0.28	Body mass index;	chr13:32760250	chr13:32420390~32420516:-
KIRP	cis	rs9915657	0.87	rs4140902	ENSG00000234899.8	SOX9-AS1	-4.72	3.93e-06	0.00132	-0.26	-0.28	Thyroid hormone levels;	chr17:72137609	chr17:72034107~72237203:-
KIRP	cis	rs9915657	0.87	rs4140903	ENSG00000234899.8	SOX9-AS1	-4.72	3.93e-06	0.00132	-0.26	-0.28	Thyroid hormone levels;	chr17:72137630	chr17:72034107~72237203:-
KIRP	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	4.72	3.93e-06	0.00132	0.39	0.28	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
KIRP	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	4.72	3.93e-06	0.00132	0.34	0.28	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
KIRP	cis	rs2562456	0.874	rs9304986	ENSG00000268555.1	RP11-678G14.3	-4.72	3.93e-06	0.00132	-0.38	-0.28	Pain;	chr19:21499260	chr19:21570822~21587322:-
KIRP	cis	rs875971	0.545	rs2420612	ENSG00000236529.1	RP13-254B10.1	4.72	3.93e-06	0.00132	0.25	0.28	Aortic root size;	chr7:66536825	chr7:65840212~65840596:+
KIRP	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	4.71	3.93e-06	0.00132	0.3	0.28	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
KIRP	cis	rs7809615	0.515	rs11772470	ENSG00000244219.5	GS1-259H13.2	-4.71	3.93e-06	0.00132	-0.32	-0.28	Blood metabolite ratios;	chr7:99583473	chr7:99598066~99610813:+
KIRP	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	4.71	3.94e-06	0.00132	0.26	0.28	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
KIRP	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	4.71	3.94e-06	0.00133	0.28	0.28	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
KIRP	cis	rs453301	0.686	rs7017868	ENSG00000253981.4	ALG1L13P	-4.71	3.94e-06	0.00133	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9015783	chr8:8236003~8244667:-
KIRP	cis	rs453301	0.686	rs3895823	ENSG00000253981.4	ALG1L13P	-4.71	3.94e-06	0.00133	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9016136	chr8:8236003~8244667:-
KIRP	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	4.71	3.94e-06	0.00133	0.4	0.28	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
KIRP	cis	rs2880765	0.545	rs17553734	ENSG00000259630.2	CTD-2262B20.1	4.71	3.94e-06	0.00133	0.27	0.28	Coronary artery disease;	chr15:85469828	chr15:85415228~85415633:+
KIRP	cis	rs2880765	0.566	rs17553790	ENSG00000259630.2	CTD-2262B20.1	4.71	3.94e-06	0.00133	0.27	0.28	Coronary artery disease;	chr15:85470434	chr15:85415228~85415633:+
KIRP	cis	rs738322	0.967	rs132985	ENSG00000233360.4	Z83844.1	4.71	3.94e-06	0.00133	0.28	0.28	Cutaneous nevi;	chr22:38167464	chr22:37641832~37658377:-
KIRP	cis	rs10266483	0.774	rs10253630	ENSG00000227986.1	TRIM60P18	4.71	3.95e-06	0.00133	0.22	0.28	Response to statin therapy;	chr7:64366962	chr7:64355078~64356199:+
KIRP	cis	rs4128705	0.959	rs12186312	ENSG00000249049.1	RP11-763F8.1	-4.71	3.95e-06	0.00133	-0.27	-0.28	Amyotrophic lateral sclerosis (sporadic);	chr4:91368188	chr4:91319034~91325306:-
KIRP	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	4.71	3.95e-06	0.00133	0.38	0.28	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
KIRP	cis	rs1044826	0.647	rs4683463	ENSG00000178631.7	ACTG1P1	4.71	3.95e-06	0.00133	0.3	0.28	Obesity-related traits;	chr3:139478104	chr3:139493809~139494937:+
KIRP	cis	rs2446066	0.659	rs2272002	ENSG00000257379.1	RP11-793H13.8	4.71	3.96e-06	0.00133	0.37	0.28	Red blood cell count;	chr12:53424132	chr12:53441741~53467528:+
KIRP	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-4.71	3.96e-06	0.00133	-0.28	-0.28	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
KIRP	cis	rs35146811	0.538	rs3823642	ENSG00000078319.8	PMS2P1	-4.71	3.96e-06	0.00133	-0.35	-0.28	Coronary artery disease;	chr7:100198449	chr7:100320992~100341908:-
KIRP	cis	rs9305354	0.908	rs2831492	ENSG00000232079.5	AL035610.1	4.71	3.96e-06	0.00133	0.38	0.28	Urinary albumin excretion;	chr21:28105085	chr21:28048404~28137611:+
KIRP	cis	rs9305354	1	rs7275716	ENSG00000232079.5	AL035610.1	4.71	3.96e-06	0.00133	0.38	0.28	Urinary albumin excretion;	chr21:28105473	chr21:28048404~28137611:+
KIRP	cis	rs9926296	0.609	rs4785710	ENSG00000260259.1	RP11-368I7.4	4.71	3.96e-06	0.00133	0.21	0.28	Vitiligo;	chr16:89730348	chr16:89682620~89686569:-
KIRP	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	4.71	3.96e-06	0.00133	0.35	0.28	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	4.71	3.96e-06	0.00133	0.35	0.28	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
KIRP	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	4.71	3.96e-06	0.00133	0.35	0.28	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
KIRP	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-4.71	3.96e-06	0.00133	-0.26	-0.28	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
KIRP	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-4.71	3.96e-06	0.00133	-0.26	-0.28	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
KIRP	cis	rs1044826	0.642	rs6787649	ENSG00000178631.7	ACTG1P1	4.71	3.97e-06	0.00133	0.3	0.28	Obesity-related traits;	chr3:139474479	chr3:139493809~139494937:+
KIRP	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-4.71	3.97e-06	0.00133	-0.23	-0.28	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
KIRP	cis	rs910316	0.737	rs108621	ENSG00000279594.1	RP11-950C14.10	-4.71	3.97e-06	0.00133	-0.27	-0.28	Height;	chr14:75013934	chr14:75011269~75012851:-
KIRP	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	4.71	3.97e-06	0.00133	0.3	0.28	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
KIRP	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	4.71	3.97e-06	0.00133	0.36	0.28	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
KIRP	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-4.71	3.97e-06	0.00133	-0.36	-0.28	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
KIRP	cis	rs2299587	0.729	rs6586676	ENSG00000254054.2	RP11-156K13.3	4.71	3.97e-06	0.00133	0.32	0.28	Economic and political preferences;	chr8:17999936	chr8:17905756~17907887:+
KIRP	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	4.71	3.97e-06	0.00134	0.28	0.28	Height;	chr14:75068316	chr14:75011269~75012851:-
KIRP	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	4.71	3.97e-06	0.00134	0.24	0.28	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
KIRP	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	4.71	3.97e-06	0.00134	0.35	0.28	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
KIRP	cis	rs79040073	0.607	rs17479289	ENSG00000259531.2	RP11-295H24.3	4.71	3.97e-06	0.00134	0.36	0.28	Lung cancer in ever smokers;	chr15:49456416	chr15:49365124~49366685:-
KIRP	cis	rs11556924	1	rs11556924	ENSG00000233559.1	AC016831.7	4.71	3.98e-06	0.00134	0.32	0.28	Platelet count;Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;Plateletcrit;Systolic blood pressure;Coronary heart disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Coronary artery disease;White blood cell count (basophil);	chr7:130023656	chr7:130853720~130928649:+
KIRP	cis	rs6479891	1	rs4745729	ENSG00000238280.1	RP11-436D10.3	-4.71	3.98e-06	0.00134	-0.4	-0.28	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:62793562~62805887:-
KIRP	cis	rs6479891	1	rs12416349	ENSG00000238280.1	RP11-436D10.3	-4.71	3.98e-06	0.00134	-0.4	-0.28	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:62793562~62805887:-
KIRP	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-4.71	3.98e-06	0.00134	-0.31	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-4.71	3.98e-06	0.00134	-0.31	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
KIRP	cis	rs910316	0.789	rs175457	ENSG00000279594.1	RP11-950C14.10	-4.71	3.98e-06	0.00134	-0.27	-0.28	Height;	chr14:75117804	chr14:75011269~75012851:-
KIRP	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-4.71	3.98e-06	0.00134	-0.23	-0.28	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
KIRP	cis	rs4128705	0.959	rs12508304	ENSG00000249049.1	RP11-763F8.1	4.71	3.98e-06	0.00134	0.27	0.28	Amyotrophic lateral sclerosis (sporadic);	chr4:91366033	chr4:91319034~91325306:-
KIRP	cis	rs5760092	0.842	rs5751763	ENSG00000228039.3	KB-1125A3.10	4.71	3.98e-06	0.00134	0.42	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23963780~23964374:+
KIRP	cis	rs7508	0.535	rs13261745	ENSG00000254054.2	RP11-156K13.3	4.71	3.98e-06	0.00134	0.31	0.28	Atrial fibrillation;	chr8:17929496	chr8:17905756~17907887:+
KIRP	cis	rs7299940	1	rs7299940	ENSG00000256250.1	RP11-989F5.1	-4.71	3.98e-06	0.00134	-0.27	-0.28	Panic disorder;	chr12:130906209	chr12:130810606~130812438:+
KIRP	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-4.71	3.99e-06	0.00134	-0.23	-0.28	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
KIRP	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	4.71	3.99e-06	0.00134	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	4.71	3.99e-06	0.00134	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	4.71	3.99e-06	0.00134	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	4.71	3.99e-06	0.00134	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	4.71	3.99e-06	0.00134	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
KIRP	cis	rs728616	0.867	rs726289	ENSG00000234382.2	RP11-40F6.1	-4.71	3.99e-06	0.00134	-0.42	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:80233664~80245367:+
KIRP	cis	rs9305354	1	rs7280205	ENSG00000232079.5	AL035610.1	4.71	3.99e-06	0.00134	0.38	0.28	Urinary albumin excretion;	chr21:28104037	chr21:28048404~28137611:+
KIRP	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-4.71	4e-06	0.00134	-0.41	-0.28	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
KIRP	cis	rs911119	1	rs6036478	ENSG00000270001.1	RP11-218C14.8	-4.71	4e-06	0.00134	-0.34	-0.28	Chronic kidney disease;	chr20:23630722	chr20:23631826~23632316:-
KIRP	cis	rs11148252	0.74	rs3803264	ENSG00000235660.1	LINC00345	4.71	4e-06	0.00134	0.3	0.28	Lewy body disease;	chr13:52397758	chr13:52484161~52484680:-
KIRP	cis	rs11148252	0.74	rs7983971	ENSG00000235660.1	LINC00345	-4.71	4e-06	0.00134	-0.3	-0.28	Lewy body disease;	chr13:52216565	chr13:52484161~52484680:-
KIRP	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	4.71	4e-06	0.00134	0.28	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
KIRP	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	4.71	4e-06	0.00134	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
KIRP	cis	rs2976388	0.669	rs1836633	ENSG00000253741.1	CTD-2292P10.4	-4.71	4e-06	0.00134	-0.32	-0.28	Urinary tract infection frequency;	chr8:142693174	chr8:142702252~142726973:-
KIRP	cis	rs6502050	0.835	rs3935816	ENSG00000266654.1	RP11-1376P16.1	-4.71	4e-06	0.00134	-0.27	-0.28	Life satisfaction;	chr17:82179297	chr17:82160056~82160452:+
KIRP	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-4.71	4.01e-06	0.00135	-0.34	-0.28	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
KIRP	cis	rs5758659	1	rs134882	ENSG00000205702.9	CYP2D7	4.71	4.01e-06	0.00135	0.21	0.28	Cognitive function;	chr22:42274959	chr22:42140203~42144577:-
KIRP	cis	rs755249	0.501	rs1889830	ENSG00000237624.1	OXCT2P1	-4.71	4.01e-06	0.00135	-0.39	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39514956~39516490:+
KIRP	cis	rs4128705	1	rs79499900	ENSG00000249049.1	RP11-763F8.1	4.71	4.01e-06	0.00135	0.25	0.28	Amyotrophic lateral sclerosis (sporadic);	chr4:91360738	chr4:91319034~91325306:-
KIRP	cis	rs9450351	0.744	rs56344601	ENSG00000203875.9	SNHG5	-4.71	4.01e-06	0.00135	-0.49	-0.28	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85660950~85678736:-
KIRP	cis	rs4604732	0.631	rs12091081	ENSG00000227135.1	GCSAML-AS1	-4.71	4.01e-06	0.00135	-0.49	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459762	chr1:247524679~247526752:-
KIRP	cis	rs295490	0.748	rs1602626	ENSG00000272656.1	RP11-219D15.3	-4.71	4.02e-06	0.00135	-0.46	-0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139364928	chr3:139349024~139349371:-
KIRP	cis	rs7674212	0.865	rs13149311	ENSG00000230069.3	LRRC37A15P	-4.71	4.02e-06	0.00135	-0.26	-0.28	Type 2 diabetes;	chr4:103056543	chr4:102727274~102730721:-
KIRP	cis	rs9311474	0.713	rs352167	ENSG00000243224.1	RP5-1157M23.2	4.71	4.02e-06	0.00135	0.25	0.28	Electroencephalogram traits;	chr3:52204640	chr3:52239258~52241097:+
KIRP	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	4.71	4.02e-06	0.00135	0.31	0.28	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
KIRP	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	4.71	4.02e-06	0.00135	0.34	0.28	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
KIRP	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	4.71	4.02e-06	0.00135	0.26	0.28	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
KIRP	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	4.71	4.03e-06	0.00135	0.39	0.28	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	4.71	4.03e-06	0.00135	0.39	0.28	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
KIRP	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	4.71	4.03e-06	0.00135	0.36	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
KIRP	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	4.71	4.03e-06	0.00135	0.36	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
KIRP	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-4.71	4.03e-06	0.00135	-0.28	-0.28	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-4.71	4.03e-06	0.00135	-0.28	-0.28	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
KIRP	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-4.71	4.03e-06	0.00135	-0.28	-0.28	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
KIRP	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	4.71	4.03e-06	0.00135	0.24	0.28	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
KIRP	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	4.71	4.03e-06	0.00135	0.2	0.28	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
KIRP	cis	rs7225151	1	rs7225151	ENSG00000234327.6	AC012146.7	-4.71	4.03e-06	0.00135	-0.4	-0.28	Alzheimer's disease (late onset);	chr17:5233752	chr17:5111468~5115004:+
KIRP	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-4.71	4.04e-06	0.00136	-0.24	-0.28	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
KIRP	cis	rs4578769	0.959	rs4800430	ENSG00000266850.1	RP11-370A5.1	4.71	4.04e-06	0.00136	0.37	0.28	Eosinophil percentage of white cells;	chr18:22803299	chr18:22723491~22907721:-
KIRP	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-4.71	4.04e-06	0.00136	-0.32	-0.28	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
KIRP	cis	rs6832769	0.925	rs60992571	ENSG00000272969.1	RP11-528I4.2	-4.71	4.04e-06	0.00136	-0.27	-0.28	Personality dimensions;	chr4:55574645	chr4:55547112~55547889:+
KIRP	cis	rs875971	0.545	rs2420612	ENSG00000224316.1	RP11-479O9.2	4.71	4.05e-06	0.00136	0.23	0.28	Aortic root size;	chr7:66536825	chr7:65773620~65802067:+
KIRP	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	4.71	4.05e-06	0.00136	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
KIRP	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	4.71	4.05e-06	0.00136	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
KIRP	cis	rs7508	0.512	rs28562392	ENSG00000254054.2	RP11-156K13.3	4.71	4.05e-06	0.00136	0.32	0.28	Atrial fibrillation;	chr8:18032922	chr8:17905756~17907887:+
KIRP	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-4.71	4.05e-06	0.00136	-0.3	-0.28	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
KIRP	cis	rs3808502	0.647	rs7821302	ENSG00000254527.1	ENPP7P12	-4.71	4.05e-06	0.00136	-0.3	-0.28	Neuroticism;	chr8:11379063	chr8:12205759~12206389:-
KIRP	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	4.71	4.05e-06	0.00136	0.34	0.28	Depression;	chr6:28096845	chr6:28073316~28074233:+
KIRP	cis	rs2486288	0.656	rs7167146	ENSG00000259433.2	CTD-2651B20.4	-4.71	4.05e-06	0.00136	-0.25	-0.28	Glomerular filtration rate;	chr15:45279188	chr15:45330209~45332634:-
KIRP	cis	rs10504130	0.569	rs12679983	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs12680128	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.53	rs4292674	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs4292675	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs76746661	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs71513549	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.502	rs4321994	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.66	rs79691523	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.569	rs12676345	ENSG00000272024.1	RP11-546K22.3	-4.71	4.06e-06	0.00136	-0.33	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51950284~51950690:+
KIRP	cis	rs2625529	0.818	rs2246225	ENSG00000260037.4	CTD-2524L6.3	4.71	4.06e-06	0.00136	0.25	0.28	Red blood cell count;	chr15:71822889	chr15:71818396~71823384:+
KIRP	cis	rs8396	1	rs11737481	ENSG00000271817.2	U3	-4.71	4.06e-06	0.00136	-0.24	-0.28	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700098	chr4:158700691~158700909:+
KIRP	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-4.71	4.06e-06	0.00136	-0.27	-0.28	Height;	chr14:75190804	chr14:75011269~75012851:-
KIRP	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-4.71	4.06e-06	0.00136	-0.27	-0.28	Height;	chr14:75193421	chr14:75011269~75012851:-
KIRP	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	4.71	4.06e-06	0.00136	0.26	0.28	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
KIRP	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-4.71	4.06e-06	0.00136	-0.26	-0.28	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
KIRP	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	4.71	4.06e-06	0.00136	0.26	0.28	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
KIRP	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-4.71	4.07e-06	0.00136	-0.24	-0.28	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
KIRP	cis	rs2562456	0.833	rs2968078	ENSG00000268555.1	RP11-678G14.3	-4.71	4.07e-06	0.00136	-0.37	-0.28	Pain;	chr19:21458942	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.755	rs2650773	ENSG00000268555.1	RP11-678G14.3	-4.71	4.07e-06	0.00136	-0.37	-0.28	Pain;	chr19:21461286	chr19:21570822~21587322:-
KIRP	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	4.71	4.07e-06	0.00136	0.35	0.28	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
KIRP	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	4.71	4.07e-06	0.00136	0.35	0.28	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
KIRP	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	4.71	4.07e-06	0.00136	0.35	0.28	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
KIRP	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	4.71	4.07e-06	0.00136	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
KIRP	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.71	4.07e-06	0.00136	0.32	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
KIRP	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-4.71	4.07e-06	0.00136	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
KIRP	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-4.71	4.07e-06	0.00136	-0.35	-0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
KIRP	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	4.71	4.07e-06	0.00136	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	4.71	4.07e-06	0.00136	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	4.71	4.07e-06	0.00136	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
KIRP	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	4.71	4.07e-06	0.00136	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
KIRP	cis	rs964611	0.58	rs75570984	ENSG00000259488.2	RP11-154J22.1	4.71	4.07e-06	0.00137	0.26	0.28	Metabolite levels (Pyroglutamine);	chr15:48361246	chr15:48312353~48331856:-
KIRP	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	4.71	4.08e-06	0.00137	0.26	0.28	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
KIRP	cis	rs964611	0.882	rs7179535	ENSG00000259488.2	RP11-154J22.1	-4.71	4.08e-06	0.00137	-0.26	-0.28	Metabolite levels (Pyroglutamine);	chr15:48287507	chr15:48312353~48331856:-
KIRP	cis	rs950169	0.922	rs4842939	ENSG00000275120.1	RP11-182J1.17	-4.71	4.08e-06	0.00137	-0.35	-0.28	Schizophrenia;	chr15:84159214	chr15:84599434~84606463:-
KIRP	cis	rs11148252	0.846	rs13431	ENSG00000235660.1	LINC00345	-4.71	4.08e-06	0.00137	-0.3	-0.28	Lewy body disease;	chr13:52413342	chr13:52484161~52484680:-
KIRP	cis	rs11148252	0.846	rs1056335	ENSG00000235660.1	LINC00345	-4.71	4.08e-06	0.00137	-0.3	-0.28	Lewy body disease;	chr13:52415728	chr13:52484161~52484680:-
KIRP	cis	rs1023500	0.505	rs134887	ENSG00000226450.2	CYP2D8P	4.71	4.08e-06	0.00137	0.21	0.28	Schizophrenia;	chr22:42278233	chr22:42149886~42155001:-
KIRP	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
KIRP	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	4.71	4.08e-06	0.00137	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
KIRP	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	4.71	4.08e-06	0.00137	0.32	0.28	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
KIRP	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-4.71	4.09e-06	0.00137	-0.34	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
KIRP	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-4.71	4.09e-06	0.00137	-0.26	-0.28	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
KIRP	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	4.71	4.09e-06	0.00137	0.43	0.28	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
KIRP	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	4.71	4.09e-06	0.00137	0.43	0.28	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
KIRP	cis	rs2562456	0.917	rs2681389	ENSG00000268555.1	RP11-678G14.3	-4.71	4.09e-06	0.00137	-0.38	-0.28	Pain;	chr19:21509773	chr19:21570822~21587322:-
KIRP	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-4.71	4.09e-06	0.00137	-0.31	-0.28	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
KIRP	cis	rs4227	0.565	rs2270341	ENSG00000233223.2	AC113189.5	4.71	4.09e-06	0.00137	0.25	0.28	IgA nephropathy;	chr17:7577229	chr17:7581964~7584072:-
KIRP	cis	rs10200159	1	rs17047094	ENSG00000272606.1	RP11-554J4.1	4.71	4.09e-06	0.00137	0.4	0.28	Vitiligo;	chr2:55570701	chr2:55617909~55618373:+
KIRP	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	4.71	4.09e-06	0.00137	0.24	0.28	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
KIRP	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	4.71	4.09e-06	0.00137	0.28	0.28	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
KIRP	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	4.71	4.09e-06	0.00137	0.28	0.28	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
KIRP	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-4.71	4.1e-06	0.00137	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
KIRP	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	4.71	4.1e-06	0.00137	0.24	0.28	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
KIRP	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	4.71	4.1e-06	0.00137	0.17	0.28	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
KIRP	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	4.71	4.11e-06	0.00138	0.23	0.28	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
KIRP	cis	rs11098499	0.644	rs10009566	ENSG00000250412.1	KLHL2P1	4.71	4.11e-06	0.00138	0.34	0.28	Corneal astigmatism;	chr4:119637453	chr4:119334329~119378233:+
KIRP	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	4.7	4.11e-06	0.00138	0.26	0.28	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
KIRP	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	4.7	4.11e-06	0.00138	0.28	0.28	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
KIRP	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-4.7	4.12e-06	0.00138	-0.36	-0.28	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
KIRP	cis	rs11148252	0.774	rs9596649	ENSG00000235660.1	LINC00345	4.7	4.12e-06	0.00138	0.29	0.28	Lewy body disease;	chr13:52360475	chr13:52484161~52484680:-
KIRP	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-4.7	4.12e-06	0.00138	-0.3	-0.28	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
KIRP	cis	rs324126	0.78	rs1993530	ENSG00000269834.4	ZNF528-AS1	-4.7	4.12e-06	0.00138	-0.29	-0.28	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52388842~52397766:-
KIRP	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-4.7	4.12e-06	0.00138	-0.3	-0.28	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-4.7	4.12e-06	0.00138	-0.3	-0.28	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-4.7	4.12e-06	0.00138	-0.3	-0.28	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
KIRP	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-4.7	4.12e-06	0.00138	-0.3	-0.28	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
KIRP	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	4.7	4.12e-06	0.00138	0.25	0.28	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
KIRP	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	4.7	4.12e-06	0.00138	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
KIRP	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	4.7	4.12e-06	0.00138	0.42	0.28	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
KIRP	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	4.7	4.12e-06	0.00138	0.42	0.28	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
KIRP	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	4.7	4.12e-06	0.00138	0.33	0.28	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
KIRP	cis	rs42648	0.819	rs10953006	ENSG00000225498.1	AC002064.5	4.7	4.13e-06	0.00138	0.21	0.28	Homocysteine levels;	chr7:90400839	chr7:90312496~90322592:+
KIRP	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-4.7	4.13e-06	0.00138	-0.57	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
KIRP	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	4.7	4.13e-06	0.00138	0.57	0.28	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
KIRP	cis	rs2239620	0.546	rs6913317	ENSG00000216775.2	RP1-152L7.5	-4.7	4.13e-06	0.00138	-0.31	-0.28	LDL cholesterol levels;	chr6:52591769	chr6:52665148~52669155:+
KIRP	cis	rs6942407	0.592	rs6966613	ENSG00000224046.1	AC005076.5	-4.7	4.13e-06	0.00138	-0.27	-0.28	Food allergy;	chr7:87164178	chr7:87151423~87152420:-
KIRP	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-4.7	4.13e-06	0.00138	-0.22	-0.28	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
KIRP	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	4.7	4.14e-06	0.00138	0.39	0.28	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
KIRP	cis	rs1065852	0.51	rs5758666	ENSG00000227370.1	RP4-669P10.19	4.7	4.14e-06	0.00138	0.28	0.28	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42132543~42132998:+
KIRP	cis	rs1552244	0.872	rs35988239	ENSG00000180385.7	EMC3-AS1	4.7	4.14e-06	0.00138	0.3	0.28	Alzheimer's disease;	chr3:10032461	chr3:9986893~10006990:+
KIRP	cis	rs4820539	0.966	rs5996470	ENSG00000275635.1	U7	4.7	4.14e-06	0.00138	0.3	0.28	Bone mineral density;	chr22:23141068	chr22:23137805~23137864:-
KIRP	cis	rs295490	0.748	rs116416768	ENSG00000272656.1	RP11-219D15.3	4.7	4.14e-06	0.00139	0.46	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139382294	chr3:139349024~139349371:-
KIRP	cis	rs10200159	0.744	rs6545510	ENSG00000272606.1	RP11-554J4.1	4.7	4.15e-06	0.00139	0.41	0.28	Vitiligo;	chr2:55607591	chr2:55617909~55618373:+
KIRP	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-4.7	4.15e-06	0.00139	-0.27	-0.28	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
KIRP	cis	rs875971	0.502	rs2465121	ENSG00000236529.1	RP13-254B10.1	-4.7	4.15e-06	0.00139	-0.26	-0.28	Aortic root size;	chr7:66156017	chr7:65840212~65840596:+
KIRP	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	4.7	4.15e-06	0.00139	0.43	0.28	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
KIRP	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.7	4.15e-06	0.00139	-0.37	-0.28	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
KIRP	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	4.7	4.15e-06	0.00139	0.38	0.28	Depression;	chr6:28379133	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	4.7	4.15e-06	0.00139	0.38	0.28	Depression;	chr6:28379168	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	4.7	4.15e-06	0.00139	0.38	0.28	Depression;	chr6:28386473	chr6:28943877~28944537:+
KIRP	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	4.7	4.15e-06	0.00139	0.38	0.28	Depression;	chr6:28391932	chr6:28943877~28944537:+
KIRP	cis	rs42648	0.869	rs12374728	ENSG00000225498.1	AC002064.5	4.7	4.15e-06	0.00139	0.2	0.28	Homocysteine levels;	chr7:90312570	chr7:90312496~90322592:+
KIRP	cis	rs4578769	0.842	rs7243256	ENSG00000266850.1	RP11-370A5.1	4.7	4.15e-06	0.00139	0.36	0.28	Eosinophil percentage of white cells;	chr18:22936411	chr18:22723491~22907721:-
KIRP	cis	rs4578769	0.842	rs9966323	ENSG00000266850.1	RP11-370A5.1	4.7	4.15e-06	0.00139	0.36	0.28	Eosinophil percentage of white cells;	chr18:22936418	chr18:22723491~22907721:-
KIRP	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-4.7	4.15e-06	0.00139	-0.3	-0.28	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-4.7	4.15e-06	0.00139	-0.3	-0.28	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
KIRP	cis	rs42648	0.869	rs6948139	ENSG00000225498.1	AC002064.5	4.7	4.15e-06	0.00139	0.2	0.28	Homocysteine levels;	chr7:90308467	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.837	rs6970750	ENSG00000225498.1	AC002064.5	4.7	4.15e-06	0.00139	0.2	0.28	Homocysteine levels;	chr7:90308877	chr7:90312496~90322592:+
KIRP	cis	rs2386661	1	rs4749853	ENSG00000228951.1	RP11-336A10.4	-4.7	4.16e-06	0.00139	-0.35	-0.28	Breast cancer;	chr10:5632795	chr10:5616862~5618161:-
KIRP	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-4.7	4.16e-06	0.00139	-0.27	-0.28	Height;	chr14:75123637	chr14:75011269~75012851:-
KIRP	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	4.7	4.16e-06	0.00139	0.38	0.28	Height;	chr6:109486036	chr6:109382795~109383666:+
KIRP	cis	rs1552244	1	rs9811771	ENSG00000180385.7	EMC3-AS1	4.7	4.16e-06	0.00139	0.26	0.28	Alzheimer's disease;	chr3:10092265	chr3:9986893~10006990:+
KIRP	cis	rs1552244	1	rs1552244	ENSG00000180385.7	EMC3-AS1	4.7	4.16e-06	0.00139	0.26	0.28	Alzheimer's disease;	chr3:10093893	chr3:9986893~10006990:+
KIRP	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-4.7	4.17e-06	0.00139	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
KIRP	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-4.7	4.17e-06	0.00139	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
KIRP	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-4.7	4.17e-06	0.00139	-0.52	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
KIRP	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.7	4.17e-06	0.00139	0.3	0.28	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
KIRP	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-4.7	4.18e-06	0.0014	-0.35	-0.28	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
KIRP	cis	rs875971	0.545	rs7810213	ENSG00000224316.1	RP11-479O9.2	4.7	4.18e-06	0.0014	0.23	0.28	Aortic root size;	chr7:66481592	chr7:65773620~65802067:+
KIRP	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-4.7	4.18e-06	0.0014	-0.33	-0.28	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
KIRP	cis	rs697003	1	rs697003	ENSG00000231057.3	RP11-122M14.1	-4.7	4.18e-06	0.0014	-0.26	-0.28	Red cell distribution width;	chr1:211669734	chr1:211675762~211690103:+
KIRP	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-4.7	4.18e-06	0.0014	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
KIRP	cis	rs1075265	0.584	rs1559037	ENSG00000272156.1	RP11-477N3.1	4.7	4.18e-06	0.0014	0.3	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54082554~54085066:+
KIRP	cis	rs4660214	0.724	rs2484751	ENSG00000237624.1	OXCT2P1	-4.7	4.18e-06	0.0014	-0.38	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39514956~39516490:+
KIRP	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.7	4.18e-06	0.0014	0.28	0.28	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
KIRP	cis	rs10504130	0.569	rs12678646	ENSG00000272024.1	RP11-546K22.3	-4.7	4.18e-06	0.0014	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51950284~51950690:+
KIRP	cis	rs1552244	1	rs55882090	ENSG00000180385.7	EMC3-AS1	4.7	4.18e-06	0.0014	0.26	0.28	Alzheimer's disease;	chr3:10097398	chr3:9986893~10006990:+
KIRP	cis	rs728616	0.867	rs12414096	ENSG00000234382.2	RP11-40F6.1	-4.7	4.18e-06	0.0014	-0.44	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:80233664~80245367:+
KIRP	cis	rs9595908	0.606	rs7988462	ENSG00000212293.1	SNORA16	4.7	4.18e-06	0.0014	0.26	0.28	Body mass index;	chr13:32806701	chr13:32420390~32420516:-
KIRP	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	4.7	4.19e-06	0.0014	0.24	0.28	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
KIRP	cis	rs4218	0.681	rs58335303	ENSG00000277144.1	RP11-59H7.4	-4.7	4.19e-06	0.0014	-0.29	-0.28	Social communication problems;	chr15:59073206	chr15:59115547~59116089:-
KIRP	cis	rs2235642	0.893	rs2076442	ENSG00000280231.1	LA16c-380F5.3	-4.7	4.19e-06	0.0014	-0.36	-0.28	Coronary artery disease;	chr16:1541111	chr16:1553655~1554130:-
KIRP	cis	rs2562456	0.876	rs62110163	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21546020	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.761	rs35008138	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21548822	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.833	rs2681388	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21549451	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.876	rs2681370	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21554036	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.876	rs11668606	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21554618	chr19:21570822~21587322:-
KIRP	cis	rs2562456	0.876	rs2681395	ENSG00000268555.1	RP11-678G14.3	4.7	4.19e-06	0.0014	0.38	0.28	Pain;	chr19:21555338	chr19:21570822~21587322:-
KIRP	cis	rs2911132	0.621	rs17480169	ENSG00000248734.2	CTD-2260A17.1	4.7	4.19e-06	0.0014	0.27	0.28	Urate levels (BMI interaction);	chr5:96753363	chr5:96784777~96785999:+
KIRP	cis	rs4694744	0.54	rs13123479	ENSG00000250696.4	RP11-704M14.1	4.7	4.19e-06	0.0014	0.37	0.28	Bacteremia;	chr4:69441005	chr4:69182100~69216766:+
KIRP	cis	rs28386778	0.799	rs2955234	ENSG00000240280.5	TCAM1P	4.7	4.19e-06	0.0014	0.34	0.28	Prudent dietary pattern;	chr17:63906241	chr17:63849292~63864379:+
KIRP	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	4.7	4.2e-06	0.0014	0.38	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
KIRP	cis	rs738322	0.64	rs738321	ENSG00000233360.4	Z83844.1	4.7	4.2e-06	0.0014	0.28	0.28	Cutaneous nevi;	chr22:38172826	chr22:37641832~37658377:-
KIRP	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-4.7	4.2e-06	0.0014	-0.29	-0.28	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
KIRP	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-4.7	4.2e-06	0.0014	-0.29	-0.28	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-4.7	4.2e-06	0.0014	-0.29	-0.28	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
KIRP	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-4.7	4.2e-06	0.0014	-0.29	-0.28	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
KIRP	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-4.7	4.2e-06	0.0014	-0.24	-0.28	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
KIRP	cis	rs79040073	0.563	rs17478618	ENSG00000259531.2	RP11-295H24.3	-4.7	4.2e-06	0.0014	-0.38	-0.28	Lung cancer in ever smokers;	chr15:49444621	chr15:49365124~49366685:-
KIRP	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-4.7	4.2e-06	0.0014	-0.28	-0.28	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
KIRP	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-4.7	4.2e-06	0.0014	-0.28	-0.28	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
KIRP	cis	rs4820539	1	rs5751589	ENSG00000275635.1	U7	-4.7	4.2e-06	0.0014	-0.3	-0.28	Bone mineral density;	chr22:23133575	chr22:23137805~23137864:-
KIRP	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	4.7	4.2e-06	0.0014	0.25	0.28	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
KIRP	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-4.7	4.2e-06	0.0014	-0.29	-0.28	Height;	chr4:55537550	chr4:55363971~55395847:-
KIRP	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-4.7	4.21e-06	0.0014	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
KIRP	cis	rs1009647	0.645	rs17742719	ENSG00000258413.1	RP11-665C16.6	4.7	4.21e-06	0.0014	0.46	0.28	Testicular germ cell tumor;	chr14:55388878	chr14:55262767~55272075:-
KIRP	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	4.7	4.21e-06	0.00141	0.3	0.28	Height;	chr4:55451489	chr4:55363971~55395847:-
KIRP	cis	rs6479891	0.908	rs61853639	ENSG00000238280.1	RP11-436D10.3	-4.7	4.22e-06	0.00141	-0.41	-0.28	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:62793562~62805887:-
KIRP	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-4.7	4.22e-06	0.00141	-0.28	-0.28	Height;	chr14:75040172	chr14:75011269~75012851:-
KIRP	cis	rs950169	0.8	rs34302901	ENSG00000275120.1	RP11-182J1.17	4.7	4.22e-06	0.00141	0.36	0.28	Schizophrenia;	chr15:84567712	chr15:84599434~84606463:-
KIRP	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	-4.7	4.22e-06	0.00141	-0.22	-0.28	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
KIRP	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	4.7	4.23e-06	0.00141	0.23	0.28	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
KIRP	cis	rs10896135	0.526	rs624561	ENSG00000255320.1	RP11-755F10.1	-4.7	4.23e-06	0.00141	-0.34	-0.28	Bipolar disorder;	chr11:66647444	chr11:66244840~66246239:-
KIRP	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-4.7	4.23e-06	0.00141	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
KIRP	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	4.7	4.23e-06	0.00141	0.34	0.28	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
KIRP	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	4.7	4.23e-06	0.00141	0.23	0.28	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
KIRP	cis	rs7916697	1	rs7916697	ENSG00000233590.1	RP11-153K11.3	4.7	4.23e-06	0.00141	0.33	0.28	Optic disc area;	chr10:68232096	chr10:68233251~68242379:-
KIRP	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-4.7	4.23e-06	0.00141	-0.26	-0.28	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
KIRP	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-4.7	4.23e-06	0.00141	-0.26	-0.28	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
KIRP	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
KIRP	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
KIRP	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	4.7	4.24e-06	0.00141	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
KIRP	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	4.7	4.24e-06	0.00141	0.41	0.28	Height;	chr6:109416945	chr6:109382795~109383666:+
KIRP	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-4.7	4.24e-06	0.00141	-0.25	-0.28	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
KIRP	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-4.7	4.24e-06	0.00141	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
KIRP	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-4.7	4.25e-06	0.00142	-0.31	-0.28	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
KIRP	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-4.7	4.25e-06	0.00142	-0.3	-0.28	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-4.7	4.25e-06	0.00142	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-4.7	4.25e-06	0.00142	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
KIRP	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	4.7	4.25e-06	0.00142	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
KIRP	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	4.7	4.25e-06	0.00142	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
KIRP	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	4.7	4.25e-06	0.00142	0.32	0.28	Depression;	chr6:28099759	chr6:28073316~28074233:+
KIRP	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	4.7	4.25e-06	0.00142	0.32	0.28	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	4.7	4.25e-06	0.00142	0.32	0.28	Depression;	chr6:28100648	chr6:28073316~28074233:+
KIRP	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	4.7	4.25e-06	0.00142	0.32	0.28	Depression;	chr6:28107222	chr6:28073316~28074233:+
KIRP	cis	rs2361701	0.929	rs1561810	ENSG00000279259.1	RP11-334C17.3	4.7	4.25e-06	0.00142	0.28	0.28	IgG glycosylation;	chr17:80095525	chr17:80147250~80148596:+
KIRP	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	4.7	4.25e-06	0.00142	0.25	0.28	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
KIRP	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	4.7	4.25e-06	0.00142	0.25	0.28	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
KIRP	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-4.7	4.26e-06	0.00142	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
KIRP	cis	rs8141529	0.719	rs5762880	ENSG00000226471.5	CTA-292E10.6	-4.7	4.26e-06	0.00142	-0.29	-0.28	Lymphocyte counts;	chr22:28891828	chr22:28800683~28848559:+
KIRP	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	4.7	4.26e-06	0.00142	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
KIRP	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-4.7	4.26e-06	0.00142	-0.41	-0.28	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
KIRP	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-4.7	4.27e-06	0.00142	-0.35	-0.28	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
KIRP	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-4.7	4.27e-06	0.00142	-0.34	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
KIRP	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	4.7	4.27e-06	0.00142	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
KIRP	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	4.7	4.27e-06	0.00142	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
KIRP	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	4.7	4.27e-06	0.00142	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
KIRP	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	4.7	4.27e-06	0.00142	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
KIRP	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-4.7	4.28e-06	0.00142	-0.23	-0.28	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
KIRP	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-4.7	4.28e-06	0.00143	-0.29	-0.28	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
KIRP	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-4.7	4.28e-06	0.00143	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
KIRP	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-4.7	4.28e-06	0.00143	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
KIRP	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	4.7	4.28e-06	0.00143	0.37	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
KIRP	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.7	4.28e-06	0.00143	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
KIRP	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-4.7	4.28e-06	0.00143	-0.26	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
KIRP	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	4.7	4.28e-06	0.00143	0.23	0.28	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
KIRP	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-4.7	4.29e-06	0.00143	-0.42	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
KIRP	cis	rs2562456	0.793	rs2562474	ENSG00000268555.1	RP11-678G14.3	-4.7	4.29e-06	0.00143	-0.37	-0.28	Pain;	chr19:21463480	chr19:21570822~21587322:-
KIRP	cis	rs6840258	0.64	rs1481947	ENSG00000251411.1	RP11-397E7.4	-4.7	4.29e-06	0.00143	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87159990	chr4:86913266~86914817:-
KIRP	cis	rs6840258	0.64	rs3193672	ENSG00000251411.1	RP11-397E7.4	-4.7	4.29e-06	0.00143	-0.25	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87161955	chr4:86913266~86914817:-
KIRP	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	4.7	4.29e-06	0.00143	0.32	0.28	Depression;	chr6:28104824	chr6:28073316~28074233:+
KIRP	cis	rs8037137	0.571	rs3743445	ENSG00000258725.1	PRC1-AS1	-4.7	4.3e-06	0.00143	-0.39	-0.28	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91017952	chr15:90966345~90988624:+
KIRP	cis	rs2880765	0.566	rs12911430	ENSG00000259630.2	CTD-2262B20.1	-4.7	4.3e-06	0.00143	-0.27	-0.28	Coronary artery disease;	chr15:85468033	chr15:85415228~85415633:+
KIRP	cis	rs2880765	0.566	rs11630381	ENSG00000259630.2	CTD-2262B20.1	-4.7	4.3e-06	0.00143	-0.27	-0.28	Coronary artery disease;	chr15:85469272	chr15:85415228~85415633:+
KIRP	cis	rs2880765	0.545	rs11631739	ENSG00000259630.2	CTD-2262B20.1	-4.7	4.3e-06	0.00143	-0.27	-0.28	Coronary artery disease;	chr15:85469347	chr15:85415228~85415633:+
KIRP	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	4.7	4.3e-06	0.00143	0.37	0.28	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
KIRP	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	4.7	4.3e-06	0.00143	0.37	0.28	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
KIRP	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	4.7	4.3e-06	0.00143	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
KIRP	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	4.7	4.3e-06	0.00143	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
KIRP	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-4.69	4.3e-06	0.00143	-0.22	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
KIRP	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	4.69	4.3e-06	0.00143	0.43	0.28	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
KIRP	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	4.69	4.3e-06	0.00143	0.43	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
KIRP	cis	rs4805272	0.849	rs17591205	ENSG00000267799.1	MAN1A2P1	4.69	4.3e-06	0.00143	0.34	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830562	chr19:28790812~28792871:-
KIRP	cis	rs72843506	0.586	rs59890010	ENSG00000270091.1	RP11-78O7.2	-4.69	4.31e-06	0.00143	-0.3	-0.28	Schizophrenia;	chr17:19960360	chr17:19896590~19897287:-
KIRP	cis	rs72843506	0.586	rs73980762	ENSG00000270091.1	RP11-78O7.2	-4.69	4.31e-06	0.00143	-0.3	-0.28	Schizophrenia;	chr17:19966113	chr17:19896590~19897287:-
KIRP	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-4.69	4.31e-06	0.00143	-0.28	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
KIRP	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-4.69	4.31e-06	0.00143	-0.28	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
KIRP	cis	rs1577917	0.696	rs10806334	ENSG00000220563.1	PKMP3	-4.69	4.31e-06	0.00143	-0.23	-0.28	Response to antipsychotic treatment;	chr6:85729611	chr6:85659892~85660606:-
KIRP	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	4.69	4.31e-06	0.00143	0.27	0.28	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
KIRP	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	4.69	4.31e-06	0.00143	0.31	0.28	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
KIRP	cis	rs950169	0.922	rs62021167	ENSG00000254414.1	RP11-182J1.1	4.69	4.31e-06	0.00143	0.35	0.28	Schizophrenia;	chr15:84574820	chr15:84631898~84633987:-
KIRP	cis	rs7189233	1	rs62048543	ENSG00000279344.1	RP11-44F14.7	4.69	4.31e-06	0.00143	0.21	0.28	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53478957~53481550:-
KIRP	cis	rs4578769	0.788	rs12962334	ENSG00000265939.1	UBE2CP2	4.69	4.31e-06	0.00143	0.25	0.28	Eosinophil percentage of white cells;	chr18:22897971	chr18:22900486~22900995:-
KIRP	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	4.69	4.31e-06	0.00144	0.56	0.28	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	4.69	4.31e-06	0.00144	0.56	0.28	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	4.69	4.31e-06	0.00144	0.56	0.28	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	4.69	4.31e-06	0.00144	0.56	0.28	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
KIRP	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	4.69	4.31e-06	0.00144	0.56	0.28	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
KIRP	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-4.69	4.32e-06	0.00144	-0.57	-0.28	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
KIRP	cis	rs4934494	0.588	rs10881683	ENSG00000232936.4	RP11-80H5.2	4.69	4.32e-06	0.00144	0.41	0.28	Red blood cell count;	chr10:89827231	chr10:89645282~89650667:+
KIRP	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-4.69	4.32e-06	0.00144	-0.23	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
KIRP	cis	rs11864453	0.927	rs1035560	ENSG00000260886.1	TAT-AS1	4.69	4.32e-06	0.00144	0.34	0.28	Fibrinogen levels;	chr16:71998831	chr16:71565789~71578187:+
KIRP	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-4.69	4.32e-06	0.00144	-0.31	-0.28	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
KIRP	cis	rs4356975	0.509	rs4371688	ENSG00000196472.4	RP13-644M16.4	4.69	4.32e-06	0.00144	0.31	0.28	Obesity-related traits;	chr4:69124323	chr4:69181660~69182372:+
KIRP	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	4.69	4.33e-06	0.00144	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
KIRP	cis	rs116095464	0.558	rs13354585	ENSG00000248925.1	CTD-2083E4.6	4.69	4.33e-06	0.00144	0.42	0.28	Breast cancer;	chr5:242148	chr5:269858~271516:-
KIRP	cis	rs116095464	0.558	rs9312956	ENSG00000248925.1	CTD-2083E4.6	4.69	4.33e-06	0.00144	0.46	0.28	Breast cancer;	chr5:201697	chr5:269858~271516:-
KIRP	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	4.69	4.33e-06	0.00144	0.25	0.28	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
KIRP	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	4.69	4.33e-06	0.00144	0.3	0.28	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
KIRP	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	4.69	4.33e-06	0.00144	0.3	0.28	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
KIRP	cis	rs858267	1	rs858267	ENSG00000230658.1	KLHL7-AS1	-4.69	4.33e-06	0.00144	-0.73	-0.28	Blood protein levels;	chr7:23170510	chr7:23101228~23105703:-
KIRP	cis	rs4820539	1	rs3788347	ENSG00000275635.1	U7	4.69	4.34e-06	0.00144	0.31	0.28	Bone mineral density;	chr22:23125617	chr22:23137805~23137864:-
KIRP	cis	rs9543976	0.688	rs56084319	ENSG00000261553.4	RP11-29G8.3	-4.69	4.34e-06	0.00144	-0.47	-0.28	Diabetic retinopathy;	chr13:75536543	chr13:75549773~75807120:+
KIRP	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	4.69	4.34e-06	0.00144	0.33	0.28	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
KIRP	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	4.69	4.34e-06	0.00144	0.39	0.28	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
KIRP	cis	rs9450351	0.744	rs7752222	ENSG00000203875.9	SNHG5	-4.69	4.34e-06	0.00144	-0.5	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85660950~85678736:-
KIRP	cis	rs9450351	0.744	rs7738777	ENSG00000203875.9	SNHG5	-4.69	4.34e-06	0.00144	-0.5	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85660950~85678736:-
KIRP	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-4.69	4.35e-06	0.00144	-0.24	-0.28	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
KIRP	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	4.69	4.35e-06	0.00144	0.25	0.28	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
KIRP	cis	rs4663866	0.901	rs35713061	ENSG00000186235.9	AC016757.3	4.69	4.35e-06	0.00144	0.53	0.28	Irritable bowel syndrome;	chr2:238275133	chr2:238224552~238231677:-
KIRP	cis	rs4663866	0.901	rs3739066	ENSG00000186235.9	AC016757.3	4.69	4.35e-06	0.00144	0.53	0.28	Irritable bowel syndrome;	chr2:238275483	chr2:238224552~238231677:-
KIRP	cis	rs6832769	0.922	rs28726308	ENSG00000272969.1	RP11-528I4.2	4.69	4.35e-06	0.00145	0.29	0.28	Personality dimensions;	chr4:55368239	chr4:55547112~55547889:+
KIRP	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-4.69	4.35e-06	0.00145	-0.27	-0.28	Height;	chr14:75135079	chr14:75011269~75012851:-
KIRP	cis	rs11148252	0.74	rs9596642	ENSG00000235660.1	LINC00345	4.69	4.35e-06	0.00145	0.3	0.28	Lewy body disease;	chr13:52326744	chr13:52484161~52484680:-
KIRP	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	4.69	4.35e-06	0.00145	0.29	0.28	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
KIRP	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	4.69	4.35e-06	0.00145	0.31	0.28	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
KIRP	cis	rs9329221	0.741	rs13264066	ENSG00000254340.1	RP11-10A14.3	-4.69	4.35e-06	0.00145	-0.33	-0.28	Neuroticism;	chr8:9946565	chr8:9141424~9145435:+
KIRP	cis	rs9329221	0.741	rs9650622	ENSG00000254340.1	RP11-10A14.3	-4.69	4.35e-06	0.00145	-0.33	-0.28	Neuroticism;	chr8:9946782	chr8:9141424~9145435:+
KIRP	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	4.69	4.36e-06	0.00145	0.24	0.28	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
KIRP	cis	rs910316	0.763	rs6574205	ENSG00000279594.1	RP11-950C14.10	4.69	4.36e-06	0.00145	0.28	0.28	Height;	chr14:74986336	chr14:75011269~75012851:-
KIRP	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	4.69	4.36e-06	0.00145	0.35	0.28	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
KIRP	cis	rs73198271	0.599	rs10103169	ENSG00000253981.4	ALG1L13P	-4.69	4.36e-06	0.00145	-0.23	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8236003~8244667:-
KIRP	cis	rs73198271	0.7	rs10103282	ENSG00000253981.4	ALG1L13P	-4.69	4.36e-06	0.00145	-0.23	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8236003~8244667:-
KIRP	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	4.69	4.36e-06	0.00145	0.28	0.28	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
KIRP	cis	rs308403	0.608	rs309362	ENSG00000224786.1	CETN4P	4.69	4.36e-06	0.00145	0.39	0.28	Blood protein levels;	chr4:122736999	chr4:122730548~122732193:-
KIRP	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	4.69	4.36e-06	0.00145	0.37	0.28	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
KIRP	cis	rs11222084	0.539	rs1021205	ENSG00000175773.11	RP11-121M22.1	-4.69	4.36e-06	0.00145	-0.37	-0.28	Pulse pressure;Blood pressure;	chr11:130401314	chr11:130314993~130403657:+
KIRP	cis	rs1858037	0.867	rs1039765	ENSG00000237979.1	AC007389.1	-4.69	4.36e-06	0.00145	-0.32	-0.28	Rheumatoid arthritis;	chr2:65387228	chr2:65500993~65502138:-
KIRP	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-4.69	4.37e-06	0.00145	-0.25	-0.28	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
KIRP	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	4.69	4.37e-06	0.00145	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
KIRP	cis	rs2299587	0.932	rs12547946	ENSG00000254054.2	RP11-156K13.3	4.69	4.37e-06	0.00145	0.33	0.28	Economic and political preferences;	chr8:18000928	chr8:17905756~17907887:+
KIRP	cis	rs8114671	0.836	rs734308	ENSG00000269202.1	RP4-614O4.12	4.69	4.37e-06	0.00145	0.2	0.28	Height;	chr20:34984293	chr20:35201747~35203288:-
KIRP	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-4.69	4.37e-06	0.00145	-0.38	-0.28	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
KIRP	cis	rs4072705	1	rs7032937	ENSG00000224020.1	MIR181A2HG	-4.69	4.38e-06	0.00145	-0.28	-0.28	Menarche (age at onset);	chr9:124575894	chr9:124658467~124698631:+
KIRP	cis	rs7208859	0.623	rs11657662	ENSG00000264538.5	SUZ12P1	4.69	4.38e-06	0.00145	0.24	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30709299~30790908:+
KIRP	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-4.69	4.38e-06	0.00146	-0.3	-0.28	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
KIRP	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-4.69	4.38e-06	0.00146	-0.35	-0.28	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
KIRP	cis	rs6840258	1	rs56201818	ENSG00000251411.1	RP11-397E7.4	-4.69	4.38e-06	0.00146	-0.27	-0.28	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031481	chr4:86913266~86914817:-
KIRP	cis	rs497273	0.552	rs1179939	ENSG00000277423.1	RP11-173P15.9	4.69	4.39e-06	0.00146	0.29	0.28	Systemic lupus erythematosus;	chr12:120889073	chr12:120703867~120704282:+
KIRP	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.69	4.39e-06	0.00146	-0.23	-0.28	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
KIRP	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-4.69	4.39e-06	0.00146	-0.3	-0.28	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
KIRP	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	4.69	4.39e-06	0.00146	0.36	0.28	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
KIRP	cis	rs35146811	0.695	rs1618851	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100213020	chr7:100320992~100341908:-
KIRP	cis	rs35146811	0.735	rs1727130	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100213841	chr7:100320992~100341908:-
KIRP	cis	rs35146811	0.735	rs1636975	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100214466	chr7:100320992~100341908:-
KIRP	cis	rs35146811	0.695	rs1727132	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100214674	chr7:100320992~100341908:-
KIRP	cis	rs35146811	0.735	rs1727133	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100215247	chr7:100320992~100341908:-
KIRP	cis	rs35146811	0.657	rs36019559	ENSG00000078319.8	PMS2P1	4.69	4.4e-06	0.00146	0.35	0.28	Coronary artery disease;	chr7:100216963	chr7:100320992~100341908:-
KIRP	cis	rs79349575	0.783	rs28409394	ENSG00000270781.1	RP11-501C14.9	-4.69	4.4e-06	0.00146	-0.29	-0.28	Type 2 diabetes;	chr17:48920756	chr17:48899131~48899748:+
KIRP	cis	rs962856	0.964	rs12473253	ENSG00000236605.1	AC023115.4	4.69	4.4e-06	0.00146	0.34	0.28	Pancreatic cancer;	chr2:67419189	chr2:67324627~67325304:+
KIRP	cis	rs2980439	0.729	rs2955585	ENSG00000173295.6	FAM86B3P	4.69	4.4e-06	0.00146	0.23	0.28	Neuroticism;	chr8:8235989	chr8:8228595~8244865:+
KIRP	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	4.69	4.41e-06	0.00146	0.23	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
KIRP	cis	rs447735	0.565	rs10852626	ENSG00000260259.1	RP11-368I7.4	-4.69	4.41e-06	0.00146	-0.22	-0.28	Hemoglobin concentration;	chr16:89848225	chr16:89682620~89686569:-
KIRP	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.69	4.42e-06	0.00147	-0.31	-0.28	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
KIRP	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	4.69	4.42e-06	0.00147	0.38	0.28	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
KIRP	cis	rs4947019	1	rs12206574	ENSG00000260273.1	RP11-425D10.10	4.69	4.42e-06	0.00147	0.62	0.28	Hematological parameters;	chr6:109746570	chr6:109382795~109383666:+
KIRP	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
KIRP	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	4.69	4.42e-06	0.00147	0.42	0.28	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
KIRP	cis	rs497273	0.512	rs1177585	ENSG00000277423.1	RP11-173P15.9	4.69	4.42e-06	0.00147	0.29	0.28	Systemic lupus erythematosus;	chr12:120887518	chr12:120703867~120704282:+
KIRP	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	4.69	4.42e-06	0.00147	0.19	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
KIRP	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	4.69	4.42e-06	0.00147	0.19	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
KIRP	cis	rs1799949	0.965	rs4793237	ENSG00000279602.1	CTD-3014M21.1	-4.69	4.43e-06	0.00147	-0.24	-0.28	Menopause (age at onset);	chr17:43359227	chr17:43360041~43361361:-
KIRP	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.69	4.43e-06	0.00147	0.23	0.28	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
KIRP	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-4.69	4.43e-06	0.00147	-0.27	-0.28	Height;	chr14:75136861	chr14:75011269~75012851:-
KIRP	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	4.69	4.43e-06	0.00147	0.39	0.28	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
KIRP	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	4.69	4.43e-06	0.00147	0.37	0.28	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
KIRP	cis	rs7824557	0.564	rs2572395	ENSG00000254527.1	ENPP7P12	-4.69	4.43e-06	0.00147	-0.3	-0.28	Retinal vascular caliber;	chr8:11377851	chr8:12205759~12206389:-
KIRP	cis	rs7824557	0.564	rs2736300	ENSG00000254527.1	ENPP7P12	-4.69	4.43e-06	0.00147	-0.3	-0.28	Retinal vascular caliber;	chr8:11378070	chr8:12205759~12206389:-
KIRP	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	4.69	4.43e-06	0.00147	0.48	0.28	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
KIRP	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.69	4.43e-06	0.00147	-0.3	-0.28	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
KIRP	cis	rs4499344	0.73	rs406470	ENSG00000201388.1	SNORA68	4.69	4.43e-06	0.00147	0.28	0.28	Mean platelet volume;	chr19:32613566	chr19:32608337~32608469:-
KIRP	cis	rs3121446	0.727	rs2798358	ENSG00000229654.1	RP1-60O19.2	-4.69	4.44e-06	0.00147	-0.3	-0.28	Daytime sleep phenotypes;	chr6:106698806	chr6:106695535~106699994:+
KIRP	cis	rs7267979	0.78	rs6050679	ENSG00000274414.1	RP5-965G21.4	-4.69	4.44e-06	0.00147	-0.26	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25239007~25245229:-
KIRP	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	4.69	4.44e-06	0.00147	0.2	0.28	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
KIRP	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	4.69	4.44e-06	0.00147	0.2	0.28	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
KIRP	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	4.69	4.44e-06	0.00147	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
KIRP	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-4.69	4.44e-06	0.00147	-0.32	-0.28	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
KIRP	cis	rs7772486	0.875	rs2492855	ENSG00000270638.1	RP3-466P17.1	4.69	4.44e-06	0.00147	0.24	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145735570~145737218:+
KIRP	cis	rs6832769	0.922	rs11133376	ENSG00000272969.1	RP11-528I4.2	4.69	4.45e-06	0.00147	0.28	0.28	Personality dimensions;	chr4:55386866	chr4:55547112~55547889:+
KIRP	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-4.69	4.45e-06	0.00147	-0.27	-0.28	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
KIRP	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	4.69	4.45e-06	0.00147	0.35	0.28	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
KIRP	cis	rs9810089	0.814	rs73226190	ENSG00000261758.1	RP11-102M11.2	4.69	4.45e-06	0.00148	0.3	0.28	Gestational age at birth (child effect);	chr3:136494468	chr3:136752630~136755780:+
KIRP	cis	rs2562456	0.755	rs2914646	ENSG00000268555.1	RP11-678G14.3	-4.69	4.45e-06	0.00148	-0.38	-0.28	Pain;	chr19:21454359	chr19:21570822~21587322:-
KIRP	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	4.69	4.45e-06	0.00148	0.51	0.28	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
KIRP	cis	rs344364	0.602	rs12325217	ENSG00000280231.1	LA16c-380F5.3	-4.69	4.45e-06	0.00148	-0.37	-0.28	Glomerular filtration rate in chronic kidney disease;	chr16:1837107	chr16:1553655~1554130:-
KIRP	cis	rs2562456	0.917	rs2650825	ENSG00000268555.1	RP11-678G14.3	4.69	4.45e-06	0.00148	0.39	0.28	Pain;	chr19:21516423	chr19:21570822~21587322:-
KIRP	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	4.69	4.46e-06	0.00148	0.41	0.28	Height;	chr6:109359125	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	4.69	4.46e-06	0.00148	0.41	0.28	Height;	chr6:109360679	chr6:109382795~109383666:+
KIRP	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	4.69	4.46e-06	0.00148	0.41	0.28	Height;	chr6:109365409	chr6:109382795~109383666:+
KIRP	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	4.69	4.46e-06	0.00148	0.35	0.28	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
KIRP	cis	rs1185460	0.967	rs1184902	ENSG00000272186.1	RP11-110I1.13	-4.69	4.46e-06	0.00148	-0.28	-0.28	Coronary artery disease;	chr11:119074627	chr11:119067374~119067698:-
KIRP	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	4.69	4.46e-06	0.00148	0.29	0.28	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
KIRP	cis	rs686320	0.667	rs550015	ENSG00000245532.5	NEAT1	-4.69	4.46e-06	0.00148	-0.29	-0.28	Hip circumference adjusted for BMI;	chr11:65418877	chr11:65422774~65445540:+
KIRP	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-4.69	4.46e-06	0.00148	-0.29	-0.28	Height;	chr4:55542948	chr4:55363971~55395847:-
KIRP	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	4.69	4.46e-06	0.00148	0.37	0.28	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
KIRP	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	4.69	4.46e-06	0.00148	0.37	0.28	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
KIRP	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-4.69	4.46e-06	0.00148	-0.33	-0.28	Depression;	chr6:28109824	chr6:28073316~28074233:+
KIRP	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-4.69	4.46e-06	0.00148	-0.3	-0.28	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
KIRP	cis	rs1799949	0.965	rs6503727	ENSG00000236383.6	LINC00854	-4.69	4.47e-06	0.00148	-0.21	-0.28	Menopause (age at onset);	chr17:43160842	chr17:43216941~43305976:-
KIRP	cis	rs8177876	0.731	rs57606521	ENSG00000261838.4	RP11-303E16.6	4.69	4.47e-06	0.00148	0.56	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103437	chr16:81069854~81076598:+
KIRP	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.69	4.47e-06	0.00148	-0.24	-0.28	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
KIRP	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	4.69	4.47e-06	0.00148	0.26	0.28	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
KIRP	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-4.69	4.47e-06	0.00148	-0.27	-0.28	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
KIRP	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-4.69	4.48e-06	0.00148	-0.35	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
KIRP	cis	rs10504130	0.696	rs77958054	ENSG00000272024.1	RP11-546K22.3	-4.69	4.48e-06	0.00148	-0.35	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51950284~51950690:+
KIRP	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	4.69	4.48e-06	0.00148	0.3	0.28	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
KIRP	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	4.69	4.48e-06	0.00148	0.32	0.28	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
KIRP	cis	rs4578769	0.959	rs9947011	ENSG00000266850.1	RP11-370A5.1	-4.69	4.48e-06	0.00148	-0.36	-0.28	Eosinophil percentage of white cells;	chr18:22840446	chr18:22723491~22907721:-
KIRP	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	4.69	4.48e-06	0.00148	0.32	0.28	Depression;	chr6:28091242	chr6:28073316~28074233:+
KIRP	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-4.69	4.48e-06	0.00148	-0.29	-0.28	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
KIRP	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	4.69	4.48e-06	0.00148	0.24	0.28	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
KIRP	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	4.69	4.48e-06	0.00148	0.23	0.28	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
KIRP	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-4.69	4.48e-06	0.00148	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
KIRP	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-4.69	4.48e-06	0.00148	-0.29	-0.28	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
KIRP	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	4.69	4.48e-06	0.00148	0.28	0.28	Height;	chr14:75064757	chr14:75011269~75012851:-
KIRP	cis	rs9595908	0.709	rs17594677	ENSG00000212293.1	SNORA16	4.69	4.48e-06	0.00148	0.27	0.28	Body mass index;	chr13:32734875	chr13:32420390~32420516:-
KIRP	cis	rs9595908	0.609	rs733487	ENSG00000212293.1	SNORA16	4.69	4.48e-06	0.00148	0.27	0.28	Body mass index;	chr13:32741068	chr13:32420390~32420516:-
KIRP	cis	rs42648	0.777	rs4728878	ENSG00000225498.1	AC002064.5	4.69	4.48e-06	0.00148	0.2	0.28	Homocysteine levels;	chr7:90294918	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.837	rs13239439	ENSG00000225498.1	AC002064.5	4.69	4.48e-06	0.00148	0.2	0.28	Homocysteine levels;	chr7:90295086	chr7:90312496~90322592:+
KIRP	cis	rs42648	0.837	rs7786771	ENSG00000225498.1	AC002064.5	4.69	4.48e-06	0.00148	0.2	0.28	Homocysteine levels;	chr7:90295453	chr7:90312496~90322592:+
KIRP	cis	rs2562456	0.917	rs6511256	ENSG00000268555.1	RP11-678G14.3	-4.69	4.48e-06	0.00148	-0.38	-0.28	Pain;	chr19:21510513	chr19:21570822~21587322:-
KIRP	cis	rs1552244	1	rs12152515	ENSG00000180385.7	EMC3-AS1	4.69	4.48e-06	0.00148	0.26	0.28	Alzheimer's disease;	chr3:10102292	chr3:9986893~10006990:+
KIRP	cis	rs116095464	0.558	rs10075018	ENSG00000248925.1	CTD-2083E4.6	4.69	4.49e-06	0.00149	0.43	0.28	Breast cancer;	chr5:239060	chr5:269858~271516:-
KIRP	cis	rs11148252	0.74	rs9596643	ENSG00000235660.1	LINC00345	4.69	4.49e-06	0.00149	0.3	0.28	Lewy body disease;	chr13:52338245	chr13:52484161~52484680:-
KIRP	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	4.69	4.49e-06	0.00149	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
KIRP	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	4.69	4.49e-06	0.00149	0.23	0.28	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
KIRP	cis	rs886774	0.866	rs2894482	ENSG00000273055.1	CTB-13F3.1	-4.69	4.49e-06	0.00149	-0.17	-0.28	Ulcerative colitis;	chr7:107869336	chr7:107942116~107942740:+
KIRP	cis	rs2904967	0.562	rs239255	ENSG00000254614.2	AP003068.23	-4.69	4.5e-06	0.00149	-0.38	-0.28	Mean corpuscular volume;	chr11:65219657	chr11:65177606~65181834:-
KIRP	cis	rs2904967	0.636	rs239256	ENSG00000254614.2	AP003068.23	-4.69	4.5e-06	0.00149	-0.38	-0.28	Mean corpuscular volume;	chr11:65219920	chr11:65177606~65181834:-
KIRP	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	4.69	4.5e-06	0.00149	0.49	0.28	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
KIRP	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	4.69	4.5e-06	0.00149	0.49	0.28	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
KIRP	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.69	4.5e-06	0.00149	0.32	0.28	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
KIRP	cis	rs10200159	1	rs1045920	ENSG00000272606.1	RP11-554J4.1	4.69	4.5e-06	0.00149	0.41	0.28	Vitiligo;	chr2:55544033	chr2:55617909~55618373:+
KIRP	cis	rs1577917	0.56	rs9450288	ENSG00000220563.1	PKMP3	4.68	4.5e-06	0.00149	0.22	0.28	Response to antipsychotic treatment;	chr6:85511868	chr6:85659892~85660606:-
KIRP	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-4.68	4.5e-06	0.00149	-0.43	-0.28	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
KIRP	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	4.68	4.51e-06	0.00149	0.27	0.28	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
KIRP	cis	rs6832769	0.961	rs10026692	ENSG00000272969.1	RP11-528I4.2	-4.68	4.51e-06	0.00149	-0.27	-0.28	Personality dimensions;	chr4:55586539	chr4:55547112~55547889:+
KIRP	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	4.68	4.51e-06	0.00149	0.41	0.